FN Clarivate Analytics Web of Science
VR 1.0
PT J
AU Kisilevsky, R
AF Kisilevsky, R
TI Anti-amyloid drugs - Potential in the treatment of diseases associated
   with aging
SO DRUGS & AGING
LA English
DT Article
ID FAMILIAL MEDITERRANEAN FEVER; PRIMARY SYSTEMIC AMYLOIDOSIS;
   ALZHEIMERS-DISEASE; BASEMENT-MEMBRANE; DIABETES-MELLITUS; ENHANCING
   FACTOR; FIBRIL FORMATION; PROTEIN; POLYPEPTIDE; COLCHICINE
AB The requirements for amyloidogenesis, as it is currently understood, include an adequate amyloid precursor pool, a nidus for fibrillogenesis, interactions with a set of common components (most of which are involved in basement membrane structure) and amyloid turnover. These factors serve as the basis for therapeutic attack. General strategies focusing on each of these factors are presented with examples from the experimental and clinical literature. These include reducing the amyloid precursor protein pool in familial amyloid polyneuropathy by liver transplantation, inhibiting nidus formation in familial Mediterranean fever by the use of colchicine, inhibiting amyloid precursor protein/heparan sulphate interaction in experimental inflammation-associated amyloidosis by the use of novel small molecule anionic sulphates and sulphonates, and the use of new analogues of doxorubicin in light chain amyloidosis to accelerate amyloid removal.
   The potential significance of local and systemic amyloid deposits is discussed in the light of new information on the genetics of Alzheimer's disease, observations made in patients receiving long term dialysis for renal failure, and the potential involvement of amyloid deposits in the pathogenesis of non-insulin-dependent diabetes mellitus.
C1 KINGSTON GEN HOSP, SYL & MOLLY APPS RES CTR, KINGSTON, ON K7L 2V7, CANADA.
C3 Queens University - Canada
RP Kisilevsky, R (corresponding author), QUEENS UNIV, DEPT PATHOL, KINGSTON, ON K7L 3N6, CANADA.
CR ARAKI S, 1994, AMYLOID AMYLOIDOSIS, P422
   AUGHEY B, 1994, J VIROL, V68, P2135
   BANKA CL, 1995, J LIPID RES, V36, P1058
   BETTER OS, 1991, DEUT MED WOCHENSCHR, V116, P548, DOI 10.1055/s-2008-1063647
   BRANDWEIN SR, 1985, LAB INVEST, V52, P319
   BRANDWEIN SR, 1994, ARTHRITIS RHEUM, V37, P1757, DOI 10.1002/art.1780371208
   BURGEVIN MC, 1994, NEUROREPORT, V5, P2429, DOI 10.1097/00001756-199412000-00006
   CAMORIANO JK, 1987, NEW ENGL J MED, V316, P1133, DOI 10.1056/NEJM198704303161806
   CAUGHEY B, 1992, J NEUROCHEM, V59, P768, DOI 10.1111/j.1471-4159.1992.tb09437.x
   COME JH, 1993, P NATL ACAD SCI USA, V90, P5959, DOI 10.1073/pnas.90.13.5959
   COOPER GJS, 1995, CLIN SCI, V88, P7, DOI 10.1042/cs0880007
   DANIELS M, 1995, AM J MED GENET, V55, P311, DOI 10.1002/ajmg.1320550313
   DEBEER MC, 1993, J BIOL CHEM, V268, P20606
   EVIN G, 1994, AMYLOID, V1, P263, DOI 10.3109/13506129409146118
   FRASER PE, 1992, J NEUROCHEM, V59, P1531, DOI 10.1111/j.1471-4159.1992.tb08470.x
   FRASER PE, 1994, AMYLOID AMYLOIDOSIS, P341
   GAL R, 1994, ARCH PATHOL LAB MED, V118, P718
   GANDY S, 1994, NEUROBIOL AGING, V15, P253, DOI 10.1016/0197-4580(94)90125-2
   GERTZ MA, 1990, ARCH INTERN MED, V150, P629, DOI 10.1001/archinte.150.3.629
   GIANNI L, 1995, BLOOD, V86, P855
   GOLDFARB LG, 1995, ANNU REV MED, V46, P57
   GUPTABANSAL R, 1995, J BIOL CHEM, V270, P18666, DOI 10.1074/jbc.270.31.18666
   HOLMGREN G, 1993, LANCET, V341, P1113, DOI 10.1016/0140-6736(93)93127-M
   HOOVER KL, 1986, CARCINOGENESIS, V7, P1143, DOI 10.1093/carcin/7.7.1143
   HOWARD J, 1990, NEUROSCI LETT, V118, P71, DOI 10.1016/0304-3940(90)90251-4
   JARRETT JT, 1992, BIOCHEMISTRY-US, V31, P12345, DOI 10.1021/bi00164a008
   JOHNSON KH, 1992, LAB INVEST, V66, P522
   KAZATCHKINE MD, 1993, B WORLD HEALTH ORGAN, V71, P105
   KEDAR I, 1977, EUR J CLIN INVEST, V7, P149
   KELLY JW, 1994, AMYLOID, V1, P186, DOI 10.3109/13506129409148451
   KISILEVSKY R, 1983, LAB INVEST, V48, P53
   KISILEVSKY R, 1995, AMYLOID, V2, P128, DOI 10.3109/13506129509031899
   KISILEVSKY R, 1995, NAT MED, V1, P143, DOI 10.1038/nm0295-143
   KISILEVSKY R, 1991, MODERN PATHOL, V4, P514
   KISILEVSKY R, 1992, LAB INVEST, V66, P778
   KISILEVSKY R, 1979, LAB INVEST, V41, P206
   KUSHNER I, 1994, BAILLIERE CLIN RHEUM, V8, P513, DOI 10.1016/S0950-3579(05)80113-X
   KYLE RA, 1985, AM J MED, V79, P708, DOI 10.1016/0002-9343(85)90521-2
   LANSBURY PT, 1995, EUR J MED CHEM, V30, pS621
   LIVNEH A, 1994, ARTHRITIS RHEUM-US, V37, P1804, DOI 10.1002/art.1780371215
   LORENZO A, 1994, NATURE, V368, P756, DOI 10.1038/368756a0
   LORENZO A, 1994, P NATL ACAD SCI USA, V91, P12243, DOI 10.1073/pnas.91.25.12243
   LYON AW, 1991, LAB INVEST, V64, P785
   LYON AW, 1990, BIOCHIM BIOPHYS ACTA, V1049, P158, DOI 10.1016/0167-4781(90)90036-2
   MCADAM KPWJ, 1978, J CLIN INVEST, V61, P390, DOI 10.1172/JCI108949
   MCCUBBIN WD, 1988, BIOCHEM J, V256, P775, DOI 10.1042/bj2560775
   MERLINI G, 1995, SEMIN HEMATOL, V32, P60
   MERLINI G, 1995, P NATL ACAD SCI USA, V92, P2959, DOI 10.1073/pnas.92.7.2959
   NARINDRASORASAK S, 1995, LAB INVEST, V72, P272
   OBRIEN TD, 1993, VET PATHOL, V30, P317, DOI 10.1177/030098589303000401
   PERFETTI V, 1994, AM J HEMATOL, V46, P189, DOI 10.1002/ajh.2830460306
   PERLMUTTER LS, 1994, MOL NEUROBIOL, V9, P33, DOI 10.1007/BF02816103
   PERLMUTTER LS, 1994, MICROSC RES TECHNIQ, V28, P204, DOI 10.1002/jemt.1070280305
   PERLMUTTER LS, 1990, BRAIN RES BULL, V24, P677, DOI 10.1016/0361-9230(90)90007-M
   POLLACK SJ, 1995, NEUROSCI LETT, V184, P113, DOI 10.1016/0304-3940(94)11182-I
   PRIOLA SA, 1994, MOL NEUROBIOL, V8, P113, DOI 10.1007/BF02780661
   PRUSINER SB, 1995, AMYLOID, V2, P39, DOI 10.3109/13506129509031887
   PRUSINER SB, 1995, EUR J MED CHEM, V30, pS11
   RAVID M, 1982, ANN RHEUM DIS, V41, P587, DOI 10.1136/ard.41.6.587
   SANDLER S, 1994, REGUL PEPTIDES, V53, P103, DOI 10.1016/0167-0115(94)90611-4
   SELKOE DJ, 1994, ANNU REV CELL BIOL, V10, P373, DOI 10.1146/annurev.cellbio.10.1.373
   SELKOE DJ, 1993, TRENDS NEUROSCI, V16, P403, DOI 10.1016/0166-2236(93)90008-A
   SHOHAT M, 1992, AM J MED GENET, V44, P183, DOI 10.1002/ajmg.1320440213
   TANG AL, 1989, CLIN NEPHROL, V32, P225
   TENNENT GA, 1995, P NATL ACAD SCI USA, V92, P4299, DOI 10.1073/pnas.92.10.4299
   VANBROECKHOVEN CL, 1995, EUR NEUROL, V35, P8, DOI 10.1159/000117083
   VANRIJSWIJK MH, 1979, LANCET, V1, P207
   WEGELIUS O, 1982, ACTA MED SCAND, V212, P273
   WESTERMARK P, 1992, DIABETOLOGIA, V35, P297, DOI 10.1007/BF00401195
   ZEMER D, 1993, AM J MED GENET, V45, P340, DOI 10.1002/ajmg.1320450311
NR 70
TC 34
Z9 53
U1 0
U2 6
PU ADIS INT LTD
PI NORTHCOTE
PA 5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND
SN 1170-229X
EI 1179-1969
J9 DRUG AGING
JI Drugs Aging
PD FEB
PY 1996
VL 8
IS 2
BP 75
EP 83
DI 10.2165/00002512-199608020-00001
PG 9
WC Geriatrics & Gerontology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Geriatrics & Gerontology; Pharmacology & Pharmacy
GA TR703
UT WOS:A1996TR70300001
PM 8845588
DA 2024-02-19
ER

PT J
AU Kosaki, K
   Kamijo-Ikemori, A
   Sugaya, T
   Tanahashi, K
   Kumagai, H
   Sawano, Y
   Akazawa, N
   Ra, SG
   Kimura, K
   Shibagaki, Y
   Maeda, S
AF Kosaki, Keisei
   Kamijo-Ikemori, Atsuko
   Sugaya, Takeshi
   Tanahashi, Koichiro
   Kumagai, Hiroshi
   Sawano, Yuriko
   Akazawa, Nobuhiko
   Ra, Song-Gyu
   Kimura, Kenjiro
   Shibagaki, Yugo
   Maeda, Seiji
TI Relationship between exercise capacity and urinary liver-type fatty
   acid-binding protein in middle-aged and older individuals
SO CLINICAL AND EXPERIMENTAL NEPHROLOGY
LA English
DT Article
DE Aerobic fitness; Muscular strength; Peritubular capillary blood flow
ID CHRONIC KIDNEY-DISEASE; INDUCED RENAL INJURY; TUBULOINTERSTITIAL INJURY;
   NITRIC-OXIDE; AGING KIDNEY; STRENGTH; HEMODYNAMICS; HYPERTENSION;
   EXCRETION; HYPOXIA
AB The underlying mechanism linking the decline in exercise capacity with renal dysfunction remains unclear. Urinary liver-type fatty acid-binding protein (L-FABP) levels reflect the degree of peritubular capillary blood flow, an important factor for renal dysfunction with aging. The aim of this study was to examine the relationship between exercise capacity and urinary L-FABP levels.
   This was a cross-sectional study of 187 middle-aged and older individuals (aged 50-83 years) without chronic kidney disease (CKD). We assessed urinary L-FABP levels, peak oxygen consumption (), and grip strength.
   Urinary L-FABP levels inversely correlated with both (r (s) = -0.349) and grip strength (r (s) = -0.485). When the participants were divided into four groups according to the median values of aerobic fitness and muscular strength ( and grip strength), urinary L-FABP levels were the highest in participants with lower levels of aerobic fitness and muscular strength (2.95 +/- 1.43 mu g/g creatinine) and the lowest in the participants with higher levels of aerobic fitness and muscular strength (1.33 +/- 0.76 mu g/g creatinine). The difference between the two groups was significant (P < 0.001).
   Our results demonstrate that both and grip strength were inversely associated with urinary L-FABP levels in middle-aged and older individuals without CKD. This suggests that a decline in exercise capacity is associated with a reduction in peritubular capillary blood flow, providing a novel insight into the underlying mechanism linking the decline in exercise capacity to the development of renal dysfunction.
C1 [Kosaki, Keisei; Tanahashi, Koichiro; Sawano, Yuriko] Univ Tsukuba, Grad Sch Comprehens Human Sci, Tsukuba, Ibaraki, Japan.
   [Kamijo-Ikemori, Atsuko; Sugaya, Takeshi; Shibagaki, Yugo] St Marianna Univ, Dept Internal Med, Div Nephrol & Hypertens, Sch Med, Kawasaki, Kanagawa, Japan.
   [Kamijo-Ikemori, Atsuko] St Marianna Univ, Sch Med, Dept Anat, Kawasaki, Kanagawa, Japan.
   [Kumagai, Hiroshi; Akazawa, Nobuhiko; Maeda, Seiji] Univ Tsukuba, Fac Hlth & Sport Sci, 1-1-1 Tennodai, Tsukuba, Ibaraki 3058574, Japan.
   [Ra, Song-Gyu] Fukuoka Univ, Fac Sports & Hlth Sci, Fukuoka, Japan.
   [Kimura, Kenjiro] JCHO Tokyo Takanawa Hosp, Tokyo, Japan.
   [Sugaya, Takeshi] CMIC Co Ltd, Tokyo, Japan.
C3 University of Tsukuba; Saint Marianna University; Saint Marianna
   University; University of Tsukuba; Fukuoka University; CMIC Holdings Co
   Ltd
RP Maeda, S (corresponding author), Univ Tsukuba, Fac Hlth & Sport Sci, 1-1-1 Tennodai, Tsukuba, Ibaraki 3058574, Japan.
EM maeda@taiiku.tsukuba.ac.jp
RI Ra, Song-Gyu/AFM-3003-2022; AKAZAWA, Nobuhiko/AAW-9680-2021
OI Ra, Song-Gyu/0000-0002-8685-4554; Kumagai, Hiroshi/0000-0002-0520-6214;
   Kosaki, Keisei/0000-0001-6001-578X
FU Japan Society for the Promotion of Science Fellows KAKENHI Grant
   [15J00614]; Grants-in-Aid for Scientific Research [15J00614] Funding
   Source: KAKEN
FX Grant-in-Aid for the Japan Society for the Promotion of Science Fellows
   KAKENHI Grant Number 15J00614.
CR BOSCH JP, 1983, AM J MED, V75, P943, DOI 10.1016/0002-9343(83)90873-2
   Chang YT, 2011, NEPHROL DIAL TRANSPL, V26, P3588, DOI 10.1093/ndt/gfr013
   Hashimoto J, 2015, HYPERTENSION, V66, P61, DOI 10.1161/HYPERTENSIONAHA.115.05236
   Hashimoto J, 2011, HYPERTENSION, V58, P839, DOI 10.1161/HYPERTENSIONAHA.111.177469
   Horio M, 2013, AM J KIDNEY DIS, V61, P197, DOI 10.1053/j.ajkd.2012.07.007
   Ichikawa D, 2015, AM J PHYSIOL-RENAL, V308, pF114, DOI 10.1152/ajprenal.00469.2014
   Ichikawa D, 2012, HYPERTENSION, V60, P973, DOI 10.1161/HYPERTENSIONAHA.112.199828
   Imai N, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126990
   Ishimitsu Toshihiko, 2005, Clin Exp Nephrol, V9, P34, DOI 10.1007/s10157-004-0331-x
   Johansen KL, 2012, AM J KIDNEY DIS, V59, P126, DOI 10.1053/j.ajkd.2011.10.008
   Jurca R, 2004, MED SCI SPORT EXER, V36, P1301, DOI 10.1249/01.MSS.0000135780.88930.A9
   Kamijo A, 2005, J LAB CLIN MED, V145, P125, DOI 10.1016/j.lab.2004.12.003
   Kamijo A, 2004, AM J PATHOL, V165, P1243, DOI 10.1016/S0002-9440(10)63384-6
   Kamijo A, 2004, J LAB CLIN MED, V143, P23, DOI 10.1016/j.lab.2003.08.001
   Kamijo-Ikemori A, 2011, DIABETES CARE, V34, P691, DOI 10.2337/dc10-1392
   Kamijo-Ikemori A, 2009, NEPHROL DIAL TRANSPL, V24, P788, DOI 10.1093/ndt/gfn573
   Kimura N, 2015, CLIN EXP NEPHROL, V19, P1114, DOI 10.1007/s10157-015-1116-0
   Kokkinos P, 2015, MAYO CLIN PROC, V90, P461, DOI 10.1016/j.mayocp.2015.01.013
   Leong DP, 2015, LANCET, V386, P266, DOI 10.1016/S0140-6736(14)62000-6
   MAATMAN RGHJ, 1992, BIOCHEM J, V288, P285, DOI 10.1042/bj2880285
   Maeda S, 2004, HYPERTENS RES, V27, P947, DOI 10.1291/hypres.27.947
   Maeda S, 2001, LIFE SCI, V69, P1005, DOI 10.1016/S0024-3205(01)01192-4
   Martin JE, 2007, J PATHOL, V211, P198, DOI 10.1002/path.2111
   Myers J, 2002, NEW ENGL J MED, V346, P793, DOI 10.1056/NEJMoa011858
   Nangaku M, 2006, J AM SOC NEPHROL, V17, P17, DOI 10.1681/ASN.2005070757
   NORRIS CS, 1984, J SURG RES, V36, P230, DOI 10.1016/0022-4804(84)90092-1
   Pialoux V, 2009, HYPERTENSION, V54, P1014, DOI 10.1161/HYPERTENSIONAHA.109.138917
   RISDON RA, 1968, LANCET, V2, P363
   Sugawara J, 2012, AM J HYPERTENS, V25, P651, DOI 10.1038/ajh.2012.24
   Tanaka T, 2006, J GERONTOL A-BIOL, V61, P795, DOI 10.1093/gerona/61.8.795
   Yamamoto T, 2007, J AM SOC NEPHROL, V18, P2894, DOI 10.1681/ASN.2007010097
   Zhou XJ, 2008, KIDNEY INT, V74, P710, DOI 10.1038/ki.2008.319
NR 32
TC 9
Z9 9
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1342-1751
EI 1437-7799
J9 CLIN EXP NEPHROL
JI Clin. Exp. Nephrol.
PD OCT
PY 2017
VL 21
IS 5
BP 810
EP 817
DI 10.1007/s10157-017-1385-x
PG 8
WC Urology & Nephrology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Urology & Nephrology
GA FK2LO
UT WOS:000413313900010
PM 28197733
DA 2024-02-19
ER

PT J
AU Yang, SJ
   Choi, JM
   Kim, L
   Park, SE
   Rhee, EJ
   Lee, WY
   Oh, KW
   Park, SW
   Park, CY
AF Yang, Soo Jin
   Choi, Jung Mook
   Kim, Lisa
   Park, Se Eun
   Rhee, Eun Jung
   Lee, Won Young
   Oh, Ki Won
   Park, Sung Woo
   Park, Cheol-Young
TI Nicotinamide improves glucose metabolism and affects the hepatic
   NAD-sirtuin pathway in a rodent model of obesity and type 2 diabetes
SO JOURNAL OF NUTRITIONAL BIOCHEMISTRY
LA English
DT Article
DE NAD; Nicotinamide; Nicotinic acid; PGC-1 alpha; Sirtuin
ID TRANSCRIPTIONAL COACTIVATOR PGC-1-ALPHA; DIET-INDUCED OBESITY;
   INSULIN-SECRETION; BETA-CELLS; PROTECTS; ACID; MICE; SIR2; BIOSYNTHESIS;
   RIBOSIDE
AB Nicotinic acid (NA) and nicotinamide (NAM) are major forms of niacin and exert their physiological functions as precursors of nicotinamide adenine dinucleotide (NAD). Sirtuins, which are NAD-dependent deacetylases, regulate glucose and lipid metabolism and are implicated in the pathophysiology of aging, diabetes, and hepatic steatosis. The aim of this study was to investigate the effects of two NAD donors, NA and NAM, on glucose metabolism and the hepatic NAD-sirtuin pathway. The effects were investigated in OLETF rats, a rodent model of obesity and type 2 diabetes. OLETF rats were divided into five groups: (1) high fat (HF) diet, (2) HF diet and 10 mg NA/kg body weight (BW)/day (NA 10), (3) HF diet and 100 mg NA/kg BW/day (NA 100), (4) HF diet and 10 mg NAM/kg BW/day (NAM 10), and (5) HF diet and 100 mg NAM/kg BW/day (NAM 100). NA and NAM were delivered via drinking water for four weeks. NAM 100 treatment affected glucose control significantly, as shown by lower levels of accumulative area under the curve during oral glucose tolerance test, serum fasting glucose, serum fasting insulin, and homeostasis model assessment of insulin resistance, and higher levels of serum adiponectin. With regard to NAD-sirtuin pathway, intracellular nicotinamide phosphoribosyltransferase, NAD, the NAD/NADH ratio, Sirt1, 2, 3, and 6 mRNA expressions, and Sirt1 activity all increased in livers of NAM 100-treated rats. These alterations were accompanied by the increased levels of proliferator-activated receptor gamma, coactivator 1 alpha and mitochondrial DNA. The effect of NA treatment was less evident than that of NAM 100. These results demonstrate that NAM is more effective than NA on the regulation of glucose metabolism and the NAD-sirtuin pathway, which may relate to the altered mitochondrial biogenesis. (C) 2014 Elsevier Inc. All rights reserved.
C1 [Yang, Soo Jin] Chonnam Natl Univ, Dept Food & Nutr, Gwangu, South Korea.
   [Yang, Soo Jin] Chonnam Natl Univ, Human Ecol Res Inst, Gwangu, South Korea.
   [Choi, Jung Mook; Kim, Lisa; Park, Cheol-Young] Sungkyunkwan Univ, Sch Med, Kangbuk Samsung Hosp, Diabet Res Inst, Seoul 110746, South Korea.
   [Park, Se Eun; Rhee, Eun Jung; Lee, Won Young; Oh, Ki Won; Park, Sung Woo; Park, Cheol-Young] Sungkyunkwan Univ, Sch Med, Kangbuk Samsung Hosp, Dept Endocrinol & Metab, Seoul 110746, South Korea.
C3 Chonnam National University; Chonnam National University; Sungkyunkwan
   University (SKKU); Samsung Medical Center; Sungkyunkwan University
   (SKKU); Samsung Medical Center
RP Park, CY (corresponding author), Sungkyunkwan Univ, Sch Med, Kangbuk Samsung Hosp, Dept Endocrinol & Metab, Seoul 110746, South Korea.
EM cydoctor@chol.com
RI LEE, WON-YOUNG/C-7249-2018; Rhee, Eun-Jung/M-9294-2015; Park,
   Cheol-Young/C-6690-2018
OI LEE, WON-YOUNG/0000-0002-1082-7592; Rhee, Eun-Jung/0000-0002-6108-7758;
   Park, Cheol-Young/0000-0002-9415-9965; Yang, Soo Jin/0000-0001-7892-7648
FU Basic Science Research Program through the National Research Foundation
   of Korea (NRF); Ministry of Education, Science and Technology
   [2012R1A1A2009143, 2012R1A1A1004861]
FX This research was supported by Basic Science Research Program through
   the National Research Foundation of Korea (NRF) funded by the Ministry
   of Education, Science and Technology (2012R1A1A2009143 to C-Y. P. and
   2012R1A1A1004861 to S.J.Y.). The funder had no role in study design,
   data collection, and analysis and interpretation, decision to publish,
   or preparation of the manuscript.
CR Arany Z, 2005, CELL METAB, V1, P259, DOI 10.1016/j.cmet.2005.03.002
   Avalos JL, 2005, MOL CELL, V17, P855, DOI 10.1016/j.molcel.2005.02.022
   Belenky P, 2007, CELL, V129, P473, DOI 10.1016/j.cell.2007.03.024
   Bieganowski P, 2004, CELL, V117, P495, DOI 10.1016/S0092-8674(04)00416-7
   Bitterman KJ, 2002, J BIOL CHEM, V277, P45099, DOI 10.1074/jbc.M205670200
   Cabrera-Rode E, 2006, AUTOIMMUNITY, V39, P333, DOI 10.1080/08916930600738383
   Cantó C, 2012, CELL METAB, V15, P838, DOI 10.1016/j.cmet.2012.04.022
   COLLINS PB, 1972, J BIOL CHEM, V247, P778
   Czubryt MP, 2003, P NATL ACAD SCI USA, V100, P1711, DOI 10.1073/pnas.0337639100
   Gale EAM, 2004, LANCET, V363, P925, DOI 10.1016/S0140-6736(04)15786-3
   Haigis MC, 2006, GENE DEV, V20, P2913, DOI 10.1101/gad.1467506
   Hou XY, 2008, J BIOL CHEM, V283, P20015, DOI 10.1074/jbc.M802187200
   Imai S, 2009, FRONT BIOSCI-LANDMRK, V14, P2983, DOI 10.2741/3428
   Imai S, 2009, CELL BIOCHEM BIOPHYS, V53, P65, DOI 10.1007/s12013-008-9041-4
   Jing EX, 2007, CELL METAB, V6, P105, DOI 10.1016/j.cmet.2007.07.003
   John CM, 2012, CURR MED CHEM, V19, P5181, DOI 10.2174/092986712803530449
   Kanfi Y, 2010, AGING CELL, V9, P162, DOI 10.1111/j.1474-9726.2009.00544.x
   Kelly G, 2010, ALTERN MED REV, V15, P245
   Kendrick AA, 2011, BIOCHEM J, V433, P505, DOI 10.1042/BJ20100791
   Krishnan J, 2012, GENE DEV, V26, P259, DOI 10.1101/gad.180406.111
   Li HM, 2011, PANCREAS, V40, P615, DOI 10.1097/MPA.0b013e31820b4b23
   Liu D, 2013, NEUROBIOL AGING, V34, P1564, DOI 10.1016/j.neurobiolaging.2012.11.020
   Liu D, 2009, NEUROMOL MED, V11, P28, DOI 10.1007/s12017-009-8058-1
   Magni G, 2004, CELL MOL LIFE SCI, V61, P19, DOI 10.1007/s00018-003-3161-1
   Magni G, 1999, ADV ENZYMOL RAMB, V73, P135, DOI 10.1002/9780470123195.ch5
   Nemoto S, 2005, J BIOL CHEM, V280, P16456, DOI 10.1074/jbc.M501485200
   Oh YT, 2011, AM J PHYSIOL-ENDOC M, V300, pE1012, DOI 10.1152/ajpendo.00650.2010
   Olesen J, 2010, PFLUG ARCH EUR J PHY, V460, P153, DOI 10.1007/s00424-010-0834-0
   Olmos PR, 2006, DIABETES RES CLIN PR, V71, P320, DOI 10.1016/j.diabres.2005.07.009
   Palacios OM, 2009, AGING-US, V1, P771, DOI 10.18632/aging.100075
   Pfluger PT, 2008, P NATL ACAD SCI USA, V105, P9793, DOI 10.1073/pnas.0802917105
   Picca A, 2012, AGE DORDR
   Revollo JR, 2007, CELL METAB, V6, P363, DOI 10.1016/j.cmet.2007.09.003
   Revollo JR, 2007, CURR OPIN GASTROEN, V23, P164, DOI 10.1097/MOG.0b013e32801b3c8f
   Revollo JR, 2004, J BIOL CHEM, V279, P50754, DOI 10.1074/jbc.M408388200
   Rongvaux A, 2003, BIOESSAYS, V25, P683, DOI 10.1002/bies.10297
   Xiao CY, 2010, J BIOL CHEM, V285, P36776, DOI 10.1074/jbc.M110.168039
   Xu F, 2010, ENDOCRINOLOGY, V151, P2504, DOI 10.1210/en.2009-1013
   Yang SJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017057
   Yoshinari O, 2010, CURR MED CHEM, V17, P2196, DOI 10.2174/092986710791299902
   Yoshino J, 2011, CELL METAB, V14, P528, DOI 10.1016/j.cmet.2011.08.014
   Zhong L, 2010, CELL, V140, P280, DOI 10.1016/j.cell.2009.12.041
NR 42
TC 88
Z9 102
U1 0
U2 42
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0955-2863
EI 1873-4847
J9 J NUTR BIOCHEM
JI J. Nutr. Biochem.
PD JAN
PY 2014
VL 25
IS 1
BP 66
EP 72
DI 10.1016/j.jnutbio.2013.09.004
PG 7
WC Biochemistry & Molecular Biology; Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Nutrition & Dietetics
GA 287HB
UT WOS:000329531500008
PM 24314867
DA 2024-02-19
ER

PT J
AU Mizukami, S
   Watanabe, Y
   Saegusa, Y
   Nakajima, K
   Ito, Y
   Masubuchi, Y
   Yoshida, T
   Shibutani, M
AF Mizukami, Sayaka
   Watanabe, Yousuke
   Saegusa, Yukie
   Nakajima, Kota
   Ito, Yuko
   Masubuchi, Yasunori
   Yoshida, Toshinori
   Shibutani, Makoto
TI Downregulation of UBE2E2 in rat liver cells after hepatocarcinogen
   treatment facilitates cell proliferation and slowing down of DNA damage
   response in GST-P-expressing preneoplastic lesions
SO TOXICOLOGY AND APPLIED PHARMACOLOGY
LA English
DT Article
DE Rat; Liver; Carcinogenesis; Ubiquitin-conjugating enzyme E2E 2 (UBE2E2);
   Glutathione S-transferase placental form (GSTP); Thioacetamide (TAA)
ID TUMOR-PROMOTION; EARLY-STAGE; ABERRANT ACTIVATION; CYCLE REGULATION;
   CARCINOGENESIS; SENESCENCE; THRESHOLD; PHASE; INDUCTION; APOPTOSIS
AB We previously found downregulation of ubiquitin-conjugating enzyme E2E 2 (UBE2E2) in GST-P-positive ((+)) proliferative lesions produced by tumor promotion from early hepatocarcinogenesis stages in rats. Here we investigated the role of UBE2E2 downregulation in preneoplastic lesions of the liver and other target organs produced by tumor promotion in rats. Increased number of UBE2E2-related ubiquitination target proteins, phosphorylated c-MYC, KDM4A and KMT5A, was found in the UBE2E2-downregulated GST-P+ foci, compared with GST-P+ foci expressing UBE2E2. However, p21(wAF1/cIP1), another UBE2E2 target protein, did not increase in the positive cells. Furthermore, the numbers of PCNA(+) cells and gamma H2AX(+) cells were increased in UBE2E2-downregulated foci. These results suggest sustained activation of c-MYC and stabilization of KMT5A to result in c-MYC-mediated transcript upregulation and following KMT5A-mediated protein stabilization of PCNA in GSTP(+) foci, as well as KDM4A stabilization resulting in slowing down of DNA damage response in these lesions. Similar results were also observed in GST-P+ foci produced by repeated treatment of rats with a hepatocarcinogen, thioacetamide, for 90 days. Hepatocarcinogen treatment for 28 or 90 days also increased the numbers of liver cells expressing UBE2E2-related ubiquitination target proteins, as well as PCNA(+) or gamma H2AX(+) cells. Conversely, UBE2E2 downregulation was lacking in PPAR alpha agonist-induced hepatocarcinogenesis, as well as in carcinogenic processes targeting other organs, suggestive of the loss of UBE2E2-related ubiquitination limited to hepatocarcinogenesis producing GST-P+ proliferative lesions. Our results suggest that repeated hepatocarcinogen treatment of rats causes stabilization of UBE2E2-related ubiquitination target proteins in liver cells to promote carcinogenesis.
C1 [Mizukami, Sayaka; Watanabe, Yousuke; Nakajima, Kota; Ito, Yuko; Masubuchi, Yasunori; Yoshida, Toshinori; Shibutani, Makoto] Tokyo Univ Agr & Technol, Inst Agr, Lab Vet Pathol, Div Anim Life Sci, 3-5-8 Saiwai Cho, Fuchu, Tokyo 1838509, Japan.
   [Mizukami, Sayaka; Watanabe, Yousuke; Nakajima, Kota; Ito, Yuko; Masubuchi, Yasunori] Gifu Univ, United Grad Sch Vet Sci, Pathogenet Vet Sci, 1-1 Yanagido, Gifu, Gifu 5011193, Japan.
   [Saegusa, Yukie] OECD, Environm Directorate, Environm Hlth & Safety Div, 2 Rue Andre Pascal, F-75775 Paris 16, France.
   [Shibutani, Makoto] Tokyo Univ Agr & Technol, Inst Global Innovat Res, 3-5-8 Saiwai Cho, Fuchu, Tokyo 1838509, Japan.
C3 Tokyo University of Agriculture & Technology; Gifu University;
   Organisation for Economic Co-operation & Development (OECD); Tokyo
   University of Agriculture & Technology
RP Shibutani, M (corresponding author), Tokyo Univ Agr & Technol, Inst Agr, Lab Vet Pathol, Div Anim Life Sci, 3-5-8 Saiwai Cho, Fuchu, Tokyo 1838509, Japan.
EM smizuka@cc.tuat.ac.jp; ywatana@cc.tuat.ac.jp; Yukie.SAEGUSA@oecd.org;
   knakaji@m2.tuat.ac.jp; yitoh@m2.tuat.ac.jp; y-masubuchi@m2.tuat.ac.jp;
   yoshida7@cc.tuat.ac.jp; mshibuta@cc.tuat.ac.jp
RI Shibutani, Makoto/AGK-2801-2022; Shibutani, Makoto/C-2510-2013; Yoshida,
   Toshinori/B-7255-2015
OI Shibutani, Makoto/0000-0003-3417-9697; Yoshida,
   Toshinori/0000-0003-2476-7794
FU Japan Society for the Promotion of Science (JSPS) [22380163]; Research
   Fund from Institute of Global Innovation Research, Tokyo University of
   Agriculture and Technology; Grants-in-Aid for Scientific Research
   [22380163] Funding Source: KAKEN
FX This work was supported by a Grant-in-Aid for Scientific Research (B)
   from the Japan Society for the Promotion of Science (JSPS; Grant No.
   22380163), and by a Research Fund from Institute of Global Innovation
   Research, Tokyo University of Agriculture and Technology.
CR [Anonymous], 2000, Toxic Rep Ser, V46, P1
   BECKER FF, 1983, J NATL CANCER I, V71, P553
   Bernard Sandra, 2006, V42, P329, DOI 10.1007/004
   Campisi J, 2013, ANNU REV PHYSIOL, V75, P685, DOI 10.1146/annurev-physiol-030212-183653
   Ciechanover A, 1998, EMBO J, V17, P7151, DOI 10.1093/emboj/17.24.7151
   Gartel AL, 2003, EXP CELL RES, V283, P17, DOI 10.1016/S0014-4827(02)00020-4
   Halicka HD, 2005, CELL CYCLE, V4, P339
   Hayashi H, 2012, J TOXICOL SCI, V37, P517
   Hirose M, 1998, INT J CANCER, V77, P773, DOI 10.1002/(SICI)1097-0215(19980831)77:5<773::AID-IJC17>3.0.CO;2-2
   Huen MSY, 2008, J BIOL CHEM, V283, P11073, DOI 10.1074/jbc.C700242200
   Ito Nobuyuki, 1998, Journal of Toxicological Sciences, V23, P103
   Kemmochi S, 2012, EXP BIOL MED, V237, P728, DOI 10.1258/ebm.2012.011319
   Kikuchihara Y, 2015, EXP TOXICOL PATHOL, V67, P349, DOI 10.1016/j.etp.2015.03.002
   Kimura M, 2016, J APPL TOXICOL, V36, P223, DOI 10.1002/jat.3163
   Kitano M, 1998, CARCINOGENESIS, V19, P1475, DOI 10.1093/carcin/19.8.1475
   Lujambio A, 2016, BIOESSAYS, V38, pS56, DOI 10.1002/bies.201670910
   Mallette FA, 2012, EMBO J, V31, P1865, DOI 10.1038/emboj.2012.47
   Mizukami S, 2017, TOXICOL LETT, V266, P13, DOI 10.1016/j.toxlet.2016.11.022
   Muguruma M, 2009, ARCH TOXICOL, V83, P183, DOI 10.1007/s00204-008-0340-8
   National Toxicology Program, 1993, Natl Toxicol Program Tech Rep Ser, V425, P1
   Sano Masashi, 1999, Journal of Toxicological Sciences, V24, P177
   Shibata E, 2011, MOL CELL BIOL, V31, P3136, DOI 10.1128/MCB.05496-11
   Shirai T, 1997, TOXICOL PATHOL, V25, P453, DOI 10.1177/019262339702500504
   Shoda T, 1999, TOXICOL PATHOL, V27, P553, DOI 10.1177/019262339902700509
   Tanaka H, 2017, CELL REP, V18, P2148, DOI 10.1016/j.celrep.2017.02.021
   Tang Y, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0163324
   Taniai E, 2012, J TOXICOL SCI, V37, P1093, DOI 10.2131/jts.37.1093
   Taniai E, 2012, J TOXICOL SCI, V37, P1113, DOI 10.2131/jts.37.1113
   Taniai E, 2009, CANCER SCI, V100, P813, DOI 10.1111/j.1349-7006.2009.01120.x
   Tsuchiya T, 2012, TOXICOLOGY, V299, P146, DOI 10.1016/j.tox.2012.05.018
   Wada S, 1998, CANCER LETT, V123, P127, DOI 10.1016/S0304-3835(97)00407-2
   Wu CH, 2007, P NATL ACAD SCI USA, V104, P13028, DOI 10.1073/pnas.0701953104
   Yafune A, 2013, TOXICOL LETT, V219, P203, DOI 10.1016/j.toxlet.2013.03.012
NR 33
TC 3
Z9 3
U1 0
U2 9
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0041-008X
EI 1096-0333
J9 TOXICOL APPL PHARM
JI Toxicol. Appl. Pharmacol.
PD NOV 1
PY 2017
VL 334
BP 207
EP 216
DI 10.1016/j.taap.2017.09.005
PG 10
WC Pharmacology & Pharmacy; Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy; Toxicology
GA FK1ZU
UT WOS:000413282900020
PM 28899750
DA 2024-02-19
ER

PT J
AU Spaulding, AC
   Sharma, A
   Messina, LC
   Zlotorzynska, M
   Miller, L
   Binswanger, IA
AF Spaulding, Anne C.
   Sharma, Akshay
   Messina, Lauren C.
   Zlotorzynska, Maria
   Miller, Lesley
   Binswanger, Ingrid A.
TI A Comparison of Liver Disease Mortality With HIV and Overdose Mortality
   Among Georgia Prisoners and Releasees: A 2-Decade Cohort Study of
   Prisoners Incarcerated in 1991
SO AMERICAN JOURNAL OF PUBLIC HEALTH
LA English
DT Article
ID C VIRUS-INFECTION; DRUG-RELATED DEATHS; HEPATITIS-C; UNITED-STATES;
   COST-EFFECTIVENESS; CARE; SOFOSBUVIR; HEALTH; RECOMMENDATIONS;
   PREVALENCE
AB Objectives. We investigated whether eventual causes of death among a cohort of inmates imprisoned in the southeastern United States differed from those in previous prisoner studies.
   Methods. We matched 23 510 prisoners in Georgia, a state with historically low levels of heroin consumption but moderate amounts of injection drug use, who were incarcerated on June 30, 1991, to death registries through 2010. Main exposure was 4-year time intervals over 2 decades of observation; main outcome was mortality from liver disease, HIV, and overdose.
   Results. Although the HIV-related mortality rate exceeded that from liver-related conditions before 2003, liver disease subsequently surpassed HIV as a cause of death. Among 3863 deaths, 22 (0.6%) occurred within 2 weeks after release from prison. Of these, only 2 were caused by accidental poisoning (likely drug overdose). Cardiovascular disease and cancer were the most frequent causes of death in this aging cohort.
   Conclusions. Our study design deemphasized immediate deaths but highlighted long-term sequelae of exposure to viral hepatitis and alcohol. Treating hepatitis C and implementing interventions to manage alcohol use disorders may improve survival among prisoners in the Southeast.
C1 [Spaulding, Anne C.; Sharma, Akshay; Messina, Lauren C.; Zlotorzynska, Maria] Emory Univ, Rollins Sch Publ Hlth, Dept Epidemiol, Atlanta, GA 30322 USA.
   [Miller, Lesley] Emory Univ, Sch Med, Div Gen Med, Atlanta, GA USA.
   [Binswanger, Ingrid A.] Univ Colorado, Sch Med, Aurora, CO USA.
C3 Emory University; Rollins School Public Health; Emory University;
   University of Colorado System; University of Colorado Anschutz Medical
   Campus
RP Spaulding, AC (corresponding author), Rollins Sch Publ Hlth, 1518 Clifton Rd, Atlanta, GA 30322 USA.
EM aspauld@sph.emory.edu
RI Binswanger, Ingrid A/X-4496-2019
OI Binswanger, Ingrid A/0000-0001-8862-8078; Sharma,
   Akshay/0000-0001-7864-5464
FU Emory Center for AIDS Research under National Institute of Allergy and
   Infectious Diseases Center for AIDS Research-National Cancer Institute
   [P30 AI050409]
FX This research was funded by Emory Center for AIDS Research (P30
   AI050409) under a supplement from the National Institute of Allergy and
   Infectious Diseases Center for AIDS Research-National Cancer Institute.
CR Anonymous, 2006, Morbidity and Mortality Weekly Report, V55, P421
   [Anonymous], 1992, INT CLASS DIS 10 REV
   [Anonymous], 2012, HIV PRISONS 2001 201
   [Anonymous], 2020, INT CLASSIFICATION D, VSecond, DOI [10.32388/5XG1QE, DOI 10.32388/5XG1QE]
   [Anonymous], 2009, POL BRIEF HIV TEST C
   Armstrong GL, 2006, ANN INTERN MED, V144, P705, DOI 10.7326/0003-4819-144-10-200605160-00004
   Binswanger IA, 2007, NEW ENGL J MED, V356, P157, DOI 10.1056/NEJMsa064115
   Bird SM, 2003, ADDICTION, V98, P185, DOI 10.1046/j.1360-0443.2003.00264.x
   Branson Bernard M., 2006, Morbidity and Mortality Weekly Report, V55, P1
   Center for Behavioral Health Statistics and Quality, 2018, 2017 NAT SURV DRUG U
   Center for Behavioral Health Statistics and Quality Substance Abuse and Mental Health Services Administration, 2014, ICPSR25221V9 CTR BEH
   Centers for Disease Control and Prevention, HIV TEST IMPL GUID C
   Clarke JG, 2013, JAMA INTERN MED, V173, P789, DOI 10.1001/jamainternmed.2013.197
   Darke S, 2008, ADDICTION, V103, P256, DOI 10.1111/j.1360-0443.2007.02115.x
   Davis GL, 2010, GASTROENTEROLOGY, V138, P513, DOI 10.1053/j.gastro.2009.09.067
   Denniston MM, 2014, ANN INTERN MED, V160, P293, DOI 10.7326/M13-1133
   Forsyth SJ, 2014, ADDICTION, V109, P1676, DOI 10.1111/add.12646
   Ginder S, 2013, MORTALITY LOCAL JAIL
   Graham A, 2003, AUST NZ J CRIMINOL, V36, P94, DOI 10.1375/acri.36.1.94
   HARDINGPINK D, 1990, MED SCI LAW, V30, P12, DOI 10.1177/002580249003000104
   Hsu CS, 2013, NEW ENGL J MED, V369, P678, DOI [10.1056/NEJMc1307641, 10.1056/NEJMoa1214853]
   Kinner SA, 2013, ADDICTION, V108, P38, DOI 10.1111/add.12010
   Kohli A, 2014, JAMA-J AM MED ASSOC, V312, P631, DOI 10.1001/jama.2014.7085
   Kowdley KV, 2014, NEW ENGL J MED, V370, P222, DOI 10.1056/NEJMoa1306227
   Liu S, 2014, ANN INTERN MED, V161, P546, DOI 10.7326/M14-0602
   Ly KN, 2012, ANN INTERN MED, V156, P271, DOI 10.7326/0003-4819-156-4-201202210-00004
   Merrall ELC, 2010, ADDICTION, V105, P1545, DOI 10.1111/j.1360-0443.2010.02990.x
   Miller L, 2012, J NATL MED ASSOC, V104, P244, DOI 10.1016/S0027-9684(15)30161-9
   Moyer VA, 2013, ANN INTERN MED, V159, P349, DOI 10.7326/0003-4819-159-5-201309030-00672
   Office of National Drug Control Policy, ADAM 2 DAT SETS
   Office of National Drug Control Policy, 2013, ANN REP ARR DRUG AB
   Office of National Drug Control Policy, DRUG US TYP CIT
   Rein DB, 2012, ANN INTERN MED, V156, P263, DOI 10.7326/0003-4819-156-4-201202210-00378
   Seaman SR, 1998, BRIT MED J, V316, P426, DOI 10.1136/bmj.316.7129.426
   Seymour A, 2000, J FORENSIC SCI, V45, P649
   Smith BD, 2012, ANN INTERN MED, V157, P817, DOI 10.7326/0003-4819-157-9-201211060-00529
   Spaulding AC, 2011, AM J EPIDEMIOL, V173, P479, DOI 10.1093/aje/kwq422
   Spaulding Anne S, 2013, Top Antivir Med, V21, P27
   Strang J, 2013, J URBAN HEALTH, V90, P983, DOI 10.1007/s11524-013-9803-1
   Sulkowski MS, 2014, NEW ENGL J MED, V370, P211, DOI 10.1056/NEJMoa1306218
   Varan AK, 2014, PUBLIC HEALTH REP, V129, P187, DOI 10.1177/003335491412900213
NR 41
TC 23
Z9 24
U1 0
U2 3
PU AMER PUBLIC HEALTH ASSOC INC
PI WASHINGTON
PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA
SN 0090-0036
EI 1541-0048
J9 AM J PUBLIC HEALTH
JI Am. J. Public Health
PD MAY
PY 2015
VL 105
IS 5
BP E51
EP E57
DI 10.2105/AJPH.2014.302546
PG 7
WC Public, Environmental & Occupational Health
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Public, Environmental & Occupational Health
GA CN3AN
UT WOS:000358295600015
PM 25790417
OA Green Published
DA 2024-02-19
ER

PT J
AU Zhai, YY
   Xu, J
   Feng, L
   Liu, QA
   Yao, WF
   Li, H
   Cao, YD
   Cheng, FF
   Bao, BH
   Zhang, L
AF Zhai, Yuanyuan
   Xu, Jia
   Feng, Li
   Liu, Qinan
   Yao, Weifeng
   Li, Hui
   Cao, Yudan
   Cheng, Fangfang
   Bao, Beihua
   Zhang, Li
TI Broad range metabolomics coupled with network analysis for explaining
   possible mechanisms of Er-Zhi-Wan in treating liver-kidney Yin
   deficiency syndrome of Traditional Chinese medicine
SO JOURNAL OF ETHNOPHARMACOLOGY
LA English
DT Article
DE Broad range metabolomics; Serum; Urine; Liver-kidney Yin deficiency
   syndrome; Er-Zhi-Wan; Network analysis
ID PARTIAL LEAST-SQUARES; DIABETES-MELLITUS; URINE; METABOLISM; PLASMA;
   SERUM; ACID; MS; CHROMATOGRAPHY; METABONOMICS
AB Ethnophannacological relevance: Er-Zhi-Wan (EZW), a famous traditional Chinese formulation, is used to prevent, or to treat, various liver and kidney diseases for its actions of replenishing liver and kidney. However, the mechanisms of treating Liver-kidney Yin deficiency syndrome (LKYDS) of EZW have not been comprehensively investigated.
   Aim of the study: In this study, a broad range metabolomics strategy coupled with network analysis was established to investigate possible mechanisms of EZW in treating LKYDS.
   Materials and method: The rat models of LKYDS were established using the mixture of thyroxine and reserpine, and the changes of biochemical indices in serum and histopathology were detected to explore the effects of EZW. Next, a broad range metabolomics strategy based on RPLC-Q-TOF/MS and HILIC-Q-TOF/MS has been developed to find the possible significant metabolites in the serum and urine of LKYDS rats. Then, network analysis was applied to visualize the relationships between identified serum and urine metabolites and in detail to find hub metabolites, which might be responsible for the effect of EZW on rats of LKYDS. Furthermore, the shortest path of "disease gene-pathway protein-metabolite" was built to investigate the possible intervention path of EZW from the systematic perspective.
   Results: Five hub metabolites, namely, arachidonic acid, t-arginine, testosterone, taurine and oxoglutaric acid, were screened out and could be adjusted to recover by EZW. After that, the shortest path starting from disease genes and ending in metabolites were identified and disclosed, and the genes of aging such as CAV1 and ACO1 were selected to explain the pathological mechanism of LKYDS.
   Conclusion: Broad range metabolomics coupled with network analysis could provide another perspective on systematically investigating the molecular mechanism of EZW in treating LKYDS at metabolomics level. In addition, EZW might prevent the pathological process of LKYDS through regulating the disturbed metabolic pathway and the aging genes such as CAV1 and ACO1, which may be potential targets for EZW in the treatment of LKYDS.
C1 [Zhai, Yuanyuan; Xu, Jia; Feng, Li; Liu, Qinan; Yao, Weifeng; Li, Hui; Cao, Yudan; Cheng, Fangfang; Bao, Beihua; Zhang, Li] Nanjing Univ Chinese Med, Sch Pharm, Nanjing 210023, Jiangsu, Peoples R China.
   [Yao, Weifeng; Cao, Yudan; Cheng, Fangfang; Bao, Beihua; Zhang, Li] Nanjing Univ Chinese Med, Jiangsu Collaborat Innovat Ctr Chinese Med Resour, Nanjing 210023, Jiangsu, Peoples R China.
   [Yao, Weifeng; Cao, Yudan; Cheng, Fangfang; Bao, Beihua; Zhang, Li] Nanjing Univ Chinese Med, Natl & Local Collaborat Engn Ctr Chinese Med Reso, Nanjing 210023, Jiangsu, Peoples R China.
C3 Nanjing University of Chinese Medicine; Nanjing University of Chinese
   Medicine; Nanjing University of Chinese Medicine
RP Zhang, L (corresponding author), Nanjing Univ Chinese Med, Sch Pharm, Nanjing 210023, Jiangsu, Peoples R China.
EM yuanyzhai@163.com; njxj0106@126.com; fenglinjucm@163.com;
   liuqinan0728@163.com; yaowf@njucm.edu.cn; missyhui2012@163.com;
   raindc@163.com; ffcheng@njucm.edu.cn; baobh@njutcm.edu.cn;
   zhangli@njucm.edu.cn
RI Yao, Weifeng/I-7394-2013
FU National Natural Science Foundation of China [81573554]; Priority
   Academic Program Development of Jiangsu Higher Education Institutions
   (PAPD); Qing Lan Project of Jiangsu Province; Six Talent Peaks Project
   in Jiangsu Province [2016-YY-026]
FX This work was financially supported by National Natural Science
   Foundation of China (Grant No. 81573554), and A Project Funded by the
   Priority Academic Program Development of Jiangsu Higher Education
   Institutions (PAPD). This research was also supported by a Project
   Funded by the Qing Lan Project of Jiangsu Province and Six Talent Peaks
   Project in Jiangsu Province (2016-YY-026).
CR Aslam R, 2008, CLIN EXP PHARMACOL P, V35, P656, DOI 10.1111/j.1440-1681.2007.04863.x
   Baker SC, 2006, BIOMATERIALS, V27, P3136, DOI 10.1016/j.biomaterials.2006.01.026
   Balliet RM, 2011, CELL CYCLE, V10, P4065, DOI 10.4161/cc.10.23.18254
   Barabási AL, 2011, NAT REV GENET, V12, P56, DOI 10.1038/nrg2918
   Basu S, 2017, BIOINFORMATICS, V33, P1545, DOI 10.1093/bioinformatics/btx012
   Becker KG, 2004, NAT GENET, V36, P431, DOI 10.1038/ng0504-431
   Boccard J, 2013, ANAL CHIM ACTA, V769, P30, DOI 10.1016/j.aca.2013.01.022
   Boudah S, 2014, J CHROMATOGR B, V966, P34, DOI 10.1016/j.jchromb.2014.04.025
   Brandes N, 2013, ELIFE, V2, DOI 10.7554/eLife.00306
   Cheng M, 2011, J ETHNOPHARMACOL, V138, P279, DOI 10.1016/j.jep.2011.09.030
   Dennis EA, 2011, CHEM REV, V111, P6130, DOI 10.1021/cr200085w
   Du J, 2017, EVID-BASED COMPL ALT, V2017, DOI 10.1155/2017/4109828
   Dunn WB, 2011, NAT PROTOC, V6, P1060, DOI 10.1038/nprot.2011.335
   Fadhal E, 2014, BMC SYST BIOL, V8, DOI 10.1186/1752-0509-8-6
   Gao L, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-017-18325-7
   Gromski PS, 2015, ANAL CHIM ACTA, V879, P10, DOI 10.1016/j.aca.2015.02.012
   Guijas C, 2018, ANAL CHEM, V90, P3156, DOI 10.1021/acs.analchem.7b04424
   Head BP, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015697
   Heckman MG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042877
   Hong M, 2017, PLOS ONE, V12, DOI [10.1371/journal.pone.0178514, 10.1371/journal.pone.0176440]
   Horai H, 2010, J MASS SPECTROM, V45, P703, DOI 10.1002/jms.1777
   Iida M, 2018, ECOTOX ENVIRON SAFE, V160, P316, DOI 10.1016/j.ecoenv.2018.05.065
   Jiang M, 2012, J ETHNOPHARMACOL, V140, P634, DOI 10.1016/j.jep.2012.01.033
   Jiang N, 2015, ACTA PHARMACOL SIN, V36, P689, DOI 10.1038/aps.2014.169
   Jiang WY, 2005, TRENDS PHARMACOL SCI, V26, P558, DOI 10.1016/j.tips.2005.09.006
   Kim K, 2009, MOL CELL PROTEOMICS, V8, P558, DOI 10.1074/mcp.M800165-MCP200
   Kwoh CK, 2007, CELL MOL LIFE SCI, V64, P1739, DOI 10.1007/s00018-007-7053-7
   Law V, 2014, NUCLEIC ACIDS RES, V42, pD1091, DOI 10.1093/nar/gkt1068
   Lee S, 2007, AM J CHINESE MED, V35, P11, DOI 10.1142/S0192415X07004576
   Li YH, 2018, NUCLEIC ACIDS RES, V46, pD1121, DOI 10.1093/nar/gkx1076
   Lisanti MP, 2011, CELL CYCLE, V10, P2059, DOI 10.4161/cc.10.13.16233
   Liu XY, 2014, J ETHNOPHARMACOL, V151, P810, DOI 10.1016/j.jep.2013.11.028
   Ma Q, 2018, BIOMED CHROMATOGR, V32, DOI 10.1002/bmc.4144
   Moretto J, 2017, EXP GERONTOL, V90, P52, DOI 10.1016/j.exger.2017.01.023
   Mostafapour S, 2015, ANAL BIOANAL CHEM, V407, P285, DOI 10.1007/s00216-014-8076-1
   Murakami H, 2008, NEUROBIOL AGING, V29, P1093, DOI 10.1016/j.neurobiolaging.2007.01.013
   Nicholson JK, 1999, XENOBIOTICA, V29, P1181, DOI 10.1080/004982599238047
   OGLETREE ML, 1987, FED PROC, V46, P133
   OMAILLE ERL, 1965, J PHYSIOL-LONDON, V180, P67
   Piñero J, 2015, DATABASE-OXFORD, DOI 10.1093/database/bav028
   Rampler E, 2018, ANALYST, V143, P1250, DOI 10.1039/c7an01984j
   Ryan VH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100858
   Simón-Manso Y, 2013, ANAL CHEM, V85, P11725, DOI 10.1021/ac402503m
   Song YN, 2018, ACTA PHARMACOL SIN, V39, P942, DOI 10.1038/aps.2017.101
   Sporková A, 2017, AM J MED SCI, V353, P568, DOI 10.1016/j.amjms.2017.04.009
   Stenvinkel P, 2013, AM J KIDNEY DIS, V62, P339, DOI 10.1053/j.ajkd.2012.11.051
   Tang DQ, 2016, MASS SPECTROM REV, V35, P574, DOI 10.1002/mas.21445
   Thomas R, 2008, CHIN J INTEGR MED, V14, P194, DOI 10.1007/s11655-008-0194-1
   Wang P, 2010, J PHARMACEUT BIOMED, V53, P631, DOI 10.1016/j.jpba.2010.04.032
   Wang XN, 2015, EVID-BASED COMPL ALT, V2015, DOI 10.1155/2015/464969
   Wang YH, 2014, SCIENCE, V346, pS13
   Want EJ, 2010, NAT PROTOC, V5, P1005, DOI 10.1038/nprot.2010.50
   Wishart DS, 2018, NUCLEIC ACIDS RES, V46, pD608, DOI 10.1093/nar/gkx1089
   Wu GY, 2009, AMINO ACIDS, V37, P1, DOI 10.1007/s00726-009-0269-0
   Wu N, 2016, BIOMOL THER, V24, P1, DOI 10.4062/biomolther.2015.078
   Xia Jianguo, 2016, Curr Protoc Bioinformatics, V55, DOI 10.1002/cpbi.11
   Xia JG, 2015, NUCLEIC ACIDS RES, V43, pW251, DOI 10.1093/nar/gkv380
   Xiang Z, 2016, ANAL BIOANAL CHEM, V408, P2607, DOI 10.1007/s00216-016-9368-4
   Xu H, 2012, J ETHNOPHARMACOL, V143, P109, DOI 10.1016/j.jep.2012.06.009
   Yao WF, 2014, ANAL BIOANAL CHEM, V406, P7367, DOI 10.1007/s00216-014-8169-x
   Zhang HY, 2015, J TRADIT CHIN MED, V35, P537
NR 61
TC 14
Z9 20
U1 15
U2 94
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0378-8741
EI 1872-7573
J9 J ETHNOPHARMACOL
JI J. Ethnopharmacol.
PD APR 24
PY 2019
VL 234
BP 57
EP 66
DI 10.1016/j.jep.2019.01.019
PG 10
WC Plant Sciences; Chemistry, Medicinal; Integrative & Complementary
   Medicine; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Plant Sciences; Pharmacology & Pharmacy; Integrative & Complementary
   Medicine
GA HP1CZ
UT WOS:000461404300007
PM 30690072
DA 2024-02-19
ER

PT J
AU BONADONNA, RC
   GROOP, LC
   SIMONSON, DC
   DEFRONZO, RA
AF BONADONNA, RC
   GROOP, LC
   SIMONSON, DC
   DEFRONZO, RA
TI FREE FATTY-ACID AND GLUCOSE-METABOLISM IN HUMAN AGING - EVIDENCE FOR
   OPERATION OF THE RANDLE CYCLE
SO AMERICAN JOURNAL OF PHYSIOLOGY
LA English
DT Article
DE INSULIN; LIPID METABOLISM; SUBSTRATE COMPETITION
ID INSULIN RESISTANCE; ELDERLY SUBJECTS; TURNOVER; OXIDATION; PLASMA; MEN;
   OBESITY; AGE; SENSITIVITY
AB Free fatty acid and glucose metabolism in human aging: evidence for operation of the Randle cycle. Am. J. Physiol. 266 (Endocrinol. Metab. 29): E501-E509, 1994. - We assessed insulin effects on plasma free fatty acid (FFA) and glucose metabolism in seven elderly (71 +/- 2 yr) and in seven younger (21 +/- 1 yr) subjects matched for body weight and body mass index but not for percent body fat (32.4 +/- 3.8% in elderly vs. 20.4 +/- 3.5% in young, P < 0.05), by performing sequential euglycemic clamps at five insulin doses (0.6, 1.5, 3, 6, and 15 pmol.min(-1).kg(-1)) in combination with indirect calorimetry and [1-C-14]palmitate plus [3-H-3]glucose infusion. At baseline, plasma FFA concentration, turnover and oxidation, and total lipid oxidation were all increased in the elderly (897 +/- 107 vs. 412 +/- 50 mu mol/l and 11.2 +/- 1.4 vs. 5.14 +/- 0.86, 3.45 +/- 0.65 vs. 1.37 +/- 0.25, and 4.63 +/- 0.72 vs. 3.01 +/- 0.33 mu mol.min(-1).kg(-1) lean body mass, P < 0.05 for all comparisons), whereas glucose turnover was similar as a result of decreased glucose oxidation (8.2 +/- 1.4 vs. 13 +/- 1.9 mu mol.min(-1).kg(-1) lean body mass, P < 0.05) and increased glucose storage (6.6 +/- 1.4 vs. 1.7 +/- 1.3 mmol.min(-1).kg(-1) lean body mass, P < 0.05). At all insulin infusions, plasma FFA concentration, turnover and oxidation, and total lipid oxidation were higher in the elderly than in the younger group (P < 0.05). However, if normalized per fat mass, all FFA and lipid metabolic fluxes, both in the postabsorptive state and during hyperinsulinemia, were comparable in the two groups. Insulin-mediated inhibition of hepatic glucose production and stimulation of glucose storage were similar in the two groups, but glucose oxidation was lower in the elderly than in the young at all insulin concentrations tested (P < 0.05). Plasma FFA turnover rate and total lipid oxidation were negatively correlated with whole body glucose uptake and oxidation in the two groups (P < 0.05-0.01). Thus, in human aging, abnormalities in insulin regulation of FFA/lipid metabolism may be secondary to increased fat mass and substrate competition between fat and glucose and may play a role in determining a reduction in insulin-mediated glucose oxidation.
C1 UNIV PISA, CNR, INST CLIN PHYSIOL, METAB UNIT, I-156100 PISA, ITALY.
   UNIV HELSINKI, DEPT MED 4, SF-00170 HELSINKI, FINLAND.
   UNIV TEXAS, HLTH SCI CTR, DIV DIABET, SAN ANTONIO, TX 78284 USA.
   AUDIE L MURPHY VET AFFAIRS HOSP, SAN ANTONIO, TX 78284 USA.
C3 Consiglio Nazionale delle Ricerche (CNR); Istituto di Fisiologia Clinica
   (IFC-CNR); University of Pisa; University of Helsinki; University of
   Texas System; University of Texas Health Science Center at San Antonio;
   US Department of Veterans Affairs; Veterans Health Administration (VHA);
   Audie L. Murphy Memorial Veterans Hospital
OI Bonadonna, Riccardo/0000-0002-9809-1005
FU NCRR NIH HHS [M01-RR-01346] Funding Source: Medline; NIDDK NIH HHS
   [DK-24092] Funding Source: Medline
CR BODEN G, 1991, J CLIN INVEST, V88, P960, DOI 10.1172/JCI115399
   BONADONNA RC, 1989, AM J PHYSIOL, V257, pE49, DOI 10.1152/ajpendo.1989.257.1.E49
   BONADONNA RC, 1990, AM J PHYSIOL, V259, pE736, DOI 10.1152/ajpendo.1990.259.5.E736
   BORKAN GA, 1983, J GERONTOL, V38, P673, DOI 10.1093/geronj/38.6.673
   BROUGHTON DL, 1991, EUR J CLIN INVEST, V21, P13, DOI 10.1111/j.1365-2362.1991.tb01352.x
   COBELLI C, 1987, AM J PHYSIOL, V252, pE679, DOI 10.1152/ajpendo.1987.252.5.E679
   DDFRONZO RA, 1979, AM J PHYSIOL, V287, pE214
   DEFRONZO RA, 1979, DIABETES, V28, P1095, DOI 10.2337/diab.28.12.1095
   DELPRATO S, 1990, DIABETOLOGIA, V33, P228, DOI 10.1007/BF00404801
   DEVLIN JT, 1985, DIABETES, V34, P973, DOI 10.2337/diabetes.34.10.973
   DURNIN JVGA, 1974, BRIT J NUTR, V32, P77, DOI 10.1079/BJN19740060
   FERRANNINI E, 1987, NEW ENGL J MED, V317, P350, DOI 10.1056/NEJM198708063170605
   FERRANNINI E, 1988, METABOLISM, V37, P287, DOI 10.1016/0026-0495(88)90110-2
   FINEGOOD DT, 1988, DIABETES, V37, P1025, DOI 10.2337/diabetes.37.8.1025
   FINK RI, 1983, J CLIN INVEST, V71, P1523, DOI 10.1172/JCI110908
   FRAZE E, 1987, J AM GERIATR SOC, V35, P224, DOI 10.1111/j.1532-5415.1987.tb02313.x
   GROOP LC, 1992, AM J PHYSIOL, V263, pE79, DOI 10.1152/ajpendo.1992.263.1.E79
   GROOP LC, 1991, J CLIN INVEST, V87, P83, DOI 10.1172/JCI115005
   HAGENFELDT L, 1975, FED PROC, V34, P2246
   HARRIS M, 1979, DIABETES, V28, P1039
   Heymsfield SB, 1992, OBESITY, P37
   JENSEN MD, 1989, J CLIN INVEST, V83, P1168, DOI 10.1172/JCI113997
   KLEIN S, 1986, J CLIN INVEST, V78, P928, DOI 10.1172/JCI112682
   MCMAHON MM, 1989, DIABETES, V38, P97, DOI 10.2337/diabetes.38.1.97
   METZ R, 1966, ANN INTERN MED, V64, P1042, DOI 10.7326/0003-4819-64-5-1042
   MIKINES KJ, 1989, J APPL PHYSIOL, V66, P695, DOI 10.1152/jappl.1989.66.2.695
   MILES J, 1983, J LIPID RES, V24, P96
   NUUTILA P, 1992, J CLIN INVEST, V89, P1767, DOI 10.1172/JCI115780
   PACINI G, 1988, J AM GERIATR SOC, V36, P317, DOI 10.1111/j.1532-5415.1988.tb02358.x
   PEIRIS AN, 1988, J CLIN ENDOCR METAB, V67, P760, DOI 10.1210/jcem-67-4-760
   RADZIUK J, 1978, AM J PHYSIOL, V234, pE84, DOI 10.1152/ajpendo.1978.234.1.E84
   RANDLE PJ, 1963, LANCET, V1, P785
   ROSENTHAL MJ, 1988, METABOLISM, V37, P645, DOI 10.1016/0026-0495(88)90083-2
   ROWE JW, 1983, J CLIN INVEST, V71, P1581, DOI 10.1172/JCI110914
   SANDBERG H, 1973, J AM GERIATR SOC, V21, P433, DOI 10.1111/j.1532-5415.1973.tb01204.x
   SHIMOKATA H, 1991, DIABETES, V40, P44, DOI 10.2337/diabetes.40.1.44
   WOLFE RR, 1990, AM J CLIN NUTR, V51, P248, DOI 10.1093/ajcn/51.2.248
   WOLFE RR, 1980, BIOMED MASS SPECTROM, V7, P168, DOI 10.1002/bms.1200070407
   Zar JH., 2014, Biostatistical analysis: Pearson new international edition, V5
NR 39
TC 82
Z9 87
U1 0
U2 2
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0002-9513
J9 AM J PHYSIOL
JI Am. J. Physiol.
PD MAR
PY 1994
VL 266
IS 3
BP E501
EP E509
PN 1
PG 9
WC Physiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Physiology
GA NF859
UT WOS:A1994NF85900058
PM 8166272
DA 2024-02-19
ER

PT J
AU Trejo, JI
   Piriz, J
   Llorens-Martin, MV
   Fernandez, AM
   Bolós, M
   LeRoith, D
   Nuñez, A
   Torres-Aleman, I
AF Trejo, J. I.
   Piriz, J.
   Llorens-Martin, M. V.
   Fernandez, A. M.
   Bolos, M.
   LeRoith, D.
   Nunez, A.
   Torres-Aleman, I.
TI Central actions of liver-derived insulin-like growth factor I underlying
   its pro-cognitive effects
SO MOLECULAR PSYCHIATRY
LA English
DT Article
DE cognitive decline; trophic factors; insulin-like growth factor I
ID IGF-I; SYNAPTIC PLASTICITY; DIABETIC-RATS; EXPRESSION; EXERCISE; AGE;
   RECEPTORS; HORMONE; MOUSE; HIPPOCAMPUS
AB Increasing evidence indicates that circulating insulin-like growth factor I (IGF-I) acts as a peripheral neuroactive signal participating not only in protection against injury but also in normal brain function. Epidemiological studies in humans as well as recent evidence in experimental animals suggest that blood-borne IGF-I may be involved in cognitive performance. In agreement with observations in humans, we found that mice with low-serum IGF-I levels due to liver-specific targeted disruption of the IGF-I gene presented cognitive deficits, as evidenced by impaired performance in a hippocampal-dependent spatial-recognition task. Mice with serum IGF-I deficiency also have disrupted long-term potentiation (LTP) in the hippocampus, but not in cortex. Impaired hippocampal LTP was associated with a reduction in the density of glutamatergic boutons that led to an imbalance in the glutamatergic/GABAergic synapse ratio in this brain area. Behavioral and synaptic deficits were ameliorated in serum IGF-I-deficient mice by prolonged systemic administration of IGF-I that normalized the density of glutamatergic boutons in the hippocampus. Altogether these results indicate that liver-derived circulating IGF-I affects crucial aspects of mature brain function; that is, learning and synaptic plasticity, through its trophic effects on central glutamatergic synapses. Declining levels of serum IGF- I during aging may therefore contribute to age-associated cognitive loss.
C1 CSIC, Inst Cajal, Neuroendocrinol Lab, E-28002 Madrid, Spain.
   Mt Sinai Hosp, Dept Med, New York, NY 10029 USA.
   Univ Autonoma Madrid, Sch Med, Dept Neuroanat, Madrid, Spain.
C3 Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto
   Cajal (IC); Icahn School of Medicine at Mount Sinai; Autonomous
   University of Madrid
RP Torres-Aleman, I (corresponding author), CSIC, Inst Cajal, Neuroendocrinol Lab, Avda dr Arce 37, E-28002 Madrid, Spain.
EM torres@cajal.csic.es
RI Nuñez, Angel/Y-9137-2019; Torres-Aleman, Ignacio/A-1613-2008; Trejo,
   Jose Luis/F-5518-2016; Bolos Jurado, Marta/J-7620-2014; Llorens-Martin,
   Maria/R-4613-2017
OI Nuñez, Angel/0000-0002-8013-4812; Torres-Aleman,
   Ignacio/0000-0001-8107-7947; Bolos Jurado, Marta/0000-0003-2652-8607;
   Llorens-Martin, Maria/0000-0001-9129-5198; Piriz,
   Joaquin/0000-0002-4588-6568; Fernandez, Ana M./0000-0001-5160-3854
CR Åberg MAI, 2000, J NEUROSCI, V20, P2896
   Aleman A, 1999, J CLIN ENDOCR METAB, V84, P471, DOI 10.1210/jc.84.2.471
   Alonso-Nanclares L, 2005, NEUROSCIENCE, V134, P59, DOI 10.1016/j.neuroscience.2005.03.038
   Arwert LI, 2005, GROWTH HORM IGF RES, V15, P416, DOI 10.1016/j.ghir.2005.09.001
   Barnes CA, 2000, NEUROBIOL AGING, V21, P613, DOI 10.1016/S0197-4580(00)00163-9
   Biessels GJ, 1998, BRAIN RES, V800, P125, DOI 10.1016/S0006-8993(98)00510-1
   Blair LAC, 1997, NEURON, V19, P421, DOI 10.1016/S0896-6273(00)80950-2
   BREESE CR, 1991, J GERONTOL, V46, pB180, DOI 10.1093/geronj/46.5.B180
   Bülow B, 2002, CLIN ENDOCRINOL, V56, P183, DOI 10.1046/j.0300-0664.2001.01461.x
   Carrascosa C, 2004, BIOMATERIALS, V25, P707, DOI 10.1016/S0142-9612(03)00562-3
   Carro E, 2005, J NEUROSCI, V25, P10884, DOI 10.1523/JNEUROSCI.2909-05.2005
   Carro E, 2001, J NEUROSCI, V21, P5678, DOI 10.1523/JNEUROSCI.21-15-05678.2001
   Carro E, 2000, J NEUROSCI, V20, P2926
   Carro E, 2002, NAT MED, V8, P1390, DOI 10.1038/nm793
   Carro Eva, 2006, Keio Journal of Medicine, V55, P59, DOI 10.2302/kjm.55.59
   Carroll RC, 2001, NAT REV NEUROSCI, V2, P315, DOI 10.1038/35072500
   CASTROALAMANCOS MA, 1994, P NATL ACAD SCI USA, V91, P10203, DOI 10.1073/pnas.91.21.10203
   Cossart R, 2001, NAT NEUROSCI, V4, P52, DOI 10.1038/82900
   Craft S, 2004, LANCET NEUROL, V3, P169, DOI 10.1016/S1474-4422(04)00681-7
   Crawley JN, 1997, PSYCHOPHARMACOLOGY, V132, P107, DOI 10.1007/s002130050327
   de la Vega AG, 2001, NEUROREPORT, V12, P1293, DOI 10.1097/00001756-200105080-00047
   DELAVEGA VG, 1998, MODULATORY EFFECTS I, P1784
   DErcole AJ, 1996, MOL NEUROBIOL, V13, P227, DOI 10.1007/BF02740625
   Dik MG, 2003, NEUROBIOL AGING, V24, P573, DOI 10.1016/S0197-4580(02)00136-7
   Ding Q, 2006, NEUROSCIENCE, V140, P823, DOI 10.1016/j.neuroscience.2006.02.084
   Donahue CP, 2006, P NATL ACAD SCI USA, V103, P6031, DOI 10.1073/pnas.0507776103
   Dunger D, 2004, HORM RES, V62, P101, DOI 10.1159/000080767
   Fernandez AM, 1999, EUR J NEUROSCI, V11, P2019, DOI 10.1046/j.1460-9568.1999.00623.x
   Fernandez AM, 1998, P NATL ACAD SCI USA, V95, P1253, DOI 10.1073/pnas.95.3.1253
   Fratiglioni L, 2004, LANCET NEUROL, V3, P343, DOI 10.1016/S1474-4422(04)00767-7
   Kalmijn S, 2000, J CLIN ENDOCR METAB, V85, P4551, DOI 10.1210/jc.85.12.4551
   Kamenetz F, 2003, NEURON, V37, P925, DOI 10.1016/S0896-6273(03)00124-7
   Kanzaki M, 1999, NAT CELL BIOL, V1, P165, DOI 10.1038/11086
   Kleschevnikov AM, 2004, J NEUROSCI, V24, P8153, DOI 10.1523/JNEUROSCI.1766-04.2004
   Koopmans GC, 2006, EUR J NEUROSCI, V23, P1035, DOI 10.1111/j.1460-9568.2006.04627.x
   Lee HK, 2005, NAT NEUROSCI, V8, P1657, DOI 10.1038/nn1586
   Lijffijt M, 2003, NEUROSCI LETT, V353, P123, DOI 10.1016/j.neulet.2003.09.028
   Lopez-Lopez C, 2004, P NATL ACAD SCI USA, V101, P9833, DOI 10.1073/pnas.0400337101
   Lupien SB, 2003, J NEUROSCI RES, V74, P512, DOI 10.1002/jnr.10791
   Man HY, 2000, NEURON, V25, P649, DOI 10.1016/S0896-6273(00)81067-3
   Markowska AL, 1998, NEUROSCIENCE, V87, P559, DOI 10.1016/S0306-4522(98)00143-2
   MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4
   MYHRER T, 1995, BRAIN RES BULL, V36, P499, DOI 10.1016/0361-9230(94)00237-U
   Nguyen PV, 2000, LEARN MEMORY, V7, P170, DOI 10.1101/lm.7.3.170
   Nuñez A, 2003, J NEUROPHYSIOL, V89, P3008, DOI 10.1152/jn.00089.2003
   Okereke O, 2007, NEUROBIOL AGING, V28, P135, DOI 10.1016/j.neurobiolaging.2005.10.012
   Paxinos G., 1997, RAT BRAIN STEROTAXIC, VThird
   Pollak DD, 2005, BEHAV BRAIN RES, V165, P240, DOI 10.1016/j.bbr.2005.07.028
   Pulford BE, 1999, EXP NEUROL, V159, P114, DOI 10.1006/exnr.1999.7143
   Ramsey MM, 2005, J NEUROPHYSIOL, V94, P247, DOI 10.1152/jn.00768.2004
   Rollero A, 1998, NEUROPSYCHOBIOLOGY, V38, P73, DOI 10.1159/000026520
   Sjögren K, 1999, P NATL ACAD SCI USA, V96, P7088, DOI 10.1073/pnas.96.12.7088
   Skeberdis VA, 2001, P NATL ACAD SCI USA, V98, P3561, DOI 10.1073/pnas.051634698
   Snyder EM, 2005, NAT NEUROSCI, V8, P1051, DOI 10.1038/nn1503
   Sonntag WE, 2000, BRAIN RES BULL, V51, P331, DOI 10.1016/S0361-9230(99)00259-2
   Svensson J, 2006, J ENDOCRINOL, V189, P617, DOI 10.1677/joe.1.06631
   Torres-Aleman I, 2000, MOL NEUROBIOL, V21, P153, DOI 10.1385/MN:21:3:153
   TORRESALEMAN I, 1994, J NEUROSCI RES, V39, P117, DOI 10.1002/jnr.490390202
   Trejo JL, 2004, GROWTH HORM IGF RES, V14, pS39, DOI 10.1016/j.ghir.2004.03.010
   Trejo JL, 2001, J NEUROSCI, V21, P1628, DOI 10.1523/JNEUROSCI.21-05-01628.2001
   Wang YT, 2000, NEURON, V25, P635, DOI 10.1016/S0896-6273(00)81066-1
   Yakar S, 1999, P NATL ACAD SCI USA, V96, P7324, DOI 10.1073/pnas.96.13.7324
   Yakar S, 2001, DIABETES, V50, P1110, DOI 10.2337/diabetes.50.5.1110
   ZONA C, 1995, NEUROSCI LETT, V186, P75, DOI 10.1016/0304-3940(95)11284-4
NR 64
TC 165
Z9 190
U1 0
U2 14
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1359-4184
EI 1476-5578
J9 MOL PSYCHIATR
JI Mol. Psychiatr.
PD DEC
PY 2007
VL 12
IS 12
BP 1118
EP 1128
DI 10.1038/sj.mp.4002076
PG 11
WC Biochemistry & Molecular Biology; Neurosciences; Psychiatry
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Neurosciences & Neurology; Psychiatry
GA 235WO
UT WOS:000251265200009
PM 17848918
DA 2024-02-19
ER

PT J
AU Dutta, D
   Sharma, R
AF Dutta, D
   Sharma, R
TI Age-dependent dietary regulation of glucocorticoid receptors in the
   liver of mice
SO BIOGERONTOLOGY
LA English
DT Article
DE aging; dietary restriction; glucocorticoid receptor; mice
ID CALORIC RESTRICTION; RAT-LIVER; GENE-EXPRESSION; BINDING; MECHANISM;
   CHROMATIN; RODENTS; COMPLEX; STRESS
AB Dietary restriction (DR) increases the resistance to different stresses, retards various age-related diseases and extends life span in a variety of animals. Here we have investigated the effect of DR (alternate days of feeding for 3 months) on glucocorticoid receptors (GRs) in the liver of adult (5 months) and old (20 months) male mice. A significant decrease was observed in the level of receptors in old mice (25%) as compared to the adult ones. DR subjected mice of both age groups showed a marked increase in the GR concentration (37% in adult and 31% in old mice) as compared to the ad libitum (AL) fed mice, whereas the affinity remained the same in both groups of animals at both ages. Scatchard analyses and the protein slot blot experiment confirmed the increase in the receptor level in AL and DR fed animals for both age groups. The magnitude of heat and salt activation of GR was higher in the adult mice as compared to the old mice who were fed AL. DR, however, significantly increased (40%) the magnitude of activation of GR in the older mice as compared to the AL fed animals, whereas no such change was observed in the adult animals. Further, DNase I digestion and extraction of nuclear bound GR-complexes showed a higher degree of extraction in adult animals (57%-59%) as compared to the old (31%-33%) animals. Mice subjected to DR revealed no significant change at either age. These findings indicate that DR regulates GR in an age-dependent manner and that it may allow animals to better adapt to metabolic regulation in older ages.
C1 NE Hill Univ, Dept Biochem, Shillong 793022, Meghalaya, India.
C3 North Eastern Hill University
RP Sharma, R (corresponding author), NE Hill Univ, Dept Biochem, Shillong 793022, Meghalaya, India.
EM rsharma@nehu.ac.in
CR Adcock I M, 2000, Monaldi Arch Chest Dis, V55, P256
   Bamberger CM, 1996, ENDOCR REV, V17, P245, DOI 10.1210/er.17.3.245
   Barnes PJ, 1998, CLIN SCI, V94, P557, DOI 10.1042/cs0940557
   BEATO M, 1972, J BIOL CHEM, V247, P7890
   Biola A, 2000, PRESSE MED, V29, P215
   BODINE PV, 1988, J BIOL CHEM, V263, P3501
   Bosscher KD, 2003, ENDOCR REV, V24, P488
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   Burton K., 1968, Methods in Enzymology XIIB, V12, P163
   CHATURVEDI MM, 1983, BIOCHEM INT, V6, P357
   Chaurasia P, 1997, MECH AGEING DEV, V95, P63, DOI 10.1016/S0047-6374(96)01843-X
   Dhahbi JM, 1999, AM J PHYSIOL-ENDOC M, V277, pE352, DOI 10.1152/ajpendo.1999.277.2.E352
   Djordjevic-Markovic R, 1999, EXP GERONTOL, V34, P971, DOI 10.1016/S0531-5565(99)00067-4
   EBERHARDT NL, 1978, ENDOCRINOLOGY, V102, P556, DOI 10.1210/endo-102-2-556
   KALIMI M, 1981, MECH AGEING DEV, V17, P19, DOI 10.1016/0047-6374(81)90125-1
   KALIMI M, 1975, J BIOL CHEM, V250, P1080
   KALIMI M, 1988, ANN NY ACAD SCI, V521, P149
   KANUNGO MS, 1994, GENES AGING
   Lane MA, 1996, P NATL ACAD SCI USA, V93, P4159, DOI 10.1073/pnas.93.9.4159
   LEAKEY JEA, 1994, ANN NY ACAD SCI, V719, P171, DOI 10.1111/j.1749-6632.1994.tb56828.x
   Lee CK, 1999, SCIENCE, V285, P1390, DOI 10.1126/science.285.5432.1390
   Lee J, 2000, EXP NEUROL, V166, P435, DOI 10.1006/exnr.2000.7512
   LYNN TF, 1998, ENV HLTH PERSPECT, V106, P313
   MASORO EJ, 1993, J AM GERIATR SOC, V41, P994, DOI 10.1111/j.1532-5415.1993.tb06767.x
   McEwan IJ, 1997, BIOESSAYS, V19, P153, DOI 10.1002/bies.950190210
   McNally JG, 2000, SCIENCE, V287, P1262, DOI 10.1126/science.287.5456.1262
   MERRY BJ, 1999, STUDIES AGING, P143
   Ranhotra HS, 2001, BIOGERONTOLOGY, V2, P245, DOI 10.1023/A:1013218528102
   SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x
   SHARMA R, 1987, BIOCHIM BIOPHYS ACTA, V930, P237, DOI 10.1016/0167-4889(87)90036-X
   Sohal RS, 1996, SCIENCE, V273, P59, DOI 10.1126/science.273.5271.59
   Weindruch R, 2001, J NUTR, V131, p918S, DOI 10.1093/jn/131.3.918S
   Weindruch R., 1988, RETARDATION AGING DI
   Whorwood CB, 2001, ENDOCRINOLOGY, V142, P2854, DOI 10.1210/en.142.7.2854
NR 34
TC 12
Z9 13
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1389-5729
EI 1573-6768
J9 BIOGERONTOLOGY
JI Biogerontology
PD JUN
PY 2004
VL 5
IS 3
BP 177
EP 184
DI 10.1023/B:BGEN.0000031155.60748.0a
PG 8
WC Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Geriatrics & Gerontology
GA 827VA
UT WOS:000221930100004
PM 15190187
DA 2024-02-19
ER

PT J
AU Hamaguchi, Y
   Mori, A
   Uemura, T
   Ogawa, K
   Fujimoto, Y
   Okajima, H
   Kaido, T
   Uemoto, S
AF Hamaguchi, Y.
   Mori, A.
   Uemura, T.
   Ogawa, K.
   Fujimoto, Y.
   Okajima, H.
   Kaido, T.
   Uemoto, S.
TI Incidence and risk factors for herpes zoster in patients undergoing
   liver transplantation
SO TRANSPLANT INFECTIOUS DISEASE
LA English
DT Article
DE herpes zoster; liver transplantation; incidence rate; risk factors;
   mycophenolate mofetil
ID MYCOPHENOLATE-MOFETIL; POSTHERPETIC NEURALGIA; KIDNEY-TRANSPLANTATION;
   RENAL-TRANSPLANTATION; VARICELLA; METAANALYSIS; INFECTION; GRAFT;
   CYTOMEGALOVIRUS; COMPLICATIONS
AB BackgroundHerpes zoster (HZ) is the most common manifestation of latent varicella zoster virus reactivation, which occurs naturally as a result of aging or in immunocompromised patients. Solid organ transplant recipients are at increased risk for HZ owing to their chronic immunosuppression. Although several reports investigated risk factors for the development of HZ in heart or renal transplantation, data in liver transplantation (LT) are limited.
   MethodsWe evaluated clinical data retrospectively in 377 adult patients undergoing LT between January 2005 and December 2012 in our institution. We analyzed the incidence rate of HZ and the standardized incidence ratio (SIR) by comparing with the general Japanese population. We additionally investigated risk factors for HZ after LT.
   ResultsHZ developed in 27 (7.16%) of the 377 patients after LT. The incidence rate of HZ after LT was 17.83 per 1000 person-years, which was significantly higher than in the general Japanese population (SIR = 4.61; 95% confidence interval [CI], 4.13-5.14). Multivariate analysis showed that older age (hazard ratio [HR] = 3.95; P < 0.001) and exposure to mycophenolate mofetil (HR = 3.03; P = 0.007) were independent risk factors for HZ after LT.
   ConclusionsThis is the first and largest study, to our knowledge, to investigate the incidence rate of HZ and risk factors for development of HZ after LT in the Japanese population. Further investigations to focus on immunosuppressive regimens to reduce the risk for HZ incidence in this high-risk population could establish a new protocol of immunosuppression after LT.
C1 [Hamaguchi, Y.; Mori, A.; Uemura, T.; Ogawa, K.; Fujimoto, Y.; Okajima, H.; Kaido, T.; Uemoto, S.] Kyoto Univ, Grad Sch Med, Div Hepatobiliary Pancreat & Transplant Surg, Dept Surg, Kyoto 6068507, Japan.
C3 Kyoto University
RP Mori, A (corresponding author), Kyoto Univ, Grad Sch Med, Div Hepatobiliary Pancreat & Transplant Surg, Dept Surg,Sakyo Ku, 54 Kawahara Cho, Kyoto 6068507, Japan.
EM akr@kuhp.kyoto-u.ac.jp
CR Chapman JR, 2011, AM J TRANSPLANT, V11, P693, DOI 10.1111/j.1600-6143.2011.03504.x
   Fishman JA, 2013, AM J TRANSPLANT, V13, P1, DOI 10.1111/ajt.12002
   Geissler EK, 2009, GUT, V58, P452, DOI 10.1136/gut.2008.163527
   Gnann JW, 2002, NEW ENGL J MED, V347, P340, DOI 10.1056/NEJMcp1302674
   Herrero JI, 2004, LIVER TRANSPLANT, V10, P1140, DOI 10.1002/lt.20219
   Hori T, 2012, CLIN TRANSPLANT, V26, pE324, DOI 10.1111/j.1399-0012.2012.01664.x
   Inomata Y, 2000, TRANSPLANTATION, V69, P258, DOI 10.1097/00007890-200001270-00011
   Ito T, 2003, TRANSPLANTATION, V76, P158, DOI 10.1097/01.TP.0000072372.42396.47
   Johnson RW, 2010, BMC MED, V8, DOI 10.1186/1741-7015-8-37
   Ko GB, 2013, TRANSPL INFECT DIS, V15, P416, DOI 10.1111/tid.12091
   Koo S, 2014, TRANSPL INFECT DIS, V16, P17, DOI 10.1111/tid.12149
   Lauzurica R, 2003, TRANSPLANT P, V35, P1758, DOI 10.1016/S0041-1345(03)00684-5
   Levitsky J, 2005, LIVER TRANSPLANT, V11, P320, DOI 10.1002/lt.20356
   Manuel O, 2008, J HEART LUNG TRANSPL, V27, P11, DOI 10.1016/j.healun.2007.09.028
   McAlister VC, 2006, AM J TRANSPLANT, V6, P1578, DOI 10.1111/j.1600-6143.2006.01360.x
   Miller GG, 2007, AM J TRANSPLANT, V7, P741, DOI 10.1111/j.1600-6143.2006.01718.x
   Moore J, 2009, TRANSPLANTATION, V87, P591, DOI 10.1097/TP.0b013e318195a421
   Morioka D, 2007, ANN SURG, V245, P315, DOI 10.1097/01.sla.0000236600.24667.a4
   Nalamachu S, 2012, DRUG AGING, V29, P863, DOI 10.1007/s40266-012-0014-3
   Ogura Y, 2010, LIVER TRANSPLANT, V16, P718, DOI 10.1002/lt.22059
   Oxman MN, 2009, J AM OSTEOPATH ASSOC, V109, pS13
   Pergam SA, 2011, TRANSPL INFECT DIS, V13, P15, DOI 10.1111/j.1399-3062.2010.00547.x
   Pourfarziani V, 2007, TRANSPL P, V39, P1237, DOI 10.1016/j.transproceed.2007.03.006
   Salah A, 2014, LIVER TRANSPLANT, V20, P200, DOI 10.1002/lt.23789
   Satoh S, 2005, TRANSPL P, V37, P1751, DOI 10.1016/j.transproceed.2005.03.072
   tersMeulen CG, 2000, NEPHROL DIAL TRANSPL, V15, P711
   Textor SC, 2000, LIVER TRANSPLANT, V6, P521, DOI 10.1053/jlts.2000.9737
   Toyama N, 2009, J MED VIROL, V81, P2053, DOI 10.1002/jmv.21599
   Ueda Y, 2014, TRANSPLANTATION, V97, P344, DOI 10.1097/01.TP.0000435702.61642.0a
   Xing S, 2014, CLIN BIOCHEM, V47, P663, DOI 10.1016/j.clinbiochem.2014.01.014
   Yawn BP, 2013, NEUROLOGY, V81, P928, DOI 10.1212/WNL.0b013e3182a3516e
   Zmonarski SC, 2003, TRANSPLANT P, V35, P2205, DOI 10.1016/S0041-1345(03)00764-4
   Zuckerman RA, 2013, AM J TRANSPLANT, V13, P55, DOI 10.1111/ajt.12003
NR 33
TC 24
Z9 27
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1398-2273
EI 1399-3062
J9 TRANSPL INFECT DIS
JI Transpl. Infect. Dis.
PD OCT
PY 2015
VL 17
IS 5
BP 671
EP 678
DI 10.1111/tid.12425
PG 8
WC Immunology; Infectious Diseases; Transplantation
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology; Infectious Diseases; Transplantation
GA CT1YB
UT WOS:000362597900006
PM 26201686
DA 2024-02-19
ER

PT J
AU KRETZSCHMAR, M
   MULLER, D
   HUBSCHER, J
   MARIN, E
   KLINGER, W
AF KRETZSCHMAR, M
   MULLER, D
   HUBSCHER, J
   MARIN, E
   KLINGER, W
TI INFLUENCE OF AGING, TRAINING AND ACUTE PHYSICAL EXERCISE ON PLASMA
   GLUTATHIONE AND LIPID PEROXIDES IN MAN
SO INTERNATIONAL JOURNAL OF SPORTS MEDICINE
LA English
DT Article
DE AGE; EXERCISE; GLUTATHIONE; LIPID PEROXIDES; MAN; PLASMA; TRAINING
ID RAT-LIVER; DISULFIDE; CIRRHOSIS; SYSTEM
AB In trained (long-distance runners) and untrained volunteers aged 22 to 57 years, basal plasma glutathione (GSH) concentration decreased significantly with increasing age. In most age groups basal GSH concentration of oxidized glutathione (GSSG) and lipid peroxides (LPO) was not influenced either by age or by training. Following acute physical exercise (bicycle ergometric test), which was maximal for each person and thus different in trained and untrained persons, plasma GSH, GSSG, and LPO concentrations were not changed at all in untrained volunteers. In trained persons, however, GSH concentration was significantly decreased by about 30%. Surprisingly, we observed a decrease in plasma LPO content by about 40%. GSSG content was not altered. The comparison with some physical-physiological parameters indicates that the changes in GSH and LPO concentrations depend on the extent of acute physical exercise rather than on previous training. Alterations of GSH and LPO in plasma could be of physiologic significance.
C1 UNIV KUOPIO, DEPT PHYSIOL, KUOPIO, FINLAND.
   UNIV JENA, DEPT SPORTS MED, O-6900 JENA, GERMANY.
C3 University of Eastern Finland; Friedrich Schiller University of Jena
RP KRETZSCHMAR, M (corresponding author), UNIV JENA, INST PHARMACOL & TOXICOL, LOBDERSTR 1, O-6900 JENA, GERMANY.
CR ADAMS JD, 1983, J PHARMACOL EXP THER, V227, P749
   ADAMS JD, 1987, CLIN CHEM, V33, P1675
   ALESSIO HM, 1988, J APPL PHYSIOL, V64, P1333, DOI 10.1152/jappl.1988.64.4.1333
   Bergmeyer H. U., 1974, METHODS ENZYMATIC AN
   BURGUNDER JM, 1987, EUR J CLIN INVEST, V17, P408, DOI 10.1111/j.1365-2362.1987.tb01135.x
   DEGROOT H, 1987, CHEM PHYS LIPIDS, V44, P209, DOI 10.1016/0009-3084(87)90051-X
   ESTRELA JM, 1988, AM J PHYSIOL, V255, pE801, DOI 10.1152/ajpendo.1988.255.6.E801
   FRENKL R, 1980, EUR J APPL PHYSIOL O, V44, P135, DOI 10.1007/BF00421091
   FRENKL R, 1980, J SPORT MED PHYS FIT, V20, P371
   GOHIL K, 1988, J APPL PHYSIOL, V64, P115, DOI 10.1152/jappl.1988.64.1.115
   HENRIKSEN JH, 1988, LIVER, V8, P88
   JENKINS RR, 1988, SPORTS MED, V5, P156, DOI 10.2165/00007256-198805030-00003
   JI LL, 1988, ARCH BIOCHEM BIOPHYS, V263, P150, DOI 10.1016/0003-9861(88)90623-6
   KAPLOWITZ N, 1985, ANNU REV PHARMACOL, V25, P715, DOI 10.1146/annurev.pharmtox.25.1.715
   KLINGER W, 1986, ARCH TOXICOL, P382
   KRETZSCHMAR M, 1989, EXP PATHOL-JENA, V36, P113, DOI 10.1016/S0232-1513(89)80127-6
   KRETZSCHMAR M, 1990, EXP PATHOL-JENA, V38, P145, DOI 10.1016/S0232-1513(11)80201-X
   LEW H, 1985, FEBS LETT, V185, P262, DOI 10.1016/0014-5793(85)80919-4
   LOVLIN R, 1987, EUR J APPL PHYSIOL, V56, P313, DOI 10.1007/BF00690898
   MARIN E, 1989, CYTOCHROME P-450 : BIOCHEMISTRY AND BIOPHYSICS /, P887
   MARIN E, IN PRESS ACTA PHYSL
   RECKNAGEL RO, 1966, EXP MOL PATHOL, V5, P108, DOI 10.1016/0014-4800(66)90008-6
   SIES H, 1985, BIOCHEM J, V226, P545, DOI 10.1042/bj2260545
   YAGI K, 1987, CHEM PHYS LIPIDS, V45, P337, DOI 10.1016/0009-3084(87)90071-5
NR 24
TC 73
Z9 81
U1 0
U2 2
PU GEORG THIEME VERLAG KG
PI STUTTGART
PA RUDIGERSTR 14, D-70469 STUTTGART, GERMANY
SN 0172-4622
EI 1439-3964
J9 INT J SPORTS MED
JI Int. J. Sports Med.
PD APR
PY 1991
VL 12
IS 2
BP 218
EP 222
DI 10.1055/s-2007-1024671
PG 5
WC Sport Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Sport Sciences
GA FM573
UT WOS:A1991FM57300010
PM 1860748
DA 2024-02-19
ER

PT J
AU DESLAURIERS, N
   GAUDREAU, P
   ABRIBAT, T
   RENIER, G
   PETITCLERC, D
   BRAZEAU, P
AF DESLAURIERS, N
   GAUDREAU, P
   ABRIBAT, T
   RENIER, G
   PETITCLERC, D
   BRAZEAU, P
TI DYNAMICS OF GROWTH-HORMONE RESPONSIVENESS TO GROWTH-HORMONE
   RELEASING-FACTOR IN AGING RATS - PERIPHERAL AND CENTRAL INFLUENCES
SO NEUROENDOCRINOLOGY
LA English
DT Article
DE AGING; GROWTH HORMONE; GROWTH HORMONE RELEASING FACTOR; SOMATOSTATIN;
   INSULIN-LIKE GROWTH FACTOR-I
ID AGE-RELATED CHANGE; OLD FEMALE RATS; PITUITARY-RESPONSE;
   ANTERIOR-PITUITARY; SECRETION; SOMATOSTATIN; INVITRO; GH; SOMATOCRININ;
   STIMULATION
AB The in vivo and in vitro dynamics of somatotroph responsiveness to rGRF (1-29) NH2 (rat growth hormone releasing factor) were evaluated in 2-, 4-, 8-, 12-, and 20-month-old male rats.  In vivo, using pentobarbital-anesthetized animals, we observed that the rGH (rat growth hormone) responsiveness to 0.4 and 1.6-mu-g/kg rGRF started to decline at the higher dose in 12-month-old rats and was completely blunted at both rGRF doses in 20-month-old animals.  In vitro, using freshly dispersed perifused pituitary cells, we also documented a decrease of rGRF-induced rGH secretion in 12- and 20-month-old rats.  Moreover, as the animals aged, the rGRF-induced rGH secretion was differentially affected by the inhibiting action of somatostatin (p < 0.001), suggesting a loss of pituitary sensitivity to somatostatin in the presence of a high concentration of rGRF.  The pituitary rGH content increased until rats reached 12 months of age, but was diminished in 20-month-old rats.  In contrast, the pituitary somatostatin content increased twofold in 20-month-old rats as compared with younger rats.  The hypothalamic somatostatin content was highest in 8-month-old rats and only slightly diminished in 20-month-old animals.  Finally, plasma insulin-like growth factor I concentrations were highest in 8-month-old rats and lowest in 20-month-old animals.  Altogether, these results indicate that the physiological loss of somatotroph responsiveness associated with the process of aging starts around 12 months of age.  Our data also suggest that sequential rises and falls of GH, somatostatin, and insulin-like growth factor I concentrations along the hypothalamo-pituitary-liver axis that occur from 8 to 20 months of age could contribute to the phenomenon.  Finally, the significant accumulation of somatostatin-like immunoreactivity in the pituitary may be considered as an aggravating factor.
C1 NOTRE DAME HOSP,RES CTR,NEUROENDOCRINOL LAB,1560 SHERBROOKE E,ROOM M-5218,MONTREAL H2L 4M1,QUEBEC,CANADA.
   UNIV MONTREAL,MONTREAL H3C 3J7,QUEBEC,CANADA.
   AGR CANADA,RES CTR,LENOXVILLE,QUEBEC,CANADA.
C3 Universite de Montreal; Universite de Montreal; Agriculture & Agri Food
   Canada
CR ABRIBAT T, 1990, DOMEST ANIM ENDOCRIN, V7, P93, DOI 10.1016/0739-7240(90)90058-8
   BENNETT JC, 1979, INBRED GENETICALLY D, V1, P277
   BERELOWITZ M, 1981, SCIENCE, V212, P1279, DOI 10.1126/science.6262917
   BRAZEAU P, 1974, ENDOCRINOLOGY, V94, P184, DOI 10.1210/endo-94-1-184
   BRAZEAU P, 1978, METABOLISM, V27, P1133, DOI 10.1016/0026-0495(78)90031-8
   BRAZEAU P, 1982, P NATL ACAD SCI-BIOL, V79, P7909, DOI 10.1073/pnas.79.24.7909
   CEDA GP, 1986, ENDOCRINOLOGY, V118, P2109, DOI 10.1210/endo-118-5-2109
   DESLAURIERS N, 1988, REGUL PEPTIDES, V20, P261, DOI 10.1016/0167-0115(88)90082-1
   FINKELSTEIN JW, 1972, J CLIN ENDOCR METAB, V35, P665, DOI 10.1210/jcem-35-5-665
   FLORINI JR, 1981, MECH AGEING DEV, V15, P165, DOI 10.1016/0047-6374(81)90072-5
   GE F, 1989, J ENDOCRINOL, V123, P53, DOI 10.1677/joe.0.1230053
   GICK GG, 1984, P NATL ACAD SCI-BIOL, V81, P1553, DOI 10.1073/pnas.81.5.1553
   HO KY, 1987, J CLIN ENDOCR METAB, V64, P51, DOI 10.1210/jcem-64-1-51
   JOUBERTBRESSION D, 1989, J CLIN ENDOCR METAB, V68, P572, DOI 10.1210/jcem-68-3-572
   LING N, 1985, QUO VADIS, V10, P309
   LOWRY OH, 1951, J BIOL CHEM, V193, P265
   MEITES J, 1990, ENDOCRINE FUNCTION AND AGING, P1
   MEITES J, 1987, EXP GERONTOL, V22, P1, DOI 10.1016/0531-5565(87)90010-6
   MOREL G, 1983, NEUROENDOCRINOLOGY, V36, P291, DOI 10.1159/000123470
   NIIMI M, 1985, ENDOCRINOL JAPON, V32, P559
   RENIER G, 1989, NEUROENDOCRINOLOGY, V50, P454, DOI 10.1159/000125262
   ROBBERECHT P, 1986, NEUROENDOCRINOLOGY, V44, P429, DOI 10.1159/000124682
   RUDMAN D, 1985, J AM GERIATR SOC, V33, P800, DOI 10.1111/j.1532-5415.1985.tb04195.x
   SINHA YN, 1972, ENDOCRINOLOGY, V91, P784, DOI 10.1210/endo-91-3-784
   SONNTAG WE, 1980, ENDOCRINOLOGY, V107, P1875, DOI 10.1210/endo-107-6-1875
   SONNTAG WE, 1988, NEUROENDOCRINOLOGY, V47, P482, DOI 10.1159/000124959
   SONNTAG WE, 1983, ENDOCRINOLOGY, V113, P2305, DOI 10.1210/endo-113-6-2305
   SONNTAG WE, 1986, BRAIN RES, V380, P229, DOI 10.1016/0006-8993(86)90217-9
   SPIK K, 1989, NEUROENDOCRINOLOGY, V50, P489, DOI 10.1159/000125269
   STACHURA ME, 1977, ENDOCRINOLOGY, V101, P1044, DOI 10.1210/endo-101-4-1044
   TAKAHASHI S, 1987, NEUROENDOCRINOLOGY, V46, P137, DOI 10.1159/000124810
   TAKAHASHI S, 1987, P SOC EXP BIOL MED, V186, P229
   WEHRENBERG WB, 1982, BIOCHEM BIOPH RES CO, V109, P382, DOI 10.1016/0006-291X(82)91732-6
   WEHRENBERG WB, 1983, NEUROENDOCRINOLOGY, V37, P463, DOI 10.1159/000123594
NR 34
TC 33
Z9 34
U1 0
U2 0
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0028-3835
J9 NEUROENDOCRINOLOGY
JI Neuroendocrinology
PD MAY
PY 1991
VL 53
IS 5
BP 439
EP 446
DI 10.1159/000125755
PG 8
WC Endocrinology & Metabolism; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Endocrinology & Metabolism; Neurosciences & Neurology
GA FK785
UT WOS:A1991FK78500002
PM 1678494
DA 2024-02-19
ER

PT J
AU Shimma, S
   Sugiura, Y
   Hayasaka, T
   Hoshikawa, Y
   Noda, T
   Setou, M
AF Shimma, Shuichi
   Sugiura, Yuki
   Hayasaka, Takahiro
   Hoshikawa, Yutaka
   Noda, Tetsuo
   Setou, Mitsutoshi
TI MALDI-based imaging mass spectrometry revealed abnormal distribution of
   phospholipids in colon cancer liver metastasis
SO JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL
   AND LIFE SCIENCES
LA English
DT Article; Proceedings Paper
CT 31st Annual Meeting of the
   Japanese-Society-for-Biomedical-Mass-Spectrometry
CY SEP 28-29, 2006
CL Nagoya, JAPAN
SP Japanese Soc Biomed Mass Spectrometry
DE imaging mass spectrometry; colon cancer; phospholipids; sphingomyelin;
   aging; molecular imaging
ID PROTEINS; TISSUE; BRAIN; PEPTIDES; LOCALIZATION; EXPRESSION; SECTIONS
AB We present the results of matrix-assisted laser desorption/ionization (MALDI) imaging and direct molecular identification using tandem mass spectrometry (MS/MS) in colon cancer liver metastasis. Cancer tissue was removed from a Japanese patient and frozen immediately without any fixations. The sections were sliced to a thickness of 3 mu m. The matrix for lipid ionization was 2,6-dihydroxy acetophenone. The matrix solution was applied with an airbrush into a thin uniform matrix layer on the tissue surface. After two-dimensional laser scanning, the images were reconstructed as a function of m/z from a few hundred obtained spectra. In the obtained images, the existence of molecules was represented by a pseudo-color corresponding to the signal intensity. In a feasibility study, we picked up a localized signal, m/z 725 in a cancerous area. The MS/MS result suggested that m/z 725 was sphingomyelin(16:0)+Na. Thus, we successfully show the feasibility of MALDI imaging as a tool for the analysis of pathological specimens. (C) 2007 Elsevier B.V. All rights reserved.
C1 Natl Inst Natur Sci, Okazaki Inst Integrat Biosci, Okazaki, Aichi 4448585, Japan.
   Grad Univ Adv Studies, Sch Life Sci, Okazaki, Aichi 4448585, Japan.
   MITILS, Machida, Tokyo 1948511, Japan.
   Tokyo Inst Technol, Dept Biosci & Biotechnol, Yokohama, Kanagawa 2268501, Japan.
   Japanese Fdn Canc Res, Genome Ctr, Tokyo, Japan.
C3 National Institutes of Natural Sciences (NINS) - Japan; Okazaki
   Institute for Integrative Bioscience (OIIB); Graduate University for
   Advanced Studies - Japan; Mitsubishi Kagaku Institute of Life Sciences
   (MITILS); Tokyo Institute of Technology; Japanese Foundation for Cancer
   Research
RP Setou, M (corresponding author), Natl Inst Natur Sci, Okazaki Inst Integrat Biosci, Okazaki, Aichi 4448585, Japan.
EM setou@nips.ac.jp
RI Shimma, Shuichi/L-5975-2019; Noda, Tetsuo/B-1667-2016
OI Sugiura, Yuki/0000-0002-6983-8958
CR Ajiki W, 2004, JPN J CLIN ONCOL, V34, P352, DOI 10.1093/jjco/hyh056
   Alessandro Riccardo, 2005, Clin Colorectal Cancer, V4, P396, DOI 10.3816/CCC.2005.n.012
   BRASITUS TA, 1986, J CLIN INVEST, V77, P831, DOI 10.1172/JCI112380
   Caprioli RM, 1997, ANAL CHEM, V69, P4751, DOI 10.1021/ac970888i
   Chaurand P, 2001, PROTEOMICS, V1, P1320, DOI 10.1002/1615-9861(200110)1:10<1320::AID-PROT1320>3.0.CO;2-G
   CULLIS PR, 1991, BIOCH LIPIDS LIPOPRO
   Di Marzio L, 2005, CANCER EPIDEM BIOMAR, V14, P856, DOI 10.1158/1055-9965.EPI-04-0434
   Dobrzynska I, 2005, MOL CELL BIOCHEM, V276, P113, DOI 10.1007/s11010-005-3557-3
   Dueck DA, 1996, MOL CELL BIOCHEM, V162, P97
   Garrett TJ, 2006, ANAL CHEM, V78, P2465, DOI 10.1021/ac0522761
   Harkins L, 2002, LANCET, V360, P1557, DOI 10.1016/S0140-6736(02)11524-8
   Hsu FF, 2003, J AM SOC MASS SPECTR, V14, P352, DOI 10.1016/S1044-0305(03)00064-3
   Huerta S, 2003, INT J ONCOL, V22, P663
   NEWELL GR, 1989, SEMIN ONCOL, V16, P3
   Okita M, 1997, INT J CANCER, V71, P31, DOI 10.1002/(SICI)1097-0215(19970328)71:1<31::AID-IJC7>3.0.CO;2-4
   Pierson J, 2005, J PROTEOME RES, V4, P223, DOI 10.1021/pr049836h
   Pierson J, 2004, J PROTEOME RES, V3, P289, DOI 10.1021/pr0499747
   Rohner TC, 2005, MECH AGEING DEV, V126, P177, DOI 10.1016/j.mad.2004.09.032
   Saito R, 2004, CANCER RES, V64, P2572, DOI 10.1158/0008-5472.CAN-03-3631
   Stoeckli M, 2001, NAT MED, V7, P493, DOI 10.1038/86573
   Stoeckli M, 2002, ANAL BIOCHEM, V311, P33, DOI 10.1016/S0003-2697(02)00386-X
   Stoeckli M, 1999, J AM SOC MASS SPECTR, V10, P67, DOI 10.1016/S1044-0305(98)00126-3
   Touboul D, 2005, J LIPID RES, V46, P1388, DOI 10.1194/jlr.M500058-JLR200
   Wakai K, 2006, J EPIDEMIOL, V16, P125, DOI 10.2188/jea.16.125
   Westra Jantine L, 2004, Clin Colorectal Cancer, V4, P252, DOI 10.3816/CCC.2004.n.024
   Woods AS, 2006, AAPS J, V8, pE391, DOI 10.1007/BF02854910
   Yanagisawa K, 2003, LANCET, V362, P433, DOI 10.1016/S0140-6736(03)14068-8
NR 27
TC 150
Z9 176
U1 0
U2 56
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1570-0232
EI 1873-376X
J9 J CHROMATOGR B
JI J. Chromatogr. B
PD AUG 1
PY 2007
VL 855
IS 1
BP 98
EP 103
DI 10.1016/j.jchromb.2007.02.037
PG 6
WC Biochemical Research Methods; Chemistry, Analytical
WE Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)
SC Biochemistry & Molecular Biology; Chemistry
GA 202HQ
UT WOS:000248893000014
PM 17369111
DA 2024-02-19
ER

PT J
AU Cheng, CLH
   Tsang, FHC
   Wei, L
   Chen, MN
   Chin, DWC
   Shen, JL
   Law, CT
   Lee, D
   Wong, CCL
   Ng, IOL
   Wong, CM
AF Cheng, Carol Lai-Hung
   Tsang, Felice Hoi-Ching
   Wei, Lai
   Chen, Mengnuo
   Chin, Don Wai-Ching
   Shen, Jialing
   Law, Cheuk-Ting
   Lee, Derek
   Wong, Carmen Chak-Lui
   Ng, Irene Oi-Lin
   Wong, Chun-Ming
TI Bromodomain-containing protein BRPF1 is a therapeutic target for liver
   cancer
SO COMMUNICATIONS BIOLOGY
LA English
DT Article
ID HEPATOCELLULAR-CARCINOMA; GENE-EXPRESSION; PHD FINGER; BET; MOZ;
   SORAFENIB; ACETYLATION; INHIBITORS; CHROMATIN; LEUKEMIA
AB Epigenetic deregulation plays an essential role in hepatocellular carcinoma (HCC) progression. Bromodomains are epigenetic "readers" of histone acetylation. Recently, bromodomain inhibitors have exhibited promising therapeutic potential for cancer treatment. Using transcriptome sequencing, we identified BRPF1 (bromodomain and PHD finger containing 1) as the most significantly upregulated gene among the 43 bromodomain-containing genes in human HCC. BRPF1 upregulation was significantly associated with poor patient survival. Gene ablation or pharmacological inactivation of BRPF1 significantly attenuated HCC cell growth in vitro and in vivo. BRPF1 was involved in cell cycle progression, senescence and cancer stemness. Transcriptome sequencing revealed that BRPF1 is a master regulator controlling the expression of multiple key oncogenes, including E2F2 and EZH2. We demonstrated that BRPF1 activated E2F2 and EZH2 expression by facilitating promoter H3K14 acetylation through MOZ/MORF complex. In conclusion, BRPF1 is frequently upregulated in human HCCs. Targeting BRPF1 may be an approach for HCC treatment.
   Cheng et al. suggest that BRPF1 plays an oncogenic role in hepatocellular carcinoma (HCC), by controlling histone acetylation in the promoter regions of E2F2 and EZH2. Its high levels are correlated with poor survival in HCC patients, and targeting it might serve as a strategy for cancer treatment.
C1 [Cheng, Carol Lai-Hung; Tsang, Felice Hoi-Ching; Wei, Lai; Chen, Mengnuo; Chin, Don Wai-Ching; Shen, Jialing; Law, Cheuk-Ting; Lee, Derek; Wong, Carmen Chak-Lui; Ng, Irene Oi-Lin; Wong, Chun-Ming] Univ Hong Kong, State Key Lab Liver Res, Pok Fu Lam, Hong Kong, Peoples R China.
   [Cheng, Carol Lai-Hung; Tsang, Felice Hoi-Ching; Wei, Lai; Chen, Mengnuo; Chin, Don Wai-Ching; Shen, Jialing; Law, Cheuk-Ting; Lee, Derek; Wong, Carmen Chak-Lui; Ng, Irene Oi-Lin; Wong, Chun-Ming] Univ Hong Kong, Li Ka Shing Fac Med, Dept Pathol, Pok Fu Lam, Hong Kong, Peoples R China.
C3 University of Hong Kong; University of Hong Kong
RP Wong, CM (corresponding author), Univ Hong Kong, State Key Lab Liver Res, Pok Fu Lam, Hong Kong, Peoples R China.; Wong, CM (corresponding author), Univ Hong Kong, Li Ka Shing Fac Med, Dept Pathol, Pok Fu Lam, Hong Kong, Peoples R China.
EM jackwong@pathology.hku.hk
RI Wong, Carmen Chak Lui/C-4660-2009; WONG, Chun-Ming/A-6739-2009; chen,
   mn/HSI-1520-2023
OI Ng, Irene Oi-lin/0000-0001-7532-2029
FU Health and Medical Research Fund [07181956]; Hong Kong Research Grants
   Council Theme-based Research Scheme [T12-704/16R]
FX We thank the Laboratory Animal Unit for animal housing. We also thank
   the Centre for Genomic Sciences and the Core Facility of LKS Faculty of
   Medicine for their technical assistance. The study was supported by
   Health and Medical Research Fund (07181956) and Hong Kong Research
   Grants Council Theme-based Research Scheme (T12-704/16R).
CR Abou-Alfa GK, 2018, NEW ENGL J MED, V379, P54, DOI 10.1056/NEJMoa1717002
   Aiello G, 2019, CELL REP, V29, P4036, DOI 10.1016/j.celrep.2019.11.046
   Au SLK, 2012, HEPATOLOGY, V56, P622, DOI 10.1002/hep.25679
   Beesley AH, 2014, BRIT J CANCER, V110, P1189, DOI 10.1038/bjc.2014.54
   Beishline K, 2015, FEBS J, V282, P224, DOI 10.1111/febs.13148
   Berthon C, 2016, LANCET HAEMATOL, V3, pE186, DOI 10.1016/S2352-3026(15)00247-1
   Bertuccio P, 2017, J HEPATOL, V67, P302, DOI 10.1016/j.jhep.2017.03.011
   Bismuth H, 1999, SEMIN LIVER DIS, V19, P311, DOI 10.1055/s-2007-1007120
   Borbely G, 2015, ONCOTARGET, V6, P33623, DOI 10.18632/oncotarget.5601
   Bruix J, 2017, LANCET, V389, P56, DOI 10.1016/S0140-6736(16)32453-9
   Bui MH, 2017, CANCER RES, V77, P2976, DOI 10.1158/0008-5472.CAN-16-1793
   Chaffanet M, 2000, GENE CHROMOSOME CANC, V28, P138, DOI 10.1002/(SICI)1098-2264(200006)28:2<138::AID-GCC2>3.0.CO;2-2
   Crowley JA, 2005, LEUKEMIA, V19, P2344, DOI 10.1038/sj.leu.2403971
   Delmore JE, 2011, CELL, V146, P903, DOI 10.1016/j.cell.2011.08.017
   Dey A, 2003, P NATL ACAD SCI USA, V100, P8758, DOI 10.1073/pnas.1433065100
   Fan DNY, 2013, HEPATOLOGY, V57, P637, DOI 10.1002/hep.26083
   Filippakopoulos P, 2010, NATURE, V468, P1067, DOI 10.1038/nature09504
   Flavahan WA, 2017, SCIENCE, V357, DOI 10.1126/science.aal2380
   Gatchalian J, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07528-9
   Goudarzi A, 2016, MOL CELL, V62, P169, DOI 10.1016/j.molcel.2016.03.014
   Hogg SJ, 2017, CELL REP, V18, P2162, DOI 10.1016/j.celrep.2017.02.011
   Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.21492, 10.3322/caac.20107]
   Jühling F, 2021, GUT, V70, P157, DOI 10.1136/gutjnl-2019-318918
   Kane RC, 2009, ONCOLOGIST, V14, P95, DOI 10.1634/theoncologist.2008-0185
   Kantarjian H, 2006, CANCER-AM CANCER SOC, V106, P1794, DOI 10.1002/cncr.21792
   Klein BJ, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12551-5
   Klein BJ, 2014, EPIGENETICS-US, V9, P186, DOI 10.4161/epi.26792
   Kool M, 2014, CANCER CELL, V25, P393, DOI 10.1016/j.ccr.2014.02.004
   Law CT, 2019, HEPATOLOGY, V69, P2013, DOI 10.1002/hep.30414
   Lee HW, 2016, CLIN MOL HEPATOL, V22, P309, DOI 10.3350/cmh.2016.0042
   Lee TI, 2006, CELL, V125, P301, DOI 10.1016/j.cell.2006.02.043
   Leone G, 2001, MOL CELL, V8, P105, DOI 10.1016/S1097-2765(01)00275-1
   Lewin J, 2018, J CLIN ONCOL, V36, P3007, DOI 10.1200/JCO.2018.78.2292
   Li GQ, 2016, ONCOTARGET, V7, P2462, DOI 10.18632/oncotarget.6275
   Liu LH, 2012, BIOINFORMATICS, V28, P2205, DOI 10.1093/bioinformatics/bts340
   Llovet JM, 2008, NEW ENGL J MED, V359, P378, DOI 10.1056/NEJMoa0708857
   McGlynn KA, 2015, CLIN LIVER DIS, V19, P223, DOI 10.1016/j.cld.2015.01.001
   Meier JC, 2017, ACS CHEM BIOL, V12, P2619, DOI 10.1021/acschembio.7b00481
   Muralidharan SV, 2016, ONCOGENE, V35, P4689, DOI 10.1038/onc.2015.521
   Ohta K, 2007, BIOCHEM J, V402, P559, DOI 10.1042/BJ20061194
   Ozakyol A, 2017, J GASTROINTEST CANC, V48, P238, DOI 10.1007/s12029-017-9959-0
   Pelletier N, 2002, ONCOGENE, V21, P2729, DOI 10.1038/sj.onc.1205367
   Personeni N, 2019, J HEPATOCELL CARCINO, V6, P31, DOI 10.2147/JHC.S168953
   Piha-Paul SA, 2019, CLIN CANCER RES, V25, P6309, DOI 10.1158/1078-0432.CCR-19-0578
   Qiu Y, 2012, GENE DEV, V26, P1376, DOI 10.1101/gad.188359.112
   Saygin C, 2019, CELL STEM CELL, V24, P25, DOI 10.1016/j.stem.2018.11.017
   Shima H, 2014, INT J HEMATOL, V99, P21, DOI 10.1007/s12185-013-1466-x
   Taniguchi Y, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17111849
   Tontsch-Grunt U, 2016, EUR J CANCER, V69, pS89, DOI 10.1016/S0959-8049(16)32862-3
   Totoki Y, 2014, NAT GENET, V46, P1267, DOI 10.1038/ng.3126
   Tsang FHC, 2019, HEPATOLOGY, V69, P2502, DOI 10.1002/hep.30544
   Ullah M, 2008, MOL CELL BIOL, V28, P6828, DOI 10.1128/MCB.01297-08
   Verdin E, 2015, NAT REV MOL CELL BIO, V16, P258, DOI 10.1038/nrm3931
   Voss AK, 2009, DEV CELL, V17, P674, DOI 10.1016/j.devcel.2009.10.006
   Wei L, 2017, J HEPATOL, V67, P758, DOI 10.1016/j.jhep.2017.05.015
   Wong CM, 2016, HEPATOLOGY, V63, P474, DOI 10.1002/hep.28304
   Yan KZ, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aax0021
   Yan KZ, 2017, AM J HUM GENET, V100, P91, DOI 10.1016/j.ajhg.2016.11.011
   Yang XJ, 2015, BBA-MOL CELL RES, V1853, P1818, DOI 10.1016/j.bbamcr.2015.04.014
   Yoo CB, 2006, NAT REV DRUG DISCOV, V5, P37, DOI 10.1038/nrd1930
   You LY, 2016, J CLIN INVEST, V126, P3247, DOI 10.1172/JCI80711
   You LY, 2015, J BIOL CHEM, V290, P7114, DOI 10.1074/jbc.M114.635250
   Zhai B, 2013, WORLD J HEPATOL, V5, P345, DOI 10.4254/wjh.v5.i7.345
   Zhu HR, 2016, CELL REP, V16, P2829, DOI 10.1016/j.celrep.2016.08.032
NR 64
TC 14
Z9 14
U1 2
U2 7
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
EI 2399-3642
J9 COMMUN BIOL
JI Commun. Biol.
PD JUL 20
PY 2021
VL 4
IS 1
AR 888
DI 10.1038/s42003-021-02405-6
PG 14
WC Biology; Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Life Sciences & Biomedicine - Other Topics; Science & Technology - Other
   Topics
GA TP4AD
UT WOS:000677535700003
PM 34285329
OA gold, Green Published
DA 2024-02-19
ER

PT J
AU Grattagliano, I
   Portincasa, P
   Cocco, T
   Moschetta, A
   Di Paola, M
   Palmieri, VO
   Palasciano, G
AF Grattagliano, I
   Portincasa, P
   Cocco, T
   Moschetta, A
   Di Paola, M
   Palmieri, VO
   Palasciano, G
TI Effect of dietary restriction and <i>N</i>-acetylcysteine
   supplementation on intestinal mucosa and liver mitochondrial redox
   status and function in aged rats
SO EXPERIMENTAL GERONTOLOGY
LA English
DT Article
DE glutathione; glutathione peroxidase; intestinal transport; mitochondrial
   respiration; nitrosothiols; protein sulfhydrils; ussing chamber
ID NITRIC-OXIDE SYNTHASE; INTRACELLULAR GLUTATHIONE; PROTEIN OXIDATION;
   PERMEABILITY TRANSITION; S-NITROSOGLUTATHIONE; OXIDIZED GLUTATHIONE;
   CALORIC RESTRICTION; PARTIAL-HEPATECTOMY; REACTIVE OXYGEN; ADULT-RATS
AB The age-related changes of glutathione (GSH) levels and the effect of hypocaloric regimen and N-acetylcysteine (NAC) supplementation were investigated in intestinal mucosa and liver mitochondria of 28 months rats.
   Old rats exhibited lower proteins, GSH and protein sulphydrils (PSH) concentrations, higher GSH-peroxidase (GSH-Px) activity and protein carbonyl deposit, partial inhibition of succinate stimulated mitochondrial state III respiration and decreased mitochondrial nitrosothiols (RSNO) concentration. Lower electric potential and current intensity were found in the colonic mucosa.
   Old rats undergone hypocaloric regimen showed higher intestinal concentrations of GSH, lower oxidized protein accumulation and GSH-Px activity and higher mitochondrial RSNO levels. Mitochondrial state III respiration and intestinal transport were improved.
   NAC supplementation enhanced GSH and PSH levels in the ileal but not in the colonic mucosa, GSH and RSNO in liver mitochondria, while GSH-Px and protein carbonyls were decreased everywhere. Mitochondrial respiration ameliorated.
   In conclusion, ageing is characterized by a spread decrease of GSH concentrations, increased protein oxidation and decreased mitochondrial NO content. Hypocaloric diet ameliorated intestinal transport and, as well as NAC, was effective in enhancing GSH levels but at different extent according to the investigated districts. Both interventions reduced the age-associated increase of GSH-Px and protein carbonyls and improved mitochondrial respiration. (C) 2004 Elsevier Inc. All rights reserved.
C1 Univ Bari, Dept Internal Med & Publ Med, Sect Internal Med, I-70124 Bari, Italy.
   Univ Bari, Dept Med Biochem & Biol, Sect Med Biochem, Bari, Italy.
   Univ Bari, Inst Biomembranes & Bioenerget, CNR, Bari, Italy.
C3 Universita degli Studi di Bari Aldo Moro; Universita degli Studi di Bari
   Aldo Moro; Universita degli Studi di Bari Aldo Moro; Consiglio Nazionale
   delle Ricerche (CNR)
RP Grattagliano, I (corresponding author), Univ Bari, Dept Internal Med & Publ Med, Sect Internal Med, Pzza G Cesare11, I-70124 Bari, Italy.
EM i.grattagliano@semeiotica.uniba.it
RI Cocco, Tiziana/AAG-9064-2020; portincasa, piero/J-7245-2018; Moschetta,
   Antonio/AAC-5295-2022; Moschetta, Antonio/K-6211-2016
OI portincasa, piero/0000-0001-5359-1471; Cocco, Tiziana
   Maria/0000-0001-7171-3460; Palasciano, Giuseppe/0000-0002-0396-488X;
   palmieri, vincenzo ostilio/0000-0002-7649-6028; Moschetta,
   Antonio/0000-0003-2123-6074
CR Altomare E, 1998, ITAL J GASTROENTEROL, V30, P82
   André M, 2003, FEBS LETT, V546, P223, DOI 10.1016/S0014-5793(03)00576-3
   AUGUSTEYN RC, 1979, EXP EYE RES, V28, P665, DOI 10.1016/0014-4835(79)90067-8
   BALLATORI N, 1989, AM J PHYSIOL, V256, pG22, DOI 10.1152/ajpgi.1989.256.1.G22
   Boscia F, 2000, INVEST OPHTH VIS SCI, V41, P2461
   BRAATEN B, 1988, AM J PHYSIOL, V255, pG72, DOI 10.1152/ajpgi.1988.255.1.G72
   Brookes PS, 2000, J BIOL CHEM, V275, P20474, DOI 10.1074/jbc.M001077200
   Brookes PS, 2002, FREE RADICAL BIO MED, V33, P755, DOI 10.1016/S0891-5849(02)00901-2
   Chen G, 2000, FREE RADICAL RES, V32, P223, DOI 10.1080/10715760000300231
   Chiba T, 1996, EUR J IMMUNOL, V26, P1164, DOI 10.1002/eji.1830260530
   CLANCY RM, 1994, P NATL ACAD SCI USA, V91, P3680, DOI 10.1073/pnas.91.9.3680
   Clementi E, 1998, P NATL ACAD SCI USA, V95, P7631, DOI 10.1073/pnas.95.13.7631
   Cocco T, 2002, J BIOENERG BIOMEMBR, V34, P251, DOI 10.1023/A:1020248300766
   Colell A, 1998, GASTROENTEROLOGY, V115, P1541, DOI 10.1016/S0016-5085(98)70034-4
   Cook JA, 1996, ANAL BIOCHEM, V238, P150, DOI 10.1006/abio.1996.0268
   DEVI BG, 1993, HEPATOLOGY, V18, P648, DOI 10.1016/0270-9139(93)90367-V
   FERRARIS RP, 1993, J NUTR, V123, P502, DOI 10.1093/jn/123.3.502
   FLOHE L, 1984, METHOD ENZYMOL, V105, P114
   Ghafourifar P, 1997, FEBS LETT, V418, P291, DOI 10.1016/S0014-5793(97)01397-5
   GinnPease ME, 1996, BIOCHEM BIOPH RES CO, V226, P695, DOI 10.1006/bbrc.1996.1416
   Giulivi C, 1998, J BIOL CHEM, V273, P11038, DOI 10.1074/jbc.273.18.11038
   Glebska J, 2003, FREE RADICAL BIO MED, V35, P310, DOI 10.1016/S0891-5849(03)00306-X
   Goodell S, 1998, MECH AGEING DEV, V101, P245, DOI 10.1016/S0047-6374(97)00182-6
   GOODRICK CL, 1983, J GERONTOL, V38, P36, DOI 10.1093/geronj/38.1.36
   Grattagliano I, 1996, J HEPATOL, V25, P28, DOI 10.1016/S0168-8278(96)80324-2
   Grattagliano I, 2003, J HEPATOL, V39, P571, DOI 10.1016/S0168-8278(03)00317-9
   Grattagliano I, 1999, J SURG RES, V86, P2, DOI 10.1006/jsre.1999.5620
   Greenwood-Van Meerveld B, 2000, LAB INVEST, V80, P1269, DOI 10.1038/labinvest.3780135
   GRIFFITH OW, 1980, ANAL BIOCHEM, V106, P207, DOI 10.1016/0003-2697(80)90139-6
   Guerrieri F, 1996, ANN NY ACAD SCI, V786, P62, DOI 10.1111/j.1749-6632.1996.tb39052.x
   HAGEN TM, 1990, AM J PHYSIOL, V259, pG530, DOI 10.1152/ajpgi.1990.259.4.G530
   HAMILOS DL, 1989, IMMUNOPHARMACOLOGY, V18, P223, DOI 10.1016/0162-3109(89)90020-9
   HARMAN D, 1992, MUTAT RES, V275, P257, DOI 10.1016/0921-8734(92)90030-S
   Huang J, 2000, J WUHAN UNIV TECHNOL, V15, P19
   Iakova P, 2003, CELL, V113, P495, DOI 10.1016/S0092-8674(03)00318-0
   Ji YB, 1999, ARCH BIOCHEM BIOPHYS, V362, P67, DOI 10.1006/abbi.1998.1013
   Kamata H, 1999, CELL SIGNAL, V11, P1, DOI 10.1016/S0898-6568(98)00037-0
   Kim YM, 1997, J BIOL CHEM, V272, P31138, DOI 10.1074/jbc.272.49.31138
   Lacza Z, 2003, FREE RADICAL BIO MED, V35, P1217, DOI 10.1016/S0891-5849(03)00510-0
   LEVINE RL, 1990, METHOD ENZYMOL, V186, P464
   LI J, 2003, FREE RADIC BIOL MED, V35, P199
   Mannick JB, 1999, SCIENCE, V284, P651, DOI 10.1126/science.284.5414.651
   MARIN L, 1984, J PEDIATR GASTR NUTR, V3, P471, DOI 10.1097/00005176-198406000-00029
   MARTENSSON J, 1990, P NATL ACAD SCI USA, V87, P1715, DOI 10.1073/pnas.87.5.1715
   Martínez M, 2000, BRAIN RES, V855, P100, DOI 10.1016/S0006-8993(99)02349-5
   MATHEWS WR, 1993, J PHARMACOL EXP THER, V267, P1529
   MCDOUGAL JN, 1984, AM J PHYSIOL, V247, pG542, DOI 10.1152/ajpgi.1984.247.5.G542
   MIQUEL J, 1992, MUTAT RES, V275, P209, DOI 10.1016/0921-8734(92)90024-J
   MIRABELLI F, 1988, ARCH BIOCHEM BIOPHYS, V264, P261, DOI 10.1016/0003-9861(88)90593-0
   Morin D, 2001, FEBS LETT, V495, P131, DOI 10.1016/S0014-5793(01)02376-6
   Moschetta A, 2003, BIOL CELL, V95, P115, DOI 10.1016/S0248-4900(03)00011-X
   NAGY IZ, 1993, MECH AGEING DEV, V71, P85
   Natale L, 2003, EUR J CLIN INVEST, V33, P704, DOI 10.1046/j.1365-2362.2003.01200.x
   Nicholls DG, 2002, INT J BIOCHEM CELL B, V34, P1372, DOI 10.1016/S1357-2725(02)00077-8
   Nishikawa M, 1998, HEPATOLOGY, V27, P422, DOI 10.1002/hep.510270216
   Nordberg J, 2001, FREE RADICAL BIO MED, V31, P1287, DOI 10.1016/S0891-5849(01)00724-9
   OLAFSDOTTIR K, 1988, BIOCHIM BIOPHYS ACTA, V964, P377, DOI 10.1016/0304-4165(88)90038-4
   ORR WC, 1994, SCIENCE, V263, P1128, DOI 10.1126/science.8108730
   Rebrin I, 2003, FREE RADICAL BIO MED, V35, P626, DOI 10.1016/S0891-5849(03)00388-5
   Sandström O, 1998, GERONTOLOGY, V44, P324, DOI 10.1159/000022036
   Schafer FQ, 2001, FREE RADICAL BIO MED, V30, P1191, DOI 10.1016/S0891-5849(01)00480-4
   Schmucker DL, 2001, MECH AGEING DEV, V122, P1397, DOI 10.1016/S0047-6374(01)00276-7
   Sies H, 1999, FREE RADICAL BIO MED, V27, P916, DOI 10.1016/S0891-5849(99)00177-X
   STADTMAN ER, 1992, SCIENCE, V257, P1220, DOI 10.1126/science.1355616
   Steffen M, 2001, BIOCHEM J, V356, P395, DOI 10.1042/0264-6021:3560395
   Tanaka T, 1998, ALCOHOL CLIN EXP RES, V22, p125S, DOI 10.1111/acer.1998.22.s3_part1.125s
   TIETZE F, 1969, ANAL BIOCHEM, V27, P502, DOI 10.1016/0003-2697(69)90064-5
   VEEZE HJ, 1994, J CLIN INVEST, V93, P461, DOI 10.1172/JCI116993
   VENDEMIALE G, 1994, SCAND J GASTROENTERO, V29, P1034, DOI 10.3109/00365529409094882
   Ventura B, 2002, BBA-BIOENERGETICS, V1553, P249, DOI 10.1016/S0005-2728(01)00246-8
   VICTOR BE, 1991, AM J PHYSIOL, V261, pG966, DOI 10.1152/ajpgi.1991.261.6.G966
   Wang L, 2003, WORLD J GASTROENTERO, V9, P2060, DOI 10.3748/wjg.v9.i9.2060
   WEINDRUCH R, 1982, SCIENCE, V215, P1415, DOI 10.1126/science.7063854
   Weindruch R, 1997, NEW ENGL J MED, V337, P986, DOI 10.1056/NEJM199710023371407
   WIELAND P, 1995, BIOCHEM BIOPH RES CO, V213, P815, DOI 10.1006/bbrc.1995.2202
   YOUNGMAN LD, 1992, P NATL ACAD SCI USA, V89, P9112, DOI 10.1073/pnas.89.19.9112
NR 76
TC 40
Z9 42
U1 0
U2 6
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0531-5565
J9 EXP GERONTOL
JI Exp. Gerontol.
PD SEP
PY 2004
VL 39
IS 9
BP 1323
EP 1332
DI 10.1016/j.exger.2004.06.001
PG 10
WC Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Geriatrics & Gerontology
GA 857UM
UT WOS:000224144000008
PM 15489055
DA 2024-02-19
ER

PT J
AU Sharma, R
   Kumari, M
   Kumari, A
   Sharma, A
   Gulati, A
   Gupta, M
   Padwad, Y
AF Sharma, Rohit
   Kumari, Madhu
   Kumari, Amita
   Sharma, Anamika
   Gulati, Ashu
   Gupta, Mahesh
   Padwad, Yogendra
TI Diet supplemented with phytochemical epigallocatechin gallate and
   probiotic <i>Lactobacillus fermentum</i> confers second generation
   synbiotic effects by modulating cellular immune responses and
   antioxidant capacity in aging mice
SO EUROPEAN JOURNAL OF NUTRITION
LA English
DT Article
DE EGCG; Probiotics; Prebiotics; Synbiotics; Immunity; Aging
ID NATURAL-KILLER-CELLS; WHOLE-GRAIN; T-CELLS; IN-VIVO; TEA; HEALTHY; GUT;
   IMMUNOSENESCENCE; CONSUMPTION; RHAMNOSUS
AB Purpose In the present study, we systematically identified and evaluated a synbiotic combination of phytochemical epigallocatechin gallate (EGCG) and probiotic bacteria in amelioration of immunosenescence and oxidative stress in aged mice.
   Methods Inhibitory effects of EGCG against different bacterial species were evaluated in vitro, followed by analysis to identify potential combination of EGCG and probiotic bacteria against alleviation of oxidative and inflammatory stress ex vivo. The best synbiotic combination, vis-a-vis prebiotic and probiotic supplementation alone, was then evaluated in aged Swiss albino mice for modulation of various immunological and antioxidative parameters.
   Results EGCG strongly inhibited the growth of pathogenic microbes as compared to probiotic bacteria. A combination of EGCG with probiotic Lactobacillus fermentum (LF) provided evidence of additive effects in the amelioration of oxidative and inflammatory stress-induced cell death. In vivo study revealed that combined supplementation of LF and EGCG significantly enhanced neutrophil oxidative index, CD3+ cell numbers and activation status, Th1/Th2 cytokines in splenic supernatants as well as liver Nrf-2 expression in comparison with treatments with LF or EGCG alone. The combined application of EGCG and LF did not simply result in additive or synergistic effects in relation with individual treatments.
   Conclusion These observations suggest that EGCG could be considered as a potential prebiotic that can offer second generation synbiotic health beneficial effects for the alleviation of some of the deleterious aspects of immunosenescence and aging.
C1 [Sharma, Rohit; Sharma, Anamika; Padwad, Yogendra] CSIR, Inst Himalayan Bioresource Technol, Food & Nutraceut Div, Pharmacol & Toxicol Lab, Palampur 176061, Himachal Prades, India.
   [Kumari, Madhu; Kumari, Amita; Gulati, Ashu; Gupta, Mahesh] CSIR, Inst Himalayan Bioresource Technol, Food & Nutraceut Div, Palampur 176061, Himachal Prades, India.
C3 Council of Scientific & Industrial Research (CSIR) - India; CSIR -
   Institute of Himalayan Bioresource Technology (IHBT); Council of
   Scientific & Industrial Research (CSIR) - India; CSIR - Institute of
   Himalayan Bioresource Technology (IHBT)
RP Sharma, R; Padwad, Y (corresponding author), CSIR, Inst Himalayan Bioresource Technol, Food & Nutraceut Div, Pharmacol & Toxicol Lab, Palampur 176061, Himachal Prades, India.
EM rohit25sharma@gmail.com; yogendra@ihbt.res.in
RI Sharma, Rohit/AAC-8355-2020; Sharma, Anamika/E-9607-2019; Gulati,
   Ashu/F-4247-2011
OI Sharma, Anamika/0000-0002-0054-9904; Sharma, Rohit/0000-0001-6209-3845;
   kumari, Amita/0000-0003-0937-7640; Padwad, Yogendra/0000-0003-1793-9340
FU Science and Engineering Research Board, Government of India, through the
   Young Scientist Scheme [YSS/2015/000758]; CSIR Government of India
   [MLP0204]
FX Authors acknowledge the Director, CSIR-IHBT, Palampur for supporting and
   providing all the necessary facilities. This work was supported by
   grants from the Science and Engineering Research Board, Government of
   India, through the Young Scientist Scheme (YSS/2015/000758) and MLP0204
   of CSIR Government of India.
CR Ampatzoglou A, 2015, J NUTR, V145, P215, DOI 10.3945/jn.114.202176
   [Anonymous], 2014, AGE, DOI DOI 10.1007/s11357-014-9686-4
   Arena MP, 2016, J FUNCT FOODS, V23, P12, DOI 10.1016/j.jff.2016.02.015
   Aw D, 2007, IMMUNOLOGY, V120, P435, DOI 10.1111/j.1365-2567.2007.02555.x
   Banerjee A, 2019, CRIT REV FOOD SCI, V59, P2903, DOI 10.1080/10408398.2018.1478795
   Bindels LB, 2015, NAT REV GASTRO HEPAT, V12, P303, DOI 10.1038/nrgastro.2015.47
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   Crowley L. C., 2016, COLD SPRING HARB PRO, V7
   Hazeldine J, 2012, AGING CELL, V11, P751, DOI 10.1111/j.1474-9726.2012.00839.x
   Holloender PLB, 2015, AM J CLIN NUTR, V102, P556, DOI 10.3945/ajcn.115.109165
   Jagger A, 2014, GERONTOLOGY, V60, P130, DOI 10.1159/000355303
   Joyce JA, 2009, NAT REV CANCER, V9, P239, DOI 10.1038/nrc2618
   Kerry RG, 2018, J FOOD DRUG ANAL, V26, P927, DOI 10.1016/j.jfda.2018.01.002
   Krautkramer KA, 2017, J BIOL CHEM, V292, P8582, DOI 10.1074/jbc.R116.761577
   Krumbeck JA, 2016, CURR OPIN GASTROEN, V32, P110, DOI 10.1097/MOG.0000000000000249
   Kumari M, 2015, GENOME ANNOUNC, V3
   Kumari M, 2015, GENOME ANNOUNC, V3
   Le Garff-Tavernier M, 2010, AGING CELL, V9, P527, DOI 10.1111/j.1474-9726.2010.00584.x
   Lee HC, 2006, RES MICROBIOL, V157, P876, DOI 10.1016/j.resmic.2006.07.004
   Lutz CT, 2011, J IMMUNOL, V186, P4590, DOI 10.4049/jimmunol.1002732
   Lutz CT, 2005, MECH AGEING DEV, V126, P722, DOI 10.1016/j.mad.2005.01.004
   Mahnke YD, 2007, CLIN LAB MED, V27, P469, DOI 10.1016/j.cII.2007.05.002
   Mair KH, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00263
   Landete JM, 2017, BIOMED RES INT, V2017, DOI 10.1155/2017/5939818
   Nikolich-Zugich J, 2014, J IMMUNOL, V193, P2622, DOI 10.4049/jimmunol.1401174
   Pirson C, 2015, CLIN VACCINE IMMUNOL, V22, P178, DOI 10.1128/CVI.00638-14
   Roller M, 2004, BRIT J NUTR, V92, P931, DOI 10.1079/BJN20041289
   Seenappanahalli Nanjundaiah Yashaswini, 2016, Biochem Biophys Rep, V6, P68, DOI 10.1016/j.bbrep.2016.03.003
   Sharma R, 2017, BIOGERONTOLOGY, V18, P367, DOI 10.1007/s10522-017-9696-6
   Sharma R, 2014, AGING CLIN EXP RES, V26, P353, DOI 10.1007/s40520-013-0190-y
   Sharma R, 2013, FOOD REV INT, V29, P201, DOI 10.1080/87559129.2012.751547
   Smelt MJ, 2013, PLOS ONE, V4
   Solana R, 1999, EXP GERONTOL, V34, P435, DOI 10.1016/S0531-5565(99)00008-X
   Sourabh A, 2013, BRAZ J MICROBIOL, V44, P709, DOI 10.1590/S1517-83822013000300007
   Su P, 2008, WORLD J MICROB BIOT, V24, P1837, DOI 10.1007/s11274-008-9682-x
   Tilstra JS, 2011, AGING DIS, V2, P449
   Tymoshok NO., 2014, EPMA J S1, V36, pA134, DOI [10.1186/1878-5085-5-S1-A134, DOI 10.1186/1878-5085-5-S1-A134]
   Unno K., 2016, J PHYS FIT SPORTS ME, V5, P117, DOI [10.7600/jpfsm.5.117, DOI 10.7600/JPFSM.5.117]
   Verburgh K, 2015, AGING CELL, V14, P17, DOI 10.1111/acel.12284
   Vodnar DC, 2012, CHEM CENT J, V6, DOI 10.1186/1752-153X-6-61
   Wang YH, 2012, AM J PHYSIOL-GASTR L, V303, pG32, DOI 10.1152/ajpgi.00024.2012
   Xu J, 2018, NUTR J, V17, DOI 10.1186/s12937-018-0335-0
   You JL, 2012, FEMS IMMUNOL MED MIC, V66, P353, DOI 10.1111/j.1574-695X.2012.01014.x
   Zhang HQ, 2015, FREE RADICAL BIO MED, V88, P314, DOI 10.1016/j.freeradbiomed.2015.05.036
   Zhang X, 2013, FOOD RES INT, V54, P1589, DOI 10.1016/j.foodres.2013.10.005
   Zhang Y, 2007, IMMUNOLOGY, V121, P258, DOI 10.1111/j.1365-2567.2007.02573.x
NR 46
TC 20
Z9 21
U1 7
U2 34
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 1436-6207
EI 1436-6215
J9 EUR J NUTR
JI Eur. J. Nutr.
PD OCT
PY 2019
VL 58
IS 7
BP 2943
EP 2957
DI 10.1007/s00394-018-01890-6
PG 15
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Nutrition & Dietetics
GA JC8YM
UT WOS:000489562000031
PM 30607562
OA Bronze
DA 2024-02-19
ER

PT J
AU Wang, XB
   Zeng, J
   Wang, X
   Li, J
   Chen, J
   Wang, N
   Zhang, M
   Feng, YB
   Guo, HL
AF Wang, Xuanbin
   Zeng, Jing
   Wang, Xiao
   Li, Ju
   Chen, Jin
   Wang, Ning
   Zhang, Miao
   Feng, Yibin
   Guo, Huailan
TI 2,3,5,4′-tetrahydroxystilbene-2-O-β-Dglucoside induces autophagy of
   liver by activating PI3K/Akt and Erk pathway in prediabetic rats
SO BMC COMPLEMENTARY MEDICINE AND THERAPIES
LA English
DT Article
DE 2,3,5,4 '-tetrahydroxystilbene-2-O-beta-D-glucoside; Liver injury;
   Prediabetes; Autophagy
ID POLYGONUM-MULTIFLORUM THUNB.; TYPE-2 DIABETES-MELLITUS; NEPHROPATHY;
   DYSFUNCTION; INHIBITION; GLUCOSIDE; APOPTOSIS; MEDICINE; CELLS
AB Background: 2,3,5,4'-tetrahydroxystilbene-2-O-beta-D-glucoside (TSG) is an active compound derived from Polygonum multiflorum Thunb., a Chinese Taoist herbal medicine, which exerts lipid lowering, anti-cancer, anti-aging, anti-inflammatory and hepatoprotective effects. However, its role in protecting hepatocytes under pre-diabetic condition remains unclear.
   Methods: In this study, we developed prediabetic SD rats by feeding high-fat and high-sugar diet. The body weight, blood lipid, blood glucose, and fasting insulin (FINS) and insulin resistance index (HOMA-IR) were detected and calculated to assess the potential risk of prediabetes. HE and Oil Red O staining was used, and blood level of biochemical index was detected to observe the liver injury. The autophagic cell death-associated signaling proteins, and the potential signaling factors p-Akt/Akt and p-Erk/Erk were detected using western blot to explore the potential effects of TSG on pre-diabetic liver and the underlying mechanisms.
   Results: The results showed that the body weight in TSG-treated group was significantly decreased vs. the model group. The blood glucose, the level of FINS and HOMA-IR, TC and TG were decreased in TSG-treated group as well. Furthermore, TSG treatment significantly ameliorated lipid droplet accumulation, enhanced liver anti-oxidative response which may be associated with an increased activity of SOD and GSH-Px, and a decrease of LDLC and MDA. The autophagic cell death-associated proteins, p-AMPK, ATG12, LC3 II, and Beclin 1 were up-regulated in the TSG-treated group, while the upstream signaling pathway, PI3K/Akt and Erk, were activated.
   Conclusions: TSG induced liver autophagic cell death to protect liver from prediabetic injury by activating PI3K/Akt and Erk.
C1 [Wang, Xuanbin] Hubei Univ Med, Renmin Hosp, Oncol Ctr, Lab Chinese Herbal Pharmacol, 39 Middle Chaoyang Rd, Shiyan 442000, Hubei, Peoples R China.
   [Wang, Xuanbin] Hubei Univ Med, Hubei Key Lab Wudang Local Chinese Med Res, 39 Middle Chaoyang Rd, Shiyan 442000, Hubei, Peoples R China.
   [Wang, Xuanbin] Hubei Univ Med, Biomed Res Inst, 39 Middle Chaoyang Rd, Shiyan 442000, Hubei, Peoples R China.
   [Zeng, Jing] Hubei Univ Med, Taihe Hosp, Dept Tradit Chinese Med, 32 South Renmin Rd, Shiyan 442000, Hubei, Peoples R China.
   [Wang, Xiao; Li, Ju; Chen, Jin; Zhang, Miao; Guo, Huailan] Hubei Univ Med, Sch Publ Hlth & Management, 30 South Renmin Rd, Shiyan 442000, Hubei, Peoples R China.
   [Wang, Ning; Feng, Yibin] Univ Hong Kong, Sch Chinese Med, Pokfulam, 10 Sassoon Rd, Hong Kong 442000, Peoples R China.
   [Guo, Huailan] Hubei Univ Med, Ctr Environm & Hlth Water Source Area South To No, 32 South Renmin Rd, Shiyan 442000, Hubei, Peoples R China.
C3 Hubei University of Medicine; Hubei University of Medicine; Hubei
   University of Medicine; Hubei University of Medicine; Hubei University
   of Medicine; University of Hong Kong; Hubei University of Medicine
RP Guo, HL (corresponding author), Hubei Univ Med, Sch Publ Hlth & Management, 30 South Renmin Rd, Shiyan 442000, Hubei, Peoples R China.; Feng, YB (corresponding author), Univ Hong Kong, Sch Chinese Med, Pokfulam, 10 Sassoon Rd, Hong Kong 442000, Peoples R China.
EM yfeng@hku.hk; guohuailan@hbmu.edu.cn
RI Wang, Xuanbin/AHE-9819-2022
OI Wang, Xuanbin/0000-0003-0769-2874; Wang, Ning/0000-0003-1410-329X
FU National Natural Science Foundation of China [81372998]; Open Project of
   Hubei Key Laboratory of Wudang Local Chinese Medicine Research (Hubei
   University of Medicine) [WDCM2018002]; Key Discipline Project of Hubei
   University of Medicine [FDFR201602, 2018YHKT01]; Foundation for
   Innovative Research Team of Hubei University of Medicine [FDFR201602,
   2018YHKT01]; Key Discipline Project of Hubei Province [2014XKJSXJ18]
FX The study was financially supported by the National Natural Science
   Foundation of China (81372998); the Open Project of Hubei Key Laboratory
   of Wudang Local Chinese Medicine Research (Hubei University of Medicine)
   (WDCM2018002); the Key Discipline Project of Hubei University of
   Medicine and the Foundation for Innovative Research Team of Hubei
   University of Medicine (FDFR201602; 2018YHKT01); the Key Discipline
   Project of Hubei Province (2014XKJSXJ18). The funders played no role in
   the design of this study, and collection, analysis and interpretation of
   data and writing the manuscript, which are fully the responsibilities of
   the authors.
CR Baiceanu A, 2016, NAT REV ENDOCRINOL, V12, P710, DOI 10.1038/nrendo.2016.124
   Burgeiro A, 2017, NUTRIENTS, V9, DOI 10.3390/nu9060638
   Chang MJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050291
   Chen GT, 2016, FOOD FUNCT, V7, P4628, DOI [10.1039/c6fo01319h, 10.1039/C6FO01319H]
   Dong QQ, 2017, CELL PHYSIOL BIOCHEM, V43, P293, DOI 10.1159/000480410
   Edwards CM, 2016, ENDOCRIN METAB CLIN, V45, P751, DOI 10.1016/j.ecl.2016.06.007
   Engin A, 2017, ADV EXP MED BIOL, V960, P443, DOI 10.1007/978-3-319-48382-5_19
   Fan YS, 2018, MOLECULES, V23, DOI 10.3390/molecules23092306
   Galluzzi L, 2012, CELL DEATH DIFFER, V19, P107, DOI 10.1038/cdd.2011.96
   Galluzzi L, 2014, CELL, V159, P1263, DOI 10.1016/j.cell.2014.11.006
   Hu RF, 2017, CHIN J NAT MEDICINES, V15, P436, DOI 10.1016/S1875-5364(17)30065-1
   Johar DR, 2017, DIABETES RES CLIN PR, V126, P222, DOI 10.1016/j.diabres.2017.02.023
   Kho MC, 2016, NUTRIENTS, V8, DOI 10.3390/nu8060369
   Koncsos G, 2016, AM J PHYSIOL-HEART C, V311, pH927, DOI 10.1152/ajpheart.00049.2016
   Li CR, 2010, EUR J PHARMACOL, V649, P382, DOI 10.1016/j.ejphar.2010.09.004
   Li HL, 2017, FOOD CHEM TOXICOL, V108, P407, DOI 10.1016/j.fct.2016.07.035
   Li HL, 2016, EXP THER MED, V12, P2317, DOI 10.3892/etm.2016.3580
   Lin LF, 2015, J ETHNOPHARMACOL, V159, P158, DOI 10.1016/j.jep.2014.11.009
   Lin MH, 2014, TOXICOLOGY, V315, P24, DOI 10.1016/j.tox.2013.11.007
   Lv LS, 2010, J AGR FOOD CHEM, V58, P2239, DOI 10.1021/jf904122q
   Makaroff LE, 2017, LANCET DIABETES ENDO, V5, P5, DOI 10.1016/S2213-8587(16)30328-X
   Mauro C, 2016, AUTOPHAGY, V12, P2496, DOI 10.1080/15548627.2016.1226738
   Mi YS, 2016, FREE RADICAL BIO MED, V90, P230, DOI 10.1016/j.freeradbiomed.2015.11.022
   Mukhopadhyay S, 2014, APOPTOSIS, V19, P555, DOI 10.1007/s10495-014-0967-2
   [孙江浩 Sun Jianghao], 2005, [中草药, Chinese Traditional and Herbal Drugs], V36, P405
   Tang WP, 2017, MOL NUTR FOOD RES, V61, DOI 10.1002/mnfr.201600871
   Valenti C, 2012, BRIT J PHARMACOL, V166, P1403, DOI 10.1111/j.1476-5381.2012.01861.x
   Wang LM, 2017, JAMA-J AM MED ASSOC, V317, P2515, DOI 10.1001/jama.2017.7596
   Xu WG, 2017, MINERVA MED, V108, P185, DOI 10.23736/S0026-4806.16.04601-2
   Zhao QP, 2017, CLIN INTERV AGING, V12, P745, DOI 10.2147/CIA.S130014
   Zheng T, 2015, BRIT J PHARMACOL, V172, P3284, DOI 10.1111/bph.13120
NR 31
TC 8
Z9 9
U1 3
U2 11
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 2662-7671
J9 BMC COMPLEMENT MED
JI BMC Complement. Med. Ther.
PD JUN 8
PY 2020
VL 20
IS 1
AR 177
DI 10.1186/s12906-020-02949-w
PG 11
WC Integrative & Complementary Medicine
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Integrative & Complementary Medicine
GA MM7YY
UT WOS:000550369900001
PM 32513151
OA gold, Green Published
DA 2024-02-19
ER

PT J
AU Linard, A
   Macaire, JP
   Christon, R
AF Linard, A
   Macaire, JP
   Christon, R
TI Phospholipid hydroperoxide glutathione peroxidase activity and vitamin E
   level in the liver microsomal membrane:: effects of age and dietary
   α-linolenic acid deficiency
SO JOURNAL OF NUTRITIONAL BIOCHEMISTRY
LA English
DT Article
DE phospholipid hydroperoxide glutathione peroxidase; vitamin E; membrane;
   aging; n-3 fatty acids
ID LIPID-PEROXIDATION; FATTY-ACIDS; RAT-LIVER; FOOD RESTRICTION;
   MODULATION; FISH; ATHEROSCLEROSIS; ANTIOXIDANTS; CHOLESTEROL; TOCOPHEROL
AB Age and diet-induced variations of phospholipid hydroperoxide glutathione peroxidase (PHGPx) activity and alpha -tocopherol concentration in the liver microsomal membrane were studied in male Wistar rats fed a semipurified diet either balanced in n-6 and n-3 polyunsaturated fatty acids (PUFA) (Control) or deprived of alpha -linolenic acid, i.e. n-3 PUFA (Deficient) over two generations. The animals were studied at the age of 6 months (adult) or 24 months (old). Both PHGPx activity and vitamin E level were significantly higher in 24-month old rats as compared to 6-month old rats. By contrast, the thiobarbituric acid reactive substances (TBARS) following stimulated in vitro peroxidation of membrane lipids were markedly lower (P < 0.01) with aging. The fatty acid composition of microsomal membrane phospholipids (PL) was also considerably modified by age. In particular, the levels of arachidonic acid and total n-6 PUFA were lower (P < 0.001) whereas n-3 PUFA levels were higher (P < 0.001) in most PL main classes. The alpha -linolenic acid deficiency markedly influenced these age-related changes. The higher PHGPx activity in the old rats as compared to the adult rats was only significant in those fed the control diet. In the 6-month old rats (but not in the 24-month old rats), the deficient diet led to a higher membrane vitamin E level and to lower TBARS production than the control diet. The results suggest that the nature of dietary PUFA may influence the age-related variations in this pair of membrane antioxidants and also in the fatty acid composition of microsomes. (C) 2001 Elsevier Science Inc. All rights reserved.
C1 Fac Pharm, INRA, F-75270 Paris 06, France.
   INRA, F-78352 Jouy En Josas, France.
C3 INRAE; INRAE; Universite Paris Saclay
RP Christon, R (corresponding author), Fac Pharm, INRA, 4 Ave Observ, F-75270 Paris 06, France.
CR Arivazhagan P, 2000, J NUTR BIOCHEM, V11, P122, DOI 10.1016/S0955-2863(99)00079-0
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   BROWN JE, 1990, CLIN CHIM ACTA, V193, P147, DOI 10.1016/0009-8981(90)90246-O
   BYUN DS, 1995, AGING-CLIN EXP RES, V7, P40, DOI 10.1007/BF03324291
   CAND F, 1989, FREE RADICAL BIO MED, V7, P59, DOI 10.1016/0891-5849(89)90101-9
   CHRISTON R, 1995, J NUTR, V125, P3062
   CHRISTON R, 1992, J NUTR BIOCHEM, V3, P510, DOI 10.1016/0955-2863(92)90072-Q
   Cockell KA, 1996, J NUTR BIOCHEM, V7, P333, DOI 10.1016/0955-2863(96)00053-8
   Crosby AJ, 1996, BBA-LIPID LIPID MET, V1303, P187, DOI 10.1016/0005-2760(96)00093-8
   DAQUINO M, 1991, FREE RADICAL RES COM, V12-3, P147, DOI 10.3109/10715769109145779
   DEQUIROGA GB, 1990, BIOCHEM J, V272, P247
   FAROOQUI MYH, 1984, LIFE SCI, V34, P2413, DOI 10.1016/0024-3205(84)90430-2
   Giannelli Paul C., 1997, VIRGINIA J SOCIAL PO, V4, P439
   Godeas C, 1997, BIOL REPROD, V57, P1502, DOI 10.1095/biolreprod57.6.1502
   HALLFRISCH J, 1994, AM J CLIN NUTR, V60, P176, DOI 10.1093/ajcn/60.2.176
   HRELIA S, 1990, BIOCHEM INT, V22, P659
   Imai H, 1998, J BIOL CHEM, V273, P1990, DOI 10.1074/jbc.273.4.1990
   LAGANIERE S, 1993, GERONTOLOGY, V39, P7, DOI 10.1159/000213509
   MAIORINO M, 1990, METHOD ENZYMOL, V186, P448
   MAIORINO M, 1989, LIPIDS, V24, P721, DOI 10.1007/BF02535211
   MEYDANI M, 1992, AGE, V15, P89, DOI 10.1007/BF02435007
   MEYDANI SN, 1987, LIPIDS, V22, P345, DOI 10.1007/BF02534004
   MEYDANI SN, 1992, J NUTR, V122, P1627, DOI 10.1093/jn/122.8.1627
   Nam SY, 1997, GENE, V198, P245, DOI 10.1016/S0378-1119(97)00321-1
   PAGLIA DE, 1967, J LAB CLIN MED, V70, P158
   PARINANDI NL, 1990, ARCH BIOCHEM BIOPHYS, V280, P45, DOI 10.1016/0003-9861(90)90516-2
   Pironi L, 1998, AM J CLIN NUTR, V68, P888, DOI 10.1093/ajcn/68.4.888
   RICHTER C, 1995, INT J BIOCHEM CELL B, V27, P647, DOI 10.1016/1357-2725(95)00025-K
   RIKANS LE, 1991, BIOCHIM BIOPHYS ACTA, V1074, P195, DOI 10.1016/0304-4165(91)90061-K
   Rosenquist A, 1996, Z ERNAHRUNGSWISS, V35, P178, DOI 10.1007/BF01622867
   Rudel LL, 1998, PROG LIPID RES, V37, P353, DOI 10.1016/S0163-7827(98)00015-0
   Sokol RJ, 1998, GASTROENTEROLOGY, V114, P164, DOI 10.1016/S0016-5085(98)70644-4
   THOMAS JP, 1990, BIOCHIM BIOPHYS ACTA, V1045, P252, DOI 10.1016/0005-2760(90)90128-K
   Ursini F, 1997, BIOMED ENVIRON SCI, V10, P327
   VATASSERY GT, 1984, J NEUROCHEM, V43, P409, DOI 10.1111/j.1471-4159.1984.tb00916.x
   Vuillemier J. P., 1992, P143
   Witztum JL, 1998, CURR OPIN LIPIDOL, V9, P441, DOI 10.1097/00041433-199810000-00008
   ZHANG LP, 1989, BIOCHIM BIOPHYS ACTA, V1006, P140, DOI 10.1016/0005-2760(89)90336-6
NR 38
TC 9
Z9 10
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010 USA
SN 0955-2863
J9 J NUTR BIOCHEM
JI J. Nutr. Biochem.
PD AUG
PY 2001
VL 12
IS 8
BP 481
EP 491
DI 10.1016/S0955-2863(01)00165-6
PG 11
WC Biochemistry & Molecular Biology; Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Nutrition & Dietetics
GA 467RT
UT WOS:000170718100006
PM 11834207
DA 2024-02-19
ER

PT J
AU Luo, Z
   Zou, YB
   Xie, JX
   Cao, H
   Chen, YC
   Ding, YB
   Li, XP
   Deng, Y
   Wu, LL
AF Luo, Zheng
   Zou, Yongbin
   Xie, Jiaxin
   Cao, Hui
   Chen, Yichen
   Ding, Yibo
   Li, Xiaopan
   Deng, Yang
   Wu, Lile
TI Influence of Demographic Factors on Long-Term Trends of Premature
   Mortality and Burden Due to Liver Cancer: Findings From a
   Population-Based Study in Shanghai, China, 1973-2019
SO FRONTIERS IN PUBLIC HEALTH
LA English
DT Article
DE liver cancer; mortality; years of life lost; difference decomposition
   method; demographic factors
ID HEPATOCELLULAR-CARCINOMA; LIFE
AB ObjectiveLiver cancer is one of the most common causes of cancer-related death. Understanding how demographic factors influence mortality due to liver cancer is crucial for optimizing disease-control strategies. We aimed to characterize the long-term trends in the mortality and years of life lost (YLL) of liver cancer in Shanghai, China, 1973-2019, and quantitatively analyze the contributions of demographic and non-demographic factors on the mortality of liver cancer. MethodsUsing mortality data from the Mortality Registration System of Pudong New Area, the largest district of Shanghai with a population of permanent resident of 5.68 million, during 1973-2019, we analyzed the temporal trends for the mortality rates and YLL by Joinpoint Regression Program. The difference decomposition method was employed to estimate the increasing mortality rates related to demographic and non-demographic factors. ResultsA total of 21,530 deaths from liver cancer occurred from 1973 to 2019. The crude mortality rates (CMR) and age-standardized mortality rate by Segi's world standard population (ASMRW) of liver cancer were 26.73/10(5) person-years and 15.72/10(5) person-years, respectively. The CMR, ASMRW, and YLL rates of liver cancer showed significantly decreasing trends in males, females and the total population from 1973 to 2019, whereas the upward trends in the YLL were seen in males, females and the total population (all P < 0.05). A significant upward trend was observed in the increased CMR caused by demographic factors, but the changing rate caused by non-demographic factors decreased. ConclusionsThe CMR and ASMRW of liver cancer continually decreased although YLL increased during 1973-2019 in Pudong New Area, Shanghai. The demographic factors, especially aging, might be responsible for the increase in the mortality of liver cancer. More effective prevention strategies tailored to liver cancer are needed to further reduce its disease burden in the elderly population.
C1 [Luo, Zheng] Shanghai Univ Med & Hlth Sci, Dept Neurol, Affiliated Zhoupu Hosp, Shanghai, Peoples R China.
   [Zou, Yongbin; Cao, Hui] Chenzhou First Peoples Hosp, Dept Oncol, Chenzhou, Peoples R China.
   [Xie, Jiaxin] Army Med Univ, Dept High Altitude Operat Med, Chongqing, Peoples R China.
   [Chen, Yichen; Li, Xiaopan] Fudan Univ, Ctr Dis Control & Prevent Pudong New Area, Pudong Inst Prevent Med, Shanghai, Peoples R China.
   [Ding, Yibo] Second Mil Med Univ, Dept Epidemiol, Shanghai, Peoples R China.
   [Deng, Yang] Shandong First Med Univ & Shandong Acad Med Sci, Sch Publ Hlth, Tai An, Shandong, Peoples R China.
   [Wu, Lile] Southwest Med Univ, Dept Hepatobiliary Surg, Affiliated Hosp, Luzhou, Peoples R China.
C3 Shanghai University of Medicine & Health Sciences; Army Medical
   University; Shanghai Center for Disease Control & Prevention; Fudan
   University; Naval Medical University; Shandong First Medical University
   & Shandong Academy of Medical Sciences; Southwest Medical University
RP Li, XP (corresponding author), Fudan Univ, Ctr Dis Control & Prevent Pudong New Area, Pudong Inst Prevent Med, Shanghai, Peoples R China.; Deng, Y (corresponding author), Shandong First Med Univ & Shandong Acad Med Sci, Sch Publ Hlth, Tai An, Shandong, Peoples R China.; Wu, LL (corresponding author), Southwest Med Univ, Dept Hepatobiliary Surg, Affiliated Hosp, Luzhou, Peoples R China.
EM xiaopanli0224@126.com; dengyang3417@126.com; wbm_bigcat@hotmail.com
RI ding, yibo/AAL-5184-2020
OI Li, Xiaopan/0000-0002-9625-478X
CR Are C, 2017, J SURG ONCOL, V115, P591, DOI 10.1002/jso.24518
   Brustugun OT, 2014, BRIT J CANCER, V111, P1014, DOI 10.1038/bjc.2014.364
   Cen XZ, 2020, CANCER MED-US, V9, P1562, DOI 10.1002/cam4.2765
   Chen HY, 2018, BMC PUBLIC HEALTH, V18, DOI [10.1186/s12889-018-5112-7, 10.1186/s12889-018-5146-x]
   Chen WQ, 2016, CA-CANCER J CLIN, V66, P115, DOI 10.3322/caac.21338
   Cheng XJ, 2020, PLOS MED, V17, DOI 10.1371/journal.pmed.1003138
   Cucchetti A, 2016, ALIMENT PHARM THER, V43, P814, DOI 10.1111/apt.13554
   Deng Y, 2020, J VIRAL HEPATITIS, V27, P1150, DOI 10.1111/jvh.13353
   Fujiwara N, 2014, EUR J GASTROEN HEPAT, V26, P1039, DOI 10.1097/MEG.0000000000000161
   Lee CL, 2003, CANCER EPIDEM BIOMAR, V12, P57
   Li M, 2017, ONCOTARGET, V8, P92470, DOI 10.18632/oncotarget.21419
   Li XP, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00579
   Li XP, 2019, PREV MED, V118, P243, DOI 10.1016/j.ypmed.2018.11.002
   Liu ZQ, 2019, CANCER MED-US, V8, P5787, DOI 10.1002/cam4.2477
   Luo Z, 2021, FRONT NEUROL, V12, DOI 10.3389/fneur.2021.625042
   Luo Z, 2020, BMC PUBLIC HEALTH, V20, DOI 10.1186/s12889-020-09593-6
   McGlynn KA, 2021, HEPATOLOGY, V73, P4, DOI 10.1002/hep.31288
   Nakajima T, 2011, PATHOL INT, V61, P572, DOI 10.1111/j.1440-1827.2011.02743.x
   Roth GA, 2018, LANCET, V392, P1736, DOI 10.1016/s0140-6736(18)32203-7
   Shi JF, 2021, INT J CANCER, V148, P1051, DOI 10.1002/ijc.33313
   Sun YY, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2017-020490
   Sung H., 2021, CA Cancer J. Clin, V71, P209, DOI DOI 10.3322/caac.21660
   Tang X, 2018, J VIRAL HEPATITIS, V25, P1008, DOI 10.1111/jvh.12901
   Wang F, 2019, INT J ENV RES PUB HE, V16, DOI 10.3390/ijerph16162878
   Wang S, 2018, CAN MED ASSOC J, V190, pE1153, DOI 10.1503/cmaj.180272
   Yin JH, 2015, CANCER PREV RES, V8, P978, DOI 10.1158/1940-6207.CAPR-15-0160
   Zhang LJ, 2020, BMC PUBLIC HEALTH, V20, DOI 10.1186/s12889-020-09390-1
   Zhou MG, 2019, LANCET, V394, P1145, DOI 10.1016/S0140-6736(19)30427-1
NR 28
TC 5
Z9 5
U1 0
U2 9
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 2296-2565
J9 FRONT PUBLIC HEALTH
JI Front. Public Health
PD FEB 15
PY 2022
VL 10
AR 808917
DI 10.3389/fpubh.2022.808917
PG 11
WC Public, Environmental & Occupational Health
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Public, Environmental & Occupational Health
GA ZK9UH
UT WOS:000763326500001
PM 35242731
OA Green Published, gold
DA 2024-02-19
ER

PT J
AU Yu, XC
   Li, Z
   Liu, XR
   Hu, JN
   Liu, R
   Zhu, N
   Li, Y
AF Yu, Xiao-Chen
   Li, Zhen
   Liu, Xin-Ran
   Hu, Jia-Ni
   Liu, Rui
   Zhu, Na
   Li, Yong
TI The Antioxidant Effects of Whey Protein Peptide on Learning and Memory
   Improvement in Aging Mice Models
SO NUTRIENTS
LA English
DT Article
DE whey protein peptide; D-galactose; antioxidation; learning and memory
ID OXIDATIVE STRESS; SYNAPTIC PLASTICITY; ALZHEIMERS-DISEASE; BRAIN;
   MECHANISMS; NEUROGENESIS
AB This study investigated the antioxidant effects of whey protein peptide on learning and memory in aging C57BL/6N mice. A total of 72 SPF male C57BL/6N mice were used. Twelve mice were randomly selected as the control group, and the other mice were intraperitoneally injected with D-galactose (100 mg/kg body weight for 6 weeks), during which, the mice in the control group were intraperitoneally injected with the same amount of normal saline. After 6 weeks, the blood was taken from the epicanthus and the serum MDA level was measured, according to which, the mice were randomly divided into the model control group, the whey protein group (1.5 g/kg body weight), and three Whey protein peptide (WHP) intervention groups (0.3 g/kg body weight, 1.5 g/kg body weight, 3.0 g/kg body weight). The water solution of the test sample was administered by oral gavage every day. The intervention period was 30 days, during which, the model control group, the whey protein group, and the whey protein peptide group continued receiving intraperitoneal injections of D-galactose, while the control group continued receiving intraperitoneal injections of normal saline. After the intervention, behavioral experiments were conducted in the following order: open field test, water maze test, and new object recognition test. After the behavioral experiment, the morphology of hippocampal formation was observed by HE staining and TUNEL labeling. Oxidative stress-related indexes in the serum, liver, and brain were detected. Expression levels of the cholinergic system-related enzymes and proinflammatory cytokines in brain tissue were detected. Western blot was used to detect the expression of synaptic plasticity-related proteins in the mouse brain. The results showed that WHP could significantly improve the accumulation of MDA and PC, increase the activities of SOD and GSH-Px, resist oxidative stress injury, and enhance the potential of endogenous antioxidant defense mechanisms. WHP can significantly improve the decline of aging-related spatial exploration, body movement, and spatial and non-spatial learning/memory ability. Its specific mechanism may be related to reducing the degeneration of hippocampal nerve cells, reducing the apoptosis of nerve cells, improving the activity of AChE, reducing the expression of inflammatory factors (TNF-alpha and IL-1 beta) in brain tissue, reducing oxidative stress injury, and improving the expression of p-CaMKII and BDNF synaptic plasticity protein. These results indicate that WHP can improve aging-related oxidative stress, as well as learning and memory impairment.
C1 [Yu, Xiao-Chen; Li, Zhen; Liu, Xin-Ran; Hu, Jia-Ni; Liu, Rui; Zhu, Na; Li, Yong] Peking Univ, Sch Publ Hlth, Dept Nutr & Food Hyg, Beijing 100191, Peoples R China.
C3 Peking University
RP Li, Y (corresponding author), Peking Univ, Sch Publ Hlth, Dept Nutr & Food Hyg, Beijing 100191, Peoples R China.
EM xiaochenyu46@126.com; lizhenbjmu@163.com; liuhappy07@163.com;
   hujiani95@163.com; lrui_pku@163.com; summer920503@163.com;
   liyong@bjmu.edu.cn
RI Zeng, Yun/JFK-6190-2023; LU, Li/JFJ-9011-2023; Lu, Wang/JVO-0416-2024
OI Li, Yong/0000-0003-3914-5840
CR Ali T, 2015, J PINEAL RES, V58, P71, DOI 10.1111/jpi.12194
   Alkadhi KA, 2019, MOL NEUROBIOL, V56, P6566, DOI 10.1007/s12035-019-1541-2
   Ano Y, 2018, NEUROBIOL AGING, V72, P23, DOI 10.1016/j.neurobiolaging.2018.07.016
   Brightwell JJ, 2007, LEARN MEMORY, V14, P195, DOI 10.1101/lm.395407
   Burke SN, 2006, NAT REV NEUROSCI, V7, P30, DOI 10.1038/nrn1809
   Chatzipaschali AA, 2012, ENERGIES, V5, P3492, DOI 10.3390/en5093492
   de Magalhaes JP, 2005, MECH AGEING DEV, V126, P1026, DOI 10.1016/j.mad.2005.04.004
   Ferreira-Vieira TH, 2016, CURR NEUROPHARMACOL, V14, P101, DOI 10.2174/1570159X13666150716165726
   Fidaleo M, 2017, BIOCHEM PHARMACOL, V141, P63, DOI 10.1016/j.bcp.2017.05.016
   Fjell AM, 2014, PROG NEUROBIOL, V117, P20, DOI 10.1016/j.pneurobio.2014.02.004
   Garaschuk O, 2018, AGEING RES REV, V43, P26, DOI 10.1016/j.arr.2018.02.003
   Garg G, 2018, APPL PHYSIOL NUTR ME, V43, P437, DOI 10.1139/apnm-2017-0578
   HARMAN D, 1956, J GERONTOL, V11, P298, DOI 10.1093/geronj/11.3.298
   Hegde AN, 2019, LEARN MEMORY, V26, P307, DOI 10.1101/lm.048769.118
   Ho SC, 2003, BIOGERONTOLOGY, V4, P15, DOI 10.1023/A:1022417102206
   Lee HC, 1997, J BIOMED SCI, V4, P319, DOI 10.1007/BF02258357
   Liguori I., 2018, CLIN INTERV AGING, V13, P757, DOI [10.2147/CIA.S158513, DOI 10.2147/CIA.S158513]
   Lu T, 2004, NATURE, V429, P883, DOI 10.1038/nature02661
   Miller DB, 2005, AGEING RES REV, V4, P123, DOI 10.1016/j.arr.2005.03.002
   Morato PN, 2013, FOOD CHEM, V139, P853, DOI 10.1016/j.foodchem.2012.12.062
   Murakoshi H, 2017, NEURON, V94, P37, DOI 10.1016/j.neuron.2017.02.036
   Nabuco HCG, 2019, SCAND J MED SCI SPOR, V29, P1101, DOI 10.1111/sms.13449
   Nam SM, 2019, NUTRIENTS, V11, DOI 10.3390/nu11010176
   Patterson SL, 2015, NEUROPHARMACOLOGY, V96, P11, DOI 10.1016/j.neuropharm.2014.12.020
   Peng XY, 2014, INT DAIRY J, V34, P80, DOI 10.1016/j.idairyj.2013.08.004
   Qi WeiWei, 2015, China Dairy Industry, V43, P4
   Shao ZP, 2020, INT J FOOD MICROBIOL, V328, DOI 10.1016/j.ijfoodmicro.2020.108663
   Sharma P, 2019, CURR NEUROPHARMACOL, V17, P1158, DOI 10.2174/1570159X17666190809165549
   Shieh KR, 2020, CHINESE J PHYSIOL, V63, P27, DOI 10.4103/CJP.CJP_47_19
   Takemoto-Kimura S, 2017, J NEUROCHEM, V141, P808, DOI 10.1111/jnc.14020
   Toricelli M, 2021, NEURAL REGEN RES, V16, P58, DOI 10.4103/1673-5374.286952
   Travaglia A, 2018, LEARN MEMORY, V25, P176, DOI 10.1101/lm.046946.117
   Ullah F, 2015, NEUROCHEM INT, V90, P114, DOI 10.1016/j.neuint.2015.07.001
   West MJ, 2004, NEUROBIOL AGING, V25, P1205, DOI 10.1016/j.neurobiolaging.2003.12.005
   Yang HG, 2016, INT J FOOD SCI NUTR, V67, P806, DOI 10.1080/09637486.2016.1198890
   Yu XW, 2017, BEHAV BRAIN RES, V322, P206, DOI 10.1016/j.bbr.2016.07.042
NR 36
TC 16
Z9 16
U1 2
U2 45
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2072-6643
J9 NUTRIENTS
JI Nutrients
PD JUN
PY 2021
VL 13
IS 6
AR 2100
DI 10.3390/nu13062100
PG 22
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Nutrition & Dietetics
GA SZ4HD
UT WOS:000666527300001
PM 34205338
OA Green Published, gold
DA 2024-02-19
ER

PT J
AU Wang, ZQ
   BellFarrow, AD
   Sonntag, W
   Cefalu, WT
AF Wang, ZQ
   BellFarrow, AD
   Sonntag, W
   Cefalu, WT
TI Effect of age and caloric restriction on insulin receptor binding and
   glucose transporter levels in aging rats
SO EXPERIMENTAL GERONTOLOGY
LA English
DT Article; Proceedings Paper
CT AFAR/AGS Scientific Meeting
CY MAY, 1996
CL CHICAGO, IL
SP Amer Federat Aging Res, Amer Geriatr Soc
DE caloric restriction; insulin binding; insulin; glucose; glucose
   transporters; aging; receptors
ID SKELETAL-MUSCLE; DIETARY RESTRICTION; LIVER MEMBRANES; RESISTANCE;
   EXERCISE; RESPONSIVENESS; MATURATION; ADIPOCYTES; DECREASE; OBESITY
AB We report on the effect of age and chronic caloric restriction (CR) on insulin binding and glucose transporter content in both diaphragm and heart muscle membrane of young (11 months), mid-age (17 months), and old (29 month) ad libitum fed and CR Brown-Norway rats. The control animals received rat chow ad lib and CR animals were allowed 60% of ad libitum food. The CR regimen was initiated at four months of age and the animals were maintained on their respective diets until necropsy. There was no effect of age on insulin binding for either ad libitum or CR animals at each age evaluated. Caloric restriction significantly lowered insulin levels at each age studied when compared to the ad libitum-fed rats. However, CR animals were noted to have increased insulin binding (p < 0.001) compared to ad libitum-fed animals at each age for diaphragm muscle. For the heart, there appeared to be a decreased binding, particularly at higher insulin concentrations, in CR-fed animals. There was no net change in Glut-1 or Glut-4 levels for heart muscle membrane, or Glut-4 levels for diaphragm muscle membrane between an libitum or CR animals. This data indicates that caloric restriction may have tissue-specific effects for insulin receptor binding, and that the improved insulin sensitivity in CR states is not a result of altered glucose transporter protein content. (C) 1997 Elsevier Science Inc.
C1 WAKE FOREST UNIV,BOWMAN GRAY SCH MED,DEPT INTERNAL MED ENDOCRINOL,WINSTON SALEM,NC 27157.
   WAKE FOREST UNIV,BOWMAN GRAY SCH MED,DEPT PHYSIOL & PHARMACOL,WINSTON SALEM,NC 27157.
C3 Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest
   University; Wake Forest Baptist Medical Center
OI sonntag, William/0000-0003-1850-2407
FU NIA NIH HHS [AG00578] Funding Source: Medline
CR BALAGE M, 1990, HORM METAB RES, V22, P207, DOI 10.1055/s-2007-1004886
   BALDINI P, 1988, MECH AGEING DEV, V42, P17, DOI 10.1016/0047-6374(88)90059-0
   BARNARD RJ, 1992, AM J PHYSIOL, V262, pE619, DOI 10.1152/ajpendo.1992.262.5.E619
   BOLINDER J, 1983, DIABETES, V32, P959, DOI 10.2337/diabetes.32.10.959
   CARTEE GD, 1994, AM J PHYSIOL, V266, pR1443, DOI 10.1152/ajpregu.1994.266.5.R1443
   CARTEE GD, 1993, J GERONTOL, V48, pB168, DOI 10.1093/geronj/48.4.B168
   CARTEE GD, 1993, J APPL PHYSIOL, V75, P972, DOI 10.1152/jappl.1993.75.2.972
   CECCHIN F, 1988, AM J PHYSIOL, V254, pE294
   CEFALU WT, 1991, CLIN CHEM, V37, P1252
   CEFALU WT, 1995, J GERONTOL A-BIOL, V50, pB337, DOI 10.1093/gerona/50A.6.B337
   Cefalu WT, 1997, J GERONTOL A-BIOL, V52, pB10, DOI 10.1093/gerona/52A.1.B10
   CLARK JB, 1982, ENDOCRINOLOGY, V111, P964, DOI 10.1210/endo-111-3-964
   DCOSTA AP, 1993, MECH AGEING DEV, V71, P59, DOI 10.1016/0047-6374(93)90035-P
   EIFFERT KC, 1991, J NUTR, V121, P1081, DOI 10.1093/jn/121.7.1081
   FREYCHET P, 1971, BIOCHEM BIOPH RES CO, V43, P400, DOI 10.1016/0006-291X(71)90767-4
   FULOP T, 1987, ARCH GERONTOL GERIAT, V6, P107, DOI 10.1016/0167-4943(87)90003-3
   GRUNDLEGER ML, 1980, AM J PHYSIOL, V239, pE363, DOI 10.1152/ajpendo.1980.239.5.E363
   GULVE EA, 1993, AM J PHYSIOL, V264, pE319, DOI 10.1152/ajpendo.1993.264.3.E319
   HALL JL, 1994, J APPL PHYSIOL, V76, P328, DOI 10.1152/jappl.1994.76.1.328
   HANSEN BC, 1993, DIABETES, V42, P1809, DOI 10.2337/diabetes.42.12.1809
   HELDERMAN JH, 1980, J GERONTOL, V35, P329, DOI 10.1093/geronj/35.3.329
   HOLLENBERG MD, 1979, MECH AGEING DEV, V11, P37, DOI 10.1016/0047-6374(79)90062-9
   HOUMARD JA, 1995, DIABETES, V44, P555, DOI 10.2337/diabetes.44.5.555
   IVY JL, 1991, MECH AGEING DEV, V61, P123, DOI 10.1016/0047-6374(91)90011-N
   JONCOURT F, 1985, GERONTOLOGY, V31, P293, DOI 10.1159/000212712
   KAHN BB, 1992, J CLIN INVEST, V89, P1367, DOI 10.1172/JCI115724
   KALANT N, 1988, MECH AGEING DEV, V46, P89, DOI 10.1016/0047-6374(88)90117-0
   KEMNITZ JW, 1994, AM J PHYSIOL, V266, pE540, DOI 10.1152/ajpendo.1994.266.4.E540
   KERN M, 1992, AM J PHYSIOL, V263, pE362, DOI 10.1152/ajpendo.1992.263.2.E362
   KLIP A, 1987, FEBS LETT, V224, P224, DOI 10.1016/0014-5793(87)80452-0
   LIN JL, 1991, DIABETOLOGIA, V34, P477, DOI 10.1007/BF00403283
   LOCKWOOD DH, 1978, DIABETES, V27, P589, DOI 10.2337/diabetes.27.5.589
   LONNROTH P, 1986, J CLIN ENDOCR METAB, V62, P433
   LORD JM, 1985, DIABETES RES CLIN EX, V2, P259
   LOUBASSOU S, 1989, ANDROLOGIA, V4, P377
   MASORO EJ, 1992, J GERONTOL, V47, pB202, DOI 10.1093/geronj/47.6.B202
   MASORO EJ, 1993, J AM GERIATR SOC, V41, P994, DOI 10.1111/j.1532-5415.1993.tb06767.x
   MASORO EJ, 1983, J NUTR, V113, P880, DOI 10.1093/jn/113.4.880
   MATTHAEI S, 1990, J ENDOCRINOL, V126, P99, DOI 10.1677/joe.0.1260099
   MCCONNELL JG, 1982, EUR J CLIN INVEST, V12, P55, DOI 10.1111/j.1365-2362.1982.tb00939.x
   MURRAY TM, 1993, METABOLISM, V42, P140, DOI 10.1016/0026-0495(93)90027-L
   *NAT RES COUNC, 1978, NUTR REQ LAB AN
   PAGANO G, 1981, METABOLISM, V30, P46, DOI 10.1016/0026-0495(81)90217-1
   REAVEN E, 1983, DIABETES, V32, P175, DOI 10.2337/diabetes.32.2.175
   REED MJ, 1993, J GERONTOL, V48, pB139, DOI 10.1093/geronj/48.4.B139
   ROWE JW, 1983, J CLIN INVEST, V71, P1581, DOI 10.1172/JCI110914
   SNYDER DL, 1989, PROGR CLIN BIOL RES, P284
   SORRENTINO SN, 1976, EXP AGING RES, V2, P191
   TCHILIAN EZ, 1990, NEUROPEPTIDES, V17, P193, DOI 10.1016/0143-4179(90)90035-W
   TRISCHITTA V, 1988, AM J PHYSIOL, V17, pE39
   VERSPOHL EJ, 1983, ENDOCRINOLOGY, V112, P2147, DOI 10.1210/endo-112-6-2147
   WEINDRUCH R, 1988, RETARDATION AGING DI
   YKIJARVINEN H, 1986, ACTA ENDOCRINOL-COP, V113, P88, DOI 10.1530/acta.0.1130088
   [No title captured]
NR 54
TC 38
Z9 39
U1 0
U2 1
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB
SN 0531-5565
J9 EXP GERONTOL
JI Exp. Gerontol.
PD NOV-DEC
PY 1997
VL 32
IS 6
BP 671
EP 684
DI 10.1016/S0531-5565(97)00054-5
PG 14
WC Geriatrics & Gerontology
WE Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)
SC Geriatrics & Gerontology
GA YJ452
UT WOS:A1997YJ45200006
PM 9785093
DA 2024-02-19
ER

PT J
AU Yu, XM
   Li, SJ
   Yang, D
   Qiu, L
   Wu, YP
   Wang, DY
   Shah, NP
   Xu, F
   Wei, H
AF Yu, Xiaomin
   Li, Shengjie
   Yang, Dong
   Qiu, Liang
   Wu, Yaoping
   Wang, Dengyuan
   Shah, Nagendra P.
   Xu, Feng
   Wei, Hua
TI A novel strain of <i>Lactobacillus</i> <i>mucosae</i> isolated from a
   Gaotian villager improves in vitro and in vivo antioxidant as well as
   biological properties in D-galactose-induced aging mice
SO JOURNAL OF DAIRY SCIENCE
LA English
DT Article
DE antioxidant activity; 2,2-diphenyl-1-picrylhydrazyl; hydroxyl radical;
   reducing power; D-galactose-induced aging mice
ID ASPARTATE-AMINOTRANSFERASE AST; OXIDATIVE STRESS; ANTIBACTERIAL
   ACTIVITIES; CAPACITY; EXOPOLYSACCHARIDES; HEALTHY; ALT
AB Twelve isolates isolated from the gastrointestinal tracts of Gaotian villagers in China, who had a lifespan of 92 yr, were examined for their antioxidants using free radical scavenging activity and 2,2-diphenyl-1-picrylhydrazyl. Three strains (i.e., Lactobacillus mucosae LMU1001, and Lactobacillus plantarum LPL0902 and LPL0302) were selected as candidates to prepare yogurt for testing their antioxidants in a model of D-galactose-induced aging mice, with vitamin C as a positive control. The results showed that L. mucosae LMU1001 was the best strain, which had similar in vivo antioxidant activity as vitamin C. A significant increase was found in the activities of glutathione peroxidase in serum and total superoxide dismutase in the liver, and a decrease in the level of malondialdehyde in serum. Regarding mRNA expression level detected quantitatively by real-time PCR, we observed that L. mucosae LMU1001 significantly upregulated antioxidant genes (i.e., MT1A and MT1M in HT-29 and Caco-2) and those genes (i.e., MT1, MT2, GPx1, and GPx2) in the intestinal tract of the model mice. Hence, this strain could be considered as a potential probiotic lactic acid bacterium for improving antioxidant levels in functional foods.
C1 [Yu, Xiaomin; Li, Shengjie; Yang, Dong; Qiu, Liang; Wu, Yaoping; Wang, Dengyuan; Xu, Feng; Wei, Hua] Nanchang Univ, State Key Lab Food Sci & Technol, Nanchang 330047, Jiangxi, Peoples R China.
   [Yu, Xiaomin; Li, Shengjie; Yang, Dong; Qiu, Liang; Wu, Yaoping; Wang, Dengyuan; Wei, Hua] Nanchang Univ, Jiangxi OAI Joint Res Inst, 235 Nanjing Donglu, Nanchang 330047, Jiangxi, Peoples R China.
   [Li, Shengjie] Jiangxi Acad Agr Sci, Inst Appl Agr Microbiol, 602 Nanlian Rd, Nanchang 330200, Jiangxi, Peoples R China.
   [Shah, Nagendra P.] Univ Hong Kong, Sch Biol Sci, Food & Nutr Sci, Pokfulam Rd, Hong Kong, Hong Kong, Peoples R China.
C3 Nanchang University; Nanchang University; Jiangxi Academy of
   Agricultural Sciences; University of Hong Kong
RP Xu, F (corresponding author), Nanchang Univ, State Key Lab Food Sci & Technol, Nanchang 330047, Jiangxi, Peoples R China.
EM ziwu211@126.com; weihua114@live.cn
RI Li, Shengjie/CAG-9358-2022; Li, Shengjie/CAG-9391-2022
OI Li, Shengjie/0000-0002-0680-2667; Yang, Dong/0000-0003-3207-7953; WEI,
   HUA/0000-0003-4341-8290
FU Chinese High-Tech RD (863) program [2014AA022209]; National Natural
   Science Foundation of China [NSF31170091, 31260363, 81160494, 31000048];
   Ganpo Talent 555 Engineering Project of Jiangxi Province; Academic and
   Technical Leaders Training Program for Major Subjects of Jiangxi
   Province
FX This project was sponsored by the Chinese High-Tech R&D (863) program
   (2014AA022209), the National Natural Science Foundation of China
   (NSF31170091, 31260363, 81160494, 31000048), Ganpo Talent 555
   Engineering Project of Jiangxi Province, and the Academic and Technical
   Leaders Training Program for Major Subjects of Jiangxi Province (2009).
CR Arasu MV, 2015, INDIAN J MICROBIOL, V55, P19, DOI 10.1007/s12088-014-0495-3
   Biagi E, 2015, METABONOMICS GUT MIC, P169
   Ceriotti F, 2010, CLIN CHEM LAB MED, V48, P1593, DOI 10.1515/CCLM.2010.315
   Çoban J, 2014, GERIATR GERONTOL INT, V14, P490, DOI 10.1111/ggi.12096
   Deelen J, 2014, HUM MOL GENET, V23, P4420, DOI 10.1093/hmg/ddu139
   Dilna SV, 2015, LWT-FOOD SCI TECHNOL, V64, P1179, DOI 10.1016/j.lwt.2015.07.040
   Feng YN, 2010, VET MICROBIOL, V140, P116, DOI 10.1016/j.vetmic.2009.07.001
   Ferreira ICFR, 2007, FOOD CHEM, V100, P1511, DOI 10.1016/j.foodchem.2005.11.043
   Joly F, 2010, BIOCHIMIE, V92, P753, DOI 10.1016/j.biochi.2010.02.015
   Kanno T, 2012, LWT-FOOD SCI TECHNOL, V47, P25, DOI 10.1016/j.lwt.2012.01.007
   LeBlanc JG, 2011, J BIOTECHNOL, V151, P287, DOI 10.1016/j.jbiotec.2010.11.008
   Li SJ, 2014, J DAIRY SCI, V97, P7334, DOI 10.3168/jds.2014-7912
   Li SQ, 2014, FOOD CHEM, V165, P262, DOI 10.1016/j.foodchem.2014.05.110
   Li W, 2014, CARBOHYD POLYM, V102, P351, DOI 10.1016/j.carbpol.2013.11.053
   London LEE, 2014, J APPL MICROBIOL, V117, P509, DOI 10.1111/jam.12542
   Makarova K, 2006, P NATL ACAD SCI USA, V103, P15611, DOI 10.1073/pnas.0607117103
   Marazza JA, 2012, J FUNCT FOODS, V4, P594, DOI 10.1016/j.jff.2012.03.005
   Mera JR, 2008, DIGEST DIS SCI, V53, P799, DOI 10.1007/s10620-007-9924-z
   Persichetti E, 2014, NUTRITION, V30, P936, DOI 10.1016/j.nut.2013.12.009
   Prather AA, 2015, TRANSL PSYCHIAT, V5, DOI 10.1038/tp.2015.81
   Ramesh T, 2012, NUTR RES, V32, P718, DOI 10.1016/j.nutres.2012.08.005
   Roos S, 2000, INT J SYST EVOL MICR, V50, P251, DOI 10.1099/00207713-50-1-251
   Schulkens IA, 2014, J VASC RES, V51, P231, DOI 10.1159/000365550
   Song X, 1999, MECH AGEING DEV, V108, P239, DOI 10.1016/S0047-6374(99)00022-6
   Van den Abbeele P, 2012, MICROB BIOTECHNOL, V5, P106, DOI 10.1111/j.1751-7915.2011.00308.x
   Woo JY, 2014, ANAEROBE, V27, P22, DOI 10.1016/j.anaerobe.2014.03.003
   Yan WS, 2006, J BIOL CHEM, V281, P7856, DOI 10.1074/jbc.M512655200
   Yang HY, 2009, NUTR RES, V29, P281, DOI 10.1016/j.nutres.2009.03.010
   Yu XM, 2015, APPL MICROBIOL BIOT, V99, P9085, DOI 10.1007/s00253-015-6888-3
   Zhang Y, 2010, EUR FOOD RES TECHNOL, V231, P151, DOI 10.1007/s00217-010-1255-1
   Zhang ZF, 2009, J AGR FOOD CHEM, V57, P7731, DOI 10.1021/jf9012357
   Zhao LA, 2011, CURR MICROBIOL, V62, P64, DOI 10.1007/s00284-010-9676-4
NR 32
TC 38
Z9 44
U1 1
U2 37
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0022-0302
EI 1525-3198
J9 J DAIRY SCI
JI J. Dairy Sci.
PD FEB
PY 2016
VL 99
IS 2
BP 903
EP 914
DI 10.3168/jds.2015-10265
PG 12
WC Agriculture, Dairy & Animal Science; Food Science & Technology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Agriculture; Food Science & Technology
GA DB4FH
UT WOS:000368468400002
PM 26709186
OA hybrid
DA 2024-02-19
ER

PT J
AU Nur, G
   Yildiz, SE
   Nazli, M
   Sözmen, M
AF Nur, Gokhan
   Yildiz, Sevda Elis
   Nazli, Mumtaz
   Sozmen, Mahmut
TI Immunohistochemical distribution of COX-1 and COX-2 in the liver to
   during the puberty period of rats applied with capsaicin
SO ANKARA UNIVERSITESI VETERINER FAKULTESI DERGISI
LA English
DT Article
DE Capsaicin; COX-1; COX-2; immunohistochemistry; liver
ID CYCLOOXYGENASE-2 EXPRESSION; CAPSICUM; PROSTAGLANDINS; RECEPTOR; DAMAGE;
   NERVE
AB In this study, the effect of capsaicin on the immunohistochemical distribution of cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) were examined in liver of the rat at the pubertal age. Thirty rats (Sprague-Dawley) aging 50 days old were used in this study. Rats were divided into three groups; experimental, sham and control group. Experimental group (n = 10) rats, was injected 1 mg / kg doses of capsaicin (10% ethanol, 1% tween, containing 80% distilled water mixture) subcutaneously every day for a period of one week. Sham group (n = 10) rats, were subcutaneously injected with a mixture containing 10% ethanol and 1% tween within 80% distilled water. The control group made no application. A week after the last injection, rats of three groups body was weighed and euthanized with ether anesthesia and liver tissues were taken. Body weights compared within the groups. The tissue localization of COX-1 and COX-2 was analysed by immunohistochemical method. Streptavidin-biotin-peroxidase complex technique was applied. COX-1 immunoreactivity experimental, sham and control groups were observed in centralis vein and the environment Kiernan centrilobuler region. Immunoreactivity was found in similar concentrations in all three groups. COX-2 is a experimental, sham and control groups were observed in centralis vein and Kiernan centrilobuler region in the portal area.
C1 [Nur, Gokhan] Hatay Gida Kontrol Lab Mudurlugu, Antakya, Turkey.
   [Yildiz, Sevda Elis] Kafkas Univ, Kars Sagl Yuksekokulu, Kars, Turkey.
   [Nazli, Mumtaz] Mehmet Akif Ersoy Univ, Tip Fak, Histol Embriyol Anabilim Dali, Burdur, Turkey.
   [Sozmen, Mahmut] Ondokuz Mayis Univ, Vet Fak, Patol Anabilim Dali, Samsun, Turkey.
C3 Kafkas University; Mehmet Akif Ersoy University; Ondokuz Mayis
   University
RP Yildiz, SE (corresponding author), Kafkas Univ, Sagl Yuksekokulu, Kars, Turkey.
EM sevdaelis36@hotmail.com
RI Sozmen, Mahmut/JUU-6343-2023
OI Sozmen, Mahmut/0000-0001-7976-4051
CR Bhandari P, 2005, HISTOPATHOLOGY, V46, P280, DOI 10.1111/j.1365-2559.2005.02053.x
   Birnbaum Y, 2005, CARDIOVASC RES, V65, P345, DOI 10.1016/j.cardiores.2004.10.018
   Cao M., 2008, J NANJING MED U, V22, P111
   Caterina MJ, 2001, ANNU REV NEUROSCI, V24, P487, DOI 10.1146/annurev.neuro.24.1.487
   Dubois RN, 1998, FASEB J, V12, P1063, DOI 10.1096/fasebj.12.12.1063
   Heitmeier MR, 2004, J BIOL CHEM, V279, P53145, DOI 10.1074/jbc.M410978200
   Inoue H, 2000, J BIOL CHEM, V275, P28028
   JANCSO G, 1983, J PHYSIOL-LONDON, V341, P359, DOI 10.1113/jphysiol.1983.sp014810
   KAWADA T, 1988, P SOC EXP BIOL MED, V188, P229, DOI 10.3181/00379727-188-2-RC1
   KAWADA T, 1986, J NUTR, V116, P1272, DOI 10.1093/jn/116.7.1272
   Keller SA, 2005, J SURG RES, V124, P126, DOI 10.1016/j.jss.2004.09.011
   Kress M, 1999, NEUROSCIENCE, V89, P303, DOI 10.1016/S0306-4522(98)00280-2
   LEMBECK F, 1987, ACTA PHYSIOL HUNG, V69, P265
   Liang YC, 1999, CARCINOGENESIS, V20, P1945, DOI 10.1093/carcin/20.10.1945
   MELNYK A, 1995, OBES RES, V3, P337, DOI 10.1002/j.1550-8528.1995.tb00159.x
   MONSEREENUSORN Y, 1983, RES COMMUN CHEM PATH, V41, P95
   Oh TW, 2003, BRIT J NUTR, V90, P515, DOI 10.1079/BJN2003919
   Park ES, 2004, J VET MED SCI, V66, P107, DOI 10.1292/jvms.66.107
   Sahin AF, 2008, THESIS DUZCE U SAGLI
   SAMBAIAH K, 1982, J BIOSCIENCE, V4, P425, DOI 10.1007/BF02704635
   Seidal T, 2001, AM J SURG PATHOL, V25, P1204, DOI 10.1097/00000478-200109000-00013
   SHU SY, 1988, NEUROSCI LETT, V85, P169, DOI 10.1016/0304-3940(88)90346-1
   Smith WL, 1996, J BIOL CHEM, V271, P33157, DOI 10.1074/jbc.271.52.33157
   Smith WL, 2000, ANNU REV BIOCHEM, V69, P145, DOI 10.1146/annurev.biochem.69.1.145
   SRINIVASAN MR, 1987, J BIOSCIENCE, V12, P143, DOI 10.1007/BF02702966
   Szallasi A, 1999, PHARMACOL REV, V51, P159
   Takahata K, 1999, LIFE SCI, V64, pPL165, DOI 10.1016/S0024-3205(99)00046-6
   Takeeda M, 2004, J PHYSIOL PHARMACOL, V55, P193
   Teng CH, 1998, J GASTROEN HEPATOL, V13, P1007, DOI 10.1111/j.1440-1746.1998.tb00562.x
   Tominaga M, 2000, JPN J PHARMACOL, V83, P20, DOI 10.1254/jjp.83.20
   Turini ME, 2002, ANNU REV MED, V53, P35, DOI 10.1146/annurev.med.53.082901.103952
   Tutuncu S, 2009, THESIS
   Vane JR, 1998, PHARMACOL TOXICOL, V38, P97
   Yar A. S., 2008, THESIS
   Zhu Q Y, 1989, Zhonghua Yi Xue Za Zhi, V69, P573
NR 35
TC 1
Z9 1
U1 1
U2 2
PU ANKARA UNIV PRESS
PI ANKARA
PA INCITAS SOKAK NO. 10, BESEVLER, ANKARA, 06510, TURKEY
SN 1300-0861
EI 1308-2817
J9 ANKARA UNIV VET FAK
JI Ank. Univ. Vet. Fak. Derg.
PY 2015
VL 62
IS 1
BP 45
EP 50
DI 10.1501/Vetfak_0000002656
PG 6
WC Veterinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Veterinary Sciences
GA CB5EW
UT WOS:000349651300008
OA Bronze
DA 2024-02-19
ER

PT J
AU Bouchlaka, MN
   Sckisel, GD
   Chen, MY
   Mirsoian, A
   Zamora, AE
   Maverakis, E
   Wilkins, DEC
   Alderson, KL
   Hsiao, HH
   Weiss, JM
   Monjazeb, AM
   Hesdorffer, C
   Ferrucci, L
   Longo, DL
   Blazar, BR
   Wiltrout, RH
   Redelman, D
   Taub, DD
   Murphy, WJ
AF Bouchlaka, Myriam N.
   Sckisel, Gail D.
   Chen, Mingyi
   Mirsoian, Annie
   Zamora, Anthony E.
   Maverakis, Emanual
   Wilkins, Danice E. C.
   Alderson, Kory L.
   Hsiao, Hui-Hua
   Weiss, Jonathan M.
   Monjazeb, Arta M.
   Hesdorffer, Charles
   Ferrucci, Luigi
   Longo, Dan L.
   Blazar, Bruce R.
   Wiltrout, Robert H.
   Redelman, Doug
   Taub, Dennis D.
   Murphy, William J.
TI Aging predisposes to acute inflammatory induced pathology after tumor
   immunotherapy
SO JOURNAL OF EXPERIMENTAL MEDICINE
LA English
DT Article
ID NECROSIS-FACTOR-ALPHA; TNF-ALPHA; IFN-GAMMA; RHEUMATOID-ARTHRITIS;
   INSULIN-RESISTANCE; IN-VIVO; INTERLEUKIN-6; CANCER; ANTITUMOR; BLOCKADE
AB Cancer commonly occurs in the elderly and immunotherapy (IT) is being increasingly applied to this population. However, the majority of preclinical mouse tumor models assessing potential efficacy and toxicities of therapeutics use young mice. We assessed the impact of age on responses to systemic immune stimulation. In contrast to young mice, systemic cancer IT regimens or LPS given to aged mice resulted in rapid and lethal toxicities affecting multiple organs correlating with heightened proinflammatory cytokines systemically and within the parenchymal tissues. This inflammatory response and increased morbidity with age was independent of T cells or NK cells. However, prior in vivo depletion of macrophages in aged mice resulted in lesser cytokine levels, increased survival, and decreased liver histopathology. Furthermore, macrophages from aged mice and normal human elderly volunteers displayed heightened TNF and IL-6 production upon in vitro stimulation. Treatment of both TNF knock-out mice and in vivo TNF blockade in aged mice resulted in significant increases in survival and lessened pathology. Importantly, TNF blockade in tumor-bearing, aged mice receiving IT displayed significant anti-tumor effects. These data demonstrate the critical role of macrophages in the age-associated hyper-inflammatory cytokine responses to systemic immuno-stimulation and underscore the importance of performing preclinical assessments in aged mice.
C1 [Bouchlaka, Myriam N.; Wilkins, Danice E. C.; Alderson, Kory L.] Univ Nevada, Dept Microbiol & Immunol, Reno Sch Med, Reno, NV 89557 USA.
   [Redelman, Doug] Univ Nevada, Dept Physiol & Cell Biol, Reno Sch Med, Reno, NV 89557 USA.
   [Sckisel, Gail D.; Mirsoian, Annie; Zamora, Anthony E.; Hsiao, Hui-Hua; Murphy, William J.] Univ Calif Davis, Dept Dermatol, Davis, CA 95817 USA.
   [Chen, Mingyi] Univ Calif Davis, Dept Pathol & Lab Med, Davis, CA 95817 USA.
   [Monjazeb, Arta M.] Univ Calif Davis, Dept Radiat Oncol, Davis, CA 95817 USA.
   [Murphy, William J.] Univ Calif Davis, Dept Internal Med, Davis, CA 95817 USA.
   [Maverakis, Emanual] VA Northern Calif Hlth Care Syst, Mather, CA 95655 USA.
   [Weiss, Jonathan M.; Wiltrout, Robert H.] NCI, Canc & Inflammat Program, Frederick, MD 21702 USA.
   [Hesdorffer, Charles; Ferrucci, Luigi] NIA, Clin Res Branch, Baltimore, MD 21224 USA.
   [Longo, Dan L.; Taub, Dennis D.] NIA, Lab Immunol, Baltimore, MD 21224 USA.
   [Blazar, Bruce R.] Univ Minnesota, Div Blood & Marrow Transplantat, Dept Pediat, Minneapolis, MN 55455 USA.
C3 Nevada System of Higher Education (NSHE); University of Nevada Reno;
   Nevada System of Higher Education (NSHE); University of Nevada Reno;
   University of California System; University of California Davis;
   University of California System; University of California Davis;
   University of California System; University of California Davis;
   University of California System; University of California Davis;
   National Institutes of Health (NIH) - USA; NIH National Cancer Institute
   (NCI); National Institutes of Health (NIH) - USA; NIH National Institute
   on Aging (NIA); National Institutes of Health (NIH) - USA; NIH National
   Institute on Aging (NIA); University of Minnesota System; University of
   Minnesota Twin Cities
RP Murphy, WJ (corresponding author), Univ Calif Davis, Dept Dermatol, Davis, CA 95817 USA.
EM wmjmurphy@ucdavis.edu
RI Maverakis, Emanual/E-1185-2013; Longo, Dan L./F-6022-2011; Maverakis,
   Emanual/JWP-9408-2024; Zamora, Anthony E./O-2836-2017
OI Zamora, Anthony E./0000-0001-5712-5339; Maverakis,
   Emanual/0000-0002-6294-6294; Bouchlaka, Myriam/0000-0003-2865-0817
FU National Institutes of Health [CA0905572, AG034874]; Intramural Research
   Program of the National Institute on Aging, National Institutes of
   Health
FX This work was supported by grants from the National Institutes of Health
   (CA0905572 and AG034874) and by the Intramural Research Program of the
   National Institute on Aging, National Institutes of Health.
CR Aggarwal BB, 2003, NAT REV IMMUNOL, V3, P745, DOI 10.1038/nri1184
   Arthur JC, 2012, SCIENCE, V338, P120, DOI 10.1126/science.1224820
   Attarwala H, 2010, J Young Pharm, V2, P332, DOI 10.4103/0975-1483.66810
   Balkwill F, 2009, NAT REV CANCER, V9, P361, DOI 10.1038/nrc2628
   Berger C, 2009, BLOOD, V114, P2417, DOI 10.1182/blood-2008-12-189266
   BLAY JY, 1992, CANCER RES, V52, P3317
   BOCCOLI G, 1990, CANCER RES, V50, P5795
   Boparai MK, 2011, MT SINAI J MED, V78, P613, DOI 10.1002/msj.20278
   Brüünsgaard H, 2003, IMMUNOL ALLERGY CLIN, V23, P15, DOI 10.1016/S0889-8561(02)00056-5
   Calzascia T, 2007, J CLIN INVEST, V117, P3833, DOI 10.1172/JCI32567
   CARSWELL EA, 1975, P NATL ACAD SCI USA, V72, P3666, DOI 10.1073/pnas.72.9.3666
   Chen X, 2009, BLOOD, V114, P891, DOI 10.1182/blood-2009-01-197178
   Chung HY, 2009, AGEING RES REV, V8, P18, DOI 10.1016/j.arr.2008.07.002
   Cressman DE, 1996, SCIENCE, V274, P1379, DOI 10.1126/science.274.5291.1379
   Demetris AJ, 1997, HEPATOLOGY, V25, P658
   Di Giacomo AM, 2010, SEMIN ONCOL, V37, P499, DOI 10.1053/j.seminoncol.2010.09.007
   Dougan M, 2009, ANNU REV IMMUNOL, V27, P83, DOI 10.1146/annurev.immunol.021908.132544
   Ferrucci L, 2005, BLOOD, V105, P2294, DOI 10.1182/blood-2004-07-2599
   Franceschi C, 2000, ANN NY ACAD SCI, V908, P244
   Franceschi C, 2007, NUTR REV, V65, pS173, DOI 10.1301/nr.2007.dec.S173-S176
   Gallimore AM, 2013, NEW ENGL J MED, V368, P282, DOI 10.1056/NEJMcibr1212341
   GANTNER F, 1995, HEPATOLOGY, V21, P190, DOI 10.1016/0270-9139(95)90428-X
   Grounds MD, 2005, CELL TISSUE RES, V320, P509, DOI 10.1007/s00441-005-1102-z
   HACK CE, 1989, BLOOD, V74, P1704
   Hodgetts S, 2006, NEUROMUSCULAR DISORD, V16, P591, DOI 10.1016/j.nmd.2006.06.011
   Hooper LV, 2012, SCIENCE, V336, P1268, DOI 10.1126/science.1223490
   Hutchison S, 2008, CLIN EXP IMMUNOL, V151, P114, DOI 10.1111/j.1365-2249.2007.03509.x
   Jin XL, 2006, HEPATOLOGY, V43, P474, DOI 10.1002/hep.21087
   Kamada N, 2013, NAT REV IMMUNOL, V13, P321, DOI 10.1038/nri3430
   Kawa K, 2010, INT IMMUNOL, V22, P157, DOI 10.1093/intimm/dxp122
   Korngold R, 2003, BIOL BLOOD MARROW TR, V9, P292, DOI 10.1016/S1083-8791(03)00087-9
   Krüttgen A, 2012, J INTERF CYTOK RES, V32, P60, DOI 10.1089/jir.2011.0062
   Leon LR, 1998, AM J PHYSIOL-REG I, V275, pR269, DOI 10.1152/ajpregu.1998.275.1.R269
   McInnes IB, 1997, NAT MED, V3, P189, DOI 10.1038/nm0297-189
   Minor DR, 2009, CANCER BIOTHER RADIO, V24, P321, DOI 10.1089/cbr.2008.0607
   Munford RS, 2006, ANNU REV PATHOL-MECH, V1, P467, DOI 10.1146/annurev.pathol.1.110304.100200
   Murphy WJ, 2003, J IMMUNOL, V170, P2727, DOI 10.4049/jimmunol.170.5.2727
   Nemoto H, 2011, EXP MOL PATHOL, V90, P264, DOI 10.1016/j.yexmp.2011.02.003
   Paludan SR, 2000, J LEUKOCYTE BIOL, V67, P18, DOI 10.1002/jlb.67.1.18
   Repetto L, 2002, LANCET ONCOL, V3, P289, DOI 10.1016/S1470-2045(02)00730-1
   Rosas GO, 2001, J MOL CELL CARDIOL, V33, P1849, DOI 10.1006/jmcc.2001.1448
   Schett G, 2011, ARTHRITIS RES THER, V13, DOI [10.1186/ar3095, 10.1186/1478-6354-13-S1-S4]
   Senn JJ, 2003, J BIOL CHEM, V278, P13740, DOI 10.1074/jbc.M210689200
   Sethi G, 2008, FRONT BIOSCI-LANDMRK, V13, P5094, DOI 10.2741/3066
   SHALABY MR, 1989, CLIN IMMUNOL IMMUNOP, V53, P488, DOI 10.1016/0090-1229(89)90010-X
   SHERON N, 1990, CLIN EXP IMMUNOL, V82, P427
   Shock NW., 1984, NORMAL HUMAN AGING B
   SMITH SR, 1994, J LEUKOCYTE BIOL, V55, P711, DOI 10.1002/jlb.55.6.711
   Sopasakis VR, 2004, DIABETOLOGIA, V47, P1879, DOI 10.1007/s00125-004-1544-y
   Suntharalingam G, 2006, NEW ENGL J MED, V355, P1018, DOI 10.1056/NEJMoa063842
   Surguladze D, 2009, CANCER RES, V69, P5643, DOI 10.1158/0008-5472.CAN-09-0487
   Taylor PC, 2010, CURR OPIN PHARMACOL, V10, P308, DOI 10.1016/j.coph.2010.01.005
   Taylor PC, 2009, NAT REV RHEUMATOL, V5, P578, DOI 10.1038/nrrheum.2009.181
   Tietze JK, 2012, BLOOD, V119, P3073, DOI 10.1182/blood-2011-07-369736
   van Horssen R, 2006, ONCOLOGIST, V11, P397, DOI 10.1634/theoncologist.11-4-397
   Vonderheide RH, 2007, J CLIN ONCOL, V25, P876, DOI 10.1200/JCO.2006.08.3311
   Waldmann TA, 2006, NAT REV IMMUNOL, V6, P595, DOI 10.1038/nri1901
   Weber JS, 2012, J CLIN ONCOL, V30, P2691, DOI 10.1200/JCO.2012.41.6750
   Wigginton JM, 1996, JNCI-J NATL CANCER I, V88, P38, DOI 10.1093/jnci/88.1.38
   Wigginton JM, 2001, J CLIN INVEST, V108, P51
   Yousem SA, 1996, J HEART LUNG TRANSPL, V15, P1
   Zhang Xia, 2008, Curr Protoc Immunol, VChapter 14, DOI 10.1002/0471142735.im1401s83
NR 62
TC 112
Z9 124
U1 0
U2 21
PU ROCKEFELLER UNIV PRESS
PI NEW YORK
PA 950 THIRD AVE, 2ND FLR, NEW YORK, NY 10022 USA
SN 0022-1007
EI 1540-9538
J9 J EXP MED
JI J. Exp. Med.
PD OCT 21
PY 2013
VL 210
IS 11
BP 2223
EP 2237
DI 10.1084/jem.20131219
PG 15
WC Immunology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology; Research & Experimental Medicine
GA 239BX
UT WOS:000325997600008
PM 24081947
OA hybrid, Green Published, Green Submitted
DA 2024-02-19
ER

PT J
AU Goyary, D
   Sharma, R
AF Goyary, Danswrang
   Sharma, Ramesh
TI Late onset of dietary restriction reverses age-related decline of
   malate-aspartate shuttle enzymes in the liver and kidney of mice
SO BIOGERONTOLOGY
LA English
DT Article
DE dietary restriction; aging; malate-aspartate shuttle enzymes; liver;
   kidney; mice
ID CALORIC RESTRICTION; PROTEIN-TURNOVER; GENE-EXPRESSION; RATS;
   AMINOTRANSFERASE; MITOCHONDRIA; METABOLISM; MECHANISMS; LONGEVITY;
   GROWTH
AB Dietary restriction (DR) influences several physiological processes, retards the incidences and severity of various age-related diseases and extends lifespan of various animal species. The effect of DR on the activities of malate-aspartate shuttle enzymes, viz. cytosolic and mitochondrial aspartate aminotransferase (c- and m-AsAT) and malate dehydrogenase (c- and m-MDH) was investigated in the liver and kidney of adult (5-months) and old (21-months) male mice. The results show that the activity (U/mg protein) of both c- and m-MDH and AsAT is decreased significantly in the liver and kidney of old mice compared to adult ones. However, DR in old mice reverses significantly the enzyme activities to a level closer to adult animals. Polyacrylamide gel electrophoresis (PAGE) and specific staining of c-AsAT, one of the selected isoenzymes of the shuttle, showed a similar pattern of activity expression as observed by activity measurements in both the tissues studied. Slot blot analysis of c-AsAT confirmed the lower protein content of this isoenzyme in old mice compared to adult ones and a higher level in old-dietary restricted mice. Thus, our results suggest that the late onset of DR in older mice reverses decline in malate-aspartate shuttle enzymes and that it may allow a better metabolic regulation in older animals.
C1 [Goyary, Danswrang; Sharma, Ramesh] NE Hill Univ, Dept Biochem, Shillong 793022, Meghalaya, India.
C3 North Eastern Hill University
RP Sharma, R (corresponding author), NE Hill Univ, Dept Biochem, Shillong 793022, Meghalaya, India.
EM rsharma@nehu.ac.in
CR [Anonymous], 1969, [No title captured], DOI DOI 10.1016/0076-6879(69)13023-2
   Bender K, 2006, BIOCHEM SOC T, V34, P811, DOI 10.1042/BST0340811
   Borst P., 1963, Funktionelle Und Morphologische Organisation Der Zelle, P137, DOI 10.1007/978-3-642-86784-2_10
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   CEDERBAUM AI, 1973, ARCH BIOCHEM BIOPHYS, V158, P263
   COLIN S, 2003, BIOGERONTOLOGY, V4, P141
   DAVIS BJ, 1964, ANN NY ACAD SCI, V121, P404, DOI 10.1111/j.1749-6632.1964.tb14213.x
   Dhahbi JM, 1999, AM J PHYSIOL-ENDOC M, V277, pE352, DOI 10.1152/ajpendo.1999.277.2.E352
   DOONAN S, 1981, COMP BIOCHEM PHYS B, V69, P747, DOI 10.1016/0305-0491(81)90379-5
   Dutta D, 2004, BIOGERONTOLOGY, V5, P177, DOI 10.1023/B:BGEN.0000031155.60748.0a
   FEUERS RJ, 1989, MECH AGEING DEV, V48, P179, DOI 10.1016/0047-6374(89)90049-3
   Goto S, 2007, ANN NY ACAD SCI, V1100, P431, DOI 10.1196/annals.1395.048
   Goyary D, 2005, INDIAN J BIOCHEM BIO, V42, P345
   Hagopian K, 2003, EXP GERONTOL, V38, P267, DOI 10.1016/S0531-5565(02)00202-4
   HERZFELD A, 1971, BIOCHIM BIOPHYS ACTA, V237, P88, DOI 10.1016/0304-4165(71)90033-X
   Hursting SD, 2003, ANNU REV MED, V54, P131, DOI 10.1146/annurev.med.54.101601.152156
   Kanungo MS, 1980, BIOCH AGEING CHANGES, P79
   KARMEN A, 1955, J CLIN INVEST, V34, P126, DOI 10.1172/JCI103055
   LARDY HA, 1965, P NATL ACAD SCI USA, V53, P1410, DOI 10.1073/pnas.53.6.1410
   Lee J, 2000, EXP NEUROL, V166, P435, DOI 10.1006/exnr.2000.7512
   LEHNINGER AL, 1951, J BIOL CHEM, V190, P345
   LEWIS SEM, 1985, EXP GERONTOL, V20, P253, DOI 10.1016/0531-5565(85)90050-6
   Lin SJ, 2000, SCIENCE, V289, P2126, DOI 10.1126/science.289.5487.2126
   Lyngdoh HG, 2001, INDIAN J BIOCHEM BIO, V38, P170
   LYNN TF, 1998, ENV HLTH PERSPECT, V106, P313
   McKenna MC, 2006, BIOCHEM PHARMACOL, V71, P399, DOI 10.1016/j.bcp.2005.10.011
   MERRY BJ, 1999, STUDIES AGING, P143
   Minárik P, 2002, GEN PHYSIOL BIOPHYS, V21, P257
   Nisoli E, 2005, SCIENCE, V310, P314, DOI 10.1126/science.1117728
   OBLED C, 1991, J NUTR, V121, P1990, DOI 10.1093/jn/121.12.1990
   Pahlavani MA, 2000, FRONT BIOSCI-LANDMRK, V5, pD580, DOI 10.2741/Pahlavani
   Ralphe JC, 2005, AM J PHYSIOL-HEART C, V288, pH2521, DOI 10.1152/ajpheart.00991.2004
   Roth GS, 2000, EUR J CLIN NUTR, V54, pS15, DOI 10.1038/sj.ejcn.1601020
   Scholz TD, 1998, AM J PHYSIOL-CELL PH, V274, pC780, DOI 10.1152/ajpcell.1998.274.3.C780
   SHARMA R, 1982, BIOCHEM INT, V5, P561
   Sharma R, 2004, CURR SCI INDIA, V87, P1203
   SHARMA R, 1992, BIOCHEM INT, V27, P1059
   SHARMA R, 2006, ANN NY ACAD SCI, V1067, P29
   SHARMA R, 1988, PHYSL BASIS AGING GE, P43
   Sohal RS, 1996, SCIENCE, V273, P59, DOI 10.1126/science.273.5271.59
   Spindler SR, 2005, MECH AGEING DEV, V126, P960, DOI 10.1016/j.mad.2005.03.016
   Van Remmen Holly, 1995, P171
   Weinert BT, 2003, J APPL PHYSIOL, V95, P1706, DOI 10.1152/japplphysiol.00288.2003
   Willcox DC, 2006, BIOGERONTOLOGY, V7, P173, DOI 10.1007/s10522-006-9008-z
NR 44
TC 10
Z9 11
U1 0
U2 5
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1389-5729
EI 1573-6768
J9 BIOGERONTOLOGY
JI Biogerontology
PD FEB
PY 2008
VL 9
IS 1
BP 11
EP 18
DI 10.1007/s10522-007-9112-8
PG 8
WC Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Geriatrics & Gerontology
GA 248MD
UT WOS:000252156500002
PM 17932783
DA 2024-02-19
ER

PT J
AU Wolfrom, C
   Martin, OC
   Laurent, M
   Deschatrette, J
AF Wolfrom, Claire
   Martin, Olivier C.
   Laurent, Michel
   Deschatrette, Jean
TI Sinusoidal swinging dynamics of the telomere repair and cell growth
   activation functions of telomerase in rat liver cancer cells
SO FEBS LETTERS
LA English
DT Article
DE non-linear dynamics; telomeres; systems biology; cancer cells;
   mathematical modeling
ID IN-VITRO; IMMORTAL CELLS; INHIBITION; PROTEINS; TRF2; SENESCENCE;
   ASSOCIATION; EXPRESSION; COOPERATE; APOPTOSIS
AB Telomerase is a multimolecular complex of reverse transcriptase, RNA template, and regulatory proteins. It has two known functions: catalysis of the addition of vertical bar TTAGGG vertical bar repeats to telomeric DNA and the activation of various genes controlling cell proliferation. The possible coordination of these two functions is a key issue in understanding the growth of cancer cells. We report long-term changes to this complex system, as shown by specific data analysis methods. We show that the dynamics of the two functions of telomerase are tightly linked, with a change in predominant function every 13-14 weeks. The conservative behavior of this dynamic system probably accounts for the persistent proliferation of cancer cells. (c) 2006 Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies.
C1 Univ Paris 11, CNRS, UMR 8080, F-91405 Orsay, France.
   Univ Paris 11, LPTMS, UMR 8626, CNRS, F-91405 Orsay, France.
C3 Universite Paris Saclay; Centre National de la Recherche Scientifique
   (CNRS); Universite Paris Saclay; Centre National de la Recherche
   Scientifique (CNRS); CNRS - Institute of Physics (INP)
RP Wolfrom, C (corresponding author), Univ Paris 11, CNRS, UMR 8080, Batiment 440, F-91405 Orsay, France.
EM claire.wolfrom@ibaic.u-psud.fr
RI Martin, Olivier C/B-6656-2012
OI Martin, Olivier C/0000-0002-5295-5963
CR ALLSOPP RC, 1995, EXP CELL RES, V219, P130, DOI 10.1006/excr.1995.1213
   Ancelin K, 2002, MOL CELL BIOL, V22, P3474, DOI 10.1128/MCB.22.10.3474-3487.2002
   Blackburn EH, 2005, FEBS LETT, V579, P859, DOI 10.1016/j.febslet.2004.11.036
   Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349
   COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x
   Cronk JD, 1996, PROTEIN SCI, V5, P1963, DOI 10.1002/pro.5560051002
   de Bruin D, 2001, NATURE, V409, P109, DOI 10.1038/35051119
   Deschatrette J., 2003, ComPlexUs, V1, P134, DOI 10.1159/000076101
   Folini M, 2005, EUR J CANCER, V41, P624, DOI 10.1016/j.ejca.2004.12.002
   Gu D, 2004, J BIOL CHEM, V279, P31171, DOI 10.1074/jbc.M403701200
   Hemann MT, 2001, CELL, V107, P67, DOI 10.1016/S0092-8674(01)00504-9
   Ji HJ, 2005, BREAST CANCER RES TR, V93, P227, DOI 10.1007/s10549-005-5156-0
   KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428
   Lei M, 2005, J BIOL CHEM, V280, P20449, DOI 10.1074/jbc.M502212200
   LEVY MZ, 1992, J MOL BIOL, V225, P951, DOI 10.1016/0022-2836(92)90096-3
   Li S, 2005, J BIOL CHEM, V280, P23709, DOI 10.1074/jbc.M502782200
   Lillard-Wetherell K, 2004, HUM MOL GENET, V13, P1919, DOI 10.1093/hmg/ddh193
   Liu D, 2004, J BIOL CHEM, V279, P51338, DOI 10.1074/jbc.M409293200
   Marcand S, 1999, EMBO J, V18, P3509, DOI 10.1093/emboj/18.12.3509
   Oh BK, 2004, EXP CELL RES, V298, P445, DOI 10.1016/j.yexcr.2004.04.032
   Opresko PL, 2004, MOL CELL, V14, P763, DOI 10.1016/j.molcel.2004.05.023
   Rubin H, 2002, NAT BIOTECHNOL, V20, P675, DOI 10.1038/nbt0702-675
   Smith LL, 2003, NAT CELL BIOL, V5, P474, DOI 10.1038/ncb985
   Smogorzewska A, 2004, ANNU REV BIOCHEM, V73, P177, DOI 10.1146/annurev.biochem.73.071403.160049
   Wolfrom C, 2000, J CELL SCI, V113, P1069
   WRIGHT WE, 1992, TRENDS GENET, V8, P193, DOI 10.1016/0168-9525(92)90232-S
   Yamaguchi Y, 1998, EXP CELL RES, V242, P120, DOI 10.1006/excr.1998.4102
   Yang Q, 2005, MOL CELL BIOL, V25, P1070, DOI 10.1128/MCB.25.3.1070-1080.2005
   Zaman Z, 2002, CURR BIOL, V12, P930, DOI 10.1016/S0960-9822(02)00865-5
NR 29
TC 3
Z9 3
U1 1
U2 3
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0014-5793
J9 FEBS LETT
JI FEBS Lett.
PD JAN 9
PY 2007
VL 581
IS 1
BP 125
EP 130
DI 10.1016/j.febslet.2006.12.007
PG 6
WC Biochemistry & Molecular Biology; Biophysics; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics; Cell Biology
GA 128JB
UT WOS:000243652900020
PM 17182040
OA Bronze
DA 2024-02-19
ER

PT J
AU Chen, YN
   Hagopian, K
   Bibus, D
   Villalba, JM
   López-Lluch, G
   Navas, P
   Kim, K
   McDonald, RB
   Ramsey, JJ
AF Chen, Yana
   Hagopian, Kevork
   Bibus, Douglas
   Villalba, Jose M.
   Lopez-Lluch, Guillermo
   Navas, Placido
   Kim, Kyoungmi
   McDonald, Roger B.
   Ramsey, Jon J.
TI The influence of dietary lipid composition on liver mitochondria from
   mice following 1 month of calorie restriction
SO BIOSCIENCE REPORTS
LA English
DT Article
DE aging; energy restriction; mitochondria; oxidative stress phospholipids;
   proton leak
ID OXYGEN SPECIES PRODUCTION; FATTY-ACID-COMPOSITION; HYDROGEN-PEROXIDE
   PRODUCTION; PROTON LEAK; OXIDATIVE STRESS; H2O2 PRODUCTION; RAT-LIVER;
   INDUCED HYPERTHYROIDISM; FOOD RESTRICTION; INNER MEMBRANE
AB To investigate the role mitochondrial membrane lipids play in the actions of CR (calorie restriction), C57BL/6 mice were assigned to four groups (control and three 40% CR groups) and the CR groups were fed diets containing soya bean oil (also in the control diet), fish oil or lard. The fatty acid composition of the major mitochondrial phospholipid classes, proton leak and H2O2 production were measured in liver mitochondria following 1 month of CR. The results indicate that mitochondrial phospholipid fatty acids reflect the PUFA (polyunsaturated fatty acid) profile of the dietary lipid sources. CR significantly decreased the capacity of ROS (reactive oxygen species) production by Complex III but did not markedly alter proton leak and ETC (electron transport chain) enzyme activities. Within the CR regimens, the CR-fish group had decreased ROS production by both Complexes I and III, and increased proton leak when compared with the other CR groups. The CR-lard group showed the lowest proton leak compared with the other CR groups. The ETC enzyme activity measurements in the CR regimens showed that Complex I activity was decreased in both the CR-fish and CR-lard groups. Moreover, the CR-fish group also had lower Complex II activity compared with the other CR groups. These results indicate that dietary lipid composition does influence liver mitochondrial phospholipid composition, ROS production, proton leak and ETC enzyme activities in CR animals.
C1 [Chen, Yana; Hagopian, Kevork; Ramsey, Jon J.] Univ Calif Davis, VM Mol Biosci, Davis, CA 95616 USA.
   [Bibus, Douglas] Lipid Technol LLC, Austin, MN USA.
   [Villalba, Jose M.] Univ Cordoba, Dept Biol Celular Fisiol & Immunol, Cordoba, Spain.
   [Lopez-Lluch, Guillermo; Navas, Placido] Univ Pablo Olavide, Inst Salud Carlos III, Ctr Andaluz Biol Desarrollo, CSIC,CIBERER, Seville, Spain.
   [Kim, Kyoungmi] Dept Publ Hlth Sci, Davis, CA USA.
   [Kim, Kyoungmi] Univ Calif Davis, Davis, CA 95616 USA.
   [McDonald, Roger B.] Univ Calif Davis, Dept Nutr, Davis, CA 95616 USA.
C3 University of California System; University of California Davis;
   Universidad de Cordoba; Instituto de Salud Carlos III; CIBER - Centro de
   Investigacion Biomedica en Red; CIBERER; Consejo Superior de
   Investigaciones Cientificas (CSIC); Universidad Pablo de Olavide; CSIC -
   Andalusian Center for Developmental Biology (CABD); University of
   California System; University of California Davis; University of
   California System; University of California Davis
RP Ramsey, JJ (corresponding author), Univ Calif Davis, VM Mol Biosci, Davis, CA 95616 USA.
EM jjramsey@ucdavis.edu
RI Lopez-Lluch, Guillermo/N-4742-2014; NAVAS, PLACIDO/R-5943-2019
OI Lopez-Lluch, Guillermo/0000-0001-9830-8502; NAVAS,
   PLACIDO/0000-0002-4115-7966
FU National Institutes of Health [R01 AG028125, P01 AG025532]
FX This work was supported by the National Institutes of Health [grant
   numbers R01 AG028125 and P01 AG025532].
CR Andreyev AI, 2005, BIOCHEMISTRY-MOSCOW+, V70, P200, DOI 10.1007/s10541-005-0102-7
   Arvier M, 2007, AM J PHYSIOL-ENDOC M, V293, pE1320, DOI 10.1152/ajpendo.00138.2007
   Ash CE, 2011, MECH AGEING DEV, V132, P43, DOI 10.1016/j.mad.2010.12.001
   Barja G, 2004, TRENDS NEUROSCI, V27, P595, DOI 10.1016/j.tins.2004.07.005
   BIRCHMACHIN MA, 1994, BIOCHEM MED METAB B, V51, P35, DOI 10.1006/bmmb.1994.1004
   BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911
   BRAND MD, 1994, COMP BIOCHEM PHYS B, V108, P181, DOI 10.1016/0305-0491(94)90064-7
   Bronnikov GE, 2010, BIOCHEMISTRY-MOSCOW+, V75, P1491, DOI 10.1134/S0006297910120102
   Brookes PS, 1998, COMP BIOCHEM PHYS B, V119, P325, DOI 10.1016/S0305-0491(97)00357-X
   Brookes PS, 2005, FREE RADICAL BIO MED, V38, P12, DOI 10.1016/j.freeradbiomed.2004.10.016
   Brookes PS, 1997, J MEMBRANE BIOL, V155, P167, DOI 10.1007/s002329900168
   Buege J A, 1978, Methods Enzymol, V52, P302
   Cha MC, 2000, METABOLISM, V49, P977, DOI 10.1053/meta.2000.7725
   Chen YN, 2012, J GERONTOL A-BIOL, V67, P1121, DOI 10.1093/gerona/gls113
   Desai VG, 1996, ARCH BIOCHEM BIOPHYS, V333, P145, DOI 10.1006/abbi.1996.0375
   Faulks SC, 2006, J GERONTOL A-BIOL, V61, P781, DOI 10.1093/gerona/61.8.781
   Forsythe CE, 2010, LIPIDS, V45, P947, DOI 10.1007/s11745-010-3467-3
   Gómez J, 2007, BIOGERONTOLOGY, V8, P555, DOI 10.1007/s10522-007-9099-1
   Gredilla R, 2005, ENDOCRINOLOGY, V146, P3713, DOI 10.1210/en.2005-0378
   Gredilla R, 2001, J BIOENERG BIOMEMBR, V33, P279, DOI 10.1023/A:1010603206190
   Guerrero A, 1999, FREE RADICAL BIO MED, V26, P73, DOI 10.1016/S0891-5849(98)00173-7
   Hagopian K, 2005, AM J PHYSIOL-ENDOC M, V288, pE674, DOI 10.1152/ajpendo.00382.2004
   Hagopian K, 2011, J BIOENERG BIOMEMBR, V43, P227, DOI 10.1007/s10863-011-9353-8
   Hagopian K, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012696
   HARMAN D, 1956, J GERONTOL, V11, P298, DOI 10.1093/geronj/11.3.298
   Harper ME, 1998, AM J PHYSIOL-ENDOC M, V275, pE197, DOI 10.1152/ajpendo.1998.275.2.E197
   Hepple RT, 2006, REJUV RES, V9, P219, DOI 10.1089/rej.2006.9.219
   HOCH FL, 1992, BIOCHIM BIOPHYS ACTA, V1113, P71, DOI 10.1016/0304-4157(92)90035-9
   Hulbert AJ, 2003, J EXP BIOL, V206, P2303, DOI 10.1242/jeb.00399
   HYSLOP PA, 1984, ANAL BIOCHEM, V141, P280, DOI 10.1016/0003-2697(84)90457-3
   Jastroch M, 2010, ESSAYS BIOCHEM, V47, P53, DOI [10.1042/BSE0470053, 10.1042/bse0470053]
   Kwong LK, 2000, ARCH BIOCHEM BIOPHYS, V373, P16, DOI 10.1006/abbi.1999.1495
   LAGANIERE S, 1991, LIPIDS, V26, P472, DOI 10.1007/BF02536075
   Lal SB, 2001, J GERONTOL A-BIOL, V56, pB116, DOI 10.1093/gerona/56.3.B116
   Lambert AJ, 2009, METHODS MOL BIOL, V554, P165, DOI 10.1007/978-1-59745-521-3_11
   Lambert AJ, 2004, J BIOL CHEM, V279, P39414, DOI 10.1074/jbc.M406576200
   Lambert AJ, 2005, J GERONTOL A-BIOL, V60, P175, DOI 10.1093/gerona/60.2.175
   Lambert AJ, 2004, AM J PHYSIOL-REG I, V286, pR71, DOI 10.1152/ajpregu.00341.2003
   Lee J, 1999, FREE RADICAL BIO MED, V26, P260, DOI 10.1016/S0891-5849(98)00195-6
   Pamplona R, 2002, ANN NY ACAD SCI, V959, P475, DOI 10.1111/j.1749-6632.2002.tb02118.x
   Porter RK, 1996, AM J PHYSIOL-REG I, V271, pR1550, DOI 10.1152/ajpregu.1996.271.6.R1550
   Quiles JL, 2002, J BIOENERG BIOMEMBR, V34, P517, DOI 10.1023/A:1022530512096
   Ramsey JJ, 2005, COMP BIOCHEM PHYS B, V140, P99, DOI 10.1016/j.cbpc.2004.09.016
   Ramsey JJ, 2004, AM J PHYSIOL-ENDOC M, V286, pE31, DOI 10.1152/ajpendo.00283.2003
   Ramsey JJ, 2000, FREE RADICAL BIO MED, V29, P946, DOI 10.1016/S0891-5849(00)00417-2
   ROLFE DFS, 1994, BBA-BIOENERGETICS, V1188, P405, DOI 10.1016/0005-2728(94)90062-0
   Sohal RS, 1996, SCIENCE, V273, P59, DOI 10.1126/science.273.5271.59
   TACCONI MT, 1991, NEUROBIOL AGING, V12, P55, DOI 10.1016/0197-4580(91)90039-M
   TAHIN QS, 1981, EUR J BIOCHEM, V121, P5, DOI 10.1111/j.1432-1033.1981.tb06421.x
   Trounce I A, 1996, Methods Enzymol, V264, P484, DOI 10.1016/S0076-6879(96)64044-0
   Venditti P, 2006, ARCH BIOCHEM BIOPHYS, V447, P11, DOI 10.1016/j.abb.2006.01.008
   Venditti P, 2004, FREE RADICAL BIO MED, V36, P348, DOI 10.1016/j.freeradbiomed.2003.11.012
   VENKATRAMAN J, 1992, MECH AGEING DEV, V63, P27, DOI 10.1016/0047-6374(92)90014-5
   Weindruch R, 1997, NEW ENGL J MED, V337, P986, DOI 10.1056/NEJM199710023371407
   Yu BP, 2002, J NUTR SCI VITAMINOL, V48, P257, DOI 10.3177/jnsv.48.257
NR 55
TC 23
Z9 24
U1 1
U2 9
PU PORTLAND PRESS LTD
PI LONDON
PA 5TH FLR, 90 HIGH HOLBORN, LONDON WC1V 6LJ, ENGLAND
SN 0144-8463
EI 1573-4935
J9 BIOSCIENCE REP
JI Biosci. Rep.
PY 2013
VL 33
BP 83
EP 95
AR e00008
DI 10.1042/BSR20120060
PN 1
PG 13
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 175PJ
UT WOS:000321242600008
OA Green Published, Green Submitted, hybrid
DA 2024-02-19
ER

PT J
AU Banasik, K
   Ribel-Madsen, R
   Gjesing, AP
   Wegner, L
   Andersson, Å
   Poulsen, P
   Borglykke, A
   Witte, DR
   Pedersen, O
   Hansen, T
   Vaag, A
AF Banasik, Karina
   Ribel-Madsen, Rasmus
   Gjesing, Anette P.
   Wegner, Lise
   Andersson, Asa
   Poulsen, Pernille
   Borglykke, Anders
   Witte, Daniel R.
   Pedersen, Oluf
   Hansen, Torben
   Vaag, Allan
TI The <i>FOXO3A</i> rs2802292 G-Allele Associates with Improved Peripheral
   and Hepatic Insulin Sensitivity and Increased Skeletal
   Muscle-<i>FOXO3A</i> mRNA Expression in Twins
SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
LA English
DT Article
ID HUMAN LONGEVITY; DIAGNOSIS; IMPACT
AB Objective: The minor G-allele of FOXO3A rs2802292 has been associated with longevity. We aimed to investigate whether a phenotype related to healthy metabolic aging could be identified in individuals carrying the longevity-associated FOXO3A rs2802292 G-allele.
   Research Design and Methods: rs2802292 was genotyped in a phenotypically well-characterized population of young and elderly twins (n = 190) and in the population-based Inter99 cohort (n = 5768). All participants underwent oral glucose tolerance tests, and the twin population was additionally examined with an iv glucose tolerance test and a hyperinsulinemic, euglycemic clamp. Basal and insulin-stimulated FOXO3A mRNA expression was assessed in skeletal muscle biopsies from the twin population.
   Results: In the twin sample, carriers of the minor G-allele of rs2802292 showed reduced fasting plasma insulin [per allele effect (beta) = -13% (-24; -1) (95% confidence interval), P = 0.03] and lower incremental area under the curve 0-120 min for insulin after an oral glucose load [beta = -14% (-23; -5), P = 0.005]. The G-allele was associated with increased peripheral insulin action [glucose disposal rate clamp, beta = 0.85 mg . kg(fat-free mass)(-1) . min(-1) (0.049; 1.64), P = 0.04] and lower hepatic insulin resistance index [beta = -13% (-25; -1), P = 0.03]. Furthermore, carriers of the G-allele had increased basal FOXO3A mRNA expression in skeletal muscle compared with T-allele carriers [beta = 16% (0; 33), P = 0.047]. In the Inter99 sample, we found an association with reduced incremental area under the curve 0-120 min for insulin after an oral glucose load [beta = -3% (-5; -0.07), P = 0.04], but this association was not significant after adjustment for body mass index.
   Conclusion: Our data indicate that the minor G-allele of FOXO3A rs2802292 is associated with enhanced peripheral and hepatic insulin sensitivity in our small twin cohort, which may be mediated through increased FOXO3A mRNA expression, although no major metabolic impact of rs2802292 was found in the large Inter99 cohort. (J Clin Endocrinol Metab 96: E119-E124, 2011)
C1 [Banasik, Karina; Gjesing, Anette P.; Wegner, Lise; Pedersen, Oluf; Hansen, Torben] Hagedorn Res Inst, DK-2820 Gentofte, Denmark.
   [Ribel-Madsen, Rasmus; Poulsen, Pernille; Witte, Daniel R.; Vaag, Allan] Steno Diabet Ctr, DK-2820 Gentofte, Denmark.
   [Banasik, Karina; Pedersen, Oluf] Univ Copenhagen, Fac Hlth Sci, DK-2200 Copenhagen, Denmark.
   [Andersson, Asa] Univ Copenhagen, Fac Pharmaceut Sci, DK-2100 Copenhagen, Denmark.
   [Borglykke, Anders] Glostrup Univ Hosp, Res Ctr Prevent & Hlth, DK-2600 Glostrup, Denmark.
   [Pedersen, Oluf] Univ Aarhus, Fac Hlth Sci, DK-8000 Aarhus, Denmark.
   [Hansen, Torben] Univ So Denmark, Fac Hlth Sci, DK-5000 Odense, Denmark.
   [Vaag, Allan] Lund Univ, Unit Diabet & Endocrinol, Dept Clin Sci, Malmo Univ Hosp, S-20502 Malmo, Sweden.
C3 Novo Nordisk; Hagedorn Research Institute; Steno Diabetes Center;
   University of Copenhagen; University of Copenhagen; University of
   Copenhagen; Aarhus University; University of Southern Denmark; Lund
   University; Skane University Hospital
RP Banasik, K (corresponding author), Hagedorn Res Inst, Niels Steensens Vej 1, DK-2820 Copenhagen, Denmark.
EM kabs@hagedorn.dk
RI Witte, Daniel/AAF-9535-2019; Gjesing, Anette/ACC-7521-2022; Banasik,
   Karina/G-1728-2013; Witte, Daniel R/C-1722-2008; Banasik,
   Karina/S-3475-2019; Pedersen, Oluf/AAG-8015-2020; Banasik,
   Karina/HJZ-4905-2023; Pedersen, Oluf/Z-1731-2019
OI Witte, Daniel/0000-0002-0769-2922; Gjesing, Anette/0000-0003-4580-1576;
   Witte, Daniel R/0000-0002-0769-2922; Banasik,
   Karina/0000-0003-2489-2499; Banasik, Karina/0000-0003-2489-2499;
   Pedersen, Oluf/0000-0002-3321-3972; Vaag, Allan
   Arthur/0000-0002-3690-2191; Thorner, Lise Wegner/0000-0003-4391-4956;
   /0000-0003-4360-7710; Hansen, Torben/0000-0001-8748-3831
FU Danish Council for Strategic Research; European Union
   [LSHM-CT-2004-005272]; Lundbeck Foundation Centre of Applied Medical
   Genomics for Personalized Disease Prediction, Prevention, and Care
   (LuCAMP); Danish Council for Independent Research (Medical Sciences);
   Danish Agency for Science, Technology, and Innovation; MRC [G0501184]
   Funding Source: UKRI; Medical Research Council [G0501184] Funding
   Source: researchfish
FX This work was supported by grants from the Danish Council for Strategic
   Research; the European Union Framework 6 Integrated Project EXGENESIS
   LSHM-CT-2004-005272; the Lundbeck Foundation Centre of Applied Medical
   Genomics for Personalized Disease Prediction, Prevention, and Care
   (LuCAMP); the Danish Council for Independent Research (Medical
   Sciences); and the Danish Agency for Science, Technology, and
   Innovation.
CR Alberti KGMM, 1998, DIABETIC MED, V15, P539, DOI 10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S
   Anselmi CV, 2009, REJUV RES, V12, P95, DOI 10.1089/rej.2008.0827
   Chen WS, 2001, GENE DEV, V15, P2203, DOI 10.1101/gad.913901
   Fallin MD, 2009, J GERONTOL A-BIOL, V64, P47, DOI 10.1093/gerona/gln021
   Flachsbart F, 2009, P NATL ACAD SCI USA, V106, P2700, DOI 10.1073/pnas.0809594106
   Hansen T, 2007, DIABETES CARE, V30, P257, DOI 10.2337/dc06-1240
   Hedrick SM, 2009, NAT IMMUNOL, V10, P1057, DOI 10.1038/ni.1784
   Jorgensen Torben, 2003, Eur J Cardiovasc Prev Rehabil, V10, P377
   Kenyon C, 2005, CELL, V120, P449, DOI 10.1016/j.cell.2005.02.002
   Kim JR, 2006, OBESITY, V14, P188, DOI 10.1038/oby.2006.24
   Kuningas M, 2007, EUR J HUM GENET, V15, P294, DOI 10.1038/sj.ejhg.5201766
   Lam EWF, 2006, BIOCHEM SOC T, V34, P722, DOI 10.1042/BST0340722
   Lunetta KL, 2007, BMC MED GENET, V8, DOI 10.1186/1471-2350-8-S1-S13
   Neale MCCL, 2013, METHODOLOGY GENETIC, V67
   Poulsen P, 2005, DIABETES, V54, P1289, DOI 10.2337/diabetes.54.5.1289
   Poulsen P, 2005, DIABETES, V54, P275, DOI 10.2337/diabetes.54.1.275
   Reaven GM, 2006, AM J CLIN NUTR, V83, P1237, DOI 10.1093/ajcn/83.6.1237
   Sebastiani Paola, 2010, Science, V2010, DOI 10.1126/science.1190532
   STEELE R, 1959, METABOLISM, V8, P512
   Wilicox BJ, 2008, P NATL ACAD SCI USA, V105, P13987, DOI 10.1073/pnas.0801030105
NR 20
TC 41
Z9 42
U1 0
U2 3
PU ENDOCRINE SOC
PI CHEVY CHASE
PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA
SN 0021-972X
J9 J CLIN ENDOCR METAB
JI J. Clin. Endocrinol. Metab.
PD JAN
PY 2011
VL 96
IS 1
BP E119
EP E124
DI 10.1210/jc.2010-0881
PG 6
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Endocrinology & Metabolism
GA 732LB
UT WOS:000288185400016
PM 20881262
OA Bronze
DA 2024-02-19
ER

PT J
AU LI, DH
   RANDERATH, K
AF LI, DH
   RANDERATH, K
TI MODULATION OF DNA MODIFICATION (I-COMPOUND) LEVELS IN RAT-LIVER AND
   KIDNEY BY DIETARY CARBOHYDRATE, PROTEIN, FAT, VITAMIN, AND
   MINERAL-CONTENT
SO MUTATION RESEARCH
LA English
DT Article
DE I-COMPOUNDS; DNA MODIFICATIONS; NUTRITION; DIET; CARCINOGENESIS; AGING
ID MECHANISM; ADDUCTS
AB I-compounds are DNA modifications detected by P-32-postlabeling that increase with age in rodents without known carcinogen exposure. Diet type (natural ingredient versus purified) greatly influences patterns and levels of I-compounds. To test the hypothesis that I-compound formation is affected, also, by dietary macro- and micronutrients, effects of carbohydrate, protein, fat, vitamin, and mineral content on rat liver and kidney I-compounds were determined. Female Sprague-Dawley rats were fed basic or modified AIN-76A purified diets for 3-6 months. High protein (HP) diet (50%, w/w) increased I-compound levels in liver but not kidney. High carbohydrate (HC) diet (78%) produced a significant increase in the polar as well as total I-compound levels in both tissues. High fat diets (20%) elicited significantly lower levels of liver I-compounds than HC, HP, and basic diets. There were few significant differences between high polyunsaturated (safflower oil) and saturated fat (lard) diet groups. No qualitative differences in I-compound profiles were observed in either tissue. In rats fed basic diet supplemented with vitamins and/or minerals, increased vitamin content reduced the levels of polar I-compounds in liver. No extra diet-induced adducts were observed; all effects were of a quantitative nature. These data provide direct evidence that nutrients significantly influence I-compound levels and support the hypothesis that normal metabolism of nutrients leads to the production of small amounts of DNA-reactive electrophiles. These observations suggest a novel mechanism where nutrient composition of the diet may play a role in development of neoplasia and other adverse health effects.
C1 BAYLOR COLL MED, DEPT PHARMACOL, DIV TOXICOL, HOUSTON, TX 77030 USA.
C3 Baylor College of Medicine
FU NCI NIH HHS [R37 CA 32157] Funding Source: Medline; NIA NIH HHS [R01 AG
   07750] Funding Source: Medline
CR AMES BN, 1983, SCIENCE, V221, P1256, DOI 10.1126/science.6351251
   ANISIMOV VN, 1988, CARCINOGENESIS AGING, P111
   BIDLACK WR, 1986, FASEB J, V45, P142
   BUCALA R, 1984, P NATL ACAD SCI-BIOL, V81, P105, DOI 10.1073/pnas.81.1.105
   CAMPBELL TC, 1977, CLIN PHARMACOL THER, V22, P699
   CERAMI A, 1985, J AM GERIATR SOC, V33, P626, DOI 10.1111/j.1532-5415.1985.tb06319.x
   DIZDAROGLU M, 1989, CANCER RES, V49, P3463
   GUENGERICH FP, 1984, ANNU REV NUTR, V4, P207, DOI 10.1146/annurev.nu.04.070184.001231
   GUPTA RC, 1984, P NATL ACAD SCI-BIOL, V81, P6943, DOI 10.1073/pnas.81.22.6943
   HENDRICH S, 1988, J CANCER RES CLIN, V114, P149, DOI 10.1007/BF00417829
   HIETANEN E, 1986, GEN PHARMACOL, V11, P443
   LI D, 1991, Proceedings of the American Association for Cancer Research Annual Meeting, V32, P108
   LI DG, 1990, CARCINOGENESIS, V11, P2227, DOI 10.1093/carcin/11.12.2227
   LI DH, 1991, J NUTR, V121, P65, DOI 10.1093/jn/121.1.65
   LI DH, 1990, CARCINOGENESIS, V11, P251, DOI 10.1093/carcin/11.2.251
   LI DH, 1990, CANCER RES, V50, P3991
   LINDMAN HR, 1974, ANAL VARIANCE COMPL, P74
   RANDERATH E, 1991, Proceedings of the American Association for Cancer Research Annual Meeting, V32, P146
   RANDERATH E, 1991, MECH AGEING DEV, V58, P279, DOI 10.1016/0047-6374(91)90099-L
   RANDERATH K, 1988, CARCINOGENESIS, V9, P1843, DOI 10.1093/carcin/9.10.1843
   RANDERATH K, 1990, MUTAT RES, V238, P245, DOI 10.1016/0165-1110(90)90016-5
   RANDERATH K, 1989, MUTAT RES, V219, P121, DOI 10.1016/0921-8734(89)90023-4
   RANDERATH K, 1986, CARCINOGENESIS, V7, P1615, DOI 10.1093/carcin/7.9.1615
   REDDY MV, 1986, CARCINOGENESIS, V7, P1543, DOI 10.1093/carcin/7.9.1543
   USA American Institute of Nutrition, 1977, Journal of Nutrition, V107, P1340
   Visek W J, 1986, Adv Exp Med Biol, V206, P163
   1982, DIET NUTRITION CANCE, P1
NR 27
TC 19
Z9 20
U1 0
U2 1
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0921-8262
J9 MUTAT RES
JI Mutat. Res.
PD JAN
PY 1992
VL 275
IS 1
BP 47
EP 56
DI 10.1016/0921-8734(92)90008-D
PG 10
WC Genetics & Heredity; Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity; Toxicology
GA HM508
UT WOS:A1992HM50800007
PM 1372687
DA 2024-02-19
ER

PT J
AU Joles, JA
   vanGoor, H
   vanderHorst, MLC
   vanTol, A
   Elema, JD
   Koomans, HA
AF Joles, JA
   vanGoor, H
   vanderHorst, MLC
   vanTol, A
   Elema, JD
   Koomans, HA
TI High lipid levels in very low density lipoprotein and intermediate
   density lipoprotein may cause proteinuria and glomerulosclerosis in
   aging female analbuminemic rats
SO LABORATORY INVESTIGATION
LA English
DT Article
DE apolipoprotein; glomerular diameter; glomerular apolipoprotein and lipid
   deposition; hypertriglyceridemia; ovariectomy
ID CHRONIC AMINONUCLEOSIDE NEPHROSIS; GLOMERULAR INJURY; NEPHRECTOMY MODEL;
   MESANGIAL CELLS; RENAL ABLATION; CULTURED HUMAN; CHOLESTEROL;
   HYPERLIPOPROTEINEMIA; MICROPUNCTURE; HEMODYNAMICS
AB BACKGROUND: Male rats are generally more prone to developing renal disease than female rats. However, female Nagase analbuminemic rats (NAR) are profoundly hyperlipidemic and develop proteinuria and glomerulosclerosis after uninephrectomy. Male NAR are less hyperlipidemic and are resistant to developing renal damage after uninephrectomy. Ovariectomy markedly decreases hepatic triglyceride secretion and plasma triglyceride levels in the female NAR.
   EXPERIMENTAL DESIGN: In this study, we investigated the relationship between plasma lipids and lipoprotein composition as well as the development of proteinuria, glomerular apolipoprotein and lipid deposition, and glomerulosclerosis in aging female and male analbuminemic rats. We also studied whether ovariectomy in female NAR at an early age would protect their renal function in old age.
   RESULTS: Aging hyperlipidemic female NAR with high triglyceride and cholesterol levels in very low density lipoprotein (VLDL) and intermediate density lipoprotein (IDL) were found to develop spontaneous proteinuria at 9 months of age. Glomerular lipid deposition and glomerulosclerosis were observed at 18 months of age. In male NAR that had lower lipid levels in VLDL and IDL, only mild proteinuria and no glomerular lipid deposition or glomerulosclerosis were observed up to the age of 22 months. Concurrently ovariectomized NAR demonstrated profound and persistent decreases in triglyceride and cholesterol content of VLDL and IDL as well as total plasma triglycerides, without much change in LDL, high density lipoprotein, total plasma cholesterol, or apolipoprotein B, and they remained completely free of proteinuria and glomerulosclerosis. Apolipoprotein B deposition in glomeruli was not different in the oldest female, male, or ovariectomized NAR No important differences were observed in glomerular diameter between the three different groups up to the age of 1 year.
   CONCLUSIONS: These findings point to an important role of elevated lipid content of the triglyceride-rich lipoproteins VLDL and IDL in the pathogenesis of proteinuria and glomerulosclerosis in the female NAR.
C1 UNIV UTRECHT,FAC MED,DEPT HYPERTENS & NEPHROL,UTRECHT,NETHERLANDS.
   UNIV GRONINGEN,FAC MED,DEPT PATHOL,9700 AB GRONINGEN,NETHERLANDS.
   ERASMUS UNIV ROTTERDAM,FAC MED & HLTH SCI,COEUR,CARDIOVASC RES INST,DEPT BIOCHEM,3000 DR ROTTERDAM,NETHERLANDS.
C3 Utrecht University; University of Groningen; Erasmus University
   Rotterdam; Erasmus MC; Erasmus MC Cardiovascular Institute
RI Joles, Jaap/AAX-3249-2020; van Goor, H./H-8035-2014
OI van Goor, H./0000-0003-0323-4876; van Goor, Harry/0000-0002-6670-1577
CR ANDERSON S, 1994, AM J PHYSIOL, V267, pF35, DOI 10.1152/ajprenal.1994.267.1.F35
   AUSTIN MA, 1991, ARTERIOSCLER THROMB, V11, P2, DOI 10.1161/01.ATV.11.1.2
   BAYLIS C, 1994, J CLIN INVEST, V94, P1823, DOI 10.1172/JCI117531
   BRADLEY WA, 1994, J INTERN MED, V236, P33
   BRANDIS A, 1986, LAB INVEST, V55, P234
   BURTON CJ, 1994, EXP NEPHROL, V2, P345
   DALLINGATHIE GM, 1985, J LIPID RES, V26, P889
   DALLINGATHIE GM, 1986, J LIPID RES, V27, P1035
   DIAMOND JR, 1990, AM J CLIN NUTR, V51, P606, DOI 10.1093/ajcn/51.4.606
   DIAMOND JR, 1987, KIDNEY INT, V32, P671, DOI 10.1038/ki.1987.259
   DIAMOND JR, 1990, AM J PHYSIOL, V258, pF1, DOI 10.1152/ajprenal.1990.258.1.F1
   ELEMA JD, 1975, LAB INVEST, V33, P554
   FOGO A, 1988, J CLIN INVEST, V82, P322, DOI 10.1172/JCI113590
   FUJIHARA CK, 1992, AM J PHYSIOL, V262, pR947, DOI 10.1152/ajpregu.1992.262.6.R947
   GRONE EF, 1992, AM J PHYSIOL, V263, pF686, DOI 10.1152/ajprenal.1992.263.4.F686
   GRONE HJ, 1989, LAB INVEST, V60, P433
   HARRIS KPG, 1990, AM J KIDNEY DIS, V15, P16, DOI 10.1016/S0272-6386(12)80587-7
   JOLES JA, 1991, ATHEROSCLEROSIS, V88, P35, DOI 10.1016/0021-9150(91)90255-2
   JOLES JA, 1995, KIDNEY INT, V47, P442, DOI 10.1038/ki.1995.57
   JOLES JA, 1995, ATHEROSCLEROSIS, V117, P51, DOI 10.1016/0021-9150(95)05557-D
   JOLES JA, 1994, KIDNEY INT, V46, P97, DOI 10.1038/ki.1994.248
   KAPPEL B, 1980, VIRCHOWS ARCH A, V387, P271, DOI 10.1007/BF00454830
   KASISKE BL, 1988, CIRC RES, V62, P367, DOI 10.1161/01.RES.62.2.367
   KASISKE BL, 1990, KIDNEY INT, V37, P880, DOI 10.1038/ki.1990.62
   KASISKE BL, 1987, KIDNEY INT, V31, P1153, DOI 10.1038/ki.1987.122
   KEANE WF, 1994, KIDNEY INT, V46, P910, DOI 10.1038/ki.1994.349
   KHAN BV, 1990, BIOCHIM BIOPHYS ACTA, V1044, P297, DOI 10.1016/0005-2760(90)90073-7
   KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125
   KUME N, 1992, J CLIN INVEST, V90, P1138, DOI 10.1172/JCI115932
   LOMBET JR, 1989, J LAB CLIN MED, V114, P66
   MUNGER K, 1988, AM J PHYSIOL, V254, pF223, DOI 10.1152/ajprenal.1988.254.2.F223
   NATH KA, 1990, J CLIN INVEST, V86, P1179, DOI 10.1172/JCI114824
   ODONNELL MP, 1985, J LAB CLIN MED, V106, P605
   ONG ACM, 1994, AM J KIDNEY DIS, V23, P205, DOI 10.1016/S0272-6386(12)80973-5
   PARTHASARATHY S, 1989, ARTERIOSCLEROSIS, V9, P398, DOI 10.1161/01.ATV.9.3.398
   RAIJ L, 1984, KIDNEY INT, V26, P137, DOI 10.1038/ki.1984.147
   RECKELHOFF JF, 1992, AM J KIDNEY DIS, V20, P70, DOI 10.1016/S0272-6386(12)80319-2
   REMUZZI A, 1992, LAB INVEST, V67, P572
   SILBIGER SR, 1995, AM J KIDNEY DIS, V25, P515, DOI 10.1016/0272-6386(95)90119-1
   SNEDECOR GW, 1979, STATISTICAL METHODS
   STROES ESG, 1995, KIDNEY INT, V48, P544, DOI 10.1038/ki.1995.325
   TAKAHASHI M, 1983, EXP ANIM TOKYO, V32, P39, DOI 10.1538/expanim1978.32.1_39
   VANDAMME B, 1976, VIRCHOWS ARCH A, V369, P283
   VANGOOR H, 1991, LAB INVEST, V64, P754
   VANGOOR H, 1994, LAB INVEST, V71, P456
   VANGOOR H, 1992, LAB INVEST, V66, P564
   VANGOOR H, 1993, AM J PATHOL, V142, P1
   VANTOL A, 1991, J LIPID RES, V32, P1719
   WHEELER DC, 1991, NEPHROL DIAL TRANSPL, V6, P701, DOI 10.1093/ndt/6.10.701
   ZHANG X, 1994, J NUTR, V122, P520
NR 50
TC 28
Z9 31
U1 0
U2 1
PU WILLIAMS & WILKINS
PI BALTIMORE
PA 351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436
SN 0023-6837
J9 LAB INVEST
JI Lab. Invest.
PD DEC
PY 1995
VL 73
IS 6
BP 912
EP 921
PG 10
WC Medicine, Research & Experimental; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine; Pathology
GA TL725
UT WOS:A1995TL72500021
PM 8558854
DA 2024-02-19
ER

PT J
AU Patel, MA
   Modi, HR
   Katyare, SS
AF Patel, Minal A.
   Modi, Hiren R.
   Katyare, Surendra S.
TI Stimulation of oxidative energy metabolism in liver mitochondria from
   old and young rats by treatment with dehydroepiandrosterone (DHEA). A
   comparative study
SO AGE
LA English
DT Article
DE ATPase activity; cytochromes; dehydroepiandrosterone (DHEA);
   dehydrogenases; liver mitochondria; oxidative energy metabolism
ID AGING BRAIN; AGE; PHOSPHORYLATION; HEPATOTOXICITY; BIOENERGETICS;
   DYSFUNCTION; FOUNTAIN; STRESS; DAMAGE; YOUTH
AB Effects of treatment with DHEA (0.2 or 1.0 mg/kg body weight for 7 days) on oxidative energy metabolism of rat liver mitochondria from old (18-24 month old) and young (8-10 weeks old) male albino rats belonging to Charles-Foster strain were examined. Treatment with 1.0 mg DHEA resulted in increased body weights of the young rats without change in the liver weight. In the old animals the liver weight increased progressively with increasing dose of DHEA without affecting body weight. The state 3 respiration rates in liver mitochondria from old animals were, in general, lower than those in the young rats. The state 3 and state 4 respiration rates increased following DHEA treatment in dose-dependent manner bringing them close to values for young animals or beyond that with the effect being more pronounced at 1.0 mg dose. Treatment with DHEA also stimulated state 3 and state 4 respiration rates in young rats in dose-dependent manner. Contents of cytochrome aa(3), b and c+c(1) increased significantly in old animals in dose-dependent manner. In the young rats the lower dose (0.2 mg) of DHEA was more effective in bringing about a maximum increase in the contents of the cytochromes; the effect declined at the higher dose (1.0 mg). DHEA treatment also stimulated the mitochondrial ATPase activity in the old as well as in the young rats. The dehydrogenases activities were considerably low in the old rats compared to the values for the young animals. Treatment with DHEA stimulated dehydrogenases activities in old rats in dose-dependent manner bringing them close to values for the young animals or beyond. Treatment with lower dose (0.2 mg) of DHEA maximally stimulated dehydrogenases activities in young animals.
C1 Maharaja Sayajirao Univ Baroda, Fac Sci, Dept Biochem, Baroda 390002, Gujarat, India.
C3 Maharaja Sayajirao University Baroda
RP Modi, HR (corresponding author), Maharaja Sayajirao Univ Baroda, Fac Sci, Dept Biochem, Baroda 390002, Gujarat, India.
EM modi_hiren@yahoo.co.in
OI Modi, Hiren/0000-0003-1731-7111
CR Alberts B., 1994, MOL BIOL CELL
   Buvat J, 2003, WORLD J UROL, V21, P346, DOI 10.1007/s00345-003-0367-7
   Celec P, 2003, PHYSIOL RES, V52, P397, DOI 10.33549/physiolres.930385
   FERREIRA J, 1984, BIOCHEM J, V218, P61, DOI 10.1042/bj2180061
   HANSFORD RG, 1983, BIOCHIM BIOPHYS ACTA, V726, P41, DOI 10.1016/0304-4173(83)90010-1
   Hinson JP, 1999, J ENDOCRINOL, V163, P1, DOI 10.1677/joe.0.1630001
   Katewa SD, 2004, DRUG CHEM TOXICOL, V27, P41, DOI 10.1081/DCT-120027898
   Katewa SD, 2003, ANAL BIOCHEM, V323, P180, DOI 10.1016/j.ab.2003.08.024
   KATYARE SS, 1989, BRIT J PHARMACOL, V96, P51, DOI 10.1111/j.1476-5381.1989.tb11783.x
   Kaushal R, 1999, ENVIRON TOXICOL PHAR, V7, P67, DOI 10.1016/S1382-6689(98)00053-2
   Kazihnitková H, 2004, STEROIDS, V69, P667, DOI 10.1016/j.steroids.2004.06.002
   LOWRY OH, 1951, J BIOL CHEM, V193, P265
   Manczak M, 2005, J NEUROCHEM, V92, P494, DOI 10.1111/j.1471-4159.2004.02884.x
   MARCUS DL, 1982, EXP GERONTOL, V17, P333, DOI 10.1016/0531-5565(82)90033-X
   MILGROM E, 1990, HORMONES MOL DIS, P387
   Nakahara H, 1998, FREE RADICAL BIO MED, V24, P85, DOI 10.1016/S0891-5849(97)00164-0
   Navarro A, 2004, AM J PHYSIOL-REG I, V287, pR1244, DOI 10.1152/ajpregu.00226.2004
   Nawata H, 2002, MECH AGEING DEV, V123, P1101, DOI 10.1016/S0047-6374(01)00393-1
   Parker CR, 1999, STEROIDS, V64, P640, DOI 10.1016/S0039-128X(99)00046-X
   Patel MA, 2007, CLIN BIOCHEM, V40, P57, DOI 10.1016/j.clinbiochem.2006.08.014
   Patel MA, 2006, MOL CELL BIOCHEM, V293, P193, DOI 10.1007/s11010-006-9242-3
   Patel MA, 2006, NEUROSCI LETT, V402, P131, DOI 10.1016/j.neulet.2006.03.057
   Poyton RO, 1996, ANNU REV BIOCHEM, V65, P563, DOI 10.1146/annurev.bi.65.070196.003023
   Racchi M, 2003, CNS DRUG REV, V9, P21, DOI 10.1111/j.1527-3458.2003.tb00242.x
   Ren Jin-min, 2005, Yaoxue Xuebao, V40, P262
   Sastre J, 1996, HEPATOLOGY, V24, P1199, DOI 10.1002/hep.510240536
   SHIMOKAWA I, 1993, J GERONTOL, V48, pB27, DOI 10.1093/geronj/48.1.B27
   Steckelbroeck S, 2002, J NEUROCHEM, V83, P713, DOI 10.1046/j.1471-4159.2002.01187.x
   SUBRAMANIAN M, 1990, MECH AGEING DEV, V54, P121, DOI 10.1016/0047-6374(90)90060-S
   Vallée M, 2000, ANAL BIOCHEM, V287, P153, DOI 10.1006/abio.2000.4841
   Weill-Engerer S, 2003, BRAIN RES, V969, P117, DOI 10.1016/S0006-8993(03)02288-1
NR 31
TC 9
Z9 9
U1 0
U2 1
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0161-9152
EI 1574-4647
J9 AGE
JI Age
PD MAR
PY 2007
VL 29
IS 1
BP 41
EP 49
DI 10.1007/s11357-007-9029-9
PG 9
WC Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Geriatrics & Gerontology
GA 162QE
UT WOS:000246102400004
PM 19424829
OA Green Published
DA 2024-02-19
ER

PT J
AU Martin, R
   Fitzl, G
   Mozet, C
   Martin, H
   Welt, K
   Wieland, E
AF Martin, R
   Fitzl, G
   Mozet, C
   Martin, H
   Welt, K
   Wieland, E
TI Effect of age and hypoxia/reoxygenation on mRNA expression of
   antioxidative enzymes in rat liver and kidneys
SO EXPERIMENTAL GERONTOLOGY
LA English
DT Article
DE mRNA expression; antioxidative enzymes; aging; hypoxia/reoxygenation;
   liver; kidney
ID OXIDATIVE STRESS; HYPOBARIC HYPOXIA; OXYGEN DEPENDENCE; REPERFUSION;
   DEFENSES; DAMAGE
AB The influence of a short-time isobaric hypoxia as well as reoxygenation on markers of oxidative stress (MDA, total SOD, GSH) and on the mRNA expression of the antioxidative enzymes (Cu/Zn-and Mn-SOD, catalase, GSH reductase and GSH peroxidase) has been studied in liver and kidneys of young (6 months) and old (22-25 months) Wistar rats.
   In livers of old animals, the concentration of GSH, the activity of SOD, and the mRNA expression of the antioxidative enzymes (except Mn-SOD) points to a restricted protection against oxidative stress or a lower production of ROS compared to young animals. Hypoxia resulted in a significant decrease of enzyme gene expression in both age groups. Reoxygenation caused an increase in mRNA of Cu/Zn-SOD and GPX in livers of young and of Mn-SOD in livers of old animals.
   In kidneys, gene expression of Cu/Zn-SOD, GSH reductase, and GPX was significantly higher in old animals compared to young animals. Whereas hypoxia caused a decrease of gene expression in the livers, it lead to a significant increase of CU/Zn-SOD, catalase, and GSH reductase mRNA in kidneys of young rats. A reduced gene expression was observed after reoxygenation. In old kidneys, the expression of all enzymes except for catalase progressively declined in the hypoxic and reoxygenation groups, These data show that gene expression of antioxidative enzymes is affected by age and significantly differs between liver and kidney. (C) 2002 Elsevier Science Inc. All rights reserved.
C1 Univ Leipzig, Inst Anat, D-04103 Leipzig, Germany.
   Univ Leipzig, Inst Lab Med Clin Chem & Mol Diagnost, D-04103 Leipzig, Germany.
   Univ Gottingen, Dept Clin Chem, D-37075 Gottingen, Germany.
C3 Leipzig University; Leipzig University; University of Gottingen
RP Fitzl, G (corresponding author), Univ Leipzig, Inst Anat, Liebigstr 13, D-04103 Leipzig, Germany.
CR Amicarelli F, 1997, MECH AGEING DEV, V97, P215, DOI 10.1016/S0047-6374(97)00061-4
   AZHAR S, 1995, J CLIN INVEST, V96, P1414, DOI 10.1172/JCI118177
   BOFFOLI D, 1994, BBA-MOL BASIS DIS, V1226, P73, DOI 10.1016/0925-4439(94)90061-2
   BURTON K, 1956, BIOCHEM J, V62, P315, DOI 10.1042/bj0620315
   CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999
   COSTA LE, 1993, AM J PHYSIOL, V264, pC1395, DOI 10.1152/ajpcell.1993.264.6.C1395
   DE AK, 1991, MECH AGEING DEV, V59, P123, DOI 10.1016/0047-6374(91)90078-E
   DeLaAsuncion JG, 1996, FASEB J, V10, P333, DOI 10.1096/fasebj.10.2.8641567
   Dobashi K, 2000, MOL CELL BIOCHEM, V205, P1, DOI 10.1023/A:1007047505107
   DogruAbbasoglu S, 1997, MECH AGEING DEV, V98, P177, DOI 10.1016/S0047-6374(97)00082-1
   FLOHE L, 1984, METHOD ENZYMOL, V105, P101
   Gasbarrini A, 1998, FREE RADICAL BIO MED, V24, P211, DOI 10.1016/S0891-5849(97)00056-7
   GONZALEZFLECHA B, 1993, HEPATOLOGY, V18, P881, DOI 10.1002/hep.1840180421
   GORES GJ, 1989, AM J PHYSIOL, V257, P347
   HARMAN D, 1994, ANN NY ACAD SCI, V717, P1, DOI 10.1111/j.1749-6632.1994.tb12069.x
   JI LL, 1993, MED SCI SPORT EXER, V25, P225
   JONES DP, 1985, ROLE OXYGEN CONCENTR, P151
   MARTIN R, 2001, CURRENT CONCEPTS EXP, P229
   Nakanishi I, 1995, J PHYSIOL-LONDON, V489, P869, DOI 10.1113/jphysiol.1995.sp021099
   RAO G, 1990, MECH AGEING DEV, V53, P49, DOI 10.1016/0047-6374(90)90033-C
   RIKANS LE, 1992, GERONTOLOGY, V38, P133
   Sanz N, 1997, J HEPATOL, V27, P525, DOI 10.1016/S0168-8278(97)80358-3
   SEMSEI I, 1989, BIOCHEM BIOPH RES CO, V164, P620, DOI 10.1016/0006-291X(89)91505-2
   SHAN XQ, 1992, BIOCHEM PHARMACOL, V43, P2421, DOI 10.1016/0006-2952(92)90322-A
   SHAN XQ, 1989, TOXICOL APPL PHARM, V101, P261, DOI 10.1016/0041-008X(89)90275-5
   Siems WG, 1996, PHARMAZEUT Z, V141, P4239
   SOHAL RS, 1995, MECH AGEING DEV, V81, P15, DOI 10.1016/0047-6374(94)01578-A
   Tian LQ, 1998, FREE RADICAL BIO MED, V24, P1477, DOI 10.1016/S0891-5849(98)00025-2
   TRIBBLE DL, 1990, BIOCHEM PHARMACOL, V39, P729, DOI 10.1016/0006-2952(90)90152-B
   UCHIYAMA M, 1978, ANAL BIOCHEM, V86, P271, DOI 10.1016/0003-2697(78)90342-1
NR 30
TC 38
Z9 42
U1 0
U2 3
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0531-5565
J9 EXP GERONTOL
JI Exp. Gerontol.
PD DEC
PY 2002
VL 37
IS 12
BP 1481
EP 1487
AR PII S0531-5565(02)00168-7
DI 10.1016/S0531-5565(02)00168-7
PG 7
WC Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Geriatrics & Gerontology
GA 630MX
UT WOS:000180112900020
PM 12559417
DA 2024-02-19
ER

PT J
AU Li, D
   Lyu, YF
   Zhao, JJ
   Ji, XY
   Zhang, YF
   Zuo, Z
AF Li, Dan
   Lyu, Yuanfeng
   Zhao, Jiajia
   Ji, Xiaoyu
   Zhang, Yufeng
   Zuo, Zhong
TI Accumulation of the Major Components from Polygoni Multiflori Radix in
   Liver and Kidney after Its Long-Term Oral Administrations in Rats
SO PLANTA MEDICA
LA English
DT Article; Early Access
DE Polygoni Multiflori Radix; Polygonum multiflorum Thunb.; 2,3,5,4
   '-tetrahydroxystilbene-2-O-beta-D-glucopyranoside; emodin;
   emodin-8-O-beta-D-glucopyranoside; physcion; liver and kidney
   distribution
ID TISSUE DISTRIBUTION; ACUTE HEPATITIS; EMODIN; PHARMACOKINETICS;
   APOPTOSIS; ANTHRAQUINONES; PATHWAY;
   2,3,5,4'-TETRAHYDROXYSTILBENE-2-O-BETA-D-GLUCOSIDE; CONSTITUENTS;
   INGESTION
AB Although Polygoni Multiflori Radix (PMR) has been widely used as a tonic and an anti-aging remedy for centuries, the extensively reported hepatotoxicity and potential kidney toxicity hindered its safe use in clinical practice. To better understand its toxicokinetics, the current study was proposed, aiming to evaluate the biodistributions of the major PMR components including 2,3,5,4'-tetrahydroxystilbene-2-O-beta-D-glucopyranoside (TSG), emodin, emodin-8-O-beta-D-glucopyranoside (EMG) and physcion as well as their corresponding glucuronides following bolus and multiple oral administrations of PMR to rats. Male Sprague-Dawley rats received a bolus dose or 21 days of oral administrations of PMR concentrated granules at 4.12 g/kg (equivalent to 20.6 g/kg raw material). Fifteen minutes after bolus dose or the last dose on day 21, rats were sacrificed and the blood, liver, and kidney were collected for the concentration determination of both parent form and glucuronides of TSG, emodin, EMG, and physcion by HPLC-MS/MS. Among all the tested analytes, TSG, EMG, EMG glucuronides in liver and TSG, EMG, as well as all the glucuronides of these analytes in the kidney demonstrated the most significant accumulation after multiple doses. Moreover, the levels of the parent analytes were all significantly higher in liver and kidney in comparison to their plasma levels. Strong tissue binding of all four analytes and accumulation of TSG, EMG, and EMG glucuronides in the liver and TSG, EMG, as well as the glucuronides of all four analytes in the kidney after multiple dosing of PMR were considered to be associated with its toxicity.
C1 [Li, Dan; Lyu, Yuanfeng; Zhao, Jiajia; Ji, Xiaoyu; Zhang, Yufeng; Zuo, Zhong] Chinese Univ Hong Kong, Fac Med, Sch Pharm, Shatin, Hong Kong, Peoples R China.
C3 Chinese University of Hong Kong
RP Zuo, Z (corresponding author), Chinese Univ Hong Kong, Fac Med, Sch Pharm, Shatin, Hong Kong, Peoples R China.
EM joanzuo@cuhk.edu.hk
RI zhang, yu/HNS-5948-2023; Zhang, Yufeng/GZL-1973-2022
OI Zhang, Yufeng/0000-0001-8236-1878; Zuo, Zhong/0000-0002-6976-6157; Zhao,
   Jiajia/0000-0001-8899-6356
CR [Anonymous], 2018, Guidance for Industry: Bioanalytical Method Validation
   But PPH, 1996, VET HUM TOXICOL, V38, P280
   Cardenas A, 2006, J CLIN GASTROENTEROL, V40, P629
   Chen, 1988, J CHINA PHARM U, V19, P179
   Cho HC, 2009, GUT LIVER, V3, P52, DOI 10.5009/gnl.2009.3.1.52
   Commission, 2015, CHINESE PHARMACOPOEI, P175
   Cui YT, 2016, FOOD CHEM TOXICOL, V92, P26, DOI 10.1016/j.fct.2016.03.013
   Dong HH, 2014, COMPLEMENT THER MED, V22, P70, DOI 10.1016/j.ctim.2013.12.008
   Dong Q, 2015, FRONT PHARMACOL, V6, DOI 10.3389/fphar.2015.00217
   Dong XX, 2018, ONCOL REP, V40, P1985, DOI 10.3892/or.2018.6620
   Fu JF, 2018, BIOMED CHROMATOGR, V32, DOI 10.1002/bmc.4190
   Gong XH, 2019, J PHARMACEUT BIOMED, V175, DOI 10.1016/j.jpba.2019.07.008
   Jing XB, 2002, JPN J CANCER RES, V93, P874, DOI 10.1111/j.1349-7006.2002.tb01332.x
   Jung KA, 2011, GUT LIVER, V5, P493, DOI 10.5009/gnl.2011.5.4.493
   Kang L, 2017, TOXICOL IN VITRO, V40, P313, DOI 10.1016/j.tiv.2017.01.022
   Laird AR, 2008, J CLIN GASTROENTEROL, V42, P861, DOI 10.1097/MCG.0b013e3181492515
   Li, 2011, FUJIAN MED J, V33, P58
   Li D, 2020, TOXINS, V12, DOI 10.3390/toxins12110729
   Li Y, 2020, INT J ANAL CHEM, V2020, P1
   Lin LF, 2015, J HAZARD MATER, V299, P249, DOI 10.1016/j.jhazmat.2015.06.014
   Lin LF, 2015, J ETHNOPHARMACOL, V159, P158, DOI 10.1016/j.jep.2014.11.009
   Lin LF, 2015, ANAL METHODS-UK, V7, P244, DOI 10.1039/c4ay02197e
   Lin SP, 2012, J ETHNOPHARMACOL, V144, P671, DOI 10.1016/j.jep.2012.10.009
   Liu Y, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01467
   Lv GY, 2011, J ETHNOPHARMACOL, V137, P449, DOI 10.1016/j.jep.2011.05.049
   Ma J, 2015, J ETHNOPHARMACOL, V162, P61, DOI 10.1016/j.jep.2014.12.045
   National Toxicology Program, 2001, Natl Toxicol Program Tech Rep Ser, V493, P1
   Park GJH, 2001, J GASTROEN HEPATOL, V16, P115, DOI 10.1046/j.1440-1746.2001.02309.x
   Peng j., 2008, World Science and Technology, V10, P64, DOI DOI 10.1016/S1876-3553(09)60004-1
   Shi YB, 2015, J DRUG DELIV SCI TEC, V30, P242, DOI 10.1016/j.jddst.2015.10.019
   Shia CS, 2011, J ETHNOPHARMACOL, V137, P1388, DOI 10.1016/j.jep.2011.08.003
   Shieh DE, 2004, LIFE SCI, V74, P2279, DOI 10.1016/j.lfs.2003.09.060
   Subramaniam A, 2013, BRIT J PHARMACOL, V170, P807, DOI 10.1111/bph.12302
   Tamura M, 2015, CHEM PHARM BULL, V63, P122, DOI 10.1248/cpb.c14-00626
   US Food and Drug Administration, 2005, INT C HARM ICH Q2 R1
   Wang LL, 2017, J PHARMACEUT BIOMED, V140, P45, DOI 10.1016/j.jpba.2017.03.016
   Wang W, 2016, GLOBAL TRADITIONAL C, V9, P414
   Xia XH, 2017, J ETHNOPHARMACOL, V203, P182, DOI 10.1016/j.jep.2017.03.046
   Yan Y, 2020, ACS OMEGA, V5, P10489, DOI 10.1021/acsomega.0c00647
   Yang JB, 2021, CURR DRUG METAB, V22, P165, DOI 10.2174/1389200221666201201091345
   Yao S, 2006, J CHROMATOGR A, V1115, P64, DOI 10.1016/j.chroma.2006.02.071
   Yu JQ, 2013, PHYTOTHER RES, V27, P251, DOI 10.1002/ptr.4703
   Zhang L, 2020, ARCH TOXICOL, V94, P245, DOI 10.1007/s00204-019-02595-3
   Zhang L, 2020, XENOBIOTICA, V50, P515, DOI 10.1080/00498254.2019.1658138
   Zhang L, 2013, J ETHNOPHARMACOL, V148, P246, DOI 10.1016/j.jep.2013.04.020
   Zhang M, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00505
   Zhang Y, 2015, INT J CLIN EXP MED, V8, P10986
   Zhao YY, 2013, J SEP SCI, V36, P863, DOI 10.1002/jssc.201200668
   Zheng XY, 2019, DRUG DES DEV THER, V13, P3171, DOI 10.2147/DDDT.S204958
NR 49
TC 5
Z9 6
U1 3
U2 22
PU GEORG THIEME VERLAG KG
PI STUTTGART
PA RUDIGERSTR 14, D-70469 STUTTGART, GERMANY
SN 0032-0943
EI 1439-0221
J9 PLANTA MED
JI Planta Med.
PD 2022 SEP
PY 2022
VL 88
IS 11
BP 950
EP 959
DI 10.1055/a-1585-5991
EA SEP 2021
PG 10
WC Plant Sciences; Chemistry, Medicinal; Integrative & Complementary
   Medicine; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Plant Sciences; Pharmacology & Pharmacy; Integrative & Complementary
   Medicine
GA 4G2GE
UT WOS:000695676800002
PM 34521133
DA 2024-02-19
ER

PT J
AU Wang, D
   Guo, ZH
   Liu, XH
   Li, YH
   Wang, H
AF Wang, Dan
   Guo, Zhao-Hui
   Liu, Xing-Han
   Li, Yue-Hua
   Wang, He
TI Examination of Hippocampal Differences Between Alzheimer Disease,
   Amnestic Mild Cognitive Impairment and Normal Aging: Diffusion Kurtosis
SO CURRENT ALZHEIMER RESEARCH
LA English
DT Article
DE Alzheimer disease; amnestic mild cognitive impairment; diffusion
   kurtosis imaging; hippocampus; magnetic resonance imaging
ID MAGNETIC-RESONANCE-SPECTROSCOPY; GAUSSIAN WATER DIFFUSION; MR; LIVER;
   TISSUE; PATTERNS
AB Purpose: To examine hippocampal differences between Alzheimer disease (AD), amnestic mild cognitive impairment (aMCI) and normal aging. Materials and methods: This study was approved by the local ethics review board, and informed consent was obtained from volunteers/guardians. The study comprised 60 subjects: 20 aMCI patients, 20 AD patients and 20 normal controls (NC group). Magnetic resonance imaging and diffusion kurtosis imaging of the hippocampus were performed. Nonlinear fitting routines and equations were used to calculate mean diffusion (MD) and mean kurtosis (MK). Analysis of variance was used to compare the bilateral MK/MD values/volumes of the hippocampus for the three groups using the Fisher least significant difference test (a two-sample t-test comparison). Pearson correlation coefficients were calculated for the correlations between mini-mental state examination (MMSE) scores and MK/MD values/volumes. Results: There were significant differences between the AD and NC groups and between the AD and aMCI groups in terms of normalized bilateral hippocampal volume. There were significant differences between the NC, aMCI and AD groups in terms of both right and left hippocampus MK values. For the right hippocampus MD values, there was a significant difference between the NC and AD groups. For the left hippocampus MD values, there were significant differences between the AD and NC groups and between the AD and aMCI groups. Pearson correlation coefficients for all correlations between MMSE scores and hippocampus MK/MD values/volumes were significant. Conclusion: The bilateral hippocampal MK/MD values may be more sensitive than volumes in the diagnosis of aMCI and AD patients.
C1 [Wang, Dan; Li, Yue-Hua] Shanghai Jiao Tong Univ, Affiliated Peoples Hosp 6, Inst Diagnost & Intervent Radiol, Shanghai 200233, Peoples R China.
   [Guo, Zhao-Hui] Harbin Med Univ, Affiliated Hosp 4, Dept Neurol, Harbin, Peoples R China.
   [Liu, Xing-Han] Harbin Med Univ, Dept Biochem, Harbin, Peoples R China.
   [Wang, He] Philips Res China, Shanghai, Peoples R China.
C3 Shanghai Jiao Tong University; Harbin Medical University; Harbin Medical
   University; Philips; Philips Research
RP Li, YH (corresponding author), Shanghai Jiao Tong Univ, Affiliated Peoples Hosp 6, 600,Yi Shan Rd, Shanghai 200233, Peoples R China.
EM liyuehuaxp@gmail.com
RI li, yueyue/IVH-9846-2023; LI, Yue/GRS-8071-2022; li, yue/HSF-7296-2023
FU National Natural Science Foundation of China [81471656]
FX This research is supported by National Natural Science Foundation of
   China No. 81471656.
CR Abrigo JM, 2014, J HEPATOL, V60, P809, DOI 10.1016/j.jhep.2013.11.018
   Agarwal A, 2013, J NEUROONCOL
   Antharam V, 2012, NEUROIMAGE, V59, P1249, DOI 10.1016/j.neuroimage.2011.08.019
   Cheung MM, 2009, NEUROIMAGE, V45, P386, DOI 10.1016/j.neuroimage.2008.12.018
   Chmelik M, 2014, NMR BIOMED, V27, P478, DOI 10.1002/nbm.3084
   Dai WY, 2009, RADIOLOGY, V250, P856, DOI 10.1148/radiol.2503080751
   Ding AY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0051704
   Gao Y, 2012, NMR BIOMED, V25, P1369, DOI 10.1002/nbm.2809
   Giannelli M, 2012, RADIOLOGY, V265, P645, DOI 10.1148/radiol.12121036
   Grinberg F, 2011, NEUROIMAGE, V57, P1087, DOI 10.1016/j.neuroimage.2011.04.050
   Harris GJ, 1998, AM J NEURORADIOL, V19, P1727
   Hong YJ, 2012, NEUROLOGICAL SCI OFF
   Hui ES, 2008, NEUROIMAGE, V42, P122, DOI 10.1016/j.neuroimage.2008.04.237
   Hui ES, 2008, IEEE ENG MED BIO, P3941, DOI 10.1109/IEMBS.2008.4650072
   Jensen JH, 2010, NMR BIOMED, V23, P698, DOI 10.1002/nbm.1518
   Jensen JH, 2005, MAGNET RESON MED, V53, P1432, DOI 10.1002/mrm.20508
   Jiang T, 2012, ABDOM IMAGING, V37, P788, DOI 10.1007/s00261-008-9451-1
   Juottonen K, 1999, AM J NEURORADIOL, V20, P139
   Laufs A, 2014, MAGN RESON MED, V71, P1670, DOI 10.1002/mrm.24835
   Li Y, 2006, AM J NEURORADIOL, V27, P912
   Lu HZ, 2006, NMR BIOMED, V19, P236, DOI 10.1002/nbm.1020
   MacMaster FP, 2008, BIOL PSYCHIAT, V63, P385, DOI 10.1016/j.biopsych.2007.05.005
   MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939
   Minati L, 2007, MAGN RESON MATER PHY, V20, P241, DOI 10.1007/s10334-007-0091-1
   Petersen RC, 2001, ARCH NEUROL-CHICAGO, V58, P1985, DOI 10.1001/archneur.58.12.1985
   ter Voert EGW, 2011, WORLD J GASTROENTERO, V17, P5133, DOI 10.3748/wjg.v17.i47.5133
   Wu EX, 2010, NMR BIOMED, V23, P836, DOI 10.1002/nbm.1506
   Yoshida S, 2013, PEDIATR RADIOL, V43, P15, DOI 10.1007/s00247-012-2496-x
NR 28
TC 20
Z9 22
U1 0
U2 11
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1567-2050
EI 1875-5828
J9 CURR ALZHEIMER RES
JI Curr. Alzheimer Res.
PY 2015
VL 12
IS 1
BP 80
EP 87
DI 10.2174/1567205012666141218142422
PG 8
WC Clinical Neurology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA AY0PS
UT WOS:000347299500009
PM 25523422
DA 2024-02-19
ER

PT J
AU Xiang, HJ
   Shao, MM
   Lu, YF
   Wang, JM
   Wu, T
   Ji, G
AF Xiang, Hongjiao
   Shao, Mingmei
   Lu, Yifei
   Wang, Junmin
   Wu, Tao
   Ji, Guang
TI Kaempferol Alleviates Steatosis and Inflammation During Early
   Non-Alcoholic Steatohepatitis Associated With Liver X Receptor
   α-Lysophosphatidylcholine Acyltransferase 3 Signaling Pathway
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE kaempferol; NASH; LXR; LPCAT3; ERS
ID ENDOPLASMIC-RETICULUM STRESS; LIPID-ACCUMULATION; ER STRESS; PPAR-ALPHA;
   TNF-ALPHA; PROGRESSION; DEATH; CELLS; IDENTIFICATION; INHIBITION
AB Background: Kaempferol (KP) has a variety of biological effects such as anti-inflammatory, anti-oxidant, anti-aging and cardiovascular protection. Whether KP has a therapeutic effect on non-alcoholic steatohepatitis (NASH), and the detailed mechanism is currently unclear. This study aims to explore the mechanism of KP in the treatment of NASH through in vivo and in vitro experiments. Methods: 1) In vivo experiment: In the C57BL/6 NASH mice model induced by high fat diet (HFD), KP was administered by gavage at a dose of 20 mg/kg/day. 2) In vitro experiment: Palmitic acid/Oleic acid (PA/OA, 0.375/0.75 mM) was used to intervene HepG2 and AML12 cells to establish a steatosis cell model. Three concentrations of KP, low (20 mu mol/L), medium (40 mu mol/L) and high (60 mu mol/L) were used in vitro. The mRNA and protein expression of related molecules involved in LXR alpha-LPCAT3-ERS pathway were detected using RT-qPCR and Western blot. Results: In the NASH mouse model, KP can significantly reduce the expression of LXR alpha, LPCAT3 and ERS-related factors PERK, eIF2 alpha, ATF6, ATF4, XBP1, CHOP, IRE1 alpha and GRP78. In the PA/OA-induced cell model, KP could decrease the content of triglyceride and lipid droplets, and also decrease the expression of LXR alpha, LPCAT3 and ERS related factors PERK, eIF2 alpha, ATF6, ATF4, XBP1, CHOP, IRE1 alpha and GRP78. Conclusion: KP may decrease the expression level of LXR alpha and LPCAT3, thus improve ERS and reduce hepatic steatosis and inflammation.
C1 [Xiang, Hongjiao; Shao, Mingmei; Lu, Yifei; Wang, Junmin; Wu, Tao] Shanghai Univ Tradit Chinese Med, Inst Interdisciplinary Integrat Med Res, Shanghai, Peoples R China.
   [Xiang, Hongjiao; Shao, Mingmei; Lu, Yifei; Wang, Junmin; Wu, Tao; Ji, Guang] Shanghai Univ Tradit Chinese Med, Longhua Hosp, Inst Digest Dis, Shanghai, Peoples R China.
C3 Shanghai University of Traditional Chinese Medicine; Shanghai University
   of Traditional Chinese Medicine
RP Wu, T (corresponding author), Shanghai Univ Tradit Chinese Med, Inst Interdisciplinary Integrat Med Res, Shanghai, Peoples R China.; Wu, T; Ji, G (corresponding author), Shanghai Univ Tradit Chinese Med, Longhua Hosp, Inst Digest Dis, Shanghai, Peoples R China.
EM wutao001827@163.com; jiliver@vip.sina.com
FU National Natural Science Foundation of China [81620108030, 81873076];
   Shanghai Talents development fund Project [2017090]; Hundred Talents
   Program from Shanghai University of Traditional Chinese Medicine
FX This work was supported by the National Natural Science Foundation of
   China (81620108030, 81873076), the Shanghai Talents development fund
   Project (2017090) and the Hundred Talents Program from Shanghai
   University of Traditional Chinese Medicine.
CR Ashrafizadeh M, 2020, PHYTOTHER RES, V34, P911, DOI 10.1002/ptr.6577
   Baeck C, 2012, GUT, V61, P416, DOI 10.1136/gutjnl-2011-300304
   Balkwill F, 2006, CANCER METAST REV, V25, P409, DOI 10.1007/s10555-006-9005-3
   Borish Larry C., 2003, Journal of Allergy and Clinical Immunology, V111, pS460
   Bourgeois T, 2021, J LIPID RES, V62, DOI [10.1194/j.jlr.RA120000737, 10.1194/jlr.RA120000737]
   Brenner C, 2013, J HEPATOL, V59, P583, DOI 10.1016/j.jhep.2013.03.033
   Chaudhari N, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00213
   Chen AY, 2013, FOOD CHEM, V138, P2099, DOI 10.1016/j.foodchem.2012.11.139
   Dabeek WM, 2019, NUTRIENTS, V11, DOI 10.3390/nu11102288
   Dasgupta D, 2020, GASTROENTEROLOGY, V159, P1487, DOI 10.1053/j.gastro.2020.06.031
   Demeure O, 2011, GENE, V470, P7, DOI 10.1016/j.gene.2010.09.002
   Demirtas L, 2016, INDIAN J MED RES, V144, P515, DOI 10.4103/0971-5916.200887
   Donnelly N, 2013, CELL MOL LIFE SCI, V70, P3493, DOI 10.1007/s00018-012-1252-6
   Estes C, 2018, J HEPATOL, V69, P896, DOI 10.1016/j.jhep.2018.05.036
   Fan JG, 2017, J HEPATOL, V67, P862, DOI 10.1016/j.jhep.2017.06.003
   Fan YT, 2020, LIVER INT, V40, P598, DOI 10.1111/liv.14307
   Ferrara PJ, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI135963
   Friedman SL, 2018, NAT MED, V24, P908, DOI 10.1038/s41591-018-0104-9
   Ghosh R, 2014, CELL, V158, P534, DOI 10.1016/j.cell.2014.07.002
   Hu H, 2019, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.03083
   Huang SJ, 2019, J BIOL CHEM, V294, P18726, DOI 10.1074/jbc.REV119.007036
   Imran M, 2019, MOLECULES, V24, DOI 10.3390/molecules24122277
   Hernández-Alvarez MI, 2019, CELL, V177, P881, DOI 10.1016/j.cell.2019.04.010
   Iurlaro R, 2016, FEBS J, V283, P2640, DOI 10.1111/febs.13598
   Jones SA, 2018, NAT REV IMMUNOL, V18, P773, DOI 10.1038/s41577-018-0066-7
   Kouhestani S, 2018, NEURAL REGEN RES, V13, P1827, DOI 10.4103/1673-5374.238714
   Lebeaupin C, 2018, HEPATOLOGY, V68, P515, DOI 10.1002/hep.29847
   Lee B, 2015, J MED FOOD, V18, P1363, DOI 10.1089/jmf.2015.3457
   Lee YJ, 2015, FOOD FUNCT, V6, P2824, DOI 10.1039/c5fo00481k
   Li BH, 2017, TRANSL RES, V180, P103, DOI 10.1016/j.trsl.2016.08.006
   Li FH, 2017, ONCOTARGET, V8, P43799, DOI 10.18632/oncotarget.16460
   Li S, 2011, BIOL PHARM BULL, V34, P1291, DOI 10.1248/bpb.34.1291
   Liu LQ, 2020, ARCH MED SCI, V16, P374, DOI 10.5114/aoms.2020.93343
   Liu W, 2014, J GASTROEN HEPATOL, V29, P614, DOI 10.1111/jgh.12430
   Lu YF, 2020, FOOD FUNCT, V11, P10058, DOI [10.1039/d0fo02123g, 10.1039/D0FO02123G]
   Luhr M, 2019, J BIOL CHEM, V294, P8197, DOI 10.1074/jbc.RA118.002829
   Malaviya R, 2017, PHARMACOL THERAPEUT, V180, P90, DOI 10.1016/j.pharmthera.2017.06.008
   Malhi H, 2011, J HEPATOL, V54, P795, DOI 10.1016/j.jhep.2010.11.005
   Marciniak SJ, 2004, GENE DEV, V18, P3066, DOI 10.1101/gad.1250704
   Marra F, 2014, GASTROENTEROLOGY, V147, P577, DOI 10.1053/j.gastro.2014.06.043
   Montagner A, 2016, GUT, V65, P1202, DOI 10.1136/gutjnl-2015-310798
   Nakagawa H, 2014, CANCER CELL, V26, P331, DOI 10.1016/j.ccr.2014.07.001
   Nobili V, 2019, NAT REV GASTRO HEPAT, V16, P517, DOI 10.1038/s41575-019-0169-z
   Ozcan L, 2012, ANNU REV MED, V63, P317, DOI 10.1146/annurev-med-043010-144749
   Pandolfi F, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21155238
   Pawlak M, 2015, J HEPATOL, V62, P720, DOI 10.1016/j.jhep.2014.10.039
   Phillips MC, 2018, J LIPID RES, V59, P749, DOI 10.1194/jlr.R082313
   Ren J, 2019, EXP THER MED, V18, P2759, DOI 10.3892/etm.2019.7886
   Rong X, 2013, CELL METAB, V18, P685, DOI 10.1016/j.cmet.2013.10.002
   Sheka AC, 2020, JAMA-J AM MED ASSOC, V323, P1175, DOI 10.1001/jama.2020.2298
   Shen XT, 2019, J CELL PHYSIOL, V234, P18169, DOI 10.1002/jcp.28450
   Singh AB, 2017, J BIOL CHEM, V292, P884, DOI 10.1074/jbc.M116.743575
   Suchal K, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18051001
   Takahashi Y, 2014, WORLD J GASTROENTERO, V20, P15539, DOI 10.3748/wjg.v20.i42.15539
   Tomita K, 2012, J HEPATOL, V57, P837, DOI 10.1016/j.jhep.2012.05.013
   van Schouwenburg PA, 2013, NAT REV RHEUMATOL, V9, P164, DOI 10.1038/nrrheum.2013.4
   Vance JE, 2015, TRAFFIC, V16, P1, DOI 10.1111/tra.12230
   Walter F, 2018, J BIOL CHEM, V293, P18270, DOI 10.1074/jbc.RA118.002121
   Wang B, 2016, CELL METAB, V23, P492, DOI 10.1016/j.cmet.2016.01.001
   Wang HJ, 2019, BIOMED PHARMACOTHER, V111, P468, DOI 10.1016/j.biopha.2018.12.105
   Wang M, 2016, NATURE, V529, P326, DOI 10.1038/nature17041
   Wang M, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/584634
   Yang YH, 2010, BIOCHIMIE, V92, P958, DOI 10.1016/j.biochi.2010.04.002
   Yoshida H, 2001, CELL, V107, P881, DOI 10.1016/S0092-8674(01)00611-0
   Younossi Z, 2018, NAT REV GASTRO HEPAT, V15, P11, DOI 10.1038/nrgastro.2017.109
   Zhang C, 2012, TOXICOL LETT, V212, P229, DOI 10.1016/j.toxlet.2012.06.002
   Zhang XQ, 2020, HEPATOL INT, V14, P828, DOI 10.1007/s12072-020-10068-4
NR 67
TC 16
Z9 16
U1 1
U2 17
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1663-9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD JUN 28
PY 2021
VL 12
AR 690736
DI 10.3389/fphar.2021.690736
PG 15
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA TH2BL
UT WOS:000671900200001
PM 34262459
OA gold, Green Published
DA 2024-02-19
ER

PT J
AU Guo, FF
   Estévez-Vázquez, O
   Benedé-Ubieto, R
   Maya-Miles, D
   Zheng, K
   Gallego-Durán, R
   Rojas, A
   Ampuero, J
   Romero-Gómez, M
   Philip, K
   Egbuniwe, IU
   Chen, CB
   Simon, J
   Delgado, TC
   Martínez-Chantar, ML
   Sun, J
   Reissing, J
   Bruns, T
   Lamas-Paz, A
   del Moral, MG
   Woitok, MM
   Vaquero, J
   Regueiro, JR
   Liedtke, C
   Trautwein, C
   Bañares, R
   Cubero, FJ
   Nevzorova, YA
AF Guo, Feifei
   Estevez-Vazquez, Olga
   Benede-Ubieto, Raquel
   Maya-Miles, Douglas
   Zheng, Kang
   Gallego-Duran, Rocio
   Rojas, Angela
   Ampuero, Javier
   Romero-Gomez, Manuel
   Philip, Kaye
   Egbuniwe, Isioma U.
   Chen, Chaobo
   Simon, Jorge
   Delgado, Teresa C.
   Martinez-Chantar, Maria Luz
   Sun, Jie
   Reissing, Johanna
   Bruns, Tony
   Lamas-Paz, Arantza
   del Moral, Manuel Gomez
   Woitok, Marius Maximilian
   Vaquero, Javier
   Regueiro, Jose R.
   Liedtke, Christian
   Trautwein, Christian
   Banares, Rafael
   Cubero, Francisco Javier
   Nevzorova, Yulia A.
TI A Shortcut from Metabolic-Associated Fatty Liver Disease (MAFLD) to
   Hepatocellular Carcinoma (HCC): c-MYC a Promising Target for
   Preventative Strategies and Individualized Therapy
SO CANCERS
LA English
DT Article
DE metabolic-associated fatty liver disease (MAFLD); c-myc; oncogene;
   tumorigenesis; metformin
ID METFORMIN; CANCER; NAFLD; PROGRESSION; EXPRESSION; ONCOGENES; MODEL;
   RISK
AB Simple Summary Metabolic-associated fatty liver disease (MAFLD) is a chronic liver disease associated with obesity, diabetes mellitus type 2 (DM2), and hyperlipidemia. It can also progress to end-stage hepatocellular carcinoma (HCC); the underlying mechanisms are still unknown, but endogenous (i.e., genetic) factors such as oncogenes have been suggested to play a role. We found that c-MYC transgenic mice with ageing are prone to develop obesity, metabolic syndrome (MS), and abnormal accumulation of lipids in the liver compared to control mice. A short-term application of the Western diet (WD) significantly worsened the phenotype and accelerate HCC development. Importantly, we found that metformin as therapeutic approach significantly attenuated MAFLD phenotype in transgenic mice. We also observed that c-MYC is up-regulated in human patients with MAFLD and MAFLD-related HCC. Altogether the current study suggests an important role of the oncogene c-MYC during the progression from MAFLD to HCC and makes c-MYC a possible target for preventative strategies and individualized therapy. Background: Metabolic-associated fatty liver disease (MAFLD) has risen as one of the leading etiologies for hepatocellular carcinoma (HCC). Oncogenes have been suggested to be responsible for the high risk of MAFLD-related HCC. We analyzed the impact of the proto-oncogene c-MYC in the development of human and murine MAFLD and MAFLD-associated HCC. Methods: alb-myc(tg) mice were studied at baseline conditions and after administration of Western diet (WD) in comparison to WT littermates. c-MYC expression was analyzed in biopsies of patients with MAFLD and MAFLD-associated HCC by immunohistochemistry. Results: Mild obesity, spontaneous hyperlipidaemia, glucose intolerance and insulin resistance were characteristic of 36-week-old alb-myc(tg) mice. Middle-aged alb-myc(tg) exhibited liver steatosis and increased triglyceride content. Liver injury and inflammation were associated with elevated ALT, an upregulation of ER-stress response and increased ROS production, collagen deposition and compensatory proliferation. At 52 weeks, 20% of transgenic mice developed HCC. WD feeding exacerbated metabolic abnormalities, steatohepatitis, fibrogenesis and tumor prevalence. Therapeutic use of metformin partly attenuated the spontaneous MAFLD phenotype of alb-myc(tg) mice. Importantly, upregulation and nuclear localization of c-MYC were characteristic of patients with MAFLD and MAFLD-related HCC. Conclusions: A novel function of c-MYC in MAFLD progression was identified opening new avenues for preventative strategies.
C1 [Guo, Feifei; Estevez-Vazquez, Olga; Benede-Ubieto, Raquel; Zheng, Kang; Chen, Chaobo; Lamas-Paz, Arantza; Regueiro, Jose R.; Banares, Rafael; Cubero, Francisco Javier; Nevzorova, Yulia A.] Univ Complutense Madrid, Dept Immunol Ophthalmol & ENT, Sch Med, 12 Octubre Imas12 Hlth Res Inst, Madrid 28040, Spain.
   [Guo, Feifei] Nanjing Univ, Dept Obstet & Gynaecol, Sch Med, Drum Tower Hosp, Nanjing 210023, Peoples R China.
   [Benede-Ubieto, Raquel] Univ Complutense Madrid, Fac Biol, Dept Physiol Genet & Microbiol, Madrid 28040, Spain.
   [Maya-Miles, Douglas; Gallego-Duran, Rocio; Rojas, Angela; Ampuero, Javier; Romero-Gomez, Manuel] Univ Seville, Inst Biomed Seville IBiS, SeLiver Grp, Virgen Rocio Univ Hosp,CSIC, Seville 41013, Spain.
   [Maya-Miles, Douglas; Gallego-Duran, Rocio; Rojas, Angela; Ampuero, Javier; Romero-Gomez, Manuel] Virgen Rocio Univ Hosp, UCM Digest Dis, Seville 41013, Spain.
   [Maya-Miles, Douglas; Gallego-Duran, Rocio; Rojas, Angela; Ampuero, Javier; Romero-Gomez, Manuel; Simon, Jorge; Martinez-Chantar, Maria Luz; Vaquero, Javier; Banares, Rafael; Cubero, Francisco Javier; Nevzorova, Yulia A.] Ctr Invest Biomed Red Enfermedades Hepat & Digest, Madrid 28220, Spain.
   [Zheng, Kang; Sun, Jie] Southeast Univ, Zhongda Hosp, Sch Med, Dept Anesthesiol, Nanjing 210009, Peoples R China.
   [Romero-Gomez, Manuel] Univ Seville, Dept Med, Seville 41009, Spain.
   [Philip, Kaye; Egbuniwe, Isioma U.] Nottingham Univ Hosp NHS Trust, Queens Med Ctr Campus, Dept Pathol, Nottingham NG7 2UH, England.
   [Chen, Chaobo] Wuxi Xishan Peoples Hosp, Dept Gen Surg, Wuxi 214000, Peoples R China.
   [Chen, Chaobo] Nanjing Univ, Sch Med, Dept Hepat Biliary Pancreat Surg, Affiliated Drum Tower Hosp, Nanjing 210023, Peoples R China.
   [Simon, Jorge; Delgado, Teresa C.; Martinez-Chantar, Maria Luz] Ctr Cooperat Res Biosci CIC bioGUNE, Liver Dis Lab, Basque Res & Technol Alliance BRTA, Derio 48160, Spain.
   [Reissing, Johanna; Bruns, Tony; Woitok, Marius Maximilian; Liedtke, Christian; Trautwein, Christian; Nevzorova, Yulia A.] Univ Hosp RWTH Aachen, Dept Internal Med 3, D-52074 Aachen, Germany.
   [del Moral, Manuel Gomez] Univ Complutense, Dept Cell Biol, Sch Med, Madrid 28040, Spain.
   [Vaquero, Javier; Banares, Rafael] Univ Gregorio Maranon, Serv Aparato Digest, Hosp Gen, Madrid 28009, Spain.
   [Vaquero, Javier; Banares, Rafael; Cubero, Francisco Javier; Nevzorova, Yulia A.] Inst Invest Sanitaria Gregorio Maranon IiSGM, Madrid 28007, Spain.
C3 Complutense University of Madrid; Nanjing University; Complutense
   University of Madrid; Consejo Superior de Investigaciones Cientificas
   (CSIC); University of Sevilla; CSIC-JA-USE - Instituto de Biomedicina de
   Sevilla (IBIS); Virgen del Rocio University Hospital; Virgen del Rocio
   University Hospital; CIBER - Centro de Investigacion Biomedica en Red;
   CIBEREHD; Southeast University - China; University of Sevilla;
   Nottingham University Hospital NHS Trust; Nanjing University; CIC
   bioGUNE; RWTH Aachen University; RWTH Aachen University Hospital;
   Complutense University of Madrid; General University Gregorio Maranon
   Hospital
RP Nevzorova, YA (corresponding author), Univ Complutense Madrid, Dept Immunol Ophthalmol & ENT, Sch Med, 12 Octubre Imas12 Hlth Res Inst, Madrid 28040, Spain.; Nevzorova, YA (corresponding author), Ctr Invest Biomed Red Enfermedades Hepat & Digest, Madrid 28220, Spain.; Nevzorova, YA (corresponding author), Univ Hosp RWTH Aachen, Dept Internal Med 3, D-52074 Aachen, Germany.; Nevzorova, YA (corresponding author), Inst Invest Sanitaria Gregorio Maranon IiSGM, Madrid 28007, Spain.
EM feiguo@ucm.es; olgaeste@ucm.es; rabenede@ucm.es; dmaya-ibis@us.es;
   kzheng@ucm.es; rgallego-ibis@us.es; marojas-ibis@us.es;
   jampuero-ibis@us.es; mromerogomez@us.es; Philip.Kaye@nuh.nhs.uk;
   Isioma.Egbuniwe@nottingham.ac.uk; chaochen@ucm.es;
   jsimon.ciberehd@cicbiogune.es; tcardoso@cicbiogune.es;
   mlmartinez@cicbiogune.es; sunjie@seu.edu.cn; joreissing@ukaachen.de;
   tbruns@ukaachen.de; arlamas@ucm.es; mgomezm@med.ucm.es;
   M.Woitok@eclevar.com; j.vaquero@iisgm.com; regueiro@med.ucm.es;
   cliedtke@ukaachen.de; ctrautwein@ukaachen.de;
   Rafael.banares@salud.madrid.org; fcubero@ucm.es; yulianev@ucm.es
RI Banares, Rafael/J-1460-2012; Delgado, Teresa/ABF-9171-2020;
   Romero-Gomez, Manuel/L-8030-2014; Bruns, Tony/C-5720-2011; Liedtke,
   Christian/DTV-1874-2022; chaobo, chen/X-6937-2019; Rojas, Ana
   M/D-5777-2011; Martinez Chantar, Maria Luz/F-5190-2011; Regueiro,
   Jose/B-5499-2014
OI Banares, Rafael/0000-0002-7860-0861; Delgado,
   Teresa/0000-0001-9204-581X; Romero-Gomez, Manuel/0000-0001-8494-8947;
   Bruns, Tony/0000-0002-5576-6914; Liedtke, Christian/0000-0003-4681-7887;
   chaobo, chen/0000-0001-5963-5295; Rojas, Ana M/0000-0003-0750-9099;
   Lamas Paz, Arantza/0000-0001-5857-4320; Benede-Ubieto,
   Raquel/0000-0003-1779-8832; Nevzorova, Yulia A/0000-0003-1390-8002;
   Gomez, Manuel/0000-0002-0642-8142; Banares, Rafael/0000-0002-0412-8437;
   Estevez Vazquez, Olga/0000-0002-7983-8521; Simon,
   Jorge/0000-0003-0404-6244; Cubero, Francisco Javier/0000-0003-1499-650X;
   Martinez Chantar, Maria Luz/0000-0002-6446-9911; Regueiro,
   Jose/0000-0001-8442-7762; Rojas, Angela/0000-0003-0853-4800
FU MINECO [Retos SAF2016-78711, SAF2017-87919-R, PID2020-117827RB-IOO,
   PID2020-117941RB-IOO, PID2020-117116RB-I00, EXOHEP-CM S2017/BMD3727,
   NanoLiver-CM Y2018/NMT-4949]; COST Action [CA17112, UCM-25/2019]; La
   Caixa Foundation Program [HR17-00601]; Asociacion Espanola Contra el
   Cancer [AECC PROYE20084 REGU]; German Research Foundation
   [403224013/A02, SFB1382, 403224013/B07]; Ramon y Cajal [RYC-2014-15242,
   RYC-2015-17438]; Beca FPI associated to MINECO [SAR2017-87919R];
   programa de Financiacion de Universidad Complutense de Madrid-Banco
   Santander [CT63/19]; CIBEREHD; Andalusian government (Proyectos
   Estrategicos-Fondos Feder) [PE-0451-2018]; Instituto de Salud Carlos III
   [PI16/01842, PI19/01404, PI19/00589]; AMMF [2018/117]
FX This work was supported by the MINECO Retos SAF2016-78711,
   SAF2017-87919-R, PID2020-117827RB-IOO, PID2020-117941RB-IOO,
   PID2020-117116RB-I00, EXOHEP-CM S2017/BMD3727, NanoLiver-CM
   Y2018/NMT-4949, AMMF 2018/117, COST Action CA17112 and UCM-25/2019, La
   Caixa Foundation ProgramHR17-00601; Asociacion Espanola Contra el Cancer
   (AECC PROYE20084 REGU); the German Research Foundation (SFB1382 Project
   ID 403224013/A02). FJC and YAN are Ramon y Cajal Researchers
   RYC-2014-15242 and RYC-2015-17438, respectively. FJC is a Gilead Liver
   Research Scholar. The research group belongs to the validated Research
   Groups Ref. 970935 "Liver Pathophysiology", 920631 "Lymphocyte
   immunobiology", 920361 "Inmunogenetica e inmunologia de las mucosas" and
   IBL-6 (imas12-associated). FG and KZ are Chinese Scholarship Council
   (CSC) fellows. O.E.-V is supported by Beca FPI associated to MINECO
   SAR2017-87919R and R.B.-U by programa de Financiacion de Universidad
   Complutense de Madrid-Banco Santander, CT63/19. DMM contract is
   supported by CIBEREHD. DMM, MRG, AR, JA and RG receive support from the
   Andalusian government (Proyectos Estrategicos-Fondos Feder PE-0451-2018)
   and from the Instituto de Salud Carlos III (PI16/01842, PI19/01404;
   PI19/00589). TB is supported by the German Research Foundation (SFB1382
   Project ID 403224013/B07).
CR Aguirre AJ, 2017, CANCER CELL, V32, P185, DOI 10.1016/j.ccell.2017.07.007
   Akinyeke T, 2013, CARCINOGENESIS, V34, P2823, DOI 10.1093/carcin/bgt307
   Alves-Bezerra M, 2018, COMPR PHYSIOL, V8, P1, DOI 10.1002/cphy.c170012
   Anstee QM, 2019, NAT REV GASTRO HEPAT, V16, P411, DOI 10.1038/s41575-019-0145-7
   Bigornia SJ, 2012, NUTR DIABETES, V2, DOI 10.1038/nutd.2012.3
   Dang CV, 2012, CELL, V149, P22, DOI 10.1016/j.cell.2012.03.003
   DeCensi A, 2010, CANCER PREV RES, V3, P1451, DOI 10.1158/1940-6207.CAPR-10-0157
   Dong Y, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-00235-2
   Du K, 2020, CELL MOL GASTROENTER, V10, P1, DOI 10.1016/j.jcmgh.2019.12.006
   Eckel RH, 2011, J CLIN ENDOCR METAB, V96, P1654, DOI 10.1210/jc.2011-0585
   Estes C, 2018, J HEPATOL, V69, P896, DOI 10.1016/j.jhep.2018.05.036
   Estes C, 2018, HEPATOLOGY, V67, P123, DOI 10.1002/hep.29466
   Gao P, 2009, NATURE, V458, P762, DOI 10.1038/nature07823
   Gouw AM, 2019, CELL METAB, V30, P556, DOI 10.1016/j.cmet.2019.07.012
   Issa D, 2017, HEPATOL SURG NUTR, V6, P401, DOI 10.21037/hbsn.2017.07.07
   Kasznicki J, 2014, ANN TRANSL MED, V2, DOI 10.3978/j.issn.2305-5839.2014.06.01
   Lai KKY, 2017, GASTROENTEROLOGY, V152, P1477, DOI 10.1053/j.gastro.2017.01.021
   Lee JS, 2004, NAT GENET, V36, P1306, DOI 10.1038/ng1481
   Li Y, 2014, J INTERN MED, V276, P52, DOI 10.1111/joim.12237
   Loomba R, 2013, NAT REV GASTRO HEPAT, V10, P686, DOI 10.1038/nrgastro.2013.171
   Lu Y, 2020, THER ADV ENDOCRINOL, V11, DOI 10.1177/2042018820923474
   Ma C, 2016, NATURE, V531, P253, DOI 10.1038/nature16969
   Marchesini G, 2005, CURR OPIN LIPIDOL, V16, P421, DOI 10.1097/01.mol.0000174153.53683.f2
   MURAKAMI H, 1993, CANCER RES, V53, P1719
   Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746
   Nevzorova YA, 2016, J HEPATOL, V64, P628, DOI 10.1016/j.jhep.2015.11.005
   Nevzorova YA, 2013, BBA-MOL BASIS DIS, V1832, P1765, DOI 10.1016/j.bbadis.2013.06.001
   Pais R, 2016, J HEPATOL, V65, P1245, DOI 10.1016/j.jhep.2016.07.033
   Piscaglia F, 2016, HEPATOLOGY, V63, P827, DOI 10.1002/hep.28368
   Poon TCW, 2006, GASTROENTEROLOGY, V131, P1262, DOI 10.1053/j.gastro.2006.08.014
   Reddy JK, 2006, AM J PHYSIOL-GASTR L, V290, pG852, DOI 10.1152/ajpgi.00521.2005
   SANDGREN EP, 1989, ONCOGENE, V4, P715
   Shen P, 2018, MOL ONCOL, V12, P1856, DOI 10.1002/1878-0261.12384
   Simon J, 2020, CELL METAB, V31, P605, DOI 10.1016/j.cmet.2020.01.013
   Sonntag R, 2018, P NATL ACAD SCI USA, V115, P9282, DOI 10.1073/pnas.1807155115
   Sunami Y, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21186799
   Tambay V, 2021, CANCERS, V13, DOI 10.3390/cancers13174484
   Wang K, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2013.499
   White DL, 2012, CLIN GASTROENTEROL H, V10, P1342, DOI 10.1016/j.cgh.2012.10.001
   Yan JB, 2020, MOL THER-ONCOLYTICS, V18, P282, DOI 10.1016/j.omto.2020.06.010
   Zhang ZJ, 2012, J CLIN ENDOCR METAB, V97, P2347, DOI 10.1210/jc.2012-1267
   Zheng K, 2017, GENES-BASEL, V8, DOI 10.3390/genes8040123
NR 42
TC 11
Z9 12
U1 1
U2 7
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2072-6694
J9 CANCERS
JI Cancers
PD JAN
PY 2022
VL 14
IS 1
AR 192
DI 10.3390/cancers14010192
PG 19
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA ZE9VV
UT WOS:000759226000001
PM 35008356
OA Green Published, Green Accepted, gold
DA 2024-02-19
ER

PT J
AU Wang, E
   Liu, DN
AF Wang, E
   Liu, DN
TI Characterization of senescence- and apoptosis-dependent forms of
   terminin as derived from a precursor found in replicating and
   nonreplicating cells
SO JOURNAL OF CELLULAR BIOCHEMISTRY
LA English
DT Article
DE immunoprecipitation; in vitro translation; V-8 digestion; peptide
   mapping
ID HEREDITARY CEREBRAL-HEMORRHAGE; ALZHEIMERS-DISEASE; POLYACRYLAMIDE GELS;
   HUMAN-FIBROBLASTS; PROTEINS; GENE; TRANSCRIPTION; PROTEOLYSIS;
   EXPRESSION; INHIBITOR
AB Previously we have reported the production of a monoclonal antibody (Mab 1.2) which recognizes a cytoplasmic protein, terminin, in three different molecular weights: 90 (Tp90), 60 (Tp60)I and 30 kDa (Tp30) forms. Further characterization shows that Tp90 is found in young growing and nongrowing quiescent fibroblasts, while Tp60 is found in permanently growth-arrested senescent fibroblasts and Tp30 in cells committed to undergo programmed cell death (apoptosis). In tissue, Tp90 is found in embryonic brain; later, in neonatal brain after terminal differentiation is completed, only Tp60 is found. Tp30 is found in crude liver fractions extracted without the protective action of protease inhibitors. In all these circumstances, Tp90 is mostly seen in the detergent-soluble fraction, while Tp60 and Tp30 are detergent-insoluble. We now report that in cultured fibroblasts, as well as in tissues such as brain and liver, Tp60 and Tp30 are derived from the Tp90 polypeptide, indicated by the fact that only the Tp90 species is identified by both immunoblotting and immunoprecipitation assays, when the cell or tissue extracts are prepared in the presence of protease inhibitors. Further evidence shows that immunoprecipitation of in vitro translation products from brain, liver, and cultured fibroblasts also present a single band of Tp90 polypeptide. Pulse-chase experiments show that during apoptosis, Tp90 is processed to Tp60, and eventually to Tp30. However, when the total protein extracts are fractionated, only Tp90 is found in the detergent-soluble fraction, with diminishing quantities during the time course of apoptosis, and Tp30, in contrast, is found as the only protein species in the insoluble fraction, with increasing quantity during the same time course. Newly processed Tp60 is not found in either of the fractions, reflecting its loss during the fractionation procedure. Limited one-dimensional peptide mapping of Tp90 yields three different bands at 30, 28, and 25 kDa, but only the one at 30 kDa is recognized by Mab 1.2. These results lead us to suggest that terminin protein is synthesized in the Tp90 form, and cleaved to lower molecular weight forms depends upon different physiologic conditions, with Tp60 processed in the terminally differentiated or senescent state and rapidly to Tp30 in apoptosis. Our findings further suggest that Tp90's processing to either Tp60 or Tp30 produces insoluble protein forms. Furthermore, the presence of Tp90 in nonapoptotic (either replicating or nonreplicating) cells may reflect the absence of necessary proteolytic action required for the execution of apoptosis. Future experiments will allow us to determine the nature of this proteolytic action, as well as whether this action is due to the autocatalytic action of Tp90 or by other endogenous proteases, and then to determine the significance of this biochemical action in cells. (C) 1996 Wiley-Liss, Inc.
C1 MCGILL UNIV,DEPT MED,MONTREAL,PQ,CANADA.
   MCGILL UNIV,DEPT ANAT,MONTREAL,PQ,CANADA.
C3 McGill University; McGill University
RP Wang, E (corresponding author), SIR MORTIMER B DAVIS JEWISH HOSP,BLOOMFIELD CTR RES AGING,LADY DAVIS INST MED RES,MONTREAL,PQ H3T 1E2,CANADA.
FU NIA NIH HHS [R01AG09278] Funding Source: Medline
CR AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408
   BLIN N, 1976, NUCLEIC ACIDS RES, V3, P2303, DOI 10.1093/nar/3.9.2303
   CAPUTO CB, 1989, NEUROBIOL AGING, V10, P451, DOI 10.1016/0197-4580(89)90096-1
   CERRETTI DP, 1992, SCIENCE, V256, P97, DOI 10.1126/science.1373520
   CHING G, 1990, J CELL BIOL, V110, P255, DOI 10.1083/jcb.110.2.255
   CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999
   CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102
   COHEN DH, 1983, J EXP MED, V158, P623, DOI 10.1084/jem.158.2.623
   DULIC V, 1993, P NATL ACAD SCI USA, V90, P11034, DOI 10.1073/pnas.90.23.11034
   ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P
   HARPER JW, 1993, CELL, V75, P805
   HEBERT L, 1994, EXP CELL RES, V210, P10, DOI 10.1006/excr.1994.1002
   KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0
   KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   LEVY E, 1990, SCIENCE, V248, P1124, DOI 10.1126/science.2111584
   LINKE RP, 1973, J IMMUNOL, V111, P10
   MITMAKER B, 1993, EUR J HISTOCHEM, V37, P295
   NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063
   PANDEY S, 1995, J CELL BIOCHEM, V58, P135, DOI 10.1002/jcb.240580203
   PRUSINER SB, 1989, ANNU REV MICROBIOL, V43, P345, DOI 10.1146/annurev.mi.43.100189.002021
   SAMBROOK J, 1982, MOL CLONING LABORATO
   SCHIPPER HM, 1994, BRAIN RES, V635, P224, DOI 10.1016/0006-8993(94)91443-5
   SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0
   SESHADRI T, 1990, SCIENCE, V247, P205, DOI 10.1126/science.2104680
   SHIRAHAM.T, 1973, J IMMUNOL, V110, P21
   STEIN GH, 1990, SCIENCE, V249, P666, DOI 10.1126/science.2166342
   STEIN GH, 1991, P NATL ACAD SCI USA, V88, P11012, DOI 10.1073/pnas.88.24.11012
   THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0
   TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350
   VAN BROECKHOVEN C, 1990, SCIENCE, V248, P1120, DOI 10.1126/science.1971458
   WANG E, 1991, J CELL PHYSIOL, V147, P514, DOI 10.1002/jcp.1041470318
   WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2
   XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0
   YANG GA, 1993, BRAIN RES, V615, P71, DOI 10.1016/0006-8993(93)91115-9
   YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9
NR 36
TC 4
Z9 4
U1 0
U2 1
PU WILEY-LISS
PI NEW YORK
PA DIV JOHN WILEY & SONS INC 605 THIRD AVE, NEW YORK, NY 10158-0012
SN 0730-2312
J9 J CELL BIOCHEM
JI J. Cell. Biochem.
PD JAN
PY 1996
VL 60
IS 1
BP 107
EP 120
DI 10.1002/(SICI)1097-4644(19960101)60:1<107::AID-JCB13>3.0.CO;2-M
PG 14
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA TT662
UT WOS:A1996TT66200013
PM 8825420
DA 2024-02-19
ER

PT J
AU Kim, KY
   Lee, EJ
   Whang, WK
   Park, CH
AF Kim, Kyung Young
   Lee, Eun Ju
   Whang, Wan Kyunn
   Park, Cho Hi
TI In vitro and in vivo anti-aging effects of compounds isolated from
   <i>Artemisia iwayomogi</i>
SO JOURNAL OF ANALYTICAL SCIENCE AND TECHNOLOGY
LA English
DT Article
DE Artemisia iwayomogi; Scopolin; Anti-wrinkle effect; Cosmeceuticals
ID POLYPHENOLS; ANTIOXIDANT; SCOPOLETIN; PARTS
AB In Korean folk medicine, Artemisia iwayomogi has largely been employed for the improvement of diabetic complications and hepatic function as well as in the treatment of female diseases and skin whitening. Accordingly, the present study sought to assess cosmeceutical activity of Artemisia iwayomogi. Through activity-guided fractionation, scopolin (AI-1), 2,4-dihydroxy-6-methoxy-acetophenone 4-O-beta-D-glucoside (AI-2), scopoletin (AI-3), kaempferol-3-O-methyl ether (AI-4) and luteolin (AI-5) were isolated from ethyl acetate and water fractions of Artemisia iwayomogi. Of them, AI-4 and AI-5 exhibited strong antioxidative and whitening effects. In addition, AI-1, AI-3, AI-4, and AI-5 demonstrated considerable anti-wrinkle performances. According to results of quantitative anAIysis of compounds isolated from Artemisia iwayomogi, scopolin (AI-1) is a major component of Artemisia iwayomogi. Moreover, O/W type cream made by water fraction which included scopolin showed unwrinkling effect for 8 weeks when it was applied to face in an in vivo study. Specific contributions of Artemisia iwayomogi were as follows: AI-1, 1.21 mg/g; AI-2, 0.26 mg/g; AI-3, 0.38 mg/g; AI-4, 0.01 mg/g; and AI-5, 0.04 mg/g.
C1 [Kim, Kyung Young] Yong In SongDam Coll, Dept Beautycare, Yongin, South Korea.
   [Lee, Eun Ju] Yeonsung Univ, Dept Beauty Stylist, Anyang, South Korea.
   [Whang, Wan Kyunn] Chung Ang Univ, Pharmaceut Bot Lab, Coll Pharm, Seoul 156756, South Korea.
   [Park, Cho Hi] Sungshin Womens Univ, Dept Beauty Ind, Dobong Ro 76 Ga Gil, Seoul 01133, South Korea.
C3 Chung Ang University; Sungshin Women's University
RP Whang, WK (corresponding author), Chung Ang Univ, Pharmaceut Bot Lab, Coll Pharm, Seoul 156756, South Korea.; Park, CH (corresponding author), Sungshin Womens Univ, Dept Beauty Ind, Dobong Ro 76 Ga Gil, Seoul 01133, South Korea.
EM whang-wk@cau.ac.kr; chohi@sungshin.ac.kr
RI 박, 초희/ABD-4745-2020; lee, wj/JNR-4926-2023; Lee, Eun-ju/JAN-8749-2023
OI park, chohi/0000-0003-1212-6877
FU Ministry of Food and Drug Safety [18172MFDS206]
FX This research was supported by a grant 18172MFDS206 from Ministry of
   Food and Drug Safety in 2018.
CR Ahn H, 2003, ARCH PHARM RES, V26, P301, DOI 10.1007/BF02976959
   Assem T, 2007, THESIS
   Bayoumi SAL, 2010, PHYTOCHEMISTRY, V71, P598, DOI 10.1016/j.phytochem.2009.10.012
   Bayoumi SAL, 2008, PHYTOCHEMISTRY, V69, P2928, DOI 10.1016/j.phytochem.2008.09.023
   HATANO T, 1989, CHEM PHARM BULL, V37, P2016
   Jang Woo-seok, 2012, [Journal of Korean Medicine, 대한한의학회지], V33, P11
   Kim NM, 2000, ARCH PHARM RES, V23, P237, DOI 10.1007/BF02976451
   Lee J.N., 2006, J SOC COSMET SCI KOR, V32, P227
   Lee SH, 2013, J NAT PROD, V76, P615, DOI 10.1021/np300824h
   Lee YK, 2017, BIOMED RES INT, V2017, DOI 10.1155/2017/7375615
   Lu YR, 2000, FOOD CHEM, V68, P81, DOI 10.1016/S0308-8146(99)00167-3
   Nguyen MTT, 2004, BIOL PHARM BULL, V27, P1414, DOI 10.1248/bpb.27.1414
   Singh AK, 1997, PHYTOCHEMISTRY, V44, P555, DOI 10.1016/S0031-9422(96)00424-4
   URBATSCH LE, 1975, PHYTOCHEMISTRY, V14, P2279, DOI 10.1016/S0031-9422(00)91116-6
   정미정, 2008, [Korean Journal of Pharmacognosy, 생약학회지], V39, P194
   Xie LP, 2003, INT J BIOCHEM CELL B, V35, P1658, DOI 10.1016/S1357-2725(03)00006-2
   Yamauchi R, 2000, FISHERIES SCI, V66, P798, DOI 10.1046/j.1444-2906.2000.00114.x
   서경순, 2008, [Korean Journal of Plant Reources., 한국자원식물학회지], V21, P292
NR 18
TC 6
Z9 7
U1 1
U2 12
PU SPRINGER INTERNATIONAL PUBLISHING AG
PI CHAM
PA GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND
SN 2093-3134
EI 2093-3371
J9 J ANAL SCI TECHNOL
JI J. Anal. Sci. Technol.
PD DEC 10
PY 2019
VL 10
IS 1
AR 35
DI 10.1186/s40543-019-0193-1
PG 8
WC Chemistry, Analytical
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Chemistry
GA KN8TY
UT WOS:000515119100001
OA gold
DA 2024-02-19
ER

PT J
AU Turgut, NH
   Mert, DG
   Kara, H
   Egilmez, HR
   Arslanbas, E
   Tepe, B
   Gungor, H
   Yilmaz, N
   Tuncel, NB
AF Turgut, Nergiz Hacer
   Mert, Derya Guliz
   Kara, Haki
   Egilmez, Hatice Reyhan
   Arslanbas, Emre
   Tepe, Bektas
   Gungor, Huseyin
   Yilmaz, Nese
   Tuncel, Necati Baris
TI Effect of black mulberry (<i>Morus nigra</i>) extract treatment on
   cognitive impairment and oxidative stress status of d-galactose-induced
   aging mice
SO PHARMACEUTICAL BIOLOGY
LA English
DT Article
DE memory retention; Antioxidant; learning; phenolic acid
ID CHLOROGENIC ACID; ANTIOXIDANT ACTIVITY; VANILLIC ACID;
   CHEMICAL-COMPOSITION; PARAMETERS; INHIBITION; APOPTOSIS; MODEL; FRUIT;
   RATS
AB Context: Morus nigra L. (Moraceae) has various uses in traditional medicine. However, the effect of M. nigra on cognitive impairment has not been investigated yet.
   Objective: The objective of this study is to determine the phenolic acid content and DNA damage protection potential of M. nigra leaf extract and to investigate the extract effect on cognitive impairment and oxidative stress in aging mice.
   Materials and methods: Phenolic acid content was determined by quantitative chromatographic analysis. DNA damage protection potential was evaluated on pBR322 plasmid DNA. Thirty-two Balb-C mice were randomly divided into four groups (control, d-galactose, d-galactose + M. nigra 50, and d-galactose + M. nigra 100). Mice were administered d-galactose (100 mg/kg, subcutaneous) and M. nigra (50 or 100 mg/kg, orally) daily for 8 weeks. Behavioral responses were evaluated with Morris water maze. Activities of antioxidant enzymes and levels of malondialdehyde (MDA) were assayed in serum, brain, and liver.
   Results: In extract, vanillic (632.093 mu g/g) and chlorogenic acids (555.0 mu g/g) were determined. The extract between 0.02 and 0.05 mg/mL effectively protected all DNA bands against the hazardous effect of UV and H2O2. Morus nigra significantly improved learning dysfunctions (p< 0.01), increased memory retention (p < 0.01), reduced MDA levels (p < 0.05), and elevated SOD, GPx, and CAT activities (p < 0.05) compared with the d-galactose group.
   Discussion and conclusion: These results show that M. nigra has the potential in improving cognitive deficits in mice and that M. nigra may be useful to suppress aging, partially due to its scavenging activity of free radicals and high antioxidant capacity.
C1 [Turgut, Nergiz Hacer] Cumhuriyet Univ, Fac Pharm, Dept Pharmacol, PK 848, TR-58140 Sivas, Turkey.
   [Mert, Derya Guliz] Cumhuriyet Univ, Fac Med, Dept Psychiat, PK 848, TR-58140 Sivas, Turkey.
   [Kara, Haki; Arslanbas, Emre; Gungor, Huseyin] Cumhuriyet Univ, Fac Vet Med, Dept Pharmacol & Toxicol, PK 848, TR-58140 Sivas, Turkey.
   [Egilmez, Hatice Reyhan] Cumhuriyet Univ, Fac Med, Dept Pathol, PK 848, TR-58140 Sivas, Turkey.
   [Tepe, Bektas] Kilis Univ, Fac Sci & Literature, Dept Mol Biol & Genet, Kilis, Turkey.
   [Yilmaz, Nese; Tuncel, Necati Baris] Canakkale 18 Mart Univ, Fac Engn, Dept Food Engn, Canakkale, Turkey.
C3 Cumhuriyet University; Cumhuriyet University; Cumhuriyet University;
   Cumhuriyet University; Canakkale Onsekiz Mart University
RP Turgut, NH (corresponding author), Cumhuriyet Univ, Fac Pharm, Dept Pharmacol, PK 848, TR-58140 Sivas, Turkey.
EM nergizht@yahoo.com
RI Turgut, Nergiz Hacer/HPD-2160-2023; Tuncel, Necati Baris/AAG-4333-2019;
   mert, derya güliz/JAC-6876-2023; YILMAZ TUNCEL, Neşe/HNC-2057-2023;
   TEPE, Bektas/GZM-5592-2022; TEPE, Bektas/N-2987-2013; kara,
   haki/AAA-2142-2020; GUNGOR, HUSEYIN/U-5831-2019
OI Turgut, Nergiz Hacer/0000-0001-5705-2475; Tuncel, Necati
   Baris/0000-0001-9885-5063; mert, derya güliz/0000-0003-0925-339X; YILMAZ
   TUNCEL, Neşe/0000-0003-2700-5840; TEPE, Bektas/0000-0001-8982-5188;
   GUNGOR, HUSEYIN/0000-0002-2506-3855
FU Cumhuriyet University Scientific Research Project (CUBAP, Sivas, Turkey)
   [V-012]
FX The authors report that they have no conflicts of interest. This study
   was supported by Cumhuriyet University Scientific Research Project V-012
   (CUBAP, Sivas, Turkey).
CR Banji D, 2013, EUR J PHARMACOL, V703, P91, DOI 10.1016/j.ejphar.2012.11.018
   Bao Q, 2014, MOL CELL ENDOCRINOL, V394, P115, DOI 10.1016/j.mce.2014.07.005
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   Calabrese V, 2010, NEUROCHEM RES, V35, P1880, DOI 10.1007/s11064-010-0307-z
   Campos PB, 2014, FRONT AGING NEUROSCI, V6, DOI 10.3389/fnagi.2014.00292
   Chou TH, 2010, EXP DERMATOL, V19, P742, DOI 10.1111/j.1600-0625.2010.01091.x
   Ercisli S, 2007, FOOD CHEM, V103, P1380, DOI 10.1016/j.foodchem.2006.10.054
   Francisco V, 2013, J ETHNOPHARMACOL, V148, P126, DOI 10.1016/j.jep.2013.03.077
   Fransen Marc, 2013, Subcell Biochem, V69, P45, DOI 10.1007/978-94-007-6889-5_3
   Göçer H, 2011, INT J FOOD SCI NUTR, V62, P821, DOI 10.3109/09637486.2011.585963
   Gulçin I, 2007, AMINO ACIDS, V32, P431, DOI 10.1007/s00726-006-0379-x
   Hara K, 2014, EUR J PHARMACOL, V723, P459, DOI 10.1016/j.ejphar.2013.10.046
   HARMAN D, 1956, J GERONTOL, V11, P298, DOI 10.1093/geronj/11.3.298
   Hélie S, 2012, NEUROPSYCHOLOGIA, V50, P2290, DOI 10.1016/j.neuropsychologia.2012.05.033
   Hwang SJ, 2014, INFLAMM RES, V63, P81, DOI 10.1007/s00011-013-0674-4
   Imran M, 2010, J ZHEJIANG UNIV-SC B, V11, P973, DOI 10.1631/jzus.B1000173
   Isabelile M, 2008, J AGR FOOD CHEM, V56, P9410, DOI 10.1021/jf801527a
   Kanchev VD, 2013, CURR MED CHEM, V20, P4784, DOI 10.2174/09298673113209990161
   Kang TH, 2006, NEUROSCI LETT, V391, P122, DOI 10.1016/j.neulet.2005.08.053
   Kim AJ, 2006, J MED FOOD, V9, P431, DOI 10.1089/jmf.2006.9.431
   Kumar Anil, 2011, Int J Alzheimers Dis, V2011, P347569, DOI 10.4061/2011/347569
   Kumar S, 2014, ENVIRON TOXICOL PHAR, V38, P643, DOI 10.1016/j.etap.2014.07.011
   Kwon SH, 2010, EUR J PHARMACOL, V649, P210, DOI 10.1016/j.ejphar.2010.09.001
   Lee K, 2012, EUR J PHARMACOL, V689, P89, DOI 10.1016/j.ejphar.2012.05.028
   Li YJ, 2008, ENVIRON TOXICOL PHAR, V26, P13, DOI 10.1016/j.etap.2007.12.008
   Li ZX, 2012, J MED FOOD, V15, P1057, DOI 10.1089/jmf.2011.2105
   Lim HH, 2013, EXP BIOL MED, V238, P1160, DOI 10.1177/1535370213498982
   MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0
   Naderi GA, 2004, PHYTOTHER RES, V18, P365, DOI 10.1002/ptr.1400
   O' Neill C, 2013, EXP GERONTOL, V48, P647, DOI 10.1016/j.exger.2013.02.025
   Obrenovich ME, 2011, CNS NEUROL DISORD-DR, V10, P192
   Ode MP, 2000, COMPLETE GUIDE MED H
   OHKAWA H, 1979, ANAL BIOCHEM, V95, P351, DOI 10.1016/0003-2697(79)90738-3
   Ooi KL, 2011, J ETHNOPHARMACOL, V135, P685, DOI 10.1016/j.jep.2011.04.001
   Orhan E, 2010, GENET MOL RES, V9, P2176, DOI 10.4238/vol9-4gmr958
   Özçelik B, 2011, PHARM BIOL, V49, P396, DOI 10.3109/13880209.2010.519390
   Öztürk N, 2007, J LIQ CHROMATOGR R T, V30, P587, DOI 10.1080/10826070601093911
   Prince PSM, 2011, EUR J PHARMACOL, V668, P233, DOI 10.1016/j.ejphar.2011.06.053
   Rakshit S, 2010, BIOCHEM PHARMACOL, V80, P1662, DOI 10.1016/j.bcp.2010.08.013
   Russo A, 2000, CELL BIOL TOXICOL, V16, P91, DOI 10.1023/A:1007685909018
   Shih PH, 2010, J NUTR BIOCHEM, V21, P598, DOI 10.1016/j.jnutbio.2009.03.008
   Singa ANB, 2005, J ETHNOPHARMACOL, V100, P333, DOI 10.1016/j.jep.2005.03.013
   Singh JCH, 2015, PHARM BIOL, V53, P630, DOI 10.3109/13880209.2014.935866
   Sokmen A, 1999, J ETHNOPHARMACOL, V67, P79, DOI 10.1016/S0378-8741(98)00189-5
   Sroka Z, 2003, FOOD CHEM TOXICOL, V41, P753, DOI 10.1016/S0278-6915(02)00329-0
   Stefanello N, 2014, MOL CELL BIOCHEM, V388, P277, DOI 10.1007/s11010-013-1919-9
   Volpato GT, 2011, J ETHNOPHARMACOL, V138, P691, DOI 10.1016/j.jep.2011.09.044
   Wan CW, 2013, PHYTOTHER RES, V27, P545, DOI 10.1002/ptr.4751
   Wang DL, 2012, BIOL PHARM BULL, V35, P2128, DOI 10.1248/bpb.b12-00238
   Xian YF, 2014, NEUROCHEM INT, V76, P42, DOI 10.1016/j.neuint.2014.06.011
   Yang WN, 2013, PHARMACOL BIOCHEM BE, V114, P31, DOI 10.1016/j.pbb.2013.10.027
   Yi ZJ, 2009, EXP GERONTOL, V44, P760, DOI 10.1016/j.exger.2009.08.011
   Zhang XL, 2008, PHYTOMEDICINE, V15, P484, DOI 10.1016/j.phymed.2008.01.001
   Zhong SZ, 2009, J NEUROL SCI, V277, P58, DOI 10.1016/j.jns.2008.10.008
NR 54
TC 28
Z9 35
U1 2
U2 45
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1388-0209
EI 1744-5116
J9 PHARM BIOL
JI Pharm. Biol.
PD JUN 2
PY 2016
VL 54
IS 6
BP 1052
EP 1064
DI 10.3109/13880209.2015.1101476
PG 13
WC Plant Sciences; Medical Laboratory Technology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Plant Sciences; Medical Laboratory Technology; Pharmacology & Pharmacy
GA DJ1QF
UT WOS:000373977600015
PM 26510817
OA Bronze
DA 2024-02-19
ER

PT J
AU Yun, AJ
   Doux, JD
AF Yun, AJ
   Doux, JD
TI Opening the floodgates: Benign prostatic hyperplasia may represent
   another disease in the compendium of ailments caused by the global
   sympathetic bias that emerges with aging
SO MEDICAL HYPOTHESES
LA English
DT Article
ID AUTONOMIC NERVOUS-SYSTEM; CIGARETTE-SMOKING; GROWTH; DENERVATION;
   ALCOHOL; GLAND; RISK; MEN
AB We have previously posited that the global sympathetic bias that emerges with aging may constitute the common etiologic thread that links a myriad of ailments associated with aging. Recent data suggests that benign prostatic hyperplasia (BPH) and associated lower urinary tract symptoms (LUTS) may also be caused by sympathetic bias as an independent etiology from androgen dysfunction. The association of BPH with heart disease, independent of other variables, supports the view that both entities represent downstream manifestations of global sympathetic bias. The risk for development of BPH increases with caffeine intake and decreases with alcohol consumption, factors which wield opposing effects on autonomic balance. Heavy smoking, which induces chronic sympathetic bias, also increases the risk of BPH, a link also previously attributed to hormonal alterations. Sympathetic dysfunction appears to have a mitogenic effect on the prostate. The high prevalence of prostate cancer, a condition detected in the autopsy of many elderly men, may arise from this activity combined with a Th2 shift induced by sympathetic bias, leading to decreased cancer surveillance by the immune system. Exercise may improve BPH by restoring autonomic balance and normalizing the sympathovagal ratio. The benefits of alpha-adrenergic blockers on BPH, generally felt to achieve symptomatic relief afforded by bladder watt and sphincter remodeling, may independently exert a direct effect on prostate growth and enlargement. Sympathetic bias may play a rote in adaptive enlargement of other organs such as the salivary glands, heart, liver, spleen, and skeletal muscles in response to stress. We envision novel pharmacologic and device-based neuromodutation therapies for BPH and related urologic dysfunctions based on these principles. (c) 2006 Elsevier Ltd. All rights reserved.
C1 Stanford Univ, Palo Alto, CA 94301 USA.
C3 Stanford University
RP Yun, AJ (corresponding author), Stanford Univ, 470 Univ Ave, Palo Alto, CA 94301 USA.
EM ayun@stanford.edu
CR Acosta S, 2001, PROSTATE, V46, P191
   Gass R, 2002, BJU INT, V90, P649, DOI 10.1046/j.1464-410X.2002.03001.x
   Konety BR, 2005, J UROLOGY, V174, P1785, DOI 10.1097/01.ju.0000177470.84735.55
   Kupeli B, 1997, BRIT J UROL, V80, P201, DOI 10.1046/j.1464-410X.1997.00299.x
   Lee PY, 2004, MED HYPOTHESES, V62, P868, DOI 10.1016/j.mehy.2003.11.024
   McVary KT, 2005, J UROLOGY, V174, P1327, DOI 10.1097/01.ju.0000173072.73702.64
   MCVARY KT, 1994, BIOL REPROD, V51, P99, DOI 10.1095/biolreprod51.1.99
   Meigs JB, 2001, J CLIN EPIDEMIOL, V54, P935, DOI 10.1016/S0895-4356(01)00351-1
   Nishimura M, 2004, NEPHROL DIAL TRANSPL, V19, P2532, DOI 10.1093/ndt/gfh361
   Platz EA, 1999, AM J EPIDEMIOL, V149, P106, DOI 10.1093/oxfordjournals.aje.a009775
   Platz EA, 1998, ARCH INTERN MED, V158, P2349, DOI 10.1001/archinte.158.21.2349
   SCHNEYER CA, 1991, AM J PHYSIOL, V261, pG723, DOI 10.1152/ajpgi.1991.261.5.G723
   SCHNEYER CA, 1993, AM J PHYSIOL, V264, pG763, DOI 10.1152/ajpgi.1993.264.4.G763
   Untergasser G, 2005, EXP GERONTOL, V40, P121, DOI 10.1016/j.exger.2004.12.008
   Weisman KM, 2000, PHARMACOTHERAPY, V20, P383, DOI 10.1592/phco.20.5.383.35053
   Yun AJ, 2005, MED HYPOTHESES, V64, P1073, DOI 10.1016/j.mehy.2004.11.040
   Yun AJ, 2005, MED HYPOTHESES, V64, P706, DOI 10.1016/j.mehy.2004.08.023
   Yun AJ, 2004, MED HYPOTHESES, V63, P344, DOI 10.1016/j.mehy.2004.02.029
NR 18
TC 5
Z9 11
U1 0
U2 0
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0306-9877
J9 MED HYPOTHESES
JI Med. Hypotheses
PY 2006
VL 67
IS 2
BP 392
EP 394
DI 10.1016/j.mehy.2005.12.008
PG 3
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA 057WD
UT WOS:000238625000036
PM 16427746
DA 2024-02-19
ER

PT J
AU Villalba, JM
   López-Domínguez, JA
   Chen, YN
   Khraiwesh, H
   González-Reyes, JA
   del Río, LF
   Gutiérrez-Casado, E
   del Río, M
   Calvo-Rubio, M
   Ariza, J
   de Cabo, R
   López-Lluch, G
   Navas, P
   Hagopian, K
   Burón, MI
   Ramsey, JJ
AF Manuel Villalba, Jose
   Alberto Lopez-Dominguez, Jose
   Chen, Yana
   Khraiwesh, Husam
   Antonio Gonzalez-Reyes, Jose
   Fernandez del Rio, Lucia
   Gutierrez-Casado, Elena
   del Rio, Mercedes
   Calvo-Rubio, Miguel
   Ariza, Julia
   de Cabo, Rafael
   Lopez-Lluch, Guillermo
   Navas, Placido
   Hagopian, Kevork
   Isabel Buron, Maria
   Ramsey, Jon Jay
TI The influence of dietary fat source on liver and skeletal muscle
   mitochondrial modifications and lifespan changes in calorie-restricted
   mice
SO BIOGERONTOLOGY
LA English
DT Article
DE Apoptotic signaling; Calorie restriction; Dietary fat; Lifespan;
   Mitochondria; Proton leak
ID OXYGEN SPECIES PRODUCTION; CARNITINE PALMITOYLTRANSFERASE-I;
   HYDROGEN-PEROXIDE PRODUCTION; LONGEVITY-RELATED DEGREE; RAT-HEART
   MITOCHONDRIA; ALL-CAUSE MORTALITY; FREE-RADICAL THEORY; PROTON LEAK;
   ACID-COMPOSITION; FISH-OIL
AB The Membrane Theory of Aging proposes that lifespan is inversely related to the level of unsaturation in membrane phospholipids. Calorie restriction (CR) without malnutrition extends lifespan in many model organisms, which may be related to alterations in membrane phospholipids fatty acids. During the last few years our research focused on studying how altering the predominant fat source affects the outcome of CR in mice. We have established four dietary groups: one control group fed 95 % of a pre-determined ad libitum intake (in order to prevent obesity), and three CR groups fed 40 % less than ad libitum intake. Lipid source for the control and one of the CR groups was soybean oil (high in n-6 PUFA) whereas the two remaining CR groups were fed diets containing fish oil (high in n-3 PUFA), or lard (high in saturated and monounsaturated fatty acids). Dietary intervention periods ranged from 1 to 18 months. We performed a longitudinal lifespan study and a cross-sectional study set up to evaluate several mitochondrial parameters which included fatty acid composition, H+ leak, activities of electron transport chain enzymes, ROS generation, lipid peroxidation, mitochondrial ultrastructure, and mitochondrial apoptotic signaling in liver and skeletal muscle. These approaches applied to different cohorts of mice have independently indicated that lard as a fat source often maximizes the effects of 40 % CR on mice. These effects could be due to significant increases of monounsaturated fatty acids levels, in accordance with the Membrane Theory of Aging.
C1 [Manuel Villalba, Jose; Alberto Lopez-Dominguez, Jose; Khraiwesh, Husam; Antonio Gonzalez-Reyes, Jose; Fernandez del Rio, Lucia; Calvo-Rubio, Miguel; Ariza, Julia; Isabel Buron, Maria] Univ Cordoba, Dept Cellular Biol Fisiol & Inmunol, Cordoba 14014, Spain.
   [Chen, Yana; Hagopian, Kevork; Ramsey, Jon Jay] Univ Calif Davis, Sch Vet Med, Dept Mol Biosci, Davis, CA 95616 USA.
   [de Cabo, Rafael] NIA, Translat Gerontol Branch, NIH, Baltimore, MD 21224 USA.
   [Lopez-Lluch, Guillermo; Navas, Placido] Univ Pablo Olavide, CSIC, CABD, Seville, Spain.
   [Lopez-Lluch, Guillermo; Navas, Placido] Inst Salud Carlos III, CIBERER, Seville, Spain.
C3 Universidad de Cordoba; University of California System; University of
   California Davis; National Institutes of Health (NIH) - USA; NIH
   National Institute on Aging (NIA); Consejo Superior de Investigaciones
   Cientificas (CSIC); Universidad Pablo de Olavide; CSIC - Andalusian
   Center for Developmental Biology (CABD); CIBER - Centro de Investigacion
   Biomedica en Red; CIBERER; Instituto de Salud Carlos III
RP Villalba, JM (corresponding author), Univ Cordoba, Dept Cellular Biol Fisiol & Inmunol, Campus Rabanales,Edificio Severo Ochoa,3 Planta, Cordoba 14014, Spain.
EM jmvillalba@uco.es
RI Lopez-Lluch, Guillermo/N-4742-2014; del Río, Mercedes/N-1818-2019;
   NAVAS, PLACIDO/R-5943-2019; González-Reyes, José A/K-1367-2014; de Cabo,
   Rafael Carlos/E-7996-2010; del Río-Moreno, Mercedes/H-6181-2017;
   Barrera, Miguel Calvo-Rubio/G-8790-2015; López-Domínguez, José
   Alberto/AAA-9275-2020; Fernandez del Rio, Lucia/AAV-8233-2021; de Cabo,
   Rafael/J-5230-2016
OI Lopez-Lluch, Guillermo/0000-0001-9830-8502; NAVAS,
   PLACIDO/0000-0002-4115-7966; González-Reyes, José A/0000-0003-1918-5490;
   de Cabo, Rafael Carlos/0000-0003-2830-5693; del Río-Moreno,
   Mercedes/0000-0002-6282-7439; López-Domínguez, José
   Alberto/0000-0001-8733-3294; Fernandez del Rio,
   Lucia/0000-0001-5657-2700; Calvo-Rubio Barrera,
   Miguel/0000-0003-3760-4118; Villalba Montoro, Jose
   Manuel/0000-0001-8554-3802; de Cabo, Rafael/0000-0002-3354-2442
FU NIH [1R01AG028125]; Ministerio de Economia y Competitividad
   [BFU2011-23578]; Junta de Andalucia Proyectos de Excelencia
   [P09-CVI-4887]; Junta de Andalucia Proyectos Internacionales grant;
   BIO-276 (Junta de Andalucia); BIO-276 (University of Cordoba); NIA/NIH;
   Spanish Ministerio de Educacion; BIO-276; Agencia Espanola de
   Cooperacion Internacional al Desarrollo
FX Supported by NIH grant 1R01AG028125 (to JJR, PN and JMV), Ministerio de
   Economia y Competitividad BFU2011-23578 (to JMV), Junta de Andalucia
   Proyectos de Excelencia grant P09-CVI-4887 (to JMV), Junta de Andalucia
   Proyectos Internacionales grant (to JMV), and BIO-276 (Junta de
   Andalucia and the University of Cordoba, to JMV). RdC is funded by the
   Intramural Research program of the NIA/NIH. JALD, JA, LFdR and EGC were
   funded by a predoctoral fellowship of the Spanish Ministerio de
   Educacion and BIO-276. HK was funded by a predoctoral fellowship of the
   Agencia Espanola de Cooperacion Internacional al Desarrollo and BIO-276.
   MCR and MdR were supported by BIO-276.
CR Adams JM, 2007, ONCOGENE, V26, P1324, DOI 10.1038/sj.onc.1210220
   Agarwal B, 2011, ANN NY ACAD SCI, V1215, P138, DOI 10.1111/j.1749-6632.2010.05850.x
   López-Domínguez JA, 2015, J GERONTOL A-BIOL, V70, P399, DOI 10.1093/gerona/glu045
   López-Domínguez JA, 2013, AGE, V35, P2027, DOI 10.1007/s11357-012-9492-9
   Asami DK, 2008, EXP GERONTOL, V43, P1069, DOI 10.1016/j.exger.2008.09.010
   Baillie RA, 1999, PROSTAG LEUKOTR ESS, V60, P351, DOI 10.1016/S0952-3278(99)80011-8
   Barja G, 2014, PROG MOL BIOL TRANSL, V127, P1, DOI 10.1016/B978-0-12-394625-6.00001-5
   Barja G, 2013, ANTIOXID REDOX SIGN, V19, P1420, DOI 10.1089/ars.2012.5148
   BARZANTI V, 1994, BRIT J NUTR, V71, P193, DOI 10.1079/BJN19940126
   Baur JA, 2006, NATURE, V444, P337, DOI 10.1038/nature05354
   BERDANIER CD, 1992, J NUTR, V122, P1309, DOI 10.1093/jn/122.6.1309
   Bevilacqua L, 2005, AM J PHYSIOL-ENDOC M, V289, pE429, DOI 10.1152/ajpendo.00435.2004
   Bevilacqua L, 2004, AM J PHYSIOL-ENDOC M, V286, pE852, DOI 10.1152/ajpendo.00367.2003
   BRAND MD, 1994, COMP BIOCHEM PHYS B, V108, P181, DOI 10.1016/0305-0491(94)90064-7
   Bronnikov GE, 2010, BIOCHEMISTRY-MOSCOW+, V75, P1491, DOI 10.1134/S0006297910120102
   Brookes PS, 1998, COMP BIOCHEM PHYS B, V119, P325, DOI 10.1016/S0305-0491(97)00357-X
   Brookes PS, 2005, FREE RADICAL BIO MED, V38, P12, DOI 10.1016/j.freeradbiomed.2004.10.016
   Brookes PS, 1997, J MEMBRANE BIOL, V155, P167, DOI 10.1007/s002329900168
   Bruss MD, 2010, AM J PHYSIOL-ENDOC M, V298, pE108, DOI 10.1152/ajpendo.00524.2009
   Calder PC, 2003, LIPIDS, V38, P343, DOI 10.1007/s11745-003-1068-y
   Calder PC, 2007, PROSTAG LEUKOTR ESS, V77, P327, DOI 10.1016/j.plefa.2007.10.015
   Calder PC, 2012, J NUTR, V142, p592S, DOI 10.3945/jn.111.155259
   Cava E, 2013, AGING-US, V5, P507, DOI 10.18632/aging.100581
   Cha MC, 2000, METABOLISM, V49, P977, DOI 10.1053/meta.2000.7725
   Chen BK, 2011, GLOBALIZATION HEALTH, V7, DOI 10.1186/1744-8603-7-45
   Chen Y, 2014, PHYSIOL RES, V63, P57, DOI 10.33549/physiolres.932529
   Chen YN, 2013, BIOSCIENCE REP, V33, P83, DOI 10.1042/BSR20120060
   Chen YN, 2012, J GERONTOL A-BIOL, V67, P1121, DOI 10.1093/gerona/gls113
   Chung HY, 2001, ANN NY ACAD SCI, V928, P327
   Chung L, 2006, BBA-MOL BASIS DIS, V1762, P103, DOI 10.1016/j.bbadis.2005.08.003
   Civitarese AE, 2007, PLOS MED, V4, P485, DOI 10.1371/journal.pmed.0040076
   Colman RJ, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4557
   Colman RJ, 2009, SCIENCE, V325, P201, DOI 10.1126/science.1173635
   Couet C, 1997, INT J OBESITY, V21, P637, DOI 10.1038/sj.ijo.0800451
   Crockett EL, 2008, J COMP PHYSIOL B, V178, P795, DOI 10.1007/s00360-008-0275-7
   DAUM G, 1985, BIOCHIM BIOPHYS ACTA, V822, P1, DOI 10.1016/0304-4157(85)90002-4
   Deckelbaum RJ, 2012, J NUTR, V142, p587S, DOI 10.3945/jn.111.148080
   Desai VG, 1996, ARCH BIOCHEM BIOPHYS, V333, P145, DOI 10.1006/abbi.1996.0375
   Dirks A, 2002, AM J PHYSIOL-REG I, V282, pR519, DOI 10.1152/ajpregu.00458.2001
   Dirks AJ, 2004, FREE RADICAL BIO MED, V36, P27, DOI 10.1016/j.freeradbiomed.2003.10.003
   Dowhan W, 2004, BBA-BIOMEMBRANES, V1666, P19, DOI 10.1016/j.bbamem.2004.04.010
   Drew B, 2003, AM J PHYSIOL-REG I, V284, pR474, DOI 10.1152/ajpregu.00455.2002
   Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317
   Faulks SC, 2006, J GERONTOL A-BIOL, V61, P781, DOI 10.1093/gerona/61.8.781
   Flachs P, 2005, DIABETOLOGIA, V48, P2365, DOI 10.1007/s00125-005-1944-7
   Fontana L, 2009, EXP GERONTOL, V44, P41, DOI 10.1016/j.exger.2008.04.005
   Gómez A, 2014, AGING CELL, V13, P551, DOI 10.1111/acel.12205
   Gómez J, 2007, BIOGERONTOLOGY, V8, P555, DOI 10.1007/s10522-007-9099-1
   Gopinath B, 2011, AM J CLIN NUTR, V93, P1073, DOI 10.3945/ajcn.110.009977
   Gredilla R, 2005, ENDOCRINOLOGY, V146, P3713, DOI 10.1210/en.2005-0378
   Gredilla R, 2004, ANN NY ACAD SCI, V1019, P333, DOI 10.1196/annals.1297.057
   Gredilla R, 2001, J BIOENERG BIOMEMBR, V33, P279, DOI 10.1023/A:1010603206190
   Hagen TM, 1997, P NATL ACAD SCI USA, V94, P3064, DOI 10.1073/pnas.94.7.3064
   Hagopian K, 2005, AM J PHYSIOL-ENDOC M, V288, pE674, DOI 10.1152/ajpendo.00382.2004
   Hagopian K, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012696
   Halade GV, 2010, J IMMUNOL, V184, P5280, DOI 10.4049/jimmunol.0903282
   HALMINSKI MA, 1991, J NUTR, V121, P1554, DOI 10.1093/jn/121.10.1554
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   HARMAN D, 1956, J GERONTOL, V11, P298, DOI 10.1093/geronj/11.3.298
   Harper ME, 1998, AM J PHYSIOL-ENDOC M, V275, pE197, DOI 10.1152/ajpendo.1998.275.2.E197
   Hepple RT, 2006, REJUV RES, V9, P219, DOI 10.1089/rej.2006.9.219
   Herrero A, 2001, MECH AGEING DEV, V122, P427, DOI 10.1016/S0047-6374(01)00214-7
   HILL JO, 1993, INT J OBESITY, V17, P223
   Hong DD, 2003, BBA-MOL CELL BIOL L, V1635, P29, DOI 10.1016/j.bbalip.2003.10.003
   Huertas JR, 1999, BIOFACTORS, V9, P337, DOI 10.1002/biof.5520090233
   Hulbert AJ, 2008, COMP BIOCHEM PHYS A, V150, P196, DOI 10.1016/j.cbpa.2006.05.014
   Hulbert AJ, 2007, PHYSIOL REV, V87, P1175, DOI 10.1152/physrev.00047.2006
   Ide T, 2000, BBA-MOL CELL BIOL L, V1485, P23, DOI 10.1016/S1388-1981(00)00026-3
   Infante JP, 2001, COMP BIOCHEM PHYS B, V130, P291, DOI 10.1016/S1096-4959(01)00443-2
   INNIS SM, 1981, BIOCHEM J, V198, P167, DOI 10.1042/bj1980167
   Jolly CA, 2001, J NUTR, V131, P2753, DOI 10.1093/jn/131.10.2753
   JONES PJH, 1989, CAN J PHYSIOL PHARM, V67, P994, DOI 10.1139/y89-156
   Jové M, 2014, AGING CELL, V13, P828, DOI 10.1111/acel.12241
   Jurk D, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5172
   Kanzler S, 2000, SEMIN CANCER BIOL, V10, P173, DOI 10.1006/scbi.2000.0318
   Khraiwesh H, 2014, EXP GERONTOL, V56, P77, DOI 10.1016/j.exger.2014.03.023
   Khraiwesh H, 2013, J GERONTOL A-BIOL, V68, P1023, DOI 10.1093/gerona/glt006
   König A, 2005, AM J PREV MED, V29, P335, DOI 10.1016/j.amepre.2005.07.001
   Kromhout D, 2000, INT J EPIDEMIOL, V29, P260, DOI 10.1093/ije/29.2.260
   LAGANIERE S, 1993, GERONTOLOGY, V39, P7, DOI 10.1159/000213509
   LAGANIERE S, 1989, MECH AGEING DEV, V48, P221, DOI 10.1016/0047-6374(89)90084-5
   Lal SB, 2001, J GERONTOL A-BIOL, V56, pB116, DOI 10.1093/gerona/56.3.B116
   Lambert AJ, 2005, J GERONTOL A-BIOL, V60, P175, DOI 10.1093/gerona/60.2.175
   Lambert AJ, 2004, AM J PHYSIOL-REG I, V286, pR71, DOI 10.1152/ajpregu.00341.2003
   Lands B, 2014, PROG LIPID RES, V55, P17, DOI 10.1016/j.plipres.2014.04.002
   Lee AG, 2004, BBA-BIOMEMBRANES, V1666, P62, DOI 10.1016/j.bbamem.2004.05.012
   León H, 2008, BMJ-BRIT MED J, V337, DOI 10.1136/bmj.a2931
   Leosdottir M, 2005, J INTERN MED, V258, P153, DOI 10.1111/j.1365-2796.2005.01520.x
   Li M, 2014, NATURE, V506, P304, DOI 10.1038/nature13058
   López-Domínguez JA, 2015, J GERONTOL A-BIOL, V70, P1181, DOI 10.1093/gerona/glu177
   López-Lluch G, 2006, P NATL ACAD SCI USA, V103, P1768, DOI 10.1073/pnas.0510452103
   López-Otín C, 2013, CELL, V153, P1194, DOI 10.1016/j.cell.2013.05.039
   Marsh D, 2008, BBA-BIOMEMBRANES, V1778, P1545, DOI 10.1016/j.bbamem.2008.01.015
   Marzetti E, 2008, MECH AGEING DEV, V129, P542, DOI 10.1016/j.mad.2008.05.005
   Marzetti E, 2008, FREE RADICAL BIO MED, V44, P160, DOI 10.1016/j.freeradbiomed.2007.05.028
   Marzetti E, 2009, MECH AGEING DEV, V130, P272, DOI 10.1016/j.mad.2008.12.008
   Masoro EJ, 2006, J GERONTOL A-BIOL, V61, P14, DOI 10.1093/gerona/61.1.14
   MASORO EJ, 1989, AM J CLIN NUTR, V49, P1217
   Mataix J, 2006, INT J VITAM NUTR RES, V76, P178, DOI 10.1024/0300-9831.76.4.178
   Mattison JA, 2012, NATURE, V489, P318, DOI 10.1038/nature11432
   MCMILLIN JB, 1992, AM J PHYSIOL, V263, pH1479, DOI 10.1152/ajpheart.1992.263.5.H1479
   Meagher EA, 2000, FREE RADICAL BIO MED, V28, P1745, DOI 10.1016/S0891-5849(00)00232-X
   Mujahid A, 2009, AM J PHYSIOL-REG I, V297, pR690, DOI 10.1152/ajpregu.90974.2008
   MURTAGHMARK CM, 1995, J GERONTOL A-BIOL, V50, pB148, DOI 10.1093/gerona/50A.3.B148
   Nakamura MT, 2014, PROG LIPID RES, V53, P124, DOI 10.1016/j.plipres.2013.12.001
   Nisoli E, 2005, SCIENCE, V310, P314, DOI 10.1126/science.1117728
   Noreen EE, 2010, J INT SOC SPORT NUTR, V7, DOI 10.1186/1550-2783-7-31
   Pamplona R, 2004, EXP GERONTOL, V39, P725, DOI 10.1016/j.exger.2004.01.006
   Pamplona R, 2002, ANN NY ACAD SCI, V959, P475, DOI 10.1111/j.1749-6632.2002.tb02118.x
   Pamplona R, 1998, J LIPID RES, V39, P1989
   Pamplona R, 2011, BIOGERONTOLOGY, V12, P409, DOI 10.1007/s10522-011-9348-1
   Phillips T, 2005, FASEB J, V19, P668, DOI 10.1096/fj.04-2870fje
   Porter RK, 1996, AM J PHYSIOL-REG I, V271, pR1550, DOI 10.1152/ajpregu.1996.271.6.R1550
   POWER GW, 1994, BIOCHEM MOL BIOL INT, V34, P671
   Power GW, 1997, J NUTR, V127, P2142, DOI 10.1093/jn/127.11.2142
   Pugh TD, 1999, NEUROBIOL AGING, V20, P157, DOI 10.1016/S0197-4580(99)00043-3
   Quiles JL, 2002, J BIOENERG BIOMEMBR, V34, P517, DOI 10.1023/A:1022530512096
   Ramsey JJ, 2005, COMP BIOCHEM PHYS B, V140, P99, DOI 10.1016/j.cbpc.2004.09.016
   Ramsey JJ, 2004, AM J PHYSIOL-ENDOC M, V286, pE31, DOI 10.1152/ajpendo.00283.2003
   Ramsey JJ, 2000, FREE RADICAL BIO MED, V29, P946, DOI 10.1016/S0891-5849(00)00417-2
   Ramsey JJ, 2006, J NUTR, V136, p1958S, DOI 10.1093/jn/136.7.1958S
   Sanchez-Roman I, 2014, J BIOENERG BIOMEMBR, V46, P159, DOI 10.1007/s10863-013-9535-7
   Sanchez-Roman I, 2010, REJUV RES, V13, P683, DOI 10.1089/rej.2010.1062
   Schmitz G, 2008, PROG LIPID RES, V47, P147, DOI 10.1016/j.plipres.2007.12.004
   Seo AY, 2008, AGING CELL, V7, P706, DOI 10.1111/j.1474-9726.2008.00418.x
   Sohal RS, 1996, SCIENCE, V273, P59, DOI 10.1126/science.273.5271.59
   Sousa-Victor P, 2014, NATURE, V506, P316, DOI 10.1038/nature13013
   Speakman JR, 2011, MOL ASPECTS MED, V32, P159, DOI 10.1016/j.mam.2011.07.001
   Spindler SR, 2014, AGE, V36, P1345, DOI 10.1007/s11357-014-9659-7
   Staessen L, 1997, EUR J CANCER PREV, V6, P374, DOI 10.1097/00008469-199708000-00010
   SU WF, 1993, J NUTR, V123, P2109
   TAHIN QS, 1981, EUR J BIOCHEM, V121, P5, DOI 10.1111/j.1432-1033.1981.tb06421.x
   Tsuboyama-Kasaoka N, 2008, AM J PHYSIOL-ENDOC M, V294, pE600, DOI 10.1152/ajpendo.00551.2007
   Tsuduki T, 2011, NUTRITION, V27, P334, DOI 10.1016/j.nut.2010.05.017
   Tucker KL, 2005, J NUTR, V135, P556, DOI 10.1093/jn/135.3.556
   Umezawa M, 2000, J NUTR, V130, P221, DOI 10.1093/jn/130.2.221
   Villalba JM, 2012, BIOFACTORS, V38, P349, DOI 10.1002/biof.1032
   Wohlgemuth SE, 2010, EXP GERONTOL, V45, P138, DOI 10.1016/j.exger.2009.11.002
   Yamagishi K, 2008, J AM COLL CARDIOL, V52, P988, DOI 10.1016/j.jacc.2008.06.018
   YAMAOKA S, 1988, J NUTR, V118, P290, DOI 10.1093/jn/118.3.290
   Yu BP, 2002, J NUTR SCI VITAMINOL, V48, P257, DOI 10.3177/jnsv.48.257
NR 141
TC 15
Z9 18
U1 0
U2 65
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1389-5729
EI 1573-6768
J9 BIOGERONTOLOGY
JI Biogerontology
PD OCT
PY 2015
VL 16
IS 5
SI SI
BP 655
EP 670
DI 10.1007/s10522-015-9572-1
PG 16
WC Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Geriatrics & Gerontology
GA CQ4CY
UT WOS:000360553100008
PM 25860863
OA Green Accepted
DA 2024-02-19
ER

PT J
AU KASTEN, TP
   MHASKAR, Y
   DUNAWAY, GA
AF KASTEN, TP
   MHASKAR, Y
   DUNAWAY, GA
TI REGULATION OF BRAIN 6-PHOSPHOFRUCTO-1-KINASE - EFFECTS OF AGING,
   FRUCTOSE-2,6-BISPHOSPHATE, AND REGIONAL SUBUNIT DISTRIBUTION
SO MOLECULAR AND CELLULAR BIOCHEMISTRY
LA English
DT Article
DE 6-PHOSPHOFRUCTO-1-KINASE; D-FRUCTOSE 2,6-BISPHOSPHATE; AGING BRAIN;
   ENERGY METABOLISM
ID CEREBRAL GLUCOSE-UTILIZATION; FRUCTOSE 2,6-BISPHOSPHATE;
   PHOSPHOFRUCTOKINASE ACTIVITY; LIVER PHOSPHOFRUCTOKINASE; ISOZYME POOLS;
   HUMAN-TISSUES; RAT-HEART; ISOENZYMES; ACTIVATION; GLYCOLYSIS
AB Total 6-phosphofructo-1-kinase (PFK) activity, amounts of each type of PFK subunit, and levels of fructose-2,6-P, in the cerebral cortex, midbrain, pons-medulla, and cerebellum of 3,12, and 25 month rats were measured. Further, the role of fructose-2,6-P2 in the regulation of brain PFK activity was examined. A positive correlation was found to exist between the.reported losses of glucose utilization as measured by 2-deoxy-D-glucose uptake and PFK activity in each region. That is, both parameters decreased to their lowest level by 12 months of age and remained decreased and fairly constant thereafter. Fructose-2,6-P2 levels did not appear to directly correlate with regional changes in glucose utilization. Also, region-specific and age-related alterations of the PFK subunits were found although these changes apparently did not correlate with decreased glucose utilization. Brain PFK is apparently saturated with fructose-2,6-P2 due to the high endogenous levels, and it contains a large proportion of the C-type subunit which dampens catalytic efficiency. Consequently, brain PFK could exist in a conformational state such that it can readily consume fructose-6-P rather than in an inhibited state requiring activation. This may explain, in part, the ability of brain to efficiently but conservatively utilize available glucose in energy production.
C1 SO ILLINOIS UNIV,SCH MED,DEPT PHARMACOL,POB 19230,SPRINGFIELD,IL 62794.
C3 Southern Illinois University System; Southern Illinois University
FU NIA NIH HHS [AG08014] Funding Source: Medline; NICHD NIH HHS [HD16666]
   Funding Source: Medline
CR BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   CLAUS TH, 1984, CURR TOP CELL REGUL, V23, P57
   CLAUS TH, 1980, P NATL ACAD SCI-BIOL, V77, P6501, DOI 10.1073/pnas.77.11.6501
   DUNAWAY GA, 1988, BRAIN RES, V456, P310, DOI 10.1016/0006-8993(88)90233-8
   DUNAWAY GA, 1989, MOL CELL BIOCHEM, V87, P71, DOI 10.1007/BF00421084
   DUNAWAY GA, 1985, J BIOL CHEM, V260, P4180
   DUNAWAY GA, 1990, BIOCHEM J, V266, P823
   DUNAWAY GA, 1983, MOL CELL BIOCHEM, V52, P75
   DUNAWAY GA, 1985, J MOL CELL CARDIOL, V17, P947, DOI 10.1016/S0022-2828(85)80075-4
   DUNAWAY GA, 1988, BIOCHEM J, V251, P677, DOI 10.1042/bj2510677
   DUNAWAY GA, 1987, BIOCHEM J, V242, P667, DOI 10.1042/bj2420667
   ERECINSKA M, 1989, J CEREBR BLOOD F MET, V9, P2, DOI 10.1038/jcbfm.1989.2
   FOE LG, 1984, ARCH BIOCHEM BIOPHYS, V228, P503, DOI 10.1016/0003-9861(84)90016-X
   FURUYA E, 1980, P NATL ACAD SCI-BIOL, V77, P5861, DOI 10.1073/pnas.77.10.5861
   HUE L, 1982, J BIOL CHEM, V257, P4308
   HUE L, 1987, BIOCHEM J, V245, P313, DOI 10.1042/bj2450313
   ISHIKAWA E, 1990, J BIOL CHEM, V265, P18875
   KAHN A, 1979, HUM GENET, V48, P93, DOI 10.1007/BF00273280
   KASTEN T, 1990, LAB ANIM SCI, V40, P399
   LAWSON JWR, 1987, J BIOL CHEM, V262, P3165
   LONDON ED, 1981, J NEUROCHEM, V37, P217, DOI 10.1111/j.1471-4159.1981.tb05311.x
   MEIENHOFER MC, 1979, BLOOD, V54, P389
   NARABAYASHI H, 1985, J BIOL CHEM, V260, P9750
   OGUSHI S, 1990, J BIOL CHEM, V265, P10943
   PILKIS SJ, 1981, J BIOL CHEM, V256, P3619
   REINHART GD, 1980, BIOCHEMISTRY-US, V19, P1491, DOI 10.1021/bi00548a036
   SOKOLOFF L, 1977, J NEUROCHEM, V28, P897, DOI 10.1111/j.1471-4159.1977.tb10649.x
   UYEDA K, 1982, MOL CELL BIOCHEM, V48, P97
   VANSCHAFTINGEN E, 1980, BIOCHEM J, V192, P263, DOI 10.1042/bj1920263
   VANSCHAFTINGEN E, 1982, EUR J BIOCHEM, V129, P191
   VORA S, 1980, P NATL ACAD SCI-BIOL, V77, P62, DOI 10.1073/pnas.77.1.62
   WILLIAMSON DH, 1974, METHOD ENZYMAT AN, V4, P2280
NR 32
TC 10
Z9 10
U1 0
U2 1
PU KLUWER ACADEMIC PUBL
PI DORDRECHT
PA SPUIBOULEVARD 50, PO BOX 17, 3300 AA DORDRECHT, NETHERLANDS
SN 0300-8177
J9 MOL CELL BIOCHEM
JI Mol. Cell. Biochem.
PD MAR 10
PY 1993
VL 120
IS 1
BP 61
EP 68
DI 10.1007/BF00925985
PG 8
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA KR384
UT WOS:A1993KR38400007
PM 8459804
DA 2024-02-19
ER

PT J
AU Samartsev, VN
   Kozhina, OV
AF Samartsev, V. N.
   Kozhina, O. V.
TI Oxidative stress as regulatory factor for fatty-acid-induced uncoupling
   involving liver mitochondrial ADP/ATP and aspartate/glutamate
   antiporters of old rats
SO BIOCHEMISTRY-MOSCOW
LA English
DT Article
DE liver mitochondria; aging; oxidative stress; reactive oxygen species;
   fatty acids; uncoupling; ADP/ATP antiporter; aspartate/glutamate
   antiporter
ID VITAMIN-E; CALORIC RESTRICTION; PHOSPHORYLATION; ADP; AGE; PEROXIDATION;
   INVOLVEMENT; RADICALS; FEATURES; CARRIER
AB Palmitate-induced uncoupling, which involves ADP/ATP and aspartate/glutamate antiporters, has been studied in liver mitochondria of old rats (22-26 months) under conditions of lipid peroxidation and inhibition of oxidative stress by antioxidants-thiourea, Trolox, and ionol. It has been shown that in liver mitochondria of old rats in the absence of antioxidants and under conditions of overproduction of conjugated dienes, the protonophoric uncoupling activity of palmitate is not suppressed by either carboxyatractylate or aspartate used separately. However, the combination of carboxyatractylate and aspartate decreased uncoupling activity of palmitate by 81%. In this case, palmitate-induced uncoupling is limited by a stage insensitive to both carboxyatractylate and aspartate. In the presence of antioxidants, the palmitate-induced protonophoric uncoupling activity is suppressed by either carboxyatractylate or aspartate used separately. Under these conditions, palmitate-induced uncoupling is limited by a stage sensitive to carboxyatractylate (ADP/ATP antiporter) or aspartate (aspartate/glutamate antiporter). In the absence of antioxidants, the uncoupling activity of palmitate is not suppressed by ADP either in the absence or in the presence of aspartate. However, in the presence of thiourea, Trolox, or ionol ADP decreased the uncoupling activity of palmitate by 38%. It is concluded that in liver mitochondria of old rats the development of oxidative stress in the presence of physiological substrates of ADP/ATP and aspartate/glutamate antiporters (ADP and aspartate) results in an increase of the protonophoric uncoupling activity of palmitate.
C1 [Samartsev, V. N.; Kozhina, O. V.] Mari State Univ, Yoshkar Ola 424001, Russia.
C3 Mari State University
RP Samartsev, VN (corresponding author), Mari State Univ, Pl Lenina 1, Yoshkar Ola 424001, Russia.
EM samvic56@mail.ru
RI Samartsev, Victor N./AAA-4206-2022
OI Samartsev, Victor/0000-0003-0673-7305
CR AMBROSIO G, 1991, J CLIN INVEST, V87, P2056, DOI 10.1172/JCI115236
   Andreyev AI, 2005, BIOCHEMISTRY-MOSCOW+, V70, P200, DOI 10.1007/s10541-005-0102-7
   ANDREYEV AY, 1989, EUR J BIOCHEM, V182, P585, DOI 10.1111/j.1432-1033.1989.tb14867.x
   Armeni T, 2003, J BIOENERG BIOMEMBR, V35, P181, DOI 10.1023/A:1023754305218
   Bakala H, 2003, EUR J BIOCHEM, V270, P2295, DOI 10.1046/j.1432-1033.2003.03598.x
   BILENKO MV, 1989, ISCHEMIA REPERFUSION
   BODROVA ME, 1995, BIOCHEMISTRY-MOSCOW+, V60, P1027
   BOHNENSACK R, 1982, BIOCHIM BIOPHYS ACTA, V680, P271, DOI 10.1016/0005-2728(82)90139-6
   Brand MD, 2004, FREE RADICAL BIO MED, V37, P755, DOI 10.1016/j.freeradbiomed.2004.05.034
   DAVIES MJ, 1988, BIOCHEM J, V255, P513
   Dröge W, 2002, PHYSIOL REV, V82, P47, DOI 10.1152/physrev.00018.2001
   GROEN AK, 1982, J BIOL CHEM, V257, P2754
   HINKLE PC, 1979, J BIOL CHEM, V254, P2450
   HUGNES G, 2005, BIOCHEM J, V389, P83
   Judge S, 2005, FASEB J, V19, P419, DOI 10.1096/fj.04-2622fje
   Kamzalov S, 2004, EXP GERONTOL, V39, P1199, DOI 10.1016/j.exger.2004.04.007
   KLINGENBERG M, 1985, ENZYMES BIOL MEMBR, V4, P511
   Korshunov SS, 1998, FEBS LETT, V435, P215, DOI 10.1016/S0014-5793(98)01073-4
   Kozhina OV, 2006, BIOL MEMBRANY, V23, P213
   Lenaz G, 1998, BBA-BIOENERGETICS, V1366, P53, DOI 10.1016/S0005-2728(98)00120-0
   Markova OV, 1999, BIOCHEMISTRY-MOSCOW+, V64, P565
   Mokhova EN, 2005, BIOCHEMISTRY-MOSCOW+, V70, P159, DOI 10.1007/s10541-005-0096-1
   PARADIES G, 1991, ARCH BIOCHEM BIOPHYS, V284, P332, DOI 10.1016/0003-9861(91)90304-2
   Samartsev VN, 1999, BIOCHEMISTRY-MOSCOW+, V64, P901
   Samartsev VN, 2005, BIOL MEMBRANY, V22, P92
   Samartsev VN, 2004, BIOCHEMISTRY-MOSCOW+, V69, P678, DOI 10.1023/B:BIRY.0000033742.57883.fa
   Samartsev VN, 1997, FEBS LETT, V412, P179, DOI 10.1016/S0014-5793(97)00667-4
   SCHWENKE WD, 1981, BIOCHEM J, V200, P405, DOI 10.1042/bj2000405
   Skulachev VP, 2006, APOPTOSIS, V11, P473, DOI 10.1007/s10495-006-5881-9
   Skulachev VP, 1998, BBA-BIOENERGETICS, V1363, P100, DOI 10.1016/S0005-2728(97)00091-1
   SOKOL RJ, 1991, J LIPID RES, V32, P1349
   VEECH RL, 1979, J BIOL CHEM, V254, P6538
   Zapadnyuk I. P., 1983, LAB ANIMALS BREEDING
   Zenkov N.K., 2001, Oxidative Stress: Biochemical and Pathophysiological Aspects
NR 34
TC 7
Z9 7
U1 0
U2 3
PU MAIK NAUKA/INTERPERIODICA/SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013-1578 USA
SN 0006-2979
EI 1608-3040
J9 BIOCHEMISTRY-MOSCOW+
JI Biochem.-Moscow
PD JUL
PY 2008
VL 73
IS 7
BP 783
EP 790
DI 10.1134/S0006297908070067
PG 8
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 333QW
UT WOS:000258168400006
PM 18707586
DA 2024-02-19
ER

PT J
AU Chen, CH
   Walker, J
   Momenan, R
   Rawlings, R
   Heilig, M
   Hommer, DW
AF Chen, Chun-Hsin
   Walker, Jonathan
   Momenan, Reza
   Rawlings, Robert
   Heilig, Markus
   Hommer, Daniel W.
TI Relationship Between Liver Function and Brain Shrinkage in Patients with
   Alcohol Dependence
SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH
LA English
DT Article
DE Alcohol Dependence; MRI; Liver Function; Brain Shrinkage
ID GAMMA-GLUTAMYL-TRANSPEPTIDASE; OXIDATIVE STRESS STATUS;
   LIPID-PEROXIDATION; CELL-DEATH; DISEASE; CONSUMPTION; WOMEN; GRAY;
   VOLUMES; ENZYME
AB Background: Oxidative stress has been proposed as one of the mechanisms of alcohol-induced brain shrinkage and alcohol-induced hepatotoxicity. The aim of this study was to assess the correlations between liver function and brain volume (BV) measurements in patients with alcohol dependence.
   Methods: We recruited 124 patients with alcohol dependence and 111 healthy control subjects from National Institute of Health, National Institute on Alcohol Abuse and Alcoholism inpatient alcohol treatment program. Gamma-glutamyl transferase (GGT), aspartate aminotransferase (AST), alanine aminotransferase (ALT), as well as hematocrit (Hct) and albumin were assayed shortly after admission. Magnetic resonance imaging examination was conducted in both groups (after 3-week abstinence in the patient group). We used stepwise linear regression analyses to determine the variables most strongly correlated with brain shrinkage.
   Results: Patients with alcohol dependence had lower BV, and greater brain shrinkage as measured by gray matter ratio (GMR), white matter ratio (WMR), brain ratio (BR), and higher cerebrospinal fluid ratio ratio (CSFR) compared with their healthy counterparts. Age and sex were significantly correlated with some BV measurements in both patient and control groups. Body mass index (BMI) was significantly correlated with CSFR, BR, GMR, and WMR; Hct with CSFR and BR; serum GGT level with BV, CSFR, BR, GMR, and WMF in the patient group. No biological variables were correlated with BV indices in the control group. In gender-stratified analysis, age was significantly correlated with brain shrinkage in male patients but not in female patients. Serum GGT level in male and female patients, Hct in male patients, and AST levels in female patients were significantly correlated with brain shrinkage.
   Conclusions: Our results showed that the higher levels of liver function indices, especially GGT, correlated with BV shrinkage as measured using CSFR, BR, GMR, and WMR in patients with alcohol dependence but not in controls. Serum GGT level outweighed aging effect on brain shrinkage in female patients.
C1 [Chen, Chun-Hsin; Walker, Jonathan; Momenan, Reza; Rawlings, Robert; Heilig, Markus; Hommer, Daniel W.] NIAAA, Lab Clin & Translat Studies, NIH, Bethesda, MD 20892 USA.
   [Chen, Chun-Hsin] Taipei Med Univ, Wan Fang Hosp, Dept Psychiat, Taipei, Taiwan.
   [Chen, Chun-Hsin] Taipei Med Univ, Sch Med, Dept Psychiat, Taipei, Taiwan.
C3 National Institutes of Health (NIH) - USA; NIH National Institute on
   Alcohol Abuse & Alcoholism (NIAAA); Taipei Medical University; Taipei
   Municipal WanFang Hospital; Taipei Medical University
RP Hommer, DW (corresponding author), NIAAA, Lab Clin & Translat Studies, NIH, 10 Ctr Dr,Bldg 10 CRC Hatfield Clin Res Ctr,Room, Bethesda, MD 20892 USA.
EM danh@mail.nih.gov
RI Momenan, Reza/P-2266-2019
OI Heilig, Markus/0000-0003-2706-2482
FU Laboratory of Clinical and Translational Studies; National Institute on
   Alcohol Abuse and Alcoholism
FX The study was funded by the Laboratory of Clinical and Translational
   Studies, National Institute on Alcohol Abuse and Alcoholism. The authors
   thank Michael Kerich for computer system management and programming, and
   the nursing and social work staff of the Alcohol Treatment Unit of NIH
   Clinical Center. Finally, we thank all participants in this study.
CR Banks WA, 2005, CURR PHARM DESIGN, V11, P973, DOI 10.2174/1381612053381684
   Becker U, 1996, HEPATOLOGY, V23, P1025, DOI 10.1002/hep.510230513
   Chen CH, 2011, ALCOHOL CLIN EXP RES, V35, P338, DOI 10.1111/j.1530-0277.2010.01349.x
   Conigrave KM, 2003, ADDICTION, V98, P31, DOI 10.1046/j.1359-6357.2003.00581.x
   Courchesne E, 2000, RADIOLOGY, V216, P672, DOI 10.1148/radiology.216.3.r00au37672
   Crews F, 2006, ALCOHOL CLIN EXP RES, V30, P1938, DOI 10.1111/j.1530-0277.2006.00239.x
   Crews FT, 2009, ALCOHOL ALCOHOLISM, V44, P115, DOI 10.1093/alcalc/agn079
   De Minicis S, 2008, J GASTROEN HEPATOL, V23, pS98, DOI 10.1111/j.1440-1746.2007.05277.x
   Drozdz R, 1998, FREE RADICAL BIO MED, V25, P786, DOI 10.1016/S0891-5849(98)00127-0
   Enoiu M, 2000, FREE RADICAL BIO MED, V29, P825, DOI 10.1016/S0891-5849(00)00370-1
   Fataccioli V, 1999, HEPATOLOGY, V29, P14, DOI 10.1002/hep.510290106
   Fein G, 2002, ALCOHOL CLIN EXP RES, V26, P558, DOI 10.1111/j.1530-0277.2002.tb02574.x
   FernandezSola J, 1997, AM J CARDIOL, V80, P481, DOI 10.1016/S0002-9149(97)00399-8
   Gonzalez-Quintela A, 2008, ALCOHOL, V42, P513, DOI 10.1016/j.alcohol.2008.04.008
   Hamelink C, 2005, J PHARMACOL EXP THER, V314, P780, DOI 10.1124/jpet.105.085779
   Hanigan MH, 1996, J HISTOCHEM CYTOCHEM, V44, P1101, DOI 10.1177/44.10.8813074
   Hommer DW, 2001, AM J PSYCHIAT, V158, P198, DOI 10.1176/appi.ajp.158.2.198
   Huang MC, 2009, J FORMOS MED ASSOC, V108, P560, DOI 10.1016/S0929-6646(09)60374-0
   JERNIGAN TL, 1991, ALCOHOL CLIN EXP RES, V15, P418, DOI 10.1111/j.1530-0277.1991.tb00540.x
   Junghanns K, 2004, ALCOHOL ALCOHOLISM, V39, P113, DOI 10.1093/alcalc/agh028
   Karp DR, 2001, J BIOL CHEM, V276, P3798, DOI 10.1074/jbc.M008484200
   Kono H, 2000, J CLIN INVEST, V106, P867, DOI 10.1172/JCI9020
   KUGELMAN A, 1994, AM J RESP CELL MOL, V11, P586, DOI 10.1165/ajrcmb.11.5.7946387
   Latvala J, 2005, AM J GASTROENTEROL, V100, P1303, DOI 10.1111/j.1572-0241.2005.41509.x
   Lim JS, 2004, FREE RADICAL BIO MED, V37, P1018, DOI 10.1016/j.freeradbiomed.2004.06.032
   LOFT S, 1987, SCAND J GASTROENTERO, V22, P1251, DOI 10.3109/00365528708996472
   Mann K, 2005, ALCOHOL CLIN EXP RES, V29, P896, DOI 10.1097/01.ALC.0000164376.69978.6B
   Mayne ST, 2003, J NUTR, V133, p933S, DOI 10.1093/jn/133.3.933S
   MCCRORY SJ, 1991, STAT MED, V10, P1711, DOI 10.1002/sim.4780101109
   Momenan R, 1997, HUM BRAIN MAPP, V5, P194, DOI 10.1002/(SICI)1097-0193(1997)5:3<194::AID-HBM4>3.0.CO;2-Z
   MONTEIRO MG, 1986, ALCOHOL, V3, P223
   MORIMOTO M, 1993, ALCOHOL, V10, P459, DOI 10.1016/0741-8329(93)90065-V
   MUTZELL S, 1992, UPSALA J MED SCI, V97, P183
   Paolicchi A, 1997, FREE RADICAL BIO MED, V22, P853, DOI 10.1016/S0891-5849(96)00422-4
   PARES A, 1986, J HEPATOL, V2, P33, DOI 10.1016/S0168-8278(86)80006-X
   PFEFFERBAUM A, 1988, ALCOHOL CLIN EXP RES, V12, P81, DOI 10.1111/j.1530-0277.1988.tb00137.x
   Pfefferbaum A, 2001, AM J PSYCHIAT, V158, P188, DOI 10.1176/appi.ajp.158.2.188
   PFEFFERBAUM A, 1992, ALCOHOL CLIN EXP RES, V16, P1078, DOI 10.1111/j.1530-0277.1992.tb00702.x
   Pfefferbaum A, 2004, AM J PSYCHIAT, V161, P1190, DOI 10.1176/appi.ajp.161.7.1190
   PFEFFERBAUM A, 1995, ALCOHOL CLIN EXP RES, V19, P1177, DOI 10.1111/j.1530-0277.1995.tb01598.x
   Pratt DS, 2000, NEW ENGL J MED, V342, P1266, DOI 10.1056/NEJM200004273421707
   Qin LY, 2007, GLIA, V55, P453, DOI 10.1002/glia.20467
   RASHBASTEP J, 1993, ARCH BIOCHEM BIOPHYS, V300, P401, DOI 10.1006/abbi.1993.1054
   SHAW S, 1981, J LAB CLIN MED, V98, P417
   Srivastava V, 2010, NEUROPSYCHOPHARMACOL, V35, P1120, DOI 10.1038/npp.2009.217
   URBANOMARQUEZ A, 1995, JAMA-J AM MED ASSOC, V274, P149, DOI 10.1001/jama.274.2.149
   Whitfield JB, 2001, CRIT REV CL LAB SCI, V38, P263, DOI 10.1080/20014091084227
   Zalit I, 1996, BIOCHEM MOL BIOL INT, V40, P1123
   Zhou ZX, 2003, AM J PATHOL, V163, P1137, DOI 10.1016/S0002-9440(10)63473-6
   Zou J, 2006, CELL MOL NEUROBIOL, V26, P385, DOI 10.1007/s10571-006-9045-9
   Zuccoli G, 2007, AM J NEURORADIOL, V28, P1328, DOI 10.3174/ajnr.A0544
NR 51
TC 22
Z9 25
U1 0
U2 6
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0145-6008
J9 ALCOHOL CLIN EXP RES
JI Alcoholism (NY)
PD APR
PY 2012
VL 36
IS 4
BP 625
EP 632
DI 10.1111/j.1530-0277.2011.01662.x
PG 8
WC Substance Abuse
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Substance Abuse
GA 916AN
UT WOS:000302068900010
PM 21995416
OA Green Accepted
DA 2024-02-19
ER

PT J
AU Araújo, WL
   Ishizaki, K
   Nunes-Nesi, A
   Tohge, T
   Larson, TR
   Krahnert, I
   Balbo, I
   Witt, S
   Dörmann, P
   Graham, IA
   Leaver, CJ
   Fernie, AR
AF Araujo, Wagner L.
   Ishizaki, Kimitsune
   Nunes-Nesi, Adriano
   Tohge, Takayuki
   Larson, Tony R.
   Krahnert, Ina
   Balbo, Ilse
   Witt, Sandra
   Doermann, Peter
   Graham, Ian A.
   Leaver, Christopher J.
   Fernie, Alisdair R.
TI Analysis of a Range of Catabolic Mutants Provides Evidence That
   Phytanoyl-Coenzyme A Does Not Act as a Substrate of the
   Electron-Transfer Flavoprotein/Electron-Transfer Flavoprotein:Ubiquinone
   Oxidoreductase Complex in Arabidopsis during Dark-Induced Senescence
SO PLANT PHYSIOLOGY
LA English
DT Article
ID ACYL-COA DEHYDROGENASES; ACID ALPHA-OXIDATION; BETA-OXIDATION;
   CHLOROPHYLL BREAKDOWN; UBIQUINONE OXIDOREDUCTASE; GAS-CHROMATOGRAPHY;
   REFSUMS-DISEASE; GENE-EXPRESSION; RAT-LIVER; CHAIN
AB The process of dark-induced senescence in plants is not fully understood, however, the functional involvement of an electron-transfer flavoprotein/electron-transfer flavoprotein: ubiquinone oxidoreductase (ETF/ETFQO), has been demonstrated. Recent studies have revealed that the enzymes isovaleryl-coenzyme A (CoA) dehydrogenase and 2-hydroxyglutarate dehydrogenase act as important electron donors to this complex. In addition both enzymes play a role in the breakdown of cellular carbon storage reserves with isovaleryl-CoA dehydrogenase being involved in degradation of the branched-chain amino acids, phytol, and lysine while 2-hydroxyglutarate dehydrogenase is exclusively involved in lysine degradation. Given that the chlorophyll breakdown intermediate phytanoyl-CoA accumulates dramatically both in knockout mutants of the ETF/ETFQO complex and of isovaleryl-CoA dehydrogenase following growth in extended dark periods we have investigated the direct importance of chlorophyll breakdown for the supply of carbon and electrons during this process. For this purpose we isolated three independent Arabidopsis (Arabidopsis thaliana) knockout mutants of phytanoyl-CoA 2-hydroxylase and grew them under the same extended darkness regime as previously used. Despite the fact that these mutants accumulated phytanoyl-CoA and also 2-hydroxyglutarate they exhibited no morphological changes in comparison to the other mutants previously characterized. These results are consistent with a single entry point of phytol breakdown into the ETF/ETFQO system and furthermore suggest that phytol is not primarily metabolized by this pathway. Furthermore analysis of isovaleryl-CoA dehydrogenase/2-hydroxyglutarate dehydrogenase double mutants generated here suggest that these two enzymes essentially account for the entire electron input via the ETF complex.
C1 [Araujo, Wagner L.; Nunes-Nesi, Adriano; Tohge, Takayuki; Krahnert, Ina; Balbo, Ilse; Witt, Sandra; Fernie, Alisdair R.] Max Planck Inst Mol Pflanzenphysiol, D-14476 Potsdam, Germany.
   [Araujo, Wagner L.; Nunes-Nesi, Adriano] Univ Fed Vicosa, Max Planck Partner Grp, Dept Biol Vegetal, BR-36570000 Vicosa, MG, Brazil.
   [Ishizaki, Kimitsune] Kyoto Univ, Grad Sch Biostudies, Kyoto 6068502, Japan.
   [Larson, Tony R.; Graham, Ian A.] Univ York, Ctr Novel Agr Prod, Dept Biol, York YO10 5YW, N Yorkshire, England.
   [Doermann, Peter] Univ Bonn, Inst Plant Mol Physiol & Biotechnol, Dept Mol Biotechnol, D-53115 Bonn, Germany.
   [Leaver, Christopher J.] Univ Oxford, Dept Plant Sci, Oxford OX1 3RB, England.
C3 Max Planck Society; Universidade Federal de Vicosa; Kyoto University;
   University of York - UK; University of Bonn; University of Oxford
RP Fernie, AR (corresponding author), Max Planck Inst Mol Pflanzenphysiol, D-14476 Potsdam, Germany.
EM fernie@mpimp-golm.mpg.de
RI Larson, Tony/AAI-4782-2020; Tohge, Takayuki/G-7924-2017; Nunes-Nesi,
   Adriano/D-6430-2013; Araújo, Wagner L./I-3291-2013; fernie,
   alisdair/IWD-9278-2023; Ishizaki, Kimitsune/L-4480-2019
OI Larson, Tony/0000-0003-1337-3482; Tohge, Takayuki/0000-0001-5555-5650;
   Araújo, Wagner L./0000-0002-4796-2616; Ishizaki,
   Kimitsune/0000-0003-0504-8196; Nunes-Nesi, Adriano/0000-0002-9581-9355
FU Max Planck Society; Deutsche Forschungsgemeinschaft [DFG-SFB429];
   Biotechnology and Biological Science Research Council; Grants-in-Aid for
   Scientific Research [22770035] Funding Source: KAKEN
FX This work was supported by the Max Planck Society (to W.L.A. and
   A.R.F.), the Deutsche Forschungsgemeinschaft (grant no. DFG-SFB429 to
   A.R.F.), and the Biotechnology and Biological Science Research Council
   (to K.I. and C.J.L.).
CR Araújo WL, 2010, PLANT CELL, V22, P1549, DOI 10.1105/tpc.110.075630
   ARAUJO WL, 2011, TRENDS PLAN IN PRESS
   BECKMANN JD, 1985, BIOCHEMISTRY-US, V24, P3913, DOI 10.1021/bi00336a016
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   Bräutigam A, 2011, PLANT PHYSIOL, V155, P43, DOI 10.1104/pp.110.164970
   Buchanan-Wollaston V, 2005, PLANT J, V42, P567, DOI 10.1111/j.1365-313X.2005.02399.x
   Cazzonelli CI, 2010, TRENDS PLANT SCI, V15, P266, DOI 10.1016/j.tplants.2010.02.003
   Chen M, 2010, CELL, V141, P1230, DOI 10.1016/j.cell.2010.05.007
   Engqvist M, 2009, J BIOL CHEM, V284, P25026, DOI 10.1074/jbc.M109.021253
   Engqvist MKM, 2011, J BIOL CHEM, V286, P11382, DOI 10.1074/jbc.M110.194175
   FRERMAN FE, 1988, BIOCHEM SOC T, V16, P416, DOI 10.1042/bst0160416
   Ghisla S, 2004, EUR J BIOCHEM, V271, P494, DOI 10.1046/j.1432-1033.2003.03946.x
   Gibon Y, 2004, PLANT CELL, V16, P3304, DOI 10.1105/tpc.104.025973
   He M, 2007, AM J HUM GENET, V81, P87, DOI 10.1086/519219
   Heazlewood JL, 2004, PLANT CELL, V16, P241, DOI 10.1105/tpc.016055
   Hörtensteiner S, 2011, BBA-BIOENERGETICS, V1807, P977, DOI 10.1016/j.bbabio.2010.12.007
   HOSKINS DD, 1961, J BIOL CHEM, V236, P177
   Ishizaki K, 2005, PLANT CELL, V17, P2587, DOI 10.1105/tpc.105.035162
   Ishizaki K, 2006, PLANT J, V47, P751, DOI 10.1111/j.1365-313X.2006.02826.x
   Jansen GA, 1999, J LIPID RES, V40, P2244
   Kleine T, 2009, TRENDS GENET, V25, P185, DOI 10.1016/j.tig.2009.02.004
   Kopka J, 2005, BIOINFORMATICS, V21, P1635, DOI 10.1093/bioinformatics/bti236
   Kunz HH, 2009, PLANT CELL, V21, P2733, DOI 10.1105/tpc.108.064857
   Larson TR, 2001, PLANT J, V25, P115, DOI 10.1046/j.1365-313x.2001.00929.x
   Lehmann M, 2009, MOL PLANT, V2, P390, DOI 10.1093/mp/ssn080
   Lisec J, 2006, NAT PROTOC, V1, P387, DOI 10.1038/nprot.2006.59
   Luedemann A, 2008, BIOINFORMATICS, V24, P732, DOI 10.1093/bioinformatics/btn023
   McDonough MA, 2005, J BIOL CHEM, V280, P41101, DOI 10.1074/jbc.M507528200
   Mihalik SJ, 1997, NAT GENET, V17, P185, DOI 10.1038/ng1097-185
   MIHALIK SJ, 1995, EUR J BIOCHEM, V232, P545, DOI 10.1111/j.1432-1033.1995.545zz.x
   Mukherji M, 2003, PROG LIPID RES, V42, P359, DOI 10.1016/S0163-7827(03)00016-X
   Mukherji M, 2001, HUM MOL GENET, V10, P1971, DOI 10.1093/hmg/10.18.1971
   Mur LAJ, 2010, NEW PHYTOL, V188, P161, DOI 10.1111/j.1469-8137.2010.03377.x
   Oh SA, 1996, PLANT MOL BIOL, V30, P739, DOI 10.1007/BF00019008
   Palmieri F, 2011, PLANT J, V66, P161, DOI 10.1111/j.1365-313X.2011.04516.x
   Pogson BJ, 2008, TRENDS PLANT SCI, V13, P602, DOI 10.1016/j.tplants.2008.08.008
   PORRA RJ, 1989, BIOCHIM BIOPHYS ACTA, V975, P384, DOI 10.1016/S0005-2728(89)80347-0
   Pruzinská A, 2005, PLANT PHYSIOL, V139, P52, DOI 10.1104/pp.105.065870
   Roessner U, 2001, PLANT CELL, V13, P11, DOI 10.1105/tpc.13.1.11
   Roessner-Tunali U, 2004, PLANT J, V39, P668, DOI 10.1111/j.1365-313X.2004.02157.x
   Roessner-Tunali U, 2003, PLANT PHYSIOL, V133, P84, DOI 10.1104/pp.103.023572
   RUZICKA FJ, 1977, J BIOL CHEM, V252, P8440
   Schauer N, 2005, FEBS LETT, V579, P1332, DOI 10.1016/j.febslet.2005.01.029
   Schelbert S, 2009, PLANT CELL, V21, P767, DOI 10.1105/tpc.108.064089
   Searls T, 2005, J LIPID RES, V46, P1660, DOI 10.1194/jlr.M500034-JLR200
   Sienkiewicz-Porzucek A, 2010, MOL PLANT, V3, P156, DOI 10.1093/mp/ssp101
   Studart-Guimaraes C, 2007, PLANT PHYSIOL, V145, P626, DOI 10.1104/pp.107.103101
   TAYLOR DC, 1990, ANAL BIOCHEM, V184, P311, DOI 10.1016/0003-2697(90)90686-4
   Tieman D, 2006, P NATL ACAD SCI USA, V103, P8287, DOI 10.1073/pnas.0602469103
   Timm S, 2008, PLANT CELL, V20, P2848, DOI 10.1105/tpc.108.062265
   Vogelstein, 2001, METABOLIC MOL BASES, P2357, DOI DOI 10.1036/OMMBID.131
   Wanders RJA, 2007, BIOCHEM SOC T, V35, P865, DOI 10.1042/BST0350865
   Wanders RJA, 2003, BBA-MOL CELL BIOL L, V1631, P119, DOI 10.1016/S1388-1981(03)00003-9
   Watmough NJ, 2010, BBA-BIOENERGETICS, V1797, P1910, DOI 10.1016/j.bbabio.2010.10.007
   Wierzbicki AS, 2002, J NEUROCHEM, V80, P727, DOI 10.1046/j.0022-3042.2002.00766.x
   Woodson JD, 2008, NAT REV GENET, V9, P383, DOI 10.1038/nrg2348
   Yang ZL, 2009, PLANT PHYSIOL, V150, P1981, DOI 10.1104/pp.109.140491
NR 57
TC 35
Z9 36
U1 0
U2 13
PU AMER SOC PLANT BIOLOGISTS
PI ROCKVILLE
PA 15501 MONONA DRIVE, ROCKVILLE, MD 20855 USA
SN 0032-0889
EI 1532-2548
J9 PLANT PHYSIOL
JI Plant Physiol.
PD SEP
PY 2011
VL 157
IS 1
BP 55
EP 69
DI 10.1104/pp.111.182188
PG 15
WC Plant Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Plant Sciences
GA 814XZ
UT WOS:000294491800005
PM 21788362
OA Green Published, hybrid
DA 2024-02-19
ER

PT J
AU Guimaraes, ARP
   Kuga, E
   Torres, RP
   Colquhoun, A
   Curi, R
   Mancini, J
AF Guimaraes, ARP
   Kuga, E
   Torres, RP
   Colquhoun, A
   Curi, R
   Mancini, J
TI Composition of fatty acids in the liver and lymphoid organs of rats fed
   fatty acid-rich diets
SO BIOCHEMISTRY AND MOLECULAR BIOLOGY INTERNATIONAL
LA English
DT Article
ID BLASTIC TRANSFORMATION; HUMAN-LYMPHOCYTES; EICOSANOIDS; METABOLISM;
   LIPIDS
AB The composition of the fatty acids in the thymus, spleen and mesenteric lymph nodes was determined in rats fed polyunsaturated (UFC) or saturated (SFC) fatty acid-rich chow during 6 weeks or 14 months. The results indicated that the lipid composition of fatty acids in these tissues was modified by the type of fat given in the diets. Interestingly, the liver did not show any dietary induced change in the composition of fatty acids. The unsaturation index was raised in the lymphoid organs by UFC either after 6 weeks or 14 months. The ageing process itself increased the degree of unsaturation of fatty acids only in the spleen of the 3 groups. A high degree of unsaturation of fatty acids in the tissues may favour the occurrence of lipid peroxidation. It was noteworthy that a linoleic acid-rich diet (UFC) did not change the content of arachidonic acid in the tissues and so would therefore be unlikely to affect eicosanoid synthesis. As shown by previous studies, these fat-rich diets caused marked changes in the key enzyme activities of glucose and glutamine metabolism in the lymphoid organs, by as yet unknown mechanisms. The results reported here suggest that the effect of fat-rich diets on intermediary metabolism does not occur through eicosanoid synthesis and may be a consequence of the lipid peroxidative process or even alterations in the transcription of the enzymes of glycolysis and glutaminolysis.
C1 UNIV SAO PAULO, INST CIENCIAS BIOMED, DEPT FIS & BIOFIS, BR-05508 SAO PAULO, SP, BRAZIL.
   UNIV SAO PAULO, FAC PHARMACEUT SCI, DEPT FOOD SCI & EXPT NUTR, BR-05508 SAO PAULO, SP, BRAZIL.
   UNIV ESTADUAL CEARA, LAB DIETARY FAT TECHNOL, TECFAT, FORTALEZA, CEARA, BRAZIL.
C3 Universidade de Sao Paulo; Universidade de Sao Paulo; Universidade
   Estadual do Ceara
RI Colquhoun, Alison/C-4031-2012; Curi, Rui/C-9351-2012
OI Colquhoun, Alison/0000-0002-0691-2364; 
CR ANEL A, 1990, BIOCHIM BIOPHYS ACTA, V1044, P323, DOI 10.1016/0005-2760(90)90076-A
   ANEL A, 1990, BIOCHIM BIOPHYS ACTA, V1044, P332, DOI 10.1016/0005-2760(90)90077-B
   Boyd E, 1932, AM J DIS CHILD, V43, P1162
   CALDER PC, 1991, INT J BIOCHEM, V23, P579
   CALDER PC, 1994, LIFE SCI, V56, P455, DOI 10.1016/0024-3205(94)00910-4
   FOLCH J, 1957, J BIOL CHEM, V226, P497
   GUIMARAES ARP, 1991, BIOCHEM INT, V23, P533
   GUIMARAES ARP, 1994, PHYSIOL BEHAV, V55, P691, DOI 10.1016/0031-9384(94)90046-9
   GUIMARAES ARP, 1990, BIOCHEM INT, V22, P1005
   HALLIWELL B, 1987, FASEB J, V1, P358, DOI 10.1096/fasebj.1.5.2824268
   HARMAN D, 1984, AGE, V7, P111, DOI 10.1007/BF02431866
   Hartman L, 1973, Lab Pract, V22, P475
   HWANG D, 1989, FASEB J, V3, P2052, DOI 10.1096/fasebj.3.9.2501132
   JOHNSTON PV, 1985, ADV LIPID RES, V21, P103
   KINSELLA JE, 1990, CRIT CARE MED, V18, pS94
   KINSELLA JE, 1990, NUTRITION, V6, P24
   Makinodan T, 1980, Adv Immunol, V29, P287, DOI 10.1016/S0065-2776(08)60047-4
   PECK MD, 1994, J NUTR BIOCHEM, V5, P466, DOI 10.1016/0955-2863(94)90025-6
   PEREIRA B, 1994, PHYSIOL BEHAV, V56, P1049, DOI 10.1016/0031-9384(94)90342-5
   ROTONDO D, 1994, BBA-MOL CELL RES, V1223, P185, DOI 10.1016/0167-4889(94)90225-9
   SILVA EL, 1994, J AM COLL NUTR, V13, P376, DOI 10.1080/07315724.1994.10718425
   TIWARI RK, 1987, NUTR RES, V7, P489, DOI 10.1016/S0271-5317(87)80005-2
NR 22
TC 8
Z9 8
U1 0
U2 1
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1039-9712
J9 BIOCHEM MOL BIOL INT
JI Biochem. Mol. Biol. Int.
PD JUN
PY 1995
VL 36
IS 2
BP 451
EP 461
PG 11
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA UG016
UT WOS:A1995UG01600025
PM 7663449
DA 2024-02-19
ER

PT J
AU LOU, MF
   XU, GT
   CUI, XL
AF LOU, MF
   XU, GT
   CUI, XL
TI FURTHER-STUDIES ON THE DYNAMIC CHANGES OF GLUTATHIONE AND PROTEIN-THIOL
   MIXED DISULFIDES IN H2O2 INDUCED CATARACT IN RAT LENSES - DISTRIBUTIONS
   AND EFFECT OF AGING
SO CURRENT EYE RESEARCH
LA English
DT Article
DE CATARACT; GLUTATHIONE; PROTEIN-CYSTEINE; PROTEIN-GSH; OXIDATIVE STRESS;
   RAT; AGING
ID THIOLTRANSFERASE; QUANTITATION; INVIVO; LIVER
AB To further investigate the role of protein-thiol mixed disulfides in cataractogenesis, an in vitro H2O2 cataract model was used with rat lenses to study the effect of aging, and the dynamic changes in the cortex, nucleus and the lens protein fractions. A group of lenses was exposed to H2O2-containing media (0.6 mM) for 1 to 3 days so that cortical cataract was induced gradually. Another group of lenses was first subjected to H2O2 exposure for one day and then recovered in the oxidant-free media for one or two days. These lenses were examined for the distribution of free glutathione and protein-thiol mixed disulfides (protein-glutathione and protein-cysteine) in the cortical and nuclear regions as well as in the water soluble and water insoluble fractions. Similar to the results reported earlier, the glutathione depletion in the whole lens occurred immediately and extensively during the 3-day H2O2 exposure. This loss was evenly distributed in the cortical and nuclear fractions. The level of protein-glutathione increased rapidly and continued throughout the 3 days. Most of the accumulation was found in the cortex and in both lens protein fractions. The protein-cysteine modification responded more slowly and less to oxidative stress. The delayed formation occurred mainly in the nucleus and in both lens protein fractions. In the recovery group, glutathione depletion was less drastic in the cortical and nuclear regions, but the elevated protein-glutathione in both regions and both protein fractions spontaneously decreased to its respective basal level within 1 day. Protein-cysteine on the other hand remained quite high, and in some cases it continued to rise in the absence of oxidation. Aging showed little effect on the response of rat lenses to oxidative stress. Similar patterns in glutathione and protein-thiol mixed disulfides occurred in both age groups (1, 23 months) and in both chronic oxidative stress and recovery conditions.
C1 UNIV NEBRASKA,CTR BIOTECHNOL,LINCOLN,NE 68583.
   UNIV NEBRASKA,MED CTR,DEPT OPHTHALMOL,OMAHA,NE 68198.
C3 University of Nebraska System; University of Nebraska Lincoln;
   University of Nebraska System; University of Nebraska Medical Center
RP LOU, MF (corresponding author), UNIV NEBRASKA,DEPT VET & BIOMED SCI,LINCOLN,NE 68583, USA.
FU NEI NIH HHS [EY 10595] Funding Source: Medline
CR CUI XL, 1993, EXP EYE RES, V57, P157
   GAN ZR, 1988, J BIOL CHEM, V263, P9050
   GIBLIN FJ, 1995, EXP EYE RES, V60, P219, DOI 10.1016/S0014-4835(05)80105-8
   GRAVINA SA, 1993, BIOCHEMISTRY-US, V32, P3368, DOI 10.1021/bi00064a021
   HATAKEYAMA M, 1984, J BIOCHEM, V95, P1811, DOI 10.1093/oxfordjournals.jbchem.a134794
   LOU MF, 1989, CURR EYE RES, V8, P883
   LOU MF, 1994, INVEST OPHTH VIS SCI, V35, P1569
   LOU MF, 1990, EXP EYE RES, V50, P819, DOI 10.1016/0014-4835(90)90133-F
   LOU MF, 1986, EXP EYE RES, V42, P607, DOI 10.1016/0014-4835(86)90050-3
   LOU MF, 1992, EXP EYE RES, V55, P889, DOI 10.1016/0014-4835(92)90015-K
   LOU MF, 1988, EXP EYE RES, V46, P517, DOI 10.1016/S0014-4835(88)80009-5
   MEIYAL JJ, 1991, BIOCHEMISTRY-US, V30, P6088
   PIRIE A, 1968, INVEST OPHTH VISUAL, V7, P634
   QIN C, 1993, INVEST OPHTH VIS SCI, V34, P758
   SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7
   VELTMAN J, 1993, INVEST OPHTH VIS SCI, V34, P758
   XU GT, 1992, EXP EYE RES, V54, P63, DOI 10.1016/0014-4835(92)90070-9
   YU LM, 1991, INVEST OPHTH VIS SCI, V32, P749
   ZIGLER JS, 1985, EXP EYE RES, V41, P67, DOI 10.1016/0014-4835(85)90095-8
   ZIGMAN S, 1991, INVEST OPHTH VIS SCI, V32, P1723
NR 20
TC 37
Z9 39
U1 0
U2 1
PU OXFORD UNIV PRESS UNITED KINGDOM
PI OXFORD
PA WALTON ST JOURNALS DEPT, OXFORD, ENGLAND OX2 6DP
SN 0271-3683
J9 CURR EYE RES
JI Curr. Eye Res.
PD OCT
PY 1995
VL 14
IS 10
BP 951
EP 958
DI 10.3109/02713689508995135
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA TB389
UT WOS:A1995TB38900011
PM 8549161
DA 2024-02-19
ER

PT J
AU Golabi, P
   Paik, J
   Reddy, R
   Bugianesi, E
   Trimble, G
   Younossi, ZM
AF Golabi, Pegah
   Paik, James
   Reddy, Rashmi
   Bugianesi, Elisabetta
   Trimble, Gregory
   Younossi, Zobair M.
TI Prevalence and long-term outcomes of non-alcoholic fatty liver disease
   among elderly individuals from the United States
SO BMC GASTROENTEROLOGY
LA English
DT Article
DE Epidemiology; Steatosis; Metabolic syndrome; Aging; Mortality
ID CHI-SQUARED TESTS; SERUM CREATININE; NATIONAL-HEALTH; EPIDEMIOLOGY;
   CALIBRATION; POPULATION; FIBROSIS; EQUATION
AB Background: The prevalence and outcomes of non-alcoholic fatty liver disease (NAFLD) among elderly have not been well described. Our aim was to assess the prevalence, risk factors and mortality of NAFLD in individuals older than 60 years.
   Methods: The data from the Third National Health and Nutrition Examination Survey with linked mortality files were utilized. NAFLD was defined by United States Fatty Liver Index in the absence of other causes of liver disease. Cox proportional hazards models were used to assess all-cause and cardiovascular (CV) mortality. All analyses were performed using SAS software.
   Results: Three thousand two hundred seventy-one NHANES-III participants were included. The prevalence rates from NAFLD were 40.3% (95% CI: 37.2-43.5%) and 39.2% (95% CI: 34.4-44.0%) among 60-74 and > 74 years old. Among aged 60-74, the risks for 5-year and 10-year all-cause mortality were associated with presence of NAFLD [adjusted hazard ratios: 1.60 (95% CI: 1.24-1.96) for 5-year and 1.22 (95%CI: 1.01-1.49) for 10-year]. CV mortality were higher in this group were (aHR: 2.12 (95% CI: 1.20-3.75) for 5-year and 1.06 (95%CI: 0.73-1.52) for 10-year]. In contrast, in individuals > 74 years old, diagnosis of NAFLD was not associated with all-cause or CVD mortality.
   Conclusions: NAFLD is common among elderly population. Although NAFLD is associated with increased risk of mortality for 60-74-year-old individuals, this risk was not increased in those older than 74 years.
C1 [Golabi, Pegah; Paik, James; Younossi, Zobair M.] Inova Hlth Syst, Betty & Guy Beatty Ctr Integrated Res, Claude Moore Hlth Educ & Res Bldg,3300 Gallows Rd, Falls Church, VA 22042 USA.
   [Bugianesi, Elisabetta] Univ Torino, Dept Med Sci, Citta Salute & Sci, Turin, Italy.
   [Reddy, Rashmi; Trimble, Gregory; Younossi, Zobair M.] Inova Fairfax Med Campus, Ctr Liver Dis, Falls Church, VA 22042 USA.
   [Reddy, Rashmi; Trimble, Gregory; Younossi, Zobair M.] Inova Fairfax Med Campus, Dept Med, Falls Church, VA 22042 USA.
C3 Inova Health System; A.O.U. Citta della Salute e della Scienza di
   Torino; University of Turin; Inova Fairfax Hospital; Inova Fairfax
   Hospital
RP Younossi, ZM (corresponding author), Inova Hlth Syst, Betty & Guy Beatty Ctr Integrated Res, Claude Moore Hlth Educ & Res Bldg,3300 Gallows Rd, Falls Church, VA 22042 USA.; Younossi, ZM (corresponding author), Inova Fairfax Med Campus, Ctr Liver Dis, Falls Church, VA 22042 USA.; Younossi, ZM (corresponding author), Inova Fairfax Med Campus, Dept Med, Falls Church, VA 22042 USA.
EM zobair.younossi@inova.org
RI Younossi, Zobair M./JRY-9916-2023
OI Golabi, Pegah/0000-0001-9818-0983
FU Betty and Guy Beatty Center for Integrated Research Fund, Inova Health
   System, Falls Church, VA
FX This study was supported by the Betty and Guy Beatty Center for
   Integrated Research Fund, Inova Health System, Falls Church, VA.
CR Allison PD, 1995, A PRACTICAL GUIDE
   Amarapurkar D, 2007, ANN HEPATOL, V6, P161, DOI 10.1016/S1665-2681(19)31922-2
   Angulo P, 2007, HEPATOLOGY, V45, P846, DOI 10.1002/hep.21496
   [Anonymous], 1994, Vital Health Stat 1, P1
   [Anonymous], 2017, CENSUS BUREAU REPORT
   [Anonymous], 2013, NCHS 2011 LINK MORT
   [Anonymous], 2015, AACE ACE GUID
   Attar BM, 2013, SCI WORLD J, DOI 10.1155/2013/481893
   Ballestri S, 2016, HEPATOL RES, V46, P1074, DOI 10.1111/hepr.12656
   Ballestri S, 2016, J GASTROEN HEPATOL, V31, P936, DOI 10.1111/jgh.13264
   Bertolotti M, 2014, WORLD J GASTROENTERO, V20, P14185, DOI 10.3748/wjg.v20.i39.14185
   Browning JD, 2004, HEPATOLOGY, V40, P1387, DOI 10.1002/hep.20466
   Browning MG, 2018, INT J OBESITY, V42, P926, DOI 10.1038/ijo.2017.309
   Chalasani NP, 2017, HEPATOLOGY, V66, p303A
   Coresh J, 2002, AM J KIDNEY DIS, V39, P920, DOI 10.1053/ajkd.2002.32765
   Frith J, 2009, GERONTOLOGY, V55, P607, DOI 10.1159/000235677
   Goff DC, 2014, CIRCULATION, V129, pS49, DOI [10.1161/01.cir.0000437741.48606.98, 10.1016/j.jacc.2013.11.005]
   Golabi P, 2018, MEDICINE, V97, DOI [10.1097/MD.0000000000010214, 10.1097/md.0000000000010214]
   Golabi P, 2016, WORLD J GASTROENTERO, V22, P6318, DOI 10.3748/wjg.v22.i27.6318
   Hossain N, 2009, CLIN GASTROENTEROL H, V7, P1224, DOI 10.1016/j.cgh.2009.06.007
   Kagansky N, 2004, LIVER INT, V24, P588, DOI 10.1111/j.1478-3231.2004.0969.x
   Koehler EM, 2012, J HEPATOL, V57, P1305, DOI 10.1016/j.jhep.2012.07.028
   Levey AS, 2006, ANN INTERN MED, V145, P247, DOI 10.7326/0003-4819-145-4-200608150-00004
   Levey AS, 2009, ANN INTERN MED, V150, P604, DOI 10.7326/0003-4819-150-9-200905050-00006
   Lonardo A, 2006, WORLD J GASTROENTERO, V12, P5826, DOI 10.3748/wjg.v12.i36.5826
   Lonardo A, 2017, WORLD J GASTROENTERO, V23, P6571, DOI 10.3748/wjg.v23.i36.6571
   Lonardo A, 2015, DIGEST LIVER DIS, V47, P181, DOI 10.1016/j.dld.2014.09.020
   National Center for Health Statistics, NCHS 2011 LINK PUBL
   National Health and Nutrition Examination Survey, 3 NAT HLTH NUTR EX S
   Noureddin M, 2013, HEPATOLOGY, V58, P1644, DOI 10.1002/hep.26465
   Park SH, 2006, J GASTROEN HEPATOL, V21, P138, DOI 10.1111/j.1440-1746.2005.04086.x
   Portillo-Sanchez P, 2015, J CLIN ENDOCR METAB, V100, P2231, DOI 10.1210/jc.2015-1966
   Rafiq N, 2009, CLIN GASTROENTEROL H, V7, P234, DOI 10.1016/j.cgh.2008.11.005
   RAO JNK, 1981, J AM STAT ASSOC, V76, P221, DOI 10.2307/2287815
   RAO JNK, 1984, ANN STAT, V12, P46, DOI 10.1214/aos/1176346391
   Ruhl CE, 2015, ALIMENT PHARM THER, V41, P65, DOI 10.1111/apt.13012
   Sayiner M, 2016, CLIN LIVER DIS, V20, P205, DOI 10.1016/j.cld.2015.10.001
   Selvin E, 2007, AM J KIDNEY DIS, V50, P918, DOI 10.1053/j.ajkd.2007.08.020
   Sheedfar F, 2013, AGING CELL, V12, P950, DOI 10.1111/acel.12128
   Wai CT, 2003, HEPATOLOGY, V38, P518, DOI 10.1053/jhep.2003.50346
   Wallace TM, 2004, DIABETES CARE, V27, P1487, DOI 10.2337/diacare.27.6.1487
   Williams CD, 2011, GASTROENTEROLOGY, V140, P124, DOI 10.1053/j.gastro.2010.09.038
   Wolter KM, 2007, STAT SOC BEHAV SC, P1, DOI 10.1007/978-0-387-35099-8
   Younossi Z, 2019, CLIN GASTROENTEROL H, V17, P748, DOI 10.1016/j.cgh.2018.05.057
   Younossi ZM, 2018, HEPATOLOGY, V68, P349, DOI 10.1002/hep.29721
   Younossi ZM, 2015, HEPATOLOGY, V62, p739A
   Younossi ZM, 2013, METABOLISM, V62, P352, DOI 10.1016/j.metabol.2012.08.005
NR 47
TC 60
Z9 62
U1 1
U2 5
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-230X
J9 BMC GASTROENTEROL
JI BMC Gastroenterol.
PD APR 16
PY 2019
VL 19
AR 56
DI 10.1186/s12876-019-0972-6
PG 8
WC Gastroenterology & Hepatology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Gastroenterology & Hepatology
GA HT9FN
UT WOS:000464873100004
PM 30991959
OA gold, Green Published
DA 2024-02-19
ER

PT J
AU Tsutsui, A
   Ogura, A
   Tahara, T
   Nozaki, S
   Urano, S
   Hara, M
   Kojima, S
   Kurbangalieva, A
   Onoe, H
   Watanabe, Y
   Taniguchi, N
   Tanaka, K
AF Tsutsui, Ayumi
   Ogura, Akihiro
   Tahara, Tsuyoshi
   Nozaki, Satoshi
   Urano, Sayaka
   Hara, Mitsuko
   Kojima, Soichi
   Kurbangalieva, Almira
   Onoe, Hirotaka
   Watanabe, Yasuyoshi
   Taniguchi, Naoyuki
   Tanaka, Katsunori
TI <i>In vivo</i> imaging of advanced glycation end products (AGEs) of
   albumin: first observations of significantly reduced clearance and liver
   deposition properties in mice
SO ORGANIC & BIOMOLECULAR CHEMISTRY
LA English
DT Article
ID SCAVENGER-RECEPTOR; BIODISTRIBUTION; ENDPRODUCTS; EXPRESSION;
   GLYCOTOXINS; PROTEINS; KINETICS; PROBES; MODEL
AB Advanced glycation end products (AGEs) are associated with various diseases, especially during aging and the development of diabetes and uremia. To better understand these biological processes, investigation of the in vivo kinetics of AGEs, i.e., analysis of trafficking and clearance properties, was carried out by molecular imaging. Following the preparation of Cy7.5-labeled AGE-albumin and intravenous injection in BALB/cA-nu/nu mice, noninvasive fluorescence kinetics analysis was performed. In vivo imaging and fluorescence microscopy analysis revealed that non-enzymatic AGEs were smoothly captured by scavenger cells in the liver, i.e., Kupffer and other sinusoidal cells, but were unable to be properly cleared from the body. Overall, these results highlight an important link between AGEs and various disorders associated with them, which may serve as a platform for future research to better understand the processes and mechanisms of these disorders.
C1 [Tsutsui, Ayumi; Ogura, Akihiro; Urano, Sayaka; Tanaka, Katsunori] RIKEN, Biofunct Synthet Chem Lab, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.
   [Tahara, Tsuyoshi; Nozaki, Satoshi; Onoe, Hirotaka; Watanabe, Yasuyoshi] RIKEN Ctr Life Sci Technol, Chuo Ku, 6-7-3 Minatojima Minamimachi, Kobe, Hyogo 6500047, Japan.
   [Hara, Mitsuko; Kojima, Soichi] RIKEN Ctr Life Sci Technol, Microsignaling Regulat Technol Unit, Wako, Saitama 3510198, Japan.
   [Kurbangalieva, Almira; Tanaka, Katsunori] Kazan Fed Univ, A Butlerov Inst Chem, Biofunct Chem Lab, 18 Kremlyovskaya St, Kazan 420008, Russia.
   [Taniguchi, Naoyuki] RIKEN, RIKEN Max Planck Joint Res Ctr Syst Chem Biol, Global Res Cluster, Dis Glyc Team, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.
   [Tanaka, Katsunori] Japan Sci & Technol Agcy PRESTO, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.
C3 RIKEN; RIKEN; RIKEN; Kazan Federal University; RIKEN
RP Tanaka, K (corresponding author), RIKEN, Biofunct Synthet Chem Lab, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.; Tanaka, K (corresponding author), Kazan Fed Univ, A Butlerov Inst Chem, Biofunct Chem Lab, 18 Kremlyovskaya St, Kazan 420008, Russia.; Tanaka, K (corresponding author), Japan Sci & Technol Agcy PRESTO, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.
EM kotzenori@riken.jp
RI Taniguchi, Naoyuki/A-7086-2016; Nozaki, Satoshi/E-3052-2010; Tanaka,
   Katsunori/N-5072-2015; Taniguchi, Naoyuki/I-4182-2014; Katsunori,
   Tanaka/AAJ-3284-2020; Kurbangalieva, Almira/F-9081-2014
OI Nozaki, Satoshi/0000-0002-9526-1902; Tanaka,
   Katsunori/0000-0001-6932-4802; Taniguchi, Naoyuki/0000-0001-5889-5968;
   Ogura, Akihiro/0000-0002-4793-5706; Tsutsui, Ayumi/0000-0002-4403-2376
FU Japan Society for the Promotion of Science [22651081, 23681047,
   25560410, 26560438]; Mizutani Foundation for Glycoscience; MEXT
   [26102743, 15H05843]; AstraZeneca; Russian Government; Grants-in-Aid for
   Scientific Research [16H03287, 15H05843, 15H04700, 26560438, 15K14481,
   22651081, 25560410] Funding Source: KAKEN
FX This work was supported by Grants-in-Aid for Scientific Research from
   the Japan Society for the Promotion of Science (22651081, 23681047,
   25560410, and 26560438), a Research Grant from the Mizutani Foundation
   for Glycoscience, MEXT Grants-in-Aid for Scientific Research on
   Innovative Areas (No. 26102743 and 15H05843), and an AstraZeneca R&D
   Grant. This work was also performed with the support of the Russian
   Government Program for Competitive Growth, granted to the Kazan Federal
   University.
CR Ametamey SM, 2008, CHEM REV, V108, P1501, DOI 10.1021/cr0782426
   AUSTYN JM, 1981, EUR J IMMUNOL, V11, P805, DOI 10.1002/eji.1830111013
   Bergmann R, 2001, NAHRUNG, V45, P182, DOI 10.1002/1521-3803(20010601)45:3&lt;182::AID-FOOD182&gt;3.0.CO;2-Q
   BROWNLEE M, 1980, DIABETES, V29, P1044, DOI 10.2337/diabetes.29.12.1044
   Carreira CM, 2001, CANCER RES, V61, P8079
   Cerami A., 1985, CELLULAR MOL ASPECTS, P79
   Hansen B, 2002, DIABETOLOGIA, V45, P1379, DOI 10.1007/s00125-002-0912-8
   Henle T, 2005, AMINO ACIDS, V29, P313, DOI 10.1007/s00726-005-0200-2
   Hoppmann S, 2008, PROTEIN EXPRES PURIF, V57, P143, DOI 10.1016/j.pep.2007.10.009
   Hultsch C, 2006, NUCL MED BIOL, V33, P865, DOI 10.1016/j.nucmedbio.2006.07.007
   Hyogo H, 2008, CURR PHARM DESIGN, V14, P969, DOI 10.2174/138161208784139701
   Kita K, 2011, ANIM SCI J, V82, P291, DOI 10.1111/j.1740-0929.2010.00837.x
   Lin RY, 2003, ATHEROSCLEROSIS, V168, P213, DOI 10.1016/S0021-9150(03)00050-9
   McCann TE, 2010, BIOCONJUGATE CHEM, V21, P1925, DOI 10.1021/bc100313p
   Naito Makoto, 2004, Medical Electron Microscopy, V37, P16, DOI 10.1007/s00795-003-0228-x
   Ogura A, 2016, SCI REP-UK, V6, DOI 10.1038/srep21797
   Ogura A, 2014, GLYCOCONJUGATE J, V31, P273, DOI 10.1007/s10719-014-9520-3
   Perkins BA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035655
   Petrov S, 2009, BIOTECHNOL BIOTEC EQ, V23, P1058, DOI 10.1080/13102818.2009.10817612
   Putta S., 2014, J GLOBAL TRENDS PHAR, V5, P1729
   Semba RD, 2010, J RENAL NUTR, V20, P74, DOI 10.1053/j.jrn.2009.08.001
   Singh R, 2001, DIABETOLOGIA, V44, P129, DOI 10.1007/s001250051591
   Smedsrod B, 1997, BIOCHEM J, V322, P567, DOI 10.1042/bj3220567
   STEVENS VJ, 1977, J BIOL CHEM, V252, P2998
   Suzuki M, 2000, B CHEM SOC JPN, V73, P1053, DOI 10.1246/bcsj.73.1053
   TAKATA K, 1988, J BIOL CHEM, V263, P14819
   Tanaka K, 2008, ORG BIOMOL CHEM, V6, P815, DOI 10.1039/b718157b
   Tekabe Y, 2013, EJNMMI RES, V3, DOI 10.1186/2191-219X-3-37
   Uribarri J, 2007, J GERONTOL A-BIOL, V62, P427, DOI 10.1093/gerona/62.4.427
   Wang X, 2015, IN VITRO CELL DEV-AN, V51, P204, DOI 10.1007/s11626-014-9823-5
   Wang ZQ, 2012, ATHEROSCLEROSIS, V221, P387, DOI 10.1016/j.atherosclerosis.2012.01.019
   Wei Y, 2009, BMC CELL BIOL, V10, DOI 10.1186/1471-2121-10-10
   Xu H., 2011, J RENAL NUTR, V21, P329
   Xu HZ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057897
   YOKOI Y, 1984, HEPATOLOGY, V4, P709, DOI 10.1002/hep.1840040425
   Zheng F, 2002, DIABETES-METAB RES, V18, P224, DOI 10.1002/dmrr.283
NR 36
TC 4
Z9 6
U1 1
U2 22
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 1477-0520
EI 1477-0539
J9 ORG BIOMOL CHEM
JI Org. Biomol. Chem.
PY 2016
VL 14
IS 24
BP 5755
EP 5760
DI 10.1039/c6ob00098c
PG 6
WC Chemistry, Organic
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Chemistry
GA DQ1AQ
UT WOS:000378933400055
PM 26932508
DA 2024-02-19
ER

PT J
AU Caro, P
   Gómez, J
   López-Torres, M
   Sánchez, I
   Naudí, A
   Jove, M
   Pamplona, R
   Barja, G
AF Caro, Pilar
   Gomez, Jose
   Lopez-Torres, Monica
   Sanchez, Ines
   Naudi, Alba
   Jove, Mariona
   Pamplona, Reinald
   Barja, Gustavo
TI Forty percent and eighty percent methionine restriction decrease
   mitochondrial ROS generation and oxidative stress in rat liver
SO BIOGERONTOLOGY
LA English
DT Article
DE mitochondria; caloric restriction; aging; oxygen radicals; longevity;
   protein damage; fatty acids; respiratory complexes
ID FREE-RADICAL GENERATION; MAXIMUM LIFE-SPAN; CALORIC RESTRICTION;
   COMPLEX-I; DNA-DAMAGE; DROSOPHILA-MELANOGASTER; PROTEIN RESTRICTION;
   DIETARY-COMPONENTS; HYDROGEN-PEROXIDE; F344 RATS
AB Dietary restriction (DR) lowers mitochondrial reactive oxygen species (ROS) generation and oxidative damage and increases maximum longevity in rodents. Protein restriction (PR) or methionine restriction (MetR), but not lipid or carbohydrate restriction, also cause those kinds of changes. However, previous experiments of MetR were performed only at 80% MetR, and substituting dietary methionine with glutamate in the diet. In order to clarify if MetR can be responsible for the lowered ROS production and oxidative stress induced by standard (40%) DR, Wistar rats were subjected to 40% or 80% MetR without changing other dietary components. It was found that both 40% and 80% MetR decrease mitochondrial ROS generation and percent free radical leak in rat liver mitochondria, similarly to what has been previously observed in 40% PR and 40% DR. The concentration of complexes I and III, apoptosis inducing factor, oxidative damage to mitochondrial DNA, five different markers of protein oxidation, glycoxidation or lipoxidation and fatty acid unsaturation were also lowered. The results show that 40% isocaloric MetR is enough to decrease ROS production and oxidative stress in rat liver. This suggests that the lowered intake of methionine is responsible for the decrease in oxidative stress observed in DR.
C1 [Caro, Pilar; Gomez, Jose; Lopez-Torres, Monica; Sanchez, Ines; Barja, Gustavo] Univ Complutense, Fac Ciencias Biol, Dept Fisiol Anim II, E-28040 Madrid, Spain.
   [Naudi, Alba; Jove, Mariona; Pamplona, Reinald] Univ Lleida IRBLLEIDA, Dept Expt Med, Lleida 25008, Spain.
C3 Complutense University of Madrid; Universitat de Lleida
RP Barja, G (corresponding author), Univ Complutense, Fac Ciencias Biol, Dept Fisiol Anim II, C-Jose Antonio Novais-2, E-28040 Madrid, Spain.
EM gbarja@bio.ucm.es
RI Barja, Gustavo/AAA-5903-2019; Font, Mariona Jove/C-5741-2011; Gomez,
   Jose/G-9705-2015; Jové, Mariona/M-9104-2016; Gustavo, Barja/B-5591-2012;
   Naudí, Alba/B-5594-2009; Pamplona, Reinald/A-7359-2010
OI Barja, Gustavo/0000-0001-5736-4735; Gomez, Jose/0000-0003-1758-4746;
   Jové, Mariona/0000-0001-5577-6162; Naudí, Alba/0000-0003-0699-1004;
   Pamplona, Reinald/0000-0003-4337-6107; Sanchez-Roman,
   Ines/0000-0003-4844-5781; Caro, Pilar/0000-0002-7531-3234
CR Ayala V, 2007, J GERONTOL A-BIOL, V62, P352, DOI 10.1093/gerona/62.4.352
   Barja G, 1998, J BIOENERG BIOMEMBR, V30, P235, DOI 10.1023/A:1020592719405
   Barja G, 2002, J BIOENERG BIOMEMBR, V34, P227, DOI 10.1023/A:1016039604958
   Barja G, 2004, TRENDS NEUROSCI, V27, P595, DOI 10.1016/j.tins.2004.07.005
   Beckman KB, 1998, PHYSIOL REV, V78, P547, DOI 10.1152/physrev.1998.78.2.547
   BOVERIS A, 1976, BIOCHEM J, V156, P435, DOI 10.1042/bj1560435
   Curran SP, 2007, PLOS GENET, V3, DOI 10.1371/journal.pgen.0030056
   DeLaAsuncion JG, 1996, FASEB J, V10, P333, DOI 10.1096/fasebj.10.2.8641567
   Dillin A, 2002, SCIENCE, V298, P2398, DOI 10.1126/science.1077780
   Dröge W, 2002, PHYSIOL REV, V82, P47, DOI 10.1152/physrev.00018.2001
   Durand P, 2001, LAB INVEST, V81, P645, DOI 10.1038/labinvest.3780275
   Genova ML, 2001, FEBS LETT, V505, P364, DOI 10.1016/S0014-5793(01)02850-2
   Gómez J, 2007, BIOGERONTOLOGY, V8, P555, DOI 10.1007/s10522-007-9099-1
   Gredilla R, 2005, ENDOCRINOLOGY, V146, P3713, DOI 10.1210/en.2005-0378
   Gredilla R, 2001, FASEB J, V15, P1589, DOI 10.1096/fj.00-0764fje
   Gredilla R, 2001, J BIOENERG BIOMEMBR, V33, P279, DOI 10.1023/A:1010603206190
   Hulbert AJ, 2007, PHYSIOL REV, V87, P1175, DOI 10.1152/physrev.00047.2006
   IWASAKI K, 1988, J GERONTOL, V43, pB13, DOI 10.1093/geronj/43.1.B13
   KHORAKOVA M, 1990, Fiziologicheskii Zhurnal (Kiev), V36, P16
   Komninou D, 2006, NUTR CANCER, V54, P202, DOI 10.1207/s15327914nc5402_6
   Kruman II, 2002, J NEUROSCI, V22, P1752, DOI 10.1523/JNEUROSCI.22-05-01752.2002
   Kruman II, 2000, J NEUROSCI, V20, P6920, DOI 10.1523/JNEUROSCI.20-18-06920.2000
   Lambert AJ, 2007, AGING CELL, V6, P607, DOI 10.1111/j.1474-9726.2007.00312.x
   LATORRE A, 1986, P NATL ACAD SCI USA, V83, P8649, DOI 10.1073/pnas.83.22.8649
   Lee SS, 2003, NAT GENET, V33, P40, DOI 10.1038/ng1056
   Loft S, 1999, METHOD ENZYMOL, V300, P166
   Mair W, 2005, PLOS BIOL, V3, P1305, DOI 10.1371/journal.pbio.0030223
   Malloy VL, 2006, AGING CELL, V5, P305, DOI 10.1111/j.1474-9726.2006.00220.x
   MASORO EJ, 1989, AM J CLIN NUTR, V49, P1217
   Miller RA, 2005, AGING CELL, V4, P119, DOI 10.1111/j.1474-9726.2005.00152.x
   Min KJ, 2006, MECH AGEING DEV, V127, P643, DOI 10.1016/j.mad.2006.02.005
   Mori N, 2000, J NUTR, V130, P2349, DOI 10.1093/jn/130.9.2349
   Ninomiya T, 2004, AM J KIDNEY DIS, V44, P437, DOI [10.1016/S0272-6386(04)00813-3, 10.1053/j.ajkd.2004.05.024]
   Pamplona R, 2005, J BIOL CHEM, V280, P21522, DOI 10.1074/jbc.M502255200
   Pamplona R, 2002, ANN NY ACAD SCI, V959, P475, DOI 10.1111/j.1749-6632.2002.tb02118.x
   Pamplona R, 2002, MECH AGEING DEV, V123, P1437, DOI 10.1016/S0047-6374(02)00076-3
   Pamplona R, 2002, FREE RADICAL RES, V36, P47, DOI 10.1080/10715760210165
   Pamplona R, 2006, BBA-BIOENERGETICS, V1757, P496, DOI 10.1016/j.bbabio.2006.01.009
   Pavillard V, 2006, BIOCHEM PHARMACOL, V71, P772, DOI 10.1016/j.bcp.2005.12.014
   Porter AG, 2006, BIOESSAYS, V28, P834, DOI 10.1002/bies.20444
   REGINA M, 1993, ARCH BIOCHEM BIOPHYS, V300, P598, DOI 10.1006/abbi.1993.1083
   RICHIE JP, 1994, FASEB J, V8, P1302, DOI 10.1096/fasebj.8.15.8001743
   Robert KA, 2007, AGING CELL, V6, P395, DOI 10.1111/j.1474-9726.2007.00287.x
   Sanz A, 2006, J BIOENERG BIOMEMBR, V38, P327, DOI 10.1007/s10863-006-9051-0
   Sanz A, 2004, J BIOENERG BIOMEMBR, V36, P545, DOI 10.1007/s10863-004-9001-7
   Sanz A, 2006, HDB MODELS HUMAN AGI, P183
   Sanz A, 2006, ANN NY ACAD SCI, V1067, P200, DOI 10.1196/annals.1354.024
   Sanz A, 2006, FASEB J, V20, P1064, DOI 10.1096/fj.05-5568com
   Shimokawa I, 1996, AGING-CLIN EXP RES, V8, P254, DOI 10.1007/BF03339576
   Stefanello FM, 2005, INT J DEV NEUROSCI, V23, P651, DOI 10.1016/j.ijdevneu.2005.06.003
   Stubbs AK, 2002, J ENDOCRINOL, V174, DOI 10.1677/joe.0.1740335
   Taylor ER, 2003, J BIOL CHEM, V278, P19603, DOI 10.1074/jbc.M209359200
   Troen AM, 2007, AGE, V29, P29, DOI 10.1007/s11357-006-9018-4
   Vahsen N, 2004, EMBO J, V23, P4679, DOI 10.1038/sj.emboj.7600461
   VELEZCARRASCO W, 2008, J NUTR BIOCH    0816
   Verhoef P, 2005, AM J CLIN NUTR, V82, P553, DOI 10.1093/ajcn/82.3.553
   Weindruch R, 2003, CLIN NEUROSCI RES, V2, P279, DOI 10.1016/S1566-2772(03)00004-5
   Zimmerman JA, 2003, EXP GERONTOL, V38, P47, DOI 10.1016/S0531-5565(02)00149-3
NR 58
TC 95
Z9 104
U1 1
U2 12
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1389-5729
EI 1573-6768
J9 BIOGERONTOLOGY
JI Biogerontology
PD JUN
PY 2008
VL 9
IS 3
BP 183
EP 196
DI 10.1007/s10522-008-9130-1
PG 14
WC Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Geriatrics & Gerontology
GA 297JV
UT WOS:000255613900006
PM 18283555
DA 2024-02-19
ER

PT J
AU RAFAL, ES
   GRIFFITHS, CEM
   DITRE, CM
   FINKEL, LJ
   HAMILTON, TA
   ELLIS, CN
   VOORHEES, JJ
AF RAFAL, ES
   GRIFFITHS, CEM
   DITRE, CM
   FINKEL, LJ
   HAMILTON, TA
   ELLIS, CN
   VOORHEES, JJ
TI TOPICAL TRETINOIN (RETINOIC ACID) TREATMENT FOR LIVER SPOTS ASSOCIATED
   WITH PHOTODAMAGE
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Article
ID PHOTOAGED SKIN; VITAMIN-A; MELANOMA; THERAPY
AB Background. The hyperpigmented lesions commonly called liver spots distress patients, in part because such lesions are associated with aging. We investigated their treatment with topical 0.1 percent tretinoin (retinoic acid).
   Methods. Fifty-eight patients completed a 10-month randomized, double-blind study in which they applied either 0.1 percent tretinoin (n = 28) or vehicle (n = 30) cream daily to the face, upper extremities, or both. Fifteen patients who responded well were then randomly assigned to continue tretinoin therapy or use vehicle alone for six more months. Patients were evaluated by physical examination every month and by analysis of biopsy specimens of lesions obtained at base line and at the end of the 10-month trial.
   Results. After one month of treatment the patients treated with tretinoin had significant lightening of hyperpigmented lesions as compared with the patients who received vehicle (P < 0.002). After 10 months, 20 (83 percent) of the 24 patients with facial lesions who were treated with tretinoin had lightening of these lesions, as compared with 8 (29 percent) of the 28 patients with facial lesions who received vehicle. The results for lesions of the upper extremities were similar. As compared with vehicle, tretinoin caused a significant decrease in the degree of epidermal pigmentation and increases in the degree of compaction of stratum corneum, thickness of the granular cell layer, and epidermal thickness. Reductions in epidermal pigmentation evident on histologic analysis were significantly correlated with the degree of clinical lightening of lesions (r = -0.53, P < 0.0001). During the 6-month follow-up study, specifically identified lesions that had disappeared during the first 10 months of tretinoin treatment did not return in any patient, and six of seven patients who continued to use tretinoin had further improvement.
   Conclusions. Topical 0.1 percent tretinoin significantly improves both clinical and microscopical manifestations of liver spots; these lesions do not return for at least six months after therapy is discontinued.
C1 UNIV MICHIGAN,MED CTR,DEPT DERMATOL,DERMATOPHARMACOL UNIT,1910 TAUBMAN CTR,1500 E MED CTR DR,ANN ARBOR,MI 48109.
C3 University of Michigan System; University of Michigan
RI Griffiths, Charlotte/JQV-8476-2023; Ellis, Charles/ABA-7264-2021;
   Griffiths, Christopher E.M./P-5448-2014
OI Ellis, Charles/0000-0001-9436-7628; Griffiths, Christopher
   E.M./0000-0001-5371-4427
CR BHAWAN J, 1991, ARCH DERMATOL, V127, P666, DOI 10.1001/archderm.127.5.666
   BOLLAG W, 1970, Agents and Actions, V1, P172, DOI 10.1007/BF01965758
   BOLLAG W, 1983, LANCET, V1, P860
   CAPUTO R, 1990, BRIT J DERMATOL, V122, P97, DOI 10.1111/j.1365-2133.1990.tb16133.x
   ELLIS CN, 1990, J AM ACAD DERMATOL, V23, P629, DOI 10.1016/0190-9622(90)70265-J
   FISHER GJ, 1991, J INVEST DERMATOL, V96, P699, DOI 10.1111/1523-1747.ep12470632
   GOLDFARB MT, 1989, J AM ACAD DERMATOL, V21, P645, DOI 10.1016/S0190-9622(89)70232-2
   HAAS AA, 1986, J AM ACAD DERMATOL, V15, P870, DOI 10.1016/S0190-9622(86)70244-2
   HODGSON C, 1963, ARCH DERMATOL, V87, P197, DOI 10.1001/archderm.1963.01590140059010
   KLIGMAN AM, 1989, J AM ACAD DERMATOL, V21, P650, DOI 10.1016/S0190-9622(89)70233-4
   KLIGMAN AM, 1986, J AM ACAD DERMATOL, V15, P836, DOI 10.1016/S0190-9622(86)70242-9
   KURKA M, 1978, HAUTARZT, V1729, P313
   LEVINE N, 1980, LANCET, V2, P224
   LOBER CW, 1987, J AM ACAD DERMATOL, V17, P109, DOI 10.1016/S0190-9622(87)70181-9
   MARKS R, 1990, BRIT J DERMATOL, V122, P93, DOI 10.1111/j.1365-2133.1990.tb16132.x
   MEYSKENS FL, 1982, J AM ACAD DERMATOL, V6, P824, DOI 10.1016/S0190-9622(82)70072-6
   MEYSKENS FL, 1986, J AM ACAD DERMATOL, V15, P822, DOI 10.1016/S0190-9622(86)70239-9
   ORLOW SJ, 1990, J INVEST DERMATOL, V94, P461, DOI 10.1111/1523-1747.ep12874568
   PECK GL, 1986, J AM ACAD DERMATOL, V15, P829, DOI 10.1016/S0190-9622(86)70241-7
   SILVERMAN AK, 1987, J AM ACAD DERMATOL, V16, P1027, DOI 10.1016/S0190-9622(87)70133-9
   WEINSTEIN GD, 1991, ARCH DERMATOL, V127, P659, DOI 10.1001/archderm.127.5.659
   WEISS JS, 1988, JAMA-J AM MED ASSOC, V259, P527, DOI 10.1001/jama.259.4.527
   Weiss JS, 1988, JAMA-J AM MED ASSOC, V260, P926
   WEISS JS, 1988, JAMA-J AM MED ASSOC, V259, P3274
NR 24
TC 115
Z9 121
U1 0
U2 5
PU MASS MEDICAL SOC
PI BOSTON
PA 10 SHATTUCK, BOSTON, MA 02115
SN 0028-4793
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD FEB 6
PY 1992
VL 326
IS 6
BP 368
EP 374
DI 10.1056/NEJM199202063260603
PG 7
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA HC386
UT WOS:A1992HC38600003
PM 1729619
OA Bronze
DA 2024-02-19
ER

PT J
AU Wang, L
   Zhang, LY
   Wang, JY
   Li, J
   Ding, J
   He, XD
AF Wang, Liang
   Zhang, Lingyi
   Wang, Junyan
   Li, Juan
   Ding, Jie
   He, Xiaodong
TI Protective Effect of Dandelion Leaf Water Extracts on APAP-Induced Liver
   Injury in Rats and Its Mechanism
SO CELLULAR AND MOLECULAR BIOLOGY
LA English
DT Article
DE dandelion leaf water extract; APAP; rats; drug-induced liver injury;
   oxidative stress; apoptosis; MAPK; NF-?B p65
ID ACETAMINOPHEN-INDUCED HEPATOTOXICITY; OXIDATIVE STRESS; TARAXACUM;
   RADICALS; ACID; MICE
AB With the advent of a large number of drugs in recent years and the aggravation of human aging, drug -induced liver injury is increasing year by year. The protective effect of dandelion extract on acetaminophen (APAP) -induced drug-induced liver injury in rats and its specific mechanism was studied by in vitro cell culture. For this aim, twenty healthy SD rats with the same physiological status were divided into model group and normal group, with 10 rats in each group. The drug-induced liver injury model was made by intragastric administration of 1 g/kg APAP for 14 days. The liver function lactate dehydrogenase (LDH), aspartate aminotransferase (AST) and alanine aminotransferase (ALT) were detected to verify the success of the model. After that, the liver tissues were aseptically isolated from the normal group and APAP model group, and the primary hepatocytes were cultured. They were divided into control group (control), liver injury model group (model), medium-dose dandelion extract group (1mm dlwe) and high dose dandelion extract group (2mm dlwe). The cell proliferation activity was detected by CCK-8 cell proliferation activity kit. Cell samples were collected at 72 hours to detect the contents of AST and ALT in cell supernatant. The contents of oxidative stress-activated oxygen (ROS), reduced glutathione (GSH) and glutathione peroxidase (GSH-Px) were detected by colorimetry, and the apoptosis was detected by flow cytometry. Inflammatory factors, key genes of liver injury, drug metabolic enzymes cytochrome P450 2E1 (CYP2E1), mitogen-activated protein kinase (MAPK) and nuclear transcription factors were detected by RT-PCR-kappa B (NF- kappa B) P65 signaling pathway-related gene expression level. Finally, the expression of CYP2E1, MAPK and NF-kB signaling pathways were analyzed by Western blot. Results showed that Serum ast, ALT and LDH increased (P < 0.05), suggesting that the liver injury model was successful. The hepatocytes in the normal group were oval, flat, evenly distributed and well adhered to the wall. The liver injury model group had more suspended cells, pseudopodia, polygonal and poor growth state. The cells in the medium-dose dandelion extract group (1mm dlwe) and high dose dandelion extract group (2 mm dlwe) adhered well, mostly oval, similar to the normal group and grew well. CCK8 found that the cells in the model group decreased significantly, the proliferation activity decreased significantly, the ast, alt, LDH and ROS in the cell supernatant of the model group increased compared with other groups (P < 0.05), and the contents of GSH and GSH PX decreased (P < 0.05). Apoptotic cells in the model group increased, and TNF in the model group-alpha, COX-2, CYP2E1, MAPK, JNK and NF KB p65 increased (P < 0.05). CYP2E1, MAPK and NF KB p65 increased in the model group (P < 0.05). Copyright: (C) 2022 by the C.M.B. Association. All rights reserved.
C1 [Wang, Liang; Zhang, Lingyi; Li, Juan; Ding, Jie] Lanzhou Univ, Dept liver Dis, Hosp 2, Lanzhou 730030, Peoples R China.
   [Wang, Junyan] Lanzhou Univ, Dept Neonatol, Hosp 2, Lanzhou 730030, Peoples R China.
   [He, Xiaodong] Lanzhou Univ, Dept Gen Surg, Hosp 2, Lanzhou 730030, Peoples R China.
C3 Lanzhou University; Lanzhou University; Lanzhou University
RP He, XD (corresponding author), Lanzhou Univ, Dept Gen Surg, Hosp 2, Lanzhou 730030, Peoples R China.
EM hxd@lzu.edu.cn
FU Science and Technology Department of Gansu Province; natural science
   foundation of Gansu Province [21JR7RA417]; Beijing liver care public
   welfare foundation, special fund for artificial liver [RGGJJ-2021-007];
   Lanzhou science and Technology Bureau, Lanzhou science and technology
   development guidance plan project [2019-ZD-72]
FX Science and Technology Department of Gansu Province, natural science
   foundation of Gansu Province (No. 21JR7RA417) ; Beijing liver care
   public welfare foundation, special fund for artificial liver (No.
   RGGJJ-2021-007) ; Lanzhou science and Technology Bureau, Lanzhou science
   and technology development guidance plan project (No. 2019-ZD-72) .
CR Almasi F, 2021, AGROTECHNIQUES IND C, V1, P19
   Aryafar S, 2021, Agrotech. Ind. Crops., V1, P139, DOI [10.22126/atic.2021.7184.1026, DOI 10.22126/ATIC.2021.7184.1026]
   Bechmann LP, 2012, J HEPATOL, V56, P952, DOI 10.1016/j.jhep.2011.08.025
   Cai LL, 2017, MOLECULES, V22, DOI 10.3390/molecules22091409
   DAHLIN DC, 1984, P NATL ACAD SCI-BIOL, V81, P1327, DOI 10.1073/pnas.81.5.1327
   Davaatseren M, 2013, FOOD CHEM TOXICOL, V58, P30, DOI 10.1016/j.fct.2013.04.023
   Delmastro MM, 2011, CLIN DEV IMMUNOL, DOI 10.1155/2011/593863
   Fan XM, 2015, DRUG METAB DISPOS, V43, P317, DOI 10.1124/dmd.114.062067
   Ghamarnia H., 2021, IND CROPS, V1, P110, DOI [10.22126/atic.2021.6791.1019, DOI 10.22126/ATIC.2021.6791.1019]
   Gunawan BK, 2006, GASTROENTEROLOGY, V131, P165, DOI 10.1053/j.gastro.2006.03.045
   HALLIWELL B, 1984, LANCET, V1, P1396
   Halliwell B, 2012, NUTR REV, V70, P257, DOI 10.1111/j.1753-4887.2012.00476.x
   Ji LL, 2013, J NUTR BIOCHEM, V24, P1911, DOI 10.1016/j.jnutbio.2013.05.007
   Kanter MZ, 2006, AM J HEALTH-SYST PH, V63, P1821, DOI 10.2146/ajhp060050
   Kanter MZ., 2009, AM J HEALTH-SYST PH, V63, P181
   Klionsky DJ, 2007, NAT REV MOL CELL BIO, V8, P931, DOI 10.1038/nrm2245
   Kumari A, 2012, LIFE SCI, V90, P561, DOI 10.1016/j.lfs.2012.01.012
   Lee KJ, 2008, FOOD CHEM TOXICOL, V46, P2445, DOI 10.1016/j.fct.2008.03.032
   Morgan OW, 2007, PLOS MED, V4, P654, DOI 10.1371/journal.pmed.0040105
   Oz HS, 2008, DIGEST DIS SCI, V53, P2980, DOI 10.1007/s10620-008-0239-5
   Park CM, 2010, PHYTOTHER RES, V24, P1347, DOI 10.1002/ptr.3121
   Perrone MA, 2020, ACTA MEDICA MEDITERR, V36, P1245, DOI 10.19193/0393-6384_2020_2_195
   PRESCOTT LF, 1980, BRIT J CLIN PHARMACO, V10, pS373, DOI 10.1111/j.1365-2125.1980.tb01825.x
   Reilly TP, 2001, CHEM RES TOXICOL, V14, P1620, DOI 10.1021/tx0155505
   RICEEVANS CA, 1995, FREE RADICAL RES, V22, P375, DOI 10.3109/10715769509145649
   Rigano D, 2009, CHEM-BIOL INTERACT, V180, P211, DOI 10.1016/j.cbi.2009.02.010
   Saito C, 2010, TOXICOL APPL PHARM, V246, P8, DOI 10.1016/j.taap.2010.04.015
   Saito C, 2010, HEPATOLOGY, V51, P246, DOI 10.1002/hep.23267
   Schütz K, 2006, J ETHNOPHARMACOL, V107, P313, DOI 10.1016/j.jep.2006.07.021
   Shaafi B., 2021, Agrotech. Ind. Crops, V1, P24, DOI [10.22126/etic.2021.6246.1004, DOI 10.22126/ETIC.2021.6246.1004]
   Shine Varghese Jancy, 2014, Asian Pacific Journal of Tropical Biomedicine, V4, P143, DOI 10.1016/S2221-1691(14)60223-9
   Toyoda Y, 2012, DRUG METAB DISPOS, V40, P169, DOI 10.1124/dmd.111.041137
   Wang AY, 2010, WORLD J GASTROENTERO, V16, P384, DOI 10.3748/wjg.v16.i3.384
   Wang HB, 2014, CARBOHYD POLYM, V103, P140, DOI 10.1016/j.carbpol.2013.12.029
   Whyte AJ, 2010, J EMERG MED, V39, P607, DOI 10.1016/j.jemermed.2008.05.007
   Yazdanparast R, 2009, FOOD CHEM, V114, P1222, DOI 10.1016/j.foodchem.2008.10.086
   Yi Ruo-Kun, 2015, Prev Nutr Food Sci, V20, P52, DOI 10.3746/pnf.2015.20.1.52
   Yousef MI, 2010, FOOD CHEM TOXICOL, V48, P3246, DOI 10.1016/j.fct.2010.08.034
   Zhao Hui, 2017, ZHONGNAN PHARM, V15, P587
   Zhu RZ, 2012, HEPATOL RES, V42, P741, DOI 10.1111/j.1872-034X.2012.00996.x
NR 40
TC 1
Z9 2
U1 4
U2 15
PU C M B  ASSOC
PI POITIERS
PA 34 BOULEVARD SOLFERINO, 86000 POITIERS, FRANCE
SN 0145-5680
EI 1165-158X
J9 CELL MOL BIOL
JI Cell. Mol. Biol.
PY 2022
VL 68
IS 5
BP 24
EP 33
DI 10.14715/cmb/2022.68.5.4
PG 10
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 4Y1FP
UT WOS:000861278500005
PM 36029509
OA hybrid
DA 2024-02-19
ER

PT J
AU Sonne, C
   Dietz, R
   Leifsson, PS
   Born, EW
   Letcher, RJ
   Kirkegaard, M
   Muir, DCG
   Riget, FF
   Hyldstrup, L
AF Sonne, C
   Dietz, R
   Leifsson, PS
   Born, EW
   Letcher, RJ
   Kirkegaard, M
   Muir, DCG
   Riget, FF
   Hyldstrup, L
TI Do organohalogen contaminants contribute to histopathology in liver from
   east Greenland polar bears (<i>Ursus maritimus</i>)?
SO ENVIRONMENTAL HEALTH PERSPECTIVES
LA English
DT Article
DE bile duct proliferation; chlordanes; dichlorodiphenyltrichloroethane;
   dieldrin; East Greenland; HCB; hexacyclohexanes; Ito cells; lipid
   granulomas; liver; mononudear cell infiltrations; polar bear;
   polybrominated diphenyl ethers; polychlorinated biphenyls; portal
   fibrosis; Sigma DDT; Sigma HCH; Sigma PBDE; Sigma PCB; Ursus maritimus
ID OC EXPOSURE IMPAIR; POLYCHLORINATED-BIPHENYLS; ORGANOCHLORINES AFFECT;
   HALICHOERUS-GRYPUS; THYROID-HORMONES; PHOCA-VITULINA; FEMALE; RETINOL;
   MERCURY; PCB
AB In East Greenland polar bears (Ursus maritimus), anthropogenic organohalogen compounds (OHCs) (e.g., polychlorinated biphenyls, dichlorodiphenyltrichloroethane, and polybrominated diphenyl ethers) contributed to renal lesions and are believed to reduce bone mineral density. Because OHCs are also hepatotoxic, we investigated liver histology of 32 subadult, 24 adult female, and 23 adult male East Greenland polar bears sampled during 1999-2002. Light microscopic changes consisted of nuclear displacement from the normal central cytoplasmic location in parenchymal cells, mononuclear cell infiltrations (mainly portally and as lipid granulomas), mad bile duct proliferation accompanied by fibrosis, and fat accumulation in hepatocytes and pluripotent Ito cells. Lipid accumulation in Ito cells and bile duct hyperplasia accompanied by portal fibrosis were correlated to age, whereas no changes were associated with either sex or season (summer vs. winter). For adult females, hepatocytic intracellular fat increased significantly with concentrations of the sum of hexachlorocyclohexanes, as was the case for lipid granulomas and hexachlorobenzene in adult males. Based on these relationships and the nature of the chronic inflammation, we suggest that these findings were caused by aging and long-term exposure to OHCs. Therefore, these changes may be used as biomarkers for OHC exposure in wildlife and humans. To our knowledge, this is the first time liver histology has been evaluated in relation to OHC concentrations in a mammalian wildlife species, and the information is important to future polar bear conservation strategies and health assessments of humans relying on OHC-contaminated food resources.
C1 Nalt Environm Res Inst, Dept Arctic Environm, DK-4000 Roskilde, Denmark.
   Royal Vet & Agr Univ, Dept Vet Basic Sci, Frederiksberg, Denmark.
   Royal Vet & Agr Univ, Dept Vet Pathobiol, Frederiksberg, Denmark.
   Greenland Inst Nat Resources, Nuuk, Greenland.
   Carleton Univ, Natl Wildlife Res Ctr, Canadian Wildlife Serv, Environm Canada, Ottawa, ON K1S 5B6, Canada.
   Environm Canada, Natl Water Res Inst, Burlington, ON, Canada.
   Hvidovre Univ Hosp, DK-2650 Hvidovre, Denmark.
C3 Aarhus University; University of Copenhagen; University of Copenhagen;
   Greenland Institute of Natural Resources; Carleton University;
   Environment & Climate Change Canada; Canadian Wildlife Service; National
   Wildlife Research Centre - Canada; Environment & Climate Change Canada;
   National Water Research Institute; University of Copenhagen
RP Sonne, C (corresponding author), Nalt Environm Res Inst, Dept Arctic Environm, Frederiksborgvej 399,POB 358, DK-4000 Roskilde, Denmark.
EM csh@dmu.dk
RI Sonne, Christian/I-7532-2013; Muir, Derek/AAD-7526-2021; Dietz,
   Rune/F-9154-2015; Dietz, Rune/L-4640-2013; Rigét, Frank/J-3245-2013
OI Sonne, Christian/0000-0001-5723-5263; Dietz, Rune/0000-0001-9652-317X;
   Muir, Derek/0000-0001-6631-9776; Leifsson, Pall S/0000-0003-1539-9491
CR AMAP, 2004, AMAP Assessment 2002: Persistent Organic Pollutants in the Arctic
   [Anonymous], 1995, THOMSONS SPECIAL VET
   [Anonymous], [No title captured]
   [Anonymous], 1991, THEORY STRATEGY HIST
   [Anonymous], [No title captured]
   Bancroft JD, 1996, THEORY PRACTICE HIST
   BERGMAN A, 1992, AMBIO, V21, P591
   Bergman A, 2001, AMBIO, V30, P397, DOI 10.1639/0044-7447(2001)030[0397:RLIBGS]2.0.CO;2
   Bergman A, 1999, APMIS, V107, P270, DOI 10.1111/j.1699-0463.1999.tb01554.x
   Bergman A., 1985, Finn. Game Res, V44, P47
   Bernhoft A, 2000, J TOXICOL ENV HEAL A, V59, P561, DOI 10.1080/009841000156682
   BOON JP, 1992, SCI TOTAL ENVIRON, V114, P113, DOI 10.1016/0048-9697(92)90418-R
   Braathen M, 2004, ENVIRON HEALTH PERSP, V112, P826, DOI 10.1289/ehp.6809
   BRUCKNER JV, 1974, FOOD COSMET TOXICOL, V12, P323, DOI 10.1016/0015-6264(74)90004-2
   CHU I, 1994, FUND APPL TOXICOL, V22, P457, DOI 10.1006/faat.1994.1051
   DEROCHER AE, 1994, J ZOOL, V234, P527, DOI 10.1111/j.1469-7998.1994.tb04863.x
   Dietz R, 2004, SCI TOTAL ENVIRON, V331, P107, DOI 10.1016/j.scitotenv.2004.03.025
   DIETZ R, 1991, SARSIA, V76, P17, DOI 10.1080/00364827.1991.10413461
   DIETZ R, 1990, SCI TOTAL ENVIRON, V95, P41, DOI 10.1016/0048-9697(90)90051-U
   Dietz R, 2000, SCI TOTAL ENVIRON, V245, P25, DOI 10.1016/S0048-9697(99)00431-3
   Fabczak J, 2000, MED WETER, V56, P788
   FRAPPIER BL, 1998, TXB VET HISTOLOGY, P164
   Haave M, 2003, ENVIRON HEALTH PERSP, V111, P431, DOI 10.1289/ehp.5553
   Heier A, 2003, VET PATHOL, V40, P196, DOI 10.1354/vp.40-2-196
   HEIER A, IN PRESS ZOO WILD ME
   JONSSON HT, 1981, ARCH ENVIRON CON TOX, V10, P171, DOI 10.1007/BF01055619
   Kakela R, 1997, COMP BIOCHEM PHYS B, V116, P27, DOI 10.1016/S0305-0491(96)00158-7
   KIMBROUGH RD, 1972, ARCH ENVIRON HEALTH, V25, P354, DOI 10.1080/00039896.1972.10666186
   KIMBROUGH RD, 1971, ARCH ENVIRON HEALTH, V22, P460, DOI 10.1080/00039896.1971.10665879
   Kirkegaard B, 2005, SCI TOTAL ENVIRON, V341, P119, DOI 10.1016/j.scitotenv.2004.09.034
   Koponen K, 2001, AMBIO, V30, P122, DOI 10.1639/0044-7447(2001)030[0122:HOFFFA]2.0.CO;2
   LEIGHTON FA, 1988, CAN J ZOOL, V66, P480, DOI 10.1139/z88-068
   Lie E, 2005, J TOXICOL ENV HEAL A, V68, P457, DOI 10.1080/15287390590903685
   Lie E, 2004, J TOXICOL ENV HEAL A, V67, P555, DOI 10.1080/15287390490425597
   Lin PP, 2003, TOXICOL SCI, V71, P20, DOI 10.1093/toxsci/71.1.20
   Luross JM, 2002, CHEMOSPHERE, V46, P665, DOI 10.1016/S0045-6535(01)00230-2
   MESSIER F, 1992, J ZOOL, V226, P219, DOI 10.1111/j.1469-7998.1992.tb03835.x
   Monitoring A., 1998, Arctic Assessment Report, P183
   Oskam IC, 2004, J TOXICOL ENV HEAL A, V67, P959, DOI 10.1080/15287390490443731
   Oskam IC, 2003, J TOXICOL ENV HEAL A, V66, P2119, DOI 10.1080/15287390390211342
   Parkinson A., 1996, Casarett and Doull's toxicology: The basic science of poisons, P113
   Prunescu CC, 2003, COMP BIOCHEM PHYS A, V134, P23
   RAMSAY MA, 1988, J ZOOL, V214, P601, DOI 10.1111/j.1469-7998.1988.tb03762.x
   RAWSON AJ, 1993, ECOTOX ENVIRON SAFE, V25, P41, DOI 10.1006/eesa.1993.1005
   Rosing-Asvid A, 2002, POLAR BIOL, V25, P878, DOI 10.1007/s00300-002-0430-7
   Sandala GM, 2004, SCI TOTAL ENVIRON, V331, P125, DOI 10.1016/j.scitotenv.2003.03.001
   Sato M, 2001, CELL STRUCT FUNCT, V26, P71, DOI 10.1247/csf.26.71
   SCHUMACHER U, 1993, J WILDLIFE DIS, V29, P103, DOI 10.7589/0090-3558-29.1.103
   SENCO H, 2001, CELLS HEPATIC SIMUSO, V8, P207
   Senoo H, 1999, CELLS OF THE HEPATIC SINUSOID, VOL 7, P34
   Skaare JU, 2001, J TOXICOL ENV HEAL A, V62, P227, DOI 10.1080/009841001459397
   Sonne C, 2004, ENVIRON HEALTH PERSP, V112, P1711, DOI 10.1289/ehp.7293
   SONNE C, IN PRESS ENV TOXICOL
   Thompson David R., 1996, P341
   van Duursen MBM, 2003, TOXICOL APPL PHARM, V190, P241, DOI 10.1016/S0041-008X(03)00166-2
   WONG S, 1992, ENV IMMUNOTOXICOLOGY, P8
   Woshner VM, 2002, TOXICOL PATHOL, V30, P209, DOI 10.1080/019262302753559542
NR 57
TC 58
Z9 63
U1 1
U2 35
PU US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE
PI RES TRIANGLE PK
PA NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233,
   RES TRIANGLE PK, NC 27709-2233 USA
SN 0091-6765
EI 1552-9924
J9 ENVIRON HEALTH PERSP
JI Environ. Health Perspect.
PD NOV
PY 2005
VL 113
IS 11
BP 1569
EP 1574
DI 10.1289/ehp.8038
PG 6
WC Environmental Sciences; Public, Environmental & Occupational Health;
   Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
   Health; Toxicology
GA 979BI
UT WOS:000232916700040
PM 16263513
OA Green Published, gold
DA 2024-02-19
ER

PT J
AU Salazar, EL
   Calzada, L
   Escontria, M
AF Salazar, EL
   Calzada, L
   Escontria, M
TI Estradiol/androgen receptors during aging: Microsomal distribution in
   human benign prostatic hypertrophy
SO ARCHIVES OF ANDROLOGY
LA English
DT Article
DE androgen receptor; estradiol receptor; microsomal distribution;
   prostatic hypertrophy
ID BREAST-CANCER; PROGESTERONE-RECEPTOR; ANDROGEN RECEPTORS;
   ESTROGEN-RECEPTOR; RAT-LIVER; MEMBRANES; TISSUES
AB Estradiol and androgen receptor levels were determined in benign prostatic hypertrophy tissue by means of dextran-coated charcoal method. 80% of the cases contained estrogen receptor, whereas 85% of cases contained the androgen receptor. In 50 year old patients, nuclear estradiol and androgen receptors were 48% and 34% higher than the cytosolic values, respectively, whereas in 70 year old patients, the levels of nuclear estradiol and androgen receptors were 6% and 57% higher than the cytosolic values, respectively. Nuclear androgen receptor in 50 year old patients was 34% higher than the estradiol receptor, and in 70 year old patients, androgen receptor was 23% higher than the estradiol receptor. Cytosolic values of estrogen receptor in 50 year old patients were diminished 50%, whereas in 70 year old patients, the ER value was increased 40% with regard to androgen receptor. On the other band, estradiol receptor values measured in microsomal fractions, and were higher when compared to androgen receptor levels (mean percentage +/- 50%). These findings suggest that the biological effects due to the subcellular distribution of AR or ER and that their microsomal distribution would constitute a reserve mechanism and activation of receptors for the continued growth of benign prostatic hypertrophy.
C1 Social Secur Mexican Inst, Resp Med Unit, Mexico City 14391, DF, Mexico.
   Hlth Ctr T3, Mexico City, DF, Mexico.
   Publ Hlth Serv Dist Federal, Sanitary Jurisdict Alvaro Obregon, Mexico City, DF, Mexico.
RP Salazar, EL (corresponding author), Social Secur Mexican Inst, Resp Med Unit, Apartado Postal 86-056, Mexico City 14391, DF, Mexico.
EM edith_lsalazar@hotmail.com
CR BARRACK ER, 1983, CANCER RES, V43, P1107
   BEAUFAY H, 1974, J CELL BIOL, V61, P188, DOI 10.1083/jcb.61.1.188
   BERNAL A, 1983, ARCH ANDROLOGY, V11, P33, DOI 10.3109/01485018308987457
   Calzada L, 1998, MED SCI RES, V26, P829
   CALZADA L, 1995, MED SCI RES, V23, P771
   CALZADA L, 1993, MED SCI RES, V21, P645
   CALZADA SL, 1995, ARCH STD HIV RES, V9, P189
   HICKS LL, 1979, STEROIDS, V33, P389, DOI 10.1016/0039-128X(79)90014-X
   Lindquist C, 2000, RADIOSURG, V3, P1
   LOWRY OH, 1951, J BIOL CHEM, V193, P265
   QUARMBY VE, 1990, MOL ENDOCRINOL, V4, P22, DOI 10.1210/mend-4-1-22
   Salazar EL, 1996, MED SCI RES, V24, P523
   Sandberg A A, 1975, Vitam Horm, V33, P155
   SCATCHARD G, 1949, ANN NY ACAD SCI, V193, P265
   SONG CS, 1969, J CELL BIOL, V41, P124, DOI 10.1083/jcb.41.1.124
   Voigt K D, 1975, Vitam Horm, V33, P417
   WERNERT N, 1988, VIRCHOWS ARCH A, V412, P387, DOI 10.1007/BF00750267
   ZAVA DT, 1979, ENDOCRINOLOGY, V104, P1008, DOI 10.1210/endo-104-4-1007
NR 18
TC 1
Z9 3
U1 0
U2 1
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0148-5016
J9 ARCH ANDROLOGY
JI Arch. Androl.
PD JAN-FEB
PY 2005
VL 51
IS 1
BP 49
EP 53
DI 10.1080/014850190513021
PG 5
WC Andrology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Endocrinology & Metabolism
GA 885DM
UT WOS:000226137300006
PM 15764417
DA 2024-02-19
ER

PT J
AU Seo, W
   Gao, YH
   He, Y
   Sung, J
   Xu, HQ
   Feng, DC
   Park, SH
   Cho, YE
   Guillot, A
   Ren, TY
   Wu, RH
   Wang, JY
   Kim, SJ
   Hwang, S
   Liangpunsakul, S
   Yang, YZ
   Niu, JQ
   Gao, B
AF Seo, Wonhyo
   Gao, Yanhang
   He, Yong
   Sung, Jing
   Xu, Hongqin
   Feng, Dechun
   Park, Seol Hee
   Cho, Young-Eun
   Guillot, Adrien
   Ren, Tianyi
   Wu, Ruihong
   Wang, Jingyun
   Kim, Seung-Jin
   Hwang, Seonghwan
   Liangpunsakul, Suthat
   Yang, Yingzi
   Niu, Junqi
   Gao, Bin
TI ALDH2 deficiency promotes alcohol-associated liver cancer by activating
   oncogenic pathways via oxidized DNA-enriched extracellular vesicles
SO JOURNAL OF HEPATOLOGY
LA English
DT Article
DE Aldehyde dehydrogenase 2; Ethanol; Acetaldehyde; Hepatocellular
   carcinoma; Cirrhosis; Extracellular vesicles; HBV; TAZ
ID RELEASE; POLYMORPHISMS; ACETALDEHYDE; SENESCENCE; EXOSOMES; ADDUCTS
AB Background & Aims: Excessive alcohol consumption is one of the major causes of hepatocellular carcinoma (HCC). Approximately 30-40% of the Asian population are deficient for aldehyde dehydrogenase 2 (ALDH2), a key enzyme that detoxifies the ethanol metabolite acetaldehyde. However, how ALDH2 deficiency affects alcohol-related HCC remains unclear.
   Methods: ALDH2 polymorphisms were studied in 646 patients with viral hepatitis B (HBV) infection, who did or did not drink alcohol. A new model of HCC induced by chronic carbon tetrachloride (CCl4) and alcohol administration was developed and studied in 3 lines of Aldh2-deficient mice: including Aldh2 global knockout (KO) mice, Aldh2*1/*2 knock-in mutant mice, and liver-specific Aldh2 KO mice.
   Results: We demonstrated that ALDH2 deficiency was not associated with liver disease progression but was associated with an increased risk of HCC development in cirrhotic patients with HBV who consumed excessive alcohol. The mechanisms underlying HCC development associated with cirrhosis and alcohol consumption were studied in Aldh2-deficient mice. We found that all 3 lines of Aldh2-deficient mice were more susceptible to CCl4 plus alcohol-associated liver fibrosis and HCC development. Furthermore, our results from in vivo and in vitro mechanistic studies revealed that after CCl4 plus ethanol exposure, Aldh2-deficient hepatocytes produced a large amount of harmful oxidized mitochondrial DNA via extracellular vesicles, which were then transferred into neighboring HCC cells and together with acetaldehyde activated multiple oncogenic pathways (INK, STAT3, BCL-2, and TAZ), thereby promoting HCC.
   Conclusions: ALDH2 deficiency is associated with an increased risk of alcohol-related HCC development from fibrosis in patients and in mice. Mechanistic studies reveal a novel mechanism that Aldh2-deficient hepatocytes promote alcohol-associated HCC by transferring harmful oxidized mitochondrial DNA-enriched extracellular vesicles into HCC and subsequently activating multiple oncogenic pathways in HCC.
   Lay summary: Alcoholics with an ALDH2 polymorphism have an increased risk of digestive tract cancer development, however, the link between ALDH2 deficiency and hepatocellular carcinoma (HCC) development has not been well established. In this study, we show that ALDH2 deficiency exacerbates alcohol-associated HCC development both in patients and mouse models. Mechanistic studies revealed that after chronic alcohol exposure, Aldh2-deficient hepatocytes produce a large amount of harmful oxidized mitochondrial DNA via extracellular vesicles, which can be delivered into neighboring HCC cells and subsequently activate multiple oncogenic pathways, promoting HCC. Published by Elsevier B.V. on behalf of European Association for the Study of the Liver.
C1 [Seo, Wonhyo; Gao, Yanhang; He, Yong; Feng, Dechun; Park, Seol Hee; Guillot, Adrien; Ren, Tianyi; Kim, Seung-Jin; Hwang, Seonghwan; Gao, Bin] NIAAA, Lab Liver Dis, NIH, Bethesda, MD 20892 USA.
   [Gao, Yanhang; Sung, Jing; Xu, Hongqin; Wu, Ruihong; Wang, Jingyun; Niu, Junqi] Jilin Univ, First Hosp Jilin Univ, Dept Hepatol, Changchun 130021, Jilin, Peoples R China.
   [Cho, Young-Eun] NIAAA, Sect Mol Pharmacol & Toxicol, Lab Membrane Biochem & Biophys, NIH, Bethesda, MD 20892 USA.
   [Liangpunsakul, Suthat] Indiana Univ, Dept Med, Div Gastroenterol & Hepatol, Indianapolis, IN USA.
   [Liangpunsakul, Suthat] Indiana Univ, Dept Biochem & Mol Biol, Indianapolis, IN 46204 USA.
   [Liangpunsakul, Suthat] Richard L Roudebush Vet Adm Med Ctr, Indianapolis, IN USA.
   [Yang, Yingzi] Harvard Sch Dent Med, Dept Dev Biol, Boston, MA USA.
C3 National Institutes of Health (NIH) - USA; NIH National Institute on
   Alcohol Abuse & Alcoholism (NIAAA); Jilin University; National
   Institutes of Health (NIH) - USA; NIH National Institute on Alcohol
   Abuse & Alcoholism (NIAAA); Indiana University System; Indiana
   University-Purdue University Indianapolis; Indiana University System;
   Indiana University-Purdue University Indianapolis; US Department of
   Veterans Affairs; Veterans Health Administration (VHA); Richard L.
   Roudebush VA Medical Center; Harvard University; Harvard School of
   Dental Medicine
RP Gao, B (corresponding author), NIAAA, Lab Liver Dis, NIH, Bethesda, MD 20892 USA.
EM bgao@mail.nih.gov
RI LI, Junhua/AAG-3919-2019; wang, jiahui/IXD-1197-2023; wang,
   jing/GRS-7509-2022; lan, lan/JWO-3679-2024; wang, dan/JEF-0836-2023;
   Feng, Dechun/Q-5962-2016; wang, jing/GVT-8700-2022; wang,
   jie/HTQ-4920-2023; WANG, JINGYI/GSJ-1241-2022; Wang, Jin/GYA-2019-2022;
   wang, jing/HJA-5384-2022
OI LI, Junhua/0000-0001-6784-1873; Guillot, Adrien/0000-0002-6002-9986; He,
   Yong/0009-0006-8681-5287; Niu, Junqi/0000-0001-5415-2024
FU intramural program of NIAAA, NIH; Natural Science and Technology Major
   Project [2017ZX10202202, 2018ZX10302206]; National Key Research Plan
   "Precision Medicine Research" key project [2017YFC0908103]; Korean
   Biomedical Scientist Fellowship Program (KBSFP) fellowship at the NIH;
   NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [ZIAAA000369,
   ZIAAA000036] Funding Source: NIH RePORTER
FX The basic research work was supported by the intramural program of
   NIAAA, NIH (BG) and the clinical study of ALDH2 polymorphisms and liver
   disease progression was supported by the Natural Science and Technology
   Major Project (2017ZX10202202 and 2018ZX10302206) and National Key
   Research Plan "Precision Medicine Research" key project (2017YFC0908103)
   (JN and YG). Dr. Wonhyo Seo was partially supported by the Korean
   Biomedical Scientist Fellowship Program (KBSFP) fellowship at the NIH.
CR Alkreathy HM, 2014, BMC COMPLEM ALTERN M, V14, DOI 10.1186/1472-6882-14-452
   [Anonymous], 2017, INT J MOL SCI
   Brooks PJ, 2014, ENVIRON MOL MUTAGEN, V55, P77, DOI 10.1002/em.21824
   Chen JH, 2007, NUCLEIC ACIDS RES, V35, P7417, DOI 10.1093/nar/gkm681
   EI-Emshaty Hoda M, 2014, Hepatogastroenterology, V61, P1393
   Gandhirajan RK, 2016, J BIOL CHEM, V291, P11596, DOI 10.1074/jbc.M115.712539
   Georgoulis A, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18091979
   Gosselin K, 2009, CANCER RES, V69, P7917, DOI 10.1158/0008-5472.CAN-08-2510
   He GB, 2011, CELL RES, V21, P159, DOI 10.1038/cr.2010.183
   Hirsova P, 2016, GASTROENTEROLOGY, V150, P956, DOI 10.1053/j.gastro.2015.12.037
   Ho JC, 2004, INT J CANCER, V111, P494, DOI 10.1002/ijc.20282
   Jin SF, 2015, P NATL ACAD SCI USA, V112, P9088, DOI 10.1073/pnas.1510757112
   Kalluri R, 2016, J CLIN INVEST, V126, P1208, DOI 10.1172/JCI81135
   Kim W, 2018, GUT, V67, P1692, DOI 10.1136/gutjnl-2017-314061
   Klotz LO, 2017, REDOX BIOL, V13, P646, DOI 10.1016/j.redox.2017.07.015
   Kwon HJ, 2014, HEPATOLOGY, V60, P146, DOI 10.1002/hep.27036
   Langevin F, 2011, NATURE, V475, P53, DOI 10.1038/nature10192
   Lau L., 2019, EXPERT OPIN THER TAR
   Lehmann BD, 2008, CANCER RES, V68, P7864, DOI 10.1158/0008-5472.CAN-07-6538
   Li H, 2009, ANN HUM GENET, V73, P335, DOI 10.1111/j.1469-1809.2009.00517.x
   Ma S, 2007, GASTROENTEROLOGY, V132, P2542, DOI 10.1053/j.gastro.2007.04.025
   Momen-Heravi F, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0623-9
   Munaka M, 2003, J CANCER RES CLIN, V129, P355, DOI 10.1007/s00432-003-0439-5
   Patel SH, 2017, GASTROENTEROLOGY, V152, P533, DOI 10.1053/j.gastro.2016.10.047
   Royo F, 2012, J EXTRACELL VESICLES, V1, DOI 10.3402/jev.v1i0.18825
   Seki E, 2012, GASTROENTEROLOGY, V143, P307, DOI 10.1053/j.gastro.2012.06.004
   Setshedi M, 2010, OXID MED CELL LONGEV, V3, P178, DOI 10.4161/oxim.3.3.12288
   Takahashi A, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15287
   Valavanidis A, 2009, J ENVIRON SCI HEAL C, V27, P120, DOI 10.1080/10590500902885684
   Verma VK, 2016, J HEPATOL, V64, P651, DOI 10.1016/j.jhep.2015.11.020
   Wang H, 2011, INT J BIOL SCI, V7, P536, DOI 10.7150/ijbs.7.536
   Wang J, 2016, TARGET ONCOL, V11, P723, DOI 10.1007/s11523-016-0446-5
   Yang Y, 2011, MED ONCOL, V28, P796, DOI 10.1007/s12032-010-9519-y
   Yokoyama A, 2001, CARCINOGENESIS, V22, P433, DOI 10.1093/carcin/22.3.433
   Zambelli VO, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3009539
NR 35
TC 100
Z9 104
U1 5
U2 59
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0168-8278
EI 1600-0641
J9 J HEPATOL
JI J. Hepatol.
PD NOV
PY 2019
VL 71
IS 5
BP 1000
EP 1011
DI 10.1016/j.jhep.2019.06.018
PG 12
WC Gastroenterology & Hepatology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Gastroenterology & Hepatology
GA JD7CU
UT WOS:000490139600020
PM 31279903
OA Green Accepted
DA 2024-02-19
ER

PT J
AU Suzen, S
   Gurkok, G
   Coban, T
AF Suzen, Sibel
   Gurkok, Gokce
   Coban, Tulay
TI Novel <i>N</i>-acyl dehydroalanine derivatives as antioxidants:: Studies
   on rat liver lipid peroxidation levels and DPPH free radical scavenging
   activity
SO JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY
LA English
DT Article
DE dehydroalanine; lipid peroxidation; radical scavenging; synthesis; free
   radical
ID IRON; CARCINOGENESIS; IDENTIFICATION; MECHANISMS; PREVENTION; RELEVANCE;
   RADIATION; OXIDATION
AB Oxidative stress has been implicated in the development of many neurodegenerative diseases such as Parkinson and Alzhemier's disease and is also responsible for aging, artherosclerosis, rheumatoid arthritis and carcinogenesis. Olefins such as dehydroalanines have been shown to inactivate free radicals by forming stabilized free radical adducts. Among these molecules N-acyl dehydroalanines; react with and scavenge oxygen and hydroxyl radicals. This study describes the synthesis, characterization and in vitro effects on rat liver lipid peroxidation levels, and DPPH free radical scavenging activities of some N-acyl dehydroalanine derivatives. Compounds c, f and j slightly scavenged the level of DPPH radical at 10(-3) M concentration by about 27, 46, and 56%, respectively while compounds a, d, e, f, g, h showed a strong inhibitory effect on lipid peroxidation at 10(-3) M and 10(-4)M concentrations and inhibition was in the range of 76-90%. The possible antioxidant mechanism of the compounds was discussed.
C1 Ankara Univ, Fac Pharm, Dept Pharmaceut Chem, TR-06100 Ankara, Turkey.
   Ankara Univ, Fac Pharm, Dept Pharmaceut Toxicol, TR-06100 Ankara, Turkey.
C3 Ankara University; Ankara University
RP Suzen, S (corresponding author), Ankara Univ, Fac Pharm, Dept Pharmaceut Chem, TR-06100 Ankara, Turkey.
EM sibel@pharmacy.ankara.edu.tr
RI Suzen, Sibel/AAF-8030-2020
CR Abreu AS, 2003, EUR J ORG CHEM, V2003, P1537, DOI 10.1002/ejoc.200390212
   AIKENS J, 1992, CHEM RES TOXICOL, V5, P263, DOI 10.1021/tx00026a018
   ATESALAGOZ Z, 2006, IN PRESS MED CHEM RE
   Bierbaum G, 1996, ANTON LEEUW INT J G, V69, P119, DOI 10.1007/BF00399417
   BLOIS MS, 1958, NATURE, V181, P1199, DOI 10.1038/1811199a0
   BOECK LD, 1992, J ANTIBIOT, V45, P1222, DOI 10.7164/antibiotics.45.1222
   BUCCALDERON P, 1989, CARCINOGENESIS, V10, P1641, DOI 10.1093/carcin/10.9.1641
   BUCCALDERON P, 1990, LIFE SCI, V46, P207, DOI 10.1016/0024-3205(90)90106-2
   BUCCALDERON P, 1990, CHEM-BIOL INTERACT, V73, P77, DOI 10.1016/0009-2797(90)90109-Z
   BUCCALDERON P, 1990, EXPERIENTIA, V46, P708, DOI 10.1007/BF01939941
   Buettner GR, 1996, RADIAT RES, V145, P532, DOI 10.2307/3579271
   Dekkers JC, 1996, SPORTS MED, V21, P213, DOI 10.2165/00007256-199621030-00005
   DIX TA, 1993, CHEM RES TOXICOL, V6, P2, DOI 10.1021/tx00031a001
   Dunn AD, 1998, J BIOL CHEM, V273, P25223, DOI 10.1074/jbc.273.39.25223
   GARRISON WM, 1987, CHEM REV, V87, P381, DOI 10.1021/cr00078a006
   GHOSHAL AK, 1990, FREE RADICAL BIO MED, V8, P3, DOI 10.1016/0891-5849(90)90137-8
   GULZAR MS, 1995, J CHEM SOC CHEM COMM, P1061, DOI 10.1039/c39950001061
   GUTTERIDGE JMC, 1994, BRIT J BIOMED SCI, V51, P288
   HARADA K, 1984, B CHEM SOC JPN, V57, P1427, DOI 10.1246/bcsj.57.1427
   Litwinienko G, 2003, J ORG CHEM, V68, P3433, DOI 10.1021/jo026917t
   Marx JJM, 1996, ACTA HAEMATOL-BASEL, V95, P49
   MCCORD JM, 1969, J BIOL CHEM, V244, P6049
   McCord JM, 1996, NUTR REV, V54, P85, DOI 10.1111/j.1753-4887.1996.tb03876.x
   MIHARA M, 1980, BIOCHEM MEDICA, V23, P303
   Monteiro L. S., 2001, P 2 INT 17 AM PEPT S, P44
   NOMOTO S, 1979, TETRAHEDRON LETT, P521, DOI 10.1016/S0040-4039(01)85989-X
   Paik SH, 1998, J BIOL CHEM, V273, P23134, DOI 10.1074/jbc.273.36.23134
   PALMER DE, 1992, J AM CHEM SOC, V114, P5634, DOI 10.1021/ja00040a024
   PARKE DV, 1991, CAN J PHYSIOL PHARM, V69, P537, DOI 10.1139/y91-081
   ROHRKASTEN A, 1988, J BIOL CHEM, V263, P15325
   SIPE HJ, 1993, CHEM-BIOL INTERACT, V86, P93, DOI 10.1016/0009-2797(93)90114-E
   Stadtman ER, 2005, BBA-PROTEINS PROTEOM, V1703, P135, DOI 10.1016/j.bbapap.2004.08.010
   Stadtman ER, 2003, AMINO ACIDS, V25, P207, DOI 10.1007/s00726-003-0011-2
   Suzen S, 1999, J PEPT SCI, V5, P283, DOI 10.1002/(SICI)1099-1387(199906)5:6<283::AID-PSC198>3.0.CO;2-O
   Süzen S, 2000, TURK J CHEM, V24, P361
   Suzen S., 1999, ANKARA ECZ FAK DERG, V28, P129
   Suzen S., 2000, FABAD J PHARM SCI, V25, P113
   SUZEN S, 2005, 2 JOINT IT SWISS M M, P137
   Toyokuni S, 1996, FREE RADICAL BIO MED, V20, P553, DOI 10.1016/0891-5849(95)02111-6
   Toyokuni S, 2002, REDOX REP, V7, P189, DOI 10.1179/135100002125000596
   VO TKO, 1991, CANCER LETT, V60, P25, DOI 10.1016/0304-3835(91)90045-J
   Wagner AFV, 1999, BIOCHEM BIOPH RES CO, V254, P306, DOI 10.1006/bbrc.1998.9931
NR 42
TC 9
Z9 12
U1 1
U2 8
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1475-6366
EI 1475-6374
J9 J ENZYM INHIB MED CH
JI J. Enzym. Inhib. Med. Chem.
PD APR
PY 2006
VL 21
IS 2
BP 179
EP 185
DI 10.1080/14756360500533109
PG 7
WC Biochemistry & Molecular Biology; Chemistry, Medicinal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy
GA 059VU
UT WOS:000238761100008
PM 16789432
DA 2024-02-19
ER

PT J
AU Avanaz, A
   Dogru, V
   Kisaoglu, A
   Yilmaz, VT
   Unal, DS
   Demiryilmaz, I
   Dinc, B
   Adanir, H
   Aydinli, B
AF Avanaz, Ali
   Dogru, Volkan
   Kisaoglu, Abdullah
   Yilmaz, Vural Taner
   Unal, Demet Saridemir
   Demiryilmaz, Ismail
   Dinc, Bora
   Adanir, Haydar
   Aydinli, Bulent
TI Impact of older age on the long-term survival in living-donor liver
   transplantation: A propensity score matching analysis
SO ASIAN JOURNAL OF SURGERY
LA English
DT Article
DE Aging; Differential mortality; Elderly; Liver transplantation; Survival
ID OUTCOMES; PREDICTION; RECIPIENTS; MODEL; MELD
AB Background: Prevalence of the end-stage liver disease in the elderly patients indicating a liver trans-plantation (LT) has been increasing. There is no universally accepted upper age limit for LT candidates but the functional status of older patients is important in pre-LT evaluation. This study aimed to examine the impact of older age on survival after living donor liver transplantation (LDLT).Method: A total of 171 LDLT recipients were assessed in two groups: age >= 65 and < 65. To eliminate selection bias propensity score matching (PSM) was performed, and 56 of 171 recipients were included in this study.Results: There were 20 recipients in the older group and 36 in the younger. The 1-, 3-, and 5-year survival rates were 65.0%, 60.0%, and 60.0% in group 1; 88.9%, 84.7%, and 71.4% in group 2, respectively. The 1-year survival was significantly lower in the older recipients; however, overall survival rates were similar between the groups. Of the 56 recipients, 15 (27%) deaths were observed in overall, and 11 (20%) in 1 -year follow-up. The univariate regression analysis after PSM revealed that MELD score affected 1-year survival and the multivariate analysis revealed that age >= 65 years and MELD score were the predictors of 1-year survival.Conclusion: At first sight, before PSM, survival appeared to be worse for older recipients. However, we have shown that there were confounding effects of clinical variables in the preliminary evaluation. After the elimination of this bias with PSM, This study highlights that older recipients have similar outcomes as youngers in LDLT for long-term survival.(c) 2021 Asian Surgical Association and Taiwan Robotic Surgery Association. Publishing services by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/ licenses/by-nc-nd/4.0/).
C1 [Avanaz, Ali; Kisaoglu, Abdullah; Yilmaz, Vural Taner; Demiryilmaz, Ismail; Aydinli, Bulent] Akdeniz Univ, Sch Med, Dept Organ Transplantat, Antalya, Turkey.
   [Dogru, Volkan; Unal, Demet Saridemir] Akdeniz Univ, Sch Med, Dept Gen Surg, Antalya, Turkey.
   [Dinc, Bora] Akdeniz Univ, Sch Med, Dept Anesthesiol, Antalya, Turkey.
   [Adanir, Haydar] Akdeniz Univ, Sch Med, Dept Gastroenterol, Antalya, Turkey.
   [Avanaz, Ali] Akdeniz Univ, Tip Fak Hastanesi, Dept Organ Transplantat, TR-07070 Konyaalti Antalya, Turkey.
C3 Akdeniz University; Akdeniz University; Akdeniz University; Akdeniz
   University; Akdeniz University
RP Avanaz, A (corresponding author), Akdeniz Univ, Sch Med, Dept Organ Transplantat, Antalya, Turkey.; Avanaz, A (corresponding author), Akdeniz Univ, Tip Fak Hastanesi, Dept Organ Transplantat, TR-07070 Konyaalti Antalya, Turkey.
EM aliavanaz@hotmail.com
RI Adanır, haydar/JEZ-5664-2023; Doğru, Volkan/AAE-9112-2019; Dinc,
   Bora/I-6733-2017; Avanaz, Ali/AAD-1134-2022; Kisaoglu,
   Abdullah/G-9996-2018; YILMAZ, VURAL TANER/I-6139-2017
OI Adanır, haydar/0000-0003-1899-5846; Doğru, Volkan/0000-0002-6468-622X;
   Dinc, Bora/0000-0001-5700-8917; Avanaz, Ali/0000-0002-4559-4258; YILMAZ,
   VURAL TANER/0000-0002-1313-8856; kisaoglu, abdullah/0000-0001-5646-7484
CR Bilbao I, 2008, CLIN TRANSPLANT, V22, P82, DOI 10.1111/j.1399-0012.2007.00749.x
   Chen CL, 2013, NAT REV GASTRO HEPAT, V10, P746, DOI 10.1038/nrgastro.2013.194
   Collins BH, 2000, TRANSPLANTATION, V70, P780, DOI 10.1097/00007890-200009150-00012
   Dopazo C, 2015, HEPATOL INT, V9, P461, DOI 10.1007/s12072-014-9577-x
   Durand F, 2019, J HEPATOL, V70, P745, DOI 10.1016/j.jhep.2018.12.009
   Eurotransplant, 2021, STAT REP LIB
   Gil E, 2018, TRANSPLANTATION, V102, P2025, DOI 10.1097/TP.0000000000002246
   Habib S, 2006, LIVER TRANSPLANT, V12, P440, DOI 10.1002/lt.20721
   Hakeem Abdul Rahman, 2021, Liver Transpl, V27, P1273, DOI 10.1002/lt.26061
   Ikegami T, 2014, LIVER TRANSPLANT, V20, P408, DOI 10.1002/lt.23825
   Kaplan A, 2021, LIVER TRANSPLANT, V27, P165, DOI 10.1002/lt.25952
   Konerman MA, 2017, TRANSPLANTATION, V101, P1645, DOI 10.1097/TP.0000000000001710
   Koshy AN, 2020, EUR HEART J-QUAL CAR, V6, P243, DOI 10.1093/ehjqcco/qcaa009
   Kuramitsu K, 2007, TRANSPLANTATION, V84, P166, DOI 10.1097/01.tp.0000269103.87633.06
   Li HY, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000002499
   Luca A, 2007, LIVER TRANSPLANT, V13, P1174, DOI 10.1002/lt.21197
   Olthoff KM, 2011, LIVER TRANSPLANT, V17, P789, DOI 10.1002/lt.22288
   Pamecha V, 2016, HEPATOL INT, V10, P657, DOI 10.1007/s12072-016-9715-8
   Procurement Organ Transplantation Network, 2021, OPTN SRTR 2019 ANN D
   Schwartz JJ, 2012, LIVER TRANSPLANT, V18, P423, DOI 10.1002/lt.23385
   Sonny A, 2015, CLIN TRANSPLANT, V29, P197, DOI 10.1111/ctr.12500
   Su F, 2016, GASTROENTEROLOGY, V150, P441, DOI 10.1053/j.gastro.2015.10.043
   Tovikkai C, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2014-006971
   Ushigome H, 2016, TRANSPL P, V48, P1115, DOI 10.1016/j.transproceed.2015.12.103
   Yoshizumi T, 2010, TRANSPLANTATION, V90, P433, DOI 10.1097/TP.0b013e3181e81b2d
NR 25
TC 1
Z9 1
U1 7
U2 13
PU ELSEVIER SINGAPORE PTE LTD
PI SINGAPORE
PA 3 KILLINEY ROAD 08-01, WINSLAND HOUSE 1, SINGAPORE, 239519, SINGAPORE
SN 1015-9584
EI 0219-3108
J9 ASIAN J SURG
JI Asian J. Surg.
PD NOV
PY 2022
VL 45
IS 11
BP 2239
EP 2245
DI 10.1016/j.asjsur.2021.11.061
PG 7
WC Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Surgery
GA 6I4MS
UT WOS:000886102000014
PM 34955343
OA gold
DA 2024-02-19
ER

PT J
AU Sullivan, EM
   Fix, A
   Crouch, MJ
   Sparagna, GC
   Zeczycki, TN
   Brown, DA
   Shaikh, SR
AF Sullivan, E. Madison
   Fix, Amy
   Crouch, Miranda J.
   Sparagna, Genevieve C.
   Zeczycki, Tonya N.
   Brown, David A.
   Shaikh, Saame Raza
TI Murine diet-induced obesity remodels cardiac and liver mitochondrial
   phospholipid acyl chains with differential effects on respiratory enzyme
   activity
SO JOURNAL OF NUTRITIONAL BIOCHEMISTRY
LA English
DT Article
DE Cardiolipin; High-fat diet; Membranes; Mitochondria; Obesity;
   Polyunsaturated fatty acids
ID POLYUNSATURATED FATTY-ACIDS; COMPLEX-I ACTIVITY; BARTH-SYNDROME;
   HEART-FAILURE; RAT-HEART; CARDIOVASCULAR-DISEASE;
   TETRALINOLEOYL-CARDIOLIPIN; SHOTGUN LIPIDOMICS; INNER MEMBRANE; FISH-OIL
AB Cardiac phospholipids, notably cardiolipin, undergo acyl chain remodeling and/or loss of content in aging and cardiovascular diseases, which is postulated to mechanistically impair mitochondrial function. Less is known about how diet-induced obesity influences cardiac phospholipid acyl chain composition and thus mitochondrial responses. Here we first tested if a high fat diet remodeled murine cardiac mitochondrial phospholipid acyl chain composition and consequently disrupted membrane packing, supercomplex formation and respiratory enzyme activity. Mass spectrometry analyses revealed that mice consuming a high fat diet displayed 0.8-3.3 fold changes in cardiac acyl chain remodeling of cardiolipin, phosphatidylcholine, and phosphatidylethanolamine. Biophysical analysis of monolayers constructed from mitochondrial phospholipids of obese mice showed impairment in the packing properties of the membrane compared to lean mice. However, the high fat diet, relative to the lean controls, had no influence on cardiac mitochondrial supercomplex formation, respiratory enzyme activity, and even respiration. To determine if the effects were tissue specific, we subsequently conducted select studies with liver tissue. Compared to the control diet, the high fat diet remodeled liver mitochondrial phospholipid acyl chain composition by 0.6-5.3-fold with notable increases in n-6 and n-3 polyunsaturation. The remodeling in the liver was accompanied by diminished complex I to III respiratory enzyme activity by 3.5-fold. Finally, qRT-PCR analyses demonstrated an upregulation of liver mRNA levels of tafazzin, which contributes to cardiolipin remodeling. Altogether, these results demonstrate that diet-induced obesity remodels acyl chains in the mitochondrial phospholipidome and exerts tissue specific impairments of respiratory enzyme activity. (C) 2017 Elsevier Inc. All rights reserved.
C1 [Sullivan, E. Madison; Fix, Amy; Crouch, Miranda J.; Zeczycki, Tonya N.; Shaikh, Saame Raza] East Carolina Univ, Brody Sch Med, Dept Biochem & Mol Biol, 115 Heart Dr, Greenville, NC 27834 USA.
   [Sullivan, E. Madison; Fix, Amy; Crouch, Miranda J.; Zeczycki, Tonya N.; Shaikh, Saame Raza] East Carolina Univ, East Carolina Diabet & Obes Inst, Brody Sch Med, 115 Heart Dr, Greenville, NC 27834 USA.
   [Sparagna, Genevieve C.] Univ Colorado Denver, Div Cardiol, Dept Med, Anschutz Med Campus, Aurora, CO 80045 USA.
   [Brown, David A.] Virginia Tech, Corp Res Ctr, Dept Human Nutr Foods & Exercise, 1981 Kraft Dr, Blacksburg, VA 24060 USA.
C3 University of North Carolina; East Carolina University; University of
   North Carolina; East Carolina University; Children's Hospital Colorado;
   University of Colorado System; University of Colorado Anschutz Medical
   Campus; Virginia Polytechnic Institute & State University
RP Shaikh, SR (corresponding author), East Carolina Univ, East Carolina Diabet & Obes Inst, Brody Sch Med, 115 Heart Dr, Greenville, NC 27834 USA.
EM shaikhsa@ecu.edu
OI Zeczycki, Tonya/0000-0002-5216-1960
FU NIH [R01HL123647, R15HL12292201]
FX Research was supported by NIH R01HL123647 (S.R.S. and D.A.B.) and NIH
   R15HL12292201 (S.R.S. and D.A.B.).
CR Acin-Pérez R, 2008, MOL CELL, V32, P529, DOI 10.1016/j.molcel.2008.10.021
   Alleman RJ, 2016, AM J PHYSIOL-HEART C, V310, pH1360, DOI 10.1152/ajpheart.00858.2015
   Arnarez C, 2013, SCI REP-UK, V3, DOI 10.1038/srep01263
   Arnarez C, 2013, J AM CHEM SOC, V135, P3112, DOI 10.1021/ja310577u
   Baile MG, 2014, J BIOL CHEM, V289, P1768, DOI 10.1074/jbc.M113.525733
   Belke DD, 2000, AM J PHYSIOL-ENDOC M, V279, pE1104, DOI 10.1152/ajpendo.2000.279.5.E1104
   BLUME A, 1979, BIOCHIM BIOPHYS ACTA, V557, P32, DOI 10.1016/0005-2736(79)90087-7
   Boudina S, 2005, CIRCULATION, V112, P2686, DOI 10.1161/CIRCULATIONAHA.105.554360
   BRADY LJ, 1983, AM J PHYSIOL, V245, pE239, DOI 10.1152/ajpendo.1983.245.3.E239
   Brainard RE, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083174
   Brown DA, 2013, PHARMACOL THERAPEUT, V140, P258, DOI 10.1016/j.pharmthera.2013.07.005
   Cao JS, 2004, J BIOL CHEM, V279, P31727, DOI 10.1074/jbc.M402930200
   Chavin KD, 1999, J BIOL CHEM, V274, P5692, DOI 10.1074/jbc.274.9.5692
   Crescenzo R, 2008, OBESITY, V16, P958, DOI 10.1038/oby.2008.10
   DeBoer MD, 2013, NUTRITION, V29, P379, DOI 10.1016/j.nut.2012.07.003
   Desagher S, 2000, TRENDS CELL BIOL, V10, P369, DOI 10.1016/S0962-8924(00)01803-1
   EBLE KS, 1990, J BIOL CHEM, V265, P19434
   Fan YY, 2003, J NUTR, V133, P1913, DOI 10.1093/jn/133.6.1913
   Genova ML, 2015, ANTIOXID REDOX SIGN, V23, P208, DOI 10.1089/ars.2014.6214
   Genova ML, 2014, BBA-BIOENERGETICS, V1837, P427, DOI 10.1016/j.bbabio.2013.11.002
   Ginsberg Henry N, 2009, J Cardiometab Syndr, V4, P113, DOI 10.1111/j.1559-4572.2008.00044.x
   Gómez LA, 2009, ARCH BIOCHEM BIOPHYS, V490, P30, DOI 10.1016/j.abb.2009.08.002
   Hagopian K, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012696
   Han XL, 2007, BIOCHEMISTRY-US, V46, P6417, DOI 10.1021/bi7004015
   Han XL, 2005, BIOCHEMISTRY-US, V44, P16684, DOI 10.1021/bi051908a
   Iverson SL, 2004, ARCH BIOCHEM BIOPHYS, V423, P37, DOI 10.1016/j.abb.2003.12.002
   Kiebish MA, 2013, J LIPID RES, V54, P1312, DOI 10.1194/jlr.M034728
   Kris-Etherton PM, 2002, CIRCULATION, V106, P2747, DOI 10.1161/01.CIR.0000038493.65177.94
   Lavie CJ, 2009, J AM COLL CARDIOL, V54, P585, DOI 10.1016/j.jacc.2009.02.084
   Le CH, 2014, CIRC-HEART FAIL, V7, P172, DOI 10.1161/CIRCHEARTFAILURE.113.000744
   Lee HJ, 2006, LIPIDS HEALTH DIS, V5, DOI 10.1186/1476-511X-5-2
   Li J., 2010, ZHONGGUO DANGDAI ERK, V12, P479, DOI [DOI 10.5194/ACP-12-7591-2012, DOI 10.1016/J.EC0INF.2010.12.003]
   Mantena SK, 2009, BIOCHEM J, V417, P183, DOI 10.1042/BJ20080868
   Marsh D, 1996, BBA-REV BIOMEMBRANES, V1286, P183, DOI 10.1016/S0304-4157(96)00009-3
   McKenzie M, 2006, J MOL BIOL, V361, P462, DOI 10.1016/j.jmb.2006.06.057
   Mulligan CM, 2014, J GERONTOL A-BIOL, V69, P799, DOI 10.1093/gerona/glt209
   Paradies G, 2002, GENE, V286, P135, DOI 10.1016/S0378-1119(01)00814-9
   Paradies G, 1999, FREE RADICAL BIO MED, V27, P42, DOI 10.1016/S0891-5849(99)00032-5
   Paradies G, 2004, CIRC RES, V94, P53, DOI 10.1161/01.RES.0000109416.56608.64
   Pennington ER, 2016, BIOCHIM BIOPHYS ACTA, V1859, P257
   Pérez-Carreras M, 2003, HEPATOLOGY, V38, P999, DOI 10.1053/jhep.2003.50398
   Perry CGR, 2013, DIABETES, V62, P1041, DOI 10.2337/db12-1219
   Petrosillo G, 2005, BBA-BIOENERGETICS, V1710, P78, DOI 10.1016/j.bbabio.2005.10.003
   Petrosillo G, 2003, FASEB J, V17, P2202, DOI 10.1096/fj.03-0012com
   Planas-Iglesias J, 2015, BIOPHYS J, V109, P1282, DOI 10.1016/j.bpj.2015.07.034
   Renner LD, 2011, P NATL ACAD SCI USA, V108, P6264, DOI 10.1073/pnas.1015757108
   Rosca MG, 2008, CARDIOVASC RES, V80, P30, DOI 10.1093/cvr/cvn184
   Schlame M, 2003, J AM COLL CARDIOL, V42, P1994, DOI 10.1016/j.jacc.2003.06.015
   Schlame M, 2002, ANN NEUROL, V51, P634, DOI 10.1002/ana.10176
   Schlame M, 2013, BBA-MOL CELL BIOL L, V1831, P582, DOI 10.1016/j.bbalip.2012.11.007
   Shaikh SR, 2014, BIOCHEMISTRY-US, V53, P5589, DOI 10.1021/bi500868g
   Shaikh SR, 2012, J NUTR BIOCHEM, V23, P101, DOI 10.1016/j.jnutbio.2011.07.001
   Shaikh SR, 2006, AM J CLIN NUTR, V84, P1277, DOI 10.1093/ajcn/84.6.1277
   Shaikh SR, 2001, BBA-BIOMEMBRANES, V1512, P317, DOI 10.1016/S0005-2736(01)00335-2
   Sorice M, 2009, FEBS LETT, V583, P2447, DOI 10.1016/j.febslet.2009.07.018
   Sparagna GC, 2005, J LIPID RES, V46, P1196, DOI 10.1194/jlr.M500031-JLR200
   Sparagna GC, 2007, J LIPID RES, V48, P1559, DOI 10.1194/jlr.M600551-JLR200
   Stanley WC, 2012, CIRC RES, V110, P764, DOI [10.1161/CIRCRESAHA.111.253104, 10.1161/circresaha.111.253104]
   Stringer DM, 2009, PEDIATR DIABETES, V10, P269, DOI 10.1111/j.1399-5448.2008.00473.x
   Taegtmeyer H, 2004, CIRCULATION, V110, P894, DOI 10.1161/01.CIR.0000139340.88769.D5
   Taylor WA, 2009, J BIOL CHEM, V284, P30360, DOI 10.1074/jbc.M109.048322
   Unsay JD, 2013, LANGMUIR, V29, P15878, DOI 10.1021/la402669z
   Van Gaal LF, 2006, NATURE, V444, P875, DOI 10.1038/nature05487
   Vecchini A, 2000, J MOL CELL CARDIOL, V32, P1061, DOI 10.1006/jmcc.2000.1140
   Vreken P, 2000, BIOCHEM BIOPH RES CO, V279, P378, DOI 10.1006/bbrc.2000.3952
   Wilkens V, 2013, J CELL SCI, V126, P103, DOI 10.1242/jcs.108852
   Williams JA, 2012, BIOPHYS J, V103, P228, DOI 10.1016/j.bpj.2012.06.016
   Xu Y, 2005, LAB INVEST, V85, P823, DOI 10.1038/labinvest.3700274
   Ye CQ, 2016, J BIOENERG BIOMEMBR, V48, P113, DOI 10.1007/s10863-014-9591-7
   Yu LP, 2014, J BIOENERG BIOMEMBR, V46, P33, DOI 10.1007/s10863-013-9530-z
   Zeczycki TN, 2014, BIOCHEM BIOPH RES CO, V450, P366, DOI 10.1016/j.bbrc.2014.05.133
   Zhang M, 2005, J BIOL CHEM, V280, P29403, DOI 10.1074/jbc.M504955200
   Zhang M, 2002, J BIOL CHEM, V277, P43553, DOI 10.1074/jbc.C200551200
NR 73
TC 28
Z9 29
U1 1
U2 10
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0955-2863
EI 1873-4847
J9 J NUTR BIOCHEM
JI J. Nutr. Biochem.
PD JUL
PY 2017
VL 45
BP 94
EP 103
DI 10.1016/j.jnutbio.2017.04.004
PG 10
WC Biochemistry & Molecular Biology; Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Nutrition & Dietetics
GA EY4VS
UT WOS:000403976300010
PM 28437736
OA Green Accepted
DA 2024-02-19
ER

PT J
AU Husler, MR
   Beamer, WG
   Boggess, D
   Sundberg, BA
   Sundberg, JP
AF Husler, MR
   Beamer, WG
   Boggess, D
   Sundberg, BA
   Sundberg, JP
TI Neoplastic and hyperplastic lesions in aging C3H/HeJ mice
SO JOURNAL OF EXPERIMENTAL ANIMAL SCIENCE
LA English
DT Article
DE C3H/HeJ; mouse tumors; mammary cancer; ovarian cancer; cystic
   endometrial hyperplasia; hepatocellular adenoma; adrenocortical adenoma;
   and pancreatic islet hyperplasia
ID GRANULOSA-CELL TUMORIGENESIS; INBRED LABORATORY MICE; TUMORS; CANCER;
   SUBSTRAIN; C57BL/6J; HORMONES
AB The C3H/HeJ inbred mouse strain is commonly used in biomedical research. An important feature of inbred mouse strains, such as C3H/HeJ, is the propensity to develop a limited variety of neoplasms, the morphologic features of which are remarkably similar between individual animals Necropsies of 864 C3H/HeJ female and male mice, ranging in age from 10 days to two years, revealed 16 types of neoplastic (mammary. liver, ovarian, adrenocortical, and other less frequent neoplasms) and three types of hyperplastic (luteal cell hyperplasia, cystic endometrial hyperplasia, and pancreatic islet hyperplasia) diseases. Most of the tumors were first observed at 10-12 months of age and increased in frequency as mice aged. Ovarian tumors, mammary adenocarcinoma, hepatocellular adenoma, and cystic endometrial hyperplasia were the most frequent lesions in female mice. Hepatocellular adenoma, adrenocortical adenoma, and pancreatic islet hyperplasia were the most common lesions in male mice. Coincidence of hepatocellular adenoma, adrenocortical adenoma, and pancreatic islet hyperplasia in male C3H/HeJ mice, and of ovarian tumors? mammary adenocarcinoma, and cystic endometrial hyperplasia in female mice were statistically significant. The most common tumors observed in this study remain the types originally described for the C3H/HeJ strain, despite long term inbreeding and changes in husbandry conditions. These data on tumor types occurring in the C3H/HeJ inbred mouse strain are valuable as baseline information for interpretation of drug safety studies and for characterization of new spontaneous or induced mutations.
C1 Jackson Lab, Bar Harbor, ME 04609 USA.
C3 Jackson Laboratory
RP Sundberg, JP (corresponding author), Jackson Lab, 600 Main St, Bar Harbor, ME 04609 USA.
EM jps@jax.org
CR ALISON RH, 1987, MONOGRAPHS PATHOLOGY, P46
   ALISON RH, 1987, GENITAL SYSTEM, P22
   ANDERVONT HB, 1950, JNCI-J NATL CANCER I, V11, P581
   [Anonymous], SPONTANEOUS HYPERPLA
   [Anonymous], PATHOBIOLOGY AGING M
   BEAMER WG, 1988, CANCER RES, V48, P5092
   BEAMER WG, 1985, CANCER RES, V45, P5575
   BECKER FF, 1982, CANCER RES, V42, P3918
   BENTVELZEN P, 1969, JNCI-J NATL CANCER I, V43, P1025
   BOOTH C, 1996, PATHOBIOLOGY AGING M, P51
   BOYD AE, 1994, HARRISONS PRINCIPLE, P2052
   BURNS EDWARD L., 1940, AMER JOUR CANCER, V39, P25
   DERINGER MK, 1959, J NATL CANCER I, V22, P995, DOI 10.1093/jnci/22.5.995
   DERINGER MK, 1969, J NATL CANCER I, V43, P1347
   DOBBIE JW, 1969, J PATHOL, V99, P1, DOI 10.1002/path.1710990102
   DRINKWATER NR, 1986, CARCINOGENESIS, V7, P1701, DOI 10.1093/carcin/7.10.1701
   Dunn T.B., 1958, PHYSIOPATHOLOGY CANC, P38
   DUNN TB, 1979, IARC SCI PUBL, V23
   ENOMOTO M, 1996, PATHOBIOLOGY AGING M, P251
   Festing MF, 1996, GENETIC VARIANTS STR, P1537
   FIRTH CH, 1994, IARC SCI PUBLICATION, V111
   FUJIMORI M, 1992, AM J HUM GENET, V50, P399
   Gorer PA, 1940, J PATHOL BACTERIOL, V50, P17, DOI 10.1002/path.1700500104
   Green M. C., 1991, HDB GENETICALLY STAN
   HANIGAN MH, 1988, CARCINOGENESIS, V9, P885, DOI 10.1093/carcin/9.6.885
   HELZLSOUER KJ, 1995, CANCER-AM CANCER SOC, V76, P2059, DOI 10.1002/1097-0142(19951115)76:10+<2059::AID-CNCR2820761325>3.0.CO;2-1
   HESTON WE, 1960, J NATL CANCER I, V24, P425
   HOWELL S, 1985, AM J PATHOL, V121, P426
   Kingpin KT, 1987, MONOGRAPHS PATHOLOGY, P36
   Lichter J B, 1992, Henry Ford Hosp Med J, V40, P199
   LLOYD RV, 1986, AM J PATHOL, V125, P45
   MEDINA D, 1974, J NATL CANCER I, V53, P213, DOI 10.1093/jnci/53.1.213
   Mohr U, 1996, PATHOBIOLOGY AGING M
   MORGAN KT, 1987, MONOGRAPHS PATHOLOGY, P42
   MURPHY ED, 1972, J NATL CANCER I, V48, P1283
   MURPHY ED, 1975, BIOL LABORATORY MOUS, P521
   OUTZEN HC, 1985, J NATL CANCER I, V75, P917, DOI 10.1093/jnci/75.5.917
   PETERS RL, 1972, INT J CANCER, V10, P273, DOI 10.1002/ijc.2910100207
   Potischman N, 1996, J NATL CANCER I, V88, P1127, DOI 10.1093/jnci/88.16.1127
   RHEM S, 1996, PATHOLOGY AGING MOUS, P318
   RHEM S, 1989, MONOGRAPHS PATHOLOGY, P319
   SHEEHAN D, 1980, THEORY PRACTICE HIST, P274
   Snedecor G. W., 1980, STAT METHODS
   *STAFF JACKS MEM L, SCIENCE, V465, P33
   STEVENS LC, 1976, AM J PATHOL, V85, P809
   SUNDBERG JP, 1991, VET PATHOL, V28, P313, DOI 10.1177/030098589102800408
   SUNDBERG JP, 1994, J INVEST DERMATOL, V102, P847, DOI 10.1111/1523-1747.ep12382416
   SUNDBERG JP, 1991, VET PATHOL, V28, P200, DOI 10.1177/030098589102800303
   SUNDBERG JP, 1994, GASTROENTEROLOGY, V107, P1726, DOI 10.1016/0016-5085(94)90813-3
   Sundberg JP, 1994, HDB MOUSE MUTATIONS, P499
   TENNENT BJ, 1993, CANCER RES, V53, P1059
   TENNENT BJ, 1990, AM J OBSTET GYNECOL, V163, P625, DOI 10.1016/0002-9378(90)91214-W
   TURUSOV V, 1994, IARC SCI PUBLICATION, V111
   VANDERVALK MA, 1981, MAMMARY TUMORS MOUSE, P45
   VANLEEUWEN F, 1995, SEMIN CANCER BIOL, V6, P127, DOI 10.1006/scbi.1995.0018
   WARD JM, 1978, J NATL CANCER I, V61, P807
   WOOLLEY GW, 1945, CANCER RES, V5, P193
   Yarrington JT, 1996, PATHOBIOLOGY AGING M, P125
   ZAK F, 1983, MONOGRAPHS PATHOLOGY, P74
NR 59
TC 4
Z9 5
U1 0
U2 2
PU ELSEVIER GMBH
PI MUNICH
PA HACKERBRUCKE 6, 80335 MUNICH, GERMANY
SN 0939-8600
J9 J EXP ANIM SCI
JI J. Exp. Anim. Sci.
PD MAR
PY 1998
VL 38
IS 4
BP 165
EP 180
PG 16
WC Zoology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Zoology
GA ZH895
UT WOS:000073158200002
DA 2024-02-19
ER

PT J
AU Higgins, J
   Proctor, D
   Denyer, G
AF Higgins, J
   Proctor, D
   Denyer, G
TI Aging changes tissue-specific glucose metabolism in rats
SO METABOLISM-CLINICAL AND EXPERIMENTAL
LA English
DT Article
ID INSULIN-RESISTANCE; SENSITIVITY; HYPERINSULINEMIA; MUSCLE; DIET; AGE
AB This study defines the tissue-specific changes in glucose metabolic flux that occur over time prior to the onset of whole-body insulin resistance in rats. Rats at 6 weeks of age were maintained on a high-carbohydrate diet for either 12 or 26 weeks, at which time euglycemic clamps were performed at basal and midphysiological plasma insulin concentrations. Following death, insulin-sensitive tissues were excised and frozen until assayed for the rate of glucose uptake, glycogenesis, and lipogenesis. Glucose metabolic flux, particularly through glycogenesis, was reduced between 18 and 32 weeks of age in all tissues except the adipose tissues. For example, the rate of glycogenesis in liver at 18 weeks (117 +/- 10 nmol glucose incorporated/min/g) was more than double that observed at 32 weeks (54 +/- 8 nmol glucose incorporated/min/g. P < .01). Despite this, animals in the 32-week group displayed no impairment in whole-body glucose disposal, due to compensatory glucose uptake in white adipose tissue (WAT) and increased glucose flux through lipogenesis in brown adipose tissue (BAT). At 32 weeks, the rate of glucose uptake in WAT (85.0 +/- 5.6 nmol 2-deoxy-D-glucose phosphate accumulated/min/g) was approximately double that at 18 weeks (46.6 +/- 5.6 nmol 2-deoxy-D-glucose phosphate accumulated/min/g) was approximately double that at 18 weeks (46.6 +/- 5.6 nmol 2-deoxy-D-glucose phosphate accumulated/min/g, P < .01). These changes in insulin responsiveness in adipose tissue of older animals may underlie the increased adiposity that is currently thought to be the causative factor in the development of age-related insulin resistance. Copyright (C) 1999 by W.B. Saunders Company.
C1 Univ Colorado, Hlth Sci Ctr, Ctr Human Nutr, Denver, CO 80262 USA.
   St Vincents Hosp, Garvan Inst Med Res, Sydney, NSW 2010, Australia.
   Univ Sydney, Dept Biochem, Sydney, NSW 2006, Australia.
C3 University of Colorado System; University of Colorado Anschutz Medical
   Campus; University of Colorado Denver; Garvan Institute of Medical
   Research; NSW Health; St Vincents Hospital Sydney; University of Sydney
RP Higgins, J (corresponding author), Univ Colorado, Hlth Sci Ctr, Ctr Human Nutr, C225,4200 E 9th Ave, Denver, CO 80262 USA.
RI denyer, gareth/E-3437-2010
OI Higgins, Janine/0000-0002-4273-194X
CR BARNARD RJ, 1995, GERONTOLOGY, V41, P205
   Barzilai N, 1996, AM J PHYSIOL-ENDOC M, V270, pE930, DOI 10.1152/ajpendo.1996.270.6.E930
   BONADONNA RC, 1993, AM J PHYSIOL, V265, pE943, DOI 10.1152/ajpendo.1993.265.6.E943
   Colwell DR, 1996, INT J BIOCHEM CELL B, V28, P115, DOI 10.1016/1357-2725(95)00110-7
   COON PJ, 1992, J CLIN ENDOCR METAB, V75, P1125, DOI 10.1210/jc.75.4.1125
   DAVIDSON MB, 1979, METABOLISM, V28, P688, DOI 10.1016/0026-0495(79)90024-6
   Ferrannini E, 1996, DIABETES, V45, P947, DOI 10.2337/diabetes.45.7.947
   Higgins JA, 1996, J NUTR, V126, P596, DOI 10.1093/jn/126.3.596
   HUGGET A, 1957, LANCET, V24, P368
   KAHN SE, 1992, J CLIN ENDOCR METAB, V74, P1336, DOI 10.1210/jc.74.6.1336
   KRAEGEN EW, 1985, AM J PHYSIOL, V248, pE353
   PENICAUD L, 1987, DIABETES, V36, P626, DOI 10.2337/diabetes.36.5.626
   RANDLE PJ, 1988, DIABETES METAB REV, V4, P623, DOI 10.1002/dmr.5610040702
   WARDZALA LJ, 1985, J CLIN INVEST, V76, P460, DOI 10.1172/JCI111994
NR 14
TC 8
Z9 8
U1 0
U2 0
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0026-0495
EI 1532-8600
J9 METABOLISM
JI Metab.-Clin. Exp.
PD NOV
PY 1999
VL 48
IS 11
BP 1445
EP 1449
DI 10.1016/S0026-0495(99)90157-9
PG 5
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Endocrinology & Metabolism
GA 256VM
UT WOS:000083747200019
PM 10582555
DA 2024-02-19
ER

PT J
AU McKinzie, PB
   McKim, KL
   Pearce, MG
   Bishop, ME
   Parsons, BL
AF McKinzie, Page B.
   McKim, Karen L.
   Pearce, Mason G.
   Bishop, Michelle E.
   Parsons, Barbara L.
TI Lifespan <i>Kras</i> mutation levels in lung and liver of
   B6C3F<sub>1</sub> mice
SO ENVIRONMENTAL AND MOLECULAR MUTAGENESIS
LA English
DT Article
DE carcinogenesis; spontaneous; quantification; oncogene mutation;
   cancer-driver mutation; ACB-PCR
ID AIRBORNE PARTICULATE MATTER; SOMATIC MUTATIONS; MUTANT FRACTION; AGING
   PROCESS; TIME COURSES; FREQUENCY; TISSUE; AGE; CANCER; CELLS
AB Somatic mutations accumulate in the human genome and are correlated with increased cancer incidence as humans age. The standard model for studying the carcinogenic effects of exposures for human risk assessment is the rodent 2-year carcinogenicity assay. However, there is little information regarding the effect of age on cancer-driver gene mutations in these models. The mutant fraction (MF) of Kras codon 12 GGT to GAT and GGT to GTT mutations, oncogenic mutations orthologous between humans and rodents, was quantified over the lifespan of B6C3F1 mice. MFs were measured in lung and liver tissue, organs that frequently develop tumors following carcinogenic exposures. The MFs were evaluated at 4, 6, 8, 12, 21, and 85 weeks, with the 12-week and 21-week time points being coincident with the conclusion of 28-day and 90-day exposure durations used in short-term toxicity testing. The highly sensitive and quantitative Allele-specific Competitive Blocker PCR (ACB-PCR) assay was used to quantify the number of mutant Kras codon 12 alleles. The mouse lung showed a slight, but significant trend increase in the Kras codon 12 GAT mutation over the 85-week period. The trend with age can be equally well-fit by several non-linear functions, but not by a linear function. In contrast, the liver GAT mutation did not increase, and the GTT mutation did not increase for either organ. Even with the slight increase in the lung GAT MFs, our results indicate that the future use of Kras mutation as a biomarker of carcinogenic effect will not be confounded by animal age. Environ. Mol. Mutagen. 59:715-721, 2018. Published 2018. This article is a U.S. Government work and is in the public domain in the USA.
C1 [McKinzie, Page B.; McKim, Karen L.; Pearce, Mason G.; Bishop, Michelle E.; Parsons, Barbara L.] Natl Ctr Toxicol Res, Div Genet & Mol Toxicol, Jefferson, AR 72079 USA.
C3 US Food & Drug Administration (FDA)
RP McKinzie, PB (corresponding author), HFT 120 3900 NCTR Rd, Jefferson, AR 72079 USA.
EM page.mckinzie@fda.hhs.gov
RI McKinzie, Page/D-1008-2009
OI McKinzie, Page/0000-0001-6886-6546; Parsons, Barbara/0000-0002-3005-2552
CR [Anonymous], GUID IND NEED LONG T
   Banda M, 2015, MUTAT RES-GEN TOX EN, V789, P53, DOI 10.1016/j.mrgentox.2015.07.003
   Birben E, 2012, WORLD ALLERGY ORGAN, V5, P9, DOI 10.1097/WOX.0b013e3182439613
   Blokzijl F, 2016, NATURE, V538, P260, DOI 10.1038/nature19768
   Cho AK, 2005, ENVIRON RES, V99, P40, DOI 10.1016/j.envres.2005.01.003
   FAILLA G, 1958, ANN NY ACAD SCI, V71, P1124, DOI 10.1111/j.1749-6632.1958.tb46828.x
   FREEMAN BA, 1982, LAB INVEST, V47, P412
   Gold LS, 2001, TOXICOL PATHOL, V29, P639, DOI 10.1080/019262301753385979
   GRIST SA, 1992, MUTAT RES, V266, P189, DOI 10.1016/0027-5107(92)90186-6
   Hill KA, 2005, ENVIRON MOL MUTAGEN, V45, P442, DOI 10.1002/em.20119
   Hill KA, 2004, ENVIRON MOL MUTAGEN, V43, P110, DOI 10.1002/em.20004
   Martin GM, 1996, HUM MOL GENET, V5, P215, DOI 10.1093/hmg/5.2.215
   McKinzie PB, 2006, MUTAGENESIS, V21, P391, DOI 10.1093/mutage/gel041
   McKinzie PB, 2011, ENVIRON MOL MUTAGEN, V52, P409, DOI 10.1002/em.20644
   McKinzie PB, 2002, MUTAT RES-GEN TOX EN, V517, P209, DOI 10.1016/S1383-5718(02)00077-3
   Melin VE, 2016, REPROD TOXICOL, V59, P159, DOI 10.1016/j.reprotox.2015.10.006
   Melin VE, 2014, REPROD TOXICOL, V50, P163, DOI 10.1016/j.reprotox.2014.07.071
   Milholland B, 2015, ONCOTARGET, V6, P24627, DOI 10.18632/oncotarget.5685
   Myers MB, 2014, METHODS MOL BIOL, V1105, P345, DOI 10.1007/978-1-62703-739-6_27
   Parsons BL, 2013, TOXICOL SCI, V136, P26, DOI 10.1093/toxsci/kft190
   ROBINSON DR, 1994, MUTAT RES-ENVIR MUTA, V313, P227, DOI 10.1016/0165-1161(94)90053-1
   Rosenbaum MD, 2010, J AM ASSOC LAB ANIM, V49, P177
   Rossi DJ, 2008, CELL, V132, P681, DOI 10.1016/j.cell.2008.01.036
   Stuart GR, 2000, GENETICS, V154, P1291
   SZILARD L, 1959, P NATL ACAD SCI USA, V45, P30, DOI 10.1073/pnas.45.1.30
   Tomasetti C, 2015, SCIENCE, V347, P78, DOI 10.1126/science.1260825
   Valavanidis A, 2008, J ENVIRON SCI HEAL C, V26, P339, DOI 10.1080/10590500802494538
   White RR, 2015, BMC GENOMICS, V16, DOI 10.1186/s12864-015-2061-8
NR 28
TC 1
Z9 1
U1 0
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0893-6692
EI 1098-2280
J9 ENVIRON MOL MUTAGEN
JI Environ. Mol. Mutagen.
PD OCT
PY 2018
VL 59
IS 8
BP 715
EP 721
DI 10.1002/em.22198
PG 7
WC Environmental Sciences; Genetics & Heredity; Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Environmental Sciences & Ecology; Genetics & Heredity; Toxicology
GA GW9AY
UT WOS:000447275100004
PM 30255594
DA 2024-02-19
ER

PT J
AU Yeo, HL
   O'Mahoney, PRA
   Lachs, M
   Michelassi, F
   Mao, JL
   Finlayson, E
   Abelson, JS
   Sedrakyan, A
AF Yeo, Heather L.
   O'Mahoney, Paul R. A.
   Lachs, Mark
   Michelassi, Fabrizio
   Mao, Jialin
   Finlayson, Emily
   Abelson, Jonathan S.
   Sedrakyan, Art
TI Surgical oncology outcomes in the aging US population
SO JOURNAL OF SURGICAL RESEARCH
LA English
DT Article
DE Gastrointestinal neoplasms; Surgical procedures; Operative; Aged; Aged;
   80 and over; Postoperative complications
ID AMERICAN-COLLEGE; RISK-FACTORS; OPERATIVE MORTALITY; ELDERLY-PATIENTS;
   ADVANCING AGE; SKILLED CARE; OLDER; SURGERY; COMORBIDITY; PATIENT
AB Background: As the population ages, an increasing number of older patients are undergoing major surgery. We examined the impact of advanced age on outcomes following major gastrointestinal cancer surgery in an era of improved surgical outcomes.
   Materials and methods: This was a population-based, retrospective cohort study using the American College of Surgeons National Surgical Quality Improvement Program database. We evaluated patients undergoing major abdominal gastrointestinal cancer surgery from 2005-2012. Multivariable logistic regression was performed to determine the independent effect of advanced age on outcomes. Our primary outcome was 30-d mortality, and our secondary outcomes were 30-d major postoperative adverse events, discharge disposition, length of stay, reoperation, and readmission.
   Results: Elderly (>= 65 y) patients were twice as likely to have multiple comorbidities as those < 65 y but prevalence of comorbidities was similar across all older age groups. Mortality increased with age across all procedures (P < 0.05). The risk of advanced age on mortality was highest in hepatectomy (odds ratio = 5.17, 95% confidence interval = 2.19-12.20) and that for major postoperative adverse events was highest in proctectomy (odds ratio = 2.32, 95% confidence interval = 1.53-3.52). Patients were more likely to be discharged to an institutional care facility as age increased across all procedures (P < 0.01).
   Conclusions: Despite being highly selected for surgery, elderly patients undergoing major gastrointestinal cancer surgery have substantially worse postoperative outcomes than younger patients (< 65 y). The risk of age on postoperative outcomes was present across all operations but had its highest association with liver and rectal cancer resections. (C) 2016 Elsevier Inc. All rights reserved.
C1 [Yeo, Heather L.; O'Mahoney, Paul R. A.; Michelassi, Fabrizio; Abelson, Jonathan S.] NewYork Presbyterian Weill Cornell Med Coll, Dept Surg, New York, NY USA.
   [Yeo, Heather L.; Mao, Jialin; Sedrakyan, Art] NewYork Presbyterian Weill Cornell Med Coll, Dept Healthcare Policy & Res, New York, NY USA.
   [Lachs, Mark] NewYork Presbyterian Weill Cornell Med Coll, Dept Geriatr & Palliat Med, New York, NY USA.
   [Finlayson, Emily] Univ Calif San Francisco, Dept Surg, Med Ctr, San Francisco, CA USA.
   [Finlayson, Emily] Univ Calif San Francisco, Med Ctr, Dept Med, San Francisco, CA USA.
   [Finlayson, Emily] Univ Calif San Francisco, Med Ctr, Dept Hlth Policy, San Francisco, CA USA.
C3 Cornell University; Weill Cornell Medicine; Cornell University; Weill
   Cornell Medicine; Cornell University; Weill Cornell Medicine; University
   of California System; University of California San Francisco; University
   of California System; University of California San Francisco; University
   of California System; University of California San Francisco
RP Yeo, HL (corresponding author), 525 East 68th St, New York, NY 10065 USA.
EM hey9002@med.cornell.edu
RI Mao, Jialin/AAA-4433-2021; Abelson, Jonathan/AAE-4692-2019
OI Mao, Jialin/0000-0001-6671-3474; 
FU New York State Empire Clinical Research Investigator Program (ECRIP)
FX H.L.Y. was supported through the New York State Empire Clinical Research
   Investigator Program (ECRIP) (salary support).
CR Al-Refaie WB, 2010, ANN SURG, V251, P311, DOI 10.1097/SLA.0b013e3181b6b04c
   Birkmeyer JD, 2003, NEW ENGL J MED, V349, P2117, DOI 10.1056/NEJMsa035205
   Cohen ME, 2016, ANN SURG, V263, P267, DOI 10.1097/SLA.0000000000001192
   Cykert S, 2010, JAMA-J AM MED ASSOC, V303, P2368, DOI 10.1001/jama.2010.793
   Duron JJ, 2011, ANN SURG, V254, P375, DOI 10.1097/SLA.0b013e318226a959
   Finks JF, 2011, NEW ENGL J MED, V364, P2128, DOI 10.1056/NEJMsa1010705
   Frakes JM, 2015, J GERIATR ONCOL, V6, P127, DOI 10.1016/j.jgo.2014.11.005
   Gajdos C, 2013, J AM GERIATR SOC, V61, P1608, DOI 10.1111/jgs.12401
   Gijsen R, 2001, J CLIN EPIDEMIOL, V54, P661, DOI 10.1016/S0895-4356(00)00363-2
   Hall BL, 2009, ANN SURG, V250, P363, DOI 10.1097/SLA.0b013e3181b4148f
   Hall Margaret Jean, 2010, Natl Health Stat Report, P1
   Hamel MB, 2005, J AM GERIATR SOC, V53, P424, DOI 10.1111/j.1532-5415.2005.53159.x
   Janssen-Heijnen MLG, 2007, EUR J CANCER, V43, P2179, DOI 10.1016/j.ejca.2007.06.008
   Kassin MT, 2012, J AM COLL SURGEONS, V215, P322, DOI 10.1016/j.jamcollsurg.2012.05.024
   Kelly KN, 2014, J GASTROINTEST SURG, V18, P35, DOI 10.1007/s11605-013-2354-7
   Kishida N, 2015, ANN SURG ONCOL, V22, P3094, DOI 10.1245/s10434-014-4350-x
   Kozower BD, 2009, J AM COLL SURGEONS, V209, P551, DOI 10.1016/j.jamcollsurg.2009.08.008
   Kuy S, 2011, AM J SURG, V201, P789, DOI 10.1016/j.amjsurg.2010.04.018
   Kwon S, 2012, AM SURGEON, V78, P1336
   Legner VJ, 2009, ANN SURG, V249, P250, DOI 10.1097/SLA.0b013e318195e12f
   Makary MA, 2006, J GASTROINTEST SURG, V10, P347, DOI 10.1016/j.gassur.2005.12.014
   Makary MA, 2010, J AM COLL SURGEONS, V210, P901, DOI 10.1016/j.jamcollsurg.2010.01.028
   Massarweh NN, 2009, ARCH SURG-CHICAGO, V144, P1108, DOI 10.1001/archsurg.2009.204
   Mohanty S, 2016, J AM COLL SURGEONS, V222, P930, DOI 10.1016/j.jamcollsurg.2015.12.026
   Nallamothu BK, 2005, J AM GERIATR SOC, V53, P1133, DOI 10.1111/j.1532-5415.2005.53356.x
   Nohra E, 2015, SURG CLIN N AM, V95, P85, DOI 10.1016/j.suc.2014.09.005
   Olshansky SJ, 2009, MILBANK Q, V87, P842, DOI 10.1111/j.1468-0009.2009.00581.x
   Partridge JSL, 2012, AGE AGEING, V41, P142, DOI 10.1093/ageing/afr182
   Pecanac KE, 2014, ANN SURG, V259, P458, DOI 10.1097/SLA.0000000000000314
   Sabel MS, 2002, ANN SURG ONCOL, V9, P210, DOI 10.1245/aso.2002.9.2.210
   Sheetz KH, 2013, ANN SURG, V258, P614, DOI 10.1097/SLA.0b013e3182a5021d
   Turrentine FE, 2006, J AM COLL SURGEONS, V203, P865, DOI 10.1016/j.jamcollsurg.2006.08.026
   van Gestel YRBM, 2013, ANN SURG ONCOL, V20, P371, DOI 10.1245/s10434-012-2663-1
   Zizza CA, 2009, J GERONTOL A-BIOL, V64, P481, DOI 10.1093/gerona/gln045
NR 34
TC 16
Z9 17
U1 0
U2 1
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0022-4804
EI 1095-8673
J9 J SURG RES
JI J. Surg. Res.
PD SEP
PY 2016
VL 205
IS 1
BP 11
EP 18
DI 10.1016/j.jss.2016.04.038
PG 8
WC Surgery
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Surgery
GA DW0VE
UT WOS:000383360300002
PM 27620993
DA 2024-02-19
ER

PT J
AU Carter, WG
   Aswad, DW
AF Carter, Wayne G.
   Aswad, Dana W.
TI Formation, localization, and repair of L-isoaspartyl sites in histones
   H2A and H2B in nucleosomes from rat liver and chicken erythrocytes
SO BIOCHEMISTRY
LA English
DT Article
ID PROTEIN-REPAIR; DEFICIENT MICE; O-METHYLTRANSFERASE; DAMAGED PROTEINS;
   DEAMIDATION; ENZYME; PEPTIDES; ASPARTYL; BRAIN; IDENTIFICATION
AB Formation Of L-isoaspartyl (isoAsp) peptide bonds is a major source of protein damage in vivo and in vitro. Accumulation of isoAsp in cells is limited by a ubiquitous repair enzyme, protein L-isoaspartyl methyltransferase (PIMT). Reduction of PIMT activity in mouse brain or rat PC 12 cells leads to a dramatic and selective accumulation of isoAsp sites in histone H2B. To learn more about the mechanism and specificity of isoAsp formation in histones, we purified mononucleosomes from rat liver and chicken erythrocytes and subjected them to in vitro aging for 0-16 days. In rat nucleosomes, the pattern of isoAsp accumulation duplicated that observed in vivo; only H2B accumulated significant isoAsp that we have now localized to the Asp25-Gly26 bond in the N-terminal tail. In chicken nucleosomes, isoAsp accumulated mainly in histone H2A and, to a lesser extent, in histone H2B. Minor sequence differences are consistent with the species-specific patterns of isoAsp accumulation and suggest that, in chicken, isoAsp occurs at the Asp121-Ser122 bond in the flexible C-terminal tail of H2A and at the Asp26-Lys27 bond in the N-terminal tail of H2B. The aging-induced accumulation of isoAsp in rat and chicken nucleosomes is repaired upon incubation of the damaged nucleosomes with PIMT and AdoMet. Our findings suggest that in vivo generation of isoAsp sites in histories occurs as a self-catalyzed process at the level of the nucleosome and is driven by the same structural features that have been shown to promote isoAsp formation in purified proteins and synthetic peptides.
C1 [Carter, Wayne G.; Aswad, Dana W.] Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA.
C3 University of California System; University of California Irvine
RP Aswad, DW (corresponding author), Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA.
EM dwaswad@uci.edu
RI Aswad, Dana/JDC-1599-2023
FU National Institutes of Health [NS17269]
FX This work was supported by National Institutes of Health Grant NS17269
   to D.W.A.
CR [Anonymous], COMMERCIAL COOLING F
   Brennan TV, 1995, DEAMIDATION ISOASPAR, P65
   CHAMBERLAIN JP, 1979, ANAL BIOCHEM, V98, P132, DOI 10.1016/0003-2697(79)90716-4
   CHIRPICH T, 1968, THESIS U CALIFORNIA
   Clarke S, 2003, AGEING RES REV, V2, P263, DOI 10.1016/S1568-1637(03)00011-4
   CLARKE S, 1987, INT J PEPT PROT RES, V30, P808, DOI 10.1111/j.1399-3011.1987.tb03390.x
   DAVID CL, 1995, PROTEIN EXPRES PURIF, V6, P312, DOI 10.1006/prep.1995.1041
   Doyle HA, 2003, J IMMUNOL, V171, P2840, DOI 10.4049/jimmunol.171.6.2840
   Farrar C, 2005, AGING CELL, V4, P1, DOI 10.1111/j.1474-9728.2004.00136.x
   Farrar C, 2002, J BIOL CHEM, V277, P27856, DOI 10.1074/jbc.M203911200
   Farrar CE, 2005, J COMP NEUROL, V493, P524, DOI 10.1002/cne.20780
   HEWISH DR, 1973, BIOCHEM BIOPH RES CO, V52, P504, DOI 10.1016/0006-291X(73)90740-7
   Ikegaya Y, 2001, HIPPOCAMPUS, V11, P287, DOI 10.1002/hipo.1043
   JOHNSON BA, 1993, J BIOL CHEM, V268, P6174
   JOHNSON BA, 1987, J BIOL CHEM, V262, P5622
   JOHNSON BA, 1995, DEAMIDATION ISOASPAR, P91
   Kim E, 1997, P NATL ACAD SCI USA, V94, P6132, DOI 10.1073/pnas.94.12.6132
   Kim E, 1999, J BIOL CHEM, V274, P20671, DOI 10.1074/jbc.274.29.20671
   Kim SC, 2006, MOL CELL, V23, P607, DOI 10.1016/j.molcel.2006.06.026
   Kinzel V, 2000, PROTEIN SCI, V9, P2269, DOI 10.1110/ps.9.11.2269
   KOSSIAKOFF AA, 1988, SCIENCE, V240, P191, DOI 10.1126/science.3353715
   LAEMMLI UK, 1973, J MOL BIOL, V80, P575, DOI 10.1016/0022-2836(73)90198-8
   LOWRY OH, 1951, J BIOL CHEM, V193, P265
   Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444
   MARTINAGE A, 1979, BIOCHIMIE, V61, P61, DOI 10.1016/S0300-9084(79)80313-2
   MCFADDEN PN, 1987, P NATL ACAD SCI USA, V84, P2595, DOI 10.1073/pnas.84.9.2595
   Reissner KJ, 2006, J BIOL CHEM, V281, P8389, DOI 10.1074/jbc.M510716200
   Reissner KJ, 2003, CELL MOL LIFE SCI, V60, P1281, DOI 10.1007/s00018-003-2287-5
   Robinson NE, 2004, J PEPT RES, V63, P426, DOI 10.1111/j.1399-3011.2004.00151.x
   Schurter BT, 2000, ANAL BIOCHEM, V282, P227, DOI 10.1006/abio.2000.4601
   USACHENKO SI, 1994, P NATL ACAD SCI USA, V91, P6845, DOI 10.1073/pnas.91.15.6845
   Vigneswara V, 2006, J BIOL CHEM, V281, P32619, DOI 10.1074/jbc.M605421200
   Vitali R, 2004, BEHAV BRAIN RES, V153, P129, DOI 10.1016/j.bbr.2003.11.007
   Volkin DB, 1997, MOL BIOTECHNOL, V8, P105, DOI 10.1007/BF02752255
   Wakankar AA, 2007, BIOCHEMISTRY-US, V46, P1534, DOI 10.1021/bi061500t
   WEIKOWSKI M, 1993, METHOD ENZYMOL, V225, P489
   WEINTRAUB H, 1975, CELL, V6, P85, DOI 10.1016/0092-8674(75)90077-X
   Yamamoto A, 1998, J NEUROSCI, V18, P2063
   Young AL, 2001, J BIOL CHEM, V276, P37161, DOI 10.1074/jbc.M106682200
   Young GW, 2005, J BIOL CHEM, V280, P26094, DOI 10.1074/jbc.M503624200
   Zhu JX, 2006, J BIOL CHEM, V281, P33802, DOI 10.1074/jbc.M606958200
NR 41
TC 13
Z9 13
U1 0
U2 8
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0006-2960
J9 BIOCHEMISTRY-US
JI Biochemistry
PD OCT 7
PY 2008
VL 47
IS 40
BP 10757
EP 10764
DI 10.1021/bi8013467
PG 8
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 353XW
UT WOS:000259603600024
PM 18795804
DA 2024-02-19
ER

PT J
AU Gomez, J
   Caro, P
   Sanchez, I
   Naudi, A
   Jove, M
   Portero-Otin, M
   Lopez-Torres, M
   Pamplona, R
   Barja, G
AF Gomez, Jose
   Caro, Pilar
   Sanchez, Ines
   Naudi, Alba
   Jove, Mariona
   Portero-Otin, Manuel
   Lopez-Torres, Monica
   Pamplona, Reinald
   Barja, Gustavo
TI Effect of methionine dietary supplementation on mitochondrial oxygen
   radical generation and oxidative DNA damage in rat liver and heart
SO JOURNAL OF BIOENERGETICS AND BIOMEMBRANES
LA English
DT Article
DE Methionine supplementation; Free radicals; Aging; ROS; Oxidative stress;
   Mitochondria; DNA damage
ID FATTY-ACID UNSATURATION; EXTENDS LIFE-SPAN; CALORIC RESTRICTION;
   COMPLEX-I; LIPID-PEROXIDATION; HYDROGEN-PEROXIDE;
   DROSOPHILA-MELANOGASTER; PROTEIN RESTRICTION; EXCESS METHIONINE;
   MOLECULAR DAMAGE
AB Methionine restriction without energy restriction increases, like caloric restriction, maximum longevity in rodents. Previous studies have shown that methionine restriction strongly decreases mitochondrial reactive oxygen species (ROS) production and oxidative damage to mitochondrial DNA, lowers membrane unsaturation, and decreases five different markers of protein oxidation in rat heart and liver mitochondria. It is unknown whether methionine supplementation in the diet can induce opposite changes, which is also interesting because excessive dietary methionine is hepatotoxic and induces cardiovascular alterations. Because the detailed mechanisms of methionine-related hepatotoxicity and cardiovascular toxicity are poorly understood and today many Western human populations consume levels of dietary protein (and thus, methionine) 2-3.3 fold higher than the average adult requirement, in the present experiment we analyze the effect of a methionine supplemented diet on mitochondrial ROS production and oxidative damage in the rat liver and heart mitochondria. In this investigation male Wistar rats were fed either a L-methionine-supplemented (2.5 g/100 g) diet without changing any other dietary components or a control (0.86 g/100 g) diet for 7 weeks. It was found that methionine supplementation increased mitochondrial ROS generation and percent free radical leak in rat liver mitochondria but not in rat heart. In agreement with these data oxidative damage to mitochondrial DNA increased only in rat liver, but no changes were observed in five different markers of protein oxidation in both organs. The content of mitochondrial respiratory chain complexes and AIF (apoptosis inducing factor) did not change after the dietary supplementation while fatty acid unsaturation decreased. Methionine, S-AdenosylMethionine and S-AdenosylHomocysteine concentration increased in both organs in the supplemented group. These results show that methionine supplementation in the diet specifically increases mitochondrial ROS production and mitochondrial DNA oxidative damage in rat liver mitochondria offering a plausible mechanism for its hepatotoxicity.
C1 [Gomez, Jose; Caro, Pilar; Sanchez, Ines; Lopez-Torres, Monica; Barja, Gustavo] Univ Complutense, Fac Biol Sci, Dept Anim Physiol 2, E-28040 Madrid, Spain.
   [Naudi, Alba; Jove, Mariona; Portero-Otin, Manuel; Pamplona, Reinald] Univ Lleida, Fac Med, Dept Expt Med, Lleida 25008, Spain.
C3 Complutense University of Madrid; Universitat de Lleida
RP Barja, G (corresponding author), Univ Complutense, Fac Biol Sci, Dept Anim Physiol 2, E-28040 Madrid, Spain.
EM gbarja@bio.ucm.es
RI Jové, Mariona/M-9104-2016; Font, Mariona Jove/C-5741-2011; Gomez,
   Jose/G-9705-2015; Naudí, Alba/B-5594-2009; Barja, Gustavo/AAA-5903-2019;
   Portero-Otin, Manuel/B-7122-2009; Gustavo, Barja/B-5591-2012; Pamplona,
   Reinald/A-7359-2010
OI Jové, Mariona/0000-0001-5577-6162; Gomez, Jose/0000-0003-1758-4746;
   Naudí, Alba/0000-0003-0699-1004; Barja, Gustavo/0000-0001-5736-4735;
   Portero-Otin, Manuel/0000-0002-1823-0299; Pamplona,
   Reinald/0000-0003-4337-6107; Caro, Pilar/0000-0002-7531-3234;
   Sanchez-Roman, Ines/0000-0003-4844-5781
FU Spanish Ministry of Science and Innovation [BFU2008-00335/BFI]; Spanish
   Ministry of Education and Science [BFU2006-14495/BFI, AGL2006-12433];
   Spanish Ministry of Health [RD06/0013/0012, 05-2241, 08-1843];
   Generalitat of Catalunya [2005SGR00101]; "La Caixa" Foundation; Spanish
   Ministry of Industry; Ministry of Education and Science
FX This study was supported in part by I+D grants from the Spanish Ministry
   of Science and Innovation (BFU2008-00335/BFI), and BSCH-UCM (for 2009)
   to G. B; grants from the Spanish Ministry of Education and Science
   (BFU2006-14495/BFI), the Spanish Ministry of Health (ISCIII, Red de
   Envejecimiento y Fragilidad, RD06/0013/0012), and the Generalitat of
   Catalunya (2005SGR00101) to R. P.; grants from the Spanish Ministry of
   Health (05-2241, 08-1843), Spanish Ministry of Education and Science
   (AGL2006-12433), and "La Caixa" Foundation to M.P.O; and the Spanish
   Ministry of Industry (Programa CENIT-METDEVFUN) to R.P. and M.P.O. P.C.
   and J.G. received predoctoral fellowships from the Ministry of Education
   and Science.
CR Ayala V, 2007, J GERONTOL A-BIOL, V62, P352, DOI 10.1093/gerona/62.4.352
   Barja G, 1998, J BIOENERG BIOMEMBR, V30, P235, DOI 10.1023/A:1020592719405
   Barja G, 2004, TRENDS NEUROSCI, V27, P595, DOI 10.1016/j.tins.2004.07.005
   BENEVENGA NJ, 1976, J NUTR, V106, P1714, DOI 10.1093/jn/106.12.1715
   BOVERIS A, 1976, BIOCHEM J, V156, P435, DOI 10.1042/bj1560435
   Caro P, 2008, BIOGERONTOLOGY, V9, P183, DOI 10.1007/s10522-008-9130-1
   Caro P, 2009, BIOGERONTOLOGY, V10, P579, DOI 10.1007/s10522-008-9200-4
   Chang L, 2004, CLIN EXP PHARMACOL P, V31, P237, DOI 10.1111/j.1440-1681.2004.03983.x
   DeLaAsuncion JG, 1996, FASEB J, V10, P333, DOI 10.1096/fasebj.10.2.8641567
   Dever JT, 2008, J PHARMACOL EXP THER, V326, P309
   Fukagawa NK, 2004, J NUTR, V134, p1569S, DOI 10.1093/jn/134.6.1569S
   Genova ML, 2001, FEBS LETT, V505, P364, DOI 10.1016/S0014-5793(01)02850-2
   Gómez J, 2007, BIOGERONTOLOGY, V8, P555, DOI 10.1007/s10522-007-9099-1
   Gomez-Cabrera MC, 2008, FREE RADICAL BIO MED, V44, P126, DOI 10.1016/j.freeradbiomed.2007.02.001
   Gredilla R, 2001, FASEB J, V15, P1589, DOI 10.1096/fj.00-0764fje
   Gredilla R, 2001, J BIOENERG BIOMEMBR, V33, P279, DOI 10.1023/A:1010603206190
   Guo YH, 2008, CHINESE MED J-PEKING, V121, P2265, DOI 10.1097/00029330-200811020-00011
   HARPER AE, 1970, PHYSIOL REV, V50, P428, DOI 10.1152/physrev.1970.50.3.428
   Hidiroglou N, 2004, J NUTR BIOCHEM, V15, P730, DOI 10.1016/j.jnutbio.2004.04.009
   IWASAKI K, 1988, J GERONTOL, V43, pB13, DOI 10.1093/geronj/43.1.B13
   KHORAKOVA M, 1990, Fiziologicheskii Zhurnal (Kiev), V36, P16
   Kudin AP, 2005, BIOMED PHARMACOTHER, V59, P163, DOI 10.1016/j.biopha.2005.03.012
   Kumagai H, 2002, KIDNEY INT, V62, P1219, DOI 10.1111/j.1523-1755.2002.kid558.x
   LABRUNE P, 1990, J PEDIATR-US, V117, P220, DOI 10.1016/S0022-3476(05)80533-5
   Lambert AJ, 2007, AGING CELL, V6, P607, DOI 10.1111/j.1474-9726.2007.00312.x
   LATORRE A, 1986, P NATL ACAD SCI USA, V83, P8649, DOI 10.1073/pnas.83.22.8649
   Loft S, 1999, METHOD ENZYMOL, V300, P166
   López-Torres M, 2008, BBA-GEN SUBJECTS, V1780, P1337, DOI 10.1016/j.bbagen.2008.01.007
   Lopez-Torres Monica, 2008, P149, DOI 10.1007/978-1-59745-420-9_9
   LOPEZTORRES M, 1993, FREE RADICAL BIO MED, V15, P133, DOI 10.1016/0891-5849(93)90052-V
   Mair W, 2005, PLOS BIOL, V3, P1305, DOI 10.1371/journal.pbio.0030223
   Malloy VL, 2006, AGING CELL, V5, P305, DOI 10.1111/j.1474-9726.2006.00220.x
   Mela L, 1979, Methods Enzymol, V55, P39
   Miller RA, 2005, AGING CELL, V4, P119, DOI 10.1111/j.1474-9726.2005.00152.x
   Min KJ, 2006, MECH AGEING DEV, V127, P643, DOI 10.1016/j.mad.2006.02.005
   Mori N, 2000, J NUTR, V130, P2349, DOI 10.1093/jn/130.9.2349
   Naudí A, 2007, REJUV RES, V10, P473, DOI 10.1089/rej.2007.0538
   Ninomiya T, 2004, AM J KIDNEY DIS, V44, P437, DOI [10.1016/S0272-6386(04)00813-3, 10.1053/j.ajkd.2004.05.024]
   Obeid R, 2006, FEBS LETT, V580, P2994, DOI 10.1016/j.febslet.2006.04.088
   ORENTREICH N, 1993, J NUTR, V123, P269
   Pamplona R, 2002, ANN NY ACAD SCI, V959, P475, DOI 10.1111/j.1749-6632.2002.tb02118.x
   Pamplona R, 1996, MECH AGEING DEV, V86, P53, DOI 10.1016/0047-6374(95)01673-2
   Pamplona R, 2006, BBA-BIOENERGETICS, V1757, P496, DOI 10.1016/j.bbabio.2006.01.009
   Park CM, 2008, J MED FOOD, V11, P667, DOI 10.1089/jmf.2007.0146
   Porter AG, 2006, BIOESSAYS, V28, P834, DOI 10.1002/bies.20444
   REGINA M, 1993, ARCH BIOCHEM BIOPHYS, V300, P598, DOI 10.1006/abbi.1993.1083
   RICHIE JP, 1994, FASEB J, V8, P1302, DOI 10.1096/fasebj.8.15.8001743
   Robert KA, 2007, AGING CELL, V6, P395, DOI 10.1111/j.1474-9726.2007.00287.x
   Sanz A, 2004, J BIOENERG BIOMEMBR, V36, P545, DOI 10.1007/s10863-004-9001-7
   Sanz A, 2006, HDB MODELS HUMAN AGI, P183
   Sanz A, 2006, ANN NY ACAD SCI, V1067, P200, DOI 10.1196/annals.1354.024
   Sanz A, 2006, FASEB J, V20, P1064, DOI 10.1096/fj.05-5568com
   Seneviratne CK, 1999, AM J PHYSIOL-HEART C, V277, pH2124, DOI 10.1152/ajpheart.1999.277.6.H2124
   Shimokawa I, 1996, AGING-CLIN EXP RES, V8, P254, DOI 10.1007/BF03339576
   Stefanello FM, 2005, INT J DEV NEUROSCI, V23, P651, DOI 10.1016/j.ijdevneu.2005.06.003
   Stipanuk MH, 2004, ANNU REV NUTR, V24, P539, DOI 10.1146/annurev.nutr.24.012003.132418
   Taylor ER, 2003, J BIOL CHEM, V278, P19603, DOI 10.1074/jbc.M209359200
   Toborek M, 1996, NUTRITION, V12, P534, DOI 10.1016/S0899-9007(96)00108-6
   Troen AM, 2003, P NATL ACAD SCI USA, V100, P15089, DOI 10.1073/pnas.2436385100
   Troen AM, 2007, AGE, V29, P29, DOI 10.1007/s11357-006-9018-4
   Tyagi N, 2009, ANTIOXID REDOX SIGN, V11, P25, DOI 10.1089/ars.2008.2073
   Vahsen N, 2004, EMBO J, V23, P4679, DOI 10.1038/sj.emboj.7600461
   Velez-Carrasco W, 2008, J NUTR BIOCHEM, V19, P362, DOI 10.1016/j.jnutbio.2007.05.005
   Verhoef P, 2005, AM J CLIN NUTR, V82, P553, DOI 10.1093/ajcn/82.3.553
   Werstuck GH, 2001, J CLIN INVEST, V107, P1263, DOI 10.1172/JCI11596
   YOKOTA F, 1978, J NUTR SCI VITAMINOL, V24, P527, DOI 10.3177/jnsv.24.527
   Zimmerman JA, 2003, EXP GERONTOL, V38, P47, DOI 10.1016/S0531-5565(02)00149-3
NR 67
TC 54
Z9 59
U1 0
U2 16
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0145-479X
EI 1573-6881
J9 J BIOENERG BIOMEMBR
JI J. Bioenerg. Biomembr.
PD JUN
PY 2009
VL 41
IS 3
BP 309
EP 321
DI 10.1007/s10863-009-9229-3
PG 13
WC Biophysics; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biophysics; Cell Biology
GA 483PQ
UT WOS:000268980200010
PM 19633937
DA 2024-02-19
ER

PT J
AU OLEA, MT
AF OLEA, MT
TI AN ULTRASTRUCTURAL-LOCALIZATION OF LYSOSOMAL ACID-PHOSPHATASE-ACTIVITY
   IN AGING MOUSE SPLEEN - A QUANTITATIVE X-RAY MICROANALYTICAL STUDY
SO ACTA HISTOCHEMICA ET CYTOCHEMICA
LA English
DT Article
ID POLYCELIS-TENUIS IIJIMA; CYTOCHEMICAL DEMONSTRATION; TRAPPING AGENT;
   CELL AUTOLYSIS; RED PULP; CERIUM; LIVER; IONS
AB The fine ultrastructural localization of acid phosphatase (AcPase) activity in mouse spleen ages; 1 day, 1 and 2 weeks, and 1, 2 and 10 months was carried out by cytochemistry, using cerium as the trapping agent. The AcPase enzyme activity was observed in the red pulp. The enzyme reaction product precipitates appeared dense and homogeneous, and were localized in the lysosomes of macrophages, phagocytic reticular cells and littoral cells. The presence of cerium in the reaction product precipitate was confirmed by X-ray microanalysis. The spectral line was present at La = 4.84 KeV and did not interfere with osmium emission line at Ma = 1.914 KeV. The results demonstrate variation in the degree of AcPase activity in different ages of the animal studied. The enzyme activity increased progressively from day one, recorded a peak on the first week and thereon, decreased gradually until the 10th month.
RP OLEA, MT (corresponding author), SHINSHU UNIV, SCH MED, DEPT ANAT & CELL BIOL, MATSUMOTO, NAGANO 390, JAPAN.
CR BACSY E, 1982, HISTOCHEM J, V14, P99, DOI 10.1007/BF01041133
   BARKA T, 1962, J HISTOCHEM CYTOCHEM, V10, P231, DOI 10.1177/10.2.231
   BARKA T, 1961, LAB INVEST, V10, P590
   BLOK J, 1982, HISTOCHEMISTRY, V75, P437, DOI 10.1007/BF00640596
   BOWEN ID, 1974, CELL TISSUE RES, V154, P265
   BOWEN ID, 1980, HISTOCHEMISTRY, V65, P173, DOI 10.1007/BF00493166
   BOWEN ID, 1976, HISTOCHEM J, V8, P319, DOI 10.1007/BF01003820
   BOWEN ID, 1975, P ROY MICROSC SOC, V10, P271
   BRAUNSTEIN H, 1958, CANCER, V11, P829, DOI 10.1002/1097-0142(195807/08)11:4<829::AID-CNCR2820110422>3.0.CO;2-6
   CHEN LT, 1973, BLOOD, V41, P529, DOI 10.1182/blood.V41.4.529.529
   CLARK SL, 1962, AM J ANAT, V110, P217, DOI 10.1002/aja.1001100303
   DAEMS WT, 1964, 3 P EUR REG C EL MIC, P217
   DEBRUIJN WC, 1980, HISTOCHEMISTRY, V66, P137, DOI 10.1007/BF00494641
   DECKER RS, 1974, J CELL BIOL, V61, P599, DOI 10.1083/jcb.61.3.599
   DIENGDOH JV, 1965, NATURE, V207, P1405, DOI 10.1038/2071405a0
   DORFMAN RF, 1961, NATURE, V190, P1021, DOI 10.1038/1901021a0
   ESSNER E, 1960, J BIOPHYS BIOCHEM CY, V7, P329, DOI 10.1083/jcb.7.2.329
   HALBHUBER KJ, 1988, HISTOCHEMISTRY, V88, P375
   HAN S S, 1961, Am J Anat, V109, P183, DOI 10.1002/aja.1001090208
   HAYASHI M, 1967, J HISTOCHEM CYTOCHEM, V15, P83, DOI 10.1177/15.2.83
   HIRASAWA Y, 1970, BLOOD-J HEMATOL, V35, P201, DOI 10.1182/blood.V35.2.201.201
   HOEFSMIT ECM, 1986, HISTOCHEMISTRY, V84, P329, DOI 10.1007/BF00482958
   HULSTAERT CE, 1983, HISTOCHEMISTRY, V78, P71, DOI 10.1007/BF00491113
   Knisely MH, 1936, ANAT REC, V65, P23, DOI 10.1002/ar.1090650104
   LEWIS GHJ, 1979, J MICROSC-OXFORD, V117, P255, DOI 10.1111/j.1365-2818.1979.tb01181.x
   LEWIS GHJ, 1982, J MICROSC-OXFORD, V126, P179
   MEIJER AE, 1961, BIOCHEM PHARMACOL, V8, P389, DOI 10.1016/0006-2952(61)90056-9
   MOLNAR Z, 1972, BLOOD-J HEMATOL, V39, P81, DOI 10.1182/blood.V39.1.81.81
   MYSLIWSKA J, 1985, EXP GERONTOL, V20, P7, DOI 10.1016/0531-5565(85)90004-X
   NAGATA T, 1990, IN PRESS J ELECTR MI, V39
   NORTH RJ, 1966, J ULTRA MOL STRUCT R, V16, P96, DOI 10.1016/S0022-5320(66)80025-4
   NOVIKOFF AB, 1961, LYSOSOMES RELATED PA, V1, P423
   OHTA Y, 1957, Okajimas Folia Anat Jpn, V30, P13
   PIAO YJ, 1983, ACTA HISTOCHEM CYTOC, V16, P353, DOI 10.1267/ahc.16.353
   RIFKIND RA, 1965, BLOOD-J HEMATOL, V26, P433, DOI 10.1182/blood.V26.4.433.433
   ROBERTS DK, 1964, ANAT REC, V148, P81, DOI 10.1002/ar.1091480108
   ROBINSON JM, 1983, J HISTOCHEM CYTOCHEM, V31, P1179
   ROOMANS GM, 1982, HISTOCHEMISTRY, V75, P485
   SCHINDELMEISER J, 1987, HISTOCHEMISTRY, V87, P13, DOI 10.1007/BF00518719
   SNOOK T, 1950, AM J ANAT, V87, P31, DOI 10.1002/aja.1000870103
   THOMAS CE, 1967, AM J ANAT, V120, P527, DOI 10.1002/aja.1001200307
   VANDORT JB, 1987, HISTOCHEMISTRY, V87, P71, DOI 10.1007/BF00518727
   VEENHUIS M, 1980, FEMS MICROBIOL LETT, V9, P285
   WAGNER HN, 1962, ARCH INTERN MED, V110, P90, DOI 10.1001/archinte.1962.03620190092014
   Weed R I, 1966, Trans Assoc Am Physicians, V79, P426
   WEISS L, 1974, BLOOD, V43, P665, DOI 10.1182/blood.V43.5.665.665
   WEISS L, 1970, SEMIN HEMATOL, V7, P272
   WEISS L, 1962, AM J ANAT, V111, P175
   WEISS L, 1977, HISTOLOGY, P545
NR 49
TC 10
Z9 13
U1 0
U2 0
PU JAPAN SOC HISTOCHEMISTRY & CYTOCHEMISTRY
PI KYOTO
PA C/O NAKANISHI PRINTING CO LTD, SHIMODACHIURI-OGAWA, KAMIGYO-KU, KYOTO,
   602-8048, JAPAN
SN 0044-5991
EI 1347-5800
J9 ACTA HISTOCHEM CYTOC
JI Acta Histochem. Cytochem.
PY 1991
VL 24
IS 2
BP 201
EP 208
DI 10.1267/ahc.24.201
PG 8
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA FX022
UT WOS:A1991FX02200007
OA Bronze
DA 2024-02-19
ER

PT J
AU Jiang, Y
   Zhao, J
   Qi, HJ
   Li, XL
   Zhang, SR
   Song, DW
   Yu, CY
   Gao, JG
AF Jiang, Yan
   Zhao, Jing
   Qi, Hui-jing
   Li, Xiao-lin
   Zhang, Shi-rong
   Song, Daniel W.
   Yu, Chi-yang
   Gao, Jian-gang
TI Accelerated ovarian aging in mice by treatment of busulfan and
   cyclophosphamide
SO JOURNAL OF ZHEJIANG UNIVERSITY-SCIENCE B
LA English
DT Article
DE Premature ovarian failure; Busulfan; Cyclophosphamide; Chemotherapy;
   Mouse model
ID BONE-MARROW; PULMONARY TOXICITY; FOLLICLES; PROGESTIN; RECEPTOR;
   HORMONES; CELLS; WOMEN
AB Busulfan/cyclophosphamide (Bu/Cy) conditioning regimen has been widely used to treat cancer patients, while their effects on major internal organs in females are not fully understood. We treated female mice with Bu/Cy, and examined the histopathology of major internal organs on Day 30 after the treatment. The results show that Bu/Cy treatment affected the ovaries most extensively, while it had less effect on the spleen, lungs, and kidneys, and no effect on the heart, liver, stomach, and pancreas. To better understand the effect of Bu/Cy on the ovaries, we counted follicles, and determined the levels of ovarian steroids. The Bu/Cy-treated mice showed a reduction of primordial and primary follicles (P < 0.01) on Day 30 and a marked loss of follicles at all developmental stages (P < 0.01) on Day 60. Plasma levels of estradiol and progesterone in Bu/Cy-treated mice decreased by 43.9% and 61.4%, respectively. Thus, there was a gradual process of follicle loss and low estradiol in Bu/Cy-treated mice; this is a profile similar to what is found in women with premature ovarian failure (POF). The Bu/Cy-treated mice may serve as a useful animal model to study the dynamics of follicle loss in women undergoing POF.
C1 [Jiang, Yan; Zhao, Jing; Li, Xiao-lin; Zhang, Shi-rong; Gao, Jian-gang] Shandong Univ, Minist Educ Expt Teratol, Key Lab, Jinan 250100, Peoples R China.
   [Jiang, Yan; Zhao, Jing; Li, Xiao-lin; Zhang, Shi-rong; Gao, Jian-gang] Shandong Univ, Sch Life Sci, Jinan 250100, Peoples R China.
   [Qi, Hui-jing] Jinan First Peoples Hosp, Jinan 250011, Peoples R China.
   [Song, Daniel W.] Dulwich Coll, Beijing 101300, Peoples R China.
   [Yu, Chi-yang] Southwest Hosp, Dept Gynecol & Obstet, Chongqing 400038, Peoples R China.
C3 Shandong University; Shandong University; Army Medical University
RP Yu, CY (corresponding author), Southwest Hosp, Dept Gynecol & Obstet, Chongqing 400038, Peoples R China.
EM chiyangyu@hotmail.com; jggao@sdu.edu.cn
RI Zhao, Xujun/IRZ-4119-2023; zhao, jing/B-3868-2019
FU National Basic Research Program (973) of China [2010CB945002]
FX Project (No. 2010CB945002) supported by the National Basic Research
   Program (973) of China
CR Al-Hashmi S, 2011, INT J CLIN EXP PATHO, V4, P596
   Barrett-Connor E, 1999, J CLIN ENDOCR METAB, V84, P1848, DOI 10.1210/jc.84.6.1848
   Benedict JC, 2000, TOXICOL SCI, V56, P382, DOI 10.1093/toxsci/56.2.382
   BURKL W, 1978, CELL TISSUE RES, V186, P351
   COPELAN EA, 1993, SEMIN ONCOL, V20, P33
   COULAM CB, 1986, OBSTET GYNECOL, V67, P604
   Danilovich N, 2006, EXP GERONTOL, V41, P117, DOI 10.1016/j.exger.2005.10.010
   deMagalhaesSilverman M, 1997, BONE MARROW TRANSPL, V19, P777, DOI 10.1038/sj.bmt.1700733
   Dierich A, 1998, P NATL ACAD SCI USA, V95, P13612, DOI 10.1073/pnas.95.23.13612
   Dixit H, 2010, REPROD BIOMED ONLINE, V20, P724, DOI 10.1016/j.rbmo.2010.02.018
   Grigg AP, 2000, BONE MARROW TRANSPL, V26, P1089, DOI 10.1038/sj.bmt.1702695
   HANKINS DG, 1978, CHEST, V73, P415, DOI 10.1378/chest.73.3.415
   HEMSWORTH BN, 1963, J REPROD FERTIL, V6, P229
   Johnson J, 2005, CELL, V122, P303, DOI 10.1016/j.cell.2005.06.031
   Jopling C, 2001, BRIT J HAEMATOL, V113, P970, DOI 10.1046/j.1365-2141.2001.02825.x
   Kaaks R, 2002, CANCER EPIDEM BIOMAR, V11, P1531
   Lopez SG, 2004, FREE RADICAL BIO MED, V36, P1366, DOI 10.1016/j.freeradbiomed.2004.02.067
   Maltaris T, 2007, EUR J OBSTET GYN R B, V130, P148, DOI 10.1016/j.ejogrb.2006.08.006
   Mayer LP, 2004, BIOL REPROD, V71, P130, DOI 10.1095/biolreprod.103.016113
   Meirow D, 2001, HUM REPROD UPDATE, V7, P535, DOI 10.1093/humupd/7.6.535
   Meirow D, 1999, HUM REPROD, V14, P1903, DOI 10.1093/humrep/14.7.1903
   Myers M, 2004, REPRODUCTION, V127, P569, DOI 10.1530/rep.1.00095
   Nair G V, 2000, Climacteric, V3, P227, DOI 10.1080/13697130008500132
   PELLOUX MC, 1988, ACTA ENDOCRINOL-COP, V118, P218, DOI 10.1530/acta.0.1180218
   Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321
   SCHALLIER D, 1983, CHEST, V84, P492, DOI 10.1378/chest.84.4.492
   Shelling AN, 2010, REPRODUCTION, V140, P633, DOI 10.1530/REP-09-0567
   Shirota M, 2003, REPRODUCTION, V125, P85, DOI 10.1530/rep.0.1250085
   Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI [10.3322/caac.20006, 10.3322/caac.21387, 10.3322/caac.21601, 10.3322/caac.20073, 10.3322/caac.21654, 10.3322/caac.21332, 10.3322/caac.21551, 10.3322/caac.21254]
   Sklar Charles, 2005, J Natl Cancer Inst Monogr, P25
   SOBLE AR, 1977, AM J ROENTGENOL, V128, P15, DOI 10.2214/ajr.128.1.15
   Ulrickson M, 2009, BIOL BLOOD MARROW TR, V15, P1447, DOI 10.1016/j.bbmt.2009.07.014
   VERGNON JM, 1988, REV MED INTERNE, V9, P377, DOI 10.1016/S0248-8663(88)80137-1
   Woad KJ, 2006, AUST NZ J OBSTET GYN, V46, P242, DOI 10.1111/j.1479-828X.2006.00585.x
NR 34
TC 34
Z9 37
U1 0
U2 9
PU ZHEJIANG UNIV PRESS
PI Hangzhou
PA Xixi Campus, Zhejiang University, No. 148 Tianmushan Road, Hangzhou,
   Zhejiang, PEOPLES R CHINA
SN 1673-1581
EI 1862-1783
J9 J ZHEJIANG UNIV-SC B
JI J. Zhejiang Univ.-SCI. B
PD APR
PY 2013
VL 14
IS 4
BP 318
EP 324
DI 10.1631/jzus.B1200181
PG 7
WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Research & Experimental Medicine
GA 126IP
UT WOS:000317607900007
PM 23549849
OA Green Published
DA 2024-02-19
ER

PT J
AU Zhang, YM
   Pu, JH
   Ding, Y
   Wu, L
   Yin, YX
   Sun, MY
   Gu, Y
   Zhang, DY
   Zhang, Z
   Zheng, QT
   He, QY
   Xu, T
   He, Y
   Su, HY
   Zhou, XW
   Li, LJ
   Ye, Y
   Li, JY
   Xu, ZC
AF Zhang, Yumeng
   Pu, Jianhong
   Ding, Yi
   Wu, Lei
   Yin, Yongxiang
   Sun, Mingya
   Gu, Ying
   Zhang, Daiyi
   Zhang, Ze
   Zheng, Qiutong
   He, Qinyuan
   Xu, Ting
   He, Yun
   Su, Hongyu
   Zhou, Xiuwen
   Li, Lingjun
   Ye, Yang
   Li, Jingyang
   Xu, Zhice
TI Sex Differences at Early Old Stage in Glycolipid Metabolism and Fatty
   Liver in Offspring Prenatally Exposed to Chinese Great Famine
SO FRONTIERS IN NUTRITION
LA English
DT Article
DE famine; glycolipd metabolism; sex differences; catch-up growth; aging
   offspring
ID CATCH-UP GROWTH; LONG-TERM CONSEQUENCES; BODY-MASS INDEX; DUTCH FAMINE;
   MATERNAL NUTRITION; EARLY-LIFE; GENDER-DIFFERENCES; LIPID-METABOLISM;
   IN-UTERO; INSULIN
AB BackgroundAbout 50 years ago, Chinese Great Famine (CGF) affected the entire population in China, and its long-term influence on the offspring has attracted significant attention for research. However, information on possible metabolic differences between sexes is limited. This study explored whether there might be sex differences in the risks of development of glucolipid metabolic dysfunction and fatty liver following prenatal exposure to CGF. Materials and MethodsThere were 11,417 subjects around 55 years of age (6,661 women and 4,756 men). They were divided as the exposed group in which the fetal stage was in CGF, and the unexposed group included those born after CGF. Analysis focused on comparisons between sexes. ResultsCompared to the unexposed group, the BMI and triglyceride (P < 0.05) in men were higher in exposed group, while waist circumference and blood sugar (P < 0.05) in the exposed women were significantly higher. With the ages being properly balanced, the risks of glycolipid metabolic dysfunction were significantly higher in both men and women in the exposed than in the unexposed group (P < 0.001). Prenatal exposure to CGF significantly increased risks of abnormal BMI (P < 0.001, 95% CI: 2.305-2.93), blood sugar (P < 0.05, 95% CI: 1.050-1.401), triglycerides (P < 0.05, 95% CI: 1.006-1.245), and fatty liver (P < 0.001, 95% CI: 1.121-1.390) in men, and increased risks of abnormal blood sugar (P < 0.05, 95% CI: 1.024-1.689) and positive urine sugar (P < 0.05, 95% CI: 1.062-6.211) in women. Height and body weight were either the same or higher in the exposed subjects compared with the unexposed ones, regardless of sexes. ConclusionThis study is the first to identify sex differences in the long-term effects of CGF on metabolism and fatty liver. Importance of the findings include the benefits of prescribing medicine for the early prevention of certain diseases for each sex before aging based on the differences revealed. This study also shows "catch-up growth" in the offspring prenatally exposed to CGF as possible mechanisms underlying the long-term effects.
C1 [Zhang, Yumeng; Zhang, Ze; Zheng, Qiutong; He, Qinyuan; Xu, Ting; He, Yun; Su, Hongyu; Zhou, Xiuwen; Li, Lingjun; Xu, Zhice] Soochow Univ, Inst Fetol, Affiliated Hosp 1, Suzhou, Peoples R China.
   [Pu, Jianhong; Zhang, Daiyi] Soochow Univ, Ctr Management, Affiliated Hosp 1, Suzhou, Peoples R China.
   [Ding, Yi] Suzhou Vocat Hlth Coll, Coll Clin Med, Dept Prevent Med, Suzhou, Peoples R China.
   [Wu, Lei] Suzhou Ind Pk Ctr Dis Control & Prevent, Suzhou, Peoples R China.
   [Yin, Yongxiang; Sun, Mingya; Gu, Ying; Ye, Yang; Li, Jingyang; Xu, Zhice] Wuxi Matern & Child Hlth Care Hosp, Wuxi, Peoples R China.
C3 Soochow University - China; Soochow University - China
RP Xu, ZC (corresponding author), Soochow Univ, Inst Fetol, Affiliated Hosp 1, Suzhou, Peoples R China.; Xu, ZC (corresponding author), Wuxi Matern & Child Hlth Care Hosp, Wuxi, Peoples R China.
EM xuzhice@suda.edu.cn
CR Almesri N, 2020, ENDOCR METAB IMMUNE, V20, P425, DOI 10.2174/1871530319666191009154528
   Ashley CD, 2000, SPORTS MED, V29, P221, DOI 10.2165/00007256-200029040-00001
   BARKER DJP, 1989, LANCET, V2, P577
   Baskaran C, 2018, CURR OPIN ENDOCRINOL, V25, P55, DOI 10.1097/MED.0000000000000381
   Blaak E, 2001, CURR OPIN CLIN NUTR, V4, P499, DOI 10.1097/00075197-200111000-00006
   Cerhan JR, 2014, MAYO CLIN PROC, V89, P335, DOI 10.1016/j.mayocp.2013.11.011
   COLLE E, 1976, PEDIATRICS, V57, P363
   de Luca A, 2017, EPIGENOMICS-UK, V9, P893, DOI 10.2217/epi-2016-0168
   Dearden L, 2018, MOL METAB, V15, P8, DOI 10.1016/j.molmet.2018.04.007
   Dulloo AG, 2008, BEST PRACT RES CL EN, V22, P155, DOI 10.1016/j.beem.2007.08.001
   Engelbregt MJT, 2004, BONE, V34, P180, DOI 10.1016/j.bone.2003.04.001
   Fukuoka Hideoki, 2014, Nihon Eiseigaku Zasshi, V69, P82
   Heijmans BT, 2008, P NATL ACAD SCI USA, V105, P17046, DOI 10.1073/pnas.0806560105
   Hidayat K, 2020, OBES REV, V21, DOI 10.1111/obr.12981
   Kawarazaki W, 2021, NAT REV NEPHROL, V17, P350, DOI 10.1038/s41581-021-00399-2
   Kay's Simon Kayemba, 2006, Pediatr Endocrinol Rev, V3, P365
   Kolovou GD, 2014, CURR MED CHEM, V21, P3455, DOI 10.2174/0929867321666140901114515
   Kyle UG, 2006, CURR OPIN CLIN NUTR, V9, P388, DOI 10.1097/01.mco.0000232898.74415.42
   Li CH, 2017, INT J EPIDEMIOL, V46, P1157, DOI 10.1093/ije/dyx013
   Li Y, 2020, NEUROLOGY, V94, pE1996, DOI 10.1212/WNL.0000000000009407
   Lizcano F, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/757461
   Lu JL, 2020, DIABETES CARE, V43, P1902, DOI 10.2337/dc19-2325
   Lumey LH, 2011, ANNU REV PUBL HEALTH, V32, P237, DOI 10.1146/annurev-publhealth-031210-101230
   Martin-Gronert MS, 2006, BIOCHEM SOC T, V34, P779, DOI 10.1042/BST0340779
   MARTORELL R, 1987, YEARB PHYS ANTHROPOL, V30, P195
   Masuyama H, 2015, ENDOCRINOLOGY, V156, P2482, DOI 10.1210/en.2014-2020
   Ngo ST, 2014, FRONT NEUROENDOCRIN, V35, P347, DOI 10.1016/j.yfrne.2014.04.004
   Painter RC, 2005, REPROD TOXICOL, V20, P345, DOI 10.1016/j.reprotox.2005.04.005
   Painter RC, 2007, J HYPERTENS, V25, P533, DOI 10.1097/HJH.0b013e328012135b
   Palmisano BT, 2018, MOL METAB, V15, P45, DOI 10.1016/j.molmet.2018.05.008
   Pellegrini M, 2014, CURR MED CHEM, V21, P2734, DOI 10.2174/0929867321666140303123602
   Cruz EP, 2014, NUTR HOSP, V29, P901, DOI 10.3305/nh.2014.29.4.7228
   Qi HY, 2020, LIVER INT, V40, P2694, DOI 10.1111/liv.14572
   Qin LL, 2020, J DIABETES RES, V2020, DOI 10.1155/2020/3251275
   Roseboom T, 2006, EARLY HUM DEV, V82, P485, DOI 10.1016/j.earlhumdev.2006.07.001
   Rosen ED, 2018, DIABETES, V67, P1923, DOI 10.2337/db18-0537
   Samaras K, 1999, DIABETES CARE, V22, P1401, DOI 10.2337/diacare.22.9.1401
   Sardinha FLC, 2006, NUTRITION, V22, P1152, DOI 10.1016/j.nut.2006.07.002
   Shi ZM, 2020, J DIABETES, V12, P134, DOI 10.1111/1753-0407.12975
   Shi ZM, 2018, J HYPERTENS, V36, P54, DOI [10.1097/HJH.0000000000001496, 10.1097/hjh.0000000000001496]
   Smil V, 1999, BMJ-BRIT MED J, V319, P1619, DOI 10.1136/bmj.319.7225.1619
   Soto N, 2003, J CLIN ENDOCR METAB, V88, P3645, DOI 10.1210/jc.2002-030031
   Tang A, 2018, PEDIATR RES, V84, P842, DOI 10.1038/s41390-018-0196-4
   Traissac P, 2016, PUBLIC HEALTH NUTR, V19, P1428, DOI 10.1017/S1368980016000689
   van Abeelen AFM, 2012, EUR HEART J, V33, P538, DOI 10.1093/eurheartj/ehr228
   Vaziri A, 2020, SCI ADV, V6, DOI 10.1126/sciadv.abc8492
   Venci RD, 2020, NUTR NEUROSCI, V23, P432, DOI 10.1080/1028415X.2018.1516845
   Verdoia M, 2015, NUTR METAB CARDIOVAS, V25, P464, DOI 10.1016/j.numecd.2015.01.009
   Wang LM, 2021, LANCET, V398, P53, DOI 10.1016/S0140-6736(21)00798-4
   Wang NJ, 2016, J CLIN ENDOCR METAB, V101, P2218, DOI 10.1210/jc.2016-1076
   Wood-Bradley RJ, 2013, CAN J PHYSIOL PHARM, V91, P412, DOI 10.1139/cjpp-2012-0352
   Wu L, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0176413
   Xu T, 2021, HYPERTENSION, V77, P491, DOI 10.1161/HYPERTENSIONAHA.120.16247
   Zhang WQ, 2020, BMC PUBLIC HEALTH, V20, DOI 10.1186/s12889-019-8017-1
   Zhang Y, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17072210
   Zhang YY, 2021, REPROD TOXICOL, V105, P91, DOI 10.1016/j.reprotox.2021.08.009
   Zhang YX, 2019, NUTR METAB CARDIOVAS, V29, P1230, DOI 10.1016/j.numecd.2019.07.004
   Zhao D, 2018, J AM COLL CARDIOL, V71, P2555, DOI 10.1016/j.jacc.2018.01.083
   Zheng J, 2021, FRONT NUTR, V8, DOI 10.3389/fnut.2021.657848
   Zhu DX, 2018, TRENDS ENDOCRIN MET, V29, P571, DOI 10.1016/j.tem.2018.06.001
NR 60
TC 0
Z9 0
U1 0
U2 6
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2296-861X
J9 FRONT NUTR
JI Front. Nutr.
PD JUN 22
PY 2022
VL 9
AR 913966
DI 10.3389/fnut.2022.913966
PG 10
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Nutrition & Dietetics
GA 2R7HA
UT WOS:000821278000001
PM 35811949
OA gold, Green Published
DA 2024-02-19
ER

PT J
AU Pesce, V
   Nicassio, L
   Fracasso, F
   Musicco, C
   Cantatore, P
   Gadaleta, MN
AF Pesce, Vito
   Nicassio, Luigi
   Fracasso, Flavio
   Musicco, Clara
   Cantatore, Palmiro
   Gadaleta, Maria Nicola
TI Acetyl-L-Carnitine Activates the Peroxisome Proliferator-Activated
   Receptor-γ Coactivators PGC-1α/PGC-1β-Dependent Signaling Cascade of
   Mitochondrial Biogenesis and Decreases the Oxidized Peroxiredoxins
   Content in Old Rat Liver
SO REJUVENATION RESEARCH
LA English
DT Article
ID ACETYLCARNITINE; TRANSCRIPTION; EXPRESSION; INSIGHTS
AB The behavior of the peroxisome proliferator-activated receptor-gamma coactivators PGC-1 alpha/PGC-beta-dependent mitochondrial biogenesis signaling pathway, as well as the level of some antioxidant enzymes and proteins involved in mitochondrial dynamics in the liver of old rats before and after 2 months of acetyl-l-carnitine (ALCAR) supplementation, was tested. The results reveal that ALCAR treatment is able to reverse the age-associated decline of PGC-1 alpha, PGC-1 beta, nuclear respiratory factor 1 (NRF-1), mitochondrial transcription factor A (TFAM), nicotinamide adenine dinucleotide (NADH) dehydrogenase subunit 1 (ND1), and cytochrome c oxidase subunit IV (COX IV) protein levels, of mitochondrial DNA (mtDNA) content, and of citrate synthase activity. Moreover, it partially reverses the mitochondrial superoxide dismutase 2 (SOD2) decline and reduces the cellular content of oxidized peroxiredoxins. These data demonstrate that ALCAR treatment is able to promote in the old rat liver a new mitochondrial population that can contribute to the cellular oxidative stress reduction. Furthermore, a remarkable decline of Drp1 and of Mfn2 proteins is reported here for the first time, suggesting a reduced mitochondrial dynamics in aging liver with no effect of ALCAR treatment.
C1 [Pesce, Vito; Nicassio, Luigi; Fracasso, Flavio; Cantatore, Palmiro; Gadaleta, Maria Nicola] Univ Bari, Dept Biochem & Mol Biol E Quagliariello, I-70126 Bari, Italy.
   [Musicco, Clara; Cantatore, Palmiro; Gadaleta, Maria Nicola] CNR, Inst Biomembranes & Bioenerget, I-70126 Bari, Italy.
C3 Universita degli Studi di Bari Aldo Moro; Consiglio Nazionale delle
   Ricerche (CNR)
RP Pesce, V (corresponding author), Univ Bari, Dept Biochem & Mol Biol E Quagliariello, Via E Orabona 4, I-70126 Bari, Italy.
EM v.pesce@biologia.uniba.it
RI Musicco, Clara/B-9480-2015
OI PESCE, VITO/0000-0002-9148-3129; Musicco, Clara/0000-0003-4359-4403
FU Sigma Tau-Industrie Farmaceutiche Riunite S.p.A.; fiRSt s.r.l., Rome,
   Italy; FIRB-MERIT [RBNE08HWLZ_012]; University of Bari-Finanziamenti di
   Ateneo
FX This work was supported by Sigma Tau-Industrie Farmaceutiche Riunite
   S.p.A. (to M.N.G.); fiRSt s.r.l. 2009, Rome, Italy (to M.N.G.);
   FIRB-MERIT 2008No RBNE08HWLZ_012 (to M.N.G. and C. M.); and University
   of Bari-Finanziamenti di Ateneo 2009 and 2010 (to V. P.).
CR Cassano P, 2006, BBA-BIOENERGETICS, V1757, P1421, DOI 10.1016/j.bbabio.2006.05.019
   Gadaleta MN, 1998, BIOCHIMIE, V80, P863, DOI 10.1016/S0300-9084(00)88881-1
   GADALETA MN, 1990, EUR J BIOCHEM, V187, P501, DOI 10.1111/j.1432-1033.1990.tb15331.x
   Galluzzi L, 2011, CURR BIOL, V21, pR478, DOI 10.1016/j.cub.2011.05.002
   Graef M, 2011, AUTOPHAGY, V7, P1245, DOI 10.4161/auto.7.10.16508
   Hagen TM, 2002, P NATL ACAD SCI USA, V99, P7184
   Lazarou M, 2009, FEBS J, V276, P6701, DOI 10.1111/j.1742-4658.2009.07384.x
   Madiraju P, 2009, EPIGENETICS-US, V4, P296
   Mollica MP, 2001, CELL MOL LIFE SCI, V58, P477, DOI 10.1007/PL00000871
   Musicco C, 2011, J PROTEOMICS, V74, P2536, DOI 10.1016/j.jprot.2011.05.041
   Musicco C, 2009, BBA-BIOENERGETICS, V1787, P890, DOI 10.1016/j.bbabio.2009.03.002
   Palermo V, 2010, AGING CELL, V9, P570, DOI 10.1111/j.1474-9726.2010.00587.x
   Pesce V, 2004, ANN NY ACAD SCI, V1019, P430, DOI 10.1196/annals.1297.077
   Pesce V, 2010, REJUV RES, V13, P148, DOI 10.1089/rej.2009.0955
   Poon HF, 2006, ANTIOXID REDOX SIGN, V8, P381, DOI 10.1089/ars.2006.8.381
   Rosca MG, 2009, ADV DRUG DELIVER REV, V61, P1332, DOI 10.1016/j.addr.2009.06.009
   Scarpulla RC, 2011, BBA-MOL CELL RES, V1813, P1269, DOI 10.1016/j.bbamcr.2010.09.019
   Seo AY, 2010, J CELL SCI, V123, P2533, DOI 10.1242/jcs.070490
   Srere P.A., 1969, METHOD ENZYMOL, V13, P3, DOI DOI 10.1016/0076-6879(69)13005-0
   Zorzano A, 2010, SEMIN CELL DEV BIOL, V21, P566, DOI 10.1016/j.semcdb.2010.01.002
NR 20
TC 26
Z9 28
U1 0
U2 13
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1549-1684
EI 1557-8577
J9 REJUV RES
JI Rejuv. Res.
PD APR
PY 2012
VL 15
IS 2
BP 136
EP 139
DI 10.1089/rej.2011.1255
PG 4
WC Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Geriatrics & Gerontology
GA 933SS
UT WOS:000303383600006
PM 22533417
DA 2024-02-19
ER

PT J
AU Chen, LJ
   Guo, J
   Zhang, SX
   Xu, Y
   Zhao, Q
   Zhang, W
   Xiao, J
   Chen, Y
AF Chen, Li-jie
   Guo, Jing
   Zhang, Song-xia
   Xu, Ying
   Zhao, Qing
   Zhang, Wei
   Xiao, Jian
   Chen, Yao
TI Sirtuin3 rs28365927 functional variant confers to the high risk of
   non-alcoholic fatty liver disease in Chinese Han population
SO LIPIDS IN HEALTH AND DISEASE
LA English
DT Article
DE Sirtuin3; Non-alcoholic fatty liver disease; Functional mutation;
   rs28365927
ID ALANINE AMINOTRANSFERASE; REDOX HOMEOSTASIS; POLYMORPHISM; PREVALENCE;
   ETIOLOGY; EPIGENETICS; GENETICS; SIRT3
AB Background Non-alcoholic fatty liver disease (NAFLD) is a multifactorial condition associated with aging, insulin resistance, metabolic syndrome, genetic factors and more. Although genetic traits are among the most important risks factors for NAFLD, the understanding of their influence is still quite limited. The present study aimed at identifying novel single nucleotide polymorphisms (SNPs) that may confer a risk for NAFLD in the Han Chinese population. Methods Based on the "two-hit hypothesis", candidate SNPs, including Sirtuin3 rs28365927, were genotyped by MassARRAY in B-type ultrasonography-proven NAFLD patients (n = 292) and healthy controls (n = 387). Results In a model analysis of individuals matched based on gender and age that compared 223 NAFLD and 223 non-NAFLD patients, the rs28365927 GA + AA genotype was a significant risk factor for the development of NAFLD in a dominant model. Rs28365927 was significantly associated with a higher NAFLD risk in both an additive model (A vs G) and genotypic model (GA vs GG). Among the NAFLD patients, serum levels of total bilirubin (TBIL), DBIL direct bilirubin (DBIL) and glutamic-pyruvic transaminase (ALT) in rs28365927 A allele carriers (GA + AA) were 11.1, 14.7 and 41.5% higher, respectively, than in non-carriers (GG). Furthermore, among the NAFLD patients, the carriers of Rs28365927 allele A were positively correlated with higher ALT levels. Conclusion Sirtuin3 rs28365927 functional variant confers to the high risk of non-alcoholic fatty liver disease in Chinese Han population. The rs28365927 A allele significantly increased the ALT levels of NAFLD patients.
C1 [Chen, Li-jie; Guo, Jing; Zhang, Song-xia; Xu, Ying; Zhao, Qing; Zhang, Wei; Chen, Yao] Cent South Univ, Xiangya Hosp, Dept Clin Pharmacol, Changsha 410008, Hunan, Peoples R China.
   [Chen, Li-jie; Guo, Jing; Zhang, Song-xia; Xu, Ying; Zhao, Qing; Zhang, Wei; Chen, Yao] Cent South Univ, Inst Clin Pharmacol, Changsha, Hunan, Peoples R China.
   [Chen, Li-jie; Guo, Jing; Zhang, Song-xia; Xu, Ying; Zhao, Qing; Zhang, Wei; Chen, Yao] Engn Res Ctr Appl Technol Pharmacogen, Minist Educ, Changsha, Hunan, Peoples R China.
   [Chen, Li-jie; Guo, Jing; Zhang, Song-xia; Xu, Ying; Zhao, Qing; Zhang, Wei; Chen, Yao] Natl Clin Res Ctr Geriatr Disorders, Changsha, Hunan, Peoples R China.
   [Xiao, Jian] Cent South Univ, Xiangya Hosp, Dept Pharm, Changsha, Hunan, Peoples R China.
C3 Central South University; Central South University; Central South
   University
RP Chen, Y (corresponding author), Cent South Univ, Xiangya Hosp, Dept Clin Pharmacol, Changsha 410008, Hunan, Peoples R China.; Chen, Y (corresponding author), Cent South Univ, Inst Clin Pharmacol, Changsha, Hunan, Peoples R China.; Chen, Y (corresponding author), Engn Res Ctr Appl Technol Pharmacogen, Minist Educ, Changsha, Hunan, Peoples R China.; Chen, Y (corresponding author), Natl Clin Res Ctr Geriatr Disorders, Changsha, Hunan, Peoples R China.
EM cbohua@csu.edu.cn
RI Zhang, Wei/AAG-9913-2019
OI Zhang, Wei/0000-0001-8679-6713
FU National Scientific Foundation of China [81974513, 81302850]; National
   Science and Technology Plan of China [2017ZX09304014]
FX This work was supported by the National Scientific Foundation of China
   (grant 81974513, 81302850), the National Science and Technology Plan of
   China (grant 2017ZX09304014). The funders had no role in the study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Ahn BH, 2008, P NATL ACAD SCI USA, V105, P14447, DOI 10.1073/pnas.0803790105
   [Anonymous], 2010, CHIN J CLIN HEPATOL
   Begriche K, 2013, HEPATOLOGY, V58, P1497, DOI 10.1002/hep.26226
   Brea A, 2005, ARTERIOSCL THROM VAS, V25, P1045, DOI 10.1161/01.ATV.0000160613.57985.18
   Bremmer DR, 2000, J DAIRY SCI, V83, P2252, DOI 10.3168/jds.S0022-0302(00)75109-5
   Brunt EM, 2015, NAT REV DIS PRIMERS, V1, DOI 10.1038/nrdp.2015.80
   Chen CH, 2007, J GASTROEN HEPATOL, V22, P1482, DOI 10.1111/j.1440-1746.2006.04615.x
   Clark JM, 2003, AM J GASTROENTEROL, V98, P960, DOI [10.1016/S0002-9270(03)00265-X, 10.1111/j.1572-0241.2003.07486.x]
   Del Campo JA, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19030911
   Eslam M, 2018, J HEPATOL, V68, P268, DOI 10.1016/j.jhep.2017.09.003
   Fan JG, 2017, J HEPATOL, V67, P862, DOI 10.1016/j.jhep.2017.06.003
   Fares R, 2015, LIVER INT, V35, P1574, DOI 10.1111/liv.12707
   Giannini EG, 2005, CAN MED ASSOC J, V172, P367, DOI 10.1503/cmaj.1040752
   Katsiki N, 2016, METABOLISM, V65, P1109, DOI 10.1016/j.metabol.2016.05.003
   Kitade H, 2017, NUTRIENTS, V9, DOI 10.3390/nu9040387
   Li RB, 2018, REDOX BIOL, V18, P229, DOI 10.1016/j.redox.2018.07.011
   Li ST, 2017, HEPATOLOGY, V66, P936, DOI 10.1002/hep.29229
   Liangpunsakul S, 2005, AM J MED SCI, V329, P111, DOI 10.1097/00000441-200503000-00001
   Luedde T, 2014, GASTROENTEROLOGY, V147, P765, DOI 10.1053/j.gastro.2014.07.018
   Mota M, 2016, METABOLISM, V65, P1049, DOI 10.1016/j.metabol.2016.02.014
   Nassir F, 2018, J LIPID RES, V59, P967, DOI 10.1194/jlr.M080952
   Pendino GM, 2005, HEPATOLOGY, V41, P1151, DOI 10.1002/hep.20689
   Podrini C, 2013, CURR PHARM DESIGN, V19, P2737, DOI 10.2174/1381612811319150009
   Qiu XL, 2010, CELL METAB, V12, P662, DOI 10.1016/j.cmet.2010.11.015
   Reimer KC, 2020, HEPATOL INT, V14, P8, DOI 10.1007/s12072-019-10001-4
   Rinella M, 2016, HEPATOLOGY, V64, P19, DOI 10.1002/hep.28524
   Shi YY, 2005, CELL RES, V15, P97, DOI 10.1038/sj.cr.7290272
   Sookoian S, 2017, CLIN MOL HEPATOL, V23, P1, DOI 10.3350/cmh.2016.0109
   Stahl EC, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02795
   Sun RM, 2020, BRIT J PHARMACOL, V177, P4166, DOI 10.1111/bph.15159
   Tao RD, 2010, MOL CELL, V40, P893, DOI 10.1016/j.molcel.2010.12.013
   Tilg H, 2017, NAT REV GASTRO HEPAT, V14, P32, DOI 10.1038/nrgastro.2016.147
   Valenti L, 2010, HEPATOLOGY, V51, P1209, DOI 10.1002/hep.23622
   Vespasiani-Gentilucci U, 2018, WORLD J GASTROENTERO, V24, P4835, DOI 10.3748/wjg.v24.i43.4835
   Wang GE, 2018, METABOLISM, V85, P227, DOI 10.1016/j.metabol.2018.04.011
   Wang Y, 2014, GENET TEST MOL BIOMA, V18, P653, DOI 10.1089/gtmb.2014.0116
   Xu X, 2019, FASEB J, V33, P7289, DOI 10.1096/fj.201802316R
   Younossi Z, 2018, NAT REV GASTRO HEPAT, V15, P11, DOI 10.1038/nrgastro.2017.109
   Zeng XL, 2019, ANTIOXID REDOX SIGN, V30, P163, DOI 10.1089/ars.2017.7172
NR 39
TC 1
Z9 2
U1 1
U2 2
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1476-511X
J9 LIPIDS HEALTH DIS
JI Lipids Health Dis.
PD AUG 26
PY 2021
VL 20
IS 1
AR 92
DI 10.1186/s12944-021-01520-x
PG 12
WC Biochemistry & Molecular Biology; Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Nutrition & Dietetics
GA UI9ZL
UT WOS:000690955200002
PM 34446002
OA gold, Green Published
DA 2024-02-19
ER

PT J
AU Kaufman, SR
AF Kaufman, Sharon R.
TI MAKING LONGEVITY IN AN AGING SOCIETY <i>linking Medicare policy and the
   new ethical field</i>
SO PERSPECTIVES IN BIOLOGY AND MEDICINE
LA English
DT Article
ID HEALTH
AB Life-extending interventions for older persons are changing medical knowledge and societal expectations about longevity. Today's consciousness about growing older is partly shaped by a new form of ethics, constituted by and enabled through the routines and institutions that comprise ordinary clinical care. Unlike bioethics, whose emphasis is on clinical decision-making in individual situations, this new form of ethics is exceptionally diffuse and can be characterized as an ethical field. It is located in and shaped by health-care policies, standard technologies, and clinical evidence, and it emerges in what patients and families come to need and want. Three developments illustrate this ethical field at work: the changing nature of disease, especially the ascent of risk awareness and risk-based strategies for life extension; the role of technology in reshaping the ends of medicine; and the role of Medicare policy in creating need and ethical necessity. Medicare's expanding criteria for payment coverage of liver transplantation and implantable cardiac devices illustrate the pervasive logic of this new form of ethics. The powerful connection between the technological imperative and its ethical necessity is rarely mentioned in Medicare reform debates.
C1 [Kaufman, Sharon R.] Univ Calif San Francisco, Dept Anthropol Hist & Social Med, San Francisco, CA 94143 USA.
   [Kaufman, Sharon R.] Univ Calif San Francisco, Inst Hlth & Aging, San Francisco, CA 94143 USA.
C3 University of California System; University of California San Francisco;
   University of California System; University of California San Francisco
RP Kaufman, SR (corresponding author), Univ Calif San Francisco, Dept Anthropol Hist & Social Med, Box 0646, San Francisco, CA 94143 USA.
EM sharon.kaufman@ucsf.edu
FU National Institute on Aging, NIH [RO1 AG28426]
FX This research was supported by National Institute on Aging, NIH, grant
   RO1 AG28426. This article is adapted from the Benjamin Lieberman
   Memorial Lecture, delivered October 13,2009, at UCSF. Thanks to the
   Lieberman family and the UCSF Division of Geriatrics for the opportunity
   to present this lecture. The author wishes to thank the patients,
   families, and health professionals who have allowed her observations and
   who have taken the time to speak candidly about medical treatment, and
   Guy Micco for his probing questions.
CR Beck Ulrich., 1992, Risk society: Towards a new modernity
   Butler R.N., 2008, The Longevity Revolution
   Chan PS, 2009, CIRC-CARDIOVASC QUAL, V2, P16, DOI 10.1161/CIRCOUTCOMES.108.807123
   Cortese DA, 2009, NEW ENGL J MED, V361, P1326, DOI 10.1056/NEJMp0907561
   Crawford R, 2006, HEALTH, V10, P401, DOI 10.1177/1363459306067310
   FLECK LM, 2009, JUST CARING HLTH CAR, P276
   FOX RC, 2002, COURAGE FAIL
   Fox ReneeC., 1992, Spare Parts: Organ Replacement in American Society
   Fuchs VR, 1975, Who Shall live? Health, economics, and social choice
   Giddens A., 1991, Modernity and self-identity. Self and society in the late modern age
   Gillick MR, 2007, PERSPECT BIOL MED, V50, P276, DOI 10.1353/pbm.2007.0017
   Hlatky MA, 2004, NEW ENGL J MED, V350, P2126, DOI 10.1056/NEJMp048071
   Jonsen Albert., 1998, BIRTH BIOETHICS
   Katz S, 2003, J AGING STUD, V17, P3, DOI 10.1016/S0890-4065(02)00086-5
   Kaufman SR, 2006, AM ETHNOL, V33, P81, DOI 10.1525/ae.2006.33.1.81
   KEDBERG RF, 2007, JAMA-J AM MED ASSOC, V298, P1564
   Koenig BA, 1988, BIOMEDICINE EXAMINED, P465
   Latour B, 2002, THEOR CULT SOC, V19, P247, DOI 10.1177/026327602761899246
   Lipshutz GS, 2007, ARCH SURG-CHICAGO, V142, P775, DOI 10.1001/archsurg.142.8.775
   Mendelson D, 2005, HEALTH AFFAIR, V24, P133, DOI 10.1377/hlthaff.24.1.133
   *OPTN, 2009, ORG PROC TRANSPL NET
   President's Council on Bioethics, 2003, THER BIOT PURS HAPP
   Rose N, 2007, POLITICS OF LIFE ITSELF: BIOMEDICINE, POWER, AND SUBJECTIVITY IN THE TWENTY-FIRST CENTURY, P1
   Rosenberg Charles E, 2007, Our Present Complaint: American Medicine, Then and Now
   Shim JK, 2008, PLOS MED, V5, P344, DOI 10.1371/journal.pmed.0050007
   Tung R, 2009, CIRCULATION, V120, P825, DOI 10.1161/CIRCULATIONAHA.109.891069
   Tunis SR, 2004, NEW ENGL J MED, V350, P2196, DOI 10.1056/NEJMe048091
   WOODWARD K, 1999, DIFFERENCES, V11, P177, DOI DOI 10.1215/10407391-11-2-177
NR 28
TC 15
Z9 15
U1 0
U2 13
PU JOHNS HOPKINS UNIV PRESS
PI BALTIMORE
PA JOURNALS PUBLISHING DIVISION, 2715 NORTH CHARLES ST, BALTIMORE, MD
   21218-4363 USA
SN 0031-5982
EI 1529-8795
J9 PERSPECT BIOL MED
JI Perspect. Biol. Med.
PD SUM
PY 2010
VL 53
IS 3
BP 407
EP 424
DI 10.1353/pbm.0.0164
PG 18
WC History & Philosophy Of Science; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC History & Philosophy of Science; Research & Experimental Medicine
GA 626VD
UT WOS:000279994500007
PM 20639608
OA Green Accepted
DA 2024-02-19
ER

PT J
AU Su, WP
   Xing, RB
   Guha, A
   Gutmann, DH
   Sherman, LS
AF Su, Weiping
   Xing, Rubing
   Guha, Abhijit
   Gutmann, David H.
   Sherman, Larry S.
TI Mice with GFAP-targeted loss of neurofibromin demonstrate increased
   axonal MET expression with aging
SO GLIA
LA English
DT Article
DE neurofibromatosis 1; astrocytes; MET; hippocampal neurons; K-RAS
ID HEPATOCYTE GROWTH-FACTOR; FACTOR-SCATTER FACTOR; NERVE SHEATH TUMOR;
   HUMAN GLIOMA-CELLS; RECEPTOR C-MET; HUMAN GLIOBLASTOMA; MOUSE MODEL;
   IN-VITRO; FACTOR/SCATTER FACTOR; ASTROCYTOMA FORMATION
AB Neurofibromatosis 1 (NF1) is a common genetic disease that predisposes patients to peripheral nerve tumors and central nervous system (CNS) abnormalities including low-grade astrocytomas and cognitive disabilities. Using mice with glial fibrillary acidic protein (GFAP)-targeted Nf1 loss (Nf1(GFAP) CKO mice), we found that Nf1(-/-) astrocytes proliferate faster and are more invasive than wild-type astrocytes. In light of our previous finding that aberrant expression of the MET receptor tyrosine kinase contributes to the invasiveness of human NF1-associated malignant peripheral nerve sheath tumors, we sought to determine whether MET expression is aberrant in the brains of Nf1 mutant mice. We found that Nf1(-/-) astrocytes express slightly more MET than wild-type cells in vitro, but do not express elevated MET in situ. However, fiber tracts containing myelinated axons in the hippocampus, midbrain, cerebral cortex, and cerebellum express higher than normal levels of MET in older (>= 6 months) Nf1(GFAP) CKO mice. Both Nf1(GFAP)CKO and wild-type astrocytes induced MET expression in neurites of wild-type hippocampal neurons in vitro, suggesting that astrocyte-derived signals may induce MET in Nf1 mutant mice. Because the Nf1 gene product functions as a RAS GTPase, we examined MET expression in the brains of mice with GFAP-targeted constitutively active forms of RAS. MET was elevated in axonal fiber tracts in mice with active K-RAS but not H-RAS. Collectively, these data suggest that loss of Nf1 in either astrocytes or GFAP(+) neural progenitor cells results in increased axonal MET expression, which may contribute to the CNS abnormalities in children and adults with NF1. (c) 2007 Wiley-Liss, Inc.
C1 Oregon Hlth & Sci Univ, Div Neurosci, Oregon Natl Primate Res Ctr, Beaverton, OR 97006 USA.
   Univ Hlth Network, Hosp Sick Children, Toronto, ON, Canada.
   Univ Hlth Network, Div Neurosurg, Arthur & Sonia Labatt Brain Tumor Res Ctr, Toronto, ON, Canada.
   Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA.
   Oregon Hlth & Sci Univ, Dept Cell & Dev Biol, Portland, OR 97201 USA.
C3 Oregon Health & Science University; Oregon National Primate Research
   Center; University of Toronto; Hospital for Sick Children (SickKids);
   University Health Network Toronto; University of Toronto; University
   Health Network Toronto; Washington University (WUSTL); Oregon Health &
   Science University
RP Sherman, LS (corresponding author), Oregon Hlth & Sci Univ, Div Neurosci, Oregon Natl Primate Res Ctr, 505 NW 185th Ave, Beaverton, OR 97006 USA.
EM shermanl@ohsu.edu
RI su, wei/GZM-3986-2022
OI Gutmann, David/0000-0002-3127-5045
FU NCRR NIH HHS [RR 0163] Funding Source: Medline
CR Abounader R, 1999, J NATL CANCER I, V91, P1548, DOI 10.1093/jnci/91.18.1548
   Abounader R, 2001, J NEUROCHEM, V76, P1497, DOI 10.1046/j.1471-4159.2001.00158.x
   Achim CL, 1997, DEV BRAIN RES, V102, P299, DOI 10.1016/S0165-3806(97)00108-9
   Bajenaru ML, 2002, MOL CELL BIOL, V22, P5100, DOI 10.1128/MCB.22.14.5100-5113.2002
   Bajenaru ML, 2003, CANCER RES, V63, P8573
   Bajenaru ML, 2001, GLIA, V33, P314, DOI 10.1002/1098-1136(20010315)33:4<314::AID-GLIA1030>3.0.CO;2-Q
   BALLESTER R, 1990, CELL, V63, P851, DOI 10.1016/0092-8674(90)90151-4
   Bauer TW, 2005, CANCER RES, V65, P7775, DOI 10.1158/0008-5472.CAN-05-0946
   Burgess T, 2006, CANCER RES, V66, P1721, DOI 10.1158/0008-5472.CAN-05-3329
   Chan PC, 2006, J BIOMED SCI, V13, P215, DOI 10.1007/s11373-005-9061-7
   Chattopadhyay N, 2002, MOL BRAIN RES, V102, P73, DOI 10.1016/S0169-328X(02)00215-2
   Costa RM, 2002, NATURE, V415, P526, DOI 10.1038/nature711
   Dasgupta B, 2005, CANCER RES, V65, P236
   Davey F, 2000, MOL CELL NEUROSCI, V15, P79, DOI 10.1006/mcne.1999.0803
   Ding H, 2001, CANCER RES, V61, P3826
   Fraser MM, 2004, CANCER RES, V64, P7773, DOI 10.1158/0008-5472.CAN-04-2487
   Friedman JM, 2002, GENET MED, V4, P105, DOI 10.1097/00125817-200205000-00002
   Funakoshi H, 2001, BIOCHEM BIOPH RES CO, V283, P606, DOI 10.1006/bbrc.2001.4819
   GIORDANO S, 1989, ONCOGENE, V4, P1383
   Griffin S, 2005, J NEUROCHEM, V95, P1015, DOI 10.1111/j.1471-4159.2005.03418.x
   Gutmann DH, 2002, NEUROLOGY, V59, P759, DOI 10.1212/WNL.59.5.759
   Hamanoue M, 1996, J NEUROSCI RES, V43, P554, DOI 10.1002/(SICI)1097-4547(19960301)43:5<554::AID-JNR5>3.0.CO;2-H
   Jackson EL, 2001, GENE DEV, V15, P3243, DOI 10.1101/gad.943001
   JUNG W, 1994, J CELL BIOL, V126, P485, DOI 10.1083/jcb.126.2.485
   Koochekpour S, 1997, CANCER RES, V57, P5391
   Korhonen L, 2000, EUR J NEUROSCI, V12, P3453, DOI 10.1046/j.1460-9568.2000.00260.x
   Kulkantrakorn K, 1998, PEDIATR NEUROL, V19, P347, DOI 10.1016/S0887-8994(98)00075-7
   Kwon CH, 2001, NAT GENET, V29, P404, DOI 10.1038/ng781
   LISTERNICK R, 1994, J PEDIATR-US, V125, P63, DOI 10.1016/S0022-3476(94)70122-9
   Listernick R, 1999, AM J MED GENET, V89, P38, DOI 10.1002/(SICI)1096-8628(19990326)89:1<38::AID-AJMG8>3.0.CO;2-M
   Malatesta P, 2003, NEURON, V37, P751, DOI 10.1016/S0896-6273(03)00116-8
   Marino S, 2000, GENE DEV, V14, P994
   MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D
   Molinari S, 1996, P NATL ACAD SCI USA, V93, P8028, DOI 10.1073/pnas.93.15.8028
   Moriyama T, 1999, CLIN EXP METASTAS, V17, P873, DOI 10.1023/A:1006729611241
   MORIYAMA T, 1995, FEBS LETT, V372, P78, DOI 10.1016/0014-5793(95)00949-A
   Nagayama T, 2004, BRAIN RES, V999, P155, DOI 10.1016/j.brainres.2003.11.052
   Nedergaard M, 2005, GLIA, V50, P281, DOI 10.1002/glia.20205
   NORTH K, 1995, DEV MED CHILD NEUROL, V37, P427, DOI 10.1111/j.1469-8749.1995.tb12026.x
   Pascual O, 2005, SCIENCE, V310, P113, DOI 10.1126/science.1116916
   Powell EM, 2003, J NEUROSCI, V23, P622, DOI 10.1523/JNEUROSCI.23-02-00622.2003
   Powell EM, 2001, NEURON, V30, P79, DOI 10.1016/S0896-6273(01)00264-1
   Rao UNM, 1997, HUM PATHOL, V28, P1066, DOI 10.1016/S0046-8177(97)90060-5
   Ricardi VM, 1986, NEUROFIBROMATOSIS PH
   Rosser T, 2002, J CHILD NEUROL, V17, P630, DOI 10.1177/088307380201700815
   Rossi A, 2005, INT J MED ROBOT COMP, V1, P64, DOI 10.1002/rcs.17
   Rubin JB, 2005, NAT REV CANCER, V5, P557, DOI 10.1038/nrc1653
   Shimamura M, 2006, HYPERTENSION, V47, P742, DOI 10.1161/01.HYP.0000208598.57687.3e
   Shimazaki K, 2003, BRAIN RES, V962, P105, DOI 10.1016/S0006-8993(02)03975-6
   Struve J, 2005, GLIA, V52, P16, DOI 10.1002/glia.20215
   Su WP, 2004, GLIA, V45, P297, DOI 10.1002/glia.10340
   Su WP, 2003, EXP MOL PATHOL, V75, P160, DOI 10.1016/S0014-4800(03)00068-6
   Sun W, 2002, MOL BRAIN RES, V103, P36, DOI 10.1016/S0169-328X(02)00168-7
   Sylvester CL, 2006, CURR OPIN OPHTHALMOL, V17, P7, DOI 10.1097/01.icu.0000193070.32369.37
   Tian GF, 2005, NAT MED, V11, P973, DOI 10.1038/nm1277
   Uchinokura S, 2006, INT J CANCER, V118, P583, DOI 10.1002/ijc.21362
   Vivarelli R, 2003, J CHILD NEUROL, V18, P338, DOI 10.1177/08830738030180050501
   Watanabe T, 2001, J CLIN PATHOL, V54, P631, DOI 10.1136/jcp.54.8.631
   Welch WC, 1999, ANTICANCER RES, V19, P1635
   XU GF, 1990, CELL, V63, P835, DOI 10.1016/0092-8674(90)90149-9
   YAMADA T, 1994, BRAIN RES, V637, P308, DOI 10.1016/0006-8993(94)91250-5
   YAMAGATA T, 1995, BIOCHEM BIOPH RES CO, V210, P231, DOI 10.1006/bbrc.1995.1651
   Yan HL, 2002, J NEUROSCI RES, V69, P597, DOI 10.1002/jnr.10323
   Zhang YW, 2003, J CELL BIOCHEM, V88, P408, DOI 10.1002/jcb.10358
   Zhu Y, 2005, DEVELOPMENT, V132, P5577, DOI 10.1242/dev.02162
NR 65
TC 3
Z9 5
U1 0
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0894-1491
EI 1098-1136
J9 GLIA
JI Glia
PD MAY
PY 2007
VL 55
IS 7
BP 723
EP 733
DI 10.1002/glia.20501
PG 11
WC Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA 156VZ
UT WOS:000245679300006
PM 17348023
DA 2024-02-19
ER

PT J
AU El-Hennamy, RE
   Elmasry, HA
AF El-Hennamy, Rehab E.
   Elmasry, Heba A.
TI Alterations in <i>Per2</i>, <i>Bcl2</i> gene expression, and oxidative
   status in aged rats liver after light pulse at night
SO SLEEP AND BIOLOGICAL RHYTHMS
LA English
DT Article; Early Access
DE Light entrainment; Circadian rhythm; Clock genes; Oxidative stress;
   Apoptosis
ID CLOCK GENES; CIRCADIAN-RHYTHM; STRESS; ACID; LIFE
AB The aging process is characterized by circadian rhythm disruption, in physiology and behavior, which could result from weak entrainment. Light is the most potent cue that entrains the central circadian clock, which in turn synchronizes peripheral clocks in animal tissues. Period 2 (Per2) is one of the clock genes that respond to light. Moreover, oxidative stress could entrain the clock. Therefore, the present work aimed to investigate the role of light when applied late at night on the Per2, B cell lymphoma 2 (Bcl2) gene expression, and oxidative status in aged rats. Aged rats were divided into a control group and a group exposed to a 30-min light pulse applied daily during the subjective night at 5 am (ZT 22) for 4 weeks. Per2 and Bcl2 gene expression were quantified in liver tissue. To evaluate oxidative status, Glutathione (GSH), nitric oxide (NO), and malondialdehyde (MDA) were estimated. The light pulse reduced the expression levels of Per2 and Bcl2 mRNA. Although it diminished the levels of malondialdehyde (MDA), nitric oxide (NO) levels were elevated and the glutathione (GSH) levels were declined. In conclusion, the light pulse late at night abolished Per2 mRNA circadian rhythm and reduced its expression in the liver of the aged rat. Similarly, it diminished the anti-apoptotic gene expression, Bcl2. Moreover, it might attenuate oxidative stress through the reduction in MDA levels.
C1 [El-Hennamy, Rehab E.; Elmasry, Heba A.] Helwan Univ, Fac Sci, Zool & Entomol Dept, Cairo, Egypt.
C3 Egyptian Knowledge Bank (EKB); Helwan University
RP El-Hennamy, RE (corresponding author), Helwan Univ, Fac Sci, Zool & Entomol Dept, Cairo, Egypt.
EM rhennamy@hotmail.com; heba.elmasry86@yahoo.com
FU Special thanks to Prof. Dr. Mona Abdel-Rahman for her kind support,
   advices, and revising the manuscript. The research was performed in the
   laboratories of the Zoology and Entomology Department, Faculty of
   Science, Helwan University, Egypt.; Helwan University, Egypt
FX Special thanks to Prof. Dr. Mona Abdel-Rahman for her kind support,
   advices, and revising the manuscript. The research was performed in the
   laboratories of the Zoology and Entomology Department, Faculty of
   Science, Helwan University, Egypt.
CR Abdel-Rahman M., 2020, Egypt J Basic Appl Sci, V7, P126
   Alaasam VJ., 2022, Life Sci, V307, P12087
   Albrecht U, 2001, J BIOL RHYTHM, V16, P100, DOI 10.1177/074873001129001791
   Castro MD, 2012, EXP GERONTOL, V47, P29, DOI 10.1016/j.exger.2011.10.002
   Dato S, 2013, INT J MOL SCI, V14, P16443, DOI 10.3390/ijms140816443
   Finlay LA, 2012, AM J PHYSIOL-REG I, V302, pR587, DOI 10.1152/ajpregu.00393.2011
   Fonken LK, 2014, ENDOCR REV, V35, P648, DOI 10.1210/er.2013-1051
   FOSTER RG, 1991, J COMP PHYSIOL A, V169, P39, DOI 10.1007/BF00198171
   Foster RG, 2014, EXP PHYSIOL, V99, P599, DOI 10.1113/expphysiol.2012.071118
   GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X
   Guan QY, 2022, ECOTOX ENVIRON SAFE, V239, DOI 10.1016/j.ecoenv.2022.113625
   Hamada T, 2011, BIOCHEM BIOPH RES CO, V409, P727, DOI 10.1016/j.bbrc.2011.05.076
   Hirota T, 2004, ZOOL SCI, V21, P359, DOI 10.2108/zsj.21.359
   Hughes S, 2015, METHOD ENZYMOL, V552, P125, DOI 10.1016/bs.mie.2014.10.018
   Husse J, 2015, BIOESSAYS, V37, P1119, DOI 10.1002/bies.201500026
   Kolker DE, 2003, J BIOL RHYTHM, V18, P159, DOI 10.1177/0748730403251802
   Lee CC, 2005, METHOD ENZYMOL, V393, P852, DOI 10.1016/S0076-6879(05)93045-0
   Magnone MC, 2015, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00289
   Mavroudis PD, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0197534
   Mohamed AE., 2021, Environ Pollut, V282, P117036
   MOORE RY, 1972, BRAIN RES, V42, P201, DOI 10.1016/0006-8993(72)90054-6
   MOORE RY, 1995, J COMP NEUROL, V352, P351, DOI 10.1002/cne.903520304
   Nahata M, 2021, NPJ AGING MECH DIS, V7, DOI 10.1038/s41514-021-00065-8
   Nakahata Y, 2009, SCIENCE, V324, P654, DOI 10.1126/science.1170803
   OHKAWA H, 1979, ANAL BIOCHEM, V95, P351, DOI 10.1016/0003-2697(79)90738-3
   Pang KCH, 2006, AGE, V28, P283, DOI 10.1007/s11357-006-9013-9
   Preitner N, 2002, CELL, V110, P251, DOI 10.1016/S0092-8674(02)00825-5
   Ramanathan C, 2009, NEUROSCIENCE, V161, P960, DOI 10.1016/j.neuroscience.2009.04.040
   Reppert SM, 2002, NATURE, V418, P935, DOI 10.1038/nature00965
   Sastre J, 2000, IUBMB LIFE, V49, P427
   SEDLAK J, 1968, ANAL BIOCHEM, V25, P192, DOI 10.1016/0003-2697(68)90092-4
   Sheehan D, 2001, BIOCHEM J, V360, P1, DOI 10.1042/0264-6021:3600001
   Sládek M, 2007, AM J PHYSIOL-REG I, V292, pR1224, DOI 10.1152/ajpregu.00184.2006
   Sun CM, 2010, PATHOL ONCOL RES, V16, P403, DOI 10.1007/s12253-009-9227-0
   Tamaru T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082006
   Touitou Y, 2017, LIFE SCI, V173, P94, DOI 10.1016/j.lfs.2017.02.008
   Zhang S, 2020, CELL SIGNAL, V69, DOI 10.1016/j.cellsig.2019.109433
NR 37
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER JAPAN KK
PI TOKYO
PA SHIROYAMA TRUST TOWER 5F, 4-3-1 TORANOMON, MINATO-KU, TOKYO, 105-6005,
   JAPAN
SN 1446-9235
EI 1479-8425
J9 SLEEP BIOL RHYTHMS
JI Sleep Biol. Rhythms
PD 2023 NOV 5
PY 2023
DI 10.1007/s41105-023-00495-9
EA NOV 2023
PG 10
WC Clinical Neurology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA X5KK1
UT WOS:001098835200001
OA hybrid
DA 2024-02-19
ER

PT J
AU Han, YZ
   Guo, YM
   Xiong, P
   Ge, FL
   Jing, J
   Niu, M
   Zhao, X
   Bai, ZF
   Song, HB
   Xiao, XH
   Wang, JB
AF Han, Yan-zhong
   Guo, Yu-ming
   Xiong, Peng
   Ge, Fei-lin
   Jing, Jing
   Niu, Ming
   Zhao, Xu
   Bai, Zhao-fang
   Song, Hai-bo
   Xiao, Xiao-he
   Wang, Jia-bo
TI Age-Associated Risk of Liver-Related Adverse Drug Reactions
SO FRONTIERS IN MEDICINE
LA English
DT Article
DE adverse drug reaction; older adults; hepatotoxicity; pharmacovigilance;
   relative risk
ID CAUSALITY ASSESSMENT; BLOOD-PRESSURE; INJURY
AB ObjectiveAging population is generally considered more sensitive to adverse drug reactions (ADRs). Yet, big data-based quantitative evidence currently does not exist to support this concept. This study aims to investigate age-associated risks of liver-related ADR (L-ADR). MethodsSpontaneous reporting data from 2012 to 2016 were retrieved from the China National ADR Monitoring System. The risk ratio (RR) was used to quantify the relative risk of L-ADR of each age group. The reporting odds ratio (ROR) was used to quantify the correlation with the risk of L-ADR of each drug category or drug in older adults. ResultsTotally, 64,702 L-ADR reports were retrieved, covering ages from 1 to 116, with a median age of 49. The RR values increased exponentially with the increase of age, which indicates that the relative risk of L-ADR increased by 33% for every 10-year increase in age. The age cutoff point for relative high risk of L-ADR was estimated at 52.0 years old (RR = 1). In 17 categories composed of 270 drugs, the top 3 drug categories with a high correlation to the risk of L-ADR in older adults were antiarrhythmic (ROR, 5.75; 95% CI: 4.45-7.42), antilipemic (ROR, 4.77; 95% CI: 4.53-5.02), and antihypertensive (ROR, 2.97; 95% CI: 2.59-3.41). ConclusionsThis research illustrates quantitatively that aging is a potential risk factor for L-ADR, with a 33% increase in relative risk for every 10-year increase in age. Risk management should be addressed for older adults when those drugs with a high correlation to the risk of L-ADR are used.
C1 [Han, Yan-zhong] Chengdu Univ Tradit Chinese Med, Coll Pharm, Chengdu, Peoples R China.
   [Han, Yan-zhong; Guo, Yu-ming; Xiong, Peng; Ge, Fei-lin; Jing, Jing; Niu, Ming; Zhao, Xu; Bai, Zhao-fang; Xiao, Xiao-he; Wang, Jia-bo] Chinese Peoples Liberat Army PLA Gen Hosp, China Mil Inst Chinese Med, Med Ctr 5, Beijing, Peoples R China.
   [Song, Hai-bo] Natl Ctr Adverse Drug React Monitoring, Beijing, Peoples R China.
   [Wang, Jia-bo] Capital Med Univ, Sch Tradit Chinese Med, Beijing, Peoples R China.
C3 Chengdu University of Traditional Chinese Medicine; Capital Medical
   University
RP Xiao, XH; Wang, JB (corresponding author), Chinese Peoples Liberat Army PLA Gen Hosp, China Mil Inst Chinese Med, Med Ctr 5, Beijing, Peoples R China.; Song, HB (corresponding author), Natl Ctr Adverse Drug React Monitoring, Beijing, Peoples R China.; Wang, JB (corresponding author), Capital Med Univ, Sch Tradit Chinese Med, Beijing, Peoples R China.
EM songhaibo@cdr-adr.org.cn; pharmacy302xxh@126.com; jiabo_wang@ccmu.edu.cn
RI Xiao, Xiao/IAN-3011-2023; Xiao, Xiao/GQP-7793-2022; Song,
   haibo/GNP-5903-2022; Guo, Yuming/I-8353-2018; xiao, xiang/GWU-6035-2022
OI Guo, Yuming/0000-0002-1766-6592; Niu, Ming/0000-0001-9101-726X; Song,
   Haibo/0000-0001-7952-6360
CR Al Khaja KAJ, 2004, AGING CLIN EXP RES, V16, P319
   Almazroo OA, 2017, CLIN LIVER DIS, V21, P1, DOI 10.1016/j.cld.2016.08.001
   Antosik-Wojcinska A, 2016, PSYCHIATR POL, V50, P1015, DOI 10.12740/PP/59104
   BENICHOU C, 1993, J CLIN EPIDEMIOL, V46, P1331, DOI 10.1016/0895-4356(93)90102-7
   Björnsson ES, 2016, HEPATOLOGY, V63, P590, DOI 10.1002/hep.28323
   Chalasani N, 2010, GASTROENTEROLOGY, V138, P2246, DOI 10.1053/j.gastro.2010.04.001
   Chen MJ, 2015, J HEPATOL, V63, P503, DOI 10.1016/j.jhep.2015.04.016
   Commission ECorduotnhaFP Committee CMDAhS, 2017, CHINESE J FRONTIERS, V9, P28, DOI DOI 10.12037/YXQY.2017.07-07
   DANAN G, 1993, J CLIN EPIDEMIOL, V46, P1323, DOI 10.1016/0895-4356(93)90101-6
   Danjuma MI, 2020, BMC GERIATR, V20, DOI 10.1186/s12877-020-01732-3
   George A, 2020, CUREUS J MED SCIENCE, V12, DOI 10.7759/cureus.10047
   George N, 2018, REGUL TOXICOL PHARM, V94, P101, DOI 10.1016/j.yrtph.2018.01.018
   Handschin A, 2015, THER UMSCH, V72, P397, DOI 10.1024/0040-5930/a000692
   Lucena MI, 2020, LANCET GASTROENTEROL, V5, P862, DOI 10.1016/S2468-1253(20)30006-6
   Lucena MI, 2009, HEPATOLOGY, V49, P2001, DOI 10.1002/hep.22895
   Kaplowitz N, 2005, NAT REV DRUG DISCOV, V4, P489, DOI 10.1038/nrd1750
   Katarey Dev, 2016, Clin Med (Lond), V16, ps104
   Kuna L, 2018, CURR DRUG METAB, V19, P830, DOI 10.2174/1389200219666180523095355
   Lawthom C, 2019, NEUROL THER, V8, P491, DOI 10.1007/s40120-019-0137-0
   Mitchell SJ, 2010, THER ADV DRUG SAF, V1, P65, DOI 10.1177/2042098610386281
   Onji M, 2009, HEPATOL RES, V39, P546, DOI 10.1111/j.1872-034X.2009.00492.x
   Ostapowicz G, 2002, ANN INTERN MED, V137, P947, DOI 10.7326/0003-4819-137-12-200212170-00007
   Rothman KJ, 2004, PHARMACOEPIDEM DR S, V13, P519, DOI 10.1002/pds.1001
   Shen T, 2019, GASTROENTEROLOGY, V156, P2230, DOI 10.1053/j.gastro.2019.02.002
   Stead LG, 2005, NEUROLOGY, V65, P1179, DOI 10.1212/01.wnl.0000180939.24845.22
   Stine Jonathan G, 2013, Curr Gastroenterol Rep, V15, P299, DOI 10.1007/s11894-012-0299-8
   STRICKER BHC, 1992, J CLIN EPIDEMIOL, V45, P1177, DOI 10.1016/0895-4356(92)90158-J
   Ushigome H, 2016, TRANSPL P, V48, P1115, DOI 10.1016/j.transproceed.2015.12.103
   Weersink RA, 2021, CLIN PHARMACOL THER, V109, P1147, DOI 10.1002/cpt.2108
NR 29
TC 1
Z9 1
U1 3
U2 12
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 2296-858X
J9 FRONT MED-LAUSANNE
JI Front. Med.
PD MAR 17
PY 2022
VL 9
AR 832557
DI 10.3389/fmed.2022.832557
PG 8
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 0G5GA
UT WOS:000778072000001
PM 35372391
OA gold, Green Published
DA 2024-02-19
ER

PT J
AU Restrepo, C
   Alvarez, B
   Valencia, JL
   García, M
   Navarrete-Muñoz, MA
   Ligos, JM
   Cabello, A
   Prieto, L
   Nistal, S
   Montoya, M
   Górgolas, M
   Rallón, N
   Benito, JM
AF Restrepo, Clara
   Alvarez, Beatriz
   Valencia, Jose L.
   Garcia, Marcial
   Navarrete-Munoz, Maria A.
   Ligos, Jose M.
   Cabello, Alfonso
   Prieto, Laura
   Nistal, Sara
   Montoya, Maria
   Gorgolas, Miguel
   Rallon, Norma
   Benito, Jose M.
TI Both HCV Infection and Elevated Liver Stiffness Significantly Impacts on
   Several Parameters of T-Cells Homeostasis in HIV-Infected Patients
SO JOURNAL OF CLINICAL MEDICINE
LA English
DT Article
DE HIV; HCV coinfection; T-cell homeostasis disturbances; liver stiffness;
   immune restoration; DAAs-based therapy
ID HEPATITIS-C VIRUS; HUMAN-IMMUNODEFICIENCY-VIRUS; ANTIRETROVIRAL THERAPY;
   NATURAL-HISTORY; COINFECTED PATIENTS; PROGRESSION; DISEASE; FIBROSIS;
   CD4(+); ACTIVATION
AB (1) Background: The role of hepatitis C virus (HCV) co-infection on the T-cell homeostasis disturbances in human immunodeficiency virus (HIV)-infected patients as well as its reversion after HCV eradication with direct acting antivirals (DAAs) therapy has not been yet clarified. We extensively analyzed the effect of HCV co-infection on immune parameters of HIV pathogenesis and its evolution after HCV eradication with DAAs. (2) Methods: Seventy individuals were included in the study-25 HIV-monoinfected patients, 25 HIV/HCV-coinfected patients and 20 HIV and HCV seronegative subjects. All patients were on antiretroviral therapy and undetectable HIV-viremia. Immune parameters, such as maturation, activation, apoptosis, senescence and exhaustion of T-cells were assessed by flow cytometry. Cross-sectional and longitudinal (comparing pre- and post-DAAs data in HIV/HCV coinfected patients) analyses were performed. Univariate and multivariate (general linear model and canonical discriminant analysis -CDA-) analyses were used to assess differences between groups. (3) Results-The CDA was able to clearly separate HIV/HCV coinfected from HIV-monoinfected patients, showing a more disturbed T-cells homeostasis in HIV/HCV patients, especially activation and exhaustion of T-cells. Interestingly, those perturbations were more marked in HIV/HCV patients with increased liver stiffness. Eradication of HCV with DAAs restored some but not all the T-cells homeostasis disturbances, with activation and exhaustion of effector CD8 T-cells remaining significantly increased three months after HCV eradication. (4) Conclusions-HCV co-infection significantly impacts on several immune markers of HIV pathogenesis, especially in patients with increased liver stiffness. Eradication of HCV with DAAs ameliorates but does not completely normalize these alterations. It is of utmost relevance to explore other mechanisms underlying the immune damage observed in HIV/HCV coinfected patients with control of both HIV and HCV replication.
C1 [Restrepo, Clara; Garcia, Marcial; Navarrete-Munoz, Maria A.; Rallon, Norma; Benito, Jose M.] Univ Autonoma Madrid, Inst Invest Sanitaria, Fdn Jimenez Diaz, HIV & Viral Hepatitis Res Lab,IIS FJD,UAM, Madrid 28933, Spain.
   [Restrepo, Clara; Garcia, Marcial; Navarrete-Munoz, Maria A.; Nistal, Sara; Rallon, Norma; Benito, Jose M.] Hosp Univ Rey Juan Carlos, Madrid 28933, Spain.
   [Alvarez, Beatriz; Cabello, Alfonso; Prieto, Laura; Gorgolas, Miguel] Fdn Jimenez Diaz, Univ Hosp, Madrid 28040, Spain.
   [Valencia, Jose L.] Univ Complutense Madrid, Fac Estudios Estadist, Dept Estadist & Invest Operat 3, Madrid 28040, Spain.
   [Ligos, Jose M.; Montoya, Maria] Ctr Nacl Invest Cardiovasc CNIC, Madrid 28029, Spain.
C3 Fundacion Jimenez Diaz; Autonomous University of Madrid; Fundacion
   Jimenez Diaz; Complutense University of Madrid; Centro Nacional de
   Investigaciones Cardiovasculares (CNIC)
RP Rallón, N (corresponding author), Univ Autonoma Madrid, Inst Invest Sanitaria, Fdn Jimenez Diaz, HIV & Viral Hepatitis Res Lab,IIS FJD,UAM, Madrid 28933, Spain.; Rallón, N (corresponding author), Hosp Univ Rey Juan Carlos, Madrid 28933, Spain.
EM clararestrepog@gmail.com; BAlvarez@quironsalud.es; joseval@estad.ucm.es;
   marcial_g_a@hotmail.com; mangelesnm94@gmail.com; jmligos@gmail.com;
   acabello@fjd.es; LPrietoPe@fjd.es; sara.nistal@hospitalreyjuancarlos.es;
   mmontoya@cnic.es; mgorgolas@fjd.es; norma.rallon@fjd.es;
   jbenito1@hotmail.com
RI Cabello, Alfonso/ABH-3203-2021; Valencia, Jose/IAO-2562-2023
OI Benito, Jose/0000-0002-7172-049X; Navarrete-Munoz, Maria
   A/0009-0008-2741-1623; Rallon, Norma/0000-0002-4643-247X; Cabello-Ubeda,
   Alfonso/0000-0001-8429-8358
FU Ministerio de Ciencia, Innovacion y Universidades (MCNU); Pro CNIC
   Foundation; Spanish plan for scientific and technical research and
   innovation from the General Sub-Directorate for research assessment and
   promotion, Spanish Carlos III Institute of Health (ISCIII) - European
   Regional Development Fund (ERDF) [PI14/00518, RD16/0025/0013]; ISCIII
   [CPII19/00025]; IIS-FJD;  [SEV-2015-0505];  [IND2018/BMD-9651]
FX The CNIC is supported by the Ministerio de Ciencia, Innovacion y
   Universidades (MCNU) and the Pro CNIC Foundation and is a Severo Ochoa
   Center of Excellence (SEV-2015-0505). This work was partially supported
   by projects PI14/00518 and RD16/0025/0013 integrated in the Spanish plan
   for scientific and technical research and innovation from the General
   Sub-Directorate for research assessment and promotion, Spanish Carlos
   III Institute of Health (ISCIII) co-funded by the European Regional
   Development Fund (ERDF). Norma Rallon is a Miguel Servet investigator
   from the ISCIII (CPII19/00025). Maria A Navarrete-Munoz is funded by
   project IND2018/BMD-9651. Clara Restrepo is funded by project
   RD16/0025/0013. Marcial Garcia is co-funded by RD16/0025/0013 project
   and an intramural research scholarship from IIS-FJD.
CR Benhamou Y, 1999, HEPATOLOGY, V30, P1054, DOI 10.1002/hep.510300409
   Bräu N, 2007, J HEPATOL, V47, P527, DOI 10.1016/j.jhep.2007.06.010
   Callendret B, 2011, NAT MED, V17, P252, DOI 10.1038/nm0311-252
   Castéra L, 2005, GASTROENTEROLOGY, V128, P343, DOI 10.1053/j.gastro.2004.11.018
   Cockerham LR, 2014, AIDS, V28, P1749, DOI 10.1097/QAD.0000000000000314
   d'Ettorre G, 2016, J MED VIROL, V88, P1347, DOI 10.1002/jmv.24475
   Feuth T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059302
   Gonzalez VD, 2009, J VIROL, V83, P11407, DOI 10.1128/JVI.01211-09
   Grady BPX, 2016, IMMUN AGEING, V13, DOI 10.1186/s12979-016-0065-0
   Hernandez MD, 2011, CURR OPIN HIV AIDS, V6, P478, DOI 10.1097/COH.0b013e32834bd365
   Hoffmann M, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005661
   Ingiliz P, 2015, CURR OPIN HIV AIDS, V10, P303, DOI 10.1097/COH.0000000000000187
   Khaitan Alka, 2011, Curr HIV/AIDS Rep, V8, P4, DOI 10.1007/s11904-010-0066-0
   Körner C, 2009, CLIN SCI, V116, P861, DOI 10.1042/CS20080532
   Korolevskaya LB, 2016, B EXP BIOL MED+, V161, P281, DOI 10.1007/s10517-016-3395-1
   Kovacs A, 2010, J INFECT DIS, V201, P823, DOI 10.1086/650997
   Kuniholm MH, 2014, JAIDS-J ACQ IMM DEF, V67, P295, DOI 10.1097/QAI.0000000000000310
   Laskus T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075921
   Lin WY, 2013, J INFECT DIS, V207, pS13, DOI 10.1093/infdis/jis926
   López-Cortés LF, 2018, J INFECT DIS, V218, P624, DOI 10.1093/infdis/jiy136
   Marchetti G, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032028
   Massanella M, 2010, ANTIVIR THER, V15, P333, DOI 10.3851/IMP1531
   Mastroianni CM, 2014, INT J MOL SCI, V15, P9184, DOI 10.3390/ijms15069184
   Matthews GV, 2008, J GASTROEN HEPATOL, V23, P1000, DOI 10.1111/j.1440-1746.2008.05489.x
   Medrano LM, 2018, AIDS, V32, P1095, DOI 10.1097/QAD.0000000000001787
   Monforte AD, 2009, CLIN INFECT DIS, V49, P612, DOI 10.1086/603557
   Núñez M, 2006, CLIN INFECT DIS, V43, P1209, DOI 10.1086/508355
   PERAZZO H, 2015, INT J HEPATOL, V2015, DOI DOI 10.1155/2015/624596
   Qurishi N, 2003, LANCET, V362, P1708, DOI 10.1016/S0140-6736(03)14844-1
   Rallón N, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0193829
   Rallón N, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0173943
   Rockstroh JK, 2005, J INFECT DIS, V192, P992, DOI 10.1086/432762
   Rodríguez-Alba JC, 2019, BIOESSAYS, V41, DOI 10.1002/bies.201800128
   Saha B, 2013, AIDS, V27, P2191, DOI 10.1097/QAD.0b013e32836285e4
   SHERMAN KE, 1993, J CLIN MICROBIOL, V31, P2679, DOI 10.1128/JCM.31.10.2679-2682.1993
   Shmagel KV, 2014, AIDS, V28, P2381, DOI 10.1097/QAD.0000000000000418
   Sikavi C, 2018, HEPATOLOGY, V67, P847, DOI 10.1002/hep.29642
   Sulkowski MS, 2002, JAMA-J AM MED ASSOC, V288, P199, DOI 10.1001/jama.288.2.199
   TELFER P, 1994, BRIT J HAEMATOL, V87, P555, DOI 10.1111/j.1365-2141.1994.tb08312.x
   Thein HH, 2008, AIDS, V22, P1979, DOI 10.1097/QAD.0b013e32830e6d51
   Thomas H, 2003, J HEPATOL, V39, pS93, DOI 10.1016/S0168-8278(03)00207-1
   van der Helm J, 2013, GASTROENTEROLOGY, V144, P751, DOI 10.1053/j.gastro.2012.12.026
   Wang LJ, 2019, J CLIN TRANSL HEPATO, V7, P313, DOI 10.14218/JCTH.2019.00040
   WHO, 2017, World Malaria Report 2017
   Wilson EMP, 2013, IMMUNOL REV, V254, P343, DOI 10.1111/imr.12064
NR 45
TC 1
Z9 1
U1 0
U2 8
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2077-0383
J9 J CLIN MED
JI J. Clin. Med.
PD SEP
PY 2020
VL 9
IS 9
AR 2978
DI 10.3390/jcm9092978
PG 14
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA OE0GG
UT WOS:000580219800001
PM 32942736
OA Green Published, gold, Green Accepted
DA 2024-02-19
ER

PT J
AU Cygan-Szczegielniak, D
   Stasiak, K
AF Cygan-Szczegielniak, Dorota
   Stasiak, Karolina
TI Effects of age and sex on the content of heavy metals in the hair, liver
   and the <i>longissimus lumborum</i> muscle of roe deer <i>Capreolus
   capreolus</i> L.
SO ENVIRONMENTAL SCIENCE AND POLLUTION RESEARCH
LA English
DT Article; Early Access
DE Roe deer; Heavy metals; Hair; Liver; Muscle; Sex and age
ID RANGING EUROPEAN BISONS; RED DEER; GENDER; CADMIUM; ACCUMULATION;
   CONTAMINANTS; LANDSCAPES; MERCURY; TISSUES; KIDNEY
AB The aim of the study was to investigate the effects of age and sex on the content of heavy metals (Pb, Cd, Zn and Cu) in the hair, liver and the longissimus lumborum muscle of roe deer (Capreolus capreolus L.). In addition, correlations between heavy metals in individual tested matrices were studied as well as an attempt was made to explain the reasons for their accumulation in specific research matrices. The levels of Zn and Cu were measured using atomic absorption spectroscopy (F-AAS). The levels of Pb and Cd were analysed by means of electrothermal atomic absorption spectroscopy (ET-AAS). In the own research, sex-related statistically significant differences in concentrations of analysed elements were confirmed. Higher levels of the elements were observed in samples collected from does (except for Cd in the liver samples of 6-7-month-old male fawns) but only in some cases, these values were statistically significantly higher. In some cases, age-related differences in the content of individual metals were also confirmed. Age-dependent increased Pb levels in the muscle and liver were reported in 6-7-month-old, <3-4-year-old, <5-6-year-old males. Similar relationships were confirmed for Zn in the bucks' muscles. In the group of does, the increase in heavy metal concentrations with aging was observed for Zn in the muscle and for Pb in the liver. In the other cases, the trend of age-related level changes regarding heavy metals was not clearly demonstrated. Significant positive correlations between Cu and Cd were found for all samples, and significant negative correlations of Cu with Pb were found for the hair and liver. There was a negative correlation of Zn with Cu in all matrices. The study also revealed a negative correlation between Zn and Pb in muscle and a strong significant negative correlation between Zn and Cd in hair and in the liver.
C1 [Cygan-Szczegielniak, Dorota; Stasiak, Karolina] Bydgoszcz Univ Sci & Technol, Fac Anim Breeding & Biol, Dept Anim Physiol & Physiotherapy, Mazowiecka 28, PL-85004 Bydgoszcz, Poland.
C3 Bydgoszcz University of Science & Technology
RP Cygan-Szczegielniak, D (corresponding author), Bydgoszcz Univ Sci & Technol, Fac Anim Breeding & Biol, Dept Anim Physiol & Physiotherapy, Mazowiecka 28, PL-85004 Bydgoszcz, Poland.
EM cygan@pbs.edu.pl
RI Stasiak, Karolina Magdalena/ITV-6816-2023
OI Stasiak, Karolina Magdalena/0000-0001-6700-141X; Cygan-Szczegielniak,
   Dorota/0000-0002-4304-7648
FU Bydgoszcz University of Science and Technology
FX The statutory activity of the Bydgoszcz University of Science and
   Technology. No funds, grants, or other support was received.
CR [Anonymous], 2004, 14084 PNEN
   [Anonymous], 2014, 13805 EN POL STAND
   Bednarska AJ, 2015, ECOTOXICOLOGY, V24, P1823, DOI 10.1007/s10646-015-1518-5
   Bokara KK, 2008, BIOMETALS, V21, P9, DOI 10.1007/s10534-007-9088-5
   Briffa J, 2020, HELIYON, V6, DOI 10.1016/j.heliyon.2020.e04691
   Burger J, 2007, ENVIRON RES, V104, P153, DOI 10.1016/j.envres.2006.08.001
   Cai Q, 2009, ENVIRON POLLUT, V157, P3078, DOI 10.1016/j.envpol.2009.05.048
   Cygan-Szczegielniak D, 2021, ANIMALS-BASEL, V11, DOI 10.3390/ani11051231
   Cygan-Szczegielniak D, 2018, FOLIA BIOL-KRAKOW, V66, P133, DOI 10.3409/fb_66-3.14
   Cygan-Szczegielniak D, 2014, FOLIA BIOL-KRAKOW, V62, P163, DOI 10.3409/fb62_3.163
   Curi NHD, 2012, BIOL TRACE ELEM RES, V147, P97, DOI 10.1007/s12011-011-9303-7
   García MHD, 2011, J ENVIRON SCI HEAL A, V46, P109, DOI 10.1080/10934529.2011.532422
   Demesko J, 2018, ARCH ENVIRON CON TOX, V74, P330, DOI 10.1007/s00244-017-0470-1
   French AS, 2017, SCI TOTAL ENVIRON, V601, P1606, DOI 10.1016/j.scitotenv.2017.05.210
   Gasparik J, 2012, J ENVIRON SCI HEAL A, V47, P1212, DOI 10.1080/10934529.2012.672065
   Gratacós-Cubarsí M, 2006, J CHROMATOGR B, V834, P14, DOI 10.1016/j.jchromb.2006.03.007
   Hoffman LC, 2007, MEAT SCI, V76, P762, DOI 10.1016/j.meatsci.2007.02.018
   Kabata-Pendias A., 1999, Biogeochemia Pierwiastkow sladowych
   Katz, 1989, HAIR ANAL APPL BIOME, P1
   Kim JJ, 2019, J TRACE ELEM MED BIO, V54, P226, DOI 10.1016/j.jtemb.2019.05.003
   Kosla T, 2011, POL J VET SCI, V14, P81, DOI 10.2478/v10181-011-0012-0
   Legras S, 2000, J EXP MAR BIOL ECOL, V246, P259, DOI 10.1016/S0022-0981(99)00187-2
   Lehel J, 2017, ENVIRON SCI POLLUT R, V24, P25372, DOI 10.1007/s11356-017-0206-9
   Lehel J, 2016, ENVIRON SCI POLLUT R, V23, P4465, DOI 10.1007/s11356-015-5658-1
   Neila C, 2017, ECOTOX ENVIRON SAFE, V140, P24, DOI 10.1016/j.ecoenv.2017.02.025
   Pérez-Barbería FJ, 2014, J ZOOL, V294, P180, DOI 10.1111/jzo.12166
   Pérez-López M, 2016, TOXICOL ENVIRON CHEM, V98, P109, DOI 10.1080/02772248.2015.1107065
   Pokorny B, 2002, ENVIRON POLLUT, V117, P35, DOI 10.1016/S0269-7491(01)00161-0
   Regulation of the Ministry of Environment, 2005, J LAWS
   The report on the state of the environment Kuyavian-Pomeranian Province in the year, 2017, VOIV INSP ENV PROT B, P1
   Wajdzik M, 2017, ECOTOX ENVIRON SAFE, V145, P16, DOI 10.1016/j.ecoenv.2017.06.070
   Wlostowski T, 2006, SCI TOTAL ENVIRON, V364, P295, DOI 10.1016/j.scitotenv.2005.12.009
   Wongsasuluk P, 2018, ENVIRON RES, V162, P106, DOI 10.1016/j.envres.2017.11.024
NR 33
TC 6
Z9 6
U1 0
U2 6
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0944-1344
EI 1614-7499
J9 ENVIRON SCI POLLUT R
JI Environ. Sci. Pollut. Res.
PD 2022 FEB
PY 2022
VL 29
IS 7
BP 10782
EP 10790
DI 10.1007/s11356-021-16425-6
EA SEP 2021
PG 9
WC Environmental Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Environmental Sciences & Ecology
GA YL0VG
UT WOS:000696153500005
PM 34528207
OA Green Published, hybrid
DA 2024-02-19
ER

PT J
AU Sheth, HR
   Lord, G
   Tkaczuk, K
   Danton, M
   Lewis, LM
   Langenberg, P
   Lim, CK
   Flaws, JA
AF Sheth, HR
   Lord, G
   Tkaczuk, K
   Danton, M
   Lewis, LM
   Langenberg, P
   Lim, CK
   Flaws, JA
TI Aging may be associated with concentrations of tamoxifen and its
   metabolites in breast cancer patients
SO JOURNAL OF WOMENS HEALTH
LA English
DT Article
ID PHARMACOKINETIC CONSIDERATIONS; MAJOR METABOLITES; LIVER-MICROSOMES;
   CELLS-INVITRO; WOMEN; MASS; DESMETHYLTAMOXIFEN; 4-HYDROXYLATION;
   PHARMACOLOGY; CARCINOMA
AB Background: Although tamoxifen (TAM) is the predominant adjuvant therapy for estrogen receptor positive (ER+) breast tumors, 50% of breast cancer patients do not respond positively to this therapy, or they experience adverse side effects. This variability in TAM responsiveness may be due to differences in TAM metabolism that stem from differences in race, age, and body mass index (BMI). Thus, the purpose of this study was to test the hypothesis that race, age, and BMI are associated with the metabolism of TAM to two primary metabolites, N-desmethyltamoxifen (N-DMT) and 4-hydroxytamoxifen (4-OHT).
   Methods: The study design was cross-sectional, and data were analyzed using independent sample t tests and multiple linear regression models. Breast cancer patients (n = 99) taking TAM for at least 30 days were recruited from a local hospital clinic. Each participant provided informed consent, completed a questionnaire, and donated a blood sample. The questionnaire was used to ascertain race, age, and BMI. The blood samples were used to measure plasma concentrations of TAM, N-DMT, and 4-OHT.
   Results: Plasma concentrations of TAM, N-DMT, and 4-OHT differed among individual patients. Age, but not race and BMI, was positively associated with plasma concentrations of TAM and N-DMT, even after adjustment for potential confounders (p = 0.02 for TAM and p = 0.03 for N-DMT).
   Conclusions: This study suggests that aging may alter the metabolism of TAM. As increased levels of TAM and TAM metabolites may provide a possible explanation for why older women taking TAM are at increased risk for adverse side effects, future studies should determine whether age-related differences in the concentrations of TAM and TAM metabolites are associated with differences in TAM toxicity or responsiveness.
C1 Univ Maryland, Sch Med, Dept Epidemiol & Prevent Med, Baltimore, MD 21201 USA.
   Univ London, MRC, Bioanalyt Sci Grp, London, England.
   Univ Maryland, Sch Med, Greenebaum Canc Ctr, Baltimore, MD 21201 USA.
C3 University System of Maryland; University of Maryland Baltimore;
   University of London; University System of Maryland; University of
   Maryland Baltimore
RP Flaws, JA (corresponding author), Univ Maryland, Sch Med, Dept Epidemiol & Prevent Med, 660 W Redwood St, Baltimore, MD 21201 USA.
EM jflaws@epi.umaryland.edu
RI Lord, Gwyn A/F-6969-2012
OI Lord, Gwyn A/0000-0002-4300-9051; Flaws, Jodi/0000-0001-5579-9268
FU NCI NIH HHS [P30 CA134274] Funding Source: Medline
CR Baker V L, 1996, Obstet Gynecol Surv, V51, P45, DOI 10.1097/00006254-199601000-00021
   Bernus I, 1997, DRUG AGING, V10, P278, DOI 10.2165/00002512-199710040-00004
   Bonanni B, 2001, BREAST CANCER RES TR, V69, P21, DOI 10.1023/A:1012241505717
   BUCKLEY MMT, 1989, DRUGS, V37, P451, DOI 10.2165/00003495-198937040-00004
   Christiansen C, 1993, Int J Fertil Menopausal Stud, V38 Suppl 1, P45
   Clarke M, 1998, LANCET, V351, P1451
   Clarke R, 2001, PHARMACOL REV, V53, P25
   Crewe HK, 1997, BIOCHEM PHARMACOL, V53, P171, DOI 10.1016/S0006-2952(96)00650-8
   Decensi A, 1999, J CLIN ONCOL, V17, P2633, DOI 10.1200/JCO.1999.17.9.2633
   ETIENNE MC, 1989, BRIT J CANCER, V60, P30, DOI 10.1038/bjc.1989.214
   FABIAN C, 1981, BIOPHARM DRUG DISPOS, V2, P381, DOI 10.1002/bdd.2510020407
   Flaws, 2000, Ann Epidemiol, V10, P463, DOI 10.1016/S1047-2797(00)00169-1
   FURR BJA, 1984, PHARMACOL THERAPEUT, V25, P127, DOI 10.1016/0163-7258(84)90043-3
   Gail MH, 1999, J NATL CANCER I, V91, P1829, DOI 10.1093/jnci/91.21.1829
   Gibbs JP, 1999, BLOOD, V93, P4436, DOI 10.1182/blood.V93.12.4436.412k16_4436_4440
   Guerrieri-Gonzaga A, 2001, CANCER EPIDEM BIOMAR, V10, P967
   Hirsimaki Pirkko, 2002, Breast J, V8, P92, DOI 10.1046/j.1524-4741.2002.08204.x
   Ifudu O, 1998, ANN INTERN MED, V128, P451, DOI 10.7326/0003-4819-128-6-199803150-00005
   JAIYESIMI IA, 1995, J CLIN ONCOL, V13, P513, DOI 10.1200/JCO.1995.13.2.513
   Jones RM, 1996, J CHROMATOGR A, V722, P249, DOI 10.1016/0021-9673(95)00794-6
   Jones RM, 1999, RAPID COMMUN MASS SP, V13, P211, DOI 10.1002/(SICI)1097-0231(19990228)13:4<211::AID-RCM436>3.0.CO;2-L
   LIEN EA, 1989, CANCER RES, V49, P2175
   LIEN EA, 1991, CANCER RES, V51, P4837
   LIEN EA, 1995, J STEROID BIOCHEM, V55, P229, DOI 10.1016/0960-0760(95)00169-Z
   MacCallum J, 1996, J CHROMATOGR B, V678, P317, DOI 10.1016/0378-4347(95)00530-7
   MacCallum J, 2000, BRIT J CANCER, V82, P1629
   MANI C, 1993, DRUG METAB DISPOS, V21, P645
   Massart F, 2001, MATURITAS, V40, P103, DOI 10.1016/S0378-5122(01)00283-3
   Mirochnick M, 2000, CLIN PHARMACOKINET, V39, P281, DOI 10.2165/00003088-200039040-00004
   Mourits MJE, 2001, OBSTET GYNECOL, V97, P855, DOI 10.1016/S0029-7844(00)01196-0
   Pasquali R, 2002, J CLIN ENDOCR METAB, V87, P166, DOI 10.1210/jc.87.1.166
   Peyrade F, 1996, CLIN PHARMACOL THER, V59, P401, DOI 10.1016/S0009-9236(96)90108-3
   PHISTER JE, 1989, DRUGS, V37, P551, DOI 10.2165/00003495-198937040-00007
   REDDEL RR, 1983, CANCER RES, V43, P4618
   REDDEL RR, 1983, EUR J CANCER CLIN ON, V19, P1179, DOI 10.1016/0277-5379(83)90047-0
   Simon T, 2001, BRIT J CLIN PHARMACO, V52, P601, DOI 10.1046/j.0306-5251.2001.01494.x
   SOININEN K, 1986, J INT MED RES, V14, P162, DOI 10.1177/030006058601400309
NR 37
TC 21
Z9 21
U1 1
U2 1
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1540-9996
EI 1931-843X
J9 J WOMENS HEALTH
JI J. Womens Health
PD OCT
PY 2003
VL 12
IS 8
BP 799
EP 808
DI 10.1089/154099903322447765
PG 10
WC Public, Environmental & Occupational Health; Medicine, General &
   Internal; Obstetrics & Gynecology; Women's Studies
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Public, Environmental & Occupational Health; General & Internal
   Medicine; Obstetrics & Gynecology; Women's Studies
GA 768FG
UT WOS:000188532500008
PM 14588130
DA 2024-02-19
ER

PT J
AU Wang, F
   Mubarik, S
   Zhang, Y
   Wang, L
   Wang, YF
   Yu, CH
   Li, H
AF Wang, Fang
   Mubarik, Sumaira
   Zhang, Yu
   Wang, Lu
   Wang, Yafeng
   Yu, Chuanhua
   Li, Hao
TI Long-Term Trends of Liver Cancer Incidence and Mortality in China
   1990-2017: A Joinpoint and Age-Period-Cohort Analysis
SO INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH
LA English
DT Article
DE liver cancer; incidence; mortality; Joinpoint regression analysis;
   age-period-cohort model; trends
ID HEPATITIS-B-VIRUS; HEALTH-CARE; POPULATION; INFECTION
AB Liver cancer (LC) is one of the most common causes of cancer-related deaths: this study aims to present the long-term trends and age-period-cohort effects of the incidence of and mortality from LC in China during 1990-2017. Incidence and mortality data were obtained from the Global Burden of Disease Study 2017. We determined trends in the age-standardized incidence rate (ASIR) and mortality rate (ASMR) using Joinpoint regression. An age-period-cohort (APC) analysis was performed to describe the long-term trends with intrinsic estimator methods. The ASMR decreased markedly before 2013 and increased thereafter, with overall average annual percent change (AAPC) values of -0.5% (95% confidence interval (CI): -0.6%, -0.3%) for men and -1.3% (-1.6%, -1.0%) for women during 1990-2017. The ASIR significantly increased by 0.2% (0.1%, 0.3%) in men and decreased by 1.1% (-1.2%, -1.0%) in women from 1990 to 2017. The risks of LC incidence and mortality increased with age in both genders. The period effect risk ratios (RRs) of incidence and mortality displayed similar monotonic increasing trends in men and remained stable in women. The cohort effect showed an overall downward trend and almost overlapping incidence and mortality in both genders, and later birth cohorts experienced lower RRs than previous birth cohorts. Older age, recent period, and birth before 1923 were associated with a higher risk of liver cancer incidence and mortality. The net age and period effects showed an increasing trend, while the cohort effects presented a decreasing trend in incidence and mortality risk. As China's population aging worsens and with the popularization of unhealthy lifestyles, the burden caused by liver cancer will remain a huge challenge in China's future.
C1 [Wang, Fang; Mubarik, Sumaira; Wang, Yafeng; Yu, Chuanhua; Li, Hao] Wuhan Univ, Sch Hlth Sci, Dept Epidemiol & Biostat, Wuhan 430071, Hubei, Peoples R China.
   [Zhang, Yu] Huazhong Univ Sci & Technol, Tongji Med Coll, Sch Publ Hlth, Wuhan 430030, Hubei, Peoples R China.
   [Wang, Lu] Hubei Univ Arts & Sci, Med Coll, Xiangyang 441053, Peoples R China.
   [Yu, Chuanhua; Li, Hao] Wuhan Univ, Global Hlth Inst, Wuhan 430072, Hubei, Peoples R China.
C3 Wuhan University; Huazhong University of Science & Technology; Hubei
   University of Arts & Science; Wuhan University
RP Yu, CH; Li, H (corresponding author), Wuhan Univ, Sch Hlth Sci, Dept Epidemiol & Biostat, Wuhan 430071, Hubei, Peoples R China.; Yu, CH; Li, H (corresponding author), Wuhan Univ, Global Hlth Inst, Wuhan 430072, Hubei, Peoples R China.
EM YuCHua@whu.edu.cn; h.li@whu.edu.cn
RI Mubarik, Sumaira/AAC-3973-2021; Mubarik, Sumaira/AAC-3825-2021; Li,
   Hao/C-8088-2013
OI Mubarik, Sumaira/0000-0001-6041-1061; Wang, Fang/0000-0001-7687-2700;
   Li, Hao/0000-0002-5155-4033
FU National Natural Science Foundation of China [81773552]; National Key
   Research and Development Program of China [2018YFC1315302, 2017YFC
   1200502]
FX This research was funded by the National Natural Science Foundation of
   China (Grant No. 81773552) and the National Key Research and Development
   Program of China (Grant No. 2018YFC1315302, 2017YFC 1200502). The
   funders had no role in the study design, data collection, analysis,
   decision to publish, or preparation of the manuscript.
CR Akinyemiju T, 2017, JAMA ONCOL, V3, P1683, DOI 10.1001/jamaoncol.2017.3055
   Arem H, 2018, CANCER MED-US, V7, P1450, DOI 10.1002/cam4.1343
   Benhamiche AM, 1998, J HEPATOL, V29, P802, DOI 10.1016/S0168-8278(98)80262-6
   Chen JG, 2011, SEMIN CANCER BIOL, V21, P59, DOI 10.1016/j.semcancer.2010.11.002
   Chen L, 2018, INT J ENV RES PUB HE, V15, DOI 10.3390/ijerph15061211
   Cocker F, 2019, AUST NZ J PUBL HEAL, V43, P267, DOI 10.1111/1753-6405.12889
   Cui FQ, 2017, EMERG INFECT DIS, V23, P765, DOI 10.3201/eid2305.161477
   Dal Masoa L, 2008, EUR J CANCER, V44, P285, DOI 10.1016/j.ejca.2007.11.009
   Ding C, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2018-025613
   Dorak M. Tevfik, 2012, Frontiers in Genetics, V3, P268, DOI 10.3389/fgene.2012.00268
   Duan T., 2008, J Shaanxi Normal Univ (Phil Soc Sci Ed), V37, P122
   Endeshaw M, 2019, CANCER-AM CANCER SOC, V125, P726, DOI 10.1002/cncr.31869
   Fang EF, 2015, AGEING RES REV, V24, P197, DOI 10.1016/j.arr.2015.08.003
   Fu J, 2018, CANCER LETT, V412, P283, DOI 10.1016/j.canlet.2017.10.008
   Ho YR, 2019, CANCER EPIDEMIOL, V59, P185, DOI 10.1016/j.canep.2019.02.005
   Huang WT, 2018, GLOB HEALTH RES POL, V3, DOI 10.1186/s41256-018-0072-0
   Im PK, 2019, BMC PUBLIC HEALTH, V19, DOI 10.1186/s12889-019-6502-1
   Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.21492, 10.3322/caac.20107]
   Jiang XH, 2011, J GASTROINTEST ONCOL, V2, P223, DOI 10.3978/j.issn.2078-6891.2011.024
   Kihn-Alarcon AJ, 2019, J GLOB ONCOL, V5, DOI 10.1200/JGO.18.00179
   Li CH, 2017, INT J EPIDEMIOL, V46, P1157, DOI 10.1093/ije/dyx013
   Liu RY, 2019, INT J ENV RES PUB HE, V16, DOI 10.3390/ijerph16010056
   LIU X, 1991, Journal of Public Health Policy, V12, P104, DOI 10.2307/3342782
   Liu X, 2018, INT J CANCER, V142, P1560, DOI 10.1002/ijc.31181
   Liu ZQ, 2019, J HEPATOL, V70, P674, DOI 10.1016/j.jhep.2018.12.001
   Luo ZB, 2012, INT J INFECT DIS, V16, pE82, DOI 10.1016/j.ijid.2011.10.009
   Mak D, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-4695-9
   Manthey J, 2019, LANCET, V393, P2493, DOI 10.1016/S0140-6736(18)32744-2
   Maucort-Boulch D, 2018, INT J CANCER, V142, P2471, DOI 10.1002/ijc.31280
   Melkonian SC, 2018, CANCER CAUSE CONTROL, V29, P833, DOI 10.1007/s10552-018-1059-3
   Millwood IY, 2019, LANCET, V393, P1831, DOI 10.1016/S0140-6736(18)31772-0
   Petrick JL, 2016, INT J CANCER, V139, P1534, DOI 10.1002/ijc.30211
   Qu CF, 2014, PLOS MED, V11, DOI 10.1371/journal.pmed.1001774
   Roth GA, 2018, LANCET, V392, P1736, DOI 10.1016/s0140-6736(18)32203-7
   SHI LY, 1993, B WORLD HEALTH ORGAN, V71, P723
   Srivatanakul Petcharin, 2004, Asian Pac J Cancer Prev, V5, P118
   Su SY, 2019, J FORMOS MED ASSOC, V118, P444, DOI 10.1016/j.jfma.2018.07.001
   Sun YY, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2017-020490
   Tapper EB, 2018, BMJ-BRIT MED J, V362, DOI [10.1136/bm1k2817, 10.1136/bmj.k2817]
   Tsai WC, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0199532
   Wang F, 2017, PRIM HEALTH CARE RES, V18, P194, DOI 10.1017/S1463423616000153
   Wang MJ, 2017, INT J INFECT DIS, V65, P15, DOI 10.1016/j.ijid.2017.09.003
   Wu J, 2018, GASTROENTEROLOGY, V154, P1719, DOI 10.1053/j.gastro.2018.01.033
   Yang F, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00370
   Yang Y, 2004, SOCIOL METHODOL, V34, P75, DOI 10.1111/j.0081-1750.2004.00148.x
   Zeng HM, 2018, LANCET GLOB HEALTH, V6, pE555, DOI 10.1016/S2214-109X(18)30127-X
   Zhang JF, 2010, LANCET, V375, P1110, DOI 10.1016/S0140-6736(10)60062-1
   Zheng RS, 2018, CHINESE J CANCER RES, V30, P571, DOI 10.21147/j.issn.1000-9604.2018.06.01
   Zhou MG, 2019, LANCET, V394, P1145, DOI 10.1016/S0140-6736(19)30427-1
NR 49
TC 31
Z9 39
U1 0
U2 33
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1660-4601
J9 INT J ENV RES PUB HE
JI Int. J. Environ. Res. Public Health
PD AUG 14
PY 2019
VL 16
IS 16
AR 2878
DI 10.3390/ijerph16162878
PG 13
WC Environmental Sciences; Public, Environmental & Occupational Health
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
   Health
GA IV7AN
UT WOS:000484419000042
PM 31408961
OA gold, Green Published, Green Submitted
DA 2024-02-19
ER

PT J
AU Zhang, CZY
   Zhang, HT
   Chen, GG
   Lai, PBS
AF Zhang, Chris Z. Y.
   Zhang, H. T.
   Chen, George G.
   Lai, Paul B. S.
TI Trichostatin A sensitizes HBx-expressing liver cancer cells to etoposide
   treatment
SO APOPTOSIS
LA English
DT Article
DE HBx; Bid; Apoptosis; Etoposide; TSA
ID VIRUS-X-PROTEIN; HISTONE DEACETYLASE INHIBITORS; INDUCED APOPTOSIS;
   HEPATOCELLULAR-CARCINOMA; SUSTAINED ACTIVATION; UP-REGULATION; P53;
   CISPLATIN; ERK; CHEMOTHERAPY
AB Agents commonly used in cancer chemotherapy rely on the induction of cell death via apoptosis, mitotic catastrophe, premature senescence and autophagy. Chemoresistance is the major factor limiting long-term treatment success in patients with hepatocellular carcinoma (HCC). Recent studies have revealed that the hepatitis B virus X protein (HBx) exerts anti-apoptotic effects, resulting in an increased drug resistance in HCC cells. In this study, we showed that etoposide treatment activated caspase-8 and caspase-3, leading to cleavages of p53, Bid and PARP, which subsequently induced apoptosis. Furthermore, p53 and Bid were accumulated in cytoplasm following etoposide treatment. However, HBx significantly attenuated etoposide-induced cell death. In HBx-expressing cells, despite the translocation of p53 and Bid to cytoplasm, the activation of caspases was inhibited. Furthermore, the phosphorylation of extracellular-signal-regulated kinase (ERK) was markedly increased in HBx-expressing cells. Moreover, the pretreatment with trichostatin A (TSA, a histone deacetylase inhibitor) or TSA in combination with etoposide significantly sensitized HCC cells to apoptosis by inhibiting ERK phosphorylation, reactivating caspases and PARP, and inducing translocation of p53 and Bid to cytoplasm. Collectively, HBx reduces the sensitivity of HCC cells to chemotherapy. TSA in combination with etoposide can significantly overcome the increased resistance of HBx-expressing HCC cells to chemotherapy.
C1 [Zhang, Chris Z. Y.; Zhang, H. T.; Chen, George G.; Lai, Paul B. S.] Chinese Univ Hong Kong, Prince Wales Hosp, Dept Surg, Shatin, Hong Kong, Peoples R China.
C3 Chinese University of Hong Kong; Prince of Wales Hospital
RP Chen, GG (corresponding author), Chinese Univ Hong Kong, Prince Wales Hosp, Dept Surg, Shatin, Hong Kong, Peoples R China.
EM gchen@cuhk.edu.hk
RI Zhang, Chris Zhiyi/F-9862-2013; Lai, Paul BS/K-8556-2015; zhang,
   hongtao/IWV-4469-2023; Chen, George Gong/I-2757-2016
OI Lai, Paul BS/0000-0002-9469-6728; 
CR Barter MJ, 2010, MATRIX BIOL, V29, P602, DOI 10.1016/j.matbio.2010.05.002
   Braillon A, 2009, WORLD J GASTROENTERO, V15, P5371, DOI 10.3748/wjg.15.5371
   Bruix J, 2004, CANCER CELL, V5, P215, DOI 10.1016/S1535-6108(04)00058-3
   Cheng ASL, 2008, BIOCHEM BIOPH RES CO, V374, P175, DOI 10.1016/j.bbrc.2008.06.098
   Cheng ASL, 2007, CANCER LETT, V253, P43, DOI 10.1016/j.canlet.2007.01.004
   Cheng P, 2009, ONCOL REP, V22, P1101, DOI 10.3892/or_00000542
   Chiu CC, 2005, APOPTOSIS, V10, P643, DOI 10.1007/s10495-005-1898-8
   Chung TW, 2004, FASEB J, V18, P1123, DOI 10.1096/fj.03-1429fje
   Clohessy JG, 2006, J BIOL CHEM, V281, P5750, DOI 10.1074/jbc.M505688200
   Cohn AL, 2008, INVEST NEW DRUG, V26, P381, DOI 10.1007/s10637-008-9124-5
   Coradini D, 2005, ACTA PHARMACOL SIN, V26, P1025, DOI 10.1111/j.1745-7254.2005.00195.x
   Cotter TG, 2009, NAT REV CANCER, V9, P501, DOI 10.1038/nrc2663
   Diao JY, 2001, CYTOKINE GROWTH F R, V12, P189, DOI 10.1016/S1359-6101(00)00034-4
   Ding QQ, 2005, MOL CELL, V19, P159, DOI 10.1016/j.molcel.2005.06.009
   Gahr S, 2007, INT J ONCOL, V31, P567
   Hajji N, 2008, ONCOGENE, V27, P3134, DOI 10.1038/sj.onc.1210976
   Henderson C, 2003, J BIOL CHEM, V278, P12579, DOI 10.1074/jbc.M213093200
   Ho R, 2002, CANCER RES, V62, P6462
   Hodgson AJ, 2008, CANCER RES, V68, P10341, DOI 10.1158/0008-5472.CAN-08-2695
   Hwang JH, 2008, J CELL PHYSIOL, V215, P243, DOI 10.1002/jcp.21308
   Kim HJ, 2008, IUBMB LIFE, V60, P473, DOI 10.1002/iub.68
   Kuo TC, 2010, BIOCHEM PHARMACOL, V80, P1093, DOI 10.1016/j.bcp.2010.06.003
   Lee JO, 2009, ANN ONCOL, V20, P1402, DOI 10.1093/annonc/mdp010
   Lee YI, 2001, J BIOL CHEM, V276, P16969, DOI 10.1074/jbc.M011263200
   Liang XH, 2007, J IMMUNOL, V178, P503, DOI 10.4049/jimmunol.178.1.503
   Marks PA, 2001, NAT REV CANCER, V1, P194, DOI 10.1038/35106079
   Muscolini M, 2008, MOL CANCER THER, V7, P1410, DOI 10.1158/1535-7163.MCT-08-0299
   Nijhara R, 2001, J VIROL, V75, P10348, DOI 10.1128/JVI.75.21.10348-10358.2001
   Noh EJ, 2004, BIOCHEM BIOPH RES CO, V319, P738, DOI 10.1016/j.bbrc.2004.05.047
   Oh SY, 2007, MOL CANCER THER, V6, P2178, DOI 10.1158/1535-7163.MCT-07-0111
   Okorokov AL, 1997, EMBO J, V16, P6008, DOI 10.1093/emboj/16.19.6008
   Sayan BS, 2006, J BIOL CHEM, V281, P13566, DOI 10.1074/jbc.M512467200
   Song G, 2009, CURR CANCER DRUG TAR, V9, P871, DOI 10.2174/156800909789760302
   Tan LJ, 2011, CANCER-AM CANCER SOC, V117, P784, DOI 10.1002/cncr.25649
   Tang H, 2009, HEPATOLOGY, V49, P60, DOI 10.1002/hep.22581
   Treszezamsky AD, 2007, CANCER RES, V67, P7078, DOI 10.1158/0008-5472.CAN-07-0601
   TRUANT R, 1995, J VIROL, V69, P1851, DOI 10.1128/JVI.69.3.1851-1859.1995
   Wang JH, 2008, CANCER SCI, V99, P888, DOI 10.1111/j.1349-7006.2008.00754.x
   Wang WH, 2008, J BIOL CHEM, V283, P25455, DOI 10.1074/jbc.M801934200
   WANG XW, 1995, CANCER RES, V55, P6012
   Ward MW, 2006, J BIOL CHEM, V281, P5837, DOI 10.1074/jbc.M511562200
   Wilstermann AM, 2007, BIOCHEMISTRY-US, V46, P8217, DOI 10.1021/bi700272u
   Yin D, 2000, J NEUROSURG, V93, P289, DOI 10.3171/jns.2000.93.2.0289
   Yuan JN, 2008, MED ONCOL, V25, P201, DOI 10.1007/s12032-007-9013-3
   Zelivianski S, 2003, INT J CANCER, V107, P478, DOI 10.1002/ijc.11413
   Zhang JL, 2005, ARCH VIROL, V150, P721, DOI 10.1007/s00705-004-0446-0
   Zhou XB, 2000, P NATL ACAD SCI USA, V97, P14329, DOI 10.1073/pnas.250494697
NR 47
TC 18
Z9 23
U1 0
U2 7
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1360-8185
EI 1573-675X
J9 APOPTOSIS
JI Apoptosis
PD JUL
PY 2011
VL 16
IS 7
BP 683
EP 695
DI 10.1007/s10495-011-0597-x
PG 13
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 766RE
UT WOS:000290803400004
PM 21468663
DA 2024-02-19
ER

PT J
AU Pleshakova, OV
   Kutsyi, MP
   Sukharev, SA
   Sadovnikov, VB
   Gaziev, AI
AF Pleshakova, OV
   Kutsyi, MP
   Sukharev, SA
   Sadovnikov, VB
   Gaziev, AI
TI Study of protein carbonyls in subcellular fractions isolated from liver
   and spleen of old and γ-irradiated rats
SO MECHANISMS OF AGEING AND DEVELOPMENT
LA English
DT Article
DE aging; gamma-irradiation; dietary antioxidants and vitamins; protein
   carbonyls; histone-associated proteases; subcellular fractions
ID OXIDATIVE DAMAGE; DECREASE; RESIDUES; HISTONES; ENZYME; NUCLEI; STRESS;
   BRAIN
AB Age- and gamma-irradiation-dependent accumulation of oxidatively modified proteins (measured as carbonyl level) was studied in cytoplasm, mitochondria and nuclei isolated from spleen and liver of 4- and 26-month-old rats. The protein carbonyl levels significantly increased with age in all fractions studied. The carbonyl content was found to be two times higher in the nuclei than in the mitochondria and cytoplasm, which may be related to an extensive modification of lysine and arginine residues in histone molecules. gamma-Irradiation of rats with 10 Gy caused a rise of protein carbonyls only in their cytoplasm and mitochondria, which was prevented in the animals fed with antioxidants and vitamins for a month before the irradiation. We observed an activation of histone-specific proteases in the nuclei of gamma-irradiated rats. The lack of carbonyl accumulation in the nuclear proteins isolated from tissues of gamma-irradiated animals may be explained by the degradation of oxidized histones by these proteases. (C) 1998 Elsevier Science Ireland Ltd. All rights reserved.
C1 Russian Acad Sci, MM Shemyakin & Yu A Ovchinnikov Inst Bioorgan Che, Pushchino 142292, Moscow Region, Russia.
   Russian Acad Sci, Inst Theoret & Expt Biophys, Pushchino 142292, Moscow Region, Russia.
C3 Russian Academy of Sciences; Pushchino Scientific Center for Biological
   Research (PSCBI) of the Russian Academy of Sciences; Institute of
   Bioorganic Chemistry of the Russian Academy of Sciences; Russian Academy
   of Sciences; Pushchino Scientific Center for Biological Research (PSCBI)
   of the Russian Academy of Sciences; Institute of Theoretical &
   Experimental Biophysics
RP Pleshakova, OV (corresponding author), Russian Acad Sci, MM Shemyakin & Yu A Ovchinnikov Inst Bioorgan Che, Pushchino 142292, Moscow Region, Russia.
EM amour@fibkh.serpukhov.su
CR AMES BN, 1995, BBA-MOL BASIS DIS, V1271, P165, DOI 10.1016/0925-4439(95)00024-X
   BARJA G, 1994, COMP BIOCHEM PHYS B, V108, P501, DOI 10.1016/0305-0491(94)90103-1
   Bezlepkin VG, 1996, MECH AGEING DEV, V92, P227, DOI 10.1016/S0047-6374(96)01840-4
   Birnie G. D, 1972, SUBCELLULAR COMPONEN
   BONNER J, 1968, METHODS ENZYMOL B, V12, P4
   CAO GH, 1995, ARCH BIOCHEM BIOPHYS, V320, P106, DOI 10.1006/abbi.1995.1347
   CARNEY JM, 1994, LIFE SCI, V55, P2097, DOI 10.1016/0024-3205(94)00390-4
   CARNEY JM, 1991, P NATL ACAD SCI USA, V88, P3633, DOI 10.1073/pnas.88.9.3633
   FRIGUET B, 1994, J BIOL CHEM, V269, P21639
   FUCCI L, 1983, P NATL ACAD SCI-BIOL, V80, P1521, DOI 10.1073/pnas.80.6.1521
   GAZIEV AI, 1992, INT J RADIAT BIOL, V61, P169, DOI 10.1080/09553009214550781
   GORDILLO E, 1988, J BIOL CHEM, V263, P8053
   GUGLIUCCI A, 1995, BIOCHEM BIOPH RES CO, V212, P56, DOI 10.1006/bbrc.1995.1935
   KUTSYI MP, 1994, RADIAT RES, V140, P221, DOI 10.2307/3578906
   KUTSYI MP, 1987, BIOKHIMIYA, V52, P315
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   LEVINE RL, 1990, METHOD ENZYMOL, V186, P464
   LIPINSKA A, 1980, INT J BIOCHEM, V11, P299, DOI 10.1016/0020-711X(80)90233-5
   LOWRY OH, 1951, J BIOL CHEM, V193, P265
   MONNIER VM, 1991, GERONTOLOGY, V37, P152
   Munch G, 1997, BRAIN RES REV, V23, P134, DOI 10.1016/S0165-0173(96)00016-1
   OLIVER CN, 1987, J BIOL CHEM, V262, P5488
   OLIVER CN, 1990, P NATL ACAD SCI USA, V87, P5144, DOI 10.1073/pnas.87.13.5144
   OXENBURG.MS, 1965, NATURE, V207, P1416, DOI 10.1038/2071416a0
   SANTAMARIA C, 1995, FEBS LETT, V374, P85
   SOHAL RS, 1994, FREE RADICAL BIO MED, V16, P621, DOI 10.1016/0891-5849(94)90062-0
   Sohal RS, 1995, LIFE SCI R, V56, P109
   SOHAL RS, 1995, MECH AGEING DEV, V81, P15, DOI 10.1016/0047-6374(94)01578-A
   STADTMAN ER, 1993, ANNU REV BIOCHEM, V62, P797, DOI 10.1146/annurev.bi.62.070193.004053
   STADTMAN ER, 1992, SCIENCE, V257, P1220, DOI 10.1126/science.1355616
   Stadtman ER, 1995, LIFE SCI R, V56, P129
   STARKEREED PE, 1989, ARCH BIOCHEM BIOPHYS, V275, P559, DOI 10.1016/0003-9861(89)90402-5
   Sukharev SA, 1997, COMP BIOCHEM PHYS B, V116, P333, DOI 10.1016/S0305-0491(96)00232-5
   Ushakova T, 1996, FREE RADICAL BIO MED, V20, P279, DOI 10.1016/0891-5849(95)02040-3
   USHAKOVA T, IN PRESS FREE RAD RE
   Whisler RL, 1997, CELL IMMUNOL, V175, P41, DOI 10.1006/cimm.1996.1048
   YOUNGMAN LD, 1992, P NATL ACAD SCI USA, V89, P9112, DOI 10.1073/pnas.89.19.9112
NR 37
TC 16
Z9 17
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0047-6374
J9 MECH AGEING DEV
JI Mech. Ageing Dev.
PD JUN 1
PY 1998
VL 103
IS 1
BP 45
EP 55
DI 10.1016/S0047-6374(98)00012-8
PG 11
WC Cell Biology; Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Geriatrics & Gerontology
GA ZW233
UT WOS:000074389000004
PM 9681878
DA 2024-02-19
ER

PT J
AU Villén, N
   Guisado-Clavero, M
   Fernández-Bertolín, S
   Troncoso-Mariño, A
   Foguet-Boreu, Q
   Amado, E
   Pons-Vigués, M
   Roso-Llorach , A
   Violán, C
AF Villen, Noemi
   Guisado-Clavero, Marina
   Fernandez-Bertolin, Sergio
   Troncoso-Marino, Amelia
   Foguet-Boreu, Quinti
   Amado, Ester
   Pons-Vigues, Mariona
   Roso-Llorach, Albert
   Violan, Concepcion
TI Multimorbidity patterns, polypharmacy and their association with liver
   and kidney abnormalities in people over 65 years of age: a longitudinal
   study
SO BMC GERIATRICS
LA English
DT Article
DE Multimorbidity; Epidemiology; Polypharmacy; Primary health care; Ageing;
   Longitudinal study
ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; HEALTH; RISK
AB Background The implementation of individual clinical practice guidelines in patients with multimorbidity often results in polypharmacy. Our aim was to analyse medication use according to longitudinal multimorbidity patterns (MP) and determine during a 5-year period (2012-16) which MP are associated with abnormal liver and kidney function in primary care patients over 65 years of age living in Catalonia. Methods Design: Longitudinal study (years 2012 to 2016) based on the electronic health records contained in Information System for Research in Primary Care database of the Catalan Institute of Health (SIDIAP).Variables: age, sex, MP, medication and polypharmacy (drug exposure obtained from the Pharmacy Invoice Registry). Medicines were classified in accordance with the Anatomical Therapeutic Chemical Classification System (ATC). Glomerular filtration rate was used to determine abnormal kidney function, and serum levels of alkaline phosphatase, alanine transaminase and gamma-glutamyl transpeptidase were used to diagnose abnormal liver function.Statistics: For medication use in MP, we calculated annual mean packages of each drug in each MP, and observed/expected ratios were obtained by dividing mean packages in the cluster by mean packages of the same drug in the overall population. Logistic regression models were fitted to estimate the association between MP at baseline and abnormal kidney and liver function tests during follow up. Results Nine hundred sixteen thousand six hundred nineteen patients were included, and 743,827 completed the follow up. We identified one polypharmacy profile per MP, and concluded that the most prescribed drugs in each pattern corresponded to the diseases overrepresented in that specific MP. The median of drugs ranged from 3 (Cluster 1 - Non-Specific) to 8 (Cluster 10 - Multisystem Pattern). Abnormal kidney function was most commonly observed in the Cluster 4 - Cardio-Circulatory and Renal (Odds Ratio [OR] 2.19; Confidence interval [CI] 95% 2.15-2.23) and Cluster 3 - Minority Metabolic Autoimmune-Inflammatory (OR 2.16; CI 95% 2.12-2.20) MP. A higher risk of abnormal liver function was observed in the Cluster 8 - Digestive (OR 3.39; CI 95% 3.30-3.49), and Cluster 4 - Cardio-Circulatory and Renal (OR 1.96; CI 95% 1.91-2.02) MP. Conclusions A higher risk of abnormal kidney and liver function was observed in specific MP. The long-term characterisation of MP and polypharmacy illustrates the burden of chronic multimorbidity and polypharmacy in the elderly population.
C1 [Villen, Noemi; Troncoso-Marino, Amelia; Amado, Ester] Inst Catala Salut, Area Medicament & Serv Farm, Gerencia Terr Barcelona, Barcelona, Spain.
   [Guisado-Clavero, Marina; Fernandez-Bertolin, Sergio; Foguet-Boreu, Quinti; Pons-Vigues, Mariona; Roso-Llorach, Albert; Violan, Concepcion] Fundacio Inst Univ Recerca Atencio Primaria Salut, Barcelona, Spain.
   [Guisado-Clavero, Marina; Fernandez-Bertolin, Sergio; Foguet-Boreu, Quinti; Pons-Vigues, Mariona; Roso-Llorach, Albert; Violan, Concepcion] Univ Autonoma Barcelona, Bellaterra, Spain.
   [Foguet-Boreu, Quinti] Vic Univ Hosp, Dept Psychiat, Vic, Spain.
   [Pons-Vigues, Mariona] Area Serveis Assistencials Serv Catala Salut, Barcelona, Spain.
C3 Autonomous University of Barcelona
RP Roso-Llorach , A; Violán, C (corresponding author), Fundacio Inst Univ Recerca Atencio Primaria Salut, Barcelona, Spain.; Roso-Llorach , A; Violán, C (corresponding author), Univ Autonoma Barcelona, Bellaterra, Spain.
EM aroso@idiapjgol.org; cviolan@idiapjgol.org
RI Violán, Concepcion/HHC-2893-2022; Pons-Vigués, Mariona/D-6079-2019
OI Violán, Concepcion/0000-0003-3309-5360; Pons-Vigués,
   Mariona/0000-0002-7929-3701; Guisado-Clavero,
   Marina/0000-0002-8448-2929; Fernandez-Bertolin,
   Sergio/0000-0002-0029-6564; Roso-Llorach, Albert/0000-0002-9264-0405
FU Instituto de Salud Carlos III, under Ministry of Science, Innovation and
   Universities [PI16/00639]; European Union ERDF funds (European Regional
   Development Fund) [SLT002/16/00058]; Department of Health of the Catalan
   Government [SLT002/16/00058]; Catalan Government [AGAUR 2017 SGR 578]
FX This work was supported by a research grant from the the Instituto de
   Salud Carlos III, under the auspices of the Ministry of Science,
   Innovation and Universities, awarded in the 2016 call under the Health
   Strategy Action 2013-2016, within the National Research Program oriented
   to Societal Challenges, within the Technical, Scientific and Innovation
   Research National Plan 2013-2016 `[grant number PI16/00639]', co-funded
   with European Union ERDF funds (European Regional Development Fund) and
   the Department of Health of the Catalan Government, in the 2017 call
   that awarded subsidies for the Strategic Plan for Research in Health
   (Pla Estrategic de Recerca i Innovacio en Salut, PERIS) 2016-2020,
   modality research oriented to Primary care `[grant number
   SLT002/16/00058]' and by the Catalan Government `[grant number AGAUR
   2017 SGR 578].
CR [Anonymous], 2012, HIPERTENSION RIESGO
   [Anonymous], 2012, MEMR ACT 2012
   Aoki T, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-21917-6
   Arfè A, 2016, BMJ-BRIT MED J, V354, DOI 10.1136/bmj.i4857
   Beard JR, 2016, LANCET, V387, P2145, DOI 10.1016/S0140-6736(15)00516-4
   Benetos A, 2015, JAMA-J AM MED ASSOC, V314, P170, DOI 10.1001/jama.2015.7517
   Bezdek J.C., 1981, PATTERN RECOGNITION
   Bhala N, 2013, LANCET, V382, P769, DOI 10.1016/S0140-6736(13)60900-9
   Bosch JA, 2016, PAUTES LHARMONITZACI
   Brownlee S, 2017, LANCET, V390, P156, DOI 10.1016/S0140-6736(16)32585-5
   Calderón-Larrañaga A, 2017, J GERONTOL A-BIOL, V72, P1417, DOI 10.1093/gerona/glw233
   Calderón-Larrañaga A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0084967
   Cooper JA, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2015-009235
   Corsonello A, 2010, CURR MED CHEM, V17, P571, DOI 10.2174/092986710790416326
   Domínguez-Berjón MF, 2008, GAC SANIT, V22, P179, DOI 10.1157/13123961
   Dreischulte T, 2015, KIDNEY INT, V88, P396, DOI 10.1038/ki.2015.101
   Duerden M., 2013, POLYPHARMACY MED OPT
   Forns J, 2019, PHARMACOEPIDEM DR S, V28, P965, DOI 10.1002/pds.4803
   Garcia-Gil M Del Mar, 2011, Inform Prim Care, V19, P135
   Guisado-Clavero M, 2019, BMC FAM PRACT, V20, DOI 10.1186/s12875-019-0969-9
   Guthrie B, 2012, BMJ-BRIT MED J, V345, DOI 10.1136/bmj.e6341
   Hajjar Emily R, 2007, Am J Geriatr Pharmacother, V5, P345, DOI 10.1016/j.amjopharm.2007.12.002
   Iglesias P, 2009, EUR J ENDOCRINOL, V160, P503, DOI 10.1530/EJE-08-0837
   Kostev K, 2018, EUR J INTERN MED, V55, P66, DOI 10.1016/j.ejim.2018.07.014
   L Morales M., 2016, REV COLOMB GASTROENT, V31, P36, DOI [DOI 10.22516/25007440.71, 10.22516/25007440.71]
   Lipska KJ, 2017, DIABETES CARE, V40, P468, DOI 10.2337/dc16-0985
   Maher RL, 2014, EXPERT OPIN DRUG SAF, V13, P57, DOI 10.1517/14740338.2013.827660
   Marengoni A, 2011, AGEING RES REV, V10, P430, DOI 10.1016/j.arr.2011.03.003
   Masnoon N, 2017, BMC GERIATR, V17, DOI 10.1186/s12877-017-0621-2
   Mata-Cases M, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-012463
   Morgan DJ, 2019, JAMA INTERN MED, V179, P240, DOI 10.1001/jamainternmed.2018.5748
   Morin L, 2018, CLIN EPIDEMIOL, V10, P289, DOI 10.2147/CLEP.S153458
   Poulose N, 2014, AGING DIS, V5, P101, DOI 10.14336/AD.2014.0500101
   Prados-Torres A, 2014, J CLIN EPIDEMIOL, V67, P254, DOI 10.1016/j.jclinepi.2013.09.021
   RABINER LR, 1989, P IEEE, V77, P257, DOI 10.1109/5.18626
   Rankin A, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008165.pub4
   Ren RT, 2017, CELL RES, V27, P483, DOI 10.1038/cr.2017.18
   Salisbury C, 2011, BRIT J GEN PRACT, V61, DOI 10.3399/bjgp11X548929
   Statistical Institute of Catalonia, 2016, STAT YB CAT
   Tejada Cifuentes Francisco, 2010, Rev Clin Med Fam, V3, P177, DOI 10.4321/s1699-695x2010000300006
   Tommelein E, 2015, EUR J CLIN PHARMACOL, V71, P1415, DOI 10.1007/s00228-015-1954-4
   Valderas JM, 2009, ANN FAM MED, V7, P357, DOI 10.1370/afm.983
   Violan C, SCI REP
   Violan C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102149
   White IR, 2011, STAT MED, V30, P377, DOI 10.1002/sim.4067
   WHO Collaborating Centre for Drug Statistics Methodology, 2013, GUID ATCCLASS DDD AS
   Woodford HJ, 2018, CLIN MED, V18, P196, DOI 10.7861/clinmedicine.18-3-196
NR 47
TC 16
Z9 16
U1 0
U2 8
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2318
J9 BMC GERIATR
JI BMC Geriatr.
PD JUN 12
PY 2020
VL 20
IS 1
AR 206
DI 10.1186/s12877-020-01580-1
PG 13
WC Geriatrics & Gerontology; Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Geriatrics & Gerontology
GA MB2SU
UT WOS:000542454900002
PM 32532213
OA gold, Green Submitted, Green Published
DA 2024-02-19
ER

PT J
AU Karanth, S
   Pope, C
AF Karanth, S
   Pope, C
TI Carboxylesterase and A-esterase activities during maturation and aging:
   Relationship to the toxicity of chlorpyrifos and parathion in rats
SO TOXICOLOGICAL SCIENCES
LA English
DT Article
DE organophosphate; age-related; chlorpyrifos oxonase; paraoxonase; PON1;
   detoxification; maturation; aging
ID SOMAN PINACOLYL METHYLPHOSPHONOFLUORIDATE; INVIVO CHOLINESTERASE
   INHIBITION; GENDER-RELATED DIFFERENCES; AGE-RELATED DIFFERENCES;
   ORGANOPHOSPHORUS COMPOUNDS; ADULT-RATS; DOWN-REGULATION; RECEPTOR-SITES;
   DETOXIFICATION; PARAOXON
AB Chlorpyrifos (CPF) and parathion (PS), two common organophosphorus (OP) pesticides, exhibit higher acute toxicity in younger animals compared to adults. Maturational differences in detoxification via carboxylesterases (CEs) and A-esterases (AEs) have been suggested as contributors to the higher sensitivity of younger animals to OP toxicants. AEs (e.g., chlorpyrifos oxonase and paraoxonase) catalytically inactivate while CEs stoichiometrically eliminate OP anticholinesterases. While earlier studies have reported a relationship between the toxicity of some OP pesticides and the maturational profile of AEs and CEs, little information exists on the relative OP-toxicant sensitivity and detoxification capacities of aged animals. In the present study, we investigated the relationship between toxicity of CPF and PS and the activity of CEs and AEs in liver, plasma, and lung of neonatal (7 day), juvenile (21-day), adult (3-month), and aged (24-month) Sprague Dawley rats. CE sensitivity in vitro to chlopyrifos oxonase and paraoxon was also evaluated across age groups. Neonatal and juvenile rats were more sensitive than adults to the acute lethality of both CPF and PS. Aged rats exhibited similar sensitivity to CPF but were markedly more sensitive than adults to PS. Levels of CEs and AEs in neonatal and juvenile rats were significantly lower than in adult tissues. Aged rats showed similar levels of AEs in all tissues and CEs in liver and lung, but plasma CE levels were significantly lower (50%) when compared to the adult rats. There were no significant age-related differences in in vitro sensitivity of CEs to either chlorpyrifos oxon or paraoxon in any tissues. In general, acute sensitivity (MTD) was highly correlated with age-related differences in both esterase activities across all 3 tissues with CPF, but only plasma carboxylesterase activity was highly correlated with sensitivity to parathion. The results suggest that both carboxylesterase and A-esterase activities can be correlated with acute sensitivity to CPF and PS, but that age-related differences in CE activity are probably more important in differential toxicity. Furthermore, plasma carboxylesterase activity may play a more pivotal role in the differential sensitivity to PS.
C1 Univ Louisiana, Coll Pharm, Dept Toxicol, Monroe, LA 71209 USA.
C3 University of Louisiana System; University of Louisiana Monroe
RP Pope, C (corresponding author), Oklahoma State Univ, Coll Vet Med, Dept Physiol Sci, 264 McElroy Hall, Stillwater, OK 74078 USA.
EM pcarey@okstate.edu
FU NIEHS NIH HHS [R01 ES09119-02] Funding Source: Medline
CR Aldridge W.N., 1996, MECH CONCEPTS TOXICO, P86
   ALDRIDGE WN, 1953, BIOCHEM J, V53, P110, DOI 10.1042/bj0530110
   [Anonymous], ENZYMATIC BASIS DETO
   Atterberry TT, 1997, TOXICOL APPL PHARM, V147, P411, DOI 10.1006/taap.1997.8303
   BENKE GM, 1975, TOXICOL APPL PHARM, V31, P254, DOI 10.1016/0041-008X(75)90161-1
   BOGDANFFY MS, 1987, TOXICOL APPL PHARM, V88, P183, DOI 10.1016/0041-008X(87)90004-4
   BRODEUR J, 1963, P SOC EXP BIOL MED, V114, P509, DOI 10.3181/00379727-114-28716
   CHAMBERS H, 1990, PESTIC BIOCHEM PHYS, V36, P308, DOI 10.1016/0048-3575(90)90040-9
   Chanda SM, 1997, FUND APPL TOXICOL, V38, P148, DOI 10.1006/faat.1997.2329
   CLEMENT JG, 1987, TOXICOL APPL PHARM, V89, P141, DOI 10.1016/0041-008X(87)90184-0
   CLEMENT JG, 1990, ARCH TOXICOL, V64, P414, DOI 10.1007/BF01973466
   CLEMENT JG, 1984, BIOCHEM PHARMACOL, V33, P3807, DOI 10.1016/0006-2952(84)90044-3
   CLEMENT JG, 1984, FUND APPL TOXICOL, V4, pS96, DOI 10.1016/0272-0590(84)90141-6
   COOPER JR, 1996, BIOCH BASIS NEUROPHA, P480
   Costa LG, 1999, CHEM-BIOL INTERACT, V119, P429, DOI 10.1016/S0009-2797(99)00055-1
   Dettbarn WD, 1999, CHEM-BIOL INTERACT, V119, P445, DOI 10.1016/S0009-2797(99)00057-5
   ECOBICHON DJ, 1970, CAN J BIOCHEM CELL B, V48, P1359, DOI 10.1139/o70-210
   Ecobichon DJ, 1996, CASARETT DOULLS TOXI, P643
   FONNUM F, 1985, FUND APPL TOXICOL, V5, pS29, DOI 10.1016/0272-0590(85)90112-5
   Fonnum F, 1981, Fundam Appl Toxicol, V1, P143, DOI 10.1016/S0272-0590(81)80050-4
   Gallo MA., 1991, Handbook of Pesticide Toxicology, P917
   GAUSTAD R, 1991, BIOCHEM PHARMACOL, V42, P1335, DOI 10.1016/0006-2952(91)90443-9
   GUPTA RC, 1987, ARCH TOXICOL, V61, P58, DOI 10.1007/BF00324549
   *JMP, 1995, JMP US GUID VER 6
   Jokanovic M, 1996, ARCH TOXICOL, V70, P444, DOI 10.1007/s002040050297
   Junge W, 1975, CRC Crit Rev Toxicol, V3, P371, DOI 10.3109/10408447509079864
   LI WF, 1995, TOXICOL LETT, V76, P219, DOI 10.1016/0378-4274(95)80006-Y
   LI WF, 2000, IN PRESS PHARMACOGEN
   Liu J, 1999, TOXICOL APPL PHARM, V158, P186, DOI 10.1006/taap.1999.8693
   LOWRY OH, 1951, J BIOL CHEM, V193, P265
   MAXWELL DM, 1987, TOXICOL APPL PHARM, V88, P66, DOI 10.1016/0041-008X(87)90270-5
   MAXWELL DM, 1992, TOXICOL APPL PHARM, V114, P306, DOI 10.1016/0041-008X(92)90082-4
   MENDOZA CE, 1976, TOXICOL APPL PHARM, V35, P229, DOI 10.1016/0041-008X(76)90284-2
   MENDOZA CE, 1977, B ENVIRON CONTAM TOX, V17, P9, DOI 10.1007/BF01685257
   MENDOZA CE, 1971, COMP BIOCHEM PHYSIOL, V40, P841, DOI 10.1016/0305-0491(71)90030-7
   MENTLEIN R, 1984, BIOCHEM PHARMACOL, V33, P1243, DOI 10.1016/0006-2952(84)90176-X
   Michalek H, 1990, Ann Ist Super Sanita, V26, P61
   MICHALEK H, 1990, ACTA NEUROBIOL EXP, V50, P237
   Mileson BE, 1998, TOXICOL SCI, V41, P8
   Mortensen S R, 1996, J Biochem Toxicol, V11, P279, DOI 10.1002/(SICI)1522-7146(1996)11:6<279::AID-JBT3>3.0.CO;2-H
   Moser VC, 1998, TOXICOL SCI, V46, P211, DOI 10.1006/toxs.1998.2526
   Moser VC, 1998, TOXICOL APPL PHARM, V149, P107, DOI 10.1006/taap.1997.8354
   Moser VC, 1999, TOXICOL APPL PHARM, V157, P94, DOI 10.1006/taap.1999.8675
   MOTULSKY HJ, 1994, GRAPHPAD PRISM VERSI
   Overstreet DH, 2000, NEUROTOXICOLOGY, V21, P75
   Padilla S, 2000, NEUROTOXICOLOGY, V21, P49
   PINTOR A, 1988, LIFE SCI, V42, P2113, DOI 10.1016/0024-3205(88)90125-7
   PINTOR A, 1990, LIFE SCI, V46, P1027, DOI 10.1016/0024-3205(90)90027-O
   POND AL, 1995, TOXICOL LETT, V78, P245, DOI 10.1016/0378-4274(95)03327-H
   POPE CN, 1991, TOXICOLOGY, V68, P51, DOI 10.1016/0300-483X(91)90061-5
   POPE CN, 1992, TOXICOLOGY, V73, P35, DOI 10.1016/0300-483X(92)90168-E
   Pope CN, 1999, J TOXICOL ENV HEAL B, V2, P161, DOI 10.1080/109374099281205
   RICHARDSON RJ, 1995, J TOXICOL ENV HEALTH, V44, P135, DOI 10.1080/15287399509531952
   SILVER A, 1974, FRONTIERS BIOL BIOL, V36
   STOOPS JK, 1975, CAN J BIOCHEM CELL B, V53, P565, DOI 10.1139/o75-077
   SULTATOS LG, 1983, FUND APPL TOXICOL, V3, P16, DOI 10.1016/S0272-0590(83)80167-5
   SULTATOS LG, 1983, DRUG METAB DISPOS, V11, P232
   SULTATOS LG, 1985, J PHARMACOL EXP THER, V232, P624
   Tang J, 1999, J BIOCHEM MOL TOXIC, V13, P261, DOI 10.1002/(SICI)1099-0461(1999)13:5<261::AID-JBT6>3.0.CO;2-0
   VERONESI B, 1990, TOXICOL APPL PHARM, V104, P440, DOI 10.1016/0041-008X(90)90166-R
   VITARIUS JA, 1994, DRUG METAB DISPOS, V22, P472
   WALKER CH, 1987, ARCH TOXICOL, V60, P30, DOI 10.1007/BF00296942
   WON YK, 2000, IN PRESS NEUROTOXICO
   Yang ZP, 1998, BIOCHEM PHARMACOL, V55, P1419, DOI 10.1016/S0006-2952(97)00650-3
NR 64
TC 115
Z9 128
U1 0
U2 10
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1096-6080
EI 1096-0929
J9 TOXICOL SCI
JI Toxicol. Sci.
PD DEC
PY 2000
VL 58
IS 2
BP 282
EP 289
DI 10.1093/toxsci/58.2.282
PG 8
WC Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Toxicology
GA 394ZG
UT WOS:000166553800009
PM 11099640
OA Bronze
DA 2024-02-19
ER

PT J
AU Tombuloglu, A
   Copoglu, H
   Aydin-Son, Y
   Guray, NT
AF Tombuloglu, Aysegul
   Copoglu, Hulya
   Aydin-Son, Yesim
   Guray, N. Tulin
TI <i>In vitro</i> effects of boric acid on human liver hepatoma cell line
   (HepG2) at the half-maximal inhibitory concentration
SO JOURNAL OF TRACE ELEMENTS IN MEDICINE AND BIOLOGY
LA English
DT Article
DE Boric acid; Ip(50); Cytotoxicity; DNA damage; Microarray; HepG2
ID MULTIPLE-MYELOMA CELLS; DIETARY BORON; DNA-DAMAGE; PROLIFERATION;
   HOMEOSTASIS; EXPRESSION; ESTROGEN; GROWTH; BORAX
AB Background: Boron is a prominent part of the human diet and one of the essential trace elements for humans. Dietary boron is mostly transformed into boric acid within the body and has been associated with desirable health outcomes. Non-dietary resources of boron, such as boron-based drugs and occupational exposure, might lead to excessive boron levels in the blood and provoke health adversities. The liver might be particularly sensitive to boron intake with ample evidence suggesting a relation between boron and liver function, although the underlying molecular processes remain largely unknown.
   Methods: In order to better understand boron-related metabolism and molecular mechanisms associated with a cytotoxic level of boric acid, the half-maximal inhibitory concentration (IC50) of boric acid for the hepatoma cell line (HepG2) was determined using the XTT assay. Cellular responses followed by boric acid treatment at this concentration were investigated using genotoxicity assays and microarray hybridizations. Enrichment analyses were carried out to find out over-represented biological processes using the list of differentially expressed genes identified within the gene expression analysis.
   Results: DNA breaks were detected in HepG2 cells treated with 24 mM boric acid, the estimated IC50-level of boric acid. On the other hand, pleiotropic transcriptomic effects, including cell cycle arrest, DNA repair, and apoptosis as well as altered expression of Phase I and Phase II enzymes, amino acid metabolism, and lipid metabolism were discerned in microarray analyses.
   Conclusion: HepG2 cells treated with a growth-inhibitory concentration of boric acid for 24 h exhibited a senescence-like transcriptomic profile along with DNA damage. Further studies might help in understanding the concentration-dependent effects and mechanisms of boric acid.
C1 [Tombuloglu, Aysegul; Aydin-Son, Yesim] Middle East Tech Univ, Grad Sch Informat, Hlth Informat Dept, Ankara, Turkey.
   [Copoglu, Hulya; Guray, N. Tulin] Middle East Tech Univ, Grad Sch Arts & Sci, Dept Biol Sci, Ankara, Turkey.
C3 Middle East Technical University; Middle East Technical University
RP Guray, NT (corresponding author), METU Biol Sci, Universiteler Mah Dumlupinar Blv 1, TR-06800 Cankaya, Turkey.
EM guray@metu.edu.tr
RI Guray, N.Tulin/AAZ-6727-2020; AYDIN SON, Yesim/F-5879-2011; Son, Yesim
   Aydin/AAF-8696-2019
OI Guray, N.Tulin/0000-0003-4572-1429; AYDIN SON,
   Yesim/0000-0002-8118-4272; Son, Yesim Aydin/0000-0002-8118-4272
FU Research Fund of the Middle East Technical University
   [BAP-07-02-2017-004-310, BAP 01 -08-2017-002]
FX This work was supported by the Research Fund of the Middle East
   Technical University [project numbers BAP-07-02-2017-004-310, BAP 01
   -08-2017-002].
CR Baer-Dubowska W, 2013, EXPERT OPIN DRUG MET, V9, P927, DOI 10.1517/17425255.2013.795219
   Baker SJ, 2009, FUTURE MED CHEM, V1, P1275, DOI 10.4155/FMC.09.71
   Barranco WT, 2004, CANCER LETT, V216, P21, DOI 10.1016/j.canlet.2004.06.001
   Barranco WT, 2006, BRIT J CANCER, V94, P884, DOI 10.1038/sj.bjc.6603009
   Basoglu A, 2010, TRACE ELEM ELECTROLY, V27, P225
   Bello M, 2018, MED HYPOTHESES, V118, P78, DOI 10.1016/j.mehy.2018.06.024
   Boccadoro M, 2005, CANCER CELL INT, V5, DOI 10.1186/1475-2867-5-18
   Canturk Z, 2016, CYTOTECHNOLOGY, V68, P87, DOI 10.1007/s10616-014-9755-7
   Capati MLF, 2016, BIOL TRACE ELEM RES, V174, P300, DOI 10.1007/s12011-016-0719-y
   Collin G, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0300-z
   Cui Y, 2004, ONCOL REP, V11, P887
   Dai MH, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni179
   Demirci S, 2016, MOL CELL BIOCHEM, V417, P119, DOI 10.1007/s11010-016-2719-9
   Donoiu I, 2018, J TRACE ELEM MED BIO, V50, P47, DOI 10.1016/j.jtemb.2018.06.003
   Eberlé D, 2004, BIOCHIMIE, V86, P839, DOI 10.1016/j.biochi.2004.09.018
   Eijssen LMT, 2013, NUCLEIC ACIDS RES, V41, pW71, DOI 10.1093/nar/gkt293
   Fenech M, 2000, MUTAT RES-FUND MOL M, V455, P81, DOI 10.1016/S0027-5107(00)00065-8
   Geyikoglu F, 2008, ENVIRON TOXICOL PHAR, V26, P342, DOI 10.1016/j.etap.2008.07.002
   Gülsoy N, 2015, EXCLI J, V14, P890, DOI 10.17179/excli2015-404
   Hacioglu C, 2020, BIOL TRACE ELEM RES, V193, P400, DOI 10.1007/s12011-019-01739-x
   Hooks K.B., 2018, NEW INSIGHTS DIAGNOS
   Hooks KB, 2018, HEPATOLOGY, V68, P89, DOI 10.1002/hep.29672
   Huang DW, 2007, NUCLEIC ACIDS RES, V35, pW169, DOI 10.1093/nar/gkm415
   Hunt CD, 1998, BIOL TRACE ELEM RES, V66, P205, DOI 10.1007/BF02783139
   Hunt CD, 1996, J TRACE ELEM EXP MED, V9, P185, DOI 10.1002/(SICI)1520-670X(1996)9:4<185::AID-JTRA6>3.0.CO;2-Q
   Kachhap SK, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011208
   Khaliq H, 2018, BIOL TRACE ELEM RES, V186, P226, DOI 10.1007/s12011-018-1280-7
   Kobylewski SE, 2017, BIOL TRACE ELEM RES, V176, P278, DOI 10.1007/s12011-016-0824-y
   Korkmaz M, 2007, ENVIRON TOXICOL, V22, P17, DOI 10.1002/tox.20229
   Lee JH, 2010, P NATL ACAD SCI USA, V107, P14639, DOI 10.1073/pnas.1008522107
   Merico D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013984
   Mitsiades N, 2003, BLOOD, V101, P2377, DOI 10.1182/blood-2002-06-1768
   Murray FJ, 1998, BIOL TRACE ELEM RES, V66, P331, DOI 10.1007/BF02783146
   Neri P, 2011, BLOOD, V118, P6368, DOI 10.1182/blood-2011-06-363911
   NIELSEN FH, 1987, FASEB J, V1, P394, DOI 10.1096/fasebj.1.5.3678698
   Nielsen FH, 2008, NUTR REV, V66, P183, DOI 10.1111/j.1753-4887.2008.00023.x
   Oesper L, 2011, SOURCE CODE BIOL MED, V6, DOI 10.1186/1751-0473-6-7
   Oliva J, 2012, EXP MOL PATHOL, V93, P26, DOI 10.1016/j.yexmp.2012.03.006
   Ozdemir A, 2014, BIOL TRACE ELEM RES, V158, P268, DOI 10.1007/s12011-014-9924-8
   Park M, 2004, MOL CELL, V16, P331, DOI 10.1016/j.molcel.2004.09.030
   PENLAND JG, 1994, ENVIRON HEALTH PERSP, V102, P65, DOI 10.2307/3431965
   Rainey CJ, 1999, J AM DIET ASSOC, V99, P335, DOI 10.1016/S0002-8223(99)00085-1
   Sahin EC, 2012, J BIOTECHNOL, V161, P46, DOI 10.1016/j.jbiotec.2012.07.149
   Sakamoto T, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07393-6
   Sakamoto T, 2011, PLANT CELL, V23, P3533, DOI 10.1105/tpc.111.086314
   Scorei R, 2012, ORIGINS LIFE EVOL B, V42, P3, DOI 10.1007/s11084-012-9269-2
   SINGH NP, 1990, MUTAT RES, V237, P123, DOI 10.1016/0921-8734(90)90018-M
   Sun PP, 2016, INT J MORPHOL, V34, P830, DOI 10.4067/S0717-95022016000300002
   Tang J, 2016, BIOL TRACE ELEM RES, V170, P208, DOI 10.1007/s12011-015-0428-y
   Toledo LI, 2008, GENE DEV, V22, P297, DOI 10.1101/gad.452308
   Touillaud MS, 2005, NUTR CANCER, V51, P162, DOI 10.1207/s15327914nc5102_6
   Turkez H, 2008, J APPL TOXICOL, V28, P658, DOI 10.1002/jat.1318
   Turkez H, 2010, ACTA BIOCHIM POL, V57, P95
   Uluisik I, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027772
   Uluisik I, 2011, GENOMICS, V97, P106, DOI 10.1016/j.ygeno.2010.10.006
   Wei Y, 2016, GENET MOL RES, V15, DOI 10.4238/gmr.15028300
   Zhao XP, 2014, DIABETES, V63, P2464, DOI 10.2337/db13-0835
NR 57
TC 11
Z9 12
U1 2
U2 16
PU ELSEVIER GMBH
PI MUNICH
PA HACKERBRUCKE 6, 80335 MUNICH, GERMANY
SN 0946-672X
J9 J TRACE ELEM MED BIO
JI J. Trace Elem. Med. Biol.
PD DEC
PY 2020
VL 62
AR 126573
DI 10.1016/j.jtemb.2020.126573
PG 9
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA OM4WV
UT WOS:000586028000014
PM 32534377
DA 2024-02-19
ER

PT J
AU Marini, V
   Pinto, VM
   Stella, M
   Fucile, C
   Lantieri, F
   Luci, G
   Gianesin, B
   Bacigalupo, L
   Forni, GL
   Mattioli, F
AF Marini, Valeria
   Pinto, Valeria Maria
   Stella, Manuela
   Fucile, Carmen
   Lantieri, Francesca
   Luci, Giacomo
   Gianesin, Barbara
   Bacigalupo, Lorenzo
   Forni, Gian Luca
   Mattioli, Francesca
TI Effect of Aging on Deferasirox Therapy in Transfusion-dependent
   Patients. A Prospective-Retrospective, Cohort-study
SO CURRENT DRUG METABOLISM
LA English
DT Article
DE Iron chelation; deferasirox; transfusion-dependent patients;
   physiologically-based pharmacokinetics; tolerability; aging; therapeutic
   drug monitoring
ID IRON CHELATION-THERAPY; THALASSEMIA PATIENTS; OVERLOAD; ICL670;
   EFFICACY; PLASMA; ADULT
AB Background: Iron-chelation therapy is life-saving in patients on a chronic transfusion regimen as it reduces organ damage related to iron deposition in the tissues. Deferasirox, an iron-chelator, is characterized by pharmacokinetics variability, and some patients may discontinue the treatment due to toxicities. Objective: Understanding whether deferasirox plasma levels are related to patients' specific characteristics could help to optimize DFX dosage. Methods: We analyzed deferasirox plasma concentration in 57 transfusion-dependent anemic patients using the HPLC method in this prospective-retrospective cohort study. All outpatients (3 to 98 years) were treated with deferasirox (film-coated tablet) for at least one year (median dose, 16.5 mg/Kg once a day). Deferasirox plasma concentration was normalized for dose/Kg (C/dose) and corrected with a linear regression model that relates C/dose and the time of blood sampling (C-ref/dose). Results: No significant differences in C-ref/dose were found between males and females, either between different types of hemoglobinopathies or depending on the presence of the UGT1A1*28 polymorphism. C-ref/dose has a positive and significant correlation with age, creatinine, and direct bilirubin. C-ref/dose, instead, has a negative and significant correlation with Liver Iron Concentration (LIC), ferritin, and eGFR. C-ref/dose was significantly different between three age categories <18yrs, 18-50yrs, and >50yrs, with C-ref/dose median values of 1.0, 1.2, and 1.5, respectively. Conclusion: The study evidenced that to ensure the efficacy of deferasirox in terms of control over LIC and, at the same time, a lesser influence on renal function, the dose of the drug to be administered to an elderly patient could be reduced.
C1 [Marini, Valeria; Stella, Manuela; Mattioli, Francesca] EO Osped Galliera, Clin Pharmacol Unit, Mura Cappuccine 14, I-16128 Genoa, Italy.
   [Marini, Valeria; Stella, Manuela; Mattioli, Francesca] Univ Genoa, Dept Internal Med, Clin Pharmacol & Toxicol Unit, Viale Benedetto XV 2, I-16132 Genoa, Italy.
   [Pinto, Valeria Maria; Gianesin, Barbara; Forni, Gian Luca] EO Osped Galliera, Ctr Microcitemia Anemie Congenite & Dismetab Ferro, Mura Cappuccine 14, I-16128 Genoa, Italy.
   [Fucile, Carmen] ASL3 San Martino Hosp, Alcohol Reg Ctr, Unit Addict & Hepatol, Largo R Benzi 10, I-16132 Genoa, Italy.
   [Lantieri, Francesca] Univ Genoa, Hlth Sci Dept, Biostat Unit, Via Pastore 1, I-16132 Genoa, Italy.
   [Luci, Giacomo] Univ Pisa, Dept Clin & Expt Med, Via Savi 10, I-56126 Pisa, Italy.
   [Gianesin, Barbara] Anemia Fdn, Via Garibaldi 7, I-16124 Genoa, Italy.
   [Bacigalupo, Lorenzo] EO Osped Galliera, Dept Diagnost Imaging Radiol & Nucl Med, Mura Cappuccine 14, I-16128 Genoa, Italy.
C3 Ente Ospedaliero Ospedali Galliera; University of Genoa; Ente
   Ospedaliero Ospedali Galliera; University of Genoa; University of Pisa;
   Ente Ospedaliero Ospedali Galliera
RP Mattioli, F (corresponding author), Univ Genoa, Dept Internal Med, Clin Pharmacol & Toxicol Unit, Viale Benedetto XV 2, I-16132 Genoa, Italy.
EM francesca.mattioli@unige.it
RI Luci, Giacomo/A-6375-2019; Pinto, Valeria/AAP-8685-2020
OI Luci, Giacomo/0000-0001-6304-536X; Pinto, Valeria/0000-0002-8375-6289;
   MATTIOLI, FRANCESCA/0000-0001-8460-0262
CR Allegra S, 2016, J PHARM PHARMACOL, V68, P1417, DOI 10.1111/jphp.12638
   Angelucci E, 2019, BLOOD, V134, DOI 10.1182/blood-2019-125575
   [Anonymous], 2022, EXJADE
   Ballas SK, 2018, AM J HEMATOL, V93, P943, DOI 10.1002/ajh.25103
   Ballas SK, 2001, SEMIN HEMATOL, V38, P30, DOI 10.1053/shem.2001.20142
   Barton James C, 2007, Curr Gastroenterol Rep, V9, P74, DOI 10.1007/s11894-008-0024-9
   Cappellini MD, 2011, BLOOD, V118, P884, DOI 10.1182/blood-2010-11-316646
   Cappellini MD, 2006, BLOOD, V107, P3455, DOI 10.1182/blood-2005-08-3430
   Castagnola E, 2021, INT J ANTIMICROB AG, V58, DOI 10.1016/j.ijantimicag.2021.106381
   Coates TD, 2019, HEMATOL-AM SOC HEMAT, P337, DOI 10.1182/hematology.2019000036
   Dou HH, 2019, ACTA HAEMATOL-BASEL, V141, P32, DOI 10.1159/000494487
   Fucile C, 2018, THER CLIN RISK MANAG, V14, P1649, DOI 10.2147/TCRM.S170761
   Gabutti V, 1996, ACTA HAEMATOL-BASEL, V95, P26, DOI 10.1159/000203853
   Galeotti L, 2021, PHARMACEUTICS, V13, DOI 10.3390/pharmaceutics13081238
   Hoffbrand AV, 2012, BLOOD, V120, P3657, DOI 10.1182/blood-2012-05-370098
   James W., 1976, RES ON OBESITY
   Kattamis A, 2018, EUR J HAEMATOL, V101, P272, DOI 10.1111/ejh.13111
   Kontoghiorghes GJ, 2009, HEMOGLOBIN, V33, P332, DOI 10.3109/03630260903217182
   Marini V, 2013, ADDICT BEHAV, V38, P1669, DOI 10.1016/j.addbeh.2012.09.015
   Mattioli F, 2015, EUR J HAEMATOL, V94, P310, DOI 10.1111/ejh.12419
   Maximova N, 2017, ONCOTARGET, V8, P63177, DOI 10.18632/oncotarget.18725
   Nafea OE, 2022, DRUG CHEM TOXICOL, V45, P93, DOI 10.1080/01480545.2019.1660362
   Piga A, 2006, HAEMATOL-HEMATOL J, V91, P873
   Pilo F, 2022, LEUKEMIA RES, V114, DOI 10.1016/j.leukres.2022.106792
   Pinto VM, 2019, BLOOD REV, V38, DOI 10.1016/j.blre.2019.100594
   Piolatto A, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-91983-w
   Porter J, 2008, EUR J HAEMATOL, V80, P168, DOI 10.1111/j.1600-0609.2007.00985.x
   Rouan MC, 2001, J CHROMATOGR B, V755, P203, DOI 10.1016/S0378-4347(01)00079-2
   Saliba AN, 2015, J BLOOD MED, V6, P197, DOI 10.2147/JBM.S72463
   Sheth S, 2019, CURR OPIN HEMATOL, V26, P139, DOI 10.1097/MOH.0000000000000499
   Taher AT, 2017, HEMATOL-AM SOC HEMAT, P265, DOI 10.1182/asheducation-2017.1.265
   Taher AT, 2017, AM J HEMATOL, V92, P420, DOI 10.1002/ajh.24668
   Tanaka C, 2014, CLIN PHARMACOKINET, V53, P679, DOI 10.1007/s40262-014-0151-4
   Tartaglione I, 2020, EXP HEMATOL ONCOL, V9, DOI 10.1186/s40164-020-00174-2
   Temraz S, 2014, CRIT REV ONCOL HEMAT, V91, P64, DOI 10.1016/j.critrevonc.2014.01.006
   Tinsley SM, 2018, J INFUS MURS, V41, P171, DOI 10.1097/NAN.0000000000000278
   Wood JC, 2005, BLOOD, V106, P1460, DOI 10.1182/blood-2004-10-3982
NR 37
TC 0
Z9 0
U1 1
U2 2
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1389-2002
EI 1875-5453
J9 CURR DRUG METAB
JI Curr. Drug Metab.
PY 2022
VL 23
IS 13
BP 1072
EP 1079
DI 10.2174/1389200224666221209144420
PG 8
WC Biochemistry & Molecular Biology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy
GA 9C6XS
UT WOS:000935558600005
PM 36503397
DA 2024-02-19
ER

PT J
AU Hunt, NJ
   Lockwood, GP
   Warren, A
   Mao, H
   McCourt, PAG
   Le Couteur, DG
   Cogger, VC
AF Hunt, Nicholas J.
   Lockwood, Glen P.
   Warren, Alessandra
   Mao, Hong
   McCourt, Peter A. G.
   Le Couteur, David G.
   Cogger, Victoria C.
TI Manipulating fenestrations in young and old liver sinusoidal endothelial
   cells
SO AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY
LA English
DT Article
DE aging; direct stochastic optical reconstruction microscopy; nicotinamide
   mononucleotide; pharmaceutical; TNF-related apoptosis-inducing ligand
ID AGE-RELATED-CHANGES; NITRIC-OXIDE; INSULIN-SECRETION; SIMVASTATIN;
   AMLODIPINE; PSEUDOCAPILLARIZATION; LOCALIZATION; DYSFUNCTION;
   PHARMACOKINETICS; MICROCIRCULATION
AB Fenestrations are pores within liver sinusoidal endothelial cells (LSECs) that enable the transfer of substrates (particularly insulin and lipoproteins) between blood and hepatocytes. With increasing age, there are marked reductions in fenestrations, referred to as pseudocapillarization. Currently, fenestrations are thought to be regulated by vascular endothelial growth factor and nitric oxide (NO) pathways promoting remodeling of the actin cytoskeleton and cell membrane lipid rafts. We investigated the effects of drugs that act on these pathways on fenestrations in old (18-24 mo) and young mice (3-4 mo). Isolated LSECs were incubated with either cytochalasin 7-ketocholesterol, sildenafil, amlodipine, simvastatin, 2, 5-dimethoxy-4-iodoamphetamine (DOI), bosentan, TNF-related apoptosis-inducing ligand (TRAIL) or nicotinamide mononucleotide (NMN). LSECs were visualized under scanning electron microscopy to quantify fenestration porosity, diameter, and frequency, as well as direct stochastic optical reconstruction microscopy to examine actin and NO synthase. In young and old LSECs, fenestration porosity, diameter and frequency were increased by 7-ketocholesterol, while porosity and/or frequency were increased with NMN, sildenafil, amlodipine, TRAIL, and cytochalasin D. In old mice only, bosentan and DOI increased fenestration porosity and/or frequency. Modification of the actin cytoskeleton was observed with all agents that increased fenestrations, while NO synthase was only increased by sildenafil, amlodipine, and TRAIL. In conclusion, agents that target NO, actin, or lipid rafts promote changes in fenestrations in mice LSECs. Regulation of fenestrations occurs via both NO-dependent and independent pathways. This work indicates that age-related defenestration can be reversed pharmacologically, which has potential translational relevance for dyslipidemia and insulin resistance.
   NEW & NOTEWORTHY We demonstrate the effects of multiple nitric oxide-dependent and -independent pharmaceutical agents on fenestrations of the liver sinusoidal endothelium. Fenestrations are reorganized in response to nicotinamide mononucleotide, sildenafil, amlodipine, and TNF-related apoptosis-inducing ligand. This work indicates that age-related defenestration can be reversed pharmacologically, which has potential translational relevance for dyslipidemia and insulin resistance in old age.
C1 [Hunt, Nicholas J.; Lockwood, Glen P.; Warren, Alessandra; Le Couteur, David G.; Cogger, Victoria C.] Concord Repatriat Gen Hosp, Ctr Educ & Res Ageing, Sydney, NSW, Australia.
   [Hunt, Nicholas J.; Lockwood, Glen P.; Le Couteur, David G.; Cogger, Victoria C.] Concord Repatriat Gen Hosp, ANZAC Res Inst, Biogerontol Grp, Sydney, NSW, Australia.
   [Hunt, Nicholas J.; Lockwood, Glen P.; McCourt, Peter A. G.; Le Couteur, David G.; Cogger, Victoria C.] Univ Sydney, Charles Perkins Ctr, Nutr Ecol Grp, Sydney, NSW, Australia.
   [Mao, Hong; McCourt, Peter A. G.] Univ Tromso, Dept Med Biol, Tromso, Norway.
C3 Concord Repatriation General Hospital; University of Sydney; ANZAC
   Research Institute; Concord Repatriation General Hospital; University of
   Sydney; UiT The Arctic University of Tromso
RP Cogger, VC (corresponding author), Concord Repatriat Gen Hosp, Ctr Educ & Res Ageing, Sydney, NSW, Australia.
EM victoria.cogger@sydney.edu.au
RI McCourt, Peter/B-3043-2009; Ekanayake, Kanchana/P-8817-2016; Mao,
   Hong/AAS-3541-2020; Hunt, Nicholas/AAD-6084-2019; Research Institute,
   ANZAC/CAE-9030-2022
OI McCourt, Peter/0000-0001-5072-4590; Mao, Hong/0000-0003-4266-3550; Hunt,
   Nicholas/0000-0002-9001-0602; Lockwood, Glen/0000-0001-5966-0191
FU Australian National Health and Medical Research Council [1141234];
   Alzheimer's Research Foundation (a Division of the Medical Foundation of
   the University of Sydney); National Health and Medical Research Council
   of Australia [1141234] Funding Source: NHMRC
FX The study was supported by Australian National Health and Medical
   Research Council Project no. 1141234 and the Aging and Alzheimer's
   Research Foundation (a Division of the Medical Foundation of the
   University of Sydney).
CR Abraldes JG, 2007, J HEPATOL, V46, P1040, DOI 10.1016/j.jhep.2007.01.020
   Andersson KE, 2018, BRIT J PHARMACOL, V175, P2554, DOI 10.1111/bph.14205
   Berkels R, 2004, PHARMACOLOGY, V70, P39, DOI 10.1159/000074241
   Bernardi S, 2018, CLIN SCI, V132, P69, DOI 10.1042/CS20171221
   Biao X, 2002, BRIT J PHARMACOL, V136, P375, DOI 10.1038/sj.bjp.0704753
   Bonkowski MS, 2016, NAT REV MOL CELL BIO, V17, P679, DOI 10.1038/nrm.2016.93
   Burgess G, 2008, EUR J CLIN PHARMACOL, V64, P43, DOI 10.1007/s00228-007-0408-z
   Cartland SP, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-01721-4
   Cogger V.C., 2009, LIVER BIOL PATHOBIOL, V5th Edn, P389
   Cogger VC, 2008, AM J PHYSIOL-GASTR L, V295, pG137, DOI 10.1152/ajpgi.00069.2008
   Cogger VC, 2015, JOVE-J VIS EXP, DOI 10.3791/52698
   Cogger VC, 2013, COMPUT STRUCT BIOTEC, V8, DOI 10.5936/csbj.201308003
   Cogger VC, 2014, J GERONTOL A-BIOL, V69, P514, DOI 10.1093/gerona/glt124
   Cogger VC, 2010, J STRUCT BIOL, V171, P382, DOI 10.1016/j.jsb.2010.06.001
   Corbin JD, 1999, J BIOL CHEM, V274, P13729, DOI 10.1074/jbc.274.20.13729
   Curran-Everett D, 2007, ADV PHYSIOL EDUC, V31, P295, DOI 10.1152/advan.00022.2007
   de Sotomayor MA, 2005, BRIT J PHARMACOL, V146, P1130, DOI 10.1038/sj.bjp.0706420
   DeLeve LD, 2015, HEPATOLOGY, V61, P1740, DOI 10.1002/hep.27376
   Di Pietro R, 2006, J CELL BIOCHEM, V97, P782, DOI 10.1002/jcb.20686
   Elvevold K, 2008, AM J PHYSIOL-GASTR L, V294, pG391, DOI 10.1152/ajpgi.00167.2007
   Gelosa P, 2007, VASC HEALTH RISK MAN, V3, P567
   Hilmer SN, 2005, HEPATOLOGY, V42, P1349, DOI 10.1002/hep.20937
   Ito Y, 2007, EXP GERONTOL, V42, P789, DOI 10.1016/j.exger.2007.04.008
   Le Couteur DG, 2007, ANN NY ACAD SCI, V1114, P79, DOI 10.1196/annals.1396.003
   Le Couteur DG, 2001, HEPATOLOGY, V33, P537, DOI 10.1053/jhep.2001.22754
   Mason RP, 2014, AM J HYPERTENS, V27, P482, DOI 10.1093/ajh/hpt202
   McLean AJ, 2003, J PATHOL, V200, P112, DOI 10.1002/path.1328
   Mitchell SJ, 2011, J GERONTOL A-BIOL, V66, P400, DOI 10.1093/gerona/glq221
   Mönkemöller V, 2015, SCI REP-UK, V5, DOI 10.1038/srep16279
   Mönkemöller V, 2014, PHYS CHEM CHEM PHYS, V16, P12576, DOI 10.1039/c4cp01574f
   Mohamad M, 2016, AGING CELL, V15, P706, DOI 10.1111/acel.12481
   Nahidiazar L, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0158884
   Parrish JC, 2005, J NEUROCHEM, V95, P1575, DOI 10.1111/j.1471-4159.2005.03477.x
   Ramsey KM, 2008, AGING CELL, V7, P78, DOI 10.1111/j.1474-9726.2007.00355.x
   Revollo JR, 2007, CELL METAB, V6, P363, DOI 10.1016/j.cmet.2007.09.003
   RICHARD V, 1995, CIRCULATION, V91, P771, DOI 10.1161/01.CIR.91.3.771
   Rikitake Y, 2005, CIRC RES, V97, P1232, DOI 10.1161/01.RES.0000196564.18314.23
   Roghani-Dehkordi F, 2016, ARYA ATHEROSCLER, V12, P104
   Rybalkin SD, 2002, J BIOL CHEM, V277, P3310, DOI 10.1074/jbc.M106562200
   Stangier J, 2000, J CLIN PHARMACOL, V40, P1347
   Svistounov D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046134
   Toque HA, 2008, BRIT J PHARMACOL, V154, P787, DOI 10.1038/bjp.2008.141
   Trammell SAJ, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12948
   van de Linde S, 2011, NAT PROTOC, V6, P991, DOI 10.1038/nprot.2011.336
   van Giersbergen PLM, 2002, BRIT J CLIN PHARMACO, V53, P589, DOI 10.1046/j.1365-2125.2002.01608.x
   Wolter S, 2012, NAT METHODS, V9, P1040, DOI 10.1038/nmeth.2224
   Yoshino J, 2011, CELL METAB, V14, P528, DOI 10.1016/j.cmet.2011.08.014
   Ziviani L, 2001, BRIT J CLIN PHARMACO, V51, P147, DOI 10.1111/j.1365-2125.2001.bcp119.x
NR 48
TC 35
Z9 40
U1 1
U2 10
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0193-1857
EI 1522-1547
J9 AM J PHYSIOL-GASTR L
JI Am. J. Physiol.-Gastroint. Liver Physiol.
PD JAN
PY 2019
VL 316
IS 1
BP G144
EP G154
DI 10.1152/ajpgi.00179.2018
PG 11
WC Gastroenterology & Hepatology; Physiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Gastroenterology & Hepatology; Physiology
GA HH4DK
UT WOS:000455670700008
PM 30285464
OA hybrid, Green Submitted, Green Published
DA 2024-02-19
ER

PT J
AU Li, Q
   Li, B
   Miao, XL
   Ramgattie, C
   Gao, ZH
   Liu, JL
AF Li, Qing
   Li, Bing
   Miao, Xiaoliang
   Ramgattie, Christopher
   Gao, Zu-hua
   Liu, Jun-Li
TI Reg2 Expression Is Required for Pancreatic Islet Compensation in
   Response to Aging and High-Fat Diet-Induced Obesity
SO ENDOCRINOLOGY
LA English
DT Article
ID MESSENGER-RNA; LIVER-REGENERATION; EXOCRINE PANCREAS; REG3-BETA GENES;
   DIABETIC MICE; RAT PANCREAS; PROTEIN; MOUSE; PAP; HYPERINSULINEMIA
AB Maintaining pancreatic b-cell mass and function is essential for normal insulin production and glucose homeostasis. Regenerating islet-derived 2 (Reg2, Reg II, human ortholog Reg1B) gene is normally expressed in pancreatic acinar cells and is significantly induced in response to diabetes, pancreatitis, and high-fat diet (HFD) and during pancreatic regeneration. To evaluate the role of endogenous Reg2 production in normal b-cell function, we characterized Reg2 gene-deficient (Reg2(-/-)) mice under normal conditions and when subjected to several pathological challenges. At a young age, Reg2 gene deficiency caused no obvious change in normal islet morphology or glucose tolerance. There was no change in the severity of streptozotocin-induced diabetes or caerulein-induced acute pancreatitis in the Reg2(-/-) mice, indicating that the increased Reg2 expression under those conditions was not essential to protect the islet or acinar cells. However, 13-to 14-month-old Reg2(-/-) mice developed glucose intolerance associated with significantly decreased islet b-cell ratio and serum insulin level. Similarly, after young mice were fed an HFD for 19 weeks, diminished islet mass expansion and serum insulin level were observed in Reg2(-/-) vs wild-type mice. This was associated with a decline in the rate of individual b-cell proliferation measured by Ki67 labeling. In both conditions, the b-cells were smaller in gene-deficient vs wild-type mice. Our results indicate that normal expression of Reg2 gene is required for appropriate compensations in pancreatic islet proliferation and expansion in response to obesity and aging.
C1 [Li, Qing; Li, Bing; Ramgattie, Christopher; Liu, Jun-Li] McGill Univ, Dept Med, Fraser Labs Diabet Res, Hlth Ctr, Montreal, PQ H4A 3J1, Canada.
   [Miao, Xiaoliang] China Pharmaceut Univ, Sch Life Sci & Technol, Nanjing 21009, Jiangsu, Peoples R China.
   [Gao, Zu-hua] McGill Univ, Dept Pathol, Hlth Ctr, Room E04-1820,1001 Decarie Blvd, Montreal, PQ H4A 3J1, Canada.
   [Liu, Jun-Li] Montreal Diabet Res Ctr, Montreal, PQ H2X 0A9, Canada.
C3 McGill University; China Pharmaceutical University; McGill University;
   Universite de Montreal
RP Gao, ZH (corresponding author), McGill Univ, Dept Pathol, Hlth Ctr, Room E04-1820,1001 Decarie Blvd, Montreal, PQ H4A 3J1, Canada.; Liu, JL (corresponding author), McGill Univ, Hlth Ctr, Res Inst, Dept Med, Room E02-7220,1001 Decarie Blvd, Montreal, PQ H4A 3J1, Canada.
EM zu-hua.gao@mcgill.ca; jun-li.liu@mcgill.ca
RI liu, jun-li/O-2115-2019; Liu, Jun-Li/A-1501-2008
OI Liu, Jun-Li/0000-0001-6251-6406
FU Canadian Diabetes Association [OG-3-11-3469-JL]; Research Institute of
   McGill University Health Centre; China Scholarship Council
FX This work was supported by Canadian Diabetes Association Grant
   OG-3-11-3469-JL, by grants from the Research Institute of McGill
   University Health Centre (to J.-L.L. and Z.G.), and by the China
   Scholarship Council (Q.L. and X.M.).
CR Abe M, 2000, GENE, V246, P111, DOI 10.1016/S0378-1119(00)00059-7
   Ahima RS, 2009, NAT MED, V15, P996, DOI 10.1038/nm0909-996
   Barbaric Ivana, 2007, Briefings in Functional Genomics & Proteomics, V6, P91, DOI 10.1093/bfgp/elm008
   Bluth MH, 2006, WORLD J GASTROENTERO, V12, P4511, DOI 10.3748/wjg.v12.i28.4511
   De León DD, 2006, PHYSIOL GENOMICS, V24, P133, DOI 10.1152/physiolgenomics.00156.2005
   Deeds MC, 2011, LAB ANIM-UK, V45, P131, DOI 10.1258/la.2010.010090
   Ferrannini E, 2010, DIABETES CARE, V33, P2217, DOI 10.2337/dc10-0612
   Fu K, 1996, DIGESTION, V57, P333, DOI 10.1159/000201354
   Gironella M, 2007, GUT, V56, P1091, DOI 10.1136/gut.2006.116087
   Graf R, 2002, J SURG RES, V105, P136, DOI 10.1006/jsre.2002.6387
   Gurr W, 2007, DIABETES, V56, P34, DOI 10.2337/db06-0669
   Ho MR, 2006, J BIOL CHEM, V281, P33566, DOI 10.1074/jbc.M604513200
   Honda H, 2002, PANCREAS, V25, P192, DOI 10.1097/00006676-200208000-00014
   Hu GY, 2011, GUT, V60, P820, DOI 10.1136/gut.2010.215178
   Huszarik K, 2010, J IMMUNOL, V185, P5120, DOI 10.4049/jimmunol.1001596
   IOVANNA J, 1991, J BIOL CHEM, V266, P24664
   IOVANNA JL, 1993, AM J PHYSIOL, V265, pG611, DOI 10.1152/ajpgi.1993.265.4.G611
   Katz A, 2000, J CLIN ENDOCR METAB, V85, P2402, DOI 10.1210/jc.85.7.2402
   Kim H, 2008, GUT LIVER, V2, P74, DOI 10.5009/gnl.2008.2.2.74
   Kushner JA, 2013, J CLIN INVEST, V123, P990, DOI 10.1172/JCI64095
   Li B, 2010, AM J PHYSIOL-GASTR L, V299, pG413, DOI 10.1152/ajpgi.00500.2009
   Lieu HT, 2006, HEPATOLOGY, V44, P1452, DOI 10.1002/hep.21434
   Liu JL, 2007, HEPATOLOGY, V45, P1584, DOI 10.1002/hep.21693
   Liu Jun-Li, 2008, Endocrine Metabolic & Immune Disorders-Drug Targets, V8, P1, DOI 10.2174/187153008783928361
   Liu L, 2010, GROWTH FACTORS, V28, P370, DOI 10.3109/08977194.2010.504721
   Lu YR, 2006, AM J PHYSIOL-ENDOC M, V291, pE50, DOI 10.1152/ajpendo.00596.2005
   Lu YR, 2004, DIABETES, V53, P3131, DOI 10.2337/diabetes.53.12.3131
   Lumeng CN, 2011, J CLIN INVEST, V121, P2111, DOI 10.1172/JCI57132
   Luo C, 2013, MOL CELL ENDOCRINOL, V365, P187, DOI 10.1016/j.mce.2012.10.018
   Mehran AE, 2012, CELL METAB, V16, P723, DOI 10.1016/j.cmet.2012.10.019
   Perfetti R, 1996, J GERONTOL A-BIOL, V51, pB308, DOI 10.1093/gerona/51A.5.B308
   Prentki M, 2006, J CLIN INVEST, V116, P1802, DOI 10.1172/JCI29103
   Qiu LH, 2005, MOL CELL PROTEOMICS, V4, P1311, DOI 10.1074/mcp.M500016-MCP200
   Templeman NM, 2015, DIABETOLOGIA, V58, P2392, DOI 10.1007/s00125-015-3676-7
   UNNO M, 1993, J BIOL CHEM, V268, P15974
   Viterbo D, 2009, J PANCREAS, V10, P15
   Wang Y, 2011, GROWTH FACTORS, V29, P72, DOI 10.3109/08977194.2011.562866
   Winzell MS, 2004, DIABETES, V53, pS215, DOI 10.2337/diabetes.53.suppl_3.S215
   Xiong XQ, 2011, AM J PHYSIOL-ENDOC M, V300, pE669, DOI 10.1152/ajpendo.00600.2010
   Yu LT, 2016, MOL CELL ENDOCRINOL, V422, P150, DOI 10.1016/j.mce.2015.12.002
   Zenilman ME, 2000, ANN SURG, V232, P646, DOI 10.1097/00000658-200011000-00005
   Zhong BH, 2007, MOL BIOL CELL, V18, P4969, DOI 10.1091/mbc.E07-02-0180
NR 42
TC 16
Z9 17
U1 0
U2 5
PU ENDOCRINE SOC
PI WASHINGTON
PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA
SN 0013-7227
EI 1945-7170
J9 ENDOCRINOLOGY
JI Endocrinology
PD JUN
PY 2017
VL 158
IS 6
BP 1634
EP 1644
DI 10.1210/en.2016-1551
PG 11
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Endocrinology & Metabolism
GA EX4UN
UT WOS:000403230500016
PM 28009527
OA Bronze
DA 2024-02-19
ER

PT J
AU Poynard, T
   Bedossa, P
   Opolon, P
AF Poynard, T
   Bedossa, P
   Opolon, P
TI Natural history of liver fibrosis progression in patients with chronic
   hepatitis C
SO LANCET
LA English
DT Article
ID NON-B-HEPATITIS; NON-A; POSTTRANSFUSION HEPATITIS; ALPHA-INTERFERON;
   FOLLOW-UP; TRANSFUSION; TRIAL
AB Background Our aim was to assess the natural history of liver fibrosis progression in hepatitis C and the factors associated with this progression.
   Methods We recruited 2235 patients from the Observatoire de l'Hepatite C (OBSVIRC) population, the Cohorte Hepatite C Pitie-Salpetriere (DOSVIRC) population, and the original METAVIR population. All the patients had a biopsy sample compatible with chronic hepatitis C as assessed by the METAVIR scoring system (grades the stage of fibrosis on a five-point scale, FO=no fibrosis, F4=cirrhosis, and histological activity on a four-point scale, AO=no activity, A3=severe activity). No patient had received interferon treatment before the liver biopsy sample was obtained, We assessed the effect of nine factors on fibrosis progression: age at biopsy; estimated duration of infection; sex; age at infection; alcohol consumption; hepatitis C virus C (HCV) genotype; HCV viraemia; cause of infection; and histological activity grade. We defined fibrosis progression per year as the ratio between fibrosis stage in METAVIR units and the duration of infection (1 unit=one stage, 4 units=cirrhosis).
   Findings The median rate of fibrosis progression per year was 0.133 fibrosis unit (95% CI 0.125-0.143), which was similar to the estimates from previous studies (0.146 to 0.154). Three independent factors were associated with an increased rate of fibrosis progression: age at infection older than 40 years, daily alcohol consumption of 50 g or more, and male sex. There was no association between fibrosis progression and HCV genotype. The median estimated duration of infection for progression to cirrhosis was 30 years (28-32), ranging from 13 years in men infected after the age of 40 to 42 years in women who did not drink alcohol and were infected before the age of 40. Without treatment, 377 (33%) patients had an expected median time to cirrhosis of less than 20 years, and 356 (31%) will never progress to cirrhosis or will not progress for at least 50 years.
   Interpretation The host factors of ageing, alcohol consumption, and male sex have a stronger association with fibrosis progression than virological factors in HCV infection.
C1 HOP BICETRE,SERV ANAT PATHOL,LE KREMLIN BICETR,FRANCE.
C3 Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre
   - APHP
RP Poynard, T (corresponding author), GRP HOSP PITIE SALPETRIERE,SERV HEPATO GASTROENTEROL,URA CNRS 1484,F-75651 PARIS 13,FRANCE.
RI Yang, Chen/G-1379-2010; Poynard, Thierry/C-1355-2010
OI Poynard, Thierry/0000-0002-3726-7230; Poynard,
   Thierry/0000-0002-2050-640X; Bedossa, Pierre/0000-0002-8487-7322
CR ALTER MJ, 1995, SEMIN LIVER DIS, V15, P5, DOI 10.1055/s-2007-1007259
   Bedossa P, 1996, HEPATOLOGY, V24, P289, DOI 10.1002/hep.510240201
   CAMPS J, 1993, J HEPATOL, V17, P390, DOI 10.1016/S0168-8278(05)80223-5
   CROWE J, 1995, GASTROENTEROLOGY, V108, pA1054, DOI 10.1016/0016-5085(95)28518-0
   Delladetsima JK, 1996, J HEPATOL, V24, P27, DOI 10.1016/S0168-8278(96)80182-6
   DESMET VJ, 1994, HEPATOLOGY, V19, P1513, DOI 10.1002/hep.1840190629
   DIBISCEGLIE AM, 1991, HEPATOLOGY, V14, P969, DOI 10.1016/0270-9139(91)90113-A
   Dusheiko GM, 1995, HEPATOLOGY, V22, P1863, DOI 10.1016/0270-9139(95)90216-3
   GENESCA J, 1991, SEMIN LIVER DIS, V11, P147, DOI 10.1055/s-2008-1040432
   GOMEZRUBIO M, 1990, J HEPATOL, V11, pS63, DOI 10.1016/0168-8278(90)90166-O
   KIYOSAWA K, 1990, HEPATOLOGY, V12, P671, DOI 10.1002/hep.1840120409
   Kobayashi M, 1996, HEPATOLOGY, V23, P695, DOI 10.1053/jhep.1996.v23.pm0008666319
   Koff RS, 1995, HEPATOLOGY, V22, P1880
   LUDWIG J, 1993, GASTROENTEROLOGY, V105, P274, DOI 10.1016/0016-5085(93)90037-D
   *METAVIR COOP GROU, 1994, HEPATOLOGY, V20, P15
   *OBS NAT HEP C GRO, 1995, GASTROENTEROL CLIN B, V19, P81
   POYNARD T, 1995, NEW ENGL J MED, V332, P1457, DOI 10.1056/NEJM199506013322201
   Poynard T, 1996, HEPATOLOGY, V24, P778
   SAEZROYUELA F, 1991, HEPATOLOGY, V13, P327, DOI 10.1016/0270-9139(91)92448-H
   TAKAHASHI M, 1993, AM J GASTROENTEROL, V88, P240
   TONG MJ, 1995, NEW ENGL J MED, V332, P1463, DOI 10.1056/NEJM199506013322202
   TREMOLADA F, 1992, J HEPATOL, V16, P273, DOI 10.1016/S0168-8278(05)80657-9
   Yano M, 1996, HEPATOLOGY, V23, P1334, DOI 10.1053/jhep.1996.v23.pm0008675148
NR 23
TC 2444
Z9 2597
U1 0
U2 99
PU LANCET LTD
PI LONDON
PA 42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL
SN 0140-6736
J9 LANCET
JI Lancet
PD MAR 22
PY 1997
VL 349
IS 9055
BP 825
EP 832
DI 10.1016/S0140-6736(96)07642-8
PG 10
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA WP403
UT WOS:A1997WP40300010
PM 9121257
DA 2024-02-19
ER

PT J
AU Tian, MY
   Zhang, X
   Wang, LH
   Li, Y
AF Tian, Mingyuan
   Zhang, Xiong
   Wang, Linhui
   Li, Yu
TI Curcumin Induces ABCA1 Expression and Apolipoprotein A-I-Mediated
   Cholesterol Transmembrane in the Chronic Cerebral Hypoperfusion Aging
   Rats
SO AMERICAN JOURNAL OF CHINESE MEDICINE
LA English
DT Article
DE Curcumin; Hypoperfusion; LXR-beta/RXR-alpha; ABCA1; ApoA-I
ID ALZHEIMERS-DISEASE; COGNITIVE FUNCTION; BRAIN CHOLESTEROL; ACTIVATION;
   NEUROINFLAMMATION; RECEPTORS; DEMENTIA; ENZYMES; MODEL; RISK
AB Cerebral hypoperfusion or aging often results in the disturbances of cholesterol and lipoprotein, which have been well depicted as a common pathological status contributing to neurodegenerative diseases such as vascular dementia (VaD) and Alzheimer's dementia (AD). The pathway of the liver X receptor-beta (LXR-beta)/retinoic X receptor-alpha (RXR-alpha)/ABCA1 plays a vital role in lipoprotein metabolism. Curcumin, a kind of phenolic compound, has been widely used. It has been reported that curcumin can reduce the levels of cholesterol in serum, but the underlying mechanisms are poorly understood. In this study, we evaluated the effects of curcumin on the cholesterol level in brain, vascular cognitive impairment and explored whether the mechanisms for those effects are through activating LXR-beta/RXR-alpha and ABCA1 expression and apoA-I. With a Morris water test, we found that curcumin treatment could attenuate cognitive impairment. With HE and Nissl staining, we found that curcumin could significantly ameliorate the abnormal changes of pyramidal neurons. Meanwhile, the expression of LXR-beta, RXR-alpha, ABCA1 and apoA-I mRNA and protein were increased in a dose-dependent manner after curcumin treatment. Interestingly, both serum HDL cholesterol and total cholesterol levels were statistically higher in the curcumin treatment group than those other groups. We conclude that curcumin has the ability to activate permissive LXR-beta/RXR-alpha signaling and thereby modulate ABCA1 and apoA-I-mediated cholesterol transmembrane transportation, which is a new preventive and therapeutic strategy for cerevascular diseases.
C1 [Tian, Mingyuan; Wang, Linhui; Li, Yu] Chongqing Med Univ, Dept Pathol, Chongqing 400016, Peoples R China.
   [Tian, Mingyuan; Zhang, Xiong; Wang, Linhui; Li, Yu] Chongqing Med Univ, Inst Neurosci, Chongqing 400016, Peoples R China.
   [Tian, Mingyuan; Zhang, Xiong; Wang, Linhui; Li, Yu] Chongqing Med Univ, Chongqing Key Lab Neurobiol, Chongqing 400016, Peoples R China.
C3 Chongqing Medical University; Chongqing Medical University; Chongqing
   Medical University
RP Li, Y (corresponding author), Chongqing Med Univ, Inst Neurosci, Dept Pathol, Key Lab Neurobiol, Yuanjiagang Yixueyuan Rd 1, Chongqing 400016, Peoples R China.
EM liyu100@163.com
RI Wei, Wei/JVM-8876-2024; wang, jing/GRS-7509-2022; wang,
   lin/GSE-3040-2022; liu, lingling/IUQ-7478-2023
OI Wei, Wei/0000-0002-4109-3878; 
FU National Basic Research Program of China (973 Program) [2009CB918300];
   National Natural Science Foundation of China (NSFC) [81271426, 81100948]
FX This work was supported by a grant from National Basic Research Program
   of China (973 Program No. 2009CB918300) and supported by the National
   Natural Science Foundation of China (NSFC: 81271426, 81100948). In the
   study, Mingyuan Tian carried out most of the study, Linhui Wang
   participated in the construction of the models, Xiong Zhang provided
   some technical help (PCR, WB, HE staining, etc.), and performed
   statistical analysis and drafted the manuscript. Mingyuan Tian and Xiong
   Zhang contributed equally to the work. Professor Li participated in the
   design of the study and provided the financial support. All authors have
   read the manuscript and agreed to send it to the journal.
CR Awad AS, 2011, J STROKE CEREBROVASC, V20, P541, DOI 10.1016/j.jstrokecerebrovasdis.2010.03.008
   Baghdasaryan A, 2010, GUT, V59, P521, DOI 10.1136/gut.2009.186528
   Björkhem I, 2004, ARTERIOSCL THROM VAS, V24, P806, DOI 10.1161/01.ATV.0000120374.59826.1b
   Cechetti F, 2012, BRAIN RES BULL, V87, P109, DOI 10.1016/j.brainresbull.2011.10.006
   Dohare P, 2008, BMC COMPLEM ALTERN M, V8, DOI 10.1186/1472-6882-8-55
   Dong SZ, 2011, MOL CELL BIOCHEM, V358, P281, DOI 10.1007/s11010-011-0978-z
   Egan ME, 2004, SCIENCE, V304, P600, DOI 10.1126/science.1093941
   Fan JJ, 2009, BIOFACTORS, V35, P239, DOI 10.1002/biof.37
   Farkas E, 2007, BRAIN RES REV, V54, P162, DOI 10.1016/j.brainresrev.2007.01.003
   Francis GA, 2003, ANNU REV PHYSIOL, V65, P261, DOI 10.1146/annurev.physiol.65.092101.142528
   Gillum RF, 2011, LIPIDS HEALTH DIS, V10, DOI 10.1186/1476-511X-10-26
   He Z, 2008, CELL MOL NEUROBIOL, V28, P613, DOI 10.1007/s10571-007-9165-x
   Joyce C, 2003, ARTERIOSCL THROM VAS, V23, P965, DOI 10.1161/01.ATV.0000055194.85073.FF
   Karasinska JM, 2009, J NEUROSCI, V29, P3579, DOI 10.1523/JNEUROSCI.4741-08.2009
   Kim T, 2009, BIOCHEM BIOPH RES CO, V388, P377, DOI 10.1016/j.bbrc.2009.08.018
   Kivipelto M, 2005, ARCH NEUROL-CHICAGO, V62, P1556, DOI 10.1001/archneur.62.10.1556
   Lai JJ, 2009, J CLIN INVEST, V119, P3739, DOI 10.1172/JCI39335
   Lewis TL, 2010, J BIOL CHEM, V285, P36958, DOI 10.1074/jbc.M110.127829
   Mahfouz MM, 2011, INT J VITAM NUTR RES, V81, P378, DOI 10.1024/0300-9831/a000084
   Morales JR, 2008, CIRCULATION, V118, P1450, DOI 10.1161/CIRCULATIONAHA.108.782300
   Negi PS, 1999, J AGR FOOD CHEM, V47, P4297, DOI 10.1021/jf990308d
   Pan MH, 1999, DRUG METAB DISPOS, V27, P486
   Raffaitin C, 2009, DIABETES CARE, V32, P169, DOI 10.2337/dc08-0272
   Repa JJ, 2007, J NEUROSCI, V27, P14470, DOI 10.1523/JNEUROSCI.4823-07.2007
   Russell DW, 2003, ANNU REV BIOCHEM, V72, P137, DOI 10.1146/annurev.biochem.72.121801.161712
   Sironi L, 2008, FEBS LETT, V582, P3396, DOI 10.1016/j.febslet.2008.08.035
   Stukas S, 2012, BBA-MOL CELL BIOL L, V1821, P536, DOI 10.1016/j.bbalip.2011.08.014
   Tanwar V, 2010, J CARDIOVASC PHARM, V55, P377, DOI 10.1097/FJC.0b013e3181d3da01
   TSUCHIYA M, 1993, EXP BRAIN RES, V95, P1
   Wahrle SE, 2004, J BIOL CHEM, V279, P40987, DOI 10.1074/jbc.M407963200
   Yokoyama S, 2006, ARTERIOSCL THROM VAS, V26, P20, DOI 10.1161/01.ATV.0000195789.39418.e8
   Zhao JF, 2012, MOL NUTR FOOD RES, V56, P691, DOI 10.1002/mnfr.201100735
NR 32
TC 22
Z9 26
U1 2
U2 21
PU WORLD SCIENTIFIC PUBL CO PTE LTD
PI SINGAPORE
PA 5 TOH TUCK LINK, SINGAPORE 596224, SINGAPORE
SN 0192-415X
EI 1793-6853
J9 AM J CHINESE MED
JI Am. J. Chin. Med.
PY 2013
VL 41
IS 5
BP 1027
EP 1042
DI 10.1142/S0192415X13500699
PG 16
WC Integrative & Complementary Medicine; Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Integrative & Complementary Medicine; General & Internal Medicine
GA 236BT
UT WOS:000325769400005
PM 24117066
DA 2024-02-19
ER

PT J
AU Ji, XW
   Jiang, Y
   Wu, H
   Zhou, P
   Tan, YT
   Li, HL
   Zhang, L
   Zhao, WS
   Xia, QH
   Bray, F
   Xiang, YB
AF Ji, Xiao Wei
   Jiang, Yu
   Wu, Hua
   Zhou, Peng
   Tan, Yu Ting
   Li, Hong Lan
   Zhang, Lei
   Zhao, Wen Sui
   Xia, Qing Hua
   Bray, Freddie
   Xiang, Yong Bing
TI Long-term liver cancer incidence and mortality trends in the Changning
   District of Shanghai, China
SO JOURNAL OF DIGESTIVE DISEASES
LA English
DT Article; Early Access
DE age-period-cohort analysis; incidence; Joinpoint regression model; liver
   cancer; mortality
ID PERIOD-COHORT ANALYSIS; HEPATOCELLULAR-CARCINOMA; URBAN SHANGHAI; RISK;
   EPIDEMIOLOGY; HEPATITIS; SEX; STATISTICS; INFECTION
AB Objective To evaluate the trends and estimate the long-term effects of age, period and birth cohort on the incidence and mortality rates of liver cancer (LC) in an urban district of Shanghai, China.
   Methods Crude and age-standardized rates of the incidence and mortality of LC were calculated from 1973 to 2013 annually by sex, and the direction and magnitude of the trends were estimated by the average annual percentage change (AAPC) using the Joinpoint Regression Model. An age-period-cohort (APC) model was also used to evaluate the non-linear effects of calendar time and birth cohort on LC incidence and mortality.
   Results In 1973-1977 and 2008-2013 the age-standardized rates of LC incidence and mortality (per 100 000) were 24.27 and 22.60 in men, and 7.50 and 7.26 in women, respectively. Declining trends of LC incidence and mortality rates were observed for both sexes (AAPC; P < 0.05 for both). The APC models indicated that the rates of LC incidence and mortality were significantly influenced both by calendar time and birth cohort effects.
   Conclusions The incidence and mortality rates of LC have decreased in both sexes in the Changning District of Shanghai over the past four decades. Although obvious descending trends of LC incidence and mortality were detected, attention should also be paid to the LC burden for a long time in the future because of huge population size in China and the continuity of population aging.
C1 [Ji, Xiao Wei; Xiang, Yong Bing] Shanghai Jiao Tong Univ, Sch Publ Hlth, Sch Med, Shanghai, Peoples R China.
   [Ji, Xiao Wei; Wu, Hua; Tan, Yu Ting; Li, Hong Lan; Xiang, Yong Bing] Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, State Key Lab Oncogene & Related Genes, 25 Lane 2200,Xietu Rd, Shanghai 200032, Peoples R China.
   [Ji, Xiao Wei; Wu, Hua; Tan, Yu Ting; Li, Hong Lan; Xiang, Yong Bing] Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, Dept Epidemiol,Shanghai Canc Inst, 25 Lane 2200,Xietu Rd, Shanghai 200032, Peoples R China.
   [Jiang, Yu; Zhou, Peng; Zhang, Lei; Zhao, Wen Sui; Xia, Qing Hua] Shanghai Changning Dist Ctr Dis Control & Prevent, 39 Yunwushan Rd, Shanghai 200051, Peoples R China.
   [Bray, Freddie] Int Agcy Res Canc, Canc Surveillance Sect, Lyon, France.
C3 Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai
   Jiao Tong University; Shanghai Center for Disease Control & Prevention;
   World Health Organization; International Agency for Research on Cancer
   (IARC)
RP Xiang, YB (corresponding author), Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, State Key Lab Oncogene & Related Genes, 25 Lane 2200,Xietu Rd, Shanghai 200032, Peoples R China.; Xiang, YB (corresponding author), Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, Dept Epidemiol,Shanghai Canc Inst, 25 Lane 2200,Xietu Rd, Shanghai 200032, Peoples R China.; Xia, QH (corresponding author), Shanghai Changning Dist Ctr Dis Control & Prevent, 39 Yunwushan Rd, Shanghai 200051, Peoples R China.
EM xiaqinghua56@126.com; ybxiang@shsci.org
FU National Key Basic Research Program of China "973 Project"
   [2015CB554000]; National Key Project of Research and Development Program
   of China [2016YFC1302503]; State Key Project Specialized for Infectious
   Diseases of China [2008ZX10002-015, 2012ZX10002008-002]
FX National Key Basic Research Program of China "973 Project", Grant/Award
   Number: 2015CB554000; National Key Project of Research and Development
   Program of China, Grant/Award Number: 2016YFC1302503; State Key Project
   Specialized for Infectious Diseases of China, Grant/Award Numbers:
   2008ZX10002-015, 2012ZX10002008-002
CR Are C, 2017, J SURG ONCOL, V115, P591, DOI 10.1002/jso.24518
   Baecker A, 2018, EUR J CANCER PREV, V27, P205, DOI [10.1097/cej.0000000000000428, 10.1097/CEJ.0000000000000428]
   Bai L, 2018, CLIN EPIDEMIOL, V10, P277, DOI 10.2147/CLEP.S153951
   Bao PP, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2313-2
   Bosetti C, 2008, HEPATOLOGY, V48, P137, DOI 10.1002/hep.22312
   Bray F, 2015, INT J CANCER, V137, P2060, DOI 10.1002/ijc.29670
   Chen JG, 2013, CANCER PREV RES, V6, P1038, DOI 10.1158/1940-6207.CAPR-13-0168
   Chen WQ, 2016, CA-CANCER J CLIN, V66, P115, DOI 10.3322/caac.21338
   Chu YJ, 2018, EUR J CANCER, V94, P37, DOI 10.1016/j.ejca.2018.02.010
   Cui YQ, 2018, J INT MED RES, V46, P5257, DOI 10.1177/0300060518807292
   de Martel C, 2015, HEPATOLOGY, V62, P1190, DOI 10.1002/hep.27969
   Doll R, 1966, CANC INCIDENCE 5 CON, VI
   El-Serag HB, 2012, GASTROENTEROLOGY, V142, P1264, DOI 10.1053/j.gastro.2011.12.061
   Fan JH, 2013, ASIAN PAC J CANCER P, V14, P7251, DOI 10.7314/APJCP.2013.14.12.7251
   Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.21492, 10.3322/caac.20107]
   Kalra M, 2008, WORLD J GASTROENTERO, V14, P5945, DOI 10.3748/wjg.14.5945
   Kew MC, 2014, J HEPATOCELL CARCINO, V1, P115, DOI 10.2147/JHC.S44381
   Kim HJ, 2000, STAT MED, V19, P335, DOI 10.1002/(SICI)1097-0258(20000215)19:3<335::AID-SIM336>3.3.CO;2-Q
   Kohi MP, 2016, J VASC INTERV RADIOL, V27, P1338, DOI 10.1016/j.jvir.2016.06.035
   Luo RH, 2005, WORLD J GASTROENTERO, V11, P4431
   Ma X, 2017, INT J CANCER, V140, P1050, DOI 10.1002/ijc.30522
   Njei B, 2015, HEPATOLOGY, V61, P191, DOI 10.1002/hep.27388
   Pan R, 2017, INT J CANCER, V141, P1315, DOI 10.1002/ijc.30825
   Petrick JL, 2016, INT J CANCER, V139, P1534, DOI 10.1002/ijc.30211
   Qu CF, 2014, PLOS MED, V11, DOI 10.1371/journal.pmed.1001774
   Rosenberg PS, 2014, CANCER EPIDEM BIOMAR, V23, P2296, DOI 10.1158/1055-9965.EPI-14-0300
   Sander Leif E, 2007, Hepatology, V46, P1304, DOI 10.1002/hep.21982
   Segi M., 1960, CANC MORTALITY SELEC
   Sia D, 2017, GASTROENTEROLOGY, V152, P745, DOI 10.1053/j.gastro.2016.11.048
   Simon TG, 2018, HEPATOLOGY, V67, P1797, DOI 10.1002/hep.29660
   Su CH, 2013, ASIAN PAC J CANCER P, V14, P4953, DOI 10.7314/APJCP.2013.14.9.4953
   Sun YY, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2017-020490
   Torre LA, 2016, CANCER EPIDEM BIOMAR, V25, P16, DOI 10.1158/1055-9965.EPI-15-0578
   Venook AP, 2010, ONCOLOGIST, V15, P5, DOI 10.1634/theoncologist.2010-S4-05
   Yang DY, 2014, CANCER-AM CANCER SOC, V120, P3707, DOI 10.1002/cncr.28912
   Yang Y, 2008, SOCIOL METHOD RES, V36, P297, DOI 10.1177/0049124106292360
   Zhang W, 2013, CANCER SCI, V104, P1353, DOI 10.1111/cas.12231
   Zhang W, 2012, J NATL CANCER I, V104, P1173, DOI 10.1093/jnci/djs277
   Zheng B, 2017, SCI CHINA LIFE SCI, V60, P575, DOI 10.1007/s11427-016-9043-9
   Zhou Y, 2016, NUTRIENTS, V8, DOI 10.3390/nu8080515
NR 40
TC 4
Z9 5
U1 0
U2 6
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1751-2972
EI 1751-2980
J9 J DIGEST DIS
JI J. Dig. Dis.
PD 2020 APR
PY 2020
VL 21
IS 4
BP 230
EP 236
DI 10.1111/1751-2980.12855
EA MAR 2020
PG 7
WC Gastroenterology & Hepatology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Gastroenterology & Hepatology
GA LL4ZQ
UT WOS:000522533400001
PM 32124559
DA 2024-02-19
ER

PT J
AU Liu, Q
   Liu, C
   Hu, FF
   Deng, X
   Zhang, YM
AF Liu, Qi
   Liu, Chang
   Hu, Feifei
   Deng, Xuan
   Zhang, Yumei
TI Non-alcoholic Fatty Liver Disease and Longitudinal Cognitive Changes in
   Middle-Aged and Elderly Adults
SO FRONTIERS IN MEDICINE
LA English
DT Article
DE longitudinal study; non-alcoholic fatty liver disease; cognitive
   impairment; middle-aged and older populations; risk factors
ID MENTAL-STATE-EXAMINATION; INSULIN-RESISTANCE; IMPAIRMENT; PREVALENCE;
   DEMENTIA; CHINESE; OBESITY; HEALTH; COHORT
AB Background and PurposeNon-alcoholic fatty liver disease (NAFLD) and cognitive impairment are common aging-related disorders. This study aims to explore the changes of cognitive function in middle-aged and elderly population with NAFLD from a Jidong impairment cohort. MethodsA total of 1,651 middle-aged and elderly participants (>40 years) without cognitive impairment were recruited into the current study in 2015 and were followed up until to 2019. Abdominal ultrasonography was used for diagnosis of NAFLD. Global cognitive function was assessed with the Mini-Mental State Examination (MMSE). Cognitive impairment was defined as a score <18 for illiterates, a score <21 for primary school graduates, and a score ResultsOut of 1,651 participants, 795 (48.2%) of them had NAFLD in 2015. Cognitive impairment occurred in 241 (14.6%) participants in 2019. Patients with NAFLD had higher 4-year incidence of cognitive impairment than non-NAFLD patients did (17.7 vs. 11.7%, p < 0.001). Multivariable linear regression analysis showed significant association of baseline NAFLD with lower MMSE score in 2019 (beta = -0.36, p < 0.05). Multivariable logistic analysis found that the adjusted odds ratio (OR) with 95% confidence interval (CI) of baseline NAFLD was 1.45 (1.00-2.11) for cognitive impairment in 2019 (p = 0.05). We also identified effects of baseline NAFLD on subsequent cognitive impairment as modified by age (interaction p < 0.01) and carotid stenosis (interaction p = 0.05) but not by gender. ConclusionsNAFLD is associated with cognitive decline, especially in middle-aged and with carotid stenosis population.
C1 [Liu, Qi; Liu, Chang] Capital Med Univ, Beijing Tiantan Hosp, Dept Neurol, Beijing, Peoples R China.
   [Hu, Feifei; Deng, Xuan] Shanghai Jiao Tong Univ, Sch Med, Shanghai Gen Hosp, Clin Res Inst, Shanghai, Peoples R China.
   [Zhang, Yumei] Capital Med Univ, Beijing Tiantan Hosp, Dept Rehabil, Beijing, Peoples R China.
   [Zhang, Yumei] Capital Med Univ, Beijing Tiantan Hosp, China Natl Clin Res Ctr Neurol Dis, Beijing, Peoples R China.
C3 Capital Medical University; Shanghai Jiao Tong University; Capital
   Medical University; Capital Medical University
RP Zhang, YM (corresponding author), Capital Med Univ, Beijing Tiantan Hosp, Dept Rehabil, Beijing, Peoples R China.; Zhang, YM (corresponding author), Capital Med Univ, Beijing Tiantan Hosp, China Natl Clin Res Ctr Neurol Dis, Beijing, Peoples R China.
EM zhangyumei95@aliyun.com
OI Liu, Qi/0000-0003-0110-7750
CR Bassendine MF, 2020, J ALZHEIMERS DIS, V75, P1, DOI 10.3233/JAD-190848
   Chung HS, 2020, ADV CLIN CHEM, V94, P261, DOI 10.1016/bs.acc.2019.07.012
   Colognesi M, 2020, BIOMEDICINES, V8, DOI 10.3390/biomedicines8070229
   De Felice FG, 2014, ALZHEIMERS DEMENT, V10, pS26, DOI 10.1016/j.jalz.2013.12.004
   de la Monte SM, 2009, CURR OPIN INVEST DR, V10, P1049
   Elliott C, 2013, DIGEST DIS SCI, V58, P2383, DOI 10.1007/s10620-013-2657-2
   Farrell GC, 2007, J GASTROEN HEPATOL, V22, P775, DOI 10.1111/j.1440-1746.2007.05002.x
   Ferretti MT, 2020, EUR J NEUROL, V27, P928, DOI 10.1111/ene.14174
   Filipovic B, 2018, CAN J GASTROENTEROL, V2018, DOI 10.1155/2018/9638797
   Fung J, 2015, LIVER INT, V35, P542, DOI 10.1111/liv.12619
   Gerber Y, 2021, BMC GASTROENTEROL, V21, DOI 10.1186/s12876-021-01681-0
   Ghareeb DA, 2011, METAB BRAIN DIS, V26, P253, DOI 10.1007/s11011-011-9261-y
   Gu DF, 2005, LANCET, V365, P1398, DOI 10.1016/S0140-6736(05)66375-1
   Harada PH, 2019, ATHEROSCLEROSIS, V284, P59, DOI 10.1016/j.atherosclerosis.2019.02.005
   He ZH, 2018, NAT MED, V24, P29, DOI 10.1038/nm.4443
   Hernaez R, 2011, HEPATOLOGY, V54, P1082, DOI 10.1002/hep.24452
   Jang H, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-38357-x
   Jia LF, 2020, LANCET NEUROL, V19, P81, DOI 10.1016/S1474-4422(19)30290-X
   KATZMAN R, 1988, J CLIN EPIDEMIOL, V41, P971, DOI 10.1016/0895-4356(88)90034-0
   Kim DG, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-015-0467-5
   Kwak MS, 2018, LIVER INT, V38, P1292, DOI 10.1111/liv.13663
   Labenz C, 2021, DIGEST DIS SCI, V66, P3179, DOI 10.1007/s10620-020-06644-1
   Li ZZ, 2014, J GASTROEN HEPATOL, V29, P42, DOI 10.1111/jgh.12428
   Livingston G, 2020, LANCET, V396, P413, DOI 10.1016/S0140-6736(20)30367-6
   Lombardi R, 2019, DIGEST LIVER DIS, V51, P1214, DOI 10.1016/j.dld.2019.05.015
   Long MT, 2015, ARTERIOSCL THROM VAS, V35, P1284, DOI 10.1161/ATVBAHA.114.305200
   Maher JJ, 2020, GASTROENTEROLOGY, V158, P1849, DOI 10.1053/j.gastro.2020.04.013
   Mukhopadhyay S, 2014, ENDOCR PRACT, V20, P1345, DOI 10.4158/EP14421.RA
   Pan YS, 2020, BMJ-BRIT MED J, V371, DOI 10.1136/bmj.m3692
   Seo SW, 2016, NEUROLOGY, V86, P1136, DOI 10.1212/WNL.0000000000002498
   Song DY, 2020, NEURAL REGEN RES, V15, P1111, DOI 10.4103/1673-5374.266070
   Touboul PJ, 2007, CEREBROVASC DIS, V23, P75, DOI 10.1159/000097034
   Trzepacz PT, 2015, BMC GERIATR, V15, DOI 10.1186/s12877-015-0103-3
   Tuttolomondo A, 2018, CARDIOVASC DIABETOL, V17, DOI 10.1186/s12933-018-0670-7
   VanWagner LB, 2017, OBESITY, V25, P642, DOI 10.1002/oby.21767
   Weinstein AA, 2018, PSYCHOSOMATICS, V59, P567, DOI 10.1016/j.psym.2018.06.001
   Weinstein G, 2019, LIVER INT, V39, P1713, DOI 10.1111/liv.14161
   Weinstein G, 2018, JAMA NEUROL, V75, P97, DOI 10.1001/jamaneurol.2017.3229
   Yuan J, 2016, ALZHEIMERS DEMENT, V12, P262, DOI 10.1016/j.jalz.2015.02.011
   Zsuga J, 2016, MED HYPOTHESES, V90, P23, DOI 10.1016/j.mehy.2016.02.020
NR 40
TC 8
Z9 8
U1 1
U2 2
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 2296-858X
J9 FRONT MED-LAUSANNE
JI Front. Med.
PD JAN 17
PY 2022
VL 8
AR 738835
DI 10.3389/fmed.2021.738835
PG 7
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA YQ4KO
UT WOS:000749279100001
PM 35111769
OA gold, Green Published
DA 2024-02-19
ER

PT J
AU CHEN, LH
   HU, N
   SNYDER, DL
AF CHEN, LH
   HU, N
   SNYDER, DL
TI EFFECTS OF AGE AND DIETARY RESTRICTION ON LIVER GLUTATHIONE TRANSFERASE
   ACTIVITIES IN LOBUND-WISTAR RATS
SO ARCHIVES OF GERONTOLOGY AND GERIATRICS
LA English
DT Article
DE GLUTATHIONE TRANSFERASES; DIETARY RESTRICTION; AGE
ID PROTEIN-FREE DIET; S-TRANSFERASE; FOOD RESTRICTION; ENZYME-ACTIVITIES;
   GERM-FREE; MICE; SUBUNITS; YOUNG; ANTIOXIDANTS; METABOLISM
AB Glutathione-S-transferases (GST) are a group of enzymes which detoxify electrophilic xenobiotics (including drugs, carcinogens and their metabolites), and thus may be involved in the age-related pathologic process. Effects of a 30% dietary restriction on liver GST activities toward seven substrates were studied in male Lobund-Wistar (L-W) rats at 6, 12, Is, 24 and 30 months of age. The enzyme activities in the ad libitum (AL) group toward 1-chloro-2,4-dinitrobenzene (CDNB), bromosulfophthalein (BSP), 4-nitropyridine-N-oxide (NPNO), p-nitrobenzyl chloride (NBC), trans-4-phenyl-3-buten-2-one (PBO) and styrene oxide (STOX) did not change with age, while those toward 1,2-dichloro-4-nitrobenzene (DCNB) decreased after middle age. The enzyme activities in the dietary restricted (DR) group toward CDNB and STOX did not change with age, while those toward DCNB, BSP, NPNO, NBC and PBO decreased after middle age. The DR group had significantly higher GST activities than the AL group, especially at 18 months, when BSP, NPNO, NBC and PBO were used as the substrates. Dietary restriction did not affect GST activities toward all seven substrates at old age. These results are substrate-specific, indicating that isozyme-specific changes in GST activities occur with dietary restriction and aging. The results suggest that dietary restriction enhances liver detoxification capability associated with GSH conjugation in middle age, which may contribute to the delaying of the age-related pathologic process until a later point in life in this animal model.
C1 UNIV NOTRE DAME,LOBUND LAB,NOTRE DAME,IN 46556.
C3 University of Notre Dame
RP CHEN, LH (corresponding author), UNIV KENTUCKY,DEPT NUTR & FOOD SCI,219 FUNKHOUSER BLDG,LEXINGTON,KY 40506, USA.
CR BIRNBAUM LS, 1979, CHEM-BIOL INTERACT, V26, P245, DOI 10.1016/0009-2797(79)90028-0
   BOYLAND E, 1969, ADV ENZYMOL RAMB, V32, P173
   CARRILLO MC, 1992, MECH AGEING DEV, V65, P301, DOI 10.1016/0047-6374(92)90043-D
   CARRILLO MC, 1990, MECH AGEING DEV, V56, P237, DOI 10.1016/0047-6374(90)90085-T
   CARRILLO MC, 1989, MECH AGEING DEV, V47, P1, DOI 10.1016/0047-6374(89)90002-X
   CARRILLO MC, 1991, BIOCHIM BIOPHYS ACTA, V1077, P325, DOI 10.1016/0167-4838(91)90547-D
   CHEN LH, 1993, ARCH GERONTOL GERIAT, V16, P69, DOI 10.1016/0167-4943(93)90028-G
   CHEN LH, 1992, ARCH GERONTOL GERIAT, V14, P17, DOI 10.1016/0167-4943(92)90003-M
   CHENGELIS CP, 1988, XENOBIOTICA, V18, P1225, DOI 10.3109/00498258809042246
   COECKE S, 1990, MECH AGEING DEV, V55, P189, DOI 10.1016/0047-6374(90)90026-C
   COLES B, 1990, CRIT REV BIOCHEM MOL, V25, P47, DOI 10.3109/10409239009090605
   FUJITA S, 1985, BIOCHEM PHARMACOL, V21, P3891
   HABIG WH, 1974, J BIOL CHEM, V249, P7130
   HAYAKAWA T, 1975, ARCH BIOCHEM BIOPHYS, V170, P438, DOI 10.1016/0003-9861(75)90139-3
   JACOBY WB, 1984, BIOCHEM PHARMACOL, V33, P2539
   JOHNSON BC, 1986, P NATL ACAD SCI USA, V83, P5659, DOI 10.1073/pnas.83.15.5659
   JOHNSON MK, 1966, BIOCHEM J, V98, P44, DOI 10.1042/bj0980044
   KAHL R, 1982, TRENDS PHARMACOL SCI, V3, P72, DOI 10.1016/0165-6147(82)91015-X
   KAPITULNIK J, 1978, CANCER RES, V38, P354
   KETTERER B, 1991, OXIDATIVE STRESS OXI, P171
   KOIZUMI A, 1987, J NUTR, V117, P361, DOI 10.1093/jn/117.2.361
   LAGANIERE S, 1989, MECH AGEING DEV, V48, P221, DOI 10.1016/0047-6374(89)90084-5
   LEAKEY JEA, 1989, MECH AGEING DEV, V48, P157, DOI 10.1016/0047-6374(89)90047-X
   LOWRY OH, 1951, J BIOL CHEM, V193, P265
   MANNERVIK B, 1988, CRC CR REV BIOCH MOL, V23, P283, DOI 10.3109/10409238809088226
   Mannervik B, 1985, Adv Enzymol Relat Areas Mol Biol, V57, P357
   MASORO EJ, 1985, J NUTR, V115, P842, DOI 10.1093/jn/115.7.842
   MASORO EJ, 1988, J GERONTOL, V43, pB59, DOI 10.1093/geronj/43.3.B59
   MEYER DJ, 1985, FEBS LETT, V184, P139, DOI 10.1016/0014-5793(85)80670-0
   MEYER DJ, 1991, BIOCHEM J, V274, P409, DOI 10.1042/bj2740409
   POLLARD M, 1971, GERONTOLOGY, V17, P333, DOI 10.1159/000211839
   ROGIERS V, 1991, BIOCHEM PHARMACOL, V42, P491, DOI 10.1016/0006-2952(91)90310-2
   SNYDER DL, 1990, J GERONTOL, V45, pB52, DOI 10.1093/geronj/45.2.B52
   SNYDER DL, 1987, LAB ANIM SCI, V37, P320
   SNYDER DL, 1989, DIETARY RESTRICTION, P135
   SPEARMAN ME, 1984, BIOCHEM PHARMACOL, V33, P1309, DOI 10.1016/0006-2952(84)90185-0
   STOHS SJ, 1986, LIVER AGING 1986 LIV, P59
   TUCKER MJ, 1979, INT J CANCER, V23, P803, DOI 10.1002/ijc.2910230611
   VAN DER RIJST M. P. J., 1955, Voeding, V16, P708
   YU BP, 1991, AGE NUTRITION, V2, P84
NR 40
TC 13
Z9 13
U1 0
U2 1
PU ELSEVIER SCI IRELAND LTD
PI CLARE
PA CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE,
   IRELAND
SN 0167-4943
J9 ARCH GERONTOL GERIAT
JI Arch. Gerontol. Geriatr.
PD MAY-JUN
PY 1994
VL 18
IS 3
BP 191
EP 205
DI 10.1016/0167-4943(94)90013-2
PG 15
WC Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Geriatrics & Gerontology
GA NR419
UT WOS:A1994NR41900004
PM 15374299
DA 2024-02-19
ER

PT J
AU McNamara, RK
   Liu, Y
   Jandacek, R
   Rider, T
   Tso, P
AF McNamara, Robert K.
   Liu, Yanhong
   Jandacek, Ronald
   Rider, Therese
   Tso, Patrick
TI The aging human orbitofrontal cortex: Decreasing polyunsaturated fatty
   acid composition and associated increases in lipogenic gene expression
   and stearoyl-CoA desaturase activity
SO PROSTAGLANDINS LEUKOTRIENES AND ESSENTIAL FATTY ACIDS
LA English
DT Article
ID MAJOR DEPRESSIVE DISORDER; RAT-LIVER MICROSOMES; AGE-RELATED-CHANGES;
   GRAY-MATTER; DOCOSAHEXAENOIC ACID; DELTA-5 DESATURASE; BIPOLAR DISORDER;
   CEREBRAL-CORTEX; FRONTAL-CORTEX; DIETARY N-3
AB Orbitofrontal cortex (OFC, Brodmann area 10) gray matter volume reductions and selective reductions in docosahexaenoic acid (DHA, 22:6n-3) are observed in adult patients with major depressive disorder (MDD). OFC gray matter volume also decreases with advancing age in healthy subjects. To examine if OFC gray matter DHA composition decreases during normal aging, we determined age-related changes in OFC gray matter fatty acid composition by gas chromatography in subjects aged 29-80 years (n = 30). We additionally determined elongase (HELO1), delta-5 desaturase (FASD1), delta-6 desaturase (FASD2), peroxisomal (PEX19), and stearoyl-CoA desaturase (SCD) mRNA expression in the same tissues. Increasing age was associated with a progressive decline in polyunsaturated fatty acid (PUFA) composition, including DHA and arachidonic acid (AA, 20:4n-6), and transient, apparently compensatory, elevations in elongase and desaturase gene expression. The age-related reduction in PUFA composition was inversely correlated with SCD expression and activity resulting in elevations in monounsaturated fatty acid composition. These dynamic age-related changes in OFC gray matter fatty acid composition and biosynthetic gene expression may contribute to the progressive decline in OFC gray matter volume found with advancing age. The implications of age-related reductions in OFC PUFA composition for affective dysregulation in the elderly are discussed. (c) 2008 Elsevier Ltd. All rights reserved.
C1 [McNamara, Robert K.; Liu, Yanhong] Univ Cincinnati, Coll Med, Dept Psychiat, Cincinnati, OH 45267 USA.
   [Jandacek, Ronald; Rider, Therese; Tso, Patrick] Univ Cincinnati, Dept Pathol, Cincinnati, OH 45237 USA.
C3 University System of Ohio; University of Cincinnati; University System
   of Ohio; University of Cincinnati
RP McNamara, RK (corresponding author), Univ Cincinnati, Coll Med, Dept Psychiat, 231 Albert Sabin Way, Cincinnati, OH 45267 USA.
EM robert.mcnamara@psychiatry.uc.edu
RI McNamara, Robert K/J-4309-2014
OI McNamara, Robert/0000-0002-9703-8114
FU NIMH NIH HHS [R21 MH073704, MH 073704, MH 074858, R21 MH073704-01A1, R21
   MH074858, R21 MH074858-01A1] Funding Source: Medline
CR Ahmad A, 2002, PEDIATR NEUROL, V26, P210, DOI 10.1016/S0887-8994(01)00383-6
   Ballmaier M, 2004, AM J PSYCHIAT, V161, P99, DOI 10.1176/appi.ajp.161.1.99
   BORDONI A, 1988, BIOCHEM INT, V17, P1001
   Bourre JM, 1997, BIOCHEM MOL BIOL INT, V41, P461
   Bremner JD, 2002, BIOL PSYCHIAT, V51, P273, DOI 10.1016/S0006-3223(01)01336-1
   Cho HP, 1999, J BIOL CHEM, V274, P471, DOI 10.1074/jbc.274.1.471
   Cho HP, 1999, J BIOL CHEM, V274, P37335, DOI 10.1074/jbc.274.52.37335
   CHRISTIANSEN EN, 1991, BIOCHIM BIOPHYS ACTA, V1082, P57, DOI 10.1016/0005-2760(91)90299-W
   Conklin SM, 2007, NEUROSCI LETT, V421, P209, DOI 10.1016/j.neulet.2007.04.086
   Cotter D, 2005, BIPOLAR DISORD, V7, P358, DOI 10.1111/j.1399-5618.2005.00230.x
   DEWILLE JW, 1992, DEV NEUROSCI-BASEL, V14, P61, DOI 10.1159/000111648
   Favrelière S, 2000, NEUROBIOL AGING, V21, P653, DOI 10.1016/S0197-4580(00)00170-6
   Garbay B, 1998, J NEUROCHEM, V71, P1719
   Götte K, 1998, MOL CELL BIOL, V18, P616
   Igarashi M, 2007, J LIPID RES, V48, P2463, DOI 10.1194/jlr.M700315-JLR200
   Kringelbach ML, 2004, PROG NEUROBIOL, V72, P341, DOI 10.1016/j.pneurobio.2004.03.006
   Kumar VB, 1999, LIFE SCI, V65, P1657, DOI 10.1016/S0024-3205(99)00414-2
   Lacerda ALT, 2004, BIOL PSYCHIAT, V55, P353, DOI 10.1016/j.biopsych.2003.08.021
   Lai TJ, 2000, BIOL PSYCHIAT, V48, P971, DOI 10.1016/S0006-3223(00)01042-8
   Lamar M, 2004, NEUROBIOL AGING, V25, P553, DOI 10.1016/j.neurobiolaging.2003.06.005
   Lamar M, 2004, NEUROIMAGE, V21, P1368, DOI 10.1016/j.neuroimage.2003.11.018
   Leonard AE, 2000, BIOCHEM J, V350, P765, DOI 10.1042/0264-6021:3500765
   LOPEZ GH, 1995, COMP BIOCHEM PHYS B, V112, P331, DOI 10.1016/0305-0491(95)00079-8
   MANIONGUI C, 1993, LIPIDS, V28, P291, DOI 10.1007/BF02536313
   MARTINEZ M, 1992, BRAIN RES, V583, P171, DOI 10.1016/S0006-8993(10)80021-6
   Matsuzono Y, 1999, P NATL ACAD SCI USA, V96, P2116, DOI 10.1073/pnas.96.5.2116
   McNamara RK, 2006, NEUROSCIENCE, V143, P141, DOI 10.1016/j.neuroscience.2006.07.015
   MCNAMARA RK, 2008, PSYCHIAT RES
   McNamara RK, 2007, BIOL PSYCHIAT, V62, P17, DOI 10.1016/j.biopsych.2006.08.026
   McNamara RK, 2006, PROSTAG LEUKOTR ESS, V75, P329, DOI 10.1016/j.plefa.2006.07.010
   Najt P, 2007, NEUROSCI LETT, V413, P183, DOI 10.1016/j.neulet.2006.10.016
   Ntambi JM, 1999, J LIPID RES, V40, P1549
   Ntambi JM, 2004, PROG LIPID RES, V43, P91, DOI 10.1016/S0163-7827(03)00039-0
   Pakkenberg B, 1997, J COMP NEUROL, V384, P312, DOI 10.1002/(SICI)1096-9861(19970728)384:2<312::AID-CNE10>3.0.CO;2-K
   Raz N, 1997, CEREB CORTEX, V7, P268, DOI 10.1093/cercor/7.3.268
   Raz N, 2004, NEUROBIOL AGING, V25, P377, DOI 10.1016/S0197-4580(03)00118-0
   Resnick SM, 2003, J NEUROSCI, V23, P3295
   Resnick SM, 2007, ANN NY ACAD SCI, V1121, P562, DOI 10.1196/annals.1401.027
   Rudisch B, 2003, BIOL PSYCHIAT, V54, P227, DOI 10.1016/S0006-3223(03)00587-0
   Sacksteder KA, 2000, J CELL BIOL, V148, P931, DOI 10.1083/jcb.148.5.931
   Sprecher H, 1999, LIPIDS, V34, pS153, DOI 10.1007/BF02562271
   Tanaka J, 2005, BIOL PHARM BULL, V28, P615, DOI 10.1248/bpb.28.615
   TERRY RD, 1987, ANN NEUROL, V21, P530, DOI 10.1002/ana.410210603
   Tisserand DJ, 2004, CEREB CORTEX, V14, P966, DOI 10.1093/cercor/bhh057
   Ulmann L, 2001, PROSTAG LEUKOTR ESS, V64, P189, DOI 10.1054/plef.2001.0260
   VanItallie TB, 2005, METABOLISM, V54, P39, DOI 10.1016/j.metabol.2005.01.012
   Zhang L, 1999, BIOCHEM J, V340, P255, DOI 10.1042/0264-6021:3400255
NR 47
TC 95
Z9 101
U1 0
U2 5
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0952-3278
J9 PROSTAG LEUKOTR ESS
JI Prostaglandins Leukot. Essent. Fatty Acids
PD APR-MAY
PY 2008
VL 78
IS 4-5
BP 293
EP 304
DI 10.1016/j.plefa.2008.04.001
PG 12
WC Biochemistry & Molecular Biology; Cell Biology; Endocrinology &
   Metabolism
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology; Endocrinology &
   Metabolism
GA 325NU
UT WOS:000257596400008
PM 18499418
OA Green Accepted
DA 2024-02-19
ER

PT J
AU Yamaguchi, M
   Nakagawa, T
AF Yamaguchi, Masayoshi
   Nakagawa, Taeko
TI Change in lipid components in the adipose and liver tissues of
   regucalcin transgenic rats with increasing age: Suppression of leptin
   and adiponectin gene expression
SO INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
LA English
DT Article
DE regucalcin; hyperlipidemia; lipid metabolism; leptin; adiponectin
ID CALCIUM-BINDING PROTEIN; HEPATOMA H4-II-E CELLS; DEOXYRIBONUCLEIC-ACID
   SYNTHESIS; NECROSIS-FACTOR-ALPHA; ENDOGENOUS REGUCALCIN; MESSENGER-RNA;
   NUCLEAR-REGULATION; SOLUBLE FRACTION; OVEREXPRESSION; INVOLVEMENT
AB Regucalcin plays a multifunctional role as a regulatory protein in intracellular signaling pathway in many cell types. Regucalcin transgenic (TG) rats have been shown to experience hyperlipidemia with increasing age. This study was undertaken to determine whether lipid components in the adipose and liver tissues are changed in regucalcin TG rats in vivo. Female regucalcin TG rats were used at 7 or 50 weeks of age. Serum triglyceride or HDL-cholesterol concentrations were significantly increased in 7-week-old regucalcin TG rats as compared with those in 7-week-old normal rats. Serum triglyceride, total cholesterol, HDL-cholesterol, or free fatty acid concentrations were significantly increased in 50-week-old regucalcin TG rats. Meanwhile, triglyceride content in the adipose tissues was significantly increased in 50-week-old regucalcin TG rats, while the free fatty acid content was not significantly changed. Triglyceride, total cholesterol, or free fatty acid content in the liver tissues was significantly decreased in 50-week-old regucalcin TG rats. Liver glycogen content was significantly decreased in 7- or 50-week-old regucalcin TG rats. In addition, regucalcin mRNA and its protein levels were seen in the adipose tissues of normal rats. Those levels were not significantly changed in regucalcin TG rats at 50 weeks of age. Leptin mRNA expression in the adipose or liver tissues was significantly decreased in 50-week-old regucalcin TG rats. Adiponectin mRNA levels were not significantly changed in the adipose tissues of 50-week-old regucalcin TG rats, while the levels were significantly decreased in the liver tissues. This study demonstrates that the disorder of lipid metabolism in the adipose and liver tissues is induced in regucalcin TG rats with aging, and that the gene expression of leptin or adiponectin is suppressed in TG rats.
C1 Univ Shizuoka, Grad Sch Nutr Sci, Lab Endocrinol & Mol Metab, Suruga Ku, Shizuoka 4228526, Japan.
C3 University of Shizuoka
RP Yamaguchi, M (corresponding author), Univ Shizuoka, Grad Sch Nutr Sci, Lab Endocrinol & Mol Metab, Suruga Ku, 52-1 Yada, Shizuoka 4228526, Japan.
EM yamaguch@u-shizuoka-ken.acjp
CR CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999
   Dyck DJ, 2006, ACTA PHYSIOL, V186, P5, DOI 10.1111/j.1748-1716.2005.01502.x
   Good CA, 1933, J BIOL CHEM, V100, P485
   Guerre-Millo M, 2002, J ENDOCRINOL INVEST, V25, P855, DOI 10.1007/BF03344048
   Havel PJ, 2004, DIABETES, V53, pS143, DOI 10.2337/diabetes.53.2007.S143
   Izumi T, 2004, J CELL BIOCHEM, V92, P296, DOI 10.1002/jcb.20056
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   LOWRY OH, 1951, J BIOL CHEM, V193, P265
   Misawa H, 2002, J CELL BIOCHEM, V84, P795, DOI 10.1002/jcb.10082
   Misawa H, 2002, J CELL BIOCHEM, V84, P143, DOI 10.1002/jcb.1274
   Misawa H, 2000, INT J MOL MED, V6, P191
   MURAKAMI T, 1995, BIOCHEM BIOPH RES CO, V209, P944, DOI 10.1006/bbrc.1995.1589
   Murata T, 1999, J BIOL CHEM, V274, P1277, DOI 10.1074/jbc.274.3.1277
   Murata T, 1998, BIOCHEM J, V329, P157, DOI 10.1042/bj3290157
   Nakagawa T, 2005, J CELL BIOCHEM, V96, P1274, DOI 10.1002/jcb.20617
   Nakashima C, 2006, J CELL BIOCHEM, V99, P1582, DOI 10.1002/jcb.21005
   Puerta M, 2002, HORM METAB RES, V34, P629, DOI 10.1055/s-2002-38252
   Ronti T, 2006, CLIN ENDOCRINOL, V64, P355, DOI 10.1111/j.1365-2265.2006.02474.x
   Sawada N, 2006, J CELL BIOCHEM, V99, P589, DOI 10.1002/jcb.20907
   SHIMOKAWA N, 1993, FEBS LETT, V327, P251, DOI 10.1016/0014-5793(93)80998-A
   SHIMOKAWA N, 1995, MOL CELL BIOCHEM, V151, P157, DOI 10.1007/BF01322338
   SHIMOKAWA N, 1992, FEBS LETT, V305, P151, DOI 10.1016/0014-5793(92)80884-J
   SHIMOKAWA N, 1993, FEBS LETT, V316, P79, DOI 10.1016/0014-5793(93)81740-Q
   Solomon SS, 2005, J LAB CLIN MED, V145, P275, DOI 10.1016/j.lab.2005.02.013
   Thiselton DL, 2002, GENOMICS, V79, P560, DOI 10.1006/geno.2002.6733
   Tsurusaki Y, 2003, J CELL BIOCHEM, V90, P619, DOI 10.1002/jcb.10652
   Tsurusaki Y, 2002, J CELL BIOCHEM, V87, P450, DOI 10.1002/jcb.10325
   Tsurusaki Y, 2002, J CELL BIOCHEM, V85, P516, DOI 10.1002/jcb.10153
   WESSENDORF JHM, 1993, J BIOL CHEM, V268, P22100
   Yamaguchi M, 2002, INT J MOL MED, V10, P377
   Yamaguchi M, 2005, INT J MOL MED, V15, P371
   YAMAGUCHI M, 1978, CHEM PHARM BULL, V26, P1915
   Yamaguchi M, 2004, INT J MOL MED, V14, P647
   Yamaguchi M, 2002, J CELL BIOCHEM, V86, P520, DOI 10.1002/jcb.10249
   Yamaguchi M, 2000, BIOCHEM BIOPH RES CO, V276, P1, DOI 10.1006/bbrc.2000.3359
   YAMAGUCHI M, 1991, FEBS LETT, V279, P281, DOI 10.1016/0014-5793(91)80168-3
   Yamaguchi M, 1999, J CELL BIOCHEM, V74, P81, DOI 10.1002/(SICI)1097-4644(19990701)74:1<81::AID-JCB9>3.0.CO;2-3
   YAMAGUCHI M, 1981, CHEM PHARM BULL, V29, P567
   YAMAGUCHI M, 1988, CHEM PHARM BULL, V36, P286
   YAMAGUCHI M, 1987, CHEM PHARM BULL, V35, P2581
   YAMAGUCHI M, 1988, CHEM PHARM BULL, V36, P321
   YAMAGUCHI M, 1993, MOL CELL BIOCHEM, V122, P65, DOI 10.1007/BF00925738
   Yamaguchi M, 2000, LIFE SCI, V66, P1769, DOI 10.1016/S0024-3205(99)00602-5
   Yamaguchi M. A., 1992, CALCIUM INHIBITION, P19
NR 44
TC 13
Z9 16
U1 0
U2 2
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1107-3756
EI 1791-244X
J9 INT J MOL MED
JI Int. J. Mol. Med.
PD SEP
PY 2007
VL 20
IS 3
BP 323
EP 328
PG 6
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA 199MM
UT WOS:000248699900007
PM 17671736
DA 2024-02-19
ER

PT J
AU Varghese, B
   Chianese, U
   Capasso, L
   Sian, V
   Bontempo, P
   Conte, M
   Benedetti, R
   Altucci, L
   Carafa, V
   Nebbioso, A
AF Varghese, Benluvankar
   Chianese, Ugo
   Capasso, Lucia
   Sian, Veronica
   Bontempo, Paola
   Conte, Mariarosaria
   Benedetti, Rosaria
   Altucci, Lucia
   Carafa, Vincenzo
   Nebbioso, Angela
TI SIRT1 activation promotes energy homeostasis and reprograms liver cancer
   metabolism
SO JOURNAL OF TRANSLATIONAL MEDICINE
LA English
DT Article
DE Liver cancer; SIRT1; SCIC2.1; PGC1 & alpha;; Energy metabolism; Stress
   response
ID OXIDATIVE STRESS; P53; SIRTUINS; GROWTH; PGC-1-ALPHA; DEACETYLASE;
   MODULATOR; PROTECTS; KINASE
AB Background Cancer cells are characterized by uncontrolled cell proliferation and impaired bioenergetics. Sirtuins are a family of highly conserved enzymes that play a fundamental role in energy metabolism regulation. SIRT1, in particular, drives many physiological stress responses and metabolic pathways following nutrient deprivation. We previously showed that SIRT1 activation using SCIC2.1 was able to attenuate genotoxic response and senescence. Here, we report that in hepatocellular carcinoma (HCC) cells under glucose-deprived conditions, SCIC2.1 treatment induced overexpression of SIRT1, SIRT3, and SIRT6, modulating metabolic response.Methods Flow cytometry was used to analyze the cell cycle. The MTT assay and xCELLigence system were used to measure cell viability and proliferation. In vitro enzymatic assays were carried out as directed by the manufacturer, and the absorbance was measured with an automated Infinite M1000 reader. Western blotting and immunoprecipitation were used to evaluate the expression of various proteins described in this study. The relative expression of genes was studied using real-time PCR. We employed a Seahorse XF24 Analyzer to determine the metabolic state of the cells. Oil Red O staining was used to measure lipid accumulation.Results SCIC2.1 significantly promoted mitochondrial biogenesis via the AMPK-p53-PGC1a pathway and enhanced mitochondrial ATP production under glucose deprivation. SIRT1 inhibition by Ex-527 further supported our hypothesis that metabolic effects are dependent on SIRT1 activation. Interestingly, SCIC2.1 reprogrammed glucose metabolism and fatty acid oxidation for bioenergetic circuits by repressing de novo lipogenesis. In addition, SCIC2.1-mediated SIRT1 activation strongly modulated antioxidant response through SIRT3 activation, and p53-dependent stress response via indirect recruitment of SIRT6.Conclusion Our results show that SCIC2.1 is able to promote energy homeostasis, attenuating metabolic stress under glucose deprivation via activation of SIRT1. These findings shed light on the metabolic action of SIRT1 in the pathogenesis of HCC and may help determine future therapies for this and, possibly, other metabolic diseases.
C1 [Varghese, Benluvankar; Chianese, Ugo; Capasso, Lucia; Sian, Veronica; Bontempo, Paola; Conte, Mariarosaria; Benedetti, Rosaria; Altucci, Lucia; Carafa, Vincenzo; Nebbioso, Angela] Univ Campania Luigi Vanvitelli, Dept Precis Med, Vico Crecchio 7, I-80138 Naples, Italy.
   [Altucci, Lucia; Carafa, Vincenzo] Mol Biol & Genet Res Inst, Biogem, Via Camporeale, I-83031 Ariano Irpino, Italy.
   [Altucci, Lucia] IEOS CNR, Via Sergio Pansini 5, I-80131 Naples, Italy.
C3 Universita della Campania Vanvitelli; Consiglio Nazionale delle Ricerche
   (CNR); Istituto per Endocrinologia e Oncologia "Gaetano Salvatore"
   (IEOS-CNR)
RP Altucci, L; Nebbioso, A (corresponding author), Univ Campania Luigi Vanvitelli, Dept Precis Med, Vico Crecchio 7, I-80138 Naples, Italy.; Altucci, L (corresponding author), Mol Biol & Genet Res Inst, Biogem, Via Camporeale, I-83031 Ariano Irpino, Italy.; Altucci, L (corresponding author), IEOS CNR, Via Sergio Pansini 5, I-80131 Naples, Italy.
EM lucia.altucci@unicampania.it; angela.nebbioso@unicampania.it
FU We thank C. Fisher for English language editing and all the participants
   involved in this study for their kindly cooperation.
FX We thank C. Fisher for English language editing and all the participants
   involved in this study for their kindly cooperation.
CR An YF, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2308-4
   Bost F, 2019, AM J CANCER RES, V9, P198
   Campbell SL, 2018, MOL CELL, V71, P398, DOI 10.1016/j.molcel.2018.07.015
   Carrizzo A, 2022, CELL MOL LIFE SCI, V79, DOI 10.1007/s00018-022-04429-5
   Chalkiadaki A, 2012, NAT REV ENDOCRINOL, V8, P287, DOI 10.1038/nrendo.2011.225
   Chang CM, 2015, MOL CELL, V60, P930, DOI 10.1016/j.molcel.2015.10.037
   Chianese U, 2022, MOL METAB, V64, DOI 10.1016/j.molmet.2022.101561
   Chini CCS, 2016, CLIN CANCER RES, V22, P2496, DOI 10.1158/1078-0432.CCR-15-1760
   Ding RB, 2017, INT J BIOL SCI, V13, P852, DOI 10.7150/ijbs.19370
   Dominy JE, 2012, MOL CELL, V48, P900, DOI 10.1016/j.molcel.2012.09.030
   Faloppi L, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/7196280
   Feige JN, 2007, TRENDS CELL BIOL, V17, P292, DOI 10.1016/j.tcb.2007.04.001
   Garcia-Peterson LM, 2021, BBA-GEN SUBJECTS, V1865, DOI 10.1016/j.bbagen.2021.129952
   German NJ, 2015, CURR BIOL, V25, pR569, DOI 10.1016/j.cub.2015.05.012
   Ghosh HS, 2011, SCI REP-UK, V1, DOI 10.1038/srep00150
   Graham NA, 2012, MOL SYST BIOL, V8, DOI 10.1038/msb.2012.20
   Guo Z, 2022, FRONT CARDIOVASC MED, V9, DOI 10.3389/fcvm.2022.821317
   Hajializadeh Z, 2022, HEART FAIL REV, V27, P725, DOI 10.1007/s10741-021-10171-0
   Hao C, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-978
   Huang QX, 2021, J AM CHEM SOC, V143, P1416, DOI 10.1021/jacs.0c10836
   Iside C, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.01225
   Jennis M, 2016, GENE DEV, V30, P918, DOI 10.1101/gad.275891.115
   Jiao FZ, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/6782872
   Kane AE, 2018, CIRC RES, V123, P868, DOI 10.1161/CIRCRESAHA.118.312498
   Kemper JK, 2013, VITAM HORM, V91, P385, DOI 10.1016/B978-0-12-407766-9.00016-X
   Lagouge M, 2006, CELL, V127, P1109, DOI 10.1016/j.cell.2006.11.013
   Li M, 2022, TOXICOL RES-UK, V11, P673, DOI 10.1093/toxres/tfac043
   Li Y, 2014, GASTROENTEROLOGY, V146, P539, DOI 10.1053/j.gastro.2013.10.059
   Li YM, 2016, ONCOTARGET, V7, P29255, DOI 10.18632/oncotarget.8711
   Limagne E, 2017, CELL REP, V19, P746, DOI 10.1016/j.celrep.2017.04.004
   Liu XL, 2022, FRONT CELL DEV BIOL, V10, DOI 10.3389/fcell.2022.972020
   Longo VD, 2016, CELL METAB, V23, P1048, DOI 10.1016/j.cmet.2016.06.001
   Mouchiroud L, 2013, CELL, V154, P430, DOI 10.1016/j.cell.2013.06.016
   Nemeth Z, 2022, FRONT BIOSCI-LANDMRK, V27, DOI 10.31083/j.fbl2709253
   Ong ALC, 2018, AGEING RES REV, V43, P64, DOI 10.1016/j.arr.2018.02.004
   Park SJ, 2017, EBIOMEDICINE, V18, P128, DOI 10.1016/j.ebiom.2017.03.019
   Qiu XL, 2010, CELL METAB, V12, P662, DOI 10.1016/j.cmet.2010.11.015
   Sasca D, 2014, BLOOD, V124, P121, DOI 10.1182/blood-2013-11-538819
   Satriano L, 2019, NAT REV GASTRO HEPAT, V16, P748, DOI 10.1038/s41575-019-0217-8
   Schiedel M, 2018, MED RES REV, V38, P147, DOI 10.1002/med.21436
   Scisciola L, 2020, EPIGENETICS-US, V15, P664, DOI 10.1080/15592294.2019.1704349
   Sen N, 2011, MOL CELL, V44, P621, DOI 10.1016/j.molcel.2011.08.044
   Song SB, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8010011
   Tan YY, 2022, NAT COMMUN, V13, DOI 10.1038/s41467-022-32101-w
   Tang BL, 2016, MOL CELLS, V39, P87, DOI 10.14348/molcells.2016.2318
   Ubaid S, 2021, INFLAMMATION, V44, P2142, DOI 10.1007/s10753-021-01457-4
   Viollet B, 2006, J PHYSIOL-LONDON, V574, P41, DOI 10.1113/jphysiol.2006.108506
   Wang P, 2011, ANN NEUROL, V69, P360, DOI 10.1002/ana.22236
   Wang YH, 2023, FRONT PHARMACOL, V14, DOI 10.3389/fphar.2023.1111320
   WARBURG O, 1956, SCIENCE, V124, P269
   Xu DJ, 2020, J PINEAL RES, V69, DOI 10.1111/jpi.12690
   Ye X, 2017, ONCOTARGET, V8, P1845, DOI 10.18632/oncotarget.12157
   Yuan J, 2012, GENE DEV, V26, P791, DOI 10.1101/gad.188482.112
   Zhang CB, 2021, ELIFE, V10, DOI [10.7554/eLife.70672, 10.7554/eLife.70672.sa0, 10.7554/eLife.70672.sa1, 10.7554/eLife.70672.sa2]
   Zhang LJ, 2022, NEURAL PLAST, V2022, DOI 10.1155/2022/5567174
   Zhang P, 2014, P NATL ACAD SCI USA, V111, P10684, DOI 10.1073/pnas.1411026111
   Zheng J, 2012, ONCOL LETT, V4, P1151, DOI 10.3892/ol.2012.928
   Zhou YY, 2021, ACTA PHARMACOL SIN B, V11, P89, DOI 10.1016/j.apsb.2020.06.016
NR 58
TC 2
Z9 2
U1 6
U2 6
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1479-5876
J9 J TRANSL MED
JI J. Transl. Med.
PD SEP 15
PY 2023
VL 21
IS 1
AR 627
DI 10.1186/s12967-023-04440-9
PG 17
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA S1MT2
UT WOS:001068888800002
PM 37715252
OA gold, Green Published, Green Submitted
DA 2024-02-19
ER

PT J
AU Meza-Torres, C
   Hernández-Camacho, JD
   Cortés-Rodríguez, AB
   Fang, L
   Bui Thanh, T
   Rodríguez-Bies, E
   Navas, P
   López-Lluch, G
AF Meza-Torres, Catherine
   Diego Hernandez-Camacho, Juan
   Belen Cortes-Rodriguez, Ana
   Fang, Luis
   Tung Bui Thanh
   Rodriguez-Bies, Elisabet
   Navas, Placido
   Lopez-Lluch, Guillermo
TI Resveratrol Regulates the Expression of Genes Involved in CoQ Synthesis
   in Liver in Mice Fed with High Fat Diet
SO ANTIOXIDANTS
LA English
DT Article
DE resveratrol; coenzyme Q; liver; antioxidant; mitochondria; high-fat diet
ID MEMBRANE REDOX SYSTEM; COENZYME-Q; OXIDATIVE STRESS; MOUSE-LIVER;
   MITOCHONDRIAL-FUNCTION; MITOFUSIN 2; HUMAN-CELLS; VITAMIN-E;
   RESTRICTION; UBIQUINONE
AB Resveratrol (RSV) is a bioactive natural molecule that induces antioxidant activity and increases protection against oxidative damage. RSV could be used to mitigate damages associated to metabolic diseases and aging. Particularly, RSV regulates different aspects of mitochondrial metabolism. However, no information is available about the effects of RSV on Coenzyme Q (CoQ), a central component in the mitochondrial electron transport chain. Here, we report for the first time that RSV modulates COQ genes and parameters associated to metabolic syndrome in mice. Mice fed with high fat diet (HFD) presented a higher weight gain, triglycerides (TGs) and cholesterol levels while RSV reverted TGs to control level but not weight or cholesterol. HFD induced a decrease of COQs gene mRNA level, whereas RSV reversed this decrease in most of the COQs genes. However, RSV did not show effect on CoQ(9), CoQ(10) and total CoQ levels, neither in CoQ-dependent antioxidant enzymes. HFD influenced mitochondrial dynamics and mitophagy markers. RSV modulated the levels of PINK1 and PARKIN and their ratio, indicating modulation of mitophagy. In summary, we report that RSV influences some of the metabolic adaptations of HFD affecting mitochondrial physiology while also regulates COQs gene expression levels in a process that can be associated with mitochondrial dynamics and turnover.
C1 [Meza-Torres, Catherine; Diego Hernandez-Camacho, Juan; Belen Cortes-Rodriguez, Ana; Tung Bui Thanh; Rodriguez-Bies, Elisabet; Navas, Placido; Lopez-Lluch, Guillermo] Univ Pablo Olavide, Ctr Andaluz Biol Desarrollo, CSIC JA, Seville 41013, Spain.
   [Meza-Torres, Catherine; Diego Hernandez-Camacho, Juan; Belen Cortes-Rodriguez, Ana; Tung Bui Thanh; Rodriguez-Bies, Elisabet; Navas, Placido; Lopez-Lluch, Guillermo] Inst Salud Carlos III, CIBERER, Seville 41013, Spain.
   [Fang, Luis] Univ Norte, Immunol & Mol Biol Grp, Barranquilla 081007, Colombia.
   [Tung Bui Thanh] Vietnam Natl Univ, Sch Med & Pharm, Hanoi 100000, Vietnam.
   [Rodriguez-Bies, Elisabet] Univ Pablo Olavide, Dept Deporte & Informat, Seville 41013, Spain.
C3 Consejo Superior de Investigaciones Cientificas (CSIC); Universidad
   Pablo de Olavide; CSIC - Andalusian Center for Developmental Biology
   (CABD); CIBER - Centro de Investigacion Biomedica en Red; CIBERER;
   Instituto de Salud Carlos III; Universidad del Norte Colombia; Vietnam
   National University Hanoi; Universidad Pablo de Olavide
RP López-Lluch, G (corresponding author), Univ Pablo Olavide, Ctr Andaluz Biol Desarrollo, CSIC JA, Seville 41013, Spain.; López-Lluch, G (corresponding author), Inst Salud Carlos III, CIBERER, Seville 41013, Spain.
EM mezacathemeza@gmail.com; jdhercam@upo.es; abcorrod@upo.es;
   lfang@uninorte.edu.co; tungasia82@yahoo.es; ecrodbie1@upo.es;
   pnavas@upo.es; glopllu@upo.es
RI Rodríguez-Bies, Elisabet/A-4459-2016; Lopez-Lluch,
   Guillermo/N-4742-2014; NAVAS, PLACIDO/R-5943-2019
OI Rodríguez-Bies, Elisabet/0000-0002-5910-2920; Lopez-Lluch,
   Guillermo/0000-0001-9830-8502; NAVAS, PLACIDO/0000-0002-4115-7966; Fang,
   Luis/0000-0002-4986-6118
FU Spanish Ministry of Education, Culture and Sports [FPU16/03264]
FX J.D.H.C. is a predoctoral research fellow from the Spanish Ministry of
   Education, Culture and Sports [FPU16/03264].
CR Aguilaniu H, 2005, GENE DEV, V19, P2399, DOI 10.1101/gad.1366505
   Akbari M, 2020, LIPIDS HEALTH DIS, V19, DOI 10.1186/s12944-020-1198-x
   Alcázar-Fabra M, 2018, ESSAYS BIOCHEM, V62, P377, DOI 10.1042/EBC20170107
   Arroyo A, 2000, ANTIOXID REDOX SIGN, V2, P251, DOI 10.1089/ars.2000.2.2-251
   Asgary S, 2019, REV ENDOCR METAB DIS, V20, P173, DOI 10.1007/s11154-019-09494-z
   Battino M, 2003, BIOFACTORS, V18, P277, DOI 10.1002/biof.5520180231
   Baur JA, 2006, NATURE, V444, P337, DOI 10.1038/nature05354
   Beal MF, 2003, ANN NY ACAD SCI, V991, P120
   Bello RI, 2003, PROTOPLASMA, V221, P129, DOI 10.1007/s00709-002-0068-x
   Bersuker K, 2019, NATURE, V575, P688, DOI 10.1038/s41586-019-1705-2
   Botham KM, 2015, NUTRIENTS, V7, P9834, DOI 10.3390/nu7125501
   Bravo E, 2012, INT J MOL SCI, V13, P1644, DOI 10.3390/ijms13021644
   Brea-Calvo G, 2015, AM J HUM GENET, V96, P309, DOI 10.1016/j.ajhg.2014.12.023
   Tung BT, 2015, AGING CLIN EXP RES, V27, P775, DOI 10.1007/s40520-015-0366-8
   Tung BT, 2015, EXP GERONTOL, V64, P1, DOI 10.1016/j.exger.2015.02.004
   Tung BT, 2014, J GERONTOL A-BIOL, V69, P398, DOI 10.1093/gerona/glt102
   Campos-Silva Carmen, 2017, Rev Esp Geriatr Gerontol, V52, P307, DOI 10.1016/j.regg.2017.03.003
   Carrasco-Pozo C, 2012, CHEM-BIOL INTERACT, V195, P199, DOI 10.1016/j.cbi.2011.12.007
   Cascajo MV, 2016, RNA BIOL, V13, P622, DOI 10.1080/15476286.2015.1119366
   de Brito OM, 2008, NATURE, V456, P605, DOI 10.1038/nature07534
   De Cabo R, 2004, EXP GERONTOL, V39, P297, DOI 10.1016/j.exger.2003.12.003
   Doll S, 2019, NATURE, V575, P693, DOI 10.1038/s41586-019-1707-0
   Duncan AJ, 2009, AM J HUM GENET, V84, P558, DOI 10.1016/j.ajhg.2009.03.018
   Fernández-Ayala DJM, 2005, BBA-BIOMEMBRANES, V1713, P129, DOI 10.1016/j.bbamem.2005.05.010
   Geisler S, 2019, EXP CELL RES, V384, DOI 10.1016/j.yexcr.2019.111641
   Gong LL, 2020, LIFE SCI, V242, DOI 10.1016/j.lfs.2019.117212
   Hernandez-Camacho JD, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.00044
   Hoseini A, 2019, FOOD FUNCT, V10, P6042, DOI [10.1039/C9FO01075K, 10.1039/c9fo01075k]
   Hosseini H, 2020, INT J BIOCHEM CELL B, V119, DOI 10.1016/j.biocel.2019.105667
   Hsieh Tze-chen, 2006, Med Chem, V2, P275, DOI 10.2174/157340606776930709
   Hyun DH, 2006, P NATL ACAD SCI USA, V103, P19908, DOI 10.1073/pnas.0608008103
   Jurado-Ruiz E, 2017, MOL NUTR FOOD RES, V61, DOI [10.1002/mnfr.201600549, 10.1002/mnfr.201770034]
   Kagan VE, 1998, FEBS LETT, V428, P43, DOI 10.1016/S0014-5793(98)00482-7
   Kim EN, 2018, AGING-US, V10, P83, DOI 10.18632/aging.101361
   Kode A, 2008, AM J PHYSIOL-LUNG C, V294, pL478, DOI 10.1152/ajplung.00361.2007
   Kühl I, 2017, ELIFE, V6, DOI 10.7554/eLife.30952
   Lagouge M, 2006, CELL, V127, P1109, DOI 10.1016/j.cell.2006.11.013
   Li SQ, 2016, MOL MED REP, V13, P1833, DOI 10.3892/mmr.2015.4710
   Liu K, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/6713194
   Liu K, 2016, AUTOPHAGY, V12, P2000, DOI 10.1080/15548627.2016.1212786
   Lohman DC, 2014, P NATL ACAD SCI USA, V111, pE4697, DOI 10.1073/pnas.1413128111
   López-Lluch G, 2005, AGE, V27, P153, DOI 10.1007/s11357-005-2726-3
   López-Lluch G, 2018, BIOGERONTOLOGY, V19, P461, DOI 10.1007/s10522-018-9768-2
   López-Lluch G, 2010, MECH AGEING DEV, V131, P225, DOI 10.1016/j.mad.2010.02.003
   Luna-Sánchez M, 2015, EMBO MOL MED, V7, P670, DOI 10.15252/emmm.201404632
   Marinkovic M, 2021, AUTOPHAGY, V17, P1232, DOI 10.1080/15548627.2020.1755120
   Mourier A, 2015, J CELL BIOL, V208, P429, DOI 10.1083/jcb.201411100
   NAVARRO F, 1995, BIOCHEM BIOPH RES CO, V212, P138, DOI 10.1006/bbrc.1995.1947
   Parrado-Fernández C, 2011, FREE RADICAL BIO MED, V50, P1728, DOI 10.1016/j.freeradbiomed.2011.03.024
   Pearson KJ, 2008, CELL METAB, V8, P157, DOI 10.1016/j.cmet.2008.06.011
   PHILLIPS WE, 1969, CAN J PHYSIOL PHARM, V47, P227, DOI 10.1139/y69-042
   Pickrell AM, 2015, NEURON, V85, P257, DOI 10.1016/j.neuron.2014.12.007
   Raffa S, 2017, HUM MOL GENET, V26, P4541, DOI 10.1093/hmg/ddx333
   Rodríguez-Aguilera JC, 2000, REDOX REP, V5, P148, DOI 10.1179/135100000101535528
   Rodríguez-Bies E, 2016, BRIT J NUTR, V116, P979, DOI 10.1017/S0007114516002920
   Rodríguez-Bies E, 2015, J GERONTOL A-BIOL, V70, P33, DOI 10.1093/gerona/glu002
   Rojo M, 2002, J CELL SCI, V115, P1663
   Ryoo IG, 2018, TOXICOL APPL PHARM, V359, P24, DOI 10.1016/j.taap.2018.09.014
   Spinazzi M, 2019, P NATL ACAD SCI USA, V116, P277, DOI 10.1073/pnas.1811938116
   Stefely JA, 2017, TRENDS BIOCHEM SCI, V42, P824, DOI 10.1016/j.tibs.2017.06.008
   Takahashi T, 2019, ARCH BIOCHEM BIOPHYS, V672, DOI 10.1016/j.abb.2019.108067
   Valenzuela R, 2017, FOOD FUNCT, V8, P1526, DOI [10.1039/c7fo00090a, 10.1039/C7FO00090A]
   Walker Jeanne M, 2019, J Clin Transl Res, V4, P122
   Xie FL, 2012, PLANT MOL BIOL, V80, P75, DOI 10.1007/s11103-012-9885-2
   Xie LTX, 2015, J LIPID RES, V56, P909, DOI 10.1194/jlr.M057919
   Yubero D, 2018, EXPERT REV MOL DIAGN, V18, P491, DOI 10.1080/14737159.2018.1478290
   Yubero D, 2016, MITOCHONDRION, V30, P51, DOI 10.1016/j.mito.2016.06.007
   Zini R, 1999, DRUG EXP CLIN RES, V25, P87
NR 68
TC 8
Z9 8
U1 1
U2 6
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2076-3921
J9 ANTIOXIDANTS-BASEL
JI Antioxidants
PD MAY
PY 2020
VL 9
IS 5
AR 431
DI 10.3390/antiox9050431
PG 17
WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Food Science &
   Technology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Food Science
   & Technology
GA LW6WJ
UT WOS:000539284200074
PM 32429295
OA Green Published, gold
DA 2024-02-19
ER

PT J
AU Nogalska, A
   Sucajtys-Szulc, E
   Swierczynski, J
AF Nogalska, A
   Sucajtys-Szulc, E
   Swierczynski, J
TI Leptin decreases lipogenic enzyme gene expression through modification
   of SREBP-1c gene expression in white adipose tissue of aging rats
SO METABOLISM-CLINICAL AND EXPERIMENTAL
LA English
DT Article
ID ELEMENT-BINDING PROTEINS; TRANSCRIPTION FACTOR; INSULIN ACTION; OBESE
   GENE; RESPONSIVENESS; RESISTANCE; REGULATORS; LIVER; FAT
AB Aging is associated with a significant reduction of lipogenic enzyme gene expression and lipogenesis in white adipose tissue (WAT). The age-related increase of lep gene expression could be, in part, responsible for these changes. Considering that sterol regulatory element binding protein 1c (SREBP-1c) plays an important role in regulation of lipogenic enzyme gene expression, it is likely that the age-related decrease of WAT lipogenic potential could be a consequence of the inhibition of SREBP-1c gene expression by leptin. We determined whether the increase of lep gene expression would account for the age-related decrease in SREBP-1c and its direct target, main lipogenic enzymes acetyl-CoA carboxylase (ACC) and fatty acid synthase (FAS), by assaying the messenger RNA (mRNA) levels of SREBP-1c, FAS, ACC, and leptin in WAT of 2-month-old (young) and 20-month-old (old) rats. Leptin mRNA level was much higher in the old animals, whereas in contrast, old rats displayed much lower mRNA levels of SREBP-1c and lipogenic enzymes. Moreover, experimentally increased plasma leptin concentration in young rats to the value observed in old rats resulted in the decrease of SREBP-1c, FAS, and ACC mRNA levels in WAT. Thus, the increase of lep gene expression could, in part, account for the reduced SREBP-1c gene expression and, consequently, the diminished lipogenic activity in WAT of old animals. (C) 2005 Elsevier Inc. All rights reserved.
C1 Med Univ Gdansk, Dept Biochem, PL-80211 Gdansk, Poland.
   Med Univ Gdansk, Dept Nephrol Transplantol & Internal Med, PL-80211 Gdansk, Poland.
C3 Fahrenheit Universities; Medical University Gdansk; Fahrenheit
   Universities; Medical University Gdansk
RP Swierczynski, J (corresponding author), Med Univ Gdansk, Dept Biochem, PL-80211 Gdansk, Poland.
EM juls@amg.gda.pl
OI Nogalska, Anna/0000-0002-1460-533X; Sucajtys-Szulc,
   Elzbieta/0000-0002-0955-6772
CR Bai YL, 1996, J BIOL CHEM, V271, P13939, DOI 10.1074/jbc.271.24.13939
   BENNETT MK, 1995, J BIOL CHEM, V270, P25578, DOI 10.1074/jbc.270.43.25578
   CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999
   Dhillon H, 2001, REGUL PEPTIDES, V99, P69, DOI 10.1016/S0167-0115(01)00237-3
   Edwards PA, 2000, BBA-MOL CELL BIOL L, V1529, P103, DOI 10.1016/S1388-1981(00)00140-2
   Freeman WM, 1999, BIOTECHNIQUES, V26, P112, DOI 10.2144/99261rv01
   Horton JD, 2002, J CLIN INVEST, V109, P1125, DOI 10.1172/JCI200215593
   Hotta K, 1999, J GERONTOL A-BIOL, V54, pB183, DOI 10.1093/gerona/54.5.B183
   Iritani N, 2000, J NUTR, V130, P1183, DOI 10.1093/jn/130.5.1183
   Kakuma T, 2000, P NATL ACAD SCI USA, V97, P8536, DOI 10.1073/pnas.97.15.8536
   Kochan Z, 1997, METABOLISM, V46, P10, DOI 10.1016/S0026-0495(97)90160-8
   LEIGHTON B, 1989, BIOCHEM J, V261, P383, DOI 10.1042/bj2610383
   Li H, 1997, DIABETES, V46, P2035, DOI 10.2337/diabetes.46.12.2035
   Ma XH, 2002, J GERONTOL A-BIOL, V57, pB225, DOI 10.1093/gerona/57.6.B225
   Marone Maria, 2001, Biological Procedures Online, V3, P19, DOI 10.1251/bpo20
   Mooradian AD, 1999, MECH AGEING DEV, V108, P139, DOI 10.1016/S0047-6374(99)00007-X
   Nogalska A, 2004, EXP GERONTOL, V39, P147, DOI 10.1016/j.exger.2003.09.013
   Nogalska A, 2003, EXP GERONTOL, V38, P415, DOI 10.1016/S0531-5565(02)00210-3
   Nogalska A, 2001, BBA-MOL CELL BIOL L, V1533, P73, DOI 10.1016/S1388-1981(01)00142-1
   Osborne TF, 2000, J BIOL CHEM, V275, P32379, DOI 10.1074/jbc.R000017200
   Shimano H, 1999, J BIOL CHEM, V274, P35832, DOI 10.1074/jbc.274.50.35832
   Shimano H, 2001, PROG LIPID RES, V40, P439, DOI 10.1016/S0163-7827(01)00010-8
   Shimomura I, 1999, J BIOL CHEM, V274, P30028, DOI 10.1074/jbc.274.42.30028
   Shimomura I, 1997, J CLIN INVEST, V99, P838, DOI 10.1172/JCI119247
   Soukas A, 2000, GENE DEV, V14, P963
   Stoeckman AK, 2002, J BIOL CHEM, V277, P27029, DOI 10.1074/jbc.M202638200
   TONTONOZ P, 1993, MOL CELL BIOL, V13, P4753, DOI 10.1128/MCB.13.8.4753
   Toth JI, 2004, MOL CELL BIOL, V24, P8288, DOI 10.1128/MCB.24.18.8288-8300.2004
   Unger RH, 2003, ANNU REV PHYSIOL, V65, P333, DOI 10.1146/annurev.physiol.65.092101.142622
   WANG X, 1994, CELL, V75, P53
   Wang ZW, 2001, FASEB J, V15, P108, DOI 10.1096/fj.00-0310com
   YOKOYAMA C, 1993, CELL, V75, P187, DOI 10.1016/S0092-8674(05)80095-9
   ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0
NR 33
TC 51
Z9 60
U1 0
U2 2
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0026-0495
EI 1532-8600
J9 METABOLISM
JI Metab.-Clin. Exp.
PD AUG
PY 2005
VL 54
IS 8
BP 1041
EP 1047
DI 10.1016/j.metabol.2005.03.007
PG 7
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Endocrinology & Metabolism
GA 955TU
UT WOS:000231251300010
PM 16092054
DA 2024-02-19
ER

PT J
AU MHASKAR, Y
   DUNAWAY, GA
AF MHASKAR, Y
   DUNAWAY, GA
TI THE SUBUNIT PROPORTIONS AND KINETIC-PROPERTIES OF
   6-PHOSPHOFRUCTO-1-KINASE ISOZYMES FROM RAT-HEART ATRIA AND VENTRICLE
   PROGRESSIVELY CHANGE DURING AGING
SO MOLECULAR AND CELLULAR BIOCHEMISTRY
LA English
DT Article
DE 6-PHOSPHOFRUCTO-1-KINASE; AGING; HEART; ENERGY METABOLISM; METABOLIC
   REGULATION; ISOZYMES
ID AGE-RELATED-CHANGES; ENZYME-ACTIVITIES; INSULIN; PHOSPHOFRUCTOKINASE;
   POOLS; BRAIN; LIVER
AB Relative to 2-3 month rats, total 6-phosphofructo-1-kinase (PFK) activity in heart atria from 12 month rats declined 31%; but, by 24 months it was decreased by only 13%.  PFK activities from 12 and 24 month ventricles relative to the 2-3 month rat were decreased by 40% and 30%, respectively.  This change in PFK activity in each heart region was associated with alterations of subunit composition.  In heart atria from 12 and 24 month rats when compared to 3 month rats, the levels of L-type subunit were not significantly different; but the levels of the M-type subunit were decreased by 43% and 38%, respectively.  With respect to levels in 2-3 month atria, the C-type subunit in 12 month atria decreased by 27%; and at 24 months it increased by 31%.  Making the same comparison for the heart ventricle at 12 and 24 months, L-type subunit decreased by 30% and 24% respectively; M-type subunit decreased by approximately 47%; and the C-type subunit increased 1.9 and 4.7 fold, respectively.  These age-related changes of subunit composition in atrial and ventricular PFK isozyme pools led to changes in their kinetic and regulatory properties suggesting that the aged rat could exhibit a diminished capacity to produce ATP from glucose.
C1 SO ILLINOIS UNIV,SCH MED,DEPT PHARMACOL,POB 19230,SPRINGFIELD,IL 62794.
C3 Southern Illinois University System; Southern Illinois University
FU NICHD NIH HHS [HD 16666] Funding Source: Medline
CR BARROWS CH, 1962, J GERONTOL, V17, P144, DOI 10.1093/geronj/17.2.144
   BASS A, 1975, GERONTOLOGY, V21, P31, DOI 10.1159/000212028
   BRACHOROMERO E, 1977, J AM GERIATR SOC, V25, P299, DOI 10.1111/j.1532-5415.1977.tb00641.x
   CHEN JC, 1972, J CELL PHYSIOL, V80, P141, DOI 10.1002/jcp.1040800115
   DUNAWAY GA, 1986, J BIOL CHEM, V261, P7831
   DUNAWAY GA, 1986, J BIOL CHEM, V261, P7170
   DUNAWAY GA, 1988, BRAIN RES, V456, P310, DOI 10.1016/0006-8993(88)90233-8
   DUNAWAY GA, 1989, MOL CELL BIOCHEM, V87, P71, DOI 10.1007/BF00421084
   DUNAWAY GA, 1986, MECH AGEING DEV, V36, P13, DOI 10.1016/0047-6374(86)90135-1
   DUNAWAY GA, 1990, BIOCHEM J, V266, P823
   DUNAWAY GA, 1983, MOL CELL BIOCHEM, V52, P75
   DUNAWAY GA, 1985, J MOL CELL CARDIOL, V17, P947, DOI 10.1016/S0022-2828(85)80075-4
   DUNAWAY GA, 1987, BIOCHEM J, V242, P667, DOI 10.1042/bj2420667
   FUKUDA H, 1984, BIOCHIM BIOPHYS ACTA, V795, P79, DOI 10.1016/0005-2760(84)90106-1
   GOLD G, 1976, BIOCHEM BIOPH RES CO, V73, P1003, DOI 10.1016/0006-291X(76)90222-9
   HRON WT, 1983, ENZYME, V30, P83, DOI 10.1159/000469554
   IWANGOFF P, 1979, INTDSCPL TOPICS GERO, V15, P13
   MASORO EJ, 1985, HDB BIOL AGING, P540
   OLEFSKY JM, 1975, ENDOCRINOLOGY, V96, P1486, DOI 10.1210/endo-96-6-1486
   RANDLE PJ, 1979, HDB PHYSL          2, V1, P805
   RICHARDSON A, 1982, LIFE SCI, V31, P605, DOI 10.1016/0024-3205(82)90761-5
   SANDARI DR, 1977, HDB BIOL AGING, P73
   SARTIN J, 1980, FED PROC, V39, P3163
   VITORICA J, 1981, NEUROCHEM RES, V6, P127, DOI 10.1007/BF00964829
   VITORICA J, 1981, MECH AGEING DEV, V16, P105, DOI 10.1016/0047-6374(81)90087-7
   WOLLENBERGER A, 1952, AM J PHYSIOL, V170, P126, DOI 10.1152/ajplegacy.1952.170.1.126
NR 26
TC 5
Z9 5
U1 0
U2 0
PU KLUWER ACADEMIC PUBL
PI DORDRECHT
PA SPUIBOULEVARD 50, PO BOX 17, 3300 AA DORDRECHT, NETHERLANDS
SN 0300-8177
J9 MOL CELL BIOCHEM
JI Mol. Cell. Biochem.
PD SEP 18
PY 1991
VL 107
IS 1
BP 39
EP 45
DI 10.1007/BF02424574
PG 7
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA GF877
UT WOS:A1991GF87700004
PM 1838402
DA 2024-02-19
ER

PT J
AU Aronis, KN
   Sahin-Efe, A
   Chamberland, JP
   Spiro, A
   Vokonas, P
   Mantzoros, CS
AF Aronis, Konstantinos N.
   Sahin-Efe, Ayse
   Chamberland, John P.
   Spiro, Avron, III
   Vokonas, Pantel
   Mantzoros, Christos S.
TI Chemerin levels as predictor of acute coronary events: A case-control
   study nested within the veterans affairs normative aging study
SO METABOLISM-CLINICAL AND EXPERIMENTAL
LA English
DT Article
DE Chemerin; Acute Coronary Events; Normative Aging Study
ID EPICARDIAL ADIPOSE-TISSUE; MESSENGER-RNA EXPRESSION; ARTERY-DISEASE;
   FATTY LIVER; INSULIN-RESISTANCE; METABOLIC SYNDROME; WEIGHT-LOSS;
   ADIPOKINE; OBESITY; PLASMA
AB Objective. Chemerin is a recently identified adipocytokine that has been positively correlated with the presence and severity of coronary artery disease (CAD). However, no studies have examined circulating chemerin levels as a predictor of acute coronary syndrome (ACS). The purpose of this study is to evaluate whether chemerin levels predict the onset of ACS.
   Materials/Methods. We studied 90 men whose serum had been collected at least 2 years before the development of ACS, and 162 controls matched with the cases in a 1:2 fashion for age and year of collection. The mean age of the cohort was 66.3 +/- 9.6 years (range 34-84 years). Serum chemerin levels were measured with a commercially available enzyme-linked immunosorbent assay.
   Results. Age was positively associated with chemerin levels (r = 0.39, p < 0.001). Logistic regression analysis, adjusting for years since blood collection, demonstrated a null association between chemerin levels and the odds ratio for development of ACS (OR: 0.99, 95% CI [0.99-1.001]). This association remained null after adjusting for age (OR: 0.99 95% CI [0.99-1.001]).
   Conclusions. Although cross-sectional and case control studies suggest a positive association between chemerin levels and CAD, we demonstrate that chemerin levels do not predict the development of ACS. (C) 2014 Elsevier Inc. All rights reserved.
C1 [Aronis, Konstantinos N.; Sahin-Efe, Ayse; Chamberland, John P.; Mantzoros, Christos S.] Harvard Univ, Sch Med, VA Boston Healthcare Syst, Endocrinol Sect, Cambridge, MA 02138 USA.
   [Aronis, Konstantinos N.; Sahin-Efe, Ayse; Chamberland, John P.; Mantzoros, Christos S.] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Endocrinol Diabet & Metab,Dept Med, Cambridge, MA 02138 USA.
   [Aronis, Konstantinos N.; Mantzoros, Christos S.] Boston Univ, Sch Med, Boston Med Ctr, Dept Med, Boston, MA 02215 USA.
   [Spiro, Avron, III; Vokonas, Pantel] VA Boston Healthcare Syst, Normat Aging Study, Jamaica Plain, MA USA.
   [Spiro, Avron, III] Boston Univ, Sch Publ Hlth, Boston, MA 02215 USA.
   [Spiro, Avron, III; Vokonas, Pantel] Boston Univ, Sch Med, Boston, MA 02215 USA.
C3 US Department of Veterans Affairs; Veterans Health Administration (VHA);
   Harvard University; VA Boston Healthcare System; Harvard University;
   Beth Israel Deaconess Medical Center; Boston Medical Center; Boston
   University; US Department of Veterans Affairs; Veterans Health
   Administration (VHA); Harvard University; VA Boston Healthcare System;
   Boston University; Boston University
RP Aronis, KN (corresponding author), VA Boston Hlth Care Syst, 150 S Huntington Ave, Jamaica Plain, MA 02130 USA.
EM konstantinos.aronis@bmc.org
RI Aronis, Konstantinos N./F-3586-2012; Mantzoros, Christos/Y-2902-2019
OI Aronis, Konstantinos N./0000-0001-7189-8434; Spiro III,
   Avron/0000-0003-4080-8621
FU Clinical Science Research and Development Service of the VA Office of
   Research and Development [1I01CX000422-01A1]; Cooperative Studies
   Program/ERIC, US Department of Veterans Affairs; Massachusetts Veterans
   Epidemiology Research and Information Center; Research Career Scientist
   award from the Clinical Science Research and Development Service, US
   Department of Veterans' Affairs
FX The Mantzoros Laboratory is supported by the Award Number
   1I01CX000422-01A1 from the Clinical Science Research and Development
   Service of the VA Office of Research and Development. NAS is supported
   by Cooperative Studies Program/ERIC, US Department of Veterans Affairs
   and is a research component of the Massachusetts Veterans Epidemiology
   Research and Information Center. Dr. Spiro is supported by a Research
   Career Scientist award from the Clinical Science Research and
   Development Service, US Department of Veterans' Affairs.
CR Aroor AR, 2013, METABOLISM, V62, P1543, DOI 10.1016/j.metabol.2013.07.001
   Becker M, 2010, DIABETES, V59, P2898, DOI 10.2337/db10-0362
   BELL B, 1966, GERONTOLOGIST, V6, P179, DOI 10.1093/geront/6.4.179
   Bozaoglu K, 2007, ENDOCRINOLOGY, V148, P4687, DOI 10.1210/en.2007-0175
   Bozaoglu K, 2010, J CLIN ENDOCR METAB, V95, P2476, DOI 10.1210/jc.2010-0042
   Bozaoglu K, 2009, J CLIN ENDOCR METAB, V94, P3085, DOI 10.1210/jc.2008-1833
   Chakaroun R, 2012, METABOLISM, V61, P706, DOI 10.1016/j.metabol.2011.10.008
   Chamberland JP, 2013, EUR J ENDOCRINOL, V169, P453, DOI 10.1530/EJE-13-0098
   Chen HD, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1003060
   Döcke S, 2013, EUR J ENDOCRINOL, V169, P547, DOI 10.1530/EJE-13-0112
   Dong BK, 2011, INTERNAL MED, V50, P1093, DOI 10.2169/internalmedicine.50.5025
   El-Mesallamy HO, 2011, METABOLISM, V60, P63, DOI 10.1016/j.metabol.2010.04.008
   Ernst MC, 2010, TRENDS ENDOCRIN MET, V21, P660, DOI 10.1016/j.tem.2010.08.001
   Gao XY, 2011, CARDIOVASC DIABETOL, V10, DOI 10.1186/1475-2840-10-87
   Giannessi D, 2011, METABOLISM, V60, P227, DOI 10.1016/j.metabol.2009.12.030
   Gisondi P, 2013, BRIT J DERMATOL, V168, P749, DOI 10.1111/bjd.12118
   Goralski KB, 2007, J BIOL CHEM, V282, P28175, DOI 10.1074/jbc.M700793200
   Gu P, 2013, CLIN EXP HYPERTENS
   Guzel EC, 2014, GYNECOL ENDOCRINOL
   Hah YJ, 2011, DIABETES METAB J, V35, P248, DOI 10.4093/dmj.2011.35.3.248
   Hirata A, 2013, METABOLISM, V62, P578, DOI 10.1016/j.metabol.2012.10.011
   Ikmal SIQS, 2013, INT J ENDOCRINOL, V2013, DOI 10.1155/2013/698567
   Jialal I, 2013, J CLIN ENDOCR METAB, V98, pE514, DOI 10.1210/jc.2012-3673
   Kaur J, 2010, BIOCHEM BIOPH RES CO, V391, P1762, DOI 10.1016/j.bbrc.2009.12.150
   Kim SH, 2013, CLIN ENDOCRINOL OXF
   Ko BJ, 2014, METABOLISM, V63, P168, DOI 10.1016/j.metabol.2013.11.004
   Kwon BJ, 2013, METABOLISM, V62, P952, DOI 10.1016/j.metabol.2013.01.006
   Lehrke M, 2009, EUR J ENDOCRINOL, V161, P339, DOI 10.1530/EJE-09-0380
   Li Q, 2012, METABOLISM, V61, P1803, DOI 10.1016/j.metabol.2012.06.001
   Li XT, 2012, CORONARY ARTERY DIS, V23, P412, DOI 10.1097/MCA.0b013e3283576a60
   Lin XH, 2012, CLIN LAB, V58, P539
   Meder W, 2003, FEBS LETT, V555, P495, DOI 10.1016/S0014-5793(03)01312-7
   Müssig K, 2009, METABOLISM, V58, P519, DOI 10.1016/j.metabol.2008.11.011
   Nagpal S, 1997, J INVEST DERMATOL, V109, P91, DOI 10.1111/1523-1747.ep12276660
   Piestrzeniewicz K, 2008, METABOLISM, V57, P488, DOI 10.1016/j.metabol.2007.11.009
   Polyzos SA, 2014, METABOLISM, V63, P207, DOI 10.1016/j.metabol.2013.09.013
   Roh SG, 2007, BIOCHEM BIOPH RES CO, V362, P1013, DOI 10.1016/j.bbrc.2007.08.104
   Roman AA, 2012, ENDOCRINE, V42, P243, DOI 10.1007/s12020-012-9698-8
   Sahin-Efe A, 2012, METABOLISM, V61, P1659, DOI 10.1016/j.metabol.2012.09.001
   Sell H, 2010, J CLIN ENDOCR METAB, V95, P2892, DOI 10.1210/jc.2009-2374
   Spiroglou SG, 2010, J ATHEROSCLER THROMB, V17, P115
   Takahashi M, 2008, FEBS LETT, V582, P573, DOI 10.1016/j.febslet.2008.01.023
   Terra X, 2013, OBES SURG, V23, P1790, DOI 10.1007/s11695-013-1033-9
   Tönjes A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013911
   de Voorde J, 2013, METABOLISM, V62, P1513, DOI 10.1016/j.metabol.2013.06.004
   Wang D, 2013, GENET MOL RES, V12, P5986, DOI 10.4238/2013.November.26.8
   Weigert J, 2010, CLIN ENDOCRINOL, V72, P342, DOI 10.1111/j.1365-2265.2009.03664.x
   Wittamer V, 2005, J IMMUNOL, V175, P487, DOI 10.4049/jimmunol.175.1.487
   Wittamer V, 2003, J EXP MED, V198, P977, DOI 10.1084/jem.20030382
   Yan Q, 2012, ENDOCRINE, V41, P281, DOI 10.1007/s12020-011-9550-6
   Yoo HJ, 2012, J ATHEROSCLER THROMB, V19, P59, DOI 10.5551/jat.9647
NR 51
TC 19
Z9 18
U1 0
U2 4
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0026-0495
EI 1532-8600
J9 METABOLISM
JI Metab.-Clin. Exp.
PD JUN
PY 2014
VL 63
IS 6
BP 760
EP 766
DI 10.1016/j.metabol.2014.02.013
PG 7
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Endocrinology & Metabolism
GA AI1UH
UT WOS:000336640100004
PM 24684821
DA 2024-02-19
ER

PT J
AU Zheng, M
   Zang, SB
   Xie, LN
   Fang, XT
   Zhang, Y
   Ma, XJ
   Liu, JF
   Lin, DX
   Huang, AM
AF Zheng, Min
   Zang, Shengbing
   Xie, Linna
   Fang, Xueting
   Zhang, Yu
   Ma, Xiaojie
   Liu, Jingfeng
   Lin, Dexin
   Huang, Aimin
TI Rheb phosphorylation is involved in p38-regulated/activated protein
   kinase-mediated tumor suppression in liver cancer
SO ONCOLOGY LETTERS
LA English
DT Article
DE Ras; p38-regulated/activated protein kinase; Rheb phosphorylation; liver
   cancer
ID RAS-INDUCED SENESCENCE; TARGET; PRAK; ACTIVATION; BARRIER; MTORC1;
   BREAST
AB Ras homolog enriched in brain (Rheb) is a key regulator of mammalian target of rapamycin complex 1 (mTORC1). The Rheb-mTORC1 axis is a pivotal pathway that mediates cell growth. It was previously reported that upon energy-stress stimulation, the phosphorylation of Rheb at serine 130 by p38-regulated/activated protein kinase (PRAK) results in the impaired nucleotide binding ability of Rheb and inhibits Rheb-mediated mTORC1 activation. However, the role of Rheb phosphorylation in cancer development remains to be elucidated. The aim of the present study was to determine the effect of Rheb phosphorylation on tumor growth in vitro and in vivo. In addition, tissue samples were obtained from 70 hepatocellular carcinoma (HCC) patients in order to determine any associations between Rheb phosphorylation and the clinicopathological characteristics of patients. In vitro and ex vivo kinase assays were performed to determine the phosphorylation of Rheb by PRAK. A xenograft assay was performed to assess tumorigenicity of MEF cell lines. In addition, western blot and immunohistochemical analyses were performed to detect Rheb protein expression and phosphorylation. The results of the present study revealed that Rheb phosphorylation may be induced through Ras overexpression. In addition, kinase-dead PRAK and dominant-negative PRAK mutation were demonstrated to abolish the Rheb phosphorylation induced by Ras overexpression. Xenograft assays in nude mice revealed that Rheb phosphorylation was involved in PRAK-mediated tumor suppression. Of note, the clinicopathological analysis of 70 HCC samples determined that Rheb phosphorylation was associated with poor proliferation and the progression of HCC. In conclusion, the results of the present study suggested that Rheb phosphorylation may have an important role as an intracellular barrier to cancer development.
C1 [Zheng, Min; Xie, Linna; Lin, Dexin] Fujian Med Univ, Sch Basic Med Sci, Dept Biochem & Mol Biol, Fuzhou 350004, Fujian, Peoples R China.
   [Zheng, Min] Fujian Med Univ, Translat Med Inst, Fuzhou 350004, Fujian, Peoples R China.
   [Zang, Shengbing; Fang, Xueting; Zhang, Yu; Ma, Xiaojie; Huang, Aimin] Fujian Med Univ, Sch Basic Med Sci, Dept Pathol, Fuzhou 350004, Fujian, Peoples R China.
   [Zang, Shengbing; Fang, Xueting; Zhang, Yu; Ma, Xiaojie; Huang, Aimin] Fujian Med Univ, Sch Basic Med Sci, Inst Oncol, Fuzhou 350004, Fujian, Peoples R China.
   [Xie, Linna] Fujian Vocat Coll Bioengn, Dept Bioengn, Fuzhou 350007, Fujian, Peoples R China.
   [Liu, Jingfeng] Fujian Med Univ, Mengchao Hepatobiliary Hosp, Liver Ctr Fujian Prov, Fuzhou 350025, Fujian, Peoples R China.
C3 Fujian Medical University; Fujian Medical University; Fujian Medical
   University; Fujian Medical University; Fujian Medical University
RP Huang, AM (corresponding author), Fujian Med Univ, Sch Basic Med Sci, Dept Pathol, 1 Xueyuan Rd, Fuzhou 350004, Fujian, Peoples R China.
EM mzheng@mail.fjmu.edu.cn; aimin@mail.fjmu.edu.cn
OI Liu, Jingfeng/0000-0003-3499-5678
FU National Natural Science Foundation of China [31100995]; Natural Science
   Foundation of Fujian Province [2011J01187]; Scientific Research Project
   of Education Department of Fujian Province [2013B009]
FX The present study was supported by grants from the National Natural
   Science Foundation of China (no. 31100995), the Natural Science
   Foundation of Fujian Province (no. 2011J01187) and the Scientific
   Research Project of Education Department of Fujian Province (no.
   2013B009).
CR Aksamitiene E, 2012, BIOCHEM SOC T, V40, P139, DOI 10.1042/BST20110609
   Babcock JT, 2011, CURR DRUG TARGETS, V12, P1223
   Bae HJ, 2012, ONCOL LETT, V4, P873, DOI 10.3892/ol.2012.875
   Braig M, 2005, NATURE, V436, P660, DOI 10.1038/nature03841
   DiMauro T, 2010, CURR CANCER DRUG TAR, V10, P869, DOI 10.2174/156800910793357998
   EDMONDSON HA, 1954, CANCER-AM CANCER SOC, V7, P462, DOI 10.1002/1097-0142(195405)7:3<462::AID-CNCR2820070308>3.0.CO;2-E
   Eom M, 2012, KOREAN J PATHOL, V46, P324, DOI 10.4132/KoreanJPathol.2012.46.4.324
   Ferbeyre G, 2007, NAT CELL BIOL, V9, P483, DOI 10.1038/ncb0507-483
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Inoki K, 2003, GENE DEV, V17, P1829, DOI 10.1101/gad.1110003
   Kobayashi T, 2010, PROSTATE, V70, P866, DOI 10.1002/pros.21120
   Kononen J, 1998, NAT MED, V4, P844, DOI 10.1038/nm0798-844
   Llovet JM, 2008, JNCI-J NATL CANCER I, V100, P698, DOI 10.1093/jnci/djn134
   Lu ZH, 2010, CANCER RES, V70, P3287, DOI 10.1158/0008-5472.CAN-09-3467
   Mavrakis KJ, 2008, GENE DEV, V22, P2178, DOI 10.1101/gad.1690808
   Menendez JA, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00262
   Nardella C, 2008, GENE DEV, V22, P2172, DOI 10.1101/gad.1699608
   New L, 2003, MOL BIOL CELL, V14, P2603, DOI 10.1091/mbc.E02-08-0538
   Prieur A, 2008, CURR OPIN CELL BIOL, V20, P150, DOI 10.1016/j.ceb.2008.01.007
   Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9
   Shaw RJ, 2006, NATURE, V441, P424, DOI 10.1038/nature04869
   Sun PQ, 2007, CELL, V128, P295, DOI 10.1016/j.cell.2006.11.050
   Wazir U, 2013, ONCOL REP, V29, P1969, DOI 10.3892/or.2013.2346
   YAMAGATA K, 1994, J BIOL CHEM, V269, P16333
   Zang SB, 2009, ANAT REC, V292, P1128, DOI 10.1002/ar.20950
   Zheng H, 2010, CANCER LETT, V297, P117, DOI 10.1016/j.canlet.2010.05.004
   Zheng M, 2011, NAT CELL BIOL, V13, P263, DOI 10.1038/ncb2168
NR 27
TC 10
Z9 14
U1 1
U2 11
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1792-1074
EI 1792-1082
J9 ONCOL LETT
JI Oncol. Lett.
PD SEP
PY 2015
VL 10
IS 3
BP 1655
EP 1661
DI 10.3892/ol.2015.3406
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA CQ9GZ
UT WOS:000360923000073
PM 26622727
OA gold, Green Published
DA 2024-02-19
ER

PT J
AU Cadenas, S
   Barja, G
   Poulsen, HE
   Loft, S
AF Cadenas, S
   Barja, G
   Poulsen, HE
   Loft, S
TI Oxidative DNA damage estimated by oxo<SUP>8</SUP>dG in the liver of
   guinea-pigs supplemented with graded dietary doses of ascorbic acid and
   α-tocopherol
SO CARCINOGENESIS
LA English
DT Article
ID VITAMIN-E; LIPID-PEROXIDATION; BETA-CAROTENE; POTASSIUM BROMATE; MALE
   SMOKERS; CANCER RISK; LUNG-CANCER; 8-HYDROXYGUANINE; ANTIOXIDANTS;
   8-HYDROXYDEOXYGUANOSINE
AB Dietary antioxidants may influence cancer risk and aging by modifying oxidative damage, The effect of graded dietary doses of the antioxidant vitamins C and E on oxidative DNA damage was studied in the liver of guineapigs under normal conditions, Like human beings, guineapigs cannot synthesize ascorbate and alpha-tocopherol, In one experiment, three groups of 6-8 guinea-pigs were fed diets containing 15 mg of vitamin E/kg chow and three different amounts of vitamin C (33 660 or 13 200 mg/kg) for 5 weeks, In a second experiment, three groups of seven guinea-pigs were fed diets containing 660 mg of vitamin C/kg and three different amounts of vitamin E (15, 150 or 1500 mg/kg) for 5 weeks, The three graded levels of each vitamin respectively represent marginal deficiency, an optimum supplementation and a megadose, Oxidative damage to liver DNA was estimated by measuring 8-oxo-7,8-dihydro-2'-deoxyguanosine (oxo(8)dG) referred to deoxyguanosine (dG) by means of high-performance liquid chromatography with simultaneous electrochemical-coulometric and ultraviolet detection, The level of ascorbate in the liver was 0.034 +/- 0.051, 1.63 +/- 1.06 and 1.99 +/- 0.44 mu mol/g in the low medium and high dose ascorbate groups (59-fold variation), The liver concentration of alpha-tocopherol was 28 +/- 11, 63 +/- 18 and 187 +/- 34 nmol/g in the low medium and high dose a-tocopherol groups (7-fold variation), The level of oxo(8)dG in the Liver DNA was 1.89 +/- 0.32, 1.94 +/- 0.78 and 1.93 +/- 0.65 per 10(5) dG in the low medium and high dose ascorbate groups (no effect: P > 0.05), In the low medium and high dose alpha-tocopherol groups oxo(8)dG level in the liver DNA was 2.85 +/- 0.70, 2.74 +/- 0.66 and 2.61 +/- 0.92 per 10(5) dG (no effect: P > 0.05), It is concluded that even very large variations in the content of the antioxidant vitamins C and E in the diet and liver have no influence on the steady-state level of oxidative damage to guanine in the liver DNA of normal unstressed guinea-pigs.
C1 Univ Complutense, Fac Biol, Dept Biol Anim Fisiol Anim 2, E-28040 Madrid, Spain.
   Univ Copenhagen, Panum Inst, Dept Pharmacol, DK-2200 Copenhagen N, Denmark.
C3 Complutense University of Madrid; University of Copenhagen
RP Barja, G (corresponding author), Univ Complutense, Fac Biol, Dept Biol Anim Fisiol Anim 2, E-28040 Madrid, Spain.
RI Cadenas, Susana/D-1523-2016; Gustavo, Barja/B-5591-2012; Barja,
   Gustavo/AAA-5903-2019
OI Barja, Gustavo/0000-0001-5736-4735; Poulsen, Henrik
   Enghusen/0000-0003-4242-9924; Cadenas, Susana/0000-0003-0726-0369
CR AMES BN, 1995, P NATL ACAD SCI USA, V92, P5258, DOI 10.1073/pnas.92.12.5258
   AMES BN, 1989, FREE RADICAL RES COM, V7, P121, DOI 10.3109/10715768909087933
   Barja G, 1996, LIPIDS, V31, P963, DOI 10.1007/BF02522690
   BARJA G, 1994, FREE RADICAL BIO MED, V17, P105, DOI 10.1016/0891-5849(94)90108-2
   BARJA G, 1996, REV ESP GERONT GERIA, V31, P153
   BLOCK G, 1992, NUTR REV, V50, P207, DOI 10.1111/j.1753-4887.1992.tb01329.x
   BLOCK G, 1992, NUTR CANCER, V18, P1, DOI 10.1080/01635589209514201
   BLOT WJ, 1993, JNCI-J NATL CANCER I, V85, P1483, DOI 10.1093/jnci/85.18.1483
   BYERS T, 1992, ANNU REV NUTR, V12, P139, DOI 10.1146/annurev.nu.12.070192.001035
   CADENAS S, 1995, INT J BIOCHEM CELL B, V27, P1175, DOI 10.1016/1357-2725(95)00077-3
   Cadenas S, 1996, FREE RADICAL RES, V24, P485, DOI 10.3109/10715769609088047
   CHENG KC, 1992, J BIOL CHEM, V267, P166
   CHUNG MH, 1991, MUTAT RES, V254, P1, DOI 10.1016/0921-8777(91)90035-N
   DEQUIROGA GB, 1991, ANAL BIOCHEM, V199, P81
   DEQUIROGA GB, 1992, FREE RADICALS AGING, P109
   DIZDAROGLU M, 1991, FREE RADICAL BIO MED, V10, P225, DOI 10.1016/0891-5849(91)90080-M
   FISCHERNIELSEN A, 1993, CARCINOGENESIS, V14, P2431, DOI 10.1093/carcin/14.11.2431
   FISHERNIELSEN A, 1992, FREE RADICAL BIO MED, V13, P121
   FLOYD RA, 1990, CARCINOGENESIS, V11, P1447, DOI 10.1093/carcin/11.9.1447
   FRAGA CG, 1991, P NATL ACAD SCI USA, V88, P11003, DOI 10.1073/pnas.88.24.11003
   GILLMAN MW, 1995, JAMA-J AM MED ASSOC, V273, P1113, DOI 10.1001/jama.273.14.1113
   GRAHAM S, 1983, CANCER RES, V43, P2409
   HALLIWELL B, 1991, FEBS LETT, V281, P9, DOI 10.1016/0014-5793(91)80347-6
   HARMAN D, 1968, J GERONTOL, V23, P476, DOI 10.1093/geronj/23.4.476
   HEINONEN OP, 1994, NEW ENGL J MED, V330, P1029
   HIRAYAMA T, 1994, HOMEOSTASIS HLTH DIS, V35, P168
   JACOB RA, 1991, AM J CLIN NUTR, V54, pS1302, DOI 10.1093/ajcn/54.6.1302s
   KASAI H, 1986, CARCINOGENESIS, V7, P1849, DOI 10.1093/carcin/7.11.1849
   KELLY JD, 1992, CARCINOGENESIS, V13, P1639, DOI 10.1093/carcin/13.9.1639
   KUCHINO Y, 1987, NATURE, V327, P77, DOI 10.1038/327077a0
   Lee YS, 1996, MUTAT RES-DNA REPAIR, V364, P227, DOI 10.1016/S0921-8777(96)00038-9
   Loft S, 1996, J MOL MED, V74, P297, DOI 10.1007/s001090050031
   LOPEZTORRES M, 1993, FREE RADICAL BIO MED, V15, P133, DOI 10.1016/0891-5849(93)90052-V
   MARMUR J, 1961, J MOL BIOL, V3, P208, DOI 10.1016/S0022-2836(61)80047-8
   MENEGHINI R, 1993, DNA FREE RADICALS, P83
   NISHIKIMI M, 1996, ASCORBIC ACID BIOCH, P17
   Omenn GS, 1996, NEW ENGL J MED, V334, P1150, DOI 10.1056/NEJM199605023341802
   ORR WC, 1992, ARCH BIOCHEM BIOPHYS, V297, P35, DOI 10.1016/0003-9861(92)90637-C
   Prieme H, 1997, AM J CLIN NUTR, V65, P503, DOI 10.1093/ajcn/65.2.503
   RAVANAT JL, 1995, CHEM RES TOXICOL, V8, P1039, DOI 10.1021/tx00050a007
   Rojas C, 1996, LIFE SCI, V59, P649, DOI 10.1016/0024-3205(96)00346-3
   Rojas C, 1996, FREE RADICAL BIO MED, V21, P907, DOI 10.1016/S0891-5849(96)00223-7
   SAI K, 1992, JPN J CANCER RES, V83, P45, DOI 10.1111/j.1349-7006.1992.tb02350.x
   SHIBUTANI S, 1991, NATURE, V349, P431, DOI 10.1038/349431a0
   TAKAGI A, 1995, CANCER LETT, V91, P139, DOI 10.1016/0304-3835(95)03734-E
   UMEGAKI K, 1993, J NUTR SCI VITAMINOL, V39, P303, DOI 10.3177/jnsv.39.303
   VANPOPPEL G, 1995, J NATL CANCER I, V87, P310, DOI 10.1093/jnci/87.4.310
   VATASSERY GT, 1988, J NEUROCHEM, V51, P621, DOI 10.1111/j.1471-4159.1988.tb01083.x
   VERHAGEN H, 1995, CARCINOGENESIS, V16, P969, DOI 10.1093/carcin/16.4.969
   Verhoeven DTH, 1996, CANCER EPIDEM BIOMAR, V5, P733
   VINA J, 1992, FREE RADICALS AGING, P136
   WITT EH, 1992, J NUTR, V122, P766, DOI 10.1093/jn/122.suppl_3.766
   Wood RD, 1996, ANNU REV BIOCHEM, V65, P135, DOI 10.1146/annurev.bi.65.070196.001031
   YAMAMOTO F, 1992, JPN J CANCER RES, V83, P351, DOI 10.1111/j.1349-7006.1992.tb00114.x
NR 54
TC 42
Z9 48
U1 0
U2 2
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0143-3334
J9 CARCINOGENESIS
JI Carcinogenesis
PD DEC
PY 1997
VL 18
IS 12
BP 2373
EP 2377
DI 10.1093/carcin/18.12.2373
PG 5
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA YQ808
UT WOS:000071425200013
PM 9450484
OA Bronze
DA 2024-02-19
ER

PT J
AU Wen, NY
   Liu, F
   Zhang, HL
   Lu, J
   Li, B
   Cheng, NS
AF Wen, Ningyuan
   Liu, Fei
   Zhang, Haili
   Lu, Jiong
   Li, Bei
   Cheng, Nansheng
TI Laparoscopic liver resection for hepatocellular carcinoma presents less
   respiratory complications compared with open procedure: A propensity
   score analysis in the elderly
SO EJSO
LA English
DT Article; Early Access
DE Laparoscopy; Elderly patients; Postoperative complications
ID OPEN HEPATECTOMY; CHRONIC HEPATITIS; CANCER INCIDENCE; METAANALYSIS;
   CIRRHOSIS; SURGERY; SEGMENTS; SURVIVAL; EFFICACY; OUTCOMES
AB Background: Resection is still the most efficacious treatment to hepatocellular carcinoma (HCC), among which laparoscopic liver resection (LLR) have controversial effects against conventional open procedure (OLR). With a predictable aging tendency of population worldwide, conventional surgical procedures need to be modified to better accommodate elderly patients. Here, we designed a retrospective study based on propensity score analysis, aiming to compare the efficacy of OLR and LLR in patients over 65 years. Methods: We retrospectively analyzed patients with an age over 65 who underwent liver resection between January 2015 and September 2018. Patients were divided into the LLR group and OLR group. Short-term and long-term outcomes were compared before and after 1:1 propensity score matching. Results: Among 240 enrolled patients, 142 were matched with comparable baseline (71 each group). In the matched cohort, LLR group presented with shorter postoperative hospital stay (median 7 vs 6 days, p = 0.003) and fewer respiratory complications (19.7% vs. 7.0%, p = 0.049), especially pleural effusion (15.5% vs. 2.8%, p = 0.020). Meanwhile, LLR had comparable overall hospital cost (6142 vs. 6243 USD, p = 0.977) compared with OLR. The overall survival (OS) and disease-free survival (DFS) did not differ in the two groups. Conclusions: Our study showed that laparoscopic liver resection for HCC in the older age groups is associated with shorter postoperative hospital stay and comparable hospital cost compared with open procedure, which could be attributable to less respiratory complications. We recommend that laparoscopy be taken as a priority option for elderly patients with resectable HCC. (c) 2021 Published by Elsevier Ltd.
C1 [Wen, Ningyuan; Lu, Jiong; Li, Bei; Cheng, Nansheng] Sichuan Univ, Dept Biliary Surg, West China Hosp, 37 Guo Xue Xiang, Chengdu 610041, Sichuan, Peoples R China.
   [Liu, Fei; Zhang, Haili] Sichuan Univ, Dept Liver Surg, West China Hosp, 37 Guo Xue Xiang, Chengdu 610041, Sichuan, Peoples R China.
C3 Sichuan University; Sichuan University
RP Li, B; Cheng, NS (corresponding author), Sichuan Univ, Dept Biliary Surg, West China Hosp, 37 Guo Xue Xiang, Chengdu 610041, Sichuan, Peoples R China.
EM libei445@163.com; nanshengcheng@yeah.net
FU National Natural Science Foundation of China [81900516]
FX This research is supported by National Natural Science Foundation of
   China, No. 81900516.
CR Altekruse SF, 2012, HEPATOLOGY, V55, P476, DOI 10.1002/hep.24710
   Amato B, 2017, AGING CLIN EXP RES, V29, pS179, DOI 10.1007/s40520-016-0675-6
   Balzan S, 2005, ANN SURG, V242, P824, DOI 10.1097/01.sla.0000189131.90876.9e
   BARDRAM L, 1995, LANCET, V345, P763, DOI 10.1016/S0140-6736(95)90643-6
   Bedossa P, 1996, HEPATOLOGY, V24, P289, DOI 10.1002/hep.510240201
   Bernard WS, 2014, INT AGENCY RES WORLD
   Brunt EM, 2000, HEPATOLOGY, V31, P241, DOI 10.1002/hep.510310136
   Celik S, 2018, MED SCI MONITOR, V24, P3244, DOI 10.12659/MSM.906973
   Chan ACY, 2014, J GASTROEN HEPATOL, V29, P1279, DOI 10.1111/jgh.12539
   Chen K, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000011703
   Cho YK, 2011, ANN SURG, V254, P838, DOI 10.1097/SLA.0b013e318235e511
   Cleary SP, 2016, SURG ENDOSC, V30, P4691, DOI 10.1007/s00464-016-4801-5
   Dindo D, 2004, ANN SURG, V240, P205, DOI 10.1097/01.sla.0000133083.54934.ae
   El-Gendi A, 2018, J LAPAROENDOSC ADV S, V28, P302, DOI 10.1089/lap.2017.0518
   Gao YF, 2020, NAT BIOMED ENG, V4, P743, DOI 10.1038/s41551-020-0583-0
   Goh EL, 2018, INT J SURG, V50, P35, DOI 10.1016/j.ijsu.2017.12.021
   KATKHOUDA N, 1992, BRIT J SURG, V79, P560, DOI 10.1002/bjs.1800790628
   Kinoshita A, 2017, GERIATR GERONTOL INT, V17, P189, DOI 10.1111/ggi.12747
   KLOTZ HP, 1993, SURG LAPAROSC ENDOSC, V3, P351
   Koc A, 2015, INT BRAZ J UROL, V41, P1202, DOI 10.1590/S1677-5538.IBJU.2015.0040
   Koch M, 2011, SURGERY, V149, P680, DOI 10.1016/j.surg.2010.12.002
   Kowal P., 2001, Definition of an older person. Proposed working definition of an older person in Africa for the MDS Project
   Li HY, 2017, SURG ENDOSC, V31, P3028, DOI 10.1007/s00464-016-5319-6
   Li HY, 2016, SURG LAPARO ENDO PER, V26, P172, DOI 10.1097/SLE.0000000000000256
   Llovet JM, 2008, JNCI-J NATL CANCER I, V100, P698, DOI 10.1093/jnci/djn134
   Machairas N, 2018, SURG LAPARO ENDO PER, V28, P203, DOI 10.1097/SLE.0000000000000562
   Marrero JA, 2018, HEPATOLOGY, V68, P723, DOI 10.1002/hep.29913
   Menahem B, 2017, LIVER TRANSPLANT, V23, P836, DOI 10.1002/lt.24758
   Morise Z, 2015, J HEPATO-BIL-PAN SCI, V22, P342, DOI 10.1002/jhbp.215
   Ome Y, 2019, ASIAN J SURG, V42, P180, DOI 10.1016/j.asjsur.2017.10.002
   Rahbari NN, 2011, HPB, V13, P528, DOI 10.1111/j.1477-2574.2011.00319.x
   Smith BD, 2009, J CLIN ONCOL, V27, P2758, DOI 10.1200/JCO.2008.20.8983
   Suarez-Pierre A, 2017, J CARDIAC SURG, V32, P783, DOI 10.1111/jocs.13249
   Tanaka S, 2018, J HEPATO-BIL-PAN SCI, V25, P377, DOI 10.1002/jhbp.568
   Taura P, 1998, SURG ENDOSC-ULTRAS, V12, P198, DOI 10.1007/s004649900633
   Tomimaru Y, 2018, WORLD J SURG, V42, P3685, DOI 10.1007/s00268-018-4655-1
   Troisi RI, 2014, HPB, V16, P75, DOI 10.1111/hpb.12077
   Twaij A, 2014, WORLD J GASTROENTERO, V20, P8274, DOI 10.3748/wjg.v20.i25.8274
   Weir HK, 2015, CANCER-AM CANCER SOC, V121, P1827, DOI 10.1002/cncr.29258
   Xu HW, 2018, SURG ENDOSC, V32, P712, DOI 10.1007/s00464-017-5727-2
   Yao XXI, 2017, JNCI-J NATL CANCER I, V109, DOI 10.1093/jnci/djw323
   Yin Z, 2013, ANN SURG ONCOL, V20, P1203, DOI 10.1245/s10434-012-2705-8
   Yu X, 2018, BMC SURG, V18, DOI 10.1186/s12893-018-0444-x
   Zeng Y, 2016, J BUON, V21, P1146
   Zhang Si-wei, 2012, Zhonghua Yu Fang Yi Xue Za Zhi, V46, P587
   Zhu GQ, 2018, EXPERT REV GASTROENT, V12, P935, DOI 10.1080/17474124.2018.1503531
NR 46
TC 6
Z9 6
U1 0
U2 5
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0748-7983
EI 1532-2157
J9 EJSO-EUR J SURG ONC
JI EJSO
PD 2021 OCT
PY 2021
VL 47
IS 10
BP 2675
EP 2681
DI 10.1016/j.ejso.2021.04.032
EA SEP 2021
PG 7
WC Oncology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Surgery
GA WG5FO
UT WOS:000707020600028
PM 34059378
DA 2024-02-19
ER

PT J
AU Hiratsuka, A
   Yamane, H
   Yamazaki, S
   Ozawa, N
   Watabe, T
AF Hiratsuka, A
   Yamane, H
   Yamazaki, S
   Ozawa, N
   Watabe, T
TI Subunit Ya-specific glutathione peroxidase activity toward cholesterol
   7-hydroperoxides of glutathione S-transferases in cytosols from rat
   liver and skin
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID MICROSOMAL LIPID HYDROPEROXIDES; LOW-DENSITY-LIPOPROTEIN; STEROL
   METABOLISM; ALPHA-OXIDE; BINDING; LIGANDIN; PROTEIN; CARCINOGEN;
   EXPRESSION; 7-HYDROPEROXYCHOLEST-5-EN-3-BETA-OL
AB Dermal 7 alpha- and 7 beta-hydroperoxycholest-5-en-3 beta-ols (cholesterol 7 alpha- and 7 beta-hydroperoxides), regarded as good aging markers in the rat (Ozawa, N., Yamazaki, S., Chiba, K., Aoyama, H., Tomisawa, H., Tateishi, M., and Watabe, T. (1991) Biochem. Biophys. Res. Commun. 178, 242-247), were reduced in the presence of glutathione (GSH) with concomitant formation of GSSG by cytosol from rat liver in which no detectable level of the hy droperoxides had been demonstrated to occur. The GSH peroxidase (GSH Pr) activity toward the toxic steroid hydroperoxides was exerted to almost the same extent by both Alpha-class GSH S-transferases (GSTs), Ya-Ya and Ya-Yc, and by selenium-containing GSH Pr (Se-GSH Pr) in rat liver cytosol. None of three Mu class GSTs, Yb1-Yb1, Yb1-Yb2, and Yb2-Yb2, and a Theta-class GST, Yrs-Yrs, from rat liver and a Pi-class GST, Yp-Yp, from rat kidney showed any appreciable GSH Pr activity toward the hydroperoxides. The subunit Ya-bearing GSTs and Se GSH Pr purified from rat liver cytosol showed marked differences in apparent specific activity toward the cholesterol hydroperoxides (GSTs Ya-Ya > Ya-Yc much greater than Se-GSH Pr). However, a kinetic study indicated that Se-GSH Pr had a higher affinity for steroid hydroperoxides than did the GSTs, so that Se GSH Pr could catalyze the reduction of lower concentrations of cholesterol 7-hydroperoxides with approximately equal V-max/K-m values to those by the GSTs. Rat skin had no GST bearing the subunit Ya but contained only a very low concentration of Se GSH Pr, possibly resulting in the accumulation of cholesterol 7-hydroperoxides in the skin but not in the liver. From rat skin cytosol, GSTs Yc-Yc, Yb1-Yb1, Yb1-Yb2, Yb2-Yb2, and Yp-Yp were isolated, purified to homogeneity, and identified with the corresponding GSTs from liver and kidney. The GSTs accounted for 0.23% of total skin cytosolic protein, and the most abundant isoform of skin GSTs was Yb2-Yb2, followed by Yc-Yc, Yp-Yp, Yb1-Yb1, and Yb1-Yb2 in decreasing order.
C1 TOKYO UNIV PHARM & LIFE SCI,SCH PHARM,DEPT DRUG METAB & MOL TOXICOL,HACHIOJI,TOKYO 19203,JAPAN.
   PHARMACIA & UPJOHN INC,TSUKUBA RES LABS,TOXICOL & EFFICACY RES,TSUKUBA,IBARAKI 30042,JAPAN.
C3 Tokyo University of Pharmacy & Life Sciences; Eisai Co Ltd; Pfizer
CR AGARWAL R, 1992, BIOCHEM PHARMACOL, V44, P2047, DOI 10.1016/0006-2952(92)90108-U
   [Anonymous], 2012, FREE RADICALS BIOL
   BLACHE D, 1995, FEBS LETT, V357, P135, DOI 10.1016/0014-5793(94)01348-5
   BLACK HS, 1971, NATURE, V234, P306, DOI 10.1038/234306a0
   BLACK HS, 1972, CANCER RES, V32, P2630
   BLACKBURN GM, 1979, J CHEM SOC CHEM COMM, P420, DOI 10.1039/c39790000420
   CARNE T, 1979, BIOCHEM J, V177, P433, DOI 10.1042/bj1770433
   Chang M, 1987, Arch Biochem Biophys, V259, P536, DOI 10.1016/0003-9861(87)90520-0
   CHISOLM GM, 1994, P NATL ACAD SCI USA, V91, P11452, DOI 10.1073/pnas.91.24.11452
   DELBOCCIO G, 1987, BIOCHEM J, V244, P21, DOI 10.1042/bj2440021
   FARRANTS AKO, 1987, BIOCHEM J, V245, P423, DOI 10.1042/bj2450423
   FLOHE L, 1976, GLUTATHIONE METABOLI, P115
   GUTHENBERG C, 1985, BIOCHEM J, V230, P609, DOI 10.1042/bj2300609
   HABIG WH, 1974, P NATL ACAD SCI USA, V71, P3879, DOI 10.1073/pnas.71.10.3879
   HABIG WH, 1974, J BIOL CHEM, V249, P7130
   HAMBERG M, 1967, J BIOL CHEM, V242, P5329
   HAYES JD, 1981, BIOCHEM J, V197, P491, DOI 10.1042/bj1970491
   HIRATSUKA A, 1990, J BIOL CHEM, V265, P11973
   HIRATSUKA A, 1994, BIOCHEM BIOPH RES CO, V202, P278, DOI 10.1006/bbrc.1994.1924
   HIRATSUKA A, 1995, BIOCHEM BIOPH RES CO, V212, P74
   KETLEY JN, 1975, J BIOL CHEM, V250, P8670
   KETTERER B, 1986, XENOBIOTICA, V16, P957, DOI 10.3109/00498258609038976
   Ketterer B, 1986, Basic Life Sci, V39, P103
   KETTERER B, 1988, GLUTATHIONE CONJUGAT, P74
   KULIG MJ, 1973, J ORG CHEM, V38, P3639, DOI 10.1021/jo00960a050
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   LAWRENCE RA, 1976, BIOCHEM BIOPH RES CO, V71, P952, DOI 10.1016/0006-291X(76)90747-6
   LITTLE C, 1972, BIOCHIM BIOPHYS ACTA, V284, P375, DOI 10.1016/0005-2744(72)90133-7
   LITWACK G, 1971, NATURE, V234, P466, DOI 10.1038/234466a0
   LOWRY OH, 1951, J BIOL CHEM, V193, P265
   MALAVASI B, 1992, CHEM PHYS LIPIDS, V62, P209, DOI 10.1016/0009-3084(92)90057-V
   MANNERVIK B, 1982, J BIOL CHEM, V257, P9909
   MANNERVIK B, 1984, FEBS LETT, V174, P289
   MEYER DJ, 1982, FEBS LETT, V150, P499, DOI 10.1016/0014-5793(82)80798-9
   MUKHTAR H, 1995, INT J ONCOL, V6, P37
   OKUDA H, 1986, BIOCHEM PHARMACOL, V35, P535, DOI 10.1016/0006-2952(86)90232-7
   OZAWA N, 1991, BIOCHEM BIOPH RES CO, V178, P242, DOI 10.1016/0006-291X(91)91805-M
   RAZA H, 1991, J INVEST DERMATOL, V96, P463, DOI 10.1111/1523-1747.ep12470150
   RAZA H, 1992, PHARM SKIN, P131
   REDDY AP, 1988, NUCLEIC ACIDS RES, V16, P5557, DOI 10.1093/nar/16.12.5557
   Sakamaki R, 1994, J Atheroscler Thromb, V1, P80
   SINGHAL SS, 1993, BIOCHIM BIOPHYS ACTA, V1163, P266, DOI 10.1016/0167-4838(93)90161-J
   SMITH LL, 1986, MUTAT RES, V161, P39, DOI 10.1016/0027-5107(86)90098-9
   SUN FF, 1986, J BIOL CHEM, V261, P8540
   TENG JI, 1973, J ORG CHEM, V38, P119, DOI 10.1021/jo00941a024
   TIPPING E, 1976, EUR J BIOCHEM, V67, P583, DOI 10.1111/j.1432-1033.1976.tb10724.x
   TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350
   TSUCHIDA S, 1987, EUR J BIOCHEM, V170, P159, DOI 10.1111/j.1432-1033.1987.tb13681.x
   WATABE T, 1979, BIOCHEM BIOPH RES CO, V87, P469, DOI 10.1016/0006-291X(79)91819-9
   WATABE T, 1984, BIOCHIM BIOPHYS ACTA, V795, P60
   WATABE T, 1981, J BIOL CHEM, V256, P2900
   WATABE T, 1982, BIOCHEM BIOPH RES CO, V108, P724, DOI 10.1016/0006-291X(82)90889-0
   Wendel A., 1980, ENZYMATIC BASIS DETO, P333
   YOSHIDA M, 1982, AGR BIOL CHEM TOKYO, V46, P41, DOI 10.1080/00021369.1982.10865023
   YOSHIMURA S, 1980, BIOCHIM BIOPHYS ACTA, V621, P130, DOI 10.1016/0005-2795(80)90068-9
NR 55
TC 33
Z9 35
U1 0
U2 1
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814
SN 0021-9258
J9 J BIOL CHEM
JI J. Biol. Chem.
PD FEB 21
PY 1997
VL 272
IS 8
BP 4763
EP 4769
DI 10.1074/jbc.272.8.4763
PG 7
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA WJ855
UT WOS:A1997WJ85500018
PM 9030530
OA hybrid
DA 2024-02-19
ER

PT J
AU KANEKO, T
   SHIMA, H
   ESUMI, H
   OCHIAI, M
   NAGASE, S
   SUGIMURA, T
   NAGAO, M
AF KANEKO, T
   SHIMA, H
   ESUMI, H
   OCHIAI, M
   NAGASE, S
   SUGIMURA, T
   NAGAO, M
TI MARKED INCREASES OF 2 KINDS OF 2-EXON-SKIPPED ALBUMIN MESSENGER-RNAS
   WITH AGING AND THEIR FURTHER INCREASE BY TREATMENT WITH
   3'-METHYL-4-DIMETHYLAMINOAZOBENZENE IN NAGASE ANALBUMINEMIC RATS
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE CARCINOGEN; RNA SPLICING; MUTATION; PROTEIN SECRETION
ID GENE; SEQUENCE; LIVER; EXON; MUTANT; CELLS; SITE
AB Nagase analbuminemic rats (NARs) have a 7-base-pair deletion at the 5' splice site of the HI intron of the albumin gene. The level of immunohistochemically albumin-positive hepatocytes is about 1 per 10(5) cells in neonatal NARs, increases with age, and further increases with chronic oral treatment with 3'-methyl-4-dimethylaminoazobenzene (3'-MeDAB). The mechanisms involved in the increase in albumin-positive hepatocytes during aging of NARs and their treatment with 3'-MeDAB were analyzed. NARs were found to have four species of albumin mRNA: intact mRNA and those lacking the regions corresponding to exon H, exon G-H, and exon H-I. In 4-week-old NARs, the level of intact albumin mRNA was about 1/4000 of that in normal rats and mRNA lacking the exon H sequence was the major species. In aged and 3'-MeDAB-treated aged NARs, all four species of mRNA increased and the relative proportion of mRNAs lacking two exon sequences to mRNAs lacking one exon sequence was greatly increased, suggesting that aging is associated with changes of the splicing pattern and that 3'-MeDAB treatment enhanced these changes. In aged NARs and 3'-MeDAB-treated aged NARs, there was an increase in the amount of aberrant 60-kDa albumin. The 60-kDa protein could be a translation product of mRNAs lacking two exons, the amount of which increases in aged NARs and 3'-MeDAB-treated NARs.
C1 NATL CANC CTR, RES INST, 5-1-1 TSUKIJI, CHUO KU, TOKYO 104, JAPAN.
   NATL CANC CTR, RES INST, DIV BIOCHEM, CHUO KU, TOKYO 104, JAPAN.
   SASAKI INST, DEPT CHEM, CHIVODA KU, TOKYO, JAPAN.
C3 National Cancer Center - Japan; National Cancer Center - Japan
CR AEBI M, 1986, CELL, V47, P555, DOI 10.1016/0092-8674(86)90620-3
   Brown J.R., 1977, ALBUMIN STRUCTURE FU, P27, DOI 10.1016/B978-0-08-019603-9.50009-0
   BROWN JR, 1982, LIPID PROTEIN INTERA, V1, P26
   CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999
   ESUMI H, 1983, P NATL ACAD SCI-BIOL, V80, P95, DOI 10.1073/pnas.80.1.95
   ESUMI H, 1982, P NATL ACAD SCI-BIOL, V79, P734, DOI 10.1073/pnas.79.3.734
   ESUMI H, 1989, P AM ASSOC CANC RES, V30, P801
   FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431
   Glover D. M., 1985, DNA CLONING
   GRANDCHAMP B, 1989, NUCLEIC ACIDS RES, V17, P6637, DOI 10.1093/nar/17.16.6637
   HOGEBOOM GH, 1948, J BIOL CHEM, V172, P619
   HORBACH GJMJ, 1984, BIOCHIM BIOPHYS ACTA, V783, P60, DOI 10.1016/0167-4781(84)90078-2
   HUMPHRIES RK, 1984, BLOOD, V64, P23
   KRAINER AR, 1984, CELL, V36, P993, DOI 10.1016/0092-8674(84)90049-7
   KRAINER AR, 1990, CELL, V62, P35, DOI 10.1016/0092-8674(90)90237-9
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   MAKINO R, 1982, BIOCHEM BIOPH RES CO, V106, P863, DOI 10.1016/0006-291X(82)91790-9
   MAKINO R, 1986, JPN J CANCER RES, V77, P153
   MARVIT J, 1987, NUCLEIC ACIDS RES, V15, P5613, DOI 10.1093/nar/15.14.5613
   MITCHELL PJ, 1986, MOL CELL BIOL, V6, P1926, DOI 10.1128/MCB.6.6.1926
   NAGASE S, 1979, SCIENCE, V205, P590, DOI 10.1126/science.451621
   ROBBERSON BL, 1990, MOL CELL BIOL, V10, P84, DOI 10.1128/MCB.10.1.84
   Sambrook J., 1989, MOL CLONING LABORATO, V2nd
   SARGENT TD, 1981, P NATL ACAD SCI-BIOL, V78, P243, DOI 10.1073/pnas.78.1.243
   SHALABY F, 1990, P NATL ACAD SCI USA, V87, P2652, DOI 10.1073/pnas.87.7.2652
   SHIMOTOHNO K, 1985, P NATL ACAD SCI USA, V82, P302, DOI 10.1073/pnas.82.2.302
   TAKESHITA K, 1984, BLOOD, V64, P13
   TANAKA H, 1990, EUR J CELL BIOL, V53, P267
   TREISMAN R, 1983, NATURE, V302, P591, DOI 10.1038/302591a0
   TREISMAN R, 1982, CELL, V29, P903, DOI 10.1016/0092-8674(82)90452-4
   WEIL D, 1989, EMBO J, V8, P1705, DOI 10.1002/j.1460-2075.1989.tb03562.x
   WIERINGA B, 1983, NATURE, V301, P38, DOI 10.1038/301038a0
   YUO CY, 1989, MOL CELL BIOL, V9, P3429, DOI 10.1128/MCB.9.8.3429
NR 33
TC 20
Z9 20
U1 0
U2 1
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD APR
PY 1991
VL 88
IS 7
BP 2707
EP 2711
DI 10.1073/pnas.88.7.2707
PG 5
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA FE864
UT WOS:A1991FE86400020
PM 2011581
OA Green Published, Bronze
DA 2024-02-19
ER

PT J
AU Delp, MD
   Evans, MV
   Duan, CP
AF Delp, MD
   Evans, MV
   Duan, CP
TI Effects of aging on cardiac output, regional blood flow, and body
   composition in Fischer-344 rats
SO JOURNAL OF APPLIED PHYSIOLOGY
LA English
DT Article
DE maturation; strain differences
ID AGE-RELATED-CHANGES; ENDOTHELIUM-DEPENDENT VASODILATION;
   CARDIOVASCULAR-RESPONSES; CEREBRAL ARTERIOLES; FAT DISTRIBUTION;
   SKELETAL-MUSCLE; EXERCISE; ARTERY; MICROVASCULATURE; MICROSPHERES
AB The purpose of this study was to determine the effects of maturation and aging on cardiac output, the distribution of cardiac output, tissue blood flow (determined by using the radioactive-microsphere technique), and body composition in conscious juvenile (2-mo-old), adult (6-mo-old), and aged (24-mo-old) male Fischer-344 rats. Cardiac output was lower in juvenile rats (51 +/- 4 ml/min) than in adult (106 +/- 5 ml/min) or aged (119 +/- 10 ml/min) rats, but cardiac index was not different among groups. The proportion of cardiac output going to most tissues did not change with increasing age. However, the fraction of cardiac output to brain and spinal cord tissue and to skeletal muscle was greater in juvenile rats than that in the two adult groups. In addition, aged rats had a greater percent cardiac output to adipose tissue and a lower percent cardiac output to cutaneous and reproductive tissues than that in juvenile and adult rats. Differences in age also had little effect on mass-specific perfusion rates in most tissues. However, juvenile rats had lower flows to the pancreas, gastrointestinal tract, thyroid and parathyroid glands, and kidneys than did adult rats, and aged rats had lower flows to the white portion of rectus femoris muscle, spleen, thyroid and parathyroid glands, and prostate gland than did adult rats. Body mass of juvenile rats was composed of a lower percent adipose mass and a greater fraction of brain and spinal cord, heart, kidney, liver, and skeletal muscle than that of the adult and aged animals. Relative to the young adult rats, the body mass of aged animals had a greater percent adipose tissue mass and a lower percent skeletal muscle and skin mass. These data demonstrate that maturation and aging have a significant effect on the distribution of cardiac output but relatively little influence on mass-specific tissue perfusion rates in conscious rats. The old-age-related alterations in cardiac output distribution to adipose and cutaneous tissues appear to be associated with the increases in percent body fat and the decreases in the fraction of skin mass, respectively, whereas the decrease in the portion of cardiac output directed to reproductive tissue of aged rats appears to be related to a decrease in mass-specific blood flow to the prostate gland.
C1 Texas A&M Univ, Dept Hlth & Kinesiol, College Stn, TX 77843 USA.
   Texas A&M Univ, Dept Med Physiol, College Stn, TX 77843 USA.
   US EPA, Natl Hlth & Environm Effects Res Lab, Res Triangle Pk, NC 27711 USA.
   Allegheny Univ Hlth Sci, Dept Surg, Pittsburgh, PA 15212 USA.
C3 Texas A&M University System; Texas A&M University College Station; Texas
   A&M University System; Texas A&M University College Station; United
   States Environmental Protection Agency
RP Delp, MD (corresponding author), Texas A&M Univ, Dept Hlth & Kinesiol, College Stn, TX 77843 USA.
OI Delp, Michael/0000-0002-2916-0783
CR ANVERSA P, 1990, CIRC RES, V67, P871, DOI 10.1161/01.RES.67.4.871
   BANKS YB, 1990, FUND APPL TOXICOL, V15, P163, DOI 10.1016/0272-0590(90)90173-H
   BERLIN M, 1976, Experimental Aging Research, V2, P125, DOI 10.1080/03610737608257984
   Brown RP, 1997, TOXICOL IND HEALTH, V13, P407, DOI 10.1177/074823379701300401
   COLEMAN GL, 1977, J GERONTOL, V32, P258, DOI 10.1093/geronj/32.3.258
   COOK JJ, 1992, J GERONTOL, V47, pB83, DOI 10.1093/geronj/47.3.B83
   DELP MD, 1995, J APPL PHYSIOL, V78, P2079, DOI 10.1152/jappl.1995.78.6.2079
   DELP MD, 1988, AM J PHYSIOL, V255, pH1509, DOI 10.1152/ajpheart.1988.255.6.H1509
   DELP MD, 1991, AM J PHYSIOL, V261, pH1478
   DESPRES JP, 1990, ARTERIOSCLEROSIS, V10, P497, DOI 10.1161/01.ATV.10.4.497
   DOCHERTY JR, 1990, PHARMACOL REV, V42, P103
   DOHI Y, 1990, BRIT J PHARMACOL, V100, P889, DOI 10.1111/j.1476-5381.1990.tb14110.x
   EGASHIRA K, 1993, CIRCULATION, V88, P77, DOI 10.1161/01.CIR.88.1.77
   ENZI G, 1986, AM J CLIN NUTR, V44, P739, DOI 10.1093/ajcn/44.6.739
   FLAIM SF, 1978, AM J PHYSIOL, V235, pH587, DOI 10.1152/ajpheart.1978.235.5.H587
   FLAIM SF, 1984, J PHARMACOL METHOD, V11, P1, DOI 10.1016/0160-5402(84)90050-0
   FLEG JL, 1988, J APPL PHYSIOL, V65, P1147, DOI 10.1152/jappl.1988.65.3.1147
   FOLKOW B, 1993, PHYSIOL REV, V73, P725, DOI 10.1152/physrev.1993.73.4.725
   Gerhard M, 1996, HYPERTENSION, V27, P849, DOI 10.1161/01.HYP.27.4.849
   HAIDET GC, 1991, AM J PHYSIOL, V260, pH173, DOI 10.1152/ajpheart.1991.260.1.H173
   HAIDET GC, 1992, J APPL PHYSIOL, V73, P2320, DOI 10.1152/jappl.1992.73.6.2320
   HAJDU MA, 1990, CIRC RES, V66, P1747, DOI 10.1161/01.RES.66.6.1747
   HOFFMAN WE, 1982, ANESTHESIOLOGY, V56, P444, DOI 10.1097/00000542-198206000-00007
   HONGO K, 1988, STROKE, V19, P892, DOI 10.1161/01.STR.19.7.892
   IRION GL, 1987, J GERONTOL, V42, P660, DOI 10.1093/geronj/42.6.660
   IRION GL, 1988, EXP GERONTOL, V23, P183, DOI 10.1016/0531-5565(88)90005-8
   ISHISE S, 1980, AM J PHYSIOL, V239, P443
   KISSEBAH AH, 1989, DIABETES METAB REV, V5, P83, DOI 10.1002/dmr.5610050202
   LAUGHLIN MH, 1982, J APPL PHYSIOL, V52, P1629, DOI 10.1152/jappl.1982.52.6.1629
   LAUGHLIN MH, 1994, PHYSICAL ACTIVITY FI, P302
   MARIN J, 1995, MECH AGEING DEV, V79, P71, DOI 10.1016/0047-6374(94)01551-V
   MAYHAN WG, 1990, AM J PHYSIOL, V258, pH1138, DOI 10.1152/ajpheart.1990.258.4.H1138
   MCDONALD RB, 1989, AM J PHYSIOL, V256, pR1069, DOI 10.1152/ajpregu.1989.256.5.R1069
   MORITOKI H, 1986, EUR J PHARMACOL, V126, P61, DOI 10.1016/0014-2999(86)90738-7
   SCHWARTZ RS, 1987, J GERONTOL, V42, P546, DOI 10.1093/geronj/42.5.546
   Sonntag WE, 1997, ENDOCRINOLOGY, V138, P3515, DOI 10.1210/en.138.8.3515
   STANEK KA, 1983, AM J PHYSIOL, V245, pH920, DOI 10.1152/ajpheart.1983.245.6.H920
   TUMA RF, 1985, AM J PHYSIOL, V249, pH485, DOI 10.1152/ajpheart.1985.249.3.H485
   TZANKOFF SP, 1977, J APPL PHYSIOL, V43, P1001, DOI 10.1152/jappl.1977.43.6.1001
   WAHREN J, 1974, SCAND J CLIN LAB INV, V33, P79, DOI 10.3109/00365517409114201
   YATES MS, 1978, EXPERIENTIA, V35, P78
NR 41
TC 116
Z9 138
U1 1
U2 8
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 8750-7587
J9 J APPL PHYSIOL
JI J. Appl. Physiol.
PD NOV
PY 1998
VL 85
IS 5
BP 1813
EP 1822
DI 10.1152/jappl.1998.85.5.1813
PG 10
WC Physiology; Sport Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Physiology; Sport Sciences
GA 136TU
UT WOS:000076875900030
PM 9804586
DA 2024-02-19
ER

PT J
AU Ciana, P
   Biserni, A
   Tatangelo, L
   Tiveron, C
   Sciarroni, AF
   Ottobrini, L
   Maggi, A
AF Ciana, Paolo
   Biserni, Andrea
   Tatangelo, Laura
   Tiveron, Cecilia
   Sciarroni, Anna Floriana
   Ottobrini, Luisa
   Maggi, Adriana
TI A novel peroxisome proliferator-activated receptor responsive
   element-luciferase reporter mouse reveals gender specificity of
   peroxisome proliferator-activated receptor activity in liver
SO MOLECULAR ENDOCRINOLOGY
LA English
DT Article
ID ALPHA PPAR-ALPHA; ESTROGEN-RECEPTOR; GENE-EXPRESSION; IN-VIVO;
   RAT-LIVER; CLOFIBRIC ACID; BETA-OXIDATION; GROWTH-HORMONE; MALE-MICE;
   DIFFERENCE
AB There is a growing interest in peroxisome proliferator-activated receptors (PPARs) as major players in the regulation of lipid and carbohydrate metabolism. Drugs targeting PPARs were in fact shown to have major relevance for the treatment of diseases associated with aging, such as arteriosclerosis and diabetes. However, a variety of toxic effects associated with PPAR ligand administration has been documented, including hepatocarcinogenesis, which may severely limit its therapeutic use. A better comprehension of the multiplicity of PPAR physiological functions is therefore mandatory for the development of novel, safer drugs. We here describe the generation of a novel transgenic mouse for the detection of the generalized activities of PPARs, the PPAR responsive element-Luc reporter mouse. In this model luciferase expression is under the control of a PPAR-inducible promoter in all target organs. By optical imaging and ex vivo analysis, we were able to demonstrate the remarkable gender specificity of the PPAR transcriptional activity in liver. In fact, in the liver of female PPAR responsive element-Luc, the PPAR reporter transgene is more than one order of magnitude less expressed, thus leading to the conclusion that the signaling in females is much less activated than in males. Diet or hormonal manipulations as demonstrated here by treatments with high-fat diet or gonad removal and hormone replacement do not influence this low activation. The extent of the gender difference in PPAR transcriptional activity and the ineffectiveness of hormone treatments or diet to significantly elevate liver PPAR activity in females led us to hypothesize that gender-specific epigenetic events occurring during development may affect PPAR signaling in the liver. This study sets the ground for understanding the differential susceptibility of the two genders to metabolic disorders; furthermore, the model generated provides a novel opportunity for the molecular characterization of PPAR activity in pathophysiological conditions.
C1 Univ Milan, Ctr Excellence Neurodegenerat Dis, Dept Pharmacol Sci, I-20133 Milan, Italy.
   Univ Milan, Inst Radiol Sci, I-20133 Milan, Italy.
   Ist Regina Elena, I-00158 Rome, Italy.
   Sigma Tau Ind Farmaceut Riunite SPA, Dept Endocrinol & Metab, I-00040 Pomezia, Italy.
C3 University of Milan; University of Milan; IRCCS Istituti Fisioterapici
   Ospitalieri (IFO); IRCCS Regina Elena
RP Maggi, A (corresponding author), Univ Milan, Ctr Excellence Neurodegenerat Dis, Dept Pharmacol Sci, I-20133 Milan, Italy.
EM adriana.maggi@unimi.it
RI Ottobrini, Luisa/K-7608-2016; Ciana, Paolo/F-9224-2012
OI Ottobrini, Luisa/0000-0002-5002-6845; Maggi,
   Adriana/0000-0001-5700-5273; CIANA, PAOLO/0000-0001-5771-5638
FU NIA NIH HHS [R01AG027713-01] Funding Source: Medline; Telethon
   [GGP02336] Funding Source: Medline
CR [Anonymous], 1994, MANIPULATING MOUSE E
   Berger J, 1999, EUR J BIOCHEM, V265, P719, DOI 10.1046/j.1432-1327.1999.00772.x
   Berger JP, 2005, TRENDS PHARMACOL SCI, V26, P244, DOI 10.1016/j.tips.2005.03.003
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   Ciana P, 2001, MOL ENDOCRINOL, V15, P1104, DOI 10.1210/me.15.7.1104
   Ciana P, 2003, NAT MED, V9, P82, DOI 10.1038/nm809
   Ciana P, 1998, EMBO J, V17, P7382, DOI 10.1093/emboj/17.24.7382
   Ciana P, 2005, ENDOCRINOLOGY, V146, P5144, DOI 10.1210/en.2005-0660
   Ciana P, 2004, E SCHERING RES FDN W, V46, P151
   Clodfelter KH, 2006, MOL ENDOCRINOL, V20, P1333, DOI 10.1210/me.2005-0489
   Contag CH, 1997, PHOTOCHEM PHOTOBIOL, V66, P523, DOI 10.1111/j.1751-1097.1997.tb03184.x
   Costet P, 1998, J BIOL CHEM, V273, P29577, DOI 10.1074/jbc.273.45.29577
   Di Lorenzo D, 2002, ENDOCRINOLOGY, V143, P4544, DOI 10.1210/en.2002-220448
   Djouadi F, 1998, J CLIN INVEST, V102, P1083, DOI 10.1172/JCI3949
   FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0
   Fourcade S, 2001, EUR J BIOCHEM, V268, P3490, DOI 10.1046/j.1432-1327.2001.02249.x
   Fredenrich A, 2005, DIABETES METAB, V31, P23, DOI 10.1016/S1262-3636(07)70162-3
   Fruchart JC, 1999, CURR OPIN LIPIDOL, V10, P245, DOI 10.1097/00041433-199906000-00007
   GOTTLICHER M, 1992, P NATL ACAD SCI USA, V89, P4653, DOI 10.1073/pnas.89.10.4653
   GRAY RH, 1984, HEPATOLOGY, V4, P520, DOI 10.1002/hep.1840040328
   Harano Y, 2006, LIVER INT, V26, P613, DOI 10.1111/j.1478-3231.2006.01265.x
   HAWKINS JM, 1987, DRUG METAB REV, V18, P441, DOI 10.3109/03602538708994130
   Honigman A, 2001, MOL THER, V4, P239, DOI 10.1006/mthe.2001.0437
   ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0
   Jalouli M, 2003, ENDOCRINOLOGY, V144, P101, DOI 10.1210/en.2002-220630
   KAWASHIMA Y, 1989, BIOCHEM J, V263, P897, DOI 10.1042/bj2630897
   KAWASHIMA Y, 1989, BIOCHEM J, V261, P595, DOI 10.1042/bj2610595
   Kemp S, 1998, NAT MED, V4, P1261, DOI 10.1038/3242
   Kersten S, 1999, J CLIN INVEST, V103, P1489, DOI 10.1172/JCI6223
   KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9
   KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0
   Klotz DM, 2002, J BIOL CHEM, V277, P8531, DOI 10.1074/jbc.M109592200
   LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953
   Leone TC, 1999, P NATL ACAD SCI USA, V96, P7473, DOI 10.1073/pnas.96.13.7473
   Lewitt MS, 2002, INT J OBESITY, V26, P1296, DOI 10.1038/sj.ijo.0802135
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   MA ZQ, 1993, P NATL ACAD SCI USA, V90, P3740, DOI 10.1073/pnas.90.8.3740
   Maggi A, 2005, NAT REV DRUG DISCOV, V4, P249, DOI 10.1038/nrd1661
   Maggi A, 2004, TRENDS PHARMACOL SCI, V25, P337, DOI 10.1016/j.tips.2004.04.007
   Nakajima T, 2000, CARCINOGENESIS, V21, P677, DOI 10.1093/carcin/21.4.677
   Patrone C, 2003, MOL CELL BIOL, V23, P8542, DOI 10.1128/MCB.23.23.8542-8552.2003
   Patrone C, 1998, MOL ENDOCRINOL, V12, P835, DOI 10.1210/me.12.6.835
   Patsouris D, 2006, ENDOCRINOLOGY, V147, P1508, DOI 10.1210/en.2005-1132
   Penza M, 2004, TOXICOLOGY, V205, P65, DOI 10.1016/j.tox.2004.06.038
   Rosen ED, 2000, GENE DEV, V14, P1293
   Stauber AJ, 2005, MOL PHARMACOL, V67, P681, DOI 10.1124/mol.104.007278
   STIEF A, 1989, NATURE, V341, P343, DOI 10.1038/341343a0
   SUGIYAMA H, 1994, BIOCHEM PHARMACOL, V47, P918, DOI 10.1016/0006-2952(94)90494-4
   SUNDSETH SS, 1992, J BIOL CHEM, V267, P3915
   SVOBODA D, 1969, J CELL BIOL, V40, P734, DOI 10.1083/jcb.40.3.734
   Tai ES, 2003, FEBS LETT, V546, P237, DOI 10.1016/S0014-5793(03)00578-7
   TUGWOOD JD, 1992, EMBO J, V11, P433, DOI 10.1002/j.1460-2075.1992.tb05072.x
   Villa R, 2004, TOXICOL APPL PHARM, V201, P137, DOI 10.1016/j.taap.2004.05.007
   YAMADA J, 1991, BIOCHIM BIOPHYS ACTA, V1092, P233, DOI 10.1016/0167-4889(91)90162-Q
   Yang X, 2006, GENOME RES, V16, P995, DOI 10.1101/gr.5217506
NR 55
TC 55
Z9 56
U1 0
U2 8
PU ENDOCRINE SOC
PI WASHINGTON
PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA
SN 0888-8809
J9 MOL ENDOCRINOL
JI Mol. Endocrinol.
PD FEB
PY 2007
VL 21
IS 2
BP 388
EP 400
DI 10.1210/me.2006-0152
PG 13
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Endocrinology & Metabolism
GA 130HP
UT WOS:000243791000006
PM 17158222
OA Bronze
DA 2024-02-19
ER

PT J
AU Bradley, EA
   Pinyoluksana, KO
   Moore-Clingenpeel, M
   Miao, YJ
   Daniels, C
AF Bradley, Elisa A.
   Pinyoluksana, Krong-on
   Moore-Clingenpeel, Melissa
   Miao, Yongjie
   Daniels, Curt
TI Isolated heart transplant and combined heart-liver transplant in adult
   congenital heart disease patients: Insights from the united network of
   organ sharing
SO INTERNATIONAL JOURNAL OF CARDIOLOGY
LA English
DT Article
DE Congenital heart disease; Heart transplant; Fontan; Combined heart-liver
   transplant
ID GENERAL-POPULATION; PREVALENCE; OUTCOMES; CHILDREN; REPAIR; AGE
AB Background/methods: The aging patient with severe congenital heart disease (CHD) faces many challenges: heart failure, arrhythmia, and in the Fontan patient, liver disease. Our goal was to define combined heart liver transplant (CHLT) and isolated orthotopic heart transplant (OHT) outcomes in U.S. adult CHD patients. The U.S. United Network for Organ Sharing (UNOS) thoracic and liver databases were queried for cardiac and CHD diagnoses, from inception-2014.
   Results: In CHLT, CHD made up 22% of waitlist patients (non-CHD n=262 vs. CHD n=58), and 20% of transplanted patients (non-CHD n=137 vs. CHD n=27). Liver function tests in the non-CHD and CHD groups were similar and there was no difference in CHD and non-CHD survival (HR 0.93, CI: 0.36-2.38, p 0.48). In isolated OHT, CHD patients comprised 2% of those listed (non-CHD n=74,080 vs. CHD n=1599) and transplanted (non-CHD n=48,985 vs. CHD n=967) and had higher early (<1year) mortality (HR 1.36, CI: 1.18-1.57, p<0.0001), but better long-term survival (HR 0.66, CI; 0.57-0.76, p<0.001) than non-CHD. Both groups benefitted from mechanical support when used (non-CHD HR 0.34, CI: 0.31-0.37 and CHD HR 0.14, CI: 0.03-0.58) and prior sternotomy had no effect on mortality in CHD (HR 0.63, CI: 0.15-2.58).
   Conclusions: Survival of CHD patients undergoing CHLT is no different than in non-CHD, encouraging consideration of CHLT when clinically appropriate. Short-term mortality is higher in CHD (vs. non-CHD) patients undergoing OHT, regardless of prior cardiac surgery status. Modifications to CHD classification within UNOS would help better understand CHD CHLT and OHT outcomes. (C) 2016 Elsevier Ireland Ltd. All rights reserved.
C1 [Bradley, Elisa A.; Pinyoluksana, Krong-on; Daniels, Curt] Ohio State Univ, 473 W 12h Ave,Suite 200, Columbus, OH 43210 USA.
   [Bradley, Elisa A.; Pinyoluksana, Krong-on; Moore-Clingenpeel, Melissa; Miao, Yongjie; Daniels, Curt] Nationwide Childrens Hosp, 700 Childrens Dr T3, Columbus, OH 43205 USA.
C3 University System of Ohio; Ohio State University; University System of
   Ohio; Ohio State University; Nationwide Childrens Hospital
RP Bradley, EA (corresponding author), 473 W 12th Ave DHL RI,Suite 200, Columbus, OH 43220 USA.
EM elisa.bradley@osumc.edu
RI Moore-Clingenpeel, Melissa/K-7232-2019; Bradley, Elisa/AAB-8276-2020
OI Bradley, Elisa/0000-0003-1479-2988
CR Atluri P, 2014, ANN THORAC SURG, V98, P858, DOI 10.1016/j.athoracsur.2014.04.100
   Bhama JK, 2013, J HEART LUNG TRANSPL, V32, P499, DOI 10.1016/j.healun.2013.01.1047
   Chen JM, 2004, ANN THORAC SURG, V78, P1352, DOI 10.1016/j.athoracsur.2004.04.012
   Colvin-Adams M, 2012, AM J TRANSPLANT, V12, P3213, DOI 10.1111/j.1600-6143.2012.04258.x
   Davies RR, 2011, CIRCULATION, V123, P759, DOI 10.1161/CIRCULATIONAHA.110.960260
   FONTAN F, 1971, THORAX, V26, P240, DOI 10.1136/thx.26.3.240
   Goldberg SW, 2014, J HEART LUNG TRANSPL, V33, P873, DOI 10.1016/j.healun.2014.05.001
   Hill AL, 2012, PEDIATR TRANSPLANT, V16, P392, DOI 10.1111/j.1399-3046.2012.01695.x
   Hollander SA, 2013, J HEART LUNG TRANSPL, V32, P368, DOI 10.1016/j.healun.2012.11.023
   Horai T, 2011, ANN THORAC SURG, V91, P600, DOI 10.1016/j.athoracsur.2010.07.078
   John AS, 2015, CARDIOL CLIN, V33, P559, DOI 10.1016/j.ccl.2015.07.010
   Lamour JM, 2009, J AM COLL CARDIOL, V54, P160, DOI 10.1016/j.jacc.2009.04.020
   Lewis M.D., 2015, J CARD FAIL, P1
   Marelli AJ, 2007, CIRCULATION, V115, P163, DOI 10.1161/CIRCULATIONAHA.106.627224
   Marelli AJ, 2014, CIRCULATION, V130, P749, DOI 10.1161/CIRCULATIONAHA.113.008396
   Mori M, 2014, PEDIATR CARDIOL, V35, P569, DOI 10.1007/s00246-014-0881-y
   Nagpal AD, 2013, ANN THORAC SURG, V95, P179, DOI 10.1016/j.athoracsur.2012.09.010
   Patel ND, 2009, ANN THORAC SURG, V88, P814, DOI 10.1016/j.athoracsur.2009.04.071
   Pigula FA, 2001, J HEART LUNG TRANSPL, V20, P297, DOI 10.1016/S1053-2498(00)00229-1
   Raichlin E, 2014, TRANSPLANTATION, V98, pE100, DOI 10.1097/TP.0000000000000542
   Simpson KE, 2014, J HEART LUNG TRANSPL, V33, P170, DOI 10.1016/j.healun.2013.10.033
   Speziali G, 1998, MAYO CLIN PROC, V73, P923, DOI 10.4065/73.10.923
   Te HS, 2008, J HEART LUNG TRANSPL, V27, P753, DOI 10.1016/j.healun.2008.04.004
   Vallabhajosyula P, 2012, J HEART LUNG TRANSPL, V31, pS112, DOI 10.1016/j.healun.2012.01.322
   Vallabhajosyula P, 2013, J THORAC CARDIOV SUR, V145, pE39, DOI 10.1016/j.jtcvs.2012.12.066
NR 25
TC 40
Z9 39
U1 6
U2 12
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0167-5273
EI 1874-1754
J9 INT J CARDIOL
JI Int. J. Cardiol.
PD FEB 1
PY 2017
VL 228
BP 790
EP 795
DI 10.1016/j.ijcard.2016.11.121
PG 6
WC Cardiac & Cardiovascular Systems
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cardiovascular System & Cardiology
GA EJ7NJ
UT WOS:000393408600124
PM 27888756
DA 2024-02-19
ER

PT J
AU Ayala, A
   Cutler, RG
AF Ayala, A
   Cutler, RG
TI Comparison of 5-hydroxy-2-amino valeric acid with carbonyl group content
   as a marker of oxidized protein in human and mouse liver tissues
SO FREE RADICAL BIOLOGY AND MEDICINE
LA English
DT Article
DE 5-hydroxy-2-amino-valeric acid; protein oxidation; hyperoxia; P450
   cytochrome; aging; free radicals
ID OXIDATIVELY MODIFIED PROTEINS; GLUTAMINE-SYNTHETASE; SELECTIVE
   PROTEOLYSIS; GENE-EXPRESSION; CYTOCHROME-P-450; INACTIVATION;
   CARCINOGENS; DITYROSINE; HEMOGLOBIN; SYSTEM
AB Previous studies indicate that 5-hydroxy-2-amino valeric acid (HAVA) is an excellent marker of oxidized arginine and proline in purified proteins. We report here experiments testing the specificity of the HAVA assay a technique using the unpurified 100,000 x g supernatant fraction prepared from mice and human liver tissue. Results are compared to carbonyl group analysis on the same tissue samples. Mice at ages 3, 12, and 30 months were exposed to 100% oxygen. Results showed a significant increase of HAVA content in each age group. No significant changes were found in carbonyl group content. Because it has been reported that carbonyl group content increases with age, we applied the HAVA assay to reexamine this question. Using mice of 1 to 30 months of age, we failed to detect any significance difference in either HAVA or carbonyl group content. However, on using human liver samples a significant decrease from age 16 to 40 years and then an increase to 85 years of age was found for both HAVA and carbonyl groups. Liver proteins may be oxidized from hydrogen peroxide produced from the cytochrome P450 detoxification system. This possibility was supported by a significant positive correlation found between HAVA and cytochrome P450 content in 18 human individuals of different ages.
C1 NIA, CTR GERONTOL RES, NIH, BALTIMORE, MD 21224 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Institute on
   Aging (NIA)
CR AYALA A, UNPUB PRODUCTION 5 H
   Cutler R.G., 1984, P1
   Cutler RG, 1986, PHYSL OXYGEN RADICAL, P251
   FAHMY MJ, 1983, CANCER RES, V43, P801
   FAHMY MJ, 1983, TERATOGEN CARCIN MUT, V3, P27, DOI 10.1002/1520-6866(1990)3:1<27::AID-TCM1770030105>3.0.CO;2-U
   GIULIVI C, 1994, METHOD ENZYMOL, V233, P363
   GIULIVI C, 1993, J BIOL CHEM, V268, P8752
   JOHANNESEN KAM, 1978, ANAL BIOCHEM, V86, P725, DOI 10.1016/0003-2697(78)90800-X
   KATO R, 1979, PHARMACOL THERAPEUT, V6, P41, DOI 10.1016/0163-7258(79)90056-1
   KIM K, 1985, J BIOL CHEM, V260, P5394
   LENZ AG, 1989, ANAL BIOCHEM, V177, P419, DOI 10.1016/0003-2697(89)90077-8
   LEVINE RL, 1990, METHOD ENZYMOL, V186, P464
   LEVINE RL, 1994, METHOD ENZYMOL, V233, P346
   LEVINE RL, 1983, J BIOL CHEM, V258, P1828
   LEVINE RL, 1983, J BIOL CHEM, V258, P1823
   LEVINE RL, 1983, J BIOL CHEM, V258, P11833
   NAKAMURA K, 1985, ARCH BIOCHEM BIOPHYS, V240, P319, DOI 10.1016/0003-9861(85)90037-2
   OLIVER CN, 1987, J AM GERIATR SOC, V35, P947, DOI 10.1111/j.1532-5415.1987.tb02297.x
   OMURA T, 1964, J BIOL CHEM, V239, P2370
   SMITH CD, 1992, ANN NY ACAD SCI, V663, P110, DOI 10.1111/j.1749-6632.1992.tb38654.x
   Stadtman E R, 1992, EXS, V62, P64
   Stadtman ER, 2006, FREE RADICAL RES, V40, P1250, DOI 10.1080/10715760600918142
   STADTMAN ER, 1986, TRENDS BIOCHEM SCI, V11, P11, DOI 10.1016/0968-0004(86)90221-5
   STADTMAN ER, 1993, TOXICOL IND HEALTH, V9, P187, DOI 10.1177/0748233793009001-213
   STADTMAN ER, 1990, FREE RADICAL BIO MED, V9, P315, DOI 10.1016/0891-5849(90)90006-5
   STARKE PE, 1987, FASEB J, V1, P36, DOI 10.1096/fasebj.1.1.2886388
NR 26
TC 13
Z9 13
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0891-5849
EI 1873-4596
J9 FREE RADICAL BIO MED
JI Free Radic. Biol. Med.
PY 1996
VL 21
IS 4
BP 551
EP 558
DI 10.1016/0891-5849(96)00125-6
PG 8
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA VH624
UT WOS:A1996VH62400017
PM 8886807
DA 2024-02-19
ER

PT J
AU Albright, JW
   Mease, RC
   Lambert, C
   Albright, JF
AF Albright, JW
   Mease, RC
   Lambert, C
   Albright, JF
TI Effects of aging on the dynamics of lymphocyte organ distribution in
   mice: use of a radioiodinated cell membrane probe
SO MECHANISMS OF AGEING AND DEVELOPMENT
LA English
DT Article
DE derivatized aminostyrylpyridinium dye; lymphocytes; splenic
   microenvironment
ID T-CELLS; EXTRACELLULAR-MATRIX; IMMUNE-SYSTEM; VASCULAR ADDRESSIN;
   CIRCULATING T; B LYMPHOCYTES; L-SELECTIN; MIGRATION; MOUSE; EXPRESSION
AB We have employed a derivatized aminostyrylpyridinium dye, [I-125]I2P-Di-6-ASP, to provide a relatively stable tag on mixed mouse splenocytes and purified B and T cells for the purpose of tracking the distribution of those cells among the organs of normal young (4 months) and aged (> 26 months) recipient mice. Cells from both young and aged donor spleens were studied. Special emphasis was placed on localization of donor cells in the spleens of the recipients because the majority of circulating lymphocytes localize in the spleen and the spleen is the principal organ of primary immune response. There was a profound difference in the efficiency of splenic acquisition of donor cells between young and aged recipients, a difference not found in the liver, lungs, kidneys or heart. In contrast young and old donor lymphocytes lodged equally well in the spleens of recipients of the same age. It was clear that the competence of the splenic microenvironment to serve as a lodging site for circulating lymphocytes deteriorated with age. Such a change could contribute significantly to the deficient immune response of aged subjects. We suggest that aging results in significant change in the splenic extracellular matrix to serve as an adhesive substratum for lymphocytes. Our data point to a need for detailed studies on age-related changes in components of the extracellular matrix within lymphoid tissues. The novel compound which we employed for cell labeling is both radioactive and fluorescent and should be quite suitable for such studies. (C) 1998 Elsevier Science Ireland Ltd. All rights reserved.
C1 George Washington Univ, Sch Med, Dept Immunol & Microbiol, Washington, DC 20037 USA.
   George Washington Univ, Sch Med, Dept Radiol, Washington, DC 20037 USA.
C3 George Washington University; George Washington University
RP Albright, JW (corresponding author), George Washington Univ, Sch Med, Dept Immunol & Microbiol, 2300 1 St NW, Washington, DC 20037 USA.
FU NCI NIH HHS [CA 32853] Funding Source: Medline; NIA NIH HHS [AG 14545]
   Funding Source: Medline
CR ALBRIGHT JW, 1988, J IMMUNOL, V141, P1318
   [Anonymous], [No title captured]
   AUDRAN R, 1995, NUCL MED BIOL, V22, P817, DOI 10.1016/0969-8051(95)00013-N
   BARRAT F, 1995, RES IMMUNOL, V146, P23, DOI 10.1016/0923-2494(96)80237-9
   BERG EL, 1991, J CELL BIOL, V114, P343, DOI 10.1083/jcb.114.2.343
   BERLIN C, 1993, CELL, V74, P185, DOI 10.1016/0092-8674(93)90305-A
   Butcher EC, 1996, SCIENCE, V272, P60, DOI 10.1126/science.272.5258.60
   CHISHOLM PM, 1979, J NUCL MED, V20, P1308
   COHEN LB, 1974, J MEMBRANE BIOL, V19, P1, DOI 10.1007/BF01869968
   DESOUSA M, 1991, IMMUNOL TODAY, V12, P262, DOI 10.1016/0167-5699(91)90123-B
   ELICES MJ, 1990, CELL, V60, P577, DOI 10.1016/0092-8674(90)90661-W
   ERNST DN, 1990, J IMMUNOL, V145, P1295
   FORD WL, 1975, PROG ALLERGY, V19, P1, DOI 10.1159/000313381
   GALLATIN WM, 1983, NATURE, V304, P30, DOI 10.1038/304030a0
   GOWANS JL, 1964, PROC R SOC SER B-BIO, V159, P257, DOI 10.1098/rspb.1964.0001
   GRAY B, 1991, Journal of Nuclear Medicine, V32, P1092
   HANNA MG, 1967, P SOC EXP BIOL MED, V125, P882
   HOFER KH, 1984, BLOOD CELLS NUCL M 2, P244
   ISSEKUTZ TB, 1991, J IMMUNOL, V147, P4178
   LABATROBERT J, 1992, ANN NY ACAD SCI, V673, P16, DOI 10.1111/j.1749-6632.1992.tb27431.x
   Lambert C, 1996, NUCL MED BIOL, V23, P417, DOI 10.1016/0969-8051(95)02101-9
   LEVESQUE JP, 1991, IMMUNOL TODAY, V12, P258, DOI 10.1016/0167-5699(91)90122-A
   MACASKILL JA, 1980, IMMUNOLOGY, V40, P629
   Mackay CR, 1996, EUR J IMMUNOL, V26, P2433, DOI 10.1002/eji.1830261025
   MACKAY CR, 1993, ADV IMMUNOL, V53, P217, DOI 10.1016/S0065-2776(08)60501-5
   MACKAY CR, 1990, J EXP MED, V171, P801, DOI 10.1084/jem.171.3.801
   Makinodan T, 1980, Adv Immunol, V29, P287, DOI 10.1016/S0065-2776(08)60047-4
   OHTSUKA A, 1992, CELL TISSUE RES, V269, P403, DOI 10.1007/BF00353895
   PABST R, 1989, IMMUNOL REV, V108, P83, DOI 10.1111/j.1600-065X.1989.tb00014.x
   PICKER LJ, 1992, ANNU REV IMMUNOL, V10, P561, DOI 10.1146/annurev.iy.10.040192.003021
   POBER JS, 1991, ADV IMMUNOL, V50, P261
   PRICE GB, 1972, J IMMUNOL, V108, P413
   SHIMIZU Y, 1991, FASEB J, V5, P2292, DOI 10.1096/fasebj.5.9.1860621
   SPRENT J, 1973, CELL IMMUNOL, V7, P40, DOI 10.1016/0008-8749(73)90181-0
   SPRENT J, 1973, CELL IMMUNOL, V7, P10, DOI 10.1016/0008-8749(73)90180-9
   SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9
   Steeber DA, 1996, J IMMUNOL, V157, P1096
   SWARTZENDRUBER D, 1961, AM J PHYSIOL, V200, P1272, DOI 10.1152/ajplegacy.1961.200.6.1272
   SZAKAL AK, 1990, ANAT REC, V227, P475, DOI 10.1002/ar.1092270411
   TENBERGE RJM, 1983, J NUCL MED, V24, P615
   WALLACE PK, 1993, CANCER RES, V53, P2358
   WEST MD, 1994, ARCH DERMATOL, V130, P87, DOI 10.1001/archderm.130.1.87
   WESTERMANN J, 1994, EUR J IMMUNOL, V24, P2312, DOI 10.1002/eji.1830241008
   WYSOCKI LJ, 1978, P NATL ACAD SCI USA, V75, P2844, DOI 10.1073/pnas.75.6.2844
NR 44
TC 10
Z9 10
U1 0
U2 1
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0047-6374
EI 1872-6216
J9 MECH AGEING DEV
JI Mech. Ageing Dev.
PD APR 1
PY 1998
VL 101
IS 3
BP 197
EP 211
DI 10.1016/S0047-6374(97)00145-0
PG 15
WC Cell Biology; Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Geriatrics & Gerontology
GA ZM092
UT WOS:000073503900002
PM 9622224
DA 2024-02-19
ER

PT J
AU Labenz, C
   Kostev, K
   Kaps, L
   Galle, PR
   Schattenberg, JM
AF Labenz, Christian
   Kostev, Karel
   Kaps, Leonard
   Galle, Peter R.
   Schattenberg, Joern M.
TI Incident Dementia in Elderly Patients with Nonalcoholic Fatty Liver
   Disease in Germany
SO DIGESTIVE DISEASES AND SCIENCES
LA English
DT Article; Early Access
DE Cognitive decline; Cognitive impairment; Aging; Metabolic inflammation;
   Database research study
ID STEATOHEPATITIS; ASSOCIATION
AB Dementia and NAFLD are two frequent conditions that share underlying risk factors mainly in the realm of metabolic disease. Additionally, an association between NAFLD and brain aging has been proposed. Therefore, we investigated the hypothesis if NAFLD is an independent risk factor for emerging dementia. In this population-based cohort study, elderly patients (>= 65 years) with NAFLD diagnosed between 2000 and 2015 were matched 1:1 to a cohort without NAFLD based on ICD-10 coding in the Disease Analyzer database. Matching criteria were age, sex, physician, index year, and co-diagnoses associated with dementia. The primary outcomes of this study were all-cause dementia diagnoses, the incidence of vascular dementia, and antidementive drug prescription. A total of 22,317 patients with NAFLD were matched to 22,317 patients without NAFLD. Within 10 years of the index date, 16.0% of patients with NAFLD and 15.6% of the patients without NAFLD were diagnosed with dementia. On Cox regression analysis, there is no association between NAFLD and the incidence of all-cause dementia (HR 0.97, 95% CI 0.92-1.04), vascular dementia (HR 0.89, 95% CI 0.78-1.02), or the new prescription of antidementive therapy (HR 0.87, 95% CI 0.76-1.01). In sensitivity analyses, there was no association between NAFLD and dementia in different age-groups as well as men or women. In conclusion, in this database study of elderly patients coded with NAFLD no independent association with incident dementia was detected. Risk assessment regarding dementia in patients with NAFLD should be carried out in the same way as for metabolic burdened patients.
C1 [Labenz, Christian; Kaps, Leonard; Galle, Peter R.; Schattenberg, Joern M.] Johannes Gutenberg Univ Mainz, Dept Internal Med 1, Univ Med Ctr, Mainz, Germany.
   [Labenz, Christian; Galle, Peter R.; Schattenberg, Joern M.] Johannes Gutenberg Univ Mainz, Cirrhosis Ctr Mainz CCM, Univ Med Ctr, Mainz, Germany.
   [Labenz, Christian; Kaps, Leonard; Schattenberg, Joern M.] Johannes Gutenberg Univ Mainz, Dept Med 1, Metab Liver Res Program, Univ Med Ctr, Langenbeckstr 1, D-55131 Mainz, Germany.
   [Kostev, Karel] IQVIA, Epidemiol, Frankfurt, Germany.
C3 Johannes Gutenberg University of Mainz; Johannes Gutenberg University of
   Mainz; Johannes Gutenberg University of Mainz; IQVIA
RP Schattenberg, JM (corresponding author), Johannes Gutenberg Univ Mainz, Dept Internal Med 1, Univ Med Ctr, Mainz, Germany.; Schattenberg, JM (corresponding author), Johannes Gutenberg Univ Mainz, Cirrhosis Ctr Mainz CCM, Univ Med Ctr, Mainz, Germany.; Schattenberg, JM (corresponding author), Johannes Gutenberg Univ Mainz, Dept Med 1, Metab Liver Res Program, Univ Med Ctr, Langenbeckstr 1, D-55131 Mainz, Germany.
EM joern.schattenberg@unimedizin-mainz.de
RI Kostev, Karel/S-4755-2019; Schattenberg, Jörn M./C-1301-2013; Galle,
   Peter/ABE-2872-2021; Galle, Peter R/T-5292-2018
OI Kostev, Karel/0000-0002-2124-7227; Schattenberg, Jörn
   M./0000-0002-4224-4703; Galle, Peter/0000-0001-8294-0992; Galle, Peter
   R/0000-0001-8294-0992
FU Projekt DEAL
FX Open Access funding enabled and organized by Projekt DEAL. This work was
   not supported by any grant or funding source.
CR Alexander M, 2019, BMC MED, V17, DOI 10.1186/s12916-019-1321-x
   Azzu V, 2020, GASTROENTEROLOGY, V158, P1899, DOI 10.1053/j.gastro.2019.12.054
   Bu XL, 2015, EUR J NEUROL, V22, P1519, DOI 10.1111/ene.12477
   Eslam M, 2020, J HEPATOL, V73, P202, DOI 10.1016/j.jhep.2020.03.039
   Estes C, 2018, J HEPATOL, V69, P896, DOI 10.1016/j.jhep.2018.05.036
   Estrada LD, 2019, FRONT AGING NEUROSCI, V11, DOI 10.3389/fnagi.2019.00174
   Gehrke N, 2020, GASTROENTEROLOGY, V158, P1929, DOI 10.1053/j.gastro.2020.02.020
   Huber Y, 2019, CLIN GASTROENTEROL H, V17, P2085, DOI 10.1016/j.cgh.2018.12.016
   Kanekiyo T, 2014, FRONT AGING NEUROSCI, V6, DOI 10.3389/fnagi.2014.00093
   Kaps L, 2020, UNITED EUR GASTROENT, V8, P942, DOI 10.1177/2050640620944098
   Karbalaei Reza, 2018, Gastroenterol Hepatol Bed Bench, V11, P27
   Kim DG, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-015-0467-5
   Labenz C, 2020, DIGEST DIS SCI, V65, P2112, DOI 10.1007/s10620-019-05986-9
   Labenz C, 2019, HEPATOL COMMUN, V3, P1472, DOI 10.1002/hep4.1428
   Labenz C, 2018, ALIMENT PHARM THER, V48, P1109, DOI 10.1111/apt.14976
   Lazarus JV, 2020, NAT REV GASTRO HEPAT, V17, P377, DOI 10.1038/s41575-020-0315-7
   Maher JJ, 2020, GASTROENTEROLOGY, V158, P1849, DOI 10.1053/j.gastro.2020.04.013
   Nho K, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2019.7978
   Petta S, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000003446
   Rathmann W, 2018, INT J CLIN PHARM TH, V56, P459, DOI 10.5414/CP203320
   Rolle A, 2018, BRIT J ANAESTH, V120, P969, DOI 10.1016/j.bja.2018.01.040
   Schattenberg JM, 2019, BMC MED, V17, DOI 10.1186/s12916-019-1357-y
   Schattenberg JM, 2011, CURR OPIN LIPIDOL, V22, P479, DOI 10.1097/MOL.0b013e32834c7cfc
   Schuppan D, 2013, J GASTROEN HEPATOL, V28, P68, DOI 10.1111/jgh.12212
   Taylor RS, 2020, GASTROENTEROLOGY, V158, P1611, DOI 10.1053/j.gastro.2020.01.043
   Weinstein G, 2019, LIVER INT, V39, P1713, DOI 10.1111/liv.14161
   Weinstein G, 2018, JAMA NEUROL, V75, P97, DOI 10.1001/jamaneurol.2017.3229
   Younossi Z, 2019, HEPATOLOGY, V69, P2672, DOI 10.1002/hep.30251
NR 28
TC 30
Z9 30
U1 0
U2 1
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0163-2116
EI 1573-2568
J9 DIGEST DIS SCI
JI Dig. Dis. Sci.
PD 2021 SEP
PY 2021
VL 66
IS 9
BP 3179
EP 3185
DI 10.1007/s10620-020-06644-1
EA OCT 2020
PG 7
WC Gastroenterology & Hepatology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Gastroenterology & Hepatology
GA UD4NG
UT WOS:000578483700003
PM 33037968
OA Green Published
DA 2024-02-19
ER

PT J
AU Dawson, HD
   Li, NQ
   DeCicco, KL
   Nibert, JA
   Ross, AC
AF Dawson, HD
   Li, NQ
   DeCicco, KL
   Nibert, JA
   Ross, AC
TI Chronic marginal vitamin A status reduces natural killer cell number and
   function in aging Lewis rats
SO JOURNAL OF NUTRITION
LA English
DT Article
DE aging; immunophenotyping; vitamin A supplementation; liver function;
   rats
ID HEALTHY ELDERLY POPULATION; ALPHA-TOCOPHEROL; LYMPHOCYTE SUBSETS; A
   SUPPLEMENTATION; PLASMA RETINOL; DIETARY; EXPRESSION; CAROTENE; PROTEIN;
   ESTERS
AB Natural killer (NK) cells function in the regulation of immune responses and, in the surveillance of malignant or other abnormal cells. Little is known of the effects of chronic marginal vitamin A (VA) status or VA supplementation, or their interaction with age, on NK cell number and: cytolytic activity. We have conducted a two-factor (diet, age) study in which male Lewis rats were fed AIN-93M diet, modified to contain either 0.3 (designated marginal), 4.0 (control) or 50 (supplemented) mg retinol equivalents (RE)/kg diet, from the time of weaning until the ages of 2.5 mo (young), 8-10 mo (middle-aged) or 18-20 mo (old). Natural killer cells were identified and quantified in peripheral blood mononuclear cells (PBMC) and spleen with the use of flow cytometry, and NK cell cytotoxicity was assayed. The number and percentage of PBMC NK cells increased with age (P < 0.0001 by two-way ANOVA). For all age groups, values were lowest in rats with marginal VA status (P < 0.0001 vs. controls). NK cell lytic activity also declined with age (P = 0.0003). As a result, NK cell lytic efficiency (lytic activity per NK cell) decreased markedly with age (P < 0.0001); Regardless of the donor's age or VA status, PBMC NK cell cytotoxicity doubled (100 +/- 25% increase) after exposure to interferon-alpha (5 x 10(5) u/L for 1 h before assay), indicating that IFN-stimulated lytic activity was related directly to basal NK cell activity. If the relationships observed in this animal model can be applied to humans, these data suggest that elderly people consuming diets chronically low in VA may be at increased risk for infectious or neoplastic diseases.
C1 Penn State Univ, Dept Nutr, University Pk, PA 16802 USA.
   Penn State Univ, Grad Program Nutr, University Pk, PA 16802 USA.
C3 Pennsylvania Commonwealth System of Higher Education (PCSHE);
   Pennsylvania State University; Pennsylvania State University -
   University Park; Pennsylvania Commonwealth System of Higher Education
   (PCSHE); Pennsylvania State University; Pennsylvania State University -
   University Park
RP Ross, AC (corresponding author), Penn State Univ, Dept Nutr, University Pk, PA 16802 USA.
RI Dawson, Harry/H-8242-2013; Dawson, Harry/ABG-2734-2021
OI Dawson, Harry/0000-0002-7648-9952; DeCicco-Skinner,
   Kathleen/0000-0002-0256-5609
FU NIA NIH HHS [AG-09739] Funding Source: Medline; NIDDK NIH HHS [R01
   DK041479, DK-41479] Funding Source: Medline
CR [Anonymous], CANC TREAT S
   [Anonymous], [No title captured]
   ANVER MR, 1982, EXPT AGING RES, V8, P3
   AZAISBRAESCO V, 1995, INT J VITAM NUTR RES, V65, P151
   BOWMAN TA, 1990, J NUTR, V120, P1264, DOI 10.1093/jn/120.10.1264
   BRADFIELD JF, 1992, LAB ANIM SCI, V42, P572
   DAWSON HD, 1999, IN PRESS CHRONIC MAR
   Fortes C, 1998, J AM GERIATR SOC, V46, P19, DOI 10.1111/j.1532-5415.1998.tb01008.x
   FRAKER LD, 1986, CANCER IMMUNOL IMMUN, V21, P114
   FUKUI H, 1987, J LEUKOCYTE BIOL, V41, P130, DOI 10.1002/jlb.41.2.130
   GARRY PJ, 1982, AM J CLIN NUTR, V36, P319, DOI 10.1093/ajcn/36.2.319
   GHONEUM M, 1987, IMMUNOLOGY, V60, P461
   GILMANSACHS A, 1991, J GERONTOL, V46, pB101, DOI 10.1093/geronj/46.3.B101
   GOONEWARDENE IM, 1993, MECH AGEING DEV, V71, P199
   GREEN MH, 1987, J NUTR, V117, P694, DOI 10.1093/jn/117.4.694
   HALLFRISCH J, 1994, AM J CLIN NUTR, V60, P176, DOI 10.1093/ajcn/60.2.176
   HARTZ SC, 1988, J AM COLL NUTR, V7, P119, DOI 10.1080/07315724.1988.10720228
   HUSSAIN MM, 1989, J BIOL CHEM, V264, P17931
   Kidd P, 1997, MANUAL CLIN LAB IMMU, P229
   Kos FJ, 1998, IMMUNOL RES, V17, P303, DOI 10.1007/BF02786453
   KRASINSKI SD, 1989, AM J CLIN NUTR, V49, P112, DOI 10.1093/ajcn/49.1.112
   MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9
   Miller Richard A., 1995, P555
   Page GG, 1995, J NEUROIMMUNOL, V63, P69
   PANEMANGALORE M, 1992, J GERONTOL, V47, pB98, DOI 10.1093/geronj/47.3.B98
   PASTORINO U, 1991, ONCOLOGY-BASEL, V48, P131
   PELEGRI C, 1995, J IMMUNOL METHODS, V187, P265, DOI 10.1016/0022-1759(95)00193-1
   PROSS HF, 1981, J CLIN IMMUNOL, V1, P51, DOI 10.1007/BF00915477
   REEVES PG, 1993, J NUTR, V123, P1939, DOI 10.1093/jn/123.11.1939
   Ross A. Catharine, 1994, P521
   SANTONI A, 1986, NAT IMMUN CELL GROW, V5, P259
   SLACK J, 1977, BRIT MED J, V2, P353, DOI 10.1136/bmj.2.6083.353
   STAUBER PM, 1991, AM J CLIN NUTR, V54, P878, DOI 10.1093/ajcn/54.5.878
   THOMPSON SC, 1986, CYTOMETRY, V7, P184, DOI 10.1002/cyto.990070210
   WOLFORD ST, 1986, J TOXICOL ENV HEALTH, V18, P161, DOI 10.1080/15287398609530859
   ZHAO ZR, 1994, NAT IMMUN, V13, P29
   ZOLFAGHARI R, 1995, ARCH BIOCHEM BIOPHYS, V323, P258, DOI 10.1006/abbi.1995.9966
NR 37
TC 50
Z9 58
U1 0
U2 4
PU AMER INST NUTRITION
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-3166
J9 J NUTR
JI J. Nutr.
PD AUG
PY 1999
VL 129
IS 8
BP 1510
EP 1517
DI 10.1093/jn/129.8.1510
PG 8
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Nutrition & Dietetics
GA 219PW
UT WOS:000081616500003
PM 10419983
OA hybrid
DA 2024-02-19
ER

PT J
AU Liang, YR
   Gao, YQ
   Hua, R
   Lu, MY
   Chen, HL
   Wang, ZR
   Li, LY
   Hu, KQ
   Yin, YM
   Xu, K
   Gao, HQ
   Liu, QF
   Qiu, Y
   Wang, Z
AF Liang, Yaru
   Gao, Yuqi
   Hua, Rui
   Lu, Maoyang
   Chen, Huiling
   Wang, Zhuoran
   Li, Liyuan
   Hu, Kaiqiang
   Yin, Yuemiao
   Xu, Kang
   Gao, Hongqi
   Liu, Qingfei
   Qiu, Ying
   Wang, Zhao
TI Calorie intake rather than food quantity consumed is the key factor for
   the anti-aging effect of calorie restriction
SO AGING-US
LA English
DT Article
DE calorie restriction; food quantity; calorie intake; healthspan; fatty
   acid biosynthesis
ID LIFE-SPAN; DIETARY RESTRICTION; RESVERATROL; RATS; MICE; AGE; LONGEVITY;
   SURVIVAL; DISEASE; HEALTH
AB Although calorie restriction has been reported to extend lifespan in several organisms, animals subjected to calorie restriction consume not only fewer calories but also smaller quantities of food. Whether it is the overall restriction of calories or the coincidental reduction in the quantity of food consumed that mediates the antiaging effects is unclear. Here, we subjected mice to five dietary interventions. We showed that both calorie and quantity restriction could improve early survival, but no maximum lifespan extension was observed in the mice fed isocaloric diet in which food quantity was reduced. Mice fed isoquant diet with fewer calories showed maximum lifespan extension and improved health among all the groups, suggesting that calorie intake rather than food quantity consumed is the key factor for the anti-aging effect of calorie restriction. Midlife liver gene expression correlations with lifespan revealed that calorie restriction raised fatty acid biosynthesis and metabolism and biosynthesis of amino acids but inhibited carbon metabolism, indicating different effects on fatty acid metabolism and carbohydrate metabolism. Our data illustrate the effects of calories and food quantity on the lifespan extension by calorie restriction and their potential mechanisms, which will provide guidance on the application of calorie restriction to humans. Copyright: (c) 2021 Liang et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
C1 [Liang, Yaru; Gao, Yuqi; Hua, Rui; Lu, Maoyang; Chen, Huiling; Li, Liyuan; Hu, Kaiqiang; Yin, Yuemiao; Xu, Kang; Liu, Qingfei; Wang, Zhao] Tsinghua Univ, Sch Pharmaceut Sci, MOE Key Lab Prot Sci, Beijing 100084, Peoples R China.
   [Wang, Zhuoran] Duke Univ, Sch Med, Dept Anesthesiol, Durham, NC 27708 USA.
   [Gao, Hongqi; Qiu, Ying] Tsinghua Univ, Sch Med, Beijing 100084, Peoples R China.
C3 Tsinghua University; Duke University; Tsinghua University
RP Wang, Z (corresponding author), Tsinghua Univ, Sch Pharmaceut Sci, MOE Key Lab Prot Sci, Beijing 100084, Peoples R China.
EM zwang@tsinghua.edu.cn
RI chen, hui/HDO-2955-2022; Xu, Kang/JEF-2563-2023
OI Xu, Kang/0000-0002-6946-8635
FU National Natural Science Foundation of China [81471396]; National Key
   R&D Program of China [2018YFD0400204]; Key International S&T Cooperation
   Program of China [2016YFE113700]; European Union [633589]
FX This work was financially supported by grants from the National Natural
   Science Foundation of China (No. 81471396), the National Key R&D Program
   of China (2018YFD0400204), the Key International S&T Cooperation Program
   of China (2016YFE113700), and the European Union's Horizon 2020 Research
   and Innovation Program (633589).
CR Baur JA, 2006, NATURE, V444, P337, DOI 10.1038/nature05354
   BERNABEU R, 1995, NEUROREPORT, V6, P1498, DOI 10.1097/00001756-199507310-00008
   Bordone L, 2005, NAT REV MOL CELL BIO, V6, P298, DOI 10.1038/nrm1616
   Brandhorst S, 2015, CELL METAB, V22, P86, DOI 10.1016/j.cmet.2015.05.012
   Brunt EM, 2004, HUM PATHOL, V35, P1070, DOI 10.1016/j.humpath.2004.04.017
   Cantó C, 2011, PHYSIOLOGY, V26, P214, DOI 10.1152/physiol.00010.2011
   Chapman T, 1996, P ROY SOC B-BIOL SCI, V263, P755, DOI 10.1098/rspb.1996.0113
   Colman RJ, 2009, SCIENCE, V325, P201, DOI 10.1126/science.1173635
   DALDERUP LM, 1969, NATURE, V222, P1050, DOI 10.1038/2221050a0
   Fontana L, 2010, SCIENCE, V328, P321, DOI 10.1126/science.1172539
   Fontana L, 2009, CURR OPIN GASTROEN, V25, P144, DOI 10.1097/MOG.0b013e32831ef1ba
   Fusco S, 2012, P NATL ACAD SCI USA, V109, P621, DOI 10.1073/pnas.1109237109
   Glass CK, 2012, CELL METAB, V15, P635, DOI 10.1016/j.cmet.2012.04.001
   Hatori M, 2012, CELL METAB, V15, P848, DOI 10.1016/j.cmet.2012.04.019
   Hong FX, 2006, BIOINFORMATICS, V22, P2825, DOI 10.1093/bioinformatics/btl476
   IWASAKI K, 1988, J GERONTOL, V43, pB13, DOI 10.1093/geronj/43.1.B13
   Jiang JC, 2000, FASEB J, V14, P2135
   Kenyon C, 2005, CELL, V120, P449, DOI 10.1016/j.cell.2005.02.002
   KLASS MR, 1977, MECH AGEING DEV, V6, P413, DOI 10.1016/0047-6374(77)90043-4
   Lin SJ, 2002, NATURE, V418, P344, DOI 10.1038/nature00829
   Lynch MA, 2004, PHYSIOL REV, V84, P87, DOI 10.1152/physrev.00014.2003
   Martin-Montalvo A, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3192
   MASORO EJ, 1989, AM J CLIN NUTR, V49, P1217
   Masoro EJ., 2002, CALORIC RESTRICTION, P165, DOI [10.1016/B978-044451162-1/50008-4, DOI 10.1016/B978-044451162-1/50008-4]
   Mattison JA, 2012, NATURE, V489, P318, DOI 10.1038/nature11432
   Milne JC, 2007, NATURE, V450, P712, DOI 10.1038/nature06261
   Pearson KJ, 2008, CELL METAB, V8, P157, DOI 10.1016/j.cmet.2008.06.011
   Speakman JR, 2011, MOL ASPECTS MED, V32, P159, DOI 10.1016/j.mam.2011.07.001
   Wang ZR, 2015, SCI REP-UK, V5, DOI 10.1038/srep12012
   Wei M, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aai8700
   WEINDRUCH R, 1982, SCIENCE, V215, P1415, DOI 10.1126/science.7063854
   Xu BL, 2015, IRAN J BASIC MED SCI, V18, P1118
   YU BP, 1985, J GERONTOL, V40, P657, DOI 10.1093/geronj/40.6.657
   Zhou B, 2012, P NATL ACAD SCI USA, V109, pE1201, DOI 10.1073/pnas.1119304109
   Zimmerman JA, 2003, EXP GERONTOL, V38, P47, DOI 10.1016/S0531-5565(02)00149-3
NR 35
TC 2
Z9 2
U1 2
U2 28
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
SN 1945-4589
J9 AGING-US
JI Aging-US
PD SEP 15
PY 2021
VL 13
IS 17
BP 21526
EP 21546
DI 10.18632/aging.203493
PG 21
WC Cell Biology; Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Geriatrics & Gerontology
GA WC6XE
UT WOS:000704398100020
PM 34493691
OA gold, Green Published
DA 2024-02-19
ER

PT J
AU Tobisawa, M
   Yamaguchi, M
AF Tobisawa, M
   Yamaguchi, M
TI Inhibitory role of regucalcin in the regulation of nitric oxide synthase
   activity in rat brain cytosol: involvement of aging
SO JOURNAL OF THE NEUROLOGICAL SCIENCES
LA English
DT Article
DE regucalcin; NO synthase; Ca2+ signaling; aging; rat brain
ID BINDING PROTEIN REGUCALCIN; PHOSPHATASE-ACTIVITY; KINASE ACTIVITY; LIVER
   CYTOSOL; CALMODULIN; EXPRESSION; GENE; DISORDERS; MESSENGER; NEURONS
AB Regucalcin is shown to play a regulatory role in intracellular signaling system in many cells. The protein has been reported to be present in rat brain neurons. The role of regucalcin in the regulation of nitric oxide (NO) synthase activity in the brain cytosol of female young and aged rats was investigated. The presence of regucalcin (10(-9) and 10(-8) M) in the enzyme reaction mixture caused a significant decrease in NO synthase activity in the absence or presence of both calcium chloride (10 muM) and calmodulin (2.5 mug/ml). The effect of regucalcin (10(-8) M) in decreasing brain cytosolic NO synthase activity was not seen in the presence of Nw-nitro-L-argine methyl ester (NAME) (10(-4) M), trifluoperazine (20 muM) or EGTA (1 mM). Regucalcin protein levels were significantly lowered in the brain cytosol of aged (50 weeks old) rats as compared with that of young (5 weeks old) rats. Brain cytosolic NO synthase activity was significantly reduced with increasing age. In aged rat brain cytosol, regucalcin caused a significant decrease in NO synthase activity. The presence of anti-regucalcin monoclonal antibody (10-50 ng/ml) caused a significant increase in NO synthase activity in the brain cytosol of young and aged rats. This elevation was completely blocked by the addition of regucalcin (10(-8) M). The present study demonstrates that endogenous regucalcin has an inhibitory effect on NO synthase activity in the brain cytosol of young and aged rats. (C) 2002 Elsevier Science B.V. All rights reserved.
C1 Univ Shizuoka, Grad Sch Nutrit Sci, Lab Endocrinol & Mol Metab, Shizuoka 4228526, Japan.
C3 University of Shizuoka
RP Yamaguchi, M (corresponding author), Univ Shizuoka, Grad Sch Nutrit Sci, Lab Endocrinol & Mol Metab, 52-1 Yada, Shizuoka 4228526, Japan.
CR BOYDE TRC, 1980, ANAL BIOCHEM, V107, P424, DOI 10.1016/0003-2697(80)90404-2
   CHEUNG WY, 1980, SCIENCE, V207, P19, DOI 10.1126/science.6243188
   Hamano T, 2001, J NEUROL SCI, V183, P33, DOI 10.1016/S0022-510X(00)00476-7
   Hamano T, 1999, INT J MOL MED, V3, P615
   Hamano T, 1999, BRAIN RES BULL, V50, P187, DOI 10.1016/S0361-9230(99)00184-7
   HEIZMANN CW, 1992, TRENDS NEUROSCI, V15, P259, DOI 10.1016/0166-2236(92)90067-I
   Katsumata T, 1998, J CELL BIOCHEM, V71, P569, DOI 10.1002/(SICI)1097-4644(19981215)71:4<569::AID-JCB11>3.0.CO;2-Z
   Kurota H, 1997, MOL CELL BIOCHEM, V177, P239, DOI 10.1023/A:1006819507433
   Lee SJ, 1998, J BIOL CHEM, V273, P27430, DOI 10.1074/jbc.273.42.27430
   LOWENSTEIN CJ, 1994, ANN INTERN MED, V120, P227, DOI 10.7326/0003-4819-120-3-199402010-00009
   LOWRY OH, 1951, J BIOL CHEM, V193, P265
   Misawa H, 2000, INT J MOL MED, V6, P191
   MORI S, 1990, CHEM PHARM BULL, V38, P2216
   NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651
   Omura M, 1998, J CELL BIOCHEM, V71, P140, DOI 10.1002/(SICI)1097-4644(19981001)71:1<140::AID-JCB14>3.3.CO;2-L
   SCHMIDT HHHW, 1994, CELL, V78, P919, DOI 10.1016/0092-8674(94)90267-4
   SHIMOKAWA N, 1995, MOL CELL BIOCHEM, V151, P157, DOI 10.1007/BF01322338
   SHIMOKAWA N, 1995, MOL CELL BIOCHEM, V143, P67, DOI 10.1007/BF00925928
   SHIMOKAWA N, 1992, FEBS LETT, V305, P151, DOI 10.1016/0014-5793(92)80884-J
   TANAKA T, 1981, BIOCHEM BIOPH RES CO, V101, P447, DOI 10.1016/0006-291X(81)91280-8
   Thiselton DL, 2002, GENOMICS, V79, P560, DOI 10.1006/geno.2002.6733
   WESSENDORF JHM, 1993, J BIOL CHEM, V268, P22100
   YAMAGUCHI M, 1978, CHEM PHARM BULL, V26, P1915
   Yamaguchi M, 2000, BRAIN RES BULL, V52, P343, DOI 10.1016/S0361-9230(00)00270-7
   Yamaguchi M, 2000, BIOCHEM BIOPH RES CO, V276, P1, DOI 10.1006/bbrc.2000.3359
   YAMAGUCHI M, 1990, BIOCHEM MED METAB B, V43, P140, DOI 10.1016/0885-4505(90)90019-W
   YAMAGUCHI M, 1993, MOL CELL BIOCHEM, V122, P65, DOI 10.1007/BF00925738
   Yamaguchi M, 1999, MOL CELL BIOCHEM, V200, P43, DOI 10.1023/A:1006928402184
   Yamaguchi M, 2000, LIFE SCI, V66, P1769, DOI 10.1016/S0024-3205(99)00602-5
NR 29
TC 11
Z9 12
U1 1
U2 2
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0022-510X
J9 J NEUROL SCI
JI J. Neurol. Sci.
PD MAY 15
PY 2003
VL 209
IS 1-2
BP 47
EP 54
DI 10.1016/S0022-510X(02)00460-4
PG 8
WC Clinical Neurology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA 672VN
UT WOS:000182543800008
PM 12686401
DA 2024-02-19
ER

PT J
AU YANG, Z
   MAKITA, Z
   HORII, Y
   BRUNELLE, S
   CERAMI, A
   SEHAJPAL, P
   SUTHANTHIRAN, M
   VLASSARA, H
AF YANG, Z
   MAKITA, Z
   HORII, Y
   BRUNELLE, S
   CERAMI, A
   SEHAJPAL, P
   SUTHANTHIRAN, M
   VLASSARA, H
TI 2 NOVEL RAT-LIVER MEMBRANE-PROTEINS THAT BIND ADVANCED GLYCOSYLATION
   ENDPRODUCTS - RELATIONSHIP TO MACROPHAGE RECEPTOR FOR GLUCOSE-MODIFIED
   PROTEINS
SO JOURNAL OF EXPERIMENTAL MEDICINE
LA English
DT Article
ID END-PRODUCTS; VASCULAR-PERMEABILITY; ALBUMIN; PURIFICATION; SEPARATION
AB Advanced glycosylation endproducts (AGEs), the glucose-derived adducts that form nonenzymatically and accumulate on tissue proteins, are implicated in many chronic complications associated with diabetes and aging. We have previously described a monocyte/macrophage surface receptor system thought to coordinate AGE protein removal and tissue remodeling, and purified a corresponding 90-kD AGE-binding protein from the murine RAW 264.7 cell line. To identify AGE-binding proteins in normal animals, the tissue distribution of I-125-AGE rat serum albumin taken up from the blood was determined in rats in vivo. These uptake studies demonstrated that the liver was a major site of AGE protein sequestration. Using a solid-phase assay system involving the immobilization of solubilized membrane proteins onto nitrocellulose to monitor binding activity, and several purification steps including affinity chromatography over an AGE bovine serum albumin matrix, two rat liver membrane proteins were isolated that specifically bound AGEs, one migrating at 60 kD (p60) and the other at 90 kD (p90) on SDS-PAGE. NH2-terminal sequence analysis revealed no significant homology between these two proteins nor to any molecules available in sequence databases. Flow cytometric analyses using avian antibodies to purified rat p60 and p90 demonstrated that both proteins are present on rat monocytes and macrophages. Competition studies revealed no crossreactivity between the two antisera; anti-p60 and anti-p90 antisera prevented AGE-protein binding to rat macrophages when added alone or in combination. These results indicate that rat liver contains at least two novel and distinct proteins that recognize AGE-modified macromolecules, although p90 may be related to the previously described 90-kD AGE receptor isolated from RAW 264.7 cells. The constitutive expression of AGE-binding proteins on rat monocytes and macrophages, and the sequestration of circulating AGE-modified proteins by the liver, provides further evidence in support of a role for these molecules in the normal removal of proteins marked as senescent by accumulated glucose-derived covalent addition products, or AGEs.
C1 ROCKEFELLER UNIV, MED BIOCHEM LAB, 1230 YORK AVE, NEW YORK, NY 10021 USA.
   CORNELL UNIV, MED CTR, COLL MED, DEPT MED, ROGOSIN INST, NEW YORK, NY 10021 USA.
C3 Rockefeller University; Cornell University
RI Suthanthiran, Manikkam/AAL-9104-2020
FU NIA NIH HHS [AGO 8245] Funding Source: Medline; NIDDK NIH HHS [DK 19655]
   Funding Source: Medline
CR BORDIER C, 1981, J BIOL CHEM, V256, P1604
   BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   BROWNLEE M, 1986, SCIENCE, V232, P1629, DOI 10.1126/science.3487117
   BUCALA R, 1991, IN PRESS ADV PHARM
   DANIEL TO, 1983, J BIOL CHEM, V258, P4606
   ESPOSITO C, 1989, J EXP MED, V170, P1387, DOI 10.1084/jem.170.4.1387
   FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0
   GARFIN DE, 1990, METHOD ENZYMOL, V182, P440
   GMELIGMEYLING F, 1980, J IMMUNOL METHODS, V33, P1, DOI 10.1016/0022-1759(80)90077-0
   HARLOW E, 1988, ANTIBODIES LABORATO
   HARRINGTON MG, 1990, METHOD ENZYMOL, V182, P488
   HORIUCHI S, 1985, J BIOL CHEM, V260, P475
   HORIUCHI S, 1986, J BIOL CHEM, V261, P4962
   KILZER P, 1985, DIABETES, V34, P333, DOI 10.2337/diabetes.34.4.333
   KILZER P, 1985, MICROVASC RES, V30, P270, DOI 10.1016/0026-2862(85)90059-7
   KIRSTEIN M, 1990, P NATL ACAD SCI USA, V87, P9010, DOI 10.1073/pnas.87.22.9010
   KIRSTEIN M, 1990, J CELL BIOCH E S, V14, P224
   KIRSTEIN M, 1990, FASEB J, V4, pA1759
   KODAMA T, 1988, P NATL ACAD SCI USA, V85, P9238, DOI 10.1073/pnas.85.23.9238
   MONNIER VM, 1981, SCIENCE, V211, P491, DOI 10.1126/science.6779377
   POLSON A, 1980, IMMUNOL COMMUN, V9, P475, DOI 10.3109/08820138009066010
   PONGOR S, 1984, P NATL ACAD SCI-BIOL, V81, P2684, DOI 10.1073/pnas.81.9.2684
   RADOFF S, 1990, DIABETES, V39, P1510, DOI 10.2337/diabetes.39.12.1510
   RADOFF S, 1988, ARCH BIOCHEM BIOPHYS, V263, P418, DOI 10.1016/0003-9861(88)90654-6
   SCHATCHARD G, 1949, ANN NY ACAD SCI, V51, P660
   SKOLNIK E, 1991, IN PRESS J EXP MED
   THOM D, 1977, BIOCHEM J, V168, P187, DOI 10.1042/bj1680187
   URDAL DL, 1988, J BIOL CHEM, V263, P2870
   VLASSARA H, 1985, P NATL ACAD SCI USA, V82, P5588, DOI 10.1073/pnas.82.17.5588
   VLASSARA H, 1988, SCIENCE, V240, P1546, DOI 10.1126/science.3259727
   VLASSARA H, 1984, J EXP MED, V160, P197, DOI 10.1084/jem.160.1.197
   WILLIAMSON JR, 1987, DIABETES, V36, P813, DOI 10.2337/diabetes.36.7.813
NR 33
TC 172
Z9 200
U1 0
U2 2
PU ROCKEFELLER UNIV PRESS
PI NEW YORK
PA 950 THIRD AVE, 2ND FLR, NEW YORK, NY 10022 USA
SN 0022-1007
EI 1540-9538
J9 J EXP MED
JI J. Exp. Med.
PD SEP 1
PY 1991
VL 174
IS 3
BP 515
EP 524
DI 10.1084/jem.174.3.515
PG 10
WC Immunology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology; Research & Experimental Medicine
GA GC960
UT WOS:A1991GC96000003
PM 1651976
OA Bronze, Green Submitted, Green Published
DA 2024-02-19
ER

PT J
AU Goldberg, DS
   Vianna, RM
   Martin, EF
   Martin, P
   Benitez, LRA
   O'Brien, CB
   Bhamidimarri, KR
AF Goldberg, David S.
   Vianna, Rodrigo M.
   Martin, Eric Fleming
   Martin, Paul
   Arosemena Benitez, Leopoldo Ramon
   O'Brien, Christopher Blackburn
   Bhamidimarri, Kalyan R.
TI Simultaneous Liver Kidney Transplant in Elderly Patients With Chronic
   Kidney Disease: Is There an Appropriate Upper Age Cutoff?
SO TRANSPLANTATION
LA English
DT Article
ID SEPTUAGENARIANS RECEIVING MODEL; NONALCOHOLIC STEATOHEPATITIS;
   HEPATOCELLULAR-CARCINOMA; EXCEPTION POINTS; SURVIVAL; IMPACT; WAITLIST;
   OUTCOMES
AB Background.
   The aging of liver transplant (LT) recipients, the weighting of the model for end-stage liver disease score, and the increased prevalence of nonalcoholic steatohepatitis has led to an increased number of older LT recipients with pre-LT chronic kidney disease (CKD). There are limited data on the impact of increased recipient age on post-simultaneous liver-kidney (SLK) transplant outcomes among patients with CKD, leading some centers to employ subjective age cutoffs for potential SLK recipients.
   Methods.
   We evaluated United Network for Organ Sharing data of adult SLK recipients from February 27, 2002, to December 31, 2018, restricted to recipients with >= 90 days of waiting time and CKD (estimated glomerular filtration rate persistently <60 mL/min/1.73 m2 for >= 90 d using the modification of diet in renal disease-4 equation). We fit mixed-effects Cox regression models (center as random effect) to evaluate the association of recipient age and patient survival.
   Results.
   Among 3146 SLK recipients with CKD, nearly two-thirds were 50-64 years of age, while 465 (14.8%) and 93 (3.0%) were 65-69 years and >= 70 years, respectively. Compared with nondiabetic SLK recipients aged 50-59 years, SLK recipients >= 70 years of age without diabetes (hazard ratio, 1.97; 95% CI, 1.20-3.23; P = 0.007) and with diabetes (hazard ratio, 1.90; 95% CI, 1.16-3.09; P = 0.01) had higher mortality compared with the reference group. In absolute terms, SLK recipients >= 70 years of age had 25% lower patient survival at 5 years compared to recipients aged 40-49 years.
   Conclusions.
   Although careful selection is required of any SLK recipient, especially those with increased comorbidities, there are no objective data to justify a specific age cutoff <70 years among potential SLK recipients with CKD.
C1 [Goldberg, David S.; Martin, Eric Fleming; Martin, Paul; Arosemena Benitez, Leopoldo Ramon; O'Brien, Christopher Blackburn; Bhamidimarri, Kalyan R.] Univ Miami, Miller Sch Med, Div Digest Hlth & Liver Dis, Miami, FL 33136 USA.
   [Vianna, Rodrigo M.; Martin, Eric Fleming; Arosemena Benitez, Leopoldo Ramon; O'Brien, Christopher Blackburn] Jackson Hlth Syst, Miami Transplant Inst, Miami, FL USA.
C3 University of Miami
RP Goldberg, DS (corresponding author), Don Soffer Clin Res Ctr, 1120 NW 14th St,Room 807, Miami, FL 33136 USA.
EM dsgoldberg@miami.edu
FU NIH [DK-R01-120561]
FX D.S.G. was funded by NIH DK-R01-120561.
CR Asrani SK, 2013, LIVER TRANSPLANT, V19, P957, DOI 10.1002/lt.23685
   Cholankeril G, 2017, DIGEST DIS SCI, V62, P2915, DOI 10.1007/s10620-017-4684-x
   Choudhury RA, 2017, TRANSPLANTATION, V101, P368, DOI 10.1097/TP.0000000000001151
   Croome KP, 2016, ANN HEPATOL, V15, P870, DOI 10.5604/16652681.1222103
   Cullaro G, 2019, TRANSPLANTATION, V103, P959, DOI 10.1097/TP.0000000000002403
   Machado AGD, 2013, ANN HEPATOL, V12, P440, DOI 10.1016/S1665-2681(19)31007-5
   Dellon ES, 2006, AM J TRANSPLANT, V6, P2183, DOI 10.1111/j.1600-6143.2006.01454.x
   Eason JD, 2008, AM J TRANSPLANT, V8, P2243, DOI 10.1111/j.1600-6143.2008.02416.x
   Golabi P, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000011518
   Goldberg D, 2017, GASTROENTEROLOGY, V152, P1090, DOI 10.1053/j.gastro.2017.01.003
   Lum EL, 2019, LIVER TRANSPLANT, V25, P797, DOI 10.1002/lt.25444
   Nadim MK, 2012, AM J TRANSPLANT, V12, P3119, DOI 10.1111/j.1600-6143.2012.04176.x
   Noureddin M, 2018, AM J GASTROENTEROL, V113, P1649, DOI 10.1038/s41395-018-0088-6
   Schwartz J, 2012, LIVER TRANSPLANT, V18, P1395, DOI 10.1002/lt.23513
   Schwartz JJ, 2012, LIVER TRANSPLANT, V18, P423, DOI 10.1002/lt.23385
   Sharma M, 2017, PROG TRANSPLANT, V27, P225, DOI 10.1177/1526924817715468
   Sharma P, 2011, AM J TRANSPLANT, V11, P2372, DOI 10.1111/j.1600-6143.2011.03703.x
   Sharma P, 2015, LIVER TRANSPLANT, V21, P308, DOI 10.1002/lt.24063
   Siddique O, 2017, J CLIN TRANSL HEPATO, V5, P193, DOI 10.14218/JCTH.2017.00003
   Su F, 2016, GASTROENTEROLOGY, V150, P441, DOI 10.1053/j.gastro.2015.10.043
   Volk ML, 2011, ANN INTERN MED, V155, P503, DOI 10.7326/0003-4819-155-8-201110180-00006
   Wong RJ, 2015, GASTROENTEROLOGY, V148, P547, DOI 10.1053/j.gastro.2014.11.039
   Wong RJ, 2014, HEPATOLOGY, V59, P2188, DOI 10.1002/hep.26986
   Younossi Z, 2019, CLIN GASTROENTEROL H, V17, P748, DOI 10.1016/j.cgh.2018.05.057
NR 24
TC 9
Z9 9
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0041-1337
EI 1534-6080
J9 TRANSPLANTATION
JI Transplantation
PD DEC
PY 2020
VL 104
IS 12
BP 2538
EP 2546
DI 10.1097/TP.0000000000003147
PG 9
WC Immunology; Surgery; Transplantation
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology; Surgery; Transplantation
GA OT1IZ
UT WOS:000590608200023
PM 33215900
OA Green Accepted
DA 2024-02-19
ER

PT J
AU Li, M
   Wang, ZQ
   Zhang, L
   Zheng, H
   Liu, DW
   Zhou, MG
AF Li Man
   Wang Zhuo Qun
   Zhang Lu
   Zheng Hao
   Liu Dian Wu
   Zhou Mai Geng
TI Burden of Cirrhosis and Other Chronic Liver Diseases Caused by Specific
   Etiologies in China, 1990-2016: Findings from the Global Burden of
   Disease Study 2016
SO BIOMEDICAL AND ENVIRONMENTAL SCIENCES
LA English
DT Article
DE Cirrhosis; Chronic liver disease; China; Epidemiology; Global burden of
   disease study
ID LIFE-YEARS DALYS; HEPATITIS-C; SYSTEMATIC ANALYSIS; NATURAL-HISTORY;
   VIRUS-INFECTION; EPIDEMIOLOGY; PREVALENCE; MANAGEMENT; INJURIES; ALCOHOL
AB Objective To estimate the burden of cirrhosis and other chronic liver diseases caused by specific etiologies in China.
   Methods Data from the Global Burden of Disease Study 2016 (GBD 2016) were used. We evaluated the burden by analyzing age-sex-province-specific prevalence, mortality, and disability-adjusted life-years (DALYs) of 33 provinces in China.
   Results From 1990 to 2016, prevalence cases in thousands increased by 73.7% from 6833.3 (95% UI: 6498.0-7180.6) to 11869.6 (95% UI: 11274.6-12504.7). Age-standardized mortality and DALY rates per 100,000 decreased by 51.2% and 53.3%, respectively. Male and elderly people (aged >= 60 years) preponderance were found for prevalence, mortality, and DALYs. The number of prevalence cases, deaths, and DALYs due to hepatitis C virus (HCV) increased by 86.6%, 8.7%, and 0.9%, respectively. Also, age-standardized prevalence rates decreased in 31 provinces, but increased in Yunnan and Shandong. The Socio-demographic Index (SDI) values were negatively correlated with age-standardized mortality and DALY rates by provinces in 2016; the correlation coefficients were -0.817 and -0.828, respectively.
   Conclusion Cirrhosis and other chronic liver diseases remain a huge health burden in China, with the increase of population and the aging of population. Hepatitis B virus (HBV) remains the leading cause of the health burden in China.
C1 [Li Man; Zhang Lu; Liu Dian Wu] Hebei Med Univ, Dept Epidemiol & Stat, Hebei Key Lab Environm & Human Hlth, Shijiazhuang 050017, Hebei, Peoples R China.
   [Wang Zhuo Qun; Zhou Mai Geng] China CDC, Natl Ctr Chron & Noncommunicable Dis Control & Pr, Beijing 100050, Peoples R China.
   [Zheng Hao] Hebei Chest Hosp, Shijiazhuang 050042, Hebei, Peoples R China.
C3 Hebei Medical University; Chinese Center for Disease Control &
   Prevention; National Center for Chronic & Noncommunicable Disease
   Control & Prevention, Chinese Center for Disease Control & Prevention
RP Zhou, MG (corresponding author), China CDC, Natl Ctr Chron & Noncommunicable Dis Control & Pr, Beijing 100050, Peoples R China.
EM zhoumaigeng@ncncd.chinacdc.cn
RI Zhou, Maigeng/HCH-7703-2022
OI Li, Man/0000-0002-6907-250X
CR [Anonymous], GLOBAL BURDEN LIVER
   [Anonymous], J XIHUA U
   [Anonymous], CHINESE J PREVENTION
   [Anonymous], 2007, MODERN PREVENTIVE ME, DOI DOI 10.20043/1003-8507(2007)20-3842-03
   [Anonymous], 2017, EX SUMM GLOB HEP REP
   Blach S, 2017, LANCET GASTROENTEROL, V2, P161, DOI 10.1016/S2468-1253(16)30181-9
   Byass P, 2014, BMC MED, V12, DOI 10.1186/s12916-014-0159-5
   Chu YJ, 2017, INT J CANCER, V141, P711, DOI 10.1002/ijc.30782
   Chuang SC, 2009, CANCER LETT, V286, P9, DOI 10.1016/j.canlet.2008.10.040
   Cohen AK, 2013, AM J PUBLIC HEALTH, V103, P997, DOI 10.2105/AJPH.2012.300993
   Cui Ying'ai, 2018, Health, V10, P1210
   D'Amico G, 2006, J HEPATOL, V44, P217, DOI 10.1016/j.jhep.2005.10.013
   Duan ZP, 2014, J CLIN GASTROENTEROL, V48, P679, DOI 10.1097/MCG.0000000000000109
   Fan JG, 2013, J GASTROEN HEPATOL, V28, P11, DOI 10.1111/jgh.12036
   Gakidou E, 2017, LANCET, V390, P1345, DOI 10.1016/S0140-6736(17)32366-8
   GBD 2016 Disease and Injury Incidence and Prevalence Collaborators, 2017, Lancet, V390, P1211, DOI 10.1016/S0140-6736(17)32154-2
   Hay SI., 2017, LANCET, V390, P1260, DOI [10.1016/S0140-6736(17)32130-X, 10. 1016/S0140-6736(17)32130-X., DOI 10.1016/S0140-6736(17)32130-X]
   He AJ, 2017, BMC HEALTH SERV RES, V17, DOI 10.1186/s12913-017-2559-7
   Hu XQ, 2019, GERIATR GERONTOL INT, V19, P938, DOI 10.1111/ggi.13746
   Jia YX, 2014, HUM VACC IMMUNOTHER, V10, P2983, DOI 10.4161/hv.29944
   Kassebaum NJ, 2016, LANCET, V388, P1603, DOI 10.1016/S0140-6736(16)31460-X
   Lavanchy D, 2011, CLIN MICROBIOL INFEC, V17, P107, DOI 10.1111/j.1469-0691.2010.03432.x
   Li YM, 2011, J DIGEST DIS, V12, P45, DOI 10.1111/j.1751-2980.2010.00477.x
   Lozano R, 2012, LANCET, V380, P2095, DOI 10.1016/S0140-6736(12)61728-0
   Mokdad AA, 2014, BMC MED, V12, DOI 10.1186/s12916-014-0145-y
   Murray CJL, 2012, LANCET, V380, P2197, DOI 10.1016/S0140-6736(12)61689-4
   Naghavi M, 2017, LANCET, V390, P1151, DOI 10.1016/S0140-6736(17)32152-9
   Nusrat S, 2014, WORLD J GASTROENTERO, V20, P5442, DOI 10.3748/wjg.v20.i18.5442
   Pol S, 2017, ALIMENT PHARM THER, V46, P1054, DOI 10.1111/apt.14352
   Poynard T, 1997, LANCET, V349, P825, DOI 10.1016/S0140-6736(96)07642-8
   Rehm J, 2013, J HEPATOL, V59, P160, DOI 10.1016/j.jhep.2013.03.007
   Schweitzer A, 2015, LANCET, V386, P1546, DOI 10.1016/S0140-6736(15)61412-X
   Stein E, 2016, J HEPATOL, V65, P998, DOI 10.1016/j.jhep.2016.06.018
   Stroffolini T, 2015, J MED VIROL, V87, P1899, DOI 10.1002/jmv.24243
   Tang YL, 2013, B WORLD HEALTH ORGAN, V91, P270, DOI 10.2471/BLT.12.107318
   Wang BH, 2014, J MED VIROL, V86, P1675, DOI 10.1002/jmv.24002
   Wang FS, 2014, HEPATOLOGY, V60, P2099, DOI 10.1002/hep.27406
   Wang HD, 2017, LANCET, V390, P1084, DOI 10.1016/S0140-6736(17)31833-0
   Wang HX, 2014, ALCOHOL CLIN EXP RES, V38, P1035, DOI 10.1111/acer.12321
   Wang MM, 2014, DIGEST DIS SCI, V59, P2571, DOI 10.1007/s10620-014-3180-9
   Wang WJ, 2019, WORLD J GASTROENTERO, V25, P1445, DOI 10.3748/wjg.v25.i12.1445
   Wong MCS, 2018, HEPATOL INT, V12, P201, DOI 10.1007/s12072-018-9865-y
   Xiao J, 2019, J HEPATOL, V71, P212, DOI 10.1016/j.jhep.2019.03.004
   Yan YP, 2014, J CLIN TRANSL HEPATO, V2, P15, DOI 10.14218/JCTH.2013.00030
   Younossi ZM, 2016, HEPATOLOGY, V64, P73, DOI 10.1002/hep.28431
   Zhang MY, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2018-028248
NR 46
TC 22
Z9 29
U1 7
U2 39
PU CHINESE CENTER DISEASE CONTROL & PREVENTION
PI BEIJING
PA 155 CHANGBAI RD, CHANGPING DISTRICT, BEIJING, 102206, PEOPLES R CHINA
SN 0895-3988
EI 2214-0190
J9 BIOMED ENVIRON SCI
JI Biomed. Environ. Sci.
PD JAN
PY 2020
VL 33
IS 1
BP 1
EP +
DI 10.3967/bes2020.001
PG 13
WC Environmental Sciences; Public, Environmental & Occupational Health
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
   Health
GA KK6XC
UT WOS:000512881800001
PM 32029053
DA 2024-02-19
ER

PT J
AU Kakkar, R
   Bains, JS
   Sharma, SP
AF Kakkar, R
   Bains, JS
   Sharma, SP
TI Effect of vitamin E on life span, malondialdehyde content and
   antioxidant enzymes in aging Zaprionus paravittiger
SO GERONTOLOGY
LA English
DT Article
DE catalase; life span; lipid peroxidation; peroxidase; vitamin E;
   Zaprionus paravittiger
ID PROTEIN OXIDATIVE DAMAGE; LIPID-PEROXIDATION; ALPHA-TOCOPHEROL;
   MUSCA-DOMESTICA; BETA-CAROTENE; FREE-RADICALS; SUPEROXIDE; CATALASE;
   LIVER; EXPECTANCY
AB Zaprionus paravittiger fed with vitamin E supplemented diet (1, 5 and 10 mu g/ml) showed an increase in median and maximum life spans. Further increase in concentration accelerated the mortality rate. Females exhibited longer life span as compared to males. Malondialdehyde (MDA) content and antioxidant enzymes (catalase and peroxidase) were measured in control and optimum concentration of vitamin E (5 mu g/ml)-fed flies at various age intervals. MDA content showed an increase with age in control and vitamin E-fed group whereas catalase and proxidase activities showed a decrease with age. The females exhibited lower MDA content and higher activities of catalase and peroxidase as compared to males in control and vitamin E group. Vitamin E feeding caused a significant decrease in MDA and increase in catalase and peroxidase activities. These findings suggest that vitamin E has dose-dependent and sex-specific influence on longevity of Z. paravittiger and support the view that longevity and activity of antioxidant enzymes are positively linked.
C1 UNIV CALGARY, DEPT PATHOL, CALGARY, AB, CANADA.
   GURU NANAK DEV UNIV, FAC SCI, DEPT ZOOL, GERONTOL LAB, AMRITSAR, PUNJAB, INDIA.
C3 University of Calgary; Guru Nanak Dev University
RP Kakkar, R (corresponding author), UNIV SASKATCHEWAN, COLL MED, SASKATOON CANC CTR, RES UNIT, SASKATOON, SK S7N 4H4, CANADA.
CR AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915
   CHAUDHARY AK, 1994, SCIENCE, V265, P1580, DOI 10.1126/science.8079172
   CHEN H, 1993, FREE RADICAL BIO MED, V14, P473, DOI 10.1016/0891-5849(93)90104-3
   CHOE M, 1995, FREE RADICAL BIO MED, V18, P977, DOI 10.1016/0891-5849(94)00217-8
   CHOW CK, 1991, FREE RADICAL BIO MED, V11, P215
   CUTLER RG, 1985, MOL BIOL AGING, P15, DOI DOI 10.2307/2499207
   FARMER KJ, 1989, FREE RADICAL BIO MED, V7, P23, DOI 10.1016/0891-5849(89)90096-8
   FRAGA CG, 1990, P NATL ACAD SCI USA, V87, P4533, DOI 10.1073/pnas.87.12.4533
   FREEMAN BA, 1982, LAB INVEST, V47, P412
   FRIDOVICH I, 1978, SCIENCE, V201, P875, DOI 10.1126/science.210504
   GEY KF, 1991, AM J CLIN NUTR, V53, pS326, DOI 10.1093/ajcn/53.1.326S
   HARMAN D, 1993, DRUG AGING, V3, P60, DOI 10.2165/00002512-199303010-00006
   HARRINGTON LA, 1988, MECH AGEING DEV, V43, P71, DOI 10.1016/0047-6374(88)90098-X
   KANNER J, 1977, J FOOD SCI, V42, P60, DOI 10.1111/j.1365-2621.1977.tb01218.x
   KAPPUS H, 1992, FREE RADICAL BIO MED, V13, P55, DOI 10.1016/0891-5849(92)90166-E
   KAR M, 1976, PLANT PHYSIOL, V57, P315, DOI 10.1104/pp.57.2.315
   KONO Y, 1982, J BIOL CHEM, V257, P5751
   KRINSKY NI, 1992, P SOC EXP BIOL MED, V200, P248
   KUMAR KB, 1983, EXP GERONTOL, V18, P409, DOI 10.1016/0531-5565(83)90019-0
   MAHAN DC, 1991, J ANIM SCI, V69, P2904, DOI 10.2527/1991.6972904x
   MAIORINO M, 1993, FEBS LETT, V330, P174, DOI 10.1016/0014-5793(93)80267-X
   MARNETT LJ, 1985, MUTAT RES, V148, P25
   MASSIE HR, 1985, MECH AGEING DEV, V29, P215, DOI 10.1016/0047-6374(85)90020-X
   MEYDANI M, 1988, LIPIDS, V23, P405, DOI 10.1007/BF02535510
   Niki Etsuo, 1993, P121
   ORR WC, 1994, SCIENCE, V263, P1128, DOI 10.1126/science.8108730
   PLACER ZA, 1966, ANAL BIOCHEM, V16, P359, DOI 10.1016/0003-2697(66)90167-9
   PRASAD K, 1993, AM HEART J, V125, P958, DOI 10.1016/0002-8703(93)90102-F
   Reznick Abraham Z., 1993, P435
   SAWADA M, 1984, EXP GERONTOL, V19, P179, DOI 10.1016/0531-5565(84)90036-6
   SAWADA M, 1990, J CELL BIOCHEM, V44, P153, DOI 10.1002/jcb.240440304
   SHARMA SP, 1995, GERONTOLOGY, V41, P86
   SHIGENAGA MK, 1994, P NATL ACAD SCI USA, V91, P10771, DOI 10.1073/pnas.91.23.10771
   SOHAL RS, 1990, MECH AGEING DEV, V53, P217, DOI 10.1016/0047-6374(90)90040-M
   SOHAL RS, 1993, P NATL ACAD SCI USA, V90, P7255, DOI 10.1073/pnas.90.15.7255
   SOHAL RS, 1986, MECH AGEING DEV, V36, P71, DOI 10.1016/0047-6374(86)90140-5
   SOHAL RS, 1995, FREE RADICAL BIO MED, V19, P499, DOI 10.1016/0891-5849(95)00037-X
   SOHAL RS, 1985, MOL BASIS AGING, P75
   Sokol Ronald J., 1993, P815
   Stadtman ER, 2006, FREE RADICAL RES, V40, P1250, DOI 10.1080/10715760600918142
   SUMMERFIELD FW, 1984, CHEM-BIOL INTERACT, V50, P87, DOI 10.1016/0009-2797(84)90134-0
   TERAO J, 1986, LIPIDS, V21, P255, DOI 10.1007/BF02536407
   VASAVI H, 1994, MOL CELL BIOCHEM, V131, P125, DOI 10.1007/BF00925948
   WADHWA R, 1986, GERONTOLOGY, V32, P141, DOI 10.1159/000212780
   WADHWA R, 1988, MECH AGEING DEV, V45, P277, DOI 10.1016/0047-6374(88)90008-5
   YAU TM, 1979, MECH AGEING DEV, V11, P137, DOI 10.1016/0047-6374(79)90031-9
   YU BP, 1994, P SOC EXP BIOL MED, V205, P97, DOI 10.3181/00379727-205-43684
NR 47
TC 13
Z9 16
U1 0
U2 2
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0304-324X
EI 1423-0003
J9 GERONTOLOGY
JI Gerontology
PD NOV-DEC
PY 1996
VL 42
IS 6
BP 312
EP 321
DI 10.1159/000213809
PG 10
WC Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Geriatrics & Gerontology
GA VR194
UT WOS:A1996VR19400002
PM 8930618
DA 2024-02-19
ER

PT J
AU Banks, MA
   Berlin, E
   Johnson, WA
   Peters, RC
AF Banks, MA
   Berlin, E
   Johnson, WA
   Peters, RC
TI Vitamin E levels and susceptibility to lipid peroxidation increase with
   aging in heart plasma membrane from miniature swine
SO JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL
   SCIENCES
LA English
DT Article
ID FATTY-ACID COMPOSITION; SUPEROXIDE RADICAL FORMATION; DELTA-6 DESATURASE
   ACTIVITY; AGE-RELATED-CHANGES; FOOD RESTRICTION; FLUORESCENCE
   POLARIZATION; LIQUID-CHROMATOGRAPHY; INSULIN BINDING; FLUIDITY; LIVER
AB Age-related changes in heart plasma membrane fatty acid composition, vitamin E content, membrane fluidify, susceptibility to lipid peroxidation, and the subcellular distribution of vitamin E: were observed in merle and female Hormel-Hanford miniswine over a wide range of ages: prepubertal, <0.5 years; young, 0.5-2.5 years; middle-aged, 5.9-10 years; and old, 11.5-13.9 years. Pigs were continuously fed the same low-fat, cholesterol-free, vitamin E-adequate stock diet at restricted maintenance levels. Membrane lipid peroxidation tended to increase in middle-aged and elderly pigs, but not significantly, perhaps being somewhat ameliorated by the significantly increased membrane vitamin E in middle-aged and old pigs. Mid-bilayer membrane fluidity was significantly increased in old pigs, but fluidity of the polar headgroup domains decreased with age. Thus, lipid peroxidation tended to increase over the long life span of miniswine even when they are food restricted.
C1 USDA ARS,MNIL,BHNRC,BELTSVILLE,MD 20705.
   US FDA,CTR FOOD SAFETY & APPL NUTR,LAUREL,MD.
C3 United States Department of Agriculture (USDA); US Food & Drug
   Administration (FDA)
CR AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915
   [Anonymous], 1993, VITAMIN HLTH DIS
   BARTLETT GR, 1959, J BIOL CHEM, V234, P466
   BARZANTI V, 1994, BRIT J NUTR, V71, P193, DOI 10.1079/BJN19940126
   BERLIN E, 1994, COMP BIOCHEM PHYS A, V109, P53, DOI 10.1016/0300-9629(94)90311-5
   BERLIN E, 1994, J NUTR BIOCHEM, V5, P591, DOI 10.1016/0955-2863(94)90014-0
   BERLIN E, 1985, ATHEROSCLEROSIS, V54, P187, DOI 10.1016/0021-9150(85)90178-9
   BERLIN E, 1992, J NUTR BIOCHEM, V3, P392, DOI 10.1016/0955-2863(92)90013-9
   BERLIN E, 1986, ANN NY ACAD SCI, V463, P80, DOI 10.1111/j.1749-6632.1986.tb21506.x
   BERLIN E, 1988, ADV DIET NUTR, V2, P193
   BERLIN E, 1995, 2 INT C INT SOC STUD
   BOWRY VW, 1992, BIOCHEM J, V288, P341, DOI 10.1042/bj2880341
   CHOI JH, 1989, AGE, V12, P133, DOI 10.1007/BF02432350
   CURTIS MT, 1984, ARCH BIOCHEM BIOPHYS, V235, P644, DOI 10.1016/0003-9861(84)90239-X
   DESAI ID, 1984, METHOD ENZYMOL, V105, P138, DOI 10.1016/S0076-6879(84)05019-9
   DINH L, 1995, ANN NUTR METAB, V39, P117, DOI 10.1159/000177851
   DINH TKL, 1993, LIPIDS, V28, P517, DOI 10.1007/BF02536083
   FERNANDES G, 1995, NUTR REV, V53, P572
   HARMAN D, 1981, P NATL ACAD SCI-BIOL, V78, P7124, DOI 10.1073/pnas.78.11.7124
   HARMAN D, 1987, CLIN NUTR ASPECTS VI, P285
   HELWIG JT, 1988, SAS STAT USERS GUIDE
   HOLLANDER CF, 1984, MATURITAS, V6, P253, DOI 10.1016/0378-5122(84)90041-0
   HSU C, 1982, PIG MODEL BIOMEDICAL, P3
   KATZ ML, 1986, FREE RADICALS AGING, P221
   KHAN MA, 1977, EXP MOL PATHOL, V26, P63, DOI 10.1016/0014-4800(77)90066-1
   KITAGAWA S, 1991, J MEMBRANE BIOL, V119, P221, DOI 10.1007/BF01868727
   KORNBRUST DJ, 1980, LIPIDS, V15, P315, DOI 10.1007/BF02533546
   KUHRY JG, 1983, CELL BIOPHYS, V5, P129, DOI 10.1007/BF02796139
   LAGANIERE S, 1991, LIPIDS, V26, P472, DOI 10.1007/BF02536075
   LAGANIERE S, 1993, GERONTOLOGY, V39, P7, DOI 10.1159/000213509
   LEHMANN J, 1982, CLIN CHEM, V28, P1784
   LIEPA GU, 1980, AM J PHYSIOL, V238, pE253, DOI 10.1152/ajpendo.1980.238.3.E253
   LOWRY OH, 1951, J BIOL CHEM, V193, P265
   MANIONGUI C, 1993, LIPIDS, V28, P291, DOI 10.1007/BF02536313
   MASORO EJ, 1990, HDB BIOL AGING, P72
   MATUSIK EJ, 1984, ANAL CHIM ACTA, V166, P179
   MURPHY MG, 1990, J NUTR BIOCHEM, V1, P68, DOI 10.1016/0955-2863(90)90052-M
   RIETJENS IMC, 1986, J TOXICOL ENV HLTH, V19, P558
   SAWADA M, 1992, J CELL BIOCHEM, V48, P296, DOI 10.1002/jcb.240480310
   SAWADA M, 1993, MECH AGEING DEV, V69, P137, DOI 10.1016/0047-6374(93)90078-6
   SHINITZKY M, 1978, BIOCHIM BIOPHYS ACTA, V515, P367, DOI 10.1016/0304-4157(78)90010-2
   SPERRY WM, 1955, J BIOL CHEM, V213, P69
   STUBBS CD, 1984, BIOCHIM BIOPHYS ACTA, V779, P89, DOI 10.1016/0304-4157(84)90005-4
   TAPPEL AL, 1968, GERIATRICS, V23, P97
   TATUM VL, 1990, LIPIDS, V25, P226, DOI 10.1007/BF02535752
   THOMAS JA, 1994, MODERN NUTR HLTH DIS, V1, P501
   TROTTER PJ, 1989, BIOCHIM BIOPHYS ACTA, V982, P131, DOI 10.1016/0005-2736(89)90183-1
   VONHAHN HP, 1983, EXPERIENTIA, V39, P47
   WAHNON R, 1989, MECH AGEING DEV, V50, P249, DOI 10.1016/0047-6374(89)90103-6
   YEAGLE PL, 1985, BIOCHIM BIOPHYS ACTA, V822, P267, DOI 10.1016/0304-4157(85)90011-5
   YU BP, 1992, MECH AGEING DEV, V65, P17, DOI 10.1016/0047-6374(92)90123-U
   Zimmer Guido, 1993, P207
NR 52
TC 3
Z9 3
U1 0
U2 0
PU GERONTOLOGICAL SOCIETY AMER
PI WASHINGTON
PA 1275 K STREET NW SUITE 350, WASHINGTON, DC 20005-4006
SN 1079-5006
J9 J GERONTOL A-BIOL
JI J. Gerontol. Ser. A-Biol. Sci. Med. Sci.
PD NOV
PY 1996
VL 51
IS 6
BP B409
EP B416
DI 10.1093/gerona/51A.6.B409
PG 8
WC Geriatrics & Gerontology; Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Geriatrics & Gerontology
GA WD352
UT WOS:A1996WD35200005
PM 8914490
OA Bronze
DA 2024-02-19
ER

PT J
AU Anisimova, VN
   Ukraintseva, SV
   Anikin, IV
   Popovich, IG
   Zabezhinski, MA
   Bertsein, LM
   Arutjunyan, AV
   Ingram, DK
   Lane, MA
   Roth, GS
AF Anisimova, VN
   Ukraintseva, SV
   Anikin, IV
   Popovich, IG
   Zabezhinski, MA
   Bertsein, LM
   Arutjunyan, AV
   Ingram, DK
   Lane, MA
   Roth, GS
TI Effects of phentermine and phenformin on biomarkers of aging in rats
SO GERONTOLOGY
LA English
DT Article
DE caloric restriction; caloric restriction mimetics; appetite; body
   temperature; reactive oxygen species
ID LIFE-SPAN; CAENORHABDITIS-ELEGANS; DIETARY RESTRICTION; CALORIE
   RESTRICTION; REGULATES LONGEVITY; SPONTANEOUS TUMORS; ENERGY-INTAKE;
   WEIGHT-LOSS; DISEASE; PROTEIN
AB Background: Caloric restriction (CR) is the only treatment known to substantially prolong both average and maximal life span in experimental animals. Interventions that mimic certain effects of CR could be potential anti-aging treatments in humans. Drugs which reduce appetite (anorexiants) represent one class of candidate treatments. Agents that reduce the glucose utilization by the organism could also represent another class of candidate CR mimetics. Objective: In our study, we addressed the following questions: ( 1) Does treatment with an anorexiant reduce caloric intake and body weight of experimental animals comparable to that caused by CR? (2) Does treatment with an antidiabetic agent influence caloric intake and body weight? ( 3) Does treatment with any of these drugs affect metabolic parameters of an organism in the way similar to that observed with CR? Methods: One hundred and twenty 6-month-old female Wistar-derived LIO rats were randomly subdivided into four groups and exposed to: ( 1) ad libitum feeding with placebo ( controls); (2) the antidiabetic drug phenformin (2 mg/kg); (3) the anorectic drug phentermine (1 mg/kg), and (4) the same amount of food as the group with the least food intake during the previous week (pair-fed controls). Food and water intake, body weight, and rectal temperature were measured weekly during 16 weeks. At the end of the 16th week of the experiment, serum levels of glucose, total beta-lipoprotein and pre-beta-lipoprotein fractions, cholesterol, triglycerides, insulin, total triiodothyronine, and free thyroxine were estimated. The contents of diene conjugates and Schiff's bases, total antioxidant activity, the activities of Cu/Zn superoxide dismutase, glutathione S-transferase, and glutathione peroxidase, and the generation of reactive oxygen species (ROS) were studied in brain and liver homogenates and in the serum. Results: The controls exposed to pair feeding had a significantly reduced food consumption (about 20%) as compared with the ad libitum fed controls and thus exhibited a moderate CR. Treatment with phentermine reduced the caloric intake by about 12% as compared with the ad libitum fed controls. Body weight and water intake in this group were only slightly decreased ( by about 2 and 5%, respectively) as compared with the controls. The mean rectal temperature in the phentermine group (38degreesC) was significantly higher than in the ad libitum fed (37.8degreesC) and pair-fed (37.6degreesC) controls. Treatment with phentermine also resulted in significantly reduced ROS levels in all tissues studied, while the highest ROS production was found in ad libitum (blood serum) and pair-fed ( brain) controls. Treatment with phenformin did not significantly influence food and water consumption, body weight, and temperature when compared with the ad libitum fed controls. Rats treated with this antidiabetic drug showed intermediate values of ROS generation. Differences among the groups in total antioxidant activity were not obvious. Conclusions: Treatment with phentermine reduces caloric intake slightly less than is commonly observed in CR studies. CR due to forcibly reduced feeding and CR due to substance-suppressed appetite appear to act through different metabolic mechanisms and thus may affect aging and longevity in different ways. Copyright (C) 2005 S. Karger AG, Basel.
C1 NN Petrov Res Inst Gerontol, Lab Carcinogenesis & Aging, St Petersburg 197758, Russia.
   DO Ott Res Inst Obstet & Gynecol, Lab Perinatal Biochem, St Petersburg, Russia.
   Duke Univ, Ctr Demog Res, Durham, NC USA.
   NIA, Lab Expt Gerontol, Gerontol Res Ctr, NIH, Baltimore, MD 21224 USA.
C3 Russian Academy of Medical Sciences; Ott Institute of Obstetrics,
   Gynecology & Reproductology; Duke University; National Institutes of
   Health (NIH) - USA; NIH National Institute on Aging (NIA)
RP Anisimova, VN (corresponding author), NN Petrov Res Inst Gerontol, Lab Carcinogenesis & Aging, Pesochny 2, St Petersburg 197758, Russia.
EM aging@mail.ru
RI Arutjunyan, Alexander/S-8364-2016
OI Arutjunyan, Alexander/0000-0002-0608-9427
CR AGOSTONI A, 1980, J CLIN CHEM CLIN BIO, V18, P771
   ALEXANDROV VA, 1980, CARCINOGENESIS, V1, P975, DOI 10.1093/carcin/1.12.975
   Alger SA, 1999, OBES RES, V7, P469, DOI 10.1002/j.1550-8528.1999.tb00435.x
   AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915
   Anisimov V., 1982, FARMAKOL TOKSIKOL, V45, P127
   ANISIMOV V N, 1982, Eksperimental'naya Onkologiya, V4, P26
   ANISIMOV VN, 1980, VOP ONKOL+, V26, P54
   ANISIMOV VN, 1980, VOP ONKOL+, V26, P42
   Anisimov VN, 2001, NEUROENDOCRINOL LETT, V22, P9
   ANISIMOV VN, 1989, J EXP CLIN CANC RES, V8, P254
   ANISIMOV VN, 1987, CARCINOGENESIS AGING
   Arutjunyan AV, 2000, METHODS EVALUATION F
   *ASHSP, 1998, AM HOSP FORM SERV DR
   BURMISTROV SO, 1997, KLIN LAB DIAGN, V11, P14
   CHENEY KE, 1983, J GERONTOL, V38, P420, DOI 10.1093/geronj/38.4.420
   CHO AK, 1994, AMPHETAMINES ITS ANA
   Clancy DJ, 2001, SCIENCE, V292, P104, DOI 10.1126/science.1057991
   Cordero-MacIntyre ZR, 2000, J AM COLL NUTR, V19, P275, DOI 10.1080/07315724.2000.10718927
   DILMAN V M, 1988, Archiv fuer Geschwulstforschung, V58, P175
   Dilman V. M., 1994, DEV AGING DIS NEW RA
   DILMAN VM, 1978, ARCH GESCHWULSTFORSC, V48, P1
   DILMAN VM, 1971, LANCET, V1, P1211
   DILMAN VM, 1982, ONCOLOGY-BASEL, V39, P13, DOI 10.1159/000225596
   DILMAN VM, 1980, GERONTOLOGY, V26, P241, DOI 10.1159/000212423
   Duan WZ, 1999, J NEUROSCI RES, V57, P195, DOI 10.1002/(SICI)1097-4547(19990715)57:2&lt;195::AID-JNR5&gt;3.0.CO;2-P
   Facchini FS, 2000, AM J CLIN NUTR, V72, P776
   Facchini FS, 2000, FREE RADICAL BIO MED, V29, P1302, DOI 10.1016/S0891-5849(00)00438-X
   Goubler EV, 1978, COMPUTING METHODS PA
   Hadley EC, 2001, J GERONTOL A-BIOL, V56, P5, DOI 10.1093/gerona/56.suppl_1.5
   Katzung BG, 2001, BASIC CLIN PHARM
   Kimura KD, 1997, SCIENCE, V277, P942, DOI 10.1126/science.277.5328.942
   Lane M., 1998, Journal of Anti-Aging Medicine, V1, P327, DOI [10.1089/rej.1.1998.1.327, DOI 10.1089/REJ.1.1998.1.327]
   Lane MA, 1997, J CLIN ENDOCR METAB, V82, P2093, DOI 10.1210/jc.82.7.2093
   LANE MA, 1995, AM J PHYSIOL-ENDOC M, V268, pE941, DOI 10.1152/ajpendo.1995.268.5.E941
   Lane MA, 2000, MECH AGEING DEV, V112, P185, DOI 10.1016/S0047-6374(99)00087-1
   LEDVINA M, 1960, LAB DELO, V3, P13
   Lee J, 1999, J NEUROSCI RES, V57, P48, DOI 10.1002/(SICI)1097-4547(19990701)57:1<48::AID-JNR6>3.3.CO;2-C
   Lin K, 1997, SCIENCE, V278, P1319, DOI 10.1126/science.278.5341.1319
   Mattson MP, 2001, J ANTI-AGING MED, V4, P225, DOI 10.1089/109454501753249993
   MCCARTY MF, 1994, MED HYPOTHESES, V43, P253, DOI 10.1016/0306-9877(94)90076-0
   Mihaylova VT, 1999, P NATL ACAD SCI USA, V96, P7427, DOI 10.1073/pnas.96.13.7427
   MOIN VM, 1986, LAB DELO, V12, P724
   Muntoni S, 1974, Adv Lipid Res, V12, P311
   PROKOPENKO VM, 1995, VOP MED KHIM, V41, P53
   Ramsey JJ, 2000, FREE RADICAL BIO MED, V29, P946, DOI 10.1016/S0891-5849(00)00417-2
   RANDLE PJ, 1965, ANN NY ACAD SCI, V131, P324, DOI 10.1111/j.1749-6632.1965.tb34800.x
   Roth GS, 1999, J AM GERIATR SOC, V47, P896, DOI 10.1111/j.1532-5415.1999.tb03851.x
   Roth GS, 2000, EUR J CLIN NUTR, V54, pS15, DOI 10.1038/sj.ejcn.1601020
   Roth JD, 1998, PSYCHOPHARMACOLOGY, V137, P99, DOI 10.1007/s002130050598
   Sell DR, 1996, P NATL ACAD SCI USA, V93, P485, DOI 10.1073/pnas.93.1.485
   STALNAYA IA, 1974, CURRENT METHODS BIOC, P63
   Tatar M, 2001, SCIENCE, V292, P107, DOI 10.1126/science.1057987
   Ulrich P, 2001, RECENT PROG HORM RES, V56, P1, DOI 10.1210/rp.56.1.1
   Verzijl N, 2001, MATRIX BIOL, V20, P409, DOI 10.1016/S0945-053X(01)00158-5
   Weindruch R., 1988, RETARDATION AGING DI
   WEINDRUCH RH, 1979, FED PROC, V38, P2007
   Yu BP, 1994, MODULATION AGING PRO
NR 57
TC 17
Z9 20
U1 0
U2 3
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0304-324X
EI 1423-0003
J9 GERONTOLOGY
JI Gerontology
PY 2005
VL 51
IS 1
BP 19
EP 28
DI 10.1159/000081430
PG 10
WC Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Geriatrics & Gerontology
GA 883LH
UT WOS:000226012800004
PM 15591752
DA 2024-02-19
ER

PT J
AU Rodríguez-López, S
   López-Bellón, S
   González-Reyes, JA
   Burón, MI
   de Cabo, R
   Villalba, JM
AF Rodriguez-Lopez, Sandra
   Lopez-Bellon, Sara
   Gonzalez-Reyes, Jose A.
   Isabel Buron, M.
   de Cabo, Rafael
   Villalba, Jose M.
TI Mitochondrial adaptations in liver and skeletal muscle to pro-longevity
   nutritional and genetic interventions: the crosstalk between calorie
   restriction and CYB5R3 overexpression in transgenic mice
SO GEROSCIENCE
LA English
DT Article; Early Access
DE Calorie restriction; Cytochrome b(5) reductase; Liver; Mitochondria;
   Skeletal muscle
ID CYTOCHROME B(5) REDUCTASE; DIETARY-LIPID COMPOSITION; MEMBRANE REDOX
   SYSTEM; FREE-RADICAL THEORY; OXIDATIVE STRESS; ENERGY-INTAKE; FAT
   SOURCE; LIFE-SPAN; BIOGENESIS; PARTICIPATION
AB Calorie restriction without malnutrition (CR) is considered as the most effective nongenetic nor pharmacological intervention that promotes healthy aging phenotypes and can extend lifespan in most model organisms. Lifelong CR leads to an increase of cytochrome b(5) reductase-3 (CYB5R3) expression and activity. Overexpression of CYB5R3 confers some of the salutary effects of CR, although the mechanisms involved might be independent because key aspects of energy metabolism and lipid profiles of tissues go in opposite ways. It is thus important to study if some of the metabolic adaptations induced by CR are affected by CYB5R3 overexpression. CYB5R3 overexpression greatly preserved body and liver weight in mice under CR conditions. In liver, CR did not modify mitochondrial abundance, but lead to increased expression of mitofusin Mfn2 and TFAM, a transcription factor involved in mitochondrial biogenesis. These changes were prevented by CYB5R3 overexpression but resulted in a decreased expression of a different mitochondrial biogenesis-related transcription factor, Nrf1. In skeletal muscle, CR strongly increased mitochondrial mass, mitofusin Mfn1, and Nrf1. However, CYB5R3 mice on CR did not show increase in muscle mitochondrial mass, regardless of a clear increase in expression of TFAM and mitochondrial complexes in this tissue. Our results support that CYB5R3 overexpression significantly modifies the metabolic adaptations of mice to CR.
C1 [Rodriguez-Lopez, Sandra; Lopez-Bellon, Sara; Gonzalez-Reyes, Jose A.; Isabel Buron, M.; Villalba, Jose M.] Univ Cordoba, Dept Biol Celular Fisiol & Inmunol, Campus Excelencia Intemac Agroalimentario CeiA3, Campus Rabanales,Edificio Severo Ochoa,3 Planta, Cordoba 14014, Spain.
   [de Cabo, Rafael] NIA, Translat Gerontol Branch, NIH, Baltimore, MD 21224 USA.
C3 Universidad de Cordoba; National Institutes of Health (NIH) - USA; NIH
   National Institute on Aging (NIA)
RP Villalba, JM (corresponding author), Univ Cordoba, Dept Biol Celular Fisiol & Inmunol, Campus Excelencia Intemac Agroalimentario CeiA3, Campus Rabanales,Edificio Severo Ochoa,3 Planta, Cordoba 14014, Spain.
EM jmvillalba@uco.es
RI González-Reyes, José A/K-1367-2014; de Cabo, Rafael Carlos/E-7996-2010
OI González-Reyes, José A/0000-0003-1918-5490; de Cabo, Rafael
   Carlos/0000-0003-2830-5693; RODRIGUEZ-LOPEZ, SANDRA/0000-0002-5088-6458;
   Villalba Montoro, Jose Manuel/0000-0001-8554-3802
FU Spanish Ministerio de Economia y Competitividad (MINECO)
   [BFU2015-64630-R]; EU FEDER funds; Ministerio de Ciencia, Innovacion y
   Universidades (MICIU) [RTI2018-100695-B-I00]; Spanish Junta de Andalucia
   [BIO-276]; Universidad de Cordoba; MINECO; Spanish Ministerio de
   Educacion, Cultura y Deporte (MECD); Intramural Research Program of the
   National Institute on Aging
FX This study was supported by Spanish Ministerio de Economia y
   Competitividad (MINECO) grant BFU2015-64630-R, cofinanced with EU FEDER
   funds, and Ministerio de Ciencia, Innovacion y Universidades (MICIU)
   grant RTI2018-100695-B-I00, Spanish Junta de Andalucia (BIO-276) and
   Universidad de Cordoba (to JMVM). SRL held a FPI predoctoral contract
   funded by MINECO. SLB held a FPU predoctoral contract awarded by the
   Spanish Ministerio de Educacion, Cultura y Deporte (MECD). RdC is
   supported by the Intramural Research Program of the National Institute
   on Aging.
CR López-Domínguez JA, 2013, AGE, V35, P2027, DOI 10.1007/s11357-012-9492-9
   Barja G, 2014, PROG MOL BIOL TRANSL, V127, P1, DOI 10.1016/B978-0-12-394625-6.00001-5
   Barja G, 2013, ANTIOXID REDOX SIGN, V19, P1420, DOI 10.1089/ars.2012.5148
   Belcourt MF, 1998, J BIOL CHEM, V273, P8875, DOI 10.1074/jbc.273.15.8875
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   Cartee GD, 2016, CELL METAB, V23, P1034, DOI 10.1016/j.cmet.2016.05.007
   Cerqueira FM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018433
   Chen CN, 2019, GEROSCIENCE, V41, P871, DOI 10.1007/s11357-019-00109-8
   Chen YN, 2013, BIOSCIENCE REP, V33, P83, DOI 10.1042/BSR20120060
   Chen YN, 2012, J GERONTOL A-BIOL, V67, P1121, DOI 10.1093/gerona/gls113
   Civitarese AE, 2007, PLOS MED, V4, P485, DOI 10.1371/journal.pmed.0040076
   Csiszar A, 2019, GEROSCIENCE, V41, P609, DOI 10.1007/s11357-019-00111-0
   de Brito OM, 2008, NATURE, V456, P605, DOI 10.1038/nature07534
   De Cabo R, 2004, EXP GERONTOL, V39, P297, DOI 10.1016/j.exger.2003.12.003
   de Cabo R, 2010, AGING-US, V2, P63
   Diaz-Ruiz A, 2018, AGING CELL, V17, DOI 10.1111/acel.12767
   Fan JS, 2020, MOL METAB, V34, P97, DOI 10.1016/j.molmet.2019.12.008
   Grünewald A, 2014, J NEUROSCI METH, V232, P143, DOI 10.1016/j.jneumeth.2014.05.026
   Guarente L, 2008, CELL, V132, P171, DOI 10.1016/j.cell.2008.01.007
   Gutiérrez-Casado E, 2019, J GERONTOL A-BIOL, V74, P760, DOI 10.1093/gerona/gly161
   Hagopian K, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012696
   HARMAN D, 1956, J GERONTOL, V11, P298, DOI 10.1093/geronj/11.3.298
   Hyun DH, 2006, P NATL ACAD SCI USA, V103, P19908, DOI 10.1073/pnas.0608008103
   Jakobs HH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105371
   JANSSON I, 1973, MOL PHARMACOL, V9, P840
   Jové M, 2014, AGING CELL, V13, P828, DOI 10.1111/acel.12241
   Khraiwesh H, 2014, EXP GERONTOL, V56, P77, DOI 10.1016/j.exger.2014.03.023
   Khraiwesh H, 2013, J GERONTOL A-BIOL, V68, P1023, DOI 10.1093/gerona/glt006
   Kunau WH, 1995, PROG LIPID RES, V34, P267, DOI 10.1016/0163-7827(95)00011-9
   LAGANIERE S, 1993, GERONTOLOGY, V39, P7, DOI 10.1159/000213509
   LAGANIERE S, 1989, MECH AGEING DEV, V48, P221, DOI 10.1016/0047-6374(89)90084-5
   Liochev SI, 2015, ANTIOXID REDOX SIGN, V23, P187, DOI 10.1089/ars.2014.5928
   López-Domínguez JA, 2015, J GERONTOL A-BIOL, V70, P1181, DOI 10.1093/gerona/glu177
   López-Lluch G, 2005, AGE, V27, P153, DOI 10.1007/s11357-005-2726-3
   López-Lluch G, 2006, P NATL ACAD SCI USA, V103, P1768, DOI 10.1073/pnas.0510452103
   Villalba JM, 2015, BIOGERONTOLOGY, V16, P655, DOI 10.1007/s10522-015-9572-1
   Martin-Montalvo A, 2016, NPJ AGING MECH DIS, V2, DOI 10.1038/npjamd.2016.6
   Martin-Montalvo A, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3192
   Mitchell SJ, 2016, CELL METAB, V23, P1093, DOI 10.1016/j.cmet.2016.05.027
   Navas P, 2007, MITOCHONDRION, V7, pS34, DOI 10.1016/j.mito.2007.02.010
   Nisoli E, 2005, SCIENCE, V310, P314, DOI 10.1126/science.1117728
   OSHINO N, 1971, J BIOCHEM, V69, P155, DOI 10.1093/oxfordjournals.jbchem.a129444
   Picca A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074644
   Ramsey JJ, 2000, FREE RADICAL BIO MED, V29, P946, DOI 10.1016/S0891-5849(00)00417-2
   REDDY VVR, 1977, J BIOL CHEM, V252, P2797
   Rieusset J, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0416-1
   Sacco JC, 2010, PHARMACOGENET GENOM, V20, P26, DOI 10.1097/FPC.0b013e3283343296
   Sakamuri SSVP, 2018, GEROSCIENCE, V40, P347, DOI 10.1007/s11357-018-0021-3
   Siendones E, 2014, ANTIOXID REDOX SIGN, V21, P1708, DOI 10.1089/ars.2013.5479
   Sohal RS, 1996, SCIENCE, V273, P59, DOI 10.1126/science.273.5271.59
   Spindler SR, 2007, ANNU REV NUTR, V27, P193, DOI 10.1146/annurev.nutr.27.061406.093743
   STOSCHECK CM, 1990, METHOD ENZYMOL, V182, P50
   Sure VN, 2018, GEROSCIENCE, V40, P365, DOI 10.1007/s11357-018-0037-8
   Tilokani L, 2018, ESSAYS BIOCHEM, V62, P341, DOI 10.1042/EBC20170104
   TOYODA A, 1995, GENE, V164, P351, DOI 10.1016/0378-1119(95)00443-A
NR 55
TC 6
Z9 6
U1 0
U2 12
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 2509-2715
EI 2509-2723
J9 GEROSCIENCE
JI GeroScience
PD 2020 JUN
PY 2020
VL 42
IS 3
SI SI
BP 977
EP 994
DI 10.1007/s11357-020-00187-z
EA APR 2020
PG 18
WC Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Geriatrics & Gerontology
GA LX9MV
UT WOS:000528104700001
PM 32323139
OA Green Published
DA 2024-02-19
ER

PT J
AU Narita, J
   Kawamura, T
   Miyaji, C
   Watanabe, H
   Honda, S
   Koya, T
   Arakawa, M
   Abo, T
AF Narita, J
   Kawamura, T
   Miyaji, C
   Watanabe, H
   Honda, S
   Koya, T
   Arakawa, M
   Abo, T
TI Abundance of NKT cells in the salivary glands but absence thereof in the
   liver and thymus of <i>aly/aly</i> mice with Sjogren syndrome
SO CELLULAR IMMUNOLOGY
LA English
DT Article
ID NATURAL-KILLER-CELLS; EXTRATHYMIC T-CELLS; INTESTINAL INTRAEPITHELIAL
   LYMPHOCYTES; INTERMEDIATE TCR CELLS; GAMMA-DELTA; MOUSE-LIVER;
   GRAVES-DISEASE; IMMUNE ORGANS; KUPFFER CELLS; MURINE LIVER
AB It is known that ALY/Nsc Jcl-aly/aly (aly/aly) mice that congenitally lack lymph nodes fall victim to Sjogren syndrome as a function of age. We investigated how TCRint cells of extrathymic origin and TCRhigh cells of thymic origin are distributed in various organs of these mice, Although the distribution of T-cell subsets was not different between control aly/+ and aly/aly mice in youth in any of the tested organs, the proportion of TCRint cells in the liver and spleen of aly/aly mice increased with aging. Usually, TCRint cells in the liver comprise a half-and-half mixture of a NK1.1(+) subset (i.e., NKT cells) and a NK1.1(-) subset. In constrast, almost all expanding TCRint cells in various immune organs of aly/aly mice were found to be NK1.1(-). A large proportion of lymphocytes, including NK cells and TCRint cells, were also present in the salivary glands of aly/aly mice. Interestingly, these TCRint cells in the salivary glands contained an NK1.1+ subset (i.e., NKT cells) that used an invariant chain of V alpha 14J alpha 281 for TCR alpha beta (>50%). Moreover, gamma delta T cells that used V gamma 1, 2, 4/V delta 1, 4, 6 mRNAs, different from those of gamma delta T cells in the liver and intestine, were abundant. Possibly reflecting the in situ generation of these T cells in the salivary glands, the expression of RAG-2 mRNA was evident by the RT-RCR method. These results suggest that (i) inflammatory lymphocytes that evoke Sjogren syndrome in aly/aly mice are NK cells or TCRint cells (both NK1.1(+) and NK1.1(-) subsets) and (ii) TCRint cells in the salivary glands might be generated in situ, (C) 1999 Academic Press.
C1 Niigata Univ, Dept Immunol, Sch Med, Niigata 9518510, Japan.
   Niigata Univ, Dept Internal Med 2, Sch Med, Niigata 9518510, Japan.
C3 Niigata University; Niigata University
RP Abo, T (corresponding author), Niigata Univ, Dept Immunol, Sch Med, Asahimachidori 1-757, Niigata 9518510, Japan.
CR ABO T, 1991, J EXP MED, V174, P417, DOI 10.1084/jem.174.2.417
   Abo T, 1995, NAT IMMUN, V14, P173
   Ackerman KD, 1996, J NEUROIMMUNOL, V68, P85, DOI 10.1016/0165-5728(96)00077-X
   Arai K, 1996, J IMMUNOL, V157, P5170
   BALCH CM, 1984, SURGERY, V95, P63
   BANDEIRA A, 1991, P NATL ACAD SCI USA, V88, P43, DOI 10.1073/pnas.88.1.43
   Baxter AG, 1997, DIABETES, V46, P572, DOI 10.2337/diabetes.46.4.572
   BENDELAC A, 1995, CURR OPIN IMMUNOL, V7, P367, DOI 10.1016/0952-7915(95)80112-X
   Catalfamo M, 1996, J IMMUNOL, V156, P804
   CRISPE IN, 1987, NATURE, V329, P336, DOI 10.1038/329336a0
   EGAN ML, 1983, ARTHRITIS RHEUM, V26, P623, DOI 10.1002/art.1780260508
   EGERTON M, 1990, INT IMMUNOL, V2, P157, DOI 10.1093/intimm/2.2.157
   ELBE A, 1992, J IMMUNOL, V149, P1694
   GOOSSENS PL, 1990, J IMMUNOL METHODS, V132, P137, DOI 10.1016/0022-1759(90)90407-M
   Haddad EK, 1997, J IMMUNOL, V158, P4886
   Hammond KJL, 1998, J EXP MED, V187, P1047, DOI 10.1084/jem.187.7.1047
   HAYAKAWA S, 1994, J IMMUNOL, V153, P4934
   Horwitz DA, 1997, IMMUNOL TODAY, V18, P538, DOI 10.1016/S0167-5699(97)01149-3
   IIAI T, 1992, IMMUNOLOGY, V77, P556
   ITOH H, 1988, J IMMUNOL, V141, P315
   Kanamori Y, 1996, J EXP MED, V184, P1449, DOI 10.1084/jem.184.4.1449
   KAWACHI Y, 1995, EUR J IMMUNOL, V25, P2272, DOI 10.1002/eji.1830250824
   KIMURA M, 1995, CELL IMMUNOL, V162, P16, DOI 10.1006/cimm.1995.1046
   Koike R, 1996, EUR J IMMUNOL, V26, P669, DOI 10.1002/eji.1830260324
   Leclercq G, 1996, J EXP MED, V184, P325, DOI 10.1084/jem.184.2.325
   MACDONALD HR, 1995, J EXP MED, V182, P633, DOI 10.1084/jem.182.3.633
   MAGILAVY DB, 1987, J EXP MED, V166, P271, DOI 10.1084/jem.166.1.271
   MASERA RG, 1994, CHRONOBIOLOGIA, V21, P127
   MIYAWAKI S, 1994, EUR J IMMUNOL, V24, P429, DOI 10.1002/eji.1830240224
   Moroda T, 1997, IMMUNOLOGY, V91, P88, DOI 10.1046/j.1365-2567.1997.00222.x
   Multhoff G, 1997, J IMMUNOL, V158, P4341
   NAITO M, 1991, LAB INVEST, V64, P664
   Nakagawa K, 1997, P NATL ACAD SCI USA, V94, P2472, DOI 10.1073/pnas.94.6.2472
   Nakayama M, 1996, BIOMED RES-TOKYO, V17, P149, DOI 10.2220/biomedres.17.149
   OGIMOTO M, 1993, J IMMUNOL, V151, P3000
   OHTEKI T, 1991, EUR J IMMUNOL, V21, P1733, DOI 10.1002/eji.1830210722
   OHTSUKA K, 1994, CELL IMMUNOL, V153, P52, DOI 10.1006/cimm.1994.1005
   Olive C, 1997, IMMUNOL CELL BIOL, V75, P102, DOI 10.1038/icb.1997.14
   ROURAMIR IC, 1993, CLIN EXP IMMUNOL, V92, P288
   SATO K, 1995, J EXP MED, V182, P759, DOI 10.1084/jem.182.3.759
   SEKI S, 1991, J IMMUNOL, V147, P1214
   SHIBATA Y, 1985, J IMMUNOL, V135, P3897
   Suri-Payer E, 1998, J IMMUNOL, V160, P1212
   TAKAGAKI Y, 1989, NATURE, V339, P712, DOI 10.1038/339712a0
   TAKEDA K, 1993, J EXP MED, V177, P155, DOI 10.1084/jem.177.1.155
   Thornton AM, 1998, J EXP MED, V188, P287, DOI 10.1084/jem.188.2.287
   Tsukahara A, 1997, HEPATOLOGY, V26, P301, DOI 10.1002/hep.510260208
   Watanabe H, 1996, J EXP MED, V184, P687, DOI 10.1084/jem.184.2.687
   WATANABE H, 1995, J IMMUNOL, V155, P2972
   Yamamoto T, 1996, AM J PATHOL, V149, P1271
   ZIEGLERHEITBROCK HWL, 1985, BLOOD, V65, P65
NR 51
TC 24
Z9 24
U1 0
U2 1
PU ACADEMIC PRESS INC
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0008-8749
J9 CELL IMMUNOL
JI Cell. Immunol.
PD MAR 15
PY 1999
VL 192
IS 2
BP 149
EP 158
DI 10.1006/cimm.1998.1450
PG 10
WC Cell Biology; Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Immunology
GA 184KY
UT WOS:000079612400008
PM 10087183
DA 2024-02-19
ER

PT J
AU LI, DH
   CHEN, S
   RANDERATH, K
AF LI, DH
   CHEN, S
   RANDERATH, K
TI NATURAL DIETARY INGREDIENTS (OATS AND ALFALFA) INDUCE COVALENT DNA
   MODIFICATIONS (I-COMPOUNDS) IN RAT-LIVER AND KIDNEY
SO NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL
LA English
DT Article
AB Mammalian tissue DNA has recently been found, via P-32 postlabeling, to contain complex profiles of age-dependent bulky carcinogen adductlike covalent modifications, which have been termed I-compounds, referring to their apparent indigenous origin without exposure to exogenous carcinogens. I-compound patterns are highly species, sex, tissue, and diet specific. As shown here, the presence of certain plant ingredients in diet, ie., ground oats and alfalfa meal significantly contributed to the formation of these DNA derivatives.
   Six groups of weanling female Sprague-Dawley rats were fed one of the following diets for three months: a natural ingredient diet containing neither oats nor alfalfa (Wayne MRH 22/5 Rodent Blox), Wayne diet supplemented with oats or alfalfa or both, a purified semisynthetic diet (AIN-76A), and AIN diet supplemented with oats. The natural ingredient diet produced more complex patterns and higher levels of I-compounds than purified diet in both liver and kidney DNA. Supplementation of either diet with oats elicited the formation of four additional oats-specific I-compounds in liver DNA. Oats and alfalfa, individually and in combination, tended to significantly raise nonpolar and diminish polar I-compound levels.
   To determine whether the oats-related extra spots were derived from mycotoxin contamination, two groups of rats were fed either Wayne diet or Wayne diet containing zearalenone (0.05 mg/kg) for three weeks. Zearalenone significantly increased the uterine weight but did not induce any DNA adduct formation. These findings establish a novel link between specific natural food ingredients and carcinogen adductlike DNA derivatives and may provide a model to investigate events occurring at the juncture of nutrition, metabolism, gene expression, aging, and cancer.
RP LI, DH (corresponding author), BAYLOR COLL MED,DEPT PHARMACOL,DIV TOXICOL,HOUSTON,TX 77030, USA.
FU NCI NIH HHS [R37-CA-32157] Funding Source: Medline; NIA NIH HHS
   [R01-AG-07750] Funding Source: Medline
NR 0
TC 17
Z9 17
U1 0
U2 1
PU LAWRENCE ERLBAUM ASSOC INC
PI MAHWAH
PA 10 INDUSTRIAL AVE, MAHWAH, NJ 07430-2262
SN 0163-5581
J9 NUTR CANCER
JI Nutr. Cancer
PY 1992
VL 17
IS 3
BP 205
EP 216
DI 10.1080/01635589209514189
PG 12
WC Oncology; Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Nutrition & Dietetics
GA JB844
UT WOS:A1992JB84400001
PM 1437640
DA 2024-02-19
ER

PT J
AU Chen, H
   Tang, XY
   Su, W
   Li, S
   Yang, RY
   Cheng, H
   Zhang, GX
   Zhou, XY
AF Chen, Han
   Tang, Xinyu
   Su, Wei
   Li, Shuo
   Yang, Ruoyun
   Cheng, Hong
   Zhang, Guoxin
   Zhou, Xiaoying
TI Causal effects of lipid-lowering therapies on aging-related outcomes and
   risk of cancers: a drug-target Mendelian randomization study
SO AGING-US
LA English
DT Article
DE lipid-lowering drugs; aging; Mendelian randomization
ID INSTRUMENTAL VARIABLES; LDL-CHOLESTEROL; STATIN THERAPY; PCSK9
AB Background: Despite the widespread use of statins, newer lipid-lowering drugs have been emerging. It remains unclear how the long-term use of novel lipid-lowering drugs affects the occurrence of cancers and age-related diseases.Methods: A drug-target Mendelian randomization study was performed. Genetic variants of nine lipid-lowering drug-target genes (HMGCR, PCKS9, NPC1L1, LDLR, APOB, CETP, LPL, APOC3, and ANGPTL3) were extracted as exposures from the summary data of Global Lipids Genetics Consortium Genome-Wide Association Studies (GWAS). GWAS summary data of cancers and noncancerous diseases were used as outcomes. The inversevariance weighted method was applied as the main statistical approach. Sensitivity tests were conducted to evaluate the robustness, pleiotropy, and heterogeneity of the results.Results: In addition to marked effects on decreased risks of atherosclerotic cardiovascular diseases, genetically proxied lipid-lowering variants of PCKS9, CETP, LPL, LDLR, and APOC3 were associated with longer human lifespans (q<0.05). Lipid-lowering variants of ANGPTL3 and LDLR were associated with reduced risks of colorectal cancer, and ANGPTL3 was also associated with lower risks of gastric cancer (q<0.05). Lipid-lowering LPL variants were associated with decreased risks of hypertension, type 2 diabetes, nonalcoholic fatty liver disease, and bladder cancer (q<0.05). Lipid-lowering variants of PCKS9 and HMGCR were associated with decreased risks of osteoporosis (q<0.05). Lipid-lowering APOB variants were associated with a decreased risk of thyroid cancer (q<0.05).Conclusions: Our study provides genetic evidence that newer nonstatin lipid-lowering agents have causal effects on decreased risks of several common cancers and cardiometabolic diseases. These data provide genetic insights into the potential benefits of newer nonstatin therapies.
C1 [Chen, Han; Su, Wei; Li, Shuo; Yang, Ruoyun; Zhang, Guoxin; Zhou, Xiaoying] Nanjing Med Univ, Affiliated Hosp 1, Dept Gastroenterol, Nanjing, Jiangsu, Peoples R China.
   [Tang, Xinyu] Nanjing Med Univ, Affiliated Hosp 1, Dept Radiat Oncol, Nanjing, Jiangsu, Peoples R China.
   [Cheng, Hong] Nanjing Med Univ, Affiliated Hosp 1, Dept Neurol, Nanjing, Jiangsu, Peoples R China.
C3 Nanjing Medical University; Nanjing Medical University; Nanjing Medical
   University
RP Zhang, GX; Zhou, XY (corresponding author), Nanjing Med Univ, Affiliated Hosp 1, Dept Gastroenterol, Nanjing, Jiangsu, Peoples R China.
EM zhangguoxinzxy@njmu.edu.cn; zhouxiaoying0926@njmu.edu.cn
OI Chen, Han/0000-0002-7513-034X
FU China Postdoctoral Science Foundation [2023M731417]; Spring Sunshine
   Program from the Ministry of Education of China [202201552]; Jiangsu
   province Hospital (the First Affiliated Hospital with Nanjing Medical
   University) Clinical Capacity Enhancement Project [JSPH-MC-2022-29]
FX This work was supported by China Postdoctoral Science Foundation (No.
   2023M731417) , Spring Sunshine Program from the Ministry of Education of
   China (No.202201552) and Jiangsu province Hospital (the First Affiliated
   Hospital with Nanjing Medical University) Clinical Capacity Enhancement
   Project (JSPH-MC-2022-29) .
CR Akoumianakis I, 2021, CURR ATHEROSCLER REP, V23, DOI 10.1007/s11883-021-00914-7
   Andrade C, 2020, J CLIN PSYCHIAT, V81, DOI 10.4088/JCP.20f13698
   Burgess S, 2016, STAT MED, V35, P1880, DOI 10.1002/sim.6835
   Cheng J, 2018, J CANCER, V9, P1500, DOI 10.7150/jca.23017
   Davies NM, 2018, BMJ-BRIT MED J, V362, DOI 10.1136/bmj.k601
   Dong B, 2014, ATHEROSCLEROSIS, V235, P449, DOI 10.1016/j.atherosclerosis.2014.05.931
   Evans Daniel S, 2022, Methods Mol Biol, V2547, P1, DOI 10.1007/978-1-0716-2573-6_1
   Fitzgerald K, 2014, LANCET, V383, P60, DOI 10.1016/S0140-6736(13)61914-5
   Fulcher J, 2019, LANCET, V393, P407, DOI 10.1016/S0140-6736(18)31942-1
   Fulcher J, 2015, LANCET, V385, P1397, DOI 10.1016/S0140-6736(14)61368-4
   Galicia-Garcia U, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21134725
   Goldstein JL, 2009, ARTERIOSCL THROM VAS, V29, P431, DOI 10.1161/ATVBAHA.108.179564
   Hemani G, 2018, ELIFE, V7, DOI 10.7554/eLife.34408
   Hemani G, 2017, PLOS GENET, V13, DOI 10.1371/journal.pgen.1007081
   Istvan ES, 2001, SCIENCE, V292, P1160, DOI 10.1126/science.1059344
   Johnson AA, 2019, AGING CELL, V18, DOI 10.1111/acel.13048
   -Jones DML, 2022, J AM COLL CARDIOL, V80, P1366, DOI 10.1016/j.jacc.2022.07.006
   Mach F, 2019, ATHEROSCLEROSIS, V290, P140, DOI [10.1016/j.atherosclerosis.2019.08.014, 10.1093/eurheartj/ehz455]
   Mattioli K, 2020, GENOME BIOL, V21, DOI 10.1186/s13059-020-02110-3
   Mutlu AS, 2021, DEV CELL, V56, P1394, DOI 10.1016/j.devcel.2021.03.034
   Nicholls SJ, 2022, NAT MED, V28, P1672, DOI 10.1038/s41591-022-01936-7
   Pakiet A, 2019, LIPIDS HEALTH DIS, V18, DOI 10.1186/s12944-019-0977-8
   Raal FJ, 2020, NEW ENGL J MED, V383, P711, DOI 10.1056/NEJMoa2004215
   Raposeiras-Roubin S, 2021, J AM COLL CARDIOL, V77, P3031, DOI 10.1016/j.jacc.2021.04.059
   Ridker PM, 2012, LANCET, V380, P565, DOI 10.1016/S0140-6736(12)61190-8
   Sattar N, 2010, LANCET, V375, P735, DOI 10.1016/S0140-6736(09)61965-6
   Schmidt AF, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16969-0
   Staiger D, 1997, ECONOMETRICA, V65, P557, DOI 10.2307/2171753
   Stroes ES, 2015, EUR HEART J, V36, P1012, DOI 10.1093/eurheartj/ehv043
   Tanaka T, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17111806
   Thompson PD, 2015, J CLIN LIPIDOL, V9, P295, DOI 10.1016/j.jacl.2015.03.003
   Timmers PRHJ, 2019, ELIFE, V8, DOI 10.7554/eLife.39856
   Wang YX, 2023, MOL CARCINOGEN, V62, P546, DOI 10.1002/mc.23506
   Willer Cristen J, 2013, Nat Genet, V45, P1274, DOI 10.1038/ng.2797
NR 34
TC 1
Z9 1
U1 1
U2 1
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
SN 1945-4589
J9 AGING-US
JI Aging-US
PD DEC 31
PY 2023
VL 15
IS 24
BP 15228
EP 15242
PG 15
WC Cell Biology; Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Geriatrics & Gerontology
GA EI2Q3
UT WOS:001138232700005
PM 38127052
DA 2024-02-19
ER

PT J
AU Oszkiel, H
   Wilczak, J
   Jank, M
AF Oszkiel, Hanna
   Wilczak, Jacek
   Jank, Michal
TI Biologically active substances-enriched diet regulates gonadotrope cell
   activation pathway in liver of adult and old rats
SO GENES AND NUTRITION
LA English
DT Article
DE Rat; Liver; Biologically active substances; Genes expression; GnRH
ID LACTATING DAIRY-COWS; OXYGEN SPECIES PRODUCTION; MESSENGER-RNA
   EXPRESSION; FATTY-ACIDS; GENE-EXPRESSION; BETA-CAROTENE; BOVINE
   SOMATOTROPIN; SMELL DYSFUNCTION; FOLLICULAR-FLUID; ADAPTER PROTEIN
AB According to the Hippocrates' theorem "Let food be your medicine and medicine be your food", dietary interventions may induce changes in the metabolic and inflammatory state by modulating the expression of important genes involved in the chronic disorders. The aim of the present study was to evaluate the influence of long-term (14 months) use of biologically active substances-enriched diet (BASE-diet) on transcriptomic profile of rats' liver. The experiment was conducted on 36 Sprague-Dawley rats divided into two experimental groups (fed with control or BASE-diet, both n = 18). Control diet was a semi-synthetic diet formulated according to the nutritional requirements for laboratory animals. The BASE-diet was enriched with a mixture of polyphenolic compounds, beta-carotene, probiotics, and n-3 and n-6 polyunsaturated fatty acids. In total, n = 3,017 differentially expressed (DE) genes were identified, including n = 218 DE genes between control and BASE groups after 3 months of feeding and n = 1,262 after 14 months. BASE-diet influenced the expression of genes involved particularly in the gonadotrope cell activation pathway and guanylate cyclase pathway, as well as in mast cell activation, gap junction regulation, melanogenesis and apoptosis. Especially genes involved in regulation of GnRH were strongly affected by BASE-diet. This effect was stronger with the age of animals and the length of diet use. It may suggest a link between the diet, reproductive system function and aging.
C1 [Oszkiel, Hanna; Wilczak, Jacek; Jank, Michal] Warsaw Univ Life Sci, Fac Vet Med, Dept Physiol Sci, PL-02776 Warsaw, Poland.
C3 Warsaw University of Life Sciences
RP Jank, M (corresponding author), Warsaw Univ Life Sci, Fac Vet Med, Dept Physiol Sci, Nowoursynowska 159 Str, PL-02776 Warsaw, Poland.
EM michal_jank@sggw.pl
OI Jank, Michal/0000-0003-1630-2938; Wilczak, Jacek/0000-0002-3053-3663
FU Ministry of Sciences and Higher Education [N N312 337939]
FX This work was supported by Grant No. N N312 337939 from the Ministry of
   Sciences and Higher Education.
CR Alam SE, 2012, CAN J PHYSIOL PHARM, V90, P989, DOI [10.1139/Y2012-105, 10.1139/y2012-105]
   Ames HM, 2013, MOL CELL BIOL, V33, P3580, DOI 10.1128/MCB.00473-13
   [Anonymous], 1995, NUTR REQ LAB AN
   Arechiga CF, 1998, J DAIRY SCI, V81, P390, DOI 10.3168/jds.S0022-0302(98)75589-4
   Arellano-Rodriguez G, 2009, J ANIM PHYSIOL AN N, V93, P710, DOI 10.1111/j.1439-0396.2008.00859.x
   Arshavsky VY, 2013, INVEST OPHTH VIS SCI, V54, P7725, DOI 10.1167/iovs.13-13281
   Astley SB, 2007, GENES NUTR, V2, P11, DOI 10.1007/s12263-007-0011-z
   Atwood CS, 2011, EXP GERONTOL, V46, P100, DOI 10.1016/j.exger.2010.09.007
   Bakker GCM, 2010, AM J CLIN NUTR, V91, P1044, DOI 10.3945/ajcn.2009.28822
   Berry DC, 2011, P NATL ACAD SCI USA, V108, P4340, DOI 10.1073/pnas.1011115108
   Bilby TR, 2006, J DAIRY SCI, V89, P3375, DOI 10.3168/jds.S0022-0302(06)72374-8
   Brann DW, 1997, ENDOCR REV, V18, P678, DOI 10.1210/er.18.5.678
   Chae KS, 2007, INVEST OPHTH VIS SCI, V48, P901, DOI 10.1167/iovs.06-0824
   Chaudhry AS, 2013, DRUG METAB DISPOS, V41, P1538, DOI 10.1124/dmd.113.051672
   Chen SK, 2007, J NEUROSCI, V27, P12168, DOI 10.1523/JNEUROSCI.3541-07.2007
   Chen ZG, 2010, BIOCHEM CELL BIOL, V88, P737, DOI 10.1139/O10-012
   Cheung LWT, 2008, FEBS J, V275, P5479, DOI 10.1111/j.1742-4658.2008.06677.x
   Colitti M, 2007, THERIOGENOLOGY, V68, P1022, DOI 10.1016/j.theriogenology.2007.07.018
   Colitti M, 2006, VET RES COMMUN, V30, P19, DOI 10.1007/s11259-005-3208-x
   Cornilescu CC, 2014, J BIOL CHEM, V289, P3055, DOI 10.1074/jbc.M113.531053
   Costello LM, 2010, REPROD FERT DEVELOP, V22, P1198, DOI 10.1071/RD10034
   Dam VS, 2014, PFLUG ARCH EUR J PHY, V466, P1391, DOI 10.1007/s00424-013-1382-1
   Datta K, 2012, RADIAT ONCOL, V7, DOI 10.1186/1748-717X-7-205
   De Haes W, 2013, 17 INT C COMP END
   De Stefano D, 2007, EUR J PHARMACOL, V566, P192, DOI 10.1016/j.ejphar.2007.03.051
   Dismuke WM, 2014, EXP EYE RES, V120, P28, DOI 10.1016/j.exer.2013.12.012
   Ferguson LR, 2007, GENES NUTR, V2, P71, DOI 10.1007/s12263-007-0046-1
   Ferretti G, 2012, NUTRIENTS, V4, P243, DOI 10.3390/nu4040243
   Gandhi AV, 2013, ANN SURG ONCOL, V20, pS636, DOI 10.1245/s10434-013-3128-x
   Garcia-Bojalil CM, 1998, J DAIRY SCI, V81, P1385, DOI 10.3168/jds.S0022-0302(98)75702-9
   Garrel G, 2011, ENDOCRINOLOGY, V152, P3905, DOI 10.1210/en.2011-1167
   Gebrie E, 2005, J ETHNOPHARMACOL, V96, P139, DOI 10.1016/j.jep.2004.08.026
   Golombek DA, 2003, FRONT BIOSCI-LANDMRK, V8, pS285, DOI 10.2741/1038
   Guyton A.C., 2006, G KHAN N AVU O LU H
   Haliloglu S, 2002, REPROD DOMEST ANIM, V37, P96, DOI 10.1046/j.1439-0531.2002.00338.x
   Hannah VC, 2001, J BIOL CHEM, V276, P4365, DOI 10.1074/jbc.M007273200
   Henkin RI, 2007, AM J MED SCI, V334, P431, DOI 10.1097/MAJ.0b013e3180de4d97
   Henkin RI, 2013, AM J OTOLARYNG, V34, P477, DOI 10.1016/j.amjoto.2013.04.006
   Henkin RI, 2009, METABOLISM, V58, P1717, DOI 10.1016/j.metabol.2009.05.027
   Huang CZ, 2013, MOL BIOL REP, V40, P5825, DOI 10.1007/s11033-013-2688-y
   Hutchinson IA, 2012, THERIOGENOLOGY, V78, P12, DOI 10.1016/j.theriogenology.2011.12.031
   Jones N, 2007, MOL CELL BIOL, V27, P4759, DOI 10.1128/MCB.00184-07
   Joseph J, 2009, J NEUROSCI, V29, P12795, DOI 10.1523/JNEUROSCI.3520-09.2009
   Kameritsch P, 2012, CARDIOVASC RES, V93, P508, DOI 10.1093/cvr/cvr345
   Kawaguchi S, 2013, J PHYSIOL-LONDON, V591, P1707, DOI 10.1113/jphysiol.2012.245787
   Kim HK, 2014, FOOD FUNCT, V5, P573, DOI 10.1039/c3fo60509d
   Lee VHY, 2008, FEBS J, V275, P5458, DOI 10.1111/j.1742-4658.2008.06676.x
   Li G, 2013, CURR MOL MED, V13, P459
   Lillycrop KA, 2012, BEST PRACT RES CL EN, V26, P667, DOI 10.1016/j.beem.2012.03.009
   Liu Q, 2010, BMC GASTROENTEROL, V10, DOI 10.1186/1471-230X-10-49
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lottenberg AM, 2012, J NUTR BIOCHEM, V23, P1027, DOI 10.1016/j.jnutbio.2012.03.004
   LUCY MC, 1993, J DAIRY SCI, V76, P1014, DOI 10.3168/jds.S0022-0302(93)77429-9
   Ma X, 2014, FASEB J, V28, P813, DOI 10.1096/fj.13-243287
   Mao Guan Kun, 2013, Front Biosci (Elite Ed), V5, P755
   Matteri RL, 2000, BIOLOGY OF ANIMAL STRESS, P43, DOI 10.1079/9780851993591.0043
   Mattos R, 2002, J DAIRY SCI, V85, P755, DOI 10.3168/jds.S0022-0302(02)74133-7
   Millar RP, 2005, ANIM REPROD SCI, V88, P5, DOI 10.1016/j.anireprosci.2005.05.032
   Okamura H, 2013, ADV EXP MED BIOL, V784, P297, DOI 10.1007/978-1-4614-6199-9_14
   Oszkiel H, 2014, J AGING RES CLIN PRA, V3, P63
   Pechánová O, 2009, PHARMACOL REP, V61, P116, DOI 10.1016/S1734-1140(09)70013-1
   Pincas H, 2014, MOL CELL ENDOCRINOL, V385, P56, DOI 10.1016/j.mce.2013.08.015
   Polovlkova O G, 2013, Mol Biol (Mosk), V47, P433
   Robinson JW, 2012, DEV BIOL, V366, P308, DOI 10.1016/j.ydbio.2012.04.019
   Rodrigo Regina, 2006, Neuropsychiatr Dis Treat, V2, P53
   Rosen MB, 2013, TOXICOLOGY, V308, P129, DOI 10.1016/j.tox.2013.03.011
   Rukoyatkina N, 2011, THROMB HAEMOSTASIS, V106, P922, DOI 10.1160/TH11-05-0319
   Savas Ü, 2009, J BIOL CHEM, V284, P16541, DOI 10.1074/jbc.M902074200
   Schweigert FJ, 2003, HUM REPROD, V18, P1259, DOI 10.1093/humrep/deg249
   Sgorlon S, 2006, SMALL RUMINANT RES, V64, P143, DOI 10.1016/j.smallrumres.2005.04.009
   Sharma S, 2013, ENDOCRINOLOGY, V154, P2188, DOI 10.1210/en.2012-2218
   Simon A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067707
   Singer A, 2012, STRAHLENTHER ONKOL, V188, P1125, DOI 10.1007/s00066-012-0228-7
   Turco MY, 2012, STEM CELLS, V30, P2423, DOI 10.1002/stem.1217
   Uehara Y, 2007, ATHEROSCLEROSIS, V191, P11, DOI 10.1016/j.atherosclerosis.2006.04.018
   Van Arnum SD, 1998, VITAMIN A VITAMIN A, V45, P99
   Virmani A, 2006, ANN NY ACAD SCI, V1074, P303, DOI 10.1196/annals.1369.027
   Virmani A, 2013, MOL NEUROBIOL, V48, P353, DOI 10.1007/s12035-013-8498-3
   Wang L, 2013, CHEMOSPHERE, V93, P2639, DOI 10.1016/j.chemosphere.2013.08.044
   Zhang G, 2013, NATURE, V497, P211, DOI 10.1038/nature12143
   Zhang QX, 2009, BIOSCIENCE REP, V29, P47, DOI 10.1042/BSR20080040
   Zhang WY, 2006, BIOCHEM BIOPH RES CO, V345, P508, DOI 10.1016/j.bbrc.2006.04.085
NR 82
TC 3
Z9 4
U1 1
U2 8
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1555-8932
EI 1865-3499
J9 GENES NUTR
JI Genes Nutr.
PD SEP
PY 2014
VL 9
IS 5
AR 427
DI 10.1007/s12263-014-0427-1
PG 14
WC Genetics & Heredity; Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity; Nutrition & Dietetics
GA AP6XG
UT WOS:000342221100012
PM 25156242
OA Green Published, hybrid
DA 2024-02-19
ER

PT J
AU Oita, RC
   Mazzatti, DJ
   Lim, FL
   Powell, JR
   Merry, BJ
AF Oita, Radu C.
   Mazzatti, Dawn J.
   Lim, Fei Ling
   Powell, Jonathan R.
   Merry, Brian J.
TI Whole-genome microarray analysis identifies up-regulation of <i>Nr4a</i>
   nuclear receptors in muscle and liver from diet-restricted rats
SO MECHANISMS OF AGEING AND DEVELOPMENT
LA English
DT Article
DE Dietary restriction; Longevity; Ageing; Nuclear orphan receptor; NR4A;
   Nur77
ID PROTEIN KNOCKOUT MICE; CALORIC RESTRICTION; SKELETAL-MUSCLE;
   GENE-EXPRESSION; GLUCOCORTICOID-RECEPTOR; GLUCOSE-METABOLISM;
   GROWTH-FACTOR; CELL-DEATH; NUR77; NOR-1
AB One of the most conserved methods to significantly increase lifespan in animals is through dietary restriction (DR). The mechanisms by which DR increases survival are controversial but are thought to include improvements in mitochondrial function concomitant with reductions in reactive oxygen species production and alterations in the insulin signalling pathway, resulting in global metabolic adaptation. In order to identify novel genes that may be important for lifespan extension of Brown Norway rats, we compared gene expression profiles from skeletal muscle of 28-month-old animals fed ad libitum or DR diets using whole-genome arrays. Following DR, 426 transcripts were significantly down-regulated whilst only 52 were up-regulated. Included in the up-regulated transcripts were three functionally related previously unidentified DR-regulated genes: Nr4a1, Nr4a2, and Nr4a3. Up-regulation of all three Nr4a receptors was also observed in liver - but not brain - of DR-fed animals. Furthermore, RT-PCR revealed up-regulation of several NR4A transcriptional targets (Ucp-3, Ampk-gamma 3, Pgc-1 alpha and Pgc-1 beta) in skeletal muscle of DR animals. Due to the proposed roles of the NR4A nuclear receptors in sensing and responding to changes in the nutritional environment and in regulating glucose and lipid metabolism and insulin sensitivity, we hypothesise that these proteins may contribute to DR-induced metabolic adaptation. (C) 2009 Elsevier Ireland Ltd. All rights reserved.
C1 [Oita, Radu C.; Mazzatti, Dawn J.; Lim, Fei Ling; Powell, Jonathan R.] Unilever R&D Colworth, Sharnbrook MK44 1LQ, Beds, England.
   [Merry, Brian J.] Univ Liverpool, Sch Biol Sci, Liverpool L69 7ZB, Merseyside, England.
C3 Unilever; University of Liverpool
RP Mazzatti, DJ (corresponding author), Unilever R&D Colworth, Colworth Sci Pk, Sharnbrook MK44 1LQ, Beds, England.
EM Dawn.Mazzatti@unilever.com
RI Oita, Radu/KBA-1827-2024
OI Lim, Fei Ling/0000-0002-7744-4836; oita, radu/0009-0001-0478-5103;
   Yeomans, Dawn/0000-0002-4960-8426
FU NucSys Marie Curie Research Training Network; European Union
   [MRTN-CT-019496]; BBSRC under the ERA Initiative [16417]
FX We thank Ann Scarborough and Andrew White for technical assistance with
   the microarrays. R.C.O. is supported by the NucSys Marie Curie Research
   Training Network funded by the European Union (contract number:
   MRTN-CT-019496). B.J.M. was supported by the BBSRC under the ERA
   Initiative (ERA Project grant 16417).
CR Ahuja HS, 2003, J BIOL REG HOMEOS AG, V17, P29
   Chao LC, 2007, MOL ENDOCRINOL, V21, P2152, DOI 10.1210/me.2007-0169
   Cheng LEC, 1997, EMBO J, V16, P1865, DOI 10.1093/emboj/16.8.1865
   DeYoung RA, 2003, J BIOL CHEM, V278, P47104, DOI 10.1074/jbc.M307496200
   Eells JB, 2003, CURR MED CHEM, V10, P857, DOI 10.2174/0929867033457700
   Fu CX, 2006, MECH AGEING DEV, V127, P905, DOI 10.1016/j.mad.2006.09.006
   Fu YC, 2007, J BIOL CHEM, V282, P31525, DOI 10.1074/jbc.M701132200
   Hardie DG, 2008, MOL CELL, V30, P263, DOI 10.1016/j.molcel.2008.04.012
   HSU HC, 2004, ALLERGY, V3, P413
   KRISTAL BS, 1992, J GERONTOL, V47, pB107, DOI 10.1093/geronj/47.4.B107
   Lambert AJ, 2004, BIOCHEM BIOPH RES CO, V316, P1196, DOI 10.1016/j.bbrc.2004.03.005
   LAW SW, 1992, MOL ENDOCRINOL, V6, P2129, DOI 10.1210/me.6.12.2129
   Le WD, 2003, NAT GENET, V33, P85, DOI 10.1038/ng1066
   LEE SL, 1995, SCIENCE, V269, P532, DOI 10.1126/science.7624775
   Linford NJ, 2007, AGING CELL, V6, P673, DOI 10.1111/j.1474-9726.2007.00319.x
   Mahoney DJ, 2005, FASEB J, V19, P1498, DOI 10.1096/fj.04-3149fje
   MASORO E J, 1988, Comprehensive Therapy, V14, P9
   Masoro EJ, 2000, EXP GERONTOL, V35, P299, DOI 10.1016/S0531-5565(00)00084-X
   Masternak MM, 2007, PPAR RES, V2007, DOI 10.1155/2007/28436
   Masternak MM, 2005, J GERONTOL A-BIOL, V60, P1394, DOI 10.1093/gerona/60.11.1394
   Masternak MM, 2005, J GERONTOL A-BIOL, V60, P1238, DOI 10.1093/gerona/60.10.1238
   Maxwell MA, 2005, J BIOL CHEM, V280, P12573, DOI 10.1074/jbc.M409580200
   Maxwell Megan A, 2006, Nucl Recept Signal, V4, pe002
   Mazzatti DJ, 2008, PHYSIOL GENOMICS, V34, P149, DOI 10.1152/physiolgenomics.00281.2007
   Merry BJ, 2005, MECH AGEING DEV, V126, P951, DOI 10.1016/j.mad.2005.03.015
   Merry BJ, 2008, MECH AGEING DEV, V129, P341, DOI 10.1016/j.mad.2008.04.004
   MILBRANDT J, 1988, NEURON, V1, P183, DOI 10.1016/0896-6273(88)90138-9
   Murphy EP, 2001, ARTHRITIS RHEUM-US, V44, P782, DOI 10.1002/1529-0131(200104)44:4<782::AID-ANR134>3.3.CO;2-8
   NELSON JF, 1995, NEUROBIOL AGING, V16, P837, DOI 10.1016/0197-4580(95)00072-M
   Nomiyama T, 2006, J BIOL CHEM, V281, P33467, DOI 10.1074/jbc.M603436200
   Pawitan Y, 2005, BIOINFORMATICS, V21, P3017, DOI 10.1093/bioinformatics/bti448
   Pearen MA, 2008, ENDOCRINOLOGY, V149, P2853, DOI 10.1210/en.2007-1202
   Pearen MA, 2006, ENDOCRINOLOGY, V147, P5217, DOI 10.1210/en.2006-0447
   Pei LM, 2006, NAT MED, V12, P1048, DOI 10.1038/nm1471
   Phillips A, 1997, MOL CELL BIOL, V17, P5952, DOI 10.1128/MCB.17.10.5952
   Phillips A, 1997, MOL CELL BIOL, V17, P5946, DOI 10.1128/MCB.17.10.5946
   Pols TWH, 2008, PIGM CELL MELANOMA R, V21, P342, DOI 10.1111/j.1755-148X.2008.00469.x
   Pols TWH, 2007, CURR OPIN LIPIDOL, V18, P515, DOI 10.1097/MOL.0b013e3282ef77d1
   Ponnio T, 2002, MOL CELL BIOL, V22, P935, DOI 10.1128/MCB.22.3.935-945.2002
   SCHINI VB, 1992, EUR J PHARMACOL, V216, P379, DOI 10.1016/0014-2999(92)90434-6
   Sohal RS, 1996, SCIENCE, V273, P59, DOI 10.1126/science.273.5271.59
   Susini S, 1998, FASEB J, V12, P1173, DOI 10.1096/fasebj.12.12.1173
   VanRemmen H, 1996, J CELL PHYSIOL, V166, P453
   Wagner J, 1999, NAT BIOTECHNOL, V17, P653, DOI 10.1038/10862
   Walford RL, 1997, J GERONTOL A-BIOL, V52, pB179, DOI 10.1093/gerona/52A.4.B179
   Wallén-Mackenzie Å, 2003, GENE DEV, V17, P3036, DOI 10.1101/gad.276003
   Wu Q, 2002, CARCINOGENESIS, V23, P1583, DOI 10.1093/carcin/23.10.1583
   Zetterstrom RH, 1997, SCIENCE, V276, P248, DOI 10.1126/science.276.5310.248
   Zhou T, 1996, J EXP MED, V183, P1879, DOI 10.1084/jem.183.4.1879
   Zhu M, 2004, EXP GERONTOL, V39, P1049, DOI 10.1016/j.exger.2004.03.024
NR 50
TC 27
Z9 33
U1 0
U2 9
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0047-6374
J9 MECH AGEING DEV
JI Mech. Ageing Dev.
PD APR
PY 2009
VL 130
IS 4
BP 240
EP 247
DI 10.1016/j.mad.2008.12.004
PG 8
WC Cell Biology; Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Geriatrics & Gerontology
GA 423RF
UT WOS:000264512700006
PM 19150624
DA 2024-02-19
ER

PT J
AU Byrne, DD
   Tate, JP
   Forde, KA
   Lim, JK
   Goetz, MB
   Rimland, D
   Rodriguez-Barradas, MC
   Butt, AA
   Gibert, CL
   Brown, ST
   Bedimo, R
   Freiberg, MS
   Justice, AC
   Kostman, JR
   Roy, JA
   Lo Re, V
AF Byrne, Dana D.
   Tate, Janet P.
   Forde, Kimberly A.
   Lim, Joseph K.
   Goetz, Matthew Bidwell
   Rimland, David
   Rodriguez-Barradas, Maria C.
   Butt, Adeel A.
   Gibert, Cynthia L.
   Brown, Sheldon T.
   Bedimo, Roger
   Freiberg, Matthew S.
   Justice, Amy C.
   Kostman, Jay R.
   Roy, Jason A.
   Lo Re, Vincent, III
TI Risk of Acute Liver Injury After Statin Initiation by Human
   Immunodeficiency Virus and Chronic Hepatitis C Virus Infection Status
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Article
DE statins; HIV; hepatitis C; hepatotoxicity; acute liver injury
ID HIV/HCV COINFECTION; CIRRHOSIS; HIV; HEPATOTOXICITY; VETERANS; FIBROSIS;
   DISEASE; REDUCE; COHORT; DRUGS
AB Background. Patients with human immunodeficiency virus (HIV) and/or chronic hepatitis C virus (HCV) infection may be prescribed statins as treatment for metabolic/cardiovascular disease, but it remains unclear if the risk of acute liver injury (ALI) is increased for statin initiators compared to nonusers in groups classified by HIV/HCV status.
   Methods. We conducted a cohort study to compare rates of ALI in statin initiators vs nonusers among 7686 HIV/HCV-coinfected, 8155 HCV-monoinfected, 17 739 HIV-monoinfected, and 36 604 uninfected persons in the Veterans Aging Cohort Study (2000-2012). We determined development of (1) liver aminotransferases >200 U/L, (2) severe ALI (coagulopathy with hyperbilirubinemia), and (3) death, all within 18 months. Cox regression was used to determine propensity score-adjusted hazard ratios (HRs) with 95% confidence intervals (CIs) of outcomes in statin initiators compared to nonusers across the groups.
   Results. Among HIV/HCV-coinfected patients, statin initiators had lower risks of aminotransferase levels >200 U/L (HR, 0.66 [95% CI,.53-.83]), severe ALI (HR, 0.23 [95% CI,.12-.46]), and death (HR, 0.36 [95% CI,.28-.46]) compared with statin nonusers. In the setting of chronic HCV alone, statin initiators had reduced risks of aminotransferase elevations (HR, 0.57 [95% CI,.45-.72]), severe ALI (HR, 0.15 [95% CI,.06-.37]), and death (HR, 0.42 [95% CI,.32-.54]) than nonusers. Among HIV-monoinfected patients, statin initiators had lower risks of aminotransferase increases (HR, 0.52 [95% CI,.40-.66]), severe ALI (HR, 0.26 [95% CI,.13-.55]), and death (HR, 0.19 [95% CI,.16-.23]) compared with nonusers. Results were similar among uninfected persons.
   Conclusions. Regardless of HIV and/or chronic HCV status, statin initiators had a lower risk of ALI and death within 18 months compared with statin nonusers.
C1 [Byrne, Dana D.; Forde, Kimberly A.; Lo Re, Vincent, III] Univ Penn, Perelman Sch Med, Dept Med, Penn Ctr AIDS Res, Philadelphia, PA 19104 USA.
   [Byrne, Dana D.; Forde, Kimberly A.; Roy, Jason A.; Lo Re, Vincent, III] Univ Penn, Dept Biostat Epidemiol & Informat, Ctr Pharmacoepidemiol Res & Training, Ctr Clin Epidemiol & Biostat,Perelman Sch Med, Philadelphia, PA 19104 USA.
   [Byrne, Dana D.] Cooper Univ Hosp, Dept Med, Camden, NJ USA.
   [Tate, Janet P.; Lim, Joseph K.; Justice, Amy C.] Vet Affairs Connecticut Healthcare Syst, West Haven, CT USA.
   [Tate, Janet P.; Lim, Joseph K.; Justice, Amy C.] Yale Univ, Sch Med, New Haven, CT USA.
   [Goetz, Matthew Bidwell] Univ Calif Los Angeles, Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
   [Goetz, Matthew Bidwell] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
   [Rimland, David] Atlanta Vet Affairs Med Ctr, Atlanta, GA USA.
   [Rimland, David] Emory Univ, Sch Med, Atlanta, GA 30322 USA.
   [Rodriguez-Barradas, Maria C.] Baylor Coll Med, Infect Dis Sect, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX USA.
   [Rodriguez-Barradas, Maria C.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA.
   [Butt, Adeel A.] Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
   [Butt, Adeel A.] Hamad Med Corp, Hamad Healthcare Qual Inst, Doha, Qatar.
   [Butt, Adeel A.] Weill Cornell Med Coll, Doha, Qatar.
   [Butt, Adeel A.] Weill Cornell Med Coll, New York, NY USA.
   [Gibert, Cynthia L.] Washington DC Vet Affairs Med Ctr, Washington, DC USA.
   [Gibert, Cynthia L.] George Washington Univ, Med Ctr, Washington, DC 20052 USA.
   [Brown, Sheldon T.] James J Peters Vet Affairs Med Ctr, New York, NY USA.
   [Brown, Sheldon T.] Mt Sinai Sch Med, New York, NY USA.
   [Bedimo, Roger] Vet Affairs North Texas Healthcare Syst, Med Serv, Dallas, TX USA.
   [Bedimo, Roger] Univ Texas Southwestern Med Ctr Dallas, Dept Med, Dallas, TX 75390 USA.
   [Freiberg, Matthew S.] Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37212 USA.
   [Kostman, Jay R.] Philadelphia Field Initiating Grp HIV Trials, John Bell Hlth Ctr, Philadelphia, PA USA.
C3 University of Pennsylvania; University of Pennsylvania; Cooper
   University Hospital; US Department of Veterans Affairs; Veterans Health
   Administration (VHA); VA Connecticut Healthcare System; Yale University;
   University of California System; University of California Los Angeles;
   US Department of Veterans Affairs; Veterans Health Administration (VHA);
   VA Greater Los Angeles Healthcare System; University of California
   System; University of California Los Angeles; University of California
   Los Angeles Medical Center; David Geffen School of Medicine at UCLA; US
   Department of Veterans Affairs; Veterans Health Administration (VHA);
   Atlanta VA Health Care System; Emory University; Baylor College of
   Medicine; US Department of Veterans Affairs; Veterans Health
   Administration (VHA); Michael E DeBakey VA Medical Center; Baylor
   College of Medicine; US Department of Veterans Affairs; Veterans Health
   Administration (VHA); VA Pittsburgh Healthcare System; Hamad Medical
   Corporation; Hamad General Hospital; Qatar Foundation (QF); Weill
   Cornell Medical College Qatar; Cornell University; Weill Cornell
   Medicine; George Washington University; Icahn School of Medicine at
   Mount Sinai; University of Texas System; University of Texas
   Southwestern Medical Center Dallas; Vanderbilt University
RP Lo Re, V (corresponding author), Univ Penn, Ctr Clin Epidemiol & Biostat, Perelman Sch Med, 836 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA.
EM vincentl@mail.med.upenn.edu
RI Freiberg, Matthew/IYJ-5456-2023; Goetz, Matthew Bidwell/GPX-4090-2022
OI Goetz, Matthew/0000-0003-4542-992X
FU Agency for Healthcare Research and Quality [R01 HS018372]; National
   Institute on Alcohol Abuse and Alcoholism [U01 AA13566, U24 AA20794, U01
   AA20790]
FX This study was supported by the Agency for Healthcare Research and
   Quality (grant number R01 HS018372) and the National Institute on
   Alcohol Abuse and Alcoholism (grant numbers U01 AA13566, U24 AA20794,
   and U01 AA20790 to A. C. J.).
CR Abraldes JG, 2016, GASTROENTEROLOGY, V150, P1160, DOI 10.1053/j.gastro.2016.01.004
   Abraldes JG, 2009, GASTROENTEROLOGY, V136, P1651, DOI 10.1053/j.gastro.2009.01.043
   Aithal GP, 2011, CLIN PHARMACOL THER, V89, P806, DOI 10.1038/clpt.2011.58
   Arnaud C, 2005, ARTERIOSCL THROM VAS, V25, P1231, DOI 10.1161/01.ATV.0000163840.63685.0c
   Björnsson E, 2012, J HEPATOL, V56, P374, DOI [10.1016/j.jhep.2011.08.016, 10.1016/j.jhep.2011.07.023]
   Braitman LE, 2002, ANN INTERN MED, V137, P693, DOI 10.7326/0003-4819-137-8-200210150-00015
   Butt AA, 2004, HEPATOLOGY, V40, P115, DOI 10.1002/hep.20289
   Butt AA, 2015, HEPATOLOGY, V62, P365, DOI 10.1002/hep.27835
   Butt AA, 2009, CLIN INFECT DIS, V49, P225, DOI 10.1086/599371
   Chalasani N, 2015, GASTROENTEROLOGY, V148, P1340, DOI 10.1053/j.gastro.2015.03.006
   Clement ME, 2016, CLIN INFECT DIS, V63, P407, DOI 10.1093/cid/ciw289
   de Denus S, 2004, PHARMACOTHERAPY, V24, P584, DOI 10.1592/phco.24.6.584.34738
   Edelman EJ, 2013, PHARMACOEPIDEM DR S, V22, P1352, DOI 10.1002/pds.3517
   Edelman EJ, 2013, DRUG AGING, V30, P613, DOI 10.1007/s40266-013-0093-9
   El-Serag HB, 2009, GASTROENTEROLOGY, V136, P1601, DOI 10.1053/j.gastro.2009.01.053
   FISHER SG, 1995, AM J EPIDEMIOL, V141, P242, DOI 10.1093/oxfordjournals.aje.a117426
   Freiberg MS, 2013, JAMA INTERN MED, V173, P614, DOI 10.1001/jamainternmed.2013.3728
   Fultz SL, 2006, MED CARE, V44, pS25, DOI 10.1097/01.mlr.0000223670.00890.74
   Gupta NK, 2008, ALIMENT PHARM THER, V28, P1021, DOI 10.1111/j.1365-2036.2008.03822.x
   Henderson LM, 2010, DIGEST DIS SCI, V55, P190, DOI 10.1007/s10620-009-0959-1
   Hosmer W, 1999, APPL SURVIVAL ANAL R
   Huang YW, 2016, AM J GASTROENTEROL, V111, P976, DOI 10.1038/ajg.2016.179
   Jain MK, 2005, NAT REV DRUG DISCOV, V4, P977, DOI 10.1038/nrd1901
   Khorashadi S, 2006, CLIN GASTROENTEROL H, V4, P902, DOI 10.1016/j.cgh.2006.03.014
   Lin WY, 2013, J INFECT DIS, V207, pS13, DOI 10.1093/infdis/jis926
   Lo Re V, 2013, PHARMACOEPIDEM DR S, V22, P861, DOI 10.1002/pds.3470
   Lomtadze N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083892
   Mehta SH, 2003, HEPATOLOGY, V38, P50, DOI 10.1053/jhep.2003.50291
   Mohanty A, 2016, GASTROENTEROLOGY, V150, P430, DOI 10.1053/j.gastro.2015.10.007
   Oliver NT, 2016, AIDS, V30, P2469, DOI 10.1097/QAD.0000000000001219
   Parra Javier L, 2003, Clin Liver Dis, V7, P415, DOI 10.1016/S1089-3261(03)00024-2
   Pencina MJ, 2014, NEW ENGL J MED, V370, P1422, DOI 10.1056/NEJMoa1315665
   Prati D, 2002, ANN INTERN MED, V137, P1, DOI 10.7326/0003-4819-137-1-200207020-00006
   Rao GA, 2011, GASTROENTEROLOGY, V140, P144, DOI 10.1053/j.gastro.2010.08.055
   Reuben A, 2010, HEPATOLOGY, V52, P2065, DOI 10.1002/hep.23937
   Russo MW, 2014, HEPATOLOGY, V60, P679, DOI 10.1002/hep.27157
   Schenker S, 1999, J HEPATOL, V31, P1098, DOI 10.1016/S0168-8278(99)80325-0
   Simon TG, 2016, HEPATOLOGY, V64, P47, DOI 10.1002/hep.28506
   Simon TG, 2015, J HEPATOL, V62, P18, DOI 10.1016/j.jhep.2014.08.013
   Soriano V, 2008, AIDS, V22, P1, DOI 10.1097/QAD.0b013e3282f0e2fd
   Sterling RK, 2006, HEPATOLOGY, V43, P1317, DOI 10.1002/hep.21178
   Stone NJ, 2014, CIRCULATION, V129, pS1, DOI 10.1161/01.cir.0000437738.63853.7a
   Walker AM, 1996, EPIDEMIOLOGY, V7, P335
   White DL, 2008, J HEPATOL, V49, P831, DOI 10.1016/j.jhep.2008.08.006
NR 44
TC 7
Z9 8
U1 0
U2 5
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1058-4838
EI 1537-6591
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD NOV 1
PY 2017
VL 65
IS 9
BP 1542
EP 1550
DI 10.1093/cid/cix564
PG 9
WC Immunology; Infectious Diseases; Microbiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology; Infectious Diseases; Microbiology
GA FJ8KI
UT WOS:000413015700015
PM 29020184
OA Green Submitted, Green Published, Bronze
DA 2024-02-19
ER

PT J
AU Gorczynski, RM
   Bessler, WG
   Chung, S
   Cinader, B
   Hoffmann, P
   Modolell, M
   Ramakrishna, V
   Reischel, ET
   Waelli, T
   Westphal, O
AF Gorczynski, RM
   Bessler, WG
   Chung, S
   Cinader, B
   Hoffmann, P
   Modolell, M
   Ramakrishna, V
   Reischel, ET
   Waelli, T
   Westphal, O
TI A fetal sheep liver extract reverses age-related increments in
   spontaneous and induced cytokine production by indirect environmental
   effects
SO IMMUNOLOGY LETTERS
LA English
DT Article
DE cytokine production; sheep fetal liver extract; reactive nitrogen
ID HUMAN PERIPHERAL-BLOOD; T-CELLS; NITRIC-OXIDE; LYMPHOCYTES-T; IFN-GAMMA;
   OLD MICE; EXPRESSION; PHOSPHORYLATION; INHIBITION; SUBSETS
AB BALB/c, DBA/2 and C57BL/6 mice of different ages (ranging from 8 to 110 weeks of age) were used as spleen cell donors to assay cytokine production from ConA activated spleen and Peyer's Patch (PP) lymphocytes. As reported in an earlier publication, there was an age-related decline in IL-2 production in all strains, with a general increase in IL-4 and IL-10 production with age, this being particularly marked for PP cell preparations. Similar conclusions were reached from independent analysis of CD44(hi) and CD44(lo) cell populations in these groups (memory vs. naive cells, respectively). Interestingly, IL-6 production was dramatically increased (some 4-5-fold in the different strains) and significantly increased levels of IL-6 were detected in the serum of aged mice. A previously described sheep fetal liver extract was able to reverse, to varying degrees, these cytokine changes associated with aging. Interestingly, when cells from aged mice were adoptively transferred to lethally irradiated young (8 week) recipients, the cytokine production phenotype of cells harvested from recipient mice 3 weeks later was that of the aged donor, unless recipients were treated continually with extract. Treatment of the donor alone produced minimal changes in cytokine production 3 weeks following adoptive transfer. The effect of extract was reversed in treated aged mice by concomitant daily intravenous infusion of the competitive inhibitor of nitric oxide synthesis (NG-monomethyl-L-arginine (NMMA)), which also decreased the increased serum nitrate levels in mice treated with extract. Our data suggest an important role for reactive nitrogen products, themselves induced by fetal liver extract, in age-associated changes in cytokine production. (C) 1998 Elsevier Science B.V. All rights reserved.
C1 Univ Toronto, Dept Surg, Transplant Res Div, Toronto, ON M5G 2C4, Canada.
   Univ Toronto, Dept Immunol, Toronto, ON, Canada.
   Univ Freiburg, Inst Immunobiol, D-7800 Freiburg, Germany.
   Univ British Columbia, Dept Surg, Montreux, Switzerland.
   Max Planck Inst, Freiburg, Germany.
   Clin La Prairie, Montreux, Switzerland.
   Forschungzentrum Borstel, Borstel, Germany.
C3 University of Toronto; University of Toronto; University of Freiburg;
   Max Planck Society; Forschungszentrum Borstel
RP Gorczynski, RM (corresponding author), Univ Toronto, Dept Surg, Transplant Res Div, 200 Elizabeth St,Room CCRW-2-850, Toronto, ON M5G 2C4, Canada.
RI Gorczynski, Reginald/AAA-1435-2019
CR CHREST FJ, 1995, CYTOMETRY, V20, P131
   DAYNES RA, 1993, J IMMUNOL, V150, P5219
   DRIESSEN C, 1994, LYMPHOKINE CYTOK RES, V13, P15
   ERNST DN, 1993, J IMMUNOL, V151, P575
   GLOBERSON A, 1995, INT ARCH ALLERGY IMM, V107, P491, DOI 10.1159/000237091
   GORCZYNSKI R, 1993, IMMUNOL LETT, V38, P243, DOI 10.1016/0165-2478(93)90013-R
   Gorczynski RM, 1997, IMMUNOLOGY, V92, P20, DOI 10.1046/j.1365-2567.1997.00327.x
   GORCZYNSKI RM, 1995, TRANSPLANTATION, V60, P707, DOI 10.1097/00007890-199510150-00016
   GORCZYNSKI RM, 1984, J IMMUNOL, V133, P2381
   GORCZYNSKI RM, 1996, IMMUNOLOGY, V87
   GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X
   GROSSMANN A, 1995, J GERONTOL A-BIOL, V50, pB205, DOI 10.1093/gerona/50A.4.B205
   HIBBS JB, 1987, SCIENCE, V235, P473, DOI 10.1126/science.2432665
   HOBBS MV, 1993, J IMMUNOL, V150, P3602
   KUBO M, 1990, EUR J IMMUNOL, V20, P1289, DOI 10.1002/eji.1830200614
   LANGREHR JM, 1992, J CLIN INVEST, V90, P679, DOI 10.1172/JCI115911
   LERNER A, 1989, EUR J IMMUNOL, V19, P977, DOI 10.1002/eji.1830190604
   MILLER AJF, 1991, IMMUNOL REV, V122, P103
   MILLER RA, 1995, NUTR REV, V53, pS8
   NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691
   ORME IM, 1993, CELL IMMUNOL, V147, P222, DOI 10.1006/cimm.1993.1062
   PASCUAL DW, 1993, HYPERTENSION, V21, P185, DOI 10.1161/01.HYP.21.2.185
   PATEL HR, 1992, EUR J IMMUNOL, V22, P253, DOI 10.1002/eji.1830220137
   ROLAND CR, 1994, J IMMUNOL, V153, P5453
   SICHER SC, 1994, J IMMUNOL, V153, P1293
   SINDERMANN J, 1993, MECH AGEING DEV, V70, P149, DOI 10.1016/0047-6374(93)90066-Z
   SPENCER NFL, 1995, ANN NEW YORK ACAD SC
   STUEHR DJ, 1989, J EXP MED, V169, P1543, DOI 10.1084/jem.169.5.1543
   UTSUYAMA M, 1992, MECH AGEING DEV, V63, P57, DOI 10.1016/0047-6374(92)90016-7
   UTSUYAMA M, 1993, INT IMMUNOL, V5, P1177, DOI 10.1093/intimm/5.9.1177
NR 30
TC 5
Z9 7
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0165-2478
J9 IMMUNOL LETT
JI Immunol. Lett.
PD FEB
PY 1998
VL 60
IS 2-3
BP 157
EP 164
DI 10.1016/S0165-2478(97)00149-1
PG 8
WC Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology
GA ZE690
UT WOS:000072820500014
PM 9557958
DA 2024-02-19
ER

PT J
AU Noland, RC
   Koves, TR
   Seiler, SE
   Lum, H
   Lust, RM
   Ilkayeva, O
   Stevens, RD
   Hegardt, FG
   Muoio, DM
AF Noland, Robert C.
   Koves, Timothy R.
   Seiler, Sarah E.
   Lum, Helen
   Lust, Robert M.
   Ilkayeva, Olga
   Stevens, Robert D.
   Hegardt, Fausto G.
   Muoio, Deborah M.
TI Carnitine Insufficiency Caused by Aging and Overnutrition Compromises
   Mitochondrial Performance and Metabolic Control
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID ACETYL-L-CARNITINE; SKELETAL-MUSCLE MITOCHONDRIA; FATTY-ACID OXIDATION;
   INSULIN-RESISTANCE; ARTIFICIAL SELECTION; DIABETES-MELLITUS; GLUCOSE
   DISPOSAL; UP-REGULATION; BIOSYNTHESIS; DEFICIENCY
AB In addition to its essential role in permitting mitochondrial import and oxidation of long chain fatty acids, carnitine also functions as an acyl group acceptor that facilitates mitochondrial export of excess carbons in the form of acylcarnitines. Recent evidence suggests carnitine requirements increase under conditions of sustained metabolic stress. Accordingly, we hypothesized that carnitine insufficiency might contribute to mitochondrial dysfunction and obesity-related impairments in glucose tolerance. Consistent with this prediction whole body carnitine dimunition was identified as a common feature of insulin-resistant states such as advanced age, genetic diabetes, and diet-induced obesity. In rodents fed a lifelong (12 month) high fat diet, compromised carnitine status corresponded with increased skeletal muscle accumulation of acylcarnitine esters and diminished hepatic expression of carnitine biosynthetic genes. Diminished carnitine reserves in muscle of obese rats was accompanied by marked perturbations in mitochondrial fuel metabolism, including low rates of complete fatty acid oxidation, elevated incomplete beta-oxidation, and impaired substrate switching from fatty acid to pyruvate. These mitochondrial abnormalities were reversed by 8 weeks of oral carnitine supplementation, in concert with increased tissue efflux and urinary excretion of acetylcarnitine and improvement of whole body glucose tolerance. Acetylcarnitine is produced by the mitochondrial matrix enzyme, carnitine acetyltransferase (CrAT). A role for this enzyme in combating glucose intolerance was further supported by the finding that CrAT overexpression in primary human skeletal myocytes increased glucose uptake and attenuated lipid-induced suppression of glucose oxidation. These results implicate carnitine insufficiency and reduced CrAT activity as reversible components of the metabolic syndrome.
C1 [Noland, Robert C.; Koves, Timothy R.; Seiler, Sarah E.; Lum, Helen; Ilkayeva, Olga; Stevens, Robert D.; Muoio, Deborah M.] Duke Univ, Sarah W Stedman Nutr & Metab Ctr, Durham, NC 27710 USA.
   [Koves, Timothy R.; Muoio, Deborah M.] Duke Univ, Dept Med, Durham, NC 27710 USA.
   [Muoio, Deborah M.] Duke Univ, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA.
   [Lust, Robert M.] E Carolina Univ, Dept Physiol, Greenville, NC 27834 USA.
   [Hegardt, Fausto G.] Univ Barcelona, Sch Pharm, Inst Salud Carlos III, CIBER Fisiopatol Obesidad & Nutr CB06 03, E-08028 Barcelona, Spain.
C3 Duke University; Duke University; Duke University; University of North
   Carolina; East Carolina University; University of Barcelona; CIBER -
   Centro de Investigacion Biomedica en Red; CIBEROBN; Instituto de Salud
   Carlos III
RP Muoio, DM (corresponding author), 4321 Med Pk Dr, Durham, NC 27704 USA.
EM Muoio@duke.edu
RI Koves, Tim/I-4806-2012; Noland, Robert C/N-1982-2017; Muoio, Debbie
   Marie/E-1147-2012
OI Koves, Tim/0000-0001-8763-5866; Muoio, Deborah/0000-0003-3760-9277;
   Noland, Robert/0000-0001-5543-3450
FU National Institutes of Health [P30-AG028716, R01-AG028930,
   F32-DK080609]; American Diabetes Association; John A. Hartford Duke
   Center for Excellence Award
FX This work was supported, in whole or in part, by National Institutes of
   Health Grants P30-AG028716 and R01-AG028930 (to D. M. M.) and
   F32-DK080609 (to R. N.). This work was also supported by the American
   Diabetes Association (to D. M. M.) and a John A. Hartford Duke Center
   for Excellence Award (to T. R. K).
CR Ames BN, 2004, ANN NY ACAD SCI, V1033, P108, DOI 10.1196/annals.1320.010
   An J, 2004, NAT MED, V10, P268, DOI 10.1038/nm995
   Anderson EJ, 2009, J CLIN INVEST, V119, P573, DOI 10.1172/JCI37048
   Arrigoni-Martelli E, 2001, DRUG EXP CLIN RES, V27, P27
   Aureli T, 1999, EUR J BIOCHEM, V263, P287, DOI 10.1046/j.1432-1327.1999.00524.x
   BECKER TC, 1994, J BIOL CHEM, V269, P21234
   BHUIYAN AKMJ, 1988, BIOCHEM J, V253, P337, DOI 10.1042/bj2530337
   Brass EP, 2003, CLIN PHARMACOL THER, V73, P338, DOI 10.1016/S0009-9236(02)17636-3
   BRASS EP, 1995, CLIN THER, V17, P176, DOI 10.1016/0149-2918(95)80017-4
   CAPALDO B, 1991, DIABETES RES CLIN PR, V14, P191, DOI 10.1016/0168-8227(91)90020-E
   CEDERBLAD G, 1987, AM J CLIN NUTR, V45, P725, DOI 10.1093/ajcn/45.4.725
   CHASE JFA, 1967, BIOCHEM J, V104, P510, DOI 10.1042/bj1040510
   Citak EC, 2006, PEDIATR HEMAT ONCOL, V23, P381, DOI 10.1080/08880010600646704
   DAVIS AT, 1986, J NUTR, V116, P760, DOI 10.1093/jn/116.5.760
   Dhitavat S, 2002, NEUROCHEM RES, V27, P501, DOI 10.1023/A:1019800703683
   Farkas V, 1996, BIOCHEM PHARMACOL, V52, P1429, DOI 10.1016/S0006-2952(96)00507-2
   FARRELL S, 1986, BIOCHIM BIOPHYS ACTA, V876, P175, DOI 10.1016/0005-2760(86)90332-2
   FARRELL SO, 1984, J BIOL CHEM, V259, P3089
   Fischer GM, 2000, BBA-MOL BASIS DIS, V1501, P200, DOI 10.1016/S0925-4439(00)00023-5
   Garcia-Roves P, 2007, P NATL ACAD SCI USA, V104, P10709, DOI 10.1073/pnas.0704024104
   Hancock CR, 2008, P NATL ACAD SCI USA, V105, P7815, DOI 10.1073/pnas.0802057105
   Haqq AM, 2005, CONTEMP CLIN TRIALS, V26, P616, DOI 10.1016/j.cct.2005.09.003
   Huang W, 1999, BIOCHEM PHARMACOL, V58, P1361, DOI 10.1016/S0006-2952(99)00219-1
   Hulver MW, 2003, AM J PHYSIOL-ENDOC M, V284, pE741, DOI 10.1152/ajpendo.00514.2002
   Kaido M, 1997, EUR NEUROL, V38, P302, DOI 10.1159/000113399
   Kelley DE, 1999, AM J PHYSIOL-ENDOC M, V277, pE1130
   Kerner J, 2001, AM J PHYSIOL-ENDOC M, V281, pE1054
   Kim SC, 2006, MOL CELL, V23, P607, DOI 10.1016/j.molcel.2006.06.026
   Koch A, 2008, EXP BIOL MED, V233, P356, DOI 10.3181/0706-RM-168
   Koch LG, 2001, PHYSIOL GENOMICS, V5, P45, DOI 10.1152/physiolgenomics.2001.5.1.45
   Koves TR, 2008, CELL METAB, V7, P45, DOI 10.1016/j.cmet.2007.10.013
   Koves TR, 2005, J BIOL CHEM, V280, P33588, DOI 10.1074/jbc.M507621200
   Li XH, 2007, NATURE, V447, P1012, DOI 10.1038/nature05861
   LligonaTrulla L, 1997, J LIPID RES, V38, P1454
   Longo N, 2006, AM J MED GENET C, V142C, P77, DOI 10.1002/ajmg.c.30087
   MacLellan JD, 2005, DIABETES, V54, P2343, DOI 10.2337/diabetes.54.8.2343
   Makowski L, 2009, FASEB J, V23, P586, DOI 10.1096/fj.08-119420
   MIKHAIL MM, 1976, CLIN CHIM ACTA, V71, P207, DOI 10.1016/0009-8981(76)90532-5
   Mingrone G, 1999, J AM COLL NUTR, V18, P77, DOI 10.1080/07315724.1999.10718830
   Morino K, 2006, DIABETES, V55, pS9, DOI 10.2337/db06-S002
   Muoio DM, 2002, DIABETES, V51, P901, DOI 10.2337/diabetes.51.4.901
   Nalecz Katarzyna A., 2004, Molecular Aspects of Medicine, V25, P551
   Noland RC, 2007, AM J PHYSIOL-ENDOC M, V293, pE31, DOI 10.1152/ajpendo.00500.2006
   Okamoto Maya, 2006, J Clin Forensic Med, V13, P26, DOI 10.1016/j.jcfm.2005.05.004
   Okudaira N, 2001, PHARMACEUT RES, V18, P439, DOI 10.1023/A:1011042008169
   Otsuka M, 1999, J NUTR SCI VITAMINOL, V45, P163, DOI 10.3177/jnsv.45.163
   PIEKLIK JR, 1975, J BIOL CHEM, V250, P4445
   Power RA, 2007, DIABETOLOGIA, V50, P824, DOI 10.1007/s00125-007-0605-4
   Puchowicz MA, 2004, MITOCHONDRION, V4, P377, DOI 10.1016/j.mito.2004.07.004
   Rahbar AR, 2005, EUR J CLIN NUTR, V59, P592, DOI 10.1038/sj.ejcn.1602109
   RANDLE PJ, 1963, LANCET, V1, P785
   REBOUCHE CJ, 1986, J NUTR, V116, P751
   Ricciolini R, 1998, J NEUROCHEM, V71, P2510
   ROE CR, 1983, ARCH DIS CHILD, V58, P916, DOI 10.1136/adc.58.11.916
   Schrauwen P, 2004, DIABETES, V53, P1412, DOI 10.2337/diabetes.53.6.1412
   Steiber Alison, 2004, Molecular Aspects of Medicine, V25, P455, DOI 10.1016/j.mam.2004.06.006
   Tein I, 2003, J INHERIT METAB DIS, V26, P147, DOI 10.1023/A:1024481016187
   Thyfault JP, 2004, AM J PHYSIOL-ENDOC M, V287, pE1076, DOI 10.1152/ajpendo.00177.2004
   UZIEL G, 1988, MUSCLE NERVE, V11, P720, DOI 10.1002/mus.880110708
   van Vlies N, 2007, BBA-BIOENERGETICS, V1767, P1134, DOI 10.1016/j.bbabio.2007.07.001
   Vaz FM, 2002, BIOCHEM J, V361, P417, DOI 10.1042/0264-6021:3610417
   Winter SC, 2003, J INHERIT METAB DIS, V26, P171, DOI 10.1023/A:1024433100257
   Wood JC, 2001, PEDIATRICS, V108, DOI 10.1542/peds.108.1.e19
NR 63
TC 250
Z9 272
U1 3
U2 27
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD AUG 21
PY 2009
VL 284
IS 34
BP 22840
EP 22852
DI 10.1074/jbc.M109.032888
PG 13
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 483KG
UT WOS:000268963100038
PM 19553674
OA Green Published, hybrid
DA 2024-02-19
ER

PT J
AU Rubio, C
   Lizárraga, E
   Alvarez-Cilleros, D
   Pérez-Pardo, P
   Sanmartín-Salinas, P
   Toledo-Lobo, MV
   Alvarez, C
   Escrivá, F
   Fernández-Lobato, M
   Guijarro, LG
   Valverde, AM
   Carrascosa, JM
AF Rubio, Carmen
   Lizarraga, Esther
   Alvarez-Cilleros, David
   Perez-Pardo, Paula
   Sanmartin-Salinas, Patricia
   Val Toledo-Lobo, M.
   Alvarez, Carmen
   Escriva, Fernando
   Fernandez-Lobato, Maria
   Guijarro, Luis G.
   Valverde, Angela M.
   Carrascosa, Jose M.
TI Aging in Male Wistar Rats Associates With Changes in Intestinal
   Microbiota, Gut Structure, and Cholecystokinin-Mediated Gut-Brain Axis
   Function
SO JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL
   SCIENCES
LA English
DT Article
DE Adiposity; Gut bacteria; Mucin; Satiety
ID LEPTIN RESISTANCE; INFLAMMATION; MUCOSA; DIET
AB Aging in mammals is characterized by failure of the homeostatic mechanisms that regulate energy balance. Several mechanisms have been proposed such as the presence of a low-grade chronic inflammation in different tissues, as well as leptin and insulin resistance, but the primary alteration is not fully elucidated. The gut microbiota has recently emerged as a key player in a variety of metabolic and neurological disorders. A main concept in this context is the gut-brain axis that refers to alterations in the gut that mediate effects in the central nervous system, including those related with the control of energy balance. Using 16S rRNA analysis, we demonstrate that aged male Wistar rats have increased presence of mucin-degrading and lipopolysaccharide (LPS)-producing bacteria. In addition, old animals exhibit a lower number of neutral mucin secreting goblet cells, and a decrease of tight junctions and adherens junctions marker proteins, zonula occludens protein-1 (ZO-1) and beta-catenin, respectively. These data are compatible with a thinner mucus layer and a weaker gut barrier in older animals that likely facilitate LPS leakage. Our data also show that cholecystokinin (CCK) satiating effect is impaired in aged rats, one of the expected effects of increased LPS leakage. In contrast, no overt signs of gut or systemic inflammation are observed. Changes in microbiota in old male Wistar rats present features of situations of increased adiposity, but different from those of obese animals. These could partly explain the increased adiposity and fat deposition in liver and heart as observed here.
C1 [Rubio, Carmen; Alvarez-Cilleros, David; Perez-Pardo, Paula; Fernandez-Lobato, Maria; Carrascosa, Jose M.] Univ Autonoma Madrid, Ctr Biol Mol Severo Ochoa UAM CSIC, Nicolas Cabrera 1, Madrid 28049, Spain.
   [Rubio, Carmen; Valverde, Angela M.] Univ Autonoma Madrid, Inst Invest Biomed Alberto Sols UAM CSIC, Madrid, Spain.
   [Rubio, Carmen; Valverde, Angela M.] ISCIII, Ctr Invest Biomed Red Diabet & Enferm Metab Asoci, Madrid, Spain.
   [Lizarraga, Esther; Alvarez, Carmen; Escriva, Fernando] Univ Complutense, Fac Farm, Dept Bioquim, Madrid, Spain.
   [Sanmartin-Salinas, Patricia; Guijarro, Luis G.] Univ Alcala, Fac Med, Dept Biol Sistemas, Madrid, Spain.
   [Sanmartin-Salinas, Patricia; Guijarro, Luis G.] ISCIII, Ctr Invest Biomed Red Enfermedades Hepat & Digest, Madrid, Spain.
   [Val Toledo-Lobo, M.] Univ Alcala, Fac Med, Dept Biomed & Biotecnol, Madrid 28871, Spain.
   [Val Toledo-Lobo, M.] Hosp Ramon & Cajal, IRYCIS, Madrid, Spain.
   [Alvarez-Cilleros, David] CSIC, Dept Metabol & Nutr, Inst Ciencia & Tecnol Alimentos & Nutr ICTAN, Madrid, Spain.
   [Perez-Pardo, Paula] Univ Utrecht, Fac Sci, Utrecht Inst Pharmaceut Sci, Div Pharmacol, Utrecht, Netherlands.
C3 Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de
   Biologia Molecular Severo Ochoa (CBM); Autonomous University of Madrid;
   Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto
   de Investigaciones Biomedicas Alberto Sols (IIBM); Autonomous University
   of Madrid; Instituto de Salud Carlos III; Complutense University of
   Madrid; Universidad de Alcala; Instituto de Salud Carlos III; CIBER -
   Centro de Investigacion Biomedica en Red; CIBEREHD; Universidad de
   Alcala; Hospital Universitario Ramon y Cajal; Consejo Superior de
   Investigaciones Cientificas (CSIC); CSIC - Instituto de Ciencia y
   Tecnologia de Alimentos y Nutricion (ICTAN); Utrecht University
RP Carrascosa, JM (corresponding author), Univ Autonoma Madrid, Ctr Biol Mol Severo Ochoa UAM CSIC, Nicolas Cabrera 1, Madrid 28049, Spain.
EM josemaria.carrascosa@uam.es
RI Lobato, Maria Fernandez/F-1338-2016; del Val Toledo Lobo,
   María/H-6094-2015; Carrascosa, Jose M/ABE-3526-2021
OI Lobato, Maria Fernandez/0000-0003-0778-7443; Carrascosa, Jose
   M/0000-0002-3574-9076; M. Val, Toledo Lobo/0000-0001-7222-8096; Martinez
   Valverde, Angela/0000-0003-1192-9045; Sanmartin Salinas,
   Patricia/0000-0003-0829-0391; Alvarez-Cilleros,
   David/0000-0002-5002-492X
FU Spanish Government [BFU2008-04901-C03-01/BFI, BIO2016-76601-C3-2-R,
   RTI2018-094052-B-100]; Centro de Investigacion Biomedica en Red de
   Diabetes y Enfermedades Metabolicas (Instituto de Salud Carlos III);
   Comunidad de Madrid, Spain [S2010/BMD-2423, S2017/BMD-3684]; Spanish
   Government
FX This work was supported by Spanish Government (grants
   BFU2008-04901-C03-01/BFI to J.M.C., BIO2016-76601-C3-2-R to M.F.-L., and
   RTI2018-094052-B-100 [MCI/AEI/FEDER, UE to A.M.V.] and Centro de
   Investigacion Biomedica en Red de Diabetes y Enfermedades Metabolicas
   (Instituto de Salud Carlos III) and Comunidad de Madrid, Spain (grants
   S2010/BMD-2423 to J.M.C., F.E., L.G.G., and A.M.V. and S2017/BMD-3684 to
   F.E. and A.M.V.). C.R. was supported by a predoctoral aid from Spanish
   Government. The Centro de Biologia Molecular is recipient of
   institutional aids from Banco de Santander and Ramon Areces Foundation.
CR Adriansjach J, 2020, J GERONTOL A-BIOL, V75, P1293, DOI 10.1093/gerona/glaa048
   Allen JM, 2015, J APPL PHYSIOL, V118, P1059, DOI 10.1152/japplphysiol.01077.2014
   Amrhein V, 2019, NATURE, V567, P305, DOI 10.1038/d41586-019-00857-9
   Bäckhed F, 2004, P NATL ACAD SCI USA, V101, P15718, DOI 10.1073/pnas.0407076101
   Caesar R, 2015, CELL METAB, V22, P658, DOI 10.1016/j.cmet.2015.07.026
   Carrascosa JM, 2011, CURR PROTEIN PEPT SC, V12, P305
   Carrascosa JM, 2009, EXP GERONTOL, V44, P20, DOI 10.1016/j.exger.2008.05.005
   Cho YE, 2018, REDOX BIOL, V18, P266, DOI 10.1016/j.redox.2018.07.012
   Claesson MJ, 2012, NATURE, V488, P178, DOI 10.1038/nature11319
   Cox LM, 2013, CELL METAB, V17, P883, DOI 10.1016/j.cmet.2013.05.004
   Croix JA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024447
   de La Serre CB, 2015, PHYSIOL BEHAV, V139, P188, DOI 10.1016/j.physbeh.2014.10.032
   Dicksved J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046399
   Everard A, 2013, P NATL ACAD SCI USA, V110, P9066, DOI 10.1073/pnas.1219451110
   Fernández-Galaz C, 2002, DIABETOLOGIA, V45, P997, DOI 10.1007/s00125-002-0851-4
   Fernández-Galaz C, 2001, J ENDOCRINOL, V171, P23, DOI 10.1677/joe.0.1710023
   Flemer B, 2017, GUT MICROBES, V8, P428, DOI 10.1080/19490976.2017.1334033
   García-San Frutos M, 2007, ENDOCRINOLOGY, V148, P5238, DOI 10.1210/en.2007-0543
   Ghosh S, 2015, J GERONTOL A-BIOL, V70, P232, DOI 10.1093/gerona/glu067
   Håkansson Å, 2015, CLIN EXP MED, V15, P107, DOI 10.1007/s10238-013-0270-5
   He XS, 2015, P NATL ACAD SCI USA, V112, P244, DOI 10.1073/pnas.1419038112
   Horrillo Daniel, 2011, Archives of Physiology and Biochemistry, V117, P140, DOI 10.3109/13813455.2011.577435
   Jeong JJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116533
   Klindworth A, 2013, NUCLEIC ACIDS RES, V41, DOI 10.1093/nar/gks808
   Tran L, 2013, J GERONTOL A-BIOL, V68, P1045, DOI 10.1093/gerona/glt106
   Liu AL, 2020, J GERONTOL A-BIOL, V75, P1284, DOI 10.1093/gerona/glz263
   Ma X, 2012, J ANIM SCI, V90, P266, DOI 10.2527/jas.50965
   Martínez-Oca P, 2020, J NUTR BIOCHEM, V81, DOI 10.1016/j.jnutbio.2020.108383
   Milan AM, 2017, NUTRIENTS, V9, DOI 10.3390/nu9040354
   Mu CL, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.00345
   Png CW, 2010, AM J GASTROENTEROL, V105, P2420, DOI 10.1038/ajg.2010.281
   Ridaura VK, 2013, SCIENCE, V341, P1079, DOI 10.1126/science.1241214
   Román ID, 2017, BIOMARKERS, V22, P133, DOI 10.1080/1354750X.2016.1252950
   Scarpace PJ, 2001, NEUROSCIENCE, V104, P1111, DOI 10.1016/S0306-4522(01)00142-7
   Schroeder M, 2009, AM J PHYSIOL-REG I, V297, pR1749, DOI 10.1152/ajpregu.00461.2009
   Seregin SS, 2017, CELL REP, V19, P733, DOI 10.1016/j.celrep.2017.03.080
   Shin NR, 2014, GUT, V63, P727, DOI 10.1136/gutjnl-2012-303839
   Sommer F, 2013, NAT REV MICROBIOL, V11, P227, DOI 10.1038/nrmicro2974
   Vrieze A, 2012, GASTROENTEROLOGY, V143, P913, DOI 10.1053/j.gastro.2012.06.031
   Wang SH, 2020, GEROSCIENCE, V42, P333, DOI 10.1007/s11357-019-00137-4
NR 40
TC 7
Z9 8
U1 1
U2 5
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1079-5006
EI 1758-535X
J9 J GERONTOL A-BIOL
JI J. Gerontol. Ser. A-Biol. Sci. Med. Sci.
PD NOV
PY 2021
VL 76
IS 11
BP 1915
EP 1921
DI 10.1093/gerona/glaa313
PG 7
WC Geriatrics & Gerontology; Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Geriatrics & Gerontology
GA WM7II
UT WOS:000711254400009
PM 33315062
OA Green Published
DA 2024-02-19
ER

PT J
AU Fok, WC
   Chen, YD
   Bokov, A
   Zhang, YQ
   Salmon, AB
   Diaz, V
   Javors, M
   Wood, WH
   Zhang, YQ
   Becker, KG
   Pérez, VI
   Richardson, A
AF Fok, Wilson C.
   Chen, Yidong
   Bokov, Alex
   Zhang, Yiqiang
   Salmon, Adam B.
   Diaz, Vivian
   Javors, Martin
   Wood, William H., III
   Zhang, Yongqing
   Becker, Kevin G.
   Perez, Viviana I.
   Richardson, Arlan
TI Mice Fed Rapamycin Have an Increase in Lifespan Associated with Major
   Changes in the Liver Transcriptome
SO PLOS ONE
LA English
DT Article
ID GENETICALLY HETEROGENEOUS MICE; INDUCED INSULIN-RESISTANCE; LARGE GENE
   LISTS; GROWTH-FACTOR; C-ELEGANS; DIETARY RESTRICTION; PROTEIN-SYNTHESIS;
   MAMMALIAN TARGET; OXIDATIVE STRESS; DOWN-REGULATION
AB Rapamycin was found to increase (11% to 16%) the lifespan of male and female C57BL/6J mice most likely by reducing the increase in the hazard for mortality (i.e., the rate of aging) term in the Gompertz mortality analysis. To identify the pathways that could be responsible for rapamycin's longevity effect, we analyzed the transcriptome of liver from 25-month-old male and female mice fed rapamycin starting at 4 months of age. Few changes (<300 transcripts) were observed in transcriptome of rapamycin-fed males; however, a large number of transcripts (>4,500) changed significantly in females. Using multidimensional scaling and heatmap analyses, the male mice fed rapamycin were found to segregate into two groups: one group that is almost identical to control males (Rapa-1) and a second group (Rapa-2) that shows a change in gene expression (>4,000 transcripts) with more than 60% of the genes shared with female mice fed Rapa. Using ingenuity pathway analysis, 13 pathways were significantly altered in both Rapa-2 males and rapamycin-fed females with mitochondrial function as the most significantly changed pathway. Our findings show that rapamycin has a major effect on the transcriptome and point to several pathways that would likely impact the longevity.
C1 [Fok, Wilson C.; Richardson, Arlan] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA.
   [Bokov, Alex; Zhang, Yiqiang; Salmon, Adam B.; Diaz, Vivian; Richardson, Arlan] Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging Studies, San Antonio, TX 78229 USA.
   [Chen, Yidong; Bokov, Alex] Univ Texas Hlth Sci Ctr San Antonio, Dept Epidemiol & Biostat, San Antonio, TX 78229 USA.
   [Chen, Yidong] Univ Texas Hlth Sci Ctr San Antonio, Greehey Childrens Canc Res Inst, San Antonio, TX 78229 USA.
   [Chen, Yidong] Univ Texas Hlth Sci Ctr San Antonio, Canc Therapy & Res Ctr, San Antonio, TX 78229 USA.
   [Zhang, Yiqiang] Univ Texas Hlth Sci Ctr San Antonio, Dept Physiol, San Antonio, TX 78229 USA.
   [Salmon, Adam B.] Univ Texas Hlth Sci Ctr San Antonio, Dept Mol Med, San Antonio, TX 78229 USA.
   [Javors, Martin] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, San Antonio, TX 78229 USA.
   [Wood, William H., III; Zhang, Yongqing; Becker, Kevin G.] NIA, Baltimore, MD 21224 USA.
   [Perez, Viviana I.] Oregon State Univ, Dept Biochem & Biophys, Linus Pauling Inst, Corvallis, OR 97331 USA.
   [Salmon, Adam B.; Richardson, Arlan] Audie Murphy VA Hosp STVHCS, Res Serv, San Antonio, TX USA.
   [Salmon, Adam B.; Richardson, Arlan] Audie Murphy VA Hosp STVHCS, Geriatr Res Educ & Clin Ctr, San Antonio, TX USA.
C3 University of Texas System; University of Texas Health Science Center at
   San Antonio; University of Texas System; University of Texas Health
   Science Center at San Antonio; University of Texas System; University of
   Texas Health Science Center at San Antonio; University of Texas System;
   University of Texas Health Science Center at San Antonio; University of
   Texas System; University of Texas Health Science Center at San Antonio;
   Cancer Therapy & Research Center; University of Texas System; University
   of Texas Health Science Center at San Antonio; University of Texas
   System; University of Texas Health Science Center at San Antonio;
   University of Texas System; University of Texas Health Science Center at
   San Antonio; National Institutes of Health (NIH) - USA; NIH National
   Institute on Aging (NIA); Oregon State University; Geriatric Research
   Education & Clinical Center
RP Richardson, A (corresponding author), Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA.
EM richardsona@uthscsa.edu
RI Zhang, Yiqiang/AAA-3143-2019; Chen, Yiyi/IAR-4632-2023; Bokov,
   Alex/O-9952-2014
OI Bokov, Alex/0000-0002-0511-9815; Fok, Wilson Chun
   Yim/0000-0003-3289-2093; Becker, Kevin/0000-0002-6794-6656; Salmon,
   Adam/0000-0002-1475-7843
FU San Antonio Nathan Shock Aging Center [1p30-AG-13319]; National
   Institutes of Health (NIH) [AG036613, AG021890]; Ellison Medical
   Foundation; Intramural Research Program of the NIH, National Institute
   on Aging; VA Merit grant from the Department of Veteran Affairs;
   National Institute on Minority Health and Health Disparities from the
   NIH [G12MD007591]
FX Financial support was provided by The San Antonio Nathan Shock Aging
   Center (1p30-AG-13319, AR), National Institutes of Health (NIH) RC2
   Grand Opportunity grant (AG036613, AR), NIH T32 Training Grant
   (AG021890, WF), the Ellison Medical Foundation (VP), the Intramural
   Research Program of the NIH, National Institute on Aging, and VA Merit
   grant (Richardson) from the Department of Veteran Affairs. Computation
   Support was provided by the Computational System Biology Core funded by
   the National Institute on Minority Health and Health Disparities
   (G12MD007591) from the NIH. The funders had no role in study design,
   data collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Anisimov VN, 2011, CELL CYCLE, V10, P4230, DOI 10.4161/cc.10.24.18486
   Bjedov I, 2010, CELL METAB, V11, P35, DOI 10.1016/j.cmet.2009.11.010
   Bokov A, 2004, MECH AGEING DEV, V125, P811, DOI 10.1016/j.mad.2004.07.009
   Bronikowski Anne, 2010, NAT ED KNOWL, V1
   BrownBorg HM, 1996, NATURE, V384, P33, DOI 10.1038/384033a0
   Chang SB, 2007, J SURG RES, V138, P37, DOI 10.1016/j.jss.2006.07.003
   Cohen E, 2006, SCIENCE, V313, P1604, DOI 10.1126/science.1124646
   Conn CS, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2003520
   Cunningham JT, 2007, NATURE, V450, P736, DOI 10.1038/nature06322
   Deak F, 2012, J GERONTOL A-BIOL, V67, P611, DOI 10.1093/gerona/gls118
   Ding QX, 2003, J NEUROCHEM, V86, P489, DOI 10.1046/j.1471-4159.2003.01885.x
   Drake JC, 2013, J GERONTOL A
   Felton-Edkins ZA, 2003, EMBO J, V22, P2422, DOI 10.1093/emboj/cdg240
   Fok WC, 2013, J GERONTOL A-BIOL, V68, P108, DOI 10.1093/gerona/gls127
   Fontana L, 2010, SCIENCE, V328, P321, DOI 10.1126/science.1172539
   Guba M, 2002, NAT MED, V8, P128, DOI 10.1038/nm0202-128
   Habib A, 2013, ARTERIOSCL THROM VAS, V33, P2425, DOI 10.1161/ATVBAHA.113.301659
   Hansen M, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.0040024
   Harrison DE, 2009, NATURE, V460, P392, DOI 10.1038/nature08221
   Hay N, 2004, GENE DEV, V18, P1926, DOI 10.1101/gad.1212704
   Haynes CM, 2007, DEV CELL, V13, P467, DOI 10.1016/j.devcel.2007.07.016
   Hine Christopher M, 2012, J Clin Exp Pathol, VS4
   Holzenberger M, 2003, NATURE, V421, P182, DOI 10.1038/nature01298
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Huang DW, 2009, NUCLEIC ACIDS RES, V37, P1, DOI 10.1093/nar/gkn923
   Huyghe E, 2007, TRANSPL INT, V20, P305, DOI 10.1111/j.1432-2277.2006.00423.x
   Hwa V, 1999, ENDOCR REV, V20, P761, DOI 10.1210/er.20.6.761
   Iadevaia V, 2012, BIOCHEM SOC T, V40, P168, DOI 10.1042/BST20110682
   Johnson SC, 2013, NATURE, V493, P338, DOI 10.1038/nature11861
   Kaeberlein M, 2011, AGING CELL, V10, P185, DOI 10.1111/j.1474-9726.2010.00665.x
   Kassel O, 2001, EMBO J, V20, P7108, DOI 10.1093/emboj/20.24.7108
   KENYON C, 1993, NATURE, V366, P461, DOI 10.1038/366461a0
   Ladiges W, 2009, AGING CELL, V8, P346, DOI 10.1111/j.1474-9726.2009.00491.x
   Lamming DW, 2012, SCIENCE, V335, P1638, DOI 10.1126/science.1215135
   Laplante M, 2012, CELL, V149, P274, DOI 10.1016/j.cell.2012.03.017
   Massagué J, 2005, GENE DEV, V19, P2783, DOI 10.1101/gad.1350705
   Miller RA, 2011, J GERONTOL A-BIOL, V66, P191, DOI 10.1093/gerona/glq178
   Morimoto RI, 2008, GENE DEV, V22, P1427, DOI 10.1101/gad.1657108
   Oh WJ, 2011, CELL CYCLE, V10, P2305, DOI 10.4161/cc.10.14.16586
   Pletcher SD, 1999, J EVOLUTION BIOL, V12, P430, DOI 10.1046/j.1420-9101.1999.00058.x
   Schieke SM, 2006, J BIOL CHEM, V281, P27643, DOI 10.1074/jbc.M603536200
   Selman C, 2009, SCIENCE, V326, P140, DOI 10.1126/science.1177221
   Sengupta S, 2010, NATURE, V468, P1100, DOI 10.1038/nature09584
   Sharp ZD, 2005, J GERONTOL A-BIOL, V60, P293, DOI 10.1093/gerona/60.3.293
   Siu ECK, 2007, MOL PHARMACOL, V71, P826, DOI 10.1124/mol.106.032086
   Stanfel MN, 2009, BBA-GEN SUBJECTS, V1790, P1067, DOI 10.1016/j.bbagen.2009.06.007
   Tan Y, 2011, DIABETES, V60, P625, DOI 10.2337/db10-1164
   Tullet JMA, 2008, CELL, V132, P1025, DOI 10.1016/j.cell.2008.01.030
   Veilleux A, 2010, MOL ENDOCRINOL, V24, P766, DOI 10.1210/me.2009-0328
   Wang LJ, 2002, CIRC RES, V91, P821, DOI 10.1161/01.RES.0000041029.97988.E9
   Wilkinson JE, 2012, AGING CELL, V11, P675, DOI 10.1111/j.1474-9726.2012.00832.x
   Wohlgemuth I, 2011, PHILOS T R SOC B, V366, P2979, DOI 10.1098/rstb.2011.0138
   Zhang Y, 2013, J GERONTOL A
NR 53
TC 97
Z9 109
U1 0
U2 14
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JAN 7
PY 2014
VL 9
IS 1
AR e83988
DI 10.1371/journal.pone.0083988
PG 12
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 286JC
UT WOS:000329463500013
PM 24409289
OA gold, Green Submitted, Green Published
DA 2024-02-19
ER

PT J
AU CAO, GH
   CUTLER, RG
AF CAO, GH
   CUTLER, RG
TI PROTEIN OXIDATION AND AGING .1. DIFFICULTIES IN MEASURING REACTIVE
   PROTEIN CARBONYLS IN TISSUES USING 2,4-DINITROPHENYLHYDRAZINE
SO ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS
LA English
DT Article
ID GLUTAMINE-SYNTHETASE; DAMAGE; BRAIN
AB A current hypothesis explaining the aging process implicates the accumulation of oxidized protein in animal tissues. This hypothesis is based on a series of reports showing an age-dependent increase in protein carbonyl content and an age-dependent loss of enzyme function, This hypothesis is also supported by the report of a novel effect of N-tert-butyl-a-phenylnitrone (PEN) in reversing these age-dependent changes. Here we specifically study the method that was used to measure reactive protein carbonyls in tissues. This method uses 2,4-dinitrophenylhydrazine (DNPH) and includes a washing procedure. Our results indicate that reactive protein carbonyls in normal crude tissue extracts cannot be reliably measured by this method, although it does reliably measure reactive carbonyls in purified proteins which have been oxidatively modified in vitro. The nucleic acids in tissues could be a major problem encountered in the assay. Using the streptomycin sulfate treatment combined with a dialysis step, we were successful in removing most nucleic acids from a crude tissue extract, but then the reactive carbonyl level in the crude tissue extract was too low to be reliably measured. This streptomycin sulfate treatment procedure, however, had no effect on the reactive carbonyl measurement of an oxidized protein sample. The unwashed free DNPH was another major problem in the assay because of its very strong absorption around 370 nm, where reactive carbonyls were quantitated. Nevertheless, on using the procedure described in the Literature to measure total ''reactive carbonyls'' in rat liver and gerbil brain cortex, no change with age or PEN treatment was found. Then, we investigated a HPLC procedure which uses sodium dodecyl sulfate in the mobile phase but this was also found to be unsuitable for the reactive protein carbonyl assay in tissues. (C) 1995 Academic Press, Inc.
C1 NIA,GERONTOL RES CTR,MOLEC & CELLULAR BIOL LAB,BALTIMORE,MD 21224.
C3 National Institutes of Health (NIH) - USA; NIH National Institute on
   Aging (NIA)
CR AGARWAL S, 1993, BIOCHEM BIOPH RES CO, V194, P1203, DOI 10.1006/bbrc.1993.1950
   AGARWAL S, 1994, ARCH BIOCHEM BIOPHYS, V309, P24, DOI 10.1006/abbi.1994.1078
   CAO GH, 1995, ARCH BIOCHEM BIOPHYS, V320, P195, DOI 10.1006/abbi.1995.1359
   CARNEY JM, 1991, P NATL ACAD SCI USA, V88, P3633, DOI 10.1073/pnas.88.9.3633
   FIELDS R, 1971, BIOCHEM J, V121, P587, DOI 10.1042/bj1210587
   FLOYD RA, 1991, SCIENCE, V254, P1597, DOI 10.1126/science.1684251
   FOLBERGROVA J, 1993, J CEREBR BLOOD F MET, V13, P145, DOI 10.1038/jcbfm.1993.17
   LEVINE RL, 1990, METHOD ENZYMOL, V186, P464
   LEVINE RL, 1994, METHOD ENZYMOL, V233, P346
   OLIVER CN, 1987, J BIOL CHEM, V262, P5488
   OLIVER CN, 1990, P NATL ACAD SCI USA, V87, P5144, DOI 10.1073/pnas.87.13.5144
   OXENBURG.MS, 1965, NATURE, V207, P1416, DOI 10.1038/2071416a0
   RIVETT AJ, 1985, J BIOL CHEM, V260, P300
   SMITH CD, 1991, P NATL ACAD SCI USA, V88, P10540, DOI 10.1073/pnas.88.23.10540
   SOHAL RS, 1994, MECH AGEING DEV, V74, P121, DOI 10.1016/0047-6374(94)90104-X
   SOHAL RS, 1993, P NATL ACAD SCI USA, V90, P7255, DOI 10.1073/pnas.90.15.7255
   SOHAL RS, 1994, FREE RADICAL BIO MED, V16, P621, DOI 10.1016/0891-5849(94)90062-0
   STADTMAN ER, 1991, J BIOL CHEM, V266, P2005
   STADTMAN ER, 1992, SCIENCE, V257, P1220, DOI 10.1126/science.1355616
   STARKEREED P, 1989, ARCH BIOCHEM BIOPHYS, V257, P559
NR 20
TC 129
Z9 135
U1 0
U2 17
PU ACADEMIC PRESS INC JNL-COMP SUBSCRIPTIONS
PI SAN DIEGO
PA 525B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495
SN 0003-9861
J9 ARCH BIOCHEM BIOPHYS
JI Arch. Biochem. Biophys.
PD JUN 20
PY 1995
VL 320
IS 1
BP 106
EP 114
DI 10.1006/abbi.1995.1347
PG 9
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA RE632
UT WOS:A1995RE63200012
PM 7793968
DA 2024-02-19
ER

PT J
AU Bengs, S
   Rossi, A
   Haberecker, M
   Mikail, N
   Meisel, A
   Haider, A
   Grämer, M
   Portmann, A
   Todorov, A
   Schönenberger, C
   Gebhard, CE
   Kuster, GM
   Regitz-Zagrosek, V
   Gebhard, C
AF Bengs, Susan
   Rossi, Alexia
   Haberecker, Martina
   Mikail, Nidaa
   Meisel, Alexander
   Haider, Ahmed
   Graemer, Muriel
   Portmann, Angela
   Todorov, Atanas
   Schoenenberger, Christof
   Gebhard, Caroline E.
   Kuster, Gabriela M.
   Regitz-Zagrosek, Vera
   Gebhard, Catherine
TI Immunoreactivity of the SARS-CoV-2 entry proteins ACE-2 and TMPRSS-2 in
   murine models of hormonal manipulation, ageing, and cardiac injury
SO SCIENTIFIC REPORTS
LA English
DT Article
ID ANGIOTENSIN-CONVERTING ENZYME; CARDIOVASCULAR-DISEASE; SEX-DIFFERENCES;
   RISK-FACTORS; COVID-19; EXPRESSION; RECEPTOR
AB Previous work indicates that SARS-CoV-2 virus entry proteins angiotensin-converting enzyme 2 (ACE-2) and the cell surface transmembrane protease serine 2 (TMPRSS-2) are regulated by sex hormones. However, clinical studies addressing this association have yielded conflicting results. We sought to analyze the impact of sex hormones, age, and cardiovascular disease on ACE-2 and TMPRSS-2 expression in different mouse models. ACE-2 and TMPRSS-2 expression was analyzed by immunostaining in a variety of tissues obtained from FVB/N mice undergoing either gonadectomy or sham-surgery and being subjected to ischemia-reperfusion injury or transverse aortic constriction surgery. In lung tissues sex did not have a significant impact on the expression of ACE-2 and TMPRSS-2. On the contrary, following myocardial injury, female sex was associated to a lower expression of ACE-2 at the level of the kidney tubules. In addition, after myocardial injury, a significant correlation between younger age and higher expression of both ACE-2 and TMPRSS-2 was observed for lung alveoli and bronchioli, kidney tubules, and liver sinusoids. Our experimental data indicate that gonadal hormones and biological sex do not alter ACE-2 and TMPRSS-2 expression in the respiratory tract in mice, independent of disease state. Thus, sex differences in ACE-2 and TMPRSS-2 protein expression observed in mice may not explain the higher disease burden of COVID-19 among men.
C1 [Bengs, Susan; Rossi, Alexia; Mikail, Nidaa; Meisel, Alexander; Graemer, Muriel; Portmann, Angela; Todorov, Atanas; Gebhard, Catherine] Univ Hosp Zurich, Dept Nucl Med, Zurich, Switzerland.
   [Bengs, Susan; Rossi, Alexia; Mikail, Nidaa; Meisel, Alexander; Graemer, Muriel; Portmann, Angela; Todorov, Atanas; Gebhard, Catherine] Univ Zurich, Ctr Mol Cardiol, Schlieren, Switzerland.
   [Haberecker, Martina] Univ Hosp Zurich, Inst Pathol & Mol Pathol, Zurich, Switzerland.
   [Haider, Ahmed] Harvard Med Sch, Massachusetts Gen Hosp, Div Nucl Med & Mol Imaging, Boston, MA 02115 USA.
   [Haider, Ahmed] Harvard Med Sch, Dept Radiol, Boston, MA 02115 USA.
   [Schoenenberger, Christof; Gebhard, Caroline E.] Univ Hosp Basel, Intens Care Unit, Basel, Switzerland.
   [Kuster, Gabriela M.] Univ Hosp Basel, Dept Cardiol, Basel, Switzerland.
   [Kuster, Gabriela M.] Univ Basel, Dept Biomed, Myocardial Res, Basel, Switzerland.
   [Regitz-Zagrosek, Vera] Charite Univ Med Berlin, Berlin, Germany.
   [Regitz-Zagrosek, Vera] DZHK German Ctr Cardiovasc Res, Partner Site Berlin, Berlin, Germany.
   [Gebhard, Catherine] Med Univ Vienna, Dept Internal Med 2, Div Cardiol, Vienna, Austria.
C3 University of Zurich; University Zurich Hospital; University of Zurich;
   University Zurich Hospital; Harvard University; Harvard Medical School;
   Massachusetts General Hospital; Harvard University; Harvard Medical
   School; University of Basel; University of Basel; University of Basel;
   Free University of Berlin; Humboldt University of Berlin; Charite
   Universitatsmedizin Berlin; German Centre for Cardiovascular Research;
   Medical University of Vienna
RP Gebhard, C (corresponding author), Univ Hosp Zurich, Dept Nucl Med, Zurich, Switzerland.; Gebhard, C (corresponding author), Univ Zurich, Ctr Mol Cardiol, Schlieren, Switzerland.; Gebhard, C (corresponding author), Med Univ Vienna, Dept Internal Med 2, Div Cardiol, Vienna, Austria.
EM catherine.gebhard@usz.ch
RI Kuster, Gabriela M/AAB-5478-2022; Gebhard, Catherine/AAT-7060-2020;
   Gebhard, Caroline Eva/HTR-8636-2023
OI Kuster, Gabriela M/0000-0002-8209-4631; Gebhard,
   Catherine/0000-0001-7240-5822; Todorov, Atanas/0000-0002-1225-4302;
   Regitz-Zagrosek, Vera/0000-0002-3566-3467; Haberecker,
   Martina/0000-0001-5704-7721; Schoenenberger, Christof
   Manuel/0000-0002-9856-3500; Gebhard, Caroline E./0000-0003-4975-2679;
   Bengs, Susan/0000-0003-2424-3894
FU Swiss National Science Foundation (SNSF) [31CA30_196140]; LOOP, Zurich,
   Switzerland; Swiss National Science Foundation (SNF) [31CA30_196140]
   Funding Source: Swiss National Science Foundation (SNF)
FX This study was supported by grants from the Swiss National Science
   Foundation (SNSF, #31CA30_196140) and the LOOP, Zurich, Switzerland.
CR Bae S, 2021, HEART, V107, P373, DOI 10.1136/heartjnl-2020-317901
   Baratchian M, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-90491-1
   Baughn LB, 2020, MAYO CLIN PROC, V95, P1989, DOI 10.1016/j.mayocp.2020.06.018
   BENETEAUBURNAT B, 1990, CLIN CHEM, V36, P344
   Bristow MR, 2020, JACC-BASIC TRANSL SC, V5, P871, DOI 10.1016/j.jacbts.2020.06.007
   Chakladar J, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21103627
   Chen JW, 2020, AGING CELL, V19, DOI 10.1111/acel.13168
   Chung MK, 2021, CIRC RES, V128, P1214, DOI 10.1161/CIRCRESAHA.121.317997
   Costeira R, 2020, ESTROGEN COVID 19 SY, DOI [10.1101/2020.07.30.20164921, DOI 10.1101/2020.07.30.20164921]
   Dalpiaz PLM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127515
   Ding T, 2021, CLIN INFECT DIS, V72, pE240, DOI 10.1093/cid/ciaa1022
   Eraslan G., 2020, Nat Med, DOI [10.1101/2020.04.19.049254, DOI 10.1038/S41591-020-01227-Z]
   Fischer M, 2002, CARDIOVASC RES, V53, P672, DOI 10.1016/S0008-6363(01)00479-5
   Gebhard C, 2020, BIOL SEX DIFFER, V11, DOI 10.1186/s13293-020-00304-9
   Ghandehari S, 2021, CHEST, V160, P74, DOI 10.1016/j.chest.2021.02.024
   Goren A, 2020, J EUR ACAD DERMATOL, DOI 10.1111/jdv.16953
   Goren A, 2020, J COSMET DERMATOL-US, V19, P1545, DOI 10.1111/jocd.13443
   Gupte M, 2012, ARTERIOSCL THROM VAS, V32, P1392, DOI 10.1161/ATVBAHA.112.248559
   Harrison SL, 2021, EUR HEART J-QUAL CAR, V7, P330, DOI 10.1093/ehjqcco/qcab029
   Jakovac H, 2020, J APPL PHYSIOL, V129, P1007, DOI 10.1152/japplphysiol.00740.2020
   Ji H, 2020, HYPERTENSION, V76, P478, DOI 10.1161/HYPERTENSIONAHA.120.15276
   Klein EA, 2021, J UROLOGY, V205, P441, DOI 10.1097/JU.0000000000001338
   Kwon D, 2021, J CLIN ONCOL, V39, DOI 10.1200/JCO.2021.39.6_suppl.37
   Lara OD, 2020, CANCER-AM CANCER SOC, V126, P4294, DOI 10.1002/cncr.33084
   Li MY, 2020, INFECT DIS POVERTY, V9, DOI 10.1186/s40249-020-00662-x
   Linschoten M, 2020, EUR HEART J-ACUTE CA, V9, P817, DOI 10.1177/2048872620974605
   Maksimowski N, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0241534
   McCoy J, 2021, J EUR ACAD DERMATOL, V35, pE243, DOI 10.1111/jdv.17021
   Montopoli M, 2021, ANN ONCOL, V32, P676, DOI 10.1016/j.annonc.2021.01.069
   Montopoli M, 2020, ANN ONCOL, V31, P1040, DOI 10.1016/j.annonc.2020.04.479
   Muus C, 2021, NAT MED, V27, P546, DOI 10.1038/s41591-020-01227-z
   Nguyen NT, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0254066
   Nicin L, 2020, EUR HEART J, V41, P1804, DOI 10.1093/eurheartj/ehaa311
   Patel VG, 2021, J CLIN ONCOL, V39, DOI 10.1200/JCO.2021.39.6_suppl.41
   Qiao YY, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2021450118
   Rastrelli G, 2021, ANDROLOGY-US, V9, P88, DOI 10.1111/andr.12821
   Rowland SP, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-03086-z
   Sarver DC, 2021, BIOCHEM BIOPH RES CO, V538, P92, DOI 10.1016/j.bbrc.2020.10.066
   Seeland U, 2020, BMC MED, V18, DOI 10.1186/s12916-020-01851-z
   Song Hanbing, 2020, bioRxiv, DOI [10.1016/j.eururo.2020.04.065, 10.1101/2020.04.24.056259]
   Stegbauer J, 2020, HYPERTENSION, V76, pE41, DOI 10.1161/HYPERTENSIONAHA.120.16261
   Stelzig KE, 2020, AM J PHYSIOL-LUNG C, V318, pL1280, DOI 10.1152/ajplung.00153.2020
   Team RC, 2020, R: A Language and Environment for Statistical
   Tucker MD, 2021, J CLIN ONCOL, V39, DOI 10.1200/JCO.2021.39.6_suppl.39
   Tucker NR, 2020, CIRCULATION, V142, P708, DOI 10.1161/CIRCULATIONAHA.120.047911
   VanVelsen A., 2020, RES SQ, DOI [10.21203/rs.3.rs-100914/v1, DOI 10.21203/RS.3.RS-100914/V1]
   Wambier CG, 2020, J AM ACAD DERMATOL, V83, P680, DOI 10.1016/j.jaad.2020.05.079
   Williamson EJ, 2020, NATURE, V584, P430, DOI 10.1038/s41586-020-2521-4
NR 48
TC 4
Z9 4
U1 0
U2 3
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD DEC 14
PY 2021
VL 11
IS 1
AR 23993
DI 10.1038/s41598-021-03181-3
PG 10
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA XP3OZ
UT WOS:000730779300052
PM 34907257
OA Green Published, gold
DA 2024-02-19
ER

PT J
AU Abrigo, J
   Marín, T
   Aguirre, F
   Tacchi, F
   Vilos, C
   Simon, F
   Arrese, M
   Cabrera, D
   Cabello-Verrugio, C
AF Abrigo, Johanna
   Marin, Tabita
   Aguirre, Francisco
   Tacchi, Franco
   Vilos, Cristian
   Simon, Felipe
   Arrese, Marco
   Cabrera, Daniel
   Cabello-Verrugio, Claudio
TI N-Acetyl Cysteine Attenuates the Sarcopenia and Muscle Apoptosis Induced
   by Chronic Liver Disease
SO CURRENT MOLECULAR MEDICINE
LA English
DT Article
DE Sarcopenia; chronic liver disease; hepatotoxin; UPP oxidative stress;
   apoptosis
ID MITOCHONDRIAL PERMEABILITY TRANSITION; SKELETAL-MUSCLE; OXIDATIVE
   STRESS; MYONUCLEAR APOPTOSIS; MOUSE MODEL; ATROPHY; ACETYLCYSTEINE;
   MANAGEMENT; MECHANISM; EXERCISE
AB Background: Sarcopenia is characterized by the loss of muscle mass and strength (muscle atrophy) because of aging or chronic diseases, such as chronic liver disease (CLD). Different mechanisms are involved in skeletal muscle atrophy, including decreased muscle fibre diameter and myosin heavy chain levels and increased ubiquitin-proteasome pathway activity, oxidative stress and myonuclear apoptosis. We recently found that all these mechanisms, except myonuclear apoptosis, which was not evaluated in the previous study, were involved in muscle atrophy associated with hepatotoxin 5-diethoxycarbonyl-1,4-dihydrocollidine (DDC)-induced CLD.
   Objective: In the present study, we evaluated the involvement of myonuclear apoptosis in CLD-associated sarcopenia and the effect of N-acetyl cysteine (NAC) treatment on muscle strength and apoptosis, using a DDC-supplemented diet-fed mouse model.
   Methods: Four-month-old male C57BL6 mice were fed with a standard or DDC-supplemented diet for six weeks in the absence or presence of NAC treatment.
   Results: Our results showed that NAC attenuated the decrease in muscle fibre diameter and muscle strength associated with CLD-induced muscle wasting in gastrocnemius (GA) muscle of DDC-supplemented diet-fed mice. In addition, in GA muscle of the mice fed with DDC-supplemented diet-induced CLD showed increased myonuclear apoptosis compared with the GA muscle of the control diet-fed mice, as evidenced by increased apoptotic nuclei number, caspase-8 and caspase-9 expression, enzymatic activity of caspase-3 and BAX/BCL-2 ratio. NAC treatment inhibited all the mechanisms associated with myonuclear apoptosis in the GA muscle.
   Conclusion: To our knowledge, this is the first study which reports the redox regulation of muscle strength and myonuclear apoptosis in CLD-induced sarcopenia.
C1 [Abrigo, Johanna; Marin, Tabita; Aguirre, Francisco; Tacchi, Franco; Cabello-Verrugio, Claudio] Univ Andres Bello, Fac Ciencias Vida, Dept Ciencias Biol, Lab Muscle Pathol Fragil & Aging, Santiago 8370146, Chile.
   [Abrigo, Johanna; Marin, Tabita; Aguirre, Francisco; Tacchi, Franco; Simon, Felipe; Cabello-Verrugio, Claudio] Millennium Inst Immunol & Immunotherapy, Santiago, Chile.
   [Abrigo, Johanna; Marin, Tabita; Aguirre, Francisco; Tacchi, Franco; Vilos, Cristian; Cabello-Verrugio, Claudio] Univ Santiago Chile, Ctr Dev Nanosci & Nanotechnol CEDENNA, Santiago, Chile.
   [Vilos, Cristian] Univ Talca, Ctr Med Res, Sch Med, Lab Nanomed & Targeted Delivery, Talca, Chile.
   [Simon, Felipe] Univ Andres Bello, Fac Ciencias Vida, Dept Ciencias Biol, Lab Integrat Physiopathol, Santiago, Chile.
   [Arrese, Marco; Cabrera, Daniel] Pontificia Univ Catolica Chile, Dept Gastroenterol, Fac Med, Santiago, Chile.
   [Cabrera, Daniel] Univ Bernardo O Higgins, Dept Ciencias Quim & Biol, Fac Salud, Santiago, Chile.
C3 Universidad Andres Bello; Universidad de Santiago de Chile; Universidad
   de Talca; Universidad Andres Bello; Pontificia Universidad Catolica de
   Chile; Universidad  Bernardo O'Higgins
RP Cabello-Verrugio, C (corresponding author), Univ Andres Bello, Fac Ciencias Vida, Dept Ciencias Biol, Lab Muscle Pathol Fragil & Aging, Santiago 8370146, Chile.
EM claudio.cabello@unab.cl
RI ARRESE, MARCO/ABB-9061-2021; Cabello-Verrugio, Claudio/AAD-1454-2020;
   CABRERA, DANIEL/AAR-5027-2020
OI Cabello-Verrugio, Claudio/0000-0001-7273-2102; CABRERA,
   DANIEL/0000-0001-9634-725X; Simon, Felipe/0000-0002-2653-9798; Abrigo,
   Johanna/0000-0002-5598-513X
FU National Fund for Science & Technology Development [FONDECYT 1161646,
   1161288, 1161438, 11171001, 1150327]; Millennium Institute on Immunology
   and Immunotherapy [P09-016-F]; Programa de Cooperacion Cientifica
   ECOS-CONICYT [C16S02]; Center for Aging and Regeneration [CARE
   PFB12/2007]; BASAL Grant CEDENNA [FB0807]; H2020-MSCA-RISE-2016
   [734801]; Nucleus-UNAB [DI 36-18/N]; Conicyt [21161353]
FX This study was supported by research grants from the National Fund for
   Science & Technology Development, [FONDECYT 1161646 (CCV), 1161288 (FS),
   1161438 (CV), 11171001 (DC), 1150327 (MA)], Millennium Institute on
   Immunology and Immunotherapy [P09-016-F (CCV, FS)]; Programa de
   Cooperacion Cientifica ECOS-CONICYT [C16S02 (CCV)]; Center for Aging and
   Regeneration [CARE PFB12/2007 (MA)]; BASAL Grant CEDENNA [FB0807
   (CCV-CV)]; H2020-MSCA-RISE-2016 [734801 MAGNAMED (CV)]; Nucleus-UNAB [DI
   36-18/N (CV)]. J. Abrigo thanks to Conicyt for providing a PhD
   Scholarship [21161353].
CR Abrigo J, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/2063179
   Abrigo J, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/9047821
   Abrigo J, 2016, CELL SIGNAL, V28, P366, DOI 10.1016/j.cellsig.2016.01.010
   Allen DL, 1997, AM J PHYSIOL-CELL PH, V273, pC579, DOI 10.1152/ajpcell.1997.273.2.C579
   Andrianjafiniony T, 2010, AM J PHYSIOL-CELL PH, V299, pC307, DOI 10.1152/ajpcell.00069.2010
   Assaly R, 2012, EUR J PHARMACOL, V675, P6, DOI 10.1016/j.ejphar.2011.11.036
   Bilodeau PA, 2016, AM J PHYSIOL-CELL PH, V311, pC392, DOI 10.1152/ajpcell.00125.2016
   Briston T, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-10673-8
   Brito-Azevedo A, 2019, EUR J GASTROEN HEPAT, V31, P618, DOI 10.1097/MEG.0000000000001366
   Campbell TL, 2016, DATA BRIEF, V7, P786, DOI 10.1016/j.dib.2016.03.009
   Campos F, 2018, PFLUG ARCH EUR J PHY, V470, P1503, DOI 10.1007/s00424-018-2167-3
   Carey EJ, 2017, LIVER TRANSPLANT, V23, P625, DOI 10.1002/lt.24750
   Choi MH, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/6842568
   Cisternas F, 2015, CLIN SCI, V128, P307, DOI 10.1042/CS20140215
   Dasarathy S, 2016, J HEPATOL, V65, P1232, DOI 10.1016/j.jhep.2016.07.040
   Dasarathy S, 2016, CURR OPIN GASTROEN, V32, P159, DOI 10.1097/MOG.0000000000000261
   Dirks AJ, 2005, SPORTS MED, V35, P473, DOI 10.2165/00007256-200535060-00002
   Elmore S, 2007, TOXICOL PATHOL, V35, P495, DOI 10.1080/01926230701320337
   Fickert P, 2007, AM J PATHOL, V171, P525, DOI 10.2353/ajpath.2007.061133
   Fidzianska A, 2002, FOLIA NEUROPATHOL, V40, P27
   Morales MG, 2016, DIS MODEL MECH, V9, P441, DOI 10.1242/dmm.023390
   Hao YL, 2011, AM J PHYSIOL-REG I, V301, pR701, DOI 10.1152/ajpregu.00840.2010
   Hayashi F, 2018, HEPATOL RES, V48, P345, DOI 10.1111/hepr.13000
   Ichiishi E, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/3458276
   Kowaltowski AJ, 2001, FEBS LETT, V495, P12, DOI 10.1016/S0014-5793(01)02316-X
   Kwong JQ, 2015, CELL METAB, V21, P206, DOI 10.1016/j.cmet.2014.12.001
   Li JG, 2014, MAT SCI ENG C-MATER, V38, P235, DOI 10.1016/j.msec.2014.02.008
   Li LF, 2018, LAB INVEST, V98, P1170, DOI 10.1038/s41374-018-0081-0
   Liguori I, 2018, CLIN INTERV AGING, V13, P757, DOI 10.2147/CIA.S158513
   Loreto C, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/616149
   Márquez-Miranda V, 2017, INT J NANOMED, V12, P1985, DOI 10.2147/IJN.S125521
   Marzetti E, 2008, MECH AGEING DEV, V129, P542, DOI 10.1016/j.mad.2008.05.005
   Marzetti E, 2008, FREE RADICAL BIO MED, V44, P160, DOI 10.1016/j.freeradbiomed.2007.05.028
   Marzetti E, 2012, GERONTOLOGY, V58, P99, DOI 10.1159/000330064
   Marzetti E, 2010, THESCIENTIFICWORLDJO, V10, P340, DOI 10.1100/tsw.2010.27
   McClung JM, 2007, AM J RESP CRIT CARE, V175, P150, DOI 10.1164/rccm.200601-142OC
   Meneses C, 2015, PFLUG ARCH EUR J PHY, V467, P1975, DOI 10.1007/s00424-014-1617-9
   Min K, 2017, SKELET MUSCLE, V7, DOI 10.1186/s13395-017-0137-7
   Nair P, 2014, METHOD ENZYMOL, V544, P99, DOI 10.1016/B978-0-12-417158-9.00005-4
   Pisano G, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17050675
   Reiser PJ, 2019, ARCH BIOCHEM BIOPHYS, V662, P129, DOI 10.1016/j.abb.2018.12.009
   Roseguini BT, 2015, J VASC SURG, V61, P777, DOI 10.1016/j.jvs.2013.10.098
   Serra AJ, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/6439138
   Simic G, 2000, J NEUROPATH EXP NEUR, V59, P398, DOI 10.1093/jnen/59.5.398
   Sudo M, 2009, J PHYSIOL SCI, V59, P405, DOI 10.1007/s12576-009-0049-3
   Tan SN, 2016, CELL BIOSCI, V6, DOI 10.1186/s13578-016-0103-9
   Toshikuni N, 2014, WORLD J GASTROENTERO, V20, P7286, DOI 10.3748/wjg.v20.i23.7286
   Wang CW, 2016, TRANSPLANTATION, V100, P1692, DOI 10.1097/TP.0000000000001232
   Whitehead NP, 2008, J PHYSIOL-LONDON, V586, P2003, DOI 10.1113/jphysiol.2007.148338
NR 49
TC 16
Z9 16
U1 2
U2 18
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1566-5240
EI 1875-5666
J9 CURR MOL MED
JI Curr. Mol. Med.
PY 2020
VL 20
IS 1
BP 60
EP 71
DI 10.2174/1566524019666190917124636
PG 12
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA KC9DM
UT WOS:000507471400007
PM 31530262
DA 2024-02-19
ER

PT J
AU Rustenbeck, I
   Munster, W
   Lenzen, S
AF Rustenbeck, I
   Munster, W
   Lenzen, S
TI Relation between accumulation of phospholipase A(2) reaction products
   and Ca2+ release in isolated liver mitochondria
SO BIOCHIMICA ET BIOPHYSICA ACTA-LIPIDS AND LIPID METABOLISM
LA English
DT Article
DE phospholipase A; calcium ion release; lysophosphatidylcholine; membrane
   permeability; mitochondrion; (rat liver)
ID TRANSMEMBRANE ION-TRANSPORT; CA-2+ TRANSPORT; CYCLOSPORINE-A;
   PERMEABILITY TRANSITION; HEART-MITOCHONDRIA; RAT-LIVER;
   ENDOPLASMIC-RETICULUM; INORGANIC-PHOSPHATE; REGULATORY ASPECTS;
   PANCREATIC-ISLETS
AB A Ca2+-dependent stimulation of mitochondrial phospholipase A(2) is often assumed to play a role in mitochondrial Ca2+ release. We sought to clarify this relation by measuring Ca2+ transport and determining phospholipase A(2) reaction products from the same sample of isolated, incubated rat liver mitochondria. When mitochondria had accumulated and spontaneously released again Ca2+, most probably by membrane permeability transition, there was no increase of phospholipase A(2) reaction products. However, when the incubation was continued after Ca2+ release, significant increases of the content of lysophosphatidylcholine and unesterified fatty acids could be seen. Quinacrine, an inhibitor of phospholipase A(2) activity, prevented Ca2+ release and p-hydroxymercuribenzoic acid, an inhibitor of lysophospholipid reesterification, induced a fast release of Ca2+ from isolated mitochondria. Such effects are usually taken as indirect evidence for a participation of phospholipase A(2) in mitochondrial Ca2+ release, but analysis of the mitochondrial lipids revealed that no significant changes of the mass of phospholipase A(2) reaction products had occurred. These experiments suggest that the accumulation of phospholipase A(2) reaction products in mitochondria is the consequence rather than the cause of the membrane permeability transition. Exogenous phospholipase A(2) products, lysophosphatidylcholine and arachidonic acid, induced mitochondrial Ca2+ release after a time lag, which decreased with aging of the mitochondrial preparation. The amount of lysophosphatidylcholine taken up by the mitochondria from the incubation medium during these experiments was measured and compared to the amount of lysophosphatidylcholine produced endogenously by mitochondrial phospholipase A(2). From these data it appears likely that the amount of lysophosphatidylcholine generated in the mitochondria after the permeability transition is sufficient to sustain the permeable state. An accumulation of mitochondrially generated phospholipase A(2) reaction products after the permeability transition could thus be a decisive factor for the limited reversibility of the membrane permeability transition.
C1 HANNOVER MED SCH,INST CLIN BIOCHEM,D-30623 HANNOVER,GERMANY.
C3 Hannover Medical School
RP Rustenbeck, I (corresponding author), UNIV GOTTINGEN,INST PHARMACOL & TOXICOL,ROBERT KOCH STR 40,D-37075 GOTTINGEN,GERMANY.
CR BECKER GL, 1980, J BIOL CHEM, V255, P9009
   BEYER K, 1985, BIOCHEMISTRY-US, V24, P3821, DOI 10.1021/bi00336a001
   BROEKEMEIER KM, 1985, J BIOL CHEM, V260, P105
   BROEKEMEIER KM, 1989, BIOCHEM BIOPH RES CO, V163, P561, DOI 10.1016/0006-291X(89)92174-8
   BURSTEIN S, 1982, BIOCHEM PHARMACOL, V31, P2361, DOI 10.1016/0006-2952(82)90530-5
   CHACON E, 1992, BIOCHEM J, V281, P871, DOI 10.1042/bj2810871
   COCKRELL RS, 1985, ARCH BIOCHEM BIOPHYS, V243, P70, DOI 10.1016/0003-9861(85)90774-X
   CROMPTON M, 1988, BIOCHEM J, V255, P357
   DALTON S, 1984, BIOCHEM J, V224, P423, DOI 10.1042/bj2240423
   FISCHER TH, 1990, BIOCHIM BIOPHYS ACTA, V1022, P215, DOI 10.1016/0005-2736(90)90117-7
   GUNTER TE, 1994, AM J PHYSIOL, V267, pC313, DOI 10.1152/ajpcell.1994.267.2.C313
   GUNTER TE, 1990, AM J PHYSIOL, V258, pC755, DOI 10.1152/ajpcell.1990.258.5.C755
   HALESTRAP AP, 1993, BIOCHEM SOC T, V21, P353, DOI 10.1042/bst0210353
   HUNTER DR, 1979, ARCH BIOCHEM BIOPHYS, V195, P468, DOI 10.1016/0003-9861(79)90373-4
   HUNTER DR, 1979, ARCH BIOCHEM BIOPHYS, V195, P460
   LAPIDUS RG, 1992, FEBS LETT, V313, P314, DOI 10.1016/0014-5793(92)81217-A
   LENTING HBM, 1988, BIOCHIM BIOPHYS ACTA, V961, P129, DOI 10.1016/0005-2760(88)90138-5
   LENTING HBM, 1988, BIOCHIM BIOPHYS ACTA, V958, P405, DOI 10.1016/0005-2760(88)90226-3
   LENZEN S, 1991, DIABETES, V40, P323, DOI 10.2337/diabetes.40.3.323
   LENZEN S, 1992, BIOCHEM J, V286, P597, DOI 10.1042/bj2860597
   LENZEN S, 1985, ANAL BIOCHEM, V149, P301, DOI 10.1016/0003-2697(85)90574-3
   LENZEN S, 1989, BIOCHIM BIOPHYS ACTA, V982, P140, DOI 10.1016/0005-2736(89)90184-3
   LENZEN S, 1986, J BIOL CHEM, V261, P6478
   MCGUINNESS O, 1990, EUR J BIOCHEM, V194, P671, DOI 10.1111/j.1432-1033.1990.tb15667.x
   MCKNIGHT GS, 1977, ANAL BIOCHEM, V78, P86, DOI 10.1016/0003-2697(77)90011-2
   METZ SA, 1986, J PHARMACOL EXP THER, V238, P809
   NAKAMURA H, 1991, J CLIN INVEST, V87, P1810, DOI 10.1172/JCI115202
   NICCHITTA CV, 1984, J BIOL CHEM, V259, P2978
   NOVGORODOV SA, 1992, J BIOL CHEM, V267, P16274
   OKAYASU T, 1985, ARCH BIOCHEM BIOPHYS, V236, P638, DOI 10.1016/0003-9861(85)90668-X
   ORRENIUS S, 1989, TRENDS PHARMACOL SCI, V10, P281, DOI 10.1016/0165-6147(89)90029-1
   PARCE JW, 1978, BIOCHEMISTRY-US, V17, P1634, DOI 10.1021/bi00602a009
   PARCE JW, 1980, BIOCHEM J, V188, P817, DOI 10.1042/bj1880817
   PETRONILLI V, 1994, BBA-BIOENERGETICS, V1187, P255, DOI 10.1016/0005-2728(94)90122-8
   PFEIFFER DR, 1979, J BIOL CHEM, V254, P1485
   RILEY WW, 1986, J BIOL CHEM, V261, P14018
   ROTTENBERG H, 1990, BIOCHIM BIOPHYS ACTA, V1016, P77, DOI 10.1016/0005-2728(90)90009-S
   RUSTENBECK I, 1994, LIPIDS, V29, P685, DOI 10.1007/BF02538912
   RUSTENBECK I, 1991, BIOCHIM BIOPHYS ACTA, V1069, P99, DOI 10.1016/0005-2736(91)90109-L
   RUSTENBECK I, 1989, BIOCHIM BIOPHYS ACTA, V982, P147, DOI 10.1016/0005-2736(89)90185-5
   RUSTENBECK I, 1993, BIOCHEM BIOPH RES CO, V194, P1261, DOI 10.1006/bbrc.1993.1959
   RUSTENBECK I, 1995, J BIOCHEM BIOPH METH, V31, P105
   SCHMID PC, 1981, J LIPID RES, V22, P882
   SECHI AM, 1978, ARCH BIOCHEM BIOPHYS, V186, P248, DOI 10.1016/0003-9861(78)90433-2
   SILIPRANDI D, 1979, BIOCHEM BIOPH RES CO, V88, P388, DOI 10.1016/0006-291X(79)92060-6
   SZABO I, 1991, J BIOL CHEM, V266, P3376
   WEIS M, 1992, J BIOL CHEM, V267, P804
   YAFEI N, 1990, BIOCHEM SOC T, V18, P884, DOI 10.1042/bst0180884
NR 48
TC 20
Z9 22
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0005-2760
J9 BBA-LIPID LIPID MET
JI Biochim. Biophys. Acta-Lipids Lipid Metab.
PD NOV 22
PY 1996
VL 1304
IS 2
BP 129
EP 138
DI 10.1016/S0005-2760(96)00113-0
PG 10
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA VV280
UT WOS:A1996VV28000005
PM 8954136
DA 2024-02-19
ER

PT J
AU Satoh, T
   Sasatomi, E
   Yamasaki, F
   Ishida, H
   Wu, LQ
   Tokunaga, O
AF Satoh, T
   Sasatomi, E
   Yamasaki, F
   Ishida, H
   Wu, LQ
   Tokunaga, O
TI Multinucleated variant endothelial cells (MVECs) of human aorta:
   Expression of tumor suppressor gene p53 and relationship to
   atherosclerosis and aging
SO ENDOTHELIUM-NEW YORK
LA English
DT Article; Proceedings Paper
CT IXth International Vascular Biology Meeting
CY SEP 04-08, 1996
CL SEATTLE, WASHINGTON
DE endothelium; variant; p53; gene; mutation; apoptosis
ID WILD-TYPE P53; PREMATURE CHROMOSOME CONDENSATION; SCANNING
   ELECTRON-MICROSCOPY; GENOMIC INSTABILITY; CYCLE CHECKPOINT; IN-VIVO;
   C-MYC; BCL-2; APOPTOSIS; ONCOPROTEIN
AB Multinucleated variant endothelial cells (MVECs) generally exist in atherosclerotic human aorta and even in nonatherosclerotic aorta. Because the number of nuclei is increased in every MVEC, and because DNA instability was suspected, a series of oncogene expressions was conducted to clarify the nature of nuclear abnormality. The tumor suppressor gene p53 was found to be specifically expressed in the multinuclei of MVECs, while double nuclei were sometimes positive, and mononuclear typical endothelial cells were always negative for p53. Polymerase chain reaction-single-strand conformation polymorphism (PCR-SSCP) revealed extra bands in exons 5 and 7 of the p53 gene, but no additional band in exons 6 and 8. In a BCL familiy, BCL-2 was coexpressed in one or two nuclei in the perinuclear space of the multinuclei of MVECs, whereas MCL-1, BCL-XS/L, and BAX were all negative, indicating that the BCL-2 coding gene is expressed only in the corresponding one or two nuclei of the multinuclei. Another oncogene, c-MET (hepatocyte growth factor receptor), was universally expressed in either type of endothelial cells, but other oncogenes, k-RAS and c-ERBB2, were not expressed in either type.
   MVECs were derived from human aorta and therefore non-tumorous somatic cells. No morphologic evidence of apoptosis was found. Although it is unclear that the extra bands came from the MVECs or just from ECs associated with atherosclerosis, combined immunocytological studies and PCR analysis suggest that MVECs express mutant type p53.
C1 Saga Med Sch, Dept Pathol, Saga 849, Japan.
C3 Saga University
RP Tokunaga, O (corresponding author), Saga Med Sch, Dept Pathol, Saga 849, Japan.
CR Bogliolo M, 1996, CHEM-BIOL INTERACT, V102, P55, DOI 10.1016/0009-2797(96)03731-3
   CLEARY ML, 1985, P NATL ACAD SCI USA, V82, P7439, DOI 10.1073/pnas.82.21.7439
   COLOMBEL M, 1993, AM J PATHOL, V143, P390
   CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434
   DAGOSTINI F, 1995, CANCER EPIDEM BIOMAR, V4, P111
   EYFJORD JE, 1995, CANCER RES, V55, P646
   HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2
   Hayashi K, 1991, PCR Methods Appl, V1, P34
   HOCKENBERY DM, 1991, P NATL ACAD SCI USA, V88, P6961, DOI 10.1073/pnas.88.16.6961
   JOHNSON RT, 1970, NATURE, V226, P717, DOI 10.1038/226717a0
   KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879
   KOZOPAS KM, 1993, P NATL ACAD SCI USA, V90, P3516, DOI 10.1073/pnas.90.8.3516
   KRAJEWSKI S, 1993, CANCER RES, V53, P4701
   KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491
   LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0
   LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6
   LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635
   MAJINO G, 1995, AM J PATHOL, V146, P3
   MATLASHEWSKI G, 1984, EMBO J, V3, P3257, DOI 10.1002/j.1460-2075.1984.tb02287.x
   OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0
   OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O
   REPIN VS, 1984, ATHEROSCLEROSIS, V50, P35, DOI 10.1016/0021-9150(84)90006-6
   RYAN JJ, 1994, P NATL ACAD SCI USA, V91, P5878, DOI 10.1073/pnas.91.13.5878
   SAMBROOK J, 1989, IN VITRO AMPLIFICATI, P1
   SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495
   STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463
   SWANSON PE, 1995, AM J PATHOL, V146, P963
   TASHIRO K, 1994, VIRCHOWS ARCH, V425, P521
   TOKUNAGA O, 1989, AM J PATHOL, V135, P967
   VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0
   WIETHEGE T, 1994, VIRCHOWS ARCH, V424, P357
   WILLIAMS GT, 1990, NATURE, V343, P76, DOI 10.1038/343076a0
   YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7
   YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0
NR 34
TC 15
Z9 16
U1 0
U2 1
PU HARWOOD ACAD PUBL GMBH
PI READING
PA C/O STBS LTD, PO BOX 90, READING, BERKS, ENGLAND RG1 8JL
SN 1062-3329
J9 ENDOTHELIUM-NEW YORK
JI Endothelium
PY 1998
VL 6
IS 2
BP 123
EP 132
DI 10.3109/10623329809072199
PG 10
WC Cell Biology; Peripheral Vascular Disease
WE Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Cardiovascular System & Cardiology
GA 157GG
UT WOS:000078051900005
PM 9930646
DA 2024-02-19
ER

PT J
AU Shechter, Y
   Mironchik, M
   Amir, S
   Sela, BA
   Tsubery, H
   Zheng, HL
   Fridkin, M
AF Shechter, Yoram
   Mironchik, Marina
   Amir, Shimon
   Sela, Ben-Ami
   Tsubery, Haim
   Zheng, Hailin
   Fridkin, Mati
TI Polymyxin B and related cyclic peptides facilitate leanness and reduce
   fat mass and triglyceride content in ageing rats: Potential prototype
   drugs against obesity
SO INTERNATIONAL JOURNAL OF PEPTIDE RESEARCH AND THERAPEUTICS
LA English
DT Article
DE insulin; obesity; polymyxin B
ID SEVERE INSULIN-RESISTANCE; RECEPTOR; KNOCKOUT; CELL; HYPOGLYCEMIA;
   INHIBITOR; ADIPOCYTE; BINDING; MUSCLE; LEADS
AB Polymyxin B (PMXB) blocks the action of insulin on glucose uptake in vitro. In vivo, it reverses hypoglycemia induced by exogenous insulin. Here we have treated mature male rats daily with PMXB over a period of two weeks. This therapy has decreased body weight by 11%, adipose fat mass by 46% and triglyceride levels by 39%, with no indication of liver or kidney toxicity. Two suboptimal parameters, however, were a decrease in food intake in the first week of treatment and some increase in fasting glucose levels. We have screened for PMXB-analogs having less associating affinity with rat-muscle phospholipids, and revealed that the same therapy using PMXB-derived peptide (nona-PMXB) is most optimal. This PMXB-analog is devoid of antibacterial activity and is four times less toxic than PMXB. Nona-PMXB therapy lower by 10, 32, 35 and 6% body weight gain, fat mass, circulating triglycerides and fasting glucose levels, respectively, in spite of normal or even elevated food intake in nona-PMXB treated rats. In summary, we found that nona-PMXB therapy is capable if inducing leanness in mature rats, particularly at the expense of decreasing fat-mass in adipose tissue. By and large, we suggest that lowering the action of insulin, on fat build-up solely, may be a therapeutically feasible task to fight with human adiposity in the future.
C1 Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel.
   Weizmann Inst Sci, Dept Organ Chem, IL-76100 Rehovot, Israel.
   Concordia Univ, Dept Psychol, Montreal, PQ, Canada.
   Chaim Sheba Med Ctr, Inst Chem Pathol, IL-52621 Tel Hashomer, Israel.
C3 Weizmann Institute of Science; Weizmann Institute of Science; Concordia
   University - Canada; Chaim Sheba Medical Center
RP Shechter, Y (corresponding author), Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel.
EM y.shechter@weizmann.ac.il
RI Amir, Shimon/AAE-4635-2022
CR AMIR S, 1987, J BIOL CHEM, V262, P6663
   AMIR S, 1985, EUR J PHARMACOL, V110, P283, DOI 10.1016/0014-2999(85)90225-0
   Arner P, 2003, TRENDS ENDOCRIN MET, V14, P137, DOI 10.1016/S1043-2760(03)00024-9
   Arner P, 2002, DIABETES-METAB RES, V18, pS5, DOI 10.1002/dmrr.254
   Bergman RN, 2001, J INVEST MED, V49, P119, DOI 10.2310/6650.2001.34108
   BERTRAND HA, 1980, J GERONTOL, V35, P827, DOI 10.1093/geronj/35.6.827
   Blüher M, 2003, SCIENCE, V299, P572, DOI 10.1126/science.1078223
   Blüher M, 2002, DEV CELL, V3, P25, DOI 10.1016/S1534-5807(02)00199-5
   Boden G, 2002, EUR J CLIN INVEST, V32, P14, DOI 10.1046/j.1365-2362.32.s3.3.x
   Borst SE, 2002, METABOLISM, V51, P1061, DOI 10.1053/meta.2002.34043
   Bruning JC, 1998, MOL CELL, V2, P559, DOI 10.1016/S1097-2765(00)80155-0
   Chalkley SM, 2002, AM J PHYSIOL-ENDOC M, V282, pE1231, DOI 10.1152/ajpendo.00173.2001
   COLDITZ GA, 1990, AM J EPIDEMIOL, V132, P501, DOI 10.1093/oxfordjournals.aje.a115686
   CZECH MP, 1985, ANNU REV PHYSIOL, V47, P357, DOI 10.1146/annurev.ph.47.030185.002041
   DANNER RL, 1989, ANTIMICROB AGENTS CH, V33, P1428, DOI 10.1128/AAC.33.9.1428
   Flier JS, 1998, J CLIN ENDOCR METAB, V83, P1407, DOI 10.1210/jc.83.5.1407
   Gabriely I, 2002, DIABETES, V51, P2951, DOI 10.2337/diabetes.51.10.2951
   Gupta G, 2000, AM J PHYSIOL-ENDOC M, V278, pE985, DOI 10.1152/ajpendo.2000.278.6.E985
   HARRISON DE, 1984, P NATL ACAD SCI-BIOL, V81, P1835, DOI 10.1073/pnas.81.6.1835
   HISSIN PJ, 1982, J CLIN INVEST, V70, P780, DOI 10.1172/JCI110674
   Hotamisligil GS, 2000, INT J OBESITY, V24, pS23, DOI 10.1038/sj.ijo.0801497
   Kahn BB, 2000, J CLIN INVEST, V106, P473, DOI 10.1172/JCI10842
   KAHN C R, 1990, P1463
   Kitamura T, 2003, ANNU REV PHYSIOL, V65, P313, DOI 10.1146/annurev.physiol.65.092101.142540
   Kulkarni RN, 1999, CELL, V96, P329, DOI 10.1016/S0092-8674(00)80546-2
   Ma XH, 2002, J GERONTOL A-BIOL, V57, pB225, DOI 10.1093/gerona/57.6.B225
   Michael MD, 2000, MOL CELL, V6, P87, DOI 10.1016/S1097-2765(00)00010-1
   Mokdad AH, 2001, JAMA-J AM MED ASSOC, V286, P1195, DOI 10.1001/jama.286.10.1195
   MOODY AJ, 1974, HORM METAB RES, V6, P12, DOI 10.1055/s-0028-1093895
   NARIMIYA M, 1984, AM J PHYSIOL, V246, pE397, DOI 10.1152/ajpendo.1984.246.5.E397
   Peraldi P, 1998, MOL CELL BIOCHEM, V182, P169, DOI 10.1023/A:1006865715292
   REAVEN GM, 1995, PHYSIOL REV, V75, P473, DOI 10.1152/physrev.1995.75.3.473
   RODBELL M, 1964, J BIOL CHEM, V239, P375
   SHECHTER Y, 1979, P NATL ACAD SCI USA, V76, P2720, DOI 10.1073/pnas.76.6.2720
   Shechter Y, 2003, COORDIN CHEM REV, V237, P3, DOI 10.1016/S0010-8545(02)00302-8
   Shechter Y, 2002, J MED CHEM, V45, P4264, DOI 10.1021/jm020042t
   SHECHTER Y, 1988, BIOCHEM PHARMACOL, V37, P1891, DOI 10.1016/0006-2952(88)90533-3
   SHECHTER Y, 1985, STUDIES INSULIN RECE
   Steppan CM, 2001, NATURE, V409, P307, DOI 10.1038/35053000
   Tsubery H, 2000, BIOCHEMISTRY-US, V39, P11837, DOI 10.1021/bi000386q
NR 40
TC 2
Z9 2
U1 0
U2 4
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1573-3149
EI 1573-3904
J9 INT J PEPT RES THER
JI Int. J. Pept. Res. Ther.
PD JUN
PY 2006
VL 12
IS 2
BP 121
EP 129
DI 10.1007/s10989-005-9009-9
PG 9
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 056UM
UT WOS:000238550600004
DA 2024-02-19
ER

PT J
AU Conigliaro, J
   Madenwald, T
   Bryant, K
   Braithwaite, S
   Gordon, A
   Fultz, SL
   Maisto, S
   Samet, J
   Kraemer, K
   Cook, R
   Day, N
   Roach, D
   Richey, S
   Justice, A
AF Conigliaro, J
   Madenwald, T
   Bryant, K
   Braithwaite, S
   Gordon, A
   Fultz, SL
   Maisto, S
   Samet, J
   Kraemer, K
   Cook, R
   Day, N
   Roach, D
   Richey, S
   Justice, A
TI The veterans aging cohort study: Observational studies of alcohol use,
   abuse, and outcomes among human immunodeficiency virus-infected veterans
SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH
LA English
DT Article
DE HIV/AIDS; alcohol; comorbidity; outcomes; homelessness
ID HEPATITIS-C; REPORTED ADHERENCE; HIV-INFECTION; ANTIRETROVIRAL THERAPY;
   PROBLEM DRINKING; CLINICAL-TRIALS; SEXUAL-BEHAVIOR; LIVER-DISEASE;
   SUBSTANCE USE; RISK
AB This article represents the proceedings of a symposium at the 2003 annual meeting of the Research Society on Alcoholism in Fort Lauderdale, FL. The organizers/chairs were Joseph Conigliaro and Amy Justice. The presentations were (1) Introduction, by Joseph Conigliaro and Tamra Madenwald; (2) Alcohol and HIV/AIDS: the importance of integrative and translational research, by Kendall Bryant; (3) Alcohol use and abuse among patients with HIV infection, by Joseph Conigliaro and Stephan Maisto; (4) Severity of comorbid alcohol use/abuse in HIV infection, by Amy Justice and Jeffrey Samet; (5) Estimating the impact of alcohol use on long-term HIV outcomes, by Scott Braithwaite and Amy Justice; (6) Homelessness, drug & alcohol use among HIV+ veterans, by Adam Gordon and Robert Cook; and (7) Hepatitis C & alcohol in the VACS 3 study, by Shawn Fultz and Kevin Kraemer. The symposium concluded with a discussion led and facilitated by Diedra Roach.
C1 VA Pittsburg Healthcare Syst, Pittsburgh, PA 15240 USA.
   CHERP, Pittsburgh, PA USA.
   MIRECC, Pittsburgh, PA USA.
   CRHC, Pittsburgh, PA USA.
   Univ Pittsburgh, Pittsburgh, PA USA.
   NIAAA, Bethesda, MD USA.
   Yale Univ, New Haven, CT USA.
   Syracuse Univ, Syracuse, NY USA.
   Boston Univ, Ctr Med, Boston, MA USA.
C3 Pennsylvania Commonwealth System of Higher Education (PCSHE); University
   of Pittsburgh; National Institutes of Health (NIH) - USA; NIH National
   Institute on Alcohol Abuse & Alcoholism (NIAAA); Yale University;
   Syracuse University; Boston University
RP Conigliaro, J (corresponding author), VA Pittsburg Healthcare Syst, Univ Dr C, Pittsburgh, PA 15240 USA.
EM joseph.conigliaro@med.va.gov
OI Samet, Jeffrey/0000-0002-0897-3400; Braithwaite, Ronald
   Scott/0000-0001-7067-3655
FU NIAAA NIH HHS [AA 13566-02] Funding Source: Medline; NIA NIH HHS [K 23
   AG00826-03] Funding Source: Medline
CR [Anonymous], 2002, Gastroenterology, V123, P2082, DOI 10.1053/gast.2002.1232082
   [Anonymous], 1995, DRINKER INVENTORY CO
   AVINS AL, 1994, JAMA-J AM MED ASSOC, V271, P515, DOI 10.1001/jama.271.7.515
   Babor TF, 1992, AUDIT ALCOHOL USE DI
   Bangsberg D, 1997, JAMA-J AM MED ASSOC, V278, P63, DOI 10.1001/jama.278.1.63
   Bica I, 2001, CLIN INFECT DIS, V32, P492, DOI 10.1086/318501
   BOSCARINO JA, 1995, J STUD ALCOHOL, V56, P642, DOI 10.15288/jsa.1995.56.642
   BROWN EJ, 2000, ABNF J, P37
   Bush K, 1998, ARCH INTERN MED, V158, P1789, DOI 10.1001/archinte.158.16.1789
   Chesney MA, 2000, CLIN INFECT DIS, V30, pS171, DOI 10.1086/313849
   Chesney MA, 2000, AIDS CARE, V12, P255, DOI 10.1080/09540120050042891
   Cohen MH, 2002, AM J MED, V113, P91, DOI 10.1016/S0002-9343(02)01169-5
   Conigliaro J, 2003, JAIDS-J ACQ IMM DEF, V33, P521, DOI 10.1097/00126334-200308010-00014
   Conigliaro J, 1998, J GEN INTERN MED, V13, P251, DOI 10.1046/j.1525-1497.1998.00075.x
   CONIGRAVE KM, 1995, ADDICTION, V90, P1349, DOI 10.1111/j.1360-0443.1995.tb03552.x
   Cook RL, 2001, J GEN INTERN MED, V16, P83, DOI 10.1046/j.1525-1497.2001.00122.x
   COTTLER LB, 1989, BRIT J ADDICT, V84, P801
   DONOVAN C, 1995, ADDICTION, V90, P319, DOI 10.1111/j.1360-0443.1995.tb03780.x
   Fiellin DA, 2000, ANN INTERN MED, V133, P815, DOI 10.7326/0003-4819-133-10-200011210-00015
   Gordon AJ, 2001, J FAM PRACTICE, V50, P313
   Haubrich R, 1999, AIDS, V13, P2411, DOI 10.1097/00002030-199912030-00013
   Haubrich RH, 1999, AIDS, V13, P1099, DOI 10.1097/00002030-199906180-00014
   Hines AM, 1998, AIDS EDUC PREV, V10, P533
   ISAACSON JH, 1994, J GEN INTERN MED, V9, P550, DOI 10.1007/BF02599279
   Justice AC, 2001, J CLIN EPIDEMIOL, V54, pS77, DOI 10.1016/S0895-4356(01)00449-8
   JUSTICE AC, 2002, 14 INT AIDS C BARC S
   Kalichman SC, 2000, SEX TRANSM INFECT, V76, P350, DOI 10.1136/sti.76.5.350
   Khan KN, 2000, ALCOHOL ALCOHOLISM, V35, P286, DOI 10.1093/alcalc/35.3.286
   Klein MB, 2003, JAIDS-J ACQ IMM DEF, V33, P365, DOI 10.1097/00126334-200307010-00011
   LEIGH BC, 1993, AM PSYCHOL, V48, P1035, DOI 10.1037/0003-066X.48.10.1035
   Loguercio C, 2000, ALCOHOL ALCOHOLISM, V35, P296, DOI 10.1093/alcalc/35.3.296
   Monga HK, 2001, CLIN INFECT DIS, V33, P240, DOI 10.1086/321819
   Paterson DL, 2000, ANN INTERN MED, V133, P21, DOI 10.7326/0003-4819-133-1-200007040-00004
   Poynard T, 1997, LANCET, V349, P825, DOI 10.1016/S0140-6736(96)07642-8
   QUAN CM, 1993, CLIN INFECT DIS, V17, P117, DOI 10.1093/clinids/17.1.117
   SAUNDERS JB, 1990, CAN MED ASSOC J, V143, P1060
   SCHEIDT DM, 1995, J STUD ALCOHOL, V56, P300, DOI 10.15288/jsa.1995.56.300
   Shapiro MF, 1999, JAMA-J AM MED ASSOC, V281, P2305, DOI 10.1001/jama.281.24.2305
   Sherman KE, 2002, CLIN INFECT DIS, V34, P831, DOI 10.1086/339042
   SKINNER HA, 1982, J STUD ALCOHOL, V43, P1157, DOI 10.15288/jsa.1982.43.1157
   Skinner HA, 1984, ALCOHOL DEPENDENCE S, P1
   Smith MY, 2000, J GEN INTERN MED, V15, P731, DOI 10.1046/j.1525-1497.2000.91003.x
   Sobell LC., 1994, TIMELINE FOLLOWBACK
   Song JY, 2000, J URBAN HEALTH, V77, P678, DOI 10.1007/BF02344031
   Staples CT, 1999, CLIN INFECT DIS, V29, P150, DOI 10.1086/520144
   Stein MD, 2000, AM J DRUG ALCOHOL AB, V26, P195, DOI 10.1081/ADA-100100600
   Wagner JH, 2001, J CLIN EPIDEMIOL, V54, pS91, DOI 10.1016/S0895-4356(01)00450-4
   ZENILMAN JM, 1994, SEX TRANSM DIS, V21, P220, DOI 10.1097/00007435-199407000-00008
NR 48
TC 43
Z9 44
U1 0
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0145-6008
EI 1530-0277
J9 ALCOHOL CLIN EXP RES
JI Alcoholism (NY)
PD FEB
PY 2004
VL 28
IS 2
BP 313
EP 321
DI 10.1097/01.ALC.0000113414.73220.21
PG 9
WC Substance Abuse
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Substance Abuse
GA 776YR
UT WOS:000189147400013
PM 15112939
DA 2024-02-19
ER

PT J
AU Ropelle, ER
   Pauli, JR
   Cintra, DE
   da Silva, AS
   De Souza, CT
   Guadagnini, D
   Carvalho, BM
   Caricilli, AM
   Katashima, CK
   Carvalho, MA
   Hirabara, S
   Curi, R
   Velloso, LA
   Saad, MJA
   Carvalheira, JBC
AF Ropelle, Eduardo R.
   Pauli, Jose R.
   Cintra, Dennys E.
   da Silva, Adelino S.
   De Souza, Claudio T.
   Guadagnini, Dioze
   Carvalho, Bruno M.
   Caricilli, Andrea M.
   Katashima, Carlos K.
   Carvalho, Marco A.
   Hirabara, Sandro
   Curi, Rui
   Velloso, Licio A.
   Saad, Mario J. A.
   Carvalheira, Jose B. C.
TI Targeted Disruption of Inducible Nitric Oxide Synthase Protects Against
   Aging, <i>S</i>-Nitrosation, and Insulin Resistance in Muscle of Male
   Mice (Publication with Expression of Concern. See vol. 72, pg. 1886,
   2023) (Publication with Expression of Concern. See vol. 72, pg. 1886,
   2023)
SO DIABETES
LA English
DT Article; Publication with Expression of Concern
ID AKT/PROTEIN KINASE-B; RECEPTOR SUBSTRATE-1; NITROSYLATION; INFLAMMATION;
   DYSFUNCTION; EXERCISE; B/AKT; LIVER; INOS
AB Accumulating evidence has demonstrated that S-nitrosation of proteins plays a critical role in several human diseases. Here, we explored the role of inducible nitric oxide synthase (iNOS) in the S-nitrosation of proteins involved in the early steps of the insulin-signaling pathway and insulin resistance in the skeletal muscle of aged mice. Aging increased iNOS expression and S-nitrosation of major proteins involved in insulin signaling, thereby reducing insulin sensitivity in skeletal muscle. Conversely, aged iNOS-null mice were protected from S-nitrosation-induced insulin resistance. Moreover, pharmacological treatment with an iNOS inhibitor and acute exercise reduced iNOS-induced S-nitrosation and increased insulin sensitivity in the muscle of aged animals. These findings indicate that the insulin resistance observed in aged mice is mainly mediated through the S-nitrosation of the insulin-signaling pathway. Diabetes 62:466-470, 2013
C1 [Ropelle, Eduardo R.; Guadagnini, Dioze; Carvalho, Bruno M.; Caricilli, Andrea M.; Katashima, Carlos K.; Carvalho, Marco A.; Velloso, Licio A.; Saad, Mario J. A.; Carvalheira, Jose B. C.] State Univ Campinas UNICAMP, Fac Med Sci, Dept Internal Med, Campinas, SP, Brazil.
   [Ropelle, Eduardo R.; Pauli, Jose R.; Cintra, Dennys E.] Univ Estadual Campinas, Sch Appl Sci, Limeira, SP, Brazil.
   [da Silva, Adelino S.] Univ Sao Paulo, Sch Phys Educ & Sport Ribeirao Preto, BR-14049 Ribeirao Preto, SP, Brazil.
   [De Souza, Claudio T.] Univ So Santa Catarina UNESC, Lab Exercise Biochem & Physiol, Hlth Sci Unit, Criciuma, SC, Brazil.
   [Hirabara, Sandro; Curi, Rui] Univ Sao Paulo, Dept Physiol & Biophys, Sao Paulo, Brazil.
C3 Universidade Estadual de Campinas; Universidade Estadual de Campinas;
   Universidade de Sao Paulo; Universidade de Sao Paulo
RP Carvalheira, JBC (corresponding author), State Univ Campinas UNICAMP, Fac Med Sci, Dept Internal Med, Campinas, SP, Brazil.
EM carvalheirajbc@uol.com.br
RI Velloso, Licio/AAJ-3778-2020; Hirabara, Sandro Massao/C-4014-2012; Saad,
   Mario/ABD-8262-2020; Silva, Adelino/J-7379-2013; Caricilli, Andrea
   M/C-6294-2012; Katashima, Carlos Kiyoshi K/I-5616-2018; Carvalho,
   Marco/AAC-1001-2020; Cintra, Dennys E/N-7758-2017; Carvalho-Filho, Marco
   Antonio/M-4335-2013; Carvalheira, Jose Barreto Campello/E-8562-2013;
   Pauli, José Rdrigo/AAD-2763-2021; Curi, Rui/C-9351-2012; Carvalheira,
   Jose B/H-8405-2012; Carvalho, Bruno/G-1255-2012; Silva,
   Adelino/P-3400-2019; Ropelle, Eduardo R/C-3977-2012
OI Hirabara, Sandro Massao/0000-0002-7392-0444; Silva,
   Adelino/0000-0002-9679-8357; Katashima, Carlos Kiyoshi
   K/0000-0002-3908-127X; Carvalho, Marco/0000-0002-2354-9640; Cintra,
   Dennys E/0000-0002-7954-5630; Carvalho-Filho, Marco
   Antonio/0000-0001-7008-4092; Carvalheira, Jose Barreto
   Campello/0000-0002-0136-0943; Pauli, José Rdrigo/0000-0002-6129-1521;
   Carvalho, Bruno/0000-0002-6792-0288; Silva, Adelino/0000-0002-9679-8357;
   Ropelle, Eduardo R/0000-0003-1655-9557
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo; Conselho Nacional
   de desenvolvimento cientifico e tecnologico
FX This study was supported by grants from Fundacao de Amparo a Pesquisa do
   Estado de Sao Paulo and Conselho Nacional de desenvolvimento cientifico
   e tecnologico.
CR Benhar M, 2009, NAT REV MOL CELL BIO, V10, P721, DOI 10.1038/nrm2764
   Carvalho MA, 2005, DIABETES, V54, P959, DOI 10.2337/diabetes.54.4.959
   Carvalho MA, 2009, DIABETOLOGIA, V52, P2425, DOI 10.1007/s00125-009-1498-1
   Carvalho-Filho MA, 2006, AM J PHYSIOL-ENDOC M, V291, pE476, DOI 10.1152/ajpendo.00422.2005
   Cha HN, 2010, EXP GERONTOL, V45, P711, DOI 10.1016/j.exger.2010.05.004
   CHALLISS RAJ, 1986, BIOCHEM J, V233, P377, DOI 10.1042/bj2330377
   Charbonneau A, 2010, DIABETES, V59, P861, DOI 10.2337/db09-1238
   Foster MW, 2009, TRENDS MOL MED, V15, P391, DOI 10.1016/j.molmed.2009.06.007
   Fujimoto M, 2005, DIABETES, V54, P1340, DOI 10.2337/diabetes.54.5.1340
   Goldfine AB, 2008, CTS-CLIN TRANSL SCI, V1, P36, DOI 10.1111/j.1752-8062.2008.00026.x
   González-Rodríguez A, 2012, AGING CELL, V11, P284, DOI 10.1111/j.1474-9726.2011.00786.x
   Ischiropoulos H, 2003, BIOCHEM BIOPH RES CO, V305, P776, DOI 10.1016/S0006-291X(03)00814-3
   Jaffrey S R, 2001, Sci STKE, V2001, ppl1, DOI 10.1126/stke.2001.86.pl1
   Kireev RA, 2010, BIOGERONTOLOGY, V11, P229, DOI 10.1007/s10522-009-9242-2
   Lewinska A, 2011, BIOGERONTOLOGY, V12, P309, DOI 10.1007/s10522-011-9329-4
   Martínez-Ruiz A, 2004, ARCH BIOCHEM BIOPHYS, V423, P192, DOI 10.1016/j.abb.2003.12.006
   Ovadia H, 2011, J BIOL CHEM, V286, P30433, DOI 10.1074/jbc.M111.235945
   Pauli JR, 2008, J PHYSIOL-LONDON, V586, P659, DOI 10.1113/jphysiol.2007.142414
   Perreault M, 2001, NAT MED, V7, P1138, DOI 10.1038/nm1001-1138
   Ropelle ER, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000465
   Ropelle ER, 2006, J PHYSIOL-LONDON, V577, P997, DOI 10.1113/jphysiol.2006.120006
   Sugita H, 2005, J BIOL CHEM, V280, P14203, DOI 10.1074/jbc.M411226200
   Wu MZ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006430
   Yasukawa T, 2005, J BIOL CHEM, V280, P7511, DOI 10.1074/jbc.M411871200
NR 24
TC 52
Z9 57
U1 0
U2 13
PU AMER DIABETES ASSOC
PI ALEXANDRIA
PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA
SN 0012-1797
EI 1939-327X
J9 DIABETES
JI Diabetes
PD FEB
PY 2013
VL 62
IS 2
BP 466
EP 470
DI 10.2337/db12-0339
PG 5
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Endocrinology & Metabolism
GA 080SM
UT WOS:000314263600022
PM 22991447
OA Green Published, Green Submitted, hybrid
DA 2024-02-19
ER

PT J
AU Tarantini, S
   Giles, CB
   Wren, JD
   Ashpole, NM
   Valcarcel-Ares, MN
   Wei, JY
   Sonntag, WE
   Ungvari, Z
   Csiszar, A
AF Tarantini, Stefano
   Giles, Cory B.
   Wren, Jonathan D.
   Ashpole, Nicole M.
   Valcarcel-Ares, M. Noa
   Wei, Jeanne Y.
   Sonntag, William E.
   Ungvari, Zoltan
   Csiszar, Anna
TI IGF-1 deficiency in a critical period early in life influences the
   vascular aging phenotype in mice by altering miRNA-mediated
   post-transcriptional gene regulation: implications for the developmental
   origins of health and disease hypothesis
SO AGE
LA English
DT Article
DE Insulin-like growth factor 1; miRNA; Epigenetics; Post-transcriptional
   regulation; microRNA
ID GROWTH-FACTOR-I; TUMOR 1-ASSOCIATING PROTEIN; HUMAN ENDOTHELIAL-CELL;
   SMOOTH-MUSCLE-CELLS; OXIDATIVE STRESS; MICRORNA EXPRESSION;
   ANGIOTENSIN-II; CONTRACTILE DYSFUNCTION; INTRACRANIAL ANEURYSM; GLOBAL
   METAANALYSIS
AB Epidemiological findings support the concept of Developmental Origins of Health and Disease, suggesting that early-life hormonal influences during a sensitive period of development have a fundamental impact on vascular health later in life. The endocrine changes that occur during development are highly conserved across mammalian species and include dramatic increases in circulating IGF-1 levels during adolescence. The present study was designed to characterize the effect of developmental IGF-1 deficiency on the vascular aging phenotype. To achieve that goal, early-onset endocrine IGF-1 deficiency was induced in mice by knockdown of IGF-1 in the liver using Cre-lox technology (Igf1 (f/f) mice crossed with mice expressing albumin-driven Cre recombinase). This model exhibits low-circulating IGF-1 levels during the peripubertal phase of development, which is critical for the biology of aging. Due to the emergence of miRNAs as important regulators of the vascular aging phenotype, the effect of early-life IGF-1 deficiency on miRNA expression profile in the aorta was examined in animals at 27 months of age. We found that developmental IGF-1 deficiency elicits persisting late-life changes in miRNA expression in the vasculature, which significantly differed from those in mice with adult-onset IGF-1 deficiency (TBG-Cre-AAV8-mediated knockdown of IGF-1 at 5 month of age in Igf1 (f/f) mice). Using a novel computational approach, we identified miRNA target genes that are co-expressed with IGF-1 and associate with aging and vascular pathophysiology. We found that among the predicted targets, the expression of multiple extracellular matrix-related genes, including collagen-encoding genes, were downregulated in mice with developmental IGF-1 deficiency. Collectively, IGF-1 deficiency during a critical period during early in life results in persistent changes in post-transcriptional miRNA-mediated control of genes critical targets for vascular health, which likely contribute to the deleterious late-life cardiovascular effects known to occur with developmental IGF-1 deficiency.
C1 [Tarantini, Stefano; Giles, Cory B.; Wren, Jonathan D.; Ashpole, Nicole M.; Valcarcel-Ares, M. Noa; Sonntag, William E.; Ungvari, Zoltan; Csiszar, Anna] Univ Oklahoma, Hlth Sci Ctr, Reynolds Oklahoma Ctr Aging, Donald W Reynolds Dept Geriatr Med, Oklahoma City, OK 73104 USA.
   [Tarantini, Stefano; Ungvari, Zoltan; Csiszar, Anna] Univ Oklahoma, Hlth Sci Ctr, Dept Physiol, Oklahoma City, OK USA.
   [Giles, Cory B.; Wren, Jonathan D.] Oklahoma Med Res Fdn, Arthrit & Clin Immunol Res Program, 825 NE 13th St, Oklahoma City, OK 73104 USA.
   [Giles, Cory B.; Wren, Jonathan D.] Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73190 USA.
   [Wei, Jeanne Y.] Univ Arkansas Med Sci, Reynolds Inst Aging, 4301 West Markham St,748, Little Rock, AR 72205 USA.
   [Wei, Jeanne Y.] Univ Arkansas Med Sci, Dept Geriatr, 4301 West Markham St,748, Little Rock, AR 72205 USA.
   [Sonntag, William E.; Ungvari, Zoltan; Csiszar, Anna] Univ Oklahoma, Hlth Sci Ctr, Peggy & Charles Stephenson Canc Ctr, Oklahoma City, OK 73104 USA.
C3 University of Oklahoma System; University of Oklahoma Health Sciences
   Center; University of Oklahoma System; University of Oklahoma Health
   Sciences Center; Oklahoma Medical Research Foundation; University of
   Oklahoma System; University of Oklahoma Health Sciences Center;
   University of Arkansas System; University of Arkansas Medical Sciences;
   University of Arkansas System; University of Arkansas Medical Sciences;
   University of Oklahoma System; University of Oklahoma Health Sciences
   Center
RP Csiszar, A (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Reynolds Oklahoma Ctr Aging, Donald W Reynolds Dept Geriatr Med, Oklahoma City, OK 73104 USA.
EM anna-csiszar@ouhsc.edu
RI Tarantini, Stefano/JMQ-7733-2023; Wrong, Wrong/ADU-0095-2022; Wren,
   Jonathan D/E-5611-2011; Ungvari, Zoltan/GZK-8127-2022
OI Tarantini, Stefano/0000-0001-5627-1430; Wren, Jonathan
   D/0000-0003-2776-3545; Valcarcel-Ares, Marta Noa/0000-0003-0668-8961;
   sonntag, William/0000-0003-1850-2407; Ungvari,
   Zoltan/0000-0002-6035-6039
FU American Heart Association; Oklahoma Center for the Advancement of
   Science and Technology; Oklahoma IDeA Network for Biomedical Research
   Excellence; NIH [AG031085, AT006526, AG038747, NS056218, 5U54GM104938];
   Ellison Medical Foundation; Arkansas Claude Pepper Older Americans
   Independence Center at University of Arkansas Medical Center [P30
   AG028718]
FX This work was supported by grants from the American Heart Association
   (ST, AC, MNVA, ZT and ZU), the Oklahoma Center for the Advancement of
   Science and Technology (to AC, ZU, WES), the Oklahoma IDeA Network for
   Biomedical Research Excellence (to AC), the NIH (AG031085 to AC;
   AT006526 to ZU; AG038747 and NS056218 to WES and AC; 5U54GM104938 to
   JW), the Ellison Medical Foundation (to WES), and the Arkansas Claude
   Pepper Older Americans Independence Center at University of Arkansas
   Medical Center (to JW and ZU; P30 AG028718).
CR Alonso-Bouzón C, 2014, AGE, V36, P495, DOI 10.1007/s11357-013-9576-1
   [Anonymous], AGING CELL
   Asada S, 2008, AM J PHYSIOL-HEART C, V295, pH2512, DOI 10.1152/ajpheart.00233.2008
   Ashpole NM, 2016, J BONE MINER RES, V31, P443, DOI 10.1002/jbmr.2689
   Bailey-Downs LC, 2012, J GERONTOL A-BIOL, V67, P553, DOI 10.1093/gerona/glr197
   Bailey-Downs LC, 2012, J GERONTOL A-BIOL, V67, P313, DOI 10.1093/gerona/glr164
   Bake S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091427
   BARKER DJP, 1989, LANCET, V2, P577
   Barker DJP, 2005, NEW ENGL J MED, V353, P1802, DOI 10.1056/NEJMoa044160
   Barker DJP, 2004, J AM COLL NUTR, V23, p588S, DOI 10.1080/07315724.2004.10719428
   Barker DJP, 2004, J EPIDEMIOL COMMUN H, V58, P114, DOI 10.1136/jech.58.2.114
   Bartke A, 2004, CURR TOP DEV BIOL, V63, P189, DOI 10.1016/S0070-2153(04)63006-7
   Bates DJ, 2010, AGING CELL, V9, P1, DOI 10.1111/j.1474-9726.2009.00529.x
   Bateson P, 2004, NATURE, V430, P419, DOI 10.1038/nature02725
   Bidlingmaier M, 2014, J CLIN ENDOCR METAB, V99, P1712, DOI 10.1210/jc.2013-3059
   Blakemore SJ, 2010, HUM BRAIN MAPP, V31, P926, DOI 10.1002/hbm.21052
   Blanton RE, 2012, NEUROSCIENCE, V217, P105, DOI 10.1016/j.neuroscience.2012.04.059
   Boehm M, 2005, SCIENCE, V310, P1954, DOI 10.1126/science.1115596
   Bonauer A, 2009, SCIENCE, V324, P1710, DOI 10.1126/science.1174381
   Boon RA, 2013, NATURE, V495, P107, DOI 10.1038/nature11919
   Brüel A, 2002, MECH AGEING DEV, V123, P627, DOI 10.1016/S0047-6374(01)00409-2
   Carter CS, 2002, TRENDS GENET, V18, P295, DOI 10.1016/S0168-9525(02)02696-3
   Che P, 2014, AGING CELL, V13, P926, DOI 10.1111/acel.12252
   Chen L, 2014, HEPATOLOGY, V59, P1118, DOI 10.1002/hep.26768
   Chen LJ, 2015, CIRC RES, V116, P1157, DOI 10.1161/CIRCRESAHA.116.305987
   Chisalita SI, 2004, AM J PHYSIOL-ENDOC M, V286, pE896, DOI 10.1152/ajpendo.00327.2003
   Cittadini A, 1997, ENDOCRINOLOGY, V138, P5161, DOI 10.1210/en.138.12.5161
   Colao A, 2004, CLIN ENDOCRINOL, V61, P360, DOI 10.1111/j.1365-2265.2004.02105.x
   Csiszar A, 2013, AM J PHYSL HEART CIR
   Csiszar A, 2008, AM J PHYSIOL-HEART C, V295, pH1882, DOI 10.1152/ajpheart.412.2008
   Csiszar A, 2007, AM J PHYSIOL-HEART C, V293, pH919, DOI 10.1152/ajpheart.01287.2006
   Csiszar A, 2014, AM J PHYSIOL-HEART C, V307, pH292, DOI 10.1152/ajpheart.00307.2014
   Daniel JM, 2014, CARDIOVASC RES, V103, P564, DOI 10.1093/cvr/cvu162
   DCOSTA AP, 1993, J REPROD FERTIL, P87
   Deak F, 2012, J GERONTOL A-BIOL, V67, P611, DOI 10.1093/gerona/gls118
   Demirci B, 2014, AGE, V36, P223, DOI 10.1007/s11357-013-9569-0
   Doebele C, 2010, BLOOD, V115, P4944, DOI 10.1182/blood-2010-01-264812
   Donato AJ, 2014, LIFE SCI, V118, P238, DOI 10.1016/j.lfs.2013.12.209
   Dozmorov MG, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-S10-S14
   Dupont S, 2011, NATURE, V474, P179, DOI 10.1038/nature10137
   Edouard T, 2009, EUR J ENDOCRINOL, V161, P43, DOI 10.1530/EJE-08-0964
   Ekenstedt KJ, 2006, ARTHRITIS RHEUM-US, V54, P3850, DOI 10.1002/art.22254
   Eriksson JG, 2000, STROKE, V31, P869, DOI 10.1161/01.STR.31.4.869
   Eriksson JG, 1999, BMJ-BRIT MED J, V318, P427, DOI 10.1136/bmj.318.7181.427
   Eriksson JG, 2007, HYPERTENSION, V49, P1415, DOI 10.1161/HYPERTENSIONAHA.106.085597
   Fenn AM, 2013, NEUROBIOL AGING, V34, P2748, DOI 10.1016/j.neurobiolaging.2013.06.007
   Fontana L, 2008, AGING CELL, V7, P681, DOI 10.1111/j.1474-9726.2008.00417.x
   FORSDAHL A, 1978, J EPIDEMIOL COMMUN H, V32, P34, DOI 10.1136/jech.32.1.34
   Franco L, 2014, AGE, V36, P1443, DOI 10.1007/s11357-014-9622-7
   Fülöp N, 2008, BIOGERONTOLOGY, V9, P139, DOI 10.1007/s10522-007-9123-5
   GAVAZZI I, 1995, CELL TISSUE RES, V281, P23
   Giedd JN, 2006, MOL CELL ENDOCRINOL, V254, P154, DOI 10.1016/j.mce.2006.04.016
   Gillman MW, 2005, NEW ENGL J MED, V353, P1848, DOI 10.1056/NEJMe058187
   Goddings AL, 2014, NEUROIMAGE, V88, P242, DOI 10.1016/j.neuroimage.2013.09.073
   González-Guardia L, 2014, AGE, V36, DOI 10.1007/s11357-014-9681-9
   Grabowska W, 2015, AGE, V37, DOI 10.1007/s11357-014-9744-y
   Grillari J, 2010, EXP GERONTOL, V45, P302, DOI 10.1016/j.exger.2010.01.007
   Guevara-Aguirre J, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3001845
   Heiss C, 2015, AGE, V37, DOI 10.1007/s11357-015-9794-9
   Helms SA, 2010, INT J BIOL SCI, V6, P475
   Hergenreider E, 2012, NAT CELL BIOL, V14, P249, DOI 10.1038/ncb2441
   Higashi Y, 2012, J GERONTOL A-BIOL, V67, P626, DOI 10.1093/gerona/gls102
   Higashi Y, 2010, TRENDS ENDOCRIN MET, V21, P245, DOI 10.1016/j.tem.2009.12.005
   Hill Cristal M, 2015, Age (Dordr), V37, P9765, DOI 10.1007/s11357-015-9765-1
   Hua YN, 2012, J CELL MOL MED, V16, P83, DOI 10.1111/j.1582-4934.2011.01307.x
   Ibáñez-Ventoso C, 2006, AGING CELL, V5, P235, DOI 10.1111/j.1474-9726.2006.00210.x
   Ikeno Y, 2003, J GERONTOL A-BIOL, V58, P291
   Inukai S, 2013, J MOL BIOL, V425, P3601, DOI 10.1016/j.jmb.2013.01.023
   Inukai S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040028
   Ito T, 2010, BIOCHEM BIOPH RES CO, V398, P735, DOI 10.1016/j.bbrc.2010.07.012
   Johansson GS, 2008, MOL CELL ENDOCRINOL, V296, P58, DOI 10.1016/j.mce.2008.07.012
   Kajantie E, 2005, INT J EPIDEMIOL, V34, P655, DOI 10.1093/ije/dyi048
   Kim CW, 2014, ARTERIOSCL THROM VAS, V34, P1412, DOI 10.1161/ATVBAHA.113.303134
   Kim JM, 2015, TRANSL STROKE RES, V6, P191, DOI 10.1007/s12975-015-0390-1
   Kimura KD, 1997, SCIENCE, V277, P942, DOI 10.1126/science.277.5328.942
   Kozomara A, 2014, NUCLEIC ACIDS RES, V42, pD68, DOI 10.1093/nar/gkt1181
   Kuehbacher A, 2007, CIRC RES, V101, P59, DOI 10.1161/CIRCRESAHA.107.153916
   Laron Z, 1999, J BONE MINER RES, V14, P156, DOI 10.1359/jbmr.1999.14.1.156
   Lee S, 2014, AGE, V36, DOI 10.1007/s11357-014-9724-2
   Leiser SF, 2010, MOL CELL BIOL, V30, P871, DOI 10.1128/MCB.01145-09
   Leung A, 2013, CIRC RES, V113, P266, DOI 10.1161/CIRCRESAHA.112.300849
   Li LJ, 2014, MOL MED REP, V10, P527, DOI 10.3892/mmr.2014.2172
   Li Q, 2007, AM J PHYSIOL-HEART C, V292, pH1398, DOI 10.1152/ajpheart.01036.2006
   Liu D, 2015, AGE, V37, DOI 10.1007/s11357-015-9836-3
   Longobardi S, 2000, GROWTH HORM IGF RES, V10, P242, DOI 10.1054/ghir.2000.0160
   Lovren F, 2012, CIRCULATION, V126, pS81, DOI 10.1161/CIRCULATIONAHA.111.084186
   Low SK, 2012, HUM MOL GENET, V21, P2102, DOI 10.1093/hmg/dds020
   Loyer X, 2014, CIRC RES, V114, P434, DOI 10.1161/CIRCRESAHA.114.302213
   Maes OC, 2008, MECH AGEING DEV, V129, P534, DOI 10.1016/j.mad.2008.05.004
   MANZ HJ, 1979, VIRCHOWS ARCH A, V384, P325, DOI 10.1007/BF00428233
   Mariño G, 2010, P NATL ACAD SCI USA, V107, P16268, DOI 10.1073/pnas.1002696107
   Maynard SP, 2006, AGING CELL, V5, P89, DOI 10.1111/j.1474-9726.2006.00187.x
   Menghini R, 2009, CIRCULATION, V120, P1524, DOI 10.1161/CIRCULATIONAHA.109.864629
   Mercken EM, 2013, AGING-US, V5, P692, DOI 10.18632/aging.100598
   Mourmoura E, 2014, AGE, V36, DOI 10.1007/s11357-014-9670-z
   Murakami S, 2003, FASEB J, V17, P1565, DOI 10.1096/fj.02-1092fje
   Nieves-Martinez E, 2010, J ENDOCRINOL, V204, P31, DOI 10.1677/JOE-09-0323
   O'Rourke JR, 2011, CIRC RES, V109, P1098, DOI 10.1161/CIRCRESAHA.111.256388
   Ono K, 2011, FEBS J, V278, P1619, DOI 10.1111/j.1742-4658.2011.08090.x
   Osmond C, 2007, STROKE, V38, P264, DOI 10.1161/01.STR.0000254471.72186.03
   Page MM, 2009, FREE RADICAL BIO MED, V46, P1109, DOI 10.1016/j.freeradbiomed.2009.01.014
   Panici JA, 2010, FASEB J, V24, P5073, DOI 10.1096/fj.10-163253
   Park TJ, 2006, MOL CELL BIOL, V26, P6272, DOI 10.1128/MCB.00472-06
   Parker DR, 1998, INT J EPIDEMIOL, V27, P970, DOI 10.1093/ije/27.6.970
   Pearson KJ, 2008, CELL METAB, V8, P157, DOI 10.1016/j.cmet.2008.06.011
   Peper JS, 2011, PSYCHONEUROENDOCRINO, V36, P1101, DOI 10.1016/j.psyneuen.2011.05.004
   Ping XL, 2014, CELL RES, V24, P177, DOI 10.1038/cr.2014.3
   Ramsey MM, 2002, ENDOCRINOLOGY, V143, P4139, DOI 10.1210/en.2002-220717
   Reddy AK, 2014, J GERONTOL A-BIOL, V69, P152, DOI 10.1093/gerona/glt055
   Reijerkerk A, 2013, J NEUROSCI, V33, P6857, DOI 10.1523/JNEUROSCI.3965-12.2013
   Rojanathammanee L, 2014, AGE, V36, DOI 10.1007/s11357-014-9687-3
   Rotllan N, 2013, ARTERIOSCL THROM VAS, V33, P1973, DOI 10.1161/ATVBAHA.113.301732
   Rutnam ZJ, 2012, J CELL SCI, V125, P2075, DOI 10.1242/jcs100818
   Salmon AB, 2005, AM J PHYSIOL-ENDOC M, V289, pE23, DOI 10.1152/ajpendo.00575.2004
   Sathyan S, 2014, META GENE, V2, P651, DOI 10.1016/j.mgene.2014.07.001
   Sato F, 2011, FEBS J, V278, P1598, DOI 10.1111/j.1742-4658.2011.08089.x
   Satterthwaite TD, 2014, P NATL ACAD SCI USA, V111, P8643, DOI 10.1073/pnas.1400178111
   Sen A, 2014, FEBS LETT, V588, P906, DOI 10.1016/j.febslet.2014.01.033
   Shai SY, 2010, ARTERIOSCL THROM VAS, V30, P1916, DOI 10.1161/ATVBAHA.110.210831
   Small TW, 2007, TRENDS CARDIOVAS MED, V17, P230, DOI 10.1016/j.tcm.2007.08.002
   Small TW, 2006, CIRC RES, V99, P1338, DOI 10.1161/01.RES.0000252289.79841.d3
   Small TW, 2009, J BIOL CHEM, V284, P24684, DOI 10.1074/jbc.M109.034629
   Smith-Vikos T, 2012, J CELL SCI, V125, P7, DOI 10.1242/jcs.099200
   Sonntag WE, 2005, AGEING RES REV, V4, P195, DOI 10.1016/j.arr.2005.02.001
   Sonntag WE, 2005, ENDOCRINOLOGY, V146, P2920, DOI 10.1210/en.2005-0058
   Sonntag WE, 2000, J ANAT, V197, P575, DOI 10.1046/j.1469-7580.2000.19740575.x
   Sonntag WE, 1999, J GERONTOL A-BIOL, V54, pB521, DOI 10.1093/gerona/54.12.B521
   Sonntag WE, 2013, FRONT AGING NEUROSCI, V5, DOI 10.3389/fnagi.2013.00027
   Sonntag WE, 2012, J GERONTOL A-BIOL, V67, P587, DOI 10.1093/gerona/gls115
   Sorensen K, 2012, EUR J ENDOCRINOL, V166, P903, DOI 10.1530/EJE-12-0106
   Stellos K, 2014, CIRC RES, V114, P3, DOI 10.1161/CIRCRESAHA.113.302762
   Steuerman R, 2011, EUR J ENDOCRINOL, V164, P485, DOI 10.1530/EJE-10-0859
   Suárez Y, 2008, P NATL ACAD SCI USA, V105, P14082, DOI 10.1073/pnas.0804597105
   Suárez Y, 2007, CIRC RES, V100, P1164, DOI 10.1161/01.RES.0000265065.26744.17
   Sukhanov S, 2007, ARTERIOSCL THROM VAS, V27, P2684, DOI 10.1161/ATVBAHA.107.156257
   Svensson D, 2014, J VASC RES, V51, P239, DOI 10.1159/000365551
   Toth P, 2015, AGING CELL, V14, P1034, DOI 10.1111/acel.12372
   Toth P, 2014, J CEREBR BLOOD F MET, V34, P1887, DOI 10.1038/jcbfm.2014.156
   Toth P, 2013, J CEREBR BLOOD F MET, V33, P1732, DOI 10.1038/jcbfm.2013.143
   Troncoso R, 2012, CARDIOVASC RES, V93, P320, DOI 10.1093/cvr/cvr321
   Tucsek Z, 2014, J GERONTOL A-BIOL, V69, P1339, DOI 10.1093/gerona/glu080
   Tucsek Z, 2014, J GERONTOL A-BIOL, V69, P1212, DOI 10.1093/gerona/glt177
   Ungvari Z, 2003, CIRCULATION, V108, P1253, DOI 10.1161/01.CIR.0000079165.84309.4D
   Ungvari Z, 2013, J GERONTOL A-BIOL, V68, P877, DOI 10.1093/gerona/gls242
   Ungvari Z, 2012, J GERONTOL A-BIOL, V67, P599, DOI 10.1093/gerona/gls072
   Ungvari Z, 2011, J GERONTOL A-BIOL, V66, P501, DOI 10.1093/gerona/glr004
   Ungvari Z, 2010, J GERONTOL A-BIOL, V65, P1145, DOI 10.1093/gerona/glq147
   van Abeelen AFM, 2012, EUR HEART J, V33, P538, DOI 10.1093/eurheartj/ehr228
   Vasa-Nicotera M, 2011, ATHEROSCLEROSIS, V217, P326, DOI 10.1016/j.atherosclerosis.2011.03.034
   Victoria B, 2015, AGING CELL, V14, P1055, DOI 10.1111/acel.12373
   Walker AE, 2014, AGE, V36, P559, DOI 10.1007/s11357-013-9585-0
   Wang M, 2012, AGING CELL, V11, P668, DOI 10.1111/j.1474-9726.2012.00833.x
   Weber M, 2014, AM J PHYSIOL-HEART C, V306, pH1192, DOI 10.1152/ajpheart.00521.2013
   Wren JD, 2004, BIOINFORMATICS, V20, P191, DOI 10.1093/bioinformatics/btg390
   Wren JD, 2009, BIOINFORMATICS, V25, P1694, DOI 10.1093/bioinformatics/btp290
   Wu W, 2011, CIRCULATION, V124, P633, DOI 10.1161/CIRCULATIONAHA.110.005108
   Yang WJ, 2005, J BIOL CHEM, V280, P9330, DOI 10.1074/jbc.M413394200
   Yasuno K, 2011, P NATL ACAD SCI USA, V108, P19707, DOI 10.1073/pnas.1117137108
   Zampetaki A, 2014, CIRC RES, V115, P857, DOI 10.1161/CIRCRESAHA.115.304361
   Zhang XM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034688
   Zhu YL, 2008, BIOINFORMATICS, V24, P2798, DOI 10.1093/bioinformatics/btn520
   Zovoilis A, 2011, EMBO J, V30, P4299, DOI 10.1038/emboj.2011.327
NR 162
TC 32
Z9 34
U1 0
U2 12
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0161-9152
EI 1574-4647
J9 AGE
JI Age
PD AUG
PY 2016
VL 38
IS 4
BP 239
EP 258
DI 10.1007/s11357-016-9943-9
PG 20
WC Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Geriatrics & Gerontology
GA DY8SJ
UT WOS:000385400700002
PM 27566308
OA Green Published
DA 2024-02-19
ER

PT J
AU POZZATO, G
   MORETTI, M
   FRANZIN, F
   CROCE, LS
   LACCHIN, T
   BENEDETTI, G
   SABLICH, R
   STEBEL, M
   CAMPANACCI, L
AF POZZATO, G
   MORETTI, M
   FRANZIN, F
   CROCE, LS
   LACCHIN, T
   BENEDETTI, G
   SABLICH, R
   STEBEL, M
   CAMPANACCI, L
TI ETHANOL-METABOLISM AND AGING - THE ROLE OF FIRST-PASS-METABOLISM AND
   GASTRIC ALCOHOL-DEHYDROGENASE ACTIVITY
SO JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL
   SCIENCES
LA English
DT Article
ID HUMAN GASTROINTESTINAL-TRACT; 1ST-PASS METABOLISM; OXIDIZING SYSTEM;
   WOMEN; LIVER; CONSUMPTION; ELIMINATION; OXIDATION; DISEASE; RAT
AB To investigate the effect of age and gender on ethanol metabolism, first-pass metabolism (FPM) and gastric alcohol-dehydrogenase (ADH) activity were compared in 32 elderly and 30 young adult nonalcoholic subjects. The FPM was obtained from the difference between the area under the curve of ethanol blood concentration after intravenous or oral administration of ethanol 0.3 g/Kg b.w. The ADH activity was determined in samples of gastric mucosa obtained during diagnostic endoscopy. In the young adult group the PM was higher in men than in women (3.3 +/- 2.3 vs 1.2 +/- 0.9 mmol/l/h, respectively, p<.01). In aged subjects FPM was found to be very low for men (1.1 +/- 0.8 mmol/l/h, p<.001); conversely, FPM was not significantly reduced in women (1.7 +/- 0.8 mmol/l/h, p=n.s.). The gastric ADH activity was significantly (p<.01) higher in young adult men than women, whereas in aged subjects the activities were low (p<.0001) in both sexes. Thus, gender-related FPM differences equalize in the elderly or are even reversed, most likely because of gastric mucosal atrophy, which occurs more in men than women.
C1 UNIV TRIESTE, SCH MED, INST CLIN MED, TRIESTE, ITALY.
   UNIV TRIESTE, SCH MED, INST BIOCHEM, TRIESTE, ITALY.
   PORDENONE GEN HOSP, DEPT GASTROENTEROL, PORDENONE, ITALY.
C3 University of Trieste; University of Trieste
RI croce', lory saveria/E-2565-2011
OI croce', lory saveria/0000-0001-9890-7011
CR ASHLEY MJ, 1977, ARCH INTERN MED, V137, P883, DOI 10.1001/archinte.137.7.883
   BOSRON WF, 1983, BIOCHEMISTRY-US, V22, P1852, DOI 10.1021/bi00277a017
   CABALLERIA J, 1987, LIFE SCI, V41, P1021, DOI 10.1016/0024-3205(87)90691-6
   CABALLERIA J, 1989, GASTROENTEROLOGY, V97, P1205, DOI 10.1016/0016-5085(89)91691-0
   DIPADOVA C, 1987, GASTROENTEROLOGY, V92, P1169, DOI 10.1016/S0016-5085(87)91073-0
   EGERER G, 1988, INT CONGR SER, V805, P115
   FERNANDEZ V, 1988, CELL BIOCHEM FUNCT, V6, P7, DOI 10.1002/cbf.290060103
   FREZZA M, 1990, NEW ENGL J MED, V322, P95, DOI 10.1056/NEJM199001113220205
   HAHN HKJ, 1983, ALCOHOL CLIN EXP RES, V7, P299, DOI 10.1111/j.1530-0277.1983.tb05464.x
   HALSTED CH, 1973, AM J CLIN NUTR, V26, P831, DOI 10.1093/ajcn/26.8.831
   Hein P M, 1989, Blutalkohol, V26, P98
   HURT RD, 1988, MAYO CLIN PROC, V63, P753, DOI 10.1016/S0025-6196(12)62354-4
   JONES MK, 1984, ALCOHOL CLIN EXP RES, V8, P24, DOI 10.1111/j.1530-0277.1984.tb05026.x
   JULIA P, 1988, EUR J BIOCHEM, V172, P73, DOI 10.1111/j.1432-1033.1988.tb13857.x
   JULKUNEN RJK, 1985, LIFE SCI, V37, P567, DOI 10.1016/0024-3205(85)90470-9
   LIEBER CS, 1970, J BIOL CHEM, V245, P2505
   MARSHALL AW, 1983, HEPATOLOGY, V3, P701
   NORRIS AH, 1963, ANN NY ACAD SCI, V110, P623, DOI 10.1111/j.1749-6632.1963.tb15784.x
   NORTON R, 1987, BMJ-BRIT MED J, V295, P80, DOI 10.1136/bmj.295.6590.80
   OHNISHI K, 1977, J BIOL CHEM, V252, P7124
   PESTALOZZI DM, 1983, GASTROENTEROLOGY, V85, P1011
   POZZATO G, 1987, ITALIAN J GASTROENTE, V19, P302
   RANGNO RE, 1981, BRIT J CLIN PHARMACO, V12, P667, DOI 10.1111/j.1365-2125.1981.tb01287.x
   SAUNDERS JB, 1981, BMJ-BRIT MED J, V282, P1140, DOI 10.1136/bmj.282.6270.1140
   SCOTT RB, 1988, J AM GERIATR SOC, V36, P255, DOI 10.1111/j.1532-5415.1988.tb01810.x
   SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7
   VESTAL RE, 1977, CLIN PHARMACOL THER, V21, P343
NR 27
TC 45
Z9 52
U1 1
U2 6
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1079-5006
J9 J GERONTOL A-BIOL
JI J. Gerontol. Ser. A-Biol. Sci. Med. Sci.
PD MAY
PY 1995
VL 50
IS 3
BP B135
EP B141
DI 10.1093/gerona/50A.3.B135
PG 7
WC Geriatrics & Gerontology; Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Geriatrics & Gerontology
GA RY603
UT WOS:A1995RY60300005
PM 7743392
DA 2024-02-19
ER

PT J
AU Abbas, H
   Perna, S
   Shah, A
   Gasparri, C
   Rondanelli, M
AF Abbas, Hanan
   Perna, Simone
   Shah, Afzal
   Gasparri, Clara
   Rondanelli, Mariangela
TI Efficacy and Safety of a Long-Term Multidisciplinary Weight Loss
   Intervention under Hospitalization in Aging Patients with Obesity: An
   Open Label Study
SO NUTRIENTS
LA English
DT Article
DE obesity; hypocaloric diet; weight loss; multidisciplinary intervention
ID LOW-CALORIE DIET; TYPE-2 DIABETES-MELLITUS; IMPROVES; RESTRICTION;
   MANAGEMENT; REDUCTION; STANDARDS; ADULTS; LIPIDS; RISK
AB The effects of the hypocaloric diet under hospitalization on blood biochemical parameters (lipid, glycaemic, thyroid and liver profiles) were not reported in literature. This study aims to evaluate the efficacy and safety of a hypocaloric diet under hospitalisation in obese patients. A total of 151 obese subjects (49 males and 102 females, aged 69.38 +/- 14.1 years, BMI 41.78 +/- 7.1) were enrolled in this study. Participants were treated with an hypocaloric diet for a maximum period of 3 months. Outcomes were assessed at the beginning and at the end of the recovery period. The average duration of the hospitalisation was 47.5 days +/- 1.3. The effect of the diet on all the outcomes was evaluated using the Analysis of Covariance (ANCOVA) and the predictors of weight loss were identified using linear regression. The diet induced a reduction in the anthropometric (BMI decrease of -2.713 points) and DXA body measurements in addition to serum lipids, glucose, Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) and C-reactive protein (CRP) levels without affecting the muscle mass, liver and thyroid profiles. During the intervention, there was a positive shift in body composition favouring fat free mass (FFM). Lower insulin but higher serum calcium and potassium levels were predictors of weight loss.
C1 [Abbas, Hanan; Perna, Simone] Univ Bahrain, Coll Sci, Dept Biol, Sakhir Campus,POB 32038, Zallaq, Bahrain.
   [Shah, Afzal] Quaid I Azam Univ, Dept Chem, Islamabad 45320, Pakistan.
   [Gasparri, Clara] Univ Pavia, Endocrinol & Nutr Unit, Azienda Serv Persona Ist Santa Margherita, I-27100 Pavia, Italy.
   [Rondanelli, Mariangela] Univ Pavia, Dept Publ Hlth Expt & Forens Med, I-27100 Pavia, Italy.
   [Rondanelli, Mariangela] IRCCS Mondino Fdn, I-27100 Pavia, Italy.
C3 University of Bahrain; Quaid I Azam University; University of Pavia;
   University of Pavia; IRCCS Fondazione Casimiro Mondino
RP Gasparri, C (corresponding author), Univ Pavia, Endocrinol & Nutr Unit, Azienda Serv Persona Ist Santa Margherita, I-27100 Pavia, Italy.
EM clara.gasparri01@universitadipavia.it
RI Perna, Simone/Y-8892-2018; Shah, Afzal/HLW-6536-2023; Shah,
   Afzal/B-2064-2015
OI Perna, Simone/0000-0002-2720-1473; Shah, Afzal/0000-0002-9465-9185;
   Shah, Afzal/0000-0002-9465-9185; rondanelli,
   Mariangela/0000-0001-8336-4851; Gasparri, Clara/0000-0002-1088-6648
CR Aigner E, 2014, NUTRIENTS, V6, P3587, DOI 10.3390/nu6093587
   Amer Diabet Associat, 2008, DIABETES CARE, V31, pS61, DOI 10.2337/dc08-S061
   American College of Sports Medicine, 2014, MED SCI SPORT EXERC, V41, P687
   Apovian Caroline M, 2016, Am J Manag Care, V22, ps176
   Baumgartner RN, 1998, AM J EPIDEMIOL, V147, P755, DOI 10.1093/oxfordjournals.aje.a009520
   Bennett JA, 2005, NURS RES, V54, P128
   Beutel M, 2001, INT J OBESITY, V25, pS96, DOI 10.1038/sj.ijo.0801709
   BOSELLO O, 1988, ANN NUTR METAB, V32, P206, DOI 10.1159/000177443
   Bray GA, 2004, J CLIN ENDOCR METAB, V89, P2583, DOI 10.1210/jc.2004-0535
   Cai XL, 2016, NUTRIENTS, V8, DOI 10.3390/nu8040183
   Chehadeh SE, 2020, GENE, V739, DOI 10.1016/j.gene.2020.144509
   Chlif M, 2017, RESP CARE, V62, P936, DOI 10.4187/respcare.04923
   Compher C, 2006, J AM DIET ASSOC, V106, P881, DOI 10.1016/j.jada.2006.02.009
   Dalle Grave R, 2005, J INTERN MED, V258, P265, DOI 10.1111/j.1365-2796.2005.01524.x
   Damms-Machado A, 2012, NUTR J, V11, DOI 10.1186/1475-2891-11-34
   Dashti HM, 2007, MOL CELL BIOCHEM, V302, P249, DOI 10.1007/s11010-007-9448-z
   DATTILO AM, 1992, AM J CLIN NUTR, V56, P320, DOI 10.1093/ajcn/56.2.320
   Davis NJ, 2006, DIABETES EDUCATOR, V32, P557, DOI 10.1177/0145721706290437
   De Lorenzo A, 2020, NUTRITION, V71, DOI 10.1016/j.nut.2019.110615
   Feingold K. R., 2018, ENDOTEXT
   Feinman RD, 2015, NUTRITION, V31, P1, DOI 10.1016/j.nut.2014.06.011
   FRAYN KN, 1983, J APPL PHYSIOL, V55, P628, DOI 10.1152/jappl.1983.55.2.628
   FRISANCHO AR, 1984, AM J CLIN NUTR, V40, P808, DOI 10.1093/ajcn/40.4.808
   Garvey W.T., 2018, BARIATRIC ENDOCRINOL, P121
   Giordani I, 2014, DIABETES METAB, V40, P158, DOI 10.1016/j.diabet.2013.12.006
   Hammer S, 2008, J AM COLL CARDIOL, V52, P1006, DOI 10.1016/j.jacc.2008.04.068
   Janssen I, 2004, AM J EPIDEMIOL, V159, P413, DOI 10.1093/aje/kwh058
   Jazet IM, 2007, DIABETES RES CLIN PR, V77, P70, DOI 10.1016/j.diabres.2006.10.019
   Keaver L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079827
   Keller U, 2019, J CLIN MED, V8, DOI 10.3390/jcm8060775
   Ko Hyun Ji, 2019, [The East Asian Society of Dietary Life, 동아시아식생활학회지], V29, P238, DOI 10.17495/easdl.2019.6.29.3.238
   Kwaifa IK, 2020, BIOMOLECULES, V10, DOI 10.3390/biom10020291
   Lau DCW, 2005, AM J PHYSIOL-HEART C, V288, pH2031, DOI 10.1152/ajpheart.01058.2004
   Lewis L., 2020, StatPearls
   Li SX, 2010, AM J CLIN NUTR, V91, P184, DOI 10.3945/ajcn.2009.28403
   Ma XM, 2020, OBES RES CLIN PRACT, V14, P1, DOI 10.1016/j.orcp.2019.12.002
   Makki Kassem, 2013, ISRN Inflamm, V2013, P139239, DOI 10.1155/2013/139239
   McCafferty BJ, 2020, TECH VASC INTERV RAD, V23, DOI 10.1016/j.tvir.2020.100653
   Mohammad A, 2017, NUTR DIABETES, V7, DOI 10.1038/nutd.2016.38
   Morel O, 2011, INT J OBESITY, V35, P1479, DOI 10.1038/ijo.2011.19
   Nguyen TD., 2020, J CRIT REV, V7, P74, DOI 10.31838/jcr.07.04.15
   Volp ACP, 2015, NUTR HOSP, V31, P1947, DOI 10.3305/nh.2015.31.5.8525
   Rolland C, 2011, CHOLESTEROL, DOI 10.1155/2011/306278
   Shama N., 2019, OBES MED, V16, P100144, DOI [10.1016/j.obmed.2019.100144, DOI 10.1016/J.OBMED.2019.100144]
   Shi H, 2000, PHYSIOL GENOMICS, V3, P75, DOI 10.1152/physiolgenomics.2000.3.2.75
   Sibuyi NRS, 2019, J NANOBIOTECHNOL, V17, DOI 10.1186/s12951-019-0554-3
   Snel M, 2012, EUR J INTERN MED, V23, P143, DOI 10.1016/j.ejim.2011.07.004
   Spiegel K, 2009, NAT REV ENDOCRINOL, V5, P253, DOI 10.1038/nrendo.2009.23
   Stanger O, 2004, Z KARDIOL, V93, P439, DOI 10.1007/s00392-004-0075-3
   Tal B, 2019, NUTRIENTS, V11, DOI 10.3390/nu11061256
   Taylor J, 2020, JNP-J NURSE PRACT, V16, P74, DOI 10.1016/j.nurpra.2019.09.021
   von Bibra H, 2014, IJC METAB ENDOCR, V2, P11, DOI 10.1016/j.ijcme.2013.12.001
   WEIR JBD, 1949, J PHYSIOL-LONDON, V109, P1, DOI 10.1113/jphysiol.1949.sp004363
   Wilding JPH, 2020, EUR J ENDOCRINOL, V182, pC13, DOI 10.1530/EJE-20-0099
   World Health Organization, 2010, Global recommendations on physical activity for health
   World Health Organization, 2017, WHO TARGET 7 HALT RI
   Wright SM, 2012, ABDOM IMAGING, V37, P730, DOI 10.1007/s00261-012-9862-x
   Wylie-Rosett J, 2007, J AM DIET ASSOC, V107, P1296, DOI 10.1016/j.jada.2007.05.009
   Yu KP, 2020, GENE, V733, DOI 10.1016/j.gene.2020.144372
   Zemel MB, 2000, FASEB J, V14, P1132, DOI 10.1096/fasebj.14.9.1132
NR 60
TC 2
Z9 2
U1 0
U2 4
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2072-6643
J9 NUTRIENTS
JI Nutrients
PD AUG
PY 2022
VL 14
IS 16
AR 3416
DI 10.3390/nu14163416
PG 15
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Nutrition & Dietetics
GA 4D3MY
UT WOS:000847049500001
PM 36014924
OA Green Published, gold
DA 2024-02-19
ER

PT J
AU Sukharev, SA
   Pleshakova, OV
   Moshnikova, AB
   Sadovnikov, VB
   Gaziev, AI
AF Sukharev, SA
   Pleshakova, OV
   Moshnikova, AB
   Sadovnikov, VB
   Gaziev, AI
TI Age- and radiation-dependent changes in carbonyl content, susceptibility
   to proteolysis, and antigenicity of soluble rat liver proteins
SO COMPARATIVE BIOCHEMISTRY AND PHYSIOLOGY B-BIOCHEMISTRY & MOLECULAR
   BIOLOGY
LA English
DT Article
DE aging; antigenicity; antioxidants; autolysis; gamma-irradiation; protein
   carbonyl; rat liver; susceptibility to proteases; vitamins
ID MIXED-FUNCTION OXIDATION; RED BLOOD-CELLS; GLUTAMINE-SYNTHETASE; OXYGEN
   RADICALS; SUPEROXIDE-DISMUTASE; OXIDIZED PROTEINS; IMMUNE-SYSTEM;
   LIFE-SPAN; DAMAGE; INACTIVATION
AB Soluble liver proteins (SLP) from old and gamma-irradiated young rats were studied with respect to their carbonyl content, the rates of autolysis and degradation by proteinase K, and their antigenicity for mice and compared with SLP from non-irradiated young animals. A significant increase in the carbonyl level was found in SLP from old and gamma-irradiated young rats as compared to SLP from intact young rats. The rates of SLP autolysis and proteolysis by proteinase K were increased in the same animal groups but did not correlate the carbonyl level. At the same time, whereas the antigenicity for mice of SLP from old rats was significantly higher than that of SLP from young rats, the antigenicity of SLP from gamma-irradiated rats did not differ from non-irradiated animals. Enrichment of the diet with antioxidant and vitamin supplements (AVS) during one month before the irradiation caused a decrease in the radiation-induced carbonyl level in rat SLP. However, this raised antioxidant level in animal diet did not influence the rates of SLP autolysis and degradation by proteinase K and also did not alter the antigenicity of these proteins. The data allow us to suggest that the increase in autolysis, degradation by the exogenous proteinase, and antigenicity of SLP from old rats are determined not only by carbonyl formation in these proteins due to action of oxygen radicals but also by other age-specific protein modifications. (C) 1997 Elsevier Science Inc.
C1 RUSSIAN ACAD SCI, INST THEORET & EXPT BIOPHYS, PUSHCHINO 142292, MOSCOW REGION, RUSSIA.
C3 Russian Academy of Sciences; Pushchino Scientific Center for Biological
   Research (PSCBI) of the Russian Academy of Sciences; Institute of
   Theoretical & Experimental Biophysics
RP Sukharev, SA (corresponding author), RUSSIAN ACAD SCI, SHEMYAKIN & OVCHINNIKOV INST BIOORGAN CHEM, PUSHCHINO 142292, MOSCOW REGION, RUSSIA.
CR AGARWAL S, 1994, ARCH BIOCHEM BIOPHYS, V309, P24, DOI 10.1006/abbi.1994.1078
   ALLEN RG, 1983, BIOCHEM J, V216, P503, DOI 10.1042/bj2160503
   AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915
   BARJA G, 1994, COMP BIOCHEM PHYS B, V108, P501, DOI 10.1016/0305-0491(94)90103-1
   BURNET FM, 1959, CLONAL SELECTION THE
   CAO GH, 1995, ARCH BIOCHEM BIOPHYS, V320, P195, DOI 10.1006/abbi.1995.1359
   CARNEY JM, 1994, LIFE SCI, V55, P2097, DOI 10.1016/0024-3205(94)00390-4
   DAVIES KJA, 1987, J BIOL CHEM, V262, P9895
   DAVIES KJA, 1987, J BIOL CHEM, V262, P8227
   DAY JF, 1979, J BIOL CHEM, V254, P9394
   FRIDOVICH I, 1978, SCIENCE, V201, P875, DOI 10.1126/science.210504
   FUCCI L, 1983, P NATL ACAD SCI-BIOL, V80, P1521, DOI 10.1073/pnas.80.6.1521
   Gaziev AI, 1996, CARCINOGENESIS, V17, P493, DOI 10.1093/carcin/17.3.493
   GAZIEV AI, 1992, INT J RADIAT BIOL, V61, P169, DOI 10.1080/09553009214550781
   GRUNE T, 1995, J BIOL CHEM, V270, P2344, DOI 10.1074/jbc.270.5.2344
   HODES RJ, 1995, J EXP MED, V182, P1, DOI 10.1084/jem.182.1.1
   KAY MMB, 1994, ANN NY ACAD SCI, V719, P419, DOI 10.1111/j.1749-6632.1994.tb56847.x
   KUTSYI MP, 1994, RADIAT RES, V140, P221, DOI 10.2307/3578906
   LEVINE RL, 1990, METHOD ENZYMOL, V186, P464
   LOPEZTORRES M, 1993, FREE RADICAL BIO MED, V15, P133, DOI 10.1016/0891-5849(93)90052-V
   MIQUEL J, 1983, INTERVENTION AGING B, P317
   MO JQ, 1995, MECH AGEING DEV, V81, P73, DOI 10.1016/0047-6374(95)01586-O
   MONNIER VM, 1991, GERONTOLOGY, V37, P152
   OLIVER CN, 1987, ARCH BIOCHEM BIOPHYS, V253, P62, DOI 10.1016/0003-9861(87)90637-0
   OLIVER CN, 1987, J BIOL CHEM, V262, P5488
   ORR WC, 1994, SCIENCE, V263, P1128, DOI 10.1126/science.8108730
   PACIFICI RE, 1989, FREE RADICAL BIO MED, V7, P521, DOI 10.1016/0891-5849(89)90028-2
   PACIFICI RE, 1991, GERONTOLOGY, V37, P166
   PAWELEC G, 1995, IMMUNOL TODAY, V16, P420, DOI 10.1016/0167-5699(95)80017-4
   RIVETT AJ, 1986, BIOCHEM SOC T, V14, P643, DOI 10.1042/bst0140643
   RIVETT AJ, 1985, J BIOL CHEM, V260, P300
   ROSEMAN JE, 1987, J BIOL CHEM, V262, P2101
   SAHAKIAN JA, 1995, ARCH BIOCHEM BIOPHYS, V318, P411, DOI 10.1006/abbi.1995.1248
   SANTAMARIA C, 1995, FEBS LETT, V374, P85
   Sies H., 1985, Oxidative Stress, P1, DOI DOI 10.1016/B978-0-12-642760-8.50005-3
   SIMIC MG, 1989, MUTAT RES, V214, P3, DOI 10.1016/0027-5107(89)90192-9
   SOHAL RS, 1993, P NATL ACAD SCI USA, V90, P7255, DOI 10.1073/pnas.90.15.7255
   Sohal RS, 1995, LIFE SCI R, V56, P109
   STADTMAN ER, 1993, ANNU REV BIOCHEM, V62, P797, DOI 10.1146/annurev.bi.62.070193.004053
   STADTMAN ER, 1991, J BIOL CHEM, V266, P2005
   Stadtman ER, 1995, LIFE SCI R, V56, P129
   STARKEREED PE, 1989, ARCH BIOCHEM BIOPHYS, V275, P559, DOI 10.1016/0003-9861(89)90402-5
   Ushakova T, 1996, FREE RADICAL BIO MED, V20, P279, DOI 10.1016/0891-5849(95)02040-3
   USHAKOVA T, 1996, IN PRESS FREE RAD RE
   XU X, 1995, CELL BIOL, V71, P549
NR 45
TC 8
Z9 8
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1096-4959
J9 COMP BIOCHEM PHYS B
JI Comp. Biochem. Physiol. B-Biochem. Mol. Biol.
PD MAR
PY 1997
VL 116
IS 3
BP 333
EP 338
DI 10.1016/S0305-0491(96)00232-5
PG 6
WC Biochemistry & Molecular Biology; Zoology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Zoology
GA WR693
UT WOS:A1997WR69300007
PM 9114493
DA 2024-02-19
ER

PT J
AU Campos, F
   Abrigo, J
   Aguirre, F
   Garcés, B
   Arrese, M
   Karpen, S
   Cabrera, D
   Andía, ME
   Simon, F
   Cabello-Verrugio, C
AF Campos, Fabian
   Abrigo, Johanna
   Aguirre, Francisco
   Garces, Bruno
   Arrese, Marco
   Karpen, Saul
   Cabrera, Daniel
   Andia, Marcelo E.
   Simon, Felipe
   Cabello-Verrugio, Claudio
TI Sarcopenia in a mice model of chronic liver disease: role of the
   ubiquitin-proteasome system and oxidative stress
SO PFLUGERS ARCHIV-EUROPEAN JOURNAL OF PHYSIOLOGY
LA English
DT Article
DE Sarcopenia; Chronic liver diseases; Hepatotoxin; UPS; Oxidative stress
ID SKELETAL-MUSCLE ATROPHY; BETA TGF-BETA; BILIARY FIBROSIS; BILE-ACIDS;
   ANGIOTENSIN-II; MOUSE MODEL; CIRRHOSIS; HYPERAMMONEMIA; EXPRESSION;
   MYOSTATIN
AB Sarcopenia is the loss of muscle mass and strength produced by aging or secondary to chronic diseases such as chronic liver disease (CLD). Although not all types of sarcopenia involve the same features, the most common are decreased fiber diameter and myosin heavy chain (MHC) levels, increased activity of ubiquitin-proteasome system (UPS) and reactive oxygen species (ROS). In this study, we aim to characterize the development of sarcopenia secondary to CLD induced by the hepatotoxin 5-diethoxycarbonyl-1,4-dihydrocollidine (DDC). For this purpose, four-months-old male C57BL6 mice were fed with normal diet or DDC supplemented diet for 6weeks. Functional tests to evaluate muscle strength, mobility, and motor skills were performed in alive mice. The muscle strength in isolated gastrocnemius was also assayed via electrophysiological measurements. Morphometric measures of fibers' diameter, total and ubiquitinated protein levels of myosin heavy chain (MHC), E3 ubiquitin ligases, ROS, and oxidation-dependent modified proteins in gastrocnemius tissue were also determined. Our results demonstrated that mice fed the DDC diet developed muscle wasting as evidenced by a loss of muscle mass and decreased muscle strength. The muscles of mice fed with DDC diet have a decreased diameter of fibers and MHC levels, also as increased MuRF-1 and atrogin-1 protein levels, ROS levels, and oxidation-modified protein levels. Additionally, control and DDC mice have the same food and water intake as well as mobility. Our results demonstrate mice with CLD develop sarcopenia involving decreased levels of myofibrillar proteins, increased UPS, and oxidative stress, but not for impaired caloric intake or immobility.
C1 [Campos, Fabian; Abrigo, Johanna; Aguirre, Francisco; Garces, Bruno; Simon, Felipe; Cabello-Verrugio, Claudio] Univ Andres Bello, Fac Ciencias Vida, Dept Ciencias Biol, Lab Patol Musculares Fragilidad & Envejecimiento, Ave Republ 239, Santiago 8370146, Chile.
   [Campos, Fabian; Abrigo, Johanna; Aguirre, Francisco; Garces, Bruno; Simon, Felipe; Cabello-Verrugio, Claudio] Millennium Inst Immunol & Immunotherapy, Santiago, Chile.
   [Arrese, Marco; Cabrera, Daniel] Pontificia Univ Catolica Chile, Fac Med, Dept Gastroenterol, Santiago, Chile.
   [Karpen, Saul] Emory Univ, Sch Med, Dept Pediat, Atlanta, GA USA.
   [Cabrera, Daniel] Univ Bernardo O Higgins, Dept Ciencias Quim & Biol, Fac Salud, Santiago, Chile.
   [Andia, Marcelo E.] Pontificia Univ Catolica Chile, Biomed Imaging Ctr, Santiago, Chile.
   [Andia, Marcelo E.] Pontificia Univ Catolica Chile, Sch Med, Dept Radiol, Santiago, Chile.
C3 Universidad Andres Bello; Pontificia Universidad Catolica de Chile;
   Emory University; Universidad  Bernardo O'Higgins; Pontificia
   Universidad Catolica de Chile; Pontificia Universidad Catolica de Chile
RP Cabello-Verrugio, C (corresponding author), Univ Andres Bello, Fac Ciencias Vida, Dept Ciencias Biol, Lab Patol Musculares Fragilidad & Envejecimiento, Ave Republ 239, Santiago 8370146, Chile.; Cabello-Verrugio, C (corresponding author), Millennium Inst Immunol & Immunotherapy, Santiago, Chile.
EM claudio.cabello@unab.cl
RI CABRERA, DANIEL/AAR-5027-2020; Cabello-Verrugio, Claudio/AAD-1454-2020;
   ARRESE, MARCO/ABB-9061-2021
OI CABRERA, DANIEL/0000-0001-9634-725X; Cabello-Verrugio,
   Claudio/0000-0001-7273-2102; Andia, Marcelo/0000-0002-1251-5832; Simon,
   Felipe/0000-0002-2653-9798; Abrigo, Johanna/0000-0002-5598-513X
FU National Fund for Science & Technology Development [FONDECYT] [1161646,
   1161288, 11171001, 1150327]; Millennium Institute on Immunology and
   Immunotherapy [P09-016-F]; Programa de Cooperacion Cientifica
   ECOS-CONICYT [C16S02]; Center for Aging and Regeneration [CARE
   PFB12/2007]; Fondequip EQM [150033]; UNAB-DI [741-15/N]; Conicyt
   [21161353]; Universidad Andres Bello-Direccion de Investigacion
FX This study was supported by research grants from the National Fund for
   Science & Technology Development [FONDECYT 1161646 (C.C.V.), 1161288
   (F.S.); 11171001 (D.C.); 1150327 (M.A.)], Millennium Institute on
   Immunology and Immunotherapy [P09-016-F (F.S.)]; Programa de Cooperacion
   Cientifica ECOS-CONICYT [C16S02 (C.C.V.)]; Center for Aging and
   Regeneration [CARE PFB12/2007 (M.A.)]; Fondequip EQM [150033 (M.E.A.)];
   UNAB-DI [741-15/N (C.C.V., F.S.)]. J.A. thanks Conicyt for providing a
   PhD Scholarship (21161353). F.C. thanks Universidad Andres
   Bello-Direccion de Investigacion for providing a PhD Scholarship.
CR Abrigo J, 2016, CELL PHYSIOL BIOCHEM, V40, P27, DOI 10.1159/000452522
   Abrigo J, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/9047821
   Abrigo J, 2016, CELL SIGNAL, V28, P366, DOI 10.1016/j.cellsig.2016.01.010
   Bachmanov AA, 2002, BEHAV GENET, V32, P435, DOI 10.1023/A:1020884312053
   Barreiro E, 2016, PROTEOMES, V4, DOI 10.3390/proteomes4020018
   Barrera F, 2015, SEMIN THROMB HEMOST, V41, P481, DOI 10.1055/s-0035-1550438
   Belizário JE, 2016, SPRINGERPLUS, V5, DOI 10.1186/s40064-016-2197-2
   Berzigotti A, 2013, EXPERT REV GASTROENT, V7, P141, DOI [10.1586/egh.12.83, 10.1586/EGH.12.83]
   Bhatnagar S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013262
   Bilodeau PA, 2016, AM J PHYSIOL-CELL PH, V311, pC392, DOI 10.1152/ajpcell.00125.2016
   Bloemberg D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035273
   Bonaldo P, 2013, DIS MODEL MECH, V6, P25, DOI 10.1242/dmm.010389
   Cabello-Verrugio C, 2017, CURR OPIN CLIN NUTR, V20, P158, DOI 10.1097/MCO.0000000000000361
   Cabello-Verrugio C, 2012, J CELL MOL MED, V16, P752, DOI 10.1111/j.1582-4934.2011.01354.x
   Cabrera D, 2016, DIGEST DIS SCI, V61, P3190, DOI 10.1007/s10620-016-4285-0
   Carey EJ, 2017, LIVER TRANSPLANT, V23, P625, DOI 10.1002/lt.24750
   Chacon-Cabrera A, 2017, J CELL PHYSIOL, V232, P3744, DOI 10.1002/jcp.25851
   Chiang JYL, 2013, COMPR PHYSIOL, V3, P1191, DOI 10.1002/cphy.c120023
   Cisternas F, 2015, CLIN SCI, V128, P307, DOI 10.1042/CS20140215
   Cunha TF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041701
   Dasarathy S, 2018, CURR OPIN CLIN NUTR, V21, P30, DOI 10.1097/MCO.0000000000000426
   Dasarathy S, 2017, J CACHEXIA SARCOPENI, V8, P864, DOI 10.1002/jcsm.12262
   Dasarathy Srinivasan, 2014, Curr Treat Options Gastroenterol, V12, P242, DOI 10.1007/s11938-014-0016-9
   Dasarathy S, 2012, J CACHEXIA SARCOPENI, V3, P225, DOI 10.1007/s13539-012-0069-3
   DEACON RMJ, 2013, JOVE J VIS EXP JUN, DOI DOI 10.3791/2610
   Desai MS, 2010, HEPATOLOGY, V51, P2097, DOI 10.1002/hep.23585
   Duarte-Rojo A, 2018, LIVER TRANSPLANT, V24, P122, DOI 10.1002/lt.24958
   Durand F, 2008, SEMIN LIVER DIS, V28, P110, DOI 10.1055/s-2008-1040325
   Ebner N, 2014, J CACHEXIA SARCOPENI, V5, P27, DOI 10.1007/s13539-014-0136-z
   Fedorova M, 2009, BBA-MOL BASIS DIS, V1792, P1185, DOI 10.1016/j.bbadis.2009.09.011
   Fermoselle C, 2012, EUR RESPIR J, V40, P851, DOI 10.1183/09031936.00137211
   Fickert P, 2007, AM J PATHOL, V171, P525, DOI 10.2353/ajpath.2007.061133
   Fickert P, 2010, LAB INVEST, V90, P844, DOI 10.1038/labinvest.2010.61
   Morales MG, 2013, CELL TISSUE RES, V353, P173, DOI 10.1007/s00441-013-1642-6
   Morales MG, 2011, J PATHOL, V225, P490, DOI 10.1002/path.2952
   Gabrielli M, 2010, TRANSPL P, V42, P299, DOI 10.1016/j.transproceed.2009.11.034
   Haddad F, 2005, J APPL PHYSIOL, V98, P911, DOI 10.1152/japplphysiol.01026.2004
   Hansen J, 2011, ENDOCRINOLOGY, V152, P164, DOI 10.1210/en.2010-0868
   Hasselgren PO, 2005, INT J BIOCHEM CELL B, V37, P2156, DOI 10.1016/j.biocel.2005.01.017
   Higashino K, 2013, J NEUROENG REHABIL, V10, DOI 10.1186/1743-0003-10-46
   Huang ZQ, 2011, CELL SIGNAL, V23, P1441, DOI 10.1016/j.cellsig.2011.05.003
   Imai K, 2017, NUTRIENTS, V9, DOI 10.3390/nu9101054
   Khan A, 2016, INT J HEPATOL, V2016, DOI 10.1155/2016/6741754
   Kim Y, 2018, APPL PHYSIOL NUTR ME, V43, P165, DOI 10.1139/apnm-2017-0272
   Kobayashi Y, 2017, INTERNAL MED, V56, P755, DOI 10.2169/internalmedicine.56.7796
   Lazaridis KN, 2015, MAYO CLIN PROC, V90, P791, DOI 10.1016/j.mayocp.2015.03.017
   Li TG, 2015, CURR OPIN GASTROEN, V31, P159, DOI 10.1097/MOG.0000000000000156
   Liedtke C, 2013, FIBROGENESIS TISSUE, V6, DOI 10.1186/1755-1536-6-19
   Márquez-Miranda V, 2017, INT J NANOMED, V12, P1985, DOI 10.2147/IJN.S125521
   Mastrocola R, 2008, FREE RADICAL BIO MED, V44, P584, DOI 10.1016/j.freeradbiomed.2007.10.047
   McClung JM, 2007, AM J RESP CRIT CARE, V175, P150, DOI 10.1164/rccm.200601-142OC
   Meneses C, 2015, PFLUG ARCH EUR J PHY, V467, P1975, DOI 10.1007/s00424-014-1617-9
   Miras AD, 2014, OBESITY FACTS, V7, P302, DOI 10.1159/000368622
   Montano-Loza AJ, 2012, CLIN GASTROENTEROL H, V10, P166, DOI 10.1016/j.cgh.2011.08.028
   Muñoz-Cánoves P, 2013, FEBS J, V280, P4131, DOI 10.1111/febs.12338
   Nikam A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066094
   Pette D, 2000, MICROSC RES TECHNIQ, V50, P500, DOI 10.1002/1097-0029(20000915)50:6<500::AID-JEMT7>3.0.CO;2-7
   Pomiès P, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0160092
   Ponziani FR, 2018, CURR PROTEIN PEPT SC, V19, P681, DOI 10.2174/1389203718666170428121647
   Powers SK, 2007, J APPL PHYSIOL, V102, P2389, DOI 10.1152/japplphysiol.01202.2006
   Powers SK, 2016, FREE RADICAL BIO MED, V98, P208, DOI 10.1016/j.freeradbiomed.2016.02.021
   Powers SK, 2010, EXP PHYSIOL, V95, P1, DOI 10.1113/expphysiol.2009.050526
   Powers SK, 2005, AM J PHYSIOL-REG I, V288, pR337, DOI 10.1152/ajpregu.00469.2004
   Qiu J, 2013, P NATL ACAD SCI USA, V110, P18162, DOI 10.1073/pnas.1317049110
   Qiu J, 2012, AM J PHYSIOL-ENDOC M, V303, pE983, DOI 10.1152/ajpendo.00183.2012
   Rom O, 2015, ADV EXP MED BIOL, V832, P1, DOI 10.1007/5584_2014_9
   Rom O, 2016, FREE RADICAL BIO MED, V98, P218, DOI 10.1016/j.freeradbiomed.2015.12.031
   Rossi Paola, 2008, Curr Aging Sci, V1, P182
   Scicchitano BM, 2018, MECH AGEING DEV, V170, P37, DOI 10.1016/j.mad.2017.08.009
   Shiraki M, 2013, HEPATOL RES, V43, P106, DOI 10.1111/hepr.12004
   Sinclair M, 2016, ALIMENT PHARM THER, V43, P765, DOI 10.1111/apt.13549
   Späte U, 2004, CURR OPIN CLIN NUTR, V7, P265, DOI 10.1097/01.mco.0000126344.88494.de
   Takeda K, 2015, PHYSIOL REP, V3, DOI 10.14814/phy2.12596
   Tandon P, 2012, LIVER TRANSPLANT, V18, P1209, DOI 10.1002/lt.23495
   TILG H, 1992, GASTROENTEROLOGY, V103, P264, DOI 10.1016/0016-5085(92)91122-K
   Tilg H, 2001, CAN J GASTROENTEROL, V15, P661, DOI 10.1155/2001/746736
   Toshikuni N, 2014, WORLD J GASTROENTERO, V20, P7286, DOI 10.3748/wjg.v20.i23.7286
   Wang CW, 2016, TRANSPLANTATION, V100, P1692, DOI 10.1097/TP.0000000000001232
   Watanabe M, 2006, NATURE, V439, P484, DOI 10.1038/nature04330
   Zhou J, 2016, TRENDS ENDOCRIN MET, V27, P335, DOI 10.1016/j.tem.2016.03.002
NR 80
TC 26
Z9 27
U1 0
U2 14
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0031-6768
EI 1432-2013
J9 PFLUG ARCH EUR J PHY
JI Pflugers Arch.
PD OCT
PY 2018
VL 470
IS 10
BP 1503
EP 1519
DI 10.1007/s00424-018-2167-3
PG 17
WC Physiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Physiology
GA GT5UX
UT WOS:000444576600008
PM 29926227
DA 2024-02-19
ER

PT J
AU Vougier, S
   Mary, J
   Friguet, B
AF Vougier, S
   Mary, J
   Friguet, B
TI Subcellular localization of methionine sulphoxide reductase A (MsrA):
   evidence for mitochondrial and cytosolic isoforms in rat liver cells
SO BIOCHEMICAL JOURNAL
LA English
DT Article
DE isoform; methionine sulphoxide reductase; post-translational
   modification; protein oxidation
ID IN-VIVO; ESCHERICHIA-COLI; OXIDATIVE STRESS; PROTEIN IMPORT;
   ACTIVE-SITE; ACCUMULATION; EXPRESSION; GENE; PEROXIREDOXINS;
   OVEROXIDATION
AB Proteins are sensitive to reactive oxygen species, and the accumulation of oxidized proteins has been implicated in the aging process and in other age-related pathologies. In proteins, methionine residues are especially sensitive to oxidation, leading to S- and R-methionine sulphoxide diastereoisomers, the reversion of which is achieved by the peptide methionine sulphoxide reductases MsrA and MsrB respectively. The MsrA enzyme, in addition to its role in repair, forms part of the reactive oxygen species scavenging systems that are important in cellular antioxidant defence. MsrA is present in most living organisms, and the mammalian enzyme has been detected in all tissues investigated. In the present study, we investigated the subcellular distribution of MsrA in rat liver cells. Since it seemed likely that MsrA may be localized in areas where reactive oxygen species are produced, rat liver mitochondrial matrix and cytosolic extracts were prepared. The presence of MsrA was assayed in these subcellular compartments by monitoring peptide methionine sulphoxide reductase enzymic activity, by Western blotting and by in situ immunolocalization by electron microscopy using a specific antibody. Moreover, MsrA was identified by MS in a partially purified cytosolic fraction and in a mitochondrial matrix crude extract. Rat MsrA isoforms are encoded by a single gene, and it is suggested that the precursor of the mitochondrial form contains an N-terminal cleavable signal sequence that localizes the MsrA to this organelle. Finally, two-dimensional gel electrophoresis followed by Western-blot analysis of partially purified MsrA from the cytosol and mitochondria, and comparison with the two-dimensional patterns of oxidized recombinant MsrA, revealed oxidative modifications of cysteine residues.
C1 Univ Denis Diderot Paris 7, Lab Biol & Biochim Cellulaire Vieillissement, F-75251 Paris 05, France.
C3 Universite Paris Cite
RP Friguet, B (corresponding author), Univ Denis Diderot Paris 7, Lab Biol & Biochim Cellulaire Vieillissement, CC 7128,2 Pl Jussieu, F-75251 Paris 05, France.
RI Mary, Jean/H-2344-2011
OI Mary, Jean/0000-0002-2438-8383
CR ABRAMS WR, 1981, P NATL ACAD SCI-BIOL, V78, P7483, DOI 10.1073/pnas.78.12.7483
   APRILLE JR, 1980, ARCH BIOCHEM BIOPHYS, V201, P564, DOI 10.1016/0003-9861(80)90546-9
   BOHNI PC, 1983, J BIOL CHEM, V258, P4937
   COURCHESNESMITH C, 1992, ARCH BIOCHEM BIOPHYS, V298, P576, DOI 10.1016/0003-9861(92)90452-3
   Davis DA, 2000, BIOCHEM J, V346, P305, DOI 10.1042/0264-6021:3460305
   EJIRI SI, 1980, ANAL BIOCHEM, V102, P393, DOI 10.1016/0003-2697(80)90173-6
   Etienne F, 2003, BIOCHEM BIOPH RES CO, V300, P378, DOI 10.1016/S0006-291X(02)02870-X
   Gabbita SP, 1999, J NEUROCHEM, V73, P1660, DOI 10.1046/j.1471-4159.1999.0731660.x
   GARNER MH, 1980, P NATL ACAD SCI-BIOL, V77, P1274, DOI 10.1073/pnas.77.3.1274
   Grimaud R, 2001, J BIOL CHEM, V276, P48915, DOI 10.1074/jbc.M105509200
   Grune T, 1997, FASEB J, V11, P526, DOI 10.1096/fasebj.11.7.9212076
   Hansel A, 2002, FASEB J, V16, P911, DOI 10.1096/fj.01-0737fje
   HAWLITSCHEK G, 1988, CELL, V53, P795, DOI 10.1016/0092-8674(88)90096-7
   HURT EC, 1984, FEBS LETT, V178, P306, DOI 10.1016/0014-5793(84)80622-5
   Jung S, 2002, FEBS LETT, V527, P91, DOI 10.1016/S0014-5793(02)03171-X
   Kryukov GV, 2002, P NATL ACAD SCI USA, V99, P4245, DOI 10.1073/pnas.072603099
   Kumar RA, 2002, J BIOL CHEM, V277, P37527, DOI 10.1074/jbc.M203496200
   Kuschel L, 1999, FEBS LETT, V456, P17, DOI 10.1016/S0014-5793(99)00917-5
   Lescure A, 1999, J BIOL CHEM, V274, P38147, DOI 10.1074/jbc.274.53.38147
   Levine RL, 1996, P NATL ACAD SCI USA, V93, P15036, DOI 10.1073/pnas.93.26.15036
   Levine RL, 1999, MECH AGEING DEV, V107, P323, DOI 10.1016/S0047-6374(98)00152-3
   Moskovitz J, 1997, P NATL ACAD SCI USA, V94, P9585, DOI 10.1073/pnas.94.18.9585
   MOSKOVITZ J, 1995, J BACTERIOL, V177, P502, DOI 10.1128/jb.177.3.502-507.1995
   Moskovitz J, 2001, P NATL ACAD SCI USA, V98, P12920, DOI 10.1073/pnas.231472998
   Neupert W, 1997, ANNU REV BIOCHEM, V66, P863, DOI 10.1146/annurev.biochem.66.1.863
   PACIFICI RE, 1989, FREE RADICAL BIO MED, V7, P521, DOI 10.1016/0891-5849(89)90028-2
   Petropoulos I, 2001, BIOCHEM J, V355, P819, DOI 10.1042/bj3550819
   Rabilloud T, 2002, J BIOL CHEM, V277, P19396, DOI 10.1074/jbc.M106585200
   RIVETT AJ, 1985, J BIOL CHEM, V260, P300
   Ruan H, 2002, P NATL ACAD SCI USA, V99, P2748, DOI 10.1073/pnas.032671199
   Sadanandom A, 2000, PLANT PHYSIOL, V123, P255, DOI 10.1104/pp.123.1.255
   Sass E, 2001, J BIOL CHEM, V276, P46111, DOI 10.1074/jbc.M106061200
   Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h
   Stuart RA, 1996, TRENDS BIOCHEM SCI, V21, P261, DOI 10.1016/0968-0004(96)10035-9
   SUZUKI T, 1989, J BIOL CHEM, V264, P2581
   Verbeke P, 1997, J HISTOCHEM CYTOCHEM, V45, P1059, DOI 10.1177/002215549704500804
   Wagner E, 2002, BIOCHEM J, V366, P777, DOI 10.1042/BJ20020525
   Weissbach H, 2002, ARCH BIOCHEM BIOPHYS, V397, P172, DOI 10.1006/abbi.2001.2664
   Yin D, 2000, CHEM RES TOXICOL, V13, P103, DOI 10.1021/tx990142a
NR 39
TC 92
Z9 96
U1 0
U2 8
PU PORTLAND PRESS
PI LONDON
PA 59 PORTLAND PLACE, LONDON W1N 3AJ, ENGLAND
SN 0264-6021
J9 BIOCHEM J
JI Biochem. J.
PD JUL 15
PY 2003
VL 373
BP 531
EP 537
DI 10.1042/BJ20030443
PN 2
PG 7
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 705HR
UT WOS:000184390100022
PM 12693988
OA Green Published
DA 2024-02-19
ER

PT J
AU Mladenov, M
   Tanska, V
   Vitkovska, T
   Gjorgoski, I
   Dinevska-Kofkarovska, S
   Stafilov, T
   Hristov, K
   Duridanova, D
AF Mladenov, Mitko
   Tanska, Vase
   Vitkovska, Tanja
   Gjorgoski, Icko
   Dinevska-Kofkarovska, Suzana
   Stafilov, Trajce
   Hristov, Kiril
   Duridanova, Desislava
TI Evidence for the influence of vitamin C on age- and heat
   exposure-dependent deterioration of biochemical function in rat's liver
   and kidney
SO JOURNAL OF THERMAL BIOLOGY
LA English
DT Article
DE Vitamin C; Aging; Heat exposure; Liver; Kidney; Rats
ID ASCORBIC-ACID; LIPID-PEROXIDATION; GLUTATHIONE; METABOLISM; STRESS;
   PLASMA; BLOOD
AB Molecular mechanisms responsible for age-dependent deterioration of biochemical functions have not been completely revealed as yet. We studied the role of ascorbic acid food supplementation in young and aged acute heat-exposed rats. The duration of heat exposure(40 +/- 0.5 degrees C) for heat-exposed Wistar rats, at the age of 35 days and 22-24 months, was approximately 2 h. In the aged heat-unexposed animals cholesterol and triglycerides were considerably high, whereas tissues ascorbic acid, glutathione and methylglyoxal were significantly low. Administration of vitamin C reverted these age-associated differences to the status comparable to young rats. The role of vitamin C supplementation was almost the same in young heat-exposed animals. In this direction in young rats suppression of LTC4 synthesis is evident during acute heat exposure as a result of vitamin C treatment. The importance of vitamin C treatment for young heat-exposed rats is in the protection of apoptosis, if it is determined across the LTC4 changes. In contrary, in old heat-exposed rats, vitamin C does not suppress the apoptotic processes. The results suggest that oxidative and apoptotic processes in the liver and the kidney as a result of the acute heat exposure is presumably subject of ascorbic acid deficiency. (c) 2008 Elsevier Ltd. All rights reserved.
C1 [Mladenov, Mitko; Tanska, Vase; Vitkovska, Tanja; Gjorgoski, Icko; Dinevska-Kofkarovska, Suzana] Sts Cyril & Methodius Univ, Fac Nat Sci & Math, Inst Biol, Skopje 1000, North Macedonia.
   [Stafilov, Trajce] Sts Cyril & Methodius Univ, Fac Nat Sci & Math, Inst Chem, Dept Analyt Chem, Skopje 1000, North Macedonia.
   [Hristov, Kiril; Duridanova, Desislava] Bulgarian Acad Sci, Inst Biophys, Dept Membrane Ion Channels, Sofia 1113, Bulgaria.
C3 Saints Cyril & Methodius University of Skopje; Saints Cyril & Methodius
   University of Skopje; Bulgarian Academy of Sciences
RP Mladenov, M (corresponding author), Sts Cyril & Methodius Univ, Fac Nat Sci & Math, Inst Biol, POB 162, Skopje 1000, North Macedonia.
EM mitkom@iunona.pmf.ukim.edu.mk
RI Mladennov, Mitko/HDM-7959-2022; Stafilov, Trajce/AAK-2378-2021
OI Mladennov, Mitko/0000-0003-3475-2131; Stafilov,
   Trajce/0000-0002-9017-6768
FU Ministry of Education and Research of Macedonia.
FX The authors wish to thank D-r. Hristo Gagov from Biological Faculty in
   Sofia for assistance with manuscript preparation. The authors gratefully
   acknowledge the financial support from the Ministry of Education and
   Research of Macedonia. The Biological Institute in the Faculty of
   Natural Sciences at the University "St Cyril and Methodius" in Skopje
   also supported this research.
CR Aoshiba K, 1999, AM J RESP CELL MOL, V21, P54, DOI 10.1165/ajrcmb.21.1.3411
   GAWEHN K, 1980, METHOD ENZYMOL, V41, P593
   GRIFFITH OW, 1980, ANAL BIOCHEM, V106, P207, DOI 10.1016/0003-2697(80)90139-6
   HA TY, 1994, J NUTR, V124, P732, DOI 10.1093/jn/124.5.732
   HA TY, 1994, J NUTR SCI, V37, P371
   Hall DM, 2001, AM J PHYSIOL-HEART C, V280, pH509, DOI 10.1152/ajpheart.2001.280.2.H509
   Hall DM, 2000, J APPL PHYSIOL, V89, P749, DOI 10.1152/jappl.2000.89.2.749
   HOLLOWAY DE, 1981, J NUTR, V111, P412, DOI 10.1093/jn/111.3.412
   HORNSBY PJ, 1983, MOL CELL ENDOCRINOL, V30, P1, DOI 10.1016/0303-7207(83)90197-1
   Kawase M, 1995, MECH AGEING DEV, V84, P55, DOI 10.1016/0047-6374(95)01632-A
   KIMURA H, 1992, J NUTR, V122, P1904, DOI 10.1093/jn/122.9.1904
   KOTZE JP, 1974, S AFR MED J, V48, P511
   KREGEL KC, 1995, J APPL PHYSIOL, V79, P1673, DOI 10.1152/jappl.1995.79.5.1673
   LOWRY OH, 1951, J BIOL CHEM, V193, P265
   MEISTER A, 1994, J BIOL CHEM, V269, P9397
   MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431
   Mladenov M, 2006, J THERM BIOL, V31, P588, DOI 10.1016/j.jtherbio.2006.08.001
   Omaye S. T., 1979, METHOD ENZYMOL, P3, DOI [DOI 10.1016/0076-6879(79)62181-X, 10.1016/0076-6879(79)62181-X, 10.1016/0076-6879(79)62181-x]
   OWENS CWI, 1965, BIOCHEM J, V94, P705, DOI 10.1042/bj0940705
   SHARMALUTHRA R, 1994, MECH AGEING DEV, V73, P39, DOI 10.1016/0047-6374(94)90036-1
   TIETZE F, 1969, ANAL BIOCHEM, V27, P502, DOI 10.1016/0003-2697(69)90064-5
   TURLEY SD, 1976, ATHEROSCLEROSIS, V24, P1, DOI 10.1016/0021-9150(76)90060-5
   WEFERS H, 1988, EUR J BIOCHEM, V174, P353, DOI 10.1111/j.1432-1033.1988.tb14105.x
   Zhang HJ, 2003, FASEB J, V17, P2293, DOI 10.1096/fj.03-0139fje
NR 24
TC 8
Z9 8
U1 0
U2 3
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0306-4565
J9 J THERM BIOL
JI J. Therm. Biol.
PD DEC
PY 2008
VL 33
IS 8
BP 431
EP 436
DI 10.1016/j.jtherbio.2008.07.001
PG 6
WC Biology; Zoology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Life Sciences & Biomedicine - Other Topics; Zoology
GA 386PL
UT WOS:000261895000002
DA 2024-02-19
ER

PT J
AU Duffy, PH
   Seng, JE
   Lewis, SM
   Mayhugh, MA
   Aidoo, A
   Hattan, DG
   Casciano, DA
   Feuers, RJ
AF Duffy, PH
   Seng, JE
   Lewis, SM
   Mayhugh, MA
   Aidoo, A
   Hattan, DG
   Casciano, DA
   Feuers, RJ
TI The effects of different levels of dietary restriction on aging and
   survival in the Sprague-Dawley rat: Implications for chronic studies
SO AGING-CLINICAL AND EXPERIMENTAL RESEARCH
LA English
DT Article
DE aging; chronic; dietary restriction; survival; rat
ID CHRONIC CALORIC RESTRICTION; FISCHER-344 RATS; MAMMARY-TUMORS;
   PATHOLOGY; TOXICITY; VARIABILITY; VARIABLES; MICE
AB A study was undertaken to determine the effects of incremental levels of dietary restriction (DR) in rats. Survival, growth, reproductive, and dietary intake (DI) variables were monitored in a chronic study in which male Sprague Dawley (SD) rats (NCTR colony) were fed their ration ad libitum (AL), or DR. The main objectives were to determine if low levels of DR could be used to increase the survival rate of SD rats in the chronic bioassay, and to identify the survival characteristics of a long-lived SD rat strain (NCTR colony). The average life span of AL rats was 115 months. At 104 weeks on study (110 weeks of age), the survival rate for the AL and 10%, 25%, and 40% DR groups was 63.4, 87.5, 87.5, and 97.5%, respectively. The largest increase in survival (24.1%) occurred between AL and 10% DR, indicating that very low levels of DR have a significant effect on survival. Whole-body, liver, prostate, and epididymis weights and body length were decreased by DR, whereas brain weight, testicular weight, and skull length were not altered by DR. Rats from the NCTR colony were found to be ideal for chronic studies because they are much longer-lived than other SD stocks. Although the 104-week survival rate for these SD, non-obese AL rats exceeds the FDA's "Redbook" survival guideline (> 50%) for chronic bioassays, the use of DR is advocated because it reduces individual variability in body weight. (C) 2001, Editrice Kurtis.
C1 US FDA, Natl Ctr Toxicol Res, Div Genet & Reprod Toxicol, Jefferson, AR 72079 USA.
C3 US Food & Drug Administration (FDA)
RP Duffy, PH (corresponding author), US FDA, Natl Ctr Toxicol Res, Div Genet & Reprod Toxicol, 3900 NCTR Rd, Jefferson, AR 72079 USA.
CR Allaben WT, 1996, TOXICOL PATHOL, V24, P776, DOI 10.1177/019262339602400622
   BERG TF, 1994, FOOD CHEM TOXICOL, V32, P45, DOI 10.1016/0278-6915(84)90035-8
   CHAPIN RE, 1993, FUND APPL TOXICOL, V20, P23, DOI 10.1006/faat.1993.1003
   Christian MS, 1998, DRUG CHEM TOXICOL, V21, P97, DOI 10.3109/01480549809017854
   DUFFY PH, 1990, CHRONOBIOL INT, V7, P291, DOI 10.3109/07420529009064635
   DUFFY PH, 1989, MECH AGEING DEV, V48, P117, DOI 10.1016/0047-6374(89)90044-4
   DUFFY PH, 1995, DIETARY RESTRICTION, P127
   HART RW, 1995, FUND APPL TOXICOL, V25, P184, DOI 10.1006/faat.1995.1054
   KEENAN KP, 1994, TOXICOL PATHOL, V22, P300, DOI 10.1177/019262339402200308
   Keenan KP, 1997, J NUTR, V127, pS851, DOI 10.1093/jn/127.5.851S
   KEENAN KP, 1992, CTR MED RES WORKSH C, P77
   KRITCHEVSKY D, 1984, CANCER RES, V44, P3174
   Laroque P, 1997, EXP TOXICOL PATHOL, V49, P459, DOI 10.1016/S0940-2993(97)80135-2
   MAEDA H, 1985, J GERONTOL, V40, P671, DOI 10.1093/geronj/40.6.671
   MASORO EJ, 1988, AGING LIVER GASTROIN, P49
   MCCARTER RJ, 1992, AM J PHYSIOL, V263, pE448, DOI 10.1152/ajpendo.1992.263.3.E448
   McCay CM, 1935, J NUTR, V10, P63, DOI 10.1093/jn/10.1.63
   Mokdad AH, 1999, JAMA-J AM MED ASSOC, V282, P1519, DOI 10.1001/jama.282.16.1519
   RAO GN, 1988, J NUTR, V118, P929, DOI 10.1093/jn/118.8.929
   ROSS M, 1976, NUTR AGING, P23
   RUGGERI BA, 1987, BIOCHIM BIOPHYS ACTA, V929, P239, DOI 10.1016/0167-4889(87)90249-7
   SARKAR NH, 1982, P NATL ACAD SCI-BIOL, V79, P7758, DOI 10.1073/pnas.79.24.7758
   Seng JE, 1998, LAB ANIMAL, V27, P35
   TANNENBAUM A, 1945, CANCER RES, V5, P609
   TARONE RE, 1975, BIOMETRIKA, V62, P679
   Turturro A, 1996, TOXICOL PATHOL, V24, P769, DOI 10.1177/019262339602400621
   WEINDRUCH R, 1988, RETARDATION AGING DI, P179
   WILLIAMS SR, 1997, NUTR DIET THERAPY, P416
   [No title captured]
NR 29
TC 54
Z9 57
U1 0
U2 2
PU EDITRICE KURTIS S R L
PI MILAN
PA VIA LUIGI ZOJA 30, 20153 MILAN, ITALY
SN 0394-9532
J9 AGING-CLIN EXP RES
JI Aging-Clin. Exp. Res.
PD AUG
PY 2001
VL 13
IS 4
BP 263
EP 272
PG 10
WC Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Geriatrics & Gerontology
GA 478JM
UT WOS:000171343300002
PM 11695495
DA 2024-02-19
ER

PT J
AU Trivedi, MK
   Mondal, S
   Gangwar, M
   Jana, S
AF Trivedi, Mahendra Kumar
   Mondal, Sambhu
   Gangwar, Mayank
   Jana, Snehasis
TI Effects of Cannabidiol Interactions with <i>CYP2R1, CYP27B1,
   CYP24A1,</i> and Vitamin D<sub>3</sub> Receptors on Spatial Memory,
   Pain, Inflammation, and Aging in Vitamin D<sub>3</sub> Deficiency
   Diet-Induced Rats
SO CANNABIS AND CANNABINOID RESEARCH
LA English
DT Article; Early Access
DE cannabidiol; CYP-450-mRNA; Morris water maze; VDR; vitamin D-3
   deficiency diet; vitamin D-3 metabolites
ID MULTIPLE-SCLEROSIS; DOUBLE-BLIND; CANNABINOIDS; EXPRESSION; SYMPTOMS;
   EPILEPSY; SEIZURES; HEALTH; MODEL; TRIAL
AB Introduction: The study was planned to investigate memory-enhancing, anti-inflammatory, and antiaging potential of cannabidiol (CBD) on vitamin D-3 deficient diet (VDD)-induced rats.Materials and Methods: Cytochrome P-450 enzymes were analyzed by RT-PCR method and others biomarkers by enzyme-linked immunosorbent assay.Results: CYP2R1 and CYP27B1-mRNA were significantly increased by 39.29 and 38.37%, respectively, while; CYP24A1-mRNA was significantly reduced by 21.39% compared to VDD. Vitamin D-3 receptor protein expression was significantly increased by 148.3%, 60.48%, and 142.03% in liver, kidney, and brain, respectively, compared to VDD group. Vitamin D-3 metabolites and serotonin were significantly increased more than 60% and 100%, respectively, compared to VDD. Spatial memory (in terms of total distance, escape latency) and pain score were improved compared to VDD. Cytokines were significantly reduced than VDD. Besides, levels of superoxide dismutase (49.61%), glutathione peroxidase (178.87%), acetylcholine (25.40%), and klotho (145.57%) were significantly increased than VDD.Conclusions: Study findings supported that CBD interacts with CYP2R1, CYP27B1, CYP24A1, and vitamin D receptors, resulting in increased vitamin D-3 metabolites, which improved memory, pain tolerance, reduced inflammation, and aging through modulating antioxidative enzymes, cytokines, and neurotransmitters in VDD-induced rats.
C1 [Trivedi, Mahendra Kumar] Trivedi Global Inc, Henderson, NV USA.
   [Mondal, Sambhu; Gangwar, Mayank; Jana, Snehasis] Trivedi Sci Res Lab Pvt Ltd, Thana, India.
   [Jana, Snehasis] Trivedi Sci Res Lab Pvt Ltd, Thana 400604, India.
RP Jana, S (corresponding author), Trivedi Sci Res Lab Pvt Ltd, Thana, India.; Jana, S (corresponding author), Trivedi Sci Res Lab Pvt Ltd, Thana 400604, India.
EM publication@trivedisrl.com
RI Mondal, sambhu/GQI-1020-2022; Trivedi, Mahendra/J-4219-2015
OI Trivedi, Mahendra/0000-0002-2548-780X
FU Dabur Research Foundation, India
FX The authors extend their sincere thanks and gratitude to Dabur Research
   Foundation, India, for providing the facilities and support that enabled
   the successful completion of the work.
CR Amini M, 2022, NEUROPSYCHOBIOLOGY, V81, P171, DOI 10.1159/000519534
   Anderson PH, 2003, J MOL ENDOCRINOL, V31, P123, DOI 10.1677/jme.0.0310123
   Atalay S, 2020, ANTIOXIDANTS-BASEL, V9, DOI 10.3390/antiox9010021
   Barton NJ, 2007, J NEUROSCI METH, V163, P67, DOI 10.1016/j.jneumeth.2007.02.012
   Bergamaschi MM, 2011, NEUROPSYCHOPHARMACOL, V36, P1219, DOI 10.1038/npp.2011.6
   Davies C, 2019, THER ADV PSYCHOPHARM, V9, DOI 10.1177/2045125319881916
   Devinsky O, 2016, LANCET NEUROL, V15, P270, DOI 10.1016/S1474-4422(15)00379-8
   Di Somma C, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18112482
   Fang, 2014, POLYPHARMACOLOGY ANA
   Guida F, 2020, BRAIN BEHAV IMMUN, V85, P128, DOI 10.1016/j.bbi.2019.04.006
   Hammell DC, 2016, EUR J PAIN, V20, P936, DOI 10.1002/ejp.818
   Hirose A, 2016, BIOL PHARM BULL, V39, P1955, DOI 10.1248/bpb.b16-00402
   Hossein-nezhad A, 2013, MAYO CLIN PROC, V88, P720, DOI 10.1016/j.mayocp.2013.05.011
   Iffland K, 2017, CANNABIS CANNABINOID, V2, P139, DOI 10.1089/can.2016.0034
   Ighodaro OM, 2018, ALEX J MED, V54, P287, DOI 10.1016/j.ajme.2017.09.001
   Jensen Troels S, 2014, Lancet Neurol, V13, P924, DOI 10.1016/S1474-4422(14)70102-4
   Kaplan JS, 2017, P NATL ACAD SCI USA, V114, P11229, DOI 10.1073/pnas.1711351114
   Knuth MM, 2021, J LIPID RES, V62, DOI 10.1016/j.jlr.2021.100142
   Li H, 2020, EUR J MED CHEM, V192, DOI 10.1016/j.ejmech.2020.112163
   Maguire Ryan F, 2021, Med Cannabis Cannabinoids, V4, P86, DOI 10.1159/000517120
   Meehan Meghan, 2014, J Aging Gerontol, V2, P60
   MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4
   Murillo-Rodríguez E, 2018, NEUROCHEM RES, V43, P1511, DOI 10.1007/s11064-018-2565-0
   National Center for Biotechnology Information, 2021, PUBCHEM GEN SUMM GEN
   Osborne AL, 2017, NEUROSCI BIOBEHAV R, V72, P310, DOI 10.1016/j.neubiorev.2016.11.012
   Ozarowski M, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22094294
   Pertwee RG, 2008, BRIT J PHARMACOL, V153, P199, DOI 10.1038/sj.bjp.0707442
   Petrescu NB, 2020, MEDICINA-LITHUANIA, V56, DOI 10.3390/medicina56110607
   Pocuca N, 2021, ARCH CLIN NEUROPSYCH, V36, P673, DOI 10.1093/arclin/acaa105
   Pretzsch CM, 2019, TRANSL PSYCHIAT, V9, DOI 10.1038/s41398-019-0654-8
   Ritu G, 2014, NUTRIENTS, V6, P729, DOI 10.3390/nu6020729
   Rog DJ, 2005, NEUROLOGY, V65, P812, DOI 10.1212/01.wnl.0000176753.45410.8b
   Russo EB, 2005, NEUROCHEM RES, V30, P1037, DOI 10.1007/s11064-005-6978-1
   Russo Ethan B, 2008, Ther Clin Risk Manag, V4, P245
   Shinki T, 1997, P NATL ACAD SCI USA, V94, P12920, DOI 10.1073/pnas.94.24.12920
   Shipton EE, 2015, PAIN THER, V4, P67, DOI 10.1007/s40122-015-0036-8
   Sultan Sadia, 2020, J Aging Res, V2020, P6097820, DOI 10.1155/2020/6097820
   Thiele EA, 2018, LANCET, V391, P1085, DOI 10.1016/S0140-6736(18)30136-3
   TRIPATHI HL, 1987, ALCOHOL DRUG RES, V7, P525
   Wade DT, 2004, MULT SCLER, V10, P434, DOI 10.1191/1352458504ms1082oa
   Wright MJ, 2013, BRIT J PHARMACOL, V170, P1365, DOI 10.1111/bph.12199
   Yarar Erhan, 2021, Med Cannabis Cannabinoids, V4, P1, DOI 10.1159/000511979
   Zajicek J, 2003, LANCET, V362, P1517, DOI 10.1016/S0140-6736(03)14738-1
   Zhang R, 2010, NUTR J, V9, DOI 10.1186/1475-2891-9-65
   Zhu JG, 2013, P NATL ACAD SCI USA, V110, P15650, DOI 10.1073/pnas.1315006110
NR 45
TC 4
Z9 4
U1 1
U2 6
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 2578-5125
EI 2378-8763
J9 CANNABIS CANNABINOID
JI Cannabis Cannabinoid Res.
PD 2023 DEC 1
PY 2023
VL 8
IS 6
BP 1019
EP 1029
DI 10.1089/can.2021.0240
EA APR 2022
PG 11
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA AA3I7
UT WOS:000791320900001
PM 35443806
DA 2024-02-19
ER

PT J
AU Nakamoto, H
   Kaneko, T
   Tahara, S
   Hayashi, E
   Naito, H
   Radak, Z
   Goto, S
AF Nakamoto, Hideko
   Kaneko, Takao
   Tahara, Shoichi
   Hayashi, Eri
   Naito, Hisashi
   Radak, Zsolt
   Goto, Sataro
TI Regular exercise reduces 8-oxodG in the nuclear and mitochondrial DNA
   and modulates the DNA repair activity in the liver of old rats
SO EXPERIMENTAL GERONTOLOGY
LA English
DT Article
DE aging; liver; regular exercise; DNA oxidation; 8-oxodG; DNA repair;
   OGG1; nucleus; mitochondria
ID OXIDATIVE STRESS; DIETARY RESTRICTION; FREE-RADICALS; DAMAGE; AGE;
   SKELETAL; INCREASE; CANCER; PREVENTION; OXIDANTS
AB Exercise is often said to increase the generation of reactive oxygen species that are potentially harmful. On the other hand, regular exercise has various health benefits even late in life. The specific aim of this study was to explore effects of regular exercise on oxidative status of DNA in aged animals. We report that 2 months of regular treadmill running of aged rats (21 month old) significantly reduced 8-oxodG content to the level of young adult animals (11 month old) in both nuclear and mitochondrial DNA of the liver. The mitochondrial DNA showed 10-fold higher content of the oxidative lesion than the nuclear DNA. The levels in old animals were 2- and 1.5-fold higher than that in young adults for the nucleus and mitochondria, respectively. The activity of the repair enzyme OGG1 was upregulated significantly in the nucleus but not in mitochondria by the exercise. To our knowledge, this is the first report demonstrating that regular exercise can reduce significantly oxidative damage to both the nuclear and mitochondrial DNA. We suggest that the apparent beneficial outcomes in reducing the DNA damage by regular exercise can be interpreted in terms of hormetic effect by moderate oxidative stress and potential adaptation to stronger stresses. (c) 2006 Elsevier Inc. All rights reserved.
C1 Toho Univ, Fac Pharmaceut Sci, Dept Biochem, Funabashi, Chiba 2748510, Japan.
   Tokyo Metropolitan Inst Gerontol, Tokyo, Japan.
   Juntendo Univ, Sch Sports Sci, Dept Sports Physiol, Tokyo, Japan.
   Semmelweis Univ, Sch Sport Sci, Exercise Physiol Lab, H-1085 Budapest, Hungary.
C3 Toho University; Tokyo Metropolitan Institute of Gerontology; Juntendo
   University; Semmelweis University
RP Goto, S (corresponding author), Toho Univ, Fac Pharmaceut Sci, Dept Biochem, Miyama 2-2-1, Funabashi, Chiba 2748510, Japan.
EM goto@phar.toho-u.ac.jp
RI Naito, Hisashi/F-5655-2011; Kaneko, Takao/Q-8779-2019
OI Naito, Hisashi/0000-0002-0522-9512; Radak, Zsolt/0000-0003-1297-6804
CR AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915
   Arumugam TV, 2006, AGEING RES REV, V5, P165, DOI 10.1016/j.arr.2006.03.003
   Bailey DM, 2006, FREE RADICAL BIO MED, V40, P591, DOI 10.1016/j.freeradbiomed.2005.09.024
   Balaban RS, 2005, CELL, V120, P483, DOI 10.1016/j.cell.2005.02.001
   Beckman KB, 1998, PHYSIOL REV, V78, P547, DOI 10.1152/physrev.1998.78.2.547
   BLAIR SN, 1989, JAMA-J AM MED ASSOC, V262, P2395, DOI 10.1001/jama.262.17.2395
   Calabrese EJ, 2006, BIOGERONTOLOGY, V7, P119, DOI 10.1007/s10522-006-0005-z
   Calabrese EJ, 2004, EMBO REP, V5, pS37, DOI 10.1038/sj.embor.7400222
   Cardozo-Pelaez F, 2000, FREE RADICAL BIO MED, V28, P779, DOI 10.1016/S0891-5849(00)00172-6
   CHENG KC, 1992, J BIOL CHEM, V267, P166
   Cooke MS, 2003, FASEB J, V17, P1195, DOI 10.1096/fj.02-0752rev
   DAVIES K J A, 1986, Journal of Free Radicals in Biology and Medicine, V2, P155, DOI 10.1016/S0748-5514(86)80066-6
   DAVIES KJA, 1982, BIOCHEM BIOPH RES CO, V107, P1198, DOI 10.1016/S0006-291X(82)80124-1
   de Souza-Pinto NC, 2001, FREE RADICAL BIO MED, V30, P916, DOI 10.1016/S0891-5849(01)00483-X
   Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687
   Galati G, 2006, FREE RADICAL BIO MED, V40, P570, DOI 10.1016/j.freeradbiomed.2005.09.014
   Ghosh R, 1999, NUCLEIC ACIDS RES, V27, P3213, DOI 10.1093/nar/27.15.3213
   Goto S, 2004, ANN NY ACAD SCI, V1019, P471, DOI 10.1196/annals.1297.085
   Hamilton ML, 2001, P NATL ACAD SCI USA, V98, P10469, DOI 10.1073/pnas.171202698
   HARMAN D, 1972, J AM GERIATR SOC, V20, P145, DOI 10.1111/j.1532-5415.1972.tb00787.x
   HARMAN D, 1956, J GERONTOL, V11, P298, DOI 10.1093/geronj/11.3.298
   Herbert KE, 2006, EUR J NUTR, V45, P97, DOI 10.1007/s00394-005-0569-4
   Hood DA, 2001, J APPL PHYSIOL, V90, P1137, DOI 10.1152/jappl.2001.90.3.1137
   Itoh H, 1998, LIFE SCI, V63, P1921, DOI 10.1016/S0024-3205(98)00468-8
   Jackson AL, 2001, MUTAT RES-FUND MOL M, V477, P7, DOI 10.1016/S0027-5107(01)00091-4
   Ji LL, 2006, ANN NY ACAD SCI, V1067, P425, DOI 10.1196/annals.1354.061
   JI LL, 1993, MED SCI SPORT EXER, V25, P225
   Judge S, 2005, AM J PHYSIOL-REG I, V289, pR1564, DOI 10.1152/ajpregu.00396.2005
   Kaneko T, 2004, FREE RADICAL RES, V38, P839, DOI 10.1080/10715760410001715167
   Klungland A, 1999, P NATL ACAD SCI USA, V96, P13300, DOI 10.1073/pnas.96.23.13300
   Larson EB, 2006, ANN INTERN MED, V144, P73, DOI 10.7326/0003-4819-144-2-200601170-00004
   Loft S, 1996, J MOL MED, V74, P297, DOI 10.1007/s001090050031
   Lombard DB, 2005, CELL, V120, P497, DOI 10.1016/j.cell.2005.01.028
   LOVLIN R, 1987, EUR J APPL PHYSIOL, V56, P313, DOI 10.1007/BF00690898
   Martin GM, 1996, NAT GENET, V13, P25, DOI 10.1038/ng0596-25
   MECOCCI P, 1993, ANN NEUROL, V34, P609, DOI 10.1002/ana.410340416
   Miller ER, 2005, ANN INTERN MED, V142, P37, DOI 10.7326/0003-4819-142-1-200501040-00110
   Nagai M, 2000, BIOGERONTOLOGY, V1, P321, DOI 10.1023/A:1026590819033
   Nishioka K, 1999, MOL BIOL CELL, V10, P1637, DOI 10.1091/mbc.10.5.1637
   Ogonovszky H, 2005, NEUROCHEM INT, V46, P635, DOI 10.1016/j.neuint.2005.02.009
   Poulsen HE, 1999, P NUTR SOC, V58, P1007, DOI 10.1017/S0029665199001329
   Poulsen HE, 1996, J SPORT SCI, V14, P343, DOI 10.1080/02640419608727720
   Radak Z, 2005, BIOGERONTOLOGY, V6, P71, DOI 10.1007/s10522-004-7386-7
   Radák Z, 2004, FASEB J, V18, P749, DOI 10.1096/fj.03-0509fje
   Radák Z, 2001, NEUROCHEM INT, V38, P17, DOI 10.1016/S0197-0186(00)00063-2
   Radák Z, 2003, LIFE SCI, V72, P1627, DOI 10.1016/S0024-3205(02)02476-1
   Radák Z, 2002, PFLUG ARCH EUR J PHY, V445, P273, DOI 10.1007/s00424-002-0918-6
   Radák Z, 1999, FREE RADICAL BIO MED, V27, P69, DOI 10.1016/S0891-5849(99)00038-6
   RATTAN SI, 2005, EMBO REP SPEC, pS25
   Rattan SIS, 2004, J GERONTOL A-BIOL, V59, P705
   Sanz A, 2005, J BIOENERG BIOMEMBR, V37, P83, DOI 10.1007/s10863-005-4131-0
   Sastre J, 2003, FREE RADICAL BIO MED, V35, P1, DOI 10.1016/S0891-5849(03)00184-9
   Sawada SS, 2003, MED SCI SPORT EXER, V35, P1546, DOI 10.1249/01.MSS.0000084525.06473.8E
   Seo AY, 2006, ANTIOXID REDOX SIGN, V8, P529, DOI 10.1089/ars.2006.8.529
   Shephard RJ, 1997, CRIT REV ONCOGENESIS, V8, P219, DOI 10.1615/CritRevOncog.v8.i2-3.40
   Singh MAF, 2002, J GERONTOL A-BIOL, V57, pM262, DOI 10.1093/gerona/57.5.M262
   Slupphaug G, 2003, MUTAT RES-FUND MOL M, V531, P231, DOI 10.1016/j.mrfmmm.2003.06.002
   Souza-Pinto NC, 1999, NUCLEIC ACIDS RES, V27, P1935, DOI 10.1093/nar/27.8.1935
   Szczesny B, 2004, MECH AGEING DEV, V125, P755, DOI 10.1016/j.mad.2004.07.005
   Szczesny B, 2003, P NATL ACAD SCI USA, V100, P10670, DOI 10.1073/pnas.1932854100
   Takao M, 1998, NUCLEIC ACIDS RES, V26, P2917, DOI 10.1093/nar/26.12.2917
   Van Remmen H, 2003, PHYSIOL GENOMICS, V16, P29, DOI 10.1152/physiolgenomics.00122.2003
   Vivekananthan DP, 2003, LANCET, V361, P2017, DOI 10.1016/S0140-6736(03)13637-9
   Vollaard NBJ, 2005, SPORTS MED, V35, P1045, DOI 10.2165/00007256-200535120-00004
   Wang J, 2005, J NEUROCHEM, V93, P953, DOI 10.1111/j.1471-4159.2005.03053.x
   WEINDRUCH R, 1992, EXP GERONTOL, V27, P575, DOI 10.1016/0531-5565(92)90012-O
NR 66
TC 78
Z9 87
U1 0
U2 21
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0531-5565
EI 1873-6815
J9 EXP GERONTOL
JI Exp. Gerontol.
PD APR
PY 2007
VL 42
IS 4
BP 287
EP 295
DI 10.1016/j.exger.2006.11.006
PG 9
WC Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Geriatrics & Gerontology
GA 154AB
UT WOS:000245478100005
PM 17204389
DA 2024-02-19
ER

PT J
AU Koehler, EM
   Plompen, EPC
   Schouten, JNL
   Hansen, BE
   Murad, SD
   Taimr, P
   Leebeek, FWG
   Hofman, A
   Stricker, BH
   Castera, L
   Janssen, HLA
AF Koehler, Edith M.
   Plompen, Elisabeth P. C.
   Schouten, Jeoffrey N. L.
   Hansen, Bettina E.
   Murad, Sarwa Darwish
   Taimr, Pavel
   Leebeek, Frank W. G.
   Hofman, Albert
   Stricker, Bruno H.
   Castera, Laurent
   Janssen, Harry L. A.
TI Presence of diabetes mellitus and steatosis is associated with liver
   stiffness in a general population: The Rotterdam study
SO HEPATOLOGY
LA English
DT Article
ID CHRONIC HEPATITIS-C; FATTY LIVER; TRANSIENT ELASTOGRAPHY; METABOLIC
   SYNDROME; CARDIOVASCULAR-DISEASE; NONINVASIVE ASSESSMENT;
   PORTAL-HYPERTENSION; FIBROSIS ASSESSMENT; CIGARETTE-SMOKING;
   RISK-FACTORS
AB Given that little is known about the prevalence of, and factors associated with, liver fibrosis in the general population, we aimed to investigate this in a large, well-characterized cohort by means of transient elastography (TE). This study was part of the Rotterdam Study, a population-based study among individuals 45 years. All participants underwent abdominal ultrasound and TE. Liver stiffness measurement (LSM) 8.0 kilopascals (kPa) was used as a cutoff suggesting clinically relevant fibrosis. Of 3,041 participants (age, 66.0 +/- 7.6 years) with reliable LSM, 169 (5.6%) participants had LSM 8.0 kPa. Age (odds ratio [OR]: 2.40; 95% confidence interval [CI]: 1.72-3.36; P<0.001), alanine aminotransferase (ALT; OR, 1.24; 95% CI: 1.12-1.38; P<0.001), smoking (OR, 1.77; 95% CI: 1.16-2.70; P=0.008), spleen size (OR, 1.23; 95% CI: 1.09-1.40; P=0.001), hepatitis B surface antigen, or anti-hepatitis C virus positivity (OR, 5.38; 95% CI: 1.60-18.0; P=0.006), and combined presence of diabetes mellitus (DM) and steatosis (OR, 5.20; 95% CI: 3.01-8.98; P<0.001 for combined presence) were associated with LSM 8.0 kPa in multivariable analyses. The adjusted predicted probability of LSM 8.0 kPa increased per age decade, with probabilities ranging from 1.4% (0.9-3.6) in participants ages 50-60 years to 9.9% (6.8-14.5) in participants >80 years. Participants with both DM and steatosis had the highest probabilities of LSM 8.0 kPa (overall probability: 17.2% [12.5-23.4]; this probability did not increase with age [P=0.8]). Conclusion: In this large population-based study of older adults, LSM 8.0 kPa, suggestive of clinically relevant fibrosis, was present in 5.6% and was strongly associated with steatosis and DM. In the context of an aging population and an increased prevalence of DM and obesity, this study illustrates that liver fibrosis may become a more prominent public health issue in the near future. (Hepatology 2016;63:138-147)
C1 [Koehler, Edith M.; Plompen, Elisabeth P. C.; Hansen, Bettina E.; Murad, Sarwa Darwish; Taimr, Pavel; Janssen, Harry L. A.] Erasmus MC Univ Hosp, Dept Gastroenterol & Hepatol, NL-3015 CE Rotterdam, Netherlands.
   [Schouten, Jeoffrey N. L.] Univ Hosp, Dept Gastroenterol & Hepatol, Ghent, Belgium.
   [Hansen, Bettina E.] Erasmus MC Univ Hosp, Dept Publ Hlth, Rotterdam, Netherlands.
   [Leebeek, Frank W. G.] Erasmus MC Univ Hosp, Dept Hematol, Rotterdam, Netherlands.
   [Hofman, Albert; Stricker, Bruno H.] Erasmus MC Univ Hosp, Dept Epidemiol, Rotterdam, Netherlands.
   [Castera, Laurent] Hop Beaujon, Dept Hepatol, Clichy, France.
   [Janssen, Harry L. A.] Univ Hlth Network, Toronto Western & Gen Hosp, Toronto Ctr Liver Dis, Toronto, ON, Canada.
C3 Erasmus University Rotterdam; Erasmus MC; Ghent University; Ghent
   University Hospital; Erasmus University Rotterdam; Erasmus MC; Erasmus
   University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus
   MC; Assistance Publique Hopitaux Paris (APHP); Universite Paris Cite;
   Hopital Universitaire Beaujon - APHP; University of Toronto; University
   Health Network Toronto
RP Murad, SD (corresponding author), Erasmus MC Univ Hosp, Dept Gastroenterol & Hepatol, S Gravendijkwal 230,Room Ha 204, NL-3015 CE Rotterdam, Netherlands.
EM s.darwishmurad@erasmusmc.nl
RI Leebeek, Frank/HJZ-1365-2023; Plompen, Elisabeth PC/P-5461-2014; Murad,
   Sarwa Darwish/AAO-5493-2020
OI Plompen, Elisabeth PC/0000-0003-1284-2398; Murad, Sarwa
   Darwish/0000-0003-2804-1165; Leebeek, Frank/0000-0001-5677-1371;
   Castera, laurent/0000-0002-6715-8588
FU Erasmus MC University Medical Center; Erasmus University Rotterdam;
   Netherlands Organization for Scientific Research (NWO); Netherlands
   Organization for Health Research and Development (ZonMw); Research
   Institute for Diseases in the Elderly (RIDE); Ministry of Education,
   Culture and Science; Ministry of Health, Welfare and Sports; European
   Commission (DG XII); Municipality of Rotterdam; Foundation for Liver
   Research (SLO), Rotterdam, The Netherlands
FX The Rotterdam Study is supported by the Erasmus MC University Medical
   Center and Erasmus University Rotterdam, the Netherlands Organization
   for Scientific Research (NWO), the Netherlands Organization for Health
   Research and Development (ZonMw), the Research Institute for Diseases in
   the Elderly (RIDE), the Ministry of Education, Culture and Science, the
   Ministry of Health, Welfare and Sports, the European Commission (DG
   XII), and by the Municipality of Rotterdam. This study was financially
   supported by the Foundation for Liver Research (SLO), Rotterdam, The
   Netherlands.
CR Adams LA, 2006, J CLIN GASTROENTEROL, V40, pS34
   Adams LA, 2005, GASTROENTEROLOGY, V129, P113, DOI 10.1053/j.gastro.2005.04.014
   Azzalini L, 2010, HEPATOLOGY, V51, P1567, DOI 10.1002/hep.23516
   Bedogni G, 2007, HEPATOLOGY, V46, P1387, DOI 10.1002/hep.21827
   Blachier M, 2013, J HEPATOL, V58, P593, DOI 10.1016/j.jhep.2012.12.005
   Bölükbas FFÖ, 1998, GASTROENTEROLOGY, V114, pA1318
   Boursier J, 2014, J GASTROENTEROL, V49, P527, DOI 10.1007/s00535-013-0819-9
   Boursier J, 2013, HEPATOLOGY, V57, P1182, DOI 10.1002/hep.25993
   Caballería L, 2010, EUR J GASTROEN HEPAT, V22, P24, DOI 10.1097/MEG.0b013e32832fcdf0
   Castera L, 2008, J HEPATOL, V48, P835, DOI 10.1016/j.jhep.2008.02.008
   Castera L, 2012, GASTROENTEROLOGY, V142, P1293, DOI 10.1053/j.gastro.2012.02.017
   Colombo S, 2011, DIGEST LIVER DIS, V43, P231, DOI 10.1016/j.dld.2010.07.008
   CORRAO G, 1994, EUR J EPIDEMIOL, V10, P657, DOI 10.1007/BF01719277
   Dam MK, 2013, SCAND J GASTROENTERO, V48, P585, DOI 10.3109/00365521.2013.777469
   Das K, 2012, HEPATOLOGY, V55, P584, DOI 10.1002/hep.24694
   Dev A, 2006, CLIN GASTROENTEROL H, V4, P797, DOI 10.1016/j.cgh.2006.03.019
   Ekstedt M, 2006, HEPATOLOGY, V44, P865, DOI 10.1002/hep.21327
   El-Zayadi AR, 2006, WORLD J GASTROENTERO, V12, P6098, DOI 10.3748/wjg.v12.i38.6098
   Floreani A, 2007, DIGEST DIS, V25, P138, DOI 10.1159/000099478
   Friedrich-Rust M, 2008, GASTROENTEROLOGY, V134, P960, DOI 10.1053/j.gastro.2008.01.034
   Frith J, 2009, AGE AGEING, V38, P11, DOI 10.1093/ageing/afn242
   Gagliano N, 2002, MECH AGEING DEV, V123, P413, DOI 10.1016/S0047-6374(01)00398-0
   Gaia S, 2011, J HEPATOL, V54, P64, DOI 10.1016/j.jhep.2010.06.022
   Goulding MR, 2003, JAMA-J AM MED ASSOC, V289, P1371
   Grundy SM, 2005, CIRCULATION, V112, P2735, DOI 10.1161/CIRCULATIONAHA.105.169404
   Hamaguchi M, 2007, AM J GASTROENTEROL, V102, P2708, DOI 10.1111/j.1572-0241.2007.01526.x
   Haring R, 2009, HEPATOLOGY, V50, P1403, DOI 10.1002/hep.23135
   Hernaez R, 2011, HEPATOLOGY, V54, P1082, DOI 10.1002/hep.24452
   Heron Melonie, 2013, Natl Vital Stat Rep, V62, P1
   Hézode C, 2003, GUT, V52, P126, DOI 10.1136/gut.52.1.126
   Hoare M, 2010, J HEPATOL, V53, P950, DOI 10.1016/j.jhep.2010.06.009
   Hofman A, 2013, EUR J EPIDEMIOL, V28, P889, DOI 10.1007/s10654-013-9866-z
   Koehler EM, 2012, J HEPATOL, V57, P1305, DOI 10.1016/j.jhep.2012.07.028
   Lim YS, 2008, CLIN LIVER DIS, V12, P733, DOI 10.1016/j.cld.2008.07.007
   Lupsor M, 2008, J GASTROINTEST LIVER, V17, P155
   Macaluso FS, 2014, J HEPATOL, V61, P523, DOI 10.1016/j.jhep.2014.04.045
   MATTHEWS DR, 1985, DIABETOLOGIA, V28, P412, DOI 10.1007/BF00280883
   Myers RP, 2012, HEPATOLOGY, V55, P199, DOI 10.1002/hep.24624
   Ong JP, 2008, J HEPATOL, V49, P608, DOI 10.1016/j.jhep.2008.06.018
   Pessione F, 2001, HEPATOLOGY, V34, P121, DOI 10.1053/jhep.2001.25385
   Petta S, 2015, HEPATOLOGY, V62, P1101, DOI 10.1002/hep.27844
   Robic MA, 2011, J HEPATOL, V55, P1017, DOI 10.1016/j.jhep.2011.01.051
   Rockey DC, 2008, GASTROENTEROLOGY, V134, P8, DOI 10.1053/j.gastro.2007.11.053
   Roulot D, 2011, GUT, V60, P977, DOI 10.1136/gut.2010.221382
   Roulot D, 2008, J HEPATOL, V48, P606, DOI 10.1016/j.jhep.2007.11.020
   Salles N, 2009, GASTROEN CLIN BIOL, V33, P126, DOI 10.1016/j.gcb.2008.12.003
   Sánchez-Conde M, 2011, J VIRAL HEPATITIS, V18, pE278, DOI 10.1111/j.1365-2893.2010.01407.x
   SCHMUCKER DL, 1990, J ELECTRON MICR TECH, V14, P106, DOI 10.1002/jemt.1060140205
   Schmucker Douglas L, 2011, Curr Gerontol Geriatr Res, V2011, P526379, DOI 10.1155/2011/526379
   Sirli R, 2009, J GASTROINTEST LIVER, V18, P57
   Targher G, 2007, DIABETES CARE, V30, P1212, DOI 10.2337/dc06-2247
   Targher G, 2010, NEW ENGL J MED, V363, P1341, DOI 10.1056/NEJMra0912063
   Vergniol J, 2011, GASTROENTEROLOGY, V140, P1970, DOI 10.1053/j.gastro.2011.02.058
   Verveer C, 2012, LIVER INT, V32, P622, DOI 10.1111/j.1478-3231.2011.02663.x
   Wieckowska A, 2007, HEPATOLOGY, V46, P582, DOI 10.1002/hep.21768
   Williamson RM, 2011, DIABETES CARE, V34, P1139, DOI 10.2337/dc10-2229
   Wong VWS, 2012, GUT, V61, P409, DOI 10.1136/gutjnl-2011-300342
   Wong VWS, 2010, HEPATOLOGY, V51, P454, DOI 10.1002/hep.23312
   World Health Organization, GLOB HLTH OBS DAT RE
   WYNNE HA, 1990, AGE AGEING, V19, P1, DOI 10.1093/ageing/19.1.1
   Yoneda M, 2008, DIGEST LIVER DIS, V40, P371, DOI 10.1016/j.dld.2007.10.019
   Yu MW, 1997, AM J EPIDEMIOL, V145, P1039, DOI 10.1093/oxfordjournals.aje.a009060
NR 62
TC 218
Z9 230
U1 0
U2 35
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-9139
EI 1527-3350
J9 HEPATOLOGY
JI Hepatology
PD JAN
PY 2016
VL 63
IS 1
BP 138
EP 147
DI 10.1002/hep.27981
PG 10
WC Gastroenterology & Hepatology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Gastroenterology & Hepatology
GA CZ3ON
UT WOS:000367014000020
PM 26171685
OA Green Published, Bronze
HC Y
HP N
DA 2024-02-19
ER

PT J
AU Willis, RA
   Anthony, M
   Loop, R
   Llanes, C
   Folkers, K
AF Willis, RA
   Anthony, M
   Loop, R
   Llanes, C
   Folkers, K
TI The effect of ethanol and/or food restriction on coenzyme Q in liver in
   rats
SO MOLECULAR ASPECTS OF MEDICINE
LA English
DT Article; Proceedings Paper
CT 9th International Symposium on Biomedical and Clinical Aspects of
   Coenzyme Q
CY MAY, 1996
CL ANCONA, ITALY
DE coenzyme Q; ubiquinone; life span; food restriction
ID HYDROGEN-PEROXIDE PRODUCTION; LIFE-SPAN; ANTIOXIDANT DEFENSES; AGING
   RAT; DIET; PATHOLOGY; LONGEVITY; SURVIVAL; MITOCHONDRIA; PROLONGATION
AB The individual and combined effects of ethanol and lovastatin on rats and their prevention tay supplemental coenzyme Q(10) (CoQ(10)) was studied. The ethanol and lovastatin findings are reported elsewhere. This paper focuses on the food restriction which occurred in rats fed 35% of energy as ethanol and those control rats pair-fed to the 35% of energy as ethanol group. Six groups of rats received 35% of energy as ethanol (with or without lovastatin and/or CoQ(10) treatment). One group served as a 0% ethanol ad libitum control and one 0% ethanol control group was pair-fed to the 35% ethanol group. Rats receiving 35% of energy as ethanol and their pair-fed controls consumed 83% of the energy/day consumed by the ad libitum controls. This was consistent regardless of lovastatin or CoQ(10) treatment. Weight gains were 84% of control. The energy reduction was consistently associated with a substantial (48%+) increase in liver CoQ(9) concentrations. Reports by others of associations between food restriction and increased longevity in rodents has focused on a decrease in oxidant damage in tissues of food restricted animals. The increase in CoQ levels in the food restricted animals would result in an increase in antioxidant protection and might explain the observed increases in longevity. (C) 1997 Elsevier Science Ltd.
C1 UNIV TEXAS,INST BIOMED RES,AUSTIN,TX 78712.
C3 University of Texas System; University of Texas Austin
CR Algeri S, 1991, Aging (Milano), V3, P388
   BARBORIAK JJ, 1972, J NUTR, V102, P1543, DOI 10.1093/jn/102.11.1543
   BEYER RE, 1985, MECH AGEING DEV, V32, P267, DOI 10.1016/0047-6374(85)90085-5
   DAVIS TA, 1983, EXP GERONTOL, V18, P427, DOI 10.1016/0531-5565(83)90021-9
   GOLDSPINK DF, 1986, CARDIOVASC RES, V20, P672, DOI 10.1093/cvr/20.9.672
   KEENAN KP, 1994, TOXICOL PATHOL, V22, P300, DOI 10.1177/019262339402200308
   KU HH, 1993, MECH AGEING DEV, V72, P67, DOI 10.1016/0047-6374(93)90132-B
   KU HH, 1993, FREE RADICAL BIO MED, V15, P621, DOI 10.1016/0891-5849(93)90165-Q
   LEMESHKO VV, 1992, MECH AGEING DEV, V63, P79, DOI 10.1016/0047-6374(92)90018-9
   LOOP RA, 1994, MOL ASPECTS MED, V155, pS195
   MASORO EJ, 1990, P SOC EXP BIOL MED, V193, P31, DOI 10.3181/00379727-193-42985
   MERRY BJ, 1985, EXP GERONTOL, V20, P15, DOI 10.1016/0531-5565(85)90005-1
   MOS J, 1987, MECH AGEING DEV, V38, P89, DOI 10.1016/0047-6374(87)90113-8
   NOHYNEK GJ, 1993, HUM EXP TOXICOL, V12, P87, DOI 10.1177/096032719301200201
   ROE FJC, 1995, FOOD CHEM TOXICOL, V33, pS1, DOI 10.1016/0278-6915(94)00139-F
   SNYDER DL, 1990, J GERONTOL, V45, pB52, DOI 10.1093/geronj/45.2.B52
   SOHAL RS, 1990, MECH AGEING DEV, V53, P209, DOI 10.1016/0047-6374(90)90039-I
   SOHAL RS, 1990, MECH AGEING DEV, V53, P217, DOI 10.1016/0047-6374(90)90040-M
   SOHAL RS, 1992, MUTAT RES, V275, P295, DOI 10.1016/0921-8734(92)90033-L
   TUCKER MJ, 1979, INT J CANCER, V23, P803, DOI 10.1002/ijc.2910230611
   WILLIS RA, 1990, P NATL ACAD SCI USA, V87, P8928, DOI 10.1073/pnas.87.22.8928
   YU BP, 1994, P SOC EXP BIOL MED, V205, P97, DOI 10.3181/00379727-205-43684
NR 22
TC 2
Z9 2
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB
SN 0098-2997
J9 MOL ASPECTS MED
JI Mol. Asp. Med.
PY 1997
VL 18
SU S
BP S205
EP S211
PG 7
WC Biochemistry & Molecular Biology; Medicine, Research & Experimental
WE Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Research & Experimental Medicine
GA XR183
UT WOS:A1997XR18300025
PM 9266523
DA 2024-02-19
ER

PT J
AU Cicogna, AC
   Brooks, WW
   Hayes, JA
   Robinson, KG
   Sen, S
   Conrad, CH
   Bing, OHL
AF Cicogna, AC
   Brooks, WW
   Hayes, JA
   Robinson, KG
   Sen, S
   Conrad, CH
   Bing, OHL
TI Effect of chronic colchicine administration on the myocardium of the
   aging spontaneously hypertensive rat
SO MOLECULAR AND CELLULAR BIOCHEMISTRY
LA English
DT Article
DE cardiac hypertrophy and failure; spontaneously hypertensive rat;
   colchicine; myocardial fibrosis
ID HEART-FAILURE; CARDIAC-HYPERTROPHY; COLLAGEN; FIBROSIS; CIRRHOSIS;
   STIFFNESS; CELLS; DYSFUNCTION; VENTRICLE; TUBULIN
AB Colchicine has been demonstrated to suppress the release of fibroblast growth factors, retard collagen formation and augment collagenase activity. Trials with colchicine in patients with hepatic fibrosis have suggested clinical benefit. The development of impaired myocardial function in the spontaneously hypertensive rat (SHR) is associated with a marked increase in myocardial fibrosis. The present study was carried out to test the hypothesis that chronic colchicine administration to the SHR would prevent the development of fibrosis and impaired myocardial performance.
   Colchicine (1 mg/l drinking water) was administered to male SHR and WKY rats from at age 13 months until 24 months or until evidence of heart failure was observed. Age-matched untreated SHR and colchicine treated and untreated WKY served as controls. At study, active and passive properties of isolated left ventricular muscle preparations were determined. Myocardial fibrosis was assessed by measuring hydroxyproline and histologic determination of interstitial cross-sectional area. Increases in LV hydroxyproline and interstitial area were found in untreated SHR relative to WKY; passive myocardial stiffness was increased and active muscle properties were depressed. In comparing colchicine treated vs untreated SHR, no differences in hydroxyproline, interstitial area or intrinsic myocardial function were found. In the WKY, colchicine increased myocardial interstitium and passive stiffness without changing hydroxyproline. Active myocardial function was not depressed.
   Thus, chronic colchicine administration neither attenuated the development of interstitial fibrosis nor prevented impaired myocardial function in the SHR. Colchicine treatment was associated with increased interstitium in WKY with increased passive myocardial stiffness.
C1 DEPT VET AFFAIRS MED CTR,BOSTON,MA.
   SCH MED,BOTUCATU,SP,BRAZIL.
   TUFTS UNIV,SCH MED,DEPT MED,BOSTON,MA 02111.
   BOSTON UNIV,SCH MED,DEPT MED,BOSTON,MA 02118.
   CLEVELAND CLIN FDN,DIV RES,CLEVELAND,OH 44195.
C3 Tufts University; Boston University; Cleveland Clinic Foundation
OI Cicogna, Antonio Carlos/0000-0002-4402-6523
FU NHLBI NIH HHS [HL27838] Funding Source: Medline
CR [Anonymous], 1952, EXP CELL RES, DOI DOI 10.1142/9789812790866_0011
   BERG RA, 1980, P NATL ACAD SCI-BIOL, V77, P4746, DOI 10.1073/pnas.77.8.4746
   BERGMAN I, 1963, ANAL CHEM, V35, P1961, DOI 10.1021/ac60205a053
   BING OHL, 1983, BASIC RES CARDIOLOGY
   BOLUYT MO, 1994, CIRC RES, V75, P23, DOI 10.1161/01.RES.75.1.23
   BUDAVARI S, 1989, MERCK INDEX, P3500
   CONRAD CH, 1991, AM J PHYSIOL, V260, pH136, DOI 10.1152/ajpheart.1991.260.1.H136
   CONRAD CH, 1995, CIRCULATION, V91, P161, DOI 10.1161/01.CIR.91.1.161
   CRIE JS, 1983, BIOCHEM J, V210, P63, DOI 10.1042/bj2100063
   DAYER JM, 1984, BIOCHEM PHARMACOL, V33, P2893, DOI 10.1016/0006-2952(84)90213-2
   DUSTIN P, 1978, MICROTUBULES, P167
   EHRLICH HP, 1974, J CELL BIOL, V62, P390, DOI 10.1083/jcb.62.2.390
   ERTEL N, 1969, ARTHRITIS RHEUM, V12, P293
   GODEAU G, 1985, CLIN PHYSIOL BIOCH, V3, P234
   HARRIS ED, 1974, NEW ENGL J MED, V291, P557, DOI 10.1056/NEJM197409122911105
   JALIL JE, 1989, CIRC RES, V64, P1041, DOI 10.1161/01.RES.64.6.1041
   KAPLAN MM, 1986, NEW ENGL J MED, V315, P1448, DOI 10.1056/NEJM198612043152304
   KERSHENOBICH D, 1988, NEW ENGL J MED, V318, P1709, DOI 10.1056/NEJM198806303182602
   KIRCHENOBICH D, 1979, GASTROENTEROLOGY, V77, P532
   KLEIN I, 1982, P SOC EXP BIOL MED, V170, P19
   KLEIN I, 1983, CARDIOVASC RES, V17, P459, DOI 10.1093/cvr/17.8.459
   Krebs HA, 1932, H-S Z PHYSIOL CHEM, V210, P33, DOI 10.1515/bchm2.1932.210.1-2.33
   LAMPIDIS TJ, 1992, P NATL ACAD SCI USA, V89, P1256, DOI 10.1073/pnas.89.4.1256
   LAMPIDIS TJ, 1986, EXP CELL RES, V164, P463, DOI 10.1016/0014-4827(86)90044-3
   LIMAS C, 1991, CIRC RES, V68, P309, DOI 10.1161/01.RES.68.1.309
   MIRSKY I, 1976, PROG CARDIOVASC DIS, V18, P277, DOI 10.1016/0033-0620(76)90023-2
   MIRSKY I, 1983, CIRC RES, V53, P767, DOI 10.1161/01.RES.53.6.767
   NAKAMURA Y, 1986, AM J PHYSIOL, V251, pH664, DOI 10.1152/ajpheart.1986.251.3.H664
   NATH K, 1978, P NATL ACAD SCI USA, V75, P319, DOI 10.1073/pnas.75.1.319
   PASIPOULARIDES A, 1986, CIRCULATION, V74, P991, DOI 10.1161/01.CIR.74.5.991
   PFEFFER JM, 1979, AM J PHYSIOL, V237, pH461
   *PROPHET STAT, 1988, US GUID STAT AN PROP
   RENNARD SI, 1988, AM REV RESPIR DIS, V137, P181, DOI 10.1164/ajrccm/137.1.181
   ROCHDI M, 1992, HUM EXP TOXICOL, V11, P510, DOI 10.1177/096032719201100612
   SAVITZKY A, 1964, ANAL CHEM, V36, P1627, DOI 10.1021/ac60214a047
   SULMAN DL, 1974, BIOCHEM BIOPH RES CO, V56, P947, DOI 10.1016/S0006-291X(74)80280-9
   TANNER MS, 1981, J PATHOL, V135, P179, DOI 10.1002/path.1711350303
   TAYLOR EW, 1965, J CELL BIOL, V25, P145, DOI 10.1083/jcb.25.1.145
   TSUTSUI H, 1993, SCIENCE, V260, P682, DOI 10.1126/science.8097594
   WEBER KT, 1991, CIRCULATION, V83, P1849, DOI 10.1161/01.CIR.83.6.1849
   WEBER KT, 1988, CIRC RES, V62, P757, DOI 10.1161/01.RES.62.4.757
   WEBER KT, 1989, J MOL CELL CARDIOL, V21, P121, DOI 10.1016/0022-2828(89)90778-5
   WEBER KT, 1990, HEART FAILURE, V6, P129
   WIEGNER AW, 1979, AM J PHYSIOL, V237, pH260, DOI 10.1152/ajpheart.1979.237.2.H260
   Wildenthal K, 1985, Adv Myocardiol, V5, P137
   YIN FCP, 1982, AM J PHYSIOL, V243, pH941, DOI 10.1152/ajpheart.1982.243.6.H941
   YONEMOCHI H, 1990, CIRCULATION, V81, P1401, DOI 10.1161/01.CIR.81.4.1401
NR 47
TC 12
Z9 13
U1 0
U2 1
PU KLUWER ACADEMIC PUBL
PI DORDRECHT
PA SPUIBOULEVARD 50, PO BOX 17, 3300 AA DORDRECHT, NETHERLANDS
SN 0300-8177
J9 MOL CELL BIOCHEM
JI Mol. Cell. Biochem.
PD JAN
PY 1997
VL 166
IS 1-2
BP 45
EP 54
DI 10.1023/A:1006889126666
PG 10
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA WJ656
UT WOS:A1997WJ65600005
PM 9046020
DA 2024-02-19
ER

PT J
AU Podder, A
   Raju, A
   Schork, NJ
AF Podder, Avijit
   Raju, Anish
   Schork, Nicholas J.
TI Cross-Species and Human Inter-Tissue Network Analysis of Genes
   Implicated in Longevity and Aging Reveal Strong Support for Nutrient
   Sensing
SO FRONTIERS IN GENETICS
LA English
DT Article
DE human aging; cross-species orthologs; protein-protein interaction
   network; pathway enrichments; nutrient sensing; drug targets
ID CONNECTIVITY MAP; GENETICS; BIOLOGY; SEARCH; CANCER; TISSUE; MECHANISMS;
   SIGNATURES; HALLMARKS; GENOTYPE
AB Intensive research efforts have been undertaken to slow human aging and therefore potentially delay the onset of age-related diseases. These efforts have generated an enormous amount of high-throughput data covering different levels in the physiologic hierarchy, e.g., genetic, epigenetic, transcriptomic, proteomic, and metabolomic, etc. We gathered 15 independent sources of information about genes potentially involved in human longevity and lifespan (N = 5836) and subjected them to various integrated analyses. Many of these genes were initially identified in non-human species, and we investigated their orthologs in three non-human species [i.e., mice (N = 967), fruit fly (N = 449), and worm (N = 411)] for further analysis. We characterized experimentally determined protein-protein interaction networks (PPIN) involving each species' genes from 9 known protein databases and studied the enriched biological pathways among the individually constructed PPINs. We observed three important signaling pathways: FoxO signaling, mTOR signaling, and autophagy to be common and highly enriched in all four species (p-value <= 0.001). Our study implies that the interaction of proteins involved in the mechanistic target of rapamycin (mTOR) signaling pathway is somewhat limited to each species or that a "rewiring " of specific networks has taken place over time. To corroborate our findings, we repeated our analysis in 43 different human tissues. We investigated conserved modules in various tissue-specific PPINs of the longevity-associated genes based upon their protein expression. This analysis also revealed mTOR signaling as shared biological processes across four different human tissue-specific PPINs for liver, heart, skeletal muscle, and adipose tissue. Further, we explored our results' translational potential by assessing the protein interactions with all the reported drugs and compounds that have been experimentally verified to promote longevity in the three-comparator species. We observed that the target proteins of the FDA-approved drug rapamycin (a known inhibitor of mTOR) were conserved across all four species. Drugs like melatonin and metformin exhibited shared targets with rapamycin in the human PPIN. The detailed information about the curated gene list, cross-species orthologs, PPIN, and pathways was assembled in an interactive data visualization portal using RStudio's Shiny framework (https://agingnetwork.shinyapps.io/frontiers/).
C1 [Podder, Avijit; Raju, Anish; Schork, Nicholas J.] Translat Genom Res Inst TGen, Dept Quantitat Med, Phoenix, AZ 85004 USA.
   [Schork, Nicholas J.] City Hope Natl Med Ctr, Dept Populat Sci & Mol & Cell Biol, Natl Med Ctr, Duarte, CA 91010 USA.
C3 Translational Genomics Research Institute; City of Hope
RP Schork, NJ (corresponding author), Translat Genom Res Inst TGen, Dept Quantitat Med, Phoenix, AZ 85004 USA.; Schork, NJ (corresponding author), City Hope Natl Med Ctr, Dept Populat Sci & Mol & Cell Biol, Natl Med Ctr, Duarte, CA 91010 USA.
EM nschork@tgen.org
RI Podder, Avijit/AAI-2748-2020
OI Podder, Avijit/0000-0002-8296-0034; Raju, Anish/0000-0003-0391-250X
FU National Institute for Aging of the National Institutes of Health
   [U19AG023122, U24AG051129S1, UH2AG064706, UH2AG064706S1]; Ben and
   Catherine Ivy Foundation; Dell Precision Medicine Program for Pediatric
   Cancer; Ottosen Family Foundation
FX Research reported in this publication was supported in part by the
   National Institute for Aging of the National Institutes of Health under
   award numbers: U19AG023122, U24AG051129S1, UH2AG064706, and
   UH2AG064706S1. This research was also made possible by grant awards from
   The Ben and Catherine Ivy Foundation, the Dell Precision Medicine
   Program for Pediatric Cancer, and The Ottosen Family Foundation. The
   content and views expressed in this article are solely those of the
   authors and do not necessarily represent the official policy or position
   of the funding sponsors.
CR Amin S, 2019, BRIT J CLIN PHARMACO, V85, P37, DOI 10.1111/bcp.13780
   Assenov Y, 2008, BIOINFORMATICS, V24, P282, DOI 10.1093/bioinformatics/btm554
   Aunan JR, 2017, AGING DIS, V8, P628, DOI 10.14336/AD.2017.0103
   Avelar RA, 2020, GENOME BIOL, V21, DOI 10.1186/s13059-020-01990-9
   Barabási AL, 1999, SCIENCE, V286, P509, DOI 10.1126/science.286.5439.509
   Barabási AL, 2011, NAT REV GENET, V12, P56, DOI 10.1038/nrg2918
   Barardo D, 2017, AGING CELL, V16, P594, DOI 10.1111/acel.12585
   Bell R, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000414
   Beltrao P, 2010, CELL, V141, P739, DOI 10.1016/j.cell.2010.05.019
   Blankenburg H, 2018, BIOGERONTOLOGY, V19, P81, DOI 10.1007/s10522-017-9741-5
   Budovsky A, 2007, MECH AGEING DEV, V128, P117, DOI 10.1016/j.mad.2006.11.018
   Carmona JJ, 2016, REV INVEST CLIN, V68, P7
   Chan SY, 2012, CIRC RES, V111, P359, DOI 10.1161/CIRCRESAHA.111.258541
   Chang W, 2022, shiny: Web Application Framework for R
   Craig T, 2015, NUCLEIC ACIDS RES, V43, pD873, DOI 10.1093/nar/gku843
   Després JP, 2020, NAT REV CARDIOL, V17, P67, DOI 10.1038/s41569-019-0310-2
   Ershler WB, 1997, JNCI-J NATL CANCER I, V89, P1489, DOI 10.1093/jnci/89.20.1489
   Ferrarini L, 2005, BIOINFORMATICS, V21, P338, DOI 10.1093/bioinformatics/bti004
   Finch CE, 1997, SCIENCE, V278, P407, DOI 10.1126/science.278.5337.407
   del Valle EPG, 2019, J BIOMED INFORM, V94, DOI 10.1016/j.jbi.2019.103206
   Georgi B, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003484
   Haynes L, 2020, FRONT AGING-LAUSANNE, V1, DOI 10.3389/fragi.2020.602108
   Hu YH, 2020, G3-GENES GENOM GENET, V10, P4531, DOI 10.1534/g3.120.401775
   Hu YH, 2018, NUCLEIC ACIDS RES, V46, pD567, DOI 10.1093/nar/gkx1116
   Jeong H, 2001, NATURE, V411, P41, DOI 10.1038/35075138
   Kanduri C, 2019, GENRANK CANDIDATE GE
   Kirkwood TBL, 2011, PHILOS T R SOC B, V366, P64, DOI 10.1098/rstb.2010.0275
   Komljenovic A, 2019, PLOS COMPUT BIOL, V15, DOI 10.1371/journal.pcbi.1007162
   Kotlyar M, 2019, NUCLEIC ACIDS RES, V47, pD581, DOI 10.1093/nar/gky1037
   Kovács IA, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09177-y
   Kriventseva EV, 2019, NUCLEIC ACIDS RES, V47, pD807, DOI 10.1093/nar/gky1053
   Kulkarni AS, 2020, CELL METAB, V32, P15, DOI 10.1016/j.cmet.2020.04.001
   Lamb J, 2006, SCIENCE, V313, P1929, DOI 10.1126/science.1132939
   Lazarov O, 2010, TRENDS NEUROSCI, V33, P569, DOI 10.1016/j.tins.2010.09.003
   Levine ME, 2016, J GERONTOL A-BIOL, V71, P703, DOI 10.1093/gerona/glv141
   Liu C, 2020, PHYS REP, V846, P1, DOI 10.1016/j.physrep.2019.12.004
   Lonsdale J, 2013, NAT GENET, V45, P580, DOI 10.1038/ng.2653
   López-Otín C, 2013, CELL, V153, P1194, DOI 10.1016/j.cell.2013.05.039
   Luck K, 2020, NATURE, V580, P402, DOI 10.1038/s41586-020-2188-x
   Lukk M, 2010, NAT BIOTECHNOL, V28, P322, DOI 10.1038/nbt0410-322
   Ma S, 2017, SEMIN CELL DEV BIOL, V70, P190, DOI 10.1016/j.semcdb.2017.08.007
   Marín M, 2019, BMC BIOINFORMATICS, V20, DOI 10.1186/s12859-019-3162-1
   Melzer D, 2020, NAT REV GENET, V21, P88, DOI 10.1038/s41576-019-0183-6
   Möller S, 2020, AGING-US, V12, P12534, DOI 10.18632/aging.103514
   Muntané G, 2018, MOL BIOL EVOL, V35, P1990, DOI 10.1093/molbev/msy105
   Murabito JM, 2012, J GERONTOL A-BIOL, V67, P470, DOI 10.1093/gerona/gls089
   Niedemhofer LJ, 2008, INT J BIOCHEM CELL B, V40, P176, DOI 10.1016/j.biocel.2007.10.008
   Papadopoli David, 2019, F1000Res, V8, DOI 10.12688/f1000research.17196.1
   Partridge L, 2011, AGING CELL, V10, P5, DOI 10.1111/j.1474-9726.2010.00649.x
   Pierson E, 2015, PLOS COMPUT BIOL, V11, DOI 10.1371/journal.pcbi.1004220
   R Core Team, 2018, MSOR connections
   Raudvere U, 2019, NUCLEIC ACIDS RES, V47, pW191, DOI 10.1093/nar/gkz369
   Reimand J, 2019, NAT PROTOC, V14, P482, DOI 10.1038/s41596-018-0103-9
   Rolyan H, 2011, BRAIN, V134, P2044, DOI 10.1093/brain/awr133
   Rouillard AD, 2016, DATABASE-OXFORD, DOI 10.1093/database/baw100
   Safari-Alighiarloo Nahid, 2014, Gastroenterol Hepatol Bed Bench, V7, P17
   Sahni N, 2013, CURR OPIN GENET DEV, V23, P649, DOI 10.1016/j.gde.2013.11.002
   Salnikov L, 2020, FRONT AGING-LAUSANNE, V1, DOI 10.3389/fragi.2020.608076
   Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303
   Singh PP, 2019, CELL, V177, P200, DOI 10.1016/j.cell.2019.02.038
   Soltow QA, 2010, INTEGR COMP BIOL, V50, P844, DOI 10.1093/icb/icq094
   Sonawane AR, 2017, CELL REP, V21, P1077, DOI 10.1016/j.celrep.2017.10.001
   Subramanian A, 2017, CELL, V171, P1437, DOI 10.1016/j.cell.2017.10.049
   Szklarczyk D, 2016, NUCLEIC ACIDS RES, V44, pD380, DOI 10.1093/nar/gkv1277
   Tacutu R, 2018, NUCLEIC ACIDS RES, V46, pD1083, DOI 10.1093/nar/gkx1042
   Tacutu R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048282
   Tacutu R, 2010, BIOGERONTOLOGY, V11, P513, DOI 10.1007/s10522-010-9265-8
   Uhlen M, 2015, SCIENCE, V347, DOI 10.1126/science.1260419
   Vidal M, 2011, CELL, V144, P986, DOI 10.1016/j.cell.2011.02.016
   Warner HR, 2005, MECH AGEING DEV, V126, P235, DOI 10.1016/j.mad.2004.08.015
   Weichhart T, 2018, GERONTOLOGY, V64, P127, DOI 10.1159/000484629
   Wickham H, 2009, USE R, P1, DOI 10.1007/978-0-387-98141-3_1
   Wolfson M, 2009, INT J BIOCHEM CELL B, V41, P516, DOI 10.1016/j.biocel.2008.08.026
   Xue HL, 2007, MOL SYST BIOL, V3, DOI 10.1038/msb4100189
   Yanai H, 2017, AGING CELL, V16, P1267, DOI 10.1111/acel.12659
   Zhang QW, 2016, HUM MOL GENET, V25, P2934, DOI 10.1093/hmg/ddw145
NR 76
TC 8
Z9 9
U1 1
U2 4
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 1664-8021
J9 FRONT GENET
JI Front. Genet.
PD AUG 27
PY 2021
VL 12
AR 719713
DI 10.3389/fgene.2021.719713
PG 16
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA UU0SL
UT WOS:000698515100001
PM 34512728
OA gold, Green Published
DA 2024-02-19
ER

PT J
AU Costa, SSF
   Wegmann, D
   Ripperger, JA
AF Costa, Sara S. Fonseca
   Wegmann, Daniel
   Ripperger, Jurgen A.
TI Normalisation against Circadian and Age-Related Disturbances Enables
   Robust Detection of Gene Expression Changes in Liver of Aged Mice
SO PLOS ONE
LA English
DT Article
ID CASEIN KINASE 1; MESSENGER-RNA; FEEDBACK LOOP; AGING RAT; CLOCK; GENOME;
   BRAIN; MOUSE; TRANSCRIPTION; OSCILLATOR
AB The expression of some genes is affected by age. To detect such age-related changes, their expression levels are related to constant marker genes. However, transcriptional noise increasing with advancing age renders difficult the identification of real age-related changes because it may affect the marker genes as well. Here, we report a selection procedure for genes appropriate to normalise the mouse liver transcriptome under various conditions including age. These genes were chosen from an initial set of 16 candidate genes defined based on a RNA-sequencing experiment and published literature. A subset of genes was selected based on rigorous statistical assessment of their variability using both RNA-sequencing and Nanostring hybridization experiments. The robustness of these marker genes was then verified by the analysis of 130 publicly available data sets using the mouse liver transcriptome. Altogether, a set of three genes, Atp5h, Gsk3 beta, and Sirt2 fulfilled our strict selection criteria in all assessments, while four more genes, Nono, Tprkb, Tspo, and Ttr passed all but one assessment and were included into the final set of marker genes to enhance robustness of normalisation against outliers. Using the geometric mean of expression of the genes to normalise Nanostring hybridization experiments we reliably identified age-related increases in the expression of Casein kinase 1 delta and 1 epsilon, and Sfpq, while the expression of the glucose transporter Glut2 decreased. The age-related changes were verified by real-time PCR and Western blot analysis. As conclusion, proper normalisation enhances the robustness of quantitative methods addressing age-related changes of a transcriptome.
C1 [Costa, Sara S. Fonseca; Wegmann, Daniel; Ripperger, Jurgen A.] Univ Fribourg, Dept Biol, Fribourg, Switzerland.
   [Wegmann, Daniel] Univ Lausanne, Swiss Inst Bioinformat, Lausanne, Switzerland.
C3 University of Fribourg; University of Lausanne; Swiss Institute of
   Bioinformatics
RP Wegmann, D; Ripperger, JA (corresponding author), Univ Fribourg, Dept Biol, Fribourg, Switzerland.; Wegmann, D (corresponding author), Univ Lausanne, Swiss Inst Bioinformat, Lausanne, Switzerland.
EM daniel.wegmann@unifr.ch; juergenalexandereduard.ripperger@unifr.ch
RI Costa, Sara Fonseca/M-1365-2015; Wegmann, Daniel/K-2199-2012
OI Wegmann, Daniel/0000-0003-2866-6739; Fonseca Costa,
   Sara/0000-0001-7794-7997
FU Canton of Fribourg; Swiss National Science Foundation (SNSF)
   [31003A_152792]; SystemsX, the Swiss Initiative of Systems Biology
   [51PHP0_J57318]; Swiss National Science Foundation (SNF) [31003A_152792]
   Funding Source: Swiss National Science Foundation (SNF)
FX This work was supported by the Canton of Fribourg, The Swiss National
   Science Foundation (SNSF) to JAR (31003A_152792), and SystemsX, the
   Swiss Initiative of Systems Biology to DW (51PHP0_J57318). The funders
   had no role in study design, data collection and analysis, decision to
   publish, or preparation of the manuscript.; We would like to thank
   Christoph Leuenberger for discussion about the statistical methods used
   in the manuscript, Ka Yi Hui and Steven Brown for comments on the
   manuscript and Keith Harshman, Corinne Peter and Leonore Wigger for
   their expert help on the Nanostring hybridization experiment, and Steven
   Brown for the gift of specific antibodies. This work was supported by
   the Canton of Fribourg, the Swiss National Science Foundation (SNSF),
   and SystemsX, the Swiss Initiative for Systems Biology.
CR Aitchison J., HONORARY SENIOR RES
   Aranda PS, 2012, ELECTROPHORESIS, V33, P366, DOI 10.1002/elps.201100335
   Bochkis IM, 2014, CELL REP, V9, P996, DOI 10.1016/j.celrep.2014.09.048
   Canaple L, 2006, MOL ENDOCRINOL, V20, P1715, DOI 10.1210/me.2006-0052
   CARTER DB, 1975, J GERONTOL, V30, P28, DOI 10.1093/geronj/30.1.28
   Chen J, 2006, J GERONTOL A-BIOL, V61, P20, DOI 10.1093/gerona/61.1.20
   Costa SSF, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00043
   De J, 2009, BIOINFORMATICS, V25, DOI [10.1093/bioinformatics/btp073, DOI 10.1093/BIOINFORMATICS/BTP073]
   Dibner C, 2010, ANNU REV PHYSIOL, V72, P517, DOI 10.1146/annurev-physiol-021909-135821
   Dunlap JC, 1999, CELL, V96, P271, DOI 10.1016/S0092-8674(00)80566-8
   Forster MJ, 2003, FASEB J, V17, P690, DOI 10.1096/fj.02-0533fje
   GARTNER K, 1992, J EXP ANIM SCI, V35, P125
   Geiss GK, 2008, NAT BIOTECHNOL, V26, P317, DOI 10.1038/nbt1385
   Hruz Tomas, 2008, Advances in Bioinformatics, V2008, P420747, DOI 10.1155/2008/420747
   Kim D, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-4-r36
   Knippschild U, 1997, ONCOGENE, V15, P1727, DOI 10.1038/sj.onc.1201541
   Kondratova AA, 2012, NAT REV NEUROSCI, V13, P325, DOI 10.1038/nrn3208
   Kowalska E, 2012, MOL CELL BIOL, V32, P4585, DOI 10.1128/MCB.00334-12
   Lamia KA, 2008, P NATL ACAD SCI USA, V105, P15172, DOI 10.1073/pnas.0806717105
   Lee HM, 2011, P NATL ACAD SCI USA, V108, P16451, DOI 10.1073/pnas.1107178108
   Liu CM, 2002, CELL, V108, P837, DOI 10.1016/S0092-8674(02)00685-2
   López-Otín C, 2013, CELL, V153, P1194, DOI 10.1016/j.cell.2013.05.039
   Lowrey PL, 2000, SCIENCE, V288, P483, DOI 10.1126/science.288.5465.483
   Nakamura TJ, 2011, J NEUROSCI, V31, P10201, DOI 10.1523/JNEUROSCI.0451-11.2011
   Nelissen K, 2010, J NEUROSCI METH, V187, P78, DOI 10.1016/j.jneumeth.2009.12.018
   Oklejewicz M, 2002, J BIOL RHYTHM, V17, P210, DOI 10.1177/07430402017003004
   Pagani L, 2011, P NATL ACAD SCI USA, V108, P7218, DOI 10.1073/pnas.1008882108
   Partridge L, 1999, TRENDS ECOL EVOL, V14, P438, DOI 10.1016/S0169-5347(99)01646-8
   Preitner N, 2002, CELL, V110, P251, DOI 10.1016/S0092-8674(02)00825-5
   Ripperger JRA, 2006, NAT GENET, V38, P369, DOI 10.1038/ng1738
   ROWLATT C, 1976, Laboratory Animals (London), V10, P419, DOI 10.1258/002367776780956917
   Sato TK, 2004, NEURON, V43, P527, DOI 10.1016/j.neuron.2004.07.018
   Shearman LP, 2000, SCIENCE, V288, P1013, DOI 10.1126/science.288.5468.1013
   Shen Y, 2012, NATURE, V488, P116, DOI 10.1038/nature11243
   Shendure J, 2005, SCIENCE, V309, P1728, DOI 10.1126/science.1117389
   Simon A, 2015, BIOINFORMATICS, V31, DOI [10.1093/bioinformatics/btu638, DOI 10.1093/BIOINFORMATICS/BTU638]
   SLAGBOOM PE, 1990, MECH AGEING DEV, V53, P243, DOI 10.1016/0047-6374(90)90042-E
   Sugathan A, 2013, MOL CELL BIOL, V33, P3594, DOI 10.1128/MCB.00280-13
   Thattai M, 2001, P NATL ACAD SCI USA, V98, P8614, DOI 10.1073/pnas.151588598
   Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034
   Waggott D, 2012, BIOINFORMATICS, V28, P1546, DOI 10.1093/bioinformatics/bts188
   Wang Q, 2013, PATTERN RECOGN LETT, V34, P34, DOI 10.1016/j.patrec.2012.06.002
   Xu Y, 2007, CELL, V128, P59, DOI 10.1016/j.cell.2006.11.043
   Zampieri M, 2010, MECH AGEING DEV, V131, P89, DOI 10.1016/j.mad.2009.12.005
NR 44
TC 4
Z9 5
U1 0
U2 8
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JAN 9
PY 2017
VL 12
IS 1
AR e0169615
DI 10.1371/journal.pone.0169615
PG 16
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA EH5WO
UT WOS:000391843900050
PM 28068403
OA gold, Green Published, Green Submitted
DA 2024-02-19
ER

PT J
AU Gómez, J
   Caro, P
   Naudí, A
   Portero-Otin, M
   Pamplona, R
   Barja, G
AF Gomez, Jose
   Caro, Pilar
   Naudi, Alba
   Portero-Otin, Manuel
   Pamplona, Reinald
   Barja, Gustavo
TI Effect of 8.5% and 25% caloric restriction on mitochondrial free radical
   production and oxidative stress in rat liver
SO BIOGERONTOLOGY
LA English
DT Article
DE aging; oxygen radicals; DNA damage; protein damage; fatty acids;
   membrane unsaturation
ID APOPTOSIS-INDUCING FACTOR; DNA-DAMAGE; HYDROGEN-PEROXIDE; COMPLEX-I;
   GENERATION; LONGEVITY; PROTEINS; GLYCOXIDATION; SUPEROXIDE; MECHANISM
AB Previous studies have consistently shown that 40% caloric restriction (CR) decreases the rate of mitochondrial ROS production and steady-state levels of markers of oxidative damage to macromolecules including mitochondrial DNA. However, few investigations have studied whether these changes also occur in lower CR regimes. This is of potential interest since moderate levels of dietary restriction are more practicable for humans. In this investigation male Wistar rats were subjected to 8.5% and 25% caloric restriction. Neither 8.5% nor 25% CR changed mitochondrial ROS production, oxygen consumption or mtDNA oxidative damage in rat liver mitochondria. However, both 8.5% and 25% CR significantly decreased the five different markers of protein oxidation, glycoxidation and lipoxidation measured, aminoadipic and glutamic semialdehyde, carboxyethyl-lysine, carboxymethyl-lysine, and malondialdehyde-lysine. The fatty acid composition of liver mitochondria was also affected and led to a moderate decrease in the degree of membrane unsaturation in both 8.5% and 25% CR. While 8.5% CR only affected complex I concentration (which was decreased), 25% CR decreased complexes I and IV and increased complexes II and III of the respiratory chain. Apoptosis-inducing factor (AIF) significantly decreased in 25% CR but not in 8.5% CR. The results show that moderate levels of caloric restriction can have beneficial effects including decreases in oxidative protein modification and a lower sensitivity of membranes to lipid peroxidation, in association with a reprogramming of the respiratory chain complexes and AIF content.
C1 Univ Complutense, Dept Anim Physiol 2, E-28040 Madrid, Spain.
   Univ Lleida, Dept Basic Med Sci, Lleida 25008, Spain.
C3 Complutense University of Madrid; Universitat de Lleida
RP Barja, G (corresponding author), Univ Complutense, Dept Anim Physiol 2, C Antonio Novais 2, E-28040 Madrid, Spain.
EM gbarja@bio.ucm.es
RI Naudí, Alba/B-5594-2009; Barja, Gustavo/AAA-5903-2019; Gustavo,
   Barja/B-5591-2012; Pamplona, Reinald/A-7359-2010; Gomez,
   Jose/G-9705-2015; Portero-Otin, Manuel/B-7122-2009
OI Naudí, Alba/0000-0003-0699-1004; Barja, Gustavo/0000-0001-5736-4735;
   Pamplona, Reinald/0000-0003-4337-6107; Gomez, Jose/0000-0003-1758-4746;
   Portero-Otin, Manuel/0000-0002-1823-0299; Caro,
   Pilar/0000-0002-7531-3234
CR AYALA V, 2007, IN PRESS J GERONTOL
   Barja G, 1998, J BIOENERG BIOMEMBR, V30, P235, DOI 10.1023/A:1020592719405
   Barja G, 2004, BIOL REV, V79, P235, DOI 10.1017/S1464793103006213
   Barja G, 2002, J BIOENERG BIOMEMBR, V34, P227, DOI 10.1023/A:1016039604958
   BIELSKI BHJ, 1983, J BIOL CHEM, V258, P4759
   BOVERIS A, 1976, BIOCHEM J, V156, P435, DOI 10.1042/bj1560435
   Cuervo AM, 2005, AUTOPHAGY, V1, P131, DOI 10.4161/auto.1.3.2017
   DeLaAsuncion JG, 1996, FASEB J, V10, P333, DOI 10.1096/fasebj.10.2.8641567
   Dhahbi JM, 2001, MECH AGEING DEV, V122, P1033, DOI 10.1016/S0047-6374(01)00230-5
   Genova ML, 2001, FEBS LETT, V505, P364, DOI 10.1016/S0014-5793(01)02850-2
   Gredilla R, 2005, ENDOCRINOLOGY, V146, P3713, DOI 10.1210/en.2005-0378
   Gredilla R, 2001, J BIOENERG BIOMEMBR, V33, P279, DOI 10.1023/A:1010603206190
   HARMAN D, 1972, J AM GERIATR SOC, V20, P145, DOI 10.1111/j.1532-5415.1972.tb00787.x
   Hulbert AJ, 2005, J THEOR BIOL, V234, P277, DOI 10.1016/j.jtbi.2004.11.024
   Koukova J., 2003, GENE DEV, V17, P313
   KU HH, 1993, FREE RADICAL BIO MED, V15, P621, DOI 10.1016/0891-5849(93)90165-Q
   LATORRE A, 1986, P NATL ACAD SCI USA, V83, P8649, DOI 10.1073/pnas.83.22.8649
   Lee CK, 1999, SCIENCE, V285, P1390, DOI 10.1126/science.285.5432.1390
   Loft S, 1999, METHOD ENZYMOL, V300, P166
   Martin B, 2006, AGEING RES REV, V5, P332, DOI 10.1016/j.arr.2006.04.002
   Modjtahedi N, 2006, TRENDS CELL BIOL, V16, P264, DOI 10.1016/j.tcb.2006.03.008
   Pamplona R, 2005, J BIOL CHEM, V280, P21522, DOI 10.1074/jbc.M502255200
   Pamplona R, 2002, ANN NY ACAD SCI, V959, P475, DOI 10.1111/j.1749-6632.2002.tb02118.x
   Pamplona R, 2002, MECH AGEING DEV, V123, P1437, DOI 10.1016/S0047-6374(02)00076-3
   Pamplona R, 2002, FREE RADICAL RES, V36, P47, DOI 10.1080/10715760210165
   Pamplona R, 2006, BBA-BIOENERGETICS, V1757, P496, DOI 10.1016/j.bbabio.2006.01.009
   Porter AG, 2006, BIOESSAYS, V28, P834, DOI 10.1002/bies.20444
   Sanz A, 2006, J BIOENERG BIOMEMBR, V38, P327, DOI 10.1007/s10863-006-9051-0
   Sanz A, 2004, J BIOENERG BIOMEMBR, V36, P545, DOI 10.1007/s10863-004-9001-7
   Sanz A, 2006, ANN NY ACAD SCI, V1067, P200, DOI 10.1196/annals.1354.024
   Sanz A, 2006, FASEB J, V20, P1064, DOI 10.1096/fj.05-5568com
   Scrofano MM, 1998, MECH AGEING DEV, V101, P277, DOI 10.1016/S0047-6374(97)00178-4
   Sell DR, 1996, P NATL ACAD SCI USA, V93, P485, DOI 10.1073/pnas.93.1.485
   Seo AY, 2006, ANTIOXID REDOX SIGN, V8, P529, DOI 10.1089/ars.2006.8.529
   Sohal RS, 1996, SCIENCE, V273, P59, DOI 10.1126/science.273.5271.59
   Vahsen N, 2004, EMBO J, V23, P4679, DOI 10.1038/sj.emboj.7600461
   van Empel VPM, 2005, CIRC RES, V96, pE92, DOI 10.1161/01.RES.0000172081.30327.28
   Weindruch R., 1988, RETARDATION AGING DI
NR 38
TC 41
Z9 44
U1 0
U2 7
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1389-5729
EI 1573-6768
J9 BIOGERONTOLOGY
JI Biogerontology
PD OCT
PY 2007
VL 8
IS 5
BP 555
EP 566
DI 10.1007/s10522-007-9099-1
PG 12
WC Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Geriatrics & Gerontology
GA 206UJ
UT WOS:000249208100010
PM 17486421
DA 2024-02-19
ER

PT J
AU Hu, XY
   Li, Y
   Li, LQ
   Zheng, Y
   Lv, JH
   Huang, SC
   Zhang, WN
   Liu, L
   Zhao, L
   Liu, ZG
   Zhao, XJ
AF Hu, Xiao-Yu
   Li, Yun
   Li, Long-Quan
   Zheng, Yuan
   Lv, Jia-Hong
   Huang, Shu-Chun
   Zhang, Weinong
   Liu, Liang
   Zhao, Ling
   Liu, Zhuiguo
   Zhao, Xiu-Ju
TI Risk factors and biomarkers of nonalcoholic fatty liver disease: an
   observational cross-sectional population survey
SO BMJ OPEN
LA English
DT Article
ID SERUM URIC-ACID; METABOLIC SYNDROME; INSULIN-RESISTANCE; PREVALENCE;
   CHINA; ESTERS; EPIDEMIOLOGY; METAANALYSIS; ASSOCIATION; ROTTERDAM
AB Objective Non-alcoholic fatty liver disease (NAFLD) is a major public health burden in China, and its prevalence is increasing. This study aimed to determine the risk factors and biomarkers of NAFLD.
   Design An observational cross-sectional primary survey.
   Setting Central China.
   Participants The study included 1479 participants aged over 18 and below 80 years, not currently being treated for cancer or infectious disease or no surgery in the previous year, and no history of cancer or an infectious disease. Participants underwent clinical examination, metabolomic assay and anthropometric assessment. Univariate and logistic regression analyses were used to evaluate associations between covariates and NAFLD.
   Main outcome measures Risk factors and metabolic biomarkers including sex, body mass index, hypertension, body fat ratio, blood triglycerides, blood fasting glucose, liver enzyme elevation, uric acid and oleic acid-hydroxy oleic acid (OAHOA).
   Results Data from the 447 participants (mean age 44.3 +/- 11.9 years) were analysed, and the prevalence of NAFLD was 24.7%. Male sex (OR 3.484, 95% CI 2.028 to 5.988), body mass index >= 24 kg/m(2) (OR 8.494, 95% CI 5.581 to 12.928), body fat ratio (>= 25 for women, >= 20 for men) (OR 1.833, 95% CI 1.286 to 2.756), triglycerides >= 1.7 mmol/L (OR 1.340, 95% CI 1.006 to 1.785), fasting glucose >= 6.1 mmol/L (OR 3.324, 95% CI 1.888 to 5.850), blood pressure >= 140/90 mm Hg or antihypertensive drug treatment (OR 1.451, 95% CI 1.069 to 1.970), uric acid (>= 357 mu mol/L for women, >= 416 mu mol/L for men) (OR 2.755, 95% CI 2.009 to 3.778) and OAHOA (< 5 nmol/L) (OR 1.340, 95% CI 1.006 to 1.785) were independent predictors of NAFLD (all P<0.05). These results were verified by all 1479 participants.
   Conclusions NAFLD was common among the study participants. In particular, NAFLD was correlated with uric acid. We identified OAHOA as a novel marker of NAFLD prevalence. It provides a reference on the prevention of NAFLD and related metabolic diseases with the rapid urbanisation, technological advancement and population ageing in China over the recent decades.
C1 [Hu, Xiao-Yu; Li, Yun; Li, Long-Quan; Zheng, Yuan; Lv, Jia-Hong; Huang, Shu-Chun; Zhang, Weinong; Liu, Liang; Zhao, Ling; Liu, Zhuiguo; Zhao, Xiu-Ju] Wuhan Polytech Univ, Sch Biol & Pharmaceut Engn, Wuhan, Hubei, Peoples R China.
   [Zhao, Xiu-Ju] Chinese Acad Agr Sci, Oil Crops Res Inst, Hubei Key Lab Lipid Chem & Nutr Oil, Wuhan, Hubei, Peoples R China.
   [Zhao, Xiu-Ju] Texas A&M Univ, Dept Nutr & Food Sci, College Stn, TX 77843 USA.
C3 Wuhan Polytechnic University; Chinese Academy of Agricultural Sciences;
   Oil Crops Research Institute, CAAS; Texas A&M University System; Texas
   A&M University College Station
RP Zhao, XJ (corresponding author), Wuhan Polytech Univ, Sch Biol & Pharmaceut Engn, Wuhan, Hubei, Peoples R China.; Zhao, XJ (corresponding author), Chinese Acad Agr Sci, Oil Crops Res Inst, Hubei Key Lab Lipid Chem & Nutr Oil, Wuhan, Hubei, Peoples R China.; Zhao, XJ (corresponding author), Texas A&M Univ, Dept Nutr & Food Sci, College Stn, TX 77843 USA.
EM dzrdez@163.com
RI yang, yijing/JWO-8234-2024; Zhang, Yanchao/JMB-7717-2023; zhao,
   xiu-ju/A-6529-2012; zhang, yu/HNS-5948-2023; wu, yi/JEP-1581-2023; zhen,
   wang/KBA-3844-2024; ZHAO, Ling/HDW-3668-2022; lu, yang/IWE-3635-2023;
   liu, jiaming/IWE-3196-2023; wang, qiang/IZW-1751-2023; zheng,
   yuan/JCN-7781-2023
OI zhao, xiu-ju/0000-0003-4962-6285; ZHAO, Ling/0000-0003-4932-499X; 
FU Opening Project of Hubei Key Laboratory of Lipid Chemistry and Nutrition
   of Oil [201506]; National Nature Science Foundation of China [21602166]
FX This work was supported in part by the Opening Project of Hubei Key
   Laboratory of Lipid Chemistry and Nutrition of Oil (201506) and the
   National Nature Science Foundation of China (21602166).
CR An DD, 2014, CELL, V156, P123, DOI 10.1016/j.cell.2013.11.042
   Ayonrinde OT, 2011, HEPATOLOGY, V53, P800, DOI 10.1002/hep.24097
   Baba M, 2011, BMC GASTROENTEROL, V11, DOI 10.1186/1471-230X-11-70
   Bano A, 2016, J CLIN ENDOCR METAB, V101, P3204, DOI 10.1210/jc.2016-1300
   Bansal Sushil K, 2012, J Cardiovasc Dis Res, V3, P117, DOI 10.4103/0975-3583.95365
   Becker K, 1997, J HEPATOL, V26, P1408, DOI 10.1016/S0168-8278(97)80479-5
   Boussageon R, 2012, PLOS MED, V9, DOI 10.1371/journal.pmed.1001204
   Cai W, 2013, ARQ BRAS ENDOCRINOL, V57, P617, DOI 10.1590/S0004-27302013000800006
   Cui J, 2016, HEPATOLOGY, V64, P1547, DOI 10.1002/hep.28674
   Dunn W, 2008, AM J GASTROENTEROL, V103, P2263, DOI 10.1111/j.1572-0241.2008.02034.x
   Fan JG, 2005, J HEPATOL, V43, P508, DOI 10.1016/j.jhep.2005.02.042
   Fan JG, 2009, J HEPATOL, V50, P204, DOI 10.1016/j.jhep.2008.10.010
   Fan NG, 2016, J DIABETES RES, V2016, DOI 10.1155/2016/3805372
   Gustafson DL, 1998, CANCER LETT, V129, P39, DOI 10.1016/S0304-3835(98)00078-0
   Hamaguchi M, 2007, AM J GASTROENTEROL, V102, P2708, DOI 10.1111/j.1572-0241.2007.01526.x
   Koehler EM, 2012, J HEPATOL, V57, P1305, DOI 10.1016/j.jhep.2012.07.028
   Kolar MJ, 2016, BIOCHEMISTRY-US, V55, P4636, DOI 10.1021/acs.biochem.6b00565
   Lee J, 2016, J BIOL CHEM, V291, P22207, DOI 10.1074/jbc.M115.703835
   Li YL, 2015, CELL BIOCHEM BIOPHYS, V72, P643, DOI 10.1007/s12013-014-0346-1
   Liu ZT, 2015, SCI REP-UK, V5, DOI 10.1038/srep14325
   Marchesini G, 1999, AM J MED, V107, P450, DOI 10.1016/S0002-9343(99)00271-5
   Menni C, 2013, INT J EPIDEMIOL, V42, P1111, DOI 10.1093/ije/dyt094
   Moraes-Vieira PM, 2016, DIABETES, V65, P1808, DOI 10.2337/db16-0221
   Nordestgaard BG, 2012, PLOS MED, V9, DOI 10.1371/journal.pmed.1001212
   Ong JP, 2008, J HEPATOL, V49, P608, DOI 10.1016/j.jhep.2008.06.018
   Pagano G, 2002, HEPATOLOGY, V35, P367, DOI 10.1053/jhep.2002.30690
   Parsons WH, 2016, NAT CHEM BIOL, V12, P367, DOI [10.1038/nchembio.2051, 10.1038/NCHEMBIO.2051]
   Qiu GK, 2016, INT J EPIDEMIOL, V45, P1507, DOI 10.1093/ije/dyw221
   ROY AK, 1983, ANNU REV PHYSIOL, V45, P37, DOI 10.1146/annurev.ph.45.030183.000345
   Schwimmer JB, 2006, PEDIATRICS, V118, P1388, DOI 10.1542/peds.2006-1212
   Sepe A, 2011, GERONTOLOGY, V57, P66, DOI 10.1159/000279755
   SITTHIAMORN C, 1993, LANCET, V342, P286, DOI 10.1016/0140-6736(93)91823-5
   Takasugi M, 2013, MECH AGEING DEV, V134, P331, DOI 10.1016/j.mad.2013.05.003
   Targher G, 2010, NEW ENGL J MED, V363, P1341, DOI 10.1056/NEJMra0912063
   Ting WH, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0154394
   Yang Y, 2016, GENET MOL RES, V15, DOI 10.4238/gmr.15028644
   Yore MM, 2014, CELL, V159, P318, DOI 10.1016/j.cell.2014.09.035
   Younossi ZM, 2016, HEPATOLOGY, V64, P73, DOI 10.1002/hep.28431
   Yusuf S, 2001, CIRCULATION, V104, P2746, DOI 10.1161/hc4601.099487
   Zhou YJ, 2007, WORLD J GASTROENTERO, V13, P6419, DOI 10.3748/wjg.13.6419
   Zhou YJ, 2016, CLIN BIOCHEM, V49, P636, DOI 10.1016/j.clinbiochem.2015.12.010
   Zhu QF, 2017, J CHROMATOGR B, V1061, P34, DOI 10.1016/j.jchromb.2017.06.045
NR 42
TC 39
Z9 41
U1 1
U2 10
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 2044-6055
J9 BMJ OPEN
JI BMJ Open
PD APR
PY 2018
VL 8
IS 4
AR e019974
DI 10.1136/bmjopen-2017-019974
PG 7
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GJ3FT
UT WOS:000435176700123
PM 29626047
OA Green Published, gold
DA 2024-02-19
ER

PT J
AU Justice, AC
   Freiberg, MS
   Tracy, R
   Kuller, L
   Tate, JP
   Goetz, MB
   Fiellin, DA
   Vanasse, GJ
   Butt, AA
   Rodriguez-Barradas, MC
   Gibert, C
   Oursler, KA
   Deeks, SG
   Bryant, K
AF Justice, Amy C.
   Freiberg, Matthew S.
   Tracy, Russ
   Kuller, Lew
   Tate, Janet P.
   Goetz, Matthew Bidwell
   Fiellin, David A.
   Vanasse, Gary J.
   Butt, Adeel A.
   Rodriguez-Barradas, Maria C.
   Gibert, Cynthia
   Oursler, Kris Ann
   Deeks, Steven G.
   Bryant, Kendall
CA VACS Project Team
TI Does an Index Composed of Clinical Data Reflect Effects of Inflammation,
   Coagulation, and Monocyte Activation on Mortality Among Those Aging With
   HIV?
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Article
ID ANTIRETROVIRAL THERAPY; COLLABORATIVE ANALYSIS; FIBROSIS; COHORT;
   CLEARANCE; INFECTION; ANEMIA; IMPACT; RISK
AB Background. When added to age, CD4 count and human immunodeficiency virus type 1 (HIV-1) RNA alone (Restricted Index), hemoglobin, FIB-4 Index, hepatitis C virus (HCV), and estimated glomerular filtration rate improve prediction of mortality. Weighted and combined, these 7 routine clinical variables constitute the Veterans Aging Cohort Study (VACS) Index. Because nonroutine biomarkers of inflammation (interleukin 6 [IL-6]), coagulation (D-dimer), and monocyte activation (sCD14) also predict mortality, we test the association of these indices and biomarkers with each other and with mortality.
   Methods. Samples from 1302 HIV-infected veterans on antiretroviral therapy were analyzed. Indices were calculated closest to date of collection. We calculated Spearman correlations stratified by HIV-1 RNA and HCV status and measured association with mortality using C statistics and net reclassification improvement (NRI).
   Results. Of 1302 subjects, 915 had HIV-1 RNA < 500 copies/mL and 154 died. The VACS Index was more correlated with IL-6, D-dimer, and sCD14 than the Restricted Index (P < .001). It was also more predictive of mortality (C statistic, 0.76; 95% confidence interval [CI],.72-.80) than any biomarker (C statistic, 0.66-0.70) or the Restricted Index (C statistic, 0.71; 95% CI,.67-.75). Compared to the Restricted Index alone, NRI resulted from incremental addition of VACS Index components (10%), D-dimer (7%), and sCD14 (4%), but not from IL-6 (0%).
   Conclusions. Among HIV-infected individuals, independent of CD4, HIV-1 RNA, and age, hemoglobin and markers of liver and renal injury are associated with inflammation. Addition of D-dimer and sCD14, but not IL-6, improves the predictive accuracy of the VACS Index for mortality.
C1 [Justice, Amy C.; Tate, Janet P.] Vet Affairs Connecticut Healthcare Syst, West Haven, CT USA.
   [Fiellin, David A.] Yale Univ, Dept Med, New Haven, CT 06520 USA.
   [Justice, Amy C.; Tate, Janet P.] Yale Univ, Gen Internal Med Sect, New Haven, CT USA.
   [Freiberg, Matthew S.; Butt, Adeel A.] Univ Pittsburgh, Sch Med, Pittsburgh, PA 15260 USA.
   [Freiberg, Matthew S.; Kuller, Lew] Univ Pittsburgh, Grad Sch Publ Hlth, Pittsburgh, PA 15260 USA.
   [Tracy, Russ] Univ Vermont, Coll Med, Burlington, VT 05405 USA.
   [Goetz, Matthew Bidwell] Vet Affairs Greater Los Angeles Hlth Care Syst, Los Angeles, CA USA.
   [Goetz, Matthew Bidwell] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
   [Vanasse, Gary J.] Harvard Univ, Sch Med, Dept Med, Brigham & Womens Hosp, Boston, MA USA.
   [Rodriguez-Barradas, Maria C.] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA.
   [Rodriguez-Barradas, Maria C.] Baylor Coll Med, Infect Dis Sect, Houston, TX 77030 USA.
   [Gibert, Cynthia] Washington DC Vet Affairs Med Ctr, Washington, DC USA.
   [Gibert, Cynthia] George Washington Univ, Sch Med, Washington, DC USA.
   [Oursler, Kris Ann] Baltimore Vet Affairs Hlth Care Syst, Baltimore, MD USA.
   [Oursler, Kris Ann] Univ Maryland, Sch Med, Baltimore, MD 21201 USA.
   [Deeks, Steven G.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA.
   [Bryant, Kendall] NIAAA, Bethesda, MD USA.
C3 US Department of Veterans Affairs; Veterans Health Administration (VHA);
   VA Connecticut Healthcare System; Yale University; Yale University;
   Pennsylvania Commonwealth System of Higher Education (PCSHE); University
   of Pittsburgh; Pennsylvania Commonwealth System of Higher Education
   (PCSHE); University of Pittsburgh; University of Vermont; US Department
   of Veterans Affairs; Veterans Health Administration (VHA); VA Greater
   Los Angeles Healthcare System; University of California System;
   University of California Los Angeles; University of California Los
   Angeles Medical Center; David Geffen School of Medicine at UCLA; Harvard
   University; Harvard Medical School; Brigham & Women's Hospital; Baylor
   College of Medicine; US Department of Veterans Affairs; Veterans Health
   Administration (VHA); Michael E DeBakey VA Medical Center; Baylor
   College of Medicine; George Washington University; University System of
   Maryland; University of Maryland Baltimore; University of California
   System; University of California San Francisco; National Institutes of
   Health (NIH) - USA; NIH National Institute on Alcohol Abuse & Alcoholism
   (NIAAA)
RP Justice, AC (corresponding author), VA CT Healthcare Syst 11ACSLG, Bldg 35A,Rm 2-212,950 Campbell Ave, West Haven, CT 06516 USA.
EM amy.justice2@va.gov
RI Freiberg, Matthew/IYJ-5456-2023; Goetz, Matthew Bidwell/GPX-4090-2022
OI Goetz, Matthew/0000-0003-4542-992X; Fiellin, David/0000-0002-4006-010X
FU National Institutes of Health; National Institute on Alcohol Abuse and
   Alcoholism [U10-AA13566]; National Heart, Lung, and Blood Institute
   [R01-HL095136, R01-HL090342, RCI-HL100347]; National Institute on Aging
   [R01-AG029154, K23 AG024896]; Training Program in Environmental
   Epidemiology [T32 ES07069]
FX This work was supported by the National Institutes of Health: National
   Institute on Alcohol Abuse and Alcoholism (U10-AA13566), National Heart,
   Lung, and Blood Institute (R01-HL095136; R01-HL090342; RCI-HL100347),
   and National Institute on Aging (R01-AG029154; K23 AG024896). J. P. T.
   was supported by the Training Program in Environmental Epidemiology (T32
   ES07069).
CR Akgun KM, 2010, AM THROACIC SOC
   Al-Mohri H, 2007, JAIDS-J ACQ IMM DEF, V44, P463, DOI 10.1097/QAI.0b013e318030ff8e
   Barraclough K, 2009, NEPHRON CLIN PRACT, V111, pC39, DOI 10.1159/000178978
   Brenchley JM, 2006, NAT MED, V12, P1365, DOI 10.1038/nm1511
   Brown ST, 2010, INT AIDS C
   Brüünsgaard H, 2003, IMMUNOL ALLERGY CLIN, V23, P15, DOI 10.1016/S0889-8561(02)00056-5
   Centers for Disease Control and Prevention, 2009, HIV AIDS SURV REP
   Cook NR, 2007, CIRCULATION, V115, P928, DOI 10.1161/CIRCULATIONAHA.106.672402
   Cook NR, 2009, ANN INTERN MED, V150, P795, DOI 10.7326/0003-4819-150-11-200906020-00007
   Deeks SG, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.a3172
   Fultz SL, 2006, MED CARE, V44, pS25, DOI 10.1097/01.mlr.0000223670.00890.74
   Harris RJ, 2008, ANTIVIR THER, V13, P959
   Justice AC, 2010, HIV MED, V11, P143, DOI 10.1111/j.1468-1293.2009.00757.x
   Justice AC, 2011, 18 C RETR OPP INF BO
   Justice Amy C, 2006, Top HIV Med, V14, P159
   Justice AC, 2006, MED CARE, V44, pS13, DOI 10.1097/01.mlr.0000223741.02074.66
   Justice Amy C, 2010, Curr HIV/AIDS Rep, V7, P69, DOI 10.1007/s11904-010-0041-9
   Kitahata MM, 2009, NEW ENGL J MED, V360, P1815, DOI 10.1056/NEJMoa0807252
   Kuller LH, 2008, PLOS MED, V5, P1496, DOI 10.1371/journal.pmed.0050203
   McGinnis KA, 2006, J CLIN ONCOL, V24, P5005, DOI 10.1200/JCO.2006.05.7984
   Mocroft A, 2009, CLIN INFECT DIS, V48, P1138, DOI 10.1086/597468
   Monforte AD, 2005, ARCH INTERN MED, V165, P416
   Moore RD, 2002, J ACQ IMMUN DEF SYND, V29, P54, DOI 10.1097/00042560-200201010-00007
   Neuhaus J, 2010, J INFECT DIS, V201, P1788, DOI 10.1086/652749
   Piasecki BA, 2004, HEPATOLOGY, V40, P892, DOI [10.1002/hep.20384, 10.1002/hep.1840400419]
   Ravasi G, 2009, HIV MED, V10, P219, DOI 10.1111/j.1468-1293.2008.00673.x
   Sandler NG, 2011, J INFECT DIS, V203, P780, DOI 10.1093/infdis/jiq118
   Sterling RK, 2006, HEPATOLOGY, V43, P1317, DOI 10.1002/hep.21178
   Sterne JAC, 2009, LANCET, V373, P1352, DOI 10.1016/S0140-6736(09)60612-7
   Tate J, 2011, INT VALIDATED MORTAL
   Tate JP, 2010, 48 ANN M INF DIS SOC
   Tate JP, 2011, 15 INT WORKSH HIV OB
   Vallet-Pichard A, 2007, HEPATOLOGY, V46, P32, DOI 10.1002/hep.21669
   Weber R, 2006, ARCH INTERN MED, V166, P1632, DOI 10.1001/archinte.166.15.1632
NR 34
TC 177
Z9 191
U1 0
U2 7
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1058-4838
EI 1537-6591
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD APR 1
PY 2012
VL 54
IS 7
BP 984
EP 994
DI 10.1093/cid/cir989
PG 11
WC Immunology; Infectious Diseases; Microbiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology; Infectious Diseases; Microbiology
GA 905TB
UT WOS:000301296200023
PM 22337823
OA Bronze, Green Published, Green Submitted
DA 2024-02-19
ER

PT J
AU Bassouni, R
   Soliman, M
   Hussein, LA
   Monir, Z
   Abd El-Meged, AA
AF Bassouni, Rania
   Soliman, Magda
   Hussein, Laila Abbas
   Monir, Zeinab
   Abd El-Meged, Ashraf A.
TI Development and evaluating the biopotency of ready to eat liver meat
   balls in fighting anaemia and vitamin A deficiency, improving selected
   nutritional biochemical indicators and promoting the cognitive function
   among mildly anaemic Egyptian children aged 3-9 years
SO PUBLIC HEALTH NUTRITION
LA English
DT Article; Early Access
DE Ready to eat liver meat balls; Egyptian children 3-9 years; Anaemia;
   Vitamin A deficiency; Systemic Ig A; Urinary hydroxyl proline index;
   Cognitive function
ID ANIMAL-SOURCED FOODS; IRON-ABSORPTION; SOY PROTEIN; SUPPLEMENTATION;
   YOUNG; BIOAVAILABILITY; INFANTS; GROWTH; GUT
AB Objective: Ready to eat fried liver meat balls (LMB) were developed to fight anaemia and vitamin A deficiency and promote cognitive function. Design: Randomised controlled trial consisting of two arms: control group with no supplement and LMB group receiving LMB supplement three times a week for 90 d. Criteria of evaluations included dietary assessment, anthropometric measurements, laboratory investigations and cognitive function by Wechsler test. Setting: Kinder Garten and primary school in Urban Giza. Participants: Sixty boys and girls aging 3-9 years. Results: The LMB supplement contributed to significant increases in the intakes of high bioavailable Fe and vitamin A in the diets of all children. Initial overall prevalence of mild and moderate anaemia was 43 %, which disappeared completely from all children aging < 72 months and from 88 % of children >= 72 months after the 90 d dietary intervention with the LMB. Faecal systemic immune globulin A, urinary hydroxyproline index and urinary iodine excretion increased significantly (P < 0 center dot 05) only after the dietary intervention with the LMB supplement for 90 d. The standard scores of verbal and non-verbal cognitive function tests (Delta day 90-day 0) increased significantly (P < 0 center dot 05) among the LMB group compared with the respective changes observed among the control group. The increase in height-for-age Z score and blood Hb were good predictors for improvement in cognitive function. Conclusion: LMB supplement is effective sustainable nutritious biotherapeutic food in fighting hidden hunger and promoting the cognitive function.
C1 [Bassouni, Rania; Soliman, Magda; Hussein, Laila Abbas] Natl Res Ctr, Dept Nutr & Food Sci, Cairo, Egypt.
   [Monir, Zeinab] Natl Res Ctr, Dept Child Hlth, Cairo, Egypt.
   [Abd El-Meged, Ashraf A.] Helwan Univ, Dept Food Sci & Nutr, Cairo, Egypt.
C3 Egyptian Knowledge Bank (EKB); National Research Centre (NRC); Egyptian
   Knowledge Bank (EKB); National Research Centre (NRC); Egyptian Knowledge
   Bank (EKB); Helwan University
RP Hussein, LA (corresponding author), Natl Res Ctr, Dept Nutr & Food Sci, Cairo, Egypt.
EM dr.lailahussein@yahoo.com
CR Abdel-Aziz S., 1997, EGYPT J NUTR, V12, P29
   AbdelAziz SA, 1997, FOOD CHEM, V60, P389, DOI 10.1016/S0308-8146(96)00357-3
   Adesogan AT, 2020, GLOB FOOD SECUR-AGR, V25, DOI 10.1016/j.gfs.2019.100325
   [Anonymous], 2004, VIT MIN REQ HUM NUTR
   [Anonymous], 2016, Guideline: Use of Multiple Micronutrient Powders for Point-of-Use Fortification of Foods Consumed by Pregnant Women
   Balehegn M, 2019, ANIM FRONT, V9, P50, DOI 10.1093/af/vfz039
   Buzina-Suboticanec Kornelia, 1998, Food and Nutrition Bulletin, V19, P298
   Cross JH, 2015, SCI REP-UK, V5, DOI 10.1038/srep16670
   DAVY KP, 1994, J APPL PHYSIOL, V76, P2059, DOI 10.1152/jappl.1994.76.5.2059
   De-Regil LM, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009666.pub2
   Delanghe JR, 2011, CLIN KIDNEY J, V4, P83, DOI 10.1093/ndtplus/sfq211
   Dostal A, 2014, BRIT J NUTR, V112, P547, DOI 10.1017/S0007114514001160
   Elnaggar B., 1982, EGYPT J HAEMATOL, V7, P179
   FAIRWEATHERTAIT SJ, 1992, ANN NUTR METAB, V36, P34, DOI 10.1159/000177696
   Garcia-Casal MN, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010187.pub2
   GORDELADZE JO, 1978, BIOCHEM MED METAB B, V20, P23, DOI 10.1016/0006-2944(78)90046-7
   HALLBERG L, 1992, NESTLE NUTR WORKS SE, V30, P169
   Headey D, 2018, AM J AGR ECON, V100, P1302, DOI 10.1093/ajae/aay053
   [Herlich K. AOAC. AOAC.], 1990, OFFICIAL METHODS ANA, V15th
   Hoppe M, 2008, EUR J CLIN NUTR, V62, P761, DOI 10.1038/sj.ejcn.1602776
   Hulett JL, 2014, BRIT J NUTR, V111, P875, DOI 10.1017/S0007114513003310
   HURRELL RF, 1992, AM J CLIN NUTR, V56, P573, DOI 10.1093/ajcn/56.3.573
   Jacobs DR, 2009, AM J CLIN NUTR, V89, pS1543, DOI 10.3945/ajcn.2009.26736B
   LaGrone LN, 2012, AM J CLIN NUTR, V95, P212, DOI 10.3945/ajcn.111.022525
   Lönnerdal B, 2017, AM J CLIN NUTR, V106, p1681S, DOI 10.3945/ajcn.117.156042
   Martorell R, 2017, AM J HUM BIOL, V29, DOI 10.1002/ajhb.22952
   McCance R. A., 2015, McCance and Widdowson's The Composition of Foods
   Mehdad A, 2010, ANN NUTR METAB, V57, P35, DOI 10.1159/000315528
   MURPHY SP, 1992, AM J CLIN NUTR, V56, P565, DOI 10.1093/ajcn/56.3.565
   Nair KM, 2013, J NUTR, V143, P852, DOI 10.3945/jn.112.171702
   Neumann CG, 2007, J NUTR, V137, P1119, DOI 10.1093/jn/137.4.1119
   OHKAWA H, 1979, ANAL BIOCHEM, V95, P351, DOI 10.1016/0003-2697(79)90738-3
   Paganini D, 2017, AM J CLIN NUTR, V106, p1688S, DOI 10.3945/ajcn.117.156067
   Pimpin L, 2019, AM J CLIN NUTR, V110, P410, DOI 10.1093/ajcn/nqy348
   Prado EL, 2016, PEDIATRICS, V138, DOI 10.1542/peds.2015-4698
   Ruiz JD, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147741
   Salam RA, 2020, NUTRIENTS, V12, DOI 10.3390/nu12010049
   Schofield W N, 1985, Hum Nutr Clin Nutr, V39 Suppl 1, P5
   SDG, The Sustainable Development Goals Report 2022
   Seong PN, 2015, KOREAN J FOOD SCI AN, V35, P179, DOI 10.5851/kosfa.2015.35.2.179
   Simpson RJ, 2009, CELL METAB, V10, P84, DOI 10.1016/j.cmet.2009.06.009
   Stein AJ, 2007, FOOD NUTR BULL, V28, P125, DOI 10.1177/156482650702800201
   1993, METHODS MEASURING IO
   van Stuijvenberg ME, 2020, MATERN CHILD NUTR, V16, DOI 10.1111/mcn.12931
   Hoang VN, 2019, APPL ECON, V51, P2001, DOI 10.1080/00036846.2018.1537476
   Wechsler D., 2001, Wechsler Individual Achievement Test -, VSecond
   West AR, 2008, WORLD J GASTROENTERO, V14, P4101, DOI 10.3748/wjg.14.4101
   WHITEHEAD RG, 1965, LANCET, V2, P567
   WHO, 2011, WHO TECH REP SER, V959, P1
   *WHO, 2006, SOFTW ASS GROWTH DEV
NR 50
TC 1
Z9 1
U1 0
U2 1
PU CAMBRIDGE UNIV PRESS
PI CAMBRIDGE
PA EDINBURGH BLDG, SHAFTESBURY RD, CB2 8RU CAMBRIDGE, ENGLAND
SN 1368-9800
EI 1475-2727
J9 PUBLIC HEALTH NUTR
JI Public Health Nutr.
PD 2022 NOV
PY 2022
VL 25
IS 11
BP 3182
EP 3194
AR PII S1368980022000970
DI 10.1017/S1368980022000970
EA APR 2022
PG 13
WC Public, Environmental & Occupational Health; Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Public, Environmental & Occupational Health; Nutrition & Dietetics
GA 5J4QH
UT WOS:000836481800001
PM 35451359
OA gold, Green Published
DA 2024-02-19
ER

PT J
AU Fukunaga, S
   Nakano, D
   Tsutsumi, T
   Kawaguchi, T
   Eslam, M
   Yoshinaga, S
   Abe, H
   Nouno, R
   Joh, S
   Mitsuyama, K
   George, J
   Torimura, T
AF Fukunaga, Shuhei
   Nakano, Dan
   Tsutsumi, Tsubasa
   Kawaguchi, Takumi
   Eslam, Mohammed
   Yoshinaga, Shinobu
   Abe, Hirohiko
   Nouno, Ryuichi
   Joh, Seiya
   Mitsuyama, Keiichi
   George, Jacob
   Torimura, Takuji
TI Lean/normal-weight metabolic dysfunction-associated fatty liver disease
   is a risk factor for reflux esophagitis
SO HEPATOLOGY RESEARCH
LA English
DT Article; Early Access
DE adiposity; body mass index; gastroesophageal reflux; obesity; overweight
ID DIABETES-MELLITUS; CLASSIFICATION; INTERLEUKIN-1; GUIDELINES; SYMPTOMS;
   LEPTIN
AB Aim Reflux esophagitis is associated with metabolic dysfunction. Recently, fatty liver has been redefined as metabolic dysfunction-associated fatty liver disease (MAFLD). We investigated the impact of MAFLD and its subtypes on the incidence of reflux esophagitis. Methods This multicenter, observational cohort study enrolled 9100 consecutive health-check examinees who underwent esophagogastroduodenoscopy and ultrasonography. All patients were classified into the MAFLD or non-MAFLD group. Based on the Asian cut-off value for body mass index (BMI), the MAFLD group was further classified into the lean/normal-weight (BMI <23 kg/m(2)) and overweight/obese (BMI >= 23 kg/m(2)) subgroups. The impact of MAFLD and its subtypes on the cumulative incidence of reflux esophagitis was evaluated using multivariable Cox proportional hazards regression analysis. Results MAFLD was diagnosed in 26.5% (2416/9100) of patients. Multivariable Cox proportional hazards regression analysis indicated that MAFLD (hazard ratio [HR] 1.2183; 95% confidence interval [CI] 1.0954-1.3550; p = 0.0003), hiatal hernia, and aging were independent risk factors for reflux esophagitis. Stratification analysis indicated that cumulative incidence of reflux esophagitis among patients with MAFLD was significantly higher in the lean/normal-weight than in the overweight/obese group (HR 1.3274; 95% CI 1.0043-1.7547; p = 0.0466). Among various metabolic factors, visceral adiposity was the only independent metabolic risk factor for reflux esophagitis (HR 2.8331; 95% CI 1.0201-7.8691; p = 0.0457) in the lean/normal-weight MAFLD group. Conclusions MAFLD, in particular lean/normal-weight MAFLD, is independent risk factor for reflux esophagitis. Furthermore, visceral adiposity was identified as the most strong metabolic risk factor for reflux esophagitis in lean/normal-weight patients with MAFLD.
C1 [Fukunaga, Shuhei; Nakano, Dan; Tsutsumi, Tsubasa; Kawaguchi, Takumi; Mitsuyama, Keiichi; Torimura, Takuji] Kurume Univ, Div Gastroenterol, Dept Med, Sch Med, 67 Asahi Machi, Kurume, Fukuoka 8300011, Japan.
   [Eslam, Mohammed; George, Jacob] Westmead Hosp, Westmead Inst Med Res, Storr Liver Ctr, Sydney, NSW, Australia.
   [Eslam, Mohammed; George, Jacob] Univ Sydney, Sydney, NSW, Australia.
   [Yoshinaga, Shinobu] Publ Util Fdn Saga Prefectural Hlth Promot Fdn, Med Examinat Sect, Med Examinat Part Facil, Saga, Japan.
   [Abe, Hirohiko; Nouno, Ryuichi] Kumamoto City Hosp, Kikuchi, Japan.
   [Joh, Seiya] Terao Hosp, Kumamoto, Japan.
C3 Kurume University; NSW Health; Westmead Hospital; University of Sydney;
   Westmead Institute for Medical Research; University of Sydney
RP Fukunaga, S (corresponding author), Kurume Univ, Div Gastroenterol, Dept Med, Sch Med, 67 Asahi Machi, Kurume, Fukuoka 8300011, Japan.
EM fukunaga_shyuuhei@med.kurume-u.ac.jp
RI 中野, 暖/IYJ-2642-2023; George, jacob/P-1496-2014; Eslam,
   Mohammed/JAD-0534-2023; Fukunaga, Shuhei/JXW-8580-2024
OI George, Jacob/0000-0002-8421-5476
FU National Health and Medical Research Council [APP1053206, APP1107178,
   APP1108422, APP1196492, APP2001692]; Japan Agency for Medical Research
   and Development [JP21fk0210090]
FX National Health and Medical Research Council, Grant/Award Numbers:
   APP1053206, APP1107178, APP1108422, APP1196492, APP2001692; Japan Agency
   for Medical Research and Development, Grant/Award Number: JP21fk0210090
CR Abdelkader NA, 2015, DIS ESOPHAGUS, V28, P691, DOI 10.1111/dote.12271
   Chen X, 2021, J HEPATOL, V75, P987, DOI 10.1016/j.jhep.2021.06.013
   Cheng YM, 2021, HEPATOL INT, V15, P405, DOI 10.1007/s12072-021-10147-0
   Dent J, 2008, BEST PRACT RES CL GA, V22, P585, DOI 10.1016/j.bpg.2008.01.002
   Duarte SMB, 2018, NUTR METAB CARDIOVAS, V28, P369, DOI 10.1016/j.numecd.2017.10.014
   El-Serag HB, 2014, GUT, V63, P871, DOI 10.1136/gutjnl-2012-304269
   Endo Y, 1998, BRIT J PHARMACOL, V125, P842, DOI 10.1038/sj.bjp.0702108
   Eslam M, 2020, J HEPATOL, V73, P202, DOI 10.1016/j.jhep.2020.03.039
   Fujiwara Y, 2005, AM J GASTROENTEROL, V100, P2633, DOI 10.1111/j.1572-0241.2005.00354.x
   Fukunaga S, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22115462
   Fuller G, 2017, DIGEST DIS SCI, V62, P593, DOI 10.1007/s10620-016-4440-7
   Hotamisligil GS, 2008, NAT REV IMMUNOL, V8, P923, DOI 10.1038/nri2449
   HUPPE D, 1992, CLIN INVESTIGATOR, V70, P740
   Inamori M, 2003, J GASTROEN HEPATOL, V18, P172, DOI 10.1046/j.1440-1746.2003.02932.x
   Irie M, 2016, EUR RESPIR J, V48, P495, DOI 10.1183/13993003.01939-2015
   Jansson C, 2007, ALIMENT PHARM THER, V26, P683, DOI 10.1111/j.1365-2036.2007.03411.x
   Kato M, 2011, J GASTROENTEROL, V46, P1361, DOI 10.1007/s00535-011-0453-3
   Katz PO, 2013, AM J GASTROENTEROL, V108, P308, DOI 10.1038/ajg.2012.444
   Kawaguchi T, 2022, CLIN MOL HEPATOL, V28, P150, DOI 10.3350/cmh.2021.0310
   Kawaguchi T, 2022, HEPATOL RES, V52, P422, DOI 10.1111/hepr.13706
   Lagergren J, 2000, GUT, V47, P26, DOI 10.1136/gut.47.1.26
   Lee YY, 2014, GUT, V63, P1053, DOI 10.1136/gutjnl-2013-305803
   Li J, 2016, ANN NY ACAD SCI, V1380, P183, DOI 10.1111/nyas.13157
   Mach F, 2019, ATHEROSCLEROSIS, V290, P140, DOI [10.1016/j.atherosclerosis.2019.08.014, 10.1093/eurheartj/ehz455]
   Min YW, 2018, J GASTROEN HEPATOL, V33, P1053, DOI 10.1111/jgh.14042
   Miwa H, 2008, DIS ESOPHAGUS, V21, P355, DOI 10.1111/j.1442-2050.2007.00788.x
   Mohammadi M, 2016, IRAN RED CRESCENT ME, V18, DOI 10.5812/ircmj.30363
   Mokrowiecka A, 2013, J PHYSIOL PHARMACOL, V64, P193
   Murata T, 2018, TOHOKU J EXP MED, V245, P45, DOI 10.1620/tjem.245.45
   Niigaki M, 2013, J GASTROENTEROL, V48, P463, DOI 10.1007/s00535-012-0671-3
   Roman S, 2014, BMJ-BRIT MED J, V349, DOI 10.1136/bmj.g6154
   Rydén L, 2013, EUR HEART J, V34, P3035, DOI 10.1093/eurheartj/eht108
   Saito K, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0212406
   Shida T, 2020, HEPATOL RES, V50, P1032, DOI 10.1111/hepr.13543
   SLOMSKI A, 2014, JAMA-J AM MED ASSOC, V311, P349
   Sun DQ, 2021, METABOLISM, V115, DOI 10.1016/j.metabol.2020.154433
   Sun XM, 2015, WORLD J GASTROENTERO, V21, P3085, DOI 10.3748/wjg.v21.i10.3085
   Suzuki T, 2001, AM J PHYSIOL-GASTR L, V281, pG1405, DOI 10.1152/ajpgi.2001.281.6.G1405
   Tomeno W, 2020, DIAGNOSTICS, V10, DOI 10.3390/diagnostics10110912
   Tsutsumi T, 2021, HEPATOL RES, V51, P1115, DOI 10.1111/hepr.13685
   Vakil N, 2006, AM J GASTROENTEROL, V101, P1900, DOI 10.1111/j.1572-0241.2006.00630.x
   Wang FW, 2010, DIGEST DIS SCI, V55, P1320, DOI 10.1007/s10620-009-0888-z
   Williams B, 2018, J HYPERTENS, V36, P2284, DOI [10.1097/HJH.0000000000001961, 10.1097/HJH.0000000000002026]
   Wong VWS, 2021, CLIN GASTROENTEROL H, V19, P2161, DOI 10.1016/j.cgh.2020.10.046
   Yamamura S, 2020, LIVER INT, V40, P3018, DOI 10.1111/liv.14675
   Yamamura S, 2020, HEPATOL RES, V50, P199, DOI 10.1111/hepr.13436
   Yoo KM, 2020, J GASTROEN HEPATOL, V35, P2088, DOI 10.1111/jgh.15082
   Zhou YJ, 2020, J HEPATOL, V73, P719, DOI 10.1016/j.jhep.2020.04.027
NR 48
TC 11
Z9 11
U1 2
U2 7
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1386-6346
EI 1872-034X
J9 HEPATOL RES
JI Hepatol. Res.
PD 2022 AUG
PY 2022
VL 52
IS 8
BP 699
EP 711
DI 10.1111/hepr.13795
EA JUN 2022
PG 13
WC Gastroenterology & Hepatology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Gastroenterology & Hepatology
GA 3N8VX
UT WOS:000807047200001
PM 35585481
DA 2024-02-19
ER

PT J
AU Uchiki, T
   Weikel, KA
   Jiao, WW
   Shang, F
   Caceres, A
   Pawlak, D
   Handa, JT
   Brownlee, M
   Nagaraj, R
   Taylor, A
AF Uchiki, Tomoaki
   Weikel, Karen A.
   Jiao, Wangwang
   Shang, Fu
   Caceres, Andrea
   Pawlak, Dorota
   Handa, James T.
   Brownlee, Michael
   Nagaraj, Ram
   Taylor, Allen
TI Glycation-altered proteolysis as a pathobiologic mechanism that links
   dietary glycemic index, aging, and age-related disease (in nondiabetics)
SO AGING CELL
LA English
DT Article
DE age-related macular degeneration; aging; glycemic index; proteolysis;
   ubiquitin
ID UBIQUITIN-PROTEASOME PATHWAY; CHAPERONE-MEDIATED AUTOPHAGY;
   END-PRODUCTS; OXIDATIVE STRESS; MACULAR DEGENERATION;
   PROTEIN-DEGRADATION; GLYOXALASE-I; HUMAN LENS; LIFE-SPAN;
   UBIQUITIN/PROTEASOME SYSTEM
AB Epidemiologic studies indicate that the risks for major age-related debilities including coronary heart disease, diabetes, and age-related macular degeneration (AMD) are diminished in people who consume lower glycemic index (GI) diets, but lack of a unifying physiobiochemical mechanism that explains the salutary effect is a barrier to implementing dietary practices that capture the benefits of consuming lower GI diets. We established a simple murine model of age-related retinal lesions that precede AMD (hereafter called AMD-like lesions). We found that consuming a higher GI diet promotes these AMD-like lesions. However, mice that consumed the lower vs. higher GI diet had significantly reduced frequency (P < 0.02) and severity (P < 0.05) of hallmark age-related retinal lesions such as basal deposits. Consuming higher GI diets was associated with > 3 fold higher accumulation of advanced glycation end products (AGEs) in retina, lens, liver, and brain in the age-matched mice, suggesting that higher GI diets induce systemic glycative stress that is etiologic for lesions. Data from live cell and cell-free systems show that the ubiquitinproteasome system (UPS) and lysosome/autophagy pathway [lysosomal proteolytic system (LPS)] are involved in the degradation of AGEs. Glycatively modified substrates were degraded significantly slower than unmodified substrates by the UPS. Compounding the detriments of glycative stress, AGE modification of ubiquitin and ubiquitin-conjugating enzymes impaired UPS activities. Furthermore, ubiquitin conjugates and AGEs accumulate and are found in lysosomes when cells are glycatively stressed or the UPS or LPS/autophagy are inhibited, indicating that the UPS and LPS interact with one another to degrade AGEs. Together, these data explain why AGEs accumulate as glycative stress increases.
C1 [Uchiki, Tomoaki; Weikel, Karen A.; Jiao, Wangwang; Shang, Fu; Caceres, Andrea; Taylor, Allen] Tufts Univ, Lab Nutr & Vis Res, USDA, Human Nutr Res Ctr Aging, Boston, MA 02111 USA.
   [Pawlak, Dorota] Harvard Univ, Sch Med, Childrens Hosp Boston, Boston, MA 02115 USA.
   [Handa, James T.] Johns Hopkins Sch Med, Wilmer Eye Inst, Baltimore, MD USA.
   [Brownlee, Michael] Albert Einstein Coll Med, Dept Med, Bronx, NY 10461 USA.
   [Nagaraj, Ram] Case Western Reserve Univ, Dept Ophthalmol & Visual Sci, Cleveland, OH 44106 USA.
C3 United States Department of Agriculture (USDA); Tufts University;
   Harvard University; Harvard Medical School; Boston Children's Hospital;
   Johns Hopkins University; Johns Hopkins Medicine; Yeshiva University;
   Albert Einstein College of Medicine; University System of Ohio; Case
   Western Reserve University
RP Taylor, A (corresponding author), Tufts Univ, Lab Nutr & Vis Res, USDA, Human Nutr Res Ctr Aging, 711 Washington St, Boston, MA 02111 USA.
EM allen.taylor@tufts.edu
OI Weikel, Karen/0000-0003-0317-7891
FU USDA [1950-510000-060-01A]; Johnson and Johnson Focused Giving; NIH [RO1
   EY 13250, RO1 EY 21212]
FX The authors are indebted to Jacqueline Nguyen and Nori Nagai for
   initiating the histology, Dr Mary Rayborn for electron microscopy, Drs
   John Baynes and Susan Thorpe for gifts of the CML antibody, A-M Cuervo
   for help in isolation of lysosomes. Dr David Ludwig contributed tissues
   from 129SvPas mice. We appreciate contributions of carbohydrates from
   National Starch. We thank Dr Obin for critical review of this
   manuscript. NIH RO1 13250, RO1 21212, USDA 1950-510000-060-01A. Funding
   from USDA 1950-510000-060-01A, Johnson and Johnson Focused Giving, NIH
   RO1 EY 13250, RO1 EY 21212 is gratefully acknowledged.
CR Ahmed EK, 2010, AGING CELL, V9, P252, DOI 10.1111/j.1474-9726.2010.00555.x
   Ahmed N, 2003, INVEST OPHTH VIS SCI, V44, P5287, DOI 10.1167/iovs.03-0573
   Augustin LS, 2002, EUR J CLIN NUTR, V56, P1049, DOI 10.1038/sj.ejcn.1601454
   Bedford L, 2008, J NEUROSCI, V28, P8189, DOI 10.1523/JNEUROSCI.2218-08.2008
   Bence NF, 2001, SCIENCE, V292, P1552, DOI 10.1126/science.292.5521.1552
   Bento CF, 2006, PLOS ONE, V5
   Brownlee M, 2001, NATURE, V414, P813, DOI 10.1038/414813a
   Bulteau AL, 2001, J BIOL CHEM, V276, P45662, DOI 10.1074/jbc.M105374200
   Caceres A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013331
   Cai WJ, 2008, AM J PATHOL, V173, P327, DOI 10.2353/ajpath.2008.080152
   Chen L, 2009, CELL MOL LIFE SCI, V66, P2559, DOI 10.1007/s00018-009-0058-7
   Chiu CJ, 2007, AM J CLIN NUTR, V86, P1210, DOI 10.1093/ajcn/86.4.1210
   Chiu CJ, 2007, AM J CLIN NUTR, V86, P180, DOI 10.1093/ajcn/86.1.180
   Chiu CJ, 2011, NUTR REV, V69, P231, DOI 10.1111/j.1753-4887.2011.00382.x
   Chiu CJ, 2011, PROG RETIN EYE RES, V30, P18, DOI 10.1016/j.preteyeres.2010.09.001
   Chiu CJ, 2007, INVEST OPHTH VIS SCI, V48, P2101
   Chylack Jr LT, 1994, INVEST OPHTH VIS SCI, V35, P42632
   CHYLACK LT, 1999, CRC MOD NUT, P25
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Dudek EJ, 2005, FASEB J, V19, P1707, DOI 10.1096/fj.05-4049fje
   Farboud B, 1999, MOL VIS, V5, pU1
   Gidalevitz T, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000399
   Glenn JV, 2009, BBA-GEN SUBJECTS, V1790, P1109, DOI 10.1016/j.bbagen.2009.04.016
   Glenn JV, 2009, INVEST OPHTH VIS SCI, V50, P441, DOI 10.1167/iovs.08-1724
   Goligorsky MS, 2009, CURR OPIN HEMATOL, V16, P215, DOI 10.1097/MOH.0b013e32832a07bd
   Guix FX, 2009, BRAIN, V132, P1335, DOI 10.1093/brain/awp023
   Hamer G, 2010, NAT METHODS, V7, P473, DOI [10.1038/NMETH.1460, 10.1038/nmeth.1460]
   Handa JT, 1999, INVEST OPHTH VIS SCI, V40, P775
   Hara T, 2006, NATURE, V441, P885, DOI 10.1038/nature04724
   Hartl FU, 2011, NATURE, V475, P324, DOI 10.1038/nature10317
   HERSHKO A, 1986, PROG NUCLEIC ACID RE, V33, P19, DOI 10.1016/S0079-6603(08)60019-7
   Hindle JV, 2010, AGE AGEING, V39, P156, DOI 10.1093/ageing/afp223
   Ihnat MA, 2007, DIABETIC MED, V24, P582, DOI 10.1111/j.1464-5491.2007.02138.x
   Ishibashi T, 1998, ARCH OPHTHALMOL-CHIC, V116, P1629, DOI 10.1001/archopht.116.12.1629
   Isken F, 2009, DIABETOLOGIA, V52, P2159, DOI 10.1007/s00125-009-1466-9
   JAHNGENHODGE J, 1992, EXP EYE RES, V55, P897, DOI 10.1016/0014-4835(92)90016-L
   JahngenHodge J, 1997, J BIOL CHEM, V272, P28218, DOI 10.1074/jbc.272.45.28218
   JENKINS DJA, 1981, AM J CLIN NUTR, V34, P362, DOI 10.1093/ajcn/34.3.362
   Jenkins DJA, 2002, AM J CLIN NUTR, V76, p266S, DOI 10.1093/ajcn/76.1.266S
   Johnston JA, 1998, J CELL BIOL, V143, P1883, DOI 10.1083/jcb.143.7.1883
   Kaganovich D, 2008, NATURE, V454, P1088, DOI 10.1038/nature07195
   Kasper M, 1999, BIOCHEM BIOPH RES CO, V261, P175, DOI 10.1006/bbrc.1999.0902
   Klionsky DJ, 2008, AUTOPHAGY, V4, P151, DOI 10.4161/auto.5338
   Koga H, 2011, AGEING RES REV, V10, P205, DOI 10.1016/j.arr.2010.02.001
   Komatsu M, 2006, NATURE, V441, P880, DOI 10.1038/nature04723
   Krishnan S, 2007, ARCH INTERN MED, V167, P2304, DOI 10.1001/archinte.167.21.2304
   Kuhla B, 2006, J NEUROSCI RES, V83, P1591, DOI 10.1002/jnr.20838
   Kwak YD, 2010, MOL NEURODEGENER, V5, DOI 10.1186/1750-1326-5-49
   Lindsten K, 2003, NAT BIOTECHNOL, V21, P897, DOI 10.1038/nbt851
   LOWE J, 1989, BRIT J HOSP MED, V42, P462
   Ludwig DS, 2002, JAMA-J AM MED ASSOC, V287, P2414, DOI 10.1001/jama.287.18.2414
   Martinez-Vicente M, 2008, J CLIN INVEST, V118, P777, DOI 10.1172/JCI32806
   Maynard CJ, 2009, P NATL ACAD SCI USA, V106, P13986, DOI 10.1073/pnas.0906463106
   Miller AG, 2006, J BIOL CHEM, V281, P11864, DOI 10.1074/jbc.M513813200
   Miyata S, 1997, J BIOL CHEM, V272, P4037, DOI 10.1074/jbc.272.7.4037
   Moheimani F, 2010, BBA-MOL BASIS DIS, V1802, P561, DOI 10.1016/j.bbadis.2010.02.007
   Morcos M, 2008, AGING CELL, V7, P260, DOI 10.1111/j.1474-9726.2008.00371.x
   Mulholland HG, 2008, BRIT J CANCER, V99, P434, DOI 10.1038/sj.bjc.6604496
   Munch IC, 2011, DIABETES RES CLIN PR, V91, P226, DOI 10.1016/j.diabres.2010.10.017
   Olzscha H, 2011, CELL, V144, P67, DOI 10.1016/j.cell.2010.11.050
   Ozdemir AM, 2008, AM J NEPHROL, V28, P14, DOI 10.1159/000108757
   Pawlak DB, 2004, LANCET, V364, P778, DOI 10.1016/S0140-6736(04)16937-7
   Rattner A, 2006, NAT REV NEUROSCI, V7, P860, DOI 10.1038/nrn2007
   Rodriguez KA, 2010, MECH AGEING DEV, V131, P144, DOI 10.1016/j.mad.2010.01.002
   Rosca MG, 2005, AM J PHYSIOL-RENAL, V289, pF420, DOI 10.1152/ajprenal.00415.2004
   Rubinsztein DC, 2006, NATURE, V443, P780, DOI 10.1038/nature05291
   Salmeron J, 1997, JAMA-J AM MED ASSOC, V277, P472, DOI 10.1001/jama.277.6.472
   Salomons FA, 2009, MOL CELL BIOL, V29, P1774, DOI 10.1128/MCB.01485-08
   Sasaki N, 1998, AM J PATHOL, V153, P1149, DOI 10.1016/S0002-9440(10)65659-3
   Scribner KB, 2008, AM J PHYSIOL-ENDOC M, V295, pE1126, DOI 10.1152/ajpendo.90487.2008
   Sebeková K, 1998, CELL MOL BIOL, V44, P1051
   SEUFERT W, 1990, EMBO J, V9, P543, DOI 10.1002/j.1460-2075.1990.tb08141.x
   SHANG F, 1995, BIOCHEM J, V307, P297, DOI 10.1042/bj3070297
   Shang F, 1997, J BIOL CHEM, V272, P23086, DOI 10.1074/jbc.272.37.23086
   Shang F, 2005, J BIOL CHEM, V280, P20365, DOI 10.1074/jbc.M414356200
   SHANG F, 1995, INVEST OPHTH VIS SCI, V36, pS528
   Shang F, 2006, ISR J CHEM, V46, P145, DOI 10.1560/A8AA-Y8RP-9DRW-Y8AX
   Shang F, 2011, FREE RADICAL BIO MED, V51, P5, DOI 10.1016/j.freeradbiomed.2011.03.031
   Snodderly DM, 2002, INVEST OPHTH VIS SCI, V43, P2815
   Stitt AW, 2005, ANN NY ACAD SCI, V1043, P582, DOI 10.1196/annals.1338.066
   SUAREZ G, 1995, ARCH BIOCHEM BIOPHYS, V321, P209, DOI 10.1006/abbi.1995.1387
   Taguchi A, 2007, SCIENCE, V317, P369, DOI 10.1126/science.1142179
   TAKIZAWA N, 1993, BIOCHEM BIOPH RES CO, V192, P700, DOI 10.1006/bbrc.1993.1471
   Taylor A, 2002, ONCOGENE, V21, P4363, DOI 10.1038/sj.onc.1205557
   Tessier F, 1999, J BIOL CHEM, V274, P20796, DOI 10.1074/jbc.274.30.20796
   Tezel G, 2007, INVEST OPHTH VIS SCI, V48, P1201, DOI 10.1167/iovs.06-0737
   Thornalley PJ, 2009, SEMIN DIALYSIS, V22, P400, DOI 10.1111/j.1525-139X.2009.00589.x
   Thornalley PJ, 2003, BIOCHEM J, V375, P581, DOI 10.1042/BJ20030763
   Thyberg J, 1999, LAB INVEST, V79, P1077
   Tian J, 2005, P NATL ACAD SCI USA, V102, P11846, DOI 10.1073/pnas.0504759102
   Tonoki A, 2009, MOL CELL BIOL, V29, P1095, DOI 10.1128/MCB.01227-08
   van Schothorst EM, 2009, FASEB J, V23, P1092, DOI 10.1096/fj.08-117119
   Verbeke P, 2000, BBA-MOL BASIS DIS, V1502, P481, DOI 10.1016/S0925-4439(00)00071-5
   Vernace VA, 2007, AGING CELL, V6, P599, DOI 10.1111/j.1474-9726.2007.00329.x
   Vlassara H, 2009, SEMIN NEPHROL, V29, P594, DOI 10.1016/j.semnephrol.2009.07.013
   Wang YP, 2007, P NATL ACAD SCI USA, V104, P10252, DOI 10.1073/pnas.0703676104
   Wang YP, 2009, HUM MOL GENET, V18, P4153, DOI 10.1093/hmg/ddp367
   Warburg O, 1924, BIOCHEM Z, V152, P51
   Wei Y, 2009, BMC CELL BIOL, V10, DOI 10.1186/1471-2121-10-10
   Weikel K, 2011, DUANES OPHTHALMOLOGY, V1
   Woltjer RL, 2003, J ALZHEIMERS DIS, V5, P467, DOI 10.3233/JAD-2003-5607
   Yamada Y, 2006, EXP EYE RES, V82, P840, DOI 10.1016/j.exer.2005.10.005
   Yao D, 2007, J BIOL CHEM, V282, P31038, DOI 10.1074/jbc.M704703200
   Yau JLW, 2007, J NEUROSCI, V27, P10487, DOI 10.1523/JNEUROSCI.2190-07.2007
   Yonekura H, 2005, J PHARMACOL SCI, V97, P305, DOI 10.1254/jphs.CPJ04005X
   Zetterberg M, 2006, INVEST OPHTH VIS SCI, V47, P3467, DOI 10.1167/iovs.05-1664
   Zhang C, 2008, NAT MED, V14, P959, DOI 10.1038/nm.1851
   Zhang NY, 2008, J BIOL CHEM, V283, P20288, DOI 10.1074/jbc.M710560200
   Zhang XY, 2007, INVEST OPHTH VIS SCI, V48, P4200, DOI 10.1167/iovs.07-0196
   Zhao ZS, 2009, ENDOCRINOLOGY, V150, P2569, DOI 10.1210/en.2008-1342
NR 110
TC 143
Z9 157
U1 0
U2 21
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1474-9726
J9 AGING CELL
JI Aging Cell
PD FEB
PY 2012
VL 11
IS 1
BP 1
EP 13
DI 10.1111/j.1474-9726.2011.00752.x
PG 13
WC Cell Biology; Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Geriatrics & Gerontology
GA 875LN
UT WOS:000299031500001
PM 21967227
OA Green Accepted, hybrid
DA 2024-02-19
ER

PT J
AU Theron, L
   Fernandez, X
   Marty-Gasset, N
   Chambon, C
   Viala, D
   Pichereaux, C
   Rossignol, M
   Astruc, T
   Molette, C
AF Theron, Laetitia
   Fernandez, Xavier
   Marty-Gasset, Nathalie
   Chambon, Christophe
   Viala, Didier
   Pichereaux, Carole
   Rossignol, Michel
   Astruc, Thierry
   Molette, Caroline
TI Proteomic Analysis of Duck Fatty Liver during Post-Mortem Storage
   Related to the Variability of Fat Loss during Cooking of "Foie Gras"
SO JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY
LA English
DT Article
DE proteomic; two-dimensional electrophoresis; mass spectrometry; shot-gun;
   fatty liver; duck; foie gras quality; technological yield
ID WATER-HOLDING CAPACITY; PROTEINS; MEAT; MUSCLES; BEEF
AB Fat loss during cooking of duck "foie gras" is the main problem for both manufacturers and consumers. Despite the efforts of the processing industry to control fat loss, the variability of fatty liver cooking yields remains high and uncontrolled. To understand the biochemical effects of postslaughter processing on fat loss during cooking, this study characterizes for the first time the protein expression of fatty liver during chilling using a proteomic approach. For this purpose the proteins were separated according to their solubility: the protein fraction soluble in a buffer of low ionic strength (S) and the protein fraction insoluble in the same buffer (IS). Two-dimensional electrophoresis was used to analyze the S fraction and mass spectrometry for the identification of spots of interest. This analysis revealed 36 (21 identified proteins) and 34 (26 identified proteins) spots of interests in the low-fat-loss and high-fat-loss groups, respectively. The expression of proteins was lower after chilling, which revealed a suppressive effect of chilling on biological processes. The shot-gun strategy was used to analyze the IS fraction, with the identification of all the proteins by mass spectrometry. This allowed identification of 554 and 562 proteins in the low-fat-loss and high-fat-loss groups, respectively. Among these proteins, only the proteins that were up-regulated in the high-fat-loss group were significant (p value = 3.17 X 10(-3)) and corresponded to protein from the cytoskeleton and its associated proteins. Taken together, these results suggest that the variability of technological yield observed in processing plants could be explained by different aging states of fatty livers during chilling, most likely associated with different proteolytic patterns.
C1 [Theron, Laetitia; Fernandez, Xavier; Marty-Gasset, Nathalie; Molette, Caroline] INRA, UMR Tissus Anim Nutr Digest Ecosyst & Metab 1289, F-31326 Castanet Tolosan, France.
   [Theron, Laetitia; Fernandez, Xavier; Marty-Gasset, Nathalie; Molette, Caroline] Univ Toulouse, INPT ENSAT, UMR Tissus Anim Nutr Digest Ecosyst Metab 1289, F-31326 Castanet Tolosan, France.
   [Theron, Laetitia; Fernandez, Xavier; Marty-Gasset, Nathalie; Molette, Caroline] Univ Toulouse, INPT ENVT, UMR Tissus Anim Nutr Digest Ecosyst Metab 1289, F-31076 Toulouse, France.
   [Pichereaux, Carole; Rossignol, Michel] CNRS, Plateforme Prote Genopole Toulouse Midi Pyrenees, IPBS IFR 40, UMR 5089, F-31077 Toulouse, France.
   [Chambon, Christophe; Viala, Didier] INRA, PFEM, F-63122 St Genes Champanelle, France.
   [Astruc, Thierry] INRA, UR QuaPA 370, F-63122 St Genes Champanelle, France.
C3 INRAE; Universite Federale Toulouse Midi-Pyrenees (ComUE); Universite de
   Toulouse; Institut National Polytechnique de Toulouse; Universite de
   Toulouse; Ecole Nationale Veterinaire de Toulouse; Centre National de la
   Recherche Scientifique (CNRS); CNRS - National Institute for Biology
   (INSB); Universite de Toulouse; Universite Toulouse III - Paul Sabatier;
   INRAE; INRAE
RP Molette, C (corresponding author), Univ Toulouse, INPT ENSAT, UMR Tissus Anim Nutr Digest Ecosyst Metab 1289, F-31326 Castanet Tolosan, France.
EM molette@ensat.fr
RI chambon, christophe/A-1788-2017
OI chambon, christophe/0000-0003-0357-9807; Pichereaux,
   Carole/0000-0002-7559-5358; Theron, Laetitia/0000-0003-3879-1496
FU INRA; CIFOG; Region Midi-Pyrenees
FX The financial support of INRA, CIFOG, and Region Midi-Pyrenees enabled
   the implementation of this project.
CR BAUDONNETLENFANT C, 1991, ANN ZOOTECH, V40, P161, DOI 10.1051/animres:19910303
   Blum J.-C., 1992, 19 WORLDS POULTR C, P240
   Borderies G, 2003, ELECTROPHORESIS, V24, P3421, DOI 10.1002/elps.200305608
   BOUILLIEROUDOT M, 2002, 5 JOURN RECH PALM FO, P172
   Bouyssié D, 2007, MOL CELL PROTEOMICS, V6, P1621, DOI 10.1074/mcp.T600069-MCP200
   FOLCH J, 1957, J BIOL CHEM, V226, P497
   Hopkins DL, 2002, AUST J AGR RES, V53, P149, DOI 10.1071/AR01079
   Koohmaraie M, 1996, Meat Sci, V43S1, P193, DOI 10.1016/0309-1740(96)00065-4
   Kristensen L, 2001, MEAT SCI, V58, P17, DOI 10.1016/S0309-1740(00)00125-X
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   Liu HB, 2004, ANAL CHEM, V76, P4193, DOI 10.1021/ac0498563
   Melody JL, 2004, J ANIM SCI, V82, P1195
   Meunier B, 2005, ANAL BIOCHEM, V340, P226, DOI 10.1016/j.ab.2005.02.028
   Molee W, 2005, COMP BIOCHEM PHYS B, V141, P437, DOI 10.1016/j.cbpc.2005.05.007
   Molly K, 1997, FOOD CHEM, V59, P539, DOI 10.1016/S0308-8146(97)00004-6
   Morzel M, 2006, J AGR FOOD CHEM, V54, P2997, DOI 10.1021/jf0528759
   RAUCH P, 1983, EXP MOL PATHOL, V39, P37, DOI 10.1016/0014-4800(83)90039-4
   Renerre M, 1996, MEAT SCI, V43, P111, DOI 10.1016/0309-1740(96)84583-9
   Renerre M, 1999, J AGR FOOD CHEM, V47, P237, DOI 10.1021/jf9805000
   Roncales P., 1995, EXPRESSION TISSUE PR, P311
   ROUSSELOTPAILLE.D, 1992, INRA PROD ANIM, V5, P167
   Sayd T, 2006, J AGR FOOD CHEM, V54, P2732, DOI 10.1021/jf052569v
   Théron L, 2011, MEAT SCI, V89, P377, DOI 10.1016/j.meatsci.2011.04.018
   Theron L, 2011, J AGR FOOD CHEM, V59, P12617, DOI 10.1021/jf203058x
   Théron L, 2011, MEAT SCI, V88, P82, DOI 10.1016/j.meatsci.2010.12.006
   Zhu M., 2010, J BIOMED BIOTECHNOL, DOI [10.1155/2010/840518, DOI 10.1155/2010/840518]
NR 26
TC 12
Z9 12
U1 0
U2 34
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0021-8561
J9 J AGR FOOD CHEM
JI J. Agric. Food Chem.
PD JAN 30
PY 2013
VL 61
IS 4
BP 920
EP 930
DI 10.1021/jf302979q
PG 11
WC Agriculture, Multidisciplinary; Chemistry, Applied; Food Science &
   Technology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Agriculture; Chemistry; Food Science & Technology
GA 083VF
UT WOS:000314492600019
PM 23234381
DA 2024-02-19
ER

PT J
AU Hamada, H
   Yatsuhashi, H
   Yano, K
   Daikoku, M
   Arisawa, K
   Inoue, S
   Koga, M
   Nakata, K
   Eguchi, K
   Yano, M
AF Hamada, H
   Yatsuhashi, H
   Yano, K
   Daikoku, M
   Arisawa, K
   Inoue, S
   Koga, M
   Nakata, K
   Eguchi, K
   Yano, M
TI Impact of aging on the development of hepatocellular carcinoma in
   patients with posttransfusion chronic hepatitis C
SO CANCER
LA English
DT Article
DE age; chronic hepatitis C virus (HCV); blood transfusion; hepatocellular
   carcinoma (HCC)
ID VIRUS-RELATED CIRRHOSIS; TERM FOLLOW-UP; NATURAL-HISTORY; CLINICAL
   CHARACTERISTICS; LIVER-CIRRHOSIS; UNITED-STATES; RISK-FACTORS; NON-A;
   INFECTION; PROGRESSION
AB BACKGROUND. Hepatitis C virus (HCV) infection is a heterogeneous disease, the natural history of which remains controversial. There is solid evidence that chronic HCV infection is responsible for the occurrence of hepatocellular carcinoma (HCC). The aim of the current cohort study was to determine the rate of the development of HCC from the time of primary HCV infection and to assess the risk factors for the development of HCC in chronic posttransfusion hepatitis C patients.
   METHODS. Four hundred sixty-nine patients with clinically compensated HCV, who had undergone a single blood transfusion comprised the current study cohort. Patients with other risk factors for chronic liver disease were excluded. All patients were referred to the liver center at the National Nagasaki Medical Center between December 1980 and December 1998 and were followed prospectively until the end of the analysis (June 2000).
   RESULTS. Follow-up data were obtained for 445 patients. The mean duration from HCV infection to the end of the observation was 28 years. Fifty-two patients (11.1%) progressed to HCC. The mean duration from the time of blood transfusion to the diagnosis of HCC was 31 years. Multivariate Cox regression analyses revealed age, fibrosis, duration from HCV infection to study entry, and alcohol consumption to be the independent factors affecting the development of HCC. The risk of developing HCC in patients age greater than or equal to 56 years was increased 7.8-fold compared with that in patients age < 56 years. The mean age of patients at the time of HCC diagnosis was 65 years (range, 58-79 years).
   CONCLUSIONS. At the time of diagnosis, 92% of the 52 HCC patients were age > 60 years and 38 of the HCC patients (73%) were in their 60s. There was a significantly negative correlation between the duration from HCV infection to the development of HCC and the age of the patient at the time of infection (correlation coefficient = 0.702; P < 0.0001; Y = 61.1-0.82X), indicating that the age of patients, rather than the duration of HCV infection, is more significant for HCC development in patients with posttransfusion HCV. Moreover, these data may contribute to the design of an optimal follow-up schedule for patients with posttransfusion HCV. (C) 2002 American Cancer Society.
C1 WHO, Inst Clin Res, Collaborating Ctr Reference & Res Viral Hepatitis, Natl Nagasaki Med Ctr, Nagasaki 8528562, Japan.
   Nagasaki Univ, Sch Med, Dept Internal Med 1, Nagasaki 852, Japan.
   Nagasaki Univ, Sch Med, Dept Prevent Med & Hlth Promot, Nagasaki 852, Japan.
C3 World Health Organization; Nagasaki University; Nagasaki University
RP Yatsuhashi, H (corresponding author), WHO, Inst Clin Res, Collaborating Ctr Reference & Res Viral Hepatitis, Natl Nagasaki Med Ctr, Kubara 2-1001-1, Nagasaki 8528562, Japan.
CR Aizawa Y, 2000, CANCER, V89, P53, DOI 10.1002/1097-0142(20000701)89:1<53::AID-CNCR8>3.3.CO;2-Y
   Alberti A, 1999, J HEPATOL, V31, P17, DOI 10.1016/S0168-8278(99)80369-9
   Alter MJ, 1999, NEW ENGL J MED, V341, P556, DOI 10.1056/NEJM199908193410802
   Balducci L, 2000, Oncologist, V5, P224, DOI 10.1634/theoncologist.5-3-224
   Corrao G, 1998, HEPATOLOGY, V27, P914, DOI 10.1002/hep.510270404
   DESMET VJ, 1994, HEPATOLOGY, V19, P1513, DOI 10.1002/hep.1840190629
   Di Bisceglie AM, 2000, HEPATOLOGY, V31, P1014, DOI 10.1053/he.2000.5762
   Goukassian D, 2000, FASEB J, V14, P1325, DOI 10.1096/fj.14.10.1325
   Hu KQ, 1999, HEPATOLOGY, V29, P1311, DOI 10.1002/hep.510290424
   Ikeda K, 1998, J HEPATOL, V28, P930, DOI 10.1016/S0168-8278(98)80339-5
   IKEDA K, 1993, HEPATOLOGY, V18, P47, DOI 10.1016/0270-9139(93)90505-H
   Kasahara A, 1998, HEPATOLOGY, V27, P1394, DOI 10.1002/hep.510270529
   Khan MH, 2000, HEPATOLOGY, V31, P513, DOI 10.1002/hep.510310236
   KIYOSAWA K, 1990, HEPATOLOGY, V12, P671, DOI 10.1002/hep.1840120409
   Kobayashi M, 1996, HEPATOLOGY, V23, P695, DOI 10.1053/jhep.1996.v23.pm0008666319
   Niederau C, 1998, HEPATOLOGY, V28, P1687, DOI 10.1002/hep.510280632
   NISHIGUCHI S, 1995, LANCET, V346, P1051, DOI 10.1016/S0140-6736(95)91739-X
   Noda K, 1996, ALCOHOL CLIN EXP RES, V20, pA95, DOI 10.1111/j.1530-0277.1996.tb01739.x
   Poynard T, 1997, LANCET, V349, P825, DOI 10.1016/S0140-6736(96)07642-8
   Schöniger-Hekele M, 2000, EUR J GASTROEN HEPAT, V12, P941, DOI 10.1097/00042737-200012080-00015
   Serfaty L, 1998, HEPATOLOGY, V27, P1435, DOI 10.1002/hep.510270535
   Shimauchi Y, 2000, ALCOHOL CLIN EXP RES, V24, p64S, DOI 10.1111/j.1530-0277.2000.tb00015.x
   SHIRATORI Y, 1995, HEPATOLOGY, V22, P1027, DOI 10.1002/hep.1840220403
   TAKANO S, 1995, HEPATOLOGY, V21, P650
   TONG MJ, 1995, NEW ENGL J MED, V332, P1463, DOI 10.1056/NEJM199506013322202
   TREMOLADA F, 1992, J HEPATOL, V16, P273, DOI 10.1016/S0168-8278(05)80657-9
   Wiley TE, 1998, HEPATOLOGY, V28, P805, DOI 10.1002/hep.510280330
   Yano M, 1996, HEPATOLOGY, V23, P1334, DOI 10.1053/jhep.1996.v23.pm0008675148
   YANO M, 1993, GUT, V34, pS13, DOI 10.1136/gut.34.2_Suppl.S13
   Yatsuhashi H, 2000, J GASTROEN HEPATOL, V15, pE111, DOI 10.1046/j.1440-1746.2000.02122.x
NR 30
TC 48
Z9 51
U1 0
U2 1
PU JOHN WILEY & SONS INC
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0008-543X
J9 CANCER
JI Cancer
PD JUL 15
PY 2002
VL 95
IS 2
BP 331
EP 339
DI 10.1002/cncr.10662
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 575CH
UT WOS:000176928100019
PM 12124834
OA hybrid
DA 2024-02-19
ER

PT J
AU Tumkosit, M
   Han, WM
   Tankittiwat, K
   Chattranukulchai, P
   Siwamogsatham, S
   Apornpong, T
   Ureaphongsukkit, T
   Kerr, SJ
   Boonyaratavej, S
   Avihingsanon, A
AF Tumkosit, Monravee
   Han, Win Min
   Tankittiwat, Kumpol
   Chattranukulchai, Pairoj
   Siwamogsatham, Sarawut
   Apornpong, Tanakorn
   Ureaphongsukkit, Thornthun
   Kerr, Stephen J.
   Boonyaratavej, Smonporn
   Avihingsanon, Anchalee
CA HIV-NAT 006 207 Study Team
TI Higher epicardial fat in older adults living with HIV with viral
   suppression and relationship with liver steatosis, coronary calcium and
   cardiometabolic risks
SO AIDS
LA English
DT Article
DE cardiovascular disease; epicardial fat volume; HIV; insulin resistance;
   liver steatosis
ID ADIPOSE-TISSUE VOLUME; INSULIN-RESISTANCE; CARDIOVASCULAR-DISEASE;
   BODY-COMPOSITION; INFLAMMATION; THERAPY; PEOPLE
AB Objectives: HIV infection is associated with ectopic fat deposition, which leads to chronic inflammation and cardiometabolic dysregulation. We assessed the epicardial adipose tissue (EAT) volume and its associated factors among people with HIV (PWH). Design: A cross-sectional study. Methods: We conducted a cross-sectional study among PWH aged at least 50 years and age-matched and sex-matched HIV-negative older individuals in Bangkok, Thailand. Participants underwent a noncontrast, cardiac computed tomography (CT) scan to assess coronary artery calcium (CAC) score and EAT between March 2016 and June 2017. Multivariate linear regression analyses were used to investigate HIV-related factors, cardiac and metabolic markers associated with EAT volume. Results: Median age was 55 years [interquartile range (IQR) 52-60] and 63% were men. Median duration of antiretroviral therapy (ART) was 16 years with 97% had HIV-1 RNA less than 50 copies/ml and median CD4(+) cell count of 617 cells/mu l. Median EAT volume was significantly higher in PWH [99 (IQR 75-122) cm(3)] than HIV-negative individuals [93 (IQR 69-117) cm(3)], P = 0.022. In adjusted model, factors associated with EAT volume included male sex (P = 0.045), older age (P < 0.001), abnormal waist circumference (P < 0.001) and HOMA-IR (P = 0.01). In addition, higher CAC score was independently associated with EAT volume. Higher mean EAT volume was seen in PWH with severe liver steatosis than those without steatosis (P = 0.018). In adjusted PWH-only model, duration of HIV was significantly associated with higher EAT volume (P = 0.028). Conclusion: In an aging cohort, PWH had higher EAT volume than HIV-negative controls. EAT was also independently associated with central fat accumulation, insulin resistance, liver steatosis and CAC score.
C1 [Tumkosit, Monravee; Tankittiwat, Kumpol] Chulalongkorn Univ, Fac Med, Dept Radiol, Bangkok, Thailand.
   [Han, Win Min; Apornpong, Tanakorn; Ureaphongsukkit, Thornthun; Kerr, Stephen J.; Avihingsanon, Anchalee] Thai Red Cross AIDS Res Ctr, HIV NAT, Bangkok, Thailand.
   [Han, Win Min; Kerr, Stephen J.] Univ New South Wales, Kirby Inst, Sydney, NSW, Australia.
   [Chattranukulchai, Pairoj; Boonyaratavej, Smonporn] Chulalongkorn Univ, Fac Med, Div Cardiovasc Med, Bangkok, Thailand.
   [Siwamogsatham, Sarawut] Chulalongkorn Univ, Fac Med, Div Ambulatory & Hosp Med, Bangkok, Thailand.
   [Siwamogsatham, Sarawut] Chulalongkorn Univ, Fac Med, Chula Clin Res Ctr, Bangkok, Thailand.
   [Kerr, Stephen J.] Chulalongkorn Univ, Fac Med, Biostat Excellence Ctr, Bangkok, Thailand.
   [Han, Win Min; Avihingsanon, Anchalee] Chulalongkorn Univ, Fac Med, Ctr Excellence TB, Bangkok, Thailand.
C3 Chulalongkorn University; Thai Red Cross Society; University of New
   South Wales Sydney; Kirby Institute; Chulalongkorn University;
   Chulalongkorn University; Chulalongkorn University; Chulalongkorn
   University; Chulalongkorn University
RP Avihingsanon, A (corresponding author), 104 Ratchadamri Rd, Bangkok 10330, Thailand.
EM anchaleea2009@gmail.com
RI Kerr, Stephen/J-6126-2012; Han, Win Min/ABB-5988-2020
OI Kerr, Stephen/0000-0002-1919-4525; 
FU Higher Education Research Promotion and National Research University
   Project of Thailand, Office of the Higher Education Commission;
   Chulalongkorn University [NRU59-(014)-HR]; Ratchadapiseksompotch Fund
   [RA59/082]
FX this study was supported by the Higher Education Research Promotion and
   National Research University Project of Thailand, Office of the Higher
   Education Commission, and Chulalongkorn University, Project code
   NRU59-(014)-HR. Coronary artery calcium scoring was performed with the
   support of Ratchadapiseksompotch Fund (#RA59/082).
CR Alexopoulos N, 2013, J AM COLL CARDIOL, V61, P1956, DOI 10.1016/j.jacc.2012.12.051
   Brener M, 2014, AIDS, V28, P1635, DOI 10.1097/QAD.0000000000000116
   Brouha SS, 2018, EUR RADIOL, V28, P1345, DOI 10.1007/s00330-017-5075-6
   Forouzandeh F, 2013, CIRC-CARDIOVASC IMAG, V6, P58, DOI 10.1161/CIRCIMAGING.112.976316
   Fourman LT, 2017, PHYSIOL REP, V5, DOI 10.14814/phy2.13386
   Guaraldi G, 2011, AIDS, V25, P1199, DOI 10.1097/QAD.0b013e3283474b9f
   Hsue PY, 2012, J INFECT DIS, V205, pS375, DOI 10.1093/infdis/jis200
   Iacobellis G, 2005, J CLIN ENDOCR METAB, V90, P6300, DOI 10.1210/jc.2005-1087
   Iacobellis G, 2008, OBESITY, V16, P179, DOI 10.1038/oby.2007.50
   Iacobellis G, 2011, TRENDS ENDOCRIN MET, V22, P450, DOI 10.1016/j.tem.2011.07.003
   Knudsen AD, 2020, J INFECT DIS, V222, P54, DOI 10.1093/infdis/jiaa057
   Liu B, 2019, HEPATOL INT, V13, P757, DOI 10.1007/s12072-019-09972-1
   Lo J, 2010, AIDS, V24, P2127, DOI 10.1097/QAD.0b013e32833c055a
   Longenecker CT, 2017, AM J CARDIOL, V120, P1427, DOI 10.1016/j.amjcard.2017.07.019
   MARCHINGTON JM, 1989, COMP BIOCHEM PHYS B, V94, P225, DOI 10.1016/0305-0491(89)90337-4
   Marcus JL, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.7954
   Marwan M, 2013, J CARDIOVASC COMPUT, V7, P3, DOI 10.1016/j.jcct.2013.01.002
   Narumi T, 2014, IJC METAB ENDOCR, V3, P14, DOI 10.1016/j.ijcme.2014.03.003
   Nerlekar N, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-63135-z
   Nerlekar N, 2017, J AM HEART ASSOC, V6, DOI 10.1161/JAHA.117.006379
   Neves Priscilla Ornellas, 2017, Radiol Bras, V50, P182, DOI 10.1590/0100-3984.2015.0235
   Nou E, 2016, AIDS, V30, P1495, DOI 10.1097/QAD.0000000000001109
   Psychari SN, 2016, ANGIOLOGY, V67, P41, DOI 10.1177/0003319715576672
   Raggi P, 2019, J AM HEART ASSOC, V8, DOI 10.1161/JAHA.119.013104
   Sacks HS, 2007, AM HEART J, V153, P907, DOI 10.1016/j.ahj.2007.03.019
   Sadouni M, 2021, AIDS, V35, P1575, DOI 10.1097/QAD.0000000000002911
   Srinivasa S, 2018, ANTIVIR THER, V23, P1, DOI 10.3851/IMP3193
   Srinivasa S, 2014, EUR J ENDOCRINOL, V170, pR185, DOI 10.1530/EJE-13-0967
   Teeraananchai S, 2017, HIV MED, V18, P256, DOI 10.1111/hiv.12421
   Fricke ACV, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20235989
   Wallace TM, 2004, DIABETES CARE, V27, P1487, DOI 10.2337/diacare.27.6.1487
   Yerramasu A, 2012, ATHEROSCLEROSIS, V220, P223, DOI 10.1016/j.atherosclerosis.2011.09.041
   Yilmaz Y, 2011, ATHEROSCLEROSIS, V217, P125, DOI 10.1016/j.atherosclerosis.2011.03.026
   Zona S, 2012, AM HEART J, V163, P1024, DOI 10.1016/j.ahj.2012.03.019
NR 34
TC 5
Z9 5
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0269-9370
EI 1473-5571
J9 AIDS
JI Aids
PD JUL 1
PY 2022
VL 36
IS 8
BP 1073
EP 1081
DI 10.1097/QAD.0000000000003204
PG 9
WC Immunology; Infectious Diseases; Virology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology; Infectious Diseases; Virology
GA 2L7DK
UT WOS:000817178000003
PM 35212667
DA 2024-02-19
ER

PT J
AU Kosaki, K
   Kamijo-Ikemori, A
   Sugaya, T
   Tanahashi, K
   Kumagai, H
   Sawano, Y
   Akazawa, N
   Osuka, Y
   Tanaka, K
   Kimura, K
   Shibagaki, Y
   Maeda, S
AF Kosaki, Keisei
   Kamijo-Ikemori, Atsuko
   Sugaya, Takeshi
   Tanahashi, Koichiro
   Kumagai, Hiroshi
   Sawano, Yuriko
   Akazawa, Nobuhiko
   Osuka, Yosuke
   Tanaka, Kiyoji
   Kimura, Kenjiro
   Shibagaki, Yugo
   Maeda, Seiji
TI Urinary liver-type fatty acid-binding protein is associated with
   subendocardial viability ratio in middle- and older-aged adults
SO CLINICAL AND EXPERIMENTAL HYPERTENSION
LA English
DT Article
DE Cardiovascular disease; intra-renal microcirculation; myocardial
   perfusion; pulse wave analysis; tubular biomarker
ID CHRONIC KIDNEY-DISEASE; CARDIOVASCULAR-DISEASE; INDEPENDENT PREDICTORS;
   RENAL-FUNCTION; AGING KIDNEY; RISK-FACTORS; ALBUMINURIA; PRESSURE;
   MICROALBUMINURIA; MORTALITY
AB Background: To identify one of the physiological underlying mechanisms of the predictive effects of urinary liver-type fatty acid-binding protein (L-FABP) for the onset of cardiovascular disease (CVD), we investigated the relationship between urinary L-FABP levels and subendocardial viability ratio (SEVR), a marker of myocardial perfusion, in middle- and older-aged adults.Methods: This was a cross-sectional study of 249 middle- and older-aged adults (aged 46-83years). We measured urinary L-FABP levels and central hemodynamic parameters, including SEVR, calculated by pulse wave analysis using an applanation tonometry.Results: In the participants stratified in accordance with the tertiles of urinary L-FABP levels, SEVR decreased in a stepwise fashion with increasing tertiles (p<0.001). Furthermore, this association remains significant after the consideration of various confounders. On the contrary, urinary albumin levels were not independently related with SEVR.Conclusion: Our results demonstrated that urinary L-FABP levels were independently associated with the SEVR of the middle- and older-aged adults. This result suggests that the increase in urinary L-FABP levels even within the normal range might be related to the decrease in myocardial perfusion (SEVR).
C1 [Kosaki, Keisei; Tanahashi, Koichiro; Sawano, Yuriko] Univ Tsukuba, Grad Sch Comprehens Human Sci, Ibaraki, Japan.
   [Kamijo-Ikemori, Atsuko; Sugaya, Takeshi; Shibagaki, Yugo] St Marianna Univ, Sch Med, Dept Internal Med, Div Nephrol & Hypertens, Kawasaki, Kanagawa, Japan.
   [Kamijo-Ikemori, Atsuko] St Marianna Univ, Sch Med, Dept Anat, Kawasaki, Kanagawa, Japan.
   [Sugaya, Takeshi] CMIC Co Ltd, Tokyo, Japan.
   [Kumagai, Hiroshi; Akazawa, Nobuhiko; Tanaka, Kiyoji; Maeda, Seiji] Univ Tsukuba, Fac Hlth & Sport Sci, 1-1-1 Tennodai, Tsukuba, Ibaraki 3058574, Japan.
   [Osuka, Yosuke] Tokyo Metropolitan Inst Gerontol, Res Team Promoting Independence Elderly, Tokyo, Japan.
   [Kimura, Kenjiro] JCHO Tokyo Takanawa Hosp, Tokyo, Japan.
C3 University of Tsukuba; Saint Marianna University; Saint Marianna
   University; CMIC Holdings Co Ltd; University of Tsukuba; Tokyo
   Metropolitan Institute of Gerontology
RP Maeda, S (corresponding author), Univ Tsukuba, Fac Hlth & Sport Sci, 1-1-1 Tennodai, Tsukuba, Ibaraki 3058574, Japan.
EM maeda.seiji.gn@u.tsukuba.ac.jp
RI AKAZAWA, Nobuhiko/AAW-9680-2021
OI Kosaki, Keisei/0000-0001-6001-578X; Kumagai, Hiroshi/0000-0002-0520-6214
CR Araki S, 2013, DIABETES CARE, V36, P1248, DOI 10.2337/dc12-1298
   BUCKBERG GD, 1972, CIRC RES, V30, P67, DOI 10.1161/01.RES.30.1.67
   Di Micco L, 2013, BLOOD PURIFICAT, V36, P26, DOI 10.1159/000350582
   Drury PL, 2011, DIABETOLOGIA, V54, P32, DOI 10.1007/s00125-010-1854-1
   Ekart R, 2015, KIDNEY BLOOD PRESS R, V40, P565, DOI 10.1159/000368532
   Hayward CS, 1997, J AM COLL CARDIOL, V30, P1863, DOI 10.1016/S0735-1097(97)00378-1
   Hillege HL, 2001, J INTERN MED, V249, P519, DOI 10.1046/j.1365-2796.2001.00833.x
   HOFFMAN JIE, 1978, AM J CARDIOL, V41, P327, DOI 10.1016/0002-9149(78)90174-1
   Horio M, 2013, AM J KIDNEY DIS, V61, P197, DOI 10.1053/j.ajkd.2012.07.007
   Imai N, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126990
   Jager A, 1999, ARTERIOSCL THROM VAS, V19, P617, DOI 10.1161/01.ATV.19.3.617
   Kamijo A, 2005, J LAB CLIN MED, V145, P125, DOI 10.1016/j.lab.2004.12.003
   Kamijo A, 2004, AM J PATHOL, V165, P1243, DOI 10.1016/S0002-9440(10)63384-6
   Kamijo A, 2004, J LAB CLIN MED, V143, P23, DOI 10.1016/j.lab.2003.08.001
   Kamijo-Ikemori A, 2006, CLIN CHIM ACTA, V374, P1, DOI 10.1016/j.cca.2006.05.038
   Kamijo-Ikemori A, 2013, CLIN CHIM ACTA, V424, P104, DOI 10.1016/j.cca.2013.05.020
   Kamijo-Ikemori A, 2011, NEPHROLOGY, V16, P539, DOI 10.1111/j.1440-1797.2011.01469.x
   Kamijo-Ikemori A, 2011, DIABETES CARE, V34, P691, DOI 10.2337/dc10-1392
   Kipsa JG, 2011, J HYPERTENS, V29, P1115, DOI 10.1097/HJH.0b013e328346a3bc
   Kosaki K, 2017, CLIN EXP NEPHROL, V21, P810, DOI 10.1007/s10157-017-1385-x
   Martin JE, 2007, J PATHOL, V211, P198, DOI 10.1002/path.2111
   Matsui K, 2016, CLIN EXP NEPHROL, V20, P195, DOI 10.1007/s10157-015-1144-9
   Ninomiya T, 2009, J AM SOC NEPHROL, V20, P1813, DOI 10.1681/ASN.2008121270
   O'Rourke MF, 2007, J AM COLL CARDIOL, V50, P1, DOI 10.1016/j.jacc.2006.12.050
   Paapstel K, 2016, KIDNEY BLOOD PRESS R, V41, P488, DOI 10.1159/000443450
   Prince CT, 2010, DIABETES VASC DIS RE, V7, P216, DOI 10.1177/1479164110375297
   SARNOFF SJ, 1958, AM J PHYSIOL, V192, P148, DOI 10.1152/ajplegacy.1957.192.1.148
   Schultz MG, 2013, AM J HYPERTENS, V26, P557, DOI 10.1093/ajh/hps077
   Smink PA, 2012, AM J KIDNEY DIS, V60, P804, DOI 10.1053/j.ajkd.2012.06.017
   Tanaka T, 2006, J GERONTOL A-BIOL, V61, P795, DOI 10.1093/gerona/61.8.795
   Theilade S, 2014, AM J HYPERTENS, V27, P1152, DOI 10.1093/ajh/hpu030
   Yamamoto T, 2007, J AM SOC NEPHROL, V18, P2894, DOI 10.1681/ASN.2007010097
   Zhou XJ, 2008, KIDNEY INT, V74, P710, DOI 10.1038/ki.2008.319
NR 33
TC 2
Z9 2
U1 0
U2 2
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1064-1963
EI 1525-6006
J9 CLIN EXP HYPERTENS
JI Clin. Exp. Hypertens.
PY 2018
VL 40
IS 3
BP 244
EP 250
DI 10.1080/10641963.2017.1356845
PG 7
WC Pharmacology & Pharmacy; Peripheral Vascular Disease
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy; Cardiovascular System & Cardiology
GA FY5UK
UT WOS:000426900900008
PM 28872349
DA 2024-02-19
ER

PT J
AU Kireev, RA
   Tresguerres, AF
   Vara, E
   Ariznavarreta, C
   Tresguerres, JAF
AF Kireev, R. A.
   Tresguerres, A. F.
   Vara, E.
   Ariznavarreta, C.
   Tresguerres, J. A. F.
TI Effect of chronic treatments with GH, melatonin, estrogens, and
   phytoestrogens on oxidative stress parameters in liver from aged female
   rats
SO BIOGERONTOLOGY
LA English
DT Article
DE aAging; antioxidant status; cytochrome C; estrogens; female; growth
   hormone; melatonin; nitric oxide; nvariectomy; phytoestrogens
ID HUMAN GROWTH-HORMONE; NITRIC-OXIDE; ANTIOXIDANT ENZYMES;
   LIPID-PEROXIDATION; GENE-EXPRESSION; CYTOCHROME-C; GLUTATHIONE
   METABOLISM; REDOX REGULATION; WISTAR RATS; MITOCHONDRIA
AB The aging theory postulates that this process may be due to the accumulation of oxidative damage in cells and molecules. The present study has investigated the effect of castration in old female rats on various parameters related to the antioxidant properties of several cellular fractions obtained from the liver, and the influence of several chronic treatments on it, both in intact and castrated animals. Sixty-one 22-month-old Wistar female rats, were used. About 21 intact animals were divided into three groups and treated for 10 weeks with GH, melatonin or saline, and 40 ovariectomized (at 12 months of age) animals were divided into five groups and treated for the same time with GH, melatonin, estrogens (Eos), phytoestrogens (Phyt) or saline. All animals were sacrificed at 24 months of age by decapitation. The activity of glutathione peroxidase (GPx) in cytosolic fraction, glutathione-S-transferase (GST) in cytosol and microsomal fractions, and the levels of Nitric oxide (NO) and cytochrome C in mitochondrial and cytosol fractions of liver were determined. A decrease in GST activity was detected in cytosol and in the microsomal fraction in ovariectomized animals as compared to intact rats. The activity of GPx was also decreased in ovariectomized as compared with the intact group. NO level was increased and cytochrome C decreased in the mitochondrial fraction of the liver in ovariectomized females as compared with the intact group, respectively. No significant changes after melatonin or GH treatments were found in GPx, GST activity and NO level in mitochondrial fraction in the intact group. Administration of GH, melatonin, Eos and Phyt in the ovariectomized groups significantly increased the GPx, and GST activity in the cytosol and microsomal fraction and decreased the level of NO in the mitochondrial fraction as compared with the untreated rats. A significant increase in the level of cytochrome C in the mitochondrial fraction and a decrease in the cytosol fraction were also found with all treatments. The administration of GH, melatonin, Eos and Phyt to castrated females seem to reduce oxidative changes in the liver from old ovariectomized rats.
C1 Univ Complutense, Sch Med, Dept Physiol, Lab Expt Endocrinol, E-28040 Madrid, Spain.
   Saratov NG Chernyshevskii State Univ, Dept Biochem & Biophys, Saratov, Russia.
   Univ Complutense, Sch Med, Dept Biochem & Mol Biol, E-28040 Madrid, Spain.
C3 Complutense University of Madrid; Saratov State University; Complutense
   University of Madrid
RP Tresguerres, JAF (corresponding author), Univ Complutense, Sch Med, Dept Physiol, Lab Expt Endocrinol, Avda Complutense S-N, E-28040 Madrid, Spain.
EM guerres@med.ucm.es
OI Kireev, Roman/0000-0002-6105-2440
CR Acuña-Castroviejo D, 2005, ENDOCRINE, V27, P159, DOI 10.1385/ENDO:27:2:159
   ADLERCREUTZ CHT, 1995, J NUTR, V125, pS757, DOI 10.1093/jn/125.3_Suppl.757S
   Allegra M, 2003, J PINEAL RES, V34, P1, DOI 10.1034/j.1600-079X.2003.02112.x
   Anantharaju A, 2002, GERONTOLOGY, V48, P343, DOI 10.1159/000065506
   [Anonymous], 1996, Handbook of Antioxidants
   Ayres S, 1996, J LAB CLIN MED, V128, P367, DOI 10.1016/S0022-2143(96)80008-4
   Borrás C, 2003, FREE RADICAL BIO MED, V34, P546, DOI 10.1016/S0891-5849(02)01356-4
   Brown GC, 2002, FREE RADICAL BIO MED, V33, P1440, DOI 10.1016/S0891-5849(02)01112-7
   Brown-Borg HM, 2003, MECH AGEING DEV, V124, P1013, DOI 10.1016/j.mad.2003.07.001
   Brown-Borg HM, 2002, EXP BIOL MED, V227, P94, DOI 10.1177/153537020222700203
   Carrillo-Vico A, 2005, ENDOCRINE, V27, P189, DOI 10.1385/ENDO:27:2:189
   Castillo C, 2004, ENDOCRINE, V25, P33, DOI 10.1385/ENDO:25:1:33
   Castillo C, 2005, ENDOCRINE, V26, P11, DOI 10.1385/ENDO:26:1:011
   Castillo C, 2005, BIOGERONTOLOGY, V6, P49, DOI 10.1007/s10522-004-7383-x
   Chernyak BV, 1997, BIOSCIENCE REP, V17, P293, DOI 10.1023/A:1027384628678
   CORPAS E, 1993, ENDOCR REV, V14, P20, DOI 10.1210/er.14.1.20
   Cuzzocrea S, 2001, EUR J PHARMACOL, V426, P1, DOI 10.1016/S0014-2999(01)01175-X
   Dhahbi JM, 1999, AM J PHYSIOL-ENDOC M, V277, pE352, DOI 10.1152/ajpendo.1999.277.2.E352
   Díaz-Flores M, 1999, LIFE SCI, V65, P2481, DOI 10.1016/S0024-3205(99)00514-7
   EDEN J, 1998, CLIN ENCOCRINOLOGY M, V12, P589
   Feng Z, 2005, FREE RADICAL BIO MED, V39, P195, DOI 10.1016/j.freeradbiomed.2005.03.007
   Gasbarrini A, 1998, SCAND J GASTROENTERO, V33, P1107
   Ghafourifar P, 1999, J BIOL CHEM, V274, P31185, DOI 10.1074/jbc.274.44.31185
   Giulivi C, 1998, J BIOL CHEM, V273, P11038, DOI 10.1074/jbc.273.18.11038
   Grandien K, 1997, INT J BIOCHEM CELL B, V29, P1343, DOI 10.1016/S1357-2725(97)89967-0
   Green PS, 2000, INT J DEV NEUROSCI, V18, P347, DOI 10.1016/S0736-5748(00)00017-4
   Ha BJ, 2004, ARCH PHARM RES, V27, P867, DOI 10.1007/BF02980181
   HARMAN D, 1992, MUTAT RES, V275, P257, DOI 10.1016/0921-8734(92)90030-S
   HAZELTON GA, 1985, MECH AGEING DEV, V29, P71, DOI 10.1016/0047-6374(85)90048-X
   HUANG JM, 1992, J BIOL CHEM, V267, P15511
   Inoue H, 2003, DIGEST DIS SCI, V48, P570, DOI 10.1023/A:1022553119715
   Jaworek J, 2005, J PINEAL RES, V38, P73, DOI 10.1111/j.1600-079X.2004.00179.x
   Karasek M, 2004, EXP GERONTOL, V39, P1723, DOI 10.1016/j.exger.2004.04.012
   Kasapoglu M, 2001, EXP GERONTOL, V36, P209, DOI 10.1016/S0531-5565(00)00198-4
   Kokoszka JE, 2001, P NATL ACAD SCI USA, V98, P2278, DOI 10.1073/pnas.051627098
   Koyuncu FM, 2006, HISTOL HISTOPATHOL, V21, P367, DOI 10.14670/HH-21.367
   Kris-Etherton Penny M., 2002, American Journal of Medicine, V113, p71S
   Lafaro KJ, 2015, SURG ONCOL CLIN N AM, V24, P1, DOI 10.1016/j.soc.2014.09.001
   Lanfranco F, 2003, J ENDOCRINOL INVEST, V26, P861, DOI 10.1007/BF03345237
   LAUGHTON MJ, 1989, BIOCHEM PHARMACOL, V38, P2859, DOI 10.1016/0006-2952(89)90442-5
   Lee Chu Hee, 1994, Archives of Pharmacal Research (Seoul), V17, P318, DOI 10.1007/BF02974169
   Lee YM, 2005, FREE RADICAL BIO MED, V39, P108, DOI 10.1016/j.freeradbiomed.2005.02.033
   León J, 2005, J PINEAL RES, V38, P1, DOI 10.1111/j.1600-079X.2004.00181.x
   Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1
   Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9
   Maeda A, 2005, BIOCHEMISTRY-US, V44, P480, DOI 10.1021/bi048016f
   Manda K, 2003, BIOGERONTOLOGY, V4, P133, DOI 10.1023/A:1024102007763
   Massafra C, 2000, J ENDOCRINOL, V167, P447, DOI 10.1677/joe.0.1670447
   MATSUBARA T, 1972, J BIOCHEM, V72, P1379, DOI 10.1093/oxfordjournals.jbchem.a130031
   MODE A, 1992, ADV ENZYME REGUL, V32, P255
   MOORADIAN AD, 1993, J STEROID BIOCHEM, V45, P509, DOI 10.1016/0960-0760(93)90166-T
   Omoya T, 2001, LIVER, V21, P183, DOI 10.1034/j.1600-0676.2001.021003183.x
   Palomero J, 2001, FREE RADICAL BIO MED, V30, P836, DOI 10.1016/S0891-5849(01)00471-3
   Persky AM, 2000, P SOC EXP BIOL MED, V223, P59, DOI 10.1046/j.1525-1373.2000.22308.x
   Pinzani M, 2001, J HEPATOL, V34, P764, DOI 10.1016/S0168-8278(01)00055-1
   Poderoso JJ, 1996, ARCH BIOCHEM BIOPHYS, V328, P85, DOI 10.1006/abbi.1996.0146
   POPPER H, 1986, PROG LIVER DIS, V8, P659
   Poynard T, 2001, J HEPATOL, V34, P730, DOI 10.1016/S0168-8278(00)00097-0
   Raynaud-Simon A, 2003, J Nutr Health Aging, V7, P267
   Reiter RJ, 1998, PROG NEUROBIOL, V56, P359, DOI 10.1016/S0301-0082(98)00052-5
   REITER RJ, 1995, AGING-CLIN EXP RES, V7, P340, DOI 10.1007/BF03324344
   Reiter RJ, 1999, BIOL SIGNAL RECEPT, V8, P56
   Rodriguez C, 2004, J PINEAL RES, V36, P1, DOI 10.1046/j.1600-079X.2003.00092.x
   Saibara T, 1999, LANCET, V354, P1299, DOI 10.1016/S0140-6736(05)76071-2
   SCHMUCKER DL, 1990, EXP GERONTOL, V25, P403, DOI 10.1016/0531-5565(90)90029-2
   Sen CK, 1996, FASEB J, V10, P709, DOI 10.1096/fasebj.10.7.8635688
   Sies H, 1998, CHEM-BIOL INTERACT, V112, P177, DOI 10.1016/S0009-2797(97)00160-9
   SLIVKA A, 1987, BRAIN RES, V409, P275, DOI 10.1016/0006-8993(87)90712-8
   Sohal RS, 2002, FREE RADICAL BIO MED, V33, P575, DOI 10.1016/S0891-5849(02)00886-9
   SOHAL RS, 1993, AGING-CLIN EXP RES, V5, P3, DOI 10.1007/BF03324120
   SRIVASTAVA PK, 1993, BIOCHEM J, V294, P159, DOI 10.1042/bj2940159
   Stirone C, 2005, MOL PHARMACOL, V68, P959, DOI 10.1124/mol.105.014662
   SUBBIAH MTR, 1993, J CLIN ENDOCR METAB, V77, P1095, DOI 10.1210/jc.77.4.1095
   SUGIOKA K, 1987, FEBS LETT, V210, P37, DOI 10.1016/0014-5793(87)81293-0
   Tan DX, 2007, J PINEAL RES, V42, P28, DOI 10.1111/j.1600-079X.2006.00407.x
   Tan DX, 2000, FREE RADICAL BIO MED, V29, P1177, DOI 10.1016/S0891-5849(00)00435-4
   Toescu EC, 2000, CELL CALCIUM, V28, P329, DOI 10.1054/ceca.2000.0167
   Tollet-Egnell P, 2001, MOL ENDOCRINOL, V15, P308, DOI 10.1210/me.15.2.308
   Troen BR, 2003, MT SINAI J MED, V70, P3
   URSINI F, 1994, FREE RADICAL BIO MED, V16, P547, DOI 10.1016/0891-5849(94)90054-X
   Viña J, 2003, ANTIOXID REDOX SIGN, V5, P549, DOI 10.1089/152308603770310194
   VINCENZINI MT, 1991, BIOCHIM BIOPHYS ACTA, V1073, P571, DOI 10.1016/0304-4165(91)90232-6
   Vom Saal Frederick S., 1994, P1213
   Vural P, 2005, ANN CLIN BIOCHEM, V42, P220, DOI 10.1258/0004563053857941
   Wang H, 2003, EXP GERONTOL, V38, P507, DOI 10.1016/S0531-5565(03)00036-6
   Wang XT, 1998, BIOCHEM J, V333, P291, DOI 10.1042/bj3330291
   WAZIERS I, 1988, DRUG METAB DISPOS, V16, P310
   Wu GY, 2004, J NUTR, V134, P489, DOI 10.1093/jn/134.10.2783S
   ZHAI P, 2001, AM J PHYSIOL, V281, P1223
NR 89
TC 34
Z9 36
U1 0
U2 5
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1389-5729
EI 1573-6768
J9 BIOGERONTOLOGY
JI Biogerontology
PD OCT
PY 2007
VL 8
IS 5
BP 469
EP 482
DI 10.1007/s10522-007-9089-3
PG 14
WC Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Geriatrics & Gerontology
GA 206UJ
UT WOS:000249208100002
PM 17476580
DA 2024-02-19
ER

PT J
AU Mulderrig, L
   Garaycoechea, JI
AF Mulderrig, Lee
   Garaycoechea, Juan I.
TI XPF-ERCC1 protects liver, kidney and blood homeostasis outside the
   canonical excision repair pathways
SO PLOS GENETICS
LA English
DT Article
ID TRANSCRIPTION-COUPLED REPAIR; CROSS-LINK REPAIR; RNA-POLYMERASE-II;
   COCKAYNE-SYNDROME; XERODERMA-PIGMENTOSUM; NUCLEAR ABNORMALITIES;
   ENDOGENOUS ALDEHYDES; GROWTH FAILURE; DNA; MICE
AB Loss of the XPF-ERCC1 endonuclease causes a dramatic phenotype that results in progeroid features associated with liver, kidney and bone marrow dysfunction. As this nuclease is involved in multiple DNA repair transactions, it is plausible that this severe phenotype results from the simultaneous inactivation of both branches of nucleotide excision repair (GG- and TC-NER) and Fanconi anaemia (FA) inter-strand crosslink (ICL) repair. Here we use genetics in human cells and mice to investigate the interaction between the canonical NER and ICL repair pathways and, subsequently, how their joint inactivation phenotypically overlaps with XPF-ERCC1 deficiency. We find that cells lacking TC-NER are sensitive to crosslinking agents and that there is a genetic interaction between NER and FA in the repair of certain endogenous crosslinking agents. However, joint inactivation of GG-NER, TC-NER and FA crosslink repair cannot account for the hypersensitivity of XPF-deficient cells to classical crosslinking agents nor is it sufficient to explain the extreme phenotype of Ercc1(-/-) mice. These analyses indicate that XPF-ERCC1 has important functions outside of its central role in NER and FA crosslink repair which are required to prevent endogenous DNA damage. Failure to resolve such damage leads to loss of tissue homeostasis in mice and humans.
   Author summary
   The integrity of DNA is essential for life so even the most primitive life forms have evolved a DNA repair 'toolkit' to detect and fix different types of DNA damage. XPF-ERCC1 is an enzyme that can cut DNA and a key player in many of these DNA repair transactions. Consistent with this, inactivating mutations of XPF-ERCC1 in humans and mice lead to a dramatic premature ageing phenotype associated with liver, kidney and bone marrow dysfunction. Here, we ask which of the many functions of XPF-ERCC1 are required to protect tissues from endogenous DNA damage. To do this, we generated cells and mice lacking two of the best characterised functions of XPF-ERCC1: nucleotide excision repair and inter-strand crosslink repair. Surprisingly, neither the cells nor mice lacking these two repair pathways behave like the XPF-ERCC1 mutants, in fact the mice are remarkable in their lack of phenotype. Our work suggests that there are functions of XPF-ERCC1 outside of the canonical repair pathways which are important for DNA repair and the homeostasis of multiple organs.
C1 [Mulderrig, Lee] MRC, Mol Biol Lab, Cambridge Biomed Campus,Francis Crick Ave, Cambridge, England.
   [Garaycoechea, Juan I.] Univ Med Ctr Utrecht, Hubrecht Inst KNAW, Utrecht, Netherlands.
C3 MRC Laboratory Molecular Biology; Royal Netherlands Academy of Arts &
   Sciences; Hubrecht Institute (KNAW); Utrecht University; Utrecht
   University Medical Center
RP Garaycoechea, JI (corresponding author), Univ Med Ctr Utrecht, Hubrecht Inst KNAW, Utrecht, Netherlands.
EM juan.g@hubrecht.eu
FU MRC Laboratory of Molecular Biology; CRUK Program; Wellcome Trust
   Investigator Grant; MRC [MC_U105178811, MC_PC_15065] Funding Source:
   UKRI
FX This work was supported by the MRC Laboratory of Molecular Biology. L.M.
   is supported by a CRUK Program grant awarded to Ketan J. Patel. J.I.G.
   was supported by the Wellcome Trust Investigator Grant awarded to Ketan
   J. Patel, King's College, Cambridge and the Hubrecht Institute. The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript
CR Ahmad A, 2008, MOL CELL BIOL, V28, P5082, DOI 10.1128/MCB.00293-08
   Al-Minawi AZ, 2008, NUCLEIC ACIDS RES, V36, P1, DOI 10.1093/nar/gkm888
   Barnhoorn S, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004686
   Bellelli R, 2018, MOL CELL, V70, P707, DOI 10.1016/j.molcel.2018.04.008
   Bennardo N, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000110
   Bradford PT, 2011, J MED GENET, V48, P168, DOI 10.1136/jmg.2010.083022
   Chatzinikolaou G, 2017, NAT CELL BIOL, V19, P421, DOI 10.1038/ncb3499
   Cheng G, 2003, CHEM RES TOXICOL, V16, P145, DOI 10.1021/tx025614r
   Cheng NC, 2000, HUM MOL GENET, V9, P1805, DOI 10.1093/hmg/9.12.1805
   Cheo DL, 1997, MUTAT RES-FUND MOL M, V374, P1, DOI 10.1016/S0027-5107(97)00046-8
   Cho JS, 2013, STEM CELLS, V31, P511, DOI 10.1002/stem.1261
   Compe E, 2012, NAT REV MOL CELL BIO, V13, P343, DOI 10.1038/nrm3350
   Cui Hai-Feng, 2012, J Anal Methods Chem, V2012, P793468, DOI 10.1155/2012/793468
   DEVRIES A, 1995, NATURE, V377, P169, DOI 10.1038/377169a0
   DiGiovanna JJ, 2012, J INVEST DERMATOL, V132, P785, DOI 10.1038/jid.2011.426
   Domenech C, 2018, STEM CELL REP, V11, P1075, DOI 10.1016/j.stemcr.2018.10.001
   Enoiu M, 2012, NUCLEIC ACIDS RES, V40, P8953, DOI 10.1093/nar/gks670
   Fousteri M, 2006, MOL CELL, V23, P471, DOI 10.1016/j.molcel.2006.06.029
   Furuta T, 2002, CANCER RES, V62, P4899
   Garaycoechea JI, 2018, NATURE, V553, P171, DOI 10.1038/nature25154
   Garaycoechea JI, 2012, NATURE, V489, P571, DOI 10.1038/nature11368
   Ghezraoui H, 2018, NATURE, V560, P122, DOI 10.1038/s41586-018-0362-1
   Hill R, 2019, NAT GENET
   Hodskinson MRG, 2014, MOL CELL, V54, P472, DOI 10.1016/j.molcel.2014.03.014
   HUANG JC, 1994, P NATL ACAD SCI USA, V91, P10394, DOI 10.1073/pnas.91.22.10394
   Ishiai M, 2004, MOL CELL BIOL, V24, P10733, DOI 10.1128/MCB.24.24.10733-10741.2004
   Ito S, 2007, MOL CELL, V26, P231, DOI 10.1016/j.molcel.2007.03.013
   Jaarsma D, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002405
   Jaspers NGJ, 2007, AM J HUM GENET, V80, P457, DOI 10.1086/512486
   Kamileri I, 2012, P NATL ACAD SCI USA, V109, P2995, DOI 10.1073/pnas.1114941109
   Kamimae-Lanning AN, 2013, BLOOD, V121, P2008, DOI 10.1182/blood-2012-06-439679
   Kashiyama K, 2013, AM J HUM GENET, V92, P807, DOI 10.1016/j.ajhg.2013.04.007
   Klein D. D., 2014, CELL, V54, P460, DOI DOI 10.1016/j.molcel.2014.03.015
   Knipscheer P, 2009, SCIENCE, V326, P1698, DOI 10.1126/science.1182372
   Kutler DI, 2003, BLOOD, V101, P1249, DOI 10.1182/blood-2002-07-2170
   KUYKENDALL JR, 1992, MUTAT RES, V283, P131, DOI 10.1016/0165-7992(92)90145-8
   Langevin F, 2011, NATURE, V475, P53, DOI 10.1038/nature10192
   Laugel V, 2013, MECH AGEING DEV, V134, P161, DOI 10.1016/j.mad.2013.02.006
   Le May N, 2012, MOL CELL, V47, P622, DOI 10.1016/j.molcel.2012.05.050
   Le May N, 2010, MOL CELL, V38, P54, DOI 10.1016/j.molcel.2010.03.004
   LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0
   Marteijn JA, 2014, NAT REV MOL CELL BIO, V15, P465, DOI 10.1038/nrm3822
   McHugh PJ, 2000, MOL CELL BIOL, V20, P3425, DOI 10.1128/MCB.20.10.3425-3433.2000
   MCWHIR J, 1993, NAT GENET, V5, P217, DOI 10.1038/ng1193-217
   Motycka TA, 2004, J BIOL CHEM, V279, P13634, DOI 10.1074/jbc.M313779200
   Muniandy PA, 2009, J BIOL CHEM, V284, P27908, DOI 10.1074/jbc.M109.029025
   Niedernhofer LJ, 2006, NATURE, V444, P1038, DOI 10.1038/nature05456
   Pace P, 2002, EMBO J, V21, P3414, DOI 10.1093/emboj/cdf355
   Parmar K, 2010, STEM CELLS, V28, P1186, DOI 10.1002/stem.437
   Pontel LB, 2015, MOL CELL, V60, P177, DOI 10.1016/j.molcel.2015.08.020
   Prasher JM, 2005, EMBO J, V24, P861, DOI 10.1038/sj.emboj.7600542
   Río P, 2002, BLOOD, V100, P2032
   Sarkar S, 2006, EMBO J, V25, P1285, DOI 10.1038/sj.emboj.7600993
   Sarker AH, 2005, MOL CELL, V20, P187, DOI 10.1016/j.molcel.2005.09.022
   Selfridge J, 2001, NUCLEIC ACIDS RES, V29, P4541, DOI 10.1093/nar/29.22.4541
   Shiomi N, 2004, MOL CELL BIOL, V24, P3712, DOI 10.1128/MCB.24.9.3712-3719.2004
   SLADEK FM, 1989, J BIOL CHEM, V264, P6755
   Tian M, 2004, MOL CELL BIOL, V24, P2237, DOI 10.1128/MCB.24.6.2237-2242.2004
   Tian M, 2004, MOL CELL BIOL, V24, P1200, DOI 10.1128/MCB.24.3.1200-1205.2004
   van der Pluijm I, 2007, PLOS BIOL, V5, P23, DOI 10.1371/journal.pbio.0050002
   vanderHorst GTJ, 1997, CELL, V89, P425, DOI 10.1016/S0092-8674(00)80223-8
   VANHOUTEN B, 1986, P NATL ACAD SCI USA, V83, P8077
   Wang AT, 2011, GENE DEV, V25, P1859, DOI 10.1101/gad.15699211
   Weeda G, 1997, CURR BIOL, V7, P427, DOI 10.1016/S0960-9822(06)00190-4
NR 64
TC 13
Z9 13
U1 0
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1553-7404
J9 PLOS GENET
JI PLoS Genet.
PD APR
PY 2020
VL 16
IS 4
AR e1008555
DI 10.1371/journal.pgen.1008555
PG 21
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA LL2DD
UT WOS:000531363700057
PM 32271760
OA Green Published, gold
DA 2024-02-19
ER

PT J
AU Malouf, C
   Ottersbach, K
AF Malouf, Camille
   Ottersbach, Katrin
TI Fetal liver Mll-AF4+hematopoietic stem and progenitor cells respond
   directly to poly(I:C), but not to a single maternal immune activation
SO EXPERIMENTAL HEMATOLOGY
LA English
DT Article
ID ACUTE LYMPHOBLASTIC-LEUKEMIA; INFECTION EXPOSURE; MLL-AF4; MODELS; MICE
AB T(4;11) MLL-AF4 acute leukemia is one of the most aggressive malignancies in infant and pediatric populations. Epidemiological and functional studies have highlighted the influence of an overstimulation of the immune system on leukemia development. This study aimed at assessing if the cell-of-origin of t(4;11) MLL-AF4 acute leukemia is sensitive to a viral or bacterial mimic and if maternal immune activation can lead to a full-blown leukemia. To answer this, we used the Mll-AF4 pre-leukemia mouse model that initiates the expression of Mll-AF4 in the first definitive hematopoietic cells formed during embryonic development. We observed an increase in proliferation upon hematopoietic differentiation of fetal liver MII-AF4+ Lineage-Scal+ckit+ (LSK) cells exposed to the immune stimulants, poly(I:C) or LPS/lipopolysaccharide. This was accompanied by increased expression of a subset of MLL-AF4 signature genes and members of the Toll-like receptor signaling pathways in fetal liver Mll-AF4+ LSK exposed to poly(I:C), suggesting that the cell-of-origin responds to inflammatory stimuli. Maternal immune activation using a single dose of poly(I:C) did not lead to the development of leukemia in Mll-AF4+ and control offspring. Instead, aging MLL-AF4+ mice showed an increased proportion of T-lymphoid cells in the spleen, lost their B-lymphoid bias, and had decreased frequencies of hematopoietic stem and multipotent progenitor cells. Overall, this study suggests that the fetal liver Mll-AF4+ LSK cells are sensitive to direct exposure to inflammatory stimuli, especially poly(I:C); however, maternal immune activation induced by a single exposure to poly(I:C) is not sufficient to initiate MLL-AF4 leukemogenesis. (C) 2019 ISEH - Society for Hematology and Stem Cells. Published by Elsevier Inc.
C1 [Malouf, Camille; Ottersbach, Katrin] Univ Edinburgh, MRC Ctr Regenerat Med, Edinburgh Bioquarter,5 Little France Dr, Edinburgh EH16 4UU, Midlothian, Scotland.
C3 University of Edinburgh
RP Ottersbach, K (corresponding author), Univ Edinburgh, MRC Ctr Regenerat Med, Edinburgh Bioquarter,5 Little France Dr, Edinburgh EH16 4UU, Midlothian, Scotland.
EM katrin.ottersbach@ed.ac.uk
OI Malouf, Camille/0000-0002-1066-8376
FU Wellcome Trust University of Edinburgh Institutional Strategic Support
   Fund (ISSF2) award; Cancer Research UK Programme Foundation Award; 
   [MR/K017047/1]; MRC [MR/K017047/1] Funding Source: UKRI
FX This study was supported by a Wellcome Trust University of Edinburgh
   Institutional Strategic Support Fund (ISSF2) award (KO) and a Cancer
   Research UK Programme Foundation Award (KO). We thank Fiona Rossi and
   Claire Cryer from the SCRM FACS Facility for cell sorting services and
   flow cytometry advice. We acknowledge the support of James Todd, Andrew
   Dyer, Hollie McGrath, Linda Dunn-Campbell, and John Agnew from the SCRM
   Animal Facility in animal experimentation. Core facilities at the
   Edinburgh MRC Centre for Regenerative Medicine are supported by Centre
   Grant MR/K017047/1.
CR Andersson AK, 2015, NAT GENET, V47, P330, DOI 10.1038/ng.3230
   Arrode-Brusés G, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-83
   Arsenault D, 2014, BRAIN BEHAV IMMUN, V38, P77, DOI 10.1016/j.bbi.2013.12.016
   Barrett NA, 2016, CELL REP, V16, P1039, DOI 10.1016/j.celrep.2016.06.046
   Bursen A, 2010, BLOOD, V115, P3570, DOI 10.1182/blood-2009-06-229542
   Chen MJ, 2009, NATURE, V457, P887, DOI 10.1038/nature07619
   Chu SH, 2018, BLOOD ADV, V2, P2478, DOI 10.1182/bloodadvances.2018021592
   Esplin BL, 2011, J IMMUNOL, V186, P5367, DOI 10.4049/jimmunol.1003438
   Essers MAG, 2009, NATURE, V458, P904, DOI 10.1038/nature07815
   Greaves M, 2018, NAT REV CANCER, V18, P471, DOI 10.1038/s41568-018-0015-6
   Greaves MF, 2003, BLOOD, V102, P2321, DOI 10.1182/blood-2002-12-3817
   Hu TY, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00268
   Kaisho T, 2006, J ALLERGY CLIN IMMUN, V117, P979, DOI 10.1016/j.jaci.2006.02.023
   Krivtsov AV, 2008, CANCER CELL, V14, P355, DOI 10.1016/j.ccr.2008.10.001
   Lin S, 2016, CANCER CELL, V30, P737, DOI 10.1016/j.ccell.2016.10.008
   Malouf C, 2018, HAEMATOLOGICA, V103, pE571, DOI 10.3324/haematol.2018.191718
   Malouf C, 2018, CELL MOL LIFE SCI, V75, P417, DOI 10.1007/s00018-017-2620-z
   Mansell E, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-39552-0
   Martín-Lorenzo A, 2015, CANCER DISCOV, V5, P1328, DOI 10.1158/2159-8290.CD-15-0892
   Meyer U, 2014, BIOL PSYCHIAT, V75, P307, DOI 10.1016/j.biopsych.2013.07.011
   Milne TA, 2017, BLOOD, V129, P2217, DOI 10.1182/blood-2016-10-691428
   Reisinger S, 2015, PHARMACOL THERAPEUT, V149, P213, DOI 10.1016/j.pharmthera.2015.01.001
   Rodríguez-Hernández G, 2017, CANCER RES, V77, P4365, DOI 10.1158/0008-5472.CAN-17-0701
   Shi LM, 2003, J NEUROSCI, V23, P297, DOI 10.1523/jneurosci.23-01-00297.2003
   Walter D, 2015, NATURE, V520, P549, DOI 10.1038/nature14131
   Zevini A, 2017, TRENDS IMMUNOL, V38, P194, DOI 10.1016/j.it.2016.12.004
NR 26
TC 5
Z9 5
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0301-472X
EI 1873-2399
J9 EXP HEMATOL
JI Exp. Hematol.
PD AUG
PY 2019
VL 76
BP 49
EP 59
DI 10.1016/j.exphem.2019.07.004
PG 11
WC Hematology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Hematology; Research & Experimental Medicine
GA JB9FZ
UT WOS:000488888200005
PM 31381950
OA hybrid, Green Published
DA 2024-02-19
ER

PT J
AU Gan, L
   von Moltke, LL
   Trepanier, LA
   Harmatz, JS
   Greenblatt, DJ
   Court, MH
AF Gan, Lu
   von Moltke, Lisa L.
   Trepanier, Lauren A.
   Harmatz, Jerold S.
   Greenblatt, David J.
   Court, Michael H.
TI Role of NADPH-Cytochrome P450 Reductase and
   Cytochrome-<i>b</i><sub>5</sub>/NADH-<i>b</i><sub>5</sub> Reductase in
   Variability of CYP3A Activity in Human Liver Microsomes
SO DRUG METABOLISM AND DISPOSITION
LA English
DT Article
ID FUNCTION OXIDASE SYSTEM; C P-450 REDUCTASE; ALPHA-LIPOIC ACID;
   RAT-LIVER; IN-VITRO; NADH-CYTOCHROME-B5 REDUCTASE; TRIAZOLAM
   BIOTRANSFORMATION; ESCHERICHIA-COLI; AGE; B(5)
AB NADPH-cytochrome P450 reductase (CPR) and cytochrome-b(5) (b(5)) together with NADH-b(5) reductase (b(5)R) play important roles in cytochrome P450 3A-mediated drug metabolism via electron transfer. However, it is not clear whether variability in expression of these accessory proteins contributes to the known interindividual variability in CYP3A activity. CPR and b(5) were measured in human liver microsomes (HLMs) by spectrophotometry and immunoblotting. HLMs from elderly (>= 46 years) male donors (n = 11) averaged 27% (P = 0.034) and 41% (P = 0.011) lower CPR levels than young (<= 45 years) male donors (n = 21) for spectrophotometric and immunoblot values, respectively. Similarly, HLMs from elderly male donors averaged 43% (P = 0.034) and 47% (P = 0.011) lower b5 levels than young male donors for spectrophotometric and immunoblot values, respectively. alpha-Lipoic acid and 6-propyl-2-thiouracil were evaluated for selectivity of inhibition of CPR and b(5)R activities, respectively, using recombinant enzymes and HLMs, as well as for effects on CYP3A-mediated triazolam hydroxylation in HLMs with either NADH or beta-NADPH. The results indicate that both compounds are relatively nonselective inhibitors of CPR and b(5)R activities. Finally, we used multivariate regression analysis and showed that variability in CPR or b(5) expression between HLMs does not contribute significantly to variability in CYP3A-mediated midazolam hydroxylation. Consequently, while aging is associated with decreased CPR and b(5) expression in human livers, this effect does not contribute to CYP3A variability.
C1 [Gan, Lu; von Moltke, Lisa L.; Harmatz, Jerold S.; Greenblatt, David J.; Court, Michael H.] Tufts Univ, Sch Med, Dept Pharmacol & Expt Therapeut, Boston, MA 02111 USA.
   [Gan, Lu; von Moltke, Lisa L.; Harmatz, Jerold S.; Greenblatt, David J.; Court, Michael H.] Tufts Med Ctr, Boston, MA USA.
   [Trepanier, Lauren A.] Univ Wisconsin, Sch Vet Med, Dept Med Sci, Madison, WI 53706 USA.
C3 Tufts University; Tufts Medical Center; University of Wisconsin System;
   University of Wisconsin Madison
RP Court, MH (corresponding author), Tufts Univ, Sch Med, Dept Pharmacol & Expt Therapeut, 136 Harrison Ave, Boston, MA 02111 USA.
EM michael.court@tufts.edu
FU National Institute of General Medical Sciences, National Institutes of
   Health [R01 GM061834, R21 GM074369, R01 GM61753]; National Institute on
   Aging [AG17880]; National Institute on Allergy and Infectious Disease,
   National Institutes of Health [AI58784]
FX This work was supported by National Institute of General Medical
   Sciences, National Institutes of Health [Grants R01 GM061834 and R21
   GM074369]; National Institute on Aging [Grant AG17880]; National
   Institute on Allergy and Infectious Disease, National Institutes of
   Health [Grant AI58784]; and National Institute of General Medical
   Sciences, National Institutes of Health [Grant R01 GM61753].
CR BADWEY JA, 1983, BLOOD, V62, P152
   Cotreau MM, 2005, CLIN PHARMACOKINET, V44, P33, DOI 10.2165/00003088-200544010-00002
   Dudka J, 2006, ANN NUTR METAB, V50, P121, DOI 10.1159/000090632
   Elmore CL, 2002, J BIOL CHEM, V277, P48960, DOI 10.1074/jbc.M210173200
   GEORGE J, 1995, BIOCHEM PHARMACOL, V50, P727, DOI 10.1016/0006-2952(95)00192-3
   Guengerich FP, 2005, ARCH BIOCHEM BIOPHYS, V440, P204, DOI 10.1016/j.abb.2005.06.019
   GUO ZY, 1993, GROWTH DEVELOP AGING, V57, P85
   He P, 2006, DRUG METAB DISPOS, V34, P1198, DOI 10.1124/dmd.105.008904
   Hesse LM, 2004, PHARMACOGENETICS, V14, P225, DOI 10.1097/00008571-200404000-00002
   HOLMANS PL, 1994, ARCH BIOCHEM BIOPHYS, V312, P554, DOI 10.1006/abbi.1994.1345
   Kurian JR, 2004, J PHARMACOL EXP THER, V311, P1171, DOI 10.1124/jpet.104.072389
   LEE E, 1986, FEBS LETT, V209, P49, DOI 10.1016/0014-5793(86)81082-1
   MALONEY AG, 1986, HEPATOLOGY, V6, P282, DOI 10.1002/hep.1840060221
   MATSUKI T, 1981, J BIOCH, V194, P327
   Murataliev MB, 2004, BBA-PROTEINS PROTEOM, V1698, P1, DOI 10.1016/j.bbapap.2003.10.003
   Parkinson A, 2004, TOXICOL APPL PHARM, V199, P193, DOI 10.1016/j.taap.2004.01.010
   Patki KC, 2004, J PHARMACOL EXP THER, V308, P874, DOI 10.1124/jpet.103.059311
   PORTER TD, 1986, BIOCHEMISTRY-US, V25, P1682, DOI 10.1021/bi00355a036
   SCHMUCKER DL, 1990, CLIN PHARMACOL THER, V48, P365, DOI 10.1038/clpt.1990.164
   SCHMUCKER DL, 1983, MECH AGEING DEV, V21, P137, DOI 10.1016/0047-6374(83)90070-2
   SCHMUCKER DL, 1987, DRUG METAB DISPOS, V15, P225
   SHEPHARD EA, 1992, ARCH BIOCHEM BIOPHYS, V294, P168, DOI 10.1016/0003-9861(92)90152-M
   SIMMONS DL, 1989, ARCH BIOCHEM BIOPHYS, V271, P10, DOI 10.1016/0003-9861(89)90250-6
   SLEPNEVA IA, 1995, BIOCHEM BIOPH RES CO, V214, P1246, DOI 10.1006/bbrc.1995.2420
   Streetman DD, 2003, ANN PHARMACOTHER, V37, P1100, DOI 10.1345/aph.1C299
   Venkatakrishnan K, 2000, DRUG METAB DISPOS, V28, P1493
   VERGERES G, 1995, BIOCHIMIE, V77, P604, DOI 10.1016/0300-9084(96)88176-4
   Voice MW, 1999, ARCH BIOCHEM BIOPHYS, V366, P116, DOI 10.1006/abbi.1999.1192
   VONMOLTKE LL, 1993, PHARMACOLOGY, V47, P268, DOI 10.1159/000139107
   vonMoltke LL, 1996, J PHARMACOL EXP THER, V276, P370
   Warrington JS, 2004, J PHARMACOL EXP THER, V309, P720, DOI 10.1124/jpet.103.061077
   Yamazaki H, 1999, DRUG METAB DISPOS, V27, P999
   Yamazaki H, 1996, ARCH BIOCHEM BIOPHYS, V325, P174, DOI 10.1006/abbi.1996.0022
   Yamazaki H, 2002, PROTEIN EXPRES PURIF, V24, P329, DOI 10.1006/prep.2001.1578
   YELINOVA VI, 1993, BIOCHEM BIOPH RES CO, V193, P1044, DOI 10.1006/bbrc.1993.1730
NR 35
TC 30
Z9 41
U1 0
U2 4
PU AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3995 USA
SN 0090-9556
J9 DRUG METAB DISPOS
JI Drug Metab. Dispos.
PD JAN
PY 2009
VL 37
IS 1
BP 90
EP 96
DI 10.1124/dmd.108.023424
PG 7
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 387CA
UT WOS:000261928100014
PM 18838505
OA Green Accepted, Green Published
DA 2024-02-19
ER

PT J
AU Ryu, S
   Suh, BS
   Chang, Y
   Kwon, MJ
   Yun, KE
   Jung, HS
   Kim, CW
   Kim, BK
   Kim, YJ
   Choi, Y
   Ahn, J
   Cho, YK
   Kim, KH
   Ahn, Y
   Park, HY
   Chung, EC
   Shin, H
   Cho, J
AF Ryu, Seungho
   Suh, Byung-Seong
   Chang, Yoosoo
   Kwon, Min-Jung
   Yun, Kyung Eun
   Jung, Hyun-Suk
   Kim, Chan-Won
   Kim, Bo-Kyoung
   Kim, Yoo Jin
   Choi, Yuni
   Ahn, Jiin
   Cho, Yong Kyun
   Kim, Kye-Hyun
   Ahn, Younjhin
   Park, Hyun-Young
   Chung, Eun Chul
   Shin, Hocheol
   Cho, Juhee
TI Menopausal stages and non-alcoholic fatty liver disease in middle-aged
   women
SO EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY
LA English
DT Article
DE Menopause; NAFLD; Menopausal transition; Obesity
ID METABOLIC SYNDROME; RISK-FACTORS; PREVALENCE; POPULATION; ESTRADIOL;
   HEALTH; AMINOTRANSFERASE; STEATOHEPATITIS; PATHOGENESIS; STEATOSIS
AB Objectives: There is no established evidence regarding the influence of the menopausal transition period on non-alcoholic fatty liver disease (NAFLD). The goal of this study was to examine the association between menopausal stages and the prevalence of NAFLD in middle-aged Korean women.
   Methods: This study was a cross-sectional analysis of 1559 women aged 44-56 years, who underwent a comprehensive health screening examination in the Kangbuk Samsung Hospital Total Healthcare Centers during 2012 and 2013. Information regarding menopause status was collected using a standardized, self-administered questionnaire. The presence of fatty liver was determined using ultrasonography. Menopausal stages were defined according to the criteria of the Stages of Reproductive Aging Workshop (STRAW+10) as follows: early menopausal transition was defined as a persistent difference in consecutive menstrual cycle length of seven or more days; late menopausal transition was defined as having an interval of amenorrhea of 60 days or more; post-menopause was defined as the absence of menstrual periods for 12 or more months since the last period; pre-menopause was defined as having a regular menstrual cycle and not meeting the above criteria. Odds ratios and 95% confidence intervals for NAFLD were estimated by menopausal stages.
   Results: Of the 1559 women, 334 had NAFLD. A higher prevalence of NAFLD was observed across menopausal stages (p for trend <0.05). After adjusting for age, center, BMI, smoking status, alcohol intake, physical activity, educational level, parity and age at menarche, the odds ratios (95% CIs) for NAFLD comparing early transition, late transition, and post-menopause to pre-menopause were 1.07 (0.68-1.67), 1.87 (1.23-2.85), and 1.67 (1.01-2.78), respectively.
   Conclusions: This study performed in middle-aged Korean women suggests that there is an increased prevalence of NAFLD in the late menopausal transition as well as post-menopausal stages, independent of a variety of potential confounders. The findings of this study suggest that early intervention strategies implemented before women begin to experience the menopausal transition are needed to reduce the risk of NAFLD. (C) 2015 Elsevier Ireland Ltd. All rights reserved.
C1 [Ryu, Seungho; Suh, Byung-Seong; Chang, Yoosoo] Sungkyunkwan Univ, Sch Med, Kangbuk Samsung Hosp, Dept Occupat & Environm Med, Seoul 100742, South Korea.
   [Ryu, Seungho; Chang, Yoosoo; Kwon, Min-Jung; Yun, Kyung Eun; Jung, Hyun-Suk; Kim, Chan-Won; Kim, Bo-Kyoung; Kim, Yoo Jin; Choi, Yuni; Ahn, Jiin; Chung, Eun Chul; Shin, Hocheol; Cho, Juhee] Sungkyunkwan Univ, Sch Med, Kangbuk Samsung Hosp, Ctr Cohort Studies,Total Healthcare Ctr, Seoul 100742, South Korea.
   [Kwon, Min-Jung] Sungkyunkwan Univ, Sch Med, Kangbuk Samsung Hosp, Dept Lab Med, Seoul 100742, South Korea.
   [Cho, Yong Kyun] Sungkyunkwan Univ, Sch Med, Kangbuk Samsung Hosp, Div Gastroenterol & Hepatol,Dept Internal Med, Seoul 100742, South Korea.
   [Kim, Kye-Hyun] Sungkyunkwan Univ, Sch Med, Kangbuk Samsung Hosp, Dept Obstet & Gynecol, Seoul 100742, South Korea.
   [Ahn, Younjhin; Park, Hyun-Young] Natl Inst Hlth, Ctr Biomed Sci, Div Cardiovasc & Rare Dis, Chungbuk, South Korea.
   [Chung, Eun Chul] Sungkyunkwan Univ, Dept Radiol, Kangbuk Samsung Hosp, Seoul 100742, South Korea.
   [Shin, Hocheol] Sungkyunkwan Univ, Sch Med, Kangbuk Samsung Hosp, Dept Family Med, Seoul 100742, South Korea.
   [Cho, Juhee] Sungkyunkwan Univ, Dept Hlth Sci & Technol, Samsung Adv Inst Hlth Sci & Technol, Seoul 100742, South Korea.
C3 Sungkyunkwan University (SKKU); Samsung Medical Center; Sungkyunkwan
   University (SKKU); Samsung Medical Center; Sungkyunkwan University
   (SKKU); Samsung Medical Center; Sungkyunkwan University (SKKU); Samsung
   Medical Center; Sungkyunkwan University (SKKU); Samsung Medical Center;
   Korea Disease Control & Prevention Agency (KDCA); Korea National
   Institute of Health (KNIH); Korea CDC Center for Biomedical Science;
   Sungkyunkwan University (SKKU); Samsung Medical Center; Sungkyunkwan
   University (SKKU); Samsung Medical Center; Sungkyunkwan University
   (SKKU); Samsung Medical Center
RP Ryu, S (corresponding author), Sungkyunkwan Univ, Sch Med, Kangbuk Samsung Hosp, Dept Occupat & Environm Med, Samsung Main Bldg B2,250,Taepyung Ro 2ga, Seoul 100742, South Korea.
EM sh703.yoo@gmail.com; byungseong.suh@samsung.com
RI Choi, Yuni/I-6298-2012; Cho, Juhee/ABD-2280-2021
OI Chang, Yoosoo/0000-0002-6945-9050; Ryu, Seungho/0000-0002-3927-8646;
   Kim, Chan-Won/0000-0001-5836-1974
FU Research of Korea Centers for Disease Control and Prevention
   [2012-E63013-00]
FX This work was supported by funds (code # 2012-E63013-00) from the
   Research of Korea Centers for Disease Control and Prevention.
CR Adams LA, 2005, J HEPATOL, V42, P132, DOI 10.1016/j.jhep.2004.09.012
   Ascha MS, 2010, HEPATOLOGY, V51, P1972, DOI 10.1002/hep.23527
   Bellentani S, 2001, J HEPATOL, V35, P531, DOI 10.1016/S0168-8278(01)00151-9
   Bruno S, 2005, BMJ-BRIT MED J, V330, P932, DOI 10.1136/bmj.38391.663287.E0
   Caldwell SH, 2004, J HEPATOL, V40, P578, DOI 10.1016/j.jhep.2004.02.013
   Carr MC, 2003, J CLIN ENDOCR METAB, V88, P2404, DOI 10.1210/jc.2003-030242
   Chalasani N, 2012, HEPATOLOGY, V55, P2005, DOI 10.1002/hep.25762
   Chang Y, 2014, J AM COLL CARDIOL, V63, P2679, DOI 10.1016/j.jacc.2014.03.042
   Chitturi S, 2007, J GASTROEN HEPATOL, V22, P967, DOI 10.1111/j.1440-1746.2007.04995.x
   Clark JM, 2003, GASTROENTEROLOGY, V124, P248, DOI 10.1053/gast.2003.50032
   Clark JM, 2002, GASTROENTEROLOGY, V122, P1649, DOI 10.1053/gast.2002.33573
   Clark JM, 2003, AM J GASTROENTEROL, V98, P960, DOI [10.1016/S0002-9270(03)00265-X, 10.1111/j.1572-0241.2003.07486.x]
   Craig CL, 2003, MED SCI SPORT EXER, V35, P1381, DOI 10.1249/01.MSS.0000078924.61453.FB
   FLORENTINO Gesira Soares de Assis, 2013, Arq. Gastroenterol., V50, P180, DOI 10.1590/S0004-28032013000200032
   Donnelly KL, 2005, J CLIN INVEST, V115, P1343, DOI 10.1172/JCI200523621
   Fan JG, 2007, HEPATOB PANCREAT DIS, V6, P572
   Fraser A, 2007, GASTROENTEROLOGY, V133, P1814, DOI 10.1053/j.gastro.2007.08.077
   Grobe YG, 2010, ANN HEPATOL, V9, P402, DOI 10.1016/S1665-2681(19)31616-3
   Harlow SD, 2012, J CLIN ENDOCR METAB, V97, P1159, DOI 10.1210/jc.2011-3362
   Joy D, 2003, EUR J GASTROEN HEPAT, V15, P539, DOI 10.1097/01.meg.0000059112.41030.2e
   Kim CW, 2013, J HEPATOL, V59, P351, DOI 10.1016/j.jhep.2013.03.035
   Kojima S, 2003, J GASTROENTEROL, V38, P954, DOI 10.1007/s00535-003-1178-8
   Lazo M, 2008, SEMIN LIVER DIS, V28, P339, DOI 10.1055/s-0028-1091978
   Marchesini G, 2005, CURR OPIN LIPIDOL, V16, P421, DOI 10.1097/01.mol.0000174153.53683.f2
   Marchesini G, 2008, J CLIN ENDOCR METAB, V93, pS74, DOI 10.1210/jc.2008-1399
   Masi CM, 2009, AM J HYPERTENS, V22, P1148, DOI 10.1038/ajh.2009.155
   Mathiesen UL, 2002, DIGEST LIVER DIS, V34, P516, DOI 10.1016/S1590-8658(02)80111-6
   Méndez-Sánchez N, 2007, LIVER INT, V27, P423, DOI 10.1111/j.1478-3231.2007.01483.x
   Oh JY, 2007, KOREAN J FAM MED, V28, P532
   Park SH, 2006, J GASTROEN HEPATOL, V21, P138, DOI 10.1111/j.1440-1746.2005.04086.x
   Park YW, 2003, ARCH INTERN MED, V163, P427, DOI 10.1001/archinte.163.4.427
   Polotsky HN, 2010, SEMIN REPROD MED, V28, P426, DOI 10.1055/s-0030-1262902
   Preiss D, 2008, CLIN SCI, V115, P141, DOI 10.1042/CS20070402
   Shimizu I, 2007, WORLD J GASTROENTERO, V13, P4295, DOI 10.3748/wjg.v13.i32.4295
   Sowers MR, 2008, J CLIN ENDOCR METAB, V93, P3847, DOI 10.1210/jc.2008-1056
   Sterling RK, 2003, GASTROENTEROLOGY, V124, pA705, DOI 10.1016/S0016-5085(03)83563-1
   Targher G, 2007, ATHEROSCLEROSIS, V191, P235, DOI 10.1016/j.atherosclerosis.2006.08.021
   Tepper PG, 2012, J CLIN ENDOCR METAB, V97, P2872, DOI 10.1210/jc.2012-1422
   Tian GX, 2012, OBES REV, V13, P381, DOI 10.1111/j.1467-789X.2011.00978.x
   Völzke H, 2007, GUT, V56, P594, DOI 10.1136/gut.2006.115345
   Wilson PWF, 1999, ARCH INTERN MED, V159, P1104, DOI 10.1001/archinte.159.10.1104
   Zelber-Sagi S, 2006, LIVER INT, V26, P856, DOI 10.1111/j.1478-3231.2006.01311.x
   Zhou YJ, 2007, WORLD J GASTROENTERO, V13, P6419, DOI 10.3748/wjg.13.6419
NR 43
TC 41
Z9 44
U1 0
U2 11
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0301-2115
EI 1872-7654
J9 EUR J OBSTET GYN R B
JI Eur. J. Obstet. Gynecol. Reprod. Biol.
PD JUL
PY 2015
VL 190
BP 65
EP 70
DI 10.1016/j.ejogrb.2015.04.017
PG 6
WC Obstetrics & Gynecology; Reproductive Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Obstetrics & Gynecology; Reproductive Biology
GA CL5IB
UT WOS:000356991900012
PM 25988514
DA 2024-02-19
ER

PT J
AU Matsuoka, H
   Maeda, K
   Hanai, T
   Sato, H
   Masumori, K
   Koide, Y
   Katsuno, H
   Endo, T
   Shiota, M
   Sugihara, K
AF Matsuoka, Hiroshi
   Maeda, Kotaro
   Hanai, Tsunekazu
   Sato, Harunobu
   Masumori, Koji
   Koide, Yosikazu
   Katsuno, Hidetoshi
   Endo, Tomoyoshi
   Shiota, Miho
   Sugihara, Kenichi
TI Surgical management of colorectal cancer for the aging population-A
   survey by the Japanese Society for Cancer of Colon and Rectum
SO ASIAN JOURNAL OF SURGERY
LA English
DT Article
DE aged patient; colorectal cancer; elderly; surgery; surgical management
AB Objective: The treatment policy of colorectal cancer in elderly patients is controversial due to a lack of specific guidelines. To clarify the present management of colorectal cancer for aged patients, a questionnaire survey was conducted by the Japanese Society for Cancer of the Colon and Rectum.
   Methods: Questionnaire forms were sent to the 430 member institutions of the Japanese Society for Cancer of the Colon and Rectum.
   Results: The response rate of the surgical department to the questionnaire was 39%. Performance status was used for preoperative assessments, and electrocardiogram and ultrasonic cardiograms were conducted for cardiovascular evaluations in many institutions. The same extent of surgical procedures was often adopted for elderly and younger patients, and the frequency of a laparoscopic procedure was the same regardless of a patient's age. A simultaneous hepatectomy for hepatic metastasis was considered in one-third of institutions. In many institutions, intersphincteric resection for patients with possible sphincter-saving surgery was not considered for elderly patients with low rectal cancer.
   Conclusion: Japanese Society for Cancer of the Colon and Rectum member institutions often used the same surgical treatment strategies for both elderly and younger patients with the exception of performing intersphincteric resection. (C) 2016 Asian Surgical Association and Taiwan Robotic Surgery Association. Publishing services by Elsevier B.V.
C1 [Matsuoka, Hiroshi; Maeda, Kotaro; Hanai, Tsunekazu; Sato, Harunobu; Masumori, Koji; Koide, Yosikazu; Katsuno, Hidetoshi; Endo, Tomoyoshi; Shiota, Miho] Fujita Hlth Univ, Dept Surg, 1-98 Dengakugakubo, Toyoake, Aichi 4701192, Japan.
   [Sugihara, Kenichi] Koujinkai Daiichi Hosp, Katsusika Ku, Tokyo, Japan.
C3 Fujita Health University
RP Matsuoka, H (corresponding author), Fujita Hlth Univ, Dept Surg, 1-98 Dengakugakubo, Toyoake, Aichi 4701192, Japan.
EM mats1025@fujita-hu.ac.jp
RI maeda, kotaro/AAD-9347-2019
OI Sato, Harunobu/0000-0003-4637-8853
CR Bircan HY, 2014, BMC SURG, V14, DOI 10.1186/1471-2482-14-44
   Chawla Neetu, 2013, Journal of the National Cancer Institute Monographs, P36, DOI 10.1093/jncimonographs/lgt009
   Egenvall M, 2014, COLORECTAL DIS, V16, P433, DOI 10.1111/codi.12575
   Kordatou Z, 2014, THER ADV MED ONCOL, V6, P128, DOI 10.1177/1758834014523328
   Kristjansson SR, 2010, CRIT REV ONCOL HEMAT, V76, P208, DOI 10.1016/j.critrevonc.2009.11.002
   Law WL, 2002, J AM COLL SURGEONS, V195, P768, DOI 10.1016/S1072-7515(02)01483-7
   Manceau G, 2012, LANCET ONCOL, V13, pE525, DOI 10.1016/S1470-2045(12)70378-9
   Manikihas GM, 2013, ADV GERONTOL, V3, P458
   Senagore AJ, 2003, ARCH SURG-CHICAGO, V138, P252, DOI 10.1001/archsurg.138.3.252
   Thelen A, 2007, INT J COLORECTAL DIS, V22, P1269, DOI 10.1007/s00384-007-0286-y
   Ugolini G, 2014, WORLD J GASTROENTERO, V20, P3762, DOI 10.3748/wjg.v20.i14.3762
   Watanabe T, 2015, INT J CLIN ONCOL, V20, P207, DOI 10.1007/s10147-015-0801-z
NR 12
TC 8
Z9 9
U1 0
U2 2
PU ELSEVIER SINGAPORE PTE LTD
PI SINGAPORE
PA 3 KILLINEY ROAD 08-01, WINSLAND HOUSE 1, SINGAPORE, 239519, SINGAPORE
SN 1015-9584
EI 0219-3108
J9 ASIAN J SURG
JI Asian J. Surg.
PD MAR
PY 2018
VL 41
IS 2
BP 192
EP 196
DI 10.1016/j.asjsur.2016.10.001
PG 5
WC Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Surgery
GA GE7PP
UT WOS:000431425600015
PM 27856106
OA gold
DA 2024-02-19
ER

PT J
AU Sultanov, R
   Ermolenko, E
   Poleschuk, T
   Denisenko, Y
   Kasyanov, S
AF Sultanov, Ruslan
   Ermolenko, Ekaterina
   Poleschuk, Tatiana
   Denisenko, Yulia
   Kasyanov, Sergey
TI Action of alkyl glycerol ethers and n-3 polyunsaturated fatty acids diet
   on hematological parameters of blood and liver plasmalogen level in aged
   rats
SO JOURNAL OF FOOD SCIENCE
LA English
DT Article; Early Access
DE ether lipids; hematopoiesis; marine organisms; n&#8208; 3 PUFA;
   plasmalogens
ID ALZHEIMERS-DISEASE; OXIDATIVE STRESS; PLATELET; 1-O-ALKYLGLYCEROLS;
   ADAPTATION; HEALTH
AB One of the ways to reduce age-related changes can be a diet correction by adding biologically active substances. We studied the effect of a diet including alkyl glycerol ethers (AGs) and n-3 polyunsaturated fatty acid (PUFA) concentrate isolated from the hepatopancreas of Berrytheuthis magister squid on hematological parameters and plasmalogens level in the liver of elderly rats. The senile animals showed decrease in hemoglobin, a three-fold decrease in leukocytes, a three-fold increase in platelet count, and a double decrease of blood coagulation time in the peripheral blood. Age-related changes in rats were characterized by the development of anemia, hypercoagulation, and a decrease in the number of immunocompetent cells. AGs, both separately and in combination with n-3 PUFAs, induced an increase in the number of red blood cells and hemoglobin, a decrease in the number of platelets, and an immunostimulating activity. Under the action of AGs and n-3 PUFAs, the concentration of plasmalogens and docosahexaenoic acid in the rat liver increased 2- and 1.5 folds, respectively.
   Practical Application This study showed that the combined use of AGs and n-3 PUFAs improves the rheological properties of the blood and the state of the immune system during aging. The enrichment of diet with dietary supplements, whose structure contains AGs and n-3 PUFAs can increase the content of plasmalogens in the body.
C1 [Sultanov, Ruslan; Ermolenko, Ekaterina; Poleschuk, Tatiana; Kasyanov, Sergey] Russian Acad Sci, AV Zhirmunsky Natl Sci Ctr Marine Biol, Far East Branch, 17 Palchevskogo Str, Vladivostok 690041, Russia.
   [Poleschuk, Tatiana] Pacific State Med Univ, 2 Ostryakova Ave, Vladivostok, Russia.
   [Denisenko, Yulia] Inst Med Climatol & Rehabil Treatment, Vladivostok Branch, Far Eastern Sci Ctr Physiol & Pathol Respirat, Vladivostok, Russia.
C3 Russian Academy of Sciences; National Scientific Center of Marine
   Biology, Far East Branch of the Russian Academy of Sciences
RP Kasyanov, S (corresponding author), Russian Acad Sci, AV Zhirmunsky Natl Sci Ctr Marine Biol, Far East Branch, 17 Palchevskogo Str, Vladivostok 690041, Russia.
EM serg724@yandex.ru
RI Denisenko, Yulia/L-2292-2015; Ermolenko, Ekaterina V/S-1562-2017;
   Sultanov, Ruslan/AAG-5987-2019
OI Denisenko, Yulia/0000-0003-4130-8899; Ermolenko,
   Ekaterina/0000-0002-0309-3033
CR Alexandru N, 2008, CLIN CHEM LAB MED, V46, P528, DOI 10.1515/CCLM.2008.104
   Bao Q, 2014, MOL CELL ENDOCRINOL, V394, P115, DOI 10.1016/j.mce.2014.07.005
   BASTYR EJ, 1990, AM J MED, V88, P601, DOI 10.1016/0002-9343(90)90525-I
   Beckman KB, 1998, PHYSIOL REV, V78, P547, DOI 10.1152/physrev.1998.78.2.547
   BJORKHEM I, 1986, J LIPID RES, V27, P786
   BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911
   Bosch-Bouju, 2019, FEED YOUR MIND DOES
   Braverman NE, 2012, BBA-MOL BASIS DIS, V1822, P1442, DOI 10.1016/j.bbadis.2012.05.008
   Brites P, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028539
   CARREAU JP, 1978, J CHROMATOGR, V151, P384, DOI 10.1016/S0021-9673(00)88356-9
   Chen S, 2013, CURR ORG CHEM, V17, P802, DOI 10.2174/1385272811317080006
   Cunnane SC, 2013, PROSTAG LEUKOTR ESS, V88, P61, DOI 10.1016/j.plefa.2012.04.006
   Dayal S, 2013, CIRCULATION, V127, P1308, DOI 10.1161/CIRCULATIONAHA.112.000966
   Donato AJ, 2013, AGING CELL, V12, P772, DOI 10.1111/acel.12103
   Dorninger F, 2020, NEUROBIOL DIS, V145, DOI 10.1016/j.nbd.2020.105061
   Ermolenko E, 2016, J FOOD SCI TECH MYS, V53, P1722, DOI 10.1007/s13197-015-2148-x
   Gaposchkin DP, 1999, J LIPID RES, V40, P495
   GLEERUP G, 1995, ANGIOLOGY, V46, P715, DOI 10.1177/000331979504600810
   Goodenowe DB, 2007, J LIPID RES, V48, P2485, DOI 10.1194/jlr.P700023-JLR200
   HARMAN D, 1972, J AM GERIATR SOC, V20, P145, DOI 10.1111/j.1532-5415.1972.tb00787.x
   HARMAN D, 1956, J GERONTOL, V11, P298, DOI 10.1093/geronj/11.3.298
   Hathaway D, 2020, INFECT CHEMOTHER, V52, P478
   Iannitti T, 2010, MAR DRUGS, V8, P2267, DOI 10.3390/md8082267
   Innes JK, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19020532
   Jang JE, 2017, HEPATOLOGY, V66, P416, DOI 10.1002/hep.29039
   Jenkins CM, 2018, J BIOL CHEM, V293, P8693, DOI 10.1074/jbc.RA117.001629
   Kulikov VI, 1998, BIOCHEMISTRY-MOSCOW+, V63, P47
   Latyshev NA, 2014, EUR J LIPID SCI TECH, V116, P1608, DOI 10.1002/ejlt.201400083
   Mann D., 2014, BRAUNWALDS HEART DIS, P240
   MAYER G A, 1955, Can Med Assoc J, V72, P927
   Montecillo-Aguado M, 2020, BRAIN SCI, V10, DOI 10.3390/brainsci10060381
   Montecino-Rodriguez E, 2013, J CLIN INVEST, V123, P958, DOI 10.1172/JCI64096
   Naudí A, 2013, FRONT PHYSIOL, V4, DOI 10.3389/fphys.2013.00372
   Orr SK, 2013, PROSTAG LEUKOTR ESS, V88, P97, DOI 10.1016/j.plefa.2012.05.008
   Pédrono F, 2004, NUTR CANCER, V48, P64, DOI 10.1207/s15327914nc4801_9
   Pédrono F, 2004, PROSTAG LEUKOTR ESS, V71, P19, DOI 10.1016/j.plefa.2003.12.003
   Pédrono F, 2004, LIFE SCI, V74, P2793, DOI 10.1016/j.lfs.2003.11.002
   Périchon R, 1998, CELL MOL LIFE SCI, V54, P641, DOI 10.1007/s000180050192
   Poleschuk TS, 2020, STRESS, V23, P213, DOI 10.1080/10253890.2019.1660316
   Pradas I, 2019, REDOX BIOL, V21, DOI 10.1016/j.redox.2019.101127
   Pugliese PT, 1998, J ALTERN COMPLEM MED, V4, P87, DOI 10.1089/acm.1998.4.1-87
   Qian LX, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096207
   Rohtstein-Rubin R., 1999, TUMOR BIOL HUMAN GEN, V9, P134
   Saccà SC, 2018, NUTRIENTS, V10, DOI 10.3390/nu10060668
   Scheff S.W., 2016, Fundamental Statistical Principles for the Neurobiologist: A survival guide, V1st
   Simopoulos A P, 2003, Forum Nutr, V56, P67
   Tomaiuolo Maurizio, 2017, Interv Cardiol Clin, V6, P1, DOI 10.1016/j.iccl.2016.08.001
   Vance J., 2002, NEW COMPR BIOCH, P233, DOI 10.1016/S0167-7306(02)36011-3
   Wood PL, 2011, ALZHEIMER'S DISEASE PATHOGENESIS - CORE CONCEPTS, SHIFTING PARADIGMS AND THERAPEUTIC TARGETS, P561
NR 49
TC 5
Z9 6
U1 1
U2 7
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0022-1147
EI 1750-3841
J9 J FOOD SCI
JI J. Food Sci.
PD 2021 JUN
PY 2021
VL 86
IS 6
BP 2727
EP 2735
DI 10.1111/1750-3841.15756
EA MAY 2021
PG 9
WC Food Science & Technology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Food Science & Technology
GA SU8SP
UT WOS:000651495400001
PM 34002853
DA 2024-02-19
ER

PT J
AU Inagaki, K
   Lewis, SM
   Wu, XL
   Ma, CR
   Munroe, DJ
   Fuess, S
   Storm, TA
   Kay, MA
   Nakai, H
AF Inagaki, Katsuya
   Lewis, Susanna M.
   Wu, Xiaolin
   Ma, Congrong
   Munroe, David J.
   Fuess, Sally
   Storm, Theresa A.
   Kay, Mark A.
   Nakai, Hiroyuki
TI DNA palindromes with a modest arm length of ≳s20 base pairs are a
   significant target for recombinant adeno-associated virus vector
   integration in the liver, muscles, and heart in mice
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID DOUBLE-STRAND BREAKS; YEAST SACCHAROMYCES-CEREVISIAE; SHORT INVERTED
   REPEATS; GENE AMPLIFICATION; HUMAN-CELLS; IN-VIVO; CHROMOSOMAL
   TRANSLOCATIONS; GENOME STABILITY; MOUSE-LIVER; FACTOR-IX
AB Our previous study has shown that recombinant adeno-associated virus (rAAV) vector integrates preferentially in genes, near transcription start sites and CpG islands in mouse liver (H. Nakai, X. Wu, S. Fuess, T. A. Storm, D. Munroe, E. Montini, S. M. Burgess, M. Grompe, and M. A. Kay, J. Virol. 79:3606-3614, 2005). However, the previous method relied on in vivo selection of rAAV integrants and could be employed for the liver but not for other tissues. Here, we describe a novel method for high-throughput rAAV integration site analysis that does not rely on marker gene expression, selection, or cell division, and therefore it can identify rAAV integration sites in nondividing cells without cell manipulations. Using this new method, we identified and characterized a total of 997 rAAV integration sites in mouse liver, skeletal muscle, and heart, transduced with rAAV2 or rAAV8 vector. The results support our previous observations, but notably they have revealed that DNA palindromes with an arm length of greater than or similar to 20 bp (total length, greater than or similar to 40 bp) are a significant target for rAAV integration. Up to similar to 30% of total integration events occurred in the vicinity of DNA palindromes with an arm length of greater than or similar to 20 bp. Considering that DNA palindromes may constitute fragile genomic sites, our results support the notion that rAAV integrates at chromosomal sites susceptible to breakage or preexisting breakage sites. The use of rAAV to label fragile genomic sites may provide an important new tool for probing the intrinsic source of ongoing genomic instability in various tissues in animals, studying DNA palindrome metabolism in vivo, and understanding their possible contributions to carcinogenesis and aging.
C1 Univ Pittsburgh, Sch Med, Dept Mol Genet & Biochem, Pittsburgh, PA 15261 USA.
   Hosp Sick Children, Res Inst, Program Genet & Genome Biol, Toronto, ON M5G 1L8, Canada.
   SAIC Frederick Inc, NCI Frederick, Lab Mol Technol, Ft Detrick, MD 21702 USA.
   Stanford Univ, Sch Med, Dept Pediat & Genet, Stanford, CA 94305 USA.
C3 Pennsylvania Commonwealth System of Higher Education (PCSHE); University
   of Pittsburgh; University of Toronto; Hospital for Sick Children
   (SickKids); National Institutes of Health (NIH) - USA; NIH National
   Cancer Institute (NCI); Science Applications International Corporation
   (SAIC); SAIC-Frederick; Stanford University
RP Nakai, H (corresponding author), Univ Pittsburgh, Sch Med, Dept Mol Genet & Biochem, W1244 BSTWR 200 Lothrop St, Pittsburgh, PA 15261 USA.
EM nakaih@pitt.edu
RI Kay, Matthew Wyatt/AAH-7336-2019
OI Kay, Matthew Wyatt/0000-0003-2756-5055; Kay, Mark/0000-0002-2799-2615
FU NCI NIH HHS [N01-CO-12400, N01CO12400] Funding Source: Medline; NHLBI
   NIH HHS [R01 HL064274, HL64274] Funding Source: Medline; NIDDK NIH HHS
   [R21 DK068636, DK68636, R01 DK048252, DK78388, R01 DK078388, R56
   DK078388] Funding Source: Medline
CR Akgun E, 1997, MOL CELL BIOL, V17, P5559, DOI 10.1128/MCB.17.9.5559
   Butler DK, 1996, CELL, V87, P1115, DOI 10.1016/S0092-8674(00)81805-X
   Collick A, 1996, EMBO J, V15, P1163, DOI 10.1002/j.1460-2075.1996.tb00455.x
   Cunningham LA, 2003, MOL CELL BIOL, V23, P8740, DOI 10.1128/MCB.23.23.8740-8750.2003
   Donsante A, 2001, GENE THER, V8, P1343, DOI 10.1038/sj.gt.3301541
   Edelmann L, 2001, AM J HUM GENET, V68, P1, DOI 10.1086/316952
   FORD M, 1986, CELL, V45, P425, DOI 10.1016/0092-8674(86)90328-4
   Goodarzi AA, 2006, EMBO J, V25, P3880, DOI 10.1038/sj.emboj.7601255
   Gotter AL, 2004, HUM MOL GENET, V13, P103, DOI 10.1093/hmg/ddh004
   Inagaki K, 2006, MOL THER, V14, P45, DOI 10.1016/j.ymthe.2006.03.014
   Jurvansuu J, 2005, J VIROL, V79, P569, DOI 10.1128/JVI.79.1.569-580.2005
   Kato T, 2006, SCIENCE, V311, P971, DOI 10.1126/science.1121452
   Katsura Y, 2007, DNA REPAIR, V6, P639, DOI 10.1016/j.dnarep.2006.12.002
   Katz RA, 1998, J BIOL CHEM, V273, P24190, DOI 10.1074/jbc.273.37.24190
   Kay MA, 2000, NAT GENET, V24, P257, DOI 10.1038/73464
   Kurahashi H, 2004, J BIOL CHEM, V279, P35377, DOI 10.1074/jbc.M400354200
   Kurahashi H, 2003, AM J HUM GENET, V72, P733, DOI 10.1086/368062
   Kurahashi H, 2001, NAT GENET, V29, P139, DOI 10.1038/ng1001-139
   Kurahashi H, 2006, DNA REPAIR, V5, P1136, DOI 10.1016/j.dnarep.2006.05.035
   Kuranaga N, 2001, BMC CANCER, V1, DOI 10.1186/1471-2407-1-10
   LEACH DRF, 1994, BIOESSAYS, V16, P893, DOI 10.1002/bies.950161207
   Lewis S, 1999, ANN NY ACAD SCI, V870, P45, DOI 10.1111/j.1749-6632.1999.tb08864.x
   Lewis SM, 2006, DNA REPAIR, V5, P1146, DOI 10.1016/j.dnarep.2006.05.014
   Lisnic B, 2005, CURR GENET, V47, P289, DOI 10.1007/s00294-005-0573-5
   Lobachev KS, 2002, CELL, V108, P183, DOI 10.1016/S0092-8674(02)00614-1
   Ma JL, 2003, MOL CELL BIOL, V23, P8820, DOI 10.1128/MCB.23.23.8820-8828.2003
   Ma YM, 2002, CELL, V108, P781, DOI 10.1016/S0092-8674(02)00671-2
   Manno CS, 2006, NAT MED, V12, P342, DOI 10.1038/nm1358
   McCarty DM, 2004, ANNU REV GENET, V38, P819, DOI 10.1146/annurev.genet.37.110801.143717
   Miller DG, 2004, NAT GENET, V36, P767, DOI 10.1038/ng1380
   Miller DG, 2002, NAT GENET, V30, P147, DOI 10.1038/ng824
   Miller DG, 2005, J VIROL, V79, P11434, DOI 10.1128/JVI.79.17.11434-11442.2005
   Nag DK, 1997, GENETICS, V146, P835
   Nakai H, 2000, J VIROL, V74, P9451, DOI 10.1128/JVI.74.20.9451-9463.2000
   Nakai H, 2005, J VIROL, V79, P3606, DOI 10.1128/JVI.79.6.3606-3614.2005
   Nakai H, 2003, NAT GENET, V34, P297, DOI 10.1038/ng1179
   Nakai H, 2003, MOL THER, V7, P101, DOI 10.1016/S1525-0016(02)00023-0
   Nakai H, 2001, J VIROL, V75, P6969, DOI 10.1128/JVI.75.15.6969-6976.2001
   Nakai H, 2002, J VIROL, V76, P11343, DOI 10.1128/JVI.76.22.11343-11349.2002
   Nakai H, 1999, J VIROL, V73, P5438, DOI 10.1128/JVI.73.7.5438-5447.1999
   Nakai H, 2005, J VIROL, V79, P214, DOI 10.1128/JVI.79.1.214-224.2005
   Narayanan V, 2006, CELL, V125, P1283, DOI 10.1016/j.cell.2006.04.042
   Neiman PE, 2006, ONCOGENE, V25, P6325, DOI 10.1038/sj.onc.1209646
   Paull TT, 1999, GENE DEV, V13, P1276, DOI 10.1101/gad.13.10.1276
   Posey JE, 2006, PLOS BIOL, V4, P1934, DOI 10.1371/journal.pbio.0040350
   Rattray AJ, 2005, GENE DEV, V19, P1390, DOI 10.1101/gad.1315805
   Rothkamm K, 2003, P NATL ACAD SCI USA, V100, P5057, DOI 10.1073/pnas.0830918100
   Schmidt M, 2002, BLOOD, V100, P2737, DOI 10.1182/blood-2002-02-0407
   Schröder ARW, 2002, CELL, V110, P521, DOI 10.1016/S0092-8674(02)00864-4
   Sedelnikova OA, 2004, NAT CELL BIOL, V6, P168, DOI 10.1038/ncb1095
   Song SH, 2004, P NATL ACAD SCI USA, V101, P2112, DOI 10.1073/pnas.0307833100
   Tanaka H, 2005, NAT GENET, V37, P320, DOI 10.1038/ng1515
   Tanaka H, 2002, P NATL ACAD SCI USA, V99, P8772, DOI 10.1073/pnas.132275999
   Tanaka Hisashi, 2006, Hum Cell, V19, P17, DOI 10.1111/j.1749-0774.2005.00003.x
   Tapia-Páez I, 2001, HUM GENET, V109, P167
   Trujillo KM, 2001, J BIOL CHEM, V276, P35458, DOI 10.1074/jbc.M105482200
   Wang GL, 2006, MUTAT RES-FUND MOL M, V598, P103, DOI 10.1016/j.mrfmmm.2006.01.019
   Wang Y, 2006, FEBS LETT, V580, P1277, DOI 10.1016/j.febslet.2006.01.045
   Wu XL, 2003, SCIENCE, V300, P1749, DOI 10.1126/science.1083413
   YASUDA LF, 1991, CELL, V67, P505, DOI 10.1016/0092-8674(91)90525-4
NR 60
TC 45
Z9 56
U1 0
U2 1
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
J9 J VIROL
JI J. Virol.
PD OCT
PY 2007
VL 81
IS 20
BP 11290
EP 11303
DI 10.1128/JVI.00963-07
PG 14
WC Virology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Virology
GA 218MK
UT WOS:000250019400044
PM 17686840
OA Green Published, Bronze
DA 2024-02-19
ER

PT J
AU HRELIA, S
   BORDONI, A
   MOTTA, P
   CELADON, M
   BIAGI, PL
AF HRELIA, S
   BORDONI, A
   MOTTA, P
   CELADON, M
   BIAGI, PL
TI KINETIC-ANALYSIS OF DELTA-6-DESATURATION IN LIVER-MICROSOMES - INFLUENCE
   OF GAMMA-LINOLEIC ACID DIETARY SUPPLEMENTATION TO YOUNG AND OLD RATS
SO PROSTAGLANDINS LEUKOTRIENES AND ESSENTIAL FATTY ACIDS
LA English
DT Article
ID DESATURATION
AB Previous experiments demonstrated the ability-of a gamma-linoleic acid (GLA) dietary supplementation (as evening primrose oil - EPO) to counteract the fall off in delta-6-desaturase (D6D) activity of linoleic acid and alpha-linoleic acid in aged rats.  Kinetic parameters of the D6D were determined in order to test the possibility that there may be a significant influence of GLA administration to young and aged rats on the Vm and Km values for 6-desaturation of both the substrates.  In young rats GLA supplementation did not affect the kinetic parameters, while in old rats it produced an increase of Vm values of 6-desaturation for both the substrates.  Thus the administration of small doses of GLA to old rats might offer substantial protection against the loss of D6D affinity observed in aging, enhancing the capacity of the enzyme itself.
RP HRELIA, S (corresponding author), UNIV BOLOGNA,DIPARTMENTO BIOCHIM,CTR RIC NUTR,VIA IRNERIO 48,I-40126 BOLOGNA,ITALY.
RI Bordoni, Alessandra/J-3047-2012; Hrelia, Silvana/P-2864-2015
OI Hrelia, Silvana/0000-0001-7857-4512; Bordoni,
   Alessandra/0000-0003-4579-1662
CR AYALA S, 1973, J LIPID RES, V14, P296
   BIAGI PL, 1991, IN PRESS BIOCH BIOPH
   BLOND JP, 1989, LIPIDS, V24, P389, DOI 10.1007/BF02535146
   BORDONI A, 1988, BIOCHEM INT, V17, P1001
   BRENNER R R, 1981, Progress in Lipid Research, V20, P41, DOI 10.1016/0163-7827(81)90012-6
   DEGOMEZ DIN, 1984, LIPIDS, V19, P91
   FOLCH J, 1957, J BIOL CHEM, V226, P497
   HORROBIN DF, 1981, MED HYPOTHESES, V7, P1211, DOI 10.1016/0306-9877(81)90064-5
   HRELIA S, 1989, BIOCHEM BIOPH RES CO, V163, P348, DOI 10.1016/0006-291X(89)92142-6
   HRELIA S, 1990, BIOCHEM INT, V22, P659
   LOWRY OH, 1951, J BIOL CHEM, V193, P265
   NIE NH, 1975, STATISTICAL PACKAGE
   PELUFFO R O, 1970, American Journal of Physiology, V218, P669
   SHAND JH, 1983, INT J BIOCHEM, V15, P1367, DOI 10.1016/0020-711X(83)90028-9
   STOFFEL W, 1959, ANAL CHEM, V31, P307, DOI 10.1021/ac60146a047
NR 15
TC 8
Z9 8
U1 1
U2 1
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH, MIDLOTHIAN, SCOTLAND EH1 3AF
SN 0952-3278
J9 PROSTAG LEUKOTR ESS
JI Prostaglandins Leukot. Essent. Fatty Acids
PD NOV
PY 1991
VL 44
IS 3
BP 191
EP 194
DI 10.1016/0952-3278(91)90055-A
PG 4
WC Biochemistry & Molecular Biology; Cell Biology; Endocrinology &
   Metabolism
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology; Endocrinology &
   Metabolism
GA GR042
UT WOS:A1991GR04200008
PM 1808628
DA 2024-02-19
ER

PT J
AU Tresguerres, IF
   Tamimi, F
   Eimar, H
   Barralet, JE
   Prieto, S
   Torres, J
   Calvo-Guirado, JL
   Tresguerres, JAF
AF Tresguerres, Isabel F.
   Tamimi, Faleh
   Eimar, Hazem
   Barralet, Jake E.
   Prieto, Santiago
   Torres, Jesus
   Luis Calvo-Guirado, Jose
   Tresguerres, Jesus A. F.
TI Melatonin Dietary Supplement as an Anti-Aging Therapy for Age-Related
   Bone Loss
SO REJUVENATION RESEARCH
LA English
DT Article
ID MESENCHYMAL STEM-CELLS; HORMONE REPLACEMENT THERAPY; PINEAL-GLAND;
   COST-EFFECTIVENESS; GROWTH-HORMONE; OSTEOPOROSIS; TEMPERATURE;
   RECEPTORS; LIVER; RATS
AB Introduction: Previous studies have shown that melatonin, an anti-oxidant molecule secreted from the pineal gland, is a positive regulator of bone mass. However, the potential effects of melatonin on bone mass have never been investigated in an old population. The aim of this study was to assess the effects of dietary melatonin supplementation on mass accrual and biomechanical properties of old rat femora.
   Methods: Twenty 22-month-old male Wistar rats were divided into two randomly assigned groups. The first group was treated for 10 weeks with melatonin, whereas the second group was untreated (control). Rat femurs were collected, and their phenotypes and biomechanical properties were investigated by micro-computed tomography, histomorphometry, and a three-point-bending test. Statistical analyses were performed by the Student two-tailed unpaired t-test. In all experiments, a value of p < 0.05 was considered significant.
   Results: Rats treated with melatonin had higher bone volume, bone trabecular number, trabecular thickness, and cortical thickness in comparison to the control group. Histomorphometric analyses confirmed the increase of bone volume in melatonin-treated rats. In agreement with these findings, melatonin-treated rats showed higher bone stiffness, flexural modulus, and ultimate load compared to controls.
   Conclusion: These compelling results are the first evidence indicating that dietary melatonin supplementation is able to exert beneficial effects against age-related bone loss in old rats, improving the microstructure and biomechanical properties of aged bones.
C1 [Tresguerres, Isabel F.] Univ Complutense Madrid, Dept Med & Oral Surg, Sch Dent, E-28040 Madrid, Spain.
   [Tamimi, Faleh; Eimar, Hazem; Barralet, Jake E.] McGill Univ, Fac Dent, Montreal, PQ, Canada.
   [Prieto, Santiago] Univ Complutense, Sch Med, E-28040 Madrid, Spain.
   [Prieto, Santiago] Doce de Octubre Hosp, Madrid, Spain.
   [Torres, Jesus] Univ Complutense, Sch Dent, Dept Med & Oral Surg, E-28040 Madrid, Spain.
   [Luis Calvo-Guirado, Jose] Univ Murcia, Sch Med & Dent, Dept Gen & Implant Dent, Murcia, Spain.
   [Tresguerres, Jesus A. F.] Univ Complutense, Sch Med, Dept Physiol, E-28040 Madrid, Spain.
C3 Complutense University of Madrid; McGill University; Complutense
   University of Madrid; Hospital Universitario 12 de Octubre; Complutense
   University of Madrid; University of Murcia; Complutense University of
   Madrid
RP Tresguerres, IF (corresponding author), Univ Complutense Madrid, Dept Med & Oral Surg, Sch Dent, Plaza Ramon & Cajal S-N, E-28040 Madrid, Spain.
EM isabelfe@ucm.es
RI Torres, Jesus/AAF-5104-2020; Tresguerres, Isabel F/JWP-1579-2024;
   guirado, jose luis calvo/O-3104-2016; guirado, jose luis
   calvo/ABG-1215-2021; Barralet, jake/A-5820-2008; Barralet,
   Jake/K-2253-2019
OI Tresguerres, Isabel F/0000-0001-5855-6325; guirado, jose luis
   calvo/0000-0002-4067-2253; guirado, jose luis calvo/0000-0002-4067-2253;
   Barralet, jake/0000-0003-3543-6042; Barralet, Jake/0000-0003-3543-6042;
   Torres, Jesus/0000-0001-9657-3767; TORRES GARCIA DENCHE,
   JESUS/0000-0002-8310-9209; Tamimi, Faleh/0000-0002-4618-8374
CR Amstrup AK, 2013, OSTEOPOROSIS INT, V24, P2919, DOI 10.1007/s00198-013-2404-8
   Barou O, 2002, INVEST RADIOL, V37, P40, DOI 10.1097/00004424-200201000-00008
   Barrett-Connor E, 2001, INT J EPIDEMIOL, V30, P423, DOI 10.1093/ije/30.3.423
   Borah B, 2001, ANAT RECORD, V265, P101, DOI 10.1002/ar.1060
   Boskey AL, 2007, ELEMENTS, V3, P385, DOI 10.2113/GSELEMENTS.3.6.385
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   CAGNACCI A, 1992, J CLIN ENDOCR METAB, V75, P447, DOI 10.1210/jc.75.2.447
   Chan GK, 2002, GERONTOLOGY, V48, P62, DOI 10.1159/000048929
   CHAPPARD D, 1987, ACTA HISTOCHEM, V81, P183, DOI 10.1016/S0065-1281(87)80012-0
   Cranney A, 2006, CAN MED ASSOC J, V175, P52, DOI 10.1503/cmaj.050929
   Cuesta S, 2011, MECH AGEING DEV, V132, P573, DOI 10.1016/j.mad.2011.10.005
   Cuesta S, 2010, EXP GERONTOL, V45, P950, DOI 10.1016/j.exger.2010.08.016
   Cutando A, 2014, ODONTOLOGY, V102, P290, DOI 10.1007/s10266-013-0122-5
   dAvis PY, 1997, BIOCHEM J, V324, P753, DOI 10.1042/bj3240753
   Dijk DJ, 1999, J PHYSIOL-LONDON, V516, P611, DOI 10.1111/j.1469-7793.1999.0611v.x
   Dubocovich ML, 2005, ENDOCRINE, V27, P101, DOI 10.1385/ENDO:27:2:101
   Duque G, 2011, J BONE MINER RES, V26, P1472, DOI 10.1002/jbmr.350
   Fleurence RL, 2007, PHARMACOECONOMICS, V25, P913, DOI 10.2165/00019053-200725110-00003
   Forman K, 2010, J PINEAL RES, V49, P312, DOI 10.1111/j.1600-079X.2010.00800.x
   Grossman E, 2011, VASC HEALTH RISK MAN, V7, P577, DOI 10.2147/VHRM.S24603
   Hardeland R, 2013, J PINEAL RES, V55, P325, DOI 10.1111/jpi.12090
   Harvey N, 2010, NAT REV RHEUMATOL, V6, P99, DOI 10.1038/nrrheum.2009.260
   Histing T, 2012, J SURG RES, V173, P83, DOI 10.1016/j.jss.2010.08.036
   Idikio HA, 2011, CARDIOL RES PRACT, V2011, DOI 10.4061/2011/836806
   Järvinen TLN, 2005, J BONE MINER RES, V20, P717, DOI 10.1359/JBMR.050211
   Jönsson B, 2011, OSTEOPOROSIS INT, V22, P967, DOI 10.1007/s00198-010-1424-x
   Kennel KA, 2009, MAYO CLIN PROC, V84, P632, DOI 10.1016/S0025-6196(11)60752-0
   Kireev RA, 2008, J PINEAL RES, V45, P394, DOI 10.1111/j.1600-079X.2008.00606.x
   Kireev RA, 2007, J PINEAL RES, V42, P64, DOI 10.1111/j.1600-079X.2006.00385.x
   Kireev RA, 2013, BIOGERONTOLOGY, V14, P431, DOI 10.1007/s10522-013-9443-6
   Kotlarczyk MP, 2012, J PINEAL RES, V52, P414, DOI 10.1111/j.1600-079X.2011.00956.x
   Koyama H, 2002, J BONE MINER RES, V17, P1219, DOI 10.1359/jbmr.2002.17.7.1219
   Ladizesky MG, 2006, J PINEAL RES, V40, P297, DOI 10.1111/j.1600-079X.2006.00316.x
   MAESTRONI GJM, 1986, J NEUROIMMUNOL, V13, P19, DOI 10.1016/0165-5728(86)90047-0
   Mosekilde L, 2000, Z RHEUMATOL, V59, P1
   Nakade O, 1999, J PINEAL RES, V27, P106, DOI 10.1111/j.1600-079X.1999.tb00603.x
   Papaioannou A, 2010, CAN MED ASSOC J, V182, P1864, DOI 10.1503/cmaj.100771
   PFEILSCHIFTER J, 1993, J BONE MINER RES, V8, P707
   Quinn R, 2005, NUTRITION, V21, P775, DOI 10.1016/j.nut.2005.04.002
   Radio NM, 2006, J PINEAL RES, V40, P332, DOI 10.1111/j.1600-079X.2006.00318.x
   Raisz LG, 2001, J BONE MINER RES, V16, P1948, DOI 10.1359/jbmr.2001.16.11.1948
   REITER RJ, 1995, EXP GERONTOL, V30, P199, DOI 10.1016/0531-5565(94)00045-5
   Roth JA, 1999, J BIOL CHEM, V274, P32528
   SACK RL, 1986, J PINEAL RES, V3, P379, DOI 10.1111/j.1600-079X.1986.tb00760.x
   Satomura K, 2007, J PINEAL RES, V42, P231, DOI 10.1111/j.1600-079X.2006.00410.x
   Schett G, 2010, NAT REV ENDOCRINOL, V6, P698, DOI 10.1038/nrendo.2010.190
   Sethi S, 2010, J PINEAL RES, V49, P222, DOI 10.1111/j.1600-079X.2010.00784.x
   Sharman EH, 2004, J PINEAL RES, V36, P165, DOI 10.1046/j.1600-079X.2003.00112.x
   Slominski RM, 2012, MOL CELL ENDOCRINOL, V351, P152, DOI 10.1016/j.mce.2012.01.004
   Sommerfeldt DW, 2001, EUR SPINE J, V10, pS86, DOI 10.1007/s005860100283
   Stehle JH, 2011, J PINEAL RES, V51, P17, DOI 10.1111/j.1600-079X.2011.00856.x
   Tan Dun-Xian, 2002, Current Topics in Medicinal Chemistry, V2, P181, DOI 10.2174/1568026023394443
   Taylor AC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055663
   Tresguerres Jesus A F, 2012, Curr Aging Sci, V5, P242
   Tuppurainen M, 2012, Minerva Ginecol, V64, P195
   Witt-Enderby PA, 2012, J PINEAL RES, V53, P374, DOI 10.1111/j.1600-079X.2012.01007.x
   Zhang LM, 2010, J PINEAL RES, V49, P364, DOI 10.1111/j.1600-079X.2010.00803.x
   Zhdanova IV, 1998, J GERONTOL A-BIOL, V53, pB293, DOI 10.1093/gerona/53A.4.B293
NR 58
TC 36
Z9 39
U1 2
U2 23
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1549-1684
EI 1557-8577
J9 REJUV RES
JI Rejuv. Res.
PD AUG
PY 2014
VL 17
IS 4
BP 341
EP 346
DI 10.1089/rej.2013.1542
PG 6
WC Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Geriatrics & Gerontology
GA AO0RF
UT WOS:000341018400004
PM 24617902
DA 2024-02-19
ER

PT J
AU Belli, LS
   Fondevila, C
   Cortesi, PA
   Conti, S
   Karam, V
   Adam, R
   Coilly, A
   Ericzon, BG
   Loinaz, C
   Cuervas-Mons, V
   Zambelli, M
   Llado, L
   Diaz-Fontenla, F
   Invernizzi, F
   Patrono, D
   Faitot, F
   Bhooori, S
   Pirenne, J
   Perricone, G
   Magini, G
   Castells, L
   Detry, O
   Cruchaga, PM
   Colmenero, J
   Berrevoet, F
   Rodriguez, G
   Ysebaert, D
   Radenne, S
   Metselaar, H
   Morelli, C
   De Carlis, LG
   Polak, WG
   Duvoux, C
AF Belli, Luca S.
   Fondevila, Constantino
   Cortesi, Paolo A.
   Conti, Sara
   Karam, Vincent
   Adam, Rene
   Coilly, Audrey
   Ericzon, Bo Goran
   Loinaz, Carmelo
   Cuervas-Mons, Valentin
   Zambelli, Marco
   Llado, Laura
   Diaz-Fontenla, Fernando
   Invernizzi, Federica
   Patrono, Damiano
   Faitot, Francois
   Bhooori, Sherrie
   Pirenne, Jacques
   Perricone, Giovanni
   Magini, Giulia
   Castells, Lluis
   Detry, Oliver
   Cruchaga, Pablo Mart
   Colmenero, Jordi
   Berrevoet, Frederick
   Rodriguez, Gonzalo
   Ysebaert, Dirk
   Radenne, Sylvie
   Metselaar, Herold
   Morelli, Cristina
   De Carlis, Luciano G.
   Polak, Wojciech G.
   Duvoux, Christophe
CA ELITA-ELTR COVID-19 Registry
TI Protective Role of Tacrolimus, Deleterious Role of Age and Comorbidities
   in Liver Transplant Recipients With Covid-19: Results From the
   ELITA/ELTR Multi-center European Study
SO GASTROENTEROLOGY
LA English
DT Article; Early Access
DE COVID-19; Liver transplantation; Outcome; Tacrolimus
ID REPLICATION
AB BACKGROUND AND AIMS: Despite concerns that liver transplant (LT) recipients may be at increased risk of unfavorable outcomes from COVID-19 due the high prevalence of co-morbidities, immunosuppression and ageing, a detailed analysis of their effects in large studies is lacking. METHODS: Data from adult LT recipients with laboratory confirmed SARS-CoV2 infection were collected across Europe. All consecutive patients with symptoms were included in the analysis. RESULTS: Between March 1 and June 27, 2020, data from 243 adult symptomatic cases from 36 centers and 9 countries were collected. Thirty-nine (16%) were managed as outpatients while 204 (84%) required hospitalization including admission to the ICU (39 of 204, 19.1%). Forty-nine (20.2%) patients died after a median of 13.5 (10-23) days, respiratory failure was the major cause. After multivariable Cox regression analysis, age >70 (HR, 4.16; 95% CI, 1.78-9.73) had a negative effect and tacrolimus (TAC) use (HR, 0.55; 95% CI, 0.31-0.99) had a positive independent effect on survival. The role of comorbidities was strongly influenced by the dominant effect of age where comorbidities increased with the increasing age of the recipients. In a second model excluding age, both diabetes (HR, 1.95; 95% CI, 1.06-3.58) and chronic kidney disease (HR, 1.97; 95% CI, 1.05-3.67) emerged as associated with death CONCLUSIONS: Twenty-five percent of patients requiring hospitalization for COVID-19 died, the risk being higher in patients older than 70 and with medical co-morbidities, such as impaired renal function and diabetes. Conversely, the use of TAC was associated with a better survival thus encouraging clinicians to keep TAC at the usual dose.
C1 [Belli, Luca S.; Perricone, Giovanni] Osped Niguarda Ca Granda, Dept Hepatol & Gastroenterol, Milan, Italy.
   [Fondevila, Constantino; Colmenero, Jordi] Univ Barcelona, Hosp Clin, Inst Invest Biomed August Pi Sunyer IDIBAPS, Dept Gen & Digest Surg,Ctr Invest Biomed Red Enfe, Barcelona, Spain.
   [Cortesi, Paolo A.; Conti, Sara] Univ Milano Bicocca, Res Ctr Publ Hlth CESP, Monza, Italy.
   [Karam, Vincent; Adam, Rene] Paris Saclay Univ, Hop Univ Paul Brousse, Assistance Publ Hop Paris, European Liver Transplant Registry,Ctr Hepatobili, Villejuif, France.
   [Coilly, Audrey] Paris Sud Saclay Univ, Ctr Hepatobiliaire, Hop Paul Brousse, Assistance Publ Hop Paris, Villejuif, France.
   [Ericzon, Bo Goran] Karolinska Univ Hosp Huddinge, Div Transplantat Surg, Stockholm, Sweden.
   [Loinaz, Carmelo] Doce Octubre Univ Complutense Madrid, Chirug Gen, Madrid, Spain.
   [Cuervas-Mons, Valentin] Univ Autonoma Madrid, Hosp Univ Puerta de Hierro, Dept Med, Madrid, Spain.
   [Zambelli, Marco] Papa Giovanni XXIII Hosp, Dept Surg, Bergamo, Lombardia, Italy.
   [Llado, Laura] Univ Barcelona, Hosp Uniersitari Bellvitge, Liver Transplant Unit, Barcelona, Spain.
   [Diaz-Fontenla, Fernando] Hosp Gen Univ Gregorio Maranon, Unidad Trasplante Hepat, Madrid, Spain.
   [Invernizzi, Federica] Univ Milan, Div Gastroenterol & Hepatol, Milan, Italy.
   [Patrono, Damiano] Molinette Mauriziano Hosp, Liver Transplantat Ctr, Turin, Italy.
   [Faitot, Francois] Hop Hautepierre, Serv Chirurg Hepatobiliaire & Transplantat, Strasbourg, France.
   [Bhooori, Sherrie] Ist Nazl Tumori, Dept Surg & Oncol, Milan, Italy.
   [Pirenne, Jacques] Univ Hosp Leuven, Dept Surg, Leuven, Belgium.
   [Magini, Giulia] Hop Univ Geneve, Serv Transplantat, Geneva, Switzerland.
   [Castells, Lluis] Hosp Univ Vall dHebron, Ctr Invest Biomed Red Enfermedades Hepat & Digest, Dept Internal Med, Liver Unit, Barcelona, Spain.
   [Detry, Oliver] Univ Liege, Ctr Hosp Univ Liege, Dept Abdominal Surg & Transplantat, Liege, Belgium.
   [Cruchaga, Pablo Mart] Clin Univ Navarra, Cirugia Gen & Digest, Pamplona, Spain.
   [Berrevoet, Frederick] Univ Ghent, Dept Gen & Hepatobiliary Surg, Ghent, Belgium.
   [Rodriguez, Gonzalo] Hosp Gen Univ Alicante, Inst Invest Sanitaria & Biomed Alicante ISABIAL, Dept Gen & Digest Surg, Alicante, Spain.
   [Ysebaert, Dirk] Antwerp Univ, Antwerp Univ Hosp, Dept Surg, Edegem, Belgium.
   [Radenne, Sylvie] Hosp Civils Lyon, Serv Hepatogastroenterol, Hop Croix Rousse, Lyon, France.
   [Metselaar, Herold] Erasmus MC, Dept Gastroenterol & Hepatol, Rotterdam, Netherlands.
   [Morelli, Cristina] Univ Bologna, St Orsola Malpighi Hosp, Liver & Multiorgan Transplantat, Bologna, Italy.
   [De Carlis, Luciano G.] Univ Milano Bicocca, Gen Surg & Abdominal Transplantat Unit, Niguarda Ca Granda Hosp, Milan, Italy.
   [De Carlis, Luciano G.] Univ Milano Bicocca, Sch Med & Surg, Milan, Italy.
   [Polak, Wojciech G.] Univ Med Ctr Rotterdam, Dept Surg, Erasmus MC, Rotterdam, Netherlands.
   [Duvoux, Christophe] Paris Est Univ, Henri Mondor Hosp, Assistance Publ Hop Paris, Dept Hepatol, Creteil, France.
   [Duvoux, Christophe] Paris Est Univ, Henri Mondor Hosp, Assistance Publ Hop Paris, Med Liver Transplant Unit, Creteil, France.
C3 IRCCS Ca Granda Ospedale Maggiore Policlinico; Ospedale Niguarda Ca'
   Granda; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS;
   University of Milano-Bicocca; Assistance Publique Hopitaux Paris (APHP);
   Hopital Universitaire Paul-Brousse - APHP; Aix-Marseille Universite;
   Assistance Publique-Hopitaux de Marseille; Universite Paris Saclay;
   Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille;
   Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire
   Paul-Brousse - APHP; Universite Paris Saclay; Karolinska Institutet;
   Karolinska University Hospital; Hospital Puerta de Hierro-Majadahonda;
   Autonomous University of Madrid; ASST Papa Giovanni XXIII; University of
   Barcelona; General University Gregorio Maranon Hospital; University of
   Milan; A.O.U. Citta della Salute e della Scienza di Torino; AOU San
   Giovanni Battista-Molinette; CHU Strasbourg; Universites de Strasbourg
   Etablissements Associes; Universite de Strasbourg; Fondazione IRCCS
   Istituto Nazionale Tumori Milan; KU Leuven; University Hospital Leuven;
   University of Geneva; Hospital Universitari Vall d'Hebron; CIBER -
   Centro de Investigacion Biomedica en Red; CIBEREHD; University of Liege;
   University of Navarra; Ghent University; General University Hospital of
   Alicante; Universidad Miguel Hernandez de Elche; Universitat d'Alacant;
   Instituto de Investigacion Sanitaria y Biomedica de Alicante (ISABIAL);
   University of Antwerp; CHU Lyon; Erasmus University Rotterdam; Erasmus
   MC; IRCCS Azienda Ospedaliero-Universitaria di Bologna; University of
   Bologna; University of Milano-Bicocca; IRCCS Ca Granda Ospedale Maggiore
   Policlinico; University of Milano-Bicocca; Erasmus University Rotterdam;
   Erasmus MC; Assistance Publique Hopitaux Paris (APHP); Universite
   Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire
   Henri-Mondor - APHP; Aix-Marseille Universite; Assistance
   Publique-Hopitaux de Marseille; Assistance Publique Hopitaux Paris
   (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital
   Universitaire Henri-Mondor - APHP; Aix-Marseille Universite; Assistance
   Publique-Hopitaux de Marseille
RP Belli, LS (corresponding author), Osped Niguarda Ca Granda, Dept Hepatol & Gastroenterol, Milan, Italy.
RI Colmenero, Jordi/AAA-6230-2021; Faitot, François/Y-9465-2019; Perricone,
   Giovanni/AAC-1205-2022; Patrono, Damiano/AAP-7491-2021; Ysebaert, Dirk
   K/J-6800-2013; Cuervas-Mons, Valentín/C-8504-2017; Ericzon,
   Bo-Goran/AAH-5328-2020; Patrono, Damiano/JMC-7416-2023; Conti,
   Sara/J-4891-2019; Invernizzi, Federica/AAC-3820-2022; Karam,
   Vincent/HLQ-6211-2023; Polak, Wojciech/AAM-6937-2021; Duvoux,
   Christophe/CAH-9481-2022; Duvoux, Christophe/CAF-3432-2022
OI Colmenero, Jordi/0000-0001-6024-8479; Faitot,
   François/0000-0001-6514-0774; Perricone, Giovanni/0000-0003-3890-5393;
   Patrono, Damiano/0000-0002-4096-4504; Ysebaert, Dirk
   K/0000-0002-3350-6994; Cuervas-Mons, Valentín/0000-0003-3086-9463;
   Conti, Sara/0000-0002-5774-3740; Polak, Wojciech/0000-0002-3096-4893;
   sylvie, radenne/0000-0001-7789-7264; Belli, Luca
   Saverio/0000-0001-8714-2439; Rodriguez Laiz, Gonzalo
   P/0000-0002-8265-8468; morelli, maria cristina/0000-0002-9742-1981;
   Invernizzi, Federica/0000-0002-7650-5879
CR Becchetti C, 2020, GUT, V69, P1832, DOI 10.1136/gutjnl-2020-321923
   Beigel JH, 2020, NEW ENGL J MED, V383, P1813, DOI 10.1056/NEJMoa2007764
   Belli LS, 2020, LANCET GASTROENTEROL, V5, P724, DOI 10.1016/S2468-1253(20)30183-7
   Bhoori S, 2020, LANCET GASTROENTEROL, V5, P532, DOI 10.1016/S2468-1253(20)30116-3
   Carbajo-Lozoya J, 2012, VIRUS RES, V165, P112, DOI 10.1016/j.virusres.2012.02.002
   Fernández-Ruiz M, 2020, AM J TRANSPLANT, V20, P1849, DOI 10.1111/ajt.15929
   Guan WJ, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00597-2020
   Horby P, NEW ENGL J MED
   Huang CL, 2020, LANCET, V395, P497, DOI [10.1016/S0140-6736(20)30183-5, 10.1016/S0140-6736(20)30211-7]
   Pereira MR, 2020, AM J TRANSPLANT, V20, P1800, DOI 10.1111/ajt.15941
   Polak WG, 2020, TRANSPL INT, V33, P1244, DOI 10.1111/tri.13680
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2052, DOI 10.1001/jama.2020.6775
   Russell B, 2020, ECANCERMEDICALSCIENC, V14, P1, DOI 10.3332/ecancer.2020.1022
   Tanaka Y, 2013, VIRUSES-BASEL, V5, P1250, DOI 10.3390/v5051250
   Tovikkai C, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2014-006971
   Webb GJ, 2020, LANCET GASTROENTEROL, V5, P643, DOI 10.1016/S2468-1253(20)30125-4
   Willicombe M, 2020, J AM SOC NEPHROL, V31, P1145, DOI 10.1681/ASN.2020030348
   World Health Organization, 2020, 51 WHO
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 20
TC 109
Z9 116
U1 2
U2 8
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0016-5085
EI 1528-0012
J9 GASTROENTEROLOGY
JI Gastroenterology
PD 2021 MAR
PY 2021
VL 160
IS 4
BP 1151
EP +
DI 10.1053/j.gastro.2020.11.045
EA MAR 2021
PG 16
WC Gastroenterology & Hepatology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Gastroenterology & Hepatology
GA QU8AE
UT WOS:000627499000037
PM 33307029
OA Green Published
HC Y
HP N
DA 2024-02-19
ER

PT J
AU Hagopian, K
   Harper, ME
   Ram, JJ
   Humble, SJ
   Weindruch, R
   Ramsey, JJ
AF Hagopian, K
   Harper, ME
   Ram, JJ
   Humble, SJ
   Weindruch, R
   Ramsey, JJ
TI Long-term calorie restriction reduces proton leak and hydrogen peroxide
   production in liver mitochondria
SO AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM
LA English
DT Article
DE energy expenditure; aging; oxidative stress; food restriction
ID ATP TURNOVER REACTIONS; FOOD RESTRICTION; DIETARY RESTRICTION;
   ENERGY-EXPENDITURE; OXIDATIVE DAMAGE; RAT; AGE; PHOSPHORYLATION;
   METABOLISM; GENERATION
AB Calorie restriction (CR) without malnutrition increases maximal life span in diverse species. It has been proposed that reduction in energy expenditure and reactive oxygen species (ROS) production could be a mechanism for life span extension with CR. As a step toward testing this theory, mitochondrial proton leak, H2O2 production, and markers of oxidative stress were measured in liver from FBNF1 rats fed control or 40% CR diets for 12 or 18 mo. CR was initiated at 6 mo of age. Proton leak kinetics curves, generated from simultaneous measures of oxygen consumption and membrane potential, indicated a decrease in proton leak after 18 mo of CR, while only a trend toward a proton leak decrease was observed after 12 mo. Significant shifts in phosphorylation and substrate oxidation curves also occurred with CR; however, these changes occurred in concert with the proton leak changes. Metabolic control analysis indicated no difference in the overall pattern of control of the oxidative phosphorylation system between control and CR animals. At 12 mo, no significant differences were observed between groups for H2O2 production or markers of oxidative stress. However, at 18 mo, protein carbonyl content was lower in CR animals, as was H2O2 production when mitochondria were respiring on either succinate alone or pyruvate plus malate in the presence of rotenone. These results indicate that long-term CR lowers mitochondrial proton leak and H2O2 production, and this is consistent with the idea that CR may act by decreasing energy expenditure and ROS production.
C1 Univ Calif Davis, Sch Vet Med, Dept Mol Biosci, Davis, CA 95616 USA.
   Vet Adm Geriatr Res Educ & Clin Ctr, Madison, WI USA.
   Univ Wisconsin, Sch Med, Dept Med, Madison, WI USA.
   Univ Ottawa, Fac Med, Dept Biochem Microbiol & Immunol, Ottawa, ON, Canada.
C3 University of California System; University of California Davis;
   Geriatric Research Education & Clinical Center; University of Wisconsin
   System; University of Wisconsin Madison; University of Ottawa
RP Ramsey, JJ (corresponding author), Univ Calif Davis, Sch Vet Med, Dept Mol Biosci, 1 Shields Ave, Davis, CA 95616 USA.
EM jjramsey@ucdavis.edu
RI Harper, Mary-Ellen/C-3103-2009
OI Harper, Mary-Ellen/0000-0003-3864-5886
FU NIA NIH HHS [R01-AG17902] Funding Source: Medline
CR Adams SH, 2000, J NUTR, V130, P711, DOI 10.1093/jn/130.4.711
   Barja G, 2002, J BIOENERG BIOMEMBR, V34, P227, DOI 10.1023/A:1016039604958
   Bevilacqua L, 2004, AM J PHYSIOL-ENDOC M, V286, pE852, DOI 10.1152/ajpendo.00367.2003
   BOVERIS A, 1973, BIOCHEM J, V134, P707, DOI 10.1042/bj1340707
   Brand MD, 1996, J THEOR BIOL, V182, P351, DOI 10.1006/jtbi.1996.0174
   BRAND MD, 1994, COMP BIOCHEM PHYS B, V108, P181, DOI 10.1016/0305-0491(94)90064-7
   BRAND MD, 1995, BIOENERGETICS PRACTI
   Brookes PS, 1998, COMP BIOCHEM PHYS B, V119, P325, DOI 10.1016/S0305-0491(97)00357-X
   Brookes PS, 1998, J NEUROCHEM, V70, P2195
   Buege J A, 1978, Methods Enzymol, V52, P302
   Cadenas S, 2000, BIOCHEM J, V351, P307, DOI 10.1042/0264-6021:3510307
   CHANCE B, 1961, J BIOL CHEM, V236, P1534
   Chappell JB, 1972, Subcellular Components, V2nd, P77, DOI DOI 10.1016/B978-0-408-70360-4.50009-2
   Desai VG, 1996, ARCH BIOCHEM BIOPHYS, V333, P145, DOI 10.1006/abbi.1996.0375
   DULLOO AG, 1993, INT J OBESITY, V17, P115
   Dumas JF, 2004, BBA-GEN SUBJECTS, V1670, P126, DOI 10.1016/j.bbagen.2003.11.002
   FEUERS RJ, 1993, MUTAT RES, V295, P191, DOI 10.1016/0921-8734(93)90020-4
   Gomi F, 1998, J GERONTOL A-BIOL, V53, pB161, DOI 10.1093/gerona/53A.3.B161
   Grav HJ, 2003, J BIOL CHEM, V278, P30525, DOI 10.1074/jbc.M303382200
   Greenberg JA, 2000, MECH AGEING DEV, V113, P37, DOI 10.1016/S0047-6374(99)00094-9
   Guerrero A, 1999, FREE RADICAL BIO MED, V26, P73, DOI 10.1016/S0891-5849(98)00173-7
   HAFNER RP, 1990, EUR J BIOCHEM, V188, P313, DOI 10.1111/j.1432-1033.1990.tb15405.x
   Hardy RW, 2002, J NUTR, V132, P3172, DOI 10.1093/jn/131.10.3172
   HARMAN D, 1956, J GERONTOL, V11, P298, DOI 10.1093/geronj/11.3.298
   Harper ME, 1998, AM J PHYSIOL-ENDOC M, V275, pE197, DOI 10.1152/ajpendo.1998.275.2.E197
   HARPER ME, 1993, J BIOL CHEM, V268, P14850
   HARPER ME, 1995, P SOC EXP BIOL MED, V208, P228
   HEINRICH R, 1974, EUR J BIOCHEM, V42, P97, DOI 10.1111/j.1432-1033.1974.tb03319.x
   HYSLOP PA, 1984, ANAL BIOCHEM, V141, P280, DOI 10.1016/0003-2697(84)90457-3
   Jezek P, 2002, INT J BIOCHEM CELL B, V34, P1190, DOI 10.1016/S1357-2725(02)00061-4
   KACSER H, 1973, S SOC EXP BIOL, V32, P65
   Kaneko T, 1997, FREE RADICAL BIO MED, V23, P76, DOI 10.1016/S0891-5849(96)00622-3
   LAGANIERE S, 1993, GERONTOLOGY, V39, P7, DOI 10.1159/000213509
   LAGANIERE S, 1989, MECH AGEING DEV, V48, P207, DOI 10.1016/0047-6374(89)90083-3
   Lambert AJ, 2004, AM J PHYSIOL-REG I, V286, pR71, DOI 10.1152/ajpregu.00341.2003
   LEVINE RL, 1990, METHOD ENZYMOL, V186, P464
   López-Torres M, 2002, FREE RADICAL BIO MED, V32, P882, DOI 10.1016/S0891-5849(02)00773-6
   MASORO EJ, 1991, ANN NY ACAD SCI, V621, P337
   MCCARTER RJ, 1992, AM J PHYSIOL, V263, pE448, DOI 10.1152/ajpendo.1992.263.3.E448
   Nedergaard J, 2003, EXP PHYSIOL, V88, P65, DOI 10.1113/eph8802502
   NOHL H, 1978, EUR J BIOCHEM, V90, P385, DOI 10.1111/j.1432-1033.1978.tb12615.x
   Pearl R., 1928, RATE LIVING
   Perez-Campo R, 1998, J COMP PHYSIOL B, V168, P149, DOI 10.1007/s003600050131
   PORTER RK, 1993, NATURE, V362, P628, DOI 10.1038/362628a0
   Porter RK, 1996, AM J PHYSIOL-REG I, V271, pR1550, DOI 10.1152/ajpregu.1996.271.6.R1550
   QUANT PA, 1993, TRENDS BIOCHEM SCI, V18, P26
   Ramsey JJ, 2004, AM J PHYSIOL-ENDOC M, V286, pE31, DOI 10.1152/ajpendo.00283.2003
   Ramsey JJ, 2000, FREE RADICAL BIO MED, V29, P946, DOI 10.1016/S0891-5849(00)00417-2
   Rolfe DFS, 1997, PHYSIOL REV, V77, P731, DOI 10.1152/physrev.1997.77.3.731
   Rolfe DFS, 1997, BIOSCIENCE REP, V17, P9, DOI 10.1023/A:1027327015957
   ROLFE DFS, 1994, BBA-BIOENERGETICS, V1188, P405, DOI 10.1016/0005-2728(94)90062-0
   Sarkela TM, 2001, J BIOL CHEM, V276, P6945, DOI 10.1074/jbc.M007625200
   Skulachev VP, 1998, BBA-BIOENERGETICS, V1363, P100, DOI 10.1016/S0005-2728(97)00091-1
   SOHAL RS, 1990, MECH AGEING DEV, V53, P209, DOI 10.1016/0047-6374(90)90039-I
   Sohal RS, 1996, SCIENCE, V273, P59, DOI 10.1126/science.273.5271.59
   SOHAL RS, 1994, MECH AGEING DEV, V76, P215, DOI 10.1016/0047-6374(94)91595-4
   Tan MGK, 2004, J BIOL CHEM, V279, P45235, DOI 10.1074/jbc.M403683200
   Tian LQ, 1998, FREE RADICAL BIO MED, V24, P1477, DOI 10.1016/S0891-5849(98)00025-2
   Venditti P, 2003, MOL CELL ENDOCRINOL, V205, P185, DOI 10.1016/S0303-7207(02)00332-5
   Weindruch R, 1997, NEW ENGL J MED, V337, P986, DOI 10.1056/NEJM199710023371407
   Yan LJ, 1998, P NATL ACAD SCI USA, V95, P12896, DOI 10.1073/pnas.95.22.12896
NR 61
TC 83
Z9 94
U1 1
U2 8
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0193-1849
EI 1522-1555
J9 AM J PHYSIOL-ENDOC M
JI Am. J. Physiol.-Endocrinol. Metab.
PD APR
PY 2005
VL 288
IS 4
BP E674
EP E684
DI 10.1152/ajpendo.00382.2004
PG 11
WC Endocrinology & Metabolism; Physiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Endocrinology & Metabolism; Physiology
GA 908YS
UT WOS:000227826700004
PM 15562252
OA Green Submitted
DA 2024-02-19
ER

PT J
AU Nikitchenko, YV
   Klochkov, VK
   Kavok, NS
   Averchenko, KA
   Karpenko, NA
   Nikitchenko, IV
   Yefimova, SL
   Bozhkov, AI
AF Nikitchenko, Yuri V.
   Klochkov, Vladimir K.
   Kavok, Nataliya S.
   Averchenko, Kateryna A.
   Karpenko, Nina A.
   Nikitchenko, Irina V.
   Yefimova, Svetlana L.
   Bozhkov, Anatoly I.
TI Anti-aging Effects of Antioxidant Rare-Earth Orthovanadate Nanoparticles
   in Wistar Rats
SO BIOLOGICAL TRACE ELEMENT RESEARCH
LA English
DT Article; Early Access
DE Rare-earth orthovanadate nanoparticles; Redox activity; Prooxidant;
   antioxidant balance; Mitochondria; Male rats
ID GLUTATHIONE SYNTHESIS; VANADIUM COMPOUNDS; CHEMICAL-SYNTHESIS;
   LNVO(4)EU3+ LN; GD; LA; METFORMIN; SURVIVAL; STRESS; RE
AB Biomedical application of rare-earth-based nanoparticles attracts much attention due to their unique optical and redox properties and quite low toxicity. Earlier, we found age-related beneficial effects of rare-earth-based orthovanadate nanoparticles (OV NPs) on the prooxidant/antioxidant balance in liver and blood of Wistar rats, as reported by Nikitchenko et al. (Biol Trace Elem Res (2020). ). However, the question remained unclear whether OV NPs' redox activity directly defines the protection ability. In the present work, antiradical, antioxidant, and membrane-protective properties of GdYVO4/Eu3+ NPs (1-2 nm), GdVO4/Eu3+ NPs (8 x 25 nm), LaVO4/Eu3+ (57 x 8 nm) were assayed in a comparative manner in various model systems. All OV NPs demonstrated the protective properties, but extra-small GdYVO4/Eu3+ NPs revealed the weakest antioxidant efficacy. In isolated mitochondria, OV NPs lowered (most evidently-extra-small NPs) respiration and oxidative phosphorylation, as well as ATP concentration. We conclude that not only the direct antioxidant effect but also slight suppression of bioenergetic processes by the OV NPs as well as the triggering of GSH-dependent antioxidant system may represent the principal mechanisms of their beneficial influences in an aged organism. This statement is consistent with improvement of the oxidative balance of 33-month-old rats due to prolonged administration of GdVO4 /Eu3+ NPs (for 11 months) accompanied by retention of the GSH signaling of the old rats at the level of 12 months mature animals. Consequently, an increase of antioxidant defense upon prolonged usage of OV NPs will lead to oxidative balance stabilization increasing the health span and survival of an organism.
C1 [Nikitchenko, Yuri V.; Nikitchenko, Irina V.; Bozhkov, Anatoly I.] Kharkov Natl Univ, 4 Svobody Sq, UA-61022 Kharkiv, Ukraine.
   [Klochkov, Vladimir K.; Kavok, Nataliya S.; Averchenko, Kateryna A.; Karpenko, Nina A.; Yefimova, Svetlana L.] Natl Acad Sci Ukraine, Inst Scintillat Mat, 60 Nauky Ave, UA-61072 Kharkiv, Ukraine.
C3 Ministry of Education & Science of Ukraine; VN Karazin Kharkiv National
   University; National Academy of Sciences Ukraine; Institute for
   Scintillation Materials of the National Academy of Sciences of Ukraine
RP Kavok, NS (corresponding author), Natl Acad Sci Ukraine, Inst Scintillat Mat, 60 Nauky Ave, UA-61072 Kharkiv, Ukraine.
EM kavok@isma.kharkov.ua
OI Klochkov, Vladimir/0000-0002-8080-1195; Averchenko,
   Kateryna/0000-0003-0981-4548; Nikitchenko, Yuri/0009-0001-9075-1179;
   Kavok, Nataliya/0000-0002-2429-2832; Yefimova,
   Svetlana/0000-0003-2092-1950; Bozhkov, Anatoly/0009-0007-0971-8763
FU State Fund for Fundamental Research
FX The authors received support from the State Fund for Fundamental
   Research (project no..64/29-2016).
CR Abdesselem M, 2014, ACS NANO, V8, P11126, DOI 10.1021/nn504170x
   Aon MA, 2007, J BIOL CHEM, V282, P21889, DOI 10.1074/jbc.M702841200
   Averchenko EA, 2014, J APPL SPECTROSC+, V81, P827, DOI 10.1007/s10812-014-0012-9
   Belostotskaia L I, 2008, Adv Gerontol, V21, P235
   BISHAYEE A, 1995, BIOL TRACE ELEM RES, V48, P275, DOI 10.1007/BF02789409
   Bishayee A, 2000, BREAST CANCER RES TR, V63, P133, DOI 10.1023/A:1006476003685
   Brunmair B, 2004, DIABETES, V53, P1052, DOI 10.2337/diabetes.53.4.1052
   Chong Y, 2016, ACS NANO, V10, P8690, DOI 10.1021/acsnano.6b04061
   Dröge W, 2005, PHILOS T R SOC B, V360, P2355, DOI 10.1098/rstb.2005.1770
   El-Mir MY, 2000, J BIOL CHEM, V275, P223, DOI 10.1074/jbc.275.1.223
   Franco R., 2007, Archives of Physiology and Biochemistry, V113, P234, DOI 10.1080/13813450701661198
   Gai SL, 2014, CHEM REV, V114, P2343, DOI 10.1021/cr4001594
   HALLIWELL B, 1987, ANAL BIOCHEM, V165, P215, DOI 10.1016/0003-2697(87)90222-3
   Harman D, 2001, ANN NY ACAD SCI, V928, P1, DOI 10.1111/j.1749-6632.2001.tb05631.x
   Hwang JT, 2004, CARCINOGENESIS, V25, P2497, DOI 10.1093/carcin/bgh253
   JAGER FC, 1968, NUTR DIETA, V10, P215
   Karpenko N.O., 2016, UKR BIOPHARM J, V0, P75, DOI [10.24959/ubphj.16.59, DOI 10.24959/UBPHJ.16.59]
   Kavok N, 2017, COLLOID SURFACE A, V529, P594, DOI 10.1016/j.colsurfa.2017.06.052
   KELLER RJ, 1989, ARCH BIOCHEM BIOPHYS, V271, P40, DOI 10.1016/0003-9861(89)90253-1
   Kim AD, 2012, BIOL TRACE ELEM RES, V147, P16, DOI 10.1007/s12011-011-9277-5
   Kim AD, 2011, INT J MOL SCI, V12, P8878, DOI 10.3390/ijms12128878
   Klochkov VK, 2011, FUNCT MATER, V18, P111
   Klochkov VK, 2012, J APPL SPECTROSC+, V79, P726, DOI 10.1007/s10812-012-9662-7
   Lamprecht W, 1965, METHOD ENZYMAT AN, P543
   Maher P, 2005, AGEING RES REV, V4, P288, DOI 10.1016/j.arr.2005.02.005
   Mamotyuk E. M., 2015, Nanoscience Advances in CBRN Agents Detection, Information and Energy Security. Proceedings, P193, DOI 10.1007/978-94-017-9697-2_20
   Marí M, 2009, ANTIOXID REDOX SIGN, V11, P2685, DOI [10.1089/ars.2009.2695, 10.1089/ARS.2009.2695]
   Martin-Castillo B, 2010, CELL CYCLE, V9, P1057, DOI 10.4161/cc.9.6.10994
   Masoro EJ, 2000, EXP GERONTOL, V35, P299, DOI 10.1016/S0531-5565(00)00084-X
   Moskalev A, 2015, AGING-US, V7, P616, DOI 10.18632/aging.100799
   Narayanan KB, 2013, ADV COLLOID INTERFAC, V201, P30, DOI 10.1016/j.cis.2013.10.008
   Nikitchenko Yu V, 2012, THESIS
   Nikitchenko YV, 2021, BIOL TRACE ELEM RES, V199, P649, DOI 10.1007/s12011-020-02196-7
   Nikitchenko YuV, 2009, PROBL STAR DOLGOLET, V18, P72
   NIKITCHENKO YV, 2020, DOP NAT AKAD NAUK UK, V2, P29, DOI DOI 10.15407/dopovidi2020.02.029
   Podder S, 2018, INORG CHEM, V57, P12727, DOI 10.1021/acs.inorgchem.8b01938
   Rizvi SI, 2018, MOL BASIS EMERGING S
   Rzigalinski BA, 2005, TECHNOL CANCER RES T, V4, P651, DOI 10.1177/153303460500400609
   Scibior A, 2019, CURR MED CHEM, V26, P5456, DOI 10.2174/0929867326666190108112255
   Shen DX, 2005, J BIOL CHEM, V280, P25305, DOI 10.1074/jbc.M500095200
   SHI XL, 1990, ARCH BIOCHEM BIOPHYS, V278, P288, DOI 10.1016/0003-9861(90)90262-W
   Soares SS, 2007, J INORG BIOCHEM, V101, P789, DOI 10.1016/j.jinorgbio.2007.01.012
   Suh JH, 2004, P NATL ACAD SCI USA, V101, P3381, DOI 10.1073/pnas.0400282101
   Thomas NO, 2016, REDOX BIOL, V10, P45, DOI 10.1016/j.redox.2016.09.010
   Tkachenko AS, 2020, WIEN MED WOCHENSCHR, V170, P189, DOI 10.1007/s10354-020-00735-4
   Vernekar AA, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6301
   Yefimova SL, 2019, J PHYS CHEM C, V123, P15323, DOI 10.1021/acs.jpcc.9b03040
   Zhao YB, 2010, J INORG BIOCHEM, V104, P371, DOI 10.1016/j.jinorgbio.2009.11.007
NR 48
TC 14
Z9 14
U1 1
U2 9
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 0163-4984
EI 1559-0720
J9 BIOL TRACE ELEM RES
JI Biol. Trace Elem. Res.
PD 2021 NOV
PY 2021
VL 199
IS 11
BP 4183
EP 4192
DI 10.1007/s12011-020-02531-y
EA JAN 2021
PG 10
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA UU3JE
UT WOS:000605536800019
PM 33409911
DA 2024-02-19
ER

PT J
AU LIGRONE, R
   POCOCK, K
   DUCKETT, JG
AF LIGRONE, R
   POCOCK, K
   DUCKETT, JG
TI A COMPARATIVE ULTRASTRUCTURAL-STUDY OF ENDOPHYTIC BASIDIOMYCETES IN THE
   PARASITIC ACHLOROPHYLLOUS HEPATIC CRYPTOTHALLUS-MIRABILIS AND THE
   CLOSELY ALLIED PHOTOSYNTHETIC SPECIES ANEURA-PINGUIS (METZGERIALES)
SO CANADIAN JOURNAL OF BOTANY-REVUE CANADIENNE DE BOTANIQUE
LA English
DT Article
DE BASIDIOMYCETES; DOLIPORES; LIVERWORTS; MYCORRHIZA; SYMBIOSIS;
   ULTRASTRUCTURE
ID ELECTRON-MICROSCOPE; SEPTAL ULTRASTRUCTURE; FUNGAL ENDOPHYTES; BRITISH
   HEPATICS; MYCORRHIZAS; LIGHT; ASSOCIATIONS; ECTOMYCORRHIZAS;
   GAMETOPHYTE; HEPATOPHYTA
AB This ultrastructural study of two closely related liverworts with contrasting modes of nutrition reveals very similar interactions with endophytic dikaryotic basidiomycetes. In both hepatics, collected from a variety of sites, the fungus is confined to specific regions of the gametophyte thallus, and hyphal contact with the substratum is via the rhizoids. The colonization cycle comprises a growth phase when the fungus forms large intracellular coils, host cytoplasm proliferates and the starch content of the plastids decreases, followed by senescence when the hyphae die back and aggregate into large masses. Repeated colonization cycles are frequent. Young hyphae contain abundant glycogen and sometimes amyloid deposits in Cryptothallus. In terms of dolipore substructure, hyphal dimensions, highly characteristic multilayered walls, absence of clamp connections, and die mode of hyphal degeneration, the endophyte in Cryptothallus is virtually identical to that in Aneura from alpine sites but very different from the fungus in Aneura from sand dunes and a chalk pit. It is suggested that Cryptothallus evolved from an Aneura-like ancestor through association with a fungal saprophyte of waterlogged peaty soils. Differences in dolipore morphology in the ectomycorrhizal fungus of Betula roots growing in association with Cryptothallus indicate that these two hosts do not share the same fungus. Remarkable similarities between the fungal associations in Cryptothallus and Aneura and orchidaceous mycorrhizae include the same colonization cycle, absence of polyphosphate granules, and separation of the host plasma membrane from thin-walled, exclusively intracellular hyphae by a prominent interfacial matrix.
C1 QUEEN MARY & WESTFIELD COLL,SCH BIOL SCI,MILE END RD,LONDON E1 4NS,ENGLAND.
   UNIV NAPOLI,DIPARTIMENTO BIOL VEGETALE,I-80139 NAPLES,ITALY.
C3 University of London; Queen Mary University London; University of Naples
   Federico II
RI Ligrone, Roberto/GVU-6415-2022
CR BENSONEVANS K, 1960, MALMB T BR BRYOL SOC, V3, P729
   Boullard B., 1979, SYLLOGEUS, V19, P1
   Clapp GL, 1912, BOT GAZ, V54, P0177, DOI 10.1086/330898
   CLEMENTS M A, 1988, Lindleyana, V3, P73
   CURRAH RS, 1992, MYCOL RES, V96, P583, DOI 10.1016/S0953-7562(09)80984-2
   DICKSON JH, 1975, LUONNON TUTKIJA, V79, P53
   DOUGLAS GC, 1989, CAN J BOT, V67, P2206, DOI 10.1139/b89-280
   Duckett J.G., 1989, B BRIT BRYOLOGICAL S, V53, P19
   DUCKETT JG, 1988, NEW PHYTOL, V110, P119, DOI 10.1111/j.1469-8137.1988.tb00244.x
   DUCKETT JG, 1991, NEW PHYTOL, V118, P259, DOI 10.1111/j.1469-8137.1991.tb00976.x
   DUCKETT JG, 1992, CAN J BOT, V70, P58, DOI 10.1139/b92-008
   DUCKETT JG, 1990, CAN J BOT, V68, P697, DOI 10.1139/b90-091
   DUCKETT JG, 1991, NEW PHYTOL, V118, P233, DOI 10.1111/j.1469-8137.1991.tb00975.x
   DUDDRIDGE JA, 1982, NEW PHYTOL, V92, P203, DOI 10.1111/j.1469-8137.1982.tb03377.x
   FILIPELLOMARCHI.V, 1985, NEW PHYTOL, V100, P623
   FONTANA ANNA, 1959, ALLIONIA, V5, P27
   FREY W, 1991, Cryptogamic Botany, V2, P73
   HADLEY G, 1974, NEW PHYTOL, V73, P475, DOI 10.1111/j.1469-8137.1974.tb02126.x
   HADLEY G, 1975, ENDOMYCORRHIZAS, P335
   Harley J.L., 1959, The biology of mycorrhiza, V1st
   HARLEY JL, 1983, MYCORRHIZAL SMYBOSIS
   Hill M.O., 1991, ATLAS BRYOPHYTES BRI, V1
   KHAN SR, 1982, MYCOTAXON, V15, P103
   KRAZAKOWA M, 1988, METHODS BRYOLOGY, P359
   LIGRONE R, 1988, BOT GAZ, V149, P92, DOI 10.1086/337695
   LIGRONE R, 1989, NEW PHYTOL, V111, P423, DOI 10.1111/j.1469-8137.1989.tb00705.x
   LUTZ RW, 1973, AM J BOT, V60, P339, DOI 10.2307/2441200
   MCCRACKENDA, 1973, AM J BOT, V60, P940
   MOORE RT, 1978, MYCOLOGIA, V70, P1007, DOI 10.2307/3759134
   NIEUWDORP PJ, 1972, ACTA BOT NEERL, V21, P128, DOI 10.1111/j.1438-8677.1972.tb00756.x
   O'Brien TP, 1981, STUDY PLANT STRUCTUR
   PATTON AM, 1978, J GEN MICROBIOL, V109, P335, DOI 10.1099/00221287-109-2-335
   PETERSON RL, 1990, CAN J BOT, V68, P1117, DOI 10.1139/b90-141
   PIGOTT CD, 1982, NEW PHYTOL, V92, P804
   POCOCK K, 1985, NEW PHYTOL, V99, P281, DOI 10.1111/j.1469-8137.1985.tb03657.x
   POCOCK K, 1985, BRYOL TIMES, V31, P2
   Purves S., 1975, ENDOMYCORRHIZAS, P175
   READ DJ, 1989, P ROY SOC EDINB B, V96, P89, DOI 10.1017/S0269727000010873
   RENZAGLIA KS, 1982, BRYPHYTORUM BIBL, V34
   ROLAND JC, 1969, J MICROSC-PARIS, V8, P263
   SCANNERINI S, 1983, CAN J BOT, V61, P917, DOI 10.1139/b83-104
   SMITH AJE, 1990, ILVERWORTS BRITAIN
   SMITH SE, 1967, NEW PHYTOL, V66, P371, DOI 10.1111/j.1469-8137.1967.tb06016.x
   SMITH SE, 1966, NEW PHYTOL, V65, P488, DOI 10.1111/j.1469-8137.1966.tb05972.x
   STAHL M, 1949, PLANTA, V37, P103, DOI 10.1007/BF01929705
   STRULLU DG, 1981, PHYSIOL VEG, V19, P367
   STRULLU DG, 1974, J MICROSC-PARIS, V20, P285
   STRULLU DG, 1985, ENCY PLANT ANATOMY, V13
   Szweykowski J., 1984, NEW MANUAL BRYOLOGY, V2, P1130
   THEODOROU C, 1991, NEW PHYTOL, V118, P279, DOI 10.1111/j.1469-8137.1991.tb00978.x
   UETAKE Y, 1992, MYCOL RES, V96, P199, DOI 10.1016/S0953-7562(09)80966-0
   WIEHLE W, 1989, Herzogia, V8, P107
   WIEHLE W, 1988, BOLETUS, V12, P15
   WILLIAMS S., 1950, TRANS BRIT BRYOL SOC, V1, P357
   WILLIAMSON B, 1970, PHYTOPATHOLOGY, V60, P1092, DOI 10.1094/Phyto-60-1092
NR 55
TC 31
Z9 34
U1 0
U2 4
PU NATL RESEARCH COUNCIL CANADA
PI OTTAWA
PA RESEARCH JOURNALS, MONTREAL RD, OTTAWA ON K1A 0R6, CANADA
SN 0008-4026
J9 CAN J BOT
JI Can. J. Bot.-Rev. Can. Bot.
PD MAY
PY 1993
VL 71
IS 5
BP 666
EP 679
DI 10.1139/b93-077
PG 14
WC Plant Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Plant Sciences
GA LN558
UT WOS:A1993LN55800003
DA 2024-02-19
ER

PT J
AU Sheffield-Moore, M
   Paddon-Jones, D
   Sanford, AP
   Rosenblatt, JI
   Matlock, AG
   Cree, MG
   Wolfe, RR
AF Sheffield-Moore, M
   Paddon-Jones, D
   Sanford, AP
   Rosenblatt, JI
   Matlock, AG
   Cree, MG
   Wolfe, RR
TI Mixed muscle and hepatic derived plasma protein metabolism is
   differentially regulated in older and younger men following resistance
   exercise
SO AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM
LA English
DT Article
DE aging; leg extension; protein turnover; plasma proteins
ID AMINO-ACIDS; ALBUMIN SYNTHESIS; SKELETAL-MUSCLE; ELDERLY-MEN;
   FIBRINOGEN; KINETICS; RECOVERY; AGE; TRANSPORT; INCREASE
AB We sought to determine whether exercise-induced muscle protein turnover alters the subsequent production of hepatically derived acute-phase plasma proteins, and whether age affects how these proteins are regulated. We measured arteriovenous (a-v) balance and the synthesis of mixed muscle protein, albumin ( A) and fibrinogen ( F) before exercise ( REST) and from the beginning of exercise to 10, 60, and 180 min following a single bout of moderate-intensity leg extension exercise (POST-EX) in postabsorptive untrained older (n = 6) and younger (n = 6) men using L-[ring-H-2(5)]phenylalanine (Phe). Subjects performed 6 sets of 8 repetitions of leg extension at 80% of their 1-RM (one-repetition maximum). All data are presented as the difference from REST (Delta from REST at 10, 60, and 180 min POST-EX). Mixed muscle fractional synthesis rate (FSR-M) increased significantly from the beginning of exercise until 10 min POST-EX in the older men (Delta FSR-M: 0.044%/h), whereas FSR-M in the younger men was not elevated until 180 min POST-EX (Delta FSR-M: 0.030%/h). FSR-A and FSR-F increased at all POST-EX periods in the older men (Delta FSR-A = 10 min: 1.90%/day; 60 min: 2.72%/day; 180 min: 2.78%/day; Delta FSR-F = 10 min: 1.00%/day; 60 min: 3.01%/day; 180 min: 3.73%/day). No change occurred in FSR-A in the younger men, but FSR-F was elevated from the beginning of exercise until 10 and 180 min POST-EX (10 min: 3.07%/day and 180 min: 3.96%/day). Net balance of Phe was positive in the older men in the immediate POST-EX period. Our data indicate that mixed muscle and hepatic derived protein synthesis is differentially regulated in younger and older men in response to a single bout of moderate-intensity leg extension exercise. Moreover, our data suggest that with age may come a greater need to salvage or make available amino acids from exercise-induced muscle protein breakdown to mount an acute-phase response.
C1 Univ Texas, Med Branch, Dept Internal Med, Div Endocrinol & Metab, Galveston, TX 77555 USA.
   Shriners Burns Hosp Children, Galveston, TX USA.
C3 University of Texas System; University of Texas Medical Branch Galveston
RP Sheffield-Moore, M (corresponding author), Univ Texas, Med Branch, Dept Internal Med, Div Endocrinol & Metab, 301 Univ Blvd, Galveston, TX 77555 USA.
EM melmoore@utmb.edu
RI Sheffield-Moore, Melinda/A-9794-2016; Cree-Green, Melanie/S-9494-2019;
   Cree-Green, Melanie/HGF-0832-2022
OI Sheffield-Moore, Melinda/0000-0001-6579-4655; Cree-Green,
   Melanie/0000-0003-1593-1695; Paddon-Jones, Douglas/0000-0002-3762-5130
FU NCRR NIH HHS [M01-RR-00073] Funding Source: Medline; NIA NIH HHS
   [R01-AG21539, P30 AG024832, P60-AG-17231-01] Funding Source: Medline
CR Balagopal P, 2001, AM J PHYSIOL-ENDOC M, V280, pE203, DOI 10.1152/ajpendo.2001.280.2.E203
   Baumgartner RN, 1996, AM J CLIN NUTR, V64, P552, DOI 10.1093/ajcn/64.4.552
   BIOLO G, 1995, AM J PHYSIOL-ENDOC M, V268, pE75, DOI 10.1152/ajpendo.1995.268.1.E75
   BIOLO G, 1995, AM J PHYSIOL-ENDOC M, V268, pE514
   Biolo G, 1997, AM J PHYSIOL-ENDOC M, V273, pE122, DOI 10.1152/ajpendo.1997.273.1.E122
   Biolo G, 1999, DIABETES, V48, P949, DOI 10.2337/diabetes.48.5.949
   Boirie Y, 1997, AM J CLIN NUTR, V65, P489
   Borsheim E, 2004, J APPL PHYSIOL, V96, P674, DOI 10.1152/japplphysiol.00333.2003
   Borsheim E, 2002, AM J PHYSIOL-ENDOC M, V283, pE648, DOI 10.1152/ajpendo.00466.2001
   CALDER AG, 1992, RAPID COMMUN MASS SP, V6, P421, DOI 10.1002/rcm.1290060704
   CLAUSS A., 1957, ACTA HAEMATOL, V17, P237
   de Sain-van der Velden MGM, 1998, KIDNEY INT, V53, P181, DOI 10.1046/j.1523-1755.1998.00729.x
   DEFEO P, 1992, AM J PHYSIOL, V263, pE794, DOI 10.1152/ajpendo.1992.263.4.E794
   DEFEO P, 1993, DIABETES, V42, P995, DOI 10.2337/diabetes.42.7.995
   Esmarck B, 2001, J PHYSIOL-LONDON, V535, P301, DOI 10.1111/j.1469-7793.2001.00301.x
   Fu AZ, 1998, AM J PHYSIOL-ENDOC M, V275, pE1023, DOI 10.1152/ajpendo.1998.275.6.E1023
   Hasten DL, 2000, AM J PHYSIOL-ENDOC M, V278, pE620, DOI 10.1152/ajpendo.2000.278.4.E620
   JORFELDT L, 1971, CLIN SCI, V41, P459, DOI 10.1042/cs0410459
   KATCH V, 1975, HUM BIOL, V47, P203
   McMillan DC, 1996, NUTRITION, V12, P602, DOI 10.1016/S0899-9007(96)00172-4
   Miller SL, 2003, MED SCI SPORT EXER, V35, P449, DOI 10.1249/01.MSS.0000053910.63105.45
   Papet I, 2003, J NUTR, V133, P215, DOI 10.1093/jn/133.1.215
   Phillips SM, 1997, AM J PHYSIOL-ENDOC M, V273, pE99, DOI 10.1152/ajpendo.1997.273.1.E99
   Phillips SM, 1999, AM J PHYSIOL-ENDOC M, V276, pE118
   Pitkänen HT, 2003, MED SCI SPORT EXER, V35, P784, DOI 10.1249/01.MSS.0000064934.51751.F9
   Raj DSC, 2004, AM J PHYSIOL-ENDOC M, V286, pE658, DOI 10.1152/ajpendo.00444.2003
   Rasmussen BB, 2003, EXERC SPORT SCI REV, V31, P127, DOI 10.1097/00003677-200307000-00005
   Rasmussen BB, 2000, J APPL PHYSIOL, V88, P386, DOI 10.1152/jappl.2000.88.2.386
   Rennie MJ, 2000, ANNU REV NUTR, V20, P457, DOI 10.1146/annurev.nutr.20.1.457
   Roy BD, 1997, J APPL PHYSIOL, V82, P1882, DOI 10.1152/jappl.1997.82.6.1882
   Sheffield-Moore M, 2004, AM J PHYSIOL-ENDOC M, V287, pE513, DOI 10.1152/ajpendo.00334.2003
   Steinfeld J L, 1964, Proc Natl Cancer Conf, V5, P401
   Tipton KD, 1996, J APPL PHYSIOL, V81, P2034, DOI 10.1152/jappl.1996.81.5.2034
   Tipton KD, 2001, AM J PHYSIOL-ENDOC M, V281, pE197, DOI 10.1152/ajpendo.2001.281.2.E197
   Tipton KD, 2001, INT J SPORT NUTR EXE, V11, P109, DOI 10.1123/ijsnem.11.1.109
   Tipton KD, 1999, AM J PHYSIOL-ENDOC M, V276, pE628, DOI 10.1152/ajpendo.1999.276.4.E628
   Trappe T, 2004, J PHYSIOL-LONDON, V554, P803, DOI 10.1113/jphysiol.2003.051755
   Wolfe RR., 1992, Radioactive and Stable Isotope Tracers in Biomedicine: Principles and Practice of Kinetic Analysis
   YARASHESKI KE, 1992, AM J PHYSIOL, V262, pE261, DOI 10.1152/ajpendo.1992.262.3.E261
   YARASHESKI KE, 1993, AM J PHYSIOL, V265, pE210, DOI 10.1152/ajpendo.1993.265.2.E210
   Zoico E, 2002, NUTR REV, V60, P39, DOI 10.1301/00296640260085949
NR 41
TC 52
Z9 61
U1 0
U2 5
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0193-1849
EI 1522-1555
J9 AM J PHYSIOL-ENDOC M
JI Am. J. Physiol.-Endocrinol. Metab.
PD MAY
PY 2005
VL 288
IS 5
BP E922
EP E929
DI 10.1152/ajpendo.00358.2004
PG 8
WC Endocrinology & Metabolism; Physiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Endocrinology & Metabolism; Physiology
GA 918VC
UT WOS:000228574700012
PM 15644460
DA 2024-02-19
ER

PT J
AU Dominici, FP
   Hauck, S
   Argentino, DP
   Bartke, A
   Turyn, D
AF Dominici, FP
   Hauck, S
   Argentino, DP
   Bartke, A
   Turyn, D
TI Increased insulin sensitivity and upregulation of insulin receptor,
   insulin receptor substrate (IRS)-1 and IRS-2 in liver of Ames dwarf mice
SO JOURNAL OF ENDOCRINOLOGY
LA English
DT Article
ID PROTEIN-KINASE-B; GROWTH-HORMONE; PHOSPHATIDYLINOSITOL 3-KINASE;
   TYROSINE PHOSPHORYLATION; GLUCOSE-TOLERANCE; TRANSGENIC MICE;
   ANIMAL-MODELS; ACTIVATION; RESISTANCE; MUSCLE
AB in the present study we have used hypopituitary Ames dwarf nice, which lack GH, prolactin and TSH, to investigate the consequences of the deficiency of these hormones on glucose homeostasis and on the initial components of the insulin signal transduction pathway in the liver. Ames dwarf mice displayed hypersensitivity to insulin since they maintained lower fasting glucose concentrations (73% of control values), had significantly reduced amounts of insulin (58% of control values), and exhibited an increased hypoglycemic response to exogenous insulin. Probably as a result of reduced insulin production, Ames dwarf mice displayed intolerance to glucose. The insulin-stimulated phosphorylation of the insulin receptor (IR) tended to be increased in the liver of Ames dwarf mice, while IR receptor protein content was increased by 38%. Insulin-stimulated phosphorylation of insulin receptor substrate (IRS)-1 and IRS-2 was increased by 61 and 72% respectively, while IRS-1 and IRS-2 protein levels were increased by 76 and 95%. The insulin-stimulated association of the p85 regulatory subunit of phosphatidylinositol (PI) 3-kinase with IRS-1 was increased by 28%, but unaltered with IRS-2. Interestingly, while the insulin-stimulated phosphotyrosine-derived PI 3-kinase activity was not changed, insulin-stimulated protein kinase B activation was increased by 41% in this tissue. These alterations may account for the insulin hypersensitivity exhibited by these animals. The present findings in long-lived Ames dwarf mice add to the evidence that insulin signaling is importantly related to the regulation of aging and life span.
C1 Univ Buenos Aires, Fac Farm & Bioquim, Inst Quim & Fisicoquim Biol, RA-1113 Buenos Aires, DF, Argentina.
   So Illinois Univ, Sch Med, Dept Physiol, Carbondale, IL 62901 USA.
C3 University of Buenos Aires; Southern Illinois University System;
   Southern Illinois University
RP Turyn, D (corresponding author), Univ Buenos Aires, Fac Farm & Bioquim, Inst Quim & Fisicoquim Biol, Junin 956, RA-1113 Buenos Aires, DF, Argentina.
RI Bartke, Andzej/D-6640-2017
OI Bartke, Andzej/0000-0002-2569-557X; Dominici, Fernando
   Pablo/0000-0002-4351-0057
CR ADER M, 1987, ENDOCRINOLOGY, V120, P725, DOI 10.1210/endo-120-2-725
   Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x
   Anai M, 1999, DIABETES, V48, P158, DOI 10.2337/diabetes.48.1.158
   Andersen B, 1995, DEV BIOL, V172, P495, DOI 10.1006/dbio.1995.8040
   [Anonymous], GENETIC VARIATION HO
   ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0
   ARGETSINGER LS, 1995, J BIOL CHEM, V270, P14685, DOI 10.1074/jbc.270.24.14685
   BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x
   Berlanga JJ, 1997, J BIOL CHEM, V272, P2050
   BORG KE, 1995, P SOC EXP BIOL MED, V210, P126
   BOUGNERES PF, 1985, J CLIN ENDOCR METAB, V61, P1152, DOI 10.1210/jcem-61-6-1152
   BrownBorg HM, 1996, NATURE, V384, P33, DOI 10.1038/384033a0
   Bruning JC, 1998, MOL CELL, V2, P559, DOI 10.1016/S1097-2765(00)80155-0
   Chandrashekar V, 1999, ENDOCRINOLOGY, V140, P1082, DOI 10.1210/en.140.3.1082
   CHEATHAM B, 1995, ENDOCR REV, V16, P117, DOI 10.1210/er.16.2.117
   Clancy DJ, 2001, SCIENCE, V292, P104, DOI 10.1126/science.1057991
   Coffer PJ, 1998, BIOCHEM J, V335, P1
   Daugaard JR, 1999, J ENDOCRINOL, V160, P127
   DAVIDSON MB, 1987, ENDOCR REV, V8, P115, DOI 10.1210/edrv-8-2-115
   Dominici FP, 1998, J ENDOCRINOL, V159, P15, DOI 10.1677/joe.0.1590015
   Dominici FP, 1999, J ENDOCRINOL, V161, P383, DOI 10.1677/joe.0.1610383
   Dominici FP, 2000, J ENDOCRINOL, V166, P579, DOI 10.1677/joe.0.1660579
   EOMINICI FP, 1999, AM J PHYSIOL, V277, pE447
   FOLLI F, 1993, J CLIN INVEST, V92, P1787, DOI 10.1172/JCI116768
   Foss MC, 1995, CLIN ENDOCRINOL, V43, P721, DOI 10.1111/j.1365-2265.1995.tb00541.x
   FOUCHEREAUPERON M, 1980, BIOCHIM BIOPHYS ACTA, V631, P451, DOI 10.1016/0304-4165(80)90021-5
   GAVIN JR, 1974, P NATL ACAD SCI USA, V71, P84, DOI 10.1073/pnas.71.1.84
   HOPWOOD NJ, 1975, AM J DIS CHILD, V129, P918, DOI 10.1001/archpedi.1975.02120450026006
   HOUSSAY BA, 1949, ENDOCRINOLOGY, V45, P627, DOI 10.1210/endo-45-6-627
   KAHN CR, 1978, ENDOCRINOLOGY, V103, P1054
   Kerouz NJ, 1997, J CLIN INVEST, V100, P3164, DOI 10.1172/JCI119872
   KIMURA KD, 1997, SCIENCE, V277, P897
   LANDGRAF R, 1977, DIABETOLOGIA, V13, P99, DOI 10.1007/BF00745135
   MATTHAEI S, 1995, J ENDOCRINOL, V144, P347, DOI 10.1677/joe.0.1440347
   Michael MD, 2000, MOL CELL, V6, P87, DOI 10.1016/S1097-2765(00)00010-1
   Ogihara T, 2001, DIABETES, V50, P573, DOI 10.2337/diabetes.50.3.573
   PARSONS JA, 1995, ENDOCRINOLOGY, V136, P2013, DOI 10.1210/en.136.5.2013
   Previs SF, 2000, J BIOL CHEM, V275, P38990, DOI 10.1074/jbc.M006490200
   Reis FM, 1997, J ENDOCRINOL, V153, P423, DOI 10.1677/joe.0.1530423
   RIDDERSTRALE M, 1995, J BIOL CHEM, V270, P3471, DOI 10.1074/jbc.270.8.3471
   RIZZA RA, 1982, DIABETES, V31, P663, DOI 10.2337/diabetes.31.8.663
   SAAD MJA, 1995, ENDOCRINOLOGY, V136, P1579, DOI 10.1210/en.136.4.1579
   SAAD MJA, 1992, J CLIN INVEST, V90, P1839, DOI 10.1172/JCI116060
   SAAD MJA, 1993, J CLIN INVEST, V92, P2065, DOI 10.1172/JCI116803
   Schaible R., 1961, Genetics, V46, P896
   SCHERNTHANER G, 1985, DIABETOLOGIA, V28, P138
   SHAH JH, 1975, DIABETES, V24, P922, DOI 10.2337/diabetes.24.10.922
   Shepherd PR, 1998, BIOCHEM J, V333, P471, DOI 10.1042/bj3330471
   SOUZA SC, 1994, J BIOL CHEM, V269, P30085
   SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0
   TAMEMOTO H, 1994, NATURE, V372, P182, DOI 10.1038/372182a0
   Tatar M, 2001, SCIENCE, V292, P107, DOI 10.1126/science.1057987
   Thirone ACP, 1999, ENDOCRINOLOGY, V140, P55, DOI 10.1210/en.140.1.55
   WHITE MF, 1997, DIABETOLOGIA, V40, P2
   Withers DJ, 1998, NATURE, V391, P900, DOI 10.1038/36116
   Yamauchi T, 1998, J BIOL CHEM, V273, P15719, DOI 10.1074/jbc.273.25.15719
NR 56
TC 154
Z9 170
U1 0
U2 3
PU SOC ENDOCRINOLOGY
PI BRISTOL
PA 17/18 THE COURTYARD, WOODLANDS, BRADLEY STOKE, BRISTOL BS32 4NQ, ENGLAND
SN 0022-0795
J9 J ENDOCRINOL
JI J. Endocrinol.
PD APR
PY 2002
VL 173
IS 1
BP 81
EP 94
DI 10.1677/joe.0.1730081
PG 14
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Endocrinology & Metabolism
GA 541JW
UT WOS:000174982300009
PM 11927387
OA Bronze
DA 2024-02-19
ER

PT J
AU Freese, K
   Seitz, T
   Dietrich, P
   Lee, SML
   Thasler, WE
   Bosserhoff, A
   Hellerbrand, C
AF Freese, Kim
   Seitz, Tatjana
   Dietrich, Peter
   Lee, Serene M. L.
   Thasler, Wolfgang E.
   Bosserhoff, Anja
   Hellerbrand, Claus
TI Histone Deacetylase Expressions in Hepatocellular Carcinoma and
   Functional Effects of Histone Deacetylase Inhibitors on Liver Cancer
   Cells In Vitro
SO CANCERS
LA English
DT Article
DE histone deacetylase; hepatocellular carcinoma; sorafenib; histone
   deacetylase inhibitor
ID CLINICAL-SIGNIFICANCE; COMBINATION THERAPY; DOWN-REGULATION;
   HEPATOMA-CELLS; APOPTOSIS; SORAFENIB; PROLIFERATION; TRICHOSTATIN;
   SENSITIVITY; PREDICTION
AB Hepatocellular carcinoma (HCC) is a leading cause for deaths worldwide. Histone deacetylase (HDAC) inhibition (HDACi) is emerging as a promising therapeutic strategy. However, most pharmacological HDACi unselectively block different HDAC classes and their molecular mechanisms of action are only incompletely understood. The aim of this study was to systematically analyze expressions of different HDAC classes in HCC cells and tissues and to functionally analyze the effect of the HDACi suberanilohydroxamic acid (SAHA) and trichostatin A (TSA) on the tumorigenicity of HCC cells. The gene expression of all HDAC classes was significantly increased in human HCC cell lines (Hep3B, HepG2, PLC, HuH7) compared to primary human hepatocytes (PHH). The analysis of HCC patient data showed the increased expression of several HDACs in HCC tissues compared to non-tumorous liver. However, there was no unified picture of regulation in three different HCC patient datasets and we observed a strong variation in the gene expression of different HDACs in tumorous as well as non-tumorous liver. Still, there was a strong correlation in the expression of HDAC class IIa (HDAC4, 5, 7, 9) as well as HDAC2 and 8 (class I) and HDAC10 (class IIb) and HDAC11 (class IV) in HCC tissues of individual patients. This might indicate a common mechanism of the regulation of these HDACs in HCC. The Cancer Genome Atlas (TCGA) dataset analysis revealed that HDAC4, HDAC7 and HDAC9 as well as HDAC class I members HDAC1 and HDAC2 is significantly correlated with patient survival. Furthermore, we observed that SAHA and TSA reduced the proliferation, clonogenicity and migratory potential of HCC cells. SAHA but not TSA induced features of senescence in HCC cells. Additionally, HDACi enhanced the efficacy of sorafenib in killing sorafenib-susceptible cells. Moreover, HDACi reestablished sorafenib sensitivity in resistant HCC cells. In summary, HDACs are significantly but differently increased in HCC, which may be exploited to develop more targeted therapeutic approaches. HDACi affect different facets of the tumorigenicity of HCC cells and appears to be a promising therapeutic approach alone or in combination with sorafenib.
C1 [Freese, Kim; Seitz, Tatjana; Dietrich, Peter; Bosserhoff, Anja; Hellerbrand, Claus] Friedrich Alexander Univ Erlangen Nurnberg, Inst Biochem, Emil Fischer Zentrum, Fahrstr 17, D-91054 Erlangen, Germany.
   [Dietrich, Peter] Friedrich Alexander Univ, Univ Hosp Erlangen, Dept Med, Med Clin 1, D-91054 Erlangen, Germany.
   [Lee, Serene M. L.] Ludwig Maximilians Univ Munchen, Dept Gen Visceral & Transplantat Surg, Biobank, Human Tissue & Cell Res Fdn, D-81377 Munich, Germany.
   [Thasler, Wolfgang E.] Hepacult GmbH, Klopferspitz 19, D-82152 Planegg Martinsried, Germany.
   [Bosserhoff, Anja; Hellerbrand, Claus] Comprehens Canc Ctr CCC Erlangen EMN, D-91054 Erlangen, Germany.
C3 University of Erlangen Nuremberg; University of Erlangen Nuremberg;
   University of Munich; University of Erlangen Nuremberg
RP Hellerbrand, C (corresponding author), Friedrich Alexander Univ Erlangen Nurnberg, Inst Biochem, Emil Fischer Zentrum, Fahrstr 17, D-91054 Erlangen, Germany.; Hellerbrand, C (corresponding author), Comprehens Canc Ctr CCC Erlangen EMN, D-91054 Erlangen, Germany.
EM kim.freese@fau.de; tatjana.seitz@fau.de; peter.dietrich@fau.de;
   serene.lee@med.uni-muenchen.de; wolfgang.thasler@swmbrk.de;
   anja.bosserhoff@fau.de; claus.hellerbrand@fau.de
RI Bosserhoff, Anja/GNH-4801-2022
OI Bosserhoff, Anja/0000-0001-8147-394X; Lee, Serene/0000-0001-5231-0607
FU German Research Association (DFG) [HE2458/15, HE2458/18]
FX This work was supported by grants from the German Research Association
   (DFG) (HE2458/15 and HE2458/18).
CR Aguirre-Gamboa R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074250
   Amann T, 2009, AM J PATHOL, V174, P1544, DOI 10.2353/ajpath.2009.080596
   Anestopoulos I, 2015, PHARMACOL THERAPEUT, V145, P103, DOI 10.1016/j.pharmthera.2014.09.005
   Armeanu S, 2005, J HEPATOL, V42, P210, DOI 10.1016/j.jhep.2004.10.020
   Bioscience B.P.S, HDAC SIRT SCREEN PRO
   Bitzer M, 2016, J HEPATOL, V65, P280, DOI 10.1016/j.jhep.2016.02.043
   Bosserhoff AK, 2003, J BIOL CHEM, V278, P15225, DOI 10.1074/jbc.M212639200
   Bruix J, 2002, HEPATOLOGY, V35, P519, DOI 10.1053/jhep.2002.32089
   Chen PJ, 2015, BIOCHIMIE, V116, P61, DOI 10.1016/j.biochi.2015.06.016
   Dietrich P, 2018, GUT, V67, P1328, DOI 10.1136/gutjnl-2017-315402
   Ding G, 2013, FEBS LETT, V587, P880, DOI 10.1016/j.febslet.2013.02.001
   Dorn C, 2010, INT J ONCOL, V36, P435, DOI 10.3892/ijo_00000517
   Eckschlager T, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18071414
   Fan J, 2014, TUMOR BIOL, V35, P11523, DOI 10.1007/s13277-014-2358-2
   García-Ruiz I, 2015, DIS MODEL MECH, V8, P183, DOI 10.1242/dmm.018234
   Ghayad SE, 2019, CANCER BIOL THER, V20, P272, DOI 10.1080/15384047.2018.1529093
   Goldman M., 2018, BIORXIV, DOI [DOI 10.1101/326470, 10.1101/326470]
   Gong D, 2019, AM J TRANSL RES, V11, P983
   Guichard C, 2012, NAT GENET, V44, P694, DOI 10.1038/ng.2256
   He B, 2018, INT J BIOL SCI, V14, P1845, DOI 10.7150/ijbs.27661
   Hellerbrand C, 2006, CARCINOGENESIS, V27, P64, DOI 10.1093/carcin/bgi201
   Hu YZ, 2019, CELL MOL BIOL, V65, P23, DOI 10.14715/cmb/2019.65.4.4
   Issa R, 2002, FASEB J, V16, P47, DOI 10.1096/fj.02-0494fje
   Ji HJ, 2019, CANCER RES, V79, P3676, DOI 10.1158/0008-5472.CAN-18-3767
   Jiang SM, 2015, J HEPATOL, V62, P371, DOI 10.1016/j.jhep.2014.09.026
   Kaletsch A, 2018, CLIN EPIGENETICS, V10, DOI 10.1186/s13148-018-0531-y
   Katzenellenbogen M, 2007, MOL CANCER RES, V5, P1159, DOI 10.1158/1541-7786.MCR-07-0172
   Lachenmayer A, 2012, J HEPATOL, V56, P1343, DOI 10.1016/j.jhep.2012.01.009
   Lee SML, 2013, JOVE-J VIS EXP, DOI 10.3791/50615
   Ler SY, 2015, ONCOL REP, V34, P2238, DOI 10.3892/or.2015.4263
   Liu LG, 2005, WORLD J GASTROENTERO, V11, P4530, DOI 10.3748/wjg.v11.i29.4530
   McNamara MG, 2018, EUR J CANCER, V105, P1, DOI 10.1016/j.ejca.2018.09.031
   Mottamal M, 2015, MOLECULES, V20, P3898, DOI 10.3390/molecules20033898
   Pathil A, 2006, HEPATOLOGY, V43, P425, DOI 10.1002/hep.21054
   Prieto-Domínguez N, 2016, J PINEAL RES, V61, P396, DOI 10.1111/jpi.12358
   Quint K, 2011, VIRCHOWS ARCH, V459, P129, DOI 10.1007/s00428-011-1103-0
   Ramakrishna G, 2013, LIVER CANCER, V2, P367, DOI 10.1159/000343852
   Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2
   Rikimaru T, 2007, ONCOLOGY-BASEL, V72, P69, DOI 10.1159/000111106
   Roessler S, 2010, CANCER RES, V70, P10202, DOI 10.1158/0008-5472.CAN-10-2607
   Schroeder FA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071323
   Sengupta N, 2004, J CELL BIOCHEM, V93, P57, DOI 10.1002/jcb.20179
   Society A.C, CANC FACTS FIG 2014
   Soukupova J, 2017, ONCOTARGET, V8, P110367, DOI 10.18632/oncotarget.22775
   Tak WY, 2018, INVEST NEW DRUG, V36, P1072, DOI 10.1007/s10637-018-0658-x
   Thasler Wolfgang E., 2003, Cell and Tissue Banking, V4, P49, DOI 10.1023/A:1026392429112
   Tsai CL, 2018, HEPATOLOGY, V67, P586, DOI 10.1002/hep.29328
   Tsilimigras DI, 2018, SURG ONCOL, V27, P611, DOI 10.1016/j.suronc.2018.07.015
   Wang Y, 2009, HEPATOLOGY, V50, P453, DOI 10.1002/hep.22978
   Wang YC, 2013, WORLD J GASTROENTERO, V19, P5159, DOI 10.3748/wjg.v19.i31.5159
   Wang ZH, 2019, ANN CLIN LAB SCI, V49, P189
   Wurmbach E, 2007, HEPATOLOGY, V45, P938, DOI 10.1002/hep.21622
   Yamashita Y, 2003, INT J CANCER, V103, P572, DOI 10.1002/ijc.10699
   Yang HD, 2019, HEPATOLOGY, V70, P1262, DOI 10.1002/hep.30657
   Yang H, 2010, EXP BIOL MED, V235, P32, DOI 10.1258/ebm.2009.009252
   Yuan H, 2014, WORLD J GASTROENTERO, V20, P4953, DOI 10.3748/wjg.v20.i17.4953
   Zhang Y, 2007, RADIAT RES, V168, P115, DOI 10.1667/RR0811.1
   Zhou J, 2016, ONCOTARGET, V7, P50612, DOI 10.18632/oncotarget.9437
NR 58
TC 65
Z9 67
U1 0
U2 13
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2072-6694
J9 CANCERS
JI Cancers
PD OCT
PY 2019
VL 11
IS 10
AR 1587
DI 10.3390/cancers11101587
PG 19
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA JQ3CF
UT WOS:000498826000184
PM 31635225
OA Green Published, gold
DA 2024-02-19
ER

PT J
AU BOERRIGTER, METI
   WEI, JY
   VIJG, J
AF BOERRIGTER, METI
   WEI, JY
   VIJG, J
TI INDUCTION AND REPAIR OF BENZO[A]PYRENE-DNA ADDUCTS IN C57BL/6 AND BALB/C
   MICE - ASSOCIATION WITH AGING AND LONGEVITY
SO MECHANISMS OF AGEING AND DEVELOPMENT
LA English
DT Article
DE MICE; AGING; DNA REPAIR; POSTLABELING ANALYSIS
ID DNA-ADDUCTS; MITOCHONDRIAL-DNA; P-32-POSTLABELING ASSAY; CALORIC
   RESTRICTION; OXIDATIVE DAMAGE; MOUSE-TISSUES; DIOL-EPOXIDE; HUMAN
   HEARTS; LIFE-SPAN; AGE
AB In this study, we employed the sensitive P-32-postlabeling assay to assess the influence of age on the formation and disappearance of benzo[a]pyrene (B[a]P) DNA adducts in six organs of two different mouse strains with different life spans, C57BL/6ByJ (C57BL/6) and BALB/cByJ (BALB/c). Following a single, intraperitoneal treatment with 50 mg B[a]P per kg of bodyweight, maximum formation of the major B[a]P-derived adduct, trans-(7R)-N-2-[10-(7 beta,8 alpha,9 alpha-trihydroxy- 7,8,9,10)-tetrahydrobenzo[a]pyrene]-yl-deoxyguanosine (BPDE-N-2-dG), appeared to be age- and organ-dependent; minor differences were observed for the same organs between the two mouse strains. The maximum formation of BPDE-N-2-dG in the various organs from young and old mice differed by a factor of 2-4 and was two- to eightfold lower in organs from old mice as compared to young mice. The removal of BPDE-N-2-dG, up to 7 days after the treatment, was apparently age- and strain-dependent; non-significant differences were observed for organs within strains at each age studied. In young C57BL/6 mice, which have a greater life expectancy than BALB/c, the rate of disappearance of BPDE-N-2-dG was significantly higher in liver and heart as compared to young BALB/c. At the older age a decrease in the rate of BPDE-N-2-dG disappearance was observed more frequently, and to a relatively greater extent, in organs from C57BL/6 mice as compared to BALB/c mice. These results are discussed in relation to the differences in life spans and the incidence of pathological lesions between the two strains of mice.
C1 BROCKTON W ROXBURY VET AFFAIRS MED CTR, GRECC, BOSTON, MA USA.
C3 Geriatric Research Education & Clinical Center; Harvard University
RP BOERRIGTER, METI (corresponding author), HARVARD UNIV, BETH ISRAEL HOSP,SCH MED,DIV AGING,DIV GERONTOL, MOLEC GENET SECT, 330 BROOKLINE AVE, BOSTON, MA 02215 USA.
CR BOERRIGTER METI, 1993, J GERONTOL, V48, pB11, DOI 10.1093/geronj/48.1.B11
   Bronson RT, 1990, GENETIC EFFECTS AGIN, P279
   CHENEY KE, 1980, EXP GERONTOL, V15, P237, DOI 10.1016/0531-5565(80)90029-7
   CONNEY AH, 1982, CANCER RES, V42, P4875
   DEMANT P, 1989, ADV CANCER RES, V53, P117
   EASTMAN A, 1978, CHEM-BIOL INTERACT, V23, P345, DOI 10.1016/0009-2797(78)90095-9
   ELDRIDGE SR, 1992, CANCER RES, V52, P5617
   Festing M. F. W., 1979, INBRED STRAINS BIOME
   FRAGA CG, 1990, P NATL ACAD SCI USA, V87, P4533, DOI 10.1073/pnas.87.12.4533
   FRITH CH, 1983, LAB ANIM SCI, V33, P273
   GENSLER HL, 1981, Q REV BIOL, V56, P279, DOI 10.1086/412317
   GINSBERG GL, 1990, CANCER RES, V50, P1189
   GINSBERG GL, 1989, CARCINOGENESIS, V10, P673, DOI 10.1093/carcin/10.4.673
   GUPTA RC, 1988, P NATL ACAD SCI USA, V85, P3513, DOI 10.1073/pnas.85.10.3513
   HANSONPAINTON O, 1983, CANCER RES, V43, P4198
   HART RW, 1974, P NATL ACAD SCI USA, V71, P2169, DOI 10.1073/pnas.71.6.2169
   HARVEY RG, 1981, ACCOUNTS CHEM RES, V14, P218, DOI 10.1021/ar00067a004
   HAYAKAWA M, 1993, MOL CELL BIOCHEM, V119, P95, DOI 10.1007/BF00926859
   HAYAKAWA M, 1992, BIOCHEM BIOPH RES CO, V189, P979, DOI 10.1016/0006-291X(92)92300-M
   HOLZ O, 1991, CARCINOGENESIS, V12, P2181, DOI 10.1093/carcin/12.11.2181
   JOE CO, 1987, MUTAT RES, V184, P129, DOI 10.1016/0167-8817(87)90069-1
   KIRKWOOD TBL, 1991, PHILOS T R SOC B, V332, P15, DOI 10.1098/rstb.1991.0028
   KOREEDA M, 1976, J AM CHEM SOC, V98, P6720, DOI 10.1021/ja00437a061
   LEAKEY JEA, 1989, MECH AGEING DEV, V48, P145, DOI 10.1016/0047-6374(89)90046-8
   LU LJW, 1986, CANCER RES, V46, P3046
   MECOCCI P, 1993, ANN NEUROL, V34, P609, DOI 10.1002/ana.410340416
   MULLAART E, 1990, MUTAT RES, V237, P189, DOI 10.1016/0921-8734(90)90001-8
   MYERS DD, 1978, GENETIC EFFECTS AGIN, V1, P41
   NEBERT DW, 1984, BIOL REPROD, V30, P363, DOI 10.1095/biolreprod30.2.363
   PARTRIDGE L, 1993, NATURE, V362, P305, DOI 10.1038/362305a0
   POIRIER MC, 1991, PROG CLIN BIOL RES, V374, P205
   RANDERATH K, 1989, MUTAT RES, V219, P121, DOI 10.1016/0921-8734(89)90023-4
   RANDERATH K, 1986, CARCINOGENESIS, V7, P1615, DOI 10.1093/carcin/7.9.1615
   REDDY MV, 1986, CARCINOGENESIS, V7, P1543, DOI 10.1093/carcin/7.9.1543
   REDDY MV, 1984, CARCINOGENESIS, V5, P231, DOI 10.1093/carcin/5.2.231
   ROGGEBAND R, 1993, CARCINOGENESIS, V14, P1945, DOI 10.1093/carcin/14.9.1945
   ROSS JA, 1995, CANCER RES, V55, P1039
   ROWLATT C, 1976, Laboratory Animals (London), V10, P419, DOI 10.1258/002367776780956917
   SAI K, 1992, Journal of Environmental Pathology Toxicology and Oncology, V11, P139
   SCHURDAK ME, 1989, CANCER RES, V49, P2633
   SHADDOCK JG, 1993, MUTAT RES, V295, P19, DOI 10.1016/0921-8734(93)90008-Q
   STADTMAN ER, 1988, J GERONTOL, V43, pB112, DOI 10.1093/geronj/43.5.B112
   STOWERS SJ, 1984, CHEM-BIOL INTERACT, V51, P151, DOI 10.1016/0009-2797(84)90027-9
   STOWERS SJ, 1985, ENVIRON HEALTH PERSP, V62, P31, DOI 10.2307/3430090
   STUTMAN O, 1974, FED PROC, V33, P2028
   VANSCHOOTEN FJ, 1991, CARCINOGENESIS, V12, P427
   VIJG J, 1987, J AM GERIATR SOC, V35, P532, DOI 10.1111/j.1532-5415.1987.tb01400.x
   WEINDRUCH R, 1982, SCIENCE, V215, P1415, DOI 10.1126/science.7063854
   WOLF NS, 1988, J GERONTOL, V43, pB71, DOI 10.1093/geronj/43.3.B71
   1986, MONOGRAPHS POLYCYC 1, V38
NR 50
TC 22
Z9 23
U1 0
U2 2
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0047-6374
J9 MECH AGEING DEV
JI Mech. Ageing Dev.
PD JUL 28
PY 1995
VL 82
IS 1
BP 31
EP 50
DI 10.1016/0047-6374(95)01603-W
PG 20
WC Cell Biology; Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Geriatrics & Gerontology
GA RP236
UT WOS:A1995RP23600003
PM 7475355
DA 2024-02-19
ER

PT J
AU Gibbs, VK
   Brewer, RA
   Miyasaki, ND
   Patki, A
   Smith, DL
AF Gibbs, Victoria K.
   Brewer, Rachel A.
   Miyasaki, Nathan D.
   Patki, Amit
   Smith, Daniel L., Jr.
TI Sex-dependent Differences in Liver and Gut Metabolomic Profiles With
   Acarbose and Calorie Restriction in C57BL/6 Mice
SO JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL
   SCIENCES
LA English
DT Article
DE Calorie restriction mimetic; Glucose; Glucosidase
ID GAMMA-GLUTAMYL CYCLE; LIFE-SPAN; GLUCOSIDASE INHIBITOR; GRADED-LEVELS;
   SHORT-TERM; PARACELLULAR PERMEABILITY; MACRONUTRIENT BALANCE; DIETARY
   RESTRICTION; AGING MICE; MIMETICS
AB Acarbose, an alpha-glucosidase inhibitor used in treating type 2 diabetes, impairs complex carbohydrate digestion and absorption and extends life span in mice (without a requisite reduction in food intake). To assess sex-differential effects coincident with calorie restriction versus a nonrestricted longevity enhancing intervention, we evaluated the metabolite profiles (by liquid chromatography-mass spectroscopy) from livers and cecal contents of C57BL/6J mice (n = 4/sex/group), which were maintained for 10 months under one of the three diet treatments: ad libitum control diet (CON), ad libitum control diet containing 0.1% acarbose (ACA), or 40% calorie restriction using the control diet (CR). Principal component analysis revealed sex-differential profiles with ACA in livers. Of the identified metabolites (n = 621) in liver, CR significantly altered similar to 44% (males: 187 up arrow/131 down arrow, females: 74 up arrow/148 down arrow) compared with CON, in contrast with ACA (M: 165 up arrow/61 down arrow, F: 52 up arrow/60 down arrow). Dissimilarity in ACA-F liver metabolites was observed for similar to 50% of common metabolites from ACA-M and CR-M/F. CR resulted in fewer significant cecal metabolite differences (n = 615 metabolites; M: 86 up arrow/66 down arrow, F: 51 up arrow/48 down arrow vs CON), relative to ACA treatment (M: 32 up arrow 189 down arrow, F: 36 up arrow/137 down arrow). Metabolomic profiling identifies sex-differential and tissue-specific effects with amino acid metabolism sub-pathways including those involving tryptophan, branch-chain and sulfur amino acids, and the urea cycle, as well as bile acid, porphyrin, and cofactor metabolism pathways.
C1 [Gibbs, Victoria K.; Brewer, Rachel A.; Miyasaki, Nathan D.; Smith, Daniel L., Jr.] Univ Alabama Birmingham, Dept Nutr Sci, 1720 2nd Ave S,WEBB 423, Birmingham, AL 35294 USA.
   [Gibbs, Victoria K.; Smith, Daniel L., Jr.] Univ Alabama Birmingham, Nathan Shock Ctr Excellence Basic Biol Aging, Birmingham, AL 35294 USA.
   [Gibbs, Victoria K.; Smith, Daniel L., Jr.] Univ Alabama Birmingham, Comprehens Ctr Hlth Aging, Birmingham, AL 35294 USA.
   [Gibbs, Victoria K.; Smith, Daniel L., Jr.] Univ Alabama Birmingham, Nutr Obes Res Ctr, Birmingham, AL 35294 USA.
   [Gibbs, Victoria K.; Smith, Daniel L., Jr.] Univ Alabama Birmingham, Nutr Obes Res Ctr, Birmingham, AL 35294 USA.
   [Gibbs, Victoria K.] Birmingham Southern Coll Alabama, Dept Biol, Birmingham, AL USA.
   [Patki, Amit] Univ Alabama Birmingham, Dept Biostat, Birmingham, AL 35294 USA.
C3 University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham
RP Smith, DL (corresponding author), Univ Alabama Birmingham, Dept Nutr Sci, 1720 2nd Ave S,WEBB 423, Birmingham, AL 35294 USA.
EM dsmithjr@uab.edu
OI Gibbs, Victoria/0000-0001-6557-8194; Smith Jr,
   Daniel/0000-0002-1602-2023
FU Ellison Medical Foundation New Scholar in Aging award; University of
   Alabama at Birmingham Nathan Shock Center of Excellence in the Biology
   of Aging [P30AG050886]; National Institute on Aging of the National
   Institutes of Health [R01AG043972]; National Institute of Diabetes and
   Digestive and Kidney Diseases of the National Institutes of Health
   [T32DK062710]
FX This work was support by the Ellison Medical Foundation New Scholar in
   Aging award and the University of Alabama at Birmingham Nathan Shock
   Center of Excellence in the Biology of Aging (P30AG050886). Preparation
   of this manuscript was supported in part by the National Institute on
   Aging of the National Institutes of Health under award number
   R01AG043972 and by the National Institute of Diabetes and Digestive and
   Kidney Diseases of the National Institutes of Health training grant
   T32DK062710 UAB Obesity Post-Doctoral Training Program to V.K.G.
CR AHRENS RA, 1980, J NUTR, V110, P725, DOI 10.1093/jn/110.4.725
   Alssema M, 2015, BRIT J NUTR, V113, P239, DOI 10.1017/S0007114514003547
   Anson RM, 2003, P NATL ACAD SCI USA, V100, P6216, DOI 10.1073/pnas.1035720100
   Barzilai N, 2016, CELL METAB, V23, P1060, DOI 10.1016/j.cmet.2016.05.011
   Brewer Rachel A, 2016, Nutr Healthy Aging, V4, P31, DOI 10.3233/NHA-160007
   Brown-Borg Holly M, 2014, Longev Healthspan, V3, P10, DOI 10.1186/2046-2395-3-10
   Cabreiro F, 2013, EMBO MOL MED, V5, P1300, DOI 10.1002/emmm.201100972
   Cabreiro F, 2013, CELL, V153, P228, DOI 10.1016/j.cell.2013.02.035
   Cao SX, 2001, P NATL ACAD SCI USA, V98, P10630, DOI 10.1073/pnas.191313598
   Chen X, 2016, SCI REP-UK, V6, DOI 10.1038/srep28423
   CLISSOLD SP, 1988, DRUGS, V35, P214, DOI 10.2165/00003495-198835030-00003
   DENEKE SM, 1989, AM J PHYSIOL, V257, pL163, DOI 10.1152/ajplung.1989.257.4.L163
   Derous D, 2016, AGING-US, V8, P642, DOI 10.18632/aging.100895
   Dhahbi JM, 2005, PHYSIOL GENOMICS, V23, P343, DOI 10.1152/physiolgenomics.00069.2005
   DUFFY PH, 1990, CHRONOBIOL INT, V7, P113, DOI 10.3109/07420529009056963
   Fukaya N, 2009, NUTRITION, V25, P657, DOI 10.1016/j.nut.2008.11.015
   Gibbs VK, 2016, EXP GERONTOL, V86, P90, DOI 10.1016/j.exger.2016.04.004
   Green CL, 2017, AGING CELL, V16, P529, DOI 10.1111/acel.12570
   Harrison DE, 2014, AGING CELL, V13, P273, DOI 10.1111/acel.12170
   Higuchi T, 2015, J CELL BIOCHEM, V116, P609, DOI 10.1002/jcb.25012
   Ingram DK, 2006, AGING CELL, V5, P97, DOI 10.1111/j.1474-9726.2006.00202.x
   Ingram DK, 2004, ANN NY ACAD SCI, V1019, P412, DOI 10.1196/annals.1297.074
   Ingram DK, 2015, AGEING RES REV, V20, P46, DOI 10.1016/j.arr.2014.11.005
   Inoue M, 2016, ARCH BIOCHEM BIOPHYS, V595, P61, DOI 10.1016/j.abb.2015.11.023
   Jiang YJ, 2013, MECH AGEING DEV, V134, P407, DOI 10.1016/j.mad.2013.08.003
   Kinoshita M, 2002, BIOCHEM BIOPH RES CO, V293, P827, DOI 10.1016/S0006-291X(02)00294-2
   KRAUSE HP, 1982, DIGESTION, V23, P232, DOI 10.1159/000198755
   Le Couteur DG, 2016, CELL MOL LIFE SCI, V73, P1237, DOI 10.1007/s00018-015-2120-y
   LEE SM, 1983, METABOLISM, V32, P793, DOI 10.1016/0026-0495(83)90109-9
   Ma SM, 2015, CELL METAB, V22, P332, DOI 10.1016/j.cmet.2015.07.005
   Mariadason JM, 1997, AM J PHYSIOL-GASTR L, V272, pG705, DOI 10.1152/ajpgi.1997.272.4.G705
   Martin-Montalvo A, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3192
   Mattson MP, 2017, AGEING RES REV, V39, P46, DOI 10.1016/j.arr.2016.10.005
   MEISTER A, 1974, LIFE SCI, V15, P177, DOI 10.1016/0024-3205(74)90206-9
   Menke A, 2015, JAMA-J AM MED ASSOC, V314, P1021, DOI 10.1001/jama.2015.10029
   Merry BJ, 2002, INT J BIOCHEM CELL B, V34, P1340, DOI 10.1016/S1357-2725(02)00038-9
   Metchnikoff E., 1908, The prolongation of life: Optimistic studies
   Mitchell SJ, 2016, CELL METAB, V23, P1093, DOI 10.1016/j.cmet.2016.05.027
   Mitchell SE, 2015, ONCOTARGET, V6, P23213, DOI 10.18632/oncotarget.4003
   Mochizuki K, 2011, METABOLISM, V60, P1560, DOI 10.1016/j.metabol.2011.03.010
   Peng LY, 2009, J NUTR, V139, P1619, DOI 10.3945/jn.109.104638
   Simpson SJ, 2009, AGING-US, V1, P875, DOI 10.18632/aging.100098
   Solon-Biet SM, 2015, P NATL ACAD SCI USA, V112, P3481, DOI 10.1073/pnas.1422041112
   Strong R, 2016, AGING CELL, V15, P872, DOI 10.1111/acel.12496
   Sun LY, 2013, ELIFE, V2, DOI 10.7554/eLife.01098
   Swindell WR, 2012, AGEING RES REV, V11, P254, DOI 10.1016/j.arr.2011.12.006
   Weaver GA, 1997, J NUTR, V127, P717, DOI 10.1093/jn/127.5.717
   Wegman MP, 2015, REJUV RES, V18, P162, DOI 10.1089/rej.2014.1624
   Weindruch R., 1988, RETARDATION AGING DI
NR 49
TC 24
Z9 26
U1 0
U2 8
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1079-5006
EI 1758-535X
J9 J GERONTOL A-BIOL
JI J. Gerontol. Ser. A-Biol. Sci. Med. Sci.
PD FEB
PY 2018
VL 73
IS 2
SI SI
BP 157
EP 165
DI 10.1093/gerona/glx127
PG 9
WC Geriatrics & Gerontology; Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Geriatrics & Gerontology
GA FW7VO
UT WOS:000425534900004
PM 28651373
OA Green Published, Bronze
DA 2024-02-19
ER

PT J
AU Caro, P
   Gomez, J
   Sanchez, I
   Garcia, R
   López-Torres, M
   Naudí, A
   Portero-Otin, M
   Pamplona, R
   Barja, G
AF Caro, Pilar
   Gomez, Jose
   Sanchez, Ines
   Garcia, Ruben
   Lopez-Torres, Monica
   Naudi, Alba
   Portero-Otin, Manuel
   Pamplona, Reinald
   Barja, Gustavo
TI Effect of 40% restriction of dietary amino acids (except methionine) on
   mitochondrial oxidative stress and biogenesis, AIF and SIRT1 in rat
   liver
SO BIOGERONTOLOGY
LA English
DT Article
DE Free radical generation; Protein restriction; Aging; Protein damage;
   Fatty acid unsaturation; Mitochondrial respiratory complexes
ID OXYGEN RADICAL GENERATION; CALORIC RESTRICTION; DNA-DAMAGE; LIFE-SPAN;
   PROTEIN RESTRICTION; MOLECULAR DAMAGE; LONGEVITY; PGC-1-ALPHA; CELLS;
   ADAPTATION
AB Previous studies have shown that the decrease in mitochondrial reactive oxygen species (mitROS) generation and oxidative damage to mitochondrial DNA (mtDNA) that occurs during life extending dietary restriction also occurs during protein or methionine restriction, whereas it does not take place during carbohydrate or lipid restriction. In order to study the possible effects of other amino acids, in this investigation all the dietary amino acids, except methionine, were restricted by 40% in male Wistar rats (RESTAAS group). After 6-7 weeks, experimental parameters were measured in the liver. Amino acid restriction did not change the levels of the methionine metabolites S-adenosylmethionine and S-adenosylhomocysteine, mitochondrial oxygen consumption and ROS generation, oxidative damage to mtDNA, amounts of the respiratory complexes I-IV, and the mitochondrial biogenesis factors PGC-1 alpha and NRF-2. On the other hand, adenylate energy charge, mitochondrial protein oxidation, lipooxidation and glycooxidation, the degree of mitochondrial fatty acid unsaturation, and the amount of the apoptosis inducing factor (AIF) were decreased in the RESTAAS group. Amino acid restriction also increased SIRT1 protein. These results, together with previous ones, strongly suggest that the decrease in mitROS generation and oxidative damage to mtDNA that occurs during dietary restriction is due to restriction of a single aminoacid: methionine. They also show for the first time that restriction of dietary amino acids different from methionine decreases mitochondrial protein oxidative modification and AIF, and increases SIRT1, in rat liver.
C1 [Caro, Pilar; Gomez, Jose; Sanchez, Ines; Garcia, Ruben; Lopez-Torres, Monica; Barja, Gustavo] Univ Complutense, Dept Fisiol Anim 2, Fac Ciencias Biol, E-28040 Madrid, Spain.
   [Naudi, Alba; Portero-Otin, Manuel; Pamplona, Reinald] Univ Lleida IRBLLEIDA, Dept Expt Med, Lleida 25008, Spain.
C3 Complutense University of Madrid; Universitat de Lleida
RP Barja, G (corresponding author), Univ Complutense, Dept Fisiol Anim 2, Fac Ciencias Biol, C Jose Antonio Novais 2, E-28040 Madrid, Spain.
EM pcaromartin@bio.ucm.es; mirumotoryu@yahoo.es; Haineskaito@hotmail.com;
   rubenggmm@hotmail.com; mltorres@bio.ucm.es; alba.naudi@mex.udl.cat;
   manuel.portero@mex.udl.cat; reinald.pamplona@mex.udl.cat;
   gbarja@bio.ucm.es
RI Martin, Ruben Garcia/AAA-8538-2021; Portero-Otin, Manuel/B-7122-2009;
   Naudí, Alba/B-5594-2009; Barja, Gustavo/AAA-5903-2019; Pamplona,
   Reinald/A-7359-2010; Gomez, Jose/G-9705-2015; Gustavo,
   Barja/B-5591-2012; Martin, Ruben/HNP-9047-2023
OI Martin, Ruben Garcia/0000-0003-2049-4960; Portero-Otin,
   Manuel/0000-0002-1823-0299; Naudí, Alba/0000-0003-0699-1004; Barja,
   Gustavo/0000-0001-5736-4735; Pamplona, Reinald/0000-0003-4337-6107;
   Gomez, Jose/0000-0003-1758-4746; Martin, Ruben/0009-0007-6879-2891;
   Caro, Pilar/0000-0002-7531-3234; Sanchez-Roman, Ines/0000-0003-4844-5781
FU Spanish Ministry of Education and Science [BFU2006-14495/BFI]; Spanish
   Ministry of Health [RD06/0013/0012]; Generalitat of Catalunya
   [2005SGR00101]; "Caixa'' Foundation; Ministry of Education and Science
   [BFU2005-02584]; CAM/UCM-GR74/07 [CCG07-UCM/BIO-2648]; Ministry of
   Education and Science
FX This study was supported in part by I + D grants from the Spanish
   Ministry of Education and Science (BFU2006-14495/BFI), the Spanish
   Ministry of Health (ISCIII, Red de Envejecimiento y Fragilidad,
   RD06/0013/0012), the Generalitat of Catalunya (2005SGR00101), and
   "Caixa'' Foundation to R. P.; and from the Ministry of Education and
   Science (BFU2005-02584) and from CAM/UCM-GR74/07 (CCG07-UCM/BIO-2648) to
   G. B. P. Caro and J. Gomez received predoctoral fellowships from the
   Ministry of Education and Science.
CR ASUNCION JG, 1996, FASEB J, V10, P333
   Ayala V, 2007, J GERONTOL A-BIOL, V62, P352, DOI 10.1093/gerona/62.4.352
   Barja G, 2004, BIOL REV, V79, P235, DOI 10.1017/S1464793103006213
   Barja G, 2002, J BIOENERG BIOMEMBR, V34, P227, DOI 10.1023/A:1016039604958
   Barja G, 2004, TRENDS NEUROSCI, V27, P595, DOI 10.1016/j.tins.2004.07.005
   Beckman KB, 1998, PHYSIOL REV, V78, P547, DOI 10.1152/physrev.1998.78.2.547
   Boily G, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001759
   Caro P, 2008, BIOGERONTOLOGY, V9, P183, DOI 10.1007/s10522-008-9130-1
   Chen D, 2007, TRENDS MOL MED, V13, P64, DOI 10.1016/j.molmed.2006.12.004
   FINKELSTEIN JD, 1986, J BIOL CHEM, V261, P1582
   Frye RA, 2000, BIOCHEM BIOPH RES CO, V273, P793, DOI 10.1006/bbrc.2000.3000
   Gredilla R, 2005, ENDOCRINOLOGY, V146, P3713, DOI 10.1210/en.2005-0378
   Holman R.T., 1954, Prog. Chem. Fats Other Lipids, V2, P51, DOI [10.1016/0079-6832(54)90004-X, DOI 10.1016/0079-6832(54)90004-X]
   Hulbert AJ, 2007, PHYSIOL REV, V87, P1175, DOI 10.1152/physrev.00047.2006
   Kilberg MS, 2005, ANNU REV NUTR, V25, P59, DOI 10.1146/annurev.nutr.24.012003.132145
   LATORRE A, 1986, P NATL ACAD SCI USA, V83, P8649, DOI 10.1073/pnas.83.22.8649
   Loft S, 1999, METHOD ENZYMOL, V300, P166
   López-Torres M, 2002, FREE RADICAL BIO MED, V32, P882, DOI 10.1016/S0891-5849(02)00773-6
   Miller RA, 2005, AGING CELL, V4, P119, DOI 10.1111/j.1474-9726.2005.00152.x
   Muller FL, 2007, FREE RADICAL BIO MED, V43, P477, DOI 10.1016/j.freeradbiomed.2007.03.034
   Naudí A, 2007, REJUV RES, V10, P473, DOI 10.1089/rej.2007.0538
   Nemoto S, 2005, J BIOL CHEM, V280, P16456, DOI 10.1074/jbc.M501485200
   Nisoli E, 2005, SCIENCE, V310, P314, DOI 10.1126/science.1117728
   Pamplona R, 2005, J BIOL CHEM, V280, P21522, DOI 10.1074/jbc.M502255200
   Pamplona R, 2002, ANN NY ACAD SCI, V959, P475, DOI 10.1111/j.1749-6632.2002.tb02118.x
   Pamplona R, 2002, MECH AGEING DEV, V123, P1437, DOI 10.1016/S0047-6374(02)00076-3
   Pamplona R, 2006, BBA-BIOENERGETICS, V1757, P496, DOI 10.1016/j.bbabio.2006.01.009
   PERNA AF, 1995, KIDNEY INT, V47, P247, DOI 10.1038/ki.1995.31
   Porter AG, 2006, BIOESSAYS, V28, P834, DOI 10.1002/bies.20444
   RICHIE JP, 1994, FASEB J, V8, P1302, DOI 10.1096/fasebj.8.15.8001743
   Rodgers JT, 2008, FEBS LETT, V582, P46, DOI 10.1016/j.febslet.2007.11.034
   Rodgers JT, 2005, NATURE, V434, P113, DOI 10.1038/nature03354
   Rogina B, 2004, P NATL ACAD SCI USA, V101, P15998, DOI 10.1073/pnas.0404184101
   Ryan MT, 2007, ANNU REV BIOCHEM, V76, P701, DOI 10.1146/annurev.biochem.76.052305.091720
   Sanz A, 2006, J BIOENERG BIOMEMBR, V38, P327, DOI 10.1007/s10863-006-9051-0
   Sanz A, 2004, J BIOENERG BIOMEMBR, V36, P545, DOI 10.1007/s10863-004-9001-7
   Sanz A, 2006, HDB MODELS HUMAN AGI, P183
   Sanz A, 2006, ANN NY ACAD SCI, V1067, P200, DOI 10.1196/annals.1354.024
   Sanz A, 2006, FASEB J, V20, P1064, DOI 10.1096/fj.05-5568com
   STOCCHI V, 1985, ANAL BIOCHEM, V146, P118, DOI 10.1016/0003-2697(85)90405-1
   Vahsen N, 2004, EMBO J, V23, P4679, DOI 10.1038/sj.emboj.7600461
   Vaquero A, 2004, MOL CELL, V16, P93, DOI 10.1016/j.molcel.2004.08.031
   Wang W, 2001, J CHROMATOGR B, V762, P59, DOI 10.1016/S0378-4347(01)00341-3
NR 43
TC 38
Z9 47
U1 0
U2 17
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1389-5729
EI 1573-6768
J9 BIOGERONTOLOGY
JI Biogerontology
PD OCT
PY 2009
VL 10
IS 5
BP 579
EP 592
DI 10.1007/s10522-008-9200-4
PG 14
WC Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Geriatrics & Gerontology
GA 486OQ
UT WOS:000269207100004
PM 19039676
DA 2024-02-19
ER

PT J
AU Suda, T
   Isokawa, O
   Aoyagi, Y
   Nomoto, M
   Tsukada, K
   Shimizu, T
   Suzuki, Y
   Naito, A
   Igarashi, H
   Yanagi, M
   Takahashi, T
   Asakura, H
AF Suda, T
   Isokawa, O
   Aoyagi, Y
   Nomoto, M
   Tsukada, K
   Shimizu, T
   Suzuki, Y
   Naito, A
   Igarashi, H
   Yanagi, M
   Takahashi, T
   Asakura, H
TI Quantitation of telomerase activity in hepatocellular carcinoma: A
   possible aid for a prediction of recurrent diseases in the remnant liver
SO HEPATOLOGY
LA English
DT Article
ID CELLULAR SENESCENCE; HUMAN FIBROBLASTS; CANCER; IMMORTALIZATION; CELLS;
   RNA
AB Because telomerase activity is necessary for cell immortality and probably associated with tumor progression, we have evaluated a possible aid for quantitation of the activity to predict intrahepatic recurrences after surgery in patients with hepatocellular carcinoma (HCC). HCC tissues obtained by surgical resection from 20 patients were studied. Telomerase activity was expressed as peaks with a periodicity through a fluorescence-based telomeric repeat amplification protocol using an autosequencer, and the quantity of activity was calculated from peak areas. A ratio of fluorescence intensity depending on telomerase to that of an internal standard was used as a value of relative telomerase activity (RTA). RTA ia serially diluted S100 extracts from HepG2 cells was well correlated with the amount of the extracts. The mean RTA value of 36.4 +/- 27.8 (mean +/- SD, 3.21 to 105) in 9 patients suffering from early recurrences after surgery was significantly higher than that (9.84 +/- 7.65; mean +/- SD, 3.00 to 29.0) in 11 patients without intrahepatic recurrences during the early period (P = .004). These results indicate that RTA value can be a useful predictor for intrahepatic recurrences during the early period after surgical resection of HCC.
C1 Niigata Univ, Sch Med, Dept Internal Med 3, Niigata 951, Japan.
   Niigata Univ, Sch Med, Dept Surg 1, Niigata 951, Japan.
   Shinrakuen Hosp, Div Surg, Niigata, Japan.
C3 Niigata University; Niigata University
RP Suda, T (corresponding author), Niigata Univ, Sch Med, Dept Internal Med 3, 1-757 Asahimachi Dori, Niigata 951, Japan.
CR ALLSOPP RC, 1992, P NATL ACAD SCI USA, V89, P10114, DOI 10.1073/pnas.89.21.10114
   CHADENEAU C, 1995, CANCER RES, V55, P2533
   COUNTER CM, 1995, BLOOD, V85, P2315, DOI 10.1182/blood.V85.9.2315.bloodjournal8592315
   EDMONDSON HA, 1954, CANCER-AM CANCER SOC, V7, P462, DOI 10.1002/1097-0142(195405)7:3<462::AID-CNCR2820070308>3.0.CO;2-E
   EGUCHI A, 1992, HEPATOLOGY, V15, P843, DOI 10.1002/hep.1840150516
   FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491
   GREIDER CW, 1989, NATURE, V337, P331, DOI 10.1038/337331a0
   GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9
   Hermanek P., 1987, TNM Classification of Malignant Tumors, V4th edn
   HIYAMA E, 1995, CANCER RES, V55, P3258
   HIYAMA E, 1995, NAT MED, V1, P249, DOI 10.1038/nm0395-249
   HIYAMA K, 1995, J NATL CANCER I, V87, P895, DOI 10.1093/jnci/87.12.895
   KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428
   LAI ECS, 1993, WORLD J SURG, V17, P786, DOI 10.1007/BF01659097
   Liver Cancer Study Group of Japan, 1992, GEN RUL CLIN PATH ST
   Piatyszek Mieczyslaw A., 1995, Methods in Cell Science, V17, P1, DOI 10.1007/BF00981880
   SAITON Y, IN PRESS JPN J CANC
   Shay JW, 1996, TRENDS GENET, V12, P129, DOI 10.1016/0168-9525(96)30018-8
   SHAY JW, 1993, ONCOGENE, V8, P1407
   TAHARA H, 1995, CANCER RES, V55, P2734
   TOBE T, 1994, CANCER-AM CANCER SOC, V74, P2772, DOI 10.1002/1097-0142(19941115)74:10<2772::AID-CNCR2820741006>3.0.CO;2-V
   WRIGHT WE, 1992, TRENDS GENET, V8, P193, DOI 10.1016/0168-9525(92)90232-S
   WRIGHT WE, 1989, MOL CELL BIOL, V9, P3088, DOI 10.1128/MCB.9.7.3088
   Wright WE, 1996, EMBO J, V15, P1734, DOI 10.1002/j.1460-2075.1996.tb00519.x
   WRIGHT WE, 1995, NUCLEIC ACIDS RES, V23, P3794, DOI 10.1093/nar/23.18.3794
   YU GL, 1990, NATURE, V344, P126, DOI 10.1038/344126a0
NR 26
TC 47
Z9 49
U1 0
U2 1
PU W B SAUNDERS CO
PI PHILADELPHIA
PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA
   19106-3399 USA
SN 0270-9139
J9 HEPATOLOGY
JI Hepatology
PD FEB
PY 1998
VL 27
IS 2
BP 402
EP 406
DI 10.1002/hep.510270213
PG 5
WC Gastroenterology & Hepatology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Gastroenterology & Hepatology
GA YU242
UT WOS:000071696500013
PM 9462637
OA Bronze
DA 2024-02-19
ER

PT J
AU Arase, Y
   Suzuki, F
   Kobayashi, M
   Suzuki, Y
   Kawamura, Y
   Matsumoto, N
   Akuta, N
   Kobayashi, M
   Sezaki, H
   Saito, S
   Hosaka, T
   Ikeda, K
   Kumada, H
   Ohmoto, Y
   Amakawa, K
   Tsuji, H
   Hsieh, SD
   Kato, K
   Tanabe, M
   Ogawa, K
   Hara, S
   Kobayashi, T
AF Arase, Yasuji
   Suzuki, Fumitaka
   Kobayashi, Mariko
   Suzuki, Yoshiyuki
   Kawamura, Yusuke
   Matsumoto, Naoki
   Akuta, Norio
   Kobayashi, Masahiro
   Sezaki, Hitomi
   Saito, Satoshi
   Hosaka, Tetsuya
   Ikeda, Kenji
   Kumada, Hiromitsu
   Ohmoto, Yuki
   Amakawa, Kazuhisa
   Tsuji, Hiroshi
   Hsieh, Shiun Dong
   Kato, Kazuhisa
   Tanabe, Maho
   Ogawa, Kyoko
   Hara, Shigeko
   Kobayashi, Tetsuro
TI The Development of Chronic Kidney Disease in Japanese Patients with
   Non-alcoholic Fatty Liver Disease
SO INTERNAL MEDICINE
LA English
DT Article
DE nonalcoholic fatty liver disease; chronic kidney disease;
   gamma-glutamyltransferase
ID GAMMA-GLUTAMYL-TRANSFERASE; INSULIN-RESISTANCE; PREDICTOR; RISK;
   AMINOTRANSFERASE; STEATOHEPATITIS; PREVALENCE; DIAGNOSIS
AB Objective Chronic kidney disease (CKD) is present in patients with nonalcoholic fatty liver disease (NAFLD). The aim of this retrospective study was to assess the cumulative development incidence and predictive factors for new onset of CKD in Japanese patients with NAFLD.
   Methods A total of 5,561 NAFLD patients without CKD were enrolled. CKD was defined as either an estimated glomerular filtration rate of <60 mL/min/1.73 m(2) or dipstick proteinuria (>= + 1). A blood sample and a urine sample were taken for routine analyses during follow-up. The mean observation period was 5.5 years. The primary goal is the new development of CKD. Independent factors associated with new development of CKD were analyzed by using the Kaplan-Meyer method and the Cox proportional hazards model.
   Results Of 5.561 NAFLD patients, 263 patients developed CKD. The cumulative development rate of CKD was 3.1% at the 5th year and 12.2% at the 10th year. Multivariate Cox proportional hazards analysis showed that CKD development in patients with NAFLD occurred when patient had low level of GFR of 60-75 mL/min/1.73 m(2) [hazard ratio: 2.75; 95% confidence interval (CI) =1.93-3.94; p<0.001], age of >= 50 years (hazard ratio: 2.67; 95% CI=2.06-3.46; p<0.001), diabetes (hazard ratio: 1.92; 95% CI=1.45-2.54; p<0.001), hypertension (hazard ratio: 1.69; 95% CI=1.25-2.29; p<0.001), and elevated serum gamma-glutamyltransferase of >= 109 IU/L(hazard ratio: 1.35; 95% CI=1.02-1.78; p=0.038).
   Conclusion Our retrospective study indicates that the annual incidence of CKD in Japanese patients with NAFLD is about 1.2%. Five factors of low eGFR level, aging, type 2 diabetes, hypertension, and elevated gamma-glutamyltransferase, increases the risk of the development of CKD.
C1 [Arase, Yasuji; Suzuki, Fumitaka; Kobayashi, Mariko; Suzuki, Yoshiyuki; Kawamura, Yusuke; Matsumoto, Naoki; Akuta, Norio; Kobayashi, Masahiro; Sezaki, Hitomi; Saito, Satoshi; Hosaka, Tetsuya; Ikeda, Kenji; Kumada, Hiromitsu] Toranomon Gen Hosp, Dept Hepatol, Tokyo, Japan.
   [Arase, Yasuji; Suzuki, Fumitaka; Kobayashi, Mariko; Suzuki, Yoshiyuki; Kawamura, Yusuke; Matsumoto, Naoki; Akuta, Norio; Kobayashi, Masahiro; Sezaki, Hitomi; Saito, Satoshi; Hosaka, Tetsuya; Ikeda, Kenji; Kumada, Hiromitsu] Toranomon Gen Hosp, Okinaka Mem Inst Med Res, Tokyo, Japan.
   [Arase, Yasuji; Ohmoto, Yuki; Amakawa, Kazuhisa; Tsuji, Hiroshi; Hsieh, Shiun Dong; Kato, Kazuhisa; Tanabe, Maho; Ogawa, Kyoko] Toranomon Gen Hosp, Dept Hlth Management Ctr, Tokyo, Japan.
   [Hara, Shigeko] Toranomon Gen Hosp, Dept Nephrol, Tokyo, Japan.
   [Arase, Yasuji; Kobayashi, Tetsuro] Univ Yamanashi, Dept Internal Med Metab 3, Yamanashi, Japan.
C3 Toranomon Hospital; Toranomon Hospital; Toranomon Hospital; Toranomon
   Hospital; University of Yamanashi
RP Arase, Y (corresponding author), Toranomon Gen Hosp, Dept Hepatol, Tokyo, Japan.
EM es9y-ars@asahi-net.or.jp
RI Kawamura, Yusuke/AAN-5925-2020
OI Hosaka, Tetsuya/0000-0003-0302-2275; Kawamura,
   Yusuke/0000-0001-6148-0042
FU Japanese Ministry of Health, Labour and Welfare
FX The present work was supported in part by the Japanese Ministry of
   Health, Labour and Welfare. Moreover, the authors greatly acknowledged
   the editorial assistance of Thomas Hughes.
CR Adams LA, 2004, HEPATOLOGY, V39, P909, DOI 10.1002/hep.20140
   Angulo P, 1999, HEPATOLOGY, V30, P1356, DOI 10.1002/hep.510300604
   Angulo P, 2002, NEW ENGL J MED, V346, P1221, DOI 10.1038/nrdp.2015.80
   Arase Y, 2009, J GASTROENTEROL, V44, P1064, DOI 10.1007/s00535-009-0091-1
   Chang Y, 2008, METABOLISM, V57, P569, DOI 10.1016/j.metabol.2007.11.022
   Chen J, 2004, ANN INTERN MED, V140, P167, DOI 10.7326/0003-4819-140-3-200402030-00007
   Eknoyan G, 2002, AM J KIDNEY DIS, V39, pS14, DOI 10.1053/ajkd.2002.30939
   Fan JG, 2007, J GASTROEN HEPATOL, V22, P1086, DOI 10.1111/j.1440-1746.2006.04781.x
   Fan JG, 2009, J HEPATOL, V50, P204, DOI 10.1016/j.jhep.2008.10.010
   FLEMING TR, 1984, CONTROL CLIN TRIALS, V5, P348, DOI 10.1016/S0197-2456(84)80014-8
   Fraser A, 2009, DIABETES CARE, V32, P741, DOI 10.2337/dc08-1870
   Fried L, 2004, J AM SOC NEPHROL, V15, P3184, DOI 10.1097/01.ASN.0000146422.45434.35
   Genuth S, 2003, DIABETES CARE, V26, P3160
   Hamaguchi M, 2007, WORLD J GASTROENTERO, V13, P1579, DOI 10.3748/wjg.v13.i10.1579
   Imai Enyu, 2007, Clin Exp Nephrol, V11, P156, DOI 10.1007/s10157-007-0463-x
   Imai Enyu, 2007, Clin Exp Nephrol, V11, P41, DOI 10.1007/s10157-006-0453-4
   Kheirandish-Gozal L, 2008, CHEST, V133, P92, DOI 10.1378/chest.07-0773
   Lee DH, 2004, FREE RADICAL RES, V38, P535, DOI 10.1080/10715760410001694026
   Lee DH, 2003, CLIN CHEM, V49, P1358, DOI 10.1373/49.8.1358
   Lonardo A, 1997, ITAL J GASTROENTEROL, V29, P351
   Lonardo A, 2006, J HEPATOL, V44, P1196, DOI 10.1016/j.jhep.2006.03.005
   Luk AOY, 2008, DIABETES CARE, V31, P2357, DOI 10.2337/dc08-0971
   Lysaght MJ, 2002, J AM SOC NEPHROL, V13, pS37
   Muniyappa R, 2008, AM J PHYSIOL-ENDOC M, V294, pE15, DOI 10.1152/ajpendo.00645.2007
   Petersen KF, 2006, P NATL ACAD SCI USA, V103, P18273, DOI 10.1073/pnas.0608537103
   Ryu S, 2007, CLIN CHEM, V53, P71, DOI 10.1373/clinchem.2006.078980
   Stern SE, 2005, DIABETES, V54, P333, DOI 10.2337/diabetes.54.2.333
   Tanné F, 2005, HEPATOLOGY, V41, P1290, DOI 10.1002/hep.20725
   Targher G, 2005, DIABETES, V54, P3541, DOI 10.2337/diabetes.54.12.3541
   Torres DM, 2008, GASTROENTEROLOGY, V134, P1682, DOI 10.1053/j.gastro.2008.02.077
   van der Poorten D, 2008, HEPATOLOGY, V48, P449, DOI 10.1002/hep.22350
   Vega GL, 2007, HEPATOLOGY, V46, P716, DOI 10.1002/hep.21727
   Vuppalanchi R, 2009, HEPATOLOGY, V49, P306, DOI 10.1002/hep.22603
   Watanabe S, 2008, J GASTROENTEROL, V43, P509, DOI 10.1007/s00535-008-2193-6
   Williams R, 2006, HEPATOLOGY, V44, P521, DOI 10.1002/hep.21347
NR 35
TC 49
Z9 53
U1 0
U2 4
PU JAPAN SOC INTERNAL MEDICINE
PI TOKYO
PA 34-3 3-CHOME HONGO BUNKYO-KU, TOKYO, 113, JAPAN
SN 0918-2918
EI 1349-7235
J9 INTERNAL MED
JI Intern. Med.
PY 2011
VL 50
IS 10
BP 1081
EP 1087
DI 10.2169/internalmedicine.50.5043
PG 7
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 778LI
UT WOS:000291705100001
PM 21576832
OA Bronze
DA 2024-02-19
ER

PT J
AU Ferraresso, M
   Turolo, S
   Belingheri, M
   Tirelli, AS
   Cortinovis, I
   Milani, S
   Edefonti, A
   Ghio, L
AF Ferraresso, Mariano
   Turolo, Stefano
   Belingheri, Mirco
   Tirelli, Amedea Silvia
   Cortinovis, Ivan
   Milani, Silvano
   Edefonti, Alberto
   Ghio, Luciana
TI Relationship between mRNA expression levels of CYP3A4, CYP3A5 and SXR in
   peripheral mononuclear blood cells and aging in young kidney transplant
   recipients under tacrolimus treatment
SO PHARMACOGENOMICS
LA English
DT Article
DE ABCB1; CYP3A4; CYP3A5; mRNA; pediatric kidney transplant; peripheral
   blood mononuclear cells; SXR; tacrolimus
ID SINGLE-NUCLEOTIDE POLYMORPHISMS; PREGNANE-X-RECEPTOR;
   MULTIDRUG-RESISTANCE GENE-1; P-GLYCOPROTEIN; CYTOCHROME-P450 3A4;
   NUCLEAR RECEPTOR; DRUG-METABOLISM; CYCLOSPORINE MICROEMULSION;
   RENAL-TRANSPLANTATION; HUMAN HEPATOCYTES
AB Aim: The activity of several key enzymes involved in the metabolism of many drugs is subject to change closely related to the age of patients. This possibility must also be considered in the case of tacrolimus, the most important calcineurins inhibitor, which is widely used in pediatric kidney transplantation. As well as in the liver and intestine, some of the enzymes involved in the metabolism of tacrolimus were also isolated in the peripheral blood mononuclear cells (PBMCs), where also appear to play an important regulatory action. Therefore, the influence of some external factors on the expression of specific mRNA can be determined noninvasively. Patients & methods: The correlation between the levels of mRNA specific for key enzymes SXR, CYP3A and ABCB1 involved in the metabolism of tacrolimus was evaluated in PBMCs obtained from a selected population of 29 young kidney transplant recipients. A possible correlation between the expression of these specific mRNAs and tacrolimus pharmacokinetics was also investigated. Results: The patients' age and their blood concentrations of SXR mRNA were directly correlated with the expression of CYP3A4, CYP3A5 mRNAs, but not of ABCB1 mRNA in the PBMCs. tacrolimus-normalized daily dose was strongly correlated with patient's age and multivariable regression indicates the CYP3A4-specific mRNA as the sole independent variable influencing tacrolimus concentration-to-dose ratio. Conclusion: Aging and SXR mRNA significantly affect the expression of CYP3A4- and CYP3A5-specific mRNA as measured by their concentration in PBMC.
C1 [Ferraresso, Mariano] Univ Milan, Dept Clin Sci & Community Hlth, I-20122 Milan, Italy.
   [Ferraresso, Mariano; Cortinovis, Ivan; Milani, Silvano] IRCCS, Div Kidney Transplantat, Ca Granda Fdn, Osped Maggiore, Milan, Italy.
   [Turolo, Stefano; Belingheri, Mirco; Edefonti, Alberto; Ghio, Luciana] IRCCS, Div Pediat Nephol & Kidney Transplantat, Ca Granda Fdn, Osped Maggiore, Milan, Italy.
   [Tirelli, Amedea Silvia] IRCCS, Lab Clin Chem & Microbiol, Ca Granda Fdn, Osped Maggiore, Milan, Italy.
   [Cortinovis, Ivan; Milani, Silvano] Campus Cascina Rosa, Unit Stat & Biometry, Milan, Italy.
C3 University of Milan; IRCCS Ca Granda Ospedale Maggiore Policlinico;
   IRCCS Ca Granda Ospedale Maggiore Policlinico; IRCCS Ca Granda Ospedale
   Maggiore Policlinico
RP Ferraresso, M (corresponding author), Univ Milan, Dept Clin Sci & Community Hlth, Via F Sforza 35, I-20122 Milan, Italy.
EM mariano.ferraresso@unimi.it
RI Edefonti, Alberto/I-6964-2015; milani, silvano/I-7889-2012; Ivan,
   Cortinovis/M-9301-2017; Ferraresso, Mariano/D-5485-2012; turolo,
   stefano/AAE-3762-2021
OI Edefonti, Alberto/0000-0003-3106-4915; milani,
   silvano/0000-0002-5677-1758; Ivan, Cortinovis/0000-0001-8750-302X;
   Ferraresso, Mariano/0000-0003-3410-9090; Turolo,
   Stefano/0000-0002-9178-0713
CR Ball SE, 1999, CLIN PHARMACOL THER, V66, P288, DOI 10.1016/S0009-9236(99)70037-8
   Barry A, 2010, THER DRUG MONIT, V32, P708, DOI 10.1097/FTD.0b013e3181f3c063
   Benkali K, 2009, CLIN PHARMACOKINET, V48, P805, DOI 10.2165/11318080-000000000-00000
   Bertilsson G, 1998, P NATL ACAD SCI USA, V95, P12208, DOI 10.1073/pnas.95.21.12208
   Blumberg B, 1998, GENE DEV, V12, P3195, DOI 10.1101/gad.12.20.3195
   Danielson PB, 2002, CURR DRUG METAB, V3, P561, DOI 10.2174/1389200023337054
   Fakhoury M, 2005, DRUG METAB DISPOS, V33, P1603, DOI 10.1124/dmd.105.005611
   Fanta S, 2008, PHARMACOGENET GENOM, V18, P77, DOI 10.1097/FPC.0b013e3282f3ef72
   Ferraresso M, 2013, PHARMACOGENOMICS, V14, P1605, DOI 10.2217/pgs.13.148
   Ferraresso M, 2012, PEDIATR TRANSPLANT, V16, P658, DOI 10.1111/j.1399-3046.2012.01751.x
   Filler G, 2005, PEDIATR TRANSPLANT, V9, P498, DOI 10.1111/j.1399-3046.2005.00334.x
   Fredericks S, 2006, TRANSPLANTATION, V82, P705, DOI 10.1097/01.tp.0000234942.78716.c0
   Gosden RG, 2007, NEW ENGL J MED, V356, P731, DOI 10.1056/NEJMe068284
   Goto M, 2008, J PHARMACOL EXP THER, V325, P610, DOI 10.1124/jpet.107.135665
   Greiner B, 1999, J CLIN INVEST, V104, P147, DOI 10.1172/JCI6663
   Jacobson PA, 2011, TRANSPLANTATION, V91, P300, DOI 10.1097/TP.0b013e318200e991
   JUSKO WJ, 1995, THER DRUG MONIT, V17, P606, DOI 10.1097/00007691-199512000-00011
   Kearns GL, 2003, CLIN PHARMACOL THER, V74, P312, DOI 10.1016/S0009-9236(03)00225-X
   Kearns GL, 2003, NEW ENGL J MED, V349, P1157, DOI 10.1056/NEJMra035092
   KLIMECKI WT, 1994, BLOOD, V83, P2451
   Kuypers DRJ, 2007, CLIN PHARMACOL THER, V82, P711, DOI 10.1038/sj.clpt.6100216
   Lee CY, 2010, TRANSPL P, V42, P834, DOI 10.1016/j.transproceed.2010.02.048
   Li L, 2011, EUR J CLIN PHARMACOL, V67, P787, DOI 10.1007/s00228-011-1010-y
   Liptrott NJ, 2009, BRIT J PHARMACOL, V156, P497, DOI 10.1111/j.1476-5381.2008.00050.x
   Margreiter R, 2002, LANCET, V359, P741, DOI 10.1016/S0140-6736(02)07875-3
   Miki Y, 2005, MOL CELL ENDOCRINOL, V231, P75, DOI 10.1016/j.mce.2004.12.005
   Miura M, 2008, STEROIDS, V73, P1052, DOI 10.1016/j.steroids.2008.04.002
   Nakamoto T, 2000, PHARMACOGENETICS, V10, P571, DOI 10.1097/00008571-200008000-00011
   Owen A, 2004, ANTIVIR THER, V9, P819
   Owen Andrew, 2004, J HIV Ther, V9, P97
   Pascussi JM, 2000, MOL PHARMACOL, V58, P361, DOI 10.1124/mol.58.2.361
   Pascussi JM, 2001, EUR J BIOCHEM, V268, P6346, DOI 10.1046/j.0014-2956.2001.02540.x
   Prasad B, 2014, DRUG METAB DISPOS, V42, P78, DOI 10.1124/dmd.113.053819
   Quattrochi LC, 2001, DRUG METAB DISPOS, V29, P615
   Raucy JL, 1997, DRUG METAB DISPOS, V25, P1429
   Renders L, 2007, CLIN PHARMACOL THER, V81, P228, DOI 10.1038/sj.clpt.6100039
   Rodríguez-Antona C, 2001, ARCH BIOCHEM BIOPHYS, V393, P308, DOI 10.1006/abbi.2001.2499
   Scott LJ, 2003, DRUGS, V63, P1247, DOI 10.2165/00003495-200363120-00006
   Siest G, 2009, CURR DRUG METAB, V10, P410, DOI 10.2174/138920009788498987
   Staatz CE, 2010, CLIN PHARMACOKINET, V49, P207, DOI 10.2165/11317550-000000000-00000
   Staatz CE, 2010, CLIN PHARMACOKINET, V49, P141, DOI 10.2165/11317350-000000000-00000
   Stevens JC, 2003, J PHARMACOL EXP THER, V307, P573, DOI 10.1124/jpet.103.054841
   Sumida A, 1999, BIOCHEM BIOPH RES CO, V262, P499, DOI 10.1006/bbrc.1999.1233
   Synold TW, 2001, NAT MED, V7, P584, DOI 10.1038/87912
   Thörn M, 2004, EUR J CLIN PHARMACOL, V60, P413, DOI 10.1007/s00228-004-0786-4
   Turolo S, 2010, PHARMACOL REP, V62, P1159, DOI 10.1016/S1734-1140(10)70378-9
   von Ahsen N, 2001, CLIN CHEM, V47, P1048
   Wakasugi H, 1998, CLIN PHARMACOL THER, V64, P123, DOI 10.1016/S0009-9236(98)90030-3
   Wong AHC, 2005, HUM MOL GENET, V14, pR11, DOI 10.1093/hmg/ddi116
NR 49
TC 3
Z9 5
U1 1
U2 6
PU FUTURE MEDICINE LTD
PI LONDON
PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3
   1QB, ENGLAND
SN 1462-2416
EI 1744-8042
J9 PHARMACOGENOMICS
JI Pharmacogenomics
PY 2015
VL 16
IS 5
BP 483
EP 491
DI 10.2217/PGS.15.18
PG 9
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA CG8UV
UT WOS:000353590800007
PM 25916520
DA 2024-02-19
ER

PT J
AU Desai, VG
   Aidoo, A
   Li, J
   Lyn-Cook, LE
   Casciano, DA
   Feuers, RJ
AF Desai, VG
   Aidoo, A
   Li, J
   Lyn-Cook, LE
   Casciano, DA
   Feuers, RJ
TI Effects of bleomycin on liver antioxidant enzymes and the electron
   transport system from ad libitum-fed and dietary-restricted female and
   male Fischer 344 rats
SO NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL
LA English
DT Article
ID MITOCHONDRIAL-DNA DAMAGE; CALORIC RESTRICTION; LIPID-PEROXIDATION;
   SKELETAL-MUSCLE; BETA-CAROTENE; HUMAN-CELLS; VITAMIN-C; DISEASE; AGE;
   TOXICOLOGY
AB Dietary restriction (DR) is the only known intervention that delays aging and age-related diseases. Mechanisms proposed to explain this DR effect include a decline in free radical production and an increase in free radical detoxification. In the present study the effect of bleomycin (BLM) as a reactive oxygen species-generating antitumor drug has been evaluated on antioxidant enzymes and the electron transport system in different cellular fractions of liver in female and male Fischer 344 rats. Animals were fed ad libitum (AL) or 60% of the AL intake (DR) and were given a single intraperitoneal injection of 2.5, 5, or 10 mg BLM/kg body wt. After four weeks, BLM significantly increased glutathione peroxidase and lactate dehydrogenase activities in liver cytosol of female AL rats and increased activity even more in male rats. Similar changes were also noted for glutathione reductase and glucose 6-phosphate dehydrogenase activities in BLM-treated AL rats. In liver mitochondria, glutathione peroxidase was increased in female and male AL rats but was increased more in female rats. Drug treatment had no significant effect on these enzyme activities in cytosolic or mitochondrial fractions of DR animals. Profound effects of BLM were noted in activities of complexes I, III, and IV of the electron transport system in AL and DR female and male rats; however, complex II demonstrated no significant diet or treatment effect. Induced antioxidant enzyme activities in BLM-treated AL rats may be a response to excessive free radical generation due to BLM metabolism in AL animals that is mitigated by DR. Furthermore, dysfunction of the electron transport system might suggest its role in a secondary generation of free radicals during BLM metabolism contributing to its toxicity.
C1 US FDA, Div Genet & Reprod Toxicol, Natl Ctr Toxicol Res, Dept Hlth & Human Serv, Jefferson, AR 72079 USA.
C3 US Food & Drug Administration (FDA)
RP Feuers, RJ (corresponding author), US FDA, Div Genet & Reprod Toxicol, Natl Ctr Toxicol Res, Dept Hlth & Human Serv, HFT-120, Jefferson, AR 72079 USA.
CR ADAMS JD, 1991, FREE RADICAL BIO MED, V10, P161, DOI 10.1016/0891-5849(91)90009-R
   AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915
   Bergmeyer HU, 1974, METHOD ENZYMAT AN, P458
   BYERS T, 1992, ANNU REV NUTR, V12, P139, DOI 10.1146/annurev.nu.12.070192.001035
   Desai VG, 1997, NUTR CANCER, V29, P127, DOI 10.1080/01635589709514613
   Desai VG, 1996, ARCH BIOCHEM BIOPHYS, V333, P145, DOI 10.1006/abbi.1996.0375
   FEUERS RJ, 1993, MUTAT RES, V295, P191, DOI 10.1016/0921-8734(93)90020-4
   FEUERS RJ, 1995, DIETARY RESTRICTION
   JANSSEN YMW, 1993, LAB INVEST, V69, P261
   JI LL, 1990, AM J PHYSIOL, V258, pR918, DOI 10.1152/ajpregu.1990.258.4.R918
   JOHNS DR, 1995, NEW ENGL J MED, V333, P638, DOI 10.1056/NEJM199509073331007
   Keenan KP, 1997, J NUTR, V127, pS851, DOI 10.1093/jn/127.5.851S
   Knight JA, 1997, ANN CLIN LAB SCI, V27, P11
   KOIZUMI A, 1987, J NUTR, V117, P361, DOI 10.1093/jn/117.2.361
   LEAKEY JEA, 1989, MECH AGEING DEV, V48, P157, DOI 10.1016/0047-6374(89)90047-X
   LIM LO, 1987, BIOCHEM PHARMACOL, V36, P2769, DOI 10.1016/0006-2952(87)90263-2
   LUHTALA TA, 1994, J GERONTOL, V49, pB231, DOI 10.1093/geronj/49.5.B231
   MAKINODAN T, 1995, DIETARY RESTRICTION
   POVIRK LF, 1991, MUTAT RES, V257, P127, DOI 10.1016/0165-1110(91)90022-N
   Poyton RO, 1996, ANNU REV BIOCHEM, V65, P563, DOI 10.1146/annurev.bi.65.070196.003023
   Ragan C.I., 1987, MITOCHONDRIA PRACTIC, P79
   RAO G, 1990, J NUTR, V120, P602, DOI 10.1093/jn/120.6.602
   Rao J, 1996, FREE RADICAL BIO MED, V21, P103, DOI 10.1016/0891-5849(95)02212-0
   SARKAR A, 1994, CARCINOGENESIS, V15, P1055, DOI 10.1093/carcin/15.5.1055
   SAUSVILLE EA, 1978, BIOCHEMISTRY-US, V17, P2740, DOI 10.1021/bi00607a007
   SHEN CC, 1995, MUTAT RES-DNA REPAIR, V337, P19, DOI 10.1016/0921-8777(95)00008-8
   TIETZ TW, 1970, FUNDAMENTALS CLIN CH, P438
   *US DEP HHS, 1986, DHHS NIH PUBL, V8
   Verdery RB, 1997, AM J PHYSIOL-ENDOC M, V273, pE714, DOI 10.1152/ajpendo.1997.273.4.E714
   VIG BK, 1978, MUTAT RES, V55, P121, DOI 10.1016/0165-1110(78)90019-2
   WEINDRUCH R, 1988, RETARDATION AGING DI
   WHEELER CR, 1990, ANAL BIOCHEM, V184, P193, DOI 10.1016/0003-2697(90)90668-Y
   Yakes FM, 1997, P NATL ACAD SCI USA, V94, P514, DOI 10.1073/pnas.94.2.514
NR 33
TC 12
Z9 12
U1 0
U2 2
PU LAWRENCE ERLBAUM ASSOC INC
PI MAHWAH
PA 10 INDUSTRIAL AVE, MAHWAH, NJ 07430-2262 USA
SN 0163-5581
J9 NUTR CANCER
JI Nutr. Cancer
PY 2000
VL 36
IS 1
BP 42
EP 51
DI 10.1207/S15327914NC3601_7
PG 10
WC Oncology; Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Nutrition & Dietetics
GA 308FH
UT WOS:000086699500007
PM 10798215
DA 2024-02-19
ER

PT J
AU Li, H
   Ren, MH
   He, QZ
   Gao, J
   Li, QY
AF Li, He
   Ren, Minhong
   He, Qianzu
   Gao, Jie
   Li, Quanyang
TI RETRACTED: Revealing the Longevity Code of Humans with up to Extreme
   Longevity in Guangxi Based on Physical Examination Indicators and
   Personalized Biomarkers of Aging (Retracted Article)
SO BIOMED RESEARCH INTERNATIONAL
LA English
DT Article; Retracted Publication
ID LEUKOCYTE TELOMERE LENGTH; CARDIOVASCULAR-DISEASE; RISK-FACTOR; AGE;
   ASSOCIATION; BLOOD; EPIDEMIOLOGY; INFLAMMATION; STATEMENT; CYTOKINES
AB Background. The pursuit of health and longevity is the eternal theme of humanity. Guangxi has a remarkable phenomenon of longevity in long-lived regions and ranks with the highest number of longevity villages in China, thus providing a natural advantage for health longevity research. Methods. In this study, we selected 117 natives of a longevity area in Guangxi, covering a large age range (38-118 years old) as subjects to measure peripheral leukocyte telomere length (LTL). Nineteen physical examination indicators and two inflammatory factor levels were measured. Results. Pearson's analysis revealed a significant negative correlation between age and LTL (r=-0.3694, p=0.003), as well as alanine aminotransferase, albumin, total bilirubin, direct bilirubin, gamma-glutamyltransferase, triglycerides, Interleukin-10, and tumor necrosis factor type-alpha. Systolic blood pressure and blood urea nitrogen were positively correlated with age. In addition, LTL decreased in people aged 38-89 years, and an upward trend was observed in people aged older than 90 years. Conclusions. Longevity individuals have characteristics, such as longer LTL, good hepatic function, and lower triglycerides and inflammation levels.
C1 [Li, He; Ren, Minhong; Gao, Jie; Li, Quanyang] Guangxi Univ, Coll Light Ind & Food Engn, Nanning, Peoples R China.
   [He, Qianzu] Guangxi Univ, Guangxi Univ Hosp, Nanning, Peoples R China.
C3 Guangxi University; Guangxi University
RP Gao, J; Li, QY (corresponding author), Guangxi Univ, Coll Light Ind & Food Engn, Nanning, Peoples R China.
EM 1816401001@st.gxu.edu.cn; msminhong@126.com; 970385891@qq.com;
   gaojie@gxu.edu.cn; liquanyang@gxu.edu.cn
RI Gao, Jie/GRX-7353-2022; 李, 河/HRC-8280-2023
OI Gao, Jie/0000-0003-4480-6420; Li, He/0000-0001-6241-1647; Ren,
   Minhong/0000-0002-4008-0995
FU Hechi Science and Technology Bureau; Donglan County People's Government;
   Fengshan County People's Government; Dahua Yao Autonomous County
   People's Government; Guangxi University Hospital; National Natural
   Science Foundation of China [31871802]; Key Research and Development
   Projects in Guangxi, China [AB18221065]
FX The authors gratefully acknowledge the support by the Hechi Science and
   Technology Bureau, the Donglan County People's Government, the Fengshan
   County People's Government, the Dahua Yao Autonomous County People's
   Government, and the Guangxi University Hospital, and we thank all
   government staff, medical personnel, and subjects who contributed to
   this experiment. This research was funded by the National Natural
   Science Foundation of China (31871802) and the Key Research and
   Development Projects in Guangxi, China (AB18221065).
CR Almeida I, 2021, BIOGERONTOLOGY, V22, P273, DOI 10.1007/s10522-021-09921-2
   Appleby S, 2017, AM J HUM BIOL, V29, DOI 10.1002/ajhb.22906
   cagg, 2021, CHIN ASS GER GER
   Caruso C, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22042044
   Cawthon RM, 2003, LANCET, V361, P393, DOI 10.1016/S0140-6736(03)12384-7
   Cawthon RM, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.10.e47
   Chen SF, 2014, AGING-US, V6, P380, DOI 10.18632/aging.100664
   Chen W, 2011, J GERONTOL A-BIOL, V66, P312, DOI 10.1093/gerona/glq223
   Croft M, 2012, TRENDS IMMUNOL, V33, P144, DOI 10.1016/j.it.2011.10.004
   Edvardsson M, 2018, CLIN CHEM LAB MED, V56, P471, DOI 10.1515/cclm-2017-0311
   Erdem HB, 2021, ENVIRON TOXICOL PHAR, V85, DOI 10.1016/j.etap.2021.103641
   Fasching CL, 2018, CRIT REV CL LAB SCI, V55, P443, DOI 10.1080/10408363.2018.1504274
   Franceschi C, 2014, J GERONTOL A-BIOL, V69, pS4, DOI 10.1093/gerona/glu057
   He YH, 2016, SCI REP-UK, V6, DOI 10.1038/srep21962
   Iwama H, 1998, HUM GENET, V102, P397, DOI 10.1007/s004390050711
   Kubben N, 2017, NAT REV MOL CELL BIO, V18, P595, DOI 10.1038/nrm.2017.68
   Lapham K, 2015, GENETICS, V200, P1061, DOI 10.1534/genetics.115.178624
   Le Couteur DG, 2010, J GERONTOL A-BIOL, V65, P712, DOI 10.1093/gerona/glq082
   Li X, 2021, EBIOMEDICINE, V66, DOI 10.1016/j.ebiom.2021.103318
   Lin WS, 2021, STEM CELL RES THER, V12, DOI 10.1186/s13287-020-02108-5
   Liu M, 2019, Zhonghua Liu Xing Bing Xue Za Zhi, V40, P290, DOI 10.3760/cma.j.issn.0254-6450.2019.03.007
   Martin P, 2019, INT PSYCHOGERIATR, V31, P455, DOI 10.1017/S1041610218001813
   de Toda IM, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/4574276
   Miller M, 2011, CIRCULATION, V123, P2292, DOI 10.1161/CIR.0b013e3182160726
   Minciullo PL, 2016, ARCH IMMUNOL THER EX, V64, P111, DOI 10.1007/s00005-015-0377-3
   Niccoli T, 2012, CURR BIOL, V22, pR741, DOI 10.1016/j.cub.2012.07.024
   Ouyang WJ, 2011, ANNU REV IMMUNOL, V29, P71, DOI 10.1146/annurev-immunol-031210-101312
   Puca AA, 2018, MECH AGEING DEV, V174, P95, DOI 10.1016/j.mad.2017.10.004
   Sarnak MJ, 2003, CIRCULATION, V108, P2154, DOI 10.1161/01.CIR.0000095676.90936.80
   Schindhelm RK, 2007, ATHEROSCLEROSIS, V191, P391, DOI 10.1016/j.atherosclerosis.2006.04.006
   Szewieczek J, 2015, AGE, V37, DOI 10.1007/s11357-014-9738-9
   Tang G.D, 2000, J CHINESE PHYS, V2, P2
   Tedone E, 2014, EXP GERONTOL, V58, P90, DOI 10.1016/j.exger.2014.06.018
   Vaarhorst AAM, 2011, AGE, V33, P219, DOI 10.1007/s11357-010-9172-6
   World Health Organization, Ageing and health
   Xu J, 2018, SHANGHAI MEDICAL PHA, V39, P46
   Zhang WG, 2014, HEART LUNG CIRC, V23, P883, DOI 10.1016/j.hlc.2013.12.016
   Zhang Y, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-67010-9
   Zhao YL, 2017, J TRANSL MED, V15, DOI 10.1186/s12967-017-1267-8
NR 39
TC 4
Z9 4
U1 7
U2 24
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2314-6133
EI 2314-6141
J9 BIOMED RES INT
JI Biomed Res. Int.
PD MAY 14
PY 2022
VL 2022
AR 2810379
DI 10.1155/2022/2810379
PG 10
WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Research & Experimental Medicine
GA 1T8JX
UT WOS:000804973300008
PM 35607300
OA gold, Green Published
DA 2024-02-19
ER

PT J
AU Jiang, L
   Zhao, NX
   Xu, MH
   Pei, J
   Lin, YD
   Yao, Q
   Hu, MJ
   Zhu, CR
AF Jiang, Lin
   Zhao, Ningxuan
   Xu, Minghan
   Pei, Jiao
   Lin, Yidie
   Yao, Qiang
   Hu, Meijing
   Zhu, Cairong
TI Incidence trends of primary liver cancer in different geographical
   regions of China from 1978 to 2012 and projections to 2032: An
   age-period-cohort analysis
SO INTERNATIONAL JOURNAL OF CANCER
LA English
DT Article; Early Access
DE age-period-cohort analysis; incidence; primary liver cancer; trend
ID HEPATITIS-B; HEPATOCELLULAR-CARCINOMA; GUANGDONG PROVINCE; TEMPORAL
   VARIATION; FUTURE BURDEN; FATTY LIVER; POPULATION; MODELS; RATES;
   EPIDEMIOLOGY
AB China accounted for 45.3% of new cases of primary liver cancer (PLC) worldwide in 2020. While variations in PLC incidence between different regions of China and decreasing incidence in overall China have been reported, incidence patterns have not been thoroughly explored by region. We examined the nearly status and temporal trends of PLC incidence in different geographical regions in China and project future trends. The age-standardized incidence rate (ASR) was estimated for 1978 to 2012 by different geographical regions and gender in China. Age-period-cohort model was adopted to evaluate age and birth cohort effects on the temporal trend of five registries of China (Hong Kong, Shanghai, Jiashan, Harbin and Zhongshan), Bayesian age-period-cohort model was adopted to project future trends for 2013 to 2032. PLC incidence in China exhibits marked geographical disparity, with the highest incidence in Southwest China, and gender differences being particularly pronounced in South China. While other registries exhibited decreasing trend, Zhongshan exhibited an increasing trend, with the cohort effect showing a marked upward trend for females born in 1916 to 1949 and males born in 1916 to 1962. During 2013 to 2032, the ASR appears to increase by 86.9% for men and 40.0% for women in Zhongshan, while the remaining registries will decline by around 50%. Since the high incidence of hepatitis B virus infection in early birth cohort, recent rise of nonviral risk factors and the severe aging of the Chinese population, it may be critical to tailor future prevention and control strategies for PLC to the distribution of risk factors in different geographical regions.
C1 [Jiang, Lin; Zhao, Ningxuan; Xu, Minghan; Pei, Jiao; Lin, Yidie; Yao, Qiang; Hu, Meijing; Zhu, Cairong] Sichuan Univ, West China Sch Publ Hlth, Dept Epidemiol & Hlth Stat, Chengdu, Peoples R China.
   [Jiang, Lin; Zhao, Ningxuan; Xu, Minghan; Pei, Jiao; Lin, Yidie; Yao, Qiang; Hu, Meijing; Zhu, Cairong] Sichuan Univ, West China Hosp 4, Chengdu, Peoples R China.
   [Pei, Jiao] Univ Elect Sci & Technol China, Sichuan Canc Hosp & Inst, Sichuan Canc Ctr, Sch Med, Chengdu, Peoples R China.
C3 Sichuan University; Sichuan University; University of Electronic Science
   & Technology of China
RP Zhu, CR (corresponding author), Sichuan Univ, West China Sch Publ Hlth, Dept Epidemiol & Hlth Stat, Chengdu, Peoples R China.; Zhu, CR (corresponding author), Sichuan Univ, West China Hosp 4, Chengdu, Peoples R China.
EM zhucairong@scu.edu.cn
OI Jiang, Lin/0009-0007-5792-1483
FU National Key R&D Program of China;  [2016YFC1302505-2]
FX National Key R&D Program of China, Grant/Award Number:
   2016YFC1302505-2This study was supported by funding from the National
   Key R&D Program of China (Grant No. 2016YFC1302505-2)
CR Bray F, 2006, NAT REV CANCER, V6, P63, DOI 10.1038/nrc1781
   Bray F, 2002, CANCER CAUSE CONTROL, V13, P175, DOI 10.1023/A:1014344519276
   Bray I, 2002, J R STAT SOC C-APPL, V51, P151, DOI 10.1111/1467-9876.00260
   Carstensen B, 2022, EPI PACKAGE STAT ANA
   Chen L, 2018, INT J ENV RES PUB HE, V15, DOI 10.3390/ijerph15061211
   CLAYTON D, 1987, STAT MED, V6, P449, DOI 10.1002/sim.4780060405
   CLAYTON D, 1987, STAT MED, V6, P469, DOI 10.1002/sim.4780060406
   Dasgupta P, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.00171
   de Martel C, 2015, HEPATOLOGY, V62, P1190, DOI 10.1002/hep.27969
   Duan T., 2008, J Shaanxi Normal Univ (Phil Soc Sci Ed), V37, P122
   European Assoc Study Liver, 2018, J HEPATOL, V69, P182, DOI 10.1016/j.jhep.2018.03.019
   HOLFORD TR, 1991, ANNU REV PUBL HEALTH, V12, P425, DOI 10.1146/annurev.pu.12.050191.002233
   Jacobs D, 2021, JAMA DERMATOL, V157, P59, DOI 10.1001/jamadermatol.2020.4102
   Liang XF, 2009, VACCINE, V27, P6550, DOI 10.1016/j.vaccine.2009.08.048
   Liu WY, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2817-9
   Liu Z, 2018, J VIRAL HEPATITIS, V25, P1543, DOI 10.1111/jvh.12938
   Liu ZQ, 2021, INT J EPIDEMIOL, V50, P128, DOI 10.1093/ije/dyaa196
   Llovet JM, 2016, NAT REV DIS PRIMERS, V2, DOI [10.1038/nrdp.2016.18, 10.1038/nrdp.2016.19]
   Ma X, 2017, INT J CANCER, V140, P1050, DOI 10.1002/ijc.30522
   Magnussen A, 2013, WORLD J GASTROENTERO, V19, P1508, DOI 10.3748/wjg.v19.i10.1508
   Mao SX., 2021, Analysis of Epidemic Characteristics and Prediction of Hepatitis-B in China
   Marengo A, 2016, ANNU REV MED, V67, P103, DOI 10.1146/annurev-med-090514-013832
   Petrick JL, 2016, INT J CANCER, V139, P1534, DOI 10.1002/ijc.30211
   Qu CF, 2014, PLOS MED, V11, DOI 10.1371/journal.pmed.1001774
   Riebler A, 2017, BIOMETRICAL J, V59, P531, DOI 10.1002/bimj.201500263
   Rue H, 2009, J ROY STAT SOC B, V71, P319, DOI 10.1111/j.1467-9868.2008.00700.x
   RYDER NB, 1965, AM SOCIOL REV, V30, P843, DOI 10.2307/2090964
   Schmid V, 2004, BIOMETRICS, V60, P1034, DOI 10.1111/j.0006-341X.2004.00259.x
   SHI LY, 1993, B WORLD HEALTH ORGAN, V71, P723
   Shih WL, 2012, INT J CANCER, V131, P2612, DOI 10.1002/ijc.27508
   Sia D, 2017, GASTROENTEROLOGY, V152, P745, DOI 10.1053/j.gastro.2016.11.048
   Simon TG, 2018, HEPATOLOGY, V67, P1797, DOI 10.1002/hep.29660
   Soerjomataram I, 2021, NAT REV CLIN ONCOL, V18, P663, DOI 10.1038/s41571-021-00514-z
   Sun ZT, 2013, CARCINOGENESIS, V34, P1800, DOI 10.1093/carcin/bgt007
   Sung H., 2021, CA Cancer J. Clin, V71, P209, DOI DOI 10.3322/caac.21660
   United Nations Department of Economics and Social Affairs, 2019, World Population Prospects: 2019 Revision: Estimated age-specific fertility rates (births per 1,000 women) by region, sub-region and country, 1950-2100, DOI DOI 10.18356/13BF5476-EN
   Valery PC, 2018, HEPATOLOGY, V67, P600, DOI 10.1002/hep.29498
   Wang F., 2019, Int J Environ Res Public Health, V16
   Wang F, 2017, PRIM HEALTH CARE RES, V18, P194, DOI 10.1017/S1463423616000153
   World Health Organization, 2023, Global Health Observatory (GHO) Data: Hepatitis B 3rd Dose (HepB3) Immunization Coverage
   Wu J, 2018, GASTROENTEROLOGY, V154, P1719, DOI 10.1053/j.gastro.2018.01.033
   Xia GL, 1996, INT HEPATOL COMMUN, V5, P62, DOI 10.1016/S0928-4346(96)82012-3
   Xiao JP, 2015, INT J ENV RES PUB HE, V12, P14055, DOI 10.3390/ijerph121114055
   Yang JD, 2010, INFECT DIS CLIN N AM, V24, P899, DOI 10.1016/j.idc.2010.07.004
   Younossi ZM, 2016, HEPATOLOGY, V64, P73, DOI 10.1002/hep.28431
   Zeng HM, 2018, LANCET GLOB HEALTH, V6, pE555, DOI 10.1016/S2214-109X(18)30127-X
   Zhang L, 2020, FOOD CONTROL, V110, DOI 10.1016/j.foodcont.2019.107034
   Zheng RS, 2018, CHINESE J CANCER RES, V30, P571, DOI 10.21147/j.issn.1000-9604.2018.06.01
   Zhuo JT, 2000, J HEPATOL, V33, P628, DOI 10.1034/j.1600-0641.2000.033004628.x
NR 49
TC 1
Z9 1
U1 12
U2 12
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0020-7136
EI 1097-0215
J9 INT J CANCER
JI Int. J. Cancer
PD 2023 SEP 14
PY 2023
DI 10.1002/ijc.34724
EA SEP 2023
PG 12
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA T4CZ1
UT WOS:001077496600001
PM 37707172
OA Bronze
DA 2024-02-19
ER

PT J
AU Caamaño, EB
   Ibáñez, JS
   Vázquez, MA
   García, AF
   Rozados, AM
   Cendón, MO
   Ruiloba, SL
   Franco, AV
   Diéguez, IA
AF Bouzas Caamano, E.
   Sanchez Ibanez, J.
   Alvarez Vazquez, M.
   Fernandez Garcia, A.
   Marino Rozados, A.
   Ojea Cendon, M.
   Leal Ruiloba, S.
   Varela Franco, A.
   Alvarez Dieguez, I.
TI Organ Donation in an Aging Population: The Experience of the Last 8
   Years in Galicia
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article; Proceedings Paper
CT 10th Congress of the Catalan-Transplantation-Society
CY FEB 22-25, 2009
CL Barcelona, SPAIN
SP Catalan Transplantat Soc
ID RATES
AB Background. Mean organ donor age has increased in recent years, conditioned by causes of death and population profile. We analyzed organ donation in Galicia during the last 8 years.
   Materials and Methods. We analyzed donors in Galicia between 2000 and 2007, studying age, cause of death, donation effectiveness, and organs transplanted per donor.
   Results. Donation rates fluctuated between 29 and 35 donors per million population (pmp) during the study period. Mean donor age increased from 51.6 years (Spain, 47.1 years) in 2000 to 63.3 years (Spain, 53.4 years) in 2007. Donors of 75 years or older increased from 7.5% to 27.2%. Cerebrovascular accident (CVA) as cause of death rose from 57% in 2000 to 75.3% in 2007. The variations in the proportions of organs transplanted between 2000 and 2007 were: kidney, 68.8% to 53.7%; liver, 86% to 88.9%; heart, 33.5% to 9.9%; and lung, 10.8% to 9.9%. Valid transplanted organs per donor decreased from 2.8 to 2.2, and effective donors from 93.5% (Spain, 90.3%) to 92.6% (Spain, 87.8%) with a mean of 94%.
   Conclusions. The population in Galicia has aged considerably and is widely dispersed. Despite the increased mean donor age, the percentage of effective donors has not diminished and donor rates have remained stable. This reflects the extremely conscientious attitude of transplant coordinators and the high degree of activity of transplant teams in Galicia.
C1 [Bouzas Caamano, E.; Sanchez Ibanez, J.; Alvarez Vazquez, M.] Galician Dept Hlth, Galician Hlth Serv, Transplant Coordinat Off, Santiago De Compostela 15703, Spain.
   [Fernandez Garcia, A.] Univ Hosp, Transplant Coordinat Off, La Coruna, Spain.
   [Marino Rozados, A.] Univ Hosp, Intens Care Unit, Santiago De Compostela, Spain.
   [Ojea Cendon, M.; Leal Ruiloba, S.] Sanatorio POVISA, Anaesthesia & Reanimat Serv, Vigo, Spain.
   [Varela Franco, A.] Sanatorio Fatima, Intens Care Unit, Vigo, Spain.
   [Alvarez Dieguez, I.] Arquitecto Marcide Hosp, Intens Care Unit, Ferrol, Spain.
C3 Complejo Hospitalario Universitario A Coruna; Complejo Hospitalario
   Universitario de Ferrol
RP Caamaño, EB (corresponding author), Galician Dept Hlth, Galician Hlth Serv, Transplant Coordinat Off, Edif Adm San Lazaro S-N, Santiago De Compostela 15703, Spain.
EM encarnacion.bouzas.caamano@sergas.es
OI Sanchez Ibanez, Jacinto/0000-0001-7232-8580
CR Chang GJ, 2003, AM J TRANSPLANT, V3, P1259, DOI 10.1046/j.1600-6143.2003.00255.x
   Coll E, 2008, MED CLIN-BARCELONA, V131, P52, DOI 10.1157/13123486
   Cuende N, 2007, AM J TRANSPLANT, V7, P1526, DOI 10.1111/j.1600-6143.2007.01792.x
   Miranda B, 2003, AM J TRANSPLANT, V3, P1189, DOI 10.1046/j.1600-6143.2003.00198.x
   *SPAN NAT STAT I, MIN REG OFF POP DAT
   *SPAN NAT TRANSPL, DOC
NR 6
TC 0
Z9 1
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0041-1345
EI 1873-2623
J9 TRANSPL P
JI Transplant. Proc.
PD JUL-AUG
PY 2009
VL 41
IS 6
BP 2050
EP 2052
DI 10.1016/j.transproceed.2009.05.027
PG 3
WC Immunology; Surgery; Transplantation
WE Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)
SC Immunology; Surgery; Transplantation
GA 489IH
UT WOS:000269413200009
PM 19715829
DA 2024-02-19
ER

PT J
AU Lkhagvadorj, S
   Qu, L
   Cai, WG
   Couture, OP
   Barb, CR
   Hausman, GJ
   Nettleton, D
   Anderson, LL
   Dekkers, JCM
   Tuggle, CK
AF Lkhagvadorj, Sender
   Qu, Long
   Cai, Weiguo
   Couture, Oliver P.
   Barb, C. Richard
   Hausman, Gary J.
   Nettleton, Dan
   Anderson, Lloyd L.
   Dekkers, Jack C. M.
   Tuggle, Christopher K.
TI Gene expression profiling of the short-term adaptive response to acute
   caloric restriction in liver and adipose tissues of pigs differing in
   feed efficiency
SO AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE
   PHYSIOLOGY
LA English
DT Article
DE microarray; transcriptional profiling; ESR1; residual feed intake;
   peroxisome proliferator-activated receptor a; peroxisome
   proliferator-activated receptor g; cAMP response element binding;
   protein
ID RECEPTOR-ALPHA GENE; AGING IMMUNE-SYSTEM; BODY-WEIGHT; BEEF-CATTLE;
   MITOCHONDRIAL-FUNCTION; THYROID-HORMONES; FOOD-CONSUMPTION; LIFE-SPAN;
   MICE; GROWTH
AB Lkhagvadorj S, Qu L, Cai W, Couture OP, Barb CR, Hausman GJ, Nettleton D, Anderson LL, Dekkers JC, Tuggle CK. Gene expression profiling of the short-term adaptive response to acute caloric restriction in liver and adipose tissues of pigs differing in feed efficiency. Am J Physiol Regul Integr Comp Physiol 298: R494-R507, 2010. First published November 25, 2009; doi:10.1152/ajpregu.00632.2009.-Residual feed intake (RFI) is a measure of feed efficiency, in which low RFI denotes improved feed efficiency. Caloric restriction (CR) is associated with feed efficiency in livestock species and to human health benefits, such as longevity and cancer prevention. We have developed pig lines that differ in RFI, and we are interested in identifying the genes and pathways that underlie feed efficiency. Prepubertal Yorkshire gilts with low RFI (n = 10) or high RFI (n = 10) were fed ad libitum or fed at restricted intake of 80% of maintenance energy requirements for 8 days. We measured serum metabolites and hormones and generated transcriptional profiles of liver and subcutaneous adipose tissue on these animals. Overall, 6,114 genes in fat and 305 genes in liver were differentially expressed (DE) in response to CR, and 311 genes in fat and 147 genes in liver were DE due to RFI differences. Pathway analyses of CR-induced DE genes indicated a dramatic switch to a conservation mode of energy usage by down-regulating lipogenesis and steroidogenesis in both liver and fat. Interestingly, CR altered expression of genes in immune and cell cycle/apoptotic pathways in fat, which may explain part of the CR-driven lifespan enhancement. In silico analysis of transcription factors revealed ESR1 as a putative regulator of the adaptive response to CR, as several targets of ESR1 in our DE fat genes were annotated as cell cycle/apoptosis genes. The lipid metabolic pathway was overrepresented by down-regulated genes due to both CR and low RFI. We propose a common energy conservation mechanism, which may be controlled by PPARA, PPARG, and/or CREB in both CR and feed-efficient pigs.
C1 [Lkhagvadorj, Sender; Qu, Long; Cai, Weiguo; Couture, Oliver P.; Anderson, Lloyd L.; Dekkers, Jack C. M.; Tuggle, Christopher K.] Iowa State Univ, Dept Anim Sci, Ames, IA 50011 USA.
   [Lkhagvadorj, Sender; Anderson, Lloyd L.; Tuggle, Christopher K.] Iowa State Univ, Interdepartmental Neurosci Program, Ames, IA 50011 USA.
   [Qu, Long; Cai, Weiguo; Nettleton, Dan] Iowa State Univ, Dept Stat, Ames, IA 50011 USA.
   [Qu, Long; Couture, Oliver P.; Nettleton, Dan; Dekkers, Jack C. M.; Tuggle, Christopher K.] Iowa State Univ, Interdepartmental Bioinformat & Computat Biol Pro, Ames, IA 50011 USA.
   [Barb, C. Richard; Hausman, Gary J.] ARS, USDA, Athens, GA USA.
C3 Iowa State University; Iowa State University; Iowa State University;
   Iowa State University; United States Department of Agriculture (USDA)
RP Tuggle, CK (corresponding author), Iowa State Univ, Dept Anim Sci, 2255 Kildee Hall, Ames, IA 50011 USA.
EM cktuggle@iastate.edu
RI Qu, Long/I-8528-2012
OI Nettleton, Dan/0000-0002-6045-1036
FU United States Department of Agriculture, National Research Initiative
   [USDA-NRI-2005-3560415618]; Center for Integrated Animal Genomics at
   Iowa State University; Hatch; State of Iowa; National Science Foundation
   [0714978]; Direct For Mathematical & Physical Scien; Division Of
   Mathematical Sciences [0714978] Funding Source: National Science
   Foundation
FX This research was supported by the United States Department of
   Agriculture, National Research Initiative Grant USDA-NRI-2005-3560415618
   and the Center for Integrated Animal Genomics at Iowa State University
   and is a journal series paper from the Iowa Agricultural and Home
   Economics Experiment Station, Ames, supported by Hatch and State of Iowa
   funds. This material is based upon work supported by the National
   Science Foundation under Grant 0714978.
CR *AFF, 2002, STAT ALG DESCR DOC
   Akha AAS, 2005, CURR OPIN IMMUNOL, V17, P486, DOI 10.1016/j.coi.2005.07.004
   ALBANES D, 1987, Nutrition and Cancer, V9, P199
   [Anonymous], 2002, In Weight Control and Physical Activity
   Arthur PF, 2001, J ANIM SCI, V79, P2805
   Atzmon G, 2006, PLOS BIOL, V4, P562, DOI 10.1371/journal.pbio.0040113
   Balan V, 2008, J BIOL CHEM, V283, P27810, DOI 10.1074/jbc.M804681200
   Barendse W, 2007, GENETICS, V176, P1893, DOI 10.1534/genetics.107.072637
   Baudin B, 2000, CLIN CHEM LAB MED, V38, P853, DOI 10.1515/CCLM.2000.123
   BEAVER EE, 1989, J ANIM SCI, V67, P2415, DOI 10.2527/jas1989.6792415x
   Bottje WG, 2009, J ANIM SCI, V87, pE48, DOI 10.2527/jas.2008-1379
   Burbach BJ, 2007, IMMUNOL REV, V218, P65, DOI 10.1111/j.1600-065X.2007.00527.x
   Bustin SA, 2002, J MOL ENDOCRINOL, V29, DOI 10.1677/jme.0.0290023
   Cai W, 2008, J ANIM SCI, V86, P287, DOI 10.2527/jas.2007-0396
   CARTWRIGHT AL, 1980, J NUTR, V110, P1262, DOI 10.1093/jn/110.6.1262
   Chao J, 1998, HUM GENE THER, V9, P21, DOI 10.1089/hum.1998.9.1-21
   CHAPIN RB, 1994, J NUTR, V124, P2365, DOI 10.1093/jn/124.12.2365
   CHEN Y, 2008, P INT SOC AN GEN
   Cohen HY, 2004, SCIENCE, V305, P390, DOI 10.1126/science.1099196
   COUTURE O, MAMM GENOME IN PRESS
   Dahlman I, 2008, PHARMACOGENET GENOM, V18, P967, DOI 10.1097/FPC.0b013e32831101ef
   Dawson HD, 2005, INFECT IMMUN, V73, P1116, DOI 10.1128/IAI.73.2.1116-1128.2005
   Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r60
   Desvergne B, 2006, PHYSIOL REV, V86, P465, DOI 10.1152/physrev.00025.2005
   ESMON CT, 1995, FASEB J, V9, P946, DOI 10.1096/fasebj.9.10.7615164
   Estep PW, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005242
   Fernandes G, 2008, IMMUNOL RES, V40, P244, DOI 10.1007/s12026-007-0021-3
   Ferrante AW, 2007, J INTERN MED, V262, P408, DOI 10.1111/j.1365-2796.2007.01852.x
   Gabarrou JF, 1997, J NUTR, V127, P2371, DOI 10.1093/jn/127.12.2371
   Gabarrou JF, 2000, BRIT J NUTR, V83, P645, DOI 10.1017/S0007114500000829
   Gallagher CJ, 2007, DIABETES, V56, P2135, DOI 10.2337/db06-1017
   Gao H, 2006, MOL ENDOCRINOL, V20, P1287, DOI 10.1210/me.2006-0012
   Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80
   Gerbitz KD, 1996, DIABETES, V45, P113, DOI 10.2337/diabetes.45.2.113
   GRAEME T, 2006, NEW S WALES DEP PRIM, V66, P1
   Harrison AP, 1996, BRIT J NUTR, V76, P841, DOI 10.1079/BJN19960091
   Hoque MA, 2009, J ANIM SCI, V87, P3069, DOI 10.2527/jas.2008-1268
   Hotamisligil GS, 2006, NATURE, V444, P860, DOI 10.1038/nature05485
   Huang Q, 2006, CHINESE MED J-PEKING, V119, P1794, DOI 10.1097/00029330-200611010-00006
   Hursting SD, 2003, ANNU REV MED, V54, P131, DOI 10.1146/annurev.med.54.101601.152156
   Ishida T, 2003, J CLIN INVEST, V111, P347, DOI [10.1172/JCI200316306, 10.1172/JCI16306]
   Jaye M, 1999, NAT GENET, V21, P424, DOI 10.1038/7766
   KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0
   Kang MJ, 2005, BIOGERONTOLOGY, V6, P27, DOI 10.1007/s10522-004-7381-z
   KANNEL WB, 1987, JAMA-J AM MED ASSOC, V258, P1183, DOI 10.1001/jama.258.9.1183
   Kenward MG, 1997, BIOMETRICS, V53, P983, DOI 10.2307/2533558
   Kim KS, 2000, MAMM GENOME, V11, P131, DOI 10.1007/s003350010025
   KING DB, 1984, J EXP ZOOL, V232, P453, DOI 10.1002/jez.1402320311
   KOCH RM, 1963, J ANIM SCI, V22, P486, DOI 10.2527/jas1963.222486x
   Lenting PJ, 1998, BLOOD, V92, P3983, DOI 10.1182/blood.V92.11.3983.423k51_3983_3996
   Li DD, 2004, J IMMUNOL, V173, P7135, DOI 10.4049/jimmunol.173.12.7135
   Li L, 2004, BIOCHEM CELL BIOL, V82, P460, DOI 10.1139/O04-045
   Liu WM, 2002, BIOINFORMATICS, V18, P1593, DOI 10.1093/bioinformatics/18.12.1593
   Lkhagvadorj S, 2009, PHYSIOL GENOMICS, V38, P98, DOI 10.1152/physiolgenomics.90372.2008
   Loftus SK, 1997, SCIENCE, V277, P232, DOI 10.1126/science.277.5323.232
   LUITING P, 1991, POULTRY SCI, V70, P1663, DOI 10.3382/ps.0701663
   Mari D, 2008, EXP GERONTOL, V43, P66, DOI 10.1016/j.exger.2007.06.014
   MASORO EJ, 1992, LAB ANIM SCI, V42, P132
   Masternak MM, 2005, J GERONTOL A-BIOL, V60, P1394, DOI 10.1093/gerona/60.11.1394
   Mattsson C, 2007, CURR MED CHEM, V14, P2918, DOI 10.2174/092986707782359972
   MILLER ER, 1987, ANNU REV NUTR, V7, P361, DOI 10.1146/annurev.nu.07.070187.002045
   Miller RA, 1996, SCIENCE, V273, P70, DOI 10.1126/science.273.5271.70
   Miskin R, 1997, J GERONTOL A-BIOL, V52, pB118, DOI 10.1093/gerona/52A.2.B118
   Mocchegiani E, 2008, NEUROIMMUNOMODULAT, V15, P344, DOI 10.1159/000156476
   *NAT RES COUNC, 1988, NUTR REQ SWIN, P93
   Nikitin A, 2003, BIOINFORMATICS, V19, P2155, DOI 10.1093/bioinformatics/btg290
   Nkrumah JD, 2007, J ANIM SCI, V85, P2147, DOI 10.2527/jas.2006-764
   Plas DR, 1996, SCIENCE, V272, P1173, DOI 10.1126/science.272.5265.1173
   *R DEV COR TEAM, 2007, R LANG ENV STAT COMP
   RENDEN JA, 1987, POULTRY SCI, V66, P1085, DOI 10.3382/ps.0661085
   Richardson EC, 2004, AUST J EXP AGR, V44, P431, DOI 10.1071/EA02221
   Roberts AJ, 2007, J ANIM SCI, V85, P2740, DOI 10.2527/jas.2007-0141
   Salmond RJ, 2009, IMMUNOL REV, V228, P9, DOI 10.1111/j.1600-065X.2008.00745.x
   Schook L, 2005, ANIM BIOTECHNOL, V16, P183, DOI 10.1080/10495390500265034
   Selman C, 2006, PHYSIOL GENOMICS, V27, P187, DOI 10.1152/physiolgenomics.00084.2006
   Sherman EL, 2008, ANIM GENET, V39, P225, DOI 10.1111/j.1365-2052.2008.01704.x
   Shillabeer G, 1998, CLIN INVEST MED, V21, P54
   Sreekumar R, 2002, AM J PHYSIOL-ENDOC M, V283, pE38, DOI 10.1152/ajpendo.00387.2001
   Storey JD, 2003, P NATL ACAD SCI USA, V100, P9440, DOI 10.1073/pnas.1530509100
   Suh Y, 2002, MECH AGEING DEV, V123, P881, DOI 10.1016/S0047-6374(02)00025-8
   Tuggle CK, 2007, INT J BIOL SCI, V3, P132
   Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034
   VidalPuig A, 1996, J CLIN INVEST, V97, P2553, DOI 10.1172/JCI118703
   Weindruch R, 2001, J NUTR, V131, p918S, DOI 10.1093/jn/131.3.918S
   Wilson CL, 2005, BIOINFORMATICS, V21, P3683, DOI 10.1093/bioinformatics/bti605
   Xie LL, 2007, J BIOL CHEM, V282, P28025, DOI 10.1074/jbc.M604857200
   Yang YH, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.4.e15
   Zha Y, 2008, AM J NEPHROL, V28, P755, DOI 10.1159/000128607
   Zhang Q, 2005, P NATL ACAD SCI USA, V102, P6948, DOI 10.1073/pnas.0501959102
NR 89
TC 71
Z9 79
U1 0
U2 22
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0363-6119
EI 1522-1490
J9 AM J PHYSIOL-REG I
JI Am. J. Physiol.-Regul. Integr. Comp. Physiol.
PD FEB
PY 2010
VL 298
IS 2
BP R494
EP R507
DI 10.1152/ajpregu.00632.2009
PG 14
WC Physiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Physiology
GA 547CI
UT WOS:000273862700032
PM 19939971
OA Green Submitted
DA 2024-02-19
ER

PT J
AU Kuang, MB
   Qiu, JJ
   Li, DD
   Hu, C
   Zhang, SH
   Sheng, GT
   Zou, Y
AF Kuang, Maobin
   Qiu, Jiajun
   Li, Dongdong
   Hu, Chong
   Zhang, Shuhua
   Sheng, Guotai
   Zou, Yang
TI The newly proposed Metabolic Score for Visceral Fat is a reliable tool
   for identifying non-alcoholic fatty liver disease, requiring attention
   to age-specific effects in both sexes
SO FRONTIERS IN ENDOCRINOLOGY
LA English
DT Article
DE NAFLD; Metabolic Visceral Fat Score; sex; METS-VF; visceral adipose
   tissue
ID ADIPOSE-TISSUE; BODY-FAT; RISK; PREVALENCE; ASSOCIATIONS; DIAGNOSIS;
   NONOBESE; OBESITY; IMPACT; INDEX
AB ObjectiveThe newly proposed Metabolic Visceral Fat Score (METS-VF) is considered a more effective measure for visceral adipose tissue (VAT) than other obesity indicators. This study aimed to reveal the association between METS-VF and non-alcoholic fatty liver disease (NAFLD), and its variations across age groups within both sexes.MethodsData from 14,251 medical examiners in the NAGALA project were employed in this study. 3D fitted surface plots were constructed based on multivariate logistic regression models to visualize the isolated and combined effects of aging and METS-VF on NAFLD. Receiver operating characteristic curve (ROC) analysis was conducted to compare the diagnostic performance of METS-VF with other VAT surrogate markers in predicting NAFLD.ResultsThe results of multivariate logistic regression analysis showed that each unit increase in METS-VF was independently associated with a 333% and 312% increase in the odds of NAFLD in males and females, respectively. Additionally, the 3D fitted surface plot showed that age significantly influenced the association between METS-VF and the odds of NAFLD in both sexes, as follows: (i) In males, when METS-VF was less than 6.2, the METS-VF-related odds of NAFLD increased gradually with age in the 20-45 age group, reached a plateau in the 45-65 age group, and then decreased in the group above 65 years old; however, when male METS-VF exceeded 6.2, aging and METS-VF combined to further increase the odds of NAFLD in all age groups, particularly in the 45-65 age group. (ii) In females, aging seemed to reduce METS-VF-related odds of NAFLD in the 18-40 age group, but significantly increased it in the 40-60 age group, particularly for those with higher METS-VF levels. Further ROC analysis revealed that compared to other VAT surrogate markers, METS-VF showed the highest diagnostic accuracy for NAFLD in females, especially in those under 45 years of age [area under the curve (AUC) = 0.9256].ConclusionsThis study firstly revealed a significant positive correlation between METS-VF and the odds of NAFLD, with METS-VF surpassing other VAT surrogate markers in NAFLD diagnosis. Moreover, age significantly influenced the METS-VF-related odds of NAFLD and METS-VF's diagnostic efficacy for NAFLD in both sexes.
C1 [Kuang, Maobin; Qiu, Jiajun; Li, Dongdong] Nanchang Univ, Jiangxi Prov Peoples Hosp, Dept Internal Med, Med Coll, Nanchang, Jiangxi, Peoples R China.
   [Kuang, Maobin; Qiu, Jiajun; Li, Dongdong; Zhang, Shuhua; Zou, Yang] Nanchang Med Coll, Jiangxi Prov Peoples Hosp, Jiangxi Cardiovasc Res Inst, Affiliated Hosp 1, Nanchang, Jiangxi, Peoples R China.
   [Kuang, Maobin; Qiu, Jiajun; Li, Dongdong; Sheng, Guotai] Nanchang Med Coll, Jiangxi Prov Geriatr Hosp, Jiangxi Prov Peoples Hosp, Affiliated Hosp 1, Nanchang, Jiangxi, Peoples R China.
   [Li, Dongdong] Nanchang Med Coll, Jiangxi Prov Peoples Hosp, Affiliated Hosp 1, Dept Pulm & Crit Care Med, Nanchang, Jiangxi, Peoples R China.
   [Hu, Chong] Nanchang Med Coll, Jiangxi Prov Peoples Hosp, Affiliated Hosp 1, Dept Gastroenterol, Nanchang, Jiangxi, Peoples R China.
C3 Nanchang University
RP Zou, Y (corresponding author), Nanchang Med Coll, Jiangxi Prov Peoples Hosp, Jiangxi Cardiovasc Res Inst, Affiliated Hosp 1, Nanchang, Jiangxi, Peoples R China.; Sheng, GT (corresponding author), Nanchang Med Coll, Jiangxi Prov Geriatr Hosp, Jiangxi Prov Peoples Hosp, Affiliated Hosp 1, Nanchang, Jiangxi, Peoples R China.
EM tgs200509@163.com; jxyxyzy@163.com
FU Applied Research and Cultivation Program of Jiangxi Provincial
   Department of Science and Technology [20212BAG70036]; Jiangxi Provincial
   Education Department foundation Project [GJJ218911]; Natural Science
   Foundation of Jiangxi Province [20232BAB216004]
FX This study was supported by the Applied Research and Cultivation Program
   of Jiangxi Provincial Department of Science and Technology [No.
   20212BAG70036 to SZ], Jiangxi Provincial Education Department foundation
   Project [No. GJJ218911 to SH-Z] and Natural Science Foundation of
   Jiangxi Province [No. 20232BAB216004 to YZ].
CR Ballestri S, 2017, ADV THER, V34, P1291, DOI 10.1007/s12325-017-0556-1
   Chalasani N, 2012, HEPATOLOGY, V55, P2005, DOI 10.1002/hep.25762
   Chung GE, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000000573
   DELONG ER, 1988, BIOMETRICS, V44, P837, DOI 10.2307/2531595
   Deng H, 2023, CARDIOVASC DIABETOL, V22, DOI 10.1186/s12933-022-01731-1
   DiStefano JK, 2020, ENDOCRINOLOGY, V161, DOI 10.1210/endocr/bqaa134
   Eguchi Y, 2012, J GASTROENTEROL, V47, P586, DOI 10.1007/s00535-012-0533-z
   Feng Ling, 2022, Diabetes Metab Syndr Obes, V15, P2249, DOI 10.2147/DMSO.S370222
   Feng YF, 2022, BRIT J NUTR, V128, P1029, DOI 10.1017/S0007114521004116
   Feng YF, 2022, NUTRITION, V93, DOI 10.1016/j.nut.2021.111443
   Fewell Z, 2007, AM J EPIDEMIOL, V166, P646, DOI 10.1093/aje/kwm165
   Finelli Carmine, 2012, J Gastrointestin Liver Dis, V21, P205
   Fishbein M, 2005, J CLIN GASTROENTEROL, V39, P619, DOI 10.1097/00004836-200508000-00012
   Hashimoto Y, 2015, J GASTROEN HEPATOL, V30, P546, DOI 10.1111/jgh.12786
   Ibrahim MM, 2010, OBES REV, V11, P11, DOI 10.1111/j.1467-789X.2009.00623.x
   Jura M, 2016, AGE, V38, DOI 10.1007/s11357-016-9884-3
   Kim D, 2016, CLIN GASTROENTEROL H, V14, P132, DOI 10.1016/j.cgh.2015.07.024
   Kim Hong-Kyu, 2023, Clin Mol Hepatol, V29, P987, DOI 10.3350/cmh.2023.0035
   Kim JH, 2019, KOREAN J ANESTHESIOL, V72, P558, DOI 10.4097/kja.19087
   Koehler EM, 2013, CLIN GASTROENTEROL H, V11, P1201, DOI 10.1016/j.cgh.2012.12.031
   Kojima S, 2003, J GASTROENTEROL, V38, P954, DOI 10.1007/s00535-003-1178-8
   Lafontan M, 2008, DIABETES METAB, V34, P317, DOI 10.1016/j.diabet.2008.04.001
   Le MH, 2023, J HEPATOL, V79, DOI 10.1016/j.jhep.2023.03.040
   Lee C, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8101259
   Lee MJ, 2019, GUT LIVER, V13, P67, DOI 10.5009/gnl18070
   Liu CJ, 2012, J GASTROEN HEPATOL, V27, P1555, DOI 10.1111/j.1440-1746.2012.07222.x
   Liu XZ, 2020, NUTR METAB CARDIOVAS, V30, P1751, DOI 10.1016/j.numecd.2020.06.001
   Manolopoulos KN, 2010, INT J OBESITY, V34, P949, DOI 10.1038/ijo.2009.286
   Meier CR, 2002, J HEPATOL, V37, P741, DOI 10.1016/S0168-8278(02)00298-2
   Mittal B, 2019, INDIAN J MED RES, V149, P571, DOI 10.4103/ijmr.IJMR_1910_18
   Okamura T, 2019, INT J OBESITY, V43, P139, DOI 10.1038/s41366-018-0076-3
   Palmer BF, 2015, MOL CELL ENDOCRINOL, V402, P113, DOI 10.1016/j.mce.2014.11.029
   Pang Q, 2015, WORLD J GASTROENTERO, V21, P1650, DOI 10.3748/wjg.v21.i5.1650
   Powell EE, 2021, LANCET, V397, P2212, DOI 10.1016/S0140-6736(20)32511-3
   Ryu S, 2007, CLIN CHEM, V53, P71, DOI 10.1373/clinchem.2006.078980
   Saadeh S, 2002, GASTROENTEROLOGY, V123, P745, DOI 10.1053/gast.2002.35354
   Schreiner PJ, 1996, AM J EPIDEMIOL, V144, P335, DOI 10.1093/oxfordjournals.aje.a008934
   Sheng GT, 2021, LIPIDS HEALTH DIS, V20, DOI 10.1186/s12944-021-01561-2
   Shuster A, 2012, BRIT J RADIOL, V85, P1, DOI 10.1259/bjr/38447238
   Swainson MG, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177175
   Tan EXX, 2022, METABOLISM, V126, DOI 10.1016/j.metabol.2021.154911
   Tao ZP, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0372-9
   Tchernof A, 2013, PHYSIOL REV, V93, P359, DOI 10.1152/physrev.00033.2011
   van Zadelhoff AC, 2023, BRIT J ANAESTH, V130, P585, DOI 10.1016/j.bja.2023.01.024
   Venetsanaki V, 2019, CURR VASC PHARMACOL, V17, P546, DOI 10.2174/1570161116666180711121949
   Waves, About Us
   Bello-Chavolla OY, 2020, CLIN NUTR, V39, P1613, DOI 10.1016/j.clnu.2019.07.012
   Ye Q, 2020, LANCET GASTROENTEROL, V5, P739, DOI 10.1016/S2468-1253(20)30077-7
   Younossi ZM, 2023, HEPATOLOGY, V77, P1335, DOI 10.1097/HEP.0000000000000004
   Younossi ZM, 2019, J HEPATOL, V70, P531, DOI 10.1016/j.jhep.2018.10.033
   Yu P, 2022, FRONT ENDOCRINOL, V13, DOI 10.3389/fendo.2022.1052736
   Yu SJ, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000002159
NR 52
TC 0
Z9 0
U1 3
U2 3
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-2392
J9 FRONT ENDOCRINOL
JI Front. Endocrinol.
PD NOV 27
PY 2023
VL 14
AR 1281524
DI 10.3389/fendo.2023.1281524
PG 12
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Endocrinology & Metabolism
GA AL3D3
UT WOS:001118572000001
PM 38089634
OA gold
DA 2024-02-19
ER

PT J
AU Dominici, FP
   Argentino, DP
   Bartke, A
   Turyn, D
AF Dominici, FP
   Argentino, DP
   Bartke, A
   Turyn, D
TI The dwarf mutation decreases high dose insulin responses in skeletal
   muscle, the opposite of effects in liver
SO MECHANISMS OF AGEING AND DEVELOPMENT
LA English
DT Article
DE insulin sensitivity; insulin signaling; aging; insulin receptor
   substrate; growth hormone
ID PROTEIN-KINASE-B; LIFE-SPAN; PHOSPHATIDYLINOSITOL 3-KINASE; RECEPTOR
   SUBSTRATE-1; SIGNALING PATHWAY; MICE LACKING; GENE; LONGEVITY;
   ACTIVATION; RESISTANCE
AB The in vivo status of the proximal components of the insulin signaling system was investigated in skeletal muscle of Ames (Prop1(df)/lProp1(df)) dwarf mice. The insulin-stimulated phosphorylation of the insulin receptor (IR) was reduced by 55% in Ames dwarf mice, while IR receptor protein content was not altered. Insulin-stimulated phosphorylation of IRS-1 and IRS-2 were decreased by 79 and 51%, respectively, while IRS-1 and IRS-2 protein levels were decreased by 66 and 43%. In addition, insulin-stimulated association of IRS-1 and IRS-2 with the p85 regulatory subunit of phosphatidylinositol (PI) 3-kinase was significantly reduced (by 80 and 41%, respectively), whereas insulin-stimulated PI 3-kinase activity was reduced by 66%. However, insulin-stimulated phosphorylation of Akt was slightly reduced (by 20%), suggesting that the attenuation of insulin signaling downstream PI 3-kinase may involve other signaling molecules. Our current results demonstrate that the Prop1 mutation decreases high dose insulin responses in skeletal muscle. This alteration is remarkable because these animals are hypersensitive to insulin and display an augmented response to insulin in liver at the same signaling steps. Reduced response to insulin in skeletal muscle could be important for the control of glucose homeostasis in these animals and could have implications in their extended longevity. (C) 2003 Elsevier Ireland Ltd. All rights reserved.
C1 Inst Quim & Fisicoquim Biol, IQUIFIB, Fac Farm & Bioquim, Buenos Aires, DF, Argentina.
   So Illinois Univ, Sch Med, Dept Physiol, Carbondale, IL 62901 USA.
C3 University of Buenos Aires; Southern Illinois University System;
   Southern Illinois University
RP Turyn, D (corresponding author), Inst Quim & Fisicoquim Biol, IQUIFIB, Fac Farm & Bioquim, Junin 956,C1113AAD, Buenos Aires, DF, Argentina.
RI Bartke, Andzej/D-6640-2017
OI Bartke, Andzej/0000-0002-2569-557X; Dominici, Fernando
   Pablo/0000-0002-4351-0057
FU NIA NIH HHS [AG 19899] Funding Source: Medline
CR Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x
   Andersen B, 1995, DEV BIOL, V172, P495, DOI 10.1006/dbio.1995.8040
   [Anonymous], GENETIC VARIATION HO
   ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0
   Bartke A, 2001, TRENDS ENDOCRIN MET, V12, P233, DOI 10.1016/S1043-2760(01)00426-X
   BARTKE A, 1964, ANAT RECORD, V149, P225, DOI 10.1002/ar.1091490206
   BORG KE, 1995, P SOC EXP BIOL MED, V210, P126
   BrownBorg HM, 1996, NATURE, V384, P33, DOI 10.1038/384033a0
   CHANDRASHEKAR V, 1993, BIOL REPROD, V48, P544, DOI 10.1095/biolreprod48.3.544
   Cho H, 2001, SCIENCE, V292, P1728, DOI 10.1126/science.292.5522.1728
   Clancy DJ, 2001, SCIENCE, V292, P104, DOI 10.1126/science.1057991
   Coffer PJ, 1998, BIOCHEM J, V335, P1
   Coschigano KT, 2000, ENDOCRINOLOGY, V141, P2608, DOI 10.1210/en.141.7.2608
   Dominici FP, 2002, J ENDOCRINOL, V173, P81, DOI 10.1677/joe.0.1730081
   Dominici FP, 1998, J ENDOCRINOL, V159, P15, DOI 10.1677/joe.0.1590015
   Dominici FP, 1999, AM J PHYSIOL-ENDOC M, V277, pE447, DOI 10.1152/ajpendo.1999.277.3.E447
   Dominici FP, 2000, J ENDOCRINOL, V166, P579, DOI 10.1677/joe.0.1660579
   Fabrizio P, 2001, SCIENCE, V292, P288, DOI 10.1126/science.1059497
   Flurkey K, 2001, P NATL ACAD SCI USA, V98, P6736, DOI 10.1073/pnas.111158898
   Flurkey K, 2002, MECH AGEING DEV, V123, P121, DOI 10.1016/S0047-6374(01)00339-6
   Hsieh CC, 2002, MECH AGEING DEV, V123, P1229, DOI 10.1016/S0047-6374(02)00036-2
   Hsieh CC, 2002, MECH AGEING DEV, V123, P1245, DOI 10.1016/S0047-6374(02)00037-4
   Kimura KD, 1997, SCIENCE, V277, P942, DOI 10.1126/science.277.5328.942
   Parr T, 1999, GERONTOLOGY, V45, P121, DOI 10.1159/000022075
   SAAD MJA, 1993, J CLIN INVEST, V92, P2065, DOI 10.1172/JCI116803
   Saltiel AR, 2001, NATURE, V414, P799, DOI 10.1038/414799a
   Shepherd PR, 1998, BIOCHEM J, V333, P471, DOI 10.1042/bj3330471
   TAMEMOTO H, 1994, NATURE, V372, P182, DOI 10.1038/372182a0
   Tatar M, 2001, SCIENCE, V292, P107, DOI 10.1126/science.1057987
   Withers DJ, 1998, NATURE, V391, P900, DOI 10.1038/36116
NR 30
TC 29
Z9 31
U1 0
U2 4
PU ELSEVIER SCI IRELAND LTD
PI CLARE
PA CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE,
   IRELAND
SN 0047-6374
J9 MECH AGEING DEV
JI Mech. Ageing Dev.
PD JUL
PY 2003
VL 124
IS 7
BP 819
EP 827
DI 10.1016/S0047-6374(03)00136-2
PG 9
WC Cell Biology; Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Geriatrics & Gerontology
GA 708MR
UT WOS:000184571800005
PM 12875745
OA Green Published
DA 2024-02-19
ER

PT J
AU Hosaka, N
   Nose, M
   Kyogoku, M
   Nagata, N
   Miyashima, S
   Good, RA
   Ikehara, S
AF Hosaka, N
   Nose, M
   Kyogoku, M
   Nagata, N
   Miyashima, S
   Good, RA
   Ikehara, S
TI Thymus transplantation, a critical factor for correction of autoimmune
   disease in aging MRL/+ mice
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
ID BONE-MARROW TRANSPLANTATION; DIABETIC MICE; STROMAL CELLS; HOST-DISEASE;
   FETAL THYMUS; PREVENTION; GRAFT
AB MRL/MP-+/+ (MRL/+) mice develop pancreatitis and sialoadenitis after they reach 7 months of age. Conventional bone marrow transplantation has been found to be ineffective in the treatment of these forms of apparent autoimmune disease. Old MRL/+ mice show a dramatic thymic involution with age. Hematolymphoid reconstitution is incomplete when fetal liver cells (as a source of hemopoietic stem cells) plus fetal bone (FB; which is used to recruit stromal cells) are transplanted from immunologically normal C57BL/6 donor mice to MRL/+ female recipients. Embryonic thymus from allogeneic C57BL/6 donors was therefore engrafted along with either bone marrow or fetal hematopoietic cells (FHCs) plus fragments of adult or fetal bone. More than seventy percent of old MRL/+ mice (>7 months) that had been given a fetal thymus (FT) transplant plus either bone marrow or FHCs and also bone fragments survived more than 100 days after treatment. The mice that received FHCs, FB, plus FT from allogeneic donors developed normal T cell and B cell functions. Serum amylase levels decreased in these mice whereas they increased in the mice that received FHCs and FB but not FT. The pancreatitis and sialoadenitis already present at the time of transplantations were fully corrected according to histological analysis by transplants of allogeneic FHCs, FB and FT in the MRL/+ mice. These findings are taken as an experimental indication that perhaps stem cell transplants along with FT grafts might represent a useful strategy for treatment of autoimmune diseases in aged humans.
C1 KANSAI MED UNIV,DEPT PATHOL 1,MORIGUCHI,OSAKA 570,JAPAN.
   TOHOKU UNIV,DEPT PATHOL 1,SENDAI,MIYAGI 98077,JAPAN.
   OTSUKA PHARMACEUT CO LTD,OTSU,SHIGA 52001,JAPAN.
   UNIV S FLORIDA,ALL CHILDRENS HOSP,DEPT PEDIAT,ST PETERSBURG,FL 33701.
C3 Kansai Medical University; Tohoku University; Otsuka Pharmaceutical;
   State University System of Florida; University of South Florida
CR ATKINSON K, 1982, TRANSPLANTATION, V33, P168, DOI 10.1097/00007890-198202000-00012
   IKEHARA S, 1985, P NATL ACAD SCI USA, V82, P2483, DOI 10.1073/pnas.82.8.2483
   IKEHARA S, 1989, P NATL ACAD SCI USA, V86, P3306, DOI 10.1073/pnas.86.9.3306
   IKEHARA S, 1985, P NATL ACAD SCI USA, V82, P7743, DOI 10.1073/pnas.82.22.7743
   ISHIDA T, 1994, J IMMUNOL, V152, P3119
   KANNO H, 1992, CLIN EXP IMMUNOL, V89, P68
   KLINGEMANN HG, 1986, BLOOD, V67, P770
   KUMAMOTO T, 1995, IMMUNOBIOLOGY, V192, P365, DOI 10.1016/S0171-2985(11)80176-2
   MAYUMI M, 1989, EUR J PEDIATR, V148, P518, DOI 10.1007/BF00441546
   NAKAGAWA T, 1993, ARTHRITIS RHEUM, V36, P263, DOI 10.1002/art.1780360220
   OYAIZU N, 1988, J EXP MED, V167, P2017, DOI 10.1084/jem.167.6.2017
   PAHWA S, 1979, CLIN IMMUNOL IMMUNOP, V14, P107
   PHAN DT, 1987, THYMUS, V9, P123
   RINGDEN O, 1985, TRANSPLANTATION, V40, P39
   WEINER RS, 1986, ANN INTERN MED, V104, P168, DOI 10.7326/0003-4819-104-2-168
   YASUMIZU R, 1987, P NATL ACAD SCI USA, V84, P6555, DOI 10.1073/pnas.84.18.6555
NR 16
TC 57
Z9 59
U1 0
U2 1
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD AUG 6
PY 1996
VL 93
IS 16
BP 8558
EP 8562
DI 10.1073/pnas.93.16.8558
PG 5
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA VB325
UT WOS:A1996VB32500074
PM 8710909
OA Green Published
DA 2024-02-19
ER

PT J
AU MICHELET, F
   GUEGUEN, R
   LEROY, P
   WELLMAN, M
   NICOLAS, A
   SIEST, G
AF MICHELET, F
   GUEGUEN, R
   LEROY, P
   WELLMAN, M
   NICOLAS, A
   SIEST, G
TI BLOOD AND PLASMA GLUTATHIONE MEASURED IN HEALTHY-SUBJECTS BY HPLC -
   RELATION TO SEX, AGING, BIOLOGICAL VARIABLES, AND LIFE HABITS
SO CLINICAL CHEMISTRY
LA English
DT Article
DE BIOLOGICAL VARIATION; GAMMA-GLUTAMYL-TRANSFERASE; ANTIOXIDANTS;
   CHOLESTEROL; FREE RADICALS; SEX- AND AGE-RELATED EFFECTS
ID MICROSOMAL LIPID-PEROXIDATION; INTRACELLULAR GLUTATHIONE;
   HUMAN-ERYTHROCYTES; VITAMIN-E; DEFICIENCY; DISULFIDE; DISEASE; LIVER;
   CELLS; CHEMOTHERAPY
AB We report an HPLC method for measuring the concentrations of reduced (GSH) and total (GSHt) free glutathione in human plasma and whole blood. The chromatographic step was coupled with a postcolumn derivatization reaction and fluorometric detection. The linear range was 0.81-13.02 mu mol/L, and the detection limit was 0.13 mu mol/L. In healthy adults (ages 18-73 years), mean concentrations were 941 +/- 155 mu mol/L for GSHt and 849 +/- 63 mu mol/L for GSH in blood (107 men, 94 women), and 3.39 +/- 1.04 mu mol/L for GSH in plasma (66 men, 58 women). Blood GSHt but not GSH was significantly lower in children (32 boys, 32 girls: 872 +/- 157 mu mol/L) than in adults. Blood GSHt and GSH appeared to be correlated positively with the number of cigarettes smoked per day and the regular practice of physical exercise, and negatively with alcohol abstinence. We observed positive correlations between blood GSHt and cholesterol and calcium concentrations, and between blood GSH and cholesterol concentration.
C1 CTR MED PREVENT,F-54500 VANDOEUVRE NANCY,FRANCE.
   FAC PHARM NANCY,CHIM ANALYT LAB,F-54000 NANCY,FRANCE.
   MED CTR,CNRS,URA 597,F-54000 NANCY,FRANCE.
C3 Universite de Lorraine; Centre National de la Recherche Scientifique
   (CNRS)
OI SIEST, Gerard/0000-0002-3001-760X
CR ADAMS JD, 1990, RES COMMUN SUBSTANCE, V11, P153
   ADAMS JD, 1987, CLIN CHEM, V33, P1675
   ALTURK WA, 1987, J PHARM PHARMACOL, V39, P13, DOI 10.1111/j.2042-7158.1987.tb07154.x
   BEUTLER E, 1985, J LAB CLIN MED, V105, P581
   BEUTLER E, 1990, BLOOD, V75, P271
   BRODIE AE, 1991, BIOCHEM BIOPH RES CO, V176, P276, DOI 10.1016/0006-291X(91)90920-3
   BUHL R, 1989, LANCET, V2, P1294
   CHAN AC, 1993, CAN J PHYSIOL PHARM, V71, P725, DOI 10.1139/y93-109
   COSTAGLIOLA C, 1990, CLIN PHYSIOL BIOCH, V8, P204
   DEQUAY B, 1992, AIDS, V6, P815, DOI 10.1097/00002030-199208000-00008
   Dufer J., 1981, Interpretation des examens de laboratoire, P224, DOI [10.1159/000401102, DOI 10.1159/000401102]
   FLAGG EW, 1993, BRIT J NUTR, V70, P797, DOI 10.1079/BJN19930175
   GIORGI G, 1984, IRCS MED SCI-BIOCHEM, V12, P560
   GOHIL K, 1988, J APPL PHYSIOL, V64, P115, DOI 10.1152/jappl.1988.64.1.115
   GRIFFITH OW, 1980, ANAL BIOCHEM, V106, P207, DOI 10.1016/0003-2697(80)90139-6
   HERCBERGS A, 1992, LANCET, V339, P1074, DOI 10.1016/0140-6736(92)90664-O
   KILINC A, 1988, NEUROSCI LETT, V87, P307, DOI 10.1016/0304-3940(88)90467-3
   KRETZSCHMAR M, 1991, INT J SPORTS MED, V12, P218, DOI 10.1055/s-2007-1024671
   LANG CA, 1992, J LAB CLIN MED, V120, P720
   LAUTERBURG BH, 1988, GUT, V29, P1153, DOI 10.1136/gut.29.9.1153
   LEEDLE RA, 1990, LIPIDS, V25, P241, DOI 10.1007/BF02544382
   LEROY P, 1993, CHROMATOGRAPHIA, V36, P130, DOI 10.1007/BF02263849
   MANSOOR MA, 1992, ANAL BIOCHEM, V200, P218, DOI 10.1016/0003-2697(92)90456-H
   MATSUBARA LS, 1991, BRAZ J MED BIOL RES, V24, P449
   MEISTER A, 1983, SCIENCE, V220, P472, DOI 10.1126/science.6836290
   MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431
   MILLS BJ, 1994, ANAL BIOCHEM, V222, P95, DOI 10.1006/abio.1994.1459
   MISTRY P, 1991, PHARMACOL THERAPEUT, V49, P125, DOI 10.1016/0163-7258(91)90026-I
   MURPHY ME, 1992, EUR J BIOCHEM, V210, P139, DOI 10.1111/j.1432-1033.1992.tb17401.x
   PAOLISSO G, 1992, AM J PHYSIOL, V263, pE435, DOI 10.1152/ajpendo.1992.263.3.E435
   SCHACHTER M, 1990, BIOCHEM SOC T, V18, P1185, DOI 10.1042/bst0181185
   SHAW S, 1993, DIGEST DIS SCI, V28, P585
   SHIGESAWA T, 1992, J GASTROEN HEPATOL, V7, P7, DOI 10.1111/j.1440-1746.1992.tb00926.x
   Snedecor G.W., 1980, STATISTICAL METHODS
   STAAL FJT, 1992, AIDS RES HUM RETROV, V8, P305, DOI 10.1089/aid.1992.8.305
   STAHLBERG MR, 1990, SCAND J CLIN LAB INV, V50, P125
   SUGAWARA E, 1991, BRIT J IND MED, V48, P239
   SUMMER KH, 1985, BIOCHEM MED METAB B, V34, P107, DOI 10.1016/0006-2944(85)90067-5
   TATE SS, 1978, P NATL ACAD SCI USA, V75, P4806, DOI 10.1073/pnas.75.10.4806
   THIOUDELLET C, 1994, EUR J BIOCHEM, V222, P1009, DOI 10.1111/j.1432-1033.1994.tb18952.x
   TIETZE F, 1969, ANAL BIOCHEM, V27, P502, DOI 10.1016/0003-2697(69)90064-5
   TOTH KM, 1986, AM REV RESPIR DIS, V134, P281
   UHLIG S, 1992, LIFE SCI, V51, P1083, DOI 10.1016/0024-3205(92)90509-N
   WINKLER BS, 1992, BIOCHIM BIOPHYS ACTA, V1117, P287, DOI 10.1016/0304-4165(92)90026-Q
NR 44
TC 279
Z9 306
U1 2
U2 32
PU AMER ASSOC CLINICAL CHEMISTRY
PI WASHINGTON
PA 2101 L STREET NW, SUITE 202, WASHINGTON, DC 20037-1526
SN 0009-9147
J9 CLIN CHEM
JI Clin. Chem.
PD OCT
PY 1995
VL 41
IS 10
BP 1509
EP 1517
PG 9
WC Medical Laboratory Technology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Medical Laboratory Technology
GA RZ004
UT WOS:A1995RZ00400019
PM 7586526
DA 2024-02-19
ER

PT J
AU Ortmeyer, HK
AF Ortmeyer, HK
TI Relationship of glycogen synthase and glycogen phosphorylase to protein
   phosphatase 2C and cAMP-dependent protein kinase in liver of obese
   rhesus monkeys
SO OBESITY RESEARCH
LA English
DT Article
DE glucose 6-phosphate; glycogen; aging; noninsulin-dependent diabetes
   mellitus; insulin resistance
ID SPONTANEOUSLY INSULIN-RESISTANT; DIABETES-MELLITUS; SKELETAL-MUSCLE;
   INVIVO INSULIN; ACTIVATION; HUMANS; ASSAY
AB The regulation of glycogen synthase (GS) and glycogen phosphorylase (GP) activity by phosphorylation/dephosphorylation has been proposed to be via changes in activities of several different protein (serine/threonine) phosphatases and kinases, including protein phosphatase (PP) 1/2A, PP2C, and cAMP-dependent protein kinase (PKA). In order to determine whether PP1/2A, PP2C, and/or PKA activities are related to GS and/or GP activities, these enzymes were measured in freeze-clamped liver biopsies obtained under basal fasting conditions from 16 obese monkeys. Four monkeys were normoglycemic and normoinsulinemic, five were hyperinsulinemic, and seven had type 2 diabetes (NIDDM). Liver glycogen and glucose 6-phosphate (G6P) contents were also determined. nasal enzyme activities and basal substrate concentrations were not significantly different between the three groups of obese monkeys; however, there were several significant linear relationships observed when the monkeys were treated as one group. Therefore, multiple regression was used to determine the correlation between key variables. GS fractional activity was correlated to GP fractional activity (p<0.05) and to PP2C activity (p=0.005) (adjusted R-2, 53%). GP independent activity was correlated to GS independent activity (p<0.07) and to PKA fractional activity (p=0.005) (adjusted R-2, 64%). PP2C activity was correlated to GS fractional activity (p<0.0005) and to PP1/2A activity (p<0.0001) (adjusted R-2, 83%). PKA fractional activity was correlated to GP total activity (p<0.0005) and to age (p=0.001) (adjusted R-2, 82%). G6P content was correlated to glycogen content (p<0.05) and to PP2C activity (p=0.0005) (adjusted R-2, 73%). In conclusion, PP2C and PKA are involved in the regulation of GS and GP activity in the basal state in liver of obese monkeys with a wide range of glucose tolerance.
C1 Univ Maryland, Sch Med, Dept Physiol, Obesit & Diabet Res Ctr, Baltimore, MD 21201 USA.
C3 University System of Maryland; University of Maryland Baltimore
RP Ortmeyer, HK (corresponding author), Univ Maryland, Sch Med, Dept Physiol, Obesit & Diabet Res Ctr, 10 S Pine St,Room 6-00, Baltimore, MD 21201 USA.
RI Ortmeyer, Heidi K/AAM-9223-2021
OI Ortmeyer, Heidi K/0000-0002-9376-7029
CR ABE S, 1996, ALPHA KETO ACID DEHY, P188
   BOGARDUS C, 1984, J CLIN INVEST, V73, P1185, DOI 10.1172/JCI111304
   FREYMOND D, 1988, J CLIN INVEST, V82, P1503, DOI 10.1172/JCI113758
   GILBOE DP, 1972, ANAL BIOCHEM, V47, P20, DOI 10.1016/0003-2697(72)90274-6
   GUINOVART JJ, 1979, FEBS LETT, V106, P284, DOI 10.1016/0014-5793(79)80515-3
   HANSEN B, 1995, PROGR OBESITY RES 94, P539
   HANSEN BC, 1993, DIABETES, V42, P1809, DOI 10.2337/diabetes.42.12.1809
   HANSEN BC, 1986, DIABETOLOGIA, V29, P713, DOI 10.1007/BF00870281
   HANSEN BC, 1995, LESSONS ANIMAL DIABE, V5, P93
   JEN KLC, 1988, AM J PRIMATOL, V14, P153, DOI 10.1002/ajp.1350140206
   JOHNSON AB, 1991, METABOLISM, V40, P252, DOI 10.1016/0026-0495(91)90106-7
   KIDA Y, 1990, J CLIN INVEST, V85, P476, DOI 10.1172/JCI114462
   KIDA Y, 1991, J CLIN INVEST, V87, P673, DOI 10.1172/JCI115045
   KIDA Y, 1992, J CLIN INVEST, V89, P610, DOI 10.1172/JCI115627
   LARNER J, 1988, DIABETES, V37, P262, DOI 10.2337/diab.37.3.262
   Mackintosh C., 1993, PROTEIN PHOSPHORYLAT, P197
   OKUBO M, 1989, J CLIN ENDOCR METAB, V69, P798, DOI 10.1210/jcem-69-4-798
   Ortmeyer H K, 1994, Obes Res, V2, P549
   ORTMEYER HK, 1993, AM J PHYSIOL, V265, pR552, DOI 10.1152/ajpregu.1993.265.3.R552
   ORTMEYER HK, 1993, DIABETOLOGIA, V36, P200, DOI 10.1007/BF00399950
   ORTMEYER HK, 1994, DIABETOLOGIA, V37, P127, DOI 10.1007/s001250050082
   Ortmeyer HK, 1997, AM J PHYSIOL-ENDOC M, V272, pE133, DOI 10.1152/ajpendo.1997.272.1.E133
   PACE N, 1947, J BIOL CHEM, V168, P459
   ROACH PJ, 1986, ENZYMES, V17, P499
   Wang Y., 1993, PROTEIN PHOSPHORYLAT, P121
NR 25
TC 8
Z9 9
U1 0
U2 3
PU NORTH AMER ASSOC STUDY OBESITY
PI ROCHESTER
PA C/O DR MICHAEL JENSEN, MAYO MEDICAL CENTER, MAYO CLIN 200 FIRST ST, SW,
   ROCHESTER, MN 55905 USA
SN 1071-7323
J9 OBES RES
JI Obes. Res.
PD NOV
PY 1997
VL 5
IS 6
BP 613
EP 621
DI 10.1002/j.1550-8528.1997.tb00583.x
PG 9
WC Endocrinology & Metabolism; Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Endocrinology & Metabolism; Nutrition & Dietetics
GA YY902
UT WOS:000072199300014
PM 9449147
OA Bronze
DA 2024-02-19
ER

PT J
AU SPIESS, S
   REIMANN, J
AF SPIESS, S
   REIMANN, J
TI THE DIVERSITY OF IN-FRAME TCR DELTA-CHAIN TRANSCRIPTS IN AGING SCID MICE
SO INTERNATIONAL IMMUNOLOGY
LA English
DT Article
DE SCID MICE; TCR DELTA CHAIN DIVERSITY; T-CELL LEAKINESS
ID COMBINED IMMUNE-DEFICIENCY; CELL RECEPTOR GAMMA; CD3+ T-CELLS;
   JUNCTIONAL SEQUENCES; GENES; MOUSE; RECOMBINATION; REARRANGEMENT;
   LYMPHOCYTES; EXPRESSION
AB From spleen, liver, bone marrow, and gut of old C.B-17 scid/scid (SCID) mice, TCR delta chain transcripts were amplified by the polymerase chain reaction (PCR) using V(delta)1-, V(delta)2-, V(delta)3-, V(delta)4-, V(delta)5-, V(delta)6-, and C(delta)-specific primers. Selectively amplified, TCR delta-chain-encoding cDNA from these organs of five old SCID mice was cloned, and 175 randomly selected clones were sequenced. In this panel, 44 distinct rearrangement events were detected, 82% (36/44) of which were in-frame. For V(delta)2, V(delta)4, V(delta)5, and V(delta)6, 34 in-frame transcripts were found in five old SCID mice. No potentially functional transcript containing V(delta)3 was found and an unusual type of transcript containing the V(delta)1 gene segment spliced directly in-frame to C(delta) was the predominant type of V(delta)1 expression. Junctional diversity was evident in most sequenced clones indicating an extensive potential diversity of SCID-derived TCR delta chains. Identical transcripts were amplified from different organs of the same old SCID mouse. No organ-specific expression of V(delta) genes was evident. TCR delta chain transcripts could be neither amplified from young SCID mice nor from young SCID mice nor from young or old scid/scid nu/nu mice (bred on a BALB/c background). Hence, an apparently thymus-dependent development of oligoclonal populations of TCRdelta+ cells is observed in old SCID mice.
C1 UNIV ULM, INST MICROBIOL, ALBERT EINSTEIN ALLEE 11, W-7900 ULM, GERMANY.
C3 Ulm University
CR ALLISON JP, 1991, ANNU REV IMMUNOL, V9, P679, DOI 10.1146/annurev.iy.09.040191.003335
   BARRY TS, 1991, J EXP MED, V173, P167, DOI 10.1084/jem.173.1.167
   BONNEVILLE M, 1990, J EXP MED, V171, P1015, DOI 10.1084/jem.171.4.1015
   BOSMA GC, 1988, J EXP MED, V167, P1016, DOI 10.1084/jem.167.3.1016
   BOSMA GC, 1983, NATURE, V301, P527, DOI 10.1038/301527a0
   BOSMA MJ, 1991, ANNU REV IMMUNOL, V9, P323, DOI 10.1146/annurev.iy.09.040191.001543
   BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025
   CARROLL AM, 1989, J IMMUNOL, V143, P1087
   CARROLL AM, 1988, EUR J IMMUNOL, V18, P1965, DOI 10.1002/eji.1830181215
   CARROLL AM, 1989, CURR TOP MICROBIOL, V152, P63
   CARROLL AM, 1989, CURR TOP MICROBIOL, V152, P117
   EZQUERRA A, 1990, J IMMUNOL, V145, P1311
   GIBSON DM, 1989, CURR TOP MICROBIOL, V152, P125
   IWASHIMA M, 1988, P NATL ACAD SCI USA, V85, P8161, DOI 10.1073/pnas.85.21.8161
   KEARNEY JF, 1989, CURR TOP MICROBIOL, V152, P137
   KIENKER LJ, 1991, J IMMUNOL, V147, P4351
   KIENKER LJ, 1991, J EXP MED, V174, P769, DOI 10.1084/jem.174.4.769
   LAFAILLE JJ, 1989, CELL, V59, P859, DOI 10.1016/0092-8674(89)90609-0
   LIEBER MR, 1988, CELL, V55, P7, DOI 10.1016/0092-8674(88)90004-9
   MALYNN BA, 1988, CELL, V54, P453, DOI 10.1016/0092-8674(88)90066-9
   RAULET DH, 1989, ANNU REV IMMUNOL, V7, P175, DOI 10.1146/annurev.iy.07.040189.001135
   REIMANN J, 1991, INT IMMUNOL, V3, P657, DOI 10.1093/intimm/3.7.657
   REIMANN J, 1993, EUR J IMMUNOL, V23, P350, DOI 10.1002/eji.1830230208
   RIGGS JE, 1991, J EXP MED, V173, P265, DOI 10.1084/jem.173.1.265
   RIGGS JE, 1992, J IMMUNOL, V148, P1389
   ROCHA B, 1992, IMMUNOL TODAY, V13, P449, DOI 10.1016/0167-5699(92)90074-H
   ROTH DB, 1992, CELL, V70, P983, DOI 10.1016/0092-8674(92)90248-B
   RUDOLPHI A, 1992, IMMUNOLOGY, V77, P157
   RUDOLPHI A, 1991, EUR J IMMUNOL, V21, P523, DOI 10.1002/eji.1830210240
   SCHULER W, 1991, EUR J IMMUNOL, V21, P589, DOI 10.1002/eji.1830210309
   SCHULER W, 1990, EUR J IMMUNOL, V20, P545, DOI 10.1002/eji.1830200313
   SCHULER W, 1988, EMBO J, V7, P2019, DOI 10.1002/j.1460-2075.1988.tb03041.x
   SCHULER W, 1986, CELL, V46, P963, DOI 10.1016/0092-8674(86)90695-1
   SCHULER W, 1990, CYTOKINES, V3, P132
   SPIESS S, 1993, IMMUNOLOGY, V78, P252
NR 35
TC 4
Z9 4
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0953-8178
EI 1460-2377
J9 INT IMMUNOL
JI Int. Immunol.
PD JUN
PY 1993
VL 5
IS 6
BP 639
EP 646
DI 10.1093/intimm/5.6.639
PG 8
WC Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology
GA LJ998
UT WOS:A1993LJ99800010
PM 8394109
DA 2024-02-19
ER

PT J
AU Fabrizi, F
   Donato, MF
   Cerutti, R
   Invernizzi, F
   Porata, G
   Frontini, G
   Raffiotta, F
   De Feo, T
   Alfieri, CM
   Lampertico, P
   Rossi, G
   Messa, P
AF Fabrizi, Fabrizio
   Donato, Maria F.
   Cerutti, Roberta
   Invernizzi, Federica
   Porata, Giulia
   Frontini, Giulia
   Raffiotta, Francesca
   De Feo, Tullia
   Alfieri, Carlo M.
   Lampertico, Pietro
   Rossi, Giorgio
   Messa, Piergiorgio
TI Acute kidney injury and chronic kidney disease after liver transplant: A
   retrospective observational study
SO NEFROLOGIA
LA English
DT Article; Early Access
DE Acute kidney injury; Chronic kidney disease; Liver transplantation;
   Solid organ transplantation; Viral hepatitis
ID STAGE RENAL-DISEASE; RISK-FACTORS; EPIDEMIOLOGY; DYSFUNCTION; MORTALITY;
   FAILURE; IMPACT
AB Background and rationale: Chronic kidney disease remains an important risk factor for morbidity and mortality among LT recipients, but its exact incidence and risk factors are still unclear.
   Material and methods: We carried out a retrospective cohort study of consecutive adults who underwent liver transplant (January 2009-December 2018) and were followed (at least 6 months) at our institution. CKD was defined following the Kidney Disease: Improving Global Outcomes (KDIGO) 2012 Clinical Practice Guidelines. Long-term kidney function was classified into 4 groups: no CKD (eGFR, >= 60 mL/min/1.73 m(2)), mild CKD (eGFR, 30-59 mL/min/1.73 m(2)), severe CKD (eGFR, 15-29 mL/min/1.73 m(2)), and end-stage renal disease (ESRD).
   Results: We enrolled 410 patients followed for 53.2 +/- 32.6 months. 39 had CKD at baseline, and 95 developed de novo CKD over the observation period. There were 184 (44.9%) anti-HCV positive, 47 (11.5%) HBsAg positive, and 33 (8.1%) HBV/HDV positive recipients. Recipient risk factors for baseline CKD were advanced age (P = 0.044), raised levels of serum uric acid (P < 0.0001), and insulin dependent DM (P = 0.0034). Early post-transplant AKI was common (n=95); logistic regression analysis found that baseline serum creatinine was an independent predictor of early post-LT AKI (P = 0.0154). According to our Cox proportional hazards model, recipient risk factors for de novo CKD included aging (P < 0.0001), early post-transplant AKI (P = 0.007), and baseline serum creatinine (P = 0.0002). At the end of follow-up, there were 116 LT recipients with CKD - 109 (93.9%) and 7 (6.1%) had stage 3 and advanced CKD, respectively. Only two of them are undergoing long-term dialysis.
   Conclusion: The incidence of CKD was high in our cohort of LT recipients, but only a slight decline in kidney function over time was recorded. Prevention of post-transplant AKI will improve kidney function in the long run. We need more studies to analyze the function of kidneys among LT recipients over extended follow-ups and their impact on mortality. (C) 2021 Sociedad Espanola de Nefrologia. Published by Elsevier Espana, S.L.U.
C1 [Fabrizi, Fabrizio; Cerutti, Roberta; Porata, Giulia; Frontini, Giulia; Raffiotta, Francesca; Alfieri, Carlo M.; Messa, Piergiorgio] Maggiore Policlin Hosp, Div Nephrol Dialysis & Renal Transplantat, Milan, Italy.
   [Fabrizi, Fabrizio; Donato, Maria F.; Cerutti, Roberta; Invernizzi, Federica; Porata, Giulia; Frontini, Giulia; Raffiotta, Francesca; De Feo, Tullia; Alfieri, Carlo M.; Lampertico, Pietro; Rossi, Giorgio; Messa, Piergiorgio] Ca Granda IRCCS Fdn, Milan, Italy.
   [Donato, Maria F.; Invernizzi, Federica; Lampertico, Pietro] Maggiore Policlin Hosp, Div Gastroenterol & Hepatol, Milan, Italy.
   [De Feo, Tullia] Maggiore Policlin Hosp, Organ & Tissue Transplantat Immunol, North Italy Transplant Program, Milan, Italy.
   [Rossi, Giorgio] Maggiore Policlin Hosp, Hepatobiliary & Liver Transplant Unit, Milan, Italy.
   [Alfieri, Carlo M.; Lampertico, Pietro; Rossi, Giorgio; Messa, Piergiorgio] Univ Sch Med, Milan, Italy.
C3 IRCCS Ca Granda Ospedale Maggiore Policlinico; IRCCS Ca Granda Ospedale
   Maggiore Policlinico; IRCCS Ca Granda Ospedale Maggiore Policlinico;
   IRCCS Ca Granda Ospedale Maggiore Policlinico; IRCCS Ca Granda Ospedale
   Maggiore Policlinico
RP Fabrizi, F (corresponding author), Maggiore Policlin Hosp, Div Nephrol Dialysis & Renal Transplantat, Milan, Italy.; Fabrizi, F (corresponding author), Ca Granda IRCCS Fdn, Milan, Italy.
EM fabrizio.fabrizi@policlinico.mi.it
RI Donato, Maria francesca/AAC-2372-2019; Lampertico, Pietro/J-8463-2018;
   Invernizzi, Federica/AAC-3820-2022
OI Lampertico, Pietro/0000-0002-1026-7476; 
CR Abdel-Khalek EE, 2018, J TRANSPLANT, V2018, DOI 10.1155/2018/5910372
   Allen AM, 2014, J HEPATOL, V61, P286, DOI 10.1016/j.jhep.2014.03.034
   Ayhan A, 2017, EXP CLIN TRANSPLANT, V15, P258, DOI 10.6002/ect.mesot2016.P126
   Bahirwani R, 2014, CLIN TRANSPLANT, V28, P205, DOI 10.1111/ctr.12298
   Basile DP, 2001, AM J PHYSIOL-RENAL, V281, pF887, DOI 10.1152/ajprenal.0050.2001
   Bloom RD, 2007, J AM SOC NEPHROL, V18, P3031, DOI 10.1681/ASN.2007040394
   Bucaloiu ID, 2012, KIDNEY INT, V81, P477, DOI 10.1038/ki.2011.405
   Burra P, 2009, DIGEST LIVER DIS, V41, P350, DOI 10.1016/j.dld.2008.09.018
   Cerdá J, 2015, CLIN J AM SOC NEPHRO, V10, P1859, DOI 10.2215/CJN.01170215
   de Boccardo G, 2008, TRANSPL P, V40, P1498, DOI 10.1016/j.transproceed.2008.03.099
   Durand F, 2018, TRANSPLANTATION, V102, P1636, DOI 10.1097/TP.0000000000002305
   Fabrizi F, 2017, CLIN LIVER DIS, V21, P303, DOI 10.1016/j.cld.2016.12.005
   Fabrizi F, 2011, DIGEST DIS SCI, V56, P1282, DOI 10.1007/s10620-010-1529-2
   Fabrizi F, 2010, INT J ARTIF ORGANS, V33, P803
   Giusto M, 2013, TRANSPLANTATION, V95, P1148, DOI 10.1097/TP.0b013e3182884890
   Horvatits T, 2018, UNITED EUR GASTROENT, V6, P104, DOI 10.1177/2050640617707089
   Herrero JI, 2018, REV ESP ENFERM DIG, V110, P538, DOI 10.17235/reed.2018.5431/2017
   Kalisvaart M, 2019, LIVER TRANSPLANT, V25, P922, DOI 10.1002/lt.25468
   KDIGO, 2013, Kidney Int, V3, P1, DOI DOI 10.1038/KISUP.2012.73
   Khwaja A, 2012, NEPHRON CLIN PRACT, V120, pC179, DOI 10.1159/000339789
   Lee JP, 2010, NEPHROL DIAL TRANSPL, V25, P2772, DOI 10.1093/ndt/gfq093
   Lee K, 2020, ANN SURG TREAT RES, V99, P52, DOI 10.4174/astr.2020.99.1.52
   Leek RB, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0219856
   Levey AS, 2009, ANN INTERN MED, V150, P604, DOI 10.7326/0003-4819-150-9-200905050-00006
   Li LC, 2017, BMC GASTROENTEROL, V17, DOI 10.1186/s12876-017-0611-z
   Li YH, 2018, EXP THER MED, V15, P3589, DOI 10.3892/etm.2018.5823
   Meraz-Muñoz A, 2019, REV GASTROENTEROL ME, V84, P57, DOI 10.1016/j.rgmx.2018.07.002
   Morath C, 2018, TRANSPLANTATION, V102, P845, DOI 10.1097/TP.0000000000002023
   O'Riordan A, 2010, TRANSPLANTATION, V89, P1378, DOI 10.1097/TP.0b013e3181d9e195
   Ojo AO, 2003, NEW ENGL J MED, V349, P931, DOI 10.1056/NEJMoa021744
   Pan HC, 2016, BMC SURG, V16, DOI 10.1186/s12893-016-0176-8
   Park JM, 2018, LIVER TRANSPLANT, V24, P1288, DOI 10.1002/lt.25302
   Provenzano M, 2019, REV CARDIOVASC MED, V20, P209, DOI 10.31083/j.rcm.2019.04.548
   Sampaio MS, 2014, CLIN LIVER DIS, V18, P543, DOI 10.1016/j.cld.2014.05.003
   Shaffi K, 2014, AM J KIDNEY DIS, V63, P1007, DOI 10.1053/j.ajkd.2014.01.436
   Sharma P, 2011, AM J TRANSPLANT, V11, P2372, DOI 10.1111/j.1600-6143.2011.03703.x
   Sharma P, 2015, ADV CHRONIC KIDNEY D, V22, P404, DOI 10.1053/j.ackd.2015.06.001
   Sharma P, 2013, J AM SOC NEPHROL, V24, P2045, DOI 10.1681/ASN.2013040436
   von Elm E, 2007, PREV MED, V45, P247, DOI 10.1016/j.ypmed.2007.08.012
   Watt KDS, 2010, AM J TRANSPLANT, V10, P1420, DOI 10.1111/j.1600-6143.2010.03126.x
   World Health Organization Council for International Organizations of Medical Sciences, 2016, INT ETH GUID HLTH RE, V4a
NR 41
TC 2
Z9 2
U1 5
U2 11
PU SOC ESPANOLA NEFROLOGIA DR RAFAEL MATESANZ
PI SANTANDER
PA C/PASAJE DE PENA 2, 3-C, SANTANDER, SPAIN
SN 0211-6995
EI 1989-2284
J9 NEFROLOGIA
JI Nefrologia
PD 2022 JAN-FEB
PY 2022
VL 42
IS 1
BP 27
EP 35
DI 10.1016/j.nefro.2021.01.009
EA JAN 2022
PG 9
WC Urology & Nephrology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Urology & Nephrology
GA ZQ6SG
UT WOS:000767232000005
PM 34112530
OA gold, Green Published
DA 2024-02-19
ER

PT J
AU Lee, DU
   Ponder, R
   Lee, KJ
   Chou, H
   Lee, K
   Jung, D
   Fan, GH
   Urrunaga, NH
AF Lee, David Uihwan
   Ponder, Reid
   Lee, Ki Jung
   Chou, Harrison
   Lee, Keeseok
   Jung, Daniel
   Fan, Gregory Hongyuan
   Urrunaga, Nathalie Helen
TI The prognostic relationship between donor age and infectious risk in
   liver transplant patients with nonalcoholic steatohepatitis: Analysis of
   UNOS database
SO DIGESTIVE AND LIVER DISEASE
LA English
DT Article; Early Access
DE Advancing donor age; Aging and frailty; Liver-transplants; NASH;
   Post-transplant prognosis
ID FIBROSIS PROGRESSION; GRAFT-SURVIVAL; RECIPIENTS
AB Background & Aims: We investigate the effects of advancing donor age on the prognostic outcomes of patients with NASH who undergo liver transplant (LT), with a specialized attention toward infectious outcomes post-LT. Methods: The UNOS-STAR registry was used to select 2005 to 2019 LT recipients with NASH, who were stratified by donor age into the following categories: recipients with younger donors (less than 50 years of age-reference), quinquagenarian donors, sexagenarian donors, septuagenarian donors, and octogenarian donors. Cox regression analyses were conducted for all-cause mortality, graft failure, infectious causes of death. Results: From a total of 8888 recipients, the quinquagenarian, septuagenarian, and octogenarian donor cohorts showed greater risk of all-cause mortality (quinquagenarian: aHR 1.16 95%CI 1.03-1.30; septuagenarian: aHR 1.20 95%CI 1.00-1.4 4; octogenarian: aHR 2.01 95%CI 1.40-2.88). With advancing donor age, there was an increased risk of death from sepsis (quinquagenarian: aHR 1.71 95% CI 1.24-2.36; sexagenarian: aHR 1.73 95% CI 1.21-2.48; septuagenarian: aHR 1.76 95% CI 1.07-2.90; octogenarian: aHR 3.58 95% CI 1.42-9.06) and infectious causes (quinquagenarian: aHR 1.46 95% CI 1.12-1.90; sexagenarian: aHR 1.58 95% CI 1.18-2.11; septuagenarian: aHR 1.73 95% CI 1.15-2.61; octogenarian: aHR 3.70 95% CI 1.78-7.69). Conclusion: NASH patients who receive grafts from elderly donors exhibit higher risk of post-LT mortality, especially due to infection. & COPY; 2023 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.
C1 [Lee, David Uihwan; Urrunaga, Nathalie Helen] Univ Maryland, Sch Med, Div Gastroenterol & Hepatol, Baltimore, MD 21201 USA.
   [Ponder, Reid; Lee, Ki Jung; Chou, Harrison; Lee, Keeseok; Fan, Gregory Hongyuan] Tufts Univ, Sch Med, Dept Med, Boston, MA USA.
   [Jung, Daniel] Univ Missouri, Kansas City Sch Med, Dept Med, Kansas City, MO USA.
C3 University System of Maryland; University of Maryland Baltimore; Tufts
   University; University of Missouri System; University of Missouri Kansas
   City
RP Lee, DU (corresponding author), Univ Maryland, Sch Med, Div Gastroenterol & Hepatol, Baltimore, MD 21201 USA.
EM dlee4@som.umaryland.edu
OI Lee, KeeSeok/0000-0002-6637-3649
CR Adam R, 2015, AM J TRANSPLANT, V15, P1267, DOI 10.1111/ajt.13171
   Anderson CD, 2008, J AM COLL SURGEONS, V207, P847, DOI 10.1016/j.jamcollsurg.2008.08.009
   Bilzer M, 2006, LIVER INT, V26, P1175, DOI 10.1111/j.1478-3231.2006.01342.x
   Castello B, 2019, ANN HEPATOL, V18, P855, DOI 10.1016/j.aohep.2019.06.014
   Cuervas-Mons V, 2015, MED CLIN-BARCELONA, V144, P337, DOI 10.1016/j.medcli.2014.07.036
   Devlin J, 2021, arXiv
   Doycheva I, 2018, J CLIN GASTROENTEROL, V52, P339, DOI 10.1097/MCG.0000000000000925
   Fine JP, 1999, J AM STAT ASSOC, V94, P496, DOI 10.2307/2670170
   Gayowski T, 1998, TRANSPLANTATION, V65, P499, DOI 10.1097/00007890-199802270-00008
   Gil E, 2018, TRANSPLANTATION, V102, P2025, DOI 10.1097/TP.0000000000002246
   Gressner A M, 1992, Z Gastroenterol, V30 Suppl 1, P5
   Heyens LJM, 2021, FRONT MED-LAUSANNE, V8, DOI 10.3389/fmed.2021.615978
   Hibi T, 2011, TRANSPLANTATION, V92, P100, DOI 10.1097/TP.0b013e31821dcae3
   Hunt NJ, 2019, COMPUT STRUCT BIOTEC, V17, P1151, DOI 10.1016/j.csbj.2019.07.021
   Katsarou A, 2020, WORLD J GASTROENTERO, V26, P1993, DOI 10.3748/wjg.v26.i17.1993
   KOSUGI I, 1992, J HEPATOL, V16, P106, DOI 10.1016/S0168-8278(05)80102-3
   Kubota T, 2018, ANN SURG, V267, P1126, DOI 10.1097/SLA.0000000000002194
   Levy G, 2006, LIVER TRANSPLANT, V12, P1464, DOI 10.1002/lt.20802
   Machicao VI, 2004, TRANSPLANTATION, V77, P84, DOI 10.1097/01.TP.0000095896.07048.BB
   Maeso-Díaz R, 2018, AGING CELL, V17, DOI 10.1111/acel.12829
   Nagai S, 2019, CLIN GASTROENTEROL H, V17, P2759, DOI 10.1016/j.cgh.2019.04.033
   O'Grady J, 2014, J HEPATOL, V60, P663, DOI 10.1016/j.jhep.2013.10.024
   Potosek J, 2014, J PALLIAT MED, V17, P1271, DOI 10.1089/jpm.2013.0167
   Schultz GS, 2009, WOUND REPAIR REGEN, V17, P153, DOI 10.1111/j.1524-475X.2009.00466.x
   Selicean S, 2021, HEPATOL INT, V15, P36, DOI 10.1007/s12072-021-10135-4
   Stahl EC, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02795
   Sullivan WJ, 2018, CELL, V175, P117, DOI 10.1016/j.cell.2018.08.017
   Terrault NA, 2012, LIVER TRANSPLANT, V18, P716, DOI 10.1002/lt.23411
   VANDENBROUCKE JP, 1991, BRIT MED J, V302, P249, DOI 10.1136/bmj.302.6771.249
   VanWagner LB, 2015, LIVER INT, V35, P2575, DOI 10.1111/liv.12872
   Videla LA, 2001, REDOX REP, V6, P155, DOI 10.1179/135100001101536265
   Wali M, 2002, GUT, V51, P248, DOI 10.1136/gut.51.2.248
   Wong RJ, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2019.20294
   Zhou J, 2021, BMC GASTROENTEROL, V21, DOI 10.1186/s12876-021-01786-6
   Zipprich A, 2012, LIVER INT, V32, P1407, DOI 10.1111/j.1478-3231.2012.02830.x
NR 35
TC 0
Z9 0
U1 2
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1590-8658
EI 1878-3562
J9 DIGEST LIVER DIS
JI Dig. Liver Dis.
PD 2023 JUN
PY 2023
VL 55
IS 6
BP 751
EP 762
DI 10.1016/j.dld.2023.01.160
EA MAY 2023
PG 12
WC Gastroenterology & Hepatology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Gastroenterology & Hepatology
GA K0FG1
UT WOS:001013286500001
PM 36797144
DA 2024-02-19
ER

PT J
AU Duran-Sandoval, D
   Mautino, G
   Martin, GV
   Percevault, F
   Barbier, O
   Fruchart, JC
   Kuipers, F
   Staels, B
AF Duran-Sandoval, D
   Mautino, G
   Martin, GV
   Percevault, F
   Barbier, O
   Fruchart, JC
   Kuipers, F
   Staels, B
TI Glucose regulates the expression of the farnesoid X receptor in liver
SO DIABETES
LA English
DT Article
ID ORPHAN NUCLEAR RECEPTOR; PYRUVATE-KINASE GENE; PENTOSE-PHOSPHATE
   PATHWAY; BILE-ACID SYNTHESIS; ACTIVATED RECEPTOR;
   CHOLESTEROL-METABOLISM; TRANSCRIPTION FACTOR; GALLBLADDER-DISEASE;
   RESPONSE ELEMENT; RAT HEPATOCYTES
AB An increased prevalence of hypertriglyceridemia and gallbladder disease occurs in patients with diabetes or insulin resistance. Hypertriglyceridemia is positively associated to gall bladder disease risk. The farnesoid X receptor (FXR) is a bile acid-activated nuclear receptor that plays a key role in bile acid and triglyceride homeostasis. The mechanisms controlling FXR gene expression are poorly understood. This study evaluated whether FXR gene expression is regulated by alterations in glucose homeostasis. FXR expression was decreased in livers of streptozotocin-induced diabetic rats and normalized upon insulin supplementation. Concomitantly with diabetes progression, FXR expression also decreased in aging diabetic Zucker rats. In primary rat hepatocytes, D-glucose increased FXR mRNA in a dose- and time-dependent manner, whereas insulin counteracted this effect. Addition of xylitol, a precursor of xylulose-5-phosphate, to primary rat hepatocytes increased FXR expression to a comparable level as D-glucose. Finally, expression of the FXR target genes, SHP and apolipoprotein C-III, were additively regulated by D-glucose and FXR ligands. This study demonstrates that FXR is decreased in animal models of diabetes. In addition, FXR is regulated by glucose likely via the pentose phosphate pathway. Dysregulation of FXR expression may contribute to alterations in lipid and bile acid metabolism in patients with diabetes or insulin resistance.
C1 Inst Pasteur, INSERM, UR 545, Atherosclerosis Dept, F-59019 Lille, France.
   Univ Lille, Fac Pharm, F-59019 Lille, France.
   Genfit SA, Loos, France.
   Univ Groningen, Univ Med Ctr Groningen, Ctr Liver Digest & Metab Dis, Pediat Lab, Groningen, Netherlands.
C3 Le Reseau International des Instituts Pasteur (RIIP); Universite de
   Lille; Institut Pasteur Lille; Institut National de la Sante et de la
   Recherche Medicale (Inserm); Universite de Lille; University of
   Groningen
RP Staels, B (corresponding author), Inst Pasteur, INSERM, UR 545, Atherosclerosis Dept, 1 Rue Prof Calmette BP245, F-59019 Lille, France.
EM bart.staels@pasteur-fille.fr
RI Staels, Bart/JAZ-0644-2023; percevault, frederic/K-1836-2015; Staels,
   Bart/N-9497-2016; Kuipers, Folkert/JZD-2819-2024
OI Staels, Bart/0000-0002-3784-1503; Staels, Bart/0000-0002-3784-1503;
   Kuipers, Folkert/0000-0003-2518-737X; Barbier,
   Olivier/0000-0002-3067-1134
CR Ananthanarayanan M, 2001, J BIOL CHEM, V276, P28857, DOI 10.1074/jbc.M011610200
   ANDERSEN E, 1987, DIABETES RES CLIN PR, V3, P207, DOI 10.1016/S0168-8227(87)80041-4
   Barbier O, 2003, GASTROENTEROLOGY, V124, P1926, DOI 10.1016/S0016-5085(03)00388-3
   BENNION LJ, 1977, NEW ENGL J MED, V296, P1365, DOI 10.1056/NEJM197706162962401
   Blanquart C, 2002, J BIOL CHEM, V277, P37254, DOI 10.1074/jbc.M110598200
   Boland LL, 2002, ANN EPIDEMIOL, V12, P131, DOI 10.1016/S1047-2797(01)00260-5
   Claudel T, 2002, J CLIN INVEST, V109, P961
   Claudel T, 2003, GASTROENTEROLOGY, V125, P544, DOI 10.1016/S0016-5085(03)00896-5
   DECAUX JF, 1989, J BIOL CHEM, V264, P11584
   Denson LA, 2001, GASTROENTEROLOGY, V121, P140, DOI 10.1053/gast.2001.25503
   DeSantis A, 1997, HEPATOLOGY, V25, P787, DOI 10.1002/hep.510250401
   DILLS WL, 1994, PROTEIN EXPRES PURIF, V5, P259, DOI 10.1006/prep.1994.1039
   Doiron B, 1996, J BIOL CHEM, V271, P5321, DOI 10.1074/jbc.271.10.5321
   Foretz M, 1999, MOL CELL BIOL, V19, P3760
   FORMAN BM, 1995, CELL, V81, P687, DOI 10.1016/0092-8674(95)90530-8
   Goodwin B, 2000, MOL CELL, V6, P517, DOI 10.1016/S1097-2765(00)00051-4
   Grober J, 1999, J BIOL CHEM, V274, P29749, DOI 10.1074/jbc.274.42.29749
   Gustafson LA, 2001, BIOCHEM J, V358, P665, DOI 10.1042/0264-6021:3580665
   Kast HR, 2002, J BIOL CHEM, V277, P2908, DOI 10.1074/jbc.M109326200
   Kast HR, 2001, MOL ENDOCRINOL, V15, P1720, DOI 10.1210/me.15.10.1720
   Kim MS, 2003, J BIOL CHEM, V278, P8988, DOI 10.1074/jbc.M212633200
   Kolm-Litty V, 1998, J CLIN INVEST, V101, P160, DOI 10.1172/JCI119875
   Laffitte BA, 2000, J BIOL CHEM, V275, P10638, DOI 10.1074/jbc.275.14.10638
   Lambert G, 2003, J BIOL CHEM, V278, P2563, DOI 10.1074/jbc.M209525200
   LEFRANCOISMARTINEZ AM, 1995, J BIOL CHEM, V270, P2640, DOI 10.1074/jbc.270.6.2640
   Liu YQ, 1996, J BIOL CHEM, V271, P8824, DOI 10.1074/jbc.271.15.8824
   Lou DQ, 1999, J BIOL CHEM, V274, P28385, DOI 10.1074/jbc.274.40.28385
   Lu TT, 2000, MOL CELL, V6, P507, DOI 10.1016/S1097-2765(00)00050-2
   Mak PA, 2002, J LIPID RES, V43, P2037, DOI 10.1194/jlr.C200014-JLR200
   Makishima M, 1999, SCIENCE, V284, P1362, DOI 10.1126/science.284.5418.1362
   Maloney PR, 2000, J MED CHEM, V43, P2971, DOI 10.1021/jm0002127
   Massillon D, 1998, J BIOL CHEM, V273, P228, DOI 10.1074/jbc.273.1.228
   Nawano M, 2000, AM J PHYSIOL-ENDOC M, V278, pE535, DOI 10.1152/ajpendo.2000.278.3.E535
   NISHIMURA M, 1995, J BIOL CHEM, V270, P26341, DOI 10.1074/jbc.270.44.26341
   Parks DJ, 1999, SCIENCE, V284, P1365, DOI 10.1126/science.284.5418.1365
   Peterson R.G., 1990, ILAR News, V32, P16, DOI DOI 10.1093/ILAR.32.3.16
   Ruhl CE, 2000, HEPATOLOGY, V31, P299, DOI 10.1002/hep.510310206
   SEOL WG, 1995, MOL ENDOCRINOL, V9, P72, DOI 10.1210/me.9.1.72
   Shih DQ, 2001, NAT GENET, V27, P375, DOI 10.1038/86871
   Sinal CJ, 2000, CELL, V102, P731, DOI 10.1016/S0092-8674(00)00062-3
   Torra IP, 2000, ENDOCRINOLOGY, V141, P3799, DOI 10.1210/en.141.10.3799
   Torra IP, 2003, MOL ENDOCRINOL, V17, P259, DOI 10.1210/me.2002-0120
   TWISK J, 1995, HEPATOLOGY, V21, P501, DOI 10.1016/0270-9139(95)90113-2
   Urizar NL, 2000, J BIOL CHEM, V275, P39313, DOI 10.1074/jbc.M007998200
   van Waarde WM, 2002, GASTROENTEROLOGY, V122, P1842, DOI 10.1053/gast.2002.33582
   Vaulont S, 2000, J BIOL CHEM, V275, P31555, DOI 10.1074/jbc.R000016200
   Wang HB, 1999, MOL CELL, V3, P543, DOI 10.1016/S1097-2765(00)80348-2
   Xu GR, 2002, J BIOL CHEM, V277, P50491, DOI 10.1074/jbc.M209176200
   Yamashita H, 2001, P NATL ACAD SCI USA, V98, P9116, DOI 10.1073/pnas.161284298
NR 49
TC 203
Z9 231
U1 2
U2 16
PU AMER DIABETES ASSOC
PI ALEXANDRIA
PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA
SN 0012-1797
J9 DIABETES
JI Diabetes
PD APR
PY 2004
VL 53
IS 4
BP 890
EP 898
DI 10.2337/diabetes.53.4.890
PG 9
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Endocrinology & Metabolism
GA 809AE
UT WOS:000220608800003
PM 15047603
OA Bronze
DA 2024-02-19
ER

PT J
AU SUGIYAMA, K
   SUGIMURA, T
   ESUMI, H
AF SUGIYAMA, K
   SUGIMURA, T
   ESUMI, H
TI DEFECTIVE SECRETION OF ALBUMIN ENCODED BY EXON-SKIPPED MESSENGER-RNA
   FOUND IN AGED ANALBUMINEMIC RAT-LIVER
SO EUROPEAN JOURNAL OF CELL BIOLOGY
LA English
DT Article
DE ANALBUMINEMIC RAT; ALBUMIN; ALTERNATIVE SPLICING; AGING; TRANSFECTION
ID ENDOPLASMIC-RETICULUM; SOMATIC REVERSION; BRATTLEBORO RAT; PROTEINS;
   ACCUMULATION; EXPRESSION; PRECURSORS; PHENOTYPE; INCREASE; SIGNAL
AB Remarkable increases in the amounts of exon H-skipped (DELTAH), exons G and H-skipped (DELTAGH), and exons H and I-skipped (DELTAHI) mRNAs of rat albumin have been found in the livers of aged or mutagen-treated analbuminemic rats (Kaneko, T., H. Shima, H. Esumi, M. Ochiai, S. Nagase, T. Sugimura, M. Nagao: Proc. Natl. Acad. Sci. USA 98, 2707-2711 (1991)), in association with increases in numbers of immunohistochemically albumin-positive hepatocytes and the accumulation of albumin(s) in the cells. To determine which type of mRNA is responsible for the accumulation of albumin(s), expression vector systems for intact mRNA and three kinds of exon-skipped albumin mRNAs were constructed and transfected into COS-1 and HepG2 cells. Transient expression and secretion of albumins were examined in these cells. DELTAHI albumin and intact albumin were efficiently expressed by both types of transfected cells. The DELTAHI albumin expressed had a similar molecular weight to the major albumin isolated from the microsome fraction of the liver of aged analbuminemic rats, as judged by SDS-PAGE. The rate of secretion of DELTAHI albumin was very low in both types of transfected cells, whereas those of DELTAH and DELTAGH albumins were normal.
   Immunocytochemical analyses of the transfected COS-1 cells with antiserum against rat albumin showed that the distribution of intact albumin had a compact Golgi-like pattern, whereas that of DELTAHI albumin had a diffuse endoplasmic reticulum-like pattern. These distribution patterns were similar to those in aged analbuminemic rat hepatocytes. These findings suggest that the albumin accumulated in the hepatocytes of aged and carcinogen-treated analbuminemic rats is DELTAHI albumin.
RP SUGIYAMA, K (corresponding author), NATL CANC CTR,RES INST,DIV BIOCHEM,5-1-1 TSUKIJI,CHUO KU,TOKYO 104,JAPAN.
CR BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5
   BURROW KL, 1991, NEUROLOGY, V41, P661, DOI 10.1212/WNL.41.5.661
   CATALDO AM, 1991, P NATL ACAD SCI USA, V88, P10998, DOI 10.1073/pnas.88.24.10998
   CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745
   ESUMI H, 1983, P NATL ACAD SCI-BIOL, V80, P95, DOI 10.1073/pnas.80.1.95
   ESUMI H, 1979, BIOCHEM BIOPH RES CO, V87, P1191, DOI 10.1016/S0006-291X(79)80033-9
   ESUMI H, 1982, P NATL ACAD SCI-BIOL, V79, P734, DOI 10.1073/pnas.79.3.734
   FRANSEN JAM, 1991, J CELL BIOL, V115, P45, DOI 10.1083/jcb.115.1.45
   FUJIWARA T, 1988, J BIOL CHEM, V263, P18545
   GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369
   HOFFMAN EP, 1990, J NEUROL SCI, V99, P9, DOI 10.1016/0022-510X(90)90195-S
   IVELL R, 1990, FRONT NEUROENDOCRIN, V11, P313
   KANEKO T, 1991, P NATL ACAD SCI USA, V88, P2707, DOI 10.1073/pnas.88.7.2707
   LE A, 1990, J BIOL CHEM, V265, P14001
   LIPPINCOTTSCHWARTZ J, 1991, CELL, V67, P601, DOI 10.1016/0092-8674(91)90534-6
   MAKINO R, 1986, JPN J CANCER RES, V77, P153
   MAQUAT LE, 1981, CELL, V27, P543, DOI 10.1016/0092-8674(81)90396-2
   NAGASE S, 1979, SCIENCE, V205, P590, DOI 10.1126/science.451621
   PELHAM HRB, 1990, TRENDS BIOCHEM SCI, V15, P483, DOI 10.1016/0968-0004(90)90303-S
   ROSENBERGER RF, 1991, MUTAT RES, V256, P255, DOI 10.1016/0921-8734(91)90016-5
   SAMBROOK J, 1989, MOL CLONING LAB MANU, P18
   SHALABY F, 1990, P NATL ACAD SCI USA, V87, P2652, DOI 10.1073/pnas.87.7.2652
   TANAKA H, 1990, EUR J CELL BIOL, V53, P267
   TANAKA S, 1992, MOL BRAIN RES, V15, P305
   VANLEEUWEN F, 1989, P NATL ACAD SCI USA, V86, P6417, DOI 10.1073/pnas.86.16.6417
NR 25
TC 1
Z9 1
U1 0
U2 0
PU WISSENSCHAFTLICHE VERLAG MBH
PI STUTTGART
PA BIRKENWALDSTRASSE 44, POSTFACH 10 10 61, 70009 STUTTGART, GERMANY
SN 0171-9335
J9 EUR J CELL BIOL
JI Eur. J. Cell Biol.
PD AUG
PY 1993
VL 61
IS 2
BP 239
EP 246
PG 8
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA LW951
UT WOS:A1993LW95100005
PM 8223714
DA 2024-02-19
ER

PT J
AU Gao, SQ
   Ramen, K
   Yu, SA
   Luo, JS
AF Gao, Shengqiang
   Ramen, Kuvaneshan
   Yu, Shian
   Luo, Jiansheng
TI Higher non-HDL-cholesterol to HDL-cholesterol ratio is linked to
   increase in non-alcoholic fatty liver disease: secondary analysis based
   on a longitudinal study
SO INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY
LA English
DT Article
DE Non-HDLc/HDLc ratio; prospective study; fatty liver disease
ID NAFLD; STEATOHEPATITIS; POPULATION; PREVALENCE
AB Background: Non-high-density lipoprotein cholesterol (non-HDLc) to HDLc ratio (non-HDLc/HDLc), is a viable predictor of metabolic syndrome, insulin resistance, and other cardiac diseases. The study aimed to assess whether non-HDLC/HDLc ratio is an independent predictor of NAFLD. Methods: The present study was a longitudinal study, involving 16173 Chinese men and women, aging 14-95 years old, who received a medical check-up program in a health examination Center in China. A total of 16173 initially NAFLD-free non-obese individuals were included, who completed a 5-year follow-up examination in the longitudinal study. NAFLD was defined by ultrasonographic detection of steatosis in the absence of other liver disease. Univariate and multivariate Cox proportional hazards analyses were used to assess the association between nonHDLC/HDLc and NAFLD. ROC curve analysis was performed to compare the predictive value between the nonHDLc/HDLc and the nonHDLc for NAFLD. Results: During the five-year follow-up period, a total of 2322 participants (14.4%) developed NAFLD. The HRs for NAFLD in the longitudinal population were 1.3 (95% CI 1.1 to 1.7) and 1.5 (95% CI 1.1 to 2.0) compared with Q1. AUC values for nonHDLc/HDLc ratios (0.705) were significantly higher than nonHDLc (0.656) (P<0.05), while the cut-off value for the detection of NAFLD was 2.26. Individuals with higher nonHDLc/HDLc ratio had an increased cumulative incidence rate of NAFLD in non-obese individuals. Conclusion: The Non-HDLc ratio/HDLc is an independent predictor of NAFLD. This may help with early identification of high-risk individuals.
C1 [Gao, Shengqiang; Yu, Shian; Luo, Jiansheng] Zhejiang Univ, Affiliated Jinhua Hosp, Sch Med, Dept Hepatobiliary & Pancreat Surg, Jinhua 321000, Zhejiang, Peoples R China.
   [Ramen, Kuvaneshan] Dept Hepatobiliary & Pancreat Surg, Vacoas Phoenix, Mauritius.
C3 Zhejiang University
RP Luo, JS (corresponding author), Zhejiang Univ, Affiliated Jinhua Hosp, Sch Med, Dept Hepatobiliary & Pancreat Surg, Jinhua 321000, Zhejiang, Peoples R China.
EM luojsheng@126.com
RI Stefanadis, Christodoulos/ABH-2232-2020
OI Stefanadis, Christodoulos/0000-0001-5974-6454
FU Fund of Zhejiang Medical and Health Science and Technology Plan Project
   Platform [2018244976]; Major Projects of Jinhua Science and Technology
   Bureau [2018-3-001a]
FX The study was supported by the Fund of Zhejiang Medical and Health
   Science and Technology Plan Project Platform (2018244976) and Major
   Projects of Jinhua Science and Technology Bureau (2018-3-001a).
CR Browning JD, 2004, HEPATOLOGY, V40, P1387, DOI 10.1002/hep.20466
   DeFilippis AP, 2013, ATHEROSCLEROSIS, V227, P429, DOI 10.1016/j.atherosclerosis.2013.01.022
   Ducheix S, 2013, BIOCHEM PHARMACOL, V86, P96, DOI 10.1016/j.bcp.2013.03.016
   Foster T, 2013, DIGEST DIS SCI, V58, P2392, DOI 10.1007/s10620-013-2652-7
   Fujita K, 2009, HEPATOLOGY, V50, P772, DOI 10.1002/hep.23094
   Kimura Y, 2010, J GASTROENTEROL, V45, P750, DOI 10.1007/s00535-010-0203-y
   Kistler KD, 2011, AM J GASTROENTEROL, V106, P460, DOI 10.1038/ajg.2010.488
   Lamprea-Montealegre JA, 2014, ATHEROSCLEROSIS, V234, P42, DOI 10.1016/j.atherosclerosis.2014.02.006
   Loomba R, 2013, NAT REV GASTRO HEPAT, V10, P686, DOI 10.1038/nrgastro.2013.171
   Lu WQ, 2003, DIABETES CARE, V26, P16, DOI 10.2337/diacare.26.1.16
   Michelotti GA, 2013, NAT REV GASTRO HEPAT, V10, P656, DOI 10.1038/nrgastro.2013.183
   Pacifico L, 2010, HEPATOLOGY, V52, P1643, DOI 10.1002/hep.23890
   Speliotes EK, 2010, HEPATOLOGY, V51, P1979, DOI 10.1002/hep.23593
   Sun DQ, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-013781
   Tacer KF, 2011, J LIPIDS, V2011, DOI 10.1155/2011/783976
   Taskinen MR, 2010, DIABETOLOGIA, V53, P1846, DOI 10.1007/s00125-010-1806-9
   Vernon G, 2011, ALIMENT PHARM THER, V34, P274, DOI 10.1111/j.1365-2036.2011.04724.x
   Vlachopoulos C, 2010, AM J HYPERTENS, V23, P1183, DOI 10.1038/ajh.2010.144
   Williams CD, 2011, GASTROENTEROLOGY, V140, P124, DOI 10.1053/j.gastro.2010.09.038
   Younossi ZM, 2002, HEPATOLOGY, V35, P746, DOI 10.1053/jhep.2002.32483
   Zelber-Sagi S, 2014, LIVER INT, V34, pE128, DOI 10.1111/liv.12318
   Zelber-Sagi S, 2012, J HEPATOL, V56, P1145, DOI 10.1016/j.jhep.2011.12.011
   Zeng MD, 2008, J DIGEST DIS, V9, P108, DOI 10.1111/j.1751-2980.2008.00331.x
NR 23
TC 3
Z9 3
U1 0
U2 1
PU E-CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1936-2625
J9 INT J CLIN EXP PATHO
JI Int. J. Clin. Exp. Pathol.
PY 2020
VL 13
IS 10
BP 2569
EP 2575
PG 7
WC Oncology; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Pathology
GA OJ3IH
UT WOS:000583858100013
PM 33165444
DA 2024-02-19
ER

PT J
AU Babenko, NA
   Kharchenko, VS
AF Babenko, N. A.
   Kharchenko, V. S.
TI Effects of inhibitors of key enzymes of sphingolipid metabolism on
   insulin-induced glucose uptake and glycogen synthesis in liver cells of
   old rats
SO BIOCHEMISTRY-MOSCOW
LA English
DT Article
DE hepatocytes; insulin resistance; aging; myriocin; fumonisin B1;
   imipramine; GW4869
ID NECROSIS-FACTOR-ALPHA; FATTY-ACID-METABOLISM; SKELETAL-MUSCLE; CERAMIDE
   SYNTHESIS; RESISTANCE; INTERLEUKIN-1-BETA; SPHINGOMYELINASE;
   HEPATOCYTES; ACTIVATION; TURNOVER
AB Sphingolipids play an important role in the development of insulin resistance. Ceramides are the most potent inhibitors of insulin signal transduction. Ceramides are generated in response to stress stimuli and in old age. In this work, we studied the possible contribution of different pathways of sphingolipid metabolism in age-dependent insulin resistance development in liver cells. Inhibition of key enzymes of sphingolipid synthesis (serine palmitoyl transferase, ceramide synthase) and degradation (neutral and acidic SMases) by means of specific inhibitors (myriocin, fumonisin B1, imipramine, and GW4869) was followed with the reduction of ceramide level and partly improved insulin regulation of glucose metabolism in "old" hepatocytes. Imipramine and GW4869 decreased significantly the acidic and neutral SMase activities, respectively. Treatment of "old" cells with myriocin or fumonisin B1 reduced the elevated in old age ceramide and SM synthesis. Ceramide and SM levels and glucose metabolism regulation by insulin could be improved with concerted action of all tested inhibitors of sphingolipid turnover on hepatocytes. The data demonstrate that not only newly synthesized ceramide and SM but also neutral and acidic SMase-dependent ceramide accumulation plays an important role in development of agedependent insulin resistance.
C1 [Babenko, N. A.; Kharchenko, V. S.] Kharkov Karazin Natl Univ, Inst Biol, Dept Physiol Ontogenesis, UA-61077 Kharkov, Ukraine.
C3 Ministry of Education & Science of Ukraine; VN Karazin Kharkiv National
   University
RP Babenko, NA (corresponding author), Kharkov Karazin Natl Univ, Inst Biol, Dept Physiol Ontogenesis, Pl Svobody 4, UA-61077 Kharkov, Ukraine.
EM babenko@univer.kharkov.ua; kharchenko_vitalina@meta.ua
FU research program "The role of sphingomyelin cycle metabolites in the
   development of resistance of cells to physiological stimuli in the
   process of aging" [0111U010555]
FX This study was financially supported within the framework of the
   research program "The role of sphingomyelin cycle metabolites in the
   development of resistance of cells to physiological stimuli in the
   process of aging" (State registration No. 0111U010555).
CR Adams JM, 2004, DIABETES, V53, P25, DOI 10.2337/diabetes.53.1.25
   Babenko NA, 2012, BIOCHEMISTRY-MOSCOW+, V77, P180, DOI 10.1134/S0006297912020095
   Babenko N. A., 2011, SATURATED FATS METAB, P71
   Babenko NA, 2014, ARCH GERONTOL GERIAT, V58, P420, DOI 10.1016/j.archger.2013.12.005
   Babenko NA, 2012, AGE, V34, P905, DOI 10.1007/s11357-011-9288-3
   Babenko NA, 2010, EXP GERONTOL, V45, P375, DOI 10.1016/j.exger.2010.02.010
   Begum N, 1996, ENDOCRINOLOGY, V137, P2441, DOI 10.1210/en.137.6.2441
   BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911
   Bruce CR, 2004, AM J PHYSIOL-ENDOC M, V287, pE616, DOI 10.1152/ajpendo.00150.2004
   Brutman-Barazani T, 2012, J CELL BIOCHEM, V113, P2064, DOI 10.1002/jcb.24078
   Bruunsgaard H, 2002, EUR CYTOKINE NETW, V13, P389
   Chavez JA, 2003, J BIOL CHEM, V278, P10297, DOI 10.1074/jbc.M212307200
   Dobierzewska A, 2012, J BIOL CHEM, V287, P44749, DOI 10.1074/jbc.M112.378836
   Dyck DJ, 2006, ACTA PHYSIOL, V186, P5, DOI 10.1111/j.1748-1716.2005.01502.x
   Galbo T, 2013, AGING-US, V5, P582, DOI 10.18632/aging.100585
   Holland WL, 2008, ENDOCR REV, V29, P381, DOI 10.1210/er.2007-0025
   Holland WL, 2007, CELL METAB, V5, P167, DOI 10.1016/j.cmet.2007.01.002
   Kanety H, 1996, J BIOL CHEM, V271, P9895, DOI 10.1074/jbc.271.17.9895
   Kirwan JP, 2001, AM J PHYSIOL-ENDOC M, V281, pE1137, DOI 10.1152/ajpendo.2001.281.6.E1137
   Kornhuber J, 2010, CELL PHYSIOL BIOCHEM, V26, P9, DOI 10.1159/000315101
   Kralik SF, 2002, ENDOCRINOLOGY, V143, P37, DOI 10.1210/en.143.1.37
   Lagathu C, 2006, DIABETOLOGIA, V49, P2162, DOI 10.1007/s00125-006-0335-z
   Larsen PJ, 2014, MOL METAB, V3, P252, DOI 10.1016/j.molmet.2014.01.011
   Leclercq IA, 2007, J HEPATOL, V47, P142, DOI 10.1016/j.jhep.2007.04.002
   LECOUTEUR DG, 2009, GERIATR AGING, V12, P319
   Li ZQ, 2011, MOL CELL BIOL, V31, P4205, DOI 10.1128/MCB.05893-11
   Lightle SA, 2000, MECH AGEING DEV, V120, P111, DOI 10.1016/S0047-6374(00)00191-3
   Luberto C, 2002, J BIOL CHEM, V277, P41128, DOI 10.1074/jbc.M206747200
   Michael MD, 2000, MOL CELL, V6, P87, DOI 10.1016/S1097-2765(00)00010-1
   Mitsutake S, 2011, J BIOL CHEM, V286, P28544, DOI 10.1074/jbc.M111.255646
   Nov O, 2010, ENDOCRINOLOGY, V151, P4247, DOI 10.1210/en.2010-0340
   Peraldi P, 1996, J BIOL CHEM, V271, P13018, DOI 10.1074/jbc.271.22.13018
   PETRENKO AY, 1991, BIOCHEMISTRY-MOSCOW+, V56, P1160
   Pileggi A, 2004, IUBMB LIFE, V56, P387, DOI 10.1080/15216540400006469
   Powell DJ, 2004, BIOCHEM J, V382, P619, DOI 10.1042/BJ20040139
   Rikans LE, 1999, MECH AGEING DEV, V108, P173, DOI 10.1016/S0047-6374(99)00012-3
   Rutkute K, 2007, HEPATOLOGY, V46, P1166, DOI 10.1002/HEP.21777
   Skovbro M, 2008, DIABETOLOGIA, V51, P1253, DOI 10.1007/s00125-008-1014-z
   Steinberg GR, 2006, CELL METAB, V4, P465, DOI 10.1016/j.cmet.2006.11.005
   Stratford S, 2001, BIOCHEM J, V354, P359, DOI 10.1042/0264-6021:3540359
   Teruel T, 2001, DIABETES, V50, P2563, DOI 10.2337/diabetes.50.11.2563
   Ugi S, 2004, MOL CELL BIOL, V24, P8778, DOI 10.1128/MCB.24.19.8778-8789.2004
   Ussher JR, 2010, DIABETES, V59, P2453, DOI 10.2337/db09-1293
   van Sluijters DA, 1999, EUR J BIOCHEM, V266, P653, DOI 10.1046/j.1432-1327.1999.00914.x
   Wadsworth JM, 2013, J AM CHEM SOC, V135, P14276, DOI 10.1021/ja4059876
   WANG E, 1991, J BIOL CHEM, V266, P14486
   Watson ML, 2009, BIOCHEM J, V417, P791, DOI 10.1042/BJ20081149
   Yamashita T, 2003, P NATL ACAD SCI USA, V100, P3445, DOI 10.1073/pnas.0635898100
   Yang G, 2009, AM J PHYSIOL-ENDOC M, V297, pE211, DOI 10.1152/ajpendo.91014.2008
   Zeghari N, 2000, INT J OBESITY, V24, P1600, DOI 10.1038/sj.ijo.0801459
   Zhao HM, 2007, DIABETES, V56, P1210, DOI 10.2337/db06-0719
NR 51
TC 9
Z9 9
U1 0
U2 11
PU MAIK NAUKA/INTERPERIODICA/SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013-1578 USA
SN 0006-2979
EI 1608-3040
J9 BIOCHEMISTRY-MOSCOW+
JI Biochem.-Moscow
PD JAN
PY 2015
VL 80
IS 1
BP 104
EP 112
DI 10.1134/S0006297915010125
PG 9
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA AZ3TC
UT WOS:000348148500012
PM 25754045
DA 2024-02-19
ER

PT J
AU Martín, M
   Macías, M
   León, J
   Escames, G
   Khaldy, H
   Acuña-Castroviejo, D
AF Martín, M
   Macías, M
   León, J
   Escames, G
   Khaldy, H
   Acuña-Castroviejo, D
TI Melatonin increases the activity of the oxidative phosphorylation
   enzymes and the production of ATP in rat brain and liver mitochondria
SO INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
LA English
DT Article
DE melatonin; mitochondria; ATP; electron chain transport; complex I;
   complex IV; oxidative stress
ID T-BUTYL HYDROPEROXIDE; HYDROGEN-PEROXIDE; NITRIC-OXIDE; DAMAGE;
   RESPIRATION; INHIBITION; STRESS; FLUORESCENCE; REDUCTION; DISEASES
AB We recently showed that melatonin counteracted mitochondrial oxidative stress and increased the activity of the mitochondrial oxidative phosphorylation (OXPHOS) enzymes both in vivo and in vitro. To further clarify these effects, we studied here the activity of OXPHOS enzymes and the synthesis of ATP in rat liver and brain mitochondria in vitro. In sub-mitochondrial particles, melatonin increases the activity of the complexes I and IV dose-dependently, the effect being significant between I and 10 nM. Blue native-PAGE followed by histochemical analysis of the OXPHOS enzymes further showed the melatonin-induced increase of complex I activity. Titration studies show that melatonin counteracts the partial inhibition of complex IV induced by 5 muM potassium cyanide. However, melatonin (up to 5 mM) was unable to recover the activity of complex IV when it was completely blocked by 100 muM cyanide. These data suggest that the indoleamine could stimulate the activity of the non-inhibited part of the complex IV. Melatonin also increases the production of ATP in control mitochondria and counteracts the cyanide-induced inhibition of ATP synthesis. These results provide new hormonal mechanism regulating mitochondrial homeostasis and may explain, at least in part, the anti-aging and neuroprotective properties of melatonin. (C) 2002 Elsevier Science Ltd. All rights reserved.
C1 Univ Granada, Inst Biotecnol, Dept Fisiol, E-18012 Granada, Spain.
C3 University of Granada
EM dacuna@ugr.es
RI Acuña-Castroviejo, Dario/N-7456-2016; Belkadi, Hoda Khaldy/I-4161-2015;
   Escames, Germaine/N-7501-2016; Leon, Pepi/K-8972-2014
OI Acuña-Castroviejo, Dario/0000-0002-9680-1560; Belkadi, Hoda
   Khaldy/0000-0002-5906-7598; Escames, Germaine/0000-0003-1256-7656; Leon,
   Pepi/0000-0002-0543-4823; Martin, Miguel/0000-0002-2036-1853
CR Acuña-Castroviejo D, 2001, J PINEAL RES, V30, P65, DOI 10.1034/j.1600-079X.2001.300201.x
   ACUNACASTROVIEJ.D, 1997, LIFE SCI, V60, P3
   [Anonymous], LIFE SCI
   Borutaite V, 1996, BIOCHEM J, V315, P295, DOI 10.1042/bj3150295
   BOVERIS A, 1984, METHOD ENZYMOL, V105, P429
   BROWN GC, 1992, BIOCHEM J, V284, P1
   Cassarino DS, 1999, BRAIN RES REV, V29, P1, DOI 10.1016/S0165-0173(98)00046-0
   Costa EJX, 1997, FEBS LETT, V416, P103, DOI 10.1016/S0014-5793(97)01178-2
   Dabbeni-Sala F, 2001, FASEB J, V15, P164, DOI 10.1096/fj.00-0129com
   de Grey, 1999, MITOCHONDRIAL FREE R
   García JJ, 1999, J BIOENERG BIOMEMBR, V31, P609, DOI 10.1023/A:1005425213253
   GARCIARUIZ C, 1995, MOL PHARMACOL, V48, P825
   Hackenbrock CR., 1978, METHOD ENZYMOL, P36, DOI [DOI 10.1016/0076-6879(78)57006-7, 10.1016/0076-6879(78)57006-7]
   HOGEBOOM GH, 1955, METHOD ENZYMOL, V1, P16, DOI 10.1016/0076-6879(55)01007-0
   JAIN A, 1991, P NATL ACAD SCI USA, V88, P1913, DOI 10.1073/pnas.88.5.1913
   JOHNSTON JD, 1987, BIOCHEM J, V245, P217, DOI 10.1042/bj2450217
   KORETSKY AP, 1987, BIOCHIM BIOPHYS ACTA, V893, P398, DOI 10.1016/0005-2728(87)90092-2
   Kuznetsov AV, 1997, BBA-MOL BASIS DIS, V1360, P142, DOI 10.1016/S0925-4439(96)00072-5
   León J, 2000, MOL PHARMACOL, V58, P967, DOI 10.1124/mol.58.5.967
   Liu H, 1996, FREE RADICAL BIO MED, V20, P433, DOI 10.1016/0891-5849(95)02093-4
   LOWRY OH, 1951, J BIOL CHEM, V193, P265
   Martín M, 2000, FASEB J, V14, P1677
   Martín M, 2000, J PINEAL RES, V28, P242, DOI 10.1034/j.1600-079X.2000.280407.x
   MEISTER A, 1994, CANCER RES, V54, pS1969
   MENENDEZPELAEZ A, 1993, J CELL BIOCHEM, V54, P1
   MIQUEL J, 1980, EXPT GERONTOLOGY, V15, P579
   MORENOSANCHEZ R, 1990, BIOCHEM J, V268, P421, DOI 10.1042/bj2680421
   MORENOSANCHEZ R, 1991, BIOCHEM PHARMACOL, V41, P1479, DOI 10.1016/0006-2952(91)90564-L
   Nicholls DG, 2000, PHYSIOL REV, V80, P315, DOI 10.1152/physrev.2000.80.1.315
   Pappolla MA, 1999, J PINEAL RES, V27, P226, DOI 10.1111/j.1600-079X.1999.tb00619.x
   Reiter RJ, 1998, PROG NEUROBIOL, V56, P359, DOI 10.1016/S0301-0082(98)00052-5
   Reiter RJ., 2000, CURR TOP BIOPHYS, V24, P171
   SCHAGGER H, 1991, ANAL BIOCHEM, V199, P223, DOI 10.1016/0003-2697(91)90094-A
   Sharman EH, 2001, NEUROBIOL AGING, V22, P629, DOI 10.1016/S0197-4580(01)00226-3
   SOTTOCASA GL, 1967, J CELL BIOL, V32, P415, DOI 10.1083/jcb.32.2.415
   Tan DX, 2000, FREE RADICAL BIO MED, V29, P1177, DOI 10.1016/S0891-5849(00)00435-4
   Tan DX, 2000, BIOL SIGNAL RECEPT, V9, P137
   Wakatsuki A, 2001, J PINEAL RES, V30, P22, DOI 10.1034/j.1600-079X.2001.300103.x
   Yamamoto HA, 1996, NEUROSCI LETT, V207, P89, DOI 10.1016/0304-3940(96)12493-9
   Zerbetto E, 1997, ELECTROPHORESIS, V18, P2059, DOI 10.1002/elps.1150181131
NR 40
TC 211
Z9 216
U1 0
U2 15
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1357-2725
EI 1878-5875
J9 INT J BIOCHEM CELL B
JI Int. J. Biochem. Cell Biol.
PD APR
PY 2002
VL 34
IS 4
BP 348
EP 357
AR PII S1357-2725(01)00138-8
DI 10.1016/S1357-2725(01)00138-8
PG 10
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 533HG
UT WOS:000174523100007
PM 11854034
DA 2024-02-19
ER

PT J
AU Danpanichkul, P
   Ng, CH
   Muthiah, MD
   Duangsonk, K
   Yong, JN
   Tan, DJH
   Lim, WH
   Wong, ZY
   Syn, N
   Tsusumi, T
   Takahashi, H
   Siddiqui, MS
   Wong, VWS
   Mantzoros, CS
   Huang, DQ
   Noureddin, M
   Loomba, R
   Sanyal, AJ
   Wijarnpreecha, K
AF Danpanichkul, Pojsakorn
   Ng, Cheng Han
   Muthiah, Mark D.
   Duangsonk, Kwanjit
   Yong, Jie Ning
   Tan, Darren Jun Hao
   Lim, Wen Hui
   Wong, Zhen Yu
   Syn, Nicholas
   Tsusumi, Tsubasa
   Takahashi, Hirokazu
   Siddiqui, Mohammad Shadab
   Wong, Vincent Wai-Sun
   Mantzoros, Christos S.
   Huang, Daniel Q.
   Noureddin, Mazen
   Loomba, Rohit
   Sanyal, Arun J.
   Wijarnpreecha, Karn
TI The silent burden of non-alcoholic fatty liver disease in the elderly: A
   global burden of disease analysis
SO ALIMENTARY PHARMACOLOGY & THERAPEUTICS
LA English
DT Article; Early Access
ID NAFLD; ASIA
AB Background: Non-alcoholic fatty liver disease (NAFLD) represents a significant health threat worldwide. The growing trend towards an aging population, along with an alarming rise in obesity and diabetes, may have significant implications for the burden of NAFLD. Aim: To assess the impact of NAFLD on the elderly. Methods: We utilised data from the Global Burden of Disease study between 2010 and 2019 to conduct a comprehensive analysis of the prevalence, mortality, and disability-adjusted life years (DALYs) associated with NAFLD in the elderly (65-89 years), stratified by region, nation, sociodemographic Index and sex. Results: Globally, there were an estimated 228 million cases, 87,230 deaths and 1.46 million DALYs attributed to NAFLD in the elderly. Geographically, the Western Pacific region had the highest burden of NAFLD in the elderly. From 2010 to 2019, there was an increasing prevalence rate in all areas, with the most pronounced change observed in the Western Pacific region (annual percentage change (APC) +0.95%, p < 0.001). Over the study period, there was a more rapid increase in NAFLD prevalence in men (APC +0.74%, p < 0.001) than in women (APC +0.63%, p < 0.001). In most regions, death and DALYs rates have declined, with the exception of the Americas, where there was a slight increase ( APC +0.25%, p = 0.002 and 0.38%, p < 0.001, respectively). Conclusion: Over the past decade, the burden of NAFLD in the elderly has been increasing, necessitating immediate and inclusive measures to tackle the rising burden.
C1 [Danpanichkul, Pojsakorn] Chiang Mai Univ, Fac Med, Dept Microbiol, Immunol Unit, Chiang Mai, Thailand.
   [Ng, Cheng Han; Muthiah, Mark D.; Yong, Jie Ning; Tan, Darren Jun Hao; Lim, Wen Hui; Syn, Nicholas; Huang, Daniel Q.] Natl Univ Singapore, Yong Loo Lin Sch Med, Singapore, Singapore.
   [Muthiah, Mark D.; Huang, Daniel Q.] Natl Univ Hlth Syst, Dept Med, Div Gastroenterol & Hepatol, Singapore, Singapore.
   [Duangsonk, Kwanjit] Chiang Mai Univ, Fac Med, Dept Microbiol, Chiang Mai, Thailand.
   [Wong, Zhen Yu] Nottingham Univ Hosp NHS Trust, Nottingham City Hosp, Nottingham, England.
   [Tsusumi, Tsubasa] Kurume Univ, Sch Med, Dept Med, Div Gastroenterol, Kurume 8300011, Japan.
   [Takahashi, Hirokazu] Saga Univ, Fac Med, Div Metab & Endocrinol, Saga, Japan.
   [Siddiqui, Mohammad Shadab; Sanyal, Arun J.] Virginia Commonwealth Univ, Dept Internal Med, Div Gastroenterol Hepatol & Nutr, Richmond, VA USA.
   [Wong, Vincent Wai-Sun] Chinese Univ Hong Kong, Inst Digest Dis, Hong Kong, Peoples R China.
   [Wong, Vincent Wai-Sun] Chinese Univ Hong Kong, Dept Med & Therapeut, Hong Kong, Peoples R China.
   [Mantzoros, Christos S.] Harvard Med Sch, Dept Internal Med, Boston VA Healthcare Syst, Boston, MA USA.
   [Mantzoros, Christos S.] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Boston, MA USA.
   [Mantzoros, Christos S.] Harvard Univ, Fac Med, Boston, MA USA.
   [Noureddin, Mazen] Houston Res Inst, Houston, TX USA.
   [Loomba, Rohit] Univ Calif San Diego, NAFLD Res Ctr, Div Gastroenterol, La Jolla, CA USA.
   [Loomba, Rohit] Univ Calif San Diego, Dept Family Med & Publ Hlth, Div Epidemiol, La Jolla, CA 92093 USA.
   [Wijarnpreecha, Karn] Univ Arizona, Coll Med, Dept Med, Div Gastroenterol & Hepatol, Phoenix, AZ USA.
   [Wijarnpreecha, Karn] Banner Univ, Dept Internal Med, Med Ctr, Div Gastroenterol & Hepatol, Phoenix, AZ USA.
   [Wijarnpreecha, Karn] Univ Arizona, Coll Med, Dept Med, Div Gastroenterol & Hepatol, Phoenix, AZ 85724 USA.
   [Wijarnpreecha, Karn] Div Gastroenterol & Hepatol, Phoenix, AZ 85724 USA.
C3 Chiang Mai University; National University of Singapore; National
   University of Singapore; Chiang Mai University; Nottingham University
   Hospital NHS Trust; Nottingham City Hospital; Kurume University; Saga
   University; Virginia Commonwealth University; Chinese University of Hong
   Kong; Chinese University of Hong Kong; Harvard University; Harvard
   Medical School; US Department of Veterans Affairs; Veterans Health
   Administration (VHA); VA Boston Healthcare System; Harvard University;
   Harvard Medical School; Beth Israel Deaconess Medical Center; Harvard
   University; University of California System; University of California
   San Diego; University of California System; University of California San
   Diego; University of Arizona; University of Arizona
RP Danpanichkul, P (corresponding author), Chiang Mai Univ, Fac Med, Dept Microbiol, Immunol Unit, Chiang Mai, Thailand.; Wijarnpreecha, K (corresponding author), Univ Arizona, Coll Med, Dept Med, Div Gastroenterol & Hepatol, Phoenix, AZ 85724 USA.; Wijarnpreecha, K (corresponding author), Div Gastroenterol & Hepatol, Phoenix, AZ 85724 USA.
EM pojsakorndan@gmail.com; dr.karn.wi@gmail.com
RI Syn, Nicholas/A-3770-2017
OI Syn, Nicholas/0000-0002-6343-176X; Danpanichkul,
   Pojsakorn/0000-0002-9121-165X; Ng, Cheng Han/0000-0002-8297-1569
FU Astellas Pharma; AbbVie GK; Sysmex; Gilead Sciences, Inventiva; Novo
   Nordisk; Gilead Sciences; Illuminatio Medical Technology Limited;
   Durect; Galmed; Conatus; Amarin; Jannsen; Lilly; Galectin, Fractyl;
   Bristol Myers Squibb; Gilead; Salix; Tobira; Norvatis; Intercept;
   EchoSens, Fractyl; Allergan; BMS; Conatus, Enanta, Madrigal; Singapore
   Ministry of Healths National Medical Research Council under its NMRC
   Research Training Fellowship; Massachusetts Life Sciences Center;
   Coherus Inc.; Merck; Elsevier; Eli Lilly; Metacrine, Inc.; NGM
   Biopharmaceuticals; Arrowhead Pharmaceuticals; Galectin Therapeutics;
   Galmed Pharmaceuticals
FX Cheng Han Ng has served as a consultant to Boxer Capital. Hirokazu
   Takahashi received a research grant from Astellas Pharma, AbbVie GK and
   Sysmex. Vincent Wai-Sun Wong served as a consultant or advisory board
   member for 3 V-BIO, AbbVie, Allergan, Boehringer Ingelheim, Echosens,
   Gilead Sciences, Inventiva, Merck, Novartis, Novo Nordisk, Pfizer,
   ProSciento, Sagimet Biosciences, TARGET PharmaSolutions, and Terns; and
   a speaker for Abbott, AbbVie, Echosens, Gilead Sciences, and Novo
   Nordisk. He has received a research grant from Gilead Sciences and is a
   co-founder of Illuminatio Medical Technology Limited. Arun J Sanyal AS
   is the President of Sanyal Biotechnology and has stock options in
   Genfit, Akarna, Tiziana, Indalo, Durect and Galmed. He has served as a
   consultant to Astra Zeneca, Nitto Denko, Enyo, Ardelyx, Conatus, Nimbus,
   Amarin, Salix, Tobira, Takeda, Jannsen, Gilead, Terns, Birdrock, Merck,
   Valeant, Boehringer-Ingelheim, Lilly, Hemoshear, Zafgen, Novartis, Novo
   Nordisk, Pfizer, Exhalenz and Genfit. He has been an unpaid consultant
   to Intercept, Echosens, Immuron, Galectin, Fractyl, Syntlogic, Affimune,
   Chemomab, Zydus, Nordic Bioscience, Albireo, Prosciento, Surrozen and
   Bristol Myers Squibb. His institution has received grant support from
   Gilead, Salix, Tobira, Bristol Myers, Shire, Intercept, Merck, Astra
   Zeneca, Malinckrodt, Cumberland, and Norvatis. He receives royalties
   from Elsevier and UptoDate. Mazen Noureddin MN has been on the advisory
   board/consultant for 89BIO, Altimmune, Gilead, cohBar, Cytodyn,
   Intercept, Pfizer, Novo Nordisk, Blade, EchoSens, Fractyl, Madrgial,
   NorthSea, Prespecturm, Terns, Siemens and Roche diagnostic; MN has
   received research support from Allergan, BMS, Gilead, Galmed, Galectin,
   Genfit, Conatus, Enanta, Madrigal, Novartis, Pfizer, Shire, Viking and
   Zydus; He is a shareholder or has stocks in Anaetos, Chrownwell, C iema,
   R ivus P harma a nd V iking. D aniel Q H uang r eceives funding support
   from the Singapore Ministry of Health's National Medical Research
   Council under its NMRC Research Training Fellowship (MOH-000595-01). In
   addition, he has served as an advisory board member for Gilead. Christos
   S. Mantzoros reports grants through his institution from Merck,
   Massachusetts Life Sciences Center and Boehringer Ingelheim, has been a
   shareholder of and has received grants through his Institution and
   personal consulting fees from Coherus Inc. and AltrixBio: he reports
   personal consulting fees from Novo Nordisk, reports personal consulting
   fees and support with research reagents from Ansh Inc., collaborative
   research support from LabCorp Inc., reports personal consulting fees
   from Genfit, Lumos, Amgen, Corcept, Intercept, 89 Bio, Madrigal and
   Regeneron, reports educational activity meals through his institution or
   national conferences from Esperion, Merck, Boehringer Ingelheim and
   travel support and fees from TMIOA, Elsevier, and the Cardio Metabolic
   Health Conference. None is related to the work presented herein. Rohit
   Loomba serves as a consultant to Aardvark Therapeutics, Altimmune,
   Anylam/ Regeneron, Amgen, Arrowhead Pharmaceuticals, AstraZeneca,
   Bristol-Myer Squibb, CohBar, Eli Lilly, Galmed, Gilead, Glympse bio,
   Hightide, Inipharma, Intercept, Inventiva, Ionis, Janssen Inc.,
   Madrigal, Metacrine, Inc., NGM Biopharmaceuticals, Novartis, Novo
   Nordisk, Merck, Pfizer, Sagimet, Theratechnologies, 89 bio, Terns
   Pharmaceuticals and Viking Therapeutics.; In addition, his institutions
   received research grants from Arrowhead Pharmaceuticals, AstraZeneca,
   Boehringer-Ingelheim, Bristol-Myers Squibb, Eli Lilly, Galectin
   Therapeutics, Galmed Pharmaceuticals, Gilead, Intercept, Hanmi,
   Intercept, Inventiva, Ionis, Janssen, Madrigal Pharmaceuticals, Merck,
   NGM Biopharmaceuticals, Novo Nordisk, Merck, Pfizer, Sonic Incytes and
   Terns Pharmaceuticals. He is also the co-founder of LipoNexus Inc.
CR Aboulghate M, 2021, FRONT PUBLIC HEALTH, V9, DOI 10.3389/fpubh.2021.718978
   Adejumo AC, 2019, ANN GASTROENTEROL, V32, P504, DOI 10.20524/aog.2019.0402
   Alqahtani SA, 2021, CLIN INTERV AGING, V16, P1633, DOI 10.2147/CIA.S295524
   Ariaratnam S, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0238566
   Balakrishnan M, 2021, CLIN GASTROENTEROL H, V19, P61, DOI 10.1016/j.cgh.2020.04.067
   Bertolotti M, 2014, WORLD J GASTROENTERO, V20, P14185, DOI 10.3748/wjg.v20.i39.14185
   Chong BY, 2023, METABOLISM, V141, DOI 10.1016/j.metabol.2023.155402
   Collaborators GBDA, 2022, BMJ-BRIT MED J, V376
   De Roza MA, 2019, LANCET GASTROENTEROL, V4, P333, DOI 10.1016/S2468-1253(19)30093-7
   Degertekin B, 2021, TURK J GASTROENTEROL, V32, P302, DOI 10.5152/tjg.2021.20062
   Diaz Luis Antonio, 2022, Curr Treat Options Gastroenterol, V20, P261, DOI 10.1007/s11938-022-00382-1
   Elbahrawy A, 2021, MICROBIOL IMMUNOL, V65, P352, DOI 10.1111/1348-0421.12916
   Engelmann C, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23020652
   Fan JG, 2017, J HEPATOL, V67, P862, DOI 10.1016/j.jhep.2017.06.003
   Geyman JP, 2022, FAM MED, V54, P688, DOI 10.22454/FamMed.2022.576797
   Golovaty I, 2020, J NUTR, V150, P91, DOI 10.1093/jn/nxz212
   Hartleb M, 2017, LIVER INT, V37, P1706, DOI 10.1111/liv.13471
   Jayawardhana T, 2023, PLOS ONE, V18, DOI 10.1371/journal.pone.0284895
   Juul F, 2022, AM J CLIN NUTR, V115, P211, DOI 10.1093/ajcn/nqab305
   Lazarus JV, 2022, J HEPATOL, V76, P771, DOI 10.1016/j.jhep.2021.10.025
   Li Y, 2022, AGING DIS, V13, P1239, DOI 10.14336/AD.2022.0318
   Lin HP, 2023, HEPATOLOGY, V77, P573, DOI 10.1002/hep.32633
   Mathus-Vliegen EMH, 2012, J CLIN GASTROENTEROL, V46, P533, DOI 10.1097/MCG.0b013e31825692ce
   Matos RA, 2021, FRONT NUTR, V8, DOI 10.3389/fnut.2021.622714
   Matthews CE, 2021, MED SCI SPORT EXER, V53, P2512, DOI 10.1249/MSS.0000000000002751
   Murray CJL, 2020, LANCET, V396, P1223, DOI [10.1016/S0140-6736(20)30752-2, 10.1016/S0140-6736(20)30925-9]
   Nanditha A, 2016, DIABETES CARE, V39, P472, DOI 10.2337/dc15-1536
   Noubiap JJ, 2022, LANCET CHILD ADOLESC, V6, P158, DOI 10.1016/S2352-4642(21)00374-6
   Noureddin M, 2013, HEPATOLOGY, V58, P1644, DOI 10.1002/hep.26465
   Ofosu A, 2018, ANN GASTROENTEROL, V31, P288, DOI 10.20524/aog.2018.0240
   Paik JM, 2022, HEPATOLOGY, V75, P1204, DOI 10.1002/hep.32228
   Park CW, 2011, CLIN TRANSPLANT, V25, pE606, DOI 10.1111/j.1399-0012.2011.01497.x
   Petrescu M., 2022, MED KAUNAS, V58, P2
   Riazi K, 2022, LANCET GASTROENTEROL, V7, P851, DOI 10.1016/S2468-1253(22)00165-0
   Romeo S, 2008, NAT GENET, V40, P1461, DOI 10.1038/ng.257
   Sarin SK, 2020, LANCET GASTROENTEROL, V5, P167, DOI 10.1016/S2468-1253(19)30342-5
   Silva LF, 2023, METABOLITES, V13, DOI 10.3390/metabo13020267
   Singh A, 2020, DIGEST DIS SCI, V65, P978, DOI 10.1007/s10620-019-05700-9
   Stepanova M, 2012, CLIN GASTROENTEROL H, V10, P646, DOI 10.1016/j.cgh.2011.12.039
   Suzuki A, 2009, WOMENS HEALTH, V5, P191, DOI 10.2217/17455057.5.2.191
   Talens M, 2021, J CLIN MED, V10, DOI 10.3390/jcm10215019
   Tateishi R, 2019, J GASTROENTEROL, V54, P367, DOI 10.1007/s00535-018-1532-5
   Teng MLP, 2023, CLIN MOL HEPATOL, V29, pS32, DOI 10.3350/cmh.2022.0365
   Vilar-Gomez E, 2018, GASTROENTEROLOGY, V155, P443, DOI 10.1053/j.gastro.2018.04.034
   Wang D, 2022, FRONT NUTR, V9, DOI 10.3389/fnut.2022.1047129
   Wu Y, 2021, SOC SCI MED, V269, DOI 10.1016/j.socscimed.2020.113601
   Yip TCF, 2022, J HEPATOL, V76, P726, DOI 10.1016/j.jhep.2021.09.024
   Younossi Z, 2018, NAT REV GASTRO HEPAT, V15, P11, DOI 10.1038/nrgastro.2017.109
NR 48
TC 2
Z9 2
U1 4
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0269-2813
EI 1365-2036
J9 ALIMENT PHARM THER
JI Aliment. Pharmacol. Ther.
PD 2023 NOV
PY 2023
VL 58
IS 10
BP 1062
EP 1074
DI 10.1111/apt.17714
EA SEP 2023
PG 13
WC Gastroenterology & Hepatology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Gastroenterology & Hepatology; Pharmacology & Pharmacy
GA W1VM4
UT WOS:001065356000001
PM 37694808
OA Bronze
DA 2024-02-19
ER

PT J
AU Wieckowska-Gacek, A
   Mietelska-Porowska, A
   Chutoranski, D
   Wydrych, M
   Dlugosz, J
   Wojda, U
AF Wieckowska-Gacek, Angelika
   Mietelska-Porowska, Anna
   Chutoranski, Dominik
   Wydrych, Malgorzata
   Dlugosz, Jan
   Wojda, Urszula
TI Western Diet Induces Impairment of Liver-Brain Axis Accelerating
   Neuroinflammation and Amyloid Pathology in Alzheimer's Disease
SO FRONTIERS IN AGING NEUROSCIENCE
LA English
DT Article
DE Alzheimer&apos; s disease; western diet; metabolic syndrome; liver-brain
   axis; neuroinflammation; astroglia; microglia; amyloid
AB Alzheimer's disease (AD) is an aging-dependent, irreversible neurodegenerative disorder and the most common cause of dementia. The prevailing AD hypothesis points to the central role of altered cleavage of amyloid precursor protein (APP) and formation of toxic amyloid-beta (A beta) deposits in the brain. The lack of efficient AD treatments stems from incomplete knowledge on AD causes and environmental risk factors. The role of lifestyle factors, including diet, in neurological diseases is now beginning to attract considerable attention. One of them is western diet (WD), which can lead to many serious diseases that develop with age. The aim of the study was to investigate whether WD-derived systemic disturbances may accelerate the brain neuroinflammation and amyloidogenesis at the early stages of AD development. To verify this hypothesis, transgenic mice expressing human APP with AD-causing mutations (APPswe) were fed with WD from the 3rd month of age. These mice were compared to APPswe mice, in which short-term high-grade inflammation was induced by injection of lipopolysaccharide (LPS) and to untreated APPswe mice. All experimental subgroups of animals were subsequently analyzed at 4-, 8-, and 12-months of age. APPswe mice at 4- and 8-months-old represent earlier pre-plaque stages of AD, while 12-month-old animals represent later stages of AD, with visible amyloid pathology. Already short time of WD feeding induced in 4-month-old animals such brain neuroinflammation events as enhanced astrogliosis, to a level comparable to that induced by the administration of pro-inflammatory LPS, and microglia activation in 8-month-old mice. Also, WD feeding accelerated increased A beta production, observed already in 8-month-old animals. These brain changes corresponded to diet-induced metabolic disorders, including increased cholesterol level in 4-months of age, and advanced hypercholesterolemia and fatty liver disease in 8-month-old mice. These results indicate that the westernized pattern of nourishment is an important modifiable risk factor of AD development, and that a healthy, balanced, diet may be one of the most efficient AD prevention methods.
C1 [Wieckowska-Gacek, Angelika; Mietelska-Porowska, Anna; Chutoranski, Dominik; Wydrych, Malgorzata; Dlugosz, Jan; Wojda, Urszula] Polish Acad Sci, Nencki Inst Expt Biol, Neurobiol Ctr, Lab Preclin Testing Higher Stand, Warsaw, Poland.
C3 Polish Academy of Sciences; Nencki Institute of Experimental Biology of
   the Polish Academy of Sciences
RP Wojda, U (corresponding author), Polish Acad Sci, Nencki Inst Expt Biol, Neurobiol Ctr, Lab Preclin Testing Higher Stand, Warsaw, Poland.
EM u.wojda@nencki.edu.pl
RI Więckowska-Gacek, Angelika/HKV-9771-2023; Wojda, Urszula/M-6079-2015
OI Więckowska-Gacek, Angelika/0000-0002-2255-0148; Mietelska-Porowska,
   Anna/0000-0002-3192-8739; Wojda, Urszula/0000-0002-4525-2004
FU National Science Center, Poland [UMO-2014/15/D/NZ4/04361,
   UMO-2018/29/N/NZ7/01724]; European Union; Polish budget; Institute
   Psychiatry and Neurology [POPC.02.03.01-00.0042/18-00]
FX This work was financed by the National Science Center, Poland, under
   research Projects Nos. UMO-2014/15/D/NZ4/04361 and
   UMO-2018/29/N/NZ7/01724. Also, this work was supported by the Digital
   Brain-digital collection of the Institute Psychiatry and Neurology
   Project No. POPC.02.03.01-00.0042/18-00 cofunded by the European Union
   and the Polish budget.
CR Abbas N, 2002, J NEUROIMMUNOL, V126, P50, DOI 10.1016/S0165-5728(02)00050-4
   Allendorf DH, 2020, J NEUROCHEM, V155, P403, DOI 10.1111/jnc.15024
   Allinquant B, 2014, CURR OPIN CLIN NUTR, V17, P319, DOI 10.1097/MCO.0000000000000069
   [Anonymous], 2020, ALZHEIMERS DEMENT, V16, P391, DOI 10.1002/alz.12068
   Astiz M, 2017, NEUROENDOCRINOLOGY, V104, P40, DOI 10.1159/000444527
   Attuquayefio T, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0172645
   Avila-Muñoz E, 2015, GLIA, V63, P2010, DOI 10.1002/glia.22874
   Avila-Muñoz E, 2014, AGEING RES REV, V18, P29, DOI 10.1016/j.arr.2014.07.004
   Bassendine MF, 2020, J ALZHEIMERS DIS, V75, P1, DOI 10.3233/JAD-190848
   Baym CL, 2014, AM J CLIN NUTR, V99, P1026, DOI 10.3945/ajcn.113.079624
   Berná G, 2020, LIVER INT, V40, P102, DOI 10.1111/liv.14360
   Besser LM, 2014, ALZ DIS ASSOC DIS, V28, P36, DOI 10.1097/WAD.0000000000000005
   Bezzi P, 2001, Prog Brain Res, V132, P255
   Bezzi P, 2001, NAT NEUROSCI, V4, P702, DOI 10.1038/89490
   Brown GC, 2003, MOL NEUROBIOL, V27, P325, DOI 10.1385/MN:27:3:325
   Burhans MS, 2019, COMPR PHYSIOL, V9, P1, DOI 10.1002/cphy.c170040
   Butovsky O, 2014, NAT NEUROSCI, V17, P131, DOI 10.1038/nn.3599
   Cai ZY, 2018, J ALZHEIMERS DIS, V63, P1223, DOI 10.3233/JAD-180098
   Canevari L, 2007, NEUROCHEM RES, V32, P739, DOI 10.1007/s11064-006-9200-1
   Cazareth J, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-132
   Chakraborty A, 2017, VASC PHARMACOL, V89, P12, DOI 10.1016/j.vph.2016.11.008
   Chen RL, 2020, FOOD FUNCT, V11, P3621, DOI [10.1039/c9fo02606a, 10.1039/C9FO02606A]
   Cheng Y, 2020, TRANSL NEURODEGENER, V9, DOI 10.1186/s40035-020-00195-1
   Chew H, 2020, FRONT PHYSIOL, V11, DOI 10.3389/fphys.2020.00598
   Chiu S, 2018, CURR OPIN CLIN NUTR, V21, P277, DOI 10.1097/MCO.0000000000000469
   Dabke K, 2019, J CLIN INVEST, V129, P4050, DOI 10.1172/JCI129194
   de Oliveira FF, 2014, INT J GERIATR PSYCH, V29, P1033, DOI 10.1002/gps.4094
   De Souza CT, 2005, ENDOCRINOLOGY, V146, P4192, DOI 10.1210/en.2004-1520
   Deane R, 2004, NEURON, V43, P333, DOI 10.1016/j.neuron.2004.07.017
   Dietschy JM, 2001, CURR OPIN LIPIDOL, V12, P105, DOI 10.1097/00041433-200104000-00003
   Du XG, 2018, TRANSL NEURODEGENER, V7, DOI 10.1186/s40035-018-0107-y
   Dubois B, 2016, ALZHEIMERS DEMENT, V12, P292, DOI 10.1016/j.jalz.2016.02.002
   Edwards GA, 2019, FRONT AGING NEUROSCI, V11, DOI 10.3389/fnagi.2019.00146
   Elenkov IJ, 1999, TRENDS ENDOCRIN MET, V10, P359, DOI 10.1016/S1043-2760(99)00188-5
   Elgazar-Carmon V, 2008, J LIPID RES, V49, P1894, DOI 10.1194/jlr.M800132-JLR200
   Francis HM, 2011, BEHAV NEUROSCI, V125, P943, DOI 10.1037/a0025998
   Franko A, 2018, NUTRIENTS, V10, DOI 10.3390/nu10091314
   Freeman LR, 2011, NUTR NEUROSCI, V14, P32, DOI 10.1179/174313211X12966635733358
   Friedman SL, 2018, NAT MED, V24, P908, DOI 10.1038/s41591-018-0104-9
   Gali CC, 2019, MOL CELL NEUROSCI, V99, DOI 10.1016/j.mcn.2019.103390
   Gamba P, 2019, FRONT NEUROSCI-SWITZ, V13, DOI 10.3389/fnins.2019.00556
   Gasparotto J, 2017, BRAIN BEHAV IMMUN, V62, P124, DOI 10.1016/j.bbi.2017.01.008
   Graham LC, 2016, SCI REP-UK, V6, DOI 10.1038/srep21568
   Granholm AC, 2008, J ALZHEIMERS DIS, V14, P133
   Gupta S, 2012, J NEUROCHEM, V120, P1060, DOI 10.1111/j.1471-4159.2012.07660.x
   Gustafson DR, 2009, NEUROLOGY, V73, P1559, DOI 10.1212/WNL.0b013e3181c0d4b6
   Gustafson DR, 2012, J ALZHEIMERS DIS, V28, P162, DOI 10.3233/JAD-2011-110917
   Haass C, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a006270
   Hare J, 2010, BIOCHEM BIOPH RES CO, V401, P219, DOI 10.1016/j.bbrc.2010.09.033
   Hargrave SL, 2016, BEHAV NEUROSCI, V130, P123, DOI 10.1037/bne0000110
   Hartz AMS, 2010, MOL PHARMACOL, V77, P715, DOI 10.1124/mol.109.061754
   Hohsfield LA, 2014, MOL CELL NEUROSCI, V63, P83, DOI 10.1016/j.mcn.2014.10.006
   Hosseini-Esfahani F, 2018, INT J ENDOCRINOL MET, V16, DOI 10.5812/ijem.84771
   Hotamisligil GS, 2017, NATURE, V542, P177, DOI 10.1038/nature21363
   Hsu TM, 2014, FRONT AGING NEUROSCI, V6, DOI 10.3389/fnagi.2014.00088
   Iliff JJ, 2014, J NEUROSCI, V34, P16180, DOI 10.1523/JNEUROSCI.3020-14.2014
   Ioannou GN, 2017, J LIPID RES, V58, P1067, DOI 10.1194/jlr.M072454
   Ito S, 2014, J ALZHEIMERS DIS, V38, P185, DOI 10.3233/JAD-122077
   Jäger S, 2009, J NEUROCHEM, V111, P1369, DOI 10.1111/j.1471-4159.2009.06420.x
   Jena PK, 2018, FASEB J, V32, P2866, DOI 10.1096/fj.201700984RR
   John CD, 2003, CURR OPIN PHARMACOL, V3, P78, DOI 10.1016/S1471-4892(02)00009-7
   Julien C, 2010, NEUROBIOL AGING, V31, P1516, DOI 10.1016/j.neurobiolaging.2008.08.022
   Kalmijn S, 2004, NEUROLOGY, V62, P275, DOI 10.1212/01.WNL.0000103860.75218.A5
   Kanoski SE, 2011, PHYSIOL BEHAV, V103, P59, DOI 10.1016/j.physbeh.2010.12.003
   Kanoski SE, 2010, J EXP PSYCHOL-ANIM B, V36, P313, DOI 10.1037/a0017228
   Kaur D, 2019, INFLAMMOPHARMACOLOGY, V27, P663, DOI 10.1007/s10787-019-00580-x
   Kim DG, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-015-0467-5
   Kivipelto M, 2005, ARCH NEUROL-CHICAGO, V62, P1556, DOI 10.1001/archneur.62.10.1556
   Kopp W, 2019, DIABET METAB SYND OB, V12, P2221, DOI 10.2147/DMSO.S216791
   Kosari S, 2012, BEHAV BRAIN RES, V235, P98, DOI 10.1016/j.bbr.2012.07.017
   Kress BT, 2014, ANN NEUROL, V76, P845, DOI 10.1002/ana.24271
   Kumashiro N, 2011, P NATL ACAD SCI USA, V108, P16381, DOI 10.1073/pnas.1113359108
   Laharrague P, 2000, INT J OBESITY, V24, P1212, DOI 10.1038/sj.ijo.0801377
   Leigh SJ, 2020, BBA-MOL BASIS DIS, V1866, DOI 10.1016/j.bbadis.2020.165767
   Lian H, 2016, J NEUROSCI, V36, P577, DOI 10.1523/JNEUROSCI.2117-15.2016
   Liang W, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0115922
   Lindenmeyer CC, 2018, CLIN LIVER DIS, V22, P11, DOI 10.1016/j.cld.2017.08.003
   Liu YX, 2020, MOL IMMUNOL, V117, P139, DOI 10.1016/j.molimm.2019.11.002
   Loera-Valencia R, 2019, J STEROID BIOCHEM, V190, P104, DOI 10.1016/j.jsbmb.2019.03.003
   Long JM, 2019, CELL, V179, P312, DOI 10.1016/j.cell.2019.09.001
   Lopes PC, 2016, INFLAMMOPHARMACOLOGY, V24, P291, DOI 10.1007/s10787-016-0283-2
   Luque-Contreras D, 2014, OXID MED CELL LONGEV, V2014, DOI 10.1155/2014/497802
   Lyons CL, 2016, NUTRIENTS, V8, DOI 10.3390/nu8050247
   Mahley RW, 2000, ANNU REV GENOM HUM G, V1, P507, DOI 10.1146/annurev.genom.1.1.507
   Martinez FO, 2013, BLOOD, V121, pE57, DOI 10.1182/blood-2012-06-436212
   Mast N, 2017, NEUROPHARMACOLOGY, V123, P465, DOI 10.1016/j.neuropharm.2017.06.026
   Mietelska-Porowska A, 2017, J IMMUNOL RES, V2017, DOI 10.1155/2017/4626540
   Milanski M, 2009, J NEUROSCI, V29, P359, DOI 10.1523/JNEUROSCI.2760-08.2009
   Mildner A, 2017, GLIA, V65, P375, DOI 10.1002/glia.23097
   Miller YI, 2020, J LIPID RES, V61, P655, DOI 10.1194/jlr.TR119000468
   Mohamed LA, 2013, DRUG METAB DISPOS, V41, P1787, DOI 10.1124/dmd.113.052514
   Molteni R, 2002, NEUROSCIENCE, V112, P803, DOI 10.1016/S0306-4522(02)00123-9
   Montagne A, 2017, J EXP MED, V214, P3151, DOI 10.1084/jem.20171406
   Monteiro CA, 2013, OBES REV, V14, P21, DOI 10.1111/obr.12107
   Monteiro R, 2010, MEDIAT INFLAMM, V2010, DOI 10.1155/2010/289645
   Morsiani C, 2019, AGEING RES REV, V51, P24, DOI 10.1016/j.arr.2019.02.002
   Moser VA, 2018, J NEUROINFLAMM, V15, DOI 10.1186/s12974-018-1340-0
   Moshage H, 1997, J PATHOL, V181, P257, DOI 10.1002/(SICI)1096-9896(199703)181:3<257::AID-PATH756>3.0.CO;2-U
   Musso G, 2003, HEPATOLOGY, V37, P909, DOI 10.1053/jhep.2003.50132
   Napier BA, 2019, P NATL ACAD SCI USA, V116, P3688, DOI 10.1073/pnas.1814273116
   Niu L, 2016, J NUTR HEALTH AGING, V20, P509, DOI 10.1007/s12603-015-0601-1
   Orihuela R, 2016, BRIT J PHARMACOL, V173, P649, DOI 10.1111/bph.13139
   Peng WG, 2016, NEUROBIOL DIS, V93, P215, DOI 10.1016/j.nbd.2016.05.015
   Pistell PJ, 2010, J NEUROIMMUNOL, V219, P25, DOI 10.1016/j.jneuroim.2009.11.010
   Pohl J, 2014, BRAIN BEHAV IMMUN, V35, P43, DOI 10.1016/j.bbi.2013.09.002
   Popkin BM, 2012, NUTR REV, V70, P3, DOI 10.1111/j.1753-4887.2011.00456.x
   Puglielli L, 2003, NAT NEUROSCI, V6, P345, DOI 10.1038/nn0403-345
   Ricci G, 2017, CLIN EXP HYPERTENS, V39, P8, DOI 10.1080/10641963.2016.1210629
   Richter M, 2020, BRAIN PATHOL, V30, P589, DOI 10.1111/bpa.12807
   Robert J, 2017, ELIFE, V6, DOI 10.7554/eLife.29595
   Rocha DM, 2016, ATHEROSCLEROSIS, V244, P211, DOI 10.1016/j.atherosclerosis.2015.11.015
   Rodrigue KM, 2012, NEUROLOGY, V78, P387, DOI 10.1212/WNL.0b013e318245d295
   Rodríguez E, 2006, J NEUROL, V253, P181, DOI 10.1007/s00415-005-0945-2
   Rosqvist F, 2019, J CLIN ENDOCR METAB, V104, P6207, DOI 10.1210/jc.2019-00160
   Rutkowsky JM, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0191909
   Ryu JC, 2019, NEUROTHERAPEUTICS, V16, P600, DOI 10.1007/s13311-019-00755-y
   Sagare A, 2007, NAT MED, V13, P1029, DOI 10.1038/nm1635
   Salter MW, 2017, NAT MED, V23, P1018, DOI 10.1038/nm.4397
   Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089
   Schwabe T, 2020, NEUROBIOL DIS, V143, DOI 10.1016/j.nbd.2020.104962
   Sheng JG, 2003, NEUROBIOL DIS, V14, P133, DOI 10.1016/S0969-9961(03)00069-X
   Shukla AK, 2019, GLIA, V67, P844, DOI 10.1002/glia.23575
   Sidoryk-Wegrzynowicz M, 2011, TOXICOL PATHOL, V39, P115, DOI 10.1177/0192623310385254
   Solfrizzi V, 2004, NEUROLOGY, V63, P1882, DOI 10.1212/01.WNL.0000144281.38555.E3
   Stranahan AM, 2008, HIPPOCAMPUS, V18, P1085, DOI 10.1002/hipo.20470
   Streit WJ, 2020, GLIA, V68, P845, DOI 10.1002/glia.23782
   Sweeney MD, 2019, PHYSIOL REV, V99, P21, DOI 10.1152/physrev.00050.2017
   Talukdar S, 2012, NAT MED, V18, P1407, DOI 10.1038/nm.2885
   Tamaki C, 2007, MOL PHARMACOL, V72, P850, DOI 10.1124/mol.107.036913
   Tamaki C, 2006, PHARM RES-DORDR, V23, P1407, DOI 10.1007/s11095-006-0208-7
   Testa G, 2016, REDOX BIOL, V10, P24, DOI 10.1016/j.redox.2016.09.001
   Thaler JP, 2012, J CLIN INVEST, V122, P153, DOI 10.1172/JCI59660
   Thirumangalakudi L, 2008, J NEUROCHEM, V106, P475, DOI 10.1111/j.1471-4159.2008.05415.x
   Tojima H, 2012, HEPATOL INT, V6, P620, DOI 10.1007/s12072-011-9301-z
   Umeda T, 2012, LIFE SCI, V91, P1169, DOI 10.1016/j.lfs.2011.12.022
   Valladolid-Acebes I, 2012, AM J PHYSIOL-ENDOC M, V302, pE396, DOI 10.1152/ajpendo.00343.2011
   van Herpen NA, 2008, PHYSIOL BEHAV, V94, P231, DOI 10.1016/j.physbeh.2007.11.049
   Vance JE, 2012, DIS MODEL MECH, V5, P746, DOI 10.1242/dmm.010124
   Vandal M, 2014, DIABETES, V63, P4291, DOI 10.2337/db14-0375
   Vogels T, 2019, ACTA NEUROPATHOL COM, V7, DOI 10.1186/s40478-019-0754-y
   Walker DG, 2015, ALZHEIMERS RES THER, V7, DOI 10.1186/s13195-015-0139-9
   WANG SW, 1994, PHYSIOL BEHAV, V56, P517, DOI 10.1016/0031-9384(94)90295-X
   Wang YR, 2017, MOL NEUROBIOL, V54, P2338, DOI 10.1007/s12035-016-9826-1
   Wang Z, 2012, BRIT J NUTR, V107, P229, DOI 10.1017/S0007114511002868
   Wharton SB, 2009, DEMENT GERIATR COGN, V27, P465, DOI 10.1159/000217729
   Whitmer RA, 2008, NEUROLOGY, V71, P1057, DOI 10.1212/01.wnl.0000306313.89165.ef
   Wilson CA, 1997, BRIT J HAEMATOL, V99, P447, DOI 10.1046/j.1365-2141.1997.3873201.x
   Wong MY, 2020, J NEUROINFLAMM, V17, DOI 10.1186/s12974-020-01869-3
   World Health Organization, 2019, RISK RED COGN DECL D
   WRIGHT SD, 1989, J EXP MED, V170, P1231, DOI 10.1084/jem.170.4.1231
   Xiang Y, 2015, ACTA NEUROPATHOL, V130, P487, DOI 10.1007/s00401-015-1477-1
   Xiu J, 2006, NEUROCHEM INT, V49, P459, DOI 10.1016/j.neuint.2006.03.007
   Xu RN, 2014, CELL MOL IMMUNOL, V11, P224, DOI 10.1038/cmi.2014.2
   Xu ZQ, 2015, MOL NEURODEGENER, V10, DOI 10.1186/s13024-015-0056-1
   Yang J, 2011, J ALZHEIMERS DIS, V27, P711, DOI 10.3233/JAD-2011-110725
   Yeh SHH, 2020, NEUROBIOL AGING, V90, P60, DOI 10.1016/j.neurobiolaging.2019.11.018
   Yuan CX, 2020, NEUROBIOL AGING, V92, P82, DOI 10.1016/j.neurobiolaging.2020.03.024
   Zhang JZ, 2017, FRONT MOL NEUROSCI, V10, DOI 10.3389/fnmol.2017.00395
   Zhang XN, 2018, MOL NUTR FOOD RES, V62, DOI 10.1002/mnfr.201700531
   Zhao XS, 2016, CLIN CHIM ACTA, V456, P107, DOI 10.1016/j.cca.2016.02.024
   Zinöcker MK, 2018, NUTRIENTS, V10, DOI 10.3390/nu10030365
   Zlokovic BV, 2010, J NEUROCHEM, V115, P1077, DOI 10.1111/j.1471-4159.2010.07002.x
   Zotova E, 2011, NEUROPATH APPL NEURO, V37, P513, DOI 10.1111/j.1365-2990.2010.01156.x
   Zotova E, 2013, BRAIN, V136, P2677, DOI 10.1093/brain/awt210
NR 164
TC 32
Z9 34
U1 4
U2 21
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1663-4365
J9 FRONT AGING NEUROSCI
JI Front. Aging Neurosci.
PD APR 1
PY 2021
VL 13
AR 654509
DI 10.3389/fnagi.2021.654509
PG 27
WC Geriatrics & Gerontology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Geriatrics & Gerontology; Neurosciences & Neurology
GA RN0UW
UT WOS:000640071600001
PM 33867971
OA gold, Green Published
DA 2024-02-19
ER

PT J
AU LIU, HC
   CHI, CW
   LIU, TY
   LIU, LH
   LUH, WM
   HSIEH, CH
   WU, WG
AF LIU, HC
   CHI, CW
   LIU, TY
   LIU, LH
   LUH, WM
   HSIEH, CH
   WU, WG
TI EFFECT OF AGING ON PHOSPHATE METABOLITES OF RAT-BRAIN AS REVEALED BY THE
   INVIVO AND INVITRO P-31 NMR MEASUREMENTS
SO LIFE SCIENCES
LA English
DT Article
ID NUCLEAR MAGNETIC-RESONANCE; DOG BRAIN; SPECTROSCOPY; AGE; MUSCLE; LIVER
AB Changes of phosphate metabolism in brains of neonate, weaning and adult rats were compared using both in vivo and in vitro nuclear magnetic resonance spectra.  Ratios of phosphocreatine/nucleoside triphosphate (PCr/NTP) were the same in neonatal brain in both in vivo and in vitro studies, but not in weaning and adult brains.  This discrepancy may have resulted from extended cerebral hypoxia due to slowed freezing of the brain by the increased skull thickness and brain mass in the weaning and adult rats.  Variations in in vitro extraction condition for this age-related study may lead to systematic errors in the adult rats.  Nevertheless, the phosphomonoester/nucleoside triphosphate (PME/NTP) ratios in extracts of brain from neonatal rats were higher than those obtained in vivo.  In addition, the glycerophosphorylethanolamine plus glycerophosphorylcholine/nucleoside triphosphate (GPE+GPC/NTP) ratios, which were not measurable in vivo, showed age-dependent increase in extracts of rat brain.  Some of the phosphomonoester and phosphodiester molecules in rat brain may be undetectable in in vivo NMR analysis because of their interaction with cellular components.  The total in vitro GPE and GPC concentration in brain from neonatal rat was estimated to be 0.34 mmole/g wet tissue.
C1 VET GEN HOSP,DEPT MED RES,TAIPEI,TAIWAN.
   NATL TSING HUA UNIV,INST LIFE SCI,HSINCHU 300,TAIWAN.
C3 National Tsing Hua University
RP LIU, HC (corresponding author), VET GEN HOSP,CTR NEUROL,TAIPEI 11217,TAIWAN.
CR BARANY M, 1975, METHOD ENZYMOL, V535, P624
   BATES TE, 1989, MAGNET RESON MED, V12, P145, DOI 10.1002/mrm.1910120116
   BENDALL MR, 1983, J MAGN RESON, V53, P365, DOI 10.1016/0022-2364(83)90211-1
   BURT CT, 1976, J BIOL CHEM, V251, P2584
   CADY EB, 1983, LANCET, V1, P1059
   CERDAN S, 1986, MAGNET RESON MED, V3, P432, DOI 10.1002/mrm.1910030308
   CHANCE B, 1978, P NATL ACAD SCI USA, V75, P4925, DOI 10.1073/pnas.75.10.4925
   CHAPMAN AG, 1981, J NEUROCHEM, V36, P179, DOI 10.1111/j.1471-4159.1981.tb02393.x
   DETRE JA, 1990, J MOL CELL CARDIOL, V22, P543, DOI 10.1016/0022-2828(90)90956-3
   EVCANOCHKO WT, 1984, BIOCHIM BIOPHYS ACTA, V805, P104
   GLONEK T, 1982, J NEUROCHEM, V39, P1210, DOI 10.1111/j.1471-4159.1982.tb12557.x
   GYULAI L, 1984, FEBS LETT, V178, P137, DOI 10.1016/0014-5793(84)81257-0
   KORETSKY AP, 1989, J MOL CELL CARDIOL, V21, P59, DOI 10.1016/0022-2828(89)90838-9
   KORETSTKY AP, 1989, P NATL ACAD SCI USA, V87, P3112
   LITT L, 1980, MAGNET RESON MED, V3, P619
   MANDEL P, 1966, J NEUROCHEM, V13, P591, DOI 10.1111/j.1471-4159.1966.tb11955.x
   MILLER AL, 1977, J NEUROCHEM, V28, P1327, DOI 10.1111/j.1471-4159.1977.tb12328.x
   NAKADA T, 1989, MAGNET RESON MED, V12, P172, DOI 10.1002/mrm.1910120204
   NORWOOD WI, 1979, J THORAC CARDIOV SUR, V78, P823
   OGAWA S, 1986, ARCH BIOCHEM BIOPHYS, V248, P43, DOI 10.1016/0003-9861(86)90399-1
   PETTEGREW JW, 1987, J NEUROPATH EXP NEUR, V46, P419, DOI 10.1097/00005072-198707000-00002
   PETTEGREW JW, 1988, ARCH NEUROL-CHICAGO, V45, P1093, DOI 10.1001/archneur.1988.00520340047010
   SATRUSTEGUI J, 1988, MECH AGEING DEV, V42, P105, DOI 10.1016/0047-6374(88)90066-8
   SCHMIDT HC, 1986, PEDIATR RADIOL, V16, P144, DOI 10.1007/BF02386640
   STOLK JA, 1987, MAGNET RESON MED, V5, P78, DOI 10.1002/mrm.1910050110
   STOLK JA, 1989, BRAIN RES, V482, P1, DOI 10.1016/0006-8993(89)90536-2
   SUN GY, 1985, PHOSPHOLIPIDS NERVOU, P81
   TOFTS P, 1985, J PHYSIOL-LONDON, V359, P417, DOI 10.1113/jphysiol.1985.sp015593
   TOFTS P, 1984, FETAL NEONATAL PHYSL
NR 29
TC 0
Z9 0
U1 0
U2 4
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB
SN 0024-3205
J9 LIFE SCI
JI Life Sci.
PY 1991
VL 48
IS 21
BP 2057
EP 2063
DI 10.1016/0024-3205(91)90162-5
PG 7
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA FH165
UT WOS:A1991FH16500009
PM 2034035
DA 2024-02-19
ER

PT J
AU DECAVANAGH, EMV
   INSERRA, F
   FERDER, L
   ROMANO, L
   ERCOLE, L
   FRAGA, CG
AF DECAVANAGH, EMV
   INSERRA, F
   FERDER, L
   ROMANO, L
   ERCOLE, L
   FRAGA, CG
TI SUPEROXIDE-DISMUTASE AND GLUTATHIONE-PEROXIDASE ACTIVITIES ARE INCREASED
   BY ENALAPRIL AND CAPTOPRIL IN MOUSE-LIVER
SO FEBS LETTERS
LA English
DT Article
DE OXYGEN RADICAL; ENALAPRIL; CAPTOPRIL ANTIOXIDANT; AGING; HYPERTENSION
ID CONVERTING ENZYME-INHIBITORS; GLOMERULAR INJURY; ANGIOTENSIN;
   HYPERTENSION; RAT; INDUCTION; REDUCTION; FIBROSIS; RADICALS; SCAVENGE
AB We have characterized the effect of angiotensin converting enzyme (ACE) inhibitors on the activity of CuZn-superoxide dismutase (CuZn-SOD), Mn-superoxide dismutase (Mn-SOD), catalase, and selenium-dependent glutathione peroxidase (Se-GPx), CF1 mice (4-month-old females) were administered water containing enalapril (20 mg/l) or captopril (50 mg/l), during 4 to 11 weeks, After 11 weeks, enalapril treatment caused an increase in the activity of CuZn-SOD, Mn-SOD and Se-GPx, from 19 +/- 4 to 46 +/- 7, 2.1 +/- 0.2 to 3.8 +/- 0.2 units/mg protein and 27 +/- 3 to 54 +/- 3 milliunits/mg protein, respectively. After 11 weeks, captopril treatment increased the activities (P < 0.05) of CuZn-SOD, MnSOD and Se-GPx to 35 +/- 4, 2.9 +/- 0.2 units/mg protein, and 38 +/- 2 milliunits/mg protein, respectively. Catalase activity was not affected by the treatments. These results suggest that ACE inhibitors may protect cell components from oxidative damage by increasing the enzymatic antioxidant defenses.
C1 UNIV BUENOS AIRES,FAC FARM & BIOQUIM,SCH PHARM & BIOCHEM,DIV PHYS CHEM,RA-1113 BUENOS AIRES,DF,ARGENTINA.
   JEWISH HOSP,INST NEPHROL,BUENOS AIRES,DF,ARGENTINA.
C3 University of Buenos Aires; University of Buenos Aires
RI Fraga, Cesar/Q-8161-2019
OI Romano, Luis/0000-0003-3144-3579; Fraga, Cesar G./0000-0003-4168-9927
CR ALVAREZ S, 1993, ARCH BIOCHEM BIOPHYS, V305, P247, DOI 10.1006/abbi.1993.1418
   ANDERSON S, 1985, J CLIN INVEST, V76, P612, DOI 10.1172/JCI112013
   ARUOMA OI, 1991, CHEM-BIOL INTERACT, V77, P303, DOI 10.1016/0009-2797(91)90039-A
   BAGCHI D, 1989, BIOCHEM BIOPH RES CO, V158, P52, DOI 10.1016/S0006-291X(89)80175-5
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   CEBALLOSPICOT I, 1992, FREE RADICALS AGING, P89
   CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527
   CHOPRA M, 1992, J CARDIOVASC PHARM, V19, P330, DOI 10.1097/00005344-199203000-00005
   CHOPRA M, 1991, OXIDATIVE DAMAGE & REPAIR, P700
   DECAVANAGH EMV, 1993, MEDICINA S2, V53, P51
   DUBININA EE, 1993, FREE RADICAL BIO MED, V15, P473
   FERDER L, 1993, AM J PHYSIOL, V265, pC15, DOI 10.1152/ajpcell.1993.265.1.C15
   FLOHE L, 1984, METHOD ENZYMOL, V105, P93
   GRONER Y, 1992, CURRENT COMMUNICATIO, V5, P263
   GUNZLER WA, 1974, Z KLIN CHEM KLIN BIO, V12, P444
   GUOCHANG Z, 1992, FREE RAD RES COMM S1, V16, P16
   Halliwell Barry, 1993, American Journal of Clinical Nutrition, V57, p715S, DOI 10.1093/ajcn/57.5.715S
   Inserra Felipe, 1993, Journal of the American Society of Nephrology, V4, P607
   IRSHENBAUM LA, 1993, AM J PHYSIOL, V265, pH484
   JALIL JE, 1991, AM J HYPERTENS, V4, P51, DOI 10.1093/ajh/4.1.51
   JOLLY SR, 1984, CIRC RES, V54, P277, DOI 10.1161/01.RES.54.3.277
   KRALL J, 1988, J BIOL CHEM, V263, P1910
   KUKREJA RC, 1990, AM J CARDIOL, V65, pI24
   LOPEZTORRES M, 1993, FREE RADICAL BIO MED, V15, P133, DOI 10.1016/0891-5849(93)90052-V
   MEYER TW, 1987, KIDNEY INT, V31, P752, DOI 10.1038/ki.1987.62
   MIRA ML, 1993, FREE RADICAL RES COM, V19, P173, DOI 10.3109/10715769309111600
   MISIK V, 1993, FREE RADICAL BIO MED, V15, P611, DOI 10.1016/0891-5849(93)90164-P
   ORR WC, 1994, SCIENCE, V263, P1128, DOI 10.1126/science.8108730
   PRZYKLENK K, 1991, AM HEART J, V121, P1319, DOI 10.1016/0002-8703(91)90134-4
   SUZUKI S, 1993, PHARMACOLOGY, V47, P61, DOI 10.1159/000139079
   VANGILST WH, 1986, J CARDIOVASC PHARM, V8, P722
   WEBER KT, 1991, CIRCULATION, V83, P1849, DOI 10.1161/01.CIR.83.6.1849
   WHITE CW, 1993, FREE RADICAL BIO MED, V15, P629, DOI 10.1016/0891-5849(93)90166-R
   YAMAOKA K, 1991, FREE RADICAL BIO MED, V11, P299, DOI 10.1016/0891-5849(91)90127-O
NR 34
TC 81
Z9 84
U1 0
U2 1
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0014-5793
J9 FEBS LETT
JI FEBS Lett.
PD MAR 13
PY 1995
VL 361
IS 1
BP 22
EP 24
DI 10.1016/0014-5793(95)00137-X
PG 3
WC Biochemistry & Molecular Biology; Biophysics; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics; Cell Biology
GA QM606
UT WOS:A1995QM60600005
PM 7890034
OA Bronze
DA 2024-02-19
ER

PT J
AU Leite, AD
   Santiago, JF
   Levy, FM
   Maria, AG
   Fernandes, MD
   Salvadori, DMF
   Ribeiro, DA
   Buzalaf, MAR
AF Leite, Aline de Lima
   Santiago, Joel Ferreira, Jr.
   Levy, Flavia Mauad
   Maria, Andrea Gutierrez
   Fernandes, Mileni da Silva
   Favero Salvadori, Daisy Maria
   Ribeiro, Daniel Araki
   Rabelo Buzalaf, Marflia Afonso
TI Absence of DNA damage in multiple organs (blood, liver, kidney, thyroid
   gland and urinary bladder) after acute fluoride exposure in rats
SO HUMAN & EXPERIMENTAL TOXICOLOGY
LA English
DT Article
DE acute exposure; comet assay; DNA damage; fluoride; rats
ID SISTER-CHROMATID EXCHANGE; ALKALINE COMET ASSAY; ORAL MUCOSAL CELLS;
   SODIUM-FLUORIDE; WISTAR RATS; IN-VITRO; GENOTOXICITY; APOPTOSIS;
   CHLORHEXIDINE; CYTOTOXICITY
AB Fluoride has been widely used in dentistry as a caries prophylactic agent. However, there has been some speculation that excess fluoride could cause an impact on genome integrity. In the current study, the potential DNA damage associated with exposure to fluoride was assessed in cells of blood, liver, kidney, thyroid gland and urinary bladder by the single cell gel (comet) assay. Male Wistar rats aging 75 days were distributed into seven groups: Groups 1 (control), 2, 3, 4, 5, 6 and 7 received 0 (deionized water), 10, 20, 40, 60, 80 and 100 mgF/Kg body weight from sodium fluoride (NaF), respectively, by gastrogavage. These groups were killed at 2 h after the administration of the fluoride doses. The level of DNA strand breaks did not increase in all organs evaluated and at all doses of NaF tested, as depicted by the mean tail moment. Taken together, our results suggest that oral exposure to NaF did not result in systemic genotoxic effect in multiple organs related to fluoride toxicity. Since DNA damage is an important step in events leading to carcinogenesis, this study represents a relevant contribution to the correct evaluation of the potential health risk associated with chemical exposure.
C1 Univ Sao Paulo, Dept Biol Sci, Bauru Dent Sch, BR-17012901 Bauru, SP, Brazil.
   Univ Estadual Paulista, Dept Pathol, Botucatu Med Sch, Sao Paulo, Brazil.
   UNIFESP, Dept Hlth Sci, Santos, SP, Brazil.
C3 Universidade de Sao Paulo; Universidade Estadual Paulista; Universidade
   Federal de Sao Paulo (UNIFESP)
RP Buzalaf, MAR (corresponding author), Univ Sao Paulo, Dept Biol Sci, Bauru Dent Sch, Alameda Octavio Pinheiro Brisolla 9-75, BR-17012901 Bauru, SP, Brazil.
EM mbuzalaf@fob.usp.br
RI Maria, Andrea Gutierrez/AAR-9211-2020; Maria, Andrea
   Gutierrez/AAR-6104-2021; Fernandes, Mileni MS/F-7359-2015; Santiago
   Junior, Joel/E-5242-2013; Salvadori, Daisy M.F./E-7744-2012; Leite,
   Aline/J-9748-2012; levy, flavia mauad/B-4870-2015; Buzalaf, Marilia
   Afonso Rabelo/C-5228-2012; Ribeiro, Daniel Araki/B-4645-2017
OI Maria, Andrea Gutierrez/0000-0002-1615-8254; Santiago Junior,
   Joel/0000-0003-1735-2224; Salvadori, Daisy M.F./0000-0001-9323-3134;
   Leite, Aline/0000-0002-2112-1309; levy, flavia
   mauad/0000-0002-4912-5272; Buzalaf, Marilia Afonso
   Rabelo/0000-0002-5985-3951; 
CR ANASUYA A, 1982, J NUTR, V112, P1787, DOI 10.1093/jn/112.9.1787
   Anuradha CD, 2001, FREE RADICAL BIO MED, V31, P367, DOI 10.1016/S0891-5849(01)00591-3
   AULETTA A, 1988, ENVIRON MOL MUTAGEN, V11, P35
   Buzalaf MAR, 2002, FLUORIDE, V35, P185
   CHAVASSIEUX P, 1993, BONE, V14, P721, DOI 10.1016/8756-3282(93)90203-M
   CHAVASSIEUX P, 1991, OSTEOPOROSIS INT, V2, P26, DOI 10.1007/BF01627075
   Cotran R., 2000, PATOLOGIA ESTRUTURAL
   Eren E, 2005, TOXICOL IND HEALTH, V21, P255, DOI 10.1191/0748233705th236oa
   GRANDJEAN P, 1992, J NATL CANCER I, V84, P1903, DOI 10.1093/jnci/84.24.1903
   Grassi TF, 2007, INT J HYG ENVIR HEAL, V210, P163, DOI 10.1016/j.ijheh.2006.09.001
   Hartmann A, 2003, MUTAGENESIS, V18, P45, DOI 10.1093/mutage/18.1.45
   KHALIL AM, 1994, ARCH ENVIRON CON TOX, V26, P60, DOI 10.1007/BF00212794
   Kleinsasser NH, 2001, LARYNGO RHINO OTOL, V80, P187
   KONO K, 1987, ENVIRON RES, V42, P415, DOI 10.1016/S0013-9351(87)80208-6
   Kono K., 1986, STUD ENVIRON SCI, V27, P407
   LI Y, 1995, J DENT RES, V74, P1468, DOI 10.1177/00220345950740080601
   LI YM, 1989, MUTAT RES, V227, P159, DOI 10.1016/0165-7992(89)90040-7
   LI YM, 1988, MUTAT RES, V195, P127, DOI 10.1016/0165-1110(88)90021-8
   He LF, 2006, WORLD J GASTROENTERO, V12, P1144, DOI 10.3748/wjg.v12.i7.1144
   Meintières S, 2003, ENVIRON MOL MUTAGEN, V41, P260, DOI 10.1002/em.10156
   MENEZES LMB, 2003, FORENSIC SCI INT, V137, P209
   OHTA T, 1995, CALCIFIED TISSUE INT, V56, P390, DOI 10.1007/BF00301608
   OLIVE PL, 1990, RADIAT RES, V122, P86, DOI 10.2307/3577587
   Ribeiro DA, 2005, ORAL SURG ORAL MED O, V99, P637, DOI 10.1016/j.tripleo.2004.07.010
   Ribeiro DA, 2004, J PERIODONTAL RES, V39, P358, DOI 10.1111/j.1600-0765.2004.00759.x
   Ribeiro DA, 2004, CARIES RES, V38, P576, DOI 10.1159/000080590
   RIDEFELT P, 1992, ACTA PHYSIOL SCAND, V145, P275, DOI 10.1111/j.1748-1716.1992.tb09365.x
   Sasaki YF, 2002, MUTAT RES-GEN TOX EN, V519, P103, DOI 10.1016/S1383-5718(02)00128-6
   Shanthakumari D, 2004, TOXICOLOGY, V204, P219, DOI 10.1016/j.tox.2004.06.058
   SLAMENOVA D, 1992, MUTAT RES, V279, P109, DOI 10.1016/0165-1218(92)90252-U
   TAKAGI M, 1982, Bulletin of Tokyo Medical and Dental University, V29, P123
   TAVES DR, 1968, TALANTA, V15, P1015, DOI 10.1016/0039-9140(68)80109-2
   Tice RR, 2000, ENVIRON MOL MUTAGEN, V35, P206, DOI 10.1002/(SICI)1098-2280(2000)35:3<206::AID-EM8>3.0.CO;2-J
   Wang YN, 2000, TOXICOLOGY, V146, P161, DOI 10.1016/S0300-483X(00)00167-0
   Whitford GM, 1996, METABOLISM TOXICITY
   *WHO, 1994, 846 WHO
NR 36
TC 17
Z9 20
U1 0
U2 4
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0960-3271
EI 1477-0903
J9 HUM EXP TOXICOL
JI Hum. Exp. Toxicol.
PD MAY
PY 2007
VL 26
IS 5
BP 435
EP 440
DI 10.1177/0960327107076288
PG 6
WC Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Toxicology
GA 191TX
UT WOS:000248156000006
PM 17623768
DA 2024-02-19
ER

PT J
AU Wang, YH
   Katzenmeyer, JB
   Arriaga, EA
AF Wang, Yaohua
   Katzenmeyer, Joseph B.
   Arriaga, Edgar A.
TI Combination of Micellar Electrokinetic and High-Performance Liquid
   Chromatographies to Assess Age-Related Changes in the In Vitro
   Metabolism of Fischer 344 Rat Liver
SO JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL
   SCIENCES
LA English
DT Article
DE Metabolism; Doxorubicin; Capillary electrophoresis; Fluorescence;
   HPLC-MS
ID LASER-INDUCED FLUORESCENCE; DRUG-METABOLISM; DOXORUBICIN METABOLISM;
   ANTICANCER DRUG; PHARMACOKINETICS; ADRIAMYCIN; GENDER; RABBIT;
   CHEMOTHERAPY; TOXICITY
AB The metabolism of doxorubicin, a widely used anticancer drug, is different in young adult and old cancer patients. In this study, we demonstrate that micellar electrokinetic chromatography with laser-induced fluorescence detection is highly suited to monitor the metabolism of doxorubicin in subcellular fractions isolated from young adult (11 months, 100% survival rate) and old (26 months, similar to 25% survival rate) Fischer 344 rat livers. The relative amounts of doxorubicin metabolized in both mitochondria-enriched and postmitochondria fractions of young adult were larger than the respective fractions of old rat liver. 7-Deoxydoxorubicinolone and 7-deoxydoxorubicinone were identified using internal standard addition and structural elucidation by high-performance liquid chromatography with combined laser-induced fluorescence and mass spectrometry detection. Although high-performance liquid chromatography with combined laser-induced fluorescence and mass spectrometry detection is more useful in the identification of compounds, micellar electrokinetic chromatography with laser-induced fluorescence detection has low-sample requirements, simplified sample processing procedures, short analysis times and low limit of detection. Therefore, the combination of these two techniques provides a powerful approach to investigate metabolism of fluorescent drugs in aging studies.
C1 [Wang, Yaohua; Katzenmeyer, Joseph B.; Arriaga, Edgar A.] Univ Minnesota, Dept Chem, Minneapolis, MN 55455 USA.
C3 University of Minnesota System; University of Minnesota Twin Cities
RP Arriaga, EA (corresponding author), Univ Minnesota, Dept Chem, 207 Pleasant St SE, Minneapolis, MN 55455 USA.
EM arriaga@umn.edu
FU Merck; NIH [T32-AG029796]
FX Y.W. was supported by a Merck Graduate Fellowship in Analytical/Physical
   Chemistry. J.B.K was supported by NIH Training grant T32-AG029796.
CR Anderson AB, 2003, ANAL CHEM, V75, P8, DOI 10.1021/ac020426r
   Arnold RD, 2004, J CHROMATOGR B, V808, P141, DOI 10.1016/j.jchromb.2004.04.030
   BLUM RH, 1974, ANN INTERN MED, V80, P249, DOI 10.7326/0003-4819-80-2-249
   Butler JM, 2008, CLIN PHARMACOKINET, V47, P297, DOI 10.2165/00003088-200847050-00002
   COLOMBO T, 1989, EXP GERONTOL, V24, P159, DOI 10.1016/0531-5565(89)90026-0
   CUSACK BJ, 1993, TOXICOL APPL PHARM, V118, P177, DOI 10.1006/taap.1993.1023
   Cusack BJ, 2003, CANCER CHEMOTH PHARM, V51, P139, DOI 10.1007/s00280-002-0544-1
   Donelli MG, 1998, EUR J CANCER, V34, P33, DOI 10.1016/S0959-8049(97)00340-7
   Eder AR, 2006, ELECTROPHORESIS, V27, P3263, DOI 10.1002/elps.200600025
   GALINSKY RE, 1990, J PHARMACOL EXP THER, V255, P577
   GEORGE J, 1995, BIOCHEM PHARMACOL, V50, P727, DOI 10.1016/0006-2952(95)00192-3
   GEWIRTZ DA, 1987, BIOCHEM PHARMACOL, V36, P1793, DOI 10.1016/0006-2952(87)90240-1
   John V, 2003, DRUG AGING, V20, P737, DOI 10.2165/00002512-200320100-00003
   Katzenmeyer JB, 2010, ANAL CHEM, V82, P8113, DOI 10.1021/ac1011415
   King CD, 2000, CURR DRUG METAB, V1, P143, DOI 10.2174/1389200003339171
   Klotz U, 2009, DRUG METAB REV, V41, P67, DOI 10.1080/03602530902722679
   Licata S, 2000, CHEM RES TOXICOL, V13, P414, DOI 10.1021/tx000013q
   Lichtman SM, 2007, J CLIN ONCOL, V25, P1832, DOI 10.1200/JCO.2007.10.6583
   Maton A., 1993, HUMAN BIOL HLTH
   Negishi M, 2001, ARCH BIOCHEM BIOPHYS, V390, P149, DOI 10.1006/abbi.2001.2368
   PETERS MA, 1970, J PHARMACOL EXP THER, V173, P233
   Pollak N, 2007, BIOCHEM J, V402, P205, DOI 10.1042/BJ20061638
   PREISS R, 1987, J CANCER RES CLIN, V113, P593, DOI 10.1007/BF00390872
   SANTAMARIA C, 1988, MECH AGEING DEV, V44, P115, DOI 10.1016/0047-6374(88)90084-X
   SCHMUCKER DL, 1990, CLIN PHARMACOL THER, V48, P365, DOI 10.1038/clpt.1990.164
   Sekine I, 1998, JPN J CLIN ONCOL, V28, P463, DOI 10.1093/jjco/28.8.463
   SHIMADA T, 1994, J PHARMACOL EXP THER, V270, P414
   Sotaniemi EA, 1997, CLIN PHARMACOL THER, V61, P331, DOI 10.1016/S0009-9236(97)90166-1
   Sturgill MG, 2000, CANCER INVEST, V18, P197, DOI 10.3109/07357900009031824
   TAKAHASHI R, 1987, ARCH GERONTOL GERIAT, V6, P73, DOI 10.1016/0167-4943(87)90040-9
   TAKANASHI S, 1976, DRUG METAB DISPOS, V4, P79
   VONHOFF DD, 1979, ANN INTERN MED, V91, P710, DOI 10.7326/0003-4819-91-5-710
   VRIGNAUD P, 1986, EUR J DRUG METAB PH, V11, P101, DOI 10.1007/BF03189834
   Wang YH, 2009, ANAL CHEM, V81, P3321, DOI 10.1021/ac802542e
   Wildiers H, 2003, CLIN PHARMACOKINET, V42, P1213, DOI 10.2165/00003088-200342140-00003
NR 35
TC 1
Z9 2
U1 0
U2 8
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1079-5006
J9 J GERONTOL A-BIOL
JI J. Gerontol. Ser. A-Biol. Sci. Med. Sci.
PD SEP
PY 2011
VL 66
IS 9
BP 935
EP 943
DI 10.1093/gerona/glr074
PG 9
WC Geriatrics & Gerontology; Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Geriatrics & Gerontology
GA 809OP
UT WOS:000294066900002
PM 21746738
OA Green Published, Bronze
DA 2024-02-19
ER

PT J
AU Danpanichkul, P
   Kongarin, S
   Permpatdechakul, S
   Polpichai, N
   Duangsonk, K
   Manosroi, W
   Chaiyakunapruk, N
   Mousa, OY
   Kim, D
   Chen, VL
   Wijarnpreecha, K
AF Danpanichkul, Pojsakorn
   Kongarin, Siwanart
   Permpatdechakul, Sarunpakorn
   Polpichai, Natchaya
   Duangsonk, Kwanjit
   Manosroi, Worapaka
   Chaiyakunapruk, Nathorn
   Mousa, Omar Y.
   Kim, Donghee
   Chen, Vincent L.
   Wijarnpreecha, Karn
TI The Surreptitious Burden of Nonalcoholic Fatty Liver Disease in the
   Elderly in the Asia-Pacific Region: An Insight from the Global Burden of
   Disease Study 2019
SO JOURNAL OF CLINICAL MEDICINE
LA English
DT Article
DE steatotic liver disease; elderly; Asia; epidemiology; geriatrics
ID NAFLD; METABOLISM; FIBROSIS; HEALTH
AB Nonalcoholic fatty liver disease (NAFLD) represents a significant health threat worldwide. The aging population and a rise in metabolic syndrome in Asia might influence the epidemiology of NAFLD among the elderly. However, there is a lack of understanding of the burden and recommendations for NAFLD in this group. Our study sought to investigate the trends in the NAFLD burden among the elderly in the Asia-Pacific region. We employed data from the Global Burden of Disease 2019 study for an in-depth analysis of the prevalence and disability-adjusted life years (DALYs) along with age-standardized rate (ASR) associated with NAFLD in elderly populations (age 65-89 years) across the Asia-Pacific region, including the Southeast Asia (SEA) and Western Pacific (WP) regions, from 2010 to 2019. This study also examined the trends and disparities in NAFLD burden across different nations and sexes. In 2019, there were over 120 million cases of NAFLD in the elderly in the Asia-Pacific region. The ASR of prevalence was higher in SEA compared to WP (36,995.37 vs. 32,821.78 per 100,000). ASR of prevalence increased with annual percentage change (APC) +0.95% in the WP while it increased by +0.87% in SEA. During the study period, the ASR of DALYs decreased in SEA (APC -0.41%) but remained stable in the WP region. The burden of NAFLD in the elderly population in Asia-Pacific has increased, underscoring the timely intervention to tackle this high and rising burden.
C1 [Danpanichkul, Pojsakorn] Chiang Mai Univ, Fac Med, Dept Microbiol, Immunol Unit, Chiang Mai 50200, Thailand.
   [Kongarin, Siwanart; Permpatdechakul, Sarunpakorn] Chiang Mai Univ, Fac Med, Chiang Mai 50200, Thailand.
   [Polpichai, Natchaya] Weiss Mem Hosp, Dept Internal Med, Chicago, IL 60640 USA.
   [Duangsonk, Kwanjit] Chiang Mai Univ, Fac Med, Dept Microbiol, Chiang Mai 50200, Thailand.
   [Manosroi, Worapaka] Chiang Mai Univ, Dept Internal Med, Div Endocrinol, Chiang Mai 50200, Thailand.
   [Manosroi, Worapaka] Chiang Mai Univ, Fac Med, Clin Epidemiol & Clin Stat Ctr, Chiang Mai 50200, Thailand.
   [Chaiyakunapruk, Nathorn] Univ Utah, Coll Pharm, Dept Pharmacotherapy, Salt Lake City, UT 84112 USA.
   [Chaiyakunapruk, Nathorn] Vet Affairs Salt Lake City Healthcare Syst, IDEAS Ctr, Salt Lake City, UT 84108 USA.
   [Mousa, Omar Y.] Mayo Clin, Dept Internal Med, Div Gastroenterol & Hepatol, Rochester, MN 55902 USA.
   [Kim, Donghee] Stanford Univ, Sch Med, Div Gastroenterol & Hepatol, Stanford, CA 94305 USA.
   [Chen, Vincent L.] Univ Michigan, Dept Internal Med, Div Gastroenterol & Hepatol, Ann Arbor, MI 41809 USA.
   [Wijarnpreecha, Karn] Univ Arizona, Dept Med, Div Gastroenterol & Hepatol, Coll Med, Phoenix, AZ 85004 USA.
   [Wijarnpreecha, Karn] Banner Univ Med Ctr, Dept Internal Med, Div Gastroenterol & Hepatol, Phoenix, AZ 85006 USA.
C3 Chiang Mai University; Chiang Mai University; Chiang Mai University;
   Chiang Mai University; Chiang Mai University; Utah System of Higher
   Education; University of Utah; US Department of Veterans Affairs; Mayo
   Clinic; Stanford University; University of Michigan System; University
   of Michigan; University of Arizona
RP Danpanichkul, P (corresponding author), Chiang Mai Univ, Fac Med, Dept Microbiol, Immunol Unit, Chiang Mai 50200, Thailand.; Wijarnpreecha, K (corresponding author), Univ Arizona, Dept Med, Div Gastroenterol & Hepatol, Coll Med, Phoenix, AZ 85004 USA.; Wijarnpreecha, K (corresponding author), Banner Univ Med Ctr, Dept Internal Med, Div Gastroenterol & Hepatol, Phoenix, AZ 85006 USA.
EM pojsakorndan@gmail.com; natchayap.md@gmail.com;
   nathorn.chaiyakunapruk@utah.edu; dhkimmd@stanford.edu;
   dr.karn.wi@gmail.com
RI ; Kim, Donghee/C-4288-2013
OI Wijarnpreecha, Karn/0000-0002-6232-6343; Manosroi,
   Worapaka/0000-0002-3007-3951; Chaiyakunapruk,
   Nathorn/0000-0003-4572-8794; Kim, Donghee/0000-0003-1919-6800; Chen,
   Vincent/0000-0002-0157-6066
FU We would like to acknowledge the use of resources from
   <uri>www.mapchart.net</uri> (accessed on 10 August 2023) in the design
   of the map figure.
FX We would like to acknowledge the use of resources from
   <URI>www.mapchart.net</URI> (accessed on 10 August 2023) in the design
   of the map figure.
CR Abbafati C, 2020, LANCET, V396, P1204, DOI 10.1016/S0140-6736(20)30925-9
   Alqahtani SA, 2021, CLIN INTERV AGING, V16, P1633, DOI 10.2147/CIA.S295524
   Bertolotti M, 2014, WORLD J GASTROENTERO, V20, P14185, DOI 10.3748/wjg.v20.i39.14185
   Cameron KA, 2010, J WOMENS HEALTH, V19, P1643, DOI 10.1089/jwh.2009.1701
   Cao WJ, 2022, ENDOCR J, V69, P1007, DOI 10.1507/endocrj.EJ21-0559
   Chen VL, 2023, GASTROENTEROLOGY, V164, P966, DOI 10.1053/j.gastro.2023.01.040
   Claramita M, 2013, ADV HEALTH SCI EDUC, V18, P15, DOI 10.1007/s10459-012-9352-5
   Cvitanovic T, 2017, HEPATOLOGY, V66, P1323, DOI 10.1002/hep.29268
   Danpanichkul P, 2023, ALIMENT PHARM THER, V58, P1062, DOI 10.1111/apt.17714
   Eslam M, 2020, HEPATOL INT, V14, P889, DOI 10.1007/s12072-020-10094-2
   Fan JG, 2017, J HEPATOL, V67, P862, DOI 10.1016/j.jhep.2017.06.003
   Forlano R, 2023, METABOLITES, V13, DOI 10.3390/metabo13040536
   Goh Victor H H, 2005, Aging Male, V8, P90, DOI 10.1080/13685530500088472
   Gu YY, 2022, ANN NUTR METAB, V78, P21, DOI 10.1159/000520368
   Hamaguchi M, 2012, WORLD J GASTROENTERO, V18, P237, DOI 10.3748/wjg.v18.i3.237
   Hartleb M, 2017, LIVER INT, V37, P1706, DOI 10.1111/liv.13471
   Herrera AP, 2010, AM J PUBLIC HEALTH, V100, pS105, DOI 10.2105/AJPH.2009.162982
   Honda Y, 2019, HEPATOL RES, V49, P1136, DOI 10.1111/hepr.13382
   Jiang W, 2023, J CLIN GASTROENTEROL, V57, P631, DOI 10.1097/MCG.0000000000001739
   Kasper P, 2021, CLIN RES CARDIOL, V110, P921, DOI 10.1007/s00392-020-01709-7
   Kim D, 2022, HEPATOBIL SURG NUTR, V11, P317, DOI 10.21037/hbsn-21-571
   Li Y, 2022, AGING DIS, V13, P1239, DOI 10.14336/AD.2022.0318
   Lomas-Soria C, 2021, J PHYSIOL-LONDON, V599, P4309, DOI 10.1113/JP281822
   Lonardo A, 2021, ADV THER, V38, P2130, DOI 10.1007/s12325-021-01690-1
   Lonardo A, 2019, HEPATOLOGY, V70, P1457, DOI 10.1002/hep.30626
   Lu FB, 2020, J GASTROEN HEPATOL, V35, P2041, DOI 10.1111/jgh.15156
   Nanditha A, 2016, DIABETES CARE, V39, P472, DOI 10.2337/dc15-1536
   Noureddin M, 2013, HEPATOLOGY, V58, P1644, DOI 10.1002/hep.26465
   Paik JM, 2023, CELL METAB, V35, P1087, DOI 10.1016/j.cmet.2023.06.012
   Paik JM, 2022, HEPATOLOGY, V75, P1204, DOI 10.1002/hep.32228
   Pennisi G, 2021, CLIN GASTROENTEROL H, V19, P1979, DOI 10.1016/j.cgh.2020.09.009
   Pramfalk C, 2015, J CLIN ENDOCR METAB, V100, P4425, DOI 10.1210/jc.2015-2649
   Rinella ME, 2023, HEPATOLOGY, V78, P1966, DOI 10.1097/HEP.0000000000000520
   Rostad B, 2009, EUR J AGEING, V6, P39, DOI 10.1007/s10433-008-0104-6
   Skubic C, 2018, EXPERT OPIN DRUG MET, V14, P831, DOI 10.1080/17425255.2018.1492552
   Solfrizzi V, 2020, ALZH DEMENT-TRCI, V6, DOI 10.1002/trc2.12065
   Song Sherlot Juan, 2024, J Hepatol, V80, pe54, DOI 10.1016/j.jhep.2023.07.021
   Targher G, 2021, DIABETES METAB, V47, DOI 10.1016/j.diabet.2020.101215
   Targher G, 2020, GUT, V69, P1691, DOI 10.1136/gutjnl-2020-320622
   Tomas TC, 2018, ACTA CHIM SLOV, V65, P253, DOI 10.17344/acsi.2018.4461
   Venetsanaki V, 2019, CURR VASC PHARMACOL, V17, P546, DOI 10.2174/1570161116666180711121949
   Wang D, 2022, FRONT NUTR, V9, DOI 10.3389/fnut.2022.1047129
   Wijampreecha K, 2019, MATURITAS, V124, P48, DOI 10.1016/j.maturitas.2019.03.016
   Wijarnpreecha K, 2023, ALIMENT PHARM THER, V57, P1014, DOI 10.1111/apt.17424
   Wong VWS, 2023, J HEPATOL, V79, P842, DOI 10.1016/j.jhep.2023.04.036
   Wu Y, 2021, SOC SCI MED, V269, DOI 10.1016/j.socscimed.2020.113601
   Yip TCF, 2022, J HEPATOL, V76, P726, DOI 10.1016/j.jhep.2021.09.024
   Younossi Z, 2018, NAT REV GASTRO HEPAT, V15, P11, DOI 10.1038/nrgastro.2017.109
NR 48
TC 1
Z9 1
U1 3
U2 3
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2077-0383
J9 J CLIN MED
JI J. Clin. Med.
PD OCT
PY 2023
VL 12
IS 20
AR 6456
DI 10.3390/jcm12206456
PG 12
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA W1PE7
UT WOS:001089412500001
PM 37892594
OA gold, Green Published
DA 2024-02-19
ER

PT J
AU Lee, G
   Lee, H
   Hong, J
   Lee, SH
   Jung, BH
AF Lee, Gakyung
   Lee, Hyunbeom
   Hong, Jongki
   Lee, Soo Hyun
   Jung, Byung Hwa
TI Quantitative profiling of bile acids in rat bile using
   ultrahigh-performance liquid chromatography-orbitrap mass spectrometry:
   Alteration of the bile acid composition with aging
SO JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL
   AND LIFE SCIENCES
LA English
DT Article
DE Aging; Bile acids (BAs); Bile; UPLC-Orbitrap-MS
ID NUCLEAR RECEPTOR; MOUSE-LIVER; PLASMA; BIOMARKERS; LIGANDS
AB Bile acids (BAs) play important roles in physiological functions, including the homeostasis of cholesterol and lipids and as ligands for G protein-coupled receptors (GPCRs). With the increasing importance of BAs, analytical methods for their quantification and screening have been developed. However, due to the diverse range and variety of BAs with different activation potency, a simple, effective, and sensitive method is required to screen BAs for accurate quantification and identification. This paper presents an application of ultrahigh-performance liquid chromatography-orbitrap mass spectrometry (UHPLC-LTQ-Orbitrap MS) for profiling BAs in bile. Using this method, along with the accurate quantification of 19 targeted BAs, 22 unknown BAs were detected and characterized by their fragmentation patterns. The method is beneficial for screening most of the BAs (quantitatively and qualitatively) in rat bile with simple preparation in a single run. The sample dilution ranges of each BA were optimized depending on the concentration of BAs in the bile to obtain good peak separation and accurate data. The method validation was performed successfully using charcoal-treated bile and the intra and inter-day coefficients of variation were less than 20% for all BAs while the recovery were above 88.5% except for the lithocholic acid. The method was applied to profile the age-dependent changes in the contents of rat BAs. Through statistical analysis, we found that as the rats aged, unconjugated BAs and glycine-conjugated BAs decreased or were unaffected, while taurine-conjugated BAs were increased in general. Among the unknown BAs, 5 of the taurine-conjugated BAs increased, while a glycine-conjugated BA decreased, in agreement with the trends of the targeted BAs. (C) 2016 Elsevier B.V. All rights reserved.
C1 [Lee, Gakyung; Lee, Hyunbeom; Jung, Byung Hwa] Korea Inst Sci & Technol, Mol Recognit Res Ctr, 5 Hwarang Ro 14 Gil, Seoul 02792, South Korea.
   [Lee, Gakyung; Hong, Jongki] Kyung Hee Univ, Dept Basic Pharmaceut Sci, Seoul 02447, South Korea.
   [Jung, Byung Hwa] Korea Univ Sci & Technol, Dept Biol Chem, Daejeon 34113, South Korea.
   [Lee, Soo Hyun] Kongju Natl Univ, Dept Med Records & Hlth Informat Management, Coll Nursing & Hlth, Kong Ju 32588, South Korea.
C3 Korea Institute of Science & Technology (KIST); Kyung Hee University;
   University of Science & Technology (UST); Kongju National University
RP Jung, BH (corresponding author), Korea Inst Sci & Technol, Mol Recognit Res Ctr, 5 Hwarang Ro 14 Gil, Seoul 02792, South Korea.
EM jbhluck@kist.re.kr
OI Lee, Hyunbeom/0000-0001-6954-7520
FU Creative Fusion Research Program through the Creative Allied Project -
   Korea Research Council of Fundamental Science and Technology
   [CAP-12-1-KIST]; Ministry of Science, ICT and Future planning through
   the National Research Foundation [NRF-2013M3A9C4078145]
FX This study was supported by the Creative Fusion Research Program through
   the Creative Allied Project funded by the Korea Research Council of
   Fundamental Science and Technology (CAP-12-1-KIST) and the Bio-Synergy
   Research Project (NRF-2013M3A9C4078145) of the Ministry of Science, ICT
   and Future planning through the National Research Foundation.
CR ALME B, 1977, J LIPID RES, V18, P339
   Alnouti Y, 2008, J CHROMATOGR B, V873, P209, DOI 10.1016/j.jchromb.2008.08.018
   Bathena SPR, 2015, TOXICOL SCI, V143, P308, DOI 10.1093/toxsci/kfu228
   Bathena SPR, 2015, TOXICOL SCI, V143, P296, DOI 10.1093/toxsci/kfu227
   Chen C., 2005, CURR PROTOC TOXICOL, V7
   Department of Health Human Services, 2001, DRUG EVAL RES
   Duboc H, 2013, GUT, V62, P531, DOI 10.1136/gutjnl-2012-302578
   Gems D, 2007, AGING CELL, V6, P421, DOI 10.1111/j.1474-9726.2007.00309.x
   Gerard P, 2014, PATHOGENS, V3, P14, DOI 10.3390/pathogens3010014
   GOTO J, 1983, J CHROMATOGR, V276, P289, DOI 10.1016/S0378-4347(00)85095-1
   He JH, 2011, GASTROENTEROLOGY, V140, P2095, DOI 10.1053/j.gastro.2011.02.055
   Hofmann AF, 2004, DRUG METAB REV, V36, P703, DOI 10.1081/DMR-200033475
   Huang JG, 2011, J PHARMACEUT BIOMED, V55, P1111, DOI 10.1016/j.jpba.2011.03.035
   Humbert L, 2012, J CHROMATOGR B, V899, P135, DOI 10.1016/j.jchromb.2012.05.015
   Jäntti SE, 2014, ANAL BIOANAL CHEM, V406, P7799, DOI 10.1007/s00216-014-8230-9
   John C, 2014, J CHROMATOGR A, V1371, P184, DOI 10.1016/j.chroma.2014.10.064
   Kawamata Y, 2003, J BIOL CHEM, V278, P9435, DOI 10.1074/jbc.M209706200
   Kim IH, 2015, CURR OPIN GASTROEN, V31, P184, DOI 10.1097/MOG.0000000000000176
   Makishima M, 2002, SCIENCE, V296, P1313, DOI 10.1126/science.1070477
   Makishima M, 1999, SCIENCE, V284, P1362, DOI 10.1126/science.284.5418.1362
   Martin FPJ, 2007, MOL SYST BIOL, V3, DOI 10.1038/msb4100153
   MASUDA N, 1981, MICROBIOL IMMUNOL, V25, P1
   Melgarejo T, 2000, DIGEST DIS SCI, V45, P407, DOI 10.1023/A:1005493416946
   Parks DJ, 1999, SCIENCE, V284, P1365, DOI 10.1126/science.284.5418.1365
   REDDY BS, 1977, CANCER RES, V37, P3238
   Ridlon JM, 2014, CURR OPIN GASTROEN, V30, P332, DOI 10.1097/MOG.0000000000000057
   RODA A, 1992, J LIPID RES, V33, P1393
   ROSSI SS, 1987, J LIPID RES, V28, P589
   Sarafian MH, 2015, ANAL CHEM, V87, P9662, DOI 10.1021/acs.analchem.5b01556
   Scherer M, 2009, J CHROMATOGR B, V877, P3920, DOI 10.1016/j.jchromb.2009.09.038
   Tagliacozzi D, 2003, CLIN CHEM LAB MED, V41, P1633, DOI 10.1515/CCLM.2003.247
   Thomas C, 2008, NAT REV DRUG DISCOV, V7, P678, DOI 10.1038/nrd2619
   Trauner Michael, 2013, Gastroenterology, V144, P844, DOI 10.1053/j.gastro.2013.02.029
   Wang HB, 1999, MOL CELL, V3, P543, DOI 10.1016/S1097-2765(00)80348-2
   Wang J, 2014, J AGR FOOD CHEM, V62, P10375, DOI 10.1021/jf503778c
   Woodmansey EJ, 2007, J APPL MICROBIOL, V102, P1178, DOI 10.1111/j.1365-2672.2007.03400.x
NR 36
TC 24
Z9 25
U1 2
U2 55
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1570-0232
EI 1873-376X
J9 J CHROMATOGR B
JI J. Chromatogr. B
PD SEP 15
PY 2016
VL 1031
BP 37
EP 49
DI 10.1016/j.jchromb.2016.07.017
PG 13
WC Biochemical Research Methods; Chemistry, Analytical
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA DV0FN
UT WOS:000382593500005
PM 27450898
DA 2024-02-19
ER

PT J
AU Kuo, YH
   Lin, TW
   Lin, JY
   Chen, YW
   Li, TJ
   Chen, CC
AF Kuo, Yu-Hsuan
   Lin, Ting-Wei
   Lin, Jing-Yi
   Chen, Yu-Wen
   Li, Tsung-Ju
   Chen, Chin-Chu
TI Identification of Common Liver Metabolites of the Natural Bioactive
   Compound Erinacine A, Purified from <i>Hericium erinaceus</i> Mycelium
SO APPLIED SCIENCES-BASEL
LA English
DT Article
DE erinacine A; metabolites; Hericium erinaceus mycelium; mass spectrometry
ID DRUG-METABOLISM; MUSHROOM; HYDROGENATION; YAMABUSHITAKE; MECHANISM;
   DISCOVERY; INJURY
AB Metabolite identification, in the early stage, for compound discovery is necessary to assess the knowledge for the pharmaceutical improvement of drug safety and efficacy. Even if the drug has been released into the market, identification and continuous evaluation of the metabolites are required to avoid the risk of post-marketing withdrawal. Hericium erinaceus (HE), a medicinal mushroom, has broadly documented nutraceutical benefits, including anti-oxidant, anti-tumor, anti-aging, hypolipidemic, and gastric mucosal protection effects. Recently, erinacine A has been reported as the main natural bioactive compound in the mycelium of HE for functional food development. In neurological studies, the consumption of enrinacine A enriched HE mycelium demonstrates its significant nutraceutical effects in Alzheimer's disease, Parkinson's disease, and ischemic stroke. For the first time, we explored the metabolic process of erinacine A molecule and identified its metabolites from the rat and human liver S9 fraction. Using a liquid chromatography/triple quadrupole mass spectrometer for quantitative analysis, we observed that 75.44% of erinacine A was metabolized within 60 min in rat, and 32.34% of erinacine A was metabolized within 120 min in human S9. Using an ultra-performance liquid chromatography/quadrupole time-of-flight mass spectrometry (UPLC-QTOF/MS) to identify the metabolites of erinacine A, five common metabolites were identified, and their possible structures were evaluated. Understanding the metabolic process of erinacine A and establishing its metabolite profile database will help promote the nutraceutical application and discovery of related biomarkers in the future.
C1 [Kuo, Yu-Hsuan; Lin, Ting-Wei; Lin, Jing-Yi; Chen, Yu-Wen; Li, Tsung-Ju; Chen, Chin-Chu] Grape King Bio, Biotech Res Inst, Taoyuan 32542, Taiwan.
   [Chen, Chin-Chu] Shih Chien Univ, Dept Food Sci Nutr & Nutraceut Biotechnol, Taipei 11031, Taiwan.
   [Chen, Chin-Chu] Chung Yuan Christian Univ, Biosci Technol, Taoyuan 32023, Taiwan.
   [Chen, Chin-Chu] Natl Taiwan Univ, Inst Food Sci & Technol, Taipei 10617, Taiwan.
C3 Shih Chien University; Chung Yuan Christian University; National Taiwan
   University
RP Li, TJ; Chen, CC (corresponding author), Grape King Bio, Biotech Res Inst, Taoyuan 32542, Taiwan.; Chen, CC (corresponding author), Shih Chien Univ, Dept Food Sci Nutr & Nutraceut Biotechnol, Taipei 11031, Taiwan.; Chen, CC (corresponding author), Chung Yuan Christian Univ, Biosci Technol, Taoyuan 32023, Taiwan.; Chen, CC (corresponding author), Natl Taiwan Univ, Inst Food Sci & Technol, Taipei 10617, Taiwan.
EM yuhsuan.kuo@grapeking.com.tw; tingwei.lin@grapeking.com.tw;
   jingyi.lin@grapeking.com.tw; annie.chen@grapeking.com.tw;
   tsungju.li@grapeking.com.tw; drccchen@g2.usc.edu.tw
RI CHEN, YU-WEN/M-2183-2018
OI CHEN, YU-WEN/0000-0002-4335-7574
CR Abrams ME, 2020, NAT MICROBIOL, V5, P929, DOI 10.1038/s41564-020-0701-5
   Alamri ZZ, 2018, International Journal of Basic Clinical Pharmacology, V7, P2271, DOI DOI 10.18203/23192003.IJBCP20184211
   Azad RK, 2019, BRIEF BIOINFORM, V20, P1957, DOI 10.1093/bib/bbx170
   Bhandari DR, 2014, ANAL BIOANAL CHEM, V406, P695, DOI 10.1007/s00216-013-7496-7
   Bockisch C, 2018, ACS EARTH SPACE CHEM, V2, P821, DOI 10.1021/acsearthspacechem.8b00030
   BOND GC, 1964, ADV CATAL, V15, P91
   Chiu CH, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19020341
   Corsini A, 2013, J CLIN PHARMACOL, V53, P463, DOI 10.1002/jcph.23
   de Montellano PRO, 2010, CHEM REV, V110, P932, DOI 10.1021/cr9002193
   Diao XX, 2019, FRONT CHEM, V7, DOI 10.3389/fchem.2019.00109
   Farnberger JE, 2018, COMMUN CHEM, V1, DOI 10.1038/s42004-018-0083-2
   HALPERN J, 1982, SCIENCE, V217, P401, DOI 10.1126/science.217.4558.401
   He XR, 2017, INT J BIOL MACROMOL, V97, P228, DOI 10.1016/j.ijbiomac.2017.01.040
   Hu T, 2020, FOOD CHEM, V331, DOI 10.1016/j.foodchem.2020.127287
   KAWAGISHI H, 1990, TETRAHEDRON LETT, V31, P373, DOI 10.1016/S0040-4039(00)94558-1
   KAWAGISHI H, 1994, TETRAHEDRON LETT, V35, P1569, DOI 10.1016/S0040-4039(00)76760-8
   Keong CY, 2007, NUTR FOOD SCI, V37, P260, DOI 10.1108/00346650710774631
   Khan Md Asaduzzaman, 2013, J Complement Integr Med, V10, DOI 10.1515/jcim-2013-0001
   Kim KH, 2012, J ANTIBIOT, V65, P575, DOI 10.1038/ja.2012.65
   Kuo HC, 2016, J TRANSL MED, V14, DOI 10.1186/s12967-016-0831-y
   Lee KF, 2014, INT J MOL SCI, V15, P15073, DOI 10.3390/ijms150915073
   Lee LY, 2021, NUTRIENTS, V13, DOI 10.3390/nu13103659
   Li IC, 2020, FRONT AGING NEUROSCI, V12, DOI 10.3389/fnagi.2020.00155
   Li IC, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0217226
   Li IC, 2014, FOOD CHEM TOXICOL, V70, P61, DOI 10.1016/j.fct.2014.04.040
   Li TJ, 2021, MOLECULES, V26, DOI 10.3390/molecules26196018
   Ma BJ, 2010, J ANTIBIOT, V63, P713, DOI 10.1038/ja.2010.112
   Mitra V, 2009, ANAEST INTENS CARE M, V10, P332, DOI 10.1016/j.mpaic.2009.03.012
   Mori K, 2009, PHYTOTHER RES, V23, P367, DOI 10.1002/ptr.2634
   Pines H., 1966, ADV CATAL, V16, P49
   Prasad B, 2011, TRAC-TREND ANAL CHEM, V30, P360, DOI 10.1016/j.trac.2010.10.014
   Richardson Samantha J, 2016, Drug Metab Lett, V10, P83
   RussellJones GJ, 1996, ADV DRUG DELIVER REV, V20, P83, DOI 10.1016/0169-409X(95)00131-P
   Shimbo M, 2005, NUTR RES, V25, P617, DOI 10.1016/j.nutres.2005.06.001
   Shugarts S, 2009, PHARM RES-DORDR, V26, P2039, DOI 10.1007/s11095-009-9924-0
   SIEGEL S, 1973, J CATAL, V30, P139, DOI 10.1016/0021-9517(73)90060-2
   Silva J., 2014, OPTIMIZATION DRUG DI, P445
   Thongbai B, 2015, MYCOL PROG, V14, DOI 10.1007/s11557-015-1105-4
   Tsai PC, 2021, MOLECULES, V26, DOI 10.3390/molecules26154510
   Tsai-Teng T, 2016, J BIOMED SCI, V23, DOI 10.1186/s12929-016-0266-z
   Tzeng TT, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19020598
   Wang MX, 2014, FOOD FUNCT, V5, P3055, DOI 10.1039/c4fo00511b
   Watanabe S, 2017, AAPS J, V19, P1148, DOI 10.1208/s12248-017-0078-4
   Zhang CC, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18081659
   Zhang DL, 2012, ACTA PHARM SIN B, V2, P549, DOI 10.1016/j.apsb.2012.10.004
   Zhou Y, 2020, MOLECULES, V25, DOI 10.3390/molecules25081775
NR 46
TC 2
Z9 2
U1 3
U2 15
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2076-3417
J9 APPL SCI-BASEL
JI Appl. Sci.-Basel
PD FEB
PY 2022
VL 12
IS 3
AR 1201
DI 10.3390/app12031201
PG 12
WC Chemistry, Multidisciplinary; Engineering, Multidisciplinary; Materials
   Science, Multidisciplinary; Physics, Applied
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Chemistry; Engineering; Materials Science; Physics
GA ZG4HA
UT WOS:000760219000001
OA gold
DA 2024-02-19
ER

PT J
AU Berenguer, M
   Prieto, M
   San Juan, F
   Rayón, JM
   Martinez, F
   Carrasco, D
   Moya, A
   Orbis, F
   Mir, J
   Berenguer, J
AF Berenguer, M
   Prieto, M
   San Juan, F
   Rayón, JM
   Martinez, F
   Carrasco, D
   Moya, A
   Orbis, F
   Mir, J
   Berenguer, J
TI Contribution of donor age to the recent decrease in patient survival
   among HCV-infected liver transplant recipients
SO HEPATOLOGY
LA English
DT Article
ID HEPATITIS-C; FIBROSIS PROGRESSION; ALLOGRAFT CIRRHOSIS; NATURAL-HISTORY;
   GRAFT-SURVIVAL; REPLICATION
AB Recurrent hepatitis occurs in the majority of patients undergoing liver transplantation for hepatitis C virus (HCV) cirrhosis, with progression to cirrhosis in up to 30% after 5 years. Based on these data, a decrease in survival can be anticipated with prolonged follow-up. Furthermore, posttransplantation HCV-fibrosis progression has been shown in recent years to increase. Our aims were (1) to describe the natural history of HCV-infected recipients, particularly to determine whether survival has decreased in recent years; (2) to compare this outcome with that observed in non-HCV-infected cirrhosis controls; and (3) to determine the factors associated with disease severity and survival. Among 522 cirrhotic patients undergoing transplantation between 1991 and 2000, 283 (54%) were infected with HCV. Yearly biopsies were performed in these recipients and at I and 5 years in the remainder. With similar follow-up, the percentage of deaths in the HCV(+) group was significantly higher than in the HCV(-) group (37% vs. 22%, P < .001), and patient survival was lower (77%, 61%, 55% vs. 87%, 76%, 70% at 1, 5, and 7 years, respectively; P = .0001). Although survival has increased in the HCV(-) group in recent years, it has significantly decreased in HCV recipients (P < .0001). The main cause of death among the latter was decompensated graft cirrhosis (n = 23/105, 22%), whereas that of HCV(-) patients was infections (n = 10/52, 19%). Reasons for the recent worse outcome in HCV(+) recipients include the increased donor age and stronger immunosuppression. In conclusion, patient survival is lower among HCV(+) recipients than among HCV(-) ones and has been decreasing in recent years. The aging of donors is a major contributor to this worse outcome.
C1 Hosp Univ La Fe, Serv Hepatogastroenterol, Valencia 46009, Spain.
   Hosp Univ La Fe, Liver Transplantat & Surg Unit, Valencia 46009, Spain.
   Hosp Univ La Fe, Pathol Serv, Valencia 46009, Spain.
C3 Hospital Universitari i Politecnic La Fe; Hospital Universitari i
   Politecnic La Fe; Hospital Universitari i Politecnic La Fe
RP Berenguer, J (corresponding author), Hosp Univ La Fe, Serv Hepatogastroenterol, Avenida Campanar 21, Valencia 46009, Spain.
EM mbhaym@teleline.es
RI Prieto, Martin/ABH-7274-2020; Berenguer, Marina/ABG-8602-2020
OI Prieto, Martin/0000-0002-8841-0543; Berenguer,
   Marina/0000-0001-9246-4264
CR Berenguer M, 2000, HEPATOLOGY, V32, P852, DOI 10.1053/jhep.2000.17924
   Berenguer M, 2000, J HEPATOL, V32, P673, DOI 10.1016/S0168-8278(00)80231-7
   Busquets J, 2001, TRANSPLANTATION, V71, P1765, DOI 10.1097/00007890-200106270-00011
   Cane EJ, 1996, NEW ENGL J MED, V334, P815, DOI 10.1056/NEJM199603283341302
   Charlton M, 1998, HEPATOLOGY, V28, P823, DOI 10.1002/hep.510280333
   DiMartino V, 1997, HEPATOLOGY, V26, P1343
   Féray C, 1999, GASTROENTEROLOGY, V117, P619, DOI 10.1016/S0016-5085(99)70454-3
   Mazzaferro V, 1996, NEW ENGL J MED, V334, P693, DOI 10.1056/NEJM199603143341104
   Nelson DR, 2001, LIVER TRANSPLANT, V7, P1064, DOI 10.1053/jlts.2001.29414
   Poynard T, 1997, LANCET, V349, P825, DOI 10.1016/S0140-6736(96)07642-8
   Prieto M, 1998, EUR J GASTROEN HEPAT, V10, P771, DOI 10.1097/00042737-199809000-00008
   Prieto M, 1999, HEPATOLOGY, V29, P250, DOI 10.1002/hep.510290122
   Rosen HR, 1997, TRANSPLANTATION, V64, P721, DOI 10.1097/00007890-199709150-00010
   Sigal SH, 1999, AM J PHYSIOL-GASTR L, V276, pG1260, DOI 10.1152/ajpgi.1999.276.5.G1260
   WRIGHT TL, 1992, GASTROENTEROLOGY, V103, P317, DOI 10.1016/0016-5085(92)91129-R
NR 15
TC 503
Z9 512
U1 1
U2 24
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-9139
EI 1527-3350
J9 HEPATOLOGY
JI Hepatology
PD JUL
PY 2002
VL 36
IS 1
BP 202
EP 210
DI 10.1053/jhep.2002.33993
PG 9
WC Gastroenterology & Hepatology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Gastroenterology & Hepatology
GA 568GP
UT WOS:000176534300025
PM 12085366
OA Bronze
DA 2024-02-19
ER

PT J
AU Wang, PS
   Wang, CG
   Li, H
   Shi, BJ
   Wang, JN
   Zhong, L
AF Wang, Pusen
   Wang, Chunguang
   Li, Hao
   Shi, Baojie
   Wang, Jianning
   Zhong, Lin
TI Impact of age on the prognosis after liver transplantation for patients
   with hepatocellular carcinoma: a single-center experience
SO ONCOTARGETS AND THERAPY
LA English
DT Article
DE age; hepatocellular carcinoma; liver transplantation; prognosis
ID CANCER STATISTICS; SURVIVAL; RECIPIENT; INVASION; OUTCOMES; TRENDS
AB Background: Liver transplantation (LT) offers the most effective treatment for hepatocellular carcinoma patients. Various preoperative variables are correlated with survival after LT, but the prognostic role of aging on LT remains controversial.
   Methods: Between January 2001 and December 2011, 290 consecutive transplants for patients with hepatocellular carcinoma performed in Shanghai First People's Hospital (People's Republic of China) were analyzed retrospectively. We compared patient characteristics and survival curves between a younger group (less than 49 years, n=135) and an aged group (50 years or older, n=155). We then performed Cox multivariate regression analysis of the risk factors for survival in aged and younger patients.
   Results: Younger age was associated with higher alpha-fetoprotein (P=0.014), larger tumor size (P=0.038), poorer differentiation (P=0.025), portal lymph node metastasis (P=0.001), and higher recurrence rate (P=0.038). Aged patients had significantly longer recurrence-free survival and overall survival (P=0.020 and P=0.014, respectively); however, there were no significant differences between the younger and aged patients who met the Milan criteria (P>0.05). The 1-, 3-, and 5-year recurrence-free survival rates were 59.7%, 44.5%, and 37.3%, respectively, in the younger group, and 67.9%, 55.3%, and 53.8%, respectively, in the aged group. The 1-, 3-, and 5-year overall survival rates were 68.4%, 45.5%, and 38.9%, respectively, in the younger group, and 76.1%, 59.7%, and 53.9%, respectively, in the aged group. Alphafetoprotein >= 400 ng/mL, microvascular invasion, and tumor size >5 cm were independent risk factors for prognosis in both groups.
   Conclusion: Younger patients in our center tended to present with more aggressive tumors and have a higher risk of recurrence. Our single-center experience suggests that younger patients should be assessed more rigorously before LT, while aged patients should be actively considered for LT after appropriate selection.
C1 [Wang, Pusen; Wang, Chunguang; Li, Hao; Shi, Baojie; Zhong, Lin] Shanghai Jiao Tong Univ, Sch Med, Shanghai Gen Hosp, Dept Gen Surg, Shanghai 200080, Peoples R China.
   [Wang, Jianning] Shandong Univ, Affiliated Qianfoshan Hosp, Dept Urol, Jinan 250014, Peoples R China.
C3 Shanghai Jiao Tong University; Shandong University
RP Zhong, L (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Shanghai Gen Hosp, Dept Gen Surg, 100 Haining Rd, Shanghai 200080, Peoples R China.
EM guowz_wps@hotmail.com; zhongl_3284@hotmail.com
CR Andreou A, 2015, HPB, V17, P168, DOI 10.1111/hpb.12345
   [Anonymous], 1997, JAMA-J AM MED ASSOC, V277, P925
   Beard RE, 2013, SURGERY, V154, P545, DOI 10.1016/j.surg.2013.02.019
   Befeler AS, 2005, GASTROENTEROLOGY, V128, P1752, DOI 10.1053/j.gastro.2005.03.033
   Bruix J, 2005, HEPATOLOGY, V42, P1208, DOI 10.1002/hep.20933
   Chen CH, 2006, J GASTROEN HEPATOL, V21, P1561, DOI 10.1111/j.1440-1746.2006.04425.x
   Chen CH, 2006, LIVER INT, V26, P766, DOI 10.1111/j.1478-3231.2006.01309.x
   Concejero AM, 2009, LIVER TRANSPLANT, V15, P1658, DOI 10.1002/lt.21930
   Crespo G, 2012, GASTROENTEROLOGY, V142, P1373, DOI 10.1053/j.gastro.2012.02.011
   Cross TJS, 2007, LIVER TRANSPLANT, V13, P1382, DOI 10.1002/lt.21181
   El-Serag HB, 2007, GASTROENTEROLOGY, V132, P2557, DOI 10.1053/j.gastro.2007.04.061
   El-Serag HB, 2004, GASTROENTEROLOGY, V127, pS27, DOI 10.1053/j.gastro.2004.09.013
   Han K, 2007, CAN J GASTROENTEROL, V21, P39, DOI 10.1155/2007/206383
   Ishigami M, 2013, HEPATOL RES, V43, P1148, DOI 10.1111/hepr.12067
   Jonas S, 2001, HEPATOLOGY, V33, P1080, DOI 10.1053/jhep.2001.23561
   Kim J, 2014, J AM COLL SURGEONS, V218, P431, DOI 10.1016/j.jamcollsurg.2013.12.001
   Lee KK, 2010, J SURG ONCOL, V101, P47, DOI 10.1002/jso.21415
   Levy MF, 2001, ANN SURG, V233, P107, DOI 10.1097/00000658-200101000-00016
   Llovet JM, 2003, LANCET, V362, P1907, DOI 10.1016/S0140-6736(03)14964-1
   Maluccio M, 2012, CA-CANCER J CLIN, V62, P394, DOI 10.3322/caac.21161
   Mazzaferro V, 2008, ANN SURG ONCOL, V15, P1001, DOI 10.1245/s10434-007-9559-5
   Nagai S, 2015, HEPATOLOGY, V61, P895, DOI 10.1002/hep.27358
   Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74
   PUGH RNH, 1973, BRIT J SURG, V60, P646, DOI 10.1002/bjs.1800600817
   Sharpton SR, 2014, TRANSPLANTATION, V98, P557, DOI 10.1097/TP.0000000000000090
   Siegel R, 2014, CA-CANCER J CLIN, V64, P9, DOI 10.3322/caac.21208
   Wai CT, 2012, TRANSPL P, V44, P516, DOI 10.1016/j.transproceed.2012.01.032
   Yao FY, 2004, HEPATOLOGY, V39, P230, DOI 10.1002/hep.20005
   Zhang WJ, 2015, ONCOTARGET, V6, P633, DOI 10.18632/oncotarget.2719
   Zheng SS, 2008, TRANSPLANTATION, V85, P1726, DOI 10.1097/TP.0b013e31816b67e4
NR 30
TC 5
Z9 6
U1 0
U2 2
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178-6930
J9 ONCOTARGETS THER
JI OncoTargets Ther.
PY 2015
VL 8
BP 3775
EP 3781
DI 10.2147/OTT.S93939
PG 7
WC Biotechnology & Applied Microbiology; Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Oncology
GA CY8TI
UT WOS:000366680800002
PM 26719705
OA Green Published, gold, Green Submitted
DA 2024-02-19
ER

PT J
AU He, YX
   Shen, A
   Salam, M
   Liu, MZ
   Wei, YY
   Yang, YC
   Li, H
AF He, Yixin
   Shen, Ai
   Salam, Muhammad
   Liu, Mengzi
   Wei, Yanyan
   Yang, Yongchuan
   Li, Hong
TI Microcystins-Loaded Aged Nanoplastics Provoke a Metabolic Shift in Human
   Liver Cells
SO ENVIRONMENTAL SCIENCE & TECHNOLOGY
LA English
DT Article; Early Access
DE nanoplastics; microcystins; HepG2 cells; toxicity; proteomicanalysis
ID TOXICITY; LR; INVOLVEMENT
AB The responseof HepG2 cells upon exposure to microcystins-loadednanoplastics, which was closer to simulate the real scenario thancoexposure (the toxin and nanoplastic) experiments, was mapped.
   Studiesconcerning the toxicity of pollutant-loaded nanoplastics(NPs) toward humans are still in their infancy. Here, we evaluatedthe adsorption of microcystins (MCs) by pristine and aged polystyrenenanoplastics (PSNPs), prepared MCs-loaded aged PSNPS (1, 5, 10, 15,and 19 & mu;g/mg), and systematically mapped the key molecular changesinduced by aged and MCs-loaded PSNPs to human hepatoblastoma (HepG2)cells. According to the results, MC-LR adsorption is increased 2.64-foldby aging, and PSNP accumulation is detected in HepG2 cells. The cytotoxicityof the MC-LR-loaded aged PSNPs showed a positive relationship withthe MC-LR amount, as the cell viability in the 19 & mu;g/mg loadingtreatment (aPS-MC19) was 10.84% lower than aged PSNPs; meanwhile,more severe oxidative damage was observed. Primary approaches involvedstressing the endoplasmic reticulum and reducing protein synthesisthat the aged PSNPs posed for HepG2 cells, while the aggravated cytotoxicityin aPS-MC19 treatment was a combined result of the metabolic energydisorder, oxidative damage, endoplasmic reticulum stress, and downregulationof the MC-LR target protein. Our results confirm that the aged PSNPscould bring more MC-LR into the HepG2 cells, significantly interferewith biological processes, and provide new insight into decipheringthe risk of NPs to humans.
C1 [He, Yixin; Salam, Muhammad; Liu, Mengzi; Yang, Yongchuan; Li, Hong] Chongqing Univ, Key Lab Ecoenvironm Three Gorges Reg, Minist Educ, 174 Shazheng St, Chongqing 400044, Peoples R China.
   [Shen, Ai] Chongqing Univ, Dept Hepatobiliary Pancreat Tumor Ctr, Canc Hosp, Chongqing 400045, Peoples R China.
   [Wei, Yanyan] Guangxi Univ, Coll Agr, Cultivat Base Guangxi Key Lab Agroenvironm & Agrop, Nanning 530004, Peoples R China.
C3 Chongqing University; Chongqing University; Guangxi University
RP Li, H (corresponding author), Chongqing Univ, Key Lab Ecoenvironm Three Gorges Reg, Minist Educ, 174 Shazheng St, Chongqing 400044, Peoples R China.
EM hongli@cqu.edu.cn
RI Yang, Yongchuan/JPK-5678-2023; Li, Hong/AEO-4662-2022
OI Yang, Yongchuan/0000-0001-7627-7776; Hong, Li/0000-0002-3065-4932
FU Fundamental Research Funds for the Central Universities
   [2021CDJYGRH-015]; Natural Science Foundation of China [NSFC 41877472];
   China Postdoctoral Science Foundation [2021M700601]; Opening Project of
   Guangxi Key Laboratory of Agro-Environment [2020-KF-03]
FX This work was jointly supported by the Fundamental Research Funds for
   the Central Universities (2021CDJYGRH-015), the Natural Science
   Foundation of China (NSFC 41877472), the China Postdoctoral Science
   Foundation (2021M700601), and the Opening Project of Guangxi Key
   Laboratory of Agro-Environment and Agro-Product Safety (2020-KF-03).
CR Ahmed R, 2022, CHEMOSPHERE, V293, DOI 10.1016/j.chemosphere.2022.133557
   Bao ZZ, 2021, SCI TOTAL ENVIRON, V764, DOI 10.1016/j.scitotenv.2020.142889
   Bhagat K, 2022, CHEMOSPHERE, V298, DOI 10.1016/j.chemosphere.2022.134238
   Castro-Castellon AT, 2022, SCI TOTAL ENVIRON, V816, DOI 10.1016/j.scitotenv.2021.151638
   Chu XG, 2022, METABOLISM, V126, DOI 10.1016/j.metabol.2021.154923
   Dawson RM, 1998, TOXICON, V36, P953, DOI 10.1016/S0041-0101(97)00102-5
   Debnath S, 2023, CERAM INT, V49, P16199, DOI 10.1016/j.ceramint.2023.01.218
   Ding YF, 2021, ENVIRON POLLUT, V280, DOI 10.1016/j.envpol.2021.116974
   Esmaeili Z, 2021, LIFE SCI, V273, DOI 10.1016/j.lfs.2021.119261
   Fan XL, 2021, J HAZARD MATER, V401, DOI [10.1016/j.jhazmat.2020.123363, 10.1016/j.jhazmal.2020.123363]
   Gong H, 2023, J HAZARD MATER, V443, DOI 10.1016/j.jhazmat.2022.130266
   González-Pleiter M, 2021, CHEMOSPHERE, V268, DOI 10.1016/j.chemosphere.2020.128824
   Guo CX, 2023, ENVIRON POLLUT, V318, DOI 10.1016/j.envpol.2022.120859
   Hasegawa T, 2022, MAR POLLUT BULL, V185, DOI 10.1016/j.marpolbul.2022.114343
   He YX, 2020, SCI TOTAL ENVIRON, V723, DOI 10.1016/j.scitotenv.2020.138180
   Kalcíková G, 2020, WATER RES, V175, DOI 10.1016/j.watres.2020.115644
   Khosrovyan A, 2021, ENVIRON POLLUT, V287, DOI 10.1016/j.envpol.2021.117334
   Kim N, 2023, J HAZARD MATER, V446, DOI 10.1016/j.jhazmat.2022.130683
   Kushawaha PK, 2022, MICROB PATHOGENESIS, V166, DOI 10.1016/j.micpath.2022.105457
   Li H, 2021, CHEMOSPHERE, V264, DOI 10.1016/j.chemosphere.2020.128556
   Li XQ, 2019, ECOTOX ENVIRON SAFE, V182, DOI 10.1016/j.ecoenv.2019.109391
   Li Y, 2023, CHEMOSPHERE, V328, DOI 10.1016/j.chemosphere.2023.138545
   Lin SY, 2022, ENVIRON SCI TECHNOL, V56, P12483, DOI 10.1021/acs.est.2c03980
   Liu GZ, 2019, ENVIRON POLLUT, V246, P26, DOI 10.1016/j.envpol.2018.11.100
   Liu XM, 2023, ENVIRON POLLUT, V317, DOI 10.1016/j.envpol.2022.120680
   Lu YY, 2022, J HAZARD MATER, V421, DOI 10.1016/j.jhazmat.2021.126770
   Luo HW, 2022, J HAZARD MATER, V423, DOI 10.1016/j.jhazmat.2021.126915
   Ma J, 2019, NUCLEIC ACIDS RES, V47, pD1211, DOI 10.1093/nar/gky869
   Ma JG, 2018, CHEMOSPHERE, V194, P773, DOI 10.1016/j.chemosphere.2017.12.051
   Malécot M, 2009, AQUAT TOXICOL, V94, P153, DOI 10.1016/j.aquatox.2009.06.012
   Mao RF, 2020, J HAZARD MATER, V393, DOI 10.1016/j.jhazmat.2020.122515
   Mao YF, 2020, ENVIRON POLLUT, V258, DOI 10.1016/j.envpol.2019.113760
   Menezes C, 2013, TOXICOL IN VITRO, V27, P138, DOI 10.1016/j.tiv.2012.09.009
   Monikh FA, 2022, NANO TODAY, V46, DOI 10.1016/j.nantod.2022.101611
   Pestana CJ, 2021, ENVIRON SCI TECHNOL, V55, P15940, DOI 10.1021/acs.est.1c05796
   Pflugmacher S, 2021, SCI TOTAL ENVIRON, V790, DOI 10.1016/j.scitotenv.2021.148166
   Pfohl P, 2022, ENVIRON SCI TECHNOL, V56, P11323, DOI 10.1021/acs.est.2c01228
   Poste AE, 2011, ENVIRON SCI TECHNOL, V45, P5806, DOI 10.1021/es200285c
   Rainieri S, 2018, ENVIRON RES, V162, P135, DOI 10.1016/j.envres.2017.12.019
   Rajpurohit YS, 2022, RES MICROBIOL, V173, DOI 10.1016/j.resmic.2021.103883
   Rihan M, 2022, BIOORG MED CHEM LETT, V59, DOI 10.1016/j.bmcl.2022.128539
   Rodrigues NB, 2022, TOXICON, V211, P70, DOI 10.1016/j.toxicon.2022.03.006
   Santori N, 2020, TOXICOL LETT, V322, P131, DOI 10.1016/j.toxlet.2020.01.007
   Schwabl P, 2019, ANN INTERN MED, V171, P453, DOI 10.7326/M19-0618
   Shi LJ, 2021, ENVIRON RES, V195, DOI 10.1016/j.envres.2021.110890
   Song Y.L., 2022, J MOL LIQ, V363, DOI [10.1016/j.molliq.2022.119819, DOI 10.1016/J.MOLLIQ.2022.119819]
   Stienbarger CD, 2021, ENVIRON POLLUT, V285, DOI 10.1016/j.envpol.2021.117653
   Tsutsuki H, 2020, BIOCHEM BIOPH RES CO, V525, P1068, DOI 10.1016/j.bbrc.2020.03.008
   Volkl M, 2022, J HAZARD MATER, V435, DOI 10.1016/j.jhazmat.2022.128955
   Wan X, 2023, ENVIRON POLLUT, V321, DOI 10.1016/j.envpol.2023.121146
   Wang H, 2022, ENVIRON INT, V166, DOI 10.1016/j.envint.2022.107349
   Wang LW, 2021, J HAZARD MATER, V401, DOI 10.1016/j.jhazmat.2020.123415
   Xi XL, 2022, J HAZARD MATER, V437, DOI 10.1016/j.jhazmat.2022.129311
   Xiong JQ, 2022, J HAZARD MATER, V427, DOI 10.1016/j.jhazmat.2021.127893
   Yang WF, 2020, ECOTOX ENVIRON SAFE, V195, DOI 10.1016/j.ecoenv.2020.110484
   Yu XQ, 2022, SCI TOTAL ENVIRON, V806, DOI 10.1016/j.scitotenv.2021.150954
   Zaki MRM, 2022, SCI TOTAL ENVIRON, V831, DOI 10.1016/j.scitotenv.2022.154757
   Zhong YH, 2023, ENVIRON POLLUT, V316, DOI 10.1016/j.envpol.2022.120617
   Zhu KC, 2020, ENVIRON INT, V145, DOI 10.1016/j.envint.2020.106137
NR 59
TC 0
Z9 0
U1 37
U2 48
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0013-936X
EI 1520-5851
J9 ENVIRON SCI TECHNOL
JI Environ. Sci. Technol.
PD 2023 JUL 14
PY 2023
VL 57
IS 29
BP 10521
EP 10531
DI 10.1021/acs.est.3c00990
EA JUL 2023
PG 11
WC Engineering, Environmental; Environmental Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Engineering; Environmental Sciences & Ecology
GA M6UD3
UT WOS:001028988600001
PM 37449315
DA 2024-02-19
ER

PT J
AU Collins, LF
   Palella, FJ 
   Mehta, CC
   Holloway, J
   Stosor, V
   Lake, JE
   Brown, TT
   Topper, EF
   Naggie, S
   Anastos, K
   Taylor, TN
   Kassaye, S
   French, AL
   Adimora, AA
   Fischl, MA
   Kempf, MC
   Koletar, SL
   Tien, PC
   Ofotokun, I
   Sheth, AN
AF Collins, Lauren F.
   Palella, Frank J., Jr.
   Mehta, C. Christina
   Holloway, JaNae
   Stosor, Valentina
   Lake, Jordan E.
   Brown, Todd T.
   Topper, Elizabeth F.
   Naggie, Susanna
   Anastos, Kathryn
   Taylor, Tonya N.
   Kassaye, Seble
   French, Audrey L.
   Adimora, Adaora A.
   Fischl, Margaret A.
   Kempf, Mirjam-Colette
   Koletar, Susan L.
   Tien, Phyllis C.
   Ofotokun, Ighovwerha
   Sheth, Anandi N.
TI Aging-Related Comorbidity Burden Among Women and Men With or At-Risk for
   HIV in the US, 2008-2019
SO JAMA NETWORK OPEN
LA English
DT Article
ID UNITED-STATES; SEX; DISEASE; HEALTH; ADULTS; PREDICTION; IMPACT; COHORT;
   CARE
AB IMPORTANCE Despite aging-related comorbidities representing a growing threat to quality-of-life and mortality among persons with HIV (PWH), clinical guidance for comorbidity screening and prevention is lacking. Understanding comorbidity distribution and severity by sex and gender is essential to informing guidelines for promoting healthy aging in adults with HIV.
   OBJECTIVE To assess the association of human immunodeficiency virus on the burden of agingrelated comorbidities among US adults in the modern treatment era.
   DESIGN, SETTING, AND PARTICIPANTS This cross-sectional analysis included data from US multisite observational cohort studies of women (Women's Interagency HIV Study) and men (Multicenter AIDS Cohort Study) with HIV and sociodemographically comparable HIV-seronegative individuals. Participants were prospectively followed from 2008 for men and 2009 for women (when more than 80% of participants with HIV reported antiretroviral therapy use) through last observation up until March 2019, at which point outcomes were assessed. Data were analyzed from July 2020 to April 2021.
   EXPOSURES HIV, age, sex.
   MAIN OUTCOMES AND MEASURES Comorbidity burden (the number of total comorbidities out of 10 assessed) per participant; secondary outcomes included individual comorbidity prevalence. Linear regression assessed the association of HIV status, age, and sex with comorbidity burden.
   RESULTS A total of 5929 individuals were included (median [IQR] age, 54 [46-61] years; 3238 women [55%]; 2787 Black [47%], 1153 Hispanic or other [19%], 1989 White [34%]). Overall, unadjusted mean comorbidity burden was higher among women vs men (3.4 [2.1] vs 3.2 [1.8]; P =.02). Comorbidity prevalence differed by sex for hypertension (2188 of 3238 women [68%] vs 2026 of 2691 men [75%]), psychiatric illness (1771 women [55%] vs 1565 men [58%]), dyslipidemia (1312 women [41%] vs 1728 men [64%]), liver (1093 women [34%] vs 1032 men [38%]), bone disease (1364 women [42%] vs 512men [19%]), lung disease (1245 women [38%] vs 259 men [10%]), diabetes (763 women [24%] vs 470 men [17%]), cardiovascular (493 women [15%] vs 407 men [15%]), kidney (444 women [14%] vs 404 men [15%]) disease, and cancer (219 women [7%] vs 321 men [12%]). In an unadjusted model, the estimated mean difference in comorbidity burden among women vs men was significantly greater in every age strata among PWH: age under 40 years, 0.33 (95% CI, 0.03-0.63); ages 40 to 49 years, 0.37 (95% CI, 0.12-0.61); ages 50 to 59 years, 0.38 (95% CI, 0.20-0.56); ages 60 to 69 years, 0.66 (95% CI, 0.42-0.90); ages 70 years and older, 0.62 (95% CI, 0.07-1.17). However, the difference between sexes varied by age strata among persons without HIV: age under 40 years, 0.52 (95% CI, 0.13 to 0.92); ages 40 to 49 years, -0.07 (95% CI, - 0.45 to 0.31); ages 50 to 59 years, 0.88 (95% CI, 0.62 to 1.14); ages 60 to 69 years, 1.39 (95% CI, 1.06 to 1.72); ages 70 years and older, 0.33 (95% CI, -0.53 to 1.19) (P for interaction =.001). In the covariate-adjusted model, findings were slightly attenuated but retained statistical significance.
   CONCLUSIONS AND RELEVANCE In this cross-sectional study, the overall burden of aging-related comorbidities was higher in women vs men, particularly among PWH, and the distribution of comorbidity prevalence differed by sex. Comorbidity screening and prevention strategies tailored by HIV serostatus and sex or gender may be needed.
C1 [Collins, Lauren F.; Mehta, C. Christina; Ofotokun, Ighovwerha; Sheth, Anandi N.] Emory Univ, Div Infect Dis, Sch Med, Atlanta, GA USA.
   [Collins, Lauren F.; Ofotokun, Ighovwerha; Sheth, Anandi N.] Ponce Leon Ctr, Grady Healthcare Syst, Atlanta, GA USA.
   [Palella, Frank J., Jr.; Stosor, Valentina] Northwestern Univ, Feinberg Sch Med, Div Infect Dis, Chicago, IL USA.
   [Holloway, JaNae] Emory Univ, Rollins Sch Publ Hlth, Dept Biostat & Bioinformat, Atlanta, GA USA.
   [Lake, Jordan E.] Univ Texas Hlth Sci Ctr, Dept Med, Houston, TX USA.
   [Brown, Todd T.] Johns Hopkins Univ, Div Endocrinol Diabet & Metab, Sch Med, Baltimore, MD USA.
   [Topper, Elizabeth F.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA.
   [Naggie, Susanna] Duke Univ, Duke Clin Res Inst, Durham, NC USA.
   [Naggie, Susanna] Duke Univ, Sch Med, Durham, NC USA.
   [Anastos, Kathryn] Albert Einstein Coll Med, Dept Med, Bronx, NY USA.
   [Taylor, Tonya N.] SUNY Downstate Hlth Sci Univ, Brooklyn, NY USA.
   [Kassaye, Seble] Georgetown Univ, Med Ctr, Washington, DC USA.
   [French, Audrey L.] John H Stroger Jr Hosp Cook Cty, Div Infect Dis, CORE Ctr, Chicago, IL USA.
   [Adimora, Adaora A.] Univ N Carolina, Sch Med, Chapel Hill, NC USA.
   [Adimora, Adaora A.] Univ N Carolina, UNC Gillings Sch Global Publ Hlth, Chapel Hill, NC USA.
   [Fischl, Margaret A.] Univ Miami, Miller Sch Med, Miami, FL USA.
   [Kempf, Mirjam-Colette] Univ Alabama, Sch Nursing Publ Hlth & Med, Birmingham, W Midlands, England.
   [Koletar, Susan L.] Ohio State Univ, Div Infect Dis, Med Ctr, Columbus, OH USA.
   [Tien, Phyllis C.] Univ Calif San Francisco, Div Infect Dis, Dept Med, San Francisco, CA USA.
   [Tien, Phyllis C.] Dept Vet Affairs, Med Serv, San Francisco, CA USA.
C3 Emory University; Northwestern University; Feinberg School of Medicine;
   Emory University; Rollins School Public Health; University of Texas
   System; University of Texas Health Science Center Houston; Johns Hopkins
   University; Johns Hopkins University; Johns Hopkins Bloomberg School of
   Public Health; Duke University; Duke University; Yeshiva University;
   Albert Einstein College of Medicine; Georgetown University; University
   of Illinois System; University of Illinois Chicago; University of
   Illinois Chicago Hospital; John H Stroger Junior Hospital Cook County;
   University of North Carolina; University of North Carolina Chapel Hill;
   University of North Carolina School of Medicine; University of North
   Carolina; University of North Carolina Chapel Hill; University of Miami;
   Aston University; University System of Ohio; Ohio State University;
   University of California System; University of California San Francisco
RP Collins, LF (corresponding author), Emory Univ, Infect Dis, Sch Med, 49 Jesse Hill Jr Dr SE, Atlanta, GA 30303 USA.; Sheth, AN (corresponding author), Emory Univ, Infect Dis, Sch Med, 341 Ponce Leon Ave NE, Atlanta, GA 30303 USA.
EM lauren.frances.collins@emory.edu; ansheth@emory.edu
RI Sheth, Anandi/IAO-2514-2023
OI Sheth, Anandi/0000-0002-6305-2727; Collins, Lauren/0000-0002-0170-5454;
   Stosor, Valentina/0000-0002-0388-5460
FU Emory Specialized Center of Research Excellence (SCORE) on Sex
   Differences [U54AG062334]; National Center for Advancing Translational
   Sciences of the NIH [UL1TR002378, KL2-TL1TR002381]; Program for
   Retaining, Supporting, and Elevating Early-career Researchers at Emory
   (PeRSEVERE) from Emory School of Medicine,
FX This work was also supported by the Emory Specialized Center of Research
   Excellence (SCORE) on Sex Differences to Dr Ofotokun (grant No.
   U54AG062334). Dr Collins is also supported by the National Center for
   Advancing Translational Sciences of the NIH (award Nos. UL1TR002378 and
   KL2-TL1TR002381) and the Program for Retaining, Supporting, and
   Elevating Early-career Researchers at Emory (PeRSEVERE) from Emory
   School of Medicine, a gift from the Doris Duke Charitable Foundation.
CR Achhra AC, 2021, CURR HIV-AIDS REP, V18, P271, DOI 10.1007/s11904-021-00567-w
   Althoff KN, 2019, LANCET HIV, V6, pE93, DOI 10.1016/S2352-3018(18)30295-9
   Bailey ZD, 2021, NEW ENGL J MED, V384, P768, DOI 10.1056/NEJMms2025396
   Bartz D, 2020, JAMA INTERN MED, V180, P574, DOI 10.1001/jamainternmed.2019.7194
   Birabaharan M, 2022, AIDS, V36, P383, DOI 10.1097/QAD.0000000000003127
   Bisquera A, 2022, LANCET REG HEALTH-EU, V12, DOI 10.1016/j.lanepe.2021.100247
   Boersma P, 2020, PREV CHRONIC DIS, V17, DOI 10.5888/pcd17.200130
   Brinkley TE, 2022, INNOV AGING, V6, DOI 10.1093/geroni/igac055
   Cardet JC, 2022, J ALLERGY CLIN IMMUN, V150, P841, DOI 10.1016/j.jaci.2022.04.030
   Castillo-Mancilla JR, 2021, OPEN FORUM INFECT DI, V8, DOI 10.1093/ofid/ofab032
   Chandran A, 2020, AIDS BEHAV, V24, P2811, DOI 10.1007/s10461-020-02830-4
   Chow FC, 2018, AIDS, V32, P1125, DOI 10.1097/QAD.0000000000001799
   Collins LF, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.8023
   Collins LF, 2021, CLIN INFECT DIS, V72, P1301, DOI 10.1093/cid/ciaa204
   COLLINS LF, 2021, CLIN INFECT DIS, V3, P3, DOI DOI 10.1093/CID/CIAA1928
   Coste J, 2022, PLOS ONE, V17, DOI 10.1371/journal.pone.0265842
   D'Souza G, 2021, AM J EPIDEMIOL, V190, P1457, DOI 10.1093/aje/kwab050
   Frazier EL, 2019, CLIN INFECT DIS, V69, P2091, DOI 10.1093/cid/ciz126
   Friedman MR, 2022, AM J PUBLIC HEALTH, V112, pS452, DOI 10.2105/AJPH.2022.306735
   Gallant J, 2017, J INFECT DIS, V216, P1525, DOI 10.1093/infdis/jix518
   Gandhi M, 2019, JAIDS-J ACQ IMM DEF, V81, pE158, DOI 10.1097/QAI.0000000000002073
   Guaraldi G, 2011, CLIN INFECT DIS, V53, P1120, DOI 10.1093/cid/cir627
   Kassaye SG, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2019.3822
   King DE, 2018, J AM BOARD FAM MED, V31, P503, DOI 10.3122/jabfm.2018.04.180008
   Lahiri CD, 2018, AIDS, V32, P2151, DOI 10.1097/QAD.0000000000001945
   Leddy AM, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0252338
   Low LL, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2019.15245
   Lv Tingxia, 2021, J Immunol Res, V2021, P7316456, DOI 10.1155/2021/7316456
   Marcus JL, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.7954
   Mathad JS, 2016, JAIDS-J ACQ IMM DEF, V73, P123, DOI 10.1097/QAI.0000000000001095
   Mauvais-Jarvis F, 2020, LANCET, V396, P565, DOI 10.1016/S0140-6736(20)31561-0
   Mehta CC, 2022, PLOS ONE, V17, DOI 10.1371/journal.pone.0272608
   Morton ZP, 2023, OPEN FORUM INFECT DI, V10, DOI 10.1093/ofid/ofac702
   Nanditha NGA, 2021, BMJ OPEN, V11, DOI 10.1136/bmjopen-2020-041734
   Palella FJ, 2019, AIDS, V33, P2327, DOI 10.1097/QAD.0000000000002349
   Patel H, 2020, J WOMENS HEALTH, V29, P770, DOI 10.1089/jwh.2019.7826
   Peters BA, 2022, J INFECT DIS, V225, P295, DOI 10.1093/infdis/jiab341
   Pond RA, 2021, OPEN FORUM INFECT DI, V8, DOI 10.1093/ofid/ofab558
   Raghavan A, 2017, CURR HIV-AIDS REP, V14, P220, DOI 10.1007/s11904-017-0366-8
   Rajasuriar R, 2017, AIDS, V31, P1393, DOI 10.1097/QAD.0000000000001475
   Reddy KP, 2016, J INFECT DIS, V214, P1672, DOI 10.1093/infdis/jiw430
   Rizzetto L, 2018, J AUTOIMMUN, V92, P12, DOI 10.1016/j.jaut.2018.05.008
   Ronit A, 2018, CLIN INFECT DIS, V67, P1291, DOI 10.1093/cid/ciy325
   Salinas JL, 2016, CLIN INFECT DIS, V63, P1423, DOI 10.1093/cid/ciw564
   Scully EP, 2018, CURR HIV-AIDS REP, V15, P136, DOI 10.1007/s11904-018-0383-2
   Skinner HG, 2016, BMC HEALTH SERV RES, V16, DOI 10.1186/s12913-016-1304-y
   Skou ST, 2022, NAT REV DIS PRIMERS, V8, DOI 10.1038/s41572-022-00376-4
   Thompson MA, 2021, CLIN INFECT DIS, V73, pE3572, DOI 10.1093/cid/ciaa1391
   Thompson-Paul AM, 2016, CLIN INFECT DIS, V63, P1508, DOI 10.1093/cid/ciw615
   US Centers for Disease Control and Prevention, 2021, HIV surveillance Supplement Report, V26
   Vaccarino V, 2021, ATHEROSCLEROSIS, V328, P74, DOI 10.1016/j.atherosclerosis.2021.05.020
   Wang RB, 2018, AIDS, V32, P2547, DOI [10.1097/QAD.0000000000001986, 10.1097/qad.0000000000001986]
   Weiser JK, 2021, JAIDS-J ACQ IMM DEF, V86, P297, DOI 10.1097/QAI.0000000000002592
   World Health Organization, Multimorbidity: Technical Series on Safer Primary Care
   Yang JY, 2018, AIDS, V32, P1699, DOI 10.1097/QAD.0000000000001864
   Yin MT, 2016, JAIDS-J ACQ IMM DEF, V72, P513, DOI 10.1097/QAI.0000000000000998
   Zierath R, 2023, JAMA NETW OPEN, V6, DOI 10.1001/jamanetworkopen.2022.52055
NR 57
TC 1
Z9 1
U1 0
U2 0
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2574-3805
J9 JAMA NETW OPEN
JI JAMA Netw. Open
PD AUG 7
PY 2023
VL 6
IS 8
AR e2327584
DI 10.1001/jamanetworkopen.2023.27584
PG 18
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA S9PS3
UT WOS:001074418100004
PM 37548977
OA gold, Green Published
DA 2024-02-19
ER

PT J
AU Martínez-Cisuelo, V
   Gómez, J
   García-Junceda, I
   Naudí, A
   Cabré, R
   Mota-Martorell, N
   López-Torres, M
   González-Sánchez, M
   Pamplona, R
   Barja, G
AF Martinez-Cisuelo, V.
   Gomez, J.
   Garcia-Junceda, I.
   Naudi, A.
   Cabre, R.
   Mota-Martorell, N.
   Lopez-Torres, M.
   Gonzalez-Sanchez, M.
   Pamplona, R.
   Barja, G.
TI Rapamycin reverses age-related increases in mitochondrial ROS production
   at complex I, oxidative stress, accumulation of mtDNA fragments inside
   nuclear DNA, and lipofuscin level, and increases autophagy, in the liver
   of middle-aged mice
SO EXPERIMENTAL GERONTOLOGY
LA English
DT Article
DE Rapamycin; Lipofuscin; Mitochondria; Free radicals; Tor; Aging
ID EXTENDS LIFE-SPAN; GENETICALLY HETEROGENEOUS MICE; SUBSTANTIA-NIGRA
   NEURONS; METHIONINE RESTRICTION; RADICAL GENERATION; LONGEVITY; HEART;
   MTOR; DISEASE; BRAIN
AB Rapamycin consistently increases longevity in mice although the mechanism of action of this drug is unknown. In the present investigation we studied the effect of rapamycin on mitochondrial oxidative stress at the same dose that is known to increase longevity in mice (14 mg of rapamycin/kg of diet). Middle aged mice (16 months old) showed significant age-related increases in mitochondrial ROS production at complex I, accumulation of mtDNA fragments inside nuclear DNA, mitochondrial protein lipoxidation, and lipofuscin accumulation compared to young animals (4 months old) in the liver. After 7 weeks of dietary treatment all those increases were totally or partially (lipofuscin) abolished by rapamycin, middle aged rapamycin-treated animals showing similar levels in those parameters to young animals. The decrease in mitochondrial ROS production was due to qualitative instead of quantitative changes in complex I. The decrease in mitochondrial protein lipoxidation was not due to decreases in the amount of highly oxidizable unsaturated fatty acids. Rapamycin also decreased the amount of RAPTOR (of mTOR complex) and increased the amounts of the PGC1-alpha and ATG13 proteins. The results are consistent with the possibility that rapamycin increases longevity in mice at least in part by lowering mitochondrial ROS production and increasing autophagy, decreasing the derived final forms of damage accumulated with age which are responsible for increased longevity. The decrease in lipofuscin accumulation induced by rapamycin adds to previous information suggesting that the increase in longevity induced by this drug can be due to a decrease in the rate of aging. (C) 2016 Elsevier Inc. All rights reserved.
C1 [Martinez-Cisuelo, V.; Lopez-Torres, M.; Barja, G.] Univ Complutense Madrid, Fac Biol Sci, Dept Anim Physiol 2, E-28040 Madrid, Spain.
   [Gomez, J.] Univ Europea, Fac Biomed Sci, Dept Basic Biomed Sci, E-28670 Madrid, Spain.
   [Garcia-Junceda, I.; Gonzalez-Sanchez, M.] Univ Complutense Madrid, Fac Biol Sci, Dept Genet, E-28040 Madrid, Spain.
   [Naudi, A.; Cabre, R.; Mota-Martorell, N.; Pamplona, R.] Univ Lleida IRBLLEIDA, Fac Med, Dept Expt Med, E-25198 Lleida, Spain.
C3 Complutense University of Madrid; Complutense University of Madrid;
   Universitat de Lleida
RP Barja, G (corresponding author), Univ Complutense, Dept Fisiol Anim 2, Fac Ciencias Biol, C Jose Antonio Novais 2, E-28040 Madrid, Spain.
EM vmcisuelo@gmail.com; jose.gomez@universidadeuropea.es;
   soyisa@hotmail.com; alba.naudi@mex.udl.cat; rosanna.cabre@mex.udl.cat;
   natalia.mota@mex.udl.cat; mltorres@bio.ucm.es; mgs@bio.ucm.es;
   reinald.pamplona@mex.udl.cat; gbarja@bio.ucm.es
RI Mota-Martorell, Natalia/ABF-6219-2021; Pamplona, Reinald/A-7359-2010;
   Naudí, Alba/B-5594-2009; Gomez, Jose/G-9705-2015; Gustavo,
   Barja/B-5591-2012; Barja, Gustavo/AAA-5903-2019; GONZALEZ-SANCHEZ,
   MONICA/M-5705-2016
OI Mota-Martorell, Natalia/0000-0001-5937-7070; Pamplona,
   Reinald/0000-0003-4337-6107; Naudí, Alba/0000-0003-0699-1004; Gomez,
   Jose/0000-0003-1758-4746; Barja, Gustavo/0000-0001-5736-4735;
   GONZALEZ-SANCHEZ, MONICA/0000-0001-7788-3516
FU Spanish Ministry of Economy and Competitiveness [RD12/0043/0018,
   PI1400328, BFU2011-23888]; Autonomous Government of Catalonia
   [2014SGR168]
FX This investigation was supported, in part, by grants from the Spanish
   Ministry of Economy and Competitiveness (RD12/0043/0018; PI1400328;
   BFU2011-23888) and the Autonomous Government of Catalonia (2014SGR168)
   to R. Pamplona or G. Barja. R. Cabre and N. Mota-Martorell received a
   pre-doctoral fellowship from the Autonomous Government of Catalonia.
CR Barja G, 2013, ANTIOXID REDOX SIGN, V19, P1420, DOI 10.1089/ars.2012.5148
   Bender A, 2006, NAT GENET, V38, P515, DOI 10.1038/ng1769
   Brunk UT, 2002, FREE RADICAL BIO MED, V33, P611, DOI 10.1016/S0891-5849(02)00959-0
   Caro P, 2010, MITOCHONDRION, V10, P479, DOI 10.1016/j.mito.2010.05.004
   Cheng X, 2012, EUR J CELL BIOL, V91, P782, DOI 10.1016/j.ejcb.2012.06.005
   Cheng X, 2010, AGING CELL, V9, P919, DOI 10.1111/j.1474-9726.2010.00607.x
   Chiao YA, 2016, AGING-US, V8, P314, DOI 10.18632/aging.100881
   Cunningham JT, 2007, NATURE, V450, P736, DOI 10.1038/nature06322
   Fischer KE, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126644
   Gomez A, 2015, J BIOENERG BIOMEMBR, V47, P199, DOI 10.1007/s10863-015-9608-x
   Gredilla R, 2001, FASEB J, V15, P1589, DOI 10.1096/fj.00-0764fje
   Halloran J, 2012, NEUROSCIENCE, V223, P102, DOI 10.1016/j.neuroscience.2012.06.054
   Harrison DE, 2009, NATURE, V460, P392, DOI 10.1038/nature08221
   Herrero A, 2001, J AM AGING ASSOC, V24, P45, DOI 10.1007/s11357-001-0006-4
   Herrero A, 2000, J BIOENERG BIOMEMBR, V32, P609, DOI 10.1023/A:1005626712319
   Hosokawa N, 2009, MOL BIOL CELL, V20, P1981, DOI 10.1091/mbc.E08-12-1248
   Hulbert AJ, 2007, PHYSIOL REV, V87, P1175, DOI 10.1152/physrev.00047.2006
   Johnson SC, 2015, FRONT GENET, V6, DOI 10.3389/fgene.2015.00247
   Johnson SC, 2013, NATURE, V493, P338, DOI 10.1038/nature11861
   Jung CH, 2010, FEBS LETT, V584, P1287, DOI 10.1016/j.febslet.2010.01.017
   Knuppertz L, 2016, MECH AGEING DEV, V153, P30, DOI 10.1016/j.mad.2016.01.003
   Kraytsberg Y, 2006, NAT GENET, V38, P518, DOI 10.1038/ng1778
   Laplante M, 2012, CELL, V149, P274, DOI 10.1016/j.cell.2012.03.017
   Livi CB, 2013, AGING-US, V5, P100, DOI 10.18632/aging.100533
   López-Torres M, 2008, BBA-GEN SUBJECTS, V1780, P1337, DOI 10.1016/j.bbagen.2008.01.007
   Miller RA, 2011, J GERONTOL A-BIOL, V66, P191, DOI 10.1093/gerona/glq178
   Miwa S, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4837
   Naudí A, 2013, FRONT PHYSIOL, V4, DOI 10.3389/fphys.2013.00372
   Neff F, 2013, J CLIN INVEST, V123, P3272, DOI 10.1172/JCI67674
   Oshiro N, 2004, GENES CELLS, V9, P359, DOI 10.1111/j.1356-9597.2004.00727.x
   Pamplona R, 2002, ANN NY ACAD SCI, V959, P475, DOI 10.1111/j.1749-6632.2002.tb02118.x
   Patrushev M, 2006, MITOCHONDRION, V6, P43, DOI 10.1016/j.mito.2005.12.001
   Patrushev M, 2004, CELL MOL LIFE SCI, V61, P3100, DOI 10.1007/s00018-004-4424-1
   RICHIE JP, 1994, FASEB J, V8, P1302, DOI 10.1096/fasebj.8.15.8001743
   RICHTER C, 1988, FEBS LETT, V241, P1, DOI 10.1016/0014-5793(88)81018-4
   Ruiz MC, 2005, MECH AGEING DEV, V126, P1106, DOI 10.1016/j.mad.2005.04.005
   Sanchez-Roman I, 2013, EXP GERONTOL, V48, P1030, DOI 10.1016/j.exger.2013.02.021
   Sato A, 2007, GENETICS, V177, P2031, DOI 10.1534/genetics.107.081026
   Song MS, 2012, NAT REV MOL CELL BIO, V13, P283, DOI 10.1038/nrm3330
   Suter M, 1999, BIOCHEMISTRY-US, V38, P459, DOI 10.1021/bi9811922
   Terman A, 2010, ANTIOXID REDOX SIGN, V12, P503, DOI 10.1089/ars.2009.2598
   Wilkinson JE, 2012, AGING CELL, V11, P675, DOI 10.1111/j.1474-9726.2012.00832.x
   Zhang YQ, 2014, J GERONTOL A-BIOL, V69, P119, DOI 10.1093/gerona/glt056
NR 43
TC 84
Z9 92
U1 2
U2 25
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0531-5565
EI 1873-6815
J9 EXP GERONTOL
JI Exp. Gerontol.
PD OCT
PY 2016
VL 83
BP 130
EP 138
DI 10.1016/j.exger.2016.08.002
PG 9
WC Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Geriatrics & Gerontology
GA DU4XG
UT WOS:000382215600016
PM 27498120
DA 2024-02-19
ER

PT J
AU Anselmi, B
   Conconi, M
   Veyrat-Durebex, C
   Turlin, E
   Biville, F
   Alliot, J
   Friguet, B
AF Anselmi, B
   Conconi, M
   Veyrat-Durebex, C
   Turlin, E
   Biville, F
   Alliot, J
   Friguet, B
TI Dietary self-selection can compensate an age-related decrease of rat
   liver 20 S proteasome activity observed with standard diet
SO JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL
   SCIENCES
LA English
DT Article
ID MODIFIED GLUTAMINE-SYNTHETASE; METAL-CATALYZED OXIDATION; PROTEIN
   OXIDATION; CALORIC RESTRICTION; ALKALINE PROTEASE; FOOD RESTRICTION;
   DNA-DAMAGE; PROTEOLYSIS; PURIFICATION; SUBUNIT
AB Aged Lou female rats (33 months) submitted to a self-selection regimen showed a decrease in protein intake (down to 11% of the total intake), whereas mature rats (18 months) selected a high percentage of protein (20% of the total intake) similar to the protein content of the standard diet. To find out if this decrease in protein intake would prevent an observed age-related decrease in proteasome activity, four peptidase activities and oxidized protein degradation were tested with proteasome purified from the liver of 18- and 33-month-old mb. The peptidylglutamyl-peptide hydrolase activity, which is decreased with age for rats fed the standard diet, was restored in the self-selecting old rats to the level observed for the mature rats. Degradation of oxidized glutamine synthetase, which is also decreased with age for rats fed the standard diet, was partly restored. Proteasome from self-selecting old rats showed a slight increase in trypsin-like and chymotrypsin-like activities as compared to proteasome from old rats fed the standard diet. Two-dimensional gel electrophoresis followed by quantitative analysis of the pattern of proteasome subunits revealed an increase in the intensity of two protein spots for proteasome from old rats fed the standard diet as compared with proteasome from either mature rats or self-selecting old rats. These findings may have important implications in aging for proteasome-mediated proteolysis and subsequent accumulation of oxidatively damaged protein.
C1 Inst Pasteur, Unite Biochim Cellulaire, F-75724 Paris, France.
   Inst Pasteur, Unite Regulat Express Genet, F-75724 Paris, France.
   Univ Blaise Pascal, Lab Biochim & Psychophysiol, Clermont Ferrand, France.
C3 Le Reseau International des Instituts Pasteur (RIIP); Universite Paris
   Cite; Institut Pasteur Paris; Le Reseau International des Instituts
   Pasteur (RIIP); Universite Paris Cite; Institut Pasteur Paris;
   Universite Clermont Auvergne (UCA); Centre National de la Recherche
   Scientifique (CNRS)
RP Friguet, B (corresponding author), Inst Pasteur, Unite Biochim Cellulaire, F-75724 Paris, France.
EM bfriguet@paris7.jussieu.fr
RI Veyrat-Durebex, Christelle/E-2558-2013
OI Veyrat-Durebex, Christelle/0000-0001-5301-6493
CR AGARWAL S, 1994, ARCH BIOCHEM BIOPHYS, V309, P24, DOI 10.1006/abbi.1994.1078
   AMES BN, 1983, SCIENCE, V221, P1256, DOI 10.1126/science.6351251
   BELL RC, 1990, FASEB J, V4, pA1043
   CARNEY JM, 1991, P NATL ACAD SCI USA, V88, P3633, DOI 10.1073/pnas.88.9.3633
   CHUNG MH, 1992, FREE RADICAL BIO MED, V12, P523, DOI 10.1016/0891-5849(92)90105-P
   Conconi M, 1996, ARCH BIOCHEM BIOPHYS, V331, P232, DOI 10.1006/abbi.1996.0303
   Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101
   FRIGUET B, 1994, J BIOL CHEM, V269, P21639
   FUJIWARA T, 1989, BIOCHEMISTRY-US, V28, P7332, DOI 10.1021/bi00444a028
   GRUNE T, 1995, J BIOL CHEM, V270, P2344, DOI 10.1074/jbc.270.5.2344
   HILT W, 1993, J BIOL CHEM, V268, P3479
   HORAKOVA M, 1988, MECH AGEING DEV, V45, P1, DOI 10.1016/0047-6374(88)90014-0
   KANAREK RB, 1985, AM J CLIN NUTR, V42, P940, DOI 10.1093/ajcn/42.5.940
   Kania MA, 1996, EUR J BIOCHEM, V236, P510, DOI 10.1111/j.1432-1033.1996.00510.x
   KOIZUMI A, 1987, J NUTR, V117, P361, DOI 10.1093/jn/117.2.361
   LAMMIKEEFE CJ, 1984, J NUTR, V114, P2235, DOI 10.1093/jn/114.12.2235
   Masoro EJ, 1996, J GERONTOL A-BIOL, V51, pB387, DOI 10.1093/gerona/51A.6.B387
   MASORO EJ, 1985, J NUTR, V115, P842, DOI 10.1093/jn/115.7.842
   PACIFICI RE, 1989, FREE RADICAL BIO MED, V7, P521, DOI 10.1016/0891-5849(89)90028-2
   RIVETT AJ, 1985, J BIOL CHEM, V260, P2600
   RIVETT AJ, 1990, ARCH BIOCHEM BIOPHYS, V278, P26, DOI 10.1016/0003-9861(90)90226-O
   SAHAKIAN JA, 1995, ARCH BIOCHEM BIOPHYS, V318, P411, DOI 10.1006/abbi.1995.1248
   Shibatani T, 1996, J GERONTOL A-BIOL, V51, pB175, DOI 10.1093/gerona/51A.2.B175
   SHIBATANI T, 1995, ARCH BIOCHEM BIOPHYS, V321, P160, DOI 10.1006/abbi.1995.1381
   Shibatani T, 1996, J GERONTOL A-BIOL, V51, pB316, DOI 10.1093/gerona/51A.5.B316
   SMITH CD, 1992, ANN NY ACAD SCI, V663, P110, DOI 10.1111/j.1749-6632.1992.tb38654.x
   STADTMAN ER, 1991, J BIOL CHEM, V266, P2005
   STARKEREED PE, 1989, ARCH BIOCHEM BIOPHYS, V275, P559, DOI 10.1016/0003-9861(89)90402-5
   TANAKA K, 1986, J BIOL CHEM, V261, P5197
   TANNENBAUM ALBERT, 1942, CANCER RES, V2, P460
   Thomson S, 1996, BIOCHEM J, V315, P733, DOI 10.1042/bj3150733
   TSUBUKI S, 1993, BIOCHEM BIOPH RES CO, V196, P1195, DOI 10.1006/bbrc.1993.2378
   TURTURRO A, 1991, ANN NY ACAD SCI, V621, P363
   Veyrat-Durebex C, 1997, PHYSIOL BEHAV, V62, P1273, DOI 10.1016/S0031-9384(97)00304-1
   WEINDRUCH R, 1983, J IMMUNOL, V130, P993
   YOUNGMAN LD, 1992, P NATL ACAD SCI USA, V89, P9112, DOI 10.1073/pnas.89.19.9112
   YOUNGMAN LD, 1992, NUTR CANCER, V18, P131, DOI 10.1080/01635589209514213
   YOUNGMAN LD, 1993, MUTAT RES, V295, P165, DOI 10.1016/0921-8734(93)90018-X
NR 38
TC 58
Z9 60
U1 0
U2 2
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1079-5006
EI 1758-535X
J9 J GERONTOL A-BIOL
JI J. Gerontol. Ser. A-Biol. Sci. Med. Sci.
PD MAY
PY 1998
VL 53
IS 3
BP B173
EP B179
DI 10.1093/gerona/53A.3.B173
PG 7
WC Geriatrics & Gerontology; Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Geriatrics & Gerontology
GA ZM037
UT WOS:000073498400004
PM 9597040
OA Bronze
DA 2024-02-19
ER

PT J
AU Aumailley, L
   Roux-Dalvai, F
   Kelly, I
   Droit, A
   Lebel, M
AF Aumailley, Lucie
   Roux-Dalvai, Florence
   Kelly, Isabelle
   Droit, Arnaud
   Lebel, Michel
TI Vitamin C alters the amount of specific endoplasmic reticulum associated
   proteins involved in lipid metabolism in the liver of mice synthesizing
   a nonfunctional Werner syndrome (Wrn) mutant protein
SO PLOS ONE
LA English
DT Article
ID SYNDROME HELICASE; TPD52 EXPRESSION; CULTURED-CELLS; SYNDROME GENE;
   MOUSE MODEL; DNA; IDENTIFICATION; RECOMBINATION; TRANSCRIPTION;
   INFLAMMATION
AB Werner syndrome (WS) is a premature aging disorder caused by mutations in a protein containing both a DNA exonuclease and DNA helicase domain. Mice lacking the helicase domain of the Wrn protein orthologue exhibit transcriptomic and metabolic alterations, some of which are reversed by vitamin C. Recent studies on these animals indicated that the mutant protein is associated with enriched endoplasmic reticulum (ER) fractions of tissues resulting in an ER stress response. In this study, we identified proteins that exhibit actual level differences in the ER enriched fraction between the liver of wild type and Wrn mutant mice using quantitative proteomic profiling with label-free Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS). Multiple Reaction Monitoring (MRM) and immunoblotting were performed to validate findings in a secondary independent cohort of wild type and Wrn mutant mice. DAVID 6.7 (NIH) was used for functional annotation analysis and indicated that the identified proteins exhibiting level changes between untreated wild type, Wrn mutant, and vitamin C treated Wrn mutant mice (ANOVA P-value < 0.05) were involved in fatty acid and steroid metabolism pathways (Bonferroni P-value = 0.0137). Finally, when we compared the transcriptomic and the proteomic data of our mouse cohorts only similar to 7% of the altered mRNA profiles encoding for ER gene products were consistent with their corresponding protein profiles measured by the label-free quantification methods. These results suggest that a great number of ER gene products are regulated at the post-transcriptional level in the liver of Wrn mutant mice exhibiting an ER stress response.
C1 [Aumailley, Lucie; Lebel, Michel] Univ Laval, CHU Quebec, Fac Med, Ctr Rech, Quebec City, PQ, Canada.
   [Roux-Dalvai, Florence; Kelly, Isabelle; Droit, Arnaud] Univ Laval, CHU Quebec, Fac Med, Ctr Rech,Proteom Platform Ctr, Quebec City, PQ, Canada.
C3 Laval University; Laval University
RP Lebel, M (corresponding author), Univ Laval, CHU Quebec, Fac Med, Ctr Rech, Quebec City, PQ, Canada.
EM michel.lebel@crchudequebec.ulaval.ca
RI ROUX-DALVAI, Florence/ABD-4524-2020; Roux-Dalvai,
   Florence/AAY-4134-2020; Droit, Arnaud/AGZ-6283-2022
OI ROUX-DALVAI, Florence/0000-0002-9961-8964; Droit,
   Arnaud/0000-0001-7922-790X
FU Canadian Institutes of Health Research (Institute of Aging)
   [MOP-257669]; Canadian Institutes of Health Research [MOP-257669]
FX We are grateful to Eric Paquet (Laval University) for help with the
   microarray analyses. This work was supported by the Canadian Institutes
   of Health Research (Institute of Aging) to M.L (grant # MOP-257669).
   L.A. is a scholar from the Fondation du CHU de Quebec.; This work was
   supported by the Canadian Institutes of Health Research (grant #
   MOP-257669) to M L. LA is a scholar from the Fondation du CHU de Quebec.
   The funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Aumailley L, 2015, EXP GERONTOL, V72, P192, DOI 10.1016/j.exger.2015.10.012
   Aumailley L, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0140292
   Balajee AS, 1999, MOL BIOL CELL, V10, P2655, DOI 10.1091/mbc.10.8.2655
   Brown MK, 2012, FRONT PHYSIOL, V3, DOI 10.3389/fphys.2012.00263
   Cogger VC, 2014, J GERONTOL A-BIOL, V69, P1076, DOI 10.1093/gerona/glt169
   Cooper MP, 2000, GENE DEV, V14, P907
   Cox J, 2008, NAT BIOTECHNOL, V26, P1367, DOI 10.1038/nbt.1511
   Croteau DL, 2014, ANNU REV BIOCHEM, V83, P519, DOI 10.1146/annurev-biochem-060713-035428
   Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r60
   Deracinois B, 2013, PROTEOMES, V1, DOI 10.3390/proteomes1030180
   Dodson M, 2013, FREE RADICAL BIO MED, V63, P207, DOI 10.1016/j.freeradbiomed.2013.05.014
   EPSTEIN CJ, 1966, MEDICINE, V45, P177, DOI 10.1097/00005792-196605000-00001
   Guo YF, 2008, ACTA BIOCH BIOPH SIN, V40, P426, DOI 10.1111/j.1745-7270.2008.00418.x
   Gygi SP, 1999, MOL CELL BIOL, V19, P1720, DOI 10.1128/mcb.19.3.1720
   Harding HP, 2000, MOL CELL, V5, P897, DOI 10.1016/S1097-2765(00)80330-5
   Head GA, 2014, FRONT PHYSIOL, V5, DOI 10.3389/fphys.2014.00493
   HOEFLER G, 1994, GENOMICS, V19, P60, DOI 10.1006/geno.1994.1013
   Huang SR, 2000, NUCLEIC ACIDS RES, V28, P2396, DOI 10.1093/nar/28.12.2396
   Ipsen DH, 2014, NUTRIENTS, V6, P5473, DOI 10.3390/nu6125473
   Ivanova AA, 2015, DOKL BIOCHEM BIOPHYS, V463, P213, DOI 10.1134/S1607672915040043
   Johnson JE, 2010, NUCLEIC ACIDS RES, V38, P1114, DOI 10.1093/nar/gkp1103
   Johnston CS, 2006, NUTR METAB, V3, DOI 10.1186/1743-7075-3-35
   Kamath-Loeb AS, 1998, J BIOL CHEM, V273, P34145, DOI 10.1074/jbc.273.51.34145
   Kamili A, 2015, J CELL SCI, V128, P3223, DOI 10.1242/jcs.167692
   Labbé A, 2011, J GERONTOL A-BIOL, V66, P264, DOI 10.1093/gerona/glq184
   Lebel M, 1998, P NATL ACAD SCI USA, V95, P13097, DOI 10.1073/pnas.95.22.13097
   Lebel M, 2001, CANCER RES, V61, P1816
   Liebler DC, 2013, BIOCHEMISTRY-US, V52, P3797, DOI 10.1021/bi400110b
   Massip L, 2006, EXP GERONTOL, V41, P157, DOI 10.1016/j.exger.2005.10.011
   Massip L, 2010, FASEB J, V24, P158, DOI 10.1096/fj.09-137133
   Nicolas-Francès V, 2014, BIOCHIMIE, V98, P86, DOI 10.1016/j.biochi.2013.11.014
   Saintigny Y, 2002, MOL CELL BIOL, V22, P6971, DOI 10.1128/MCB.22.20.6971-6978.2002
   SALK D, 1982, HUM GENET, V62, P1, DOI 10.1007/BF00295598
   Seiler SE, 2014, J LIPID RES, V55, P635, DOI 10.1194/jlr.M043448
   Tang WL, 2016, HUM MOL GENET, V25, P2060, DOI 10.1093/hmg/ddw079
   Trapeaux J, 2013, BRIT J PHARM
   Turaga RVN, 2007, AGING CELL, V6, P471, DOI 10.1111/j.1474-9726.2007.00301.x
   Turaga RVN, 2009, CELL CYCLE, V8, P2080, DOI 10.4161/cc.8.13.8925
   Vizcaíno JA, 2016, NUCLEIC ACIDS RES, V44, pD447, DOI 10.1093/nar/gkv1145
   Wang Y, 2016, ONCOTARGET, V7, P6323, DOI 10.18632/oncotarget.6319
   Westin MAK, 2005, J BIOL CHEM, V280, P38125, DOI 10.1074/jbc.M508479200
   Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258
NR 42
TC 8
Z9 8
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAR 1
PY 2018
VL 13
IS 3
AR e0193170
DI 10.1371/journal.pone.0193170
PG 23
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA FX8RR
UT WOS:000426363200027
PM 29494634
OA gold, Green Published, Green Submitted
DA 2024-02-19
ER

PT J
AU Hirode, G
   Saab, S
   Wong, RJ
AF Hirode, Grishma
   Saab, Sammy
   Wong, Robert J.
TI Trends in the Burden of Chronic Liver Disease Among Hospitalized US
   Adults
SO JAMA NETWORK OPEN
LA English
DT Article
ID UNITED-STATES; HEPATOCELLULAR-CARCINOMA; HEART-FAILURE; PREVALENCE;
   CARE; CIRRHOSIS; COHORT; MORTALITY
AB Importance One factor associated with the rapidly increasing clinical and economic burden of chronic liver disease (CLD) is inpatient health care utilization. Objective To understand trends in the hospitalization burden of CLD in the US. Design, Setting, and Participants This cross-sectional study of hospitalized adults in the US used data from the National Inpatient Sample from 2012 to 2016 on adult CLD-related hospitalizations. Data were analyzed from June to October 2019. Main Outcomes and Measures Hospitalizations identified using a comprehensive review of CLD-specific International Classification of Diseases, Ninth Revision, Clinical Modification and International Statistical Classification of Diseases, Tenth Revision, Clinical Modification codes. Survey-weighted annual trends in national estimates of CLD-related hospitalizations, in-hospital mortality, and hospitalization costs, stratified by demographic and clinical characteristics. Results This study included 1 016 743 CLD-related hospitalizations (mean [SD] patient age, 57.4 [14.4] years; 582 197 [57.3%] male; 633 082 [62.3%] white). From 2012 to 2016, the rate of CLD-related hospitalizations per 100 000 hospitalizations increased from 3056 (95% CI, 3042-3069) to 3757 (95% CI, 3742-3772), and total inpatient hospitalization costs increased from $14.9 billion (95% CI, $13.9 billion to $15.9 billion) to $18.8 billion (95% CI, $17.6 billion to $20.0 billion). Mean (SD) patient age increased (56.8 [14.2] years in 2012 to 57.8 [14.6] years in 2016) and, subsequently, the proportion with Medicare also increased (41.7% [95% CI, 41.1%-42.2%] to 43.6% [95% CI, 43.1%-44.1%]) (P for trend < .001 for both). The proportion of hospitalizations of patients with hepatitis C virus was similar throughout the period of study (31.6% [95% CI, 31.3%-31.9%]), and the proportion with alcoholic cirrhosis and nonalcoholic fatty liver disease showed increases. The mortality rate was higher among hospitalizations with alcoholic cirrhosis (11.9% [95% CI, 11.7%-12.0%]) compared with other etiologies. Presence of hepatocellular carcinoma was also associated with a high mortality rate (9.8% [95% CI, 9.5%-10.1%]). Cost burden increased across all etiologies, with a higher total cost burden among hospitalizations with alcoholic cirrhosis ($22.7 billion [95% CI, $22.1 billion to $23.2 billion]) or hepatitis C virus ($22.6 billion [95% CI, $22.1 billion to $23.2 billion]). Presence of cirrhosis, complications of cirrhosis, and comorbidities added to the CLD burden. Conclusions and Relevance Over the study period, the total estimated national hospitalization costs in patients with CLD reached $81.1 billion. The inpatient CLD burden in the US is likely increasing because of an aging CLD population with increases in concomitant comorbid conditions.
C1 [Hirode, Grishma; Wong, Robert J.] Highland Hosp, Alameda Hlth Syst, Div Gastroenterol & Hepatol, 1411E 31st St, Oakland, CA 94602 USA.
   [Saab, Sammy] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA.
C3 University of California System; University of California Los Angeles;
   University of California Los Angeles Medical Center; David Geffen School
   of Medicine at UCLA
RP Wong, RJ (corresponding author), Highland Hosp, Alameda Hlth Syst, Div Gastroenterol & Hepatol, 1411E 31st St, Oakland, CA 94602 USA.
EM robertwong123@gmail.com
RI Hirode, Grishma/JHU-5259-2023
OI Hirode, Grishma/0000-0003-1530-5950; Wong, Robert/0000-0002-8923-2806
CR Allen AM, 2018, HEPATOLOGY, V68, P2230, DOI 10.1002/hep.30094
   Allen AM, 2018, HEPATOLOGY, V67, P1726, DOI 10.1002/hep.29546
   Asrani SK, 2019, AM J GASTROENTEROL, V114, P98, DOI 10.1038/s41395-018-0365-4
   Asrani SK, 2019, J HEPATOL, V70, P151, DOI 10.1016/j.jhep.2018.09.014
   Asrani SK, 2018, GASTROENTEROLOGY, V155, P719, DOI 10.1053/j.gastro.2018.05.032
   Asrani SK, 2013, GASTROENTEROLOGY, V145, P375, DOI 10.1053/j.gastro.2013.04.005
   Bennett DA, 2001, AUST NZ J PUBL HEAL, V25, P464, DOI 10.1111/j.1467-842X.2001.tb00294.x
   Beste LA, 2015, GASTROENTEROLOGY, V149, P1471, DOI 10.1053/j.gastro.2015.07.056
   Bureau of Labor Statistics, CPI INFL CALC
   Centers for Disease Control and Prevention, AD OV OB
   Centers for Disease Control and Prevention, National diabetes statistics report
   Chen J, 2011, JAMA-J AM MED ASSOC, V306, P1669, DOI 10.1001/jama.2011.1474
   Dang K, 2019, AM J GASTROENTEROL, DOI [10.14309/ajg.000000000000038, DOI 10.14309/AJG.000000000000038]
   Davis GL, 2010, GASTROENTEROLOGY, V138, P513, DOI 10.1053/j.gastro.2009.09.067
   Gibson T., 2016, HCUP METHODS SERIES
   Goldberg D, 2017, GASTROENTEROLOGY, V152, P1090, DOI 10.1053/j.gastro.2017.01.003
   Haut ER, 2012, JAMA-J AM MED ASSOC, V307, P2589, DOI 10.1001/jama.2012.6626
   Healthcare Cost and Utilization Project, 2018, INTR HCUP NAT INP SA
   Hernaez R, 2017, GUT, V66, P541, DOI 10.1136/gutjnl-2016-312670
   Hirode G, 2019, J CLIN GASTROENTEROL, V53, P765, DOI 10.1097/MCG.0000000000001229
   Hirode G, 2019, DIGEST DIS SCI, V64, P1448, DOI 10.1007/s10620-019-05576-9
   Kanwal F, 2019, HEPATOLOGY, V69, P1787, DOI 10.1002/hep.30489
   Kanwal F, 2016, HEPATOLOGY, V64, P569, DOI 10.1002/hep.28558
   Kanwal F, 2016, CLIN GASTROENTEROL H, V14, P301, DOI 10.1016/j.cgh.2015.08.010
   Kanwal F, 2010, CLIN GASTROENTEROL H, V8, P709, DOI 10.1016/j.cgh.2010.03.028
   Khera R, 2017, JAMA-J AM MED ASSOC, V318, P2011, DOI 10.1001/jama.2017.17653
   Kim D, 2018, GASTROENTEROLOGY, V155, P1154, DOI 10.1053/j.gastro.2018.07.008
   Kim WR, 2017, AM J TRANSPLANT, V17, DOI 10.1111/ajt.14126
   Kim WR, 2016, AM J TRANSPLANT, V16, P69, DOI 10.1111/ajt.13668
   Liu TL, 2016, DIGEST DIS SCI, V61, P3335, DOI 10.1007/s10620-016-4261-8
   Marcellin P, 2018, LIVER INT, V38, P2, DOI 10.1111/liv.13682
   Moon AM, 2017, ALIMENT PHARM THER, V45, P1201, DOI 10.1111/apt.14021
   Nguyen AL, 2019, DIGEST DIS SCI, V64, P698, DOI 10.1007/s10620-018-5326-7
   Nguyen MH, 2019, J HEPATOL, V70, P24, DOI 10.1016/j.jhep.2018.09.021
   Phillips CO, 2004, JAMA-J AM MED ASSOC, V291, P1358, DOI 10.1001/jama.291.11.1358
   Ratib S, 2014, J HEPATOL, V60, P282, DOI 10.1016/j.jhep.2013.09.027
   Rein DB, 2012, ANN INTERN MED, V156, P263, DOI 10.7326/0003-4819-156-4-201202210-00378
   Rinella ME, 2015, JAMA-J AM MED ASSOC, V313, P2263, DOI 10.1001/jama.2015.5370
   Schafer JL, 1999, STAT METHODS MED RES, V8, P3, DOI 10.1191/096228099671525676
   Tapper EB, 2018, BMJ-BRIT MED J, V362, DOI [10.1136/bm1k2817, 10.1136/bmj.k2817]
   Tapper EB, 2016, CANCER-AM CANCER SOC, V122, P852, DOI 10.1002/cncr.29855
   Tapper EB, 2016, CLIN GASTROENTEROL H, V14, P753, DOI 10.1016/j.cgh.2015.08.041
   Tapper EB, 2015, AM J GASTROENTEROL, V110, P1298, DOI 10.1038/ajg.2015.241
   Volk ML, 2012, AM J GASTROENTEROL, V107, P247, DOI 10.1038/ajg.2011.314
   von Elm E, 2008, J CLIN EPIDEMIOL, V61, P344, DOI 10.2471/BLT.07.045120
   Ward JW, 2015, NEW ENGL J MED, V373, P2678, DOI 10.1056/NEJMe1513245
   Wong T, 2019, JAMA-J AM MED ASSOC, V321, P1723, DOI 10.1001/jama.2019.2276
   World Health Organization, Overweight and obesity
   Younossi ZM, 2020, GUT, V69, P564, DOI 10.1136/gutjnl-2019-318813
   Younossi ZM, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2013-004318
   Younossi ZM, 2011, CLIN GASTROENTEROL H, V9, P524, DOI 10.1016/j.cgh.2011.03.020
NR 51
TC 112
Z9 121
U1 1
U2 3
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2574-3805
J9 JAMA NETW OPEN
JI JAMA Netw. Open
PD APR 2
PY 2020
VL 3
IS 4
AR e201997
DI 10.1001/jamanetworkopen.2020.1997
PG 15
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA LA0US
UT WOS:000523672700001
PM 32239220
OA gold, Green Published
DA 2024-02-19
ER

PT J
AU KEENAN, KP
   SMITH, PF
   HERTZOG, P
   SOPER, K
   BALLAM, GC
   CLARK, RL
AF KEENAN, KP
   SMITH, PF
   HERTZOG, P
   SOPER, K
   BALLAM, GC
   CLARK, RL
TI THE EFFECTS OF OVERFEEDING AND DIETARY RESTRICTION ON SPRAGUE-DAWLEY RAT
   SURVIVAL AND EARLY PATHOLOGY BIOMARKERS OF AGING
SO TOXICOLOGIC PATHOLOGY
LA English
DT Article
DE CALORIC RESTRICTION; CELL PROLIFERATION; BROMODEOXYURIDINE LABELING;
   PITUITARY HYPERPLASIA; NEOPLASIA; NEPHROPATHY; CARDIOMYOPATHY
AB A significant correlation exists between average daily food consumption and 2-yr survival in control ad libitum (AL)-fed Sprague-Dawley (SD) rats. SD rats were fed Purina Rodent Chow 5002 or a modified chow, 5002-9, with lower protein, fat, metabolizable energy and increased fiber AL or by dietary restriction (DR) to 65% of the AL amount by measurement or time (6.5 hr). At 52 wk, food consumption and key pathology biomarkers correlated with 106-wk survival. The modified chow, 5002-9 fed AL, did not significantly improve survival. SD rats fed either diet AL consumed the greatest amount of feed and kcal/rat but consumed the same amount of feed per gram body weight as DR-fed rats. At 52 wk, AL rats fed either diet had the same brain weights as DR rats, but the AL-fed rats had greater body weight and body fat content and increased heart, lung, kidney, liver, adrenal, thyroid, and pituitary weights as well as an increased incidence and severity of degenerative and/or proliferative lesions in these organs. This study demonstrates that overfeeding best correlates with low 2-yr survival in SD rats and that simple DR by caloric restriction modifies key pathology biomarkers in the pituitary, mammary gland, kidney, and heart of SD rats at 52 wk that are predictive of 106-wk survival.
RP KEENAN, KP (corresponding author), MERCK SHARP & DOHME LTD,RES LABS,DEPT SAFETY ASSESSMENT,WP 45-222,W POINT,PA 19486, USA.
NR 0
TC 109
Z9 113
U1 0
U2 1
PU SOC TOXICOLOGIC PATHOLOGISTS
PI LAWRENCE
PA 1041 NEW HAMPSHIRE ST PO BOX 368, LAWRENCE, KS 66044
SN 0192-6233
J9 TOXICOL PATHOL
JI Toxicol. Pathol.
PD MAY-JUN
PY 1994
VL 22
IS 3
BP 300
EP 315
DI 10.1177/019262339402200308
PG 16
WC Pathology; Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pathology; Toxicology
GA PG622
UT WOS:A1994PG62200008
PM 7817120
DA 2024-02-19
ER

PT J
AU Martínez, D
   Pentinat, T
   Ribó, S
   Daviaud, C
   Bloks, VW
   Cebrià, J
   Villalmanzo, N
   Kalko, SG
   Ramón-Krauel, M
   Díaz, R
   Plösch, T
   Tost, J
   Jiménez-Chillarón, JC
AF Martinez, Debora
   Pentinat, Thais
   Ribo, Silvia
   Daviaud, Christian
   Bloks, Vincent W.
   Cebria, Judith
   Villalmanzo, Nuria
   Kalko, Susana G.
   Ramon-Krauel, Marta
   Diaz, Ruben
   Ploesch, Torsten
   Tost, Joerg
   Jimenez-Chillaron, Josep C.
TI In Utero Undernutrition in Male Mice Programs Liver Lipid Metabolism in
   the Second-Generation Offspring Involving Altered <i>Lxra</i> DNA
   Methylation
SO CELL METABOLISM
LA English
DT Article
ID TRANSGENERATIONAL EPIGENETIC INHERITANCE; LOW-BIRTH-WEIGHT; HIGH-FAT
   DIET; GLUCOSE-INTOLERANCE; PRENATAL EXPOSURE; GENE; CHOLESTEROL;
   GENERATION; NUTRITION; OBESITY
AB Obesity and type 2 diabetes have a heritable component that is not attributable to genetic factors. Instead, epigenetic mechanisms may play a role. We have developed a mouse model of intrauterine growth restriction (IUGR) by in utero malnutrition. IUGR mice developed obesity and glucose intolerance with aging. Strikingly, offspring of IUGR male mice also developed glucose intolerance. Here, we show that in utero malnutrition of F1 males influenced the expression of lipogenic genes in livers of F2 mice, partly due to altered expression of Lxra. In turn, Lxra expression is attributed to altered DNA methylation of its 5' UTR region. We found the same epigenetic signature in the sperm of their progenitors, F1 males. Our data indicate that in utero malnutrition results in epigenetic modifications in germ cells (F1) that are subsequently transmitted and maintained in somatic cells of the F2, thereby influencing health and disease risk of the offspring.
C1 [Martinez, Debora; Pentinat, Thais; Ribo, Silvia; Cebria, Judith; Villalmanzo, Nuria; Ramon-Krauel, Marta; Diaz, Ruben; Jimenez-Chillaron, Josep C.] Hosp St Joan de Deu, Barcelona 08950, Spain.
   [Daviaud, Christian; Tost, Joerg] CEA, Inst Genom, Ctr Natl Genotypage, Lab Epigenet & Environm, F-91057 Evry, France.
   [Bloks, Vincent W.] Univ Groningen, Univ Med Ctr Groningen, Ctr Liver Digest & Metab Dis, Dept Pediat, NL-9713 GZ Groningen, Netherlands.
   [Kalko, Susana G.] Univ Barcelona, Hosp Clin Barcelona, Inst Invest Biomed August Pi & Sunyer IDIBAPS, Bioinformat Core Facil, E-08036 Barcelona, Spain.
   [Diaz, Ruben] Univ Barcelona, Fac Med, Barcelona 08950, Spain.
   [Ploesch, Torsten] Univ Groningen, Univ Med Ctr Groningen, Dept Obstet & Gynaecol, NL-9713 GZ Groningen, Netherlands.
C3 University of Barcelona; Universite Paris Saclay; CEA; University of
   Groningen; University of Barcelona; Hospital Clinic de Barcelona;
   IDIBAPS; University of Barcelona; University of Groningen
RP Jiménez-Chillarón, JC (corresponding author), Hosp St Joan de Deu, Barcelona 08950, Spain.
EM jjimenezc@fsjd.org
RI Tost, Joerg/H-7129-2019; Vehi, Josep/D-6602-2013; Plösch,
   Torsten/X-6808-2019; Bloks, Vincent W/A-7609-2012; Ribo,
   Silvia/ABI-5622-2020
OI Tost, Joerg/0000-0002-2683-0817; Vehi, Josep/0000-0001-6884-9789;
   Plösch, Torsten/0000-0002-9305-4045; Bloks, Vincent
   W/0000-0001-6493-7482; Ribo, Silvia/0000-0001-8983-827X; Ramon-Krauel,
   Marta/0000-0003-3027-9105; Kalko, Susana/0000-0002-6701-0233
FU Ministerio de Economia y Competitividad [BFU2008-03759, BFU2011-29739];
   Instituto de Salud Carlos III [CP11/00312]; European Foundation for the
   Study of Diabetes (EFS/Novo Nordisk Programme) [80800]; Ministerio de
   Ciencia e Innovacion, Spain [BES-2009-012961]; Infojobs, Spain
FX This work has been supported by grants to J.C.J.-C. from Ministerio de
   Economia y Competitividad (BFU2008-03759, BFU2011-29739), Instituto de
   Salud Carlos III (CP11/00312), and European Foundation for the Study of
   Diabetes (EFS/Novo Nordisk Programme, 2010; 80800). T. Pentinat has been
   recipient of a fellowship from Ministerio de Ciencia e Innovacion, Spain
   (BES-2009-012961). S.R. has been supported by Infojobs, Spain. We are
   grateful to Jordi Ubanell for his graphic designs in Figures 3A and 3B
   (http://zitruslab.com).
CR Anway MD, 2005, SCIENCE, V308, P1466, DOI 10.1126/science.1108190
   Benyshek DC, 2006, DIABETOLOGIA, V49, P1117, DOI 10.1007/s00125-006-0196-5
   Blewitt ME, 2006, PLOS GENET, V2, P399, DOI 10.1371/journal.pgen.0020049
   BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911
   Boissonnas CC, 2010, EUR J HUM GENET, V18, P73, DOI 10.1038/ejhg.2009.117
   Breitling R, 2004, FEBS LETT, V573, P83, DOI 10.1016/j.febslet.2004.07.055
   Burdge GC, 2007, BRIT J NUTR, V97, P435, DOI 10.1017/S0007114507352392
   Burdge GC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028282
   Bygren LO, 2001, ACTA BIOTHEOR, V49, P53, DOI 10.1023/A:1010241825519
   Carone BR, 2010, CELL, V143, P1084, DOI 10.1016/j.cell.2010.12.008
   Daxinger L, 2012, NAT REV GENET, V13, P153, DOI 10.1038/nrg3188
   Dunn GA, 2011, ENDOCRINOLOGY, V152, P2228, DOI 10.1210/en.2010-1461
   Dunn GA, 2009, ENDOCRINOLOGY, V150, P4999, DOI 10.1210/en.2009-0500
   Ferguson-Smith AC, 2011, CELL METAB, V13, P115, DOI 10.1016/j.cmet.2011.01.011
   Fullston T, 2013, FASEB J, V27, P4226, DOI 10.1096/fj.12-224048
   Gluckman PD, 2007, BIOESSAYS, V29, P145, DOI 10.1002/bies.20522
   Grossniklaus U, 2013, NAT REV GENET, V14, P228, DOI 10.1038/nrg3435
   Guerrero-Bosagna C, 2012, MOL CELL ENDOCRINOL, V354, P3, DOI 10.1016/j.mce.2011.10.004
   Guerrero-Bosagna C, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013100
   Hackett JA, 2013, CELL, V153, P737, DOI 10.1016/j.cell.2013.04.044
   Hackett JA, 2013, SCIENCE, V339, P448, DOI 10.1126/science.1229277
   Hu SH, 2013, ELIFE, V2, DOI 10.7554/eLife.00726
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249
   Jimenez-Chillaron JC, 2005, DIABETES, V54, P702, DOI 10.2337/diabetes.54.3.702
   Jiménez-Chillarón JC, 2012, BIOCHIMIE, V94, P2242, DOI 10.1016/j.biochi.2012.06.012
   Jimenez-Chillaron JC, 2009, DIABETES, V58, P460, DOI 10.2337/db08-0490
   Jirtle RL, 2007, NAT REV GENET, V8, P253, DOI 10.1038/nrg2045
   Kaati G, 2002, EUR J HUM GENET, V10, P682, DOI 10.1038/sj.ejhg.5200859
   Kalaany NY, 2005, CELL METAB, V1, P231, DOI 10.1016/j.cmet.2005.03.001
   King V, 2013, ENDOCRINOLOGY, V154, P2514, DOI 10.1210/en.2013-1013
   Ng SF, 2010, NATURE, V467, P963, DOI 10.1038/nature09491
   Padmanabhan N, 2013, CELL, V155, P81, DOI 10.1016/j.cell.2013.09.002
   Painter RC, 2008, BJOG-INT J OBSTET GY, V115, P1243, DOI 10.1111/j.1471-0528.2008.01822.x
   Patti ME, 2013, CELL MOL LIFE SCI, V70, P1597, DOI 10.1007/s00018-013-1298-0
   Peet DJ, 1998, CELL, V93, P693, DOI 10.1016/S0092-8674(00)81432-4
   Pembrey ME, 2006, EUR J HUM GENET, V14, P159, DOI 10.1038/sj.ejhg.5201538
   Pentinat T, 2010, ENDOCRINOLOGY, V151, P5617, DOI 10.1210/en.2010-0684
   Rakyan VK, 2003, P NATL ACAD SCI USA, V100, P2538, DOI 10.1073/pnas.0436776100
   Repa JJ, 2000, ANNU REV CELL DEV BI, V16, P459, DOI 10.1146/annurev.cellbio.16.1.459
   Repa JJ, 2000, GENE DEV, V14, P2819, DOI 10.1101/gad.844900
   Rönn T, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003572
   Seisenberger S, 2012, MOL CELL, V48, P849, DOI 10.1016/j.molcel.2012.11.001
   Skinner MK, 2008, REPROD TOXICOL, V25, P2, DOI 10.1016/j.reprotox.2007.09.001
   Skinner MK, 2010, NATURE, V467, P922, DOI 10.1038/467922a
   Spruijt CG, 2013, CELL, V152, P1146, DOI 10.1016/j.cell.2013.02.004
   Tontonoz P, 2003, MOL ENDOCRINOL, V17, P985, DOI 10.1210/me.2003-0061
   Tost J, 2007, NAT PROTOC, V2, P2265, DOI 10.1038/nprot.2007.314
   van der Veen JN, 2007, J LIPID RES, V48, P337, DOI 10.1194/jlr.M600170-JLR200
   Vasicek TJ, 1997, GENETICS, V147, P777
   Vassoler FM, 2013, NAT NEUROSCI, V16, P42, DOI 10.1038/nn.3280
   Veena SR, 2007, DIABETOLOGIA, V50, P43, DOI 10.1007/s00125-006-0516-9
   Veenendaal MVE, 2013, BJOG-INT J OBSTET GY, V120, P548, DOI 10.1111/1471-0528.12136
   Walker BR, 1998, BRIT MED J, V316, P834, DOI 10.1136/bmj.316.7134.834
   Youngson NA, 2008, ANNU REV GENOM HUM G, V9, P233, DOI 10.1146/annurev.genom.9.081307.164445
   Zambrano E, 2006, J PHYSIOL-LONDON, V571, P221, DOI 10.1113/jphysiol.2005.100313
   Zeybel M, 2012, NAT MED, V18, P1369, DOI 10.1038/nm.2893
NR 57
TC 142
Z9 148
U1 1
U2 36
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 1550-4131
EI 1932-7420
J9 CELL METAB
JI Cell Metab.
PD JUN 3
PY 2014
VL 19
IS 6
BP 941
EP 951
DI 10.1016/j.cmet.2014.03.026
PG 11
WC Cell Biology; Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Endocrinology & Metabolism
GA AO5PD
UT WOS:000341396300009
PM 24794974
OA Green Published, hybrid
DA 2024-02-19
ER

PT J
AU Shen, Q
   Bai, YC
   Chang, KCN
   Wang, YJ
   Burris, TP
   Freedman, LP
   Thompson, CC
   Nagpal, S
AF Shen, Qi
   Bai, Yuchen
   Chang, Ken C. N.
   Wang, Yongjun
   Burris, Thomas P.
   Freedman, Leonard P.
   Thompson, Catherine C.
   Nagpal, Sunil
TI Liver X Receptor-Retinoid X Receptor (LXR-RXR) Heterodimer Cistrome
   Reveals Coordination of LXR and AP1 Signaling in Keratinocytes
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID PEPTIDYLARGININE DEIMINASE; ATOPIC-DERMATITIS; EPIDERMAL
   DIFFERENTIATION; TRANSCRIPTION FACTORS; PERMEABILITY BARRIER; MURINE
   EPIDERMIS; GENE-EXPRESSION; BINDING; ACTIVATORS; PROMOTER
AB Liver X receptors (LXRs) play a critical role in regulating lipid synthesis and transport in numerous tissues. In the skin, activation of LXR induces keratinocyte differentiation and improves epidermal permeability barrier homeostasis. To elucidate the mechanism of LXR action in skin, we mapped its cistrome by identifying LXR beta-RXR alpha binding sites using ChIP-on-chip in normal human epidermal keratinocytes (NHEKs). The cistrome was integrated with transcription data to obtain a global view of LXR action in keratinocyte biology. Here, we identify 2035 LXR beta-RXR alpha binding sites containing 4794 LXR response elements in NHEKs and show the presence of consensus heterodimer active regions in genes involved in keratinocyte lipid transport/synthesis and terminal differentiation. Bioinformatics analysis of the cistrome revealed an enrichment of AP1 cis-regulatory motifs in the vicinity of the LXR beta-RXR alpha binding sites. Importantly, we have demonstrated a direct interaction between LXR and Jun/Fos, indicating that the cooperation between LXR and AP1 may orchestrate keratinocyte differentiation. Finally, we corroborated these results by genome-wide mapping of the c-Fos and c-Jun cistromes in NHEKs, demonstrating that 77% of all the LXR beta-RXR alpha binding regions show the presence of AP1 motifs at adjacent locations. Our findings provide new insight into the mechanism of LXR action in keratinocyte differentiation, lipid production and barrier formation, further strengthening the validation of LXR as a potential therapeutic target for skin disorders including skin aging, psoriasis, and atopic dermatitis.
C1 [Shen, Qi; Bai, Yuchen; Chang, Ken C. N.; Freedman, Leonard P.; Thompson, Catherine C.; Nagpal, Sunil] Wyeth Res, Dept Womens Hlth & Musculoskeletal Biol, Nucl Receptors & Dermatol, Collegeville, PA 19426 USA.
   [Wang, Yongjun; Burris, Thomas P.] Scripps Res Inst, Jupiter, FL 33458 USA.
C3 Pfizer; State University System of Florida; University of Florida;
   Herbert Wertheim UF Scripps Institute for Biomedical Innovation &
   Technology
RP Nagpal, S (corresponding author), Merck Res Labs, 770 Sumneytown Pike, West Point, PA 19486 USA.
EM sunil.nagpal@merck.com
RI Burris, Thomas P/B-3886-2016; Burris, Thomas P/H-5078-2011; Yan,
   Miaochen/JLL-5061-2023
OI Burris, Thomas P/0000-0003-2922-4449; 
CR Carroll JS, 2006, NAT GENET, V38, P1289, DOI 10.1038/ng1901
   Carroll JS, 2005, CELL, V122, P33, DOI 10.1016/j.cell.2005.05.008
   Chang KCN, 2008, MOL ENDOCRINOL, V22, P2407, DOI 10.1210/me.2008-0232
   Chavanas S, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003408
   Chawla A, 2001, SCIENCE, V294, P1866, DOI 10.1126/science.294.5548.1866
   Costet P, 2000, J BIOL CHEM, V275, P28240
   Crish JF, 2008, J INVEST DERMATOL, V128, P530, DOI 10.1038/sj.jid.5701049
   DiSepio D, 1999, DRUG DISCOV TODAY, V4, P222, DOI 10.1016/S1359-6446(99)01335-5
   Elias Peter M, 2009, Clin Med Dermatol, V2, P1
   Fleischmann A, 2000, GENE DEV, V14, P2695, DOI 10.1101/gad.187900
   Fowler AJ, 2003, J INVEST DERMATOL, V120, P246, DOI 10.1046/j.1523-1747.2003.12033.x
   Hanley K, 2000, J INVEST DERMATOL, V114, P545, DOI 10.1046/j.1523-1747.2000.00895.x
   Ishida-Yamamoto A, 2000, J INVEST DERMATOL, V114, P701, DOI 10.1046/j.1523-1747.2000.00936.x
   Jang SI, 1996, J BIOL CHEM, V271, P24105, DOI 10.1074/jbc.271.39.24105
   Jang SI, 2002, J BIOL CHEM, V277, P42268, DOI 10.1074/jbc.M205593200
   Ji XW, 2006, NUCLEIC ACIDS RES, V34, pW551, DOI 10.1093/nar/gkl322
   Jiang YJ, 2008, J INVEST DERMATOL, V128, P104, DOI 10.1038/sj.jid.5700944
   Jiang YJ, 2006, J LIPID RES, V47, P2248, DOI 10.1194/jlr.M600163-JLR200
   Johnson WE, 2006, P NATL ACAD SCI USA, V103, P12457, DOI 10.1073/pnas.0601180103
   Joseph SB, 2002, J BIOL CHEM, V277, P11019, DOI 10.1074/jbc.M111041200
   Kennedy MA, 2001, J BIOL CHEM, V276, P39438, DOI 10.1074/jbc.M105863200
   Kömüves LG, 2002, J INVEST DERMATOL, V118, P25, DOI 10.1046/j.0022-202x.2001.01628.x
   Laffitte BA, 2001, P NATL ACAD SCI USA, V98, P507, DOI 10.1073/pnas.021488798
   Lefèvre C, 2003, HUM MOL GENET, V12, P2369, DOI 10.1093/hmg/ddg235
   Lefterova MI, 2008, GENE DEV, V22, P2941, DOI 10.1101/gad.1709008
   Li M, 2006, P NATL ACAD SCI USA, V103, P11736, DOI 10.1073/pnas.0604575103
   Man MQ, 2006, J INVEST DERMATOL, V126, P386, DOI 10.1038/sj.jid.5700046
   Massie CE, 2007, EMBO REP, V8, P871, DOI 10.1038/sj.embor.7401046
   Matys V, 2003, NUCLEIC ACIDS RES, V31, P374, DOI 10.1093/nar/gkg108
   Nakashima K, 2002, J BIOL CHEM, V277, P49562, DOI 10.1074/jbc.M208795200
   Nemoto-Hasebe I, 2009, J INVEST DERMATOL, V129, P682, DOI 10.1038/jid.2008.280
   Ohsawa T, 1999, J DERMATOL SCI, V19, P68, DOI 10.1016/S0923-1811(98)00051-6
   Palmer CNA, 2006, NAT GENET, V38, P441, DOI 10.1038/ng1767
   Rossi A, 1998, J INVEST DERMATOL, V110, P34, DOI 10.1046/j.1523-1747.1998.00071.x
   Sandelin A, 2004, NUCLEIC ACIDS RES, V32, pD91, DOI 10.1093/nar/gkh012
   Schmuth M, 2004, J INVEST DERMATOL, V123, P41, DOI 10.1111/j.0022-202X.2004.22707.x
   Schultz JR, 2000, GENE DEV, V14, P2831, DOI 10.1101/gad.850400
   Singh M, 2006, DERMATOL THER, V19, P297, DOI 10.1111/j.1529-8019.2006.00087.x
   Strong CD, 2010, HUM MOL GENET, V19, P1453, DOI 10.1093/hmg/ddq019
   Tarcsa E, 1996, J BIOL CHEM, V271, P30709, DOI 10.1074/jbc.271.48.30709
   Yoshikawa T, 2001, MOL CELL BIOL, V21, P2991, DOI 10.1128/MCB.21.9.2991-3000.2001
   Zenz R, 2005, NATURE, V437, P369, DOI 10.1038/nature03963
   Zheng Y, 2005, J INVEST DERMATOL, V124, P867, DOI 10.1111/j.0022-202X.2005.23716.x
   Zuo Y, 2008, J BIOL CHEM, V283, P36624, DOI 10.1074/jbc.M807377200
NR 44
TC 40
Z9 43
U1 0
U2 4
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD APR 22
PY 2011
VL 286
IS 16
BP 14554
EP 14563
DI 10.1074/jbc.M110.165704
PG 10
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 750NW
UT WOS:000289556200075
PM 21349840
OA Green Published, hybrid
DA 2024-02-19
ER

PT J
AU Li, XM
   Xin, N
   Guo, TL
   Wu, ZY
   Zheng, Y
   Lin, L
   Li, QW
   Lin, F
AF Li, Xiaoming
   Xin, Ning
   Guo, Tailin
   Wu, Ziyu
   Zheng, Ying
   Lin, Lan
   Li, Qianwen
   Lin, Fan
TI Follicle-stimulating hormone is negatively associated with nonalcoholic
   fatty liver disease in a Chinese elderly population: a retrospective
   observational study
SO BMC ENDOCRINE DISORDERS
LA English
DT Article
DE Nonalcoholic fatty liver disease; Follicle-stimulating hormone; Elderly;
   Men; Women
ID ACTIVIN-A; WOMEN
AB BackgroundSeveral studies have explored the connection between follicle-stimulating hormone (FSH) and nonalcoholic fatty liver disease (NAFLD). However, the impact of FSH elevation on NAFLD remains a topic of debate. Hence, this investigation aimed to evaluate the potential correlation between FSH levels and NAFLD in the aging population.MethodsThis was a retrospective observational cross-sectional study between July 2017 and August 2018 in our hospital. We used data obtained from 455 patients over 60 years old. Anthropometrics and laboratory tests were performed for each patient. NAFLD was diagnosed by sonographic features and the fatty liver index (LFI).ResultsOf the 455 patients, 200 (43.96%) had NAFLD on their ultrasound and 169 (37.14%) had NAFLD according to the LFI. An intraclass correlation coefficient of the two methods was 80.4% (P < 0.001). People with NAFLD on their ultrasound showed lower FSH levels (52.68 vs. 61.39 IU/L) and more unfavorable metabolic profiles. FSH was negatively correlated with age, alanine aminotransferase, estradiol, testosterone, systolic blood pressure, waist, body mass index, fasting blood glucose, postload plasma glucose and positive associated with total cholesterol, high-density lipoprotein-cholesterol and low-density lipoprotein-cholesterol by Spearman correlation analysis (all P < 0.05). By controlling for all confounding factors, the odds ratios (OR) of FSH for NAFLD were determined in elderly individuals, both men and women, aged 60-70 years and over 70 years. These ORs were found to be 0.937, 0.982, 0.983, and 0.973, respectively, with corresponding 95% confidence intervals (CI) of 0.892-0.984 (P = 0.009), 0.971-0.993 (P = 0.002), 0.967-0.999 (P = 0.033), and 0.958-0.989 (P = 0.001). In addition, our findings demonstrated no significant correlation between FSH and advanced fibrosis when adjusting for potential covariates. The OR for advanced fibrosis was 0.979 (95% CI, 0.938-1.022, P = 0.339). Additionally, ROC curve analysis showed an optimal cut-off value of 66.91 for women and 15.25 for men for NAFLD diagnosis.ConclusionsThere was an inverse relationship observed between levels of FSH in the blood serum and NAFLD in the elderly population. These findings suggest that reduced FSH levels might serve as a potential risk factor or biomarker for NAFLD in the elderly.
C1 [Li, Xiaoming; Xin, Ning; Guo, Tailin; Wu, Ziyu; Zheng, Ying; Lin, Fan] Fujian Med Univ, Fujian Prov Hosp, Fujian Prov Inst Clin Geriatr, Dept Geriatr Med,Fujian Prov Key Lab Geriatr Dis, Fuzhou 350001, Peoples R China.
   [Lin, Lan; Li, Qianwen] Fujian Med Univ, Fujian Prov Hosp, Key Lab Med Big Data Project Fujian Prov, Fuzhou 350001, Peoples R China.
C3 Fujian Provincial Hospital; Fujian Medical University; Fujian Provincial
   Hospital; Fujian Medical University
RP Lin, F (corresponding author), Fujian Med Univ, Fujian Prov Hosp, Fujian Prov Inst Clin Geriatr, Dept Geriatr Med,Fujian Prov Key Lab Geriatr Dis, Fuzhou 350001, Peoples R China.
EM linfan@fjmu.edu.cn
RI Lin, Fan/JZT-1441-2024; 王, 娅冰/JGE-0541-2023; WANG, YANG/JFA-8821-2023
CR Adams LA, 2005, GASTROENTEROLOGY, V129, P113, DOI 10.1053/j.gastro.2005.04.014
   American Diabetes Association, 2020, Diabetes Care, V43, pS14, DOI 10.2337/dc20-S002
   Andersen GO, 2011, DIABETES, V60, P1544, DOI 10.2337/db10-1493
   Bedogni G, 2006, BMC GASTROENTEROL, V6, DOI 10.1186/1471-230X-6-33
   Chobanian AV, 2003, HYPERTENSION, V42, P1206, DOI 10.1161/01.HYP.0000107251.49515.c2
   Craven L, 2020, AM J GASTROENTEROL, V115, P1055, DOI 10.14309/ajg.0000000000000661
   Cui HX, 2012, J LIPID RES, V53, P909, DOI 10.1194/jlr.M025403
   de Alwis NMW, 2008, J HEPATOL, V48, pS104, DOI 10.1016/j.jhep.2008.01.009
   Diehl AM, 2017, NEW ENGL J MED, V377, P2063, DOI 10.1056/NEJMra1503519
   Fabbrini E, 2010, HEPATOLOGY, V51, P679, DOI 10.1002/hep.23280
   Friedman SL, 2018, NAT MED, V24, P908, DOI 10.1038/s41591-018-0104-9
   Galmés-Pascual BM, 2020, FREE RADICAL BIO MED, V150, P148, DOI 10.1016/j.freeradbiomed.2020.02.016
   Ge SJ, 2023, J DIABETES, V15, P640, DOI 10.1111/1753-0407.13394
   Grossmann M, 2019, ENDOCR REV, V40, P417, DOI 10.1210/er.2018-00158
   Kim C, 2015, OBESITY, V23, P228, DOI 10.1002/oby.20917
   Landomiel F, 2014, MOL CELL ENDOCRINOL, V382, P452, DOI 10.1016/j.mce.2013.09.035
   Li XM, 2018, EUR J OBSTET GYN R B, V222, P166, DOI 10.1016/j.ejogrb.2018.01.034
   Liu XM, 2015, AGING CELL, V14, P409, DOI 10.1111/acel.12331
   Mancinelli R, 2009, AM J PHYSIOL-GASTR L, V297, pG11, DOI 10.1152/ajpgi.00025.2009
   Mir BA, 2022, NEW ENGL J MED, V386, P295, DOI 10.1056/NEJMc2118255
   Phan H, 2020, LIVER INT
   Qiao S, 2023, NAT COMMUN, V14, DOI 10.1038/s41467-023-36681-z
   Randolph JF, 2011, J CLIN ENDOCR METAB, V96, P746, DOI 10.1210/jc.2010-1746
   Reame NE, 1998, J CLIN ENDOCR METAB, V83, P3302, DOI 10.1210/jc.83.9.3302
   Santoro N, 1999, FERTIL STERIL, V71, P658, DOI 10.1016/S0015-0282(98)00529-9
   Sanyal AJ, 2019, NAT REV GASTRO HEPAT, V16, P377, DOI 10.1038/s41575-019-0144-8
   Sarkar M, 2019, CLIN GASTROENTEROL H
   Serviente C, 2019, MENOPAUSE, V26, P540, DOI 10.1097/GME.0000000000001273
   Söderberg C, 2010, HEPATOLOGY, V51, P595, DOI 10.1002/hep.23314
   Sokka T, 2008, CLIN EXP RHEUMATOL, V26, pS35, DOI 10.1161/CIRCULATIONAHA.109.192644
   Song Y, 2016, J CLIN ENDOCR METAB, V101, P253, DOI 10.1210/jc.2015-2724
   Stefan N, 2022, LANCET DIABETES ENDO, V10, P284, DOI 10.1016/S2213-8587(22)00003-1
   Sun L, 2006, CELL, V125, P247, DOI 10.1016/j.cell.2006.01.051
   Wang HM, 2021, FASEB J, V35, DOI 10.1096/fj.202002752RR
   Wang JC, 2022, FRONT PHYSIOL, V13, DOI 10.3389/fphys.2022.1046497
   Wang NJ, 2016, J GASTROEN HEPATOL, V31, P1196, DOI 10.1111/jgh.13271
   Wang NJ, 2016, ACTA DIABETOL, V53, P227, DOI 10.1007/s00592-015-0769-1
   Wide L, 2007, J CLIN ENDOCR METAB, V92, P4410, DOI 10.1210/jc.2007-1342
   Xu Y, 2013, JAMA-J AM MED ASSOC, V310, P948, DOI 10.1001/jama.2013.168118
   Younossi Z, 2019, HEPATOLOGY, V69, P2672, DOI 10.1002/hep.30251
   Zhu YX, 2021, BMC GERIATR, V21, DOI 10.1186/s12877-021-02490-6
NR 41
TC 0
Z9 0
U1 6
U2 6
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1472-6823
J9 BMC ENDOCR DISORD
JI BMC Endocr. Disord.
PD AUG 7
PY 2023
VL 23
IS 1
AR 165
DI 10.1186/s12902-023-01427-x
PG 9
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Endocrinology & Metabolism
GA O3CF1
UT WOS:001042623600001
PM 37620904
OA Green Published, gold
DA 2024-02-19
ER

PT J
AU McCormick, KG
   Scorletti, E
   Bhatia, L
   Calder, PC
   Griffin, MJ
   Clough, GF
   Byrne, CD
AF McCormick, Keith G.
   Scorletti, Eleonora
   Bhatia, Lokpal
   Calder, Philip C.
   Griffin, Michael J.
   Clough, Geraldine F.
   Byrne, Christopher D.
TI Impact of high dose <i>n</i>-3 polyunsaturated fatty acid treatment on
   measures of microvascular function and vibration perception in
   non-alcoholic fatty liver disease: results from the randomised WELCOME
   trial
SO DIABETOLOGIA
LA English
DT Article
DE n-3 Fatty acid; Insulin resistance; Microcirculation; Non-alcoholic
   fatty liver disease; Omacor/Lovaza; Sensory nerves; Type 2 diabetes;
   Vibration perception threshold
ID DIABETIC PERIPHERAL NEUROPATHY; IMPAIRED GLUCOSE-TOLERANCE; INTIMA-MEDIA
   THICKNESS; INSULIN-RESISTANCE; CARDIOVASCULAR RISK; ENDOTHELIAL
   DYSFUNCTION; VIBROTACTILE THRESHOLDS; EICOSAPENTAENOIC ACID;
   DOCOSAHEXAENOIC ACID; FIBER NEUROPATHY
AB Aims/hypothesis The effect of n-3 fatty acid treatment on vibration perception thresholds (VPTs) and cutaneous microvascular reactivity is not known. We tested whether: (1) a 1518 month treatment with high dose (4 g/day) docosahexaenoic (DHA) plus eicosapentaenoic (EPA) acid improved VPT and microvascular reactivity in patients with non-alcoholic fatty liver disease; and (2) there are associations between VPT, microvascular reactivity and metabolic variables.
   Methods In the completed single centre, randomised, parallel group, placebo controlled Wessex Evaluation of fatty Liver and Cardiovascular markers in non-alcoholic fatty liver disease with OMacor thErapy (WELCOME) trial, we tested the effect of DHA+EPA on VPT at 125 Hz (big toe) and the cutaneous hyperaemic response (forearm) to arterial occlusion (ratio of maximum to resting blood flux [MF/RF]). Allocation and dispensing was carried out by an independent research pharmacist; all participants and research team members were blinded to group assignment.
   Results In all, 51 and 49 patients were randomised to placebo and DHA+ EPA, respectively (mean age 51.4 years). Of these, 32 had type 2 diabetes. Forty-six (placebo) and 47 (DHA+ EPA) patients completed the study; there were no important adverse (or unexpected) effects or side effects. In multivariable-adjusted regression models (intention-to-treat analyses), DHA+ EPA treatment was associated with an increase in VPT (beta coefficient 1.49 [95% CI 0.04, 2.94], p=0.04). For VPT, the adjusted mean differences (95% CIs) in the placebo and DHA+ EPA treatment groups were -0.725 (-1.71, 0.25) and 0.767 (-0.21, 1.75) m/s(2), respectively. With DHA+ EPA treatment, there was no change in MF/RF (beta coefficient 0.07 [95% CI -0.56, 0.70], p=0.84), the adjusted mean differences (95% CIs) in the placebo and DHA+ EPA treatment groups were -0.549 (-1.03, -0.07) and -0.295 (-0.77, 0.18) respectively. VPT was independently associated with age (beta coefficient 0.019 [95% CI 0.010, 0.029], p<0.0001) and MF/RF (beta coefficient -0.074 [95% CI -0.132, -0.016], p=0.013), but not with diabetes (p=0.38).
   Conclusions/interpretation High dose n-3 fatty acid treatment did not improve measures of microvascular function or vibration perception. Ageing and microvascular reactivity are associated with a measure of peripheral nerve function.
C1 [McCormick, Keith G.; Scorletti, Eleonora; Bhatia, Lokpal; Calder, Philip C.; Clough, Geraldine F.; Byrne, Christopher D.] Southampton Univ Hosp, Fac Med, Human Dev & Hlth Acad Unit, Southampton SO16 6YD, Hants, England.
   [McCormick, Keith G.; Scorletti, Eleonora; Bhatia, Lokpal; Calder, Philip C.; Byrne, Christopher D.] Univ Southampton, Natl Inst Hlth Res, Southampton Biomed Res Ctr, Southampton, Hants, England.
   [McCormick, Keith G.; Scorletti, Eleonora; Bhatia, Lokpal; Calder, Philip C.; Byrne, Christopher D.] Univ Hosp Southampton NHS Fdn Trust, Southampton, Hants, England.
   [Griffin, Michael J.] Univ Southampton, Inst Sound & Vibrat Res, Southampton, Hants, England.
C3 University of Southampton; University of Southampton; University of
   Southampton; University Hospital Southampton NHS Foundation Trust;
   University of Southampton
RP Byrne, CD (corresponding author), Southampton Univ Hosp, Fac Med, Human Dev & Hlth Acad Unit, MP887,IDS Bldg,Tremona Rd, Southampton SO16 6YD, Hants, England.
EM cdtb@soton.ac.uk
RI Scorletti, Eleonora/GMX-0079-2022; Calder, Philip C/E-9739-2013
OI Calder, Philip C/0000-0002-6038-710X; Griffin,
   Michael/0000-0003-0743-9502; Scorletti, Eleonora/0000-0002-7547-146X;
   Byrne, Christopher D/0000-0001-6322-7753
FU National Institute for Health Research (NIHR) Southampton Biomedical
   Research Unit grant; Diabetes UK [BDA 09/0003937]; NIHR Southampton
   Biomedical Research Centre; National Institute for Health Research UK
FX The study was funded by the National Institute for Health Research UK
   and Diabetes UK.; Omacor and placebo were provided by Pronova Biopharma
   through Abbott Laboratories, Southampton, UK. This work was supported by
   a National Institute for Health Research (NIHR) Southampton Biomedical
   Research Unit grant and by a Diabetes UK allied health research training
   fellowship awarded to KGM (Diabetes UK. BDA 09/0003937). CDB, PCC and ES
   are supported in part by the NIHR Southampton Biomedical Research
   Centre.
CR Abbott CA, 2011, DIABETES CARE, V34, P2220, DOI 10.2337/dc11-1108
   Angulo P, 2007, HEPATOLOGY, V45, P846, DOI 10.1002/hep.21496
   Bhatia LS, 2012, EUR HEART J, V33, P1190, DOI 10.1093/eurheartj/ehr453
   Byrne CD, 2010, PROSTAG LEUKOTR ESS, V82, P265, DOI 10.1016/j.plefa.2010.02.012
   Callaghan BC, 2012, LANCET NEUROL, V11, P521, DOI 10.1016/S1474-4422(12)70065-0
   CELERMAJER DS, 1994, J AM COLL CARDIOL, V24, P471, DOI 10.1016/0735-1097(94)90305-0
   Clough GF, 2011, MICROCIRCULATION, V18, P74, DOI 10.1111/j.1549-8719.2010.00070.x
   Clough GF, 2009, DIABETES, V58, P1185, DOI 10.2337/db08-1688
   Corretti MC, 2002, J AM COLL CARDIOL, V39, P257, DOI 10.1016/S0735-1097(01)01746-6
   Coste TC, 2003, DIABETES, V52, P2578, DOI 10.2337/diabetes.52.10.2578
   Crawford F, 2007, QJM-INT J MED, V100, P65
   De Boer MP, 2012, MICROCIRCULATION, V19, P5, DOI 10.1111/j.1549-8719.2011.00130.x
   de Jongh RT, 2008, MICROVASC RES, V75, P256, DOI 10.1016/j.mvr.2007.08.001
   de Jongh RT, 2004, CIRCULATION, V109, P2529, DOI 10.1161/01.CIR.0000129772.26647.6F
   Ghoreishi Z, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-355
   Gu C, 2013, MED ENG PHYS, V35, P1221, DOI 10.1016/j.medengphy.2012.12.011
   Gu C, 2011, SOMATOSENS MOT RES, V28, P86, DOI 10.3109/08990220.2011.622493
   Guha IN, 2008, HEPATOLOGY, V47, P455, DOI 10.1002/hep.21984
   Herman RM, 2007, INT J OBESITY, V31, P226, DOI 10.1038/sj.ijo.0803418
   Holowatz LA, 2008, J APPL PHYSIOL, V105, P370, DOI 10.1152/japplphysiol.00858.2007
   Im S, 2012, DIABETES CARE, V35, P834, DOI 10.2337/dc11-1001
   Karaca Ü, 2014, DIABETES RES CLIN PR, V103, P382, DOI 10.1016/j.diabres.2013.12.012
   Kärvestedt L, 2009, DIABETES CARE, V32, P317, DOI 10.2337/dc08-1250
   Levy BI, 2008, CIRCULATION, V118, P968, DOI 10.1161/CIRCULATIONAHA.107.763730
   Lv WS, 2013, WORLD J GASTROENTERO, V19, P3134, DOI 10.3748/wjg.v19.i20.3134
   MATTHEWS DR, 1985, DIABETOLOGIA, V28, P412, DOI 10.1007/BF00280883
   Mori TA, 2000, CIRCULATION, V102, P1264, DOI 10.1161/01.CIR.102.11.1264
   Okuda Y, 1996, J DIABETES COMPLICAT, V10, P280, DOI 10.1016/1056-8727(95)00081-X
   Oni ET, 2013, ATHEROSCLEROSIS, V230, P258, DOI 10.1016/j.atherosclerosis.2013.07.052
   Pinarbasi B, 2012, TURK J GASTROENTEROL, V23, P720, DOI 10.4318/tjg.2012.0489
   Polak JF, 2011, STROKE, V42, P3017, DOI 10.1161/STROKEAHA.111.625186
   Richard JL, 2014, INT WOUND J, V11, P147, DOI 10.1111/j.1742-481X.2012.01051.x
   Roustit M, 2013, TRENDS PHARMACOL SCI, V34, P373, DOI 10.1016/j.tips.2013.05.007
   Scorletti E, 2014, CONTEMP CLIN TRIALS, V37, P301, DOI 10.1016/j.cct.2014.02.002
   Seah SA, 2008, INT ARCH OCC ENV HEA, V81, P535, DOI 10.1007/s00420-007-0252-6
   Shun CT, 2004, BRAIN, V127, P1593, DOI 10.1093/brain/awh180
   Simon A, 2010, ARTERIOSCL THROM VAS, V30, P182, DOI 10.1161/ATVBAHA.109.196980
   Spruce MC, 2012, INT J LOW EXTR WOUND, V11, P43, DOI 10.1177/1534734612438055
   Sumner CJ, 2003, NEUROLOGY, V60, P108, DOI 10.1212/WNL.60.1.108
   Sveen KA, 2013, DIABETES CARE, V36, P3712, DOI 10.2337/dc13-0788
   Tan LS, 2010, DIABETES RES CLIN PR, V90, P1, DOI 10.1016/j.diabres.2010.06.021
   Targher G, 2013, J CLIN ENDOCR METAB, V98, P483, DOI 10.1210/jc.2012-3093
   Tesfaye S, 2012, DIABETES-METAB RES, V28, P8, DOI 10.1002/dmrr.2239
   Tesfaye S, 2010, DIABETES CARE, V33, P2285, DOI 10.2337/dc10-1303
   Turzyniecka M, 2009, DIABETIC MED, V26, P1112, DOI 10.1111/j.1464-5491.2009.02822.x
   Villanova N, 2005, HEPATOLOGY, V42, P473, DOI 10.1002/hep.20781
   Yokoyama H, 2007, DIABETIC MED, V24, P1329, DOI 10.1111/j.1464-5491.2007.02278.x
   Young LH, 2009, JAMA-J AM MED ASSOC, V301, P1547, DOI 10.1001/jama.2009.476
   YOUNG MJ, 1994, DIABETES CARE, V17, P557, DOI 10.2337/diacare.17.6.557
NR 49
TC 18
Z9 18
U1 0
U2 14
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0012-186X
EI 1432-0428
J9 DIABETOLOGIA
JI Diabetologia
PD AUG
PY 2015
VL 58
IS 8
BP 1916
EP 1925
DI 10.1007/s00125-015-3628-2
PG 10
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Endocrinology & Metabolism
GA CO0XN
UT WOS:000358877300031
PM 26021488
OA Green Accepted, Bronze
DA 2024-02-19
ER

PT J
AU Le, F
   Wang, LY
   Wang, N
   Li, L
   Li, LJ
   Zheng, YM
   Lou, HY
   Liu, XZ
   Xu, XR
   Sheng, JZ
   Huang, HF
   Jin, F
AF Le, Fang
   Wang, Li Ya
   Wang, Ning
   Li, Lei
   Li, Le Jun
   Zheng, Ying Ming
   Lou, Hang Ying
   Liu, Xiao Zhen
   Xu, Xiang Rong
   Sheng, Jian Zhong
   Huang, He Feng
   Jin, Fan
TI In Vitro Fertilization Alters Growth and Expression of
   <i>Igf2</i>/<i>H19</i> and Their Epigenetic Mechanisms in the Liver and
   Skeletal Muscle of Newborn and Elder Mice
SO BIOLOGY OF REPRODUCTION
LA English
DT Article
DE aging; DNA methylation; elder; epigenetics; epigenetic mechanisms;
   growth; H19; Igf2; insulin-like growth factor (IGF/IGF receptors); in
   vitro fertilization; mice; newborn
ID ASSISTED REPRODUCTIVE TECHNOLOGY; BECKWITH-WIEDEMANN-SYNDROME;
   MESSENGER-RNA EXPRESSION; DNA METHYLATION; MOUSE EMBRYOS; PERINATAL
   OUTCOMES; CHILDHOOD GROWTH; IMPRINTED GENES; CHILDREN BORN; H19
AB Epidemiological studies have reported a higher incidence of growth disorders among newborns conceived by in vitro fertilization (IVF), suggesting that IVF may be disruptive to the process of embryonic and fetal growth. However, the long-term effects of IVF on the growth and molecular mechanisms remain unclear. Therefore, we evaluated the body weight of IVF mice from birth to the age of 1.5 yr. In addition, we analyzed gene expression of insulin-like growth factor 2 (Igf2), H19, Igf2 receptor (Igf2r), and miR-483 and their DNA methylation status using real-time quantitative PCR, Western blot, and pyrosequencing. The results showed that when compared with the in vivo group, the body weight of IVF mice was significantly higher at birth, but lower at 3 wk; in addition, gene expression of Igf2 was significantly up-regulated, with down-regulated expression of H19 and miR-483 in both liver and skeletal muscle. At the same time, there were significant differences in the DNA methylation rates of Igf2/H19 differentially methylated regions (DMRs) and the IGF2 protein expression between the two groups. In the IVF treatment group, the differences in growth and expression disappeared at 10 wk. However, at 1.5 yr of age, aberrant expressions of Igf2/H19, Igf2r, and miR-483 and changes in DNA methylation rates in the liver or skeletal muscle were again observed in IVF mice. Our results indicate that IVF causes alterations in mouse growth during the postnatal periods that may be associated with alterations in Igf2/H19 expression and likely involve the regulation of miR-483 and the methylation status of Igf2/H19 DMRs.
C1 [Le, Fang; Wang, Li Ya; Wang, Ning; Li, Lei; Li, Le Jun; Zheng, Ying Ming; Lou, Hang Ying; Liu, Xiao Zhen; Xu, Xiang Rong; Huang, He Feng; Jin, Fan] Zhejiang Univ, Sch Med, Womens Hosp, Ctr Reprod Med, Hangzhou 310006, Zhejiang, Peoples R China.
   [Huang, He Feng; Jin, Fan] Zhejiang Univ, Minist Educ, Womens Reprod Hlth Lab Zhejiang, Key Lab Reprod Genet, Hangzhou 310006, Zhejiang, Peoples R China.
   [Sheng, Jian Zhong] Zhejiang Univ, Sch Med, Dept Pathophysiol, Hangzhou 310006, Zhejiang, Peoples R China.
   [Li, Lei] Henan Canc Hosp, Dept Gynecol Oncol, Zhengzhou, Peoples R China.
C3 Zhejiang University; Zhejiang University; Zhejiang University; Zhengzhou
   University
RP Jin, F (corresponding author), Zhejiang Univ, Sch Med, Womens Hosp, Dept Reprod Endocrinol, 1 Xueshi Rd, Hangzhou 310006, Zhejiang, Peoples R China.
EM jinfan@zju.edu.cn
RI Huang, Hefeng/AAR-7184-2021; Wang, Tao/AAT-3028-2020; Huang,
   He-Feng/AAN-7985-2020; liu, xinyu/IWD-6630-2023; Huang,
   Hefeng/ABF-1117-2020; Xu, Xiangrong/B-7054-2011
OI Wang, Tao/0000-0003-1225-0173; Huang, He-Feng/0000-0003-4344-8019; 
FU National Basic Research Programs of China; National Natural Science
   Foundation of China; Natural Science Foundation Projects of Zhejiang
   [2012CB944901, 81070532, 81200475, Y2100397]
FX Supported by the National Basic Research Programs of China, the National
   Natural Science Foundation of China, and Natural Science Foundation
   Projects of Zhejiang (grant numbers 2012CB944901, 81070532, 81200475,
   and Y2100397). Presented in part at the 27th Annual Meeting of the
   European Society of Human Reproduction and Embryology, July 4, 2012,
   Stockholm, Sweden.
CR ALBERTSSONWIKLAND K, 1994, ACTA PAEDIATR, V83, P64, DOI 10.1111/j.1651-2227.1994.tb13292.x
   Arney KL, 2003, TRENDS GENET, V19, P17, DOI 10.1016/S0168-9525(02)00004-5
   Ay L, 2009, J CLIN ENDOCR METAB, V94, P2023, DOI 10.1210/jc.2008-2045
   Barton-Davis ER, 1998, P NATL ACAD SCI USA, V95, P15603, DOI 10.1073/pnas.95.26.15603
   Benchaib M, 2005, HUM REPROD, V20, P768, DOI 10.1093/humrep/deh684
   Boissonnas CC, 2010, EUR J HUM GENET, V18, P73, DOI 10.1038/ejhg.2009.117
   Bonduelle M, 2005, HUM REPROD, V20, P413, DOI 10.1093/humrep/deh592
   Borghol N, 2006, GENOMICS, V87, P417, DOI 10.1016/j.ygeno.2005.10.008
   BRANDEIS M, 1993, EMBO J, V12, P3669, DOI 10.1002/j.1460-2075.1993.tb06041.x
   Brandt I, 2005, J PEDIATR-US, V147, P662, DOI 10.1016/j.jpeds.2005.06.034
   Cai XZ, 2007, RNA, V13, P313, DOI 10.1261/rna.351707
   Calkins K, 2011, CURR PROB PEDIATR AD, V41, P158, DOI 10.1016/j.cppeds.2011.01.001
   CARONI P, 1994, J CELL BIOL, V125, P893, DOI 10.1083/jcb.125.4.893
   Ceelen M, 2008, FERTIL STERIL, V90, P1662, DOI 10.1016/j.fertnstert.2007.09.005
   Ceelen M, 2009, HUM REPROD, V24, P2788, DOI 10.1093/humrep/dep273
   Chang HJ, 2009, FERTIL STERIL, V91, P2381, DOI 10.1016/j.fertnstert.2008.03.066
   Chung K, 2006, FERTIL STERIL, V86, P1634, DOI 10.1016/j.fertnstert.2006.04.038
   COHICK WS, 1993, ANNU REV PHYSIOL, V55, P131, DOI 10.1146/annurev.ph.55.030193.001023
   DeBaun MR, 2003, AM J HUM GENET, V72, P156, DOI 10.1086/346031
   Eriksson JG, 2003, DIABETES CARE, V26, P3006, DOI 10.2337/diacare.26.11.3006
   Fauque P, 2007, BMC DEV BIOL, V7, DOI 10.1186/1471-213X-7-116
   FEIL R, 1994, DEVELOPMENT, V120, P2933
   Fernández-Gonzalez R, 2004, P NATL ACAD SCI USA, V101, P5880, DOI 10.1073/pnas.0308560101
   Fontanière S, 2006, ENDOCR-RELAT CANCER, V13, P1223, DOI 10.1677/erc.1.01294
   Geiman TM, 2010, MOL REPROD DEV, V77, P105, DOI 10.1002/mrd.21118
   Gray RH, 2000, AM J PUBLIC HEALTH, V90, P1452, DOI 10.2105/AJPH.90.9.1452
   Greenbaum D, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-117
   He RH, 2006, LIFE SCI, V79, P423, DOI 10.1016/j.lfs.2006.01.020
   Heijmans BT, 2008, P NATL ACAD SCI USA, V105, P17046, DOI 10.1073/pnas.0806560105
   Helmerhorst FM, 2004, BRIT MED J, V328, P261, DOI 10.1136/bmj.37957.560278.EE
   Jackson RA, 2004, OBSTET GYNECOL, V103, P551, DOI 10.1097/01.AOG.0000114989.84822.51
   Kai CM, 2006, J CLIN ENDOCR METAB, V91, P4352, DOI 10.1210/jc.2006-0701
   Khosla S, 2001, BIOL REPROD, V64, P918, DOI 10.1095/biolreprod64.3.918
   Kobayashi H, 2009, EUR J HUM GENET, V17, P1582, DOI 10.1038/ejhg.2009.68
   Lambert RD, 2003, HUM REPROD, V18, P1987, DOI 10.1093/humrep/deg361
   Le Roith Derek, 2003, Exp Diabesity Res, V4, P205, DOI 10.1155/EDR.2003.205
   Lee SH, 2010, INT J NURS STUD, V47, P1159, DOI 10.1016/j.ijnurstu.2010.02.006
   LEIGHTON PA, 1995, NATURE, V375, P34, DOI 10.1038/375034a0
   Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427
   Li L, 2011, REPROD TOXICOL, V32, P98, DOI 10.1016/j.reprotox.2011.05.016
   Li T, 2005, MOL HUM REPROD, V11, P631, DOI 10.1093/molehr/gah230
   Maher ER, 2003, J MED GENET, V40, P62, DOI 10.1136/jmg.40.1.62
   McDonald S, 2005, AM J OBSTET GYNECOL, V193, P141, DOI 10.1016/j.ajog.2004.11.064
   Miles HL, 2007, J CLIN ENDOCR METAB, V92, P3441, DOI 10.1210/jc.2006-2465
   Moore T, 1997, P NATL ACAD SCI USA, V94, P12509, DOI 10.1073/pnas.94.23.12509
   Murrell A, 2001, EMBO REP, V2, P1101, DOI 10.1093/embo-reports/kve248
   Ogawa H, 2003, REPRODUCTION, V126, P549, DOI 10.1530/rep.0.1260549
   Pauli SA, 2009, PEDIATR CLIN N AM, V56, P467, DOI 10.1016/j.pcl.2009.04.001
   Rivera RM, 2008, HUM MOL GENET, V17, P1, DOI 10.1093/hmg/ddm280
   Sato F, 2011, FEBS J, V278, P1598, DOI 10.1111/j.1742-4658.2011.08089.x
   Van Laere AS, 2003, NATURE, V425, P832, DOI 10.1038/nature02064
   Veronese A, 2010, CANCER RES, V70, P3140, DOI 10.1158/0008-5472.CAN-09-4456
   Wienholds E, 2005, FEBS LETT, V579, P5911, DOI 10.1016/j.febslet.2005.07.070
   Wutz A, 2001, DEVELOPMENT, V128, P1881
   Wylie AA, 2003, AM J PATHOL, V162, P321, DOI 10.1016/S0002-9440(10)63823-0
   Young LE, 2001, NAT GENET, V27, P153, DOI 10.1038/84769
   Zhang JL, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-478
NR 57
TC 37
Z9 40
U1 0
U2 25
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0006-3363
EI 1529-7268
J9 BIOL REPROD
JI Biol. Reprod.
PD MAR
PY 2013
VL 88
IS 3
AR 75
DI 10.1095/biolreprod.112.106070
PG 10
WC Reproductive Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Reproductive Biology
GA 124NJ
UT WOS:000317471100016
PM 23390160
OA Bronze
DA 2024-02-19
ER

PT J
AU Tan, WS
   Low, WY
   Ng, CJ
   Tan, WK
   Tong, SF
   Ho, C
   Khoo, EM
   Lee, G
   Lee, BC
   Lee, V
   Tan, HM
AF Tan, Wei Shen
   Low, Wah Yun
   Ng, Chirk Jenn
   Tan, Wei Keith
   Tong, Seng Fah
   Ho, Christopher
   Khoo, Ee Ming
   Lee, George
   Lee, Boon Cheok
   Lee, Verna
   Tan, Hui Meng
TI Efficacy and safety of long-acting intramuscular testosterone
   undecanoate in aging men: a randomised controlled study
SO BJU INTERNATIONAL
LA English
DT Article
DE testosterone deficiency; hypogonadism; testosterone undecanoate;
   efficacy; safety
ID LATE-ONSET HYPOGONADISM; MIDDLE-AGED MEN; QUALITY-OF-LIFE; REPLACEMENT
   THERAPY; DOUBLE-BLIND; DEFICIENCY SYNDROME; METABOLIC SYNDROME;
   BODY-COMPOSITION; OLDER MEN; ERECTILE DYSFUNCTION
AB Objective
   To evaluate the efficacy and safety of long-acting i.m. testosterone undecanoate (TU) in Malaysian men with testosterone deficiency (TD).
   Patients and Methods
   A total of 120 men, aged 40-70 years, with TD (serum total testosterone [ TT] <= 12 nmol/L) were randomised to receive either i.m. TU (1000 mg) or placebo.
   In all, 58 and 56 men in the placebo and treatment arm, respectively, completed the study.
   Participants were seen six times in the 48-week period and the following data were collected: physical examination results, haemoglobin, haematocrit, TT, lipid profile, fasting blood glucose, sex hormone-binding globulin, liver function test, prostate-specific antigen (PSA) and adverse events.
   Results
   The mean (SD) age of the participants was 53.4 (7.6) years.
   A significant increase in serum TT (P < 0.001), PSA (P = 0.010), haematocrit (P < 0.001), haemoglobin (P < 0.001) and total bilirubin (P = 0.001) were seen in the treatment arm over the 48-week period.
   Two men in the placebo arm and one man in the treatment arm developed myocardial infarction.
   Common adverse events observed in the treatment arm included itching/swelling/pain at the site of injection, flushing and acne.
   Overall, TU injections were well tolerated.
   Conclusions TU significantly increases serum testosterone in men with TD.
   PSA, haemoglobin and haematocrit were significantly elevated but were within clinically safe limits.
   There was no significant adverse reaction that led to the cessation of treatment.
C1 [Tan, Wei Shen] UCL, Div Surg & Intervent Sci, London WC1E 6AU, England.
   [Tan, Wei Shen] Whittington Hosp, Dept Urol, London N19 5NF, England.
   [Tan, Wei Keith] Univ Bristol, Sch Med, Bristol, Avon, England.
   [Low, Wah Yun; Tan, Hui Meng] Univ Malaya, Med Res Dev Unit, Kuala Lumpur, Malaysia.
   [Ng, Chirk Jenn; Khoo, Ee Ming] Univ Malaya, Dept Primary Care Med, Kuala Lumpur, Malaysia.
   [Tong, Seng Fah] Univ Kebangsaan Malaysia, Dept Family Med, Kuala Lumpur, Malaysia.
   [Ho, Christopher] Univ Kebangsaan Malaysia, Dept Surg, Kuala Lumpur, Malaysia.
   [Lee, George] Int Med Univ, Gleaneagles Intan Med Ctr, Dept Urol, Kuala Lumpur 57000, Malaysia.
   [Lee, Boon Cheok; Tan, Hui Meng] Int Med Univ, Sime Darby Med Ctr, Dept Urol, Kuala Lumpur 57000, Malaysia.
   [Lee, Verna] Int Med Univ, Dept Family Med, Kuala Lumpur 57000, Malaysia.
C3 University of London; University College London; University of London;
   University College London; University of Bristol; Universiti Malaya;
   Universiti Malaya; Universiti Kebangsaan Malaysia; Universiti Kebangsaan
   Malaysia; International Medical University Malaysia; International
   Medical University Malaysia; International Medical University Malaysia
RP Tan, WS (corresponding author), UCL, Div Surg & Intervent Sci, Med Sch Bldg,4th Floor,74 Huntley St, London WC1E 6AU, England.
EM tanweishen@hotmail.com
RI Tong, Seng Fah/D-4283-2013; NG, CHIRK JENN/C-1344-2010; KHOO, EE
   MING/B-8785-2010; Ho, Christopher/C-1421-2011; Low, Wah-Yun/B-1775-2009;
   Tan, Wei Shen/H-8835-2019
OI Tong, Seng Fah/0000-0002-8725-1536; KHOO, EE MING/0000-0003-3191-1264;
   Ho, Christopher/0000-0002-8757-6867; Low, Wah-Yun/0000-0003-4409-1509;
   Tan, Wei Shen/0000-0002-6119-4043; Ng, Chirk Jenn/0000-0002-8320-1603
CR Aversa A, 2010, J SEX MED, V7, P3495, DOI 10.1111/j.1743-6109.2010.01931.x
   Basaria S, 2010, NEW ENGL J MED, V363, P109, DOI 10.1056/NEJMoa1000485
   Behre HM, 1997, J CLIN ENDOCR METAB, V82, P2386, DOI 10.1210/jc.82.8.2386
   BEHRE HM, 1994, CLIN ENDOCRINOL, V40, P341
   Bhasin S, 2005, J CLIN ENDOCR METAB, V90, P678, DOI 10.1210/jc.2004-1184
   Bhasin S, 2003, J ANDROL, V24, P299
   Bhasin S, 2010, J CLIN ENDOCR METAB, V95, P2536, DOI 10.1210/jc.2009-2354
   Bhasin S, 2008, STEROIDS, V73, P1311, DOI 10.1016/j.steroids.2008.07.003
   Boloña ER, 2007, MAYO CLIN PROC, V82, P20, DOI 10.4065/82.1.20
   Cunningham GR, 2011, J CLIN ENDOCR METAB, V96, P38, DOI 10.1210/jc.2010-0266
   de Ronde W, 2009, HUM REPROD, V24, P425, DOI 10.1093/humrep/den372
   ERIKSSEN G, 1993, J INTERN MED, V234, P493, DOI 10.1111/j.1365-2796.1993.tb00783.x
   Feldman HA, 2002, J CLIN ENDOCR METAB, V87, P589, DOI 10.1210/jc.87.2.589
   Haddad RM, 2007, MAYO CLIN PROC, V82, P29
   HANDELSMAN DJ, 1985, ENDOCR REV, V6, P151, DOI 10.1210/edrv-6-2-151
   Ho CCK, 2012, BJU INT, V110, P260, DOI 10.1111/j.1464-410X.2011.10755.x
   Isidori AM, 2005, CLIN ENDOCRINOL, V63, P280, DOI 10.1111/j.1365-2265.2005.02339.x
   Jones TH, 2011, DIABETES CARE, V34, P828, DOI 10.2337/dc10-1233
   Kalinchenko S Y, 2003, Aging Male, V6, P94, DOI 10.1080/713604767
   Kalinchenko SY, 2010, CLIN ENDOCRINOL, V73, P602, DOI 10.1111/j.1365-2265.2010.03845.x
   Kapoor D, 2006, EUR J ENDOCRINOL, V154, P899, DOI 10.1530/eje.1.02166
   Kaufman JM, 2011, J SEX MED, V8, P2079, DOI 10.1111/j.1743-6109.2011.02265.x
   Kelleher S, 1999, CLIN ENDOCRINOL, V51, P469
   Lowe GDO, 1997, BRIT J HAEMATOL, V96, P168, DOI 10.1046/j.1365-2141.1997.8532481.x
   Marks LS, 2006, JAMA-J AM MED ASSOC, V296, P2351, DOI 10.1001/jama.296.19.2351
   Fernández-Balsells MM, 2010, J CLIN ENDOCR METAB, V95, P2560, DOI 10.1210/jc.2009-2575
   Minnemann T, 2008, J ENDOCRINOL INVEST, V31, P718, DOI 10.1007/BF03346421
   Minnemann T, 2007, AGING MALE, V10, P155, DOI 10.1080/13685530701437510
   Moon DG, 2010, J SEX MED, V7, P2253, DOI 10.1111/j.1743-6109.2010.01765.x
   Morgentaler A, 2011, EUR UROL, V59, P465, DOI 10.1016/j.eururo.2010.12.027
   Mulligan T, 2006, INT J CLIN PRACT, V60, P762, DOI 10.1111/j.1742-1241.2006.00992.x
   Murphy M, 2000, Am J Clin Dermatol, V1, P361, DOI 10.2165/00128071-200001060-00004
   Navarro JF, 2003, NEPHROL DIAL TRANSPL, V18, P2222, DOI 10.1093/ndt/gfg370
   Pasquali R, 1997, METABOLISM, V46, P526, DOI 10.1016/S0026-0495(97)90189-X
   Permpongkosol S, 2010, J SEX MED, V7, P3765, DOI 10.1111/j.1743-6109.2010.01994.x
   Rhoden EL, 2004, NEW ENGL J MED, V350, P482, DOI 10.1056/NEJMra022251
   Roddam AW, 2008, J NATL CANCER I, V100, P170, DOI 10.1093/jnci/djm323
   SEE KL, 1992, LIVER, V12, P73
   Selvin E, 2007, DIABETES CARE, V30, P234, DOI 10.2337/dc06-1579
   Shabsigh R, 2005, J SEX MED, V2, P785, DOI 10.1111/j.1743-6109.2005.00139.x
   Shigehara K, 2011, AGING MALE, V14, P53, DOI 10.3109/13685538.2010.518178
   Sih R, 1997, J CLIN ENDOCR METAB, V82, P1661, DOI 10.1210/jc.82.6.1661
   Simon D, 2001, DIABETES CARE, V24, P2149, DOI 10.2337/diacare.24.12.2149
   Srinivas-Shankar U, 2010, J CLIN ENDOCR METAB, V95, P639, DOI 10.1210/jc.2009-1251
   Svartberg J, 2004, EUR J EPIDEMIOL, V19, P657, DOI 10.1023/B:EJEP.0000036809.30558.8f
   Tan WS, 2011, AGING MALE, V14, P231, DOI 10.3109/13685538.2011.597463
   Tong SF, 2012, ASIAN J ANDROL, V14, P604, DOI 10.1038/aja.2011.178
   Van Vliet M, 2005, AM J RESP CRIT CARE, V172, P1105, DOI 10.1164/rccm.200501-114OC
   Wang C, 2008, EUR J ENDOCRINOL, V159, P507, DOI 10.1530/EJE-08-0601
   Wang C, 1996, J CLIN ENDOCR METAB, V81, P3578, DOI 10.1210/jc.81.10.3578
   Yeap BB, 2009, EUR J ENDOCRINOL, V161, P591, DOI 10.1530/EJE-09-0348
   Zitzmann M, 2013, J SEX MED, V10, P579, DOI 10.1111/j.1743-6109.2012.02853.x
NR 52
TC 38
Z9 41
U1 0
U2 18
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1464-4096
EI 1464-410X
J9 BJU INT
JI BJU Int.
PD JUN
PY 2013
VL 111
IS 7
BP 1130
EP 1140
DI 10.1111/bju.12037
PG 11
WC Urology & Nephrology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Urology & Nephrology
GA 142PQ
UT WOS:000318809900024
PM 23651425
DA 2024-02-19
ER

PT J
AU Oriaku, ET
   Chen, FX
   Desai, VG
   Pipkin, JL
   Shaddock, JG
   Weindruch, R
   Hart, RW
   Feuers, RJ
AF Oriaku, ET
   Chen, FX
   Desai, VG
   Pipkin, JL
   Shaddock, JG
   Weindruch, R
   Hart, RW
   Feuers, RJ
TI A circadian study of liver antioxidant enzyme systems of female
   Fischer-344 rats subjected to dietary restriction for six weeks.
SO AGE
LA English
DT Article
ID CHRONIC CALORIC RESTRICTION; AGING PROCESS; FREE-RADICALS; METABOLISM;
   AGE; GLUTATHIONE; CATALASE; DISEASE
AB We examined the influences of dietary restriction (DR) on the circadian profile of liver catalase (CAT), glutathione peroxidase (GPx), and interacting systems required for removal of H2O2 (support systems), in 18-week old female Fischer 344 rats fed 60% of their ad libitum (AL) diet for six weeks. Food was presented to the DR animals during the early light-span. Regardless of diet, enzyme levels were generally consistent with circadian patterns. In CR animals, maximum activities often occurred at the time of food presentation. CAT and GPx activities generally were significantly higher in DR animals than in AL animals at the time of feeding. When assessing glucose-6-phosphate dehydrogenase (G6PDH) activity using saturating substrate (NADP(+)) concentrations, higher activities were seen at all times of day in the AL animals; however, when activity was measured in the presence of lower (i.e., physiologic) NADP(+) concentrations, the reverse was true. In contrast, glutathione reductase (GR) activity was not influenced by DR.
   Cytosolic levels of NADPH peaked and were higher in DR than in AL rodents prior to feeding. NADH levels were not influenced by diet, but did manifest a significant circadian pattern with a maximum occurring toward the middle of the dark span. These data suggest that even at a young age and following only a relatively brief duration of DR, there exists an enhanced enzymatic capability in rats subjected to DR to remove free radicals generated as a consequence of normal oxidative metabolism Further, these data support emerging trends suggesting metabolic regulation of antioxidant defense systems in response to free radical generation.
C1 US FDA, Dept Hlth & Human Serv, Natl Ctr Toxicol Res, Jefferson, AR 72079 USA.
   Univ Wisconsin, Dept Med, Madison, WI 53706 USA.
   Univ Wisconsin, VA GRECC, Madison, WI 53706 USA.
   Florida A&M Univ, Coll Pharm & Pharmaceut Sci, Tallahassee, FL 32307 USA.
C3 US Food & Drug Administration (FDA); University of Wisconsin System;
   University of Wisconsin Madison; Geriatric Research Education & Clinical
   Center; University of Wisconsin System; University of Wisconsin Madison;
   State University System of Florida; Florida A&M University
RP Oriaku, ET (corresponding author), US FDA, Dept Hlth & Human Serv, Natl Ctr Toxicol Res, Jefferson, AR 72079 USA.
CR AEBI H, 1984, METHOD ENZYMOL, V105, P121
   Bergmeyer HU, 1974, METHOD ENZYMAT AN, P458
   CARNEY JM, 1994, LIFE SCI, V55, P2097, DOI 10.1016/0024-3205(94)00390-4
   CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527
   Davies KJA, 1995, BIOCHEM SOC SYMP, P1, DOI 10.1042/bss0610001
   DUFFY PH, 1989, MECH AGEING DEV, V48, P117, DOI 10.1016/0047-6374(89)90044-4
   EATON JW, 1991, J LAB CLIN MED, V118, P3
   FEUERS RJ, 1993, MUTAT RES, V295, P191, DOI 10.1016/0921-8734(93)90020-4
   FEUERS RJ, 1989, MECH AGEING DEV, V48, P179, DOI 10.1016/0047-6374(89)90049-3
   Feuers RJ, 1997, AGE, V20, P215, DOI 10.1007/s11357-997-0021-1
   FEUERS RJ, 1980, ANAL BIOCHEM, V101, P123, DOI 10.1016/0003-2697(80)90050-0
   Feuers RJ, 1995, DIETARY RESTRICTION, P181
   FLORA AD, 1974, BIOCHEM BIOPH RES CO, V59, P406
   FLORENCE TM, 1995, AUST NZ J OPHTHALMOL, V23, P3, DOI 10.1111/j.1442-9071.1995.tb01638.x
   GUTTERIDGE JMC, 1992, MED LAB SCI, V49, P313
   Halberg F., 1972, PHYSIOL TEACH, V1, P1
   HARMAN D, 1981, P NATL ACAD SCI-BIOL, V78, P7124, DOI 10.1073/pnas.78.11.7124
   HARMAN D, 1992, MUTAT RES, V275, P257, DOI 10.1016/0921-8734(92)90030-S
   Harman D., 1986, FREE RADICALS AGING, P3
   HOLLAN S, 1995, HAEMATOLOGIA, V26, P177
   Klingenberg M, 1974, METHOD ENZYMAT AN, P2045, DOI [DOI 10.1016/B978-0-12-091304-6.50060-4, 10.1016/B978-0-12-091304-6.50060-4]
   KOIZUMI A, 1987, J NUTR, V117, P361, DOI 10.1093/jn/117.2.361
   Kowald A, 1996, MUTAT RES-DNAGING G, V316, P209, DOI 10.1016/S0921-8734(96)90005-3
   Laval J, 1996, PATHOL BIOL, V44, P14
   LOWRY OH, 1951, J BIOL CHEM, V193, P265
   MANOS P, 1991, BIOCHEM J, V276, P245, DOI 10.1042/bj2760245
   MASORO EJ, 1984, J AM GERIATR SOC, V32, P296, DOI 10.1111/j.1532-5415.1984.tb02025.x
   MCCARTER RJM, 1995, CLIN GERIATR MED, V11, P553, DOI 10.1016/S0749-0690(18)30256-8
   McCay CM, 1935, J NUTR, V10, P63, DOI 10.1093/jn/10.1.63
   RAO G, 1990, J NUTR, V120, P602, DOI 10.1093/jn/120.6.602
   RIKANS LE, 1991, BIOCHIM BIOPHYS ACTA, V1074, P195, DOI 10.1016/0304-4165(91)90061-K
   ROSS MH, 1961, J NUTR, V75, P197, DOI 10.1093/jn/75.2.197
   SOHAL RS, 1992, ANN NY ACAD SCI, V663, P74, DOI 10.1111/j.1749-6632.1992.tb38651.x
   TANNENBAUM ALBERT, 1942, CANCER RES, V2, P460
   Weindruch R, 1996, SCI AM, V274, P46, DOI 10.1038/scientificamerican0196-46
   Weindruch R., 1988, RETARDATION AGING DI
   WHEELER CR, 1990, ANAL BIOCHEM, V184, P193, DOI 10.1016/0003-2697(90)90668-Y
NR 37
TC 3
Z9 3
U1 0
U2 1
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0161-9152
EI 1574-4647
J9 AGE
JI Age
PD OCT
PY 1997
VL 20
IS 4
BP 221
EP 228
DI 10.1007/s11357-997-0022-0
PG 8
WC Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Geriatrics & Gerontology
GA ZW198
UT WOS:000074385500003
PM 23604324
OA Green Published
DA 2024-02-19
ER

PT J
AU Dai, BL
   Lei, CY
   Lin, R
   Tao, LF
   Bin, Y
   Peng, H
   Lei, B
AF Dai, Bingling
   Lei, Chunyan
   Lin, Ru
   Tao, Lifei
   Bin, Yue
   Peng, Hui
   Lei, Bo
TI Activation of liver X receptor α protects amyloid β<sub>1-40</sub>
   induced inflammatory and senescent responses in human retinal pigment
   epithelial cells
SO INFLAMMATION RESEARCH
LA English
DT Article
DE Retinal pigment epithelium; P16INK4a; Liver X receptor; ATP-binding
   cassette transporter A1; Amyloida; Age-related macular degeneration
ID NF-KAPPA-B; COMPLEMENT ACTIVATION; MACULAR DEGENERATION; BETA;
   EXPRESSION; MECHANISM; OLIGOMERS; IDENTIFICATION; HOMEOSTASIS;
   INTEGRATORS
AB To investigate whether activation of the liver X receptors (LXRs) inhibits amyloid beta(1-40) (A beta(1-40)) induced inflammatory and senescent responses in human retinal pigment epithelial (RPE) cells.
   Confluent cultures of human primary RPE and ARPE-19 cells pretreated with 5 mu Ie of TO901317 (TO90), a synthetic agonist of LXR, or vehicle were incubated with 1 mu Ie of A beta(1-40) or A beta(40-1). The optimum concentrations of A beta(1-40) and TO90 were determined by cell viability assay. Pro-inflammatory cytokines IL-6, IL-8, MCP-1 were detected by real-time polymerase chain reaction (PCR) and enzyme-linked immunosorbent assay (ELISA). Expression and localization of an aging protein p16INK4a (p16) were analyzed by western blotting and immunofluorescence. Expressions of LXRs and one of their target genes ATP-binding cassette transporter A1 (ABCA1) were examined by real-time PCR and western blotting. Phosphorylated transcription inhibition factor-kappa B-alpha (p-I kappa B-alpha) was assessed by western blotting.
   A negative linear relationship between the A beta(1-40) concentration and the cell viability was evident, indicating A beta(1-40) decreased ARPE-19 cell viability in a dose-dependent manner. A beta(1-40) enhanced the expression of IL-6, IL-8, MCP-1 as well as p16 in both RPE cell lines at both mRNA and protein levels, whereas TO90 counteracted the detrimental effects. TO90 upregulated the expression of LXR alpha and its target gene ABCA1, but it did not affect the expression of LXR beta. Meanwhile, TO90 inhibited the phosphorylation of I kappa B-alpha mediated by A beta(1-40) stimulation.
   Activation of the LXR alpha-ABCA1 axis may alleviate A beta(1-40) induced inflammatory and senescent responses in RPE cells. The beneficial effect appears associated with the inhibition of the NF-kappa B signaling pathway.
C1 [Dai, Bingling; Lei, Chunyan; Lin, Ru; Tao, Lifei; Bin, Yue; Peng, Hui; Lei, Bo] Chongqing Med Univ, Affiliated Hosp 1, Chongqing Eye Inst, Chongqing Key Lab Ophthalmol, 1 Youyi Rd, Chongqing 400016, Peoples R China.
   [Lei, Bo] Zhengzhou Univ, Henan Prov Peoples Hosp, Henan Eye Inst, Henan Eye Hosp,Peoples Hosp, 7 Weiwu Rd, Zhengzhou 450003, Peoples R China.
C3 Chongqing Medical University; Zhengzhou University
RP Peng, H; Lei, B (corresponding author), Chongqing Med Univ, Affiliated Hosp 1, Chongqing Eye Inst, Chongqing Key Lab Ophthalmol, 1 Youyi Rd, Chongqing 400016, Peoples R China.; Lei, B (corresponding author), Zhengzhou Univ, Henan Prov Peoples Hosp, Henan Eye Inst, Henan Eye Hosp,Peoples Hosp, 7 Weiwu Rd, Zhengzhou 450003, Peoples R China.
EM pengh9@sina.com; bolei99@126.com
RI LEI, BO/AAJ-3686-2020
OI LEI, BO/0000-0002-5497-0905; Chunyan, Lei/0000-0003-4640-4601
FU National Natural Science Foundation of China [81271033, 81470621];
   Chongqing Science and Technology Commission [2014pt-sy10002]; National
   Key Clinical Specialties Construction Program of China; Chongqing Health
   Bureau [2012-1-026]
FX This study was supported by the National Natural Science Foundation of
   China Grants (81271033, 81470621), Chongqing Science and Technology
   Commission (2014pt-sy10002), National Key Clinical Specialties
   Construction Program of China and a key project of Chongqing Health
   Bureau (2012-1-026).
CR BEHL C, 1994, CELL, V77, P817, DOI 10.1016/0092-8674(94)90131-7
   Boquoi A, 2015, AGING CELL, V14, P139, DOI 10.1111/acel.12279
   Bruban J, 2011, NEUROBIOL DIS, V42, P55, DOI 10.1016/j.nbd.2011.01.004
   Bruban J, 2009, AGING CELL, V8, P162, DOI 10.1111/j.1474-9726.2009.00456.x
   Cao LN, 2013, INVEST OPHTH VIS SCI, V54, P3738, DOI 10.1167/iovs.13-11612
   Carrero I, 2012, EXP NEUROL, V236, P215, DOI 10.1016/j.expneurol.2012.05.004
   Chen Y, 2014, INVEST OPHTH VIS SCI, V55, DOI 10.1167/iovs.14-15029
   Cherry JD, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0411-8
   Collins JL, 2002, J MED CHEM, V45, P1963, DOI 10.1021/jm0255116
   Cui W, 2012, NEUROSCIENCE, V210, P200, DOI 10.1016/j.neuroscience.2012.02.047
   Demuro A, 2005, J BIOL CHEM, V280, P17294, DOI 10.1074/jbc.M500997200
   Doerks T, 2002, GENOME RES, V12, P47, DOI 10.1101/gr.203201
   Dwyer MA, 2011, MOL ENDOCRINOL, V25, P360, DOI 10.1210/me.2010-0392
   Eckert GP, 2007, NEUROSCI LETT, V423, P47, DOI 10.1016/j.neulet.2007.05.063
   Ferrera D, 2014, NEUROBIOL AGING, V35, P2444, DOI 10.1016/j.neurobiolaging.2014.05.023
   Fiala M, 1998, MOL MED, V4, P480, DOI 10.1007/BF03401753
   Guo L, 2007, P NATL ACAD SCI USA, V104, P13444, DOI 10.1073/pnas.0703707104
   Hassan WM, 2015, NEUROBIOL AGING, V36, P857, DOI 10.1016/j.neurobiolaging.2014.10.016
   Hazra S, 2012, DIABETES, V61, P3270, DOI 10.2337/db11-1596
   He N, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.437
   Huang XM, 2012, NEUROBIOL AGING, V33, DOI 10.1016/j.neurobiolaging.2011.10.007
   Ito A, 2015, ELIFE, V4, DOI 10.7554/eLife.08009
   Janowski BA, 1996, NATURE, V383, P728, DOI 10.1038/383728a0
   Johnson LV, 2002, P NATL ACAD SCI USA, V99, P11830, DOI 10.1073/pnas.192203399
   Jonas JB, 2012, ACTA OPHTHALMOL, V90, pe381, DOI 10.1111/j.1755-3768.2012.02414.x
   Jurk D, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5172
   Kayed R, 2003, SCIENCE, V300, P486, DOI 10.1126/science.1079469
   Kidani Y, 2012, IMMUNOL REV, V249, P72, DOI 10.1111/j.1600-065X.2012.01153.x
   Koldamova T, 2005, J BIOL CHEM, V280, P4079, DOI 10.1074/jbc.M411420200
   Kurji KH, 2010, INVEST OPHTH VIS SCI, V51, P1151, DOI 10.1167/iovs.09-3622
   Lee M, 2015, NEUROBIOL AGING, V36, P42, DOI 10.1016/j.neurobiolaging.2014.07.024
   Liu RZT, 2014, EXP EYE RES, V127, P49, DOI 10.1016/j.exer.2014.07.003
   Liu RT, 2013, INVEST OPHTH VIS SCI, V54, P2225, DOI 10.1167/iovs.12-10849
   Nagai A, 2001, NEUROBIOL DIS, V8, P1057, DOI 10.1006/nbdi.2001.0437
   Ohno-Matsui K, 2011, PROG RETIN EYE RES, V30, P217, DOI 10.1016/j.preteyeres.2011.02.004
   Park SW, 2014, NEUROBIOL AGING, V35, P2013, DOI 10.1016/j.neurobiolaging.2014.03.008
   Phillips MC, 2014, J BIOL CHEM, V289, P24020, DOI 10.1074/jbc.R114.583658
   Qiu YG, 2015, SCI REP-UK, V5, DOI 10.1038/srep14362
   Sene A, 2014, TRENDS ENDOCRIN MET, V25, P107, DOI 10.1016/j.tem.2013.10.007
   Shi S, 2016, EUR J IMMUNOL, V46, P665, DOI 10.1002/eji.201545855
   Tao LF, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0489-7
   Wang JY, 2009, J CELL PHYSIOL, V220, P119, DOI 10.1002/jcp.21742
   Yang HX, 2014, INVEST OPHTH VIS SCI, V55, P2795, DOI 10.1167/iovs.13-13323
   Ye HH, 2014, INVEST OPHTH VIS SCI, V55, P6374, DOI 10.1167/iovs.14-14899
   Yoshida T, 2005, J CLIN INVEST, V115, P2793, DOI 10.1172/JCI24635
   Zelcer N, 2006, J CLIN INVEST, V116, P607, DOI 10.1172/JCI27883
   Zhao T, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0337-1
   Zheng S, 2014, INVEST OPHTH VIS SCI, V56, P1168
   Zheng WC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037926
   Zhu Y, 2015, MOL VIS, V21, P1122
   Zhu Y, 2013, MOL VIS, V19, P1826
NR 51
TC 12
Z9 13
U1 0
U2 15
PU SPRINGER BASEL AG
PI BASEL
PA PICASSOPLATZ 4, BASEL, 4052, SWITZERLAND
SN 1023-3830
EI 1420-908X
J9 INFLAMM RES
JI Inflamm. Res.
PD JUN
PY 2017
VL 66
IS 6
BP 523
EP 534
DI 10.1007/s00011-017-1036-4
PG 12
WC Cell Biology; Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Immunology
GA ET8ZY
UT WOS:000400595400007
PM 28361293
DA 2024-02-19
ER

PT J
AU Portero-Otín, M
   Bellmunt, MJ
   Ruiz, MC
   Barja, G
   Pamplona, R
AF Portero-Otín, M
   Bellmunt, MJ
   Ruiz, MC
   Barja, G
   Pamplona, R
TI Correlation of fatty acid unsaturation of the major liver mitochondrial
   phospholipid classes in mammals to their maximum life span potential
SO LIPIDS
LA English
DT Article
ID FREE-RADICAL THEORY; LIPID-PEROXIDATION; PROTEIN MODIFICATION;
   MEMBRANE-STRUCTURE; OXIDATIVE DAMAGE; BODY-MASS; HEART; TISSUES; AGE;
   BIOSYNTHESIS
AB Free radical damage is considered a determinant factor in the rate of aging. Unsaturated fatty acids are the tissue macromolecules that are most sensitive to oxidative damage. Therefore, the presence of low proportions of fatty acid unsaturation is expected in the tissues of long-lived animals. Accordingly, the fatty acid compositions of the major liver mitochondrial phospholipid classes from eight mammals, ranging in maximum life span potential (MLSP) from 3.5 to 46 yr, show that the total number of double bonds is inversely correlated with MLSP in both phosphatidylcholine (PtdCho) and phosphatidylethanolamine (PtdEtn) (r = 0.757, P < 0.03, and r = 0.862, P < 0.006, respectively), but not in cardiolipin (P = 0.323). This is due not to a low content of unsaturated fatty acids in long-lived animals, but mainly to a redistribution between kinds of fatty acids on PtdCho and PtdEtn, shirting from arachidonic (r = 0.911, P < 0.002, and r = 0.681, P = 0.05, respectively), docosahexaenoic (r = 0.931 and r = 0.965, P < 0.0001, respectively) and palmitic (r = 0.944 and r = 0.974, P < 0.0001, respectively) acids to linoleic acid (r = 0.942, P < 0.0001, for PtdCho; and r = 0.957, P < 0.0001, for PtdEtn). For cardiolipin, only arachidonic acid showed a significantly inverse correlation with MLSP (r = 0.904, P < 0.002), This pattern strongly suggests the presence of a species-specific desaturation pathway and deacylation-reacylation cycle in determining the mitochondrial membrane composition, maintaining a low degree of fatty acid unsaturation in long-lived animals.
C1 Univ Lleida, Fac Med, Dept Basic Med Sci, Metab Physiopathol Res Grp, E-25198 Lleida, Spain.
C3 Universitat de Lleida
RP Pamplona, R (corresponding author), Univ Lleida, Fac Med, Dept Basic Med Sci, Metab Physiopathol Res Grp, Av Rovira Roure 44, E-25198 Lleida, Spain.
EM manuel.portero@cmb.udl.es
RI Barja, Gustavo/AAA-5903-2019; Portero-Otin, Manuel/B-7122-2009;
   Pamplona, Reinald/A-7359-2010; Gustavo, Barja/B-5591-2012; Curcó, Maria
   Josep Bellmunt/C-3784-2011
OI Barja, Gustavo/0000-0001-5736-4735; Portero-Otin,
   Manuel/0000-0002-1823-0299; Pamplona, Reinald/0000-0003-4337-6107;
   Curcó, Maria Josep Bellmunt/0000-0002-3187-1576
CR ADELMAN R, 1988, P NATL ACAD SCI USA, V85, P2706, DOI 10.1073/pnas.85.8.2706
   ALTMAN PL, 1972, BIOL DATA BOOK, V1, P29
   Barja G, 2000, FASEB J, V14, P312, DOI 10.1096/fasebj.14.2.312
   Barja G, 1999, J BIOENERG BIOMEMBR, V31, P347, DOI 10.1023/A:1005427919188
   BOVERIS A, 1999, OXIDAT STRESS DIS, V2, P1
   BRENNER RR, 1984, PROG LIPID RES, V23, P69, DOI 10.1016/0163-7827(84)90008-0
   CHARNOCK JS, 1992, COMP BIOCHEM PHYS A, V101, P387, DOI 10.1016/0300-9629(92)90551-Z
   Cocco T, 1999, FREE RADICAL BIO MED, V27, P51, DOI 10.1016/S0891-5849(99)00034-9
   COUTURE P, 1995, AM J PHYSIOL-REG I, V268, pR641, DOI 10.1152/ajpregu.1995.268.3.R641
   COUTURE P, 1995, J MEMBRANE BIOL, V148, P27
   CUTLER RG, 1985, P NATL ACAD SCI USA, V82, P4798, DOI 10.1073/pnas.82.14.4798
   DAUM G, 1985, BIOCHIM BIOPHYS ACTA, V822, P1, DOI 10.1016/0304-4157(85)90002-4
   Dowhan W, 1997, ANNU REV BIOCHEM, V66, P199, DOI 10.1146/annurev.biochem.66.1.199
   DRAPER HH, 1995, LIPIDS, V30, P959, DOI 10.1007/BF02537489
   Finch CE, 1997, SCIENCE, V278, P407, DOI 10.1126/science.278.5337.407
   FOLCH J, 1957, J BIOL CHEM, V226, P497
   FORSMARKANDREE P, 1995, FREE RADICAL BIO MED, V19, P749, DOI 10.1016/0891-5849(95)00076-A
   GRAHAM JM, 1993, BIOMEMBRANE PROTOCOL, V19, P1
   GUDBJARNASON S, 1989, J INTERN MED, V225, P117, DOI 10.1111/j.1365-2796.1989.tb01445.x
   GUTIERREZ AM, 1997, INT J BIOCHEM CELL B, V32, P73
   HARMAN D, 1994, ANN NY ACAD SCI, V717, P1, DOI 10.1111/j.1749-6632.1994.tb12069.x
   Hatch GM, 1998, INT J MOL MED, V1, P33
   Infante JP, 1998, FEBS LETT, V431, P1, DOI 10.1016/S0014-5793(98)00720-0
   LAGANIERE S, 1987, BIOCHEM BIOPH RES CO, V145, P1185, DOI 10.1016/0006-291X(87)91562-2
   LAGANIERE S, 1993, GERONTOLOGY, V39, P7, DOI 10.1159/000213509
   LAGANIERE S, 1989, MECH AGEING DEV, V48, P221, DOI 10.1016/0047-6374(89)90084-5
   LEE AG, 1991, PROG LIPID RES, V30, P323, DOI 10.1016/0163-7827(91)90002-M
   PALMPLONA R, 2000, MECH AGEING DEV, V112, P169
   Pamplona R, 2000, J GERONTOL A-BIOL, V55, pB286, DOI 10.1093/gerona/55.6.B286
   Pamplona R, 1996, MECH AGEING DEV, V86, P53, DOI 10.1016/0047-6374(95)01673-2
   Pamplona R, 1999, MECH AGEING DEV, V106, P283, DOI 10.1016/S0047-6374(98)00121-3
   Pamplona R, 1998, J LIPID RES, V39, P1989
   Perez-Campo R, 1998, J COMP PHYSIOL B, V168, P149, DOI 10.1007/s003600050131
   PORTA EA, 1988, CELLULAR ANTIOXIDANT, V8, P2
   PORTER RK, 1993, NATURE, V362, P628, DOI 10.1038/362628a0
   Refsgaard HHF, 2000, P NATL ACAD SCI USA, V97, P611, DOI 10.1073/pnas.97.2.611
   Sato A, 1998, BIOL PHARM BULL, V21, P1271, DOI 10.1248/bpb.21.1271
   SEGURA R, 1985, 21 INT S ADV CHROM O
   SOHAL RS, 1990, MECH AGEING DEV, V53, P209, DOI 10.1016/0047-6374(90)90039-I
   Sola R, 1997, FREE RADICAL BIO MED, V22, P1037, DOI 10.1016/S0891-5849(96)00490-X
   YEAGLE PL, 1989, FASEB J, V3, P1833, DOI 10.1096/fasebj.3.7.2469614
   Yu BP, 1996, ANN NY ACAD SCI, V786, P1, DOI 10.1111/j.1749-6632.1996.tb39047.x
   YU BP, 1992, MECH AGEING DEV, V65, P17, DOI 10.1016/0047-6374(92)90123-U
   YU BP, 1989, OXYGEN RADICALS BIOL, P1067
NR 44
TC 48
Z9 55
U1 0
U2 9
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0024-4201
EI 1558-9307
J9 LIPIDS
JI Lipids
PD MAY
PY 2001
VL 36
IS 5
BP 491
EP 498
DI 10.1007/s11745-001-0748-y
PG 8
WC Biochemistry & Molecular Biology; Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Nutrition & Dietetics
GA 443BJ
UT WOS:000169319200008
PM 11432462
DA 2024-02-19
ER

PT J
AU Haggerty, C
   Hoggard, N
   Brown, DS
   Clapham, JC
   Speakman, JR
AF Haggerty, C.
   Hoggard, N.
   Brown, D. S.
   Clapham, J. C.
   Speakman, J. R.
TI Intra-specific variation in resting metabolic rate in MF1 mice is not
   associated with membrane lipid desaturation in the liver
SO MECHANISMS OF AGEING AND DEVELOPMENT
LA English
DT Article
DE membrane pacemaker; RMR; lifespan; ageing; metabolism
ID FATTY-ACID UNSATURATION; MAXIMUM LIFE-SPAN; MOLECULAR ACTIVITY; ACYL
   COMPOSITION; BODY-SIZE; DOCOSAHEXAENOIC ACID; INDIVIDUAL VARIATION;
   COMPARATIVE BIOLOGY; ENERGY-EXPENDITURE; SODIUM-PUMP
AB The 'membrane pacemaker' hypothesis provides a putative mechanistic linkage between variations in energy metabolism, rates of ageing and lifespan across different species. Within species we have found positive associations between longevity and metabolism, which contrast the interspecific trends. It is of interest to know therefore how levels of lipid desaturation in membranes are linked to variation in metabolism between individuals within species. We explored this problem by extracting membrane fatty acids from the livers of mice that varied in their metabolic rate, in a strain (MF1) where we have previously demonstrated a positive association between metabolism and lifespan. We measured resting metabolic rate (RMR) in 60 mice, each measured on three occasions, and measured their body compositions using dual energy X-ray absorptiometry (DXA). We selected 28 individuals that exhibited a wide variation in their mean resting metabolic rates (RMR) and extracted membrane lipids from the livers of these mice post mortem and analysed them for the patterns of contribution of different fatty acids. We then sought associations between the levels of membrane desaturation and the individual variability in RMR, using the proportional contributions of each fatty acid as predictors in a stepwise regression or by re-describing the variation in fatty acyl lipids using a PCA analysis and then seeking associations between scores on the derived components and RMR. We used whole animal RMRs and also RMR with the effects of body composition (fat free mass) removed. The level of individual variation in RMR was consistent with our previous observations. There was a significant positive association (p = 0.019) between the proportion of palmitic acid (16:0) in the membranes and RMR, which was strengthened (p = 0.014) when we adjusted RMR for differences in fat free mass. The proportion of palmitic acid (16:0) explained 20.9% of the individual variation in residual RMR. There was no association between RMR or mass adjusted RMR and the proportional representation of any other fatty acid, including 22:6 (DHA) predicted by the membrane pacemaker hypothesis to be of particular significance. High levels of saturated fatty acids in the membranes of mice with high rates of metabolism may contribute to their greater longevity, but the mechanism tying together increased membrane saturation with elevated RMR remains unclear. (C) 2007 Elsevier Ireland Ltd. All rights reserved.
C1 [Haggerty, C.; Hoggard, N.; Brown, D. S.; Speakman, J. R.] Univ Aberdeen, Sch Biol Sci, ACERO, Rowett Res Inst, Aberdeen AB21 9SB, Scotland.
   [Haggerty, C.; Speakman, J. R.] Univ Aberdeen, Sch Biol Sci, ACERO, Aberdeen AB24 2TZ, Scotland.
   [Clapham, J. C.] Astrazeneca, Molndal, Sweden.
C3 University of Aberdeen; University of Aberdeen; AstraZeneca
RP Speakman, JR (corresponding author), Univ Aberdeen, Sch Biol Sci, ACERO, Rowett Res Inst, Aberdeen AB21 9SB, Scotland.
EM J.Speakman@abdn.ac.uk
RI John, Speakman R/A-9494-2008; Clapham, John/AAK-4715-2020
OI Hoggard, Nigel/0000-0002-7403-5375
FU Biotechnology and Biological Sciences Research Council Funding Source:
   Medline
CR [Anonymous], 1984, SIZE FUNCTION LIFE H
   [Anonymous], 2002, Bioenergetics
   Astrup A, 1999, INT J OBESITY, V23, P1030, DOI 10.1038/sj.ijo.0801040
   AUSTAD SN, 1991, J GERONTOL, V46, pB47, DOI 10.1093/geronj/46.2.B47
   Barja G, 1998, ANN NY ACAD SCI, V854, P224, DOI 10.1111/j.1749-6632.1998.tb09905.x
   BENNETT PM, 1987, J ZOOL, V213, P327, DOI 10.1111/j.1469-7998.1987.tb03708.x
   Brand MD, 2003, BIOCHEM J, V376, P741, DOI 10.1042/BJ20030984
   Brand MD, 2000, EXP GERONTOL, V35, P811, DOI 10.1016/S0531-5565(00)00135-2
   Brookes PS, 1998, COMP BIOCHEM PHYS B, V119, P325, DOI 10.1016/S0305-0491(97)00357-X
   Brookes PS, 2005, FREE RADICAL BIO MED, V38, P12, DOI 10.1016/j.freeradbiomed.2004.10.016
   Carey J. R., 2000, LONGEVITY RECORDS LI
   Casteilla L, 2001, IUBMB LIFE, V52, P181, DOI 10.1080/15216540152845984
   COUTURE P, 1995, J MEMBRANE BIOL, V148, P27
   Else PL, 1999, J COMP PHYSIOL B, V169, P296, DOI 10.1007/s003600050224
   Fridell YWC, 2005, CELL METAB, V1, P145, DOI 10.1016/j.cmet.2005.01.005
   Halliwell B, 1996, ANNU REV NUTR, V16, P33, DOI 10.1146/annurev.nu.16.070196.000341
   HAYES JP, 1992, PHYSIOL ZOOL, V65, P604, DOI 10.1086/physzool.65.3.30157972
   HOLMES DJ, 1995, AM ZOOL, V35, P307
   Holmes DJ, 2001, EXP GERONTOL, V36, P869, DOI 10.1016/S0531-5565(00)00247-3
   HOLMES DJ, 1995, J GERONTOL A-BIOL, V50, pB59, DOI 10.1093/gerona/50A.2.B59
   Hulbert AJ, 1999, J THEOR BIOL, V199, P257, DOI 10.1006/jtbi.1999.0955
   Hulbert AJ, 2005, J THEOR BIOL, V234, P277, DOI 10.1016/j.jtbi.2004.11.024
   Hulbert AJ, 2000, ANNU REV PHYSIOL, V62, P207, DOI 10.1146/annurev.physiol.62.1.207
   Hulbert AJ, 2006, J COMP PHYSIOL B, V176, P93, DOI 10.1007/s00360-005-0025-z
   Hulbert AJ, 2005, J EXP BIOL, V208, P1593, DOI 10.1242/jeb.01482
   Hulbert AJ, 2003, J EXP BIOL, V206, P2303, DOI 10.1242/jeb.00399
   HULBERT AJ, 1991, AM J PHYSIOL, V261, pR561, DOI 10.1152/ajpregu.1991.261.3.R561
   Hulbert AJ, 2002, J EXP BIOL, V205, P3561
   Hulbert AJ, 2002, COMP BIOCHEM PHYS B, V132, P515, DOI 10.1016/S1096-4959(02)00066-0
   HULBERT AJ, 2007, LIPIDS           APR
   Jackson DM, 2001, J ANIM ECOL, V70, P633, DOI 10.1046/j.1365-2656.2001.00518.x
   Johnson MS, 2001, J EXP BIOL, V204, P1937
   Johnston SL, 2005, OBES RES, V13, P1558, DOI 10.1038/oby.2005.191
   Johnstone AM, 2005, AM J CLIN NUTR, V82, P941, DOI 10.1093/ajcn/82.5.941
   Król E, 2003, J EXP BIOL, V206, P4283, DOI 10.1242/jeb.00676
   Labocha MK, 2004, P ROY SOC B-BIOL SCI, V271, P367, DOI 10.1098/rspb.2003.2612
   LEPAGE G, 1986, J LIPID RES, V27, P114
   Lin SJ, 2002, NATURE, V418, P344, DOI 10.1038/nature00829
   LINDSTEDT SL, 1976, CONDOR, V78, P91, DOI 10.2307/1366920
   McKechnie AE, 2004, PHYSIOL BIOCHEM ZOOL, V77, P502, DOI 10.1086/383511
   Oklejewicz M, 2002, J BIOL RHYTHM, V17, P210, DOI 10.1177/07430402017003004
   Oklejewicz M, 1997, J BIOL RHYTHM, V12, P413, DOI 10.1177/074873049701200503
   Pamplona R, 2000, J GERONTOL A-BIOL, V55, pB286, DOI 10.1093/gerona/55.6.B286
   Pamplona R, 2002, ANN NY ACAD SCI, V959, P475, DOI 10.1111/j.1749-6632.2002.tb02118.x
   Pörtner HO, 2008, SCIENCE, V322, P690, DOI 10.1126/science.1163156
   Porter RK, 1996, AM J PHYSIOL-REG I, V271, pR1550, DOI 10.1152/ajpregu.1996.271.6.R1550
   Portero-Otín M, 2001, LIPIDS, V36, P491, DOI 10.1007/s11745-001-0748-y
   Prinzinger R, 2005, EMBO REP, V6, pS14, DOI 10.1038/sj.embor.7400425
   PROMISLOW DEL, 1993, J GERONTOL, V48, pB115, DOI 10.1093/geronj/48.4.B115
   Reynolds PS, 1996, AM NAT, V147, P735, DOI 10.1086/285877
   Ricklefs RE, 2001, EXP GERONTOL, V36, P845, DOI 10.1016/S0531-5565(00)00245-X
   Rizzo MR, 2005, J CLIN ENDOCR METAB, V90, P409, DOI 10.1210/jc.2004-0390
   ROHNER M, 1908, PROBLEM LEBENSDAUR S
   Selman C, 2001, J EXP BIOL, V204, P777
   Speakman Jr, 2003, ADV CELL AGING GERON, V14, P35
   Speakman JR, 2004, PHYSIOL BIOCHEM ZOOL, V77, P900, DOI 10.1086/427059
   Speakman JR, 2005, AGING CELL, V4, P167, DOI 10.1111/j.1474-9726.2005.00162.x
   Speakman JR, 2005, PHYSIOL BIOCHEM ZOOL, V78, P650, DOI 10.1086/430234
   Speakman JR, 2005, J EXP BIOL, V208, P1717, DOI 10.1242/jeb.01556
   Speakman JR, 2004, AGING CELL, V3, P87, DOI 10.1111/j.1474-9728.2004.00097.x
   Speakman JR, 2003, AGING CELL, V2, P265, DOI 10.1046/j.1474-9728.2003.00061.x
   Speakman JR, 2002, J NUTR, V132, p1583S, DOI 10.1093/jn/132.6.1583S
   SPEAKMAN JR, 2000, LIVING COLD, V3
   Stillwell W, 1997, LIPIDS, V32, P497, DOI 10.1007/s11745-997-0064-6
   Turner N, 2005, AM J PHYSIOL-REG I, V288, pR301, DOI 10.1152/ajpregu.00297.2004
   Turner N, 2003, NATURWISSENSCHAFTEN, V90, P521, DOI 10.1007/s00114-003-0470-z
   Valencak TG, 2007, AGING CELL, V6, P15, DOI 10.1111/j.1474-9726.2006.00257.x
   Valencak TG, 2003, J COMP PHYSIOL B, V173, P695, DOI 10.1007/s00360-003-0382-4
   Weyer C, 2000, AM J CLIN NUTR, V72, P946
   Wu BJ, 2004, AM J PHYSIOL-REG I, V287, pR633, DOI 10.1152/ajpregu.00549.2003
   Wu BJ, 2001, J EXP BIOL, V204, P4271
NR 71
TC 22
Z9 25
U1 0
U2 3
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0047-6374
EI 1872-6216
J9 MECH AGEING DEV
JI Mech. Ageing Dev.
PD MAR
PY 2008
VL 129
IS 3
BP 129
EP 137
DI 10.1016/j.mad.2007.11.001
PG 9
WC Cell Biology; Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Geriatrics & Gerontology
GA 275WT
UT WOS:000254103600003
PM 18160096
DA 2024-02-19
ER

PT J
AU Kimura, W
   Okubo, K
   Han, I
   Kanai, S
   Matsushita, A
   Muto, T
   Miyasaka, K
AF Kimura, W
   Okubo, K
   Han, I
   Kanai, S
   Matsushita, A
   Muto, T
   Miyasaka, K
TI Effects of pancreatic duct ligation and aging on acute
   taurocholate-induced pancreatitis - Experiments in the perfused pancreas
   in rats
SO INTERNATIONAL JOURNAL OF PANCREATOLOGY
LA English
DT Article
DE isolated perfused pancreas; acute pancreatitis; pancreatic duct
   hypertension
ID ACUTE NECROTIZING PANCREATITIS; HEMORRHAGIC-PANCREATITIS;
   CLASSIFICATION-SYSTEM; EXOCRINE FUNCTION; PROGNOSTIC SIGNS;
   FREE-RADICALS; ACINAR-CELL; APACHE-II; PATHOGENESIS; SECRETION
AB Conclusion: When taurocholate was injected into the common bile duct, high ductal pressure due to ligation of the pancreatic duct did not produce more damage in the pancreas of both old rats and young adult rats, and levels of pancreatic enzymes in portal venous effluent were lower in old rats than in younger rats.
   Background: The effects of ligation of the pancreatic duct and aging on acute pancreatitis caused by taurocholate are still unclear.
   Methods: Young adult and old male Wistar rats were used. Six hours after ligation of the common bile duct in both the duodenum and liver hilus, rats were killed and the pancreata were perfused. Taurocholate or normal saline was injected retrogradely into the common bile duct. The levels of amylase and lipase in the portal venous effluent were determined as markers of damage to the pancreas. The pancreas was also histologically examined after the perfusion experiments using an Image Analysis System.
   Results: (1) A nonsignificant elevation of pancreatic enzymes was found in portal venous effluent by the retrograde injection of saline into the common bile duct. Injection of taurocholate caused a marked elevation of enzymes in the effluent for the first 30 min after injection, which then gradually decreased, (2) Basal levels of pancreatic enzymes were significantly higher in the ligation group than in the nonligation group. Injection of saline into the common bile duct had no apparent effect on enzymes in the effluent. In contrast, taurocholate injection into the common bile duct produced a marked increase in enzymes in the portal venous effluent. However, no significant difference was found between the ligation group and the nonligation group. (3) Similar findings were obtained when old rats were used. (4) Although basal levels of enzymes were almost the same in nonligated old and young adult rats, taurocholate injection into the pancreatic duct in old rats resulted in a significant depression of enzymes compared to that in young adult rats. In the ligation group, pancreatic enzymes in the portal venous effluent following taurocholate injection tended to be lower in old rats than in young adult rats. The results were histologically supported in that various degrees of fibrosis were found in the pancreata of old rats.
C1 YOKOHAMA CITY UNIV,DEPT INTERNAL MED 3,YOKOHAMA,KANAGAWA,JAPAN.
   TOKYO METROPOLITAN INST GERONTOL,DEPT CLIN PHYSIOL,TOKYO,JAPAN.
   TOKYO METROPOLITAN GERIATR HOSP,TOKYO 173,JAPAN.
C3 Yokohama City University; Tokyo Metropolitan Institute of Gerontology;
   Tokyo Metropolitan Institute of Gerontology
RP Kimura, W (corresponding author), UNIV TOKYO,FAC MED,DEPT SURG 1,BUNKYO KU,7-3-1 HONGO,TOKYO 113,JAPAN.
CR ACOSTA JM, 1974, NEW ENGL J MED, V290, P484, DOI 10.1056/NEJM197402282900904
   ADLER G, 1986, EXOCRINE PANCREAS BI, P407
   BARTOS V, 1969, GERONTOL CLIN, V11, P56, DOI 10.1159/000245215
   BLACKSTONE MO, 1987, NEW ENGL J MED, V317, P319
   BLACKSTONE MO, 1987, N ENGL J MOD, V317, P320
   CARTER DC, 1989, PANCREATITIS, P58
   CAVUOTI OP, 1988, SURGERY, V103, P361
   CLEMENS JA, 1989, PANCREATITIS, P1
   DREILING DA, 1979, AM J GASTROENTEROL, V71, P424
   DREILING DA, 1958, MT SINAI J MED, V25, P128
   FIKRY ME, 1968, J AM GERIATR SOC, V16
   FUNAKOSHI T, 1982, JPN J GERONTOL, V19, P616
   GOEKAS MC, 1985, ANN INTERN MED, V103, P86
   GREENBERG RE, 1986, DIGEST DIS SCI, V31, P970, DOI 10.1007/BF01303218
   GUICE KS, 1986, AM J SURG, V151, P163, DOI 10.1016/0002-9610(86)90027-9
   GULLO L, 1983, GERONTOLOGY, V29, P407, DOI 10.1159/000213152
   HARVEY MH, 1988, AM J SURG, V155, P49, DOI 10.1016/S0002-9610(88)80257-5
   HOLLANDER D, 1984, GERONTOLOGY, V30, P218, DOI 10.1159/000212635
   IMRIE CW, 1978, BRIT J SURG, V65, P337, DOI 10.1002/bjs.1800650514
   ISHIKAWA T, 1988, BIOMED RES-TOKYO, V9, P287, DOI 10.2220/biomedres.9.287
   KHALIL T, 1985, AM J SURG, V149, P120, DOI 10.1016/S0002-9610(85)80020-9
   KIMURA W, 1989, INT J PANCREATOL, V5, P1
   KIMURA W, 1992, GASTROENTEROLOGY, V103, P1916, DOI 10.1016/0016-5085(92)91452-A
   KIMURA W, IN PRESS PATHOPHYSIO
   KIMURA W, 1992, PANCREAS, V8, P70
   KNAUS WA, 1981, CRIT CARE MED, V9, P591, DOI 10.1097/00003246-198108000-00008
   KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009
   KNAUS WA, 1984, CRIT CARE MED, V12, P213
   KOIKE H, 1982, AM J PHYSIOL, V242, pG297, DOI 10.1152/ajpgi.1982.242.4.G297
   LAUGIER R, 1984, GASTROINTESTINAL TRA, P243
   LERCH MM, 1992, GASTROENTEROLOGY, V103, P205, DOI 10.1016/0016-5085(92)91114-J
   LERCH MM, 1993, GASTROENTEROLOGY, V104, P853, DOI 10.1016/0016-5085(93)91022-A
   Malagelada J R, 1986, Pancreas, V1, P270, DOI 10.1097/00006676-198605000-00011
   MIYASAKA K, 1989, DIGEST DIS SCI, V34, P841, DOI 10.1007/BF01540268
   MIYASAKA K, 1987, PANCREAS, V2, P523, DOI 10.1097/00006676-198709000-00006
   MIYASAKA K, 1992, ARCH GERONTOL GERIAT, V14, P167, DOI 10.1016/0167-4943(92)90051-5
   NAGAI H, 1989, GASTROENTEROLOGY, V96, P838
   NIEDERAU C, 1988, J CLIN INVEST, V81, P229, DOI 10.1172/JCI113300
   NIEDERAU C, 1986, J CLIN INVEST, V78, P1056, DOI 10.1172/JCI112661
   ODAIRA C, 1986, DIGESTION, V34, P68, DOI 10.1159/000199313
   Opie EL, 1901, B JOHNS HOPKINS HOSP, V12, P182
   OSBORNE DH, 1981, BRIT J SURG, V68, P758, DOI 10.1002/bjs.1800681103
   POWERS RE, 1986, J CLIN INVEST, V77, P1668, DOI 10.1172/JCI112484
   RANSON JHC, 1976, SURG GYNECOL OBSTET, V143, P209
   RANSON JHC, 1974, ANN SURG, V179, P557
   RANSON JHC, 1974, SURG GYNECOL OBSTET, V139, P69
   RANSON JHC, 1983, SURGERY PANCREAS, P146
   RINDERKNECHT H, 1986, DIGEST DIS SCI, V31, P314, DOI 10.1007/BF01318124
   ROSENBERG IR, 1966, GASTROENTEROLOGY, V50, P191
   RUTLEDGE PL, 1987, GASTROENTEROLOGY, V93, P41, DOI 10.1016/0016-5085(87)90311-8
   SENNINGER N, 1986, SURGERY, V99, P688
   WALKER NI, 1987, AM J PATHOL, V126, P439
   WEDGWOOD K, 1987, SURG DIS PANCREAS, P371
   WEDGWOOD KR, 1986, GASTROENTEROLOGY, V90, P32, DOI 10.1016/0016-5085(86)90071-5
   WISNER J, 1988, GUT, V29, P1516, DOI 10.1136/gut.29.11.1516
NR 55
TC 5
Z9 6
U1 0
U2 0
PU HUMANA PRESS INC
PI TOTOWA
PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512
SN 0169-4197
J9 INT J PANCREATOL
JI Int. J. Pancreatol.
PD APR
PY 1996
VL 19
IS 2
BP 117
EP 127
PG 11
WC Endocrinology & Metabolism; Physiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Endocrinology & Metabolism; Physiology
GA UH743
UT WOS:A1996UH74300006
PM 8723554
DA 2024-02-19
ER

PT J
AU Concepcion, AR
   Salas, JT
   Sáez, E
   Sarvide, S
   Ferrer, A
   Portu, A
   Uriarte, I
   Hervás-Stubbs, S
   Elferink, RPJO
   Prieto, J
   Medina, JF
AF Concepcion, Axel R.
   Salas, January T.
   Saez, Elena
   Sarvide, Sarai
   Ferrer, Alex
   Portu, Ainhoa
   Uriarte, Iker
   Hervas-Stubbs, Sandra
   Elferink, Ronald P. J. Oude
   Prieto, Jesus
   Medina, Juan F.
TI CD8<SUP>+</SUP> T cells undergo activation and programmed death-1
   repression in the liver of aged
   Ae2<sub><i>a</i>,<i>b</i></sub><SUP>-/-</SUP> mice favoring autoimmune
   cholangitis
SO ONCOTARGET
LA English
DT Article
DE Na+-independent Cl-/HCO3(-) anion exchanger AE2; mouse model of
   autoimmune cholangitis; intracellular pH homeostasis; age-related
   changes; self-tolerance breakdown; Immunology and Microbiology Section;
   Immune response; Immunity
ID PRIMARY BILIARY-CIRRHOSIS; ANION-EXCHANGER 2; BICARBONATE SECRETION;
   HCO3-UMBRELLA; EXPRESSION; PD-1; PATHOGENESIS; SPECIFICITY; MODELS
AB Primary biliary cirrhosis (PBC) is a chronic cholestatic disease of unknown etiopathogenesis showing progressive autoimmune-mediated cholangitis. In PBC patients, the liver and lymphocytes exhibit diminished expression of AE2/SLC4A2, a Cl-/HCO3- anion exchanger involved in biliary bicarbonate secretion and intracellular pH regulation. Decreased AE2 expression may be pathogenic as Ae2(a,b)(-/-) mice reproduce hepatobiliary and immunological features resembling PBC. To understand the role of AE2 deficiency for autoimmunity predisposition we focused on the phenotypic changes of T cells that occur over the life-span of Ae2(a,b)(-/-) mice. At early ages (1-9 months), knockout mice had reduced numbers of intrahepatic T cells, which exhibited increased activation, programmed-cell-death (PD)-1 expression, and apoptosis. Moreover, young knockouts had upregulated PD-1 ligand (PD-L1) on bile-duct cells, and administration of neutralizing anti-PD-L1 antibodies prevented their intrahepatic T-cell deletion. Older (>= 10 months) knockouts, however, showed intrahepatic accumulation of cytotoxic CD8(+) T cells with downregulated PD-1 and diminished apoptosis. In-vitro DNA demethylation with 5-aza-2'-deoxycytidine partially reverted PD-1 downregulation of intrahepatic CD8(+) T cells from aged knockouts. Conclusion: Early in life, AE2 deficiency results in intrahepatic T-cell activation and PD-1/PDL1 mediated deletion. With aging, intrahepatic CD8(+) T cells epigenetically suppress PD-1, and their consequential expansion and further activation favor autoimmune cholangitis.
C1 [Concepcion, Axel R.; Saez, Elena; Sarvide, Sarai; Portu, Ainhoa; Uriarte, Iker; Hervas-Stubbs, Sandra; Prieto, Jesus; Medina, Juan F.] Sch Med, Ctr Appl Med Res CIMA, Pamplona, Spain.
   [Concepcion, Axel R.; Saez, Elena; Sarvide, Sarai; Portu, Ainhoa; Uriarte, Iker; Hervas-Stubbs, Sandra; Prieto, Jesus; Medina, Juan F.] Univ Navarra Clin, Pamplona, Spain.
   [Concepcion, Axel R.; Saez, Elena; Sarvide, Sarai; Portu, Ainhoa; Uriarte, Iker; Hervas-Stubbs, Sandra; Prieto, Jesus; Medina, Juan F.] Ciberehd, Pamplona, Spain.
   [Salas, January T.] Univ Penn, Dept Pathol & Lab Med, Perelman Sch Med, Philadelphia, PA USA.
   [Ferrer, Alex] Mayo Clin, Coll Med, Dept Immunol, Rochester, MN USA.
   [Elferink, Ronald P. J. Oude] Univ Amsterdam, Acad Med Ctr, Tytgat Inst Liver & Intestinal Res, NL-1105 AZ Amsterdam, Netherlands.
C3 University of Navarra; University of Navarra; CIBER - Centro de
   Investigacion Biomedica en Red; CIBEREHD; University of Pennsylvania;
   Mayo Clinic; University of Amsterdam; Academic Medical Center Amsterdam
RP Medina, JF (corresponding author), Sch Med, Ctr Appl Med Res CIMA, Pamplona, Spain.
EM jprieto@unav.es; jfmedina@unav.es
RI URIARTE, IKER/Z-2161-2019; Uriarte, Iker/AFP-1514-2022; Uriarte,
   Iker/AFP-1513-2022; Hervas-Stubbs, Sandra/C-9053-2018
OI URIARTE, IKER/0000-0001-5237-7799; Prieto, Jesus/0000-0002-1091-9593;
   Saez De Blas, Elena/0000-0002-6494-9739; Hervas-Stubbs,
   Sandra/0000-0003-3391-1516; Ferrer, Alejandro/0000-0002-4883-3023;
   Concepcion, Axel R./0000-0003-2971-3488
FU UTE for CIMA Project; Spanish Ministry of Science and Innovation
   [SAF2006-07818, SAF2009-11538, SAF2012-35455]; Carlos III Institute of
   Health [Ciberehd CB06/04/0067]; Subprogram "Torres Quevedo" (Spanish
   Ministry of Science and Innovation) [PTQ-10-04247]; Subprogram "Torres
   Quevedo" (European Union) [PTQ-10-04247]
FX This work was supported through the "UTE for CIMA Project" and by grants
   from the Spanish Ministry of Science and Innovation (SAF2006-07818,
   SAF2009-11538 and SAF2012-35455, each including FEDER supply), and by
   the Carlos III Institute of Health (Ciberehd CB06/04/0067). ARC had
   financial support from the Subprogram "Torres Quevedo" (Spanish Ministry
   of Science and Innovation & the European Union, PTQ-10-04247).
CR Alper SL, 2009, J EXP BIOL, V212, P1672, DOI 10.1242/jeb.029454
   Banales JM, 2012, HEPATOLOGY, V56, P687, DOI 10.1002/hep.25691
   Beuers U, 2010, HEPATOLOGY, V52, P1489, DOI 10.1002/hep.23810
   Concepcion AR, 2015, CURR PHARM DESIGN, V21, P2401, DOI 10.2174/1381612821666150316121622
   Concepcion AR, 2014, EUR J IMMUNOL, V44, P1341, DOI 10.1002/eji.201344218
   Concepcion AR, 2012, CLIN RES HEPATOL GAS, V36, P21, DOI 10.1016/j.clinre.2011.07.007
   Concepcion AR, 2014, FRONT PHYSIOL, V4, DOI 10.3389/fphys.2013.00413
   Corpechot C, 2005, GASTROENTEROLOGY, V128, P297, DOI 10.1053/j.gastro.2004.11.009
   Crispe IN, 2011, J HEPATOL, V54, P357, DOI 10.1016/j.jhep.2010.10.005
   Dhirapong A, 2013, HEPATOLOGY, V57, P708, DOI 10.1002/hep.26067
   Dong HD, 2004, IMMUNITY, V20, P327, DOI 10.1016/S1074-7613(04)00050-0
   Fehérvari Z, 2004, J CLIN INVEST, V114, P1209, DOI 10.1172/JCI200434495
   Francisco LM, 2010, IMMUNOL REV, V236, P219, DOI 10.1111/j.1600-065X.2010.00923.x
   Francisco LM, 2009, J EXP MED, V206, P3015, DOI 10.1084/jem.20090847
   Gong AY, 2009, J IMMUNOL, V182, P1325, DOI 10.4049/jimmunol.182.3.1325
   He XS, 2006, CELL IMMUNOL, V239, P1, DOI 10.1016/j.cellimm.2006.04.006
   Hohenester S, 2012, HEPATOLOGY, V55, P173, DOI 10.1002/hep.24691
   Hohenester S, 2009, SEMIN IMMUNOPATHOL, V31, P283, DOI 10.1007/s00281-009-0164-5
   Huang CT, 2004, IMMUNITY, V21, P503, DOI 10.1016/j.immuni.2004.08.010
   Huang WT, 2014, J AUTOIMMUN, V50, P123, DOI 10.1016/j.jaut.2014.01.034
   Jain N, 2010, P NATL ACAD SCI USA, V107, P1524, DOI 10.1073/pnas.0910341107
   Kaplan MM, 2005, NEW ENGL J MED, V353, P1261, DOI 10.1056/NEJMra043898
   Kawata K, 2013, HEPATOLOGY, V58, P1094, DOI 10.1002/hep.26418
   Kita H, 2002, J CLIN INVEST, V109, P1231, DOI 10.1172/JCI200214698
   Lan RY, 2006, HEPATOLOGY, V43, P729, DOI 10.1002/hep.21123
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lleo A, 2014, HEPATOLOGY, V60, P1314, DOI 10.1002/hep.27230
   Lleo A, 2009, HEPATOLOGY, V49, P871, DOI 10.1002/hep.22736
   Medina JF, 2003, P NATL ACAD SCI USA, V100, P15847, DOI 10.1073/pnas.2536127100
   Medina JF, 2011, DIGEST DIS, V29, P103, DOI 10.1159/000324144
   MENNONE A, 1995, P NATL ACAD SCI USA, V92, P6527, DOI 10.1073/pnas.92.14.6527
   Odin JA, 2001, J CLIN INVEST, V108, P223, DOI 10.1172/JCI10716
   Poupon R, 2010, J HEPATOL, V52, P745, DOI 10.1016/j.jhep.2009.11.027
   Prieto J, 1999, GASTROENTEROLOGY, V117, P167, DOI 10.1016/S0016-5085(99)70564-0
   Rong GH, 2011, HEPATOLOGY, V54, P196, DOI 10.1002/hep.24355
   Salas JT, 2008, GASTROENTEROLOGY, V134, P1482, DOI 10.1053/j.gastro.2008.02.020
   Salter KD, 2000, LAB INVEST, V80, P1775, DOI 10.1038/labinvest.3780187
   Sasaki M, 2007, J CLIN PATHOL, V60, P1102, DOI 10.1136/jcp.2006.044776
   Trivedi PJ, 2013, HEPATOL INT, V7, P28, DOI 10.1007/s12072-012-9362-7
   Tsuda M, 2011, HEPATOLOGY, V54, P1293, DOI 10.1002/hep.24526
   Ueno Y, 2010, CURR OPIN GASTROEN, V26, P274, DOI 10.1097/MOG.0b013e32833755aa
   Uriarte I, 2010, HEPATOLOGY, V51, P891, DOI 10.1002/hep.23403
   Vroman B, 1996, LAB INVEST, V74, P303
   Yang GX, 2011, J IMMUNOL, V186, P1259, DOI 10.4049/jimmunol.1001597
   Youngblood B, 2013, J IMMUNOL, V191, P540, DOI 10.4049/jimmunol.1203161
   Youngblood B, 2011, IMMUNITY, V35, P400, DOI 10.1016/j.immuni.2011.06.015
NR 46
TC 25
Z9 29
U1 0
U2 6
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD OCT 6
PY 2015
VL 6
IS 30
BP 28588
EP 28606
DI 10.18632/oncotarget.5665
PG 19
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA CU0CL
UT WOS:000363183200017
PM 26396175
OA gold, Green Submitted, Green Published
DA 2024-02-19
ER

PT J
AU Kuo, CS
   Lu, YW
   Hsu, CY
   Chang, CC
   Chou, RH
   Liu, LK
   Chen, LK
   Huang, PH
   Chen, JW
   Lin, SJ
AF Kuo, Chin-Sung
   Lu, Ya-Wen
   Hsu, Chien-Yi
   Chang, Chun-Chin
   Chou, Ruey-Hsing
   Liu, Li-Kuo
   Chen, Liang-Kung
   Huang, Po-Hsun
   Chen, Jaw-Wen
   Lin, Shing-Jong
TI Increased activin A levels in prediabetes and association with carotid
   intima-media thickness: a cross-sectional analysis from I-Lan
   Longitudinal Aging Study
SO SCIENTIFIC REPORTS
LA English
DT Article
ID TYPE-2 DIABETES-MELLITUS; FATTY LIVER-DISEASE; CARDIOVASCULAR-DISEASE;
   CIRCULATING FOLLISTATIN; MYOCARDIAL-INFARCTION; INSULIN-SECRETION;
   PANCREATIC-ISLETS; INFLAMMATION; INTERVENTION; METAANALYSIS
AB Activin A and its binding protein follistatin may be crucial in glucose homeostasis, as multifunctional proteins mediating inflammatory and anti-inflammatory effects. However, clinical data on the activin A level in prediabetes, and the association between the circulating activin A level and carotid intima-media thickness (cIMT), are lacking. We aimed to investigate activin A and follistatin levels and their associations with cIMT. In total, 470 inhabitants of I-Lan county (235 men; mean age 69 +/- 9 years) with measurements of serum activin A and follistatin levels were included. Patients with prediabetes and diabetes had significantly increased activin A concentrations compared with those in the normal glycemic group (both p < 0.001). A multivariable logistic regression model demonstrated that the circulating activin A level was associated with prediabetes and diabetes independently of other risk factors. Moreover, the circulating activin A levels were associated positively with cIMT in prediabetes (r(s) = 0.264, p = 0.001). In conclusion, activin A level, but not follistatin, was elevated independent of demographic variables with borderline significance and was correlated positively with cIMT in prediabetes. Activin A and follistatin levels were elevated in diabetes. In addition, elevated activin A was an independent risk factor for prediabetes and diabetes.
C1 [Kuo, Chin-Sung] Taipei Vet Gen Hosp, Dept Med, Div Endocrinol & Metab, Taipei, Taiwan.
   [Kuo, Chin-Sung; Lu, Ya-Wen; Chang, Chun-Chin; Chou, Ruey-Hsing; Huang, Po-Hsun; Chen, Jaw-Wen; Lin, Shing-Jong] Natl Yang Ming Univ, Cardiovasc Res Ctr, Taipei, Taiwan.
   [Kuo, Chin-Sung; Hsu, Chien-Yi; Chang, Chun-Chin; Chou, Ruey-Hsing; Huang, Po-Hsun; Lin, Shing-Jong] Natl Yang Ming Univ, Inst Clin Med, Taipei, Taiwan.
   [Lu, Ya-Wen; Chang, Chun-Chin; Chou, Ruey-Hsing; Huang, Po-Hsun; Chen, Jaw-Wen; Lin, Shing-Jong] Taipei Vet Gen Hosp, Dept Med, Div Cardiol, Taipei, Taiwan.
   [Hsu, Chien-Yi; Lin, Shing-Jong] Taipei Med Univ, Sch Med, Dept Internal Med, Taipei, Taiwan.
   [Hsu, Chien-Yi] Taipei Med Univ Hosp, Div Cardiol, Dept Internal Med, Taipei, Taiwan.
   [Hsu, Chien-Yi] Taipei Med Univ Hosp, Cardiovasc Res Ctr, Dept Internal Med, Taipei, Taiwan.
   [Liu, Li-Kuo; Chen, Liang-Kung] Taipei Vet Gen Hosp, Ctr Geriatr & Gerontol, Taipei, Taiwan.
   [Liu, Li-Kuo; Chen, Liang-Kung] Natl Yang Ming Univ, Aging & Hlth Res Ctr, Taipei, Taiwan.
   [Chen, Liang-Kung] Natl Yang Ming Univ, Inst Publ Hlth, Taipei, Taiwan.
   [Huang, Po-Hsun] Taipei Vet Gen Hosp, Dept Crit Care Med, Taipei, Taiwan.
   [Chen, Jaw-Wen] Natl Yang Ming Univ, Inst Pharmacol, Taipei, Taiwan.
   [Chen, Jaw-Wen] Taipei Vet Gen Hosp, Dept Med Res, Taipei, Taiwan.
   [Lin, Shing-Jong] Taipei Vet Gen Hosp, Healthcare & Serv Ctr, Taipei, Taiwan.
C3 Taipei Veterans General Hospital; National Yang Ming Chiao Tung
   University; National Yang Ming Chiao Tung University; Taipei Veterans
   General Hospital; Taipei Medical University; Taipei Medical University
   Hospital; Taipei Medical University; Taipei Medical University; Taipei
   Medical University Hospital; Taipei Veterans General Hospital; National
   Yang Ming Chiao Tung University; National Yang Ming Chiao Tung
   University; Taipei Veterans General Hospital; National Yang Ming Chiao
   Tung University; Taipei Veterans General Hospital; Taipei Veterans
   General Hospital
RP Huang, PH; Lin, SJ (corresponding author), Natl Yang Ming Univ, Cardiovasc Res Ctr, Taipei, Taiwan.; Huang, PH; Lin, SJ (corresponding author), Natl Yang Ming Univ, Inst Clin Med, Taipei, Taiwan.; Huang, PH; Lin, SJ (corresponding author), Taipei Vet Gen Hosp, Dept Med, Div Cardiol, Taipei, Taiwan.; Lin, SJ (corresponding author), Taipei Med Univ, Sch Med, Dept Internal Med, Taipei, Taiwan.; Chen, LK (corresponding author), Taipei Vet Gen Hosp, Ctr Geriatr & Gerontol, Taipei, Taiwan.; Chen, LK (corresponding author), Natl Yang Ming Univ, Aging & Hlth Res Ctr, Taipei, Taiwan.; Chen, LK (corresponding author), Natl Yang Ming Univ, Inst Publ Hlth, Taipei, Taiwan.; Huang, PH (corresponding author), Taipei Vet Gen Hosp, Dept Crit Care Med, Taipei, Taiwan.; Lin, SJ (corresponding author), Taipei Vet Gen Hosp, Healthcare & Serv Ctr, Taipei, Taiwan.
EM lkchen2@vghtpe.gov.tw; huangbsvgh@vghtpe.gov.tw; sjlin@vghtpe.gov.tw
RI Chen, Liang-Kung/JBI-8802-2023; chen, jw/IQW-1558-2023; Kuo,
   Chin-Sung/HSF-5153-2023
OI Chen, Liang-Kung/0000-0002-2387-8508; Kuo,
   Chin-Sung/0000-0001-7943-2647; Hsu, Chien-Yi/0000-0002-9493-7325; Chen,
   Jaw-Wen/0000-0002-7178-2316
FU Ministry of Science and Technology of Taiwan [MOST 104-2314-B-075-047,
   MOST 106-2314-B-010-033-MY3, MOST 106-2314-B-075-078-MY3]; Novel
   Bioengineering and Technological Approaches to Solve Two Major Health
   Problems in Taiwan - Taiwan Ministry of Science and Technology Academic
   Excellence Program [MOST 106-2633-B-009-001]; Ministry of Health and
   Welfare [MOHW106-TDU-B-211-113001]; Taipei Veterans General Hospital
   [V105C-207, V106C-045]
FX This study was supported, in part, by research grants from the Ministry
   of Science and Technology of Taiwan (MOST 104-2314-B-075-047, MOST
   106-2314-B-010-033-MY3, MOST 106-2314-B-075-078-MY3), the Novel
   Bioengineering and Technological Approaches to Solve Two Major Health
   Problems in Taiwan sponsored by the Taiwan Ministry of Science and
   Technology Academic Excellence Program (MOST 106-2633-B-009-001), the
   Ministry of Health and Welfare (MOHW106-TDU-B-211-113001), and Taipei
   Veterans General Hospital (V105C-207, V106C-045). These funding agencies
   had no influence on the study design, data collection or analysis, or
   decision to publish or preparation of the manuscript.
CR Anastasilakis AD, 2017, METABOLISM, V73, P1, DOI 10.1016/j.metabol.2017.05.002
   Andersen GO, 2011, DIABETES, V60, P1544, DOI 10.2337/db10-1493
   Brohall G, 2006, DIABETIC MED, V23, P609, DOI 10.1111/j.1464-5491.2005.01725.x
   Chang CC, 2016, SCI REP-UK, V6, DOI 10.1038/srep39434
   Chen Y, 2014, CYTOKINE, V69, P255, DOI 10.1016/j.cyto.2014.06.017
   de Kretser DM, 2012, MOL CELL ENDOCRINOL, V359, P101, DOI 10.1016/j.mce.2011.10.009
   Eijken M, 2007, FASEB J, V21, P2949, DOI 10.1096/fj.07-8080com
   Einarson TR, 2010, CARDIOVASC DIABETOL, V9, DOI 10.1186/1475-2840-9-37
   Engelse MA, 1999, CIRC RES, V85, P931
   Florio P, 2000, J ENDOCRINOL INVEST, V23, P231, DOI 10.1007/BF03343713
   Fruchart JC, 2014, CARDIOVASC DIABETOL, V13, DOI 10.1186/1475-2840-13-26
   Gavin JR, 1997, DIABETES CARE, V20, P1183
   Genuth S, 2003, DIABETES CARE, V26, P3160
   Greulich S, 2012, CIRCULATION, V126, P2324, DOI 10.1161/CIRCULATIONAHA.111.039586
   Hansen J, 2013, DIABETES-METAB RES, V29, P463, DOI 10.1002/dmrr.2415
   Hansen JS, 2016, J CLIN ENDOCR METAB, V101, P550, DOI 10.1210/jc.2015-3668
   Hansen JS, 2016, MOL CELL ENDOCRINOL, V433, P87, DOI 10.1016/j.mce.2016.06.002
   Laakso M, 2001, J INTERN MED, V249, P225, DOI 10.1046/j.1365-2796.2001.00789.x
   Liu LK, 2014, GERIATR GERONTOL INT, V14, P36, DOI 10.1111/ggi.12208
   Lorenz MW, 2007, CIRCULATION, V115, P459, DOI 10.1161/CIRCULATIONAHA.106.628875
   Mahmood SS, 2014, LANCET, V383, P999, DOI 10.1016/S0140-6736(13)61752-3
   Miyoshi T, 2009, CLIN CHIM ACTA, V401, P3, DOI 10.1016/j.cca.2008.10.027
   Mora S, 2010, CIRCULATION, V121, P1069, DOI 10.1161/CIRCULATIONAHA.109.906479
   Ofstad AP, 2013, CARDIOVASC DIABETOL, V12, DOI 10.1186/1475-2840-12-126
   Oshima Y, 2009, CIRCULATION, V120, P1606, DOI 10.1161/CIRCULATIONAHA.109.872200
   Phillips DJ, 2009, CYTOKINE GROWTH F R, V20, P153, DOI 10.1016/j.cytogfr.2009.02.007
   Polyzos SA, 2016, METABOLISM, V65, P1550, DOI 10.1016/j.metabol.2016.07.009
   PYORALA K, 1987, Diabetes Metabolism Reviews, V3, P463
   Risbridger GP, 2001, ENDOCR REV, V22, P836, DOI 10.1210/er.22.6.836
   Smith C, 2004, J AM COLL CARDIOL, V44, P369, DOI 10.1016/j.jacc.2004.03.069
   Teede H, 2013, METABOLISM, V62, P1394, DOI 10.1016/j.metabol.2013.05.003
   TOTSUKA Y, 1988, BIOCHEM BIOPH RES CO, V156, P335, DOI 10.1016/S0006-291X(88)80845-3
   Ueland T, 2012, DIABETES VASC DIS RE, V9, P234, DOI 10.1177/1479164111431171
   Ungerleider NA, 2013, ENDOCRINOLOGY, V154, P2025, DOI 10.1210/en.2012-1844
   Vellas B, 1999, NUTRITION, V15, P116, DOI 10.1016/S0899-9007(98)00171-3
   Weyer C, 1999, J CLIN INVEST, V104, P787, DOI 10.1172/JCI7231
   Wu H, 2012, EXP DIABETES RES, DOI 10.1155/2012/410579
   Yamasaki Y, 2000, DIABETES CARE, V23, P1310, DOI 10.2337/diacare.23.9.1310
   Yndestad A, 2009, AM J GASTROENTEROL, V104, P2196, DOI 10.1038/ajg.2009.318
   Zhang XP, 2010, DIABETES CARE, V33, P1665, DOI 10.2337/dc09-1939
NR 40
TC 10
Z9 11
U1 0
U2 6
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD JUL 2
PY 2018
VL 8
AR 9957
DI 10.1038/s41598-018-27795-2
PG 9
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA GL2MG
UT WOS:000436955000012
PM 29967428
OA Green Published, gold
DA 2024-02-19
ER

PT J
AU Imai, K
   Takai, K
   Watanabe, S
   Hanai, T
   Suetsugu, A
   Shiraki, M
   Shimizu, M
AF Imai, Kenji
   Takai, Koji
   Watanabe, Satoshi
   Hanai, Tatsunori
   Suetsugu, Atsushi
   Shiraki, Makoto
   Shimizu, Masahito
TI Sarcopenia Impairs Prognosis of Patients with Hepatocellular Carcinoma:
   The Role of Liver Functional Reserve and Tumor-Related Factors in Loss
   of Skeletal Muscle Volume
SO NUTRIENTS
LA English
DT Article
DE hepatocellular carcinoma; skeletal muscle depletion; sarcopenia;
   prognostic factor
ID CIRRHOSIS; SURVIVAL; DISEASE; GUIDELINES; DEPLETION; RESECTION;
   PREDICTS; EXERCISE; OBESITY; SYSTEM
AB Sarcopenia impairs survival in patients with hepatocellular carcinoma (HCC). This study aimed to clarify the factors that contribute to decreased skeletal muscle volume in patients with HCC. The third lumbar vertebra skeletal muscle index (L3 SMI) in 351 consecutive patients with HCC was calculated to identify sarcopenia. Sarcopenia was defined as an L3 SMI value <= 29.0 cm(2)/m(2) for women and < 36.0 cm(2)/m(2) for men. The factors affecting L3 SMI were analyzed by multiple linear regression analysis and tree-based models. Of the 351 HCC patients, 33 were diagnosed as having sarcopenia and showed poor prognosis compared with non-sarcopenia patients (p = 0.007). However, this significant difference disappeared after the adjustments for age, sex, Child-Pugh score, maximum tumor size, tumor number, and the degree of portal vein invasion by propensity score matching analysis. Multiple linear regression analysis showed that age (p = 0.015) and sex (p < 0.0001) were significantly correlated with a decrease in L3 SMI. Tree-based models revealed that sex (female) is the most significant factor that affects L3 SMI. In male patients, L3 SMI was decreased by aging, increased Child-Pugh score (>= 56 years), and enlarged tumor size (< 56 years). Maintaining liver functional reserve and early diagnosis and therapy for HCC are vital to prevent skeletal muscle depletion and improve the prognosis of patients with HCC.
C1 [Imai, Kenji; Takai, Koji; Watanabe, Satoshi; Hanai, Tatsunori; Suetsugu, Atsushi; Shiraki, Makoto; Shimizu, Masahito] Gifu Univ, Grad Sch Med, Dept Gastroenterol Internal Med, Gifu 5011194, Japan.
C3 Gifu University
RP Imai, K (corresponding author), Gifu Univ, Grad Sch Med, Dept Gastroenterol Internal Med, Gifu 5011194, Japan.
EM ikenji@gifu-u.ac.jp; koz@gifu-u.ac.jp; ronkalevala777@yahoo.co.jp;
   hanai0606@yahoo.co.jp; asue327@yahoo.co.jp; mshiraki-gif@umin.ac.jp;
   shimim-gif@umin.ac.jp
OI Hanai, Tatsunori/0000-0001-7797-9534
CR [Anonymous], 2010, Hepatol Res, V40 Suppl 1, P2, DOI 10.1111/j.1872-034X.2010.00650.x
   Austin PC, 2007, J THORAC CARDIOV SUR, V134, P1128, DOI 10.1016/j.jtcvs.2007.07.021
   Banerjee M, 2014, J CLIN ENDOCR METAB, V99, P3737, DOI 10.1210/jc.2014-2197
   Cruz-Jentoft AJ, 2010, AGE AGEING, V39, P412, DOI 10.1093/ageing/afq034
   Fujiwara N, 2015, J HEPATOL, V63, P131, DOI 10.1016/j.jhep.2015.02.031
   Grossmann M, 2012, CLIN ENDOCRINOL, V77, P323, DOI 10.1111/j.1365-2265.2012.04347.x
   Hanai T, 2016, HEPATOL RES, V46, P743, DOI 10.1111/hepr.12616
   Hanai T, 2015, NUTRITION, V31, P193, DOI 10.1016/j.nut.2014.07.005
   Imai K, 2015, INT J MOL SCI, V16, P9612, DOI 10.3390/ijms16059612
   Iritani S, 2015, J GASTROENTEROL, V50, P323, DOI 10.1007/s00535-014-0964-9
   Jones JC, 2012, LIVER TRANSPLANT, V18, P146, DOI 10.1002/lt.22472
   Kudo M, 2003, J GASTROENTEROL, V38, P207, DOI 10.1007/s005350300038
   Llovet JM, 1999, SEMIN LIVER DIS, V19, P329, DOI 10.1055/s-2007-1007122
   Manghisi G, 1998, HEPATOLOGY, V28, P751
   Marchesini G, 2003, GASTROENTEROLOGY, V124, P1792, DOI 10.1016/S0016-5085(03)00323-8
   Mir O, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037563
   Mitsiopoulos N, 1998, J APPL PHYSIOL, V85, P115, DOI 10.1152/jappl.1998.85.1.115
   Montano-Loza AJ, 2012, CLIN GASTROENTEROL H, V10, P166, DOI 10.1016/j.cgh.2011.08.028
   Moriwaki H, 2008, HEPATOL RES, V38, pS102, DOI 10.1111/j.1872-034X.2008.00434.x
   Muto Y, 2005, CLIN GASTROENTEROL H, V3, P705, DOI 10.1016/S1542-3565(05)00017-0
   Nishikawa H, 2016, HEPATOL RES, V46, P951, DOI 10.1111/hepr.12774
   Plauth M, 2006, CLIN NUTR, V25, P285, DOI 10.1016/j.clnu.2006.01.018
   Pociot F, 2004, AM J HUM GENET, V74, P647, DOI 10.1086/383095
   Poon RTP, 2011, HEPATOLOGY, V54, P757, DOI 10.1002/hep.24569
   Prado CMM, 2008, LANCET ONCOL, V9, P629, DOI 10.1016/S1470-2045(08)70153-0
   Prado CMM, 2011, CURR OPIN CLIN NUTR, V14, P250, DOI 10.1097/MCO.0b013e3283455d45
   Riggio O, 2003, CLIN NUTR, V22, P553, DOI 10.1016/S0261-5614(03)00058-X
   Rosenberg IH, 1997, J NUTR, V127, pS990, DOI 10.1093/jn/127.5.990S
   Sabel MS, 2011, ANN SURG ONCOL, V18, P3579, DOI 10.1245/s10434-011-1976-9
   Tan BHL, 2009, CLIN CANCER RES, V15, P6973, DOI 10.1158/1078-0432.CCR-09-1525
   van Vledder MG, 2012, BRIT J SURG, V99, P550, DOI 10.1002/bjs.7823
   Vincent HK, 2012, AGEING RES REV, V11, P361, DOI 10.1016/j.arr.2012.03.002
NR 32
TC 38
Z9 39
U1 2
U2 9
PU MDPI AG
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
SN 2072-6643
J9 NUTRIENTS
JI Nutrients
PD OCT
PY 2017
VL 9
IS 10
AR 1054
DI 10.3390/nu9101054
PG 10
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Nutrition & Dietetics
GA FM0DM
UT WOS:000414629900010
PM 28937616
OA Green Published, gold, Green Submitted
DA 2024-02-19
ER

PT J
AU Sarg, B
   Koutzamani, E
   Helliger, W
   Rundquist, I
   Lindner, HH
AF Sarg, B
   Koutzamani, E
   Helliger, W
   Rundquist, I
   Lindner, HH
TI Postsynthetic trimethylation of histone H4 at lysine 20 in mammalian
   tissues is associated with aging
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID PERFORMANCE CAPILLARY ELECTROPHORESIS; INTERACTION
   LIQUID-CHROMATOGRAPHY; ARGININE-RICH HISTONE; HP1 CHROMO DOMAIN; CORE
   HISTONES; METHYL GROUPS; GLYCINE-RICH; CELL-CYCLE; IN-VIVO; H3
AB Methylation of the N-terminal region of histories was first described more than 35 years ago, but its biological significance has remained unclear. Proposed functions range from transcriptional regulation to the higher order packing of chromatin in progress of mitotic condensation. Primarily because of the recent discovery of the SET domain-depending H3-specific historic methyl-transferases SUV39H1 and Suv39h1, which selectively methylate lysine 9 of the H3 N terminus, this posttranslational modification has regained scientific interest. In the past, investigations concerning the biological significance of histone methylation were largely limited because of a lack of simple and sensitive analytical procedures for detecting this modification. The present work investigated the methylation pattern of histone H4 both in different mammalian organs of various ages and in cell lines by applying mass spectrometric analysis and a newly developed hydrophilic-interaction liquid chromatographic method enabling the simultaneous separation of methylated and acetylated forms, which obviates the need to work with radioactive materials. In rat kidney and liver the dimethylated lysine 20 was found to be the main methylation product, whereas the monomethyl derivative was present in much smaller amounts. In addition, for the first time a trimethylated form of lysine 20 of H4 was found in mammalian tissue. A significant increase in this trimethylated histone H4 was detected in organs of animals older than 30 days, whereas the amounts of mono- and dimethylated forms did not essentially change in organs from young (10 days old) or old animals (30 and 450 days old). Trimethylated H4 was also detected in transformed cells; although it was present in only trace amounts in logarithmically growing cells, we found an increase in trimethylated lysine 20 in cells in the stationary phase.
C1 Univ Innsbruck, Dept Med Chem & Biochem, A-6020 Innsbruck, Austria.
   Linkoping Univ, Fac Hlth Sci, Dept Biomed & Surg, Div Cell Biol, SE-58185 Linkoping, Sweden.
C3 University of Innsbruck; Linkoping University
RP Lindner, HH (corresponding author), Univ Innsbruck, Dept Med Chem & Biochem, Fritz Pregl Str 3, A-6020 Innsbruck, Austria.
EM herbert.lindner@uibk.ac.at
RI Koutzamani, Elisavet/N-4112-2015
OI Koutzamani, Elisavet/0000-0003-3059-5191; Sarg,
   Bettina/0000-0002-4785-8739
CR ANNUNZIATO AT, 1995, BIOCHEMISTRY-US, V34, P2916, DOI 10.1021/bi00009a023
   Bannister AJ, 2001, NATURE, V410, P120, DOI 10.1038/35065138
   Bauer UM, 2002, EMBO REP, V3, P39, DOI 10.1093/embo-reports/kvf013
   BAXTER CS, 1975, BIOCHEM BIOPH RES CO, V63, P286, DOI 10.1016/S0006-291X(75)80041-6
   Boggs BA, 2002, NAT GENET, V30, P73, DOI 10.1038/ng787
   BORUN TW, 1972, J BIOL CHEM, V247, P4288
   BYVOET P, 1972, ARCH BIOCHEM BIOPHYS, V148, P558, DOI 10.1016/0003-9861(72)90174-9
   Chen DG, 1999, SCIENCE, V284, P2174, DOI 10.1126/science.284.5423.2174
   DELANGE RJ, 1970, BIOCHEM BIOPH RES CO, V40, P989, DOI 10.1016/0006-291X(70)91001-6
   DESAI LS, 1970, BIOCHEM J, V119, P165, DOI 10.1042/bj1190165
   DESROSIERS R, 1988, J BIOL CHEM, V263, P4686
   DUERRE JA, 1985, BIOCHIM BIOPHYS ACTA, V843, P58, DOI 10.1016/0304-4165(85)90049-2
   GRIMES S, 1987, EXP CELL RES, V173, P534, DOI 10.1016/0014-4827(87)90293-X
   Gupta S, 2000, SEMIN CANCER BIOL, V10, P161
   HEMPEL K, 1979, H-S Z PHYSIOL CHEM, V360, P869, DOI 10.1515/bchm2.1979.360.2.869
   HENDZEL MJ, 1989, J BIOL CHEM, V264, P19208
   HONDA BM, 1975, J BIOL CHEM, V250, P8681
   Jacobs SA, 2001, EMBO J, V20, P5232, DOI 10.1093/emboj/20.18.5232
   Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127
   Jenuwein T, 2001, TRENDS CELL BIOL, V11, P266, DOI 10.1016/S0962-8924(01)02001-3
   Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132
   Lindner H, 1996, J CHROMATOGR A, V743, P137, DOI 10.1016/0021-9673(96)00131-8
   LINDNER H, 1992, BIOCHEM J, V283, P467, DOI 10.1042/bj2830467
   Lindner H, 1997, J CHROMATOGR A, V782, P55, DOI 10.1016/S0021-9673(97)00468-8
   LINDNER H, 1992, J CHROMATOGR, V608, P211, DOI 10.1016/0021-9673(92)87126-S
   Lindner H, 1998, J BIOL CHEM, V273, P13324, DOI 10.1074/jbc.273.21.13324
   OGAWA Y, 1969, J BIOL CHEM, V244, P4387
   Paik W. K., 1980, PROTEIN METHYLATION
   PAIK WK, 1969, ARCH BIOCHEM BIOPHYS, V134, P632, DOI 10.1016/0003-9861(69)90327-0
   Rice JC, 2001, CURR OPIN CELL BIOL, V13, P263, DOI 10.1016/S0955-0674(00)00208-8
   SARNOW P, 1981, BIOCHIM BIOPHYS ACTA, V655, P349, DOI 10.1016/0005-2787(81)90045-9
   STARBUCK WC, 1968, J BIOL CHEM, V243, P2038
   Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412
   Strahl BD, 2001, CURR BIOL, V11, P996, DOI 10.1016/S0960-9822(01)00294-9
   Strahl BD, 1999, P NATL ACAD SCI USA, V96, P14967, DOI 10.1073/pnas.96.26.14967
   SUNG MT, 1977, BIOCHEMISTRY-US, V16, P279, DOI 10.1021/bi00621a019
   THOMAS G, 1975, EUR J BIOCHEM, V51, P609, DOI 10.1111/j.1432-1033.1975.tb03963.x
   Turner BM, 2000, BIOESSAYS, V22, P836, DOI 10.1002/1521-1878(200009)22:9<836::AID-BIES9>3.0.CO;2-X
   Wang HB, 2001, SCIENCE, V293, P853, DOI 10.1126/science.1060781
   WOLD F, 1981, ANNU REV BIOCHEM, V50, P783, DOI 10.1146/annurev.bi.50.070181.004031
   WU RS, 1986, CRIT REV BIOCHEM MOL, V20, P201, DOI 10.3109/10409238609083735
NR 41
TC 197
Z9 224
U1 0
U2 11
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
J9 J BIOL CHEM
JI J. Biol. Chem.
PD OCT 18
PY 2002
VL 277
IS 42
BP 39195
EP 39201
DI 10.1074/jbc.M205166200
PG 7
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 605EA
UT WOS:000178662500019
PM 12154089
OA hybrid
DA 2024-02-19
ER

PT J
AU Lahiri, DK
   Ge, YW
   Sharman, EH
   Bondy, SC
AF Lahiri, DK
   Ge, YW
   Sharman, EH
   Bondy, SC
TI Age-related changes in serum melatonin in mice: higher levels of
   combined melatonin and 6-hydroxymelatonin sulfate in the cerebral cortex
   than serum, heart, liver and kidney tissues
SO JOURNAL OF PINEAL RESEARCH
LA English
DT Article
DE aging; brain; diet; melatonin; mouse; supplementation; enzyme-linked
   assay; youth
ID PINEAL-GLAND; LIGHT
AB Age-related changes in levels of melatonin and 6-hydroxymelatonin sulfate and effects of dietary melatonin on their levels in different tissues were determined in mice. Levels of melatonin were highest in the serum followed by liver, kidney, cerebral cortex and heart as measured by a quantitative and sensitive enzyme-labeled immunosorbent assay (ELISA). Serum melatonin levels decreased with age, and were reduced by 80% in 27-month old mice relative to 12-month old mice. Levels of 6-hydroxymelatonin sulfate were measured independently in various tissues. Levels of the melatonin metabolite, 6-hydroxymelatonin sulfate were significantly higher than free melatonin in all tissues tested. Levels of 6-hydroxymelatonin sulfate were highest in the cerebral cortex followed by the serum, heart, kidney, and liver. In 12-month old mice 6-hydroxymelatonin sulfate concentration was approximately 1000-fold greater than that of melatonin in the cerebral cortex, it was only 3-fold greater than melatonin levels in the serum. Thus only 0.1% of total melatonin in the brain was present in the free and unconjugated form but the corresponding value for serum was 27.4%. The cerebral cortex had the highest levels of combined melatonin and 6-hydroxymelatonin sulfate than other tissue tested in control mice. There was no significant change in 6-hydroxymelatonin sulfate levels between young and old mice. There was also no age-dependent change in levels of serotonin or cortisol in the serum samples. Dietary supplementation with melatonin resulted in a significant increase in levels of melatonin in the serum and all other tissue samples tested. Thus, any age-related decline of tissue melatonin can be reversed by supplementation with dietary melatonin.
C1 Indiana Univ, Sch Med, Dept Psychiat, Inst Psychiat Res, Indianapolis, IN 46202 USA.
   Univ Calif Irvine, Ctr Occupat & Environm Hlth, Dept Commun & Environm Med, Irvine, CA 92717 USA.
C3 Indiana University System; Indiana University-Purdue University
   Indianapolis; University of California System; University of California
   Irvine
RP Lahiri, DK (corresponding author), Indiana Univ, Sch Med, Dept Psychiat, Inst Psychiat Res, 791 Union Dr,PR-313, Indianapolis, IN 46202 USA.
EM dlahiri@iupui.edu
RI Lahiri, Debomoy/AAZ-3322-2020
FU NIA NIH HHS [AG-18379, AG16794, AG 18884] Funding Source: Medline; NIEHS
   NIH HHS [ES 7992] Funding Source: Medline
CR AXELROD J, 1974, SCIENCE, V184, P1341, DOI 10.1126/science.184.4144.1341
   BOORMAN GA, 1996, TOXIC REP SER, V58, pB1
   Buijs RM, 2003, J ENDOCRINOL, V177, P17, DOI 10.1677/joe.0.1770017
   Conti A, 1996, J PINEAL RES, V20, P138, DOI 10.1111/j.1600-079X.1996.tb00249.x
   de Kloet E Ronald, 2003, Endocr Regul, V37, P51
   Fourtillan JB, 2000, BIOPHARM DRUG DISPOS, V21, P15, DOI 10.1002/1099-081X(200001)21:1<15::AID-BDD215>3.0.CO;2-H
   GOTO M, 1989, J PINEAL RES, V7, P195, DOI 10.1111/j.1600-079X.1989.tb00667.x
   Harenberg J, 2000, BRIT J HAEMATOL, V109, P182, DOI 10.1046/j.1365-2141.2000.01966.x
   Kennaway DJ, 2002, AM J PHYSIOL-REG I, V282, pR358, DOI 10.1152/ajpregu.00360.2001
   LAHIRI DK, 1993, BIOCHEM MED METAB B, V49, P36, DOI 10.1006/bmmb.1993.1004
   Masana MI, 2003, BIOCHEM PHARMACOL, V65, P731, DOI 10.1016/S0006-2952(02)01627-1
   Noonan CW, 2002, J OCCUP ENVIRON MED, V44, P769, DOI 10.1097/00043764-200208000-00012
   Nurnberger JI, 2000, ARCH GEN PSYCHIAT, V57, P572, DOI 10.1001/archpsyc.57.6.572
   Persengiev SP, 2001, J STEROID BIOCHEM, V77, P151, DOI 10.1016/S0960-0760(01)00037-1
   Reiter RJ, 1999, ANN NY ACAD SCI, V890, P471, DOI 10.1111/j.1749-6632.1999.tb08028.x
   REITER RJ, 1992, BIOESSAYS, V14, P169, DOI 10.1002/bies.950140307
   Roseboom PH, 1998, MOL BRAIN RES, V63, P189, DOI 10.1016/S0169-328X(98)00273-3
   SHARMAN EH, IN PRESS J PINEAL RE
   SINGER SS, 1995, J PINEAL RES, V18, P49, DOI 10.1111/j.1600-079X.1995.tb00139.x
   Vivien-Roels B, 1998, J BIOL RHYTHM, V13, P403, DOI 10.1177/074873098129000228
NR 20
TC 79
Z9 85
U1 0
U2 8
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0742-3098
EI 1600-079X
J9 J PINEAL RES
JI J. Pineal Res.
PD MAY
PY 2004
VL 36
IS 4
BP 217
EP 223
DI 10.1111/j.1600-079X.2004.00120.x
PG 7
WC Endocrinology & Metabolism; Neurosciences; Physiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Endocrinology & Metabolism; Neurosciences & Neurology; Physiology
GA 809GD
UT WOS:000220624300001
PM 15066045
DA 2024-02-19
ER

PT J
AU Laaksi, I
AF Laaksi, Ilkka
TI Symposium 4: Vitamins, infectious and chronic disease during adulthood
   and aging Vitamin D and respiratory infection in adults
SO PROCEEDINGS OF THE NUTRITION SOCIETY
LA English
DT Article
DE Vitamin D; Respiratory; Infection; Insufficiency
ID YOUNG FINNISH MEN; SERUM 25-HYDROXYVITAMIN D; PLACEBO-CONTROLLED TRIAL;
   D ENDOCRINE SYSTEM; TRACT INFECTION; HUMAN-SKIN; D-RECEPTOR;
   ANTIMICROBIAL PEPTIDES; D SUPPLEMENTATION; D DEFICIENCY
AB Vitamin D insufficiency is a global issue that has significant implications for health. The classical role of vitamin D in bone mineralisation is well known; vitamin D deficiency leads to rickets, osteomalacia or osteoporosis. The role of vitamin D in an immune system is less known. Vitamin D is not an actual vitamin but a secosteroid hormone produced in the skin from 7-dehydrocholesterol after exposure to sunlight UVB radiation. Nutrition and supplements are main sources of vitamin D in wintertime in northern countries as sunlight exposure is inadequate for the production. For activation vitamin D needs to be hydroxylated in liver to form 25-hydroxyvitamin D and in kidney to 1,25-dihydroxyvitamin D, the most active hormone in Ca absorption in the gut. For determination of vitamin D status serum 25-hydroxyvitamin D level, the major circulating form of the hormone is to be measured. Vitamin D regulates gene expression through binding with vitamin D receptors, which dimerises with retinoid X receptor. This complex binds to vitamin D-responsive elements inside the promoter regions of vitamin D-responsive genes. Vitamin D has a key role in innate immunity activation; the production of antimicrobial peptides (cathelicidin and defensins) following Toll-like receptor stimulation by pathogen lipopeptides is dependent on sufficient level of 25-hydroxyvitamin D. Clinically, there is evidence of the association of vitamin D insufficiency and respiratory tract infections. There is also some evidence of the prevention of infections by vitamin D supplementation. Randomised controlled trials are warranted to explore this preventive effect.
C1 Univ Tampere, Dept Cell Biol & Anat, Sch Med, Tampere 33014, Finland.
C3 Tampere University
RP Laaksi, I (corresponding author), Univ Tampere, Dept Cell Biol & Anat, Sch Med, Medisiinarinkatu 3, Tampere 33014, Finland.
EM ilkka.laaksi@uta.fi
FU Finnish Defence Forces; Tampere University Hospital
FX The author declares no conflicts of interest. This work was financially
   supported by a medical research fund from the Finnish Defence Forces and
   competitive research funding from the Tampere University Hospital.
CR Aloia JF, 2007, EPIDEMIOL INFECT, V135, P1095, DOI 10.1017/S0950268807008308
   [Anonymous], ETHN DIS S5, DOI DOI 10.1136/JMG.2004.024083
   Armas LAG, 2004, J CLIN ENDOCR METAB, V89, P5387, DOI 10.1210/jc.2004-0360
   Avenell A, 2007, AGE AGEING, V36, P574, DOI 10.1093/ageing/afm091
   Belisle SE, 2010, AM J CLIN NUTR, V92, P106, DOI 10.3945/ajcn.2010.29207
   Berry DJ, 2011, BRIT J NUTR, V106, P1433, DOI 10.1017/S0007114511001991
   Bikle DD, 2008, CURR OPIN NEPHROL HY, V17, P348, DOI 10.1097/MNH.0b013e3282ff64a3
   Binkley N, 2009, J CLIN DENSITOM, V12, P417, DOI 10.1016/j.jocd.2009.06.001
   Bouillon R, 1998, OSTEOPOROSIS INT, V8, pS13, DOI 10.1007/PL00022727
   Bresee JS, 1996, PEDIATR INFECT DIS J, V15, P777, DOI 10.1097/00006454-199609000-00008
   Cannell JJ, 2006, EPIDEMIOL INFECT, V134, P1129, DOI 10.1017/S0950268806007175
   Cannell JJ, 2008, VIROL J, V5, DOI 10.1186/1743-422X-5-29
   Chapuy MC, 1997, OSTEOPOROSIS INT, V7, P439, DOI 10.1007/s001980050030
   Christakos S, 2011, ENDOCRINOLOGY, V152, P2930, DOI 10.1210/en.2011-0243
   Compston JE, 1998, BRIT MED J, V317, P1466, DOI 10.1136/bmj.317.7171.1466
   Correale J, 2009, BRAIN, V132, P1146, DOI 10.1093/brain/awp033
   Dawson-Hughes B, 2005, OSTEOPOROSIS INT, V16, P713, DOI 10.1007/s00198-005-1867-7
   Gascon-Barré M, 2001, CLIN ENDOCRINOL, V54, P107, DOI 10.1046/j.1365-2265.2001.01160.x
   Ginde AA, 2009, ARCH INTERN MED, V169, P384, DOI 10.1001/archinternmed.2008.560
   Gottfried E, 2006, BIOCHEM BIOPH RES CO, V349, P209, DOI 10.1016/j.bbrc.2006.08.034
   Guryev O, 2003, P NATL ACAD SCI USA, V100, P14754, DOI 10.1073/pnas.2336107100
   Hansdottir S, 2008, J IMMUNOL, V181, P7090, DOI 10.4049/jimmunol.181.10.7090
   Harkness L, 2005, OSTEOPOROSIS INT, V16, P109, DOI 10.1007/s00198-004-1656-8
   Heaney RP, 2007, J BONE MINER RES, V22, pV25, DOI 10.1359/JBMR.07S205
   HOLICK MF, 1980, SCIENCE, V210, P203, DOI 10.1126/science.6251551
   Holick MF, 2003, J CELL BIOCHEM, V88, P296, DOI 10.1002/jcb.10338
   Holick MF, 2004, AM J CLIN NUTR, V80, p1678S, DOI 10.1093/ajcn/80.6.1678S
   HOLICK MF, 1989, LANCET, V2, P1104
   HOLICK MF, 1994, AM J CLIN NUTR, V60, P619, DOI 10.1093/ajcn/60.4.619
   HOLICK MF, 1980, NEW ENGL J MED, V303, P349, DOI 10.1056/NEJM198008143030701
   HOLICK MF, 1979, BIOCHEMISTRY-US, V18, P1003, DOI 10.1021/bi00573a011
   HOLICK MF, 1981, SCIENCE, V211, P590, DOI 10.1126/science.6256855
   Houghton LA, 2006, AM J CLIN NUTR, V84, P694, DOI 10.1093/ajcn/84.4.694
   Hyppönen E, 2001, LANCET, V358, P1500, DOI 10.1016/S0140-6736(01)06580-1
   Kato S, 2000, J BIOCHEM, V127, P717, DOI 10.1093/oxfordjournals.jbchem.a022662
   KRALL EA, 1989, NEW ENGL J MED, V321, P1777, DOI 10.1056/NEJM198912283212602
   Kresfelder TL, 2011, J MED VIROL, V83, P1834, DOI 10.1002/jmv.22179
   Laaksi IT, 2006, EUR J CLIN NUTR, V60, P1035, DOI 10.1038/sj.ejcn.1602414
   Laaksi I, 2007, AM J CLIN NUTR, V86, P714, DOI 10.1093/ajcn/86.3.714
   Laaksi I, 2010, J INFECT DIS, V202, P809, DOI 10.1086/654881
   Lamberg-Allardt CJE, 2001, J BONE MINER RES, V16, P2066, DOI 10.1359/jbmr.2001.16.11.2066
   Laubel DM, 2006, CURR TOP MICROBIOL, V306, P153
   Lee HY, 2004, BMC INFECT DIS, V4, DOI 10.1186/1471-2334-4-12
   Lehmann B, 2003, RECENT RESULTS CANC, V164, P135
   Lehmann B, 2010, DERMATOL THER, V23, P2, DOI 10.1111/j.1529-8019.2009.01286.x
   Li-Ng M, 2009, EPIDEMIOL INFECT, V137, P1396, DOI 10.1017/S0950268809002404
   Liu PT, 2006, SCIENCE, V311, P1770, DOI 10.1126/science.1123933
   MACLAUGHLIN J, 1985, J CLIN INVEST, V76, P1536, DOI 10.1172/JCI112134
   MACLAUGHLIN JA, 1982, SCIENCE, V216, P1001, DOI 10.1126/science.6281884
   Mantell DJ, 2000, CIRC RES, V87, P214, DOI 10.1161/01.RES.87.3.214
   MATSUOKA LY, 1987, J CLIN ENDOCR METAB, V64, P1165, DOI 10.1210/jcem-64-6-1165
   MATSUOKA LY, 1992, J CLIN ENDOCR METAB, V75, P1099, DOI 10.1210/jc.75.4.1099
   Matusiak D, 2005, CANCER EPIDEM BIOMAR, V14, P2370, DOI 10.1158/1055-9965.EPI-05-0257
   McCarthy K, 2009, ANTICANCER RES, V29, P155
   McKenna MJ, 1998, ANN INTERN MED, V128, P507, DOI 10.7326/0003-4819-128-6-199803150-00026
   MELLANBY E, 1976, NUTR REV, V34, P338
   Mohr SB, 2009, ANN EPIDEMIOL, V19, P79, DOI 10.1016/j.annepidem.2008.10.003
   Norman AW, 2008, AM J CLIN NUTR, V88, p491S, DOI 10.1093/ajcn/88.2.491S
   Norman AW, 1998, AM J CLIN NUTR, V67, P1108, DOI 10.1093/ajcn/67.6.1108
   Pierrot-Deseilligny C, 2010, BRAIN, V133, P1869, DOI 10.1093/brain/awq147
   Pikuleva I, 1999, Mol Aspects Med, V20, P33
   Ross AC, 2011, J CLIN ENDOCR METAB, V96, P53, DOI 10.1210/jc.2010-2704
   Roth DE, 2008, J INFECT DIS, V197, P676, DOI 10.1086/527488
   Sakaki T, 2005, FRONT BIOSCI, V10, P119
   Schleithoff SS, 2006, AM J CLIN NUTR, V83, P754, DOI 10.1093/ajcn/83.4.754
   Schwalfenberg GK, 2011, MOL NUTR FOOD RES, V55, P96, DOI 10.1002/mnfr.201000174
   Schwartz GG, 1997, CANCER EPIDEM BIOMAR, V6, P727
   STAMP TCB, 1977, LANCET, V1, P1341
   Steenbock H, 1924, Science, V60, P224, DOI 10.1126/science.60.1549.224
   Sugimoto N, 2006, BIOFACTORS, V28, P9, DOI 10.1002/biof.5520280102
   Thacher TD, 2010, J BONE MINER RES, V25, P1988, DOI 10.1002/jbmr.99
   Tjabringa GS, 2003, J IMMUNOL, V171, P6690, DOI 10.4049/jimmunol.171.12.6690
   Tokar EJ, 2005, CLIN EXP METASTAS, V22, P265, DOI 10.1007/s10585-005-8394-y
   Trang HM, 1998, AM J CLIN NUTR, V68, P854, DOI 10.1093/ajcn/68.4.854
   Utiger RD, 1998, NEW ENGL J MED, V338, P828, DOI 10.1056/NEJM199803193381209
   Välimäki VV, 2004, J CLIN ENDOCR METAB, V89, P76, DOI 10.1210/jc.2003-030817
   Vantieghem K, 2006, J PHOTOCH PHOTOBIO B, V85, P72, DOI 10.1016/j.jphotobiol.2006.05.001
   Vlaminckx BJM, 2005, CLIN MICROBIOL INFEC, V11, P226, DOI 10.1111/j.1469-0691.2004.01068.x
   von Essen MR, 2010, NAT IMMUNOL, V11, P344, DOI 10.1038/ni.1851
   Wang TT, 2004, J IMMUNOL, V173, P2909, DOI 10.4049/jimmunol.173.5.2909
   WEBB AR, 1988, J CLIN ENDOCR METAB, V67, P373, DOI 10.1210/jcem-67-2-373
   Wolpowitz D, 2006, J AM ACAD DERMATOL, V54, P301, DOI 10.1016/j.jaad.2005.11.1057
   Ylikomi T, 2002, VITAM HORM, V64, P357, DOI 10.1016/S0083-6729(02)64010-5
   Zasloff M, 2006, NAT MED, V12, P388, DOI 10.1038/nm0406-388
   Zasloff M, 2002, NEW ENGL J MED, V347, P1199, DOI 10.1056/NEJMe020106
   Zasloff M, 2002, NATURE, V415, P389, DOI 10.1038/415389a
NR 86
TC 54
Z9 59
U1 0
U2 3
PU CAMBRIDGE UNIV PRESS
PI CAMBRIDGE
PA EDINBURGH BLDG, SHAFTESBURY RD, CB2 8RU CAMBRIDGE, ENGLAND
SN 0029-6651
J9 P NUTR SOC
JI Proc. Nutr. Soc.
PD FEB
PY 2012
VL 71
IS 1
BP 90
EP 97
DI 10.1017/S0029665111003351
PG 8
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Nutrition & Dietetics
GA 886WI
UT WOS:000299884200011
PM 22115013
OA Bronze
DA 2024-02-19
ER

PT J
AU Kirschner, SK
   Ghane, P
   Park, JK
   Simbo, SY
   Ivanov, I
   Braga-Neto, UM
   Ten Have, GAM
   Thaden, JJ
   Engelen, MPKJ
   Deutz, NEP
AF Kirschner, Sarah K.
   Ghane, Parisa
   Park, Jaekwan K.
   Simbo, Sunday Y.
   Ivanov, Ivan
   Braga-Neto, Ulisses M.
   Ten Have, Gabriella A. M.
   Thaden, John J.
   Engelen, Marielle P. K. J.
   Deutz, Nicolaas E. P.
TI Short-chain fatty acid production in accessible and inaccessible body
   pools as assessed by novel stable tracer pulse approach is reduced by
   aging independent of presence of COPD
SO METABOLISM-CLINICAL AND EXPERIMENTAL
LA English
DT Article
DE Compartmental modeling; Stable isotopes; SCFA rate of appearance; SCFA
   production rate; Aging; Chronic Obstructive Pulmonary Disease
ID PROTEIN BREAKDOWN; METABOLISM; PHENYLALANINE; PROPIONATE; TURNOVER;
   KINETICS; HUMANS
AB Background: Production rates of the short-chain fatty acids (SCFA) acetate, propionate, and butyrate, which are beneficial metabolites of the intestinal microbiota, are difficult to measure in humans due to inaccessibility of the intestine to perform measurements, and the high first-pass metabolism of SCFAs in colonocytes and liver. We developed a stable tracer pulse approach to estimate SCFA whole-body production (WBP) in the accessible pool representing the systemic circulation and interstitial fluid. Compartmental modeling of plasma enrichment data allowed us to additionally calculate SCFA kinetics and pool sizes in the inaccessible pool likely representing the intestine with microbiota. We also studied the effects of aging and the presence of Chronic Obstructive Pulmonary Disease (COPD) on SCFA kinetics. Methods: In this observational study, we designed a two-compartmental model to determine SCFA kinetics in 31 young (20-29 y) and 71 older (55-87 y) adults, as well as in 33 clinically stable patients with moderate to very severe COPD (mean (SD) FEV1, 46.5 (16.2)% of predicted). Participants received in the fasted state a pulse containing stable tracers of acetate, propionate, and butyrate intravenously and blood was sampled four times over a 30 min period. We measured tracer-tracee ratios by GC-MS and used parameters obtained from two-exponential curve fitting to calculate non-compartmental SCFA WBP and perform compartmental analysis. Statistics were done by ANCOVA. Results: Acetate, propionate, and butyrate WBP and fluxes between the accessible and inaccessible pools were lower in older than young adults (all q < 0.0001). Moreover, older participants had lower acetate (q < 0.0001) and propionate (q = 0.019) production rates in the inaccessible pool as well as smaller sizes of the accessible and inaccessible acetate pools (both q < 0.0001) than young participants. WBP, compartmental SCFA kinetics, and pool sizes did not differ between COPD patients and older adults (all q > 0.05). Overall and independent of the group studied, calculated production rates in the inaccessible pool were on average 7 (acetate), 11 (propionate), and 16 (butyrate) times higher than non-compartmental WBP, and sizes of inaccessible pools were 24 (acetate), 31 (propionate), and 55 (butyrate) times higher than sizes of accessible pools (all p < 0.0001).Conclusion: Non-compartmental production measurements of SCFAs in the accessible pool (i.e. systemic circulation) substantially underestimate the SCFA production in the inaccessible pool, which likely represents the intestine with microbiota, as assessed by compartmental analysis.
C1 [Kirschner, Sarah K.; Ghane, Parisa; Park, Jaekwan K.; Simbo, Sunday Y.; Ten Have, Gabriella A. M.; Thaden, John J.; Engelen, Marielle P. K. J.; Deutz, Nicolaas E. P.] Texas A&M Univ, Ctr Translat Res Aging & Longev, College Stn, TX USA.
   [Ghane, Parisa; Ivanov, Ivan; Braga-Neto, Ulisses M.] Texas A&M Univ, Dept Elect & Comp Engn, College Stn, TX USA.
   [Ivanov, Ivan] Texas A&M Univ, Dept Vet Physiol & Pharmacol, College Stn, TX USA.
   [Deutz, Nicolaas E. P.] Texas A&M Univ, Ctr Translat Res Aging & Longev, 675 John Kimbrough Blvd, College Stn, TX 77845 USA.
C3 Texas A&M University System; Texas A&M University College Station; Texas
   A&M University System; Texas A&M University College Station; Texas A&M
   University System; Texas A&M University College Station; Texas A&M
   University System; Texas A&M University College Station
RP Deutz, NEP (corresponding author), Texas A&M Univ, Ctr Translat Res Aging & Longev, 675 John Kimbrough Blvd, College Stn, TX 77845 USA.
EM nep.deutz@ctral.org
FU European Society of Clinical Nutrition and Metabolism (ESPEN); George
   Abramson Donation
FX <B>Funding</B> This work was supported by a Research Fellowship awarded
   to Sarah Kirschner by the European Society of Clinical Nutrition and
   Metabolism (ESPEN) ; and the George Abramson Donation.
CR ABUMRAD NN, 1981, METABOLISM, V30, P936, DOI 10.1016/0026-0495(81)90074-3
   Auger C, 2021, METABOLISM, V118, DOI 10.1016/j.metabol.2021.154733
   Boets E, 2017, J PHYSIOL-LONDON, V595, P541, DOI 10.1113/JP272613
   Boets E, 2015, NUTRIENTS, V7, P8916, DOI 10.3390/nu7115440
   Bowerman KL, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19701-0
   CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8
   Clauss M, 2021, FRONT NUTR, V8, DOI 10.3389/fnut.2021.637010
   Cobelli C, 2007, Tracer kinetics in biomedical research: from data to model
   Cruthirds CL, 2021, J APPL PHYSIOL, V130, P435, DOI 10.1152/japplphysiol.00783.2020
   Cruz-Jentoft AJ, 2019, AGE AGEING, V48, P16, DOI 10.1093/ageing/afy169
   den Besten G, 2013, AM J PHYSIOL-GASTR L, V305, pG900, DOI 10.1152/ajpgi.00265.2013
   Deutz NEP, 2018, METABOLISM, V78, P167, DOI 10.1016/j.metabol.2017.09.015
   Dong YT, 2019, EUR J CLIN NUTR, V73, P1172, DOI 10.1038/s41430-018-0372-y
   Engelen MPKJ, 2019, CURR OPIN CLIN NUTR, V22, P337, DOI 10.1097/MCO.0000000000000583
   Furutate R, 2011, INT J CHRONIC OBSTR, V6, P423, DOI 10.2147/COPD.S22885
   Ghane P, 2018, Curr Dev Nutr, V2, P38
   Ghosh TS, 2022, NAT REV GASTRO HEPAT, V19, P565, DOI 10.1038/s41575-022-00605-x
   Glickman ME, 2014, J CLIN EPIDEMIOL, V67, P850, DOI 10.1016/j.jclinepi.2014.03.012
   Jonker R, 2019, CLIN NUTR, V38, P1684, DOI 10.1016/j.clnu.2018.08.006
   Joppa P, 2016, J AM MED DIR ASSOC, V17, P712, DOI 10.1016/j.jamda.2016.03.020
   Kirschner S, 2022, Curr Dev Nutr, V6, P33
   Kirschner SK, 2021, AM J PHYSIOL-ENDOC M, V321, pE665, DOI 10.1152/ajpendo.00121.2021
   Kirschner SK, 2022, JPEN-PARENTER ENTER, V46, P660, DOI 10.1002/jpen.2193
   Kirschner SK, 2021, CLIN NUTR, V40, P2270, DOI 10.1016/j.clnu.2020.10.010
   Li NJ, 2021, RESP RES, V22, DOI 10.1186/s12931-021-01872-z
   MAHLER DA, 1988, CHEST, V93, P580, DOI 10.1378/chest.93.3.580
   Markowiak-Kopec P, 2020, NUTRIENTS, V12, DOI 10.3390/nu12041107
   Mason A, 2017, AM J PHYSIOL-ENDOC M, V313, pE63, DOI 10.1152/ajpendo.00362.2016
   MATTHEWS DE, 1984, AM J PHYSIOL, V246, pE519, DOI 10.1152/ajpendo.1984.246.6.E519
   Montandon SA, 2017, GENES-BASEL, V8, DOI 10.3390/genes8100250
   Neis EPJG, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0166161
   Oliver A, 2021, MSYSTEMS, V6, DOI 10.1128/mSystems.00115-21
   Pouteau E, 1996, AM J PHYSIOL-ENDOC M, V271, pE58, DOI 10.1152/ajpendo.1996.271.1.E58
   Pouteau E, 2008, BRIT J NUTR, V99, P287, DOI 10.1017/S0007114507815790
   Salazar N, 2019, NUTRIENTS, V11, DOI 10.3390/nu11081765
   Santos-Marcos JA, 2018, MATURITAS, V116, P43, DOI 10.1016/j.maturitas.2018.07.008
   Sun CX, 2022, FRONT CARDIOVASC MED, V9, DOI 10.3389/fcvm.2022.972603
   Ten Have GAM, 2017, AM J PHYSIOL-ENDOC M, V312, pE519, DOI 10.1152/ajpendo.00351.2016
   van der Hee B, 2021, TRENDS MICROBIOL, V29, P700, DOI 10.1016/j.tim.2021.02.001
   Vogelmeier CF, 2017, AM J RESP CRIT CARE, V195, P557, DOI 10.1164/rccm.201701-0218PP
   WALTER JH, 1989, CLIN CHIM ACTA, V182, P141, DOI 10.1016/0009-8981(89)90073-9
   Wolfe RR, 2005, Isotope tracers in metabolic research, VSecond, P51
NR 42
TC 0
Z9 0
U1 2
U2 3
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0026-0495
EI 1532-8600
J9 METABOLISM
JI Metab.-Clin. Exp.
PD APR
PY 2023
VL 141
AR 155399
DI 10.1016/j.metabol.2023.155399
EA JAN 2023
PG 9
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Endocrinology & Metabolism
GA EW0V8
UT WOS:001141861100001
PM 36642114
DA 2024-02-19
ER

PT J
AU De Ita, JR
   Castilla-Cortázar, I
   Aguirre, GA
   Sánchez-Yago, C
   Santos-Ruiz, MO
   Guerra-Menéndez, L
   Martín-Estal, I
   García-Magariño, M
   Lara-Díaz, VJ
   Puche, JE
   Muñoz, U
AF Rodriguez De Ita, J.
   Castilla-Cortazar, I.
   Aguirre, G. A.
   Sanchez-Yago, C.
   Olleros Santos-Ruiz, M.
   Guerra-Menendez, L.
   Martin-Estal, I.
   Garcia-Magarino, M.
   Lara-Diaz, V. J.
   Puche, J. E.
   Munoz, U.
TI Altered liver expression of genes involved in lipid and glucose
   metabolism in mice with partial IGF-1 deficiency: an experimental
   approach to metabolic syndrome
SO JOURNAL OF TRANSLATIONAL MEDICINE
LA English
DT Article
DE Metabolism; Metabolic syndrome; IGF-1; Type 2 diabetes; Growth hormone;
   Gluconeogenesis; Glucogenolysis; Glucose-6-phosphate (G6P);
   Phosphoenolpyruvate carboxykinase (PEPCK); ATP-citrate lyase (Acly);
   Acetyl-CoA acyltransferase (Acaa1b); Insulin resistance; Oxidative
   damage; Dyslipidemia
ID GROWTH-FACTOR-I; INSULIN-RESISTANCE; CARDIOVASCULAR-DISEASE; COENZYME-A;
   DIABETES-MELLITUS; LARON-SYNDROME; FACTOR AXIS; AGING RATS; HORMONE;
   HOMEOSTASIS
AB Background: Insulin growth factor 1 (IGF-1) has multiple effects on metabolism. Much evidence suggests that the deficiency of this hormone increases insulin resistance, impairs lipid metabolism, augments oxidative damage and deregulates the neuro-hormonal axis. An inverse relationship between IGF-1 levels and the prevalence of Metabolic Syndrome (MetS) with its cardiovascular complications has been identified. However, the underlying mechanisms linking IGF-1 and MetS are still poorly understood. In order to elucidate such mechanisms, the aim of this work was to study, in mice with partial IGF-1 deficiency, liver expression of genes involved in glucose and lipid metabolism as well as serum levels of glucose, triglycerides and cholesterol, as well as liver malondialdehyde (MDA) levels, as a marker for oxidative damage.
   Methods: Three experimental groups were studied in parallel: Controls (CO), wild type mice (igf-1(+/+)); untreated heterozygous mice (Hz, igf-1(+/-)) and Hz (igf-1(+/-)) mice treated with low doses of IGF-1 for 10 days (Hz + IGF-1).
   Results: A reduction of IGF-1 serum levels in the Hz group was found, which was normalized by IGF-1 therapy. Serum levels of glucose, triglycerides and cholesterol were significantly increased in the untreated Hz group as compared to both controls and Hz + IGF-1 groups. The expression of genes involved in gluconeogenesis, glycogenolysis, lipid synthesis and transport, and catabolism were altered in untreated Hz animals and the expression of most of them was normalized by IGF-1 therapy; MDA was also significantly increased in the Hz untreated group.
   Conclusions: The mere partial IGF-1 deficiency is responsible for the reduction in the expression of genes involved in glucose and lipid metabolism, resulting in dyslipidemia and hyperglycemia. Such genetic alterations may seriously contribute to the establishment of MetS.
C1 [Rodriguez De Ita, J.; Castilla-Cortazar, I.; Aguirre, G. A.; Martin-Estal, I.; Garcia-Magarino, M.; Lara-Diaz, V. J.] Tecnol Monterrey, Escuela Med, Monterrey 64710, Nuevo Leon, Mexico.
   [Castilla-Cortazar, I.; Olleros Santos-Ruiz, M.] Fdn Invest HM Hosp, Madrid 28015, Spain.
   [Sanchez-Yago, C.; Guerra-Menendez, L.; Puche, J. E.; Munoz, U.] Univ CEU San Pablo, Sch Med, IMMA, Dept Med Physiol, Madrid 28668, Spain.
C3 Tecnologico de Monterrey; San Pablo CEU University
RP Castilla-Cortázar, I (corresponding author), Tecnol Monterrey, Escuela Med, Ave Morones Prieto 3000 Pte Col Los Doctores, Monterrey 64710, Nuevo Leon, Mexico.
EM iccortazar@itesm.mx
RI Aguirre, Gabriel A/K-7839-2017; MORON, URSULA MUÑOZ/L-4561-2017;
   Martín-Estal, Irene/L-7290-2019; Castilla-Cortazar, Inma/K-7883-2017;
   García-Magariño, Mariano/M-4128-2016; LARA-DIAZ, VICTOR
   JAVIER/G-9582-2011; Puche, Juan E/HMP-2853-2023; Martin Del Estal,
   Irene/K-6158-2017; Guerra-Menéndez, Lucía/L-9839-2015
OI Aguirre, Gabriel A/0000-0003-4125-2661; MORON, URSULA
   MUÑOZ/0000-0001-6024-4697; Martín-Estal, Irene/0000-0002-8987-3240;
   Castilla-Cortazar, Inma/0000-0002-2230-5927; García-Magariño,
   Mariano/0000-0003-1970-5599; LARA-DIAZ, VICTOR
   JAVIER/0000-0002-1498-8561; Martin Del Estal, Irene/0000-0002-8987-3240;
   Guerra-Menéndez, Lucía/0000-0001-8724-6385
FU Fundacion de Investigacion HM Hospitales; Tecnologico de Monterrey
FX The authors would like to express their gratitude to Prof. A.
   Efstratiadis (Columbia University, College of Physicians and Surgeons,
   New York, USA) for kindly providing the transgenic IGF-1 mice and to
   Chiron Company (Emeryville, CA) for granting the recombinant human IGF-I
   used in this study. A very special thank to Ms. Susana Arahuetes and Ms.
   Paloma Fernandez for their expert technical assistance. We are also very
   grateful to Karl Steinmetz for the English revision of the manuscript
   and Jesus Ortiz for his efficient contribution with figures. This work
   was supported by grants from "Fundacion de Investigacion HM Hospitales"
   and "Tecnologico de Monterrey".
CR Akanji AO, 2012, METAB SYNDR RELAT D, V10, P3, DOI 10.1089/met.2011.0083
   Beigneux AP, 2004, J BIOL CHEM, V279, P9557, DOI 10.1074/jbc.M310512200
   Bereket A, 1999, HORM METAB RES, V31, P172, DOI 10.1055/s-2007-978716
   Boucher J, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1905
   Cameron AJ, 2004, ENDOCRIN METAB CLIN, V33, P351, DOI 10.1016/j.ecl.2004.03.005
   Castilla-Cortazar I, 2014, J PHYSIOL BIOCHEM, V70, P129, DOI 10.1007/s13105-013-0287-y
   CastillaCortazar I, 1997, GASTROENTEROLOGY, V113, P1682, DOI 10.1053/gast.1997.v113.pm9352873
   Chen YX, 2014, ARTERIOSCL THROM VAS, V34, P365, DOI 10.1161/ATVBAHA.113.301301
   Clemmons DR, 2012, ENDOCRIN METAB CLIN, V41, P425, DOI 10.1016/j.ecl.2012.04.017
   Clemmons DR, 2004, J CLIN INVEST, V113, P25, DOI 10.1172/JCI200420660
   Fidaleo M, 2011, BIOCHIMIE, V93, P876, DOI 10.1016/j.biochi.2011.02.001
   Franco Celina, 2006, Metabolic Syndrome and Related Disorders, V4, P51, DOI 10.1089/met.2006.4.51
   Frystyk J, 2004, GROWTH HORM IGF RES, V14, P337, DOI 10.1016/j.ghir.2004.06.001
   García-Fernández M, 2008, ENDOCRINOLOGY, V149, P2433, DOI 10.1210/en.2007-1190
   Garg N, 2011, BIOCHEM BIOPH RES CO, V413, P476, DOI 10.1016/j.bbrc.2011.08.123
   Ginsberg S, 2009, OBES RES CLIN PRACT, V3, P3, DOI 10.1016/j.orcp.2008.11.001
   Grundy SM, 2008, ARTERIOSCL THROM VAS, V28, P629, DOI 10.1161/ATVBAHA.107.151092
   Grundy SM, 2006, J AM COLL CARDIOL, V47, P1093, DOI 10.1016/j.jacc.2005.11.046
   Guerra-Menéndez L, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-271
   HanaireBroutin H, 1996, DIABETES METAB, V22, P245
   Hanson RL, 2002, DIABETES, V51, P3120, DOI 10.2337/diabetes.51.10.3120
   Holt RIG, 2003, DIABETIC MED, V20, P3, DOI 10.1046/j.1464-5491.2003.00827.x
   Hu G, 2004, ARCH INTERN MED, V164, P1066, DOI 10.1001/archinte.164.10.1066
   Irizarry RA, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng015
   Jeppesen J, 2007, J AM COLL CARDIOL, V49, P2112, DOI 10.1016/j.jacc.2007.01.088
   Johnson WE, 2007, BIOSTATISTICS, V8, P118, DOI 10.1093/biostatistics/kxj037
   Kim HJ, 2004, ARCH INTERN MED, V164, P2169, DOI 10.1001/archinte.164.19.2169
   Kotronen A, 2007, J CLIN ENDOCR METAB, V92, P3490, DOI 10.1210/jc.2007-0482
   Lam CSP, 2010, ARTERIOSCL THROM VAS, V30, P1479, DOI 10.1161/ATVBAHA.110.203943
   Laron Z, 2004, EUR J ENDOCRINOL, V151, P103, DOI 10.1530/eje.0.1510103
   Latrech H, 2012, HORM RES PAEDIAT, V78, P193, DOI 10.1159/000339158
   Lebovitz HE, 1999, CLIN CHEM, V45, P1339
   Lee IK, 2014, DIABETES METAB J, V38, P181
   LeRoith D, 1997, NEW ENGL J MED, V336, P633, DOI 10.1056/NEJM199702273360907
   LIU JP, 1993, CELL, V75, P59, DOI 10.1016/S0092-8674(05)80084-4
   Liu Wei, 2014, Zhongguo Dang Dai Er Ke Za Zhi, V16, P203
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Malík J, 2008, PHYSIOL RES, V57, P919, DOI 10.33549/physiolres.931281
   Mallea-Gil Maria Susana, 2012, Acta Gastroenterol Latinoam, V42, P20
   Meigs JB, 2007, DIABETES CARE, V30, P1219, DOI 10.2337/dc06-2484
   Moses AC, 2005, ENDOCRIN DEV, V9, P121, DOI 10.1159/000085762
   Ness GC, 2000, P SOC EXP BIOL MED, V224, P8, DOI 10.1046/j.1525-1373.2000.22359.x
   OBrien RM, 1996, PHYSIOL REV, V76, P1109, DOI 10.1152/physrev.1996.76.4.1109
   Postic C, 2004, DIABETES METAB, V30, P398, DOI 10.1016/S1262-3636(07)70133-7
   Puche JE, 2008, ENDOCRINOLOGY, V149, P2620, DOI 10.1210/en.2007-1563
   Ren J, 2015, BIOCHEM PHARMACOL, V93, P409, DOI 10.1016/j.bcp.2014.12.006
   ROKOSZ LL, 1994, ARCH BIOCHEM BIOPHYS, V312, P1, DOI 10.1006/abbi.1994.1273
   Sattar N, 2008, LANCET, V371, P1927, DOI 10.1016/S0140-6736(08)60602-9
   Saukkonen T, 2006, DIABETES, V55, P2365, DOI 10.2337/db05-1646
   Savastano S, 2014, GROWTH HORM IGF RES, V24, P221, DOI 10.1016/j.ghir.2014.09.002
   Saydah S, 2009, CANCER CAUSE CONTROL, V20, P1309, DOI 10.1007/s10552-009-9351-x
   Steussy CN, 2013, BIOCHEMISTRY-US, V52, P5195, DOI 10.1021/bi400335g
   Succurro E, 2010, EUR J ENDOCRINOL, V163, P75, DOI 10.1530/EJE-10-0113
   Troncoso R, 2014, TRENDS ENDOCRIN MET, V25, P128, DOI 10.1016/j.tem.2013.12.002
   Wang W, 1999, Sheng Li Ke Xue Jin Zhan, V30, P5
   Yakar S, 1999, P NATL ACAD SCI USA, V96, P7324, DOI 10.1073/pnas.96.13.7324
   Yakar S, 2004, J CLIN INVEST, V113, P96, DOI 10.1172/JCI200417763
NR 57
TC 27
Z9 27
U1 0
U2 13
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1479-5876
J9 J TRANSL MED
JI J. Transl. Med.
PD OCT 14
PY 2015
VL 13
AR 326
DI 10.1186/s12967-015-0684-9
PG 13
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA CT5TQ
UT WOS:000362874200001
PM 26467524
OA Green Published, gold
DA 2024-02-19
ER

PT J
AU Saaoud, F
   Liu, L
   Xu, KM
   Cueto, R
   Shao, Y
   Lu, YF
   Sun, Y
   Snyder, NW
   Wu, S
   Yang, L
   Zhou, Y
   Williams, DL
   Li, CF
   Martinez, L
   Vazquez-Padron, RI
   Zhao, HQ
   Jiang, XH
   Wang, H
   Yang, XF
AF Saaoud, Fatma
   Liu, Lu
   Xu, Keman
   Cueto, Ramon
   Shao, Ying
   Lu, Yifan
   Sun, Yu
   Snyder, Nathaniel W.
   Wu, Sheng
   Yang, Ling
   Zhou, Yan
   Williams, David L.
   Li, Chuanfu
   Martinez, Laisel
   Vazquez-Padron, Roberto I.
   Zhao, Huaqing
   Jiang, Xiaohua
   Wang, Hong
   Yang, Xiaofeng
TI Aorta- and liver-generated TMAO enhances trained immunity for increased
   inflammation via ER stress/mitochondrial ROS/glycolysis pathways
SO JCI INSIGHT
LA English
DT Article
ID TRIMETHYLAMINE-N-OXIDE; ENDOTHELIAL-CELL ACTIVATION; PROTEIN-COUPLED
   RECEPTORS; MONOCYTE DIFFERENTIATION; CONDITIONAL DANGER;
   ATHEROSCLEROSIS; SUCCINATE; EXPRESSION; STRESS; CREB
AB We determined whether gut microbiota-produced trimethylamine (TMA) is oxidized into trimethylamine N-oxide (TMAO) in nonliver tissues and whether TMAO promotes inflammation via trained immunity (TI). We found that endoplasmic reticulum (ER) stress genes were coupregulated with MitoCarta genes in chronic kidney diseases (CKD); TMAO upregulated 190 genes in human aortic endothelial cells (HAECs); TMAO synthesis enzyme flavin-containing monooxygenase 3 (FMO3) was expressed in human and mouse aortas; TMAO transdifferentiated HAECs into innate immune cells; TMAO phosphorylated 12 kinases in cytosol via its receptor PERK and CREB, and integrated with PERK pathways; and PERK inhibitors suppressed TMAO-induced ICAM-1. TMAO upregulated 3 mitochondrial genes, downregulated inflammation inhibitor DARS2, and induced mitoROS, and mitoTEMPO inhibited TMAO-induced ICAM-1. beta-Glucan priming, followed by TMAO restimulation, upregulated TNF-alpha by inducing metabolic reprogramming, and glycolysis inhibitor suppressed TMAO-induced ICAM-1. Our results have provided potentially novel insights regarding TMAO roles in inducing EC activation and innate immune transdifferentiation and inducing metabolic reprogramming and TI for enhanced vascular inflammation, and they have provided new therapeutic targets for treating cardiovascular diseases (CVD), CKD-promoted CVD, inflammation, transplantation, aging, and cancer.
C1 [Saaoud, Fatma; Xu, Keman; Shao, Ying; Lu, Yifan; Sun, Yu; Jiang, Xiaohua; Yang, Xiaofeng] Temple Univ, Ctr Cardiovasc Res, Lewis Katz Sch Med, Philadelphia, PA USA.
   [Liu, Lu; Cueto, Ramon; Snyder, Nathaniel W.; Wu, Sheng; Jiang, Xiaohua; Wang, Hong; Yang, Xiaofeng] Temple Univ, Lewis Katz Sch Med, Metabol Dis Res & Thrombosis Res, Dept Cardiovasc Sci, Philadelphia, PA USA.
   [Yang, Ling] Temple Univ, Lewis Katz Sch Med, Dept Med Genet & Mol Biochem, Philadelphia, PA USA.
   [Zhou, Yan] Temple Hlth, Fox Chase Canc Ctr, Biostat & Bioinformat Facil, Philadelphia, PA USA.
   [Williams, David L.; Li, Chuanfu] East Tennessee State Univ, Dept Surg, Quillen Coll Med, Ctr Excellence Inflammat Infect Dis & Immun, Johnson City, TN USA.
   [Martinez, Laisel; Vazquez-Padron, Roberto I.] Univ Miami, Leonard M Miller Sch Med, DeWitt Daughtry Family Dept Surg, Miami, FL USA.
   [Zhao, Huaqing] Temple Univ, Lewis Katz Sch Med, Dept Biomed Educ & Data Sci, Ctr Biostat & Epidemiol, Philadelphia, PA USA.
C3 Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple
   University; Pennsylvania Commonwealth System of Higher Education
   (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher
   Education (PCSHE); Temple University; Fox Chase Cancer Center; East
   Tennessee State University; University of Miami; Pennsylvania
   Commonwealth System of Higher Education (PCSHE); Temple University
RP Yang, XF (corresponding author), Temple Univ, Lewis Katz Sch Med, Dept Cardiovasc Sci, 3500 North Broad St, Philadelphia, PA 19140 USA.
EM xfyang@temple.edu
OI Snyder, Nathaniel/0000-0001-5643-8747; XU, KEMAN/0000-0002-0816-1760
FU NIH/National Heart, Lung, and Blood Institute [HL131460, HL132399,
   HL138749, HL147565, HL130233, DK104116, DK113775]
FX Our research activities are supported by grants from the NIH/National
   Heart, Lung, and Blood Institute (HL131460, HL132399, HL138749,
   HL147565, HL130233, DK104116, and DK113775). The content in this article
   is solely the responsibility of the authors and does not necessarily
   represent the official views of the NIH.
CR Ahumada-Castro U, 2021, BBA-MOL CELL RES, V1868, DOI 10.1016/j.bbamcr.2021.119099
   Almanza A, 2019, FEBS J, V286, P241, DOI 10.1111/febs.14608
   Andreucci M, 2021, BIOMOLECULES, V11, DOI 10.3390/biom11020194
   Andrienko TN, 2017, J MOL CELL CARDIOL, V110, P1, DOI 10.1016/j.yjmcc.2017.06.016
   Aradjanski M, 2017, HUM MOL GENET, V26, P4181, DOI 10.1093/hmg/ddx307
   Arts RJW, 2016, CELL METAB, V24, P807, DOI 10.1016/j.cmet.2016.10.008
   Bekkering S, 2016, ATHEROSCLEROSIS, V254, P228, DOI 10.1016/j.atherosclerosis.2016.10.019
   Bekkering S, 2014, ARTERIOSCL THROM VAS, V34, P1731, DOI 10.1161/ATVBAHA.114.303887
   Bennett BJ, 2013, CELL METAB, V17, P49, DOI 10.1016/j.cmet.2012.12.011
   Boini KM, 2017, CELL PHYSIOL BIOCHEM, V44, P152, DOI 10.1159/000484623
   Bourdillon MC, 2000, ARTERIOSCL THROM VAS, V20, P2630, DOI 10.1161/01.ATV.20.12.2630
   Chan MM, 2019, NUTRIENTS, V11, DOI 10.3390/nu11081821
   Chen ML, 2017, J AM HEART ASSOC, V6, DOI 10.1161/JAHA.117.006347
   Chen SF, 2019, CELL METAB, V30, P1141, DOI 10.1016/j.cmet.2019.08.021
   Cheng JL, 2017, ADV EXP MED BIOL, V982, P359, DOI 10.1007/978-3-319-55330-6_20
   Cheng SC, 2014, SCIENCE, V345, P1579, DOI 10.1126/science.1250684
   Chou WC, 2022, CELL MOL IMMUNOL, V19, P337, DOI 10.1038/s41423-021-00780-y
   Christ A, 2018, CELL, V172, P162, DOI 10.1016/j.cell.2017.12.013
   Chung JJ, 2020, J AM SOC NEPHROL, V31, P2341, DOI 10.1681/ASN.2020020220
   Ciscato F, 2020, EMBO REP, V21, DOI 10.15252/embr.201949117
   Covarrubias AJ, 2015, SEMIN IMMUNOL, V27, P286, DOI 10.1016/j.smim.2015.08.001
   Cui HT, 2021, EUR HEART J, V42, P4373, DOI 10.1093/eurheartj/ehab605
   Dastghaib S, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9112339
   Deerhake ME, 2021, TRENDS IMMUNOL, V42, P891, DOI 10.1016/j.it.2021.08.005
   Dong F, 2022, FREE RADICAL BIO MED, V179, P288, DOI 10.1016/j.freeradbiomed.2021.11.010
   Drummer C, 2021, ARTERIOSCL THROM VAS, V41, P1032, DOI 10.1161/ATVBAHA.120.315452
   Drummer CIV, 2021, J IMMUNOL RES, V2021, DOI 10.1155/2021/3928323
   Fagenson AM, 2020, PATHOGENS, V9, DOI 10.3390/pathogens9110879
   Fagerberg L, 2014, MOL CELL PROTEOMICS, V13, P397, DOI 10.1074/mcp.M113.035600
   Fang P, 2019, ARTERIOSCL THROM VAS, V39, P2097, DOI 10.1161/ATVBAHA.119.313138
   Fang P, 2014, DIABETES, V63, P4275, DOI 10.2337/db14-0809
   Galluzzi L, 2017, FUTUR SCI OA, V3, DOI 10.4155/fsoa-2017-0020
   Gisterå A, 2017, NAT REV NEPHROL, V13, DOI 10.1038/nrneph.2017.51
   Gomez-Suaga P, 2017, CURR BIOL, V27, P371, DOI 10.1016/j.cub.2016.12.038
   Gosline SJC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019118
   Govindarajulu M, 2020, FRONT MOL NEUROSCI, V13, DOI 10.3389/fnmol.2020.00138
   Hai T, 2001, GENE, V273, P1, DOI 10.1016/S0378-1119(01)00551-0
   Hai X, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0143731
   Hénaut L, 2018, TOXINS, V10, DOI 10.3390/toxins10060218
   Hong QQ, 2022, BIOMED PHARMACOTHER, V155, DOI 10.1016/j.biopha.2022.113639
   Hu H, 2019, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.03083
   Huang SJ, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.630188
   Ieronymaki E, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01330
   Itabe H, 2017, LIPIDS HEALTH DIS, V16, DOI 10.1186/s12944-017-0473-y
   Jane-wit D, 2013, CIRCULATION, V128, P2504, DOI 10.1161/CIRCULATIONAHA.113.002972
   Janeiro MH, 2018, NUTRIENTS, V10, DOI 10.3390/nu10101398
   Jiang S, 2021, REDOX BIOL, V46, DOI 10.1016/j.redox.2021.102115
   Jonsson AL, 2017, NAT REV CARDIOL, V14, P79, DOI 10.1038/nrcardio.2016.183
   Kamo N, 2013, HEPATOLOGY, V57, P289, DOI 10.1002/hep.25958
   Kan H, 2021, EXP MOL MED, V53, P1379, DOI 10.1038/s12276-021-00671-2
   Kanitsoraphan Chanavuth, 2018, Curr Nutr Rep, V7, P207, DOI 10.1007/s13668-018-0252-z
   Kapetanaki S, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms222111864
   Kawakami T, 2010, AM J PHYSIOL-RENAL, V299, pF568, DOI 10.1152/ajprenal.00659.2009
   Keller M, 2008, CELL, V132, P818, DOI 10.1016/j.cell.2007.12.040
   Kikuchi D, 2016, BIOCHEM BIOPH RES CO, V469, P243, DOI 10.1016/j.bbrc.2015.11.113
   Kim SJ, 2022, ISCIENCE, V25, DOI 10.1016/j.isci.2022.104669
   Lai B, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02612
   Li XY, 2020, REDOX BIOL, V28, DOI 10.1016/j.redox.2019.101373
   Li XY, 2018, J BIOL CHEM, V293, P11033, DOI 10.1074/jbc.RA118.002752
   Li XY, 2018, ARTERIOSCL THROM VAS, V38, P599, DOI 10.1161/ATVBAHA.117.310626
   Li XY, 2017, CAN J PHYSIOL PHARM, V95, P247, DOI 10.1139/cjpp-2016-0515
   Li XY, 2016, ARTERIOSCL THROM VAS, V36, P1090, DOI 10.1161/ATVBAHA.115.306964
   Li XY, 2013, J HEMATOL ONCOL, V6, DOI 10.1186/1756-8722-6-19
   Li YF, 2016, FRONT BIOSCI-LANDMRK, V21, P70, DOI 10.2741/4377
   Lin JH, 2008, ANNU REV PATHOL-MECH, V3, P399, DOI 10.1146/annurev.pathmechdis.3.121806.151434
   Liu M, 2021, FRONT CARDIOVASC MED, V8, DOI 10.3389/fcvm.2021.713170
   Liu M, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.554301
   Liu Z, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.183
   Lorey MB, 2017, MOL CELL PROTEOMICS, V16, pS187, DOI 10.1074/mcp.M116.064840
   Lu YF, 2019, REDOX BIOL, V24, DOI 10.1016/j.redox.2019.101221
   Mai JT, 2016, J BIOL CHEM, V291, P4939, DOI 10.1074/jbc.M115.690081
   Mai JT, 2013, J HEMATOL ONCOL, V6, DOI 10.1186/1756-8722-6-61
   Melms JC, 2021, NATURE, V595, P114, DOI 10.1038/s41586-021-03569-1
   Monroy MA, 2015, FRONT BIOSCI-LANDMRK, V20, P784, DOI 10.2741/4337
   Murphy RM, 2013, J PHYSIOL-LONDON, V591, P719, DOI 10.1113/jphysiol.2012.243279
   Nakagawa N, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-64123-z
   Nakagawa S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0136994
   Nanayakkara GK, 2019, ARCH BIOCHEM BIOPHYS, V662, P68, DOI 10.1016/j.abb.2018.12.002
   Ni D, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.678201
   Noh S, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-67457-w
   O'Neill LAJ, 2020, NAT REV IMMUNOL, V20, P335, DOI 10.1038/s41577-020-0337-y
   O'Neill LAJ, 2016, NAT REV IMMUNOL, V16, P553, DOI 10.1038/nri.2016.70
   Onogi Y, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-019-57368-w
   Pakos-Zebrucka K, 2016, EMBO REP, V17, P1374, DOI 10.15252/embr.201642195
   Pelletier CC, 2019, TOXINS, V11, DOI 10.3390/toxins11110635
   Pirruccello JP, 2022, NAT GENET, V54, P40, DOI 10.1038/s41588-021-00962-4
   POBER JS, 1986, J IMMUNOL, V136, P1680
   Poplawski MM, 2010, ENDOCRINOLOGY, V151, P5206, DOI 10.1210/en.2010-0702
   Prag HA, 2021, CARDIOVASC RES, V117, P1188, DOI 10.1093/cvr/cvaa148
   Qi JJ, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-02779-1
   Qu LH, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.665376
   Rakocevic J, 2017, EXP MOL PATHOL, V102, P303, DOI 10.1016/j.yexmp.2017.02.005
   Rath S, 2021, NUCLEIC ACIDS RES, V49, pD1541, DOI 10.1093/nar/gkaa1011
   Roncal C, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-52082-z
   Rubic T, 2008, NAT IMMUNOL, V9, P1261, DOI 10.1038/ni.1657
   Rudnicki M, 2018, ELIFE, V7, DOI 10.7554/eLife.39780
   Safdar A, 2018, CSH PERSPECT MED, V8, DOI 10.1101/cshperspect.a029827
   Schnack L, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00013
   Schugar RC, 2017, CELL REP, V19, P2451, DOI 10.1016/j.celrep.2017.05.077
   Sen T, 2017, J NEUROSCI, V37, P5900, DOI 10.1523/JNEUROSCI.2343-16.2017
   Sha XJ, 2015, J BIOL CHEM, V290, P19307, DOI 10.1074/jbc.M115.663286
   Shao Y, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.653110
   Shao Y, 2020, ARTERIOSCL THROM VAS, V40, pE138, DOI 10.1161/ATVBAHA.120.314330
   Shao Y, 2018, ANTIOXID REDOX SIGN, V28, P973, DOI 10.1089/ars.2017.7069
   Shao Y, 2016, J CARDIOVASC TRANSL, V9, P49, DOI 10.1007/s12265-015-9664-y
   Shao Y, 2014, J HEMATOL ONCOL, V7, DOI 10.1186/s13045-014-0080-6
   Shen HT, 2019, FRONT BIOSCI-LANDMRK, V24, P96, DOI 10.2741/4710
   Shepshelovich J, 2005, J CELL SCI, V118, P1577, DOI 10.1242/jcs.02294
   Shimizu T, 2021, SCI SIGNAL, V14, DOI 10.1126/scisignal.abb3616
   Singh GB, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20143570
   Sohrabi Y, 2019, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.03155
   Sorge S, 2020, CELL REP, V31, DOI 10.1016/j.celrep.2020.107659
   Stubbs JR, 2019, CLIN J AM SOC NEPHRO, V14, P261, DOI 10.2215/CJN.06190518
   Stubbs JR, 2016, J AM SOC NEPHROL, V27, P305, DOI 10.1681/ASN.2014111063
   Sun XL, 2016, BIOCHEM BIOPH RES CO, V481, P63, DOI 10.1016/j.bbrc.2016.11.017
   Sun Y, 2020, REDOX BIOL, V37, DOI 10.1016/j.redox.2020.101696
   Sun Y, 2018, FRONT BIOSCI-LANDMRK, V23, P348, DOI 10.2741/4595
   Tan JK, 2017, ANNU REV IMMUNOL, V35, P371, DOI 10.1146/annurev-immunol-051116-052235
   Tomlinson JAP, 2017, KIDNEY INT, V92, P809, DOI 10.1016/j.kint.2017.03.053
   Torre-Villaluazo I, 2019, NUTR RES, V72, P1, DOI 10.1016/j.nutres.2019.06.006
   Tucker NR, 2020, CIRCULATION, V142, P466, DOI 10.1161/CIRCULATIONAHA.119.045401
   Virtue A, 2017, J BIOL CHEM, V292, P1267, DOI 10.1074/jbc.M116.739839
   Wang H, 2022, CELL METAB, V34, P581, DOI 10.1016/j.cmet.2022.02.010
   Wang X, 2016, J CARDIOVASC TRANSL, V9, P343, DOI 10.1007/s12265-016-9700-6
   Wang ZN, 2011, NATURE, V472, P57, DOI 10.1038/nature09922
   Wen AY, 2010, J IMMUNOL, V185, P6413, DOI 10.4049/jimmunol.1001829
   Winckelmans E, 2017, ENVIRON HEALTH-GLOB, V16, DOI 10.1186/s12940-017-0292-7
   Wong J, 2020, BMC NEPHROL, V21, DOI 10.1186/s12882-020-01779-9
   Wu P, 2020, J CELL PHYSIOL, V235, P6582, DOI 10.1002/jcp.29518
   Ximerakis M, 2019, NAT NEUROSCI, V22, P1696, DOI 10.1038/s41593-019-0491-3
   Xu KM, 2021, FRONT CARDIOVASC MED, V8, DOI 10.3389/fcvm.2021.773473
   Yang Xiao-Feng, 2008, Drug Discov Today Ther Strateg, V5, P125, DOI 10.1016/j.ddstr.2008.11.003
   Yang Y, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/352371
   Yin Y, 2015, ARTERIOSCL THROM VAS, V35, P804, DOI 10.1161/ATVBAHA.115.305282
   Yin Y, 2013, FRONT BIOSCI-LANDMRK, V18, P638, DOI 10.2741/4127
   Yuan T, 2021, THER ADV CHRONIC DIS, V12, DOI 10.1177/2040622320987057
   Zaslona Z, 2020, MOL CELL, V78, P814, DOI 10.1016/j.molcel.2020.04.002
   Zeng HH, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.00516
   Zhang DQ, 2012, CIRC RES, V111, P37, DOI [10.1161/CIRCRESAHA.112.269472, 10.1161/circresaha.112.269472]
   Zhang DQ, 2009, CIRCULATION, V120, P1893, DOI 10.1161/CIRCULATIONAHA.109.866889
   Zhang RJ, 2021, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.632239
   Zhang RJ, 2020, REDOX BIOL, V34, DOI 10.1016/j.redox.2020.101460
   Zhang XL, 2020, ARTERIOSCL THROM VAS, V40, P751, DOI 10.1161/ATVBAHA.119.313414
   Zhong C, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00284
   Zhou YY, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09234-6
   Zilionis R, 2019, IMMUNITY, V50, P1317, DOI 10.1016/j.immuni.2019.03.009
NR 146
TC 13
Z9 15
U1 6
U2 14
PU AMER SOC CLINICAL INVESTIGATION INC
PI ANN ARBOR
PA 2015 MANCHESTER RD, ANN ARBOR, MI 48104 USA
EI 2379-3708
J9 JCI INSIGHT
JI JCI Insight
PD JAN 10
PY 2023
VL 8
IS 1
AR e158183
DI 10.1172/jci.insight.158183
PG 22
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA U8IN9
UT WOS:001087184600008
PM 36394956
OA gold, Green Published
HC Y
HP N
DA 2024-02-19
ER

PT J
AU Kwong, AJ
   Devuni, D
   Wang, CN
   Boike, J
   Jo, J
   VanWagner, L
   Serper, M
   Jones, L
   Sharma, R
   Verna, EC
   Shor, J
   German, MN
   Hristov, A
   Lee, A
   Spengler, E
   Koteish, AA
   Sehmbey, G
   Seetharam, A
   John, N
   Patel, Y
   Kappus, MR
   Couri, T
   Paul, S
   Salgia, RJ
   Nhu, Q
   Frenette, CT
   Lai, JC
   Goel, A
AF Kwong, Allison J.
   Devuni, Deepika
   Wang, Connie
   Boike, Justin
   Jo, Jennifer
   VanWagner, Lisa
   Serper, Marina
   Jones, Lauren
   Sharma, Rajani
   Verna, Elizabeth C.
   Shor, Julia
   German, Margarita N.
   Hristov, Alexander
   Lee, Alexander
   Spengler, Erin
   Koteish, Ayman A.
   Sehmbey, Gurbir
   Seetharam, Anil
   John, Nimy
   Patel, Yuval
   Kappus, Matthew R.
   Couri, Thomas
   Paul, Sonali
   Salgia, Reena J.
   Nhu, Quan
   Frenette, Catherine T.
   Lai, Jennifer C.
   Goel, Aparna
CA REALT Consortium
TI Outcomes of Liver Transplantation Among Older Recipients With
   Nonalcoholic Steatohepatitis in a Large Multicenter US Cohort: the
   Re-Evaluating Age Limits in Transplantation Consortium
SO LIVER TRANSPLANTATION
LA English
DT Article; Early Access
ID HEPATOCELLULAR-CARCINOMA; CARDIOVASCULAR RISK; GRAFT FAILURE; SURVIVAL
AB The liver transplantation (LT) population is aging, with the need for transplant being driven by the growing prevalence of nonalcoholic steatohepatitis (NASH). Older LT recipients with NASH may be at an increased risk for adverse outcomes after LT. Our objective is to characterize outcomes in these recipients in a large multicenter cohort. All primary LT recipients >= 65 years from 2010 to 2016 at 13 centers in the Re-Evaluating Age Limits in Transplantation (REALT) consortium were included. Of 1023 LT recipients, 226 (22.1%) were over 70 years old, and 207 (20.2%) had NASH. Compared with other LT recipients, NASH recipients were older (68.0 versus 67.3 years), more likely to be female (47.3% versus 32.8%), White (78.3% versus 68.0%), Hispanic (12.1% versus 9.2%), and had higher Model for End-Stage Liver Disease-sodium (21 versus 18) at LT (P < 0.05 for all). Specific cardiac risk factors including diabetes with or without chronic complications (69.6%), hypertension (66.3%), hyperlipidemia (46.3%), coronary artery disease (36.7%), and moderate-to-severe renal disease (44.4%) were highly prevalent among NASH LT recipients. Graft survival among NASH patients was 90.3% at 1 year and 82.4% at 3 years compared with 88.9% at 1 year and 80.4% at 3 years for non-NASH patients (log-rankP = 0.58 andP = 0.59, respectively). Within 1 year after LT, the incidence of graft rejection (17.4%), biliary strictures (20.9%), and solid organ cancers (4.9%) were comparable. Rates of cardiovascular (CV) complications, renal failure, and infection were also similar in both groups. We observed similar posttransplant morbidity and mortality outcomes for NASH and non-NASH LT recipients. Certain CV risk factors were more prevalent in this population, although posttransplant outcomes within 1 year including CV events and renal failure were similar to non-NASH LT recipients.
C1 [Kwong, Allison J.; John, Nimy; Goel, Aparna] Stanford Univ, Dept Med, Div Gastroenterol & Hepatol, Palo Alto, CA 94304 USA.
   [Devuni, Deepika; Lai, Jennifer C.] Univ Massachusetts, Med Ctr, Worcester, MA USA.
   [Wang, Connie; Shor, Julia] Univ Calif San Francisco, Dept Med, Div Gastroenterol & Hepatol, San Francisco, CA 94143 USA.
   [Boike, Justin; Jo, Jennifer; VanWagner, Lisa] Northwestern Univ, Dept Med, Div Gastroenterol & Hepatol, Chicago, IL 60611 USA.
   [Serper, Marina; Jones, Lauren] Univ Penn, Dept Med, Div Gastroenterol & Hepatol, Philadelphia, PA 19104 USA.
   [Sharma, Rajani; Verna, Elizabeth C.] Columbia Univ, Med Ctr, Ctr Liver Dis & Transplantat, New York, NY USA.
   [German, Margarita N.; Hristov, Alexander; Lee, Alexander; Spengler, Erin] Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, Div Gastroenterol & Hepatol, Madison, WI USA.
   [Koteish, Ayman A.] Johns Hopkins Univ Hosp, Dept Med, Baltimore, MD 21287 USA.
   [Sehmbey, Gurbir; Seetharam, Anil] Banner Univ, Med Ctr, Transplant Hepatol, Phoenix, AZ USA.
   [Patel, Yuval; Kappus, Matthew R.] Duke Univ, Sch Med, Dept Med, Div Gastroenterol, Durham, NC 27706 USA.
   [Couri, Thomas; Paul, Sonali] Univ Chicago, Ctr Liver Dis, Chicago, IL 60637 USA.
   [Salgia, Reena J.] Henry Ford, Dept Med, Div Gastroenterol, Detroit, MI USA.
   [Nhu, Quan; Frenette, Catherine T.] Scripps Clin, San Diego, CA USA.
C3 Stanford University; University of Massachusetts System; University of
   Massachusetts Worcester; University of California System; University of
   California San Francisco; Northwestern University; University of
   Pennsylvania; Columbia University; University of Wisconsin System;
   University of Wisconsin Madison; Johns Hopkins University; Johns Hopkins
   Medicine; Duke University; University of Chicago; Henry Ford Health
   System; Henry Ford Hospital; Scripps Research Institute
RP Goel, A (corresponding author), Stanford Univ, Dept Med, Div Gastroenterol & Hepatol, 430 Broadway St,3rd Floor, Redwood City, CA 94063 USA.
EM goela21@stanford.edu
RI Boike, Justin/AAF-8174-2020; VanWagner, Lisa B/AFO-4489-2022; Lee,
   Alexander/JQJ-3667-2023
OI Boike, Justin/0000-0001-9364-8807; VanWagner, Lisa
   B/0000-0002-6264-2573; John, Nimy/0000-0002-5437-8864; Serper,
   Marina/0000-0003-4899-2160; Kwong, Allison/0000-0002-3874-6612;
   Frenette, Catherine/0000-0002-2245-8173
FU National Institute of Allergy and Infectious Diseases [R25AI147369];
   National Heart, Lung and Blood Institute [K23 HL136891]; National
   Institute of Diabetes and Digestive and Kidney Diseases [R01AG059183];
   Target PharmaSolutions; Intercept Pharmaceuticals; GENFIT
FX Allison J. Kwong is supported by National Institute of Allergy and
   Infectious Diseases grant R25AI147369. Lisa VanWagner is supported by
   National Heart, Lung and Blood Institute grant K23 HL136891. Jennifer C.
   Lai is supported by National Institute of Diabetes and Digestive and
   Kidney Diseases grant R01AG059183.; Lisa VanWagner consults for Gilead
   Sciences; and is on the speakers' bureau, has grants from, and consults
   for W. L. Gore & Associates. Yuval Patel consults for Intercept
   Pharmaceuticals. Sonali Paul has grants from Target PharmaSolutions,
   Intercept Pharmaceuticals, and GENFIT. Jennifer C. Lai consults for
   Axcella Health, Ambys Medicines, and BioMarin Pharmaceuticals.
CR Afzali A, 2012, LIVER TRANSPLANT, V18, P29, DOI 10.1002/lt.22435
   CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8
   Charlton MR, 2011, GASTROENTEROLOGY, V141, P1249, DOI 10.1053/j.gastro.2011.06.061
   Cholankeril G, 2017, DIGEST DIS SCI, V62, P2915, DOI 10.1007/s10620-017-4684-x
   Duffy JP, 2009, J AM COLL SURGEONS, V208, P896, DOI 10.1016/j.jamcollsurg.2008.12.032
   Feng S, 2006, AM J TRANSPLANT, V6, P783, DOI 10.1111/j.1600-6143.2006.01242.x
   Goff DC, 2014, J AM COLL CARDIOL, V63, P2935, DOI [10.1161/01.cir.0000437741.48606.98, 10.1016/j.jacc.2013.11.005]
   Haldar D, 2019, J HEPATOL, V71, P313, DOI 10.1016/j.jhep.2019.04.011
   Houlihan DD, 2011, LIVER TRANSPLANT, V17, P1292, DOI 10.1002/lt.22382
   Kwong A, 2020, AM J TRANSPLANT, V20, DOI 10.1111/ajt.15674
   Levey AS, 1999, ANN INTERN MED, V130, P461, DOI 10.7326/0003-4819-130-6-199903160-00002
   Levitsky J, 2017, CLIN GASTROENTEROL H, V15, P584, DOI 10.1016/j.cgh.2016.07.035
   Mehta N, 2017, JAMA ONCOL, V3, P493, DOI 10.1001/jamaoncol.2016.5116
   Molnar MZ, 2019, LIVER TRANSPLANT, V25, P399, DOI 10.1002/lt.25367
   Nagai S, 2019, CLIN GASTROENTEROL H, V17, P2759, DOI 10.1016/j.cgh.2019.04.033
   Piano S, 2019, LIVER TRANSPLANT, V25, P362, DOI 10.1002/lt.25413
   Scientific Registry of Transplant Recipients, PROGR SPEC REP
   Su F, 2016, GASTROENTEROLOGY, V150, P441, DOI 10.1053/j.gastro.2015.10.043
   Targher G, 2016, J HEPATOL, V65, P589, DOI 10.1016/j.jhep.2016.05.013
   VanWagner LB, 2017, HEPATOLOGY, V66, P1968, DOI 10.1002/hep.29329
   VanWagner LB, 2015, LIVER INT, V35, P2575, DOI 10.1111/liv.12872
   VanWagner LB, 2012, HEPATOLOGY, V56, P1741, DOI 10.1002/hep.25855
   Wang XF, 2014, CLIN GASTROENTEROL H, V12, P394, DOI 10.1016/j.cgh.2013.09.023
   Wong RJ, 2014, HEPATOLOGY, V59, P2188, DOI 10.1002/hep.26986
NR 24
TC 14
Z9 14
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1527-6465
EI 1527-6473
J9 LIVER TRANSPLANT
JI Liver Transplant.
PD 2020 NOV
PY 2020
VL 26
IS 11
BP 1492
EP 1503
DI 10.1002/lt.25863
EA OCT 2020
PG 12
WC Gastroenterology & Hepatology; Surgery; Transplantation
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Gastroenterology & Hepatology; Surgery; Transplantation
GA OG2FF
UT WOS:000578716100001
PM 33047893
OA Green Submitted, Green Accepted
DA 2024-02-19
ER

PT J
AU Ravindran, R
   Jaganathan, R
   Periandavan, K
AF Ravindran, Rajeswari
   Jaganathan, Ravindran
   Periandavan, Kalaiselvi
TI EGCG exerts its protective effect by mitigating the release of lysosomal
   enzymes in aged rat liver on exposure to high cholesterol diet
SO CELL BIOCHEMISTRY AND FUNCTION
LA English
DT Article; Early Access
DE aging; EGCG; lysosomal membrane permeabilization; lysosomes; reactive
   oxygen species
ID GREEN TEA; EPIGALLOCATECHIN-GALLATE; CATHEPSIN-D; CELL-DEATH;
   ANTIOXIDANT; EXPRESSION; HYPERCHOLESTEROLEMIA; METABOLISM; ACTIVATION;
   APOPTOSIS
AB The aim is to test the hypothesis whether the cholesterol loaded lysosomes are capable of mediating lysosomal membrane permeabilization (LMP) during aging and to study the efficacy of epigallocatechin-3-gallate (EGCG) in preserving the lysosomal membrane stability. Aged rats were fed with high cholesterol diet (HCD) and treated with EGCG orally. Serum and tissue lipid status, cholesterol levels in lysosomal fraction, activities of lysosomal enzymes in lysosomal, and cytosolic fractions were measured. Transmission electron microscopic studies (TEM), oil red "O" (ORO) staining, and immunohistochemical analysis of oxidized low density lipoprotein (OxLDL) were carried out. Significant increase in serum, tissue lipid profile, and lysosomal cholesterol levels were observed in aged HCD-fed rats with a concomitant decrease in high density lipoprotein (HDL) levels. We also observed a significant increase in lipid accumulation in hepatocytes of aged HCD-fed rats by TEM, ORO, and immunohistochemical staining. Upon treatment with EGCG to aged HCD-fed animals, we found augmented levels of HDL with a concomitant decrease in lysosomal cholesterol levels and other lipoproteins. TEM studies and immunohistochemistry of OxLDL also showed a marked reduction in lipid deposition of hepatocytes. Thus, EGCG has preserved the lysosomal membrane stability in HCD stressed aged rats. Significance of the study The research article is focused mainly on the effect of EGCG and its capability on mitigating the release of lysosomal enzymes in aged animals fed with HCD. The study signifies the cellular function of the organelle lysosome following administration of aged rats with HCD, which would make the readers to understand the action of EGCG and the interrelationship of both cholesterol and activity of lysosomes when cholesterol is loaded.
C1 [Ravindran, Rajeswari; Periandavan, Kalaiselvi] Univ Madras, DR ALM PG IBMS, Dept Med Biochem, Chennai 600113, Tamil Nadu, India.
   [Jaganathan, Ravindran] Univ Kuala Lumpur, Royal Coll Med Perak, Fac Med, Preclin Dept, Ipoh, Malaysia.
C3 University of Madras; University of Kuala Lumpur
RP Periandavan, K (corresponding author), Univ Madras, DR ALM PG IBMS, Dept Med Biochem, Chennai 600113, Tamil Nadu, India.
EM pkalaiselvi2011@gmail.com
RI JAGANATHAN, RAVINDRAN/B-4312-2012
OI JAGANATHAN, RAVINDRAN/0000-0002-2654-1855; Ravindran,
   Rajeswari/0000-0001-7844-5243
FU DST-INSPIRE fellowship [DST/INSPIRE Fellowship/2011/264A]; UGC-SAP;
   DST-INSPIRE SRF
FX DST-INSPIRE fellowship, Grant/Award Number: DST/INSPIRE
   Fellowship/2011/264A; UGC-SAP; DST-INSPIRE SRF
CR Ahmad RS, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0436-x
   [Anonymous], 2009, 2008-2013 action plan for the global strategy for the prevention and control of noncommunicable diseases: prevent and control cardiovascular diseases, cancers, chronic respiratory diseases and diabetes
   Appelqvist H, 2012, ANN CLIN LAB SCI, V42, P231
   ARAI K, 1991, J BIOCHEM, V110, P541, DOI 10.1093/oxfordjournals.jbchem.a123616
   BASS DA, 1981, LAB INVEST, V44, P403
   BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311
   Choi AMK, 2013, NEW ENGL J MED, V368, P1845, DOI 10.1056/NEJMc1303158
   Devika PT, 2008, CHEM-BIOL INTERACT, V172, P245, DOI 10.1016/j.cbi.2008.01.003
   Dubland JA, 2015, FRONT CELL DEV BIOL, V3, DOI 10.3389/fcell.2015.00003
   Duncan AK, 1996, MAYO CLIN PROC, V71, P184, DOI 10.4065/71.2.184
   Egert S, 2011, ADV NUTR, V2, P8, DOI [10.3945/an.110.000026., 10.3945/an.110.000026]
   Emert-Sedlak L, 2005, MOL CANCER THER, V4, P733, DOI 10.1158/1535-7163.MCT-04-0301
   Field PA, 2000, METABOLISM, V49, P492, DOI 10.1016/S0026-0495(00)80014-1
   FOLCH J, 1957, J BIOL CHEM, V226, P497
   FOLKOW B, 1993, PHYSIOL REV, V73, P725, DOI 10.1152/physrev.1993.73.4.725
   Franceschi C, 2000, ANN NY ACAD SCI, V908, P244
   Gan L, 2011, CURR GERONTOL GERIAT, V31536
   Ganesan B, 2009, CELL STRESS CHAPERON, V14, P661, DOI 10.1007/s12192-009-0111-3
   Ghosh PM, 2012, J ENDOCRINOL, V213, P251, DOI 10.1530/JOE-11-0406
   Gomori G., 1952, MICROSCOPIC HISTOCHE
   Goto T, 2012, BRIT J NUTR, V107, P769, DOI 10.1017/S0007114511003758
   Green CJ, 2014, NUTRIENTS, V6, P5018, DOI 10.3390/nu6115018
   Gyrd-Hansen M, 2006, MOL CELL BIOL, V26, P7880, DOI 10.1128/MCB.00716-06
   Harman D, 2003, ANTIOXID REDOX SIGN, V5, P557, DOI 10.1089/152308603770310202
   Hendrikx T, 2014, OBES REV, V15, P424, DOI 10.1111/obr.12159
   HRON WT, 1981, J LIPID RES, V22, P377
   Jeong YJ, 2005, BRIT J NUTR, V93, P581, DOI 10.1079/BJN20041397
   Johansson AC, 2010, APOPTOSIS, V15, P527, DOI 10.1007/s10495-009-0452-5
   Kågedal K, 2005, INT J EXP PATHOL, V86, P309, DOI 10.1111/j.0959-9673.2005.00442.x
   Kainuma M, 2006, J GASTROENTEROL, V41, P971, DOI 10.1007/s00535-006-1883-1
   Kanwar Jyoti, 2012, Front Biosci (Elite Ed), V4, P111
   KAWAI Y, 1971, BIOCHIM BIOPHYS ACTA, V242, P428, DOI 10.1016/0005-2744(71)90234-8
   Khan N, 2015, ARCH MED SCI, V11, P1261, DOI 10.5114/aoms.2015.56353
   Khundakar A, 2011, INT PSYCHOGERIATR, V23, P644, DOI 10.1017/S1041610210001444
   King J., 1965, Practical Clinical Enzymology, P191
   Koo SI, 2007, J NUTR BIOCHEM, V18, P179, DOI 10.1016/j.jnutbio.2006.12.005
   Krishnan TR, 2014, FOOD FUNCT, V5, P916, DOI 10.1039/c3fo60345h
   Kuhn DJ, 2004, BBA-MOL CELL BIOL L, V1682, P1, DOI 10.1016/j.bbalip.2003.12.006
   Kumaran VS, 2008, EXP GERONTOL, V43, P176, DOI 10.1016/j.exger.2007.10.017
   Kumaran VS, 2009, EXP GERONTOL, V44, P745, DOI 10.1016/j.exger.2009.08.010
   Kurz T, 2011, INT J BIOCHEM CELL B, V43, P1686, DOI 10.1016/j.biocel.2011.08.016
   LEFFLER HH, 1963, AM J CLIN PATHOL, V39, P311, DOI 10.1093/ajcp/39.3_ts.311
   Liu L, 2015, BIOMED RES INT, V607531
   Luzio JP, 2007, NAT REV MOL CELL BIO, V8, P622, DOI 10.1038/nrm2217
   MARUHN D, 1976, CLIN CHIM ACTA, V73, P453, DOI 10.1016/0009-8981(76)90147-9
   Meydani M, 2010, NUTRIENTS, V2, P737, DOI 10.3390/nu2070737
   Montilla P, 2006, CLIN NUTR, V25, P146, DOI 10.1016/j.clnu.2005.10.004
   Naumovski N, 2015, ANTIOXIDANTS-BASEL, V4, P373, DOI 10.3390/antiox4020373
   Oshaghi EA, 2015, CHOLESTEROL, DOI 10.1155/2015/958560
   Ostenfeld MS, 2005, CANCER RES, V65, P8975, DOI 10.1158/0008-5472.CAN-05-0269
   PAREKH AC, 1970, ANAL CHEM, V42, P1423, DOI 10.1021/ac60294a044
   Premoli A, 2009, Minerva Gastroenterol Dietol, V55, P71
   Raben N, 2009, METHOD ENZYMOL, V453, P417, DOI 10.1016/S0076-6879(08)04021-4
   Rice E.W., 1970, STANDARD METHODS CLI, P215
   SAPOLSKY AI, 1973, FED PROC, V32, P1489
   Schmitz G, 2009, BBA-MOL CELL BIOL L, V1791, P524, DOI 10.1016/j.bbalip.2008.12.007
   Schmucker DL, 1998, J GERONTOL A-BIOL, V53, pB315, DOI 10.1093/gerona/53A.5.B315
   Sinija V. R., 2008, Journal of Nutritional & Environmental Medicine (Abingdon), V17, P232, DOI 10.1080/13590840802518785
   Slawik M, 2006, AGEING RES REV, V5, P144, DOI 10.1016/j.arr.2006.03.004
   Terman A, 2006, IUBMB LIFE, V58, P531, DOI 10.1080/15216540600904885
   Terman A, 2004, INT J BIOCHEM CELL B, V36, P1400, DOI 10.1016/j.biocel.2003.08.009
   Turk B, 2007, FEBS LETT, V581, P2761, DOI 10.1016/j.febslet.2007.05.038
   Uranga RM, 2010, CURR GERONTOL GERIAT, V219683
   Walenbergh SMA, 2013, J HEPATOL, V58, P801, DOI 10.1016/j.jhep.2012.11.014
   Werneburg NW, 2002, AM J PHYSIOL-GASTR L, V283, pG947, DOI 10.1152/ajpgi.00151.2002
   Wilhelmsen L, 1999, J INTERN MED, V242, P199
   Xie YH, 2015, BRAZ J MICROBIOL, V46, P389, DOI 10.1590/S1517-838246220131278
   Xu XL, 2014, HEART LUNG CIRC, V23, P1194, DOI 10.1016/j.hlc.2014.05.013
   Yan CH, 2006, TOXICON, V47, P521, DOI 10.1016/j.toxicon.2006.01.010
   Yin JG, 2016, INT J MOL MED, V37, P398, DOI 10.3892/ijmm.2015.2422
   Zhong W, 2015, EXP THER MED, V9, P405, DOI 10.3892/etm.2014.2135
   Zhou JY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092828
NR 72
TC 1
Z9 1
U1 1
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0263-6484
EI 1099-0844
J9 CELL BIOCHEM FUNCT
JI Cell Biochem. Funct.
PD 2020 APR
PY 2020
VL 38
IS 3
BP 309
EP 318
DI 10.1002/cbf.3490
EA JAN 2020
PG 10
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA LJ3SQ
UT WOS:000506552700001
PM 31926118
DA 2024-02-19
ER

PT J
AU Kaneko, T
   Tahara, S
   Tanno, M
   Taguchi, T
AF Kaneko, T
   Tahara, S
   Tanno, M
   Taguchi, T
TI Age-related changes in the induction of DNA polymerases in rat liver by
   γ-ray irradiation
SO MECHANISMS OF AGEING AND DEVELOPMENT
LA English
DT Article
DE aging; DNA repair; oxidative damage; 8-oxo-2 '-deoxyguanosine; DNA
   polymerase; PCNA
ID NUCLEAR ANTIGEN PCNA; OXIDATIVE DAMAGE; MITOCHONDRIAL-DNA;
   HUMAN-FIBROBLASTS; EXCISION-REPAIR; BETA; FIDELITY; GENE; BASE;
   8-HYDROXY-2'-DEOXYGUANOSINE
AB DNA polymerase activities related to DNA repair were examined in the livers of young (6-month-old) and aged (27-month-old) rats irradiated with gamma-rays. The activity of DNA polymerase a was little changed in the livers Of gamma-ray irradiated rats, while DNA polymerases beta and gamma were induced in the livers of young and aged rats exposed by gamma-ray irradiation. These enzymes were induced from 2 to 6 It after irradiation of young and aged rats, respectively, although the induction in aged rats was weak. DNA polyinerase beta activity in the livers of young rats irradiated with gamma-rays was 2-fold that in aged rats. Similarly, DNA polymerase gamma activity in the livers of young rats subjected to gamma-ray irradiation was 3-fold that in aged rats. The, induction of proliferating cell nuclear antigen (PCNA) in the livers of aged rats irradiated with gamma-rays was also delayed compared with young rats. These results indicate that the decline in repair activity in aged rats leads to the accumulation of oxidative damage and DNA mutations in aged tissues. (C) 2002 Elsevier Science Ireland Ltd. All rights reserved.
C1 Tokyo Metropolitan Inst Gerontol, Redox Regulat Res Grp, Itabashi Ku, Tokyo 1730015, Japan.
   Tokyo Metropolitan Geriatr Hosp, Dept Nucl Med & Radiol Sci, Tokyo 1730015, Japan.
   Tokyo Metropolitan Inst Gerontol, Dept Gene Regulat & Prot Funct, Itabashi Ku, Tokyo 1730015, Japan.
C3 Tokyo Metropolitan Institute of Gerontology; Tokyo Metropolitan
   Institute of Gerontology; Tokyo Metropolitan Institute of Gerontology
RP Kaneko, T (corresponding author), Tokyo Metropolitan Inst Gerontol, Redox Regulat Res Grp, Itabashi Ku, 35-2 Sakaecho, Tokyo 1730015, Japan.
CR [Anonymous], 1993, DNA FREE RADICALS
   ARUOMA OI, 1989, J BIOL CHEM, V264, P13024
   ASANO K, 1992, MECH AGEING DEV, V62, P85
   BRAVO R, 1985, EMBO J, V4, P655, DOI 10.1002/j.1460-2075.1985.tb03679.x
   FEIG DI, 1993, BIOCHEMISTRY-US, V32, P4466, DOI 10.1021/bi00067a040
   FRAGA CG, 1990, P NATL ACAD SCI USA, V87, P4533, DOI 10.1073/pnas.87.12.4533
   HUSSAIN SP, 1994, ONCOGENE, V9, P2277
   Kaneko T, 1996, MUTAT RES-DNAGING G, V316, P277, DOI 10.1016/S0921-8734(96)90010-7
   Kaneko T, 2003, ARCH GERONTOL GERIAT, V36, P23, DOI 10.1016/S0167-4943(02)00056-0
   Kaneko T, 2000, LIPIDS, V35, P961, DOI 10.1007/s11745-000-0606-y
   KATSURA H, 1992, AM J RESP CELL MOL, V6, P190, DOI 10.1165/ajrcmb/6.2.190
   KRAUSS SW, 1982, BIOCHEMISTRY-US, V21, P1002, DOI 10.1021/bi00534a027
   KUCHINO Y, 1987, NATURE, V327, P77, DOI 10.1038/327077a0
   MACDONALD-BRAVO H, 1985, Experimental Cell Research, V156, P455, DOI 10.1016/0014-4827(85)90552-X
   MIURA M, 1992, EXP CELL RES, V201, P541, DOI 10.1016/0014-4827(92)90308-U
   Nealon K, 1996, NUCLEIC ACIDS RES, V24, P3763, DOI 10.1093/nar/24.19.3763
   NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063
   PINZ KG, 1995, J BIOL CHEM, V270, P9202, DOI 10.1074/jbc.270.16.9202
   QUINTANILLA M, 1986, NATURE, V322, P78, DOI 10.1038/322078a0
   Savio M, 1998, CARCINOGENESIS, V19, P591, DOI 10.1093/carcin/19.4.591
   Shen HM, 1996, MUTAT RES-REV GENET, V366, P23, DOI 10.1016/S0165-1110(96)90005-6
   SINGHAL RK, 1993, J BIOL CHEM, V268, P15906
   SRIVASTAVA V, 1992, EXP GERONTOL, V27, P593, DOI 10.1016/0531-5565(92)90014-Q
   SZILARD L, 1959, P NATL ACAD SCI USA, V45, P30, DOI 10.1073/pnas.45.1.30
   Taguchi T, 1998, MECH AGEING DEV, V105, P75, DOI 10.1016/S0047-6374(98)00083-9
   Taguchi T, 1997, MECH AGEING DEV, V99, P33, DOI 10.1016/S0047-6374(97)00092-4
   TANHAUSER SM, 1995, J BIOL CHEM, V270, P24769, DOI 10.1074/jbc.270.42.24769
   Tanno M, 1996, MECH AGEING DEV, V92, P53, DOI 10.1016/S0047-6374(96)01802-7
NR 28
TC 12
Z9 14
U1 0
U2 1
PU ELSEVIER SCI IRELAND LTD
PI CLARE
PA CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE,
   IRELAND
SN 0047-6374
J9 MECH AGEING DEV
JI Mech. Ageing Dev.
PD SEP
PY 2002
VL 123
IS 11
BP 1521
EP 1528
AR PII S0047-6374(02)00119-7
DI 10.1016/S0047-6374(02)00119-7
PG 8
WC Cell Biology; Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Geriatrics & Gerontology
GA 618JN
UT WOS:000179415100010
PM 12425958
DA 2024-02-19
ER

PT J
AU Rodriguez, KA
   Edrey, YH
   Osmulski, P
   Gaczynska, M
   Buffenstein, R
AF Rodriguez, Karl A.
   Edrey, Yael H.
   Osmulski, Pawel
   Gaczynska, Maria
   Buffenstein, Rochelle
TI Altered Composition of Liver Proteasome Assemblies Contributes to
   Enhanced Proteasome Activity in the Exceptionally Long-Lived Naked
   Mole-Rat
SO PLOS ONE
LA English
DT Article
ID SISTER-CHROMATID SEPARATION; NF-KAPPA-B; OXIDATIVE-STRESS; 20S
   PROTEASOME; LIVING RODENT; PROTEIN-DEGRADATION; IMMUNOPROTEASOME;
   LONGEVITY; MECHANISMS; RESISTANCE
AB The longest-lived rodent, the naked mole-rat (Bathyergidae; Heterocephalus glaber), maintains robust health for at least 75% of its 32 year lifespan, suggesting that the decline in genomic integrity or protein homeostasis routinely observed during aging, is either attenuated or delayed in this extraordinarily long-lived species. The ubiquitin proteasome system (UPS) plays an integral role in protein homeostasis by degrading oxidatively-damaged and misfolded proteins. In this study, we examined proteasome activity in naked mole-rats and mice in whole liver lysates as well as three subcellular fractions to probe the mechanisms behind the apparently enhanced effectiveness of UPS. We found that when compared with mouse samples, naked mole-rats had significantly higher chymotrypsin-like (ChT-L) activity and a two-fold increase in trypsin-like (T-L) in both whole lysates as well as cytosolic fractions. Native gel electrophoresis of the whole tissue lysates showed that the 20S proteasome was more active in the longer-lived species and that 26S proteasome was both more active and more populous. Western blot analyses revealed that both 19S subunits and immunoproteasome catalytic subunits are present in greater amounts in the naked mole-rat suggesting that the observed higher specific activity may be due to the greater proportion of immunoproteasomes in livers of healthy young adults. It thus appears that proteasomes in this species are primed for the efficient removal of stress-damaged proteins. Further characterization of the naked mole-rat proteasome and its regulation could lead to important insights on how the cells in these animals handle increased stress and protein damage to maintain a longer health in their tissues and ultimately a longer life.
C1 [Rodriguez, Karl A.; Edrey, Yael H.; Osmulski, Pawel; Gaczynska, Maria; Buffenstein, Rochelle] Univ Texas San Antonio, Hlth Sci Ctr, Sam & Ann Barshop Inst Aging & Longev Studies, San Antonio, TX USA.
   [Rodriguez, Karl A.; Edrey, Yael H.; Buffenstein, Rochelle] Univ Texas San Antonio, Hlth Sci Ctr, Dept Physiol, San Antonio, TX 78284 USA.
   [Osmulski, Pawel; Gaczynska, Maria] Univ Texas San Antonio, Hlth Sci Ctr, Dept Mol Med, San Antonio, TX USA.
   [Buffenstein, Rochelle] Univ Texas San Antonio, Hlth Sci Ctr, Dept Cellular & Struct Biol, San Antonio, TX 78284 USA.
C3 University of Texas System; University of Texas Health Science Center at
   San Antonio; University of Texas System; University of Texas Health
   Science Center at San Antonio; University of Texas System; University of
   Texas Health Science Center at San Antonio; University of Texas System;
   University of Texas Health Science Center at San Antonio
RP Rodriguez, KA (corresponding author), Univ Texas San Antonio, Hlth Sci Ctr, Sam & Ann Barshop Inst Aging & Longev Studies, San Antonio, TX USA.
EM Buffenstein@uthscsa.edu
RI Osmulski, Pawel/C-7751-2019; Rodriguez, Karl A/F-2689-2012
OI Osmulski, Pawel/0000-0002-5359-9200; 
FU Institutional Postdoctoral Fellow Training Grant [T32 AG021890-08];
   Ellison Medical Foundation [AGSS-178006]; Glenn Foundation for Medical
   Research
FX T32 AG021890-08 (NIA) Institutional Postdoctoral Fellow Training Grant
   (KR), AGSS-178006 (RB is PI) Ellison Medical Foundation (Genomic
   Stability in the Naked Mole-Rat: A Role for Cancer Resistance and
   Extended Longevity) (http://www.ellisonfoundation.org/), and Glenn
   Foundation for Medical Research (RB is PI). (Comparative biological
   mechanisms of aging, insights from the longest lived rodent, the naked
   mole-rat) (http://glennfoundation.org/). The funders had no role in
   study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR AKI M, 1994, J BIOCHEM, V115, P257, DOI 10.1093/oxfordjournals.jbchem.a124327
   Andziak B, 2006, AGING CELL, V5, P463, DOI 10.1111/j.1474-9726.2006.00237.x
   Arendt CS, 1997, P NATL ACAD SCI USA, V94, P7156, DOI 10.1073/pnas.94.14.7156
   Bajorek M, 2004, CELL MOL LIFE SCI, V61, P1579, DOI 10.1007/s00018-004-4131-y
   Baugh JM, 2009, J MOL BIOL, V386, P814, DOI 10.1016/j.jmb.2008.12.081
   Brooks CL, 2003, CURR OPIN CELL BIOL, V15, P164, DOI 10.1016/S0955-0674(03)00003-6
   Buffenstein R, 2005, J GERONTOL A-BIOL, V60, P1369, DOI 10.1093/gerona/60.11.1369
   Buffenstein R, 2008, J COMP PHYSIOL B, V178, P439, DOI 10.1007/s00360-007-0237-5
   Cusimano A, 2010, CELL CYCLE, V9, P1399, DOI 10.4161/cc.9.7.11254
   Dahlmann B, 2000, J MOL BIOL, V303, P643, DOI 10.1006/jmbi.2000.4185
   Dasuri K, 2009, FREE RADICAL RES, V43, P28, DOI 10.1080/10715760802534812
   Dasuri K, 2010, FREE RADICAL BIO MED, V49, P1290, DOI 10.1016/j.freeradbiomed.2010.07.014
   de Magalhaes JP, 2007, J GERONTOL A-BIOL, V62, P149
   Edrey YH, 2011, ILAR J, V52, P41, DOI 10.1093/ilar.52.1.41
   Elsasser S, 2005, METHOD ENZYMOL, V398, P353, DOI 10.1016/S0076-6879(05)98029-4
   Enenkel C, 1998, EMBO J, V17, P6144, DOI 10.1093/emboj/17.21.6144
   Ferrington DA, 2008, J NEUROCHEM, V106, P158, DOI 10.1111/j.1471-4159.2008.05345.x
   Funabiki H, 1996, NATURE, V381, P438, DOI 10.1038/381438a0
   Gaczynska M, 2005, METHOD ENZYMOL, V398, P425, DOI 10.1016/S0076-6879(05)98035-X
   Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001
   Groll M, 2000, NAT STRUCT BIOL, V7, P1062, DOI 10.1038/80992
   Grune T, 2004, INT J BIOCHEM CELL B, V36, P2519, DOI 10.1016/j.biocel.2004.04.020
   Hanna J, 2007, FEBS LETT, V581, P2854, DOI 10.1016/j.febslet.2007.03.053
   HENDIL KB, 1993, ENZYME PROTEIN, V47, P232, DOI 10.1159/000468682
   Hoffmann A, 2002, SCIENCE, V298, P1241, DOI 10.1126/science.1071914
   Hussong SA, 2010, J NEUROCHEM, V113, P1481, DOI 10.1111/j.1471-4159.2010.06688.x
   Ikeno Y, 2005, J GERONTOL A-BIOL, V60, P1510, DOI 10.1093/gerona/60.12.1510
   Jung T, 2008, IUBMB LIFE, V60, P743, DOI 10.1002/iub.114
   Kaeberlein M, 2011, AGING CELL, V10, P185, DOI 10.1111/j.1474-9726.2010.00665.x
   Kapahi P, 1999, FREE RADICAL BIO MED, V26, P495, DOI 10.1016/S0891-5849(98)00323-2
   Kaspar JW, 2009, FREE RADICAL BIO MED, V47, P1304, DOI 10.1016/j.freeradbiomed.2009.07.035
   Kim EB, 2011, NATURE, V479, P223, DOI 10.1038/nature10533
   Kim HM, 2011, BBA-GENE REGUL MECH, V1809, P67, DOI 10.1016/j.bbagrm.2010.08.008
   Kloetzel PM, 2001, NAT REV MOL CELL BIO, V2, P179, DOI 10.1038/35056572
   Kruegel U, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002253
   Krüger E, 2004, REV PHYSIOL BIOCH P, V148, P81, DOI 10.1007/s10254-003-0010-4
   Kwak MK, 2003, MOL CELL BIOL, V23, P8786, DOI 10.1128/MCB.23.23.8786-8794.2003
   Lam YA, 2002, NATURE, V416, P763, DOI 10.1038/416763a
   Lander GC, 2012, NATURE, V482, P186, DOI 10.1038/nature10774
   Lattanzi L, 2011, IMMUNOBIOLOGY, V216, P537, DOI 10.1016/j.imbio.2010.10.003
   Lewis KN, 2010, INTEGR COMP BIOL, V50, P829, DOI 10.1093/icb/icq034
   Li J, 2011, FASEB J, V25, P883, DOI 10.1096/fj.10-160895
   Li NX, 1999, FASEB J, V13, P1137, DOI 10.1096/fasebj.13.10.1137
   Liang ST, 2010, AGING CELL, V9, P626, DOI 10.1111/j.1474-9726.2010.00588.x
   Liu CW, 2006, MOL CELL, V24, P39, DOI 10.1016/j.molcel.2006.08.025
   McColl G, 2010, CELL METAB, V12, P260, DOI 10.1016/j.cmet.2010.08.004
   Noda C, 2000, BIOCHEM BIOPH RES CO, V277, P348, DOI 10.1006/bbrc.2000.3676
   PACIFICI RE, 1993, J BIOL CHEM, V268, P15405
   Pérez VI, 2009, P NATL ACAD SCI USA, V106, P3059, DOI 10.1073/pnas.0809620106
   Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503
   Pickering AM, 2010, BIOCHEM J, V432, P585, DOI 10.1042/BJ20100878
   Rechsteiner M, 2005, TRENDS CELL BIOL, V15, P27, DOI 10.1016/j.tcb.2004.11.003
   Rock KL, 2002, ADV IMMUNOL, V80, P1, DOI 10.1016/S0065-2776(02)80012-8
   Rodgers KJ, 2003, INT J BIOCHEM CELL B, V35, P716, DOI 10.1016/S1357-2725(02)00391-6
   Rodriguez KA, 2010, MECH AGEING DEV, V131, P144, DOI 10.1016/j.mad.2010.01.002
   Seifert U, 2010, CELL, V142, P613, DOI 10.1016/j.cell.2010.07.036
   Tai HC, 2010, FRONT MOL NEUROSCI, V3, DOI 10.3389/fnmol.2010.00012
   Unno M, 2002, STRUCTURE, V10, P609, DOI 10.1016/S0969-2126(02)00748-7
   Vasuri F, 2010, BIOCHEM BIOPH RES CO, V397, P301, DOI 10.1016/j.bbrc.2010.05.104
   Vernace VA, 2007, FASEB J, V21, P2672, DOI 10.1096/fj.06-6751com
   Wang JL, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001048
   Wójcik C, 2003, INT J BIOCHEM CELL B, V35, P579, DOI 10.1016/S1357-2725(02)00380-1
   Yanagida M, 2000, GENES CELLS, V5, P1, DOI 10.1046/j.1365-2443.2000.00306.x
   Yu CF, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026729
   Zwickl P, 2002, ADV PROTEIN CHEM, V59, P187
NR 65
TC 80
Z9 97
U1 0
U2 18
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 2
PY 2012
VL 7
IS 5
AR e35890
DI 10.1371/journal.pone.0035890
PG 11
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 959US
UT WOS:000305341500034
PM 22567116
OA Green Published, Green Submitted, gold
DA 2024-02-19
ER

PT J
AU Mustafa, A
   Bai, SP
   Zeng, QF
   Ding, XM
   Wang, JP
   Xuan, Y
   Su, ZW
   Zhang, KY
AF Mustafa, Ahsan
   Bai, Shiping
   Zeng, Qiufeng
   Ding, Xuemei
   Wang, Jianping
   Xuan, Yue
   Su, Zhuowei
   Zhang, Keying
TI Limitation and Potential Effects of Different Levels of Aging Corn on
   Performance, Antioxidative Capacity, Intestinal Health, and Microbiota
   in Broiler Chickens
SO ANIMALS
LA English
DT Article
DE aging corn; oxidative stress; broiler performance; intestinal health;
   microbiota
ID GROWTH-PERFORMANCE; DIETARY FIBER; OXIDIZED OIL; RICE GRAINS; MEAT
   DUCKS; STORAGE; STARCH; EXPRESSION; GENES; DERMATITIS
AB Simple Summary Corn is an important ingredient and staple food in China; thus, corn storage has a certain importance to ensure domestic food resources. Normally, corn has been stored for 3 or more years under the proper storage conditions in national barns before it is used as a feed ingredient. This study aimed to investigate the effect of different levels of aging corn (AC) on performance, antioxidative capacity, intestinal health, and microbiota in broilers. In the present study, AC grains were stored for 4 years under the proper storage conditions at the national storage facility. The results indicated that a lower level of AC diet showed improved performance and overall bird health than a higher level of AC, and comparable with a normal corn diet. However, antioxidative capacity is reduced by AC diets.
   Three-hundred and sixty-day-old male broilers underwent three treatments with six replicates of 20 birds per treatment. The experimental diets included NC: normal corn diet; ACL: lower level (39.6-41.24%) of AC; and ACH: a higher level (56.99-59.12%) of AC. During phase 1 (0-21 d), broilers fed on AC showed lower (p < 0.05) body weight (BW), body weight gain (BWG), and feed conversion ratio (FCR) as compared with the NC group. During phase 2 (22-42 d), the NC group and ACL group showed better (p < 0.05) BW, BWG, and FCR than the ACH group. The footpad lesion score (p = 0.05) and litter moisture percentage (p < 0.05) were found to be higher in the ACH group. During phase 1, the ACL group showed a lower level of malondialdehyde (MDA) contents (p < 0.05) in serum; moreover, catalase (CAT) (p < 0.05) and glutathione peroxidase (GSH-Px) activities (p < 0.05) were found lower in both AC-containing groups. During phase 2, CAT activity in serum was found higher (p < 0.05) in the ACH group. During phase 1, the NC group showed higher CAT (p = 0.05), GSH-Px (p < 0.05), and superoxide dismutase (SOD) activity (p = 0.03); however, it showed lower MDA (p < 0.05) and total-antioxidative capability (T-AOC) (p < 0.05) in the liver. During phase 1, in breast muscle, CAT, SOD, and T-AOC were higher (p < 0.05) in the NC group. During phase 1, total cholesterol and high-density lipoprotein were found to be lower (p < 0.05) in the ACL group. Similarly, triglyceride and low-density lipoprotein were found to be lower (p < 0.05) in the ACL group than the ACH group. During phase 1, villus height was found to be higher (p < 0.05) in the ACH group. Moreover, the goblet cell (GC) was found to be higher (p < 0.05) in the NC group than the ACL group. During phase 2, GC was found to be higher (p < 0.05) in the ACL group. In ileal digesta, during phase 1, acetic acid, propionic acid, and butyric acid (BA) levels were found to be higher (p < 0.05) in the ACL group. In cecal digesta, BA was significantly lower (p < 0.05) in the NC group.
C1 [Mustafa, Ahsan; Bai, Shiping; Zeng, Qiufeng; Ding, Xuemei; Wang, Jianping; Xuan, Yue; Su, Zhuowei; Zhang, Keying] Sichuan Agr Univ, Minist Educ, Inst Anim Nutr, Key Lab Anim Dis Resistance Nutr China, Chengdu 611130, Peoples R China.
C3 Sichuan Agricultural University
RP Zhang, KY (corresponding author), Sichuan Agr Univ, Minist Educ, Inst Anim Nutr, Key Lab Anim Dis Resistance Nutr China, Chengdu 611130, Peoples R China.
EM ahsan.mustafa@gmail.com; shipingbai@sicau.edu.cn; zqf@sicau.edu.cn;
   dingxuemei0306@163.com; wangjianping@sicau.edu.cn;
   xuanyuede1007@hotmail.com; wzs698@126.com; zkeying@sicau.edu.cn
RI Ding, Xuemei/B-6619-2013; Mustafa, Ahsan/AAO-3251-2021; zhang,
   ke/AAH-8217-2019
OI Ding, Xuemei/0000-0002-1830-1990; Mustafa, Ahsan/0000-0002-8790-1121;
   Bai, Shiping/0000-0002-5775-1900; Zhang, Keying/0000-0002-2909-3357;
   Wang, Jianping/0000-0002-6596-8771
FU Sichuan Provincial Science and Technology Project [2016NZ0003]; Nutreco
   RD. project
FX FundingThis work was supported financially by Sichuan Provincial Science
   and Technology Project (2016NZ0003) and Nutreco R&D. project.
CR AOAC International, 2006, OFFICIAL METHODS ANA
   Attia YA, 2018, ITAL J ANIM SCI, V17, P686, DOI [10.1080/1828051X.2017.1416961, 10.1080/1828051x.2017.1416961]
   Bailly C, 2002, SEED SCI RES, V12, P47, DOI 10.1079/SSR200197
   Chao PM, 2001, J NUTR, V131, P3166, DOI 10.1093/jn/131.12.3166
   Che LQ, 2015, NEONATOLOGY, V107, P93, DOI 10.1159/000368179
   Chen Z, 2014, POULTRY SCI, V93, P2490, DOI 10.3382/ps.2013-03398
   CHRASTIL J, 1990, J AGR FOOD CHEM, V38, P1804, DOI 10.1021/jf00099a005
   CHRASTIL J, 1990, J CEREAL SCI, V11, P71, DOI 10.1016/S0733-5210(09)80182-3
   Dauksiene A, 2021, ANIMALS-BASEL, V11, DOI 10.3390/ani11030610
   de Coca-Sinova A, 2008, POULTRY SCI, V87, P2613, DOI 10.3382/ps.2008-00182
   DHALIWAL YS, 1991, CEREAL CHEM, V68, P18
   Eder K, 1999, LIPIDS, V34, P717, DOI 10.1007/s11745-999-0418-0
   GALLIARD T, 1986, J CEREAL SCI, V4, P179, DOI 10.1016/S0733-5210(86)80020-0
   Garbaba CA, 2017, J STORED PROD RES, V70, P7, DOI 10.1016/j.jspr.2016.10.004
   García-Rosas M, 2009, STARCH-STARKE, V61, P414, DOI 10.1002/star.200800147
   Gregori R, 2013, FOOD CONTROL, V30, P280, DOI 10.1016/j.foodcont.2012.06.033
   Han HY, 2017, POULTRY SCI, V96, P4333, DOI 10.3382/ps/pex268
   Jha R, 2019, FRONT VET SCI, V6, DOI 10.3389/fvets.2019.00048
   Kimiaeitalab MV, 2017, POULTRY SCI, V96, P581, DOI 10.3382/ps/pew263
   Koch A, 2007, J NUTR, V137, P2018, DOI 10.1093/jn/137.9.2018
   Labuschagne M, 2014, J STORED PROD RES, V56, P16, DOI 10.1016/j.jspr.2013.11.004
   Li J, 2019, ANIMALS-BASEL, V9, DOI 10.3390/ani9080493
   Li X, 2019, BIOMOLECULES, V9, DOI 10.3390/biom9090486
   Liao XD, 2020, POULTRY SCI, V99, P5883, DOI 10.1016/j.psj.2020.08.033
   Liu Biyi, 2013, Chinese Journal of Animal Nutrition, V25, P1077
   Liu F, 2009, J ANIM SCI, V87, P1941, DOI 10.2527/jas.2008-1624
   Liu JB, 2020, ASIAN AUSTRAL J ANIM, V33, P605, DOI 10.5713/ajas.19.0224
   Liu R, 2016, ADV SCI ENG MED, V8, P188, DOI [10.1166/asem.2016.1847, DOI 10.1166/ASEM.2016.1847]
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lozupone C, 2005, APPL ENVIRON MICROB, V71, P8228, DOI 10.1128/AEM.71.12.8228-8235.2005
   Luo B, 2019, ANIMALS-BASEL, V9, DOI 10.3390/ani9090624
   Matsukura U, 2000, J JPN SOC FOOD SCI, V47, P523
   Mayne RK, 2007, BRIT POULTRY SCI, V48, P538, DOI 10.1080/00071660701573045
   MCFARLANE JM, 1989, POULTRY SCI, V68, P501, DOI 10.3382/ps.0680501
   MCILROY SG, 1987, AVIAN PATHOL, V16, P93, DOI 10.1080/03079458708436355
   Mu YD, 2019, J ANIM PHYSIOL AN N, V103, P135, DOI 10.1111/jpn.13017
   National Research Council (NRC), 1994, NUTR REQ POULTR, V9th, P57
   Oviedo-Rondón EO, 2019, ANIM FEED SCI TECH, V250, P1, DOI 10.1016/j.anifeedsci.2019.01.009
   Pomeranz Y., 1971, CRC Critical Reviews in Food Technology, V2, P45
   Qamar SH, 2019, INT J AGRIC BIOL, V21, P201, DOI [10.17957/ijab/15.0882, 10.17957/IJAB/15.0882]
   Qin SM, 2019, POULTRY SCI, V98, P3523, DOI 10.3382/ps/pez186
   Qin SM, 2019, POULTRY SCI, V98, P6340, DOI 10.3382/ps/pez456
   Salman H, 2007, CEREAL CHEM, V84, P600, DOI 10.1094/CCHEM-84-6-0600
   Santos RR, 2015, AVIAN PATHOL, V44, P19, DOI 10.1080/03079457.2014.988122
   Setiawan S, 2010, J AGR FOOD CHEM, V58, P12260, DOI 10.1021/jf102838j
   Shao YJ, 2013, POULTRY SCI, V92, P1764, DOI 10.3382/ps.2013-03029
   Sheng SY, 2018, FOOD SCI HUM WELL, V7, P185, DOI [10.1016/j.fshw.2018.09.003, 10.1016/j.fshw.2018.09.001]
   Subedi KD, 2009, AGR ISSUES POLICIES, P1
   Sülzle A, 2004, J NUTR, V134, P1375, DOI 10.1093/jn/134.6.1375
   Tian G, 2017, MOL NUTR FOOD RES, V61, DOI 10.1002/mnfr.201700012
   Trostle R., 2010, GLOBAL AGR SUPPLY DE
   Wang FW, 2012, PLANT GROWTH REGUL, V66, P49, DOI 10.1007/s10725-011-9628-4
   Yin DF, 2017, ANIM NUTR, V3, P252, DOI 10.1016/j.aninu.2017.04.007
   Yuan ShiBin, 2007, Asian-Australasian Journal of Animal Sciences, V20, P1600
   Zhou L, 2019, ANIM FEED SCI TECH, V256, DOI 10.1016/j.anifeedsci.2019.114242
   Zhou XianQing, 2007, Journal of Maize Sciences, V15, P80
   Zhou Z, 2002, J CEREAL SCI, V35, P65, DOI 10.1006/jcrs.2001.0418
   Zia-Ur-Rehman, 2006, FOOD CHEM, V95, P53, DOI 10.1016/j.foodchem.2004.12.017
NR 58
TC 2
Z9 2
U1 4
U2 10
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
SN 2076-2615
J9 ANIMALS-BASEL
JI Animals
PD OCT
PY 2021
VL 11
IS 10
AR 2832
DI 10.3390/ani11102832
PG 18
WC Agriculture, Dairy & Animal Science; Veterinary Sciences; Zoology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Agriculture; Veterinary Sciences; Zoology
GA WN4MU
UT WOS:000711744700001
PM 34679852
OA Green Published, gold
DA 2024-02-19
ER

PT J
AU Osburn, SC
   Mesquita, PHC
   Neal, FK
   Rumbley, MN
   Holmes, MT
   Ruple, BA
   Mobley, CB
   Brown, MD
   McCullough, DJ
   Kavazis, AN
   Roberts, MD
AF Osburn, Shelby C.
   Mesquita, Paulo H. C.
   Neal, Frances K.
   Rumbley, Melissa N.
   Holmes, Matthew T.
   Ruple, Bradley A.
   Mobley, Christopher B.
   Brown, Michael D.
   McCullough, Danielle J.
   Kavazis, Andreas N.
   Roberts, Michael D.
TI Long-term voluntary wheel running effects on markers of long
   interspersed nuclear element-1 in skeletal muscle, liver, and brain
   tissue of female rats
SO AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY
LA English
DT Article
DE cGAS-STING; exercise; L1; methylation
ID TRANSPOSABLE ELEMENTS; LINE-1 RETROTRANSPOSONS; L1 RETROTRANSPOSONS;
   DNA; ENDONUCLEASE; GENOMES; MOBILE; MEMORY; ORF1P; AGE
AB We sought to determine the effects of long-term voluntary wheel running on markers of long interspersed nuclear element-1 (L1) in skeletal muscle, liver, and the hippocampus of female rats. In addition, markers of the cGAS-STING DNA-sensing pathway that results in inflammation were interrogated. Female Lewis rats (n = 34) were separated into one of three groups including a 6-moold group to serve as a young comparator group (CTL, n = 10), a group that had access to a running wheel for voluntary wheel running (EX, n = 12), and an age-matched group that did not (SED, n = 12). Both SED and EX groups were carried out from 6 mo to 15 mo of age. There were no significant differences in L1 mRNA expression for any of the tissues between groups. Methylation of the L1 promoter in the soleus and hippocampus was significantly higher in SED and EX than in CTL group (P < 0.05). ORF1p expression was higher in older SED and EX rats than in CTL rats for every tissue (P < 0.05). There were no differences between groups for L1 mRNA or cGAS-STING pathway markers. Our results suggest there is an increased ORF1 protein expression across tissues with aging that is not mitigated by voluntary wheel running. In addition, although previous data imply that L1 methylation changes may play a role in acute exercise for L1 RNA expression, this does not seem to occur during extended periods of voluntary wheel running.
C1 [Osburn, Shelby C.; Mesquita, Paulo H. C.; Neal, Frances K.; Rumbley, Melissa N.; Holmes, Matthew T.; Ruple, Bradley A.; Mobley, Christopher B.; McCullough, Danielle J.; Kavazis, Andreas N.; Roberts, Michael D.] Auburn Univ, Sch Kinesiol, Auburn, AL 36849 USA.
   [Brown, Michael D.] Univ Maryland, Sch Publ Hlth, College Pk, MD USA.
   [McCullough, Danielle J.; Roberts, Michael D.] Edward Via Coll Osteopath Med, Auburn, AL 36832 USA.
C3 Auburn University System; Auburn University; University System of
   Maryland; University of Maryland College Park
RP Roberts, MD (corresponding author), Auburn Univ, Sch Kinesiol, Auburn, AL 36849 USA.; Roberts, MD (corresponding author), Edward Via Coll Osteopath Med, Auburn, AL 36832 USA.
EM mdr0024@auburn.edu
CR Alves G, 1996, GENE, V176, P39, DOI 10.1016/0378-1119(96)00205-3
   Beck CR, 2010, CELL, V141, P1159, DOI 10.1016/j.cell.2010.05.021
   Beiter T, 2020, J CELL PHYSIOL, V235, P5476, DOI 10.1002/jcp.29535
   Brocks D, 2017, NAT GENET, V49, P1052, DOI 10.1038/ng.3889
   Burns KH, 2017, NAT REV CANCER, V17, P415, DOI 10.1038/nrc.2017.35
   Callahan KE, 2012, NUCLEIC ACIDS RES, V40, P813, DOI 10.1093/nar/gkr728
   Cecco M, 2013, AGING CELL, V12, P247, DOI 10.1111/acel.12047
   Cost GJ, 1998, BIOCHEMISTRY-US, V37, P18081, DOI 10.1021/bi981858s
   Coufal NG, 2009, NATURE, V460, P1127, DOI 10.1038/nature08248
   De Cecco M, 2013, AGING-US, V5, P867, DOI 10.18632/aging.100621
   DeBerardinis RJ, 1998, NAT GENET, V20, P288, DOI 10.1038/3104
   Feng QH, 1996, CELL, V87, P905, DOI 10.1016/S0092-8674(00)81997-2
   Fiuza-Luces C, 2013, PHYSIOLOGY, V28, P330, DOI 10.1152/physiol.00019.2013
   Folch J, 2018, CURR NEUROPHARMACOL, V16, P1466, DOI 10.2174/1570159X15666170707155345
   Gibbs RA, 2004, NATURE, V428, P493, DOI 10.1038/nature02426
   Hancks DC, 2016, MOBILE DNA-UK, V7, DOI 10.1186/s13100-016-0065-9
   Jang HS, 2019, NAT GENET, V51, P611, DOI 10.1038/s41588-019-0373-3
   Kazazian HH, 2017, NEW ENGL J MED, V377, P361, DOI 10.1056/NEJMra1510092
   Kazazian HH, 1998, NAT GENET, V19, P19, DOI 10.1038/ng0598-19
   Keller K, 2019, WIEN MED WOCHENSCHR, V169, P157, DOI 10.1007/s10354-018-0618-2
   Kirilyuk A, 2008, NUCLEIC ACIDS RES, V36, P648, DOI 10.1093/nar/gkm1045
   Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062
   Li P, 2017, NUCLEIC ACIDS RES, V45, P4619, DOI 10.1093/nar/gkx178
   Li XY, 2013, J BIOL CHEM, V288, P21148, DOI 10.1074/jbc.M113.465856
   López-Otín C, 2013, CELL, V153, P1194, DOI 10.1016/j.cell.2013.05.039
   Lowdon RF, 2016, TRENDS GENET, V32, P269, DOI 10.1016/j.tig.2016.03.001
   Martin SL, 2010, RNA BIOL, V7, P706, DOI 10.4161/rna.7.6.13766
   MATHIAS SL, 1991, SCIENCE, V254, P1808, DOI 10.1126/science.1722352
   Mitchell SJ, 2015, ANNU REV ANIM BIOSCI, V3, P283, DOI 10.1146/annurev-animal-022114-110829
   Muckenfuss H, 2006, J BIOL CHEM, V281, P22161, DOI 10.1074/jbc.M601716200
   Mumford PW, 2019, AM J PHYSIOL-REG I, V317, pR397, DOI 10.1152/ajpregu.00110.2019
   Muotri AR, 2009, HIPPOCAMPUS, V19, P1002, DOI 10.1002/hipo.20564
   Osburn SC, 2022, BMC RES NOTES, V15, DOI 10.1186/s13104-022-06113-0
   Ostertag EM, 2001, ANNU REV GENET, V35, P501, DOI 10.1146/annurev.genet.35.102401.091032
   Pizarro JG, 2016, FRONT CELL DEV BIOL, V4, DOI 10.3389/fcell.2016.00014
   Radak Z, 2008, FREE RADICAL BIO MED, V44, P153, DOI 10.1016/j.freeradbiomed.2007.01.029
   Richardson SR, 2015, MICROBIOL SPECTR, V3, DOI 10.1128/microbiolspec.MDNA3-0061-2014
   Roberson PA, 2019, J APPL PHYSIOL, V127, P895, DOI 10.1152/japplphysiol.00352.2019
   Romero MA, 2019, AM J PHYSIOL-CELL PH, V317, pC1313, DOI 10.1152/ajpcell.00301.2019
   Romero MA, 2018, AM J PHYSIOL-CELL PH, V314, pC379, DOI 10.1152/ajpcell.00192.2017
   Rosenfeld CS, 2017, J NEUROSCI RES, V95, P279, DOI 10.1002/jnr.23896
   Ruple BA, 2021, FASEB J, V35, DOI 10.1096/fj.202100873RR
   RUSSELL JC, 1987, J APPL PHYSIOL, V63, P2549, DOI 10.1152/jappl.1987.63.6.2549
   Saini A, 2009, AGEING RES REV, V8, P251, DOI 10.1016/j.arr.2009.02.001
   Seaborne RA, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-20287-3
   Sedivy JM, 2013, BIOESSAYS, V35, P1035, DOI 10.1002/bies.201300097
   Sengupta P, 2013, INT J PREVENTIVE MED, V4, P624
   Sharples AP, 2016, AGING CELL, V15, P603, DOI 10.1111/acel.12486
   Shi X, 2007, MOL CELL BIOL, V27, P1264, DOI 10.1128/MCB.01888-06
   Simon M, 2019, CELL METAB, V29, P871, DOI 10.1016/j.cmet.2019.02.014
   Thomas DR, 2007, CLIN NUTR, V26, P389, DOI 10.1016/j.clnu.2007.03.008
   Tunbak H, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19170-5
   Waterston RH, 2002, NATURE, V420, P520, DOI 10.1038/nature01262
   Wicker T, 2007, NAT REV GENET, V8, P973, DOI 10.1038/nrg2165
   WILSON VL, 1987, J BIOL CHEM, V262, P9948
   Xie MC, 2013, NAT GENET, V45, P836, DOI 10.1038/ng.2649
   Xie Y, 2013, MOBILE DNA-UK, V4, DOI 10.1186/1759-8753-4-10
NR 57
TC 2
Z9 2
U1 0
U2 0
PU AMER PHYSIOLOGICAL SOC
PI Rockville
PA 6120 Executive Blvd, Suite 600, Rockville, MD, UNITED STATES
SN 0363-6143
EI 1522-1563
J9 AM J PHYSIOL-CELL PH
JI Am. J. Physiol.-Cell Physiol.
PD SEP
PY 2022
VL 323
IS 3
BP C907
EP C919
DI 10.1152/ajpcell.00234.2022
PG 13
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Physiology
GA 6S3EJ
UT WOS:000892873800006
PM 35938680
DA 2024-02-19
ER

PT J
AU Yehuda, R
   Bierer, LM
   Andrew, R
   Schmeidler, J
   Seckl, JR
AF Yehuda, Rachel
   Bierer, Linda M.
   Andrew, Ruth
   Schmeidler, James
   Seckl, Jonathan R.
TI Enduring effects of severe developmental adversity, including
   nutritional deprivation, on cortisol metabolism in aging Holocaust
   survivors
SO JOURNAL OF PSYCHIATRIC RESEARCH
LA English
DT Article
DE Posttraumatic stress disorder; Glucocorticoid metabolism; Biological
   markers; 5 alpha-Tetrahydrocortisol; 11 beta-hydroxysteroid
   dehydrogenase; Child psychiatry
ID POSTTRAUMATIC-STRESS-DISORDER; PITUITARY-ADRENAL AXIS;
   11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE-1; BETA-HYDROXYSTEROID
   DEHYDROGENASE; PRENATAL EXPOSURE; BLOOD-PRESSURE; PTSD SCALE; LIVER;
   ENZYMES; 5-ALPHA-REDUCTASE
AB Objective: In animal models, early life exposure to major environmental challenges such as malnutrition and stress results in persisting cardiometabolic, neuroendocrine and affective effects. While such effects have been associated with pathogenesis, the widespread occurrence of 'developmental programming' suggests it has adaptive function. Glucocorticoids may mediate 'programming' and their metabolism is known to be affected by early life events in rodents. To examine these relationships in humans, cortisol metabolism and cardiometabolic disease manifestations were examined in Holocaust survivors in relation to age at exposure and affective dysfunction, notably lifetime posttraumatic stress disorder (PTSD).
   Methods: Fifty-one Holocaust survivors and 22 controls without Axis I disorder collected 24-h urine samples and were evaluated for psychiatric disorders and cardiometabolic diagnoses. Corticosteroids and their metabolites were assayed by gas chromatography-mass spectroscopy (GC-MS); cortisol was also measured by radioimmunoassay (RIA).
   Results: Holocaust survivors showed reduced cortisol by RIA, and decreased levels of 5 alpha-tetrahydrocortisol (5 alpha-THF) and total glucocorticoid production by GC-MS. The latter was associated with lower cortisol metabolism by 5 alpha-reductase and 11 beta-hydroxysteroid dehydrogenase (11 beta-HSD) type-2. The greatest decrements were associated with earliest age of Holocaust exposure and less severe PTSD symptomatology. Cardiometabolic manifestations were associated with decreased 11 beta-HSD-2 activity. In controls, 5 alpha-reductase was positively associated with trauma-related symptoms (i.e., to traumatic exposures unrelated to the Holocaust).
   Conclusion: Extreme malnutrition and related stress during development is associated with long-lived alterations in specific pathways of glucocorticoid metabolism. These effects may be adaptive and link with lower risks of cardiometabolic and stress-related disorders in later life. Published by Elsevier Ltd.
C1 [Yehuda, Rachel; Bierer, Linda M.; Schmeidler, James] Mt Sinai Sch Med, Traumat Stress Studies Div, Bronx, NY 10468 USA.
   [Yehuda, Rachel; Bierer, Linda M.; Schmeidler, James] James J Peters Bronx Vet Affairs Med Ctr, Bronx, NY 10468 USA.
   [Andrew, Ruth; Seckl, Jonathan R.] Univ Edinburgh, Queens Med Res Inst, Endocrinol Unit, Edinburgh EH16 4TJ, Midlothian, Scotland.
C3 Icahn School of Medicine at Mount Sinai; US Department of Veterans
   Affairs; Veterans Health Administration (VHA); James J. Peters VA
   Medical Center; University of Edinburgh
RP Yehuda, R (corresponding author), Mt Sinai Sch Med, Traumat Stress Studies Div, 130 W Kingsbridge Rd, Bronx, NY 10468 USA.
EM rachel.yehuda@va.gov
RI Seckl, Jonathan R/C-3555-2013; Andrew, Ruth/C-2727-2008
OI Andrew, Ruth/0000-0002-6916-2994
FU NIMH [5 R01 MH064675-02]; Wellcome Trust; Medical Research Council
   [G0700704B] Funding Source: researchfish
FX This work was supported by NIMH 5 R01 MH064675-02 to Rachel Yehuda and
   by grants from the Wellcome Trust to Ruth Andrew and Jonathan R. Seckl.
   Neither the NIMH nor the Wellcome Trust had any further role in study
   design; in the collection, analysis or interpretation of data; in
   manuscript preparation; or in the decision to submit the paper for
   publication.
CR Andrew R, 1998, J CLIN ENDOCR METAB, V83, P1806, DOI 10.1210/jc.83.5.1806
   Andrew R, 2002, EXP CLIN ENDOCR DIAB, V110, P284, DOI 10.1055/s-2002-34591
   [Anonymous], 1995, Structured Clinical Interview for DSM-IV
   Barker DJ., 1998, Mothers, babies, and health in later life, V2
   BENEDIKTSSON R, 1993, LANCET, V341, P339, DOI 10.1016/0140-6736(93)90138-7
   Best R, 1997, CLIN ENDOCRINOL, V47, P231, DOI 10.1046/j.1365-2265.1997.2471061.x
   BLAKE DD, 1995, J TRAUMA STRESS, V8, P75, DOI 10.1002/jts.2490080106
   Bremner JD, 2003, BIOL PSYCHIAT, V54, P710, DOI 10.1016/S0006-3223(02)01912-1
   DANNAN GA, 1986, J BIOL CHEM, V261, P728
   DAVIDSON JRT, 1991, PSYCHOL MED, V21, P713, DOI 10.1017/S0033291700022352
   DEBELLIS MD, 1994, J CLIN ENDOCR METAB, V78, P249, DOI 10.1210/jc.78.2.249
   Doyle LW, 2000, CLIN SCI, V98, P137, DOI 10.1042/CS19990211
   EBERLY RE, 1991, HOSP COMMUNITY PSYCH, V42, P807
   FUNDER JW, 1988, SCIENCE, V242, P583, DOI 10.1126/science.2845584
   Gluckman PD, 2004, SCIENCE, V305, P1733, DOI 10.1126/science.1095292
   GUSTAFSSON JA, 1974, J BIOL CHEM, V249, P711
   Johnstone AM, 2004, EUR J ENDOCRINOL, V150, P185, DOI 10.1530/eje.0.1500185
   Kaffman A, 2007, J CHILD PSYCHOL PSYC, V48, P224, DOI 10.1111/j.1469-7610.2007.01730.x
   Lauterbach D, 1997, J TRAUMA STRESS, V10, P499, DOI 10.1002/jts.2490100313
   Lindsay RS, 1996, HYPERTENSION, V27, P1200, DOI 10.1161/01.HYP.27.6.1200
   Lovati E, 1999, J CLIN ENDOCR METAB, V84, P3745, DOI 10.1210/jc.84.10.3745
   Painter RC, 2006, AM J CLIN NUTR, V84, P322
   Paterson JM, 2007, ENDOCRINOLOGY, V148, P961, DOI 10.1210/en.2006-0603
   Phillips DIW, 2007, J INTERN MED, V261, P453, DOI 10.1111/j.1365-2796.2007.01801.x
   Raalte EVDHV, 2007, AM J ORTHOPSYCHIAT, V77, P514, DOI 10.1037/0002-9432.77.4.514
   Rask E, 2001, J CLIN ENDOCR METAB, V86, P1418, DOI 10.1210/jc.86.3.1418
   Ravelli ACJ, 1998, LANCET, V351, P173, DOI 10.1016/S0140-6736(97)07244-9
   RUSSELL DW, 1994, ANNU REV BIOCHEM, V63, P25, DOI 10.1146/annurev.bi.63.070194.000325
   Seckl JR, 2001, ENDOCRINOLOGY, V142, P1371, DOI 10.1210/en.142.4.1371
   Seckl JR, 2004, ANN NY ACAD SCI, V1032, P63, DOI 10.1196/annals.1314.006
   Shimada M, 1997, ARCH BIOCHEM BIOPHYS, V337, P34, DOI 10.1006/abbi.1996.9764
   SUSSER ES, 1992, ARCH GEN PSYCHIAT, V49, P983
   van der Hal-van Raalte EAM, 2008, J CLIN PSYCHOL, V64, P1352, DOI 10.1002/jclp.20528
   WALKER BR, 1993, CLIN ENDOCRINOL, V39, P221, DOI 10.1111/j.1365-2265.1993.tb01778.x
   Westerbacka J, 2003, J CLIN ENDOCR METAB, V88, P4924, DOI 10.1210/jc.2003-030596
   Yau JLW, 2001, P NATL ACAD SCI USA, V98, P4716, DOI 10.1073/pnas.071562698
   Yehuda R, 2002, NEW ENGL J MED, V346, P108, DOI 10.1056/NEJMra012941
   Yehuda R, 2005, J CLIN ENDOCR METAB, V90, P4115, DOI 10.1210/jc.2005-0550
   Yehuda R, 2005, AM J PSYCHIAT, V162, P998, DOI 10.1176/appi.ajp.162.5.998
   Yehuda R, 2004, BIOL PSYCHIAT, V55, P1110, DOI 10.1016/j.biopsych.2004.02.010
   Yehuda R, 2002, PSYCHIAT CLIN N AM, V25, P341, DOI 10.1016/S0193-953X(02)00002-3
   Yehuda R, 2007, J TRAUMA STRESS, V20, P757, DOI 10.1002/jts.20228
   Yehuda R, 2006, BIOL PSYCHIAT, V60, P714, DOI 10.1016/j.biopsych.2006.03.069
   Young EA, 2004, ARCH GEN PSYCHIAT, V61, P394, DOI 10.1001/archpsyc.61.4.394
NR 44
TC 71
Z9 78
U1 0
U2 13
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0022-3956
EI 1879-1379
J9 J PSYCHIATR RES
JI J. Psychiatr. Res.
PD JUN
PY 2009
VL 43
IS 9
BP 877
EP 883
DI 10.1016/j.jpsychires.2008.12.003
PG 7
WC Psychiatry
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Psychiatry
GA 452XC
UT WOS:000266573500009
PM 19162277
OA Green Accepted
DA 2024-02-19
ER

PT J
AU Green, CL
   Mitchell, SE
   Derous, D
   Wang, YC
   Chen, LN
   Han, JDJ
   Promislow, DEL
   Lusseau, D
   Douglas, A
   Speakman, JR
AF Green, Cara L.
   Mitchell, Sharon E.
   Derous, Davina
   Wang, Yingchun
   Chen, Luonan
   Han, Jing-Dong J.
   Promislow, Daniel E. L.
   Lusseau, David
   Douglas, Alex
   Speakman, John R.
TI The effects of graded levels of calorie restriction: IX. Global
   metabolomic screen reveals modulation of carnitines, sphingolipids and
   bile acids in the liver of C57BL/6 mice
SO AGING CELL
LA English
DT Article
DE aging; bile acid; calorie restriction; carnitine; Metabolomics;
   sphingolipid
ID SHORT-TERM CALORIE; DIETARY RESTRICTION; PROTEIN RESTRICTION; OXIDATIVE
   STRESS; LIFE-SPAN; BODY-TEMPERATURE; GENE-EXPRESSION; MISSING VALUES;
   INSULIN; AGE
AB Calorie restriction (CR) remains the most robust intervention to extend lifespan and improve health span. Using a global mass spectrometry-based metabolomic approach, we identified 193 metabolites that were significantly differentially expressed (SDE) in the livers of C57BL/6 mice, fed graded levels of CR (10, 20, 30 and 40% CR) compared to mice fed ad libitum for 12 h a day. The differential expression of metabolites also varied with the different feeding groups. Pathway analysis revealed that graded CR had an impact on carnitine synthesis and the carnitine shuttle pathway, sphingosine-1-phosphate (S1P) signalling and methionine metabolism. S1P, sphingomyelin and L-carnitine were negatively correlated with body mass, leptin, insulin-like growth factor- 1 (IGF-1) and major urinary proteins (MUPs). In addition, metabolites which showed a graded effect, such as ceramide, S1P, taurocholic acid and L-carnitine, responded in the opposite direction to previously observed age-related changes. We suggest that the modulation of this set of metabolites may improve liver processes involved in energy release from fatty acids. S1P also negatively correlated with catalase activity and body temperature, and positively correlated with food anticipatory activity. Injecting mice with S1P or an S1P receptor 1 agonist did not precipitate changes in body temperature, physical activity or food intake suggesting that these correlations were not causal relationships.
C1 [Green, Cara L.; Mitchell, Sharon E.; Derous, Davina; Lusseau, David; Douglas, Alex; Speakman, John R.] Univ Aberdeen, Inst Biol & Environm Sci, Aberdeen, Scotland.
   [Wang, Yingchun; Speakman, John R.] Chinese Acad Sci, Inst Genet & Dev Biol, State Key Lab Mol Dev Biol, Beijing, Peoples R China.
   [Chen, Luonan] Chinese Acad Sci, Key Lab Syst Biol, Innovat Ctr Cell Signaling Network, Inst Biochem & Cell Biol,Shanghai Inst Biol Sci, Shanghai, Peoples R China.
   [Han, Jing-Dong J.] Chinese Acad Sci, Key Lab Computat Biol, Max Planck Partner Inst Computat Biol, Shanghai Inst Biol Sci, Shanghai, Peoples R China.
   [Promislow, Daniel E. L.] Univ Washington, Dept Pathol, Seattle, WA 98195 USA.
   [Promislow, Daniel E. L.] Univ Washington, Dept Biol, Seattle, WA 98195 USA.
C3 University of Aberdeen; Chinese Academy of Sciences; Institute of
   Genetics & Developmental Biology, CAS; Chinese Academy of Sciences;
   Center for Excellence in Molecular Cell Science, CAS; Max Planck
   Society; Chinese Academy of Sciences; University of Washington;
   University of Washington Seattle; University of Washington; University
   of Washington Seattle
RP Speakman, JR (corresponding author), Inst Biol & Environm Sci, Zool Bldg,Tillydrone Ave, Aberdeen AB24 2TZ, Scotland.
EM j.speakman@abdn.ac.uk
RI Mitchell, Sharon/GYD-4854-2022; John, Speakman R/A-9494-2008; Promislow,
   Daniel/AAF-3332-2019; Derous, Davina/AAH-4740-2020; Lusseau,
   David/AAV-9295-2021
OI Derous, Davina/0000-0002-9041-4607; Lusseau, David/0000-0003-1245-3747;
   Douglas, Alex/0000-0001-6606-1058; Promislow, Daniel/0000-0001-7088-4495
FU UK Biotechnology and Biological Sciences Research Council BBSRC
   [BB/G009953/1, BB/J020028/1]; BBSRC; laboratory of DP; NIH [AGO49494];
   BBSRC [BB/J020028/1, BB/G009953/1] Funding Source: UKRI; Biotechnology
   and Biological Sciences Research Council [1438803, BB/G009953/1,
   BB/J020028/1] Funding Source: researchfish
FX The work was supported by the UK Biotechnology and Biological Sciences
   Research Council BBSRC (BB/G009953/1 and BB/J020028/1 to JRS) and a
   studentship of CG from the BBSRC EastBio Doctoral Training Partnership.
   CG received support from the laboratory of DP; DP was supported in part
   by NIH grant AGO49494.
CR Babenko NA, 2014, ARCH GERONTOL GERIAT, V58, P420, DOI 10.1016/j.archger.2013.12.005
   BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x
   Bertolotti M, 2007, EUR J CLIN INVEST, V37, P501, DOI 10.1111/j.1365-2362.2007.01808.x
   Blanchard G, 2002, J NUTR, V132, P204, DOI 10.1093/jn/132.2.204
   Bowne J, 2013, METABOLOMICS COLLECT
   BOZDOGAN H, 1987, PSYCHOMETRIKA, V52, P345, DOI 10.1007/BF02294361
   Bruss MD, 2010, AM J PHYSIOL-ENDOC M, V298, pE108, DOI 10.1152/ajpendo.00524.2009
   Chiang JYL, 2013, COMPR PHYSIOL, V3, P1191, DOI 10.1002/cphy.c120023
   Collino S, 2013, METABOLITES, V3, P881, DOI 10.3390/metabo3040881
   Colman RJ, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4557
   Conti B, 2006, SCIENCE, V314, P825, DOI 10.1126/science.1132191
   De Guzman JM, 2013, AGE, V35, P1091, DOI 10.1007/s11357-012-9430-x
   DELACRUZ J, 1990, INT J BIOCHEM, V22, P729, DOI 10.1016/0020-711X(90)90008-Q
   Derous D, 2016, AGING-US, V8, P642, DOI 10.18632/aging.100895
   Dong J, 2014, CLIN EXP IMMUNOL, V177, P94, DOI 10.1111/cei.12304
   Dumitru CA, 2007, ANTIOXID REDOX SIGN, V9, P1535, DOI 10.1089/ars.2007.1692
   FERLAND G, 1989, LIPIDS, V24, P842, DOI 10.1007/BF02535757
   Ferreira JA., 2007, The International Journal of Biostatistics, V3, pArticl, DOI [10.2202/1557-4679.1065, DOI 10.2202/1557-4679.1065]
   Flanagan JL, 2010, NUTR METAB, V7, DOI 10.1186/1743-7075-7-30
   Fok WC, 2014, AGING CELL, V13, P311, DOI 10.1111/acel.12175
   Fontana L, 2010, SCIENCE, V328, P321, DOI 10.1126/science.1172539
   Friedman Jeffrey M., 2011, Keio Journal of Medicine, V60, P1, DOI 10.2302/kjm.60.1
   Fukai T, 2011, ANTIOXID REDOX SIGN, V15, P1583, DOI 10.1089/ars.2011.3999
   Ge PL, 2015, BIOSCI TRENDS, V9, P42, DOI 10.5582/bst.2015.01000
   Gomez-Muñoz A, 2016, PROG LIPID RES, V61, P51, DOI 10.1016/j.plipres.2015.09.002
   Gromski PS, 2014, METABOLITES, V4, P433, DOI 10.3390/metabo4020433
   HERBENER GH, 1976, J GERONTOL, V31, P8, DOI 10.1093/geronj/31.1.8
   Hoffman JM, 2014, AGING CELL, V13, P596, DOI 10.1111/acel.12215
   Huan T, 2015, ANAL CHEM, V87, P1306, DOI 10.1021/ac5039994
   Huang XH, 2014, BBA-MOL CELL BIOL L, V1841, P657, DOI 10.1016/j.bbalip.2013.08.006
   JAVITT NB, 1994, FASEB J, V8, P1308, DOI 10.1096/fasebj.8.15.8001744
   Johnson SC, 2013, NATURE, V493, P338, DOI 10.1038/nature11861
   Jové M, 2014, AGING CELL, V13, P828, DOI 10.1111/acel.12241
   Jun DJ, 2006, ENDOCRINOLOGY, V147, P5835, DOI 10.1210/en.2006-0579
   Keil G, 2015, BIOGERONTOLOGY, V16, P383, DOI 10.1007/s10522-015-9571-2
   Keller J, 2013, NUTR METAB, V10, DOI 10.1186/1743-7075-10-28
   Kim SS, 2016, MOL GENET GENOMICS, V291, P831, DOI 10.1007/s00438-015-1150-3
   Kirkwood TBL, 2008, NATURE, V451, P644, DOI 10.1038/451644a
   KNOPF JL, 1983, MOL CELL BIOL, V3, P2232, DOI 10.1128/MCB.3.12.2232
   Krajcovicová-Kudlácková M, 2000, PHYSIOL RES, V49, P399
   Kuhla A, 2014, J GERONTOL A-BIOL, V69, P915, DOI 10.1093/gerona/glt160
   Lecour S, 2006, J CARDIOVASC PHARM, V47, P158, DOI 10.1097/01.fjc.0000198520.28674.41
   Levin BE, 1999, AM J PHYSIOL-REG I, V276, pR1223
   Li SZ, 2013, PLOS COMPUT BIOL, V9, DOI 10.1371/journal.pcbi.1003123
   Li SZ, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-11-r115
   Lightle SA, 2000, MECH AGEING DEV, V120, P111, DOI 10.1016/S0047-6374(00)00191-3
   Meijer AJ, 2003, J NUTR, V133, p2057S, DOI 10.1093/jn/133.6.2057S
   Mingorance C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034268
   Mitchell SJ, 2016, CELL METAB, V23, P1093, DOI 10.1016/j.cmet.2016.05.027
   Mitchell SE, 2016, ONCOTARGET, V7, P19147, DOI 10.18632/oncotarget.8158
   Mitchell SE, 2015, ONCOTARGET, V6, P23213, DOI 10.18632/oncotarget.4003
   Mitchell SE, 2015, ONCOTARGET, V6, P18314, DOI 10.18632/oncotarget.4506
   Mitchell SE, 2015, ONCOTARGET, V6, P15902, DOI 10.18632/oncotarget.4142
   Navé BT, 1999, BIOCHEM J, V344, P427, DOI 10.1042/0264-6021:3440427
   Nogueira LM, 2012, CANCER MED-US, V1, P275, DOI 10.1002/cam4.23
   Pekala J, 2011, CURR DRUG METAB, V12, P667, DOI 10.2174/138920011796504536
   Pinheiro J.J., 2018, nlme: Linear and nonlinear mixed-effects models, P1, DOI DOI 10.4018/978-1-4666-7244-4.CH001
   Plank M, 2012, MOL BIOSYST, V8, P1339, DOI 10.1039/c2mb05255e
   Qi YP, 2015, BBA-MOL CELL BIOL L, V1851, P19, DOI 10.1016/j.bbalip.2014.04.008
   Rector RS, 2010, J HEPATOL, V52, P727, DOI 10.1016/j.jhep.2009.11.030
   Regev A, 2001, GASTROENTEROL CLIN N, V30, P547, DOI 10.1016/S0889-8553(05)70195-3
   Rosen ED, 2006, NATURE, V444, P847, DOI 10.1038/nature05483
   Schmucker Douglas L, 2011, Curr Gerontol Geriatr Res, V2011, P526379, DOI 10.1155/2011/526379
   Selman C, 2006, PHYSIOL GENOMICS, V27, P187, DOI 10.1152/physiolgenomics.00084.2006
   Sepe A, 2011, GERONTOLOGY, V57, P66, DOI 10.1159/000279755
   Shaham O, 2008, MOL SYST BIOL, V4, DOI 10.1038/msb.2008.50
   Shoelson SE, 2006, J CLIN INVEST, V116, P1793, DOI 10.1172/JCI29069
   Silva VRR, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5859
   Smyth GK., 2004, Stat Appl Genet Mol Biol, V3, P1, DOI DOI 10.2202/1544-6115.1027
   Speakman JR, 2016, EXP GERONTOL, V86, P28, DOI 10.1016/j.exger.2016.03.011
   Speakman JR, 2011, MOL ASPECTS MED, V32, P159, DOI 10.1016/j.mam.2011.07.001
   Stekhoven D. J., 2011, USING MISSFOREST PAC
   Stekhoven DJ, 2012, BIOINFORMATICS, V28, P112, DOI 10.1093/bioinformatics/btr597
   Swindell WR, 2012, AGEING RES REV, V11, P254, DOI 10.1016/j.arr.2011.12.006
   Team RC, 2020, R: A Language and Environment for Statistical
   Tosato M, 2007, CLIN INTERV AGING, V2, P401
   Turturro A, 1999, J GERONTOL A-BIOL, V54, pB492, DOI 10.1093/gerona/54.11.B492
   Van Brocklyn JR, 2012, COMP BIOCHEM PHYS B, V163, P26, DOI 10.1016/j.cbpb.2012.05.006
   van Echten-Deckert G, 2014, CELL PHYSIOL BIOCHEM, V34, P148, DOI 10.1159/000362991
   Wanichthanarak W, 2015, BIOMARK INSIGHTS, V10, P1, DOI 10.4137/BMI.S29511
   Wei YR, 2007, J NUTR BIOCHEM, V18, P1, DOI 10.1016/j.jnutbio.2006.03.013
   Weindruch R., 1988, RETARDATION AGING DI
   Westerhuis JA, 2010, METABOLOMICS, V6, P119, DOI 10.1007/s11306-009-0185-z
   Xu YC, 2014, FUNCT ECOL, V28, P402, DOI 10.1111/1365-2435.12168
   Yang G, 2009, AM J PHYSIOL-ENDOC M, V297, pE211, DOI 10.1152/ajpendo.91014.2008
   YU BP, 1985, J GERONTOL, V40, P657, DOI 10.1093/geronj/40.6.657
   Zhang YQ, 2008, FEBS LETT, V582, P10, DOI 10.1016/j.febslet.2007.11.015
   Zheng SQ, 2008, EUR J PHARMACOL, V584, P118, DOI 10.1016/j.ejphar.2008.01.045
NR 88
TC 42
Z9 46
U1 0
U2 19
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1474-9718
EI 1474-9726
J9 AGING CELL
JI Aging Cell
PD JUN
PY 2017
VL 16
IS 3
BP 529
EP 540
DI 10.1111/acel.12570
PG 12
WC Cell Biology; Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Geriatrics & Gerontology
GA EW3TY
UT WOS:000402426900012
PM 28139067
OA Green Published, gold
DA 2024-02-19
ER

PT J
AU Ge, YK
   Zhang, ZH
AF Ge, Yakun
   Zhang, Zhehan
TI RETRACTED: Effect of Tumor Red Blood Cell Immunity and Tumor Cell Cycle
   in Mice Bearing Solid Liver Cancer with Intelligent Cancer Zhongning
   Therapeutic Apparatus (Retracted Article)
SO JOURNAL OF HEALTHCARE ENGINEERING
LA English
DT Article; Retracted Publication
ID LUNG
AB People's unhealthy lifestyles, especially the number of smoking and passive smoking populations, are increasing year by year and the population is aging. With the development and progress of lung cancer cell and molecular biology, the incidence rate and mortality rate of lung cancer are increasing year by year. The existing tumor biochemotherapy has rapidly developed from preliminary research and animal research to clinical research. The smart cancer Zhongning therapeutic device can induce necrosis and apoptosis of tumor cells. The effect of treating tumors is getting more and more attention. Therefore, this article focuses on the effect of the smart cancer Zhongning therapeutic device on the tumor red blood cells and tumor cell cycle of mice with solid liver cancer. The immunological effects of the drug were discussed. Forty mice were randomly divided into high-dose group, low-dose group, 5-FU group, and model group. The effects of different treatment stages on tumor red blood cell immune function and cell cycle were recorded and evaluated, and the survival rate by multiplying the positive limit method was calculated. The model group is controlled by the exact probability method, and the Pss18.0 system is used to test the hypothesis of survival rate comparison. The experimental results showed that the tumor inhibition rate in this group was 65.8%. Compared with the 5-FU group and model group, the dose group has shown an antitumor effect and had significantly improved the tumor-bearing body's antitumor red blood cell immune function and tumor cell cycle.
C1 [Ge, Yakun] Hangzhou Dianzi Univ, Inst Biomed Engn, Hangzhou 310018, Zhejiang, Peoples R China.
   [Zhang, Zhehan] Zhejiang Chinese Med Univ, Coll Pharmaceut, Hangzhou 310053, Zhejiang, Peoples R China.
C3 Hangzhou Dianzi University; Zhejiang Chinese Medical University
RP Ge, YK (corresponding author), Hangzhou Dianzi Univ, Inst Biomed Engn, Hangzhou 310018, Zhejiang, Peoples R China.
EM gyk@hdu.edu.cn; crabdabell@163.com
CR Ahmed R, 2016, CELL REP, V17, P2811, DOI 10.1016/j.celrep.2016.11.037
   [Anonymous], 2019, GLAND SURG
   Bain B.J., 2017, Medicine, V45, P187
   Chang XT, 2019, CANCER BIOL MED, V16, P729, DOI 10.20892/j.issn.2095-3941.2019.0065
   Chen SS, 2015, TRANSL LUNG CANCER R, V4, P775, DOI 10.3978/j.issn.2218-6751.2015.11.03
   Erkan D, 2016, TURK J HEMATOL, V33, P1, DOI 10.4274/tjh.2015.0197
   Hossain MS, 2017, IEEE SYST J, V11, P118, DOI 10.1109/JSYST.2015.2470644
   Jiang D, 2020, THERANOSTICS, V10, P7260, DOI 10.7150/thno.46332
   Jiang QH, 2017, MOL NEUROBIOL, V54, P594, DOI 10.1007/s12035-015-9670-8
   Kannan Narayanan, 2015, Asian Pac J Cancer Prev, V16, P8119
   Li Y., 2021, International Journal of Cognitive Computing in Engineering, V2, P21, DOI DOI 10.1016/J.IJCCE.2020.12.004
   Lu CY, 2016, ADV FUNCT MATER, V26, P3250, DOI 10.1002/adfm.201505312
   Maghsoudi A, 2020, POULTRY SCI, V99, P4758, DOI 10.1016/j.psj.2020.06.058
   Medová M, 2016, DRUG FUTURE, V41, P659, DOI 10.1358/dof.2016.041.11.2555984
   Mego M, 2017, ONCOTARGET, V8, P35656, DOI 10.18632/oncotarget.10290
   Metz EP, 2020, BMC CANCER, V20, DOI 10.1186/s12885-020-07370-7
   Montano R, 2017, ONCOTARGET, V8, P67754, DOI 10.18632/oncotarget.18834
   Ohkuri T, 2017, CANCER IMMUNOL IMMUN, V66, P705, DOI 10.1007/s00262-017-1975-1
   Seshadri A, 2019, J TRAUMA ACUTE CARE, V87, P337, DOI 10.1097/TA.0000000000002264
   Tinhofer Ingeborg, 2016, Cancers Head Neck, V1, P8, DOI 10.1186/s41199-016-0009-6
   Twitchell EL, 2016, GUT PATHOG, V8, DOI 10.1186/s13099-016-0136-y
   Wang MH, 2019, BIOSENS BIOELECTRON, V142, DOI 10.1016/j.bios.2019.111536
   Wong J, 2016, CANCER CONTROL, V23, P30, DOI 10.1177/107327481602300106
   Yu ZC, 2021, IEEE ACCESS, V9, P39043, DOI 10.1109/ACCESS.2021.3062687
   Zhang LL, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0679-5
NR 25
TC 2
Z9 3
U1 0
U2 5
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2040-2295
EI 2040-2309
J9 J HEALTHC ENG
JI J. Healthc. Eng.
PD JUN 7
PY 2021
VL 2021
AR 3329800
DI 10.1155/2021/3329800
PG 13
WC Health Care Sciences & Services
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Health Care Sciences & Services
GA SY3ZH
UT WOS:000665829000004
PM 34194680
OA Green Published, gold
DA 2024-02-19
ER

PT J
AU Kacírová, M
   Zelezná, B
   Blazková, M
   Holubová, M
   Popelová, A
   Kunes, J
   Sedivá, B
   Maletínská, L
AF Kacirova, Miroslava
   Zelezna, Blanka
   Blazkova, Michaela
   Holubova, Martina
   Popelova, Andrea
   Kunes, Jaroslav
   Sediva, Blanka
   Maletinska, Lenka
TI Aging and high-fat diet feeding lead to peripheral insulin resistance
   and sex-dependent changes in brain of mouse model of tau pathology
   THY-Tau22
SO JOURNAL OF NEUROINFLAMMATION
LA English
DT Article
DE Alzheimer's disease; THY-Tau22 mouse; Obesity; Neuroinflammation;
   Peripheral insulin resistance; Sex differences
ID PROLACTIN-RELEASING PEPTIDE; COGNITIVE DECLINE; INDUCED OBESITY;
   PHOSPHORYLATION; PROTEIN; NEUROINFLAMMATION; KINASE
AB Background Obesity leads to low-grade inflammation in the adipose tissue and liver and neuroinflammation in the brain. Obesity-induced insulin resistance (IR) and neuroinflammation seem to intensify neurodegeneration including Alzheimer's disease. In this study, the impact of high-fat (HF) diet-induced obesity on potential neuroinflammation and peripheral IR was tested separately in males and females of THY-Tau22 mice, a model of tau pathology expressing mutated human tau protein. Methods Three-, 7-, and 11-month-old THY-Tau22 and wild-type males and females were tested for mobility, anxiety-like behavior, and short-term spatial memory in open-field and Y-maze tests. Plasma insulin, free fatty acid, cholesterol, and leptin were evaluated with commercial assays. Liver was stained with hematoxylin and eosin for histology. Brain sections were 3 ',3 '-diaminobenzidine (DAB) and/or fluorescently detected for ionized calcium-binding adapter molecule 1 (Iba1), glial fibrillary acidic protein (GFAP), and tau phosphorylated at T231 (pTau (T231)), and analyzed. Insulin signaling cascade, pTau, extracellular signal-regulated kinase 1/2 (ERK1/2), and protein phosphatase 2A (PP2A) were quantified by western blotting of hippocampi of 11-month-old mice. Data are mean +/- SEM and were subjected to Mann-Whitney t test within age and sex and mixed-effects analysis and Bonferroni's post hoc test for age comparison. Results Increased age most potently decreased mobility and increased anxiety in all mice. THY-Tau22 males showed impaired short-term spatial memory. HF diet increased body, fat, and liver weights and peripheral IR. HF diet-fed THY-Tau22 males showed massive Iba1+ microgliosis and GFAP+ astrocytosis in the hippocampus and amygdala. Activated astrocytes colocalized with pTau (T231) in THY-Tau22, although no significant difference in hippocampal tau phosphorylation was observed between 11-month-old HF and standard diet-fed THY-Tau22 mice. Eleven-month-old THY-Tau22 females, but not males, on both diets showed decreased synaptic and postsynaptic plasticity. Conclusions Significant sex differences in neurodegenerative signs were found in THY-Tau22. Impaired short-term spatial memory was observed in 11-month-old THY-tau22 males but not females, which corresponded to increased neuroinflammation colocalized with pTau(T231) in the hippocampi and amygdalae of THY-Tau22 males. A robust decrease in synaptic and postsynaptic plasticity was observed in 11-month-old females but not males. HF diet caused peripheral but not central IR in mice of both sexes.
C1 [Kacirova, Miroslava; Zelezna, Blanka; Blazkova, Michaela; Holubova, Martina; Popelova, Andrea; Kunes, Jaroslav; Maletinska, Lenka] Czech Acad Sci, Inst Organ Chem & Biochem, Flemingovo Namesti 542-2, Prague 16000 6, Czech Republic.
   [Kunes, Jaroslav] Czech Acad Sci, Inst Physiol, Videnska 1083, Prague 14220 4, Czech Republic.
   [Sediva, Blanka] Univ West Bohemia, Dept Math, Univ 2732-8, Plzen 30100, Czech Republic.
C3 Czech Academy of Sciences; Institute of Organic Chemistry & Biochemistry
   of the Czech Academy of Sciences; Czech Academy of Sciences; Institute
   of Physiology of the Czech Academy of Sciences; University of West
   Bohemia Pilsen
RP Maletínská, L (corresponding author), Czech Acad Sci, Inst Organ Chem & Biochem, Flemingovo Namesti 542-2, Prague 16000 6, Czech Republic.
EM lenka.maletinska@uochb.cas.cz
RI Šedivá, Blanka/O-8881-2017; Kunes, Jaroslav/B-7079-2012
OI Šedivá, Blanka/0000-0002-2480-5837; Kunes, Jaroslav/0000-0002-1474-5201
FU Czech Science Foundation [20-00546S]; Academy of Sciences of the Czech
   Republic [RVO: 61388963, RVO: 67985823]
FX This study was supported by Czech Science Foundation [grant number
   20-00546S] and by the Academy of Sciences of the Czech Republic [grant
   numbers RVO: 61388963 and RVO: 67985823].
CR Alford S, 2018, OBES REV, V19, P269, DOI 10.1111/obr.12629
   Becker K, 2012, NEUROSCI LETT, V516, P306, DOI 10.1016/j.neulet.2012.04.022
   Belarbi K, 2011, CURR ALZHEIMER RES, V8, P633, DOI 10.2174/156720511796717230
   Bray GA, 2004, J CLIN ENDOCR METAB, V89, P2583, DOI 10.1210/jc.2004-0535
   Ebbert JO, 2013, NUTRIENTS, V5, P498, DOI 10.3390/nu5020498
   Ferrari A, 2003, J BIOL CHEM, V278, P40162, DOI 10.1074/jbc.M308243200
   Ferrer I, 2018, NEUROGLIA, V1, P126, DOI [10.3390/neuroglia1010010, DOI 10.3390/NEUROGLIA1010010]
   GRUNDKEIQBAL I, 1986, P NATL ACAD SCI USA, V83, P4913, DOI 10.1073/pnas.83.13.4913
   Guillemot-Legris O, 2017, TRENDS NEUROSCI, V40, P237, DOI 10.1016/j.tins.2017.02.005
   Hanger DP, 2009, TRENDS MOL MED, V15, P112, DOI 10.1016/j.molmed.2009.01.003
   Hao S, 2016, BRAIN BEHAV IMMUN, V51, P230, DOI 10.1016/j.bbi.2015.08.023
   Holubová M, 2019, NEUROPHARMACOLOGY, V144, P377, DOI 10.1016/j.neuropharm.2018.11.002
   Kacírová M, 2020, CLIN SCI, V134, P547, DOI 10.1042/CS20191313
   Korínková L, 2020, J MOL ENDOCRINOL, V64, P77, DOI 10.1530/JME-19-0188
   Ksiezak-Reding H, 2003, BBA-MOL BASIS DIS, V1639, P159, DOI 10.1016/j.bbadis.2003.09.001
   Laurent C, 2017, BRAIN, V140, P184, DOI 10.1093/brain/aww270
   Leboucher A, 2019, NEUROBIOL DIS, V125, P14, DOI 10.1016/j.nbd.2019.01.008
   Leboucher A, 2013, DIABETES, V62, P1681, DOI 10.2337/db12-0866
   Lin HK, 2014, CELL RES, V24, P785, DOI 10.1038/cr.2014.57
   Luo Y, 2002, BRAIN RES, V925, P42, DOI 10.1016/S0006-8993(01)03258-9
   Maletínská L, 2015, INT J OBESITY, V39, P986, DOI 10.1038/ijo.2015.28
   Mangold CA, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-017-0920-8
   Matysková R, 2008, PHYSIOL RES, V57, P727, DOI 10.33549/physiolres.931274
   Moroz N, 2008, J ALZHEIMERS DIS, V15, P29
   Pelantová H, 2016, MOL CELL ENDOCRINOL, V431, P88, DOI 10.1016/j.mce.2016.05.003
   Popelová A, 2018, J ALZHEIMERS DIS, V62, P1725, DOI 10.3233/JAD-171041
   Prazienková V, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0183449
   Qi HL, 2016, J BIOL CHEM, V291, P7742, DOI 10.1074/jbc.M115.700914
   Reynolds CH, 2000, J NEUROCHEM, V74, P1587, DOI 10.1046/j.1471-4159.2000.0741587.x
   Robison LS, 2020, ENEURO, V7, DOI 10.1523/ENEURO.0391-19.2019
   Schindowski K, 2006, AM J PATHOL, V169, P599, DOI 10.2353/ajpath.2006.060002
   Schwalbe M, 2015, STRUCTURE, V23, P1448, DOI 10.1016/j.str.2015.06.002
   Seibenhener ML, 2015, JOVE-J VIS EXP, DOI 10.3791/52434
   Spolcová A, 2014, BMC NEUROSCI, V15, DOI 10.1186/1471-2202-15-111
   Stoothoff WH, 2005, BBA-MOL BASIS DIS, V1739, P280, DOI 10.1016/j.bbadis.2004.06.017
   Thaler JP, 2012, J CLIN INVEST, V122, P153, DOI 10.1172/JCI59660
   Utton MA, 1997, BIOCHEM J, V323, P741, DOI 10.1042/bj3230741
   van der Harg JM, 2015, FRONT NEUROSCI-SWITZ, V9, DOI 10.3389/fnins.2015.00432
   Van der Jeugd A, 2013, J ALZHEIMERS DIS, V37, P777, DOI 10.3233/JAD-130110
NR 39
TC 14
Z9 15
U1 4
U2 20
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1742-2094
J9 J NEUROINFLAMM
JI J. Neuroinflamm.
PD JUN 22
PY 2021
VL 18
IS 1
AR 141
DI 10.1186/s12974-021-02190-3
PG 22
WC Immunology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology; Neurosciences & Neurology
GA SW4MT
UT WOS:000664491200001
PM 34158075
OA Green Published, gold
DA 2024-02-19
ER

PT J
AU Noureen, S
   Hussain, T
   Noureen, A
   Altyar, AE
AF Noureen, Saleha
   Hussain, Tanveer
   Noureen, Aasma
   Altyar, Ahmed E. E.
TI Effect of <i>Lactobacillus brevis</i> (MG000874) on antioxidant-related
   gene expression of the liver and kidney in D-galactose-induced oxidative
   stress mice model
SO ENVIRONMENTAL SCIENCE AND POLLUTION RESEARCH
LA English
DT Article; Early Access
DE Aging; Antioxidant; D-galactose; Lactic acid bacteria; Mice; Oxidative
   stress; RT-PCR
ID IMPAIRMENT; DAMAGE; RAT
AB Oxidative stress (OS) is a phenomenon induced by excessive production and accumulation of reactive oxygen species (ROS) in living cells. These increased ROS productions connected, coupled with many neurological and physiological diseases. Several antioxidants were utilized recently to combat OS, and lactic acid bacteria have a potent radical-scavenging activity to minimize OS. The present work was designed to find out the protective effects of Lactobacillus brevis MG000874 (L. brevis MG000874) against oxidative injuries induced by D-galactose (D-gal) in vivo and to explore the gene expression of OS-related gene mice. Sixty male mice were randomly split into six groups. The first four groups were different control groups as no treatment (N), positive (G), probiotic (B), and ascorbic acid (A); the remaining two groups were treatment groups such as probiotic treatment (BG) and ascorbic acid treatment (AG). L. brevis MG000874 (0.2 ml of 10(10) CFU/ml) and ascorbic acid (0.2 ml of 25 mg/ml) were administered orally daily for 5 weeks. It was revealed that these significantly affect the weight of treated mice: 40.22 & PLUSMN; 1.5 and 33.0 & PLUSMN; 0.57 g on days 0 and 36, respectively. D-gal induction in mice declined the levels of SOD and CAT determined by spectrophotometer. Administration of L. brevis MG000874 improved the antioxidant status of the stress mice and recovered the antioxidant activities of SOD and CAT enzymes. In addition, L. brevis MG000874-altered gene expression of OS marker at the messenger RNA (mRNA) levels was determined by RT-PCR in the mouse model. L. brevis MG000874 significantly improved the GST, GPX, SOD, CAT, and ss-actin levels in the kidney and the liver of the D-gal-induced mice (p < 0.05). Moreover, the histological investigation indicated that L. brevis MG000874 mitigated damage to the kidney and liver effectively in mice induced by D-gal. Therefore, it could be concluded from the current results that L. brevis MG000874 may act as a powerful antioxidant agent, and this study can provide the baseline data for drug development against OS-linked diseases.
C1 [Noureen, Saleha; Hussain, Tanveer; Noureen, Aasma] Virtual Univ Pakistan, Dept Biol, Lahore 54590, Pakistan.
   [Noureen, Aasma] Govt Coll Women Univ, Dept Zool, Faisalabad 38000, Pakistan.
   [Altyar, Ahmed E. E.] King Abdulaziz Univ, Fac Pharm, Pharm Practice, 80260, Jeddah 21589, Saudi Arabia.
C3 Virtual University of Pakistan; King Abdulaziz University
RP Noureen, S (corresponding author), Virtual Univ Pakistan, Dept Biol, Lahore 54590, Pakistan.
EM salehanoureen@yahoo.com
FU NAHE Higher Education Commission of Pakistan [532/IPFP-II
   (Batch-I)/SRGP/NAHE/HEC/2020/130]
FX & nbsp;This research was funded by the NAHE Higher Education Commission
   of Pakistan through grant no. 532/IPFP-II
   (Batch-I)/SRGP/NAHE/HEC/2020/130.
CR Almaghrabi OA, 2015, SAUDI J BIOL SCI, V22, P227, DOI 10.1016/j.sjbs.2014.12.008
   Arya A, 2021, BIOMOLECULES, V11, DOI 10.3390/biom11030350
   Asan-Ozusaglam M, 2022, J FOOD SAF FOOD QUAL, V73, P58, DOI 10.2376/0003-925X-73-58
   Brown RAM, 2018, BMC BIOTECHNOL, V18, DOI 10.1186/s12896-018-0421-6
   Chen ZQ, 2020, FOOD FUNCT, V11, P8099, DOI 10.1039/d0fo01663b
   Clairbone A, 1985, Handbook of Methods of Oxygen Radical Research, P283, DOI [10.1201/9781351072922, DOI 10.1201/9781351072922]
   DIMEO S, 2016, OXID MED CELL LONGEV, V2016, DOI DOI 10.1155/2016/1245049
   Eissa N, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0156289
   El-Sayed A, 2021, ENVIRON SCI POLLUT R, V28, P36967, DOI 10.1007/s11356-021-14593-z
   Fanzo J, 2020, GLOB FOOD SECUR-AGR, V26, DOI 10.1016/j.gfs.2020.100397
   Feng Y, 2016, PHARM BIOL, V54, P1027, DOI 10.3109/13880209.2015.1093510
   Ge QF, 2021, BMC MICROBIOL, V21, DOI 10.1186/s12866-021-02248-5
   Germoush MO, 2022, ENVIRON SCI POLLUT R, V29, P11320, DOI 10.1007/s11356-021-16481-y
   Ghazi S, 2022, BIOL TRACE ELEM RES, V200, P364, DOI 10.1007/s12011-021-02631-3
   Hart PC, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7053
   Hassani S, 2018, EXCLI J, V17, P57, DOI 10.17179/excli2017-760
   Iqbal N, 2022, BIOMED PHARMACOTHER, V156, DOI 10.1016/j.biopha.2022.113840
   Li F, 2020, FOOD SCI NUTR, V8, P379, DOI 10.1002/fsn3.1318
   Li JJ, 2015, BRAIN RES, V1595, P19, DOI 10.1016/j.brainres.2014.10.012
   Li WY, 2022, FOOD FUNCT, V13, P3690, DOI [10.1039/d1fo03538j, 10.1039/D1FO03538J]
   Liguori I, 2018, CLIN INTERV AGING, V13, P757, DOI 10.2147/CIA.S158513
   Lin XN, 2018, J FOOD SCI, V83, P1990, DOI 10.1111/1750-3841.14200
   Landete JM, 2017, BIOMED RES INT, V2017, DOI 10.1155/2017/5939818
   Motataianu A, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23169339
   Noureen S, 2019, J APPL MICROBIOL, V126, P1221, DOI 10.1111/jam.14189
   Qian Y, 2018, MOLECULES, V23, DOI 10.3390/molecules23113026
   Qiu Y, 2017, J MED FOOD, V20, P557, DOI 10.1089/jmf.2016.3870
   Ramos OY, 2020, J APPL MICROBIOL, V128, P1248, DOI 10.1111/jam.14469
   Rehman FU, 2022, PHARMACEUTICALS-BASE, V15, DOI 10.3390/ph15091064
   Rezaei M, 2020, LWT-FOOD SCI TECHNOL, V132, DOI 10.1016/j.lwt.2020.109823
   Sang Y, 2017, FOOD FUNCT, V8, P2331, DOI [10.1039/c7fo00037e, 10.1039/C7FO00037E]
   Selvaratnam JS, 2016, BIOL REPROD, V95, DOI 10.1095/biolreprod.116.141671
   Sharma VK, 2021, BIOMOLECULES, V11, DOI 10.3390/biom11050678
   Shen M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123418
   Shen QA, 2011, CURR MICROBIOL, V62, P1097, DOI 10.1007/s00284-010-9827-7
   Shwe T, 2018, EXP GERONTOL, V101, P13, DOI 10.1016/j.exger.2017.10.029
   Stroustrup N, 2018, CURR OPIN CELL BIOL, V55, P129, DOI 10.1016/j.ceb.2018.07.004
   Unban K, 2021, FERMENTATION-BASEL, V7, DOI 10.3390/fermentation7030195
   Wells JC, 2020, LANCET, V395, P75, DOI 10.1016/S0140-6736(19)32472-9
   Woo JY, 2014, ANAEROBE, V27, P22, DOI 10.1016/j.anaerobe.2014.03.003
   Xu C, 2018, FISH SHELLFISH IMMUN, V76, P48, DOI 10.1016/j.fsi.2018.02.041
   Xu LQ, 2016, FOOD FUNCT, V7, P4545, DOI 10.1039/c6fo01057a
   Yadav R, 2019, PROBIOTICS ANTIMICRO, V11, P509, DOI 10.1007/s12602-018-9429-4
   Zhao JC, 2018, FOOD FUNCT, V9, P917, DOI [10.1039/c7fo01574g, 10.1039/C7FO01574G]
   Zheng GQ, 2016, J FUNCT FOODS, V27, P310, DOI 10.1016/j.jff.2016.09.015
NR 45
TC 1
Z9 1
U1 5
U2 5
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0944-1344
EI 1614-7499
J9 ENVIRON SCI POLLUT R
JI Environ. Sci. Pollut. Res.
PD 2023 JUL
PY 2023
VL 30
IS 35
BP 84099
EP 84109
DI 10.1007/s11356-023-28203-7
EA JUN 2023
PG 11
WC Environmental Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Environmental Sciences & Ecology
GA S7EY7
UT WOS:001020055900003
PM 37355509
OA Green Submitted
DA 2024-02-19
ER

PT J
AU MAZIN, AL
AF MAZIN, AL
TI THE GENOME LOSES ALL 5-METHYLCYTOSINE DURING THE LIFE-SPAN - HOW IS THIS
   RELATED TO ACCUMULATION OF MUTATIONS WITH AGING
SO MOLECULAR BIOLOGY
LA English
DT Article
AB The 5-methylcytosine (5mC) content in liver DNA was determined for rats of different age. The rate of the 5mC loss from DNA is maximal in pre- and neonatal rats, 1.28% per day, then it decreases to 0.33%, and becomes minimal and constant in adult rats, 0.028% per day. During embryonal and the first 15 days of postnatal development the rat genome loses 49% of 5mC. Within the next 45 days, a furter 15 % of 5mC disappears, and during the maximal rat lifespan, which is about four years, 39% of the genomic 5mC may be lost. Thus it was found for the first time that the animal genome can lose practically all 5mC residues during the lifespan. Analysis of the literature data shows that for embryos the rate of 5mC loss from DNA proves to be higher than that for adult animals: 96 times for mice, 69 for rats, and 29 for cows. The rate of embryonal DNA hypomethylation is inversely proportional to the pregnancy duration of species. In adult animals it correlates inversely with their maximal lifespan, being 0.028% daily for mice, 0.024% for rats, 0.007% for hamsters, 0.004% for cows, and 0.0004% for humans. During ontogeny, the genome of a mouse loses 93% of the 5mC residues, that of a rat 101%, and that of a cow 87%. The age-dependent loss of 5mC from DNA is also typical for cell lines aging in vitro. As a rule, it is constant and correlates with the number of cell population doublings (PD). The removal of all 5mC from DNA corresponds to 70-130 PD for human, 40-60 PD for hamster, and 6 PD for mouse cells. In immortal lines the level of DNA methylation is stable or grows with age. A possible mechanism of age-related 5mC loss from DNA is discussed. DNA hypomethylation may result from 5mC deamination directly in the course of replicative DNA methylation and subsequent repair of the G . T mispairs which leads to accumulation of 5mC --> T+C substitutions in the genome with each cell division. Hence, DNA methylation may serve as an ideal mechanism for counting cell divisions in vivo and in vitro. The calculated average rate of accumulation of the 5mC --> T transitions was 7.8 . 10(-7) for mouse, 6.8 . 10(-7) for rat, 3.4 . 10(-7) for hamster, 0.9 . 10(-7) for cow, and 2.3 . 10(-8) for human cells per nucleotide per day. It is inferred that enzymatic DNA methylation is one of the powerful generators of mutations in cell.
RP MAZIN, AL (corresponding author), MOSCOW MV LOMONOSOV STATE UNIV, AN BELOZERSKY INST PHYSICOCHEM BIOL, MOSCOW 119899, RUSSIA.
CR ADAMS RLP, 1990, BIOCHEM J, V265, P309, DOI 10.1042/bj2650309
   ADAMS RLP, 1990, FEBS LETT, V269, P29, DOI 10.1016/0014-5793(90)81111-Z
   ALEKSANDRUSHKINA N I, 1991, Biokhimiya, V56, P361
   BERDYSHEV G. D., 1967, BIOKHIMIYA, V32, P988
   BROWN TC, 1987, CELL, V50, P945, DOI 10.1016/0092-8674(87)90521-6
   CARRANO AV, 1989, GENOME, V31, P458, DOI 10.1139/g89-079
   CATANIA J, 1991, MUTAT RES, V256, P283, DOI 10.1016/0921-8734(91)90019-8
   CHOCHLOV AN, 1988, ISVEST ACAD SCI US B, V3, P476
   COOPER DN, 1988, HUM GENET, V78, P151, DOI 10.1007/BF00278187
   CULP LA, 1970, ARCH BIOCHEM BIOPHYS, V136, P73, DOI 10.1016/0003-9861(70)90328-0
   DIAMOND JM, 1987, NATURE, V329, P487, DOI 10.1038/329487a0
   DOERFLER W, 1990, FEBS LETT, V268, P329, DOI 10.1016/0014-5793(90)81280-2
   DRINKWATER RD, 1989, MUTAT RES, V219, P29, DOI 10.1016/0921-8734(89)90038-6
   EHRLICH M, 1990, MUTAT RES, V238, P277, DOI 10.1016/0165-1110(90)90019-8
   FAIRWEATHER DS, 1987, EXP CELL RES, V168, P153, DOI 10.1016/0014-4827(87)90424-1
   GOLBUS J, 1990, EUR J IMMUNOL, V20, P1869, DOI 10.1002/eji.1830200836
   GRAFSTROM RH, 1985, NUCLEIC ACIDS RES, V13, P2827, DOI 10.1093/nar/13.8.2827
   GRAY MD, 1991, J CELL PHYSIOL, V149, P477, DOI 10.1002/jcp.1041490317
   GRIPPO P, 1970, BIOCHEMISTRY-US, V9, P2605, DOI 10.1021/bi00815a007
   GRIST SA, 1992, MUTAT RES, V266, P189, DOI 10.1016/0027-5107(92)90186-6
   HAYFLICK L, 1991, MUTAT RES, V256, P69, DOI 10.1016/0921-8734(91)90002-S
   HELDEN EGH, 1989, MUTAT RES, V219, P263
   HOLLIDAY R, 1975, FED PROC, V34, P51
   HOWLETT D, 1989, MUTAT RES, V219, P101, DOI 10.1016/0921-8734(89)90020-9
   INAMIZU T, 1986, P NATL ACAD SCI USA, V83, P2488, DOI 10.1073/pnas.83.8.2488
   IVANETICH KM, 1992, PROG NUCLEIC ACID RE, V42, P127, DOI 10.1016/S0079-6603(08)60575-9
   JEFFREYS AJ, 1988, NATURE, V332, P278, DOI 10.1038/332278a0
   JOSSE J, 1961, J BIOL CHEM, V236, P864
   KAUTIAINEN TL, 1986, J BIOL CHEM, V261, P1594
   MATSUMURA T, 1989, EXP CELL RES, V184, P148, DOI 10.1016/0014-4827(89)90373-X
   MAZIN A L, 1985, Molekulyarnaya Biologiya (Moscow), V19, P903
   MAZIN A L, 1987, Molekulyarnaya Biologiya (Moscow), V21, P678
   MAZIN AL, 1987, MOL BIOL+, V21, P914
   MAZIN AL, 1987, MOL BIOL+, V21, P566
   MAZIN AL, 1984, DOKL AKAD NAUK SSSR+, V276, P760
   MONK M, 1990, PHILOS T R SOC B, V326, P299, DOI 10.1098/rstb.1990.0013
   ORGEL LE, 1970, P NATL ACAD SCI USA, V67, P1476, DOI 10.1073/pnas.67.3.1476
   REIS RJS, 1982, P NATL ACAD SCI-BIOL, V79, P3949, DOI 10.1073/pnas.79.13.3949
   RIGGS AD, 1990, PHILOS T R SOC B, V326, P285, DOI 10.1098/rstb.1990.0012
   ROMANOV GA, 1981, BIOCHIM BIOPHYS ACTA, V653, P204, DOI 10.1016/0005-2787(81)90156-8
   RYDBERG B, 1982, EMBO J, V1, P211, DOI 10.1002/j.1460-2075.1982.tb01149.x
   SANFORD J, 1984, NUCLEIC ACIDS RES, V12, P2823, DOI 10.1093/nar/12.6.2823
   SINGHAL RP, 1987, MECH AGEING DEV, V41, P199, DOI 10.1016/0047-6374(87)90040-6
   SLAGBOOM PE, 1991, MUTAT RES, V256, P311, DOI 10.1016/0921-8734(91)90022-4
   STURM KS, 1981, NUCLEIC ACIDS RES, V9, P4537, DOI 10.1093/nar/9.18.4537
   SULLIVAN KF, 1986, P NATL ACAD SCI USA, V83, P4327, DOI 10.1073/pnas.83.12.4327
   TAWA R, 1992, MECH AGEING DEV, V62, P255, DOI 10.1016/0047-6374(92)90111-P
   TAWA R, 1990, DIFFERENTIATION, V45, P44, DOI 10.1111/j.1432-0436.1990.tb00455.x
   THEISS G, 1987, EUR J BIOCHEM, V167, P89, DOI 10.1111/j.1432-1033.1987.tb13307.x
   VANYUSHI.BF, 1973, GERONTOLOGY, V19, P138, DOI 10.1159/000211967
   VANYUSHIN B F, 1979, Biokhimiya, V44, P78
   VANYUSHIN BF, 1973, BIOCHIM BIOPHYS ACTA, V229, P397
   VIJG J, 1990, J GERONTOL, V45, pB179, DOI 10.1093/geronj/45.5.B179
   WILKS A, 1984, NUCLEIC ACIDS RES, V12, P1163, DOI 10.1093/nar/12.2.1163
   WILSON VL, 1987, J BIOL CHEM, V262, P9948
   WILSON VL, 1983, SCIENCE, V220, P1054
   WOODCOCK DM, 1988, GENE, V74, P151, DOI 10.1016/0378-1119(88)90273-9
   ZIN'KOVSKAYA G G, 1978, Biokhimiya, V43, P1883
NR 58
TC 2
Z9 2
U1 0
U2 2
PU MAIK NAUKA/INTERPERIODICA/SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013-1578 USA
SN 0026-8933
EI 1608-3245
J9 MOL BIOL+
JI Mol. Biol.
PD JAN-FEB
PY 1993
VL 27
IS 1
BP 96
EP 104
PN 2
PG 9
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA MJ856
UT WOS:A1993MJ85600005
DA 2024-02-19
ER

PT J
AU Li, GJ
   Xiang, S
   Pan, YN
   Long, XY
   Cheng, YJ
   Han, L
   Zhao, X
AF Li, Guijie
   Xiang, Sha
   Pan, Yanni
   Long, Xingyao
   Cheng, Yujiao
   Han, Leng
   Zhao, Xin
TI Effects of Cold-Pressing and Hydrodistillation on the Active
   Non-volatile Components in Lemon Essential Oil and the Effects of the
   Resulting Oils on Aging-Related Oxidative Stress in Mice
SO FRONTIERS IN NUTRITION
LA English
DT Article
DE cold-expression; furocoumarins; coumarins; antioxidant; oxidative stress
ID ORANGE PEEL OIL; VITAMIN-C; IN-VITRO; ANTIOXIDANT ACTIVITY;
   PLANT-EXTRACTS; CITRUS-LIMON; DAMAGE; PERFORMANCE; CAPACITY; PROTECTS
AB The aim of this study was to analyze the non-volatile composition and antioxidant differences of lemon essential oils (LEOs) obtained by cold-pressing vs. hydrodistillation. Pathological observations showed that LEO effectively inhibited liver injury caused by oxidative stress, and CPLEO was more effective than HDLEO. CPLEO increased serum T-AOC, SOD, GSH, and GSH-Px levels while decreasing NO, COX-2, IL-6, IL-1 beta, IFN-gamma, and TNF-alpha levels in mice with oxidative damage. The effects of CPLEO were stronger than those of HDLEO and similar to those of vitamin C. CPLEO upregulated mRNA and protein expressions of Cu/Zn-SOD, Mn-SOD, CAT, HO-1, Nrf2, and NQO1 while downregulating nNOS, iNOS, IL-1 beta, COX-2, TNF-alpha, and NF-kappa B mRNA expression and nNOS, eNOS, iNOS, and COX-2 protein expression in mice with oxidative damage. The results demonstrate that LEO has good antioxidant effects and that CPLEO has a better antioxidant effect than HDLEO as it retains more active non-volatile substances.
C1 [Li, Guijie; Cheng, Yujiao; Han, Leng] Southwest Univ, Citrus Res Inst, Natl Citrus Engn Res Ctr, Chongqing, Peoples R China.
   [Pan, Yanni; Long, Xingyao; Zhao, Xin] Chongqing Univ Educ, Chongqing Engn Lab Res & Dev Funct Food, Chongqing Engn Res Ctr Funct Food, Chongqing Collaborat Innovat Ctr Funct Food, Chongqing, Peoples R China.
   [Li, Guijie; Cheng, Yujiao] Natl Citrus Engn Res Ctr, Chongqing, Peoples R China.
   [Xiang, Sha] Army Med Univ, Xinqiao Hosp, Dept Dermatol, Chongqing, Peoples R China.
C3 Southwest University - China; Chongqing University of Education; Army
   Medical University
RP Han, L (corresponding author), Southwest Univ, Citrus Res Inst, Natl Citrus Engn Res Ctr, Chongqing, Peoples R China.; Zhao, X (corresponding author), Chongqing Univ Educ, Chongqing Engn Lab Res & Dev Funct Food, Chongqing Engn Res Ctr Funct Food, Chongqing Collaborat Innovat Ctr Funct Food, Chongqing, Peoples R China.
EM hanleng5@cric.cn; zhaoxin@cque.edu.cn
FU Fundamental Research Funds for the Central Universities [XDJK2020C026];
   Natural Science Foundation of Chongqing [cstc2019jcyj-bshX0104];
   Open-project of National Citrus Engineering Research Centre of China
   [NCERC2019004]; University-local Authorities Cooperation Project of
   Southwest University [2020001040]
FX This research was funded by Fundamental Research Funds for the Central
   Universities, Grant Number XDJK2020C026; Natural Science Foundation of
   Chongqing, Grant Number cstc2019jcyj-bshX0104; Open-project of National
   Citrus Engineering Research Centre of China, Grant Number NCERC2019004;
   and University-local Authorities Cooperation Project of Southwest
   University, Grant Number 2020001040.
CR Amiri H, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/728065
   Apak R, 2016, J AGR FOOD CHEM, V64, P1046, DOI 10.1021/acs.jafc.5b04744
   Balogh GT, 2003, ARCH BIOCHEM BIOPHYS, V410, P76, DOI 10.1016/S0003-9861(02)00661-6
   Ben Hsouna A, 2017, LIPIDS HEALTH DIS, V16, DOI 10.1186/s12944-017-0487-5
   Bertuzzi G., 2013, European Journal of Medicinal Plants, V3, P1
   Caldwell CR, 2001, ANAL BIOCHEM, V293, P232, DOI 10.1006/abio.2001.5134
   Ceccarelli I, 2004, BRAIN RES, V1001, P78, DOI 10.1016/j.brainres.2003.10.063
   Chen HH, 2012, FREE RADICAL BIO MED, V52, P1054, DOI 10.1016/j.freeradbiomed.2011.12.012
   Chen YL, 2014, J AGR FOOD CHEM, V62, P8786, DOI 10.1021/jf501079r
   Chiang YM, 2005, BRIT J PHARMACOL, V146, P352, DOI 10.1038/sj.bjp.0706343
   Choi JS, 2011, PLANTA MED, V77, P1512, DOI 10.1055/s-0030-1270917
   Dugo P, 2011, MED AROMAT PLANTS-IN, V49, P405
   Ferhat M.A., 2016, ELECTRON J BIOL, V1, P30
   Ferhat MA, 2007, FLAVOUR FRAG J, V22, P494, DOI 10.1002/ffj.1829
   Gedikoglu A, 2019, FOOD SCI NUTR, V7, P1704, DOI 10.1002/fsn3.1007
   Goven D, 2009, FEBS LETT, V583, P3508, DOI 10.1016/j.febslet.2009.10.010
   Gultekin F, 2001, ARCH TOXICOL, V75, P88, DOI 10.1007/s002040100219
   Kirkan B, 2019, FLAVOUR FRAG J, V34, P436, DOI 10.1002/ffj.3522
   Lacza Z, 2003, FREE RADICAL BIO MED, V35, P1217, DOI 10.1016/S0891-5849(03)00510-0
   Lee Hyunjoo, 2018, Prev Nutr Food Sci, V23, P8, DOI 10.3746/pnf.2018.23.1.8
   Li F, 2020, FOOD SCI NUTR, V8, P379, DOI 10.1002/fsn3.1318
   Li GJ, 2018, APPL SCI-BASEL, V8, DOI 10.3390/app8050752
   Li GJ, 2021, DRUG DES DEV THER, V15, P937, DOI 10.2147/DDDT.S299678
   Li GJ, 2020, J FUNCT FOODS, V67, DOI 10.1016/j.jff.2020.103834
   Lin CH, 2002, J PHARM PHARMACOL, V54, P1271, DOI 10.1211/002235702320402125
   Liu XY, 2018, J FUNCT FOODS, V45, P110, DOI 10.1016/j.jff.2018.03.037
   Liu YY, 2020, ACS OMEGA, V5, P25467, DOI 10.1021/acsomega.0c04318
   Miyake Y, 1999, J AGR FOOD CHEM, V47, P3151, DOI 10.1021/jf980999y
   Odewumi CO, 2011, TOXICOL IN VITRO, V25, P1733, DOI 10.1016/j.tiv.2011.08.013
   Pan YN, 2020, J FOOD BIOCHEM, V44, DOI 10.1111/jfbc.13291
   Perdones A, 2016, FOOD CHEM, V197, P979, DOI 10.1016/j.foodchem.2015.11.054
   Qian Y, 2018, MOLECULES, V23, DOI 10.3390/molecules23112848
   Rafiee F, 2016, J ANIM PHYSIOL AN N, V100, P807, DOI 10.1111/jpn.12457
   Reziwan K, 2019, CELL BIOCHEM FUNCT, V37, P256, DOI 10.1002/cbf.3394
   Thomas CJ, 1999, CHEMOSPHERE, V39, P2489, DOI 10.1016/S0045-6535(99)00161-7
   Wang X, 2020, EVID-BASED COMPL ALT, V2020, DOI 10.1155/2020/8860603
   Warraich UEA, 2020, HELIYON, V6, DOI 10.1016/j.heliyon.2020.e04107
   Watson K, 2019, COMPLEMENT THER MED, V42, P366, DOI 10.1016/j.ctim.2018.12.016
   Willoughby DA, 2000, LANCET, V355, P646, DOI 10.1016/S0140-6736(99)12031-2
   Wrona M, 2021, FOOD CONTROL, V120, DOI 10.1016/j.foodcont.2020.107536
   Yang CM, 2020, BIOMOLECULES, V10, DOI 10.3390/biom10030381
   Yosr Z, 2013, IND CROP PROD, V43, P412, DOI 10.1016/j.indcrop.2012.07.044
   You W, 2019, PHARMAZIE, V74, P698, DOI 10.1691/ph.2019.9615
   Yu G, 2016, IRAN J BASIC MED SCI, V19, P1136
   Zhao DR, 2019, J FUNCT FOODS, V55, P95, DOI 10.1016/j.jff.2019.01.047
   Zhou YL, 2019, ANTIOXIDANTS-BASEL, V8, DOI 10.3390/antiox8110524
   Zhu K, 2019, FOOD SCI NUTR, V7, P4105, DOI 10.1002/fsn3.1278
NR 47
TC 11
Z9 12
U1 1
U2 20
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2296-861X
J9 FRONT NUTR
JI Front. Nutr.
PD JUN 14
PY 2021
VL 8
AR 689094
DI 10.3389/fnut.2021.689094
PG 15
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Nutrition & Dietetics
GA TA1WR
UT WOS:000667045400001
PM 34195220
OA gold, Green Published
DA 2024-02-19
ER

PT J
AU Kassassir, H
   Karolczak, K
   Siewiera, KM
   Wojkowska, DW
   Braun, M
   Watala, CW
AF Kassassir, Hassan
   Karolczak, Kamil
   Siewiera, Karolina M.
   Wojkowska, Dagmara W.
   Braun, Marcin
   Watala, Cezary W.
TI Time-dependent interactions of blood platelets and cancer cells,
   accompanied by extramedullary hematopoiesis, lead to increased platelet
   activation and reactivity in a mouse orthotopic model of breast cancer -
   implications for pulmonary and liver metastasis
SO AGING-US
LA English
DT Article
DE platelets; metastasis; breast cancer
ID VON-WILLEBRAND-FACTOR; INTEGRIN ALPHA(IIB)BETA(3);
   CARDIOVASCULAR-DISEASE; TUMOR PROGRESSION; GLYCOPROTEIN-IB;
   RISK-FACTORS; AGGREGATION; COAGULATION; INHIBITION; ADHESION
AB Aging has become a significant risk factor for several diseases, including breast cancer.
   Platelet activation and platelet-cancer cell aggregate fractions were found to increase with tumor progression in a mouse model of breast cancer. At advanced stages of tumor development, platelets from mice with breast cancer were hyperreactive to low agonist concentrations and hyporeactive to high ones. Platelet activation and reactivity were strongly associated with breast cancer metastasis in the lungs and extramedullary hematopoiesis in the liver. A greater fraction of platelet aggregates was observed in 4T1-injected mice at the advanced stages of breast cancer. In vitro, platelet activation was elevated after incubation with 4T1 cells, and thrombin-stimulated platelets formed aggregates with 4T1 cells. Neither GPIba, nor GPIIb/IIIa blocking antibodies, were able to affect platelet-cancer cell aggregation in vitro. The primed circulating platelets became more sensitive to subthreshold stimuli at advanced stages of tumor development, and the formation of platelet-cancer cell aggregates increased with cancer progression. Our findings demonstrate that the age-associated progression of breast cancer cells is connected with increased platelet functioning, and that it can be manifested by the increased number of metastases and extramedullary hematopoiesis in a time-dependent-manner.
C1 [Kassassir, Hassan; Karolczak, Kamil; Siewiera, Karolina M.; Wojkowska, Dagmara W.; Watala, Cezary W.] Med Univ Lodz, Fac Hlth Sci, Dept Haemostat Disorders, Lodz, Poland.
   [Braun, Marcin] Med Univ Lodz, Dept Pathol, Lodz, Poland.
   [Braun, Marcin] Warsaw Med Univ, Postgrad Sch Mol Med, Warsaw, Poland.
   [Siewiera, Karolina M.] Med Univ Lodz, Dept Cytobiol & Prote, Lodz, Poland.
C3 Medical University Lodz; Medical University Lodz; Medical University of
   Warsaw; Medical University Lodz
RP Karolczak, K (corresponding author), Med Univ Lodz, Fac Hlth Sci, Dept Haemostat Disorders, Lodz, Poland.
EM kamilkarolczak@gmail.com
RI Karolczak, Kamil/HDM-6855-2022; Braun, Marcin Grzegorz/N-9235-2019;
   Watala, Cezary/ABF-4863-2020
OI Karolczak, Kamil/0000-0001-5866-7244; Braun, Marcin
   Grzegorz/0000-0003-3804-7042; Watala, Cezary/0000-0002-5627-7872;
   Wojkowska, Dagmara/0000-0002-9317-9817
FU National Center for Research and Development (Cracow, Poland) under the
   Polish Strategic Framework Program STRATEGMED "Prevention practices and
   treatment of civilization" [STRATEGMED1/233226/11/NCBR/2015]
FX This work was supported by grant "Prostacyclin, nitric oxide and carbon
   monoxide -based pharmacotherapy of endothelial dysfunction and platelet
   activation - a novel strategy to inhibit cancer metastasis" (acronym:
   METENDOPHA) funded by the National Center for Research and Development
   (Cracow, Poland) under the Polish Strategic Framework Program STRATEGMED
   "Prevention practices and treatment of civilization" (grant coordinated
   by Jagiellonian Center for Experimental Therapeutics - Jagiellonian
   University, Cracow, Poland), No. STRATEGMED1/233226/11/NCBR/2015. The
   founders had no roles in a study design, data collection and analysis, a
   decision to publish, or a preparation of the manuscript.
CR Abaeva AA, 2013, J BIOL CHEM, V288, P29621, DOI 10.1074/jbc.M113.474163
   Akinbami A, 2013, CASP J INTERN MED, V4, P574
   Alexander ET, 2015, CANCER BIOL THER, V16, P1802, DOI 10.1080/15384047.2015.1078025
   Arndt V, 2002, BRIT J CANCER, V86, P1034, DOI 10.1038/sj.bjc.6600209
   Aunan JR, 2017, AGING DIS, V8, P628, DOI 10.14336/AD.2017.0103
   Benz CC, 2008, CRIT REV ONCOL HEMAT, V66, P65, DOI 10.1016/j.critrevonc.2007.09.001
   Bergmeier W, 2002, CYTOMETRY, V48, P80, DOI 10.1002/cyto.10114
   Bottsford-Miller J, 2015, CLIN CANCER RES, V21, P602, DOI 10.1158/1078-0432.CCR-14-0870
   Bouillon K, 2011, J AM COLL CARDIOL, V57, P445, DOI 10.1016/j.jacc.2010.08.638
   Bradshaw PT, 2016, EPIDEMIOLOGY, V27, P6, DOI 10.1097/EDE.0000000000000394
   Buczek E, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-4445-z
   Chaari M, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-991
   Chen ZS, 2016, ARTIF ORGANS, V40, P659, DOI 10.1111/aor.12606
   Chou YC, 2007, BREAST CANCER RES TR, V101, P199, DOI 10.1007/s10549-006-9278-9
   Cooke NM, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1634-x
   Coupland LA, 2012, CANCER RES, V72, P4662, DOI 10.1158/0008-5472.CAN-11-4010
   Cranmer SL, 2011, BLOOD, V117, P2718, DOI 10.1182/blood-2010-07-296194
   De Meyer SF, 2010, ARTERIOSCL THROM VAS, V30, P1949, DOI 10.1161/ATVBAHA.110.208918
   DEMARCO L, 1986, J CLIN INVEST, V77, P1272, DOI 10.1172/JCI112430
   Elaïb Z, 2016, BLOOD, V128, P1129, DOI 10.1182/blood-2015-10-678383
   Falange A, 2017, CRIT REV ONCOL HEMAT, V118, P79, DOI 10.1016/j.critrevonc.2017.08.003
   Fillmore C, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1673
   GASIC GJ, 1968, P NATL ACAD SCI USA, V61, P46, DOI 10.1073/pnas.61.1.46
   Gebremeskel S, 2015, INT J CANCER, V136, P234, DOI 10.1002/ijc.28947
   Gomes FG, 2017, THROMB RES, V159, P24, DOI 10.1016/j.thromres.2017.09.019
   Greenwell Jean, 1991, Hawaiian Journal of History, V25, P121
   Hooning MJ, 2007, JNCI-J NATL CANCER I, V99, P365, DOI 10.1093/jnci/djk064
   Hron G, 2007, THROMB HAEMOSTASIS, V97, P119, DOI 10.1160/TH06-03-0141
   Johns JL, 2012, VET PATHOL, V49, P508, DOI 10.1177/0300985811432344
   Jurasz P, 2001, BRIT J PHARMACOL, V134, P1104, DOI 10.1038/sj.bjp.0704343
   Kim CH, 2010, J BLOOD MED, V1, P13, DOI 10.2147/JBM.S7224
   Kuroiwa T, 2001, J CLIN INVEST, V107, P1365, DOI 10.1172/JCI11808
   Labelle M, 2014, P NATL ACAD SCI USA, V111, pE3053, DOI 10.1073/pnas.1411082111
   Laresche C, 2014, J INVEST DERMATOL, V134, P176, DOI 10.1038/jid.2013.288
   Le Behot A, 2014, BLOOD, V123, P3354, DOI 10.1182/blood-2013-12-543074
   Leoncini G, 2007, J CELL BIOCHEM, V100, P1255, DOI 10.1002/jcb.21123
   Li R, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-167
   Lin J, 2010, CANCER RES, V70, P2397, DOI 10.1158/0008-5472.CAN-09-3648
   Liu YY, 2009, J BIOMED BIOTECHNOL, DOI 10.1155/2009/829243
   Liu Y, 2011, CANCER RES, V71, P6492, DOI 10.1158/0008-5472.CAN-11-1145
   Lonsdorf AS, 2012, J BIOL CHEM, V287, P2168, DOI 10.1074/jbc.M111.269811
   Lou XL, 2015, CHINESE J CANCER RES, V27, P450, DOI 10.3978/j.issn.1000-9604.2015.04.10
   Macki M, 2013, J CLIN NEUROSCI, V20, P1664, DOI 10.1016/j.jocn.2013.06.003
   Makoni SN, 2004, AM J HEMATOL, V76, P92, DOI 10.1002/ajh.20046
   Maronpot RR., NONNEOPLASTIC LESION
   Marx I, 2008, BLOOD, V112, P603, DOI 10.1182/blood-2008-02-142943
   Mattheij NJA, 2016, HAEMATOLOGICA, V101, P427, DOI 10.3324/haematol.2015.131441
   Mattheij NJA, 2013, J BIOL CHEM, V288, P13325, DOI 10.1074/jbc.M112.428359
   McCarty OJT, 2006, J THROMB HAEMOST, V4, P1367, DOI 10.1111/j.1538-7836.2006.01966.x
   Melani C, 2003, BLOOD, V102, P2138, DOI 10.1182/blood-2003-01-0190
   Mitrugno A, 2014, BLOOD, V123, P249, DOI 10.1182/blood-2013-03-492447
   Morganti M, 1996, BIOMED PHARMACOTHER, V50, P373, DOI 10.1016/S0753-3322(96)89671-5
   Naimushin YA, 2004, PLATELETS, V15, P419, DOI 10.1080/09537100410001721333
   Nikitenko LL, 2009, CELL TISSUE RES, V335, P223, DOI 10.1007/s00441-008-0707-4
   Olas B, 2001, CANCER LETT, V169, P165, DOI 10.1016/S0304-3835(01)00545-6
   Olas B, 2001, PLATELETS, V12, P431, DOI 10.1080/09537100120085469
   Paschall AV, 2016, JOVE-J VIS EXP, DOI 10.3791/54040
   Patnaik JL, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2901
   Pham CM, 2013, AM J DERMATOPATH, V35, pE34, DOI 10.1097/DAD.0b013e3182761362
   Przygodzki T, 2018, PLATELETS, V29, P476, DOI 10.1080/09537104.2017.1332365
   Qi CL, 2015, ONCOTARGET, V6, P6584, DOI 10.18632/oncotarget.3164
   Quinn MJ, 2003, ARTERIOSCL THROM VAS, V23, P945, DOI 10.1161/01.ATV.0000066686.46338.F1
   Ravelli A, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317695023
   Ricardo S, 2011, J CLIN PATHOL, V64, P937, DOI 10.1136/jcp.2011.090456
   Röhsig LM, 2001, BRAZ J MED BIOL RES, V34, P1125
   Rossaint J, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13464
   Rozalski M, 2014, THROMB RES, V133, P1097, DOI 10.1016/j.thromres.2014.03.041
   Sarratt KL, 2005, BLOOD, V106, P1268, DOI 10.1182/blood-2004-11-4434
   Schober JM, 2003, J THROMB HAEMOST, V1, P2404, DOI 10.1046/j.1538-7836.2003.00417.x
   Shipitsin M, 2007, CANCER CELL, V11, P259, DOI 10.1016/j.ccr.2007.01.013
   Smetana K, 2016, ANTICANCER RES, V36, P5009, DOI 10.21873/anticanres.11069
   Solinas C, 2017, BREAST, V35, P142, DOI 10.1016/j.breast.2017.07.005
   TERRES W, 1991, THROMB RES, V62, P649, DOI 10.1016/0049-3848(91)90369-8
   Tesfamariam B, 2016, PHARMACOL THERAPEUT, V157, P112, DOI 10.1016/j.pharmthera.2015.11.005
   Thomas GA, 2009, CLIN ONCOL-UK, V21, P81, DOI 10.1016/j.clon.2008.11.006
   TSAMANDAS AC, 1995, MODERN PATHOL, V8, P671
   Tseng CC, 2013, DIS MARKERS, V2013, P301, DOI 10.1155/2013/715472
   Vaezzadeh N, 2014, THROMB HAEMOSTASIS, V112, P412, DOI 10.1160/TH13-11-0919
   Vassiliou Vassilios, 2012, J Gastrointest Cancer, V43 Suppl 1, pS131, DOI 10.1007/s12029-012-9370-9
   Wang S, 2016, J TRADIT CHIN MED, V36, P530
   Wannemacher KM, 2010, BLOOD, V116, P5707, DOI 10.1182/blood-2010-04-279943
   Wenzel J, 2010, CLIN EXP METASTAS, V27, P25, DOI 10.1007/s10585-009-9299-y
   Xu XR, 2018, BLOOD, V131, P1777, DOI 10.1182/blood-2017-05-743187
   Yang H, 2009, BLOOD, V114, P425, DOI 10.1182/blood-2008-03-145821
   Yang XJ, 2013, CLIN EXP METASTAS, V30, P711, DOI 10.1007/s10585-012-9559-0
   Yokota N, 2014, J THROMB HAEMOST, V12, P71, DOI 10.1111/jth.12442
   Zara Marta, 2017, TH Open, V1, pe155, DOI 10.1055/s-0037-1613674
   Zarà M, 2018, CELL SIGNAL, V48, P45, DOI 10.1016/j.cellsig.2018.04.008
   Zhao FL, 2014, CANCER LETT, V344, P62, DOI 10.1016/j.canlet.2013.10.019
   Zinger A, 2017, AGING DIS, V8, P611, DOI 10.14336/AD.2016.1230
   Zuchtriegel G, 2016, PLOS BIOL, V14, DOI 10.1371/journal.pbio.1002459
NR 91
TC 11
Z9 11
U1 0
U2 15
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
SN 1945-4589
J9 AGING-US
JI Aging-US
PD MAR 31
PY 2020
VL 12
IS 6
BP 5091
EP 5120
DI 10.18632/aging.102933
PG 30
WC Cell Biology; Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Geriatrics & Gerontology
GA KY7DD
UT WOS:000522733300027
PM 32191918
OA gold, Green Published
DA 2024-02-19
ER

PT J
AU Rickabaugh, TM
   Kilpatrick, RD
   Hultin, LE
   Hultin, PM
   Hausner, MA
   Sugar, CA
   Althoff, KN
   Margolick, JB
   Rinaldo, CR
   Detels, R
   Phair, J
   Effros, RB
   Jamieson, BD
AF Rickabaugh, Tammy M.
   Kilpatrick, Ryan D.
   Hultin, Lance E.
   Hultin, Patricia M.
   Hausner, Mary Ann
   Sugar, Catherine A.
   Althoff, Keri N.
   Margolick, Joseph B.
   Rinaldo, Charles R.
   Detels, Roger
   Phair, John
   Effros, Rita B.
   Jamieson, Beth D.
TI The Dual Impact of HIV-1 Infection and Aging on Naive CD4<SUP>+</SUP>
   T-Cells: Additive and Distinct Patterns of Impairment
SO PLOS ONE
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; ACTIVE ANTIRETROVIRAL THERAPY; MARKED
   INCREASE; MORTALITY-RATES; ANAL CANCER; IN-VIVO; AT-RISK; AIDS; AGE;
   RESTORATION
AB HIV-1-infected adults over the age of 50 years progress to AIDS more rapidly than adults in their twenties or thirties. In addition, HIV-1-infected individuals receiving antiretroviral therapy (ART) present with clinical diseases, such as various cancers and liver disease, more commonly seen in older uninfected adults. These observations suggest that HIV-1 infection in older persons can have detrimental immunological effects that are not completely reversed by ART. As naive T-cells are critically important in responses to neoantigens, we first analyzed two subsets (CD45RA(+)CD31(+) and CD45RA(+)CD31(-)) within the naive CD4(+) T-cell compartment in young (20-32 years old) and older (39-58 years old), ART-naive, HIV-1 seropositive individuals within 1-3 years of infection and in age-matched seronegative controls. HIV-1 infection in the young cohort was associated with lower absolute numbers of, and shorter telomere lengths within, both CD45RA(+)CD31(+)CD4(+) and CD45RA(+)CD31(-)CD4(+) T-cell subsets in comparison to age-matched seronegative controls, changes that resembled seronegative individuals who were decades older. Longitudinal analysis provided evidence of thymic emigration and reconstitution of CD45RA(+)CD31(+)CD4(+) T-cells two years post-ART, but minimal reconstitution of the CD45RA(+)CD31(-)CD4(+) subset, which could impair de novo immune responses. For both ART-naive and ART-treated HIV-1-infected adults, a renewable pool of thymic emigrants is necessary to maintain CD4(+) T-cell homeostasis. Overall, these results offer a partial explanation both for the faster disease progression of older adults and the observation that viral responders to ART present with clinical diseases associated with older adults.
C1 [Rickabaugh, Tammy M.; Kilpatrick, Ryan D.; Hultin, Lance E.; Hausner, Mary Ann; Effros, Rita B.; Jamieson, Beth D.] Univ Calif Los Angeles, David Geffen Sch Med, UCLA AIDS Inst, Dept Med, Los Angeles, CA 90095 USA.
   [Effros, Rita B.] Univ Calif Los Angeles, UCLA AIDS Inst, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA.
   [Sugar, Catherine A.] Univ Calif Los Angeles, Sch Publ Hlth, Dept Biostat, Los Angeles, CA 90095 USA.
   [Althoff, Keri N.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA.
   [Margolick, Joseph B.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Mol Microbiol & Immunol, Baltimore, MD USA.
   [Rinaldo, Charles R.] Univ Pittsburgh, Grad Sch Publ Hlth, Pittsburgh, PA USA.
   [Kilpatrick, Ryan D.; Hultin, Patricia M.; Detels, Roger] Univ Calif Los Angeles, Sch Publ Hlth, Dept Epidemiol, Los Angeles, CA 90095 USA.
   [Phair, John] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA.
C3 University of California System; University of California Los Angeles;
   University of California Los Angeles Medical Center; David Geffen School
   of Medicine at UCLA; University of California System; University of
   California Los Angeles; University of California System; University of
   California Los Angeles; Johns Hopkins University; Johns Hopkins
   Bloomberg School of Public Health; Johns Hopkins University; Johns
   Hopkins Bloomberg School of Public Health; Pennsylvania Commonwealth
   System of Higher Education (PCSHE); University of Pittsburgh; University
   of California System; University of California Los Angeles; Northwestern
   University; Feinberg School of Medicine
RP Rickabaugh, TM (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, UCLA AIDS Inst, Dept Med, Los Angeles, CA 90095 USA.
EM jamieson@mednet.ucla.edu
RI Althoff, Keri N/HGC-5595-2022; Serei, Virian D/B-4616-2015
OI Kilpatrick, Ryan/0000-0003-1388-3669; Althoff, Keri/0000-0002-5068-6595
FU NIAID [5RO1-AI-058845]; NIA [1RO1-AG-030327]; National Institutes of
   Health [CA-16042, AI-28697]; National Cancer Institute [5 T32 CA009120];
   National Institute of Allergy and Infectious Diseases; National Cancer
   Institute and the National Heart, Lung and Blood Institute
   [UO1-AI-35042, 5-MO1-RR-00722 (GCRC), UO1-AI-35043, UO1-AI-37984,
   UO1-AI-35039, UO1-AI-35040, UO1-AI-37613, UO1-AI-35041]; JCCC; UCLA AIDS
   Institute; David Geffen School of Medicine at UCLA
FX This study was supported by NIAID Grant 5RO1-AI-058845 and NIA Grant
   1RO1-AG-030327 awarded to B. D. Jamieson, P. I. T. M. Rickabaugh was
   also supported by the National Institutes of Health under Ruth L.
   Kirschstein National Research Service Award, 5 T32 CA009120, from the
   National Cancer Institute. The MACS is funded by the National Institute
   of Allergy and Infectious Diseases, with additional supplemental funding
   from the National Cancer Institute and the National Heart, Lung and
   Blood Institute: UO1-AI-35042, 5-MO1-RR-00722 (GCRC), UO1-AI-35043,
   UO1-AI-37984, UO1-AI-35039, UO1-AI-35040, UO1-AI-37613, UO1-AI-35041.
   Flow cytometry was performed in the UCLA Jonsson Comprehensive Cancer
   Center (JCCC) and Center for AIDS Research Flow Cytometry Core Facility
   that is supported by National Institutes of Health awards CA-16042 and
   AI-28697, and by the JCCC, the UCLA AIDS Institute, and the David Geffen
   School of Medicine at UCLA. The funders had no role in study design,
   data collection and analysis, decision to publish or preparation of the
   manuscript.
CR Abbatecola AM, 2004, J AM GERIATR SOC, V52, P399, DOI 10.1111/j.1532-5415.2004.52112.x
   Appay V, 2008, J PATHOL, V214, P231, DOI 10.1002/path.2276
   Arnold DM, 2006, BLOOD, V108, P460, DOI 10.1182/blood-2005-11-4407
   Aspinall R, 2000, J CLIN IMMUNOL, V20, P250, DOI 10.1023/A:1006611518223
   Azevedo RI, 2009, BLOOD, V113, P2999, DOI 10.1182/blood-2008-07-166223
   Baker JV, 2008, JAIDS-J ACQ IMM DEF, V48, P541, DOI 10.1097/QAI.0b013e31817bebb3
   Baker JV, 2008, AIDS, V22, P841, DOI 10.1097/QAD.0b013e3282f7cb76
   Bar-Or D, 2001, BIOCHEM BIOPH RES CO, V282, P356, DOI 10.1006/bbrc.2001.4533
   Barbieri M, 2003, AM J PHYSIOL-ENDOC M, V284, pE481, DOI 10.1152/ajpendo.00319.2002
   Bestilny LJ, 2000, AIDS, V14, P771, DOI 10.1097/00002030-200005050-00002
   Brenchley JM, 2004, J VIROL, V78, P1160, DOI 10.1128/JVI.78.3.1160-1168.2004
   Cawthon RM, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.10.e47
   Chattopadhyay PK, 2006, AIDS RES HUM RETROV, V22, P501, DOI 10.1089/aid.2006.22.501
   D'Souza G, 2008, JAIDS-J ACQ IMM DEF, V48, P491, DOI 10.1097/QAI.0b013e31817aebfe
   Darby SC, 1996, LANCET, V347, P1573, DOI 10.1016/S0140-6736(96)91073-9
   Deeks SG, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.a3172
   Desquilbet L, 2007, J GERONTOL A-BIOL, V62, P1279, DOI 10.1093/gerona/62.11.1279
   Detels R, 1998, JAMA-J AM MED ASSOC, V280, P1497, DOI 10.1001/jama.280.17.1497
   Dorrucci M, 2001, J ACQ IMMUN DEF SYND, V26, P377, DOI 10.1097/00126334-200104010-00016
   Douek DC, 1998, NATURE, V396, P690, DOI 10.1038/25374
   Eckstein DA, 2001, IMMUNITY, V15, P671, DOI 10.1016/S1074-7613(01)00217-5
   Effros RB, 2000, MECH AGEING DEV, V121, P161
   Efron B., 1994, INTRO BOOTSTRAP, DOI [DOI 10.1201/9780429246593, 10.1201/9780429246593]
   Engels EA, 2010, JAIDS-J ACQ IMM DEF, V54, P78, DOI 10.1097/01.qai.0000371677.48743.8d
   Fausto A, 2006, BONE, V38, P893, DOI 10.1016/j.bone.2005.11.001
   Fulop T, 2006, MECH AGEING DEV, V127, P526, DOI 10.1016/j.mad.2006.01.025
   Herndler-Brandstetter D, 2006, WIEN MED WOCHENSCHR, V156, P130, DOI 10.1007/s10354-006-0267-8
   Hogg R, 2008, LANCET, V372, P293, DOI 10.1016/S0140-6736(08)61113-7
   Hooshyar D, 2007, AIDS, V21, P2093, DOI 10.1097/QAD.0b013e3282e9a664
   Hsue PY, 2008, AIDS, V22, P825, DOI 10.1097/QAD.0b013e3282f7cd42
   Hultdin M, 1998, NUCLEIC ACIDS RES, V26, P3651, DOI 10.1093/nar/26.16.3651
   Hultin L, 2006, MANUAL OF MOLECULAR AND CLINICAL LABORATORY IMMUNOLOGY, 7TH EDITION, P147
   Iyer SB, 1998, CYTOMETRY, V33, P206, DOI 10.1002/(SICI)1097-0320(19981001)33:2<206::AID-CYTO15>3.0.CO;2-Y
   IYER SB, 1997, 233496 BDIS
   Jamieson BD, 1999, IMMUNITY, V10, P569, DOI 10.1016/S1074-7613(00)80056-4
   KASLOW RA, 1987, AM J EPIDEMIOL, V126, P310, DOI 10.1093/aje/126.2.310
   Kelley CF, 2009, CLIN INFECT DIS, V48, P787, DOI 10.1086/597093
   Kilpatrick RD, 2008, J IMMUNOL, V180, P1499, DOI 10.4049/jimmunol.180.3.1499
   Kimmig S, 2002, J EXP MED, V195, P789, DOI 10.1084/jem.20011756
   Kohler S, 2005, EUR J IMMUNOL, V35, P1987, DOI 10.1002/eji.200526181
   Lange CG, 2002, CLIN IMMUNOL, V102, P154, DOI 10.1006/clim.2001.5164
   Lucas GM, 2007, AIDS, V21, P2435, DOI 10.1097/QAD.0b013e32827038ad
   MASCOLINI M, 2010, RES INITIATIVE TREAT, V15, P1
   Nichols WS, 1999, SCAND J IMMUNOL, V49, P302, DOI 10.1046/j.1365-3083.1999.00505.x
   Pham T, 2003, CLIN DIAGN LAB IMMUN, V10, P323, DOI 10.1128/CDLI.10.2.323-328.2003
   Piketty C, 2008, AIDS, V22, P1203, DOI 10.1097/QAD.0b013e3283023f78
   PLAEGERMARSHALL S, 1993, J ACQ IMMUN DEF SYND, V6, P984
   Pommier JP, 1997, VIROLOGY, V231, P148, DOI 10.1006/viro.1997.8512
   RABIN RL, 1995, J CLIN INVEST, V95, P2054, DOI 10.1172/JCI117891
   Richardson MW, 2000, BIOMED PHARMACOTHER, V54, P21, DOI 10.1016/S0753-3322(00)88637-0
   Robertson JD, 2000, BRIT J HAEMATOL, V109, P272, DOI 10.1046/j.1365-2141.2000.01970.x
   RODRIGUEZ B, 2010, CLIN IMMUNOL
   ROEDERER M, 1995, J CLIN INVEST, V95, P2061, DOI 10.1172/JCI117892
   ROSENBERG PS, 1994, AIDS, V8, P803, DOI 10.1097/00002030-199406000-00013
   SCHMID I, 1992, CYTOMETRY, V13, P204, DOI 10.1002/cyto.990130216
   Sergio G, 2008, INFLAMM RES, V57, P558, DOI 10.1007/s00011-008-7243-2
   Smit C, 2006, AIDS, V20, P741, DOI 10.1097/01.aids.0000216375.99560.a2
   Teixeira L, 2001, AIDS, V15, P1749, DOI 10.1097/00002030-200109280-00002
   Thomas J, 2003, JAIDS-J ACQ IMM DEF, V33, P281, DOI 10.1097/00126334-200307010-00001
   Triant VA, 2007, J CLIN ENDOCR METAB, V92, P2506, DOI 10.1210/jc.2006-2190
   VAZIRI H, 1994, P NATL ACAD SCI USA, V91, P9857, DOI 10.1073/pnas.91.21.9857
   Viard JP, 2001, J INFECT DIS, V183, P1290, DOI 10.1086/319678
   Vignoli M, 1998, AIDS, V12, P999, DOI 10.1097/00002030-199809000-00005
   von Zglinicki T, 2002, TRENDS BIOCHEM SCI, V27, P339, DOI 10.1016/S0968-0004(02)02110-2
   Vrisekoop N, 2008, J IMMUNOL, V181, P1573, DOI 10.4049/jimmunol.181.2.1573
   Weber R, 2006, ARCH INTERN MED, V166, P1632, DOI 10.1001/archinte.166.15.1632
   Webster RG, 2000, VACCINE, V18, P1686, DOI 10.1016/S0264-410X(99)00507-1
   Whisler RL, 1996, CELL IMMUNOL, V168, P201, DOI 10.1006/cimm.1996.0067
   Wolthers KC, 1999, AIDS RES HUM RETROV, V15, P1053, DOI 10.1089/088922299310340
   Zanni F, 2003, EXP GERONTOL, V38, P981, DOI 10.1016/S0531-5565(03)00160-8
   Zhang LQ, 1999, J EXP MED, V190, P725, DOI 10.1084/jem.190.5.725
NR 71
TC 60
Z9 67
U1 1
U2 8
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JAN 26
PY 2011
VL 6
IS 1
AR e16459
DI 10.1371/journal.pone.0016459
PG 10
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 712JL
UT WOS:000286662800044
PM 21298072
OA Green Submitted, Green Published, Green Accepted, gold
DA 2024-02-19
ER

PT J
AU Komatsu, T
   Trindade, LS
   Chiba, T
   Hayashi, H
   Henmi, T
   Ushiroda, Y
   Mori, R
   Shimokawa, I
AF Komatsu, Toshimitsu
   Trindade, Lucas S.
   Chiba, Takuya
   Hayashi, Hiroko
   Henmi, Tomoko
   Ushiroda, Yoko
   Mori, Ryoichi
   Shimokawa, Isao
TI Acute stress response modified by modest inhibition of growth hormone
   axis: A potential machinery of the anti-aging effect of calorie
   restriction
SO MECHANISMS OF AGEING AND DEVELOPMENT
LA English
DT Article
DE Calorie restriction; Growth hormone; Endotoxin; Inflammation
ID LIFE-SPAN EXTENSION; FACTOR-I AXIS; OXIDATIVE STRESS; GENE-EXPRESSION;
   BIOLOGICAL-ACTIVITIES; INSULIN; RESISTANCE; ENDOTOXIN; LIVER; RATS
AB Calorie restriction (CR) may exert antiaging effects by inhibiting the growth hormone (GH)/IGF-1 axis. The present study investigated the effect of modest inhibition of GH signaling on stress response and compared it with the effect of CR. Heterozygous (tg/-) rats of a transgenic strain of male rats, whose GH signaling was inhibited by overexpression of the anti-sense GH gene, and wild-type (WT) rats were used. Rats were fed ad libitum (AL) or 30% CR diets from 6 weeks of age. At 6 months of age, rats were killed between 0 and 8 h after lipopolysaccharide (LPS) injection to evaluate the acute phase stress response. tg/- rats had less tissue injury, indicated by blood aspartate aminotransferase (AST) concentrations, than WT rats. Successive waves of incremental plasma TNF-alpha, IL-6, and interferon (IFN)-gamma levels were also attenuated in tg/- rats. Activation of NF-kappa B, a redox-sensitive transcription factor, was slightly diminished in tg/- rats, whereas the AP-1 activity was increased. Similar trends were also observed in the CR groups as compared to the AL groups. The present results suggest an involvement of the GH/IGF-1 axis in the effect of CR for stress response, even if CR does not act solely through the GH axis. (C) 2011 Elsevier Ireland Ltd. All rights reserved.
C1 [Komatsu, Toshimitsu; Trindade, Lucas S.; Chiba, Takuya; Hayashi, Hiroko; Henmi, Tomoko; Ushiroda, Yoko; Mori, Ryoichi; Shimokawa, Isao] Nagasaki Univ, Grad Sch Biomed Sci, Unit Basic Med Sci, Dept Invest Pathol, Nagasaki 852852K3, Japan.
C3 Nagasaki University
RP Shimokawa, I (corresponding author), Nagasaki Univ, Grad Sch Biomed Sci, Unit Basic Med Sci, Dept Invest Pathol, 1-12-4 Sakamoto, Nagasaki 852852K3, Japan.
EM shimo@nagasaki-u.ac.jp
OI Shimokawa, Isao/0000-0001-8901-1029; Mori, Ryoichi/0000-0002-7596-9620
FU Japan Society for the Promotion of Science [15390128, 16790226];
   Grants-in-Aid for Scientific Research [15390128, 23650484, 16790226,
   22790383] Funding Source: KAKEN
FX We are grateful to Yutaka Araki, Yuko Moriyama, Rieko Tahara, and the
   staff at the Laboratory Animal Center for Biomedical Research, Center
   for Frontier Sciences at Nagasaki University, for their excellent
   technical support. This work was supported by Grants-in-Aid for Science
   Research from the Japan Society for the Promotion of Science (Nos.
   15390128 and 16790226).
CR Apte UM, 2002, TOXICOL SCI, V69, P448, DOI 10.1093/toxsci/69.2.448
   Bartke A, 2001, NATURE, V414, P412, DOI 10.1038/35106646
   Bonkowski MS, 2006, P NATL ACAD SCI USA, V103, P7901, DOI 10.1073/pnas.0600161103
   BREESE CR, 1991, J GERONTOL, V46, pB180, DOI 10.1093/geronj/46.5.B180
   Chiba T, 2008, EXP GERONTOL, V43, P595, DOI 10.1016/j.exger.2008.03.003
   Chung HY, 2006, ANTIOXID REDOX SIGN, V8, P572, DOI 10.1089/ars.2006.8.572
   Corsini E, 1997, J INVEST DERMATOL, V108, P892, DOI 10.1111/1523-1747.ep12292696
   Coschigano KT, 2000, ENDOCRINOLOGY, V141, P2608, DOI 10.1210/en.141.7.2608
   EDWARDS CK, 1992, INFECT IMMUN, V60, P2514, DOI 10.1128/IAI.60.6.2514-2521.1992
   EDWARDS CK, 1988, SCIENCE, V239, P769, DOI 10.1126/science.2829357
   FAN J, 1995, AM J PHYSIOL-ENDOC M, V269, pE33, DOI 10.1152/ajpendo.1995.269.1.E33
   FU YK, 1991, J IMMUNOL, V146, P1602
   Gao CH, 1999, HEPATOLOGY, V30, P1405, DOI 10.1002/hep.510300602
   Guha M, 2001, CELL SIGNAL, V13, P85, DOI 10.1016/S0898-6568(00)00149-2
   Harper JM, 2006, MECH AGEING DEV, V127, P687, DOI 10.1016/j.mad.2006.04.002
   Hauck SJ, 2002, HORM METAB RES, V34, P481, DOI 10.1055/s-2002-34787
   Holzenberger M, 2003, NATURE, V421, P182, DOI 10.1038/nature01298
   HSU SM, 1981, AM J CLIN PATHOL, V75, P816, DOI 10.1093/ajcp/75.6.816
   Kim HJ, 2002, EXP GERONTOL, V37, P1041, DOI 10.1016/S0531-5565(02)00082-7
   Kim HJ, 2002, FREE RADICAL BIO MED, V32, P991, DOI 10.1016/S0891-5849(02)00798-0
   Klöcker U, 2000, J VIROL, V74, P5525, DOI 10.1128/JVI.74.12.5525-5533.2000
   Liao W, 1996, EUR J CLIN INVEST, V26, P254, DOI 10.1046/j.1365-2362.1996.140268.x
   Liao W, 1997, ENDOCRINOLOGY, V138, P289, DOI 10.1210/en.138.1.289
   Madsen MA, 2004, BIOCHEM BIOPH RES CO, V318, P998, DOI 10.1016/j.bbrc.2004.04.126
   Masoro EJ, 1998, EXP GERONTOL, V33, P61, DOI 10.1016/S0531-5565(97)00071-5
   MASORO EJ, 2003, SCI AGING KNOWLEDGE, pRE2
   MATSUMOTO K, 1993, MOL REPROD DEV, V36, P53, DOI 10.1002/mrd.1080360109
   Murakami S, 2003, FASEB J, V17, P1565, DOI 10.1096/fj.02-1092fje
   Ouchi N, 1999, CIRCULATION, V100, P2473, DOI 10.1161/01.CIR.100.25.2473
   Panici JA, 2010, FASEB J, V24, P5073, DOI 10.1096/fj.10-163253
   Sanz A, 2005, BIOGERONTOLOGY, V6, P15, DOI 10.1007/s10522-004-7380-0
   Schumacher B, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000161
   Shimokawa I, 2003, FASEB J, V17, P1108, DOI 10.1096/fj.02-0819fje
   Shimokawa I, 2002, AM J PATHOL, V160, P2259, DOI 10.1016/S0002-9440(10)61173-X
   Shimokawa I, 2008, MOL CELLS, V26, P427
   Stefanski SA, 1990, PATHOLOGY FISCHER RA, P369
   Sun DX, 2001, CLIN DIAGN LAB IMMUN, V8, P1003, DOI 10.1128/CDLI.8.5.1003-1011.2001
   Tsuchiya T, 2005, MECH AGEING DEV, V126, P568, DOI 10.1016/j.mad.2004.11.007
   Van Amersfoort ES, 2003, CLIN MICROBIOL REV, V16, P379, DOI 10.1128/CMR.16.3.379-414.2003
   Wang XD, 2008, MOL ENDOCRINOL, V22, P1427, DOI 10.1210/me.2007-0561
   WARWICKDAVIES J, 1995, J IMMUNOL, V154, P1909
   Yamaza H, 2007, J GERONTOL A-BIOL, V62, P27, DOI 10.1093/gerona/62.1.27
NR 42
TC 4
Z9 4
U1 0
U2 5
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0047-6374
EI 1872-6216
J9 MECH AGEING DEV
JI Mech. Ageing Dev.
PD MAR
PY 2011
VL 132
IS 3
BP 103
EP 109
DI 10.1016/j.mad.2011.01.002
PG 7
WC Cell Biology; Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Geriatrics & Gerontology
GA 751FZ
UT WOS:000289604200004
PM 21291903
DA 2024-02-19
ER

PT J
AU Loi, CM
   Parker, BM
   Cusack, BJ
   Vestal, RE
AF Loi, CM
   Parker, BM
   Cusack, BJ
   Vestal, RE
TI Aging and drug interactions .3. Individual and combined effects of
   cimetidine and ciprofloxacin on theophylline metabolism in healthy male
   and female nonsmokers
SO JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
LA English
DT Article
ID LIQUID-CHROMATOGRAPHIC DETERMINATION; HUMAN LIVER CYTOCHROMES-P-450;
   PHARMACOKINETIC INTERACTIONS; CIGARETTE-SMOKING; AGE; CLEARANCE; SERUM;
   URINE; INHIBITION; MICROSOMES
AB The individual and combined effects of cimetidine and ciprofloxacin on theophylline metabolism were examined in healthy young and elderly male and female nonsmokers. Single-dose studies of theophylline pharmacokinetics were performed at base line and on the fifth day of each of three treatment regimens consisting of 400 mg cimetidine every 12 hr, 500 mg ciprofloxacin every 12 hr and the combination of cimetidine and ciprofloxacin. Base-line theophylline plasma clearance and formation clearance of theophylline metabolites decreased with age in both gender groups to a similar extent (20% less in elderly men than in young men; 24% less in elderly women than in young women). Individually, cimetidine and ciprofloxacin produced proportionate declines in plasma theophylline clearance that were similar among the four groups (range, 23.4-32.7% decrease). The combined regimen yielded further impairment in theophylline elimination compared with each agent alone (range, 35.9-42.6% decrease). Cimetidine was a nonselective inhibitor of theophylline metabolic pathways in young men, but it exerted a greater inhibitory effect on N-demethylation pathways in the other groups. Ciprofloxacin inhibited N-demethylations of theophylline to a greater extent than the hydroxylation pathway. Coadministration of these two inhibitors further reduced the formation of theophylline metabolites. The proportionate reduction in formation clearance of theophylline metabolites was similar among the four groups. Thus, the response to inhibition of theophylline metabolism by cimetidine and ciprofloxacin is not influenced by age or gender.
C1 DEPT VET AFFAIRS MED CTR,CLIN PHARMACOL & GERONTOL RES UNIT,RES SERV 151,BOISE,ID 83702.
   MT STATES MED RES INST,BOISE,ID.
   UNIV WASHINGTON,DEPT MED,SEATTLE,WA.
   UNIV WASHINGTON,DEPT PHARMACOL,SEATTLE,WA 98195.
C3 University of Washington; University of Washington Seattle; University
   of Washington; University of Washington Seattle
CR ADEBAYO GI, 1987, BIOPHARM DRUG DISPOS, V8, P149, DOI 10.1002/bdd.2510080206
   ANTAL EJ, 1981, BRIT J CLIN PHARMACO, V12, P637, DOI 10.1111/j.1365-2125.1981.tb01282.x
   AWNI WM, 1987, J CHROMATOGR-BIOMED, V419, P414, DOI 10.1016/0378-4347(87)80309-2
   BIRKETT DJ, 1983, BRIT J CLIN PHARMACO, V15, P117, DOI 10.1111/j.1365-2125.1983.tb01475.x
   BONATE PL, 1991, J CLIN PHARMACOL, V31, P684, DOI 10.1002/j.1552-4604.1991.tb03760.x
   CROWLEY JJ, 1988, J PHARMACOL EXP THER, V245, P513
   CUSACK BJ, 1985, CLIN PHARMACOL THER, V37, P330, DOI 10.1038/clpt.1985.48
   DAVIS JD, 1994, PHARMACEUT RES, V11, P1424, DOI 10.1023/A:1018991822440
   DAVIS RL, 1992, ANN PHARMACOTHER, V26, P11, DOI 10.1177/106002809202600102
   DURNAS C, 1990, CLIN PHARMACOKINET, V19, P359, DOI 10.2165/00003088-199019050-00002
   FORRESTER LM, 1992, BIOCHEM J, V281, P359, DOI 10.1042/bj2810359
   GLADZIWA U, 1993, CLIN PHARMACOKINET, V24, P319, DOI 10.2165/00003088-199324040-00005
   GRYGIEL JJ, 1980, CLIN PHARMACOL THER, V28, P456, DOI 10.1038/clpt.1980.188
   GU L, 1992, PHARMACOGENETICS, V2, P73, DOI 10.1097/00008571-199204000-00004
   HUNT CM, 1990, BIOCHEM PHARMACOL, V40, P1666, DOI 10.1016/0006-2952(90)90470-6
   HUNT CM, 1992, BIOCHEM PHARMACOL, V44, P275, DOI 10.1016/0006-2952(92)90010-G
   JACKSON SHD, 1989, EUR J CLIN PHARMACOL, V36, P29, DOI 10.1007/BF00561019
   JUSKO WJ, 1979, J PHARM SCI, V68, P1358, DOI 10.1002/jps.2600681106
   KNODELL RG, 1991, GASTROENTEROLOGY, V101, P1680, DOI 10.1016/0016-5085(91)90408-D
   LEBEL M, 1986, PHARMACOTHERAPY, V6, P87
   LELO A, 1986, BRIT J CLIN PHARMACO, V22, P177, DOI 10.1111/j.1365-2125.1986.tb05246.x
   LJUNGBERG B, 1989, EUR J CLIN MICROBIOL, V8, P515, DOI 10.1007/BF01967470
   LOI CM, 1991, CLIN PHARMACOL THER, V49, P571, DOI 10.1038/clpt.1991.67
   LOI CM, 1993, BRIT J CLIN PHARMACO, V36, P195, DOI 10.1111/j.1365-2125.1993.tb04216.x
   MIHALY GW, 1982, J PHARM SCI, V71, P590, DOI 10.1002/jps.2600710528
   MUIR KT, 1980, J CHROMATOGR, V221, P85, DOI 10.1016/S0378-4347(00)81010-5
   NIX DE, 1987, J ANTIMICROB CHEMOTH, V19, P263, DOI 10.1093/jac/19.2.263
   POWELL JR, 1977, AM REV RESPIR DIS, V116, P17
   REITBERG DP, 1981, ANN INTERN MED, V95, P582, DOI 10.7326/0003-4819-95-5-582
   ROBSON RA, 1990, BRIT J CLIN PHARMACO, V29, P491, DOI 10.1111/j.1365-2125.1990.tb03669.x
   SARKAR M, 1990, ANTIMICROB AGENTS CH, V34, P594, DOI 10.1128/AAC.34.4.594
   SARKAR MA, 1992, DRUG METAB DISPOS, V20, P31
   SCHMUCKER DL, 1990, CLIN PHARMACOL THER, V48, P365, DOI 10.1038/clpt.1990.164
   SCHWARTZ J, 1988, ANTIMICROB AGENTS CH, V32, P75, DOI 10.1128/AAC.32.1.75
   SHANNON M, 1993, ANN INTERN MED, V119, P1161, DOI 10.7326/0003-4819-119-12-199312150-00002
   SHANNON M, 1990, ARCH INTERN MED, V150, P2045, DOI 10.1001/archinte.150.10.2045
   SHIMADA T, 1994, J PHARMACOL EXP THER, V270, P414
   UPTON RA, 1991, CLIN PHARMACOKINET, V20, P66, DOI 10.2165/00003088-199120010-00005
   UPTON RA, 1991, CLIN PHARMACOKINET, V20, P135, DOI 10.2165/00003088-199120020-00005
   VANCEBRYAN K, 1990, CLIN PHARMACOKINET, V19, P434, DOI 10.2165/00003088-199019060-00003
   VESTAL RE, 1983, CIRCULATION, V67, P162, DOI 10.1161/01.CIR.67.1.162
   VESTAL RE, 1987, J PHARMACOL EXP THER, V241, P488
   VESTAL RE, 1983, BRIT J CLIN PHARMACO, V15, P411, DOI 10.1111/j.1365-2125.1983.tb01523.x
   WEI XX, 1995, BIOCHEM PHARMACOL, V49, P1657, DOI 10.1016/0006-2952(95)00103-7
   WIJNANDS WJA, 1986, BRIT J CLIN PHARMACO, V22, P677, DOI 10.1111/j.1365-2125.1986.tb02957.x
   WYNNE HA, 1989, HEPATOLOGY, V9, P297, DOI 10.1002/hep.1840090222
   ZIEMNIAK JA, 1981, CLIN CHEM, V27, P272
NR 47
TC 35
Z9 35
U1 0
U2 3
PU WILLIAMS & WILKINS
PI BALTIMORE
PA 351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436
SN 0022-3565
J9 J PHARMACOL EXP THER
JI J. Pharmacol. Exp. Ther.
PD FEB
PY 1997
VL 280
IS 2
BP 627
EP 637
PG 11
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA WG580
UT WOS:A1997WG58000015
PM 9023273
DA 2024-02-19
ER

PT J
AU Qiu, Y
   Ai, PF
   Song, JJ
   Liu, C
   Li, ZW
AF Qiu, Yan
   Ai, Peng-Fei
   Song, Jian-Jun
   Liu, Chang
   Li, Zhi-Wei
TI Total Flavonoid Extract from <i>Abelmoschus manihot</i> (L.) Medic
   Flowers Attenuates D-Galactose-Induced Oxidative Stress in Mouse Liver
   Through the Nrf2 Pathway
SO JOURNAL OF MEDICINAL FOOD
LA English
DT Article
DE Abelmoschus manihot (L.) Medic; antioxidant activity; D-galactose; Nrf2;
   oxidative stress; total flavonoids
ID ALPHA-LIPOIC ACID; IN-VITRO; ANTIOXIDANT ACTIVITIES; SIGNALING PATHWAY;
   HUANGKUI CAPSULE; FREE-RADICALS; MICE; RATS; DISEASE; DAMAGE
AB Abelmoschus manihot (L.) Medic is an edible hibiscus that is rich in flavonoids, and its use as Chinese herbal medicine for the treatment of diseases and health maintenance dates back to ancient times. The chemical compositions of total flavonoid of A. manihot (L.) Medic flower extract (TFAE) were identified and determined by high performance liquid chromatography (HPLC). The effects of TFAE on antioxidative activities in a D-galactose (D-gal)-induced mouse model and Nrf2-mediated antioxidant responses were evaluated. Male Kunming mice were randomly divided into normal control group, D-gal aging model group, D-gal+ascorbic acid group that served as a positive control, and D-gal+TFAE (40, 80, and 160 mg TFAE/kg) group. After 42 days, the antioxidant effects of these treatments were determined by biochemical studies, Western blotting, quantitative real-time polymerase chain reaction, and histological analysis. The results showed that the groups administered TFAE exhibited significant elevation in liver activities of antioxidant enzymes, including catalase (CAT), glutathione peroxidase (GPx), superoxide dismutase (SOD), and total antioxidant capacity (T-AOC), and decreased malondialdehyde (MDA) production in a dose-dependent manner compared with the D-gal-induced model group. Expression of Nrf2 and its target antioxidants (HO-1 and NQO1) was manifestly increased by TFAE treatment. TFAE also increased mRNA expression of GPx, SOD, and CAT and decreased tumor necrosis factor-alpha (TNF-alpha) and interleukin-1 beta (IL-1 beta). Furthermore, the microstructure of livers in TFAE-administered mice was obviously improved as compared with the D-gal model group. These results suggest that TFAE protects mice against D-gal-induced oxidative stress, and the effect is related to the activation of Nrf2 signaling.
C1 [Qiu, Yan; Ai, Peng-Fei; Song, Jian-Jun; Liu, Chang] Hebei Univ Sci & Technol, Coll Biosci & Bioengn, Shijiazhuang 050018, Peoples R China.
   [Li, Zhi-Wei] Hebei Univ Sci & Technol, Coll Chem & Pharmaceutial Engn, Shijiazhuang, Peoples R China.
C3 Hebei University of Science & Technology; Hebei University of Science &
   Technology
RP Qiu, Y (corresponding author), Hebei Univ Sci & Technol, Coll Biosci & Bioengn, Shijiazhuang 050018, Peoples R China.
EM qiuyan2015@126.com
RI AI, Pengfei/G-1443-2015; ai, P/JVZ-8342-2024
FU Natural Science Foundation of Hebei Province, China [C2014208084];
   Foundation for High-Level Talents of Hebei Province, China [C2015005013]
FX This work was supported by the Natural Science Foundation of Hebei
   Province, China (No. C2014208084) and the Foundation for High-Level
   Talents of Hebei Province, China (No. C2015005013).
CR Ai G, 2013, J ETHNOPHARMACOL, V146, P794, DOI 10.1016/j.jep.2013.02.005
   Anand KV, 2012, GERIATR GERONTOL INT, V12, P741, DOI 10.1111/j.1447-0594.2012.00843.x
   Birt DF, 2001, PHARMACOL THERAPEUT, V90, P157, DOI 10.1016/S0163-7258(01)00137-1
   Buelna-Chontal M, 2013, CELL SIGNAL, V25, P2548, DOI 10.1016/j.cellsig.2013.08.007
   Buendia I, 2016, PHARMACOL THERAPEUT, V157, P84, DOI 10.1016/j.pharmthera.2015.11.003
   Cui X, 2006, J NEUROSCI RES, V83, P1584, DOI 10.1002/jnr.20845
   Dar AA, 2014, J PHARMACEUT BIOMED, V100, P300, DOI 10.1016/j.jpba.2014.07.034
   Das J, 2012, TOXICOL APPL PHARM, V260, P35, DOI 10.1016/j.taap.2012.01.015
   Del Rio D, 2005, NUTR METAB CARDIOVAS, V15, P316, DOI 10.1016/j.numecd.2005.05.003
   Flis S, 2012, J PHARMACEUT BIOMED, V62, P68, DOI 10.1016/j.jpba.2012.01.005
   Forman HJ, 2016, FREE RADICAL BIO MED, V97, P398, DOI 10.1016/j.freeradbiomed.2016.07.003
   Geetha Thiraviam, 2005, Indian Journal of Experimental Biology, V43, P61
   Guo JM, 2011, PHYTOMEDICINE, V18, P1250, DOI 10.1016/j.phymed.2011.06.012
   Kalaz EB, 2014, J PHYSIOL BIOCHEM, V70, P15, DOI 10.1007/s13105-013-0275-2
   Kaur H, 2011, NEUROCHEM RES, V36, P1435, DOI 10.1007/s11064-011-0469-3
   Lai XY, 2009, J CHROMATOGR SCI, V47, P206, DOI 10.1093/chromsci/47.3.206
   Lei LH, 2016, J CHIN MED ASSOC, V79, P205, DOI 10.1016/j.jcma.2015.06.023
   Li HG, 2014, ATHEROSCLEROSIS, V237, P208, DOI 10.1016/j.atherosclerosis.2014.09.001
   Li YN, 2014, OXID MED CELL LONGEV, V2014, DOI 10.1155/2014/320513
   Li YX, 2016, BIOORG MED CHEM LETT, V26, P2035, DOI 10.1016/j.bmcl.2016.02.079
   Liao WZ, 2014, J AGR FOOD CHEM, V62, P8648, DOI 10.1021/jf502359x
   Liu JF, 2013, EUR J NUTR, V52, P927, DOI 10.1007/s00394-012-0400-y
   Liu M, 2009, ANAT REC, V292, P412, DOI 10.1002/ar.20864
   Lu J, 2007, BIOCHEM PHARMACOL, V74, P1078, DOI 10.1016/j.bcp.2007.07.007
   Magiera S, 2015, J PHARMACEUT BIOMED, V102, P468, DOI 10.1016/j.jpba.2014.10.004
   Mao ZM, 2015, J ETHNOPHARMACOL, V173, P256, DOI 10.1016/j.jep.2015.07.036
   Ou Y, 2012, TOXICOL LETT, V215, P25, DOI 10.1016/j.toxlet.2012.09.017
   Oueslati S, 2012, FOOD CHEM, V132, P943, DOI 10.1016/j.foodchem.2011.11.072
   Poon HF, 2004, J GERONTOL A-BIOL, V59, P478
   Puel C, 2005, J ETHNOPHARMACOL, V99, P55, DOI 10.1016/j.jep.2005.01.047
   Qiu Y., 2006, J HEBEI NORMAL U NAT, V30, P713
   Rezaie A, 2007, DIGEST DIS SCI, V52, P2015, DOI 10.1007/s10620-006-9622-2
   Sofidiya MO, 2015, J ETHNOPHARMACOL, V171, P240, DOI 10.1016/j.jep.2015.05.059
   Surh YJ, 2008, PLANTA MED, V74, P1526, DOI 10.1055/s-0028-1088302
   Tu Y, 2013, J ETHNOPHARMACOL, V147, P311, DOI 10.1016/j.jep.2013.03.006
   Vicente SJV, 2014, J AGR FOOD CHEM, V62, P116, DOI 10.1021/jf401777m
   Wen JY, 2012, AM J CHINESE MED, V35, P653
   Wu PP, 2015, FOOD CHEM, V173, P194, DOI 10.1016/j.foodchem.2014.10.023
   Xu LQ, 2016, FOOD FUNCT, V7, P4545, DOI 10.1039/c6fo01057a
   Xu YB, 2011, J CHIN MED MAT, V34, P888
   Yu YH, 2015, PHARMACOL BIOCHEM BE, V133, P122, DOI 10.1016/j.pbb.2015.03.020
   Yu YH, 2015, MOL CELL BIOCHEM, V403, P287, DOI 10.1007/s11010-015-2358-6
   Zhang DD, 2006, DRUG METAB REV, V38, P769, DOI 10.1080/03602530600971974
   Zhang L, 2014, AM J KIDNEY DIS, V64, P57, DOI 10.1053/j.ajkd.2014.01.431
   Zhou XL, 2015, FOOD CHEM, V186, P63, DOI 10.1016/j.foodchem.2015.02.058
   Zitka O, 2012, ONCOL LETT, V4, P1247, DOI 10.3892/ol.2012.931
   Zou Z, 2016, FOOD CHEM, V196, P885, DOI 10.1016/j.foodchem.2015.09.072
NR 47
TC 26
Z9 26
U1 0
U2 47
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1096-620X
EI 1557-7600
J9 J MED FOOD
JI J. Med. Food
PD JUN
PY 2017
VL 20
IS 6
BP 557
EP 567
DI 10.1089/jmf.2016.3870
PG 11
WC Chemistry, Medicinal; Food Science & Technology; Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy; Food Science & Technology; Nutrition &
   Dietetics
GA EX9DC
UT WOS:000403554300004
PM 28472605
DA 2024-02-19
ER

PT J
AU Muzica, CM
   Stanciu, C
   Cijevschi-Prelipcean, C
   Girleanu, I
   Huiban, L
   Petrea, OC
   Singeap, AM
   Cojocariu, C
   Cuciureanu, T
   Sfarti, C
   Zenovia, S
   Chriac, S
   Stefanescu, G
   Ciortescu, I
   Lupascu-Ursulescu, C
   Miftode, E
   Trifan, A
AF Muzica, Cristina Maria
   Stanciu, Carol
   Cijevschi-Prelipcean, Cristina
   Girleanu, Irina
   Huiban, Laura
   Petrea, Oana Cristina
   Singeap, Ana-Maria
   Cojocariu, Camelia
   Cuciureanu, Tudor
   Sfarti, Catalin
   Zenovia, Sebastian
   Chriac, Stefan
   Stefanescu, Gabriela
   Ciortescu, Irina
   Lupascu-Ursulescu, Corina
   Miftode, Egidia
   Trifan, Anca
TI Long-Term Risk of Hepatocellular Carcinoma Following Direct-Acting
   Antiviral Therapy in Compensated Liver Cirrhosis Induced by Hepatitis C
   Virus Infection
SO HEPATITIS MONTHLY
LA English
DT Article
DE Direct-Acting Antivirals; Hepatitis C Virus; Hepatocellular Carcinoma;
   Long-Term Risk
ID SUSTAINED VIROLOGICAL RESPONSE; INTERFERON; ERADICATION; RECURRENCE;
   SURVIVAL; HCC
AB Background: Considering the excellent safety profile and the high efficacy rates, great benefits were expected with the availability of the new direct-acting antivirals (DAAs) in treating hepatitis C virus (HCV) infection. Following the publication of two articles in 2016 on the high incidence rates of hepatocelullar carcinoma (HCC) following DAAs, several papers revealed contradictory results, thereby casting shadows on the role of DAAs in hepatocarcinogenesis.
   Objectives: The present study aimed to assess the incidence and risk factors of HCC in patients with HCV genotype 1b infection and compensated cirrhosis with the sustained virological response (SVR) following DAAs.
   Methods: This multicentric prospective study encompassed 479 patients with HCV genotype 1b compensated cirrhosis treated with paritaprevir/ritonavir/ombitasvir and dasabuvir (PrOD) +/- ribavirin (RBV) for 12 weeks in two tertiary centers in Northeastern Romania. The patients were prospectively followed up in the Institute of Gastroenterology Iasi, Romania, from November 2015 to December 2020.
   Results: During the follow-up period (mean 60.11 +/- 3.87 months), 23 patients (4.8%) developed HCC. The 1-, 3-, and 5-year cumulative incidence rates of HCC were 1.1,1.9, and 2.6%, respectively. At the time of the diagnosis,15 patients (65%) had a single tumor,12 patients (52.2%) were within the Milan criteria, and nine persons (39%) had Barcelona liver cancer stage O-A. In this regard, the mean AFP level was 35.3 +/- 93.1 ng/mL. A multivariate analysis, age above 65 years, and a cutoff point of AFP >= 10 ng/mL at the end of treatment were independent factors associated with HCC. A majority of the patients (n =11, 47.8%) received curative treatment by surgical resection. In this study, histopathological examination identified a moderately differentiated tumor (G2) in 5 patients, five patients had a poorly differentiated tumor (G3), and only one patient had a well-differentiated tumor (G1).
   Conclusions: Our study revealed no evidence of the high incidence rate of HCC after the long-term follow-up of patients with HCV-related liver cirrhosis and SVR following DAA treatment. However, the cumulative 5-year risk remained above the cutoff point, and this makes the HCC screening cost-effective. The HCC occurrence appears to be associated with aging and a moderately increased AFP level at EOT (>= 10 ng/mL).
C1 [Muzica, Cristina Maria; Stanciu, Carol; Cijevschi-Prelipcean, Cristina; Girleanu, Irina; Huiban, Laura; Petrea, Oana Cristina; Singeap, Ana-Maria; Cojocariu, Camelia; Cuciureanu, Tudor; Sfarti, Catalin; Zenovia, Sebastian; Chriac, Stefan; Stefanescu, Gabriela; Ciortescu, Irina; Trifan, Anca] Grigore T Popa Univ Med & Pharm, Dept Gastroenterol & Hepatol, Iasi, Romania.
   [Lupascu-Ursulescu, Corina] Grigore T Popa Univ Med & Pharm, Dept Radiol, Iasi, Romania.
   [Miftode, Egidia] Grigore T Popa Univ Med & Pharm, Dept Infect Dis, Iasi, Romania.
C3 Grigore T Popa University of Medicine & Pharmacy; Grigore T Popa
   University of Medicine & Pharmacy; Grigore T Popa University of Medicine
   & Pharmacy
RP Stanciu, C (corresponding author), Grigore T Popa Univ Med & Pharm, Dept Gastroenterol & Hepatol, Iasi, Romania.
EM stancincarol@yahoo.com
RI ciortescu, irina/AAF-4983-2022; Muzica, Cristina Maria/AAF-6801-2019;
   Sebastian, Zenovia/AAS-7256-2020; ciortescu, irina/AFJ-8114-2022
OI Muzica, Cristina Maria/0000-0003-0891-5961; Sebastian,
   Zenovia/0000-0003-0441-3980; Stefanescu, Gabriela/0000-0002-1394-8648
CR Abdelaziz AO, 2019, EUR J GASTROEN HEPAT, V31, P75, DOI 10.1097/MEG.0000000000001264
   Brown JL, 2000, GUT, V47, P610, DOI 10.1136/gut.47.5.610
   Carrat F, 2019, LANCET, V393, P1453, DOI 10.1016/S0140-6736(18)32111-1
   Cheung MCM, 2016, J HEPATOL, V65, P741, DOI 10.1016/j.jhep.2016.06.019
   Conti F, 2016, J HEPATOL, V65, P727, DOI 10.1016/j.jhep.2016.06.015
   El Fayoumie M, 2020, GASTROINTEST TUMORS, V7, P50, DOI 10.1159/000505326
   Fatima T, 2020, CUREUS J MED SCIENCE, V12, DOI 10.7759/cureus.11565
   Gad, 2020, J ANTIVIR ANTIRETROV, V12, P202
   Ioannou GN, 2018, J HEPATOL, V68, P25, DOI 10.1016/j.jhep.2017.08.030
   Janjua NZ, 2017, J HEPATOL, V66, P504, DOI 10.1016/j.jhep.2016.10.028
   Kanwal F, 2020, HEPATOLOGY, V71, P44, DOI 10.1002/hep.30823
   Kanwal F, 2017, GASTROENTEROLOGY, V153, P996, DOI 10.1053/j.gastro.2017.06.012
   Khalid J, 2020, INFECT AGENTS CANCER, V15, DOI 10.1186/s13027-020-00300-z
   Laursen TL, 2020, WORLD J GASTROENTERO, V26, P2931, DOI 10.3748/wjg.v26.i22.2931
   Mettke F, 2018, ALIMENT PHARM THER, V47, P516, DOI 10.1111/apt.14427
   Muzica CM, 2020, WORLD J GASTROENTERO, V26, DOI 10.3748/wjg.v26.i43.6770
   Nahon P, 2017, GASTROENTEROLOGY, V152, P142, DOI 10.1053/j.gastro.2016.09.009
   Nakao Y, 2018, J HEPATOL, V68, P854, DOI 10.1016/j.jhep.2017.11.011
   Pawlotsky JM, 2020, J HEPATOL, V73, P1170, DOI 10.1016/j.jhep.2020.08.018
   Petrick JL, 2020, INT J CANCER, V147, P317, DOI 10.1002/ijc.32723
   Poordad F, 2020, J VIRAL HEPATITIS, V27, P497, DOI 10.1111/jvh.13261
   Reig M, 2016, J HEPATOL, V65, P719, DOI 10.1016/j.jhep.2016.04.008
   Renzulli M, 2018, EUR RADIOL, V28, P506, DOI 10.1007/s00330-017-5033-3
   Sangiovanni A, 2004, GASTROENTEROLOGY, V126, P1005, DOI 10.1053/j.gastro.2003.12.049
   Sangiovanni A, 2020, J HEPATOL, V73, P593, DOI 10.1016/j.jhep.2020.03.030
   Singer AW, 2018, ALIMENT PHARM THER, V47, P1278, DOI 10.1111/apt.14593
   Sung H, 2021, CA-CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660
   Tada T, 2016, LIVER INT, V36, P817, DOI 10.1111/liv.13071
   Webster DP, 2015, LANCET, V385, P1124, DOI [10.1016/S0140-6736(14)62401-6, 10.1016/S0140-6736(14)61932-2]
   WHO, 2012, GLOBAL TUBERCULOSIS REPORT 2012, P1
   Yu ML, 2006, ANTIVIR THER, V11, P985
NR 31
TC 0
Z9 0
U1 0
U2 4
PU BRIEFLAND
PI Shertogenbosch
PA 25 Derde Morgen, Shertogenbosch, NETHERLANDS
SN 1735-143X
EI 1735-3408
J9 HEPAT MON
JI Hepat. Mon.
PD JUN
PY 2021
VL 21
IS 6
AR e115910
DI 10.5812/hepatmon.115910
PG 7
WC Gastroenterology & Hepatology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Gastroenterology & Hepatology
GA UX7DM
UT WOS:000701001300001
OA gold
DA 2024-02-19
ER

PT J
AU Holyoak, T
   Zhang, B
   Deng, JP
   Tang, QL
   Prasannan, CB
   Fenton, AW
AF Holyoak, Todd
   Zhang, Bing
   Deng, Junpeng
   Tang, Qingling
   Prasannan, Charulata B.
   Fenton, Aron W.
TI Energetic Coupling between an Oxidizable Cysteine and the
   Phosphorylatable N-Terminus of Human Liver Pyruvate Kinase
SO BIOCHEMISTRY
LA English
DT Article
ID REPERFUSION INJURY; PROTEIN; CELLS; INHIBITION; MUTATION; HYPOXIA;
   ELEMENT; STRESS; ACID; GENE
AB During our efforts to characterize the regulatory properties of human liver pyruvate kinase (L-PYK), we have noted that the affinity of the protein for phosphoenolpyruvate (PEP) becomes reduced several days after cell lysis. A 1.8 angstrom crystallographic structure of L-PYK with the S12D mimic of phosphorylation indicates that Cys436 is oxidized, the first potential insight into explaining the effect of "aging". Interestingly, the oxidation is only to sulfenic acid despite the crystal growth time period of 2 weeks. Mutagenesis confirms that the side chain of residue 436 is energetically coupled to PEP binding. Mass spectrometry confirms that the oxidation is present in solution and is not an artifact caused by X-ray exposure. Exposure of the L-PYK mutations to H2O2 also confirms that PEP affinity is sensitive to the nature of the side chain at position 436. A 1.95 angstrom structure of the C436M mutant of L-PYK, the only mutation at position 436 that has been shown to strengthen PEP affinity, revealed that the methionine substitution results in the ordering of several N-terminal residues that have not been ordered in previous structures. This result allowed speculation that oxidation of Cys436 and phosphorylation of the N-terminus at Ser12 may function through a similar mechanism, namely the interruption of an activating interaction between the nonphosphorylated N-terminus with the nonoxidized main body of the protein. Mutant cycles were used to provide evidence that mutations of Cys436 are energetically synergistic with N-terminal modifications, a result that is consistent with phosphorylation of the N-terminus and oxidation of Cys436 functioning through mechanisms with common features. Alanine-scanning mutagenesis was used to confirm that the newly ordered N-terminal residues were important to the regulation of enzyme function by the N-terminus of the enzyme (i.e., not an artifact caused by the introduced methionine substitution) and to further define which residues in the N-terminus are energetically coupled to PEP affinity. Collectively, these studies indicate energetic coupling (and potentially mechanistic similarities) between the oxidation of Cys436 and phosphorylation of Ser12 in the N-terminus of L-PYK.
C1 [Holyoak, Todd; Tang, Qingling; Prasannan, Charulata B.; Fenton, Aron W.] Univ Kansas, Med Ctr, Dept Biochem & Mol Biol, Kansas City, KS 66160 USA.
   [Zhang, Bing; Deng, Junpeng] Oklahoma State Univ, Dept Biochem & Mol Biol, Stillwater, OK 74078 USA.
C3 University of Kansas; University of Kansas Medical Center; Oklahoma
   State University System; Oklahoma State University - Stillwater
RP Fenton, AW (corresponding author), Univ Kansas, Med Ctr, Dept Biochem & Mol Biol, MS 3030,3901 Rainbow Blvd, Kansas City, KS 66160 USA.
EM afenton@kumc.edu
FU National Institutes of Health [DK78076]; Department of Energy Office of
   Biological and Environmental Research; National Institutes of Health
   National Center for Research Resources, Biomedical Technology Program;
   National Institutes of Health National Center for Research Resources,
   National Institute of General Medical Sciences
FX This work was supported by National Institutes of Health Grant DK78076.;
   Portions of this research were conducted at the Stanford Synchrotron
   Radiation Laboratory, a national user facility operated by Stanford
   University on behalf of the U.S. Portions of this research were
   conducted at the Advanced Photon Source. Department of Energy Office of
   Basic Energy Sciences. The Stanford Synchrotron Radiation Laboratory
   Structural Molecular Biology Program is supported by the Department of
   Energy Office of Biological and Environmental Research and by the
   National Institutes of Health National Center for Research Resources,
   Biomedical Technology Program, and the National Institute of General
   Medical Sciences. We thank Dr. Aileen Alontaga for her efforts to
   recover oxidized protein by addition of DTT and The Mass
   Spectrometry/Proteomics Core at The University of Kansas Medical Center
   (directed by Dr. Anotonio Artigues) for mass detection of oxidized
   cysteine.
CR Aisaki KI, 2007, EXP HEMATOL, V35, P1190, DOI 10.1016/j.exphem.2007.05.005
   Alexiev U, 2000, J BIOL CHEM, V275, P13431, DOI 10.1074/jbc.275.18.13431
   Alontaga AY, 2011, BIOCHEMISTRY-US, V50, P1934, DOI 10.1021/bi200052e
   Anastasiou D, 2011, SCIENCE, V334, P1278, DOI 10.1126/science.1211485
   BERGSTROM G, 1978, BIOCHIM BIOPHYS ACTA, V532, P259, DOI 10.1016/0005-2795(78)90580-9
   BULKLEY GB, 1994, LANCET, V344, P934, DOI 10.1016/S0140-6736(94)92276-4
   Chen VB, 2010, ACTA CRYSTALLOGR D, V66, P12, DOI 10.1107/S0907444909042073
   Deng JP, 2004, ACTA CRYSTALLOGR D, V60, P203, DOI 10.1107/S0907444903024491
   Discher DJ, 1998, J BIOL CHEM, V273, P26087, DOI 10.1074/jbc.273.40.26087
   Ellis HR, 1997, BIOCHEMISTRY-US, V36, P15013, DOI 10.1021/bi972191x
   Faustova I, 2012, PROTEIN J, V31, P592, DOI 10.1007/s10930-012-9438-1
   Fenton AW, 2012, METHODS MOL BIOL, V796, P369, DOI 10.1007/978-1-61779-334-9_20
   Fenton AW, 2009, METHOD ENZYMOL, V466, P83, DOI 10.1016/S0076-6879(09)66005-5
   Fenton AW, 2009, BIOCHEMISTRY-US, V48, P3816, DOI 10.1021/bi900421f
   Fenton AW, 2009, ARCH BIOCHEM BIOPHYS, V484, P16, DOI 10.1016/j.abb.2009.01.011
   GRACE PA, 1994, BRIT J SURG, V81, P637, DOI 10.1002/bjs.1800810504
   Grüning NM, 2011, CELL METAB, V14, P415, DOI 10.1016/j.cmet.2011.06.017
   Jacob C, 2004, ORG BIOMOL CHEM, V2, P1953, DOI 10.1039/b406180b
   Jiang P, 2011, NAT CELL BIOL, V13, P310, DOI 10.1038/ncb2172
   Kiley PJ, 2004, PLOS BIOL, V2, P1714, DOI 10.1371/journal.pbio.0020400
   Krones A, 2001, ENDOCRINOLOGY, V142, P2707, DOI 10.1210/en.142.6.2707
   Livesay DR, 2012, METHODS MOL BIOL, V796, P385, DOI 10.1007/978-1-61779-334-9_21
   Luft JR, 2003, J STRUCT BIOL, V142, P170, DOI 10.1016/S1047-8477(03)00048-0
   Narli N, 2005, PEDIATR HEMAT ONCOL, V22, P567, DOI 10.1080/08880010500198616
   Ogasawara Y, 2008, BIOL PHARM BULL, V31, P1875, DOI 10.1248/bpb.31.1875
   Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X
   Pendergrass DC, 2006, IUBMB LIFE, V58, P31, DOI 10.1080/15216540500531705
   Prasannan CB, 2012, METHODS MOL BIOL, V796, P335, DOI 10.1007/978-1-61779-334-9_18
   Reinhart GD, 2004, METHOD ENZYMOL, V380, P187
   Shimizu T, 2004, J NEUROCHEM, V91, P167, DOI 10.1111/j.1471-4159.2004.02702.x
   Valentini G, 2002, J BIOL CHEM, V277, P23807, DOI 10.1074/jbc.M202107200
   ZIERZ S, 1983, H-S Z PHYSIOL CHEM, V364, P1447, DOI 10.1515/bchm2.1983.364.2.1447
NR 32
TC 31
Z9 35
U1 0
U2 13
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0006-2960
J9 BIOCHEMISTRY-US
JI Biochemistry
PD JAN 22
PY 2013
VL 52
IS 3
BP 466
EP 476
DI 10.1021/bi301341r
PG 11
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 078FA
UT WOS:000314082700003
PM 23270483
OA Green Accepted
DA 2024-02-19
ER

PT J
AU Dozmorov, I
   Bartke, A
   Miller, RA
AF Dozmorov, I
   Bartke, A
   Miller, RA
TI Array-based expression analysis of mouse liver genes:: Effect of age and
   of the longevity mutant <i>Prop1<SUP>df</SUP></i>
SO JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL
   SCIENCES
LA English
DT Article
ID CAPACITY
AB Ames dwarf mice, homozygous fur the df allele at the Prop1 locus, live 40% to 70% longer than nonmutant siblings and represent the first single-gene mutant that extends life span in a mammal. To gain insight into the basis for the longevity of the Ames dwarf mouse, we measured liver mRNA levels for 265 genes in a group of 11 df/df mice, (three to four mice per age group), at ages 5, 13, and 22 months, and in 13 age- and sex-matched control mice. The analysis showed seven genes where the effects of age reach p < .01 in normal mice and six others with possible age effects in dwarf mice, but none of these met Bonferroni-adjusted significance thresholds. Thirteen genes showed possible effects of the df/df genotype at p <.01. One of these, insulin-like growth factor I (IGF-I), was statistically significant even after adjustment fur multiple comparisons; and genes for two IGF-binding proteins, a cyclin, a heat shock protein, p38 mitogen-activated protein kinase, and an inducible cytochrome P450 were among those implicated by the survey. In young control mice, half of the expressed genes showed SDs that were more than 58% of the mean, and a simulation study showed that genes with this degree of interanimal variation would often produce false-positive findings when conclusions were based on ratio calculations alone (i.e., without formal significance testing). Many genes in our data set showed apparent young-to-old or normal-to-dwarf ratios above 2, but the large majority of these proved to be genes where high interanimal variation could create high ratios by chance alone, and only a few of the genes with large ratios achieved p < .05. The proportion of genes showing relatively large changes between 5 and 13 months, or from 13 to 22 months of age, was not diminished by the df/df genotype, providing no support for the idea that the dwarf mutation leads to global delay or deceleration of the pare of age-dependent changes in gene expression. These survey data provide the foundation for replication studies that should provide convincing proof for age- and genotype-specific effects on gene expression and thus reveal key similarities among the growing number of mouse models of decelerated aging.
C1 Univ Michigan, Geriatr Ctr, Ann Arbor, MI 48109 USA.
   Univ Michigan, Inst Gerontol, Dept Pathol, Ann Arbor, MI 48109 USA.
   So Illinois Univ, Dept Physiol, Carbondale, IL 62901 USA.
   Ann Arbor DVA Med Ctr, Ann Arbor, MI USA.
C3 University of Michigan System; University of Michigan; University of
   Michigan System; University of Michigan; Southern Illinois University
   System; Southern Illinois University
RP Miller, RA (corresponding author), Univ Michigan, Geriatr Ctr, 5316 CCGCB, Ann Arbor, MI 48109 USA.
RI Bartke, Andzej/D-6640-2017
OI Bartke, Andzej/0000-0002-2569-557X
FU NIA NIH HHS [AG08808, AG13283] Funding Source: Medline
CR BrownBorg HM, 1996, NATURE, V384, P33, DOI 10.1038/384033a0
   EIGENMANN JE, 1988, ACTA ENDOCRINOL-COP, V118, P105, DOI 10.1530/acta.0.1180105
   EIGENMANN JE, 1984, ACTA ENDOCRINOL-COP, V106, P448, DOI 10.1530/acta.0.1060448
   Gage PJ, 1996, MOL ENDOCRINOL, V10, P1570, DOI 10.1210/me.10.12.1570
   Han ES, 2000, MECH AGEING DEV, V115, P157, DOI 10.1016/S0047-6374(00)00119-6
   Lee CK, 1999, SCIENCE, V285, P1390, DOI 10.1126/science.285.5432.1390
   Li Y, 1996, J GERONTOL A-BIOL, V51, pB403, DOI 10.1093/gerona/51A.6.B403
   Ly DH, 2000, SCIENCE, V287, P2486, DOI 10.1126/science.287.5462.2486
   Miller RA, 1999, J GERONTOL A-BIOL, V54, pB297, DOI 10.1093/gerona/54.7.B297
   Miller RA, 2001, J GERONTOL A-BIOL, V56, pB52, DOI 10.1093/gerona/56.2.B52
   SOMSON MW, 1996, NATURE, V384, P327
   MOL GENETICS AGING R
NR 12
TC 38
Z9 42
U1 0
U2 2
PU GERONTOLOGICAL SOCIETY AMER
PI WASHINGTON
PA 1275 K STREET NW SUITE 350, WASHINGTON, DC 20005-4006 USA
SN 1079-5006
J9 J GERONTOL A-BIOL
JI J. Gerontol. Ser. A-Biol. Sci. Med. Sci.
PD FEB
PY 2001
VL 56
IS 2
BP B72
EP B80
DI 10.1093/gerona/56.2.B72
PG 9
WC Geriatrics & Gerontology; Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Geriatrics & Gerontology
GA 401PL
UT WOS:000166936400004
PM 11213270
OA Bronze
DA 2024-02-19
ER

PT J
AU Mecitoglu, Z
   Topal, O
   Kacar, Y
   Batmaz, H
AF Mecitoglu, Zafer
   Topal, Onur
   Kacar, Yigit
   Batmaz, Hasan
TI Comparing the effects of treatment with ammonium molybdate versus
   ammonium molybdate and phenoxy-2-methyl-2-propionic acid on liver
   functions in natural copper poisoning of sheep
SO SMALL RUMINANT RESEARCH
LA English
DT Article
DE Copper poisoning; Sheep; Ammonium molybdate;
   Phenoxy-2-methyl-2-propionic acid; (PMPA); AST; GGT
ID PEROXISOME PROLIFERATOR NAFENOPIN; ACTIVATED RECEPTOR-ALPHA;
   LIPID-PEROXIDATION; PROPIONIC-ACID; FATTY LIVER; DAIRY-COWS; METABOLISM;
   TOXICOSIS; TETRATHIOMOLYBDATE; MOLYBDENUM
AB Aim of the presented study is to compare the effects of treatment with ammonium molybdate versus ammonium molybdate and phenoxy-2-methyl-2-propionic acid on liver functions in natural copper poisoning of sheep and overall treatment responses in sheep naturally poisoned with copper (Cu). Study was conducted on 80 yearlings aging between 6-9 months. AM + PMPA group (n =50) received ammonium molybdate and PMPA and AM group (n =30) received only ammonium molybdate. First blood samples were collected before the treatments. PMPA was administered once daily intramuscularly at dose of 10 mg/kg for the first three days of the study to AM + PMPA group. AM + PMPA and AM groups both received ammonium molybdate two times with one week interval at dose of 1.34 mg/kg (1 cc per 10 kg BW, of %1.34 ammonium molybdate in saline solution) subcutaneously. Second blood samples were collected from all 80 animals on day 21 of the study. Cu levels were measured in a subgroup of randomly selected 9 (5 from AM + PMPA and 4 from AM group) animals on days 0 and 21 of the study. Mean Cu levels were 158.25 +/- 14 mu g/dl and 156.75 +/- 9 mu g/dlon day 0 and 129 +/- 9 mu g/dl and 154.5 +/- 22 mu g/dl in AM + PMPA and AM group respectively. AST levels decreased from 502 +/- 67.2114 to 168 +/- 10.1 IU/L in AM + PMPA group (P < 0.001) and from 423 +/- 71.1 IU/Lto 202 +/- 17.1 IU/L in AM group (P = 0.005) on day 21 of the study. GGT levels were 250 +/- 24.2 IU/L and 248 +/- 28.1 IU/L on day 0 and decreased to 160 +/- 16.41 U/L and 166 +/- 22.2 IU/L on day 21 in AM + PMPA and AM group with significance of P=0.001 and P=0.037 respectively. Two animals from AM group and one from AM + PMPA group died during the study period. Based on the more pronounced decrease in AST and GGT levels in AM + PMPA group we conclude that PMPA has beneficial effects on liver functions in chronic copper poisoning of sheep probably as a result of decreased lipid peroxidation in hepatocytes and/or increased Cu elimination by cholerectic effects of PMPA. (C) 2017 Elsevier B.V. All rights reserved.
C1 [Mecitoglu, Zafer; Topal, Onur; Kacar, Yigit; Batmaz, Hasan] Uludag Univ, Dept Internal Med, Fac Vet Med, TR-16059 Gorukle, Bursa, Turkey.
C3 Uludag University
RP Mecitoglu, Z (corresponding author), Uludag Univ, Dept Internal Med, Fac Vet Med, TR-16059 Gorukle, Bursa, Turkey.
EM zmecitoglu@uludag.edu.tr; onurtopal@uludag.edu.tr;
   vetyigitkacar@gmail.com; hbatmaz@uludag.edu.tr
RI MECITOGLU, Zafer/AAH-1677-2021; Kacar, Yigit/AAH-4972-2021; Batmaz,
   Hasan/AAH-1712-2021; TOPAL, Onur/S-8278-2017
OI MECITOGLU, Zafer/0000-0002-5557-121X; Kacar, Yigit/0000-0002-8389-4833;
   Batmaz, Hasan/0000-0003-1991-8957; TOPAL, Onur/0000-0002-1933-7354
CR Aparicio-Cecilio A, 2012, CZECH J ANIM SCI, V57, P550, DOI 10.17221/6412-CJAS
   BAYLY AC, 1994, J CELL BIOL, V125, P197, DOI 10.1083/jcb.125.1.197
   BOSTWICK JL, 1982, J AM VET MED ASSOC, V180, P386
   Britton RS, 1996, SEMIN LIVER DIS, V16, P3, DOI 10.1055/s-2007-1007214
   CHEEKE PR, 1988, J ANIM SCI, V66, P2343
   Darrell L.R, 2012, SHEEP GOAT MED, P23
   FERNANDES A, 1988, FREE RADICAL RES COM, V4, P291, DOI 10.3109/10715768809066894
   Gaetke LM, 2003, TOXICOLOGY, V189, P147, DOI 10.1016/S0300-483X(03)00159-8
   García-Fernández AJ, 1999, CAN VET J, V40, P799
   Gümüs U, 2013, TURK J VET ANIM SCI, V37, P653, DOI 10.3906/vet-1212-28
   Harano Y, 2006, LIVER INT, V26, P613, DOI 10.1111/j.1478-3231.2006.01265.x
   HIDIROGLOU M, 1984, CAN VET J, V25, P377
   Huber WW, 1997, ARCH TOXICOL, V71, P575, DOI 10.1007/s002040050429
   HUMPHRIES WR, 1988, VET REC, V123, P51, DOI 10.1136/vr.123.2.51
   HUMPHRIES WR, 1986, VET REC, V119, P596
   Jia Y, 2015, MOL NUTR FOOD RES, V59, P344, DOI 10.1002/mnfr.201400399
   Kennerman E., 2002, YYU VET FAK DERG, V8, P32
   KERR LA, 1991, J AM VET MED ASSOC, V198, P99
   Maiorka PC, 1998, VET HUM TOXICOL, V40, P99
   MOSHTAGHINIA SA, 1989, CAN J ANIM SCI, V69, P187, DOI 10.4141/cjas89-022
   Navvarre CB., 2012, SHEEP GOAT MED, P100
   Ortolani EL, 2003, VET HUM TOXICOL, V45, P289
   Oruc HH, 2009, J VET DIAGN INVEST, V21, P540, DOI 10.1177/104063870902100420
   Radostits O.M., 2007, VET MED TXB DIS CATT, V10th, P1820
   Rizzo A, 2014, ENDOCR METAB IMMUNE, V14, P113, DOI 10.2174/1871530314666140223184913
   Roubies N, 2008, J VET PHARMACOL THER, V31, P181, DOI 10.1111/j.1365-2885.2007.00933.x
   Sommerville GF, 1978, NZ VET J, V33, P98
   TODD J. R., 1963, BRIT VET JOUR, V119, P161
   Turnlund JR, 1998, AM J CLIN NUTR, V67, p960S, DOI 10.1093/ajcn/67.5.960S
NR 29
TC 3
Z9 3
U1 0
U2 18
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0921-4488
EI 1879-0941
J9 SMALL RUMINANT RES
JI Small Ruminant Res.
PD MAY
PY 2017
VL 150
BP 93
EP 96
DI 10.1016/j.smallrumres.2017.03.010
PG 4
WC Agriculture, Dairy & Animal Science
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Agriculture
GA EW0YU
UT WOS:000402217900015
DA 2024-02-19
ER

PT J
AU HIGAMI, Y
   SHIMOKAWA, I
   OKIMOTO, T
   IKEDA, T
AF HIGAMI, Y
   SHIMOKAWA, I
   OKIMOTO, T
   IKEDA, T
TI VULNERABILITY TO OXYGEN RADICALS IS MORE IMPORTANT THAN IMPAIRED REPAIR
   IN HEPATOCYTIC DEOXYRIBONUCLEIC-ACID DAMAGE IN AGING
SO LABORATORY INVESTIGATION
LA English
DT Article
DE DNA DAMAGE; DNA VULNERABILITY; DNA REPAIR; OXYGEN RADICALS; SINGLE-CELL
   GEL ELECTROPHORESIS; HEPATOCYTES; F344 RAT
ID INDIVIDUAL HUMAN-LYMPHOCYTES; DNA DAMAGE; AGE; LIVER; MICE; RESTRICTION;
   ABSENCE; ASSAY
AB BACKGROUND: Many previous reports have shown an age-related increase in DNA damage in hepatocytes. This change is thought to result from alterations in DNA repair capacity, DNA vulnerability to oxygen radicals, or both.
   EXPERIMENTAL DESIGN: Single-cell gel electrophoresis (comet assay), which measures single-strand breaks/alkali-labile sites in the DNA of individual cells, was used to compare DNA repair capacity and vulnerability to damage in hepatocytes prepared from the livers of young (6 to 11 months) and old (26 to 29 months) male Fischer 344 rats. DNA damage was induced in a portion of the cells by exposure to 882 mM hydrogen peroxide. Comet images (migration distance of DNA (MDD) were assessed at the basal level (before exposure) and at 0, 1, 2, and 4 hours' incubation after-exposure.
   RESULTS: The mean basal values of MDD (MV-MDD) and the proportion of hepatocytes with highly damaged DNA (P-HDD) were found to be significantly higher in advanced age. When cells were challenged with hydrogen peroxide, MV-MDD did not differ significantly between the two groups. Interestingly, however, cellular distribution analysis revealed a larger subpopulation of cells with high DNA vulnerability to hydrogen peroxide in rats of advanced age. Furthermore, both MV-MDD and P-HDD were restored almost to basal level at 2 hours incubation after exposure in cells from young rats, while neither recovered even at 4 hours incubation in cells from old rats. This contrast suggests that there is a significant age-related decline in DNA repair capacity.
   CONCLUSIONS: The low repair capacity in advanced age depends on a subpopulation of cells showing high DNA vulnerability to hydrogen peroxide. Therefore, an increase in the proportion of hepatocytes exhibiting high vulnerability to oxygen radicals is more important than the deterioration in DNA repair capacity in the age-related increase in DNA damage.
RP HIGAMI, Y (corresponding author), NAGASAKI UNIV,SCH MED,DEPT PATHOL,1-21-4 SAKAMOTO,NAGASAKI 852,JAPAN.
OI Higami, Yoshikazu/0000-0003-1381-0777; Shimokawa,
   Isao/0000-0001-8901-1029
CR AMES BN, 1989, MUTAT RES, V214, P41, DOI 10.1016/0027-5107(89)90196-6
   Bernstein C., 1991, Aging, sex and DNA repair
   CHETSANGA CJ, 1975, NATURE, V253, P130, DOI 10.1038/253130a0
   DEAN RG, 1978, EXP GERONTOL, V13, P287, DOI 10.1016/0531-5565(78)90036-0
   FINCH CE, 1979, AGE, V2, P45, DOI 10.1007/BF02432255
   FU CS, 1991, J GERONTOL, V46, pB78, DOI 10.1093/geronj/46.2.B78
   HARRIS G, 1986, INT J RADIAT BIOL, V50, P685, DOI 10.1080/09553008614551091
   HART RW, 1974, P NATL ACAD SCI USA, V71, P2169, DOI 10.1073/pnas.71.6.2169
   HIGAMI Y, 1994, MUTAT RES-DNAGING G, V316, P59, DOI 10.1016/0921-8734(94)90008-6
   HOLMES GE, 1992, MUTAT RES, V275, P305, DOI 10.1016/0921-8734(92)90034-M
   MULLAART E, 1990, MUTAT RES, V237, P189, DOI 10.1016/0921-8734(90)90001-8
   OLIVE PL, 1990, RADIAT RES, V122, P86, DOI 10.2307/3577587
   OLIVE PL, 1992, EXP CELL RES, V198, P259, DOI 10.1016/0014-4827(92)90378-L
   ONO T, 1976, EXP GERONTOL, V11, P127, DOI 10.1016/0531-5565(76)90022-X
   ONO T, 1978, INT J RADIAT BIOL, V33, P403, DOI 10.1080/09553007814550321
   OVE P, 1978, MECH AGEING DEV, V8, P363, DOI 10.1016/0047-6374(78)90035-0
   PACIFICI RE, 1991, GERONTOLOGY, V37, P166
   PLESKO MM, 1984, BIOCHEM BIOPH RES CO, V118, P730, DOI 10.1016/0006-291X(84)91455-4
   PRICE GB, 1971, SCIENCE, V171, P917, DOI 10.1126/science.171.3974.917
   Seglen P O, 1976, Methods Cell Biol, V13, P29, DOI 10.1016/S0091-679X(08)61797-5
   SHADDOCK JG, 1993, MUTAT RES, V295, P19, DOI 10.1016/0921-8734(93)90008-Q
   SINGH NP, 1990, MUTAT RES, V237, P123, DOI 10.1016/0921-8734(90)90018-M
   SINGH NP, 1991, MUTAT RES, V256, P1, DOI 10.1016/0921-8734(91)90026-8
NR 23
TC 16
Z9 16
U1 0
U2 0
PU WILLIAMS & WILKINS
PI BALTIMORE
PA 351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436
SN 0023-6837
J9 LAB INVEST
JI Lab. Invest.
PD NOV
PY 1994
VL 71
IS 5
BP 650
EP 656
PG 7
WC Medicine, Research & Experimental; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine; Pathology
GA PV926
UT WOS:A1994PV92600004
PM 7967519
DA 2024-02-19
ER

PT J
AU Hong, J
   Shin, WK
   Lee, JW
   Lee, SY
   Kim, Y
AF Hong, Jihye
   Shin, Woo-Kyoung
   Lee, Jung Woo
   Lee, Seung-Yeon
   Kim, Yookyung
TI Associations of Serum Vitamin D Level with Sarcopenia, Non-Alcoholic
   Fatty Liver Disease (NAFLD), and Sarcopenia in NAFLD Among People Aged
   50 Years and Older: The Korea National Health and Nutrition Examination
   Survey IV-V
SO METABOLIC SYNDROME AND RELATED DISORDERS
LA English
DT Article; Early Access
DE skeletal muscle index; muscle mass; nonalcoholic steatohepatitis; serum
   vitamin D; aging; KNHANES
ID METABOLIC SYNDROME; INSULIN-RESISTANCE; RISK-FACTORS; OBESITY;
   STEATOHEPATITIS; METAANALYSIS; PREVALENCE
AB Background: The role of serum 25-hydroxyvitamin D [25(OH)D] levels in the development of sarcopenia in non-alcoholic fatty liver disease (NAFLD) remains controversial. We investigated the association between vitamin D levels, occurrence of sarcopenia, NAFLD, and sarcopenia in NAFLD in adults aged >50 years.Methods: This study used data pertaining to 5396 adults aged >50 years (1870 men and 3526 women) from the 2008-2011 Korea National Health and Nutrition Examination Survey. Appendicular skeletal muscle mass adjusted by weight (ASM/Wt) was used to diagnose sarcopenia, and NAFLD was diagnosed using the NAFLD fat score.Results: The lowest quintile of serum 25(OH)D level (4.85-15.26 ng/mL) was associated with an increased occurrence of sarcopenia [odds ratio (OR) 2.65; 95% confidence interval (CI) 1.64-4.27], NAFLD (OR 1.82; 95% CI 1.19-2.96), and sarcopenia in NAFLD (OR 2.25; 95% CI 1.26-4.03) in men. In women, sarcopenia (OR 1.80; 95% CI 1.29-2.51) was also significantly associated with serum vitamin D levels, whereas high levels of vitamin D were not significantly related to NAFLD.Conclusions: Serum vitamin D levels are associated with sarcopenia, NAFLD, and sarcopenia in NAFLD. Vitamin D level can be a useful marker of sarcopenia and NAFLD, especially in men.
C1 [Hong, Jihye; Lee, Jung Woo; Kim, Yookyung] Korea Univ, Grad Sch, Dept Human Ecol, Seoul 02841, South Korea.
   [Shin, Woo-Kyoung] Seoul Natl Univ, Coll Med, Dept Prevent Med, Seoul, South Korea.
   [Lee, Seung-Yeon] Univ Cincinnati, Dept Nutr Sci, Acad Hlth Ctr, Cincinnati, OH USA.
C3 Korea University; Seoul National University (SNU); University System of
   Ohio; University of Cincinnati
RP Kim, Y (corresponding author), Korea Univ, Grad Sch, Dept Human Ecol, Seoul 02841, South Korea.
EM yookyung_kim@korea.ac.kr
RI Hong, Jihye/ITW-2516-2023
OI Kim, Yookyung/0000-0002-8438-0121; Lee, Jung Woo/0000-0003-1509-6909;
   Lee, Seung-Yeon/0000-0002-5865-749X; Hong, Jihye/0000-0003-3012-1316
CR Awad AB, 2012, CRIT REV FOOD SCI, V52, P103, DOI 10.1080/10408391003785458
   Barchetta I, 2012, HEPATOLOGY, V56, P2180, DOI 10.1002/hep.25930
   Bauer J, 2019, J CACHEXIA SARCOPENI, V10, P956, DOI 10.1002/jcsm.12483
   Baumgartner RN, 1998, AM J EPIDEMIOL, V147, P755, DOI 10.1093/oxfordjournals.aje.a009520
   Calvani R, 2013, J FRALITY AGING, V2, P38
   Camey SA, 2014, CAD SAUDE PUBLICA, V30, P21
   Cawthon PM, 2014, J GERONTOL A-BIOL, V69, P567, DOI 10.1093/gerona/glu023
   Ceglia L, 2013, CALCIFIED TISSUE INT, V92, P151, DOI 10.1007/s00223-012-9645-y
   Ceglia L, 2010, J MOL HISTOL, V41, P137, DOI 10.1007/s10735-010-9270-x
   Colombini A, 2015, INT J MOL SCI, V16, P3722, DOI 10.3390/ijms16023722
   Cruz-Jentoft AJ, 2019, AGE AGEING, V48, P16, DOI 10.1093/ageing/afy169
   De Fré CH, 2019, OBES REV, V20, P353, DOI 10.1111/obr.12776
   Derstine BA, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-29825-5
   Ding C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061707
   Dionyssiotis Y., 2017, FRAILTY SARCOPENIA O
   Eliades M, 2013, ALIMENT PHARM THER, V38, P246, DOI 10.1111/apt.12377
   FISHER NM, 1990, ARCH PHYS MED REHAB, V71, P729
   Graffy PM, 2019, BRIT J RADIOL, V92, DOI 10.1259/bjr.20190327
   Hong HC, 2014, HEPATOLOGY, V59, P1772, DOI 10.1002/hep.26716
   Hyppönen E, 2008, DIABETES, V57, P298, DOI 10.2337/db07-1122
   Kim KM, 2016, KOREAN J INTERN MED, V31, P643, DOI 10.3904/kjim.2016.015
   Kotronen A, 2009, GASTROENTEROLOGY, V137, P865, DOI 10.1053/j.gastro.2009.06.005
   Kweon S, 2014, INT J EPIDEMIOL, V43, P69, DOI 10.1093/ije/dyt228
   Lee S, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/ijerph18031195
   Lee YH, 2016, HEPATOLOGY, V63, P776, DOI 10.1002/hep.28376
   Lee YH, 2015, J HEPATOL, V63, P486, DOI 10.1016/j.jhep.2015.02.051
   Li Andrew A, 2020, Clin Liver Dis (Hoboken), V16, P73, DOI 10.1002/cld.900
   Lim S, 2010, DIABETES CARE, V33, P1652, DOI 10.2337/dc10-0107
   Long Cheng, 2015, 2015 IEEE Power & Energy Society General Meeting, P1, DOI 10.1109/PESGM.2015.7286147
   McCormick R, 2018, BIOGERONTOLOGY, V19, P519, DOI 10.1007/s10522-018-9775-3
   Mutt SJ, 2012, FASEB J, V26, P4400, DOI 10.1096/fj.12-210880
   Nelson JE, 2016, AM J GASTROENTEROL, V111, P852, DOI 10.1038/ajg.2016.51
   Okubo T, 2020, HEPATOL RES, V50, P588, DOI 10.1111/hepr.13485
   Park D, 2017, J KOREAN MED SCI, V32, P95, DOI 10.3346/jkms.2017.32.1.95
   Park JE, 2018, J OBES METAB SYNDR, V27, P223, DOI 10.7570/jomes.2018.27.4.223
   Rietman A, 2014, EUR J CLIN NUTR, V68, P973, DOI 10.1038/ejcn.2014.123
   Visser M, 2003, J CLIN ENDOCR METAB, V88, P5766, DOI 10.1210/jc.2003-030604
   Walrand S, 2011, CLIN GERIATR MED, V27, P365, DOI 10.1016/j.cger.2011.03.005
   Willett W., 2012, NUTR EPIDEMIOLOGY
   Yu R, 2018, BMC GASTROENTEROL, V18, DOI 10.1186/s12876-018-0776-0
   Zhang YG, 2021, NUTR CANCER, V73, P1261, DOI 10.1080/01635581.2020.1797127
NR 41
TC 4
Z9 4
U1 3
U2 12
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1540-4196
EI 1557-8518
J9 METAB SYNDR RELAT D
JI Metab. Syndr. Relat. Disord.
PD 2022 MAY
PY 2022
VL 20
IS 4
BP 210
EP 218
DI 10.1089/met.2021.0106
EA JAN 2022
PG 9
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA S6IH6
UT WOS:000749850100001
PM 35100057
DA 2024-02-19
ER

PT J
AU NAGASE, T
   SUGIYAMA, T
   KAWATA, S
   TARUI, S
   DEUTSCH, HF
   TANIGUCHI, N
AF NAGASE, T
   SUGIYAMA, T
   KAWATA, S
   TARUI, S
   DEUTSCH, HF
   TANIGUCHI, N
TI ANALYSES OF POLYPEPTIDES IN THE LIVER OF A NOVEL MUTANT (LEC RATS) TO
   HEREDITARY HEPATITIS AND HEPATOMA BY 2-DIMENSIONAL GEL-ELECTROPHORESIS -
   IDENTIFICATION OF P29/6.8 AS CARBONIC ANHYDRASE-III AND TRIOSEPHOSPHATE
   ISOMERASE
SO COMPARATIVE BIOCHEMISTRY AND PHYSIOLOGY B-BIOCHEMISTRY & MOLECULAR
   BIOLOGY
LA English
DT Article
ID HEPATOCELLULAR-CARCINOMA; SEXUAL-DIFFERENTIATION; HUMAN CERULOPLASMIN;
   SKELETAL-MUSCLE; GROWTH-HORMONE; SEQUENCE; PROTEINS; ISOZYMES;
   METABOLISM; EVOLUTION
AB 1.  Total cellular proteins from the livers of 4-, 16- and 52-week-old hepatitis- and hepatoma-predisposed Long-Evans Cinnamon (LEC) rats were compared to those from the livers of the corresponding control rats [Long-Evans Agouti (LEA) rats] by two-dimensional gel electrophoresis.
   2.  A polypeptide, p50/7.2 (molecular weight x 10(-3)/isoelectric point) was only found in the LEC rats, and the p43/6.4 component was greater and the p51/6.8 component was less in the LEC rats than in the LEA rats during aging.
   3.  A polypeptide, p29/6.8, was dramatically greater in 4-week-old LEC rats than in 4-week-old LEA rats.
   4.  By sequencing and Western blotting analysis, the marked differences in the level of the p29/6.8 component were found to be due to carbonic anhydrase III.
C1 OSAKA UNIV,SCH MED,DEPT BIOCHEM,2-2 YAMADAOKA,SUITA,OSAKA 565,JAPAN.
   OSAKA UNIV,SCH MED,DEPT INTERNAL MED 2,FUKUSHIMA KU,OSAKA 553,JAPAN.
C3 Osaka University; Osaka University
RI Taniguchi, Naoyuki/A-7086-2016; Taniguchi, Naoyuki/I-4182-2014
OI Taniguchi, Naoyuki/0000-0001-5889-5968
CR ADAMS CE, 1972, REPRODUCTION MAMMALS, V4, P128
   Brady R.O., 1978, METABOLIC BASIS INHE, P718
   BRADY RO, 1965, BIOCHEM BIOPH RES CO, V18, P221, DOI 10.1016/0006-291X(65)90743-6
   CARTER N, 1979, BIOCHEM GENET, V17, P837, DOI 10.1007/BF00504307
   CARTER ND, 1984, ANN NY ACAD SCI, V429, P287, DOI 10.1111/j.1749-6632.1984.tb12352.x
   CARTER ND, 1981, FEBS LETT, V128, P114, DOI 10.1016/0014-5793(81)81094-0
   CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102
   FARRELL GC, 1975, LANCET, V1, P430
   GAITSKHOKI VS, 1975, BIOCHEM GENET, V13, P533, DOI 10.1007/BF00484913
   HEWETTEMMETT D, 1984, ANN NY ACAD SCI, V429, P338, DOI 10.1111/j.1749-6632.1984.tb12359.x
   HOLMES RS, 1977, EUR J BIOCHEM, V78, P511, DOI 10.1111/j.1432-1033.1977.tb11764.x
   JABUSCH JR, 1980, J BIOL CHEM, V255, P9196
   JABUSCH JR, 1984, BIOCHEM GENET, V22, P357, DOI 10.1007/BF00484234
   KELLY CD, 1988, BIOSCIENCE REP, V8, P401, DOI 10.1007/BF01121636
   KYHSEANDERSEN J, 1984, J BIOCHEM BIOPH METH, V10, P203, DOI 10.1016/0165-022X(84)90040-X
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   LU HS, 1984, J BIOL CHEM, V259, P1958
   MASUDA R, 1988, JPN J CANCER RES, V79, P828, DOI 10.1111/j.1349-7006.1988.tb00044.x
   MASUDA R, 1988, LAB ANIM, V22, P166, DOI 10.1258/002367788780864402
   MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035
   MODE A, 1982, ENDOCRINOLOGY, V111, P1692, DOI 10.1210/endo-111-5-1692
   NAGASUE N, 1985, GASTROENTEROLOGY, V89, P643, DOI 10.1016/0016-5085(85)90463-9
   NAGASUE N, 1986, CANCER, V57, P87, DOI 10.1002/1097-0142(19860101)57:1<87::AID-CNCR2820570118>3.0.CO;2-K
   NISHITA T, 1981, BIOCHEM BIOPH RES CO, V103, P573, DOI 10.1016/0006-291X(81)90490-3
   NORSTEDT G, 1982, ENDOCRINOLOGY, V110, P2107, DOI 10.1210/endo-110-6-2107
   NORSTEDT G, 1984, CELL, V36, P805, DOI 10.1016/0092-8674(84)90030-8
   OFARRELL PH, 1975, J BIOL CHEM, V250, P4007
   OSULLIVAN JP, 1976, LANCET, V1, P1124
   PATRICK AD, 1965, BIOCHEM J, V97, pC17, DOI 10.1042/bj0970017C
   RAMALEY JA, 1982, HORMONES DEV AGING, P305
   SASAKI M, 1985, RAT NEWS LETT, V14, P4
   SATO M, 1990, J BIOL CHEM, V265, P2533
   SHIELS A, 1983, BIOCHIM BIOPHYS ACTA, V760, P335, DOI 10.1016/0304-4165(83)90370-7
   SIMPKINS JW, 1977, ENDOCRINOLOGY, V100, P1672, DOI 10.1210/endo-100-6-1672
   SUGIYAMA T, 1988, CARCINOGENESIS, V9, P1569, DOI 10.1093/carcin/9.9.1569
   TAKAHASHI N, 1983, P NATL ACAD SCI-BIOL, V80, P115, DOI 10.1073/pnas.80.1.115
   TASHIAN RE, 1983, ISOZYMES-CURR T BIOL, V7, P79
   WENDORFF KM, 1985, J BIOL CHEM, V260, P6129
   WIRTH PJ, 1986, CANCER RES, V46, P400
   YOSHIDA MC, 1987, J HERED, V78, P361, DOI 10.1093/oxfordjournals.jhered.a110416
NR 40
TC 4
Z9 5
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB
SN 0305-0491
J9 COMP BIOCHEM PHYS B
JI Comp. Biochem. Physiol. B-Biochem. Mol. Biol.
PY 1991
VL 99
IS 1
BP 193
EP 201
DI 10.1016/0305-0491(91)90029-D
PG 9
WC Biochemistry & Molecular Biology; Zoology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Zoology
GA FP841
UT WOS:A1991FP84100028
PM 1659965
DA 2024-02-19
ER

PT J
AU Koike, M
   Nagao, M
   Iwase, Y
   Kaneko, K
   Ishijima, M
   Nojiri, H
AF Koike, Masato
   Nagao, Masashi
   Iwase, Yoshiyuki
   Kaneko, Kazuo
   Ishijima, Muneaki
   Nojiri, Hidetoshi
TI Clinical Efficacy of Melon GliSODin® for the Treatment of Aging-Related
   Dysfunction in Motor Organs-A Double Blind, Randomized
   Placebo-Controlled Study
SO JOURNAL OF CLINICAL MEDICINE
LA English
DT Article
DE body fat percentage; locomotive syndrome; melon glisodin;
   osteoarthritis; osteoporosis; oxidative stress; sarcopenia; superoxide
   dismutase
ID SUPEROXIDE-DISMUTASE; ORAL SUPPLEMENTATION; JAPANESE PEOPLE; MOBILITY;
   PAIN
AB Background: Locomotive syndrome is a concept proposed in Japan involving decreased mobility due to osteoarthritis, osteoporosis, and sarcopenia. This double-blind, randomized study aimed to investigate the effects of superoxide dismutase (SOD)-rich melon extract (Melon GliSODin (R)) on locomotive syndrome. Methods: For 6 months, we administered oral Melon GliSODin (R) (500.4 mg/day) or a placebo to 24 and 22 women, respectively (aged 50-80 years), with knee or lower back discomfort or pain. Using baseline and 6-month data, changes in the Verbal Rating Scale and in subjective symptoms (determined using the Japanese Knee Osteoarthritis Measure, Locomo 25, the Roland-Morris Disability questionnaire, and the Chalder Fatigue Scale) were assessed, along with various oxidative markers, antioxidants, inflammatory markers, renal and liver function biochemical markers, bone metabolism markers, body composition, and motor function. Results: Oral Melon GliSODin (R) administration tended to be associated with a larger improvement in subjective symptom scores, a reduction in oxidative markers (malondialdehyde and diacron reactive oxygen metabolites) and tumor necrosis factor-alpha, and a significant increase in non-fat mass between baseline and 6 months. However, no statistically significant differences were observed between the groups for outcomes at 6 months. Conclusions: Melon GliSODin (R) tended to improve the subjective symptoms of participants who had knee or lower back pain or discomfort. Melon GliSODin (R) administration may help to prevent the progression of locomotive syndrome. Future studies involving larger sample sizes and more stringent randomization protocols are needed to determine differences between the placebo and Melon GliSODin (R) groups.
C1 [Koike, Masato; Iwase, Yoshiyuki; Nojiri, Hidetoshi] Juntendo Tokyo Koto Geriatr Med Ctr, Dept Orthopaed Surg, Tokyo 1360075, Japan.
   [Nagao, Masashi; Kaneko, Kazuo; Ishijima, Muneaki; Nojiri, Hidetoshi] Juntendo Univ, Dept Orthopaed Surg, Grad Sch Med, Tokyo 1138421, Japan.
   [Nagao, Masashi] Juntendo Univ, Dept Orthopaed Surg, Med Technol Innovat Ctr, Grad Sch Hlth & Sports Sci,Clin Res & Trial Ctr, Tokyo 1138421, Japan.
C3 Juntendo University; Juntendo University; Juntendo University
RP Nojiri, H (corresponding author), Juntendo Tokyo Koto Geriatr Med Ctr, Dept Orthopaed Surg, Tokyo 1360075, Japan.; Nojiri, H (corresponding author), Juntendo Univ, Dept Orthopaed Surg, Grad Sch Med, Tokyo 1138421, Japan.
EM ortho-m.koike@juntendo.ac.jp; nagao@juntendo.ac.jp;
   iwase@juntendo.gmc.ac.jp; k-kaneko@juntendo.ac.jp;
   ishijima@juntendo.ac.jp; hnojiri@juntendo.ac.jp
OI Nagao, Masashi/0000-0002-8909-4650
FU Nutrition Act Co., Ltd., Tokyo, Japan
FX This study was funded by Nutrition Act Co., Ltd., Tokyo, Japan.
CR Aicher B, 2012, CEPHALALGIA, V32, P185, DOI 10.1177/0333102411430856
   Aigner T, 2006, ARTHRITIS RHEUM-US, V54, P3533, DOI 10.1002/art.22174
   Akai M, 2005, J RHEUMATOL, V32, P1524
   Brieger K, 2012, SWISS MED WKLY, V142, DOI 10.4414/smw.2012.13659
   CHALDER T, 1993, J PSYCHOSOM RES, V37, P147, DOI 10.1016/0022-3999(93)90081-P
   Cloarec M, 2007, Eur Ann Allergy Clin Immunol, V39, P45
   Hame SL, 2013, CURR REV MUSCULOSKE, V6, P182, DOI 10.1007/s12178-013-9164-0
   Harada ND, 1999, ARCH PHYS MED REHAB, V80, P837, DOI 10.1016/S0003-9993(99)90236-8
   Ishibashi Hideaki, 2018, Osteoporos Sarcopenia, V4, P86, DOI 10.1016/j.afos.2018.09.004
   Kobayashi K, 2015, SCI REP-UK, V5, DOI 10.1038/srep09148
   Koike M, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0203944
   Koike M, 2015, SCI REP-UK, V5, DOI 10.1038/srep11722
   Kubo Y, 2021, NUTRIENTS, V13, DOI 10.3390/nu13062093
   Kuwahara H, 2010, FREE RADICAL BIO MED, V48, P1252, DOI 10.1016/j.freeradbiomed.2010.02.011
   Leung L, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-27
   Muth CM, 2004, FREE RADICAL RES, V38, P927, DOI 10.1080/10715760412331273197
   Nagaoka I, 2018, FUNCT FOOD RES, V14, P48, DOI [10.32153/ffr.14.0_48, DOI 10.32153/FFR.14.0_48]
   Nakamura K, 2016, CLIN REV BONE MINER, V14, P56, DOI 10.1007/s12018-016-9208-2
   Ofori-Asenso R, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2019.8398
   PODSIADLO D, 1991, J AM GERIATR SOC, V39, P142, DOI 10.1111/j.1532-5415.1991.tb01616.x
   Romao S, 2015, NUTRITION, V31, P430, DOI 10.1016/j.nut.2014.10.006
   Ruiz-Romero C, 2009, MOL CELL PROTEOMICS, V8, P172, DOI 10.1074/mcp.M800292-MCP200
   Sarban S, 2005, CLIN BIOCHEM, V38, P981, DOI 10.1016/j.clinbiochem.2005.08.003
   Sasaki E, 2013, J ORTHOP SCI, V18, P121, DOI 10.1007/s00776-012-0329-2
   Scott JL, 2010, ANN RHEUM DIS, V69, P1502, DOI 10.1136/ard.2009.119966
   Skarpanska-Stejnborn A, 2011, INT J SPORT NUTR EXE, V21, P124, DOI 10.1123/ijsnem.21.2.124
   Suantawee T, 2013, J CLIN DIAGN RES, V7, P1855, DOI 10.7860/JCDR/2013/5802.3333
   Taniguchi M, 2021, BMC GERIATR, V21, DOI 10.1186/s12877-021-02440-2
   Wang H, 2008, CLIN J PAIN, V24, P273, DOI 10.1097/AJP.0b013e31816111d3
   Yasuda Mitsuhiro, 2002, Gastric Cancer, V5, P148, DOI 10.1007/s101200200026
   Yoh K, 2011, JPN CLIN MED, V2, P9, DOI 10.4137/JCM.S6224
   Yoshimura N, 2015, J ORTHOP SCI, V20, P896, DOI 10.1007/s00776-015-0741-5
   Yoshizawa T., 2010, RIGAKURYOHO KAGAKU, V25, P33, DOI [10.1589/rika.25.33, DOI 10.1589/RIKA.25.33]
   Zahan Oana-Maria, 2020, Med Pharm Rep, V93, P12, DOI 10.15386/mpr-1422
NR 34
TC 0
Z9 0
U1 0
U2 1
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2077-0383
J9 J CLIN MED
JI J. Clin. Med.
PD MAY
PY 2022
VL 11
IS 10
AR 2747
DI 10.3390/jcm11102747
PG 9
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 1P1ME
UT WOS:000801781000001
PM 35628874
OA Green Published, gold
DA 2024-02-19
ER

PT J
AU Szymanska, H
   Lechowska-Piskorowska, J
   Krysiak, E
   Strzalkowska, A
   Unrug-Bielawska, K
   Grygalewicz, B
   Skurzak, HM
   Pienkowska-Grela, B
   Gajewska, M
AF Szymanska, H.
   Lechowska-Piskorowska, J.
   Krysiak, E.
   Strzalkowska, A.
   Unrug-Bielawska, K.
   Grygalewicz, B.
   Skurzak, H. M.
   Pienkowska-Grela, B.
   Gajewska, M.
TI Neoplastic and Nonneoplastic Lesions in Aging Mice of Unique and Common
   Inbred Strains Contribution to Modeling of Human Neoplastic Diseases
SO VETERINARY PATHOLOGY
LA English
DT Article
DE mouse inbred strains; leukemia; lymphoma; neoplasms; nonneoplastic
   lesions
ID MOUSE MODELS; JOINT PUBLICATION; REVISED GUIDES; COLLABORATIVE CROSS;
   BETHESDA PROPOSALS; CONSENSUS REPORT; CELL TUMORS; KDKD MICE;
   RECOMMENDATIONS; PATHOLOGY
AB The evaluation of spontaneous lesions in classical inbred strains of mice has become increasingly important because genetically engineered mice (GEMs) are created on these backgrounds. Novel inbred strains-genetically diverse from classic strains-are valuable both as a new background for GEM mice and to increase the genetic variation found in laboratory mice. Newly arising spontaneous genetic alterations in commonly used strains may also lead to new and valuable mouse models of disease. This report evaluates gross and histological lesions in relatively new, classic, and rarely explored mouse inbred strains. Pathological lesions of 1273 mice from 12 inbred strains (129S1/SvW, A.CA-H2(f)/W, AKR/W, BALB/cW, BN/aW, C57BL/6 W, C57BL/10 W, C3H/W, C3H(wad)/W, CBA/W, DBA/2 W, and WOM/W) are reported. BN/aW, WOM/W, and C3H(wad)/W are novel inbred strains produced and maintained in the Department of Genetics and Laboratory Animal Breeding at the Center of Oncology, Warsaw, Poland. Both neoplastic and nonneoplastic lesions were examined. The prevalence of lung neoplasms was significantly higher in A. CA-H2(f)/W (33.3%) and BALB/cW (33.8%) mice (P < .01). The prevalence of liver neoplasms was significantly higher in the CBA/W strain (P < .01). Mammary gland neoplasms arose at a greater frequency in C3H/W mice (P < .01). The occurrence of uterine neoplasms was higher in DBA/W and 129S1/SvW mice. AKR/W and WOM/W mice developed T-cell lymphoblastic lymphoma with high frequency (110/121 [90.9%] and 159/175 [90.9%], respectively) before 1 year of age. The occurrence of nonneoplastic lesions in the kidneys of BN/aW mice was increased (P < .01).
C1 [Szymanska, H.; Lechowska-Piskorowska, J.; Krysiak, E.; Strzalkowska, A.; Unrug-Bielawska, K.; Gajewska, M.] Maria Sklodowska Curie Mem Canc Ctr, Dept Genet & Lab Anim Breeding, PL-02781 Warsaw, Poland.
   [Szymanska, H.; Lechowska-Piskorowska, J.; Krysiak, E.; Strzalkowska, A.; Unrug-Bielawska, K.; Grygalewicz, B.; Skurzak, H. M.; Pienkowska-Grela, B.; Gajewska, M.] Inst Oncol, Warsaw, Poland.
   [Skurzak, H. M.] Maria Sklodowska Curie Mem Canc Ctr, Dept Immunol, PL-02781 Warsaw, Poland.
   [Grygalewicz, B.; Pienkowska-Grela, B.] Maria Sklodowska Curie Mem Canc Ctr, Cytogenet Lab, PL-02781 Warsaw, Poland.
C3 Maria Sklodowska-Curie National Research Institute of Oncology; Maria
   Sklodowska-Curie National Research Institute of Oncology; Maria
   Sklodowska-Curie National Research Institute of Oncology; Maria
   Sklodowska-Curie National Research Institute of Oncology
RP Szymanska, H (corresponding author), Maria Sklodowska Curie Mem Canc Ctr, Roentgena 5, PL-02781 Warsaw, Poland.
EM hszymanska@coi.waw.pl
RI Gajewska, Marta/AAY-8817-2021
OI Unrug-Bielawska, Katarzyna/0000-0003-3453-1590; Grygalewicz,
   Beata/0000-0002-9592-5174
CR [Anonymous], 1983, MONOGRAPHS PATHOLOGY
   [Anonymous], 1999, PATHOLOGY MOUSE
   ASADA Y, 1994, NAT GENET, V6, P363, DOI 10.1038/ng0494-363
   Avenaud P, 2003, INFECT IMMUN, V71, P3667, DOI 10.1128/IAI.71.6.3667-3672.2003
   BLACKWELL BN, 1995, TOXICOL PATHOL, V23, P570, DOI 10.1177/019262339502300503
   Boivin GP, 2003, GASTROENTEROLOGY, V124, P762, DOI 10.1053/gast.2003.50094
   Borowsky AD, 2004, COMPARATIVE MED, V54, P258
   Borowsky AD, 2003, COMPARATIVE MED, V53, P248
   Brayton C, 2001, VET PATHOL, V38, P1, DOI 10.1354/vp.38-1-1
   Brayton C, 2006, MOUSE BIOMEDICAL RES, V3, P623
   Brayton CF, 2012, VET PATHOL, V49, P85, DOI 10.1177/0300985811430696
   Cardiff RD, 2000, ONCOGENE, V19, P968, DOI 10.1038/sj.onc.1203277
   CHANDRA M, 1994, EXP TOXICOL PATHOL, V46, P189, DOI 10.1016/S0940-2993(11)80080-1
   Churchill G, 2004, NAT GENET, V36, P1133, DOI 10.1038/ng1104-1133
   CZARNOMSKA A, 1971, GENET POL, V12, P529
   Doetschman T, 1999, LAB ANIM SCI, V49, P137
   Doetschman Thomas, 2009, V530, P423, DOI 10.1007/978-1-59745-471-1_23
   Dunphy CH, 2004, ARCH PATHOL LAB MED, V128, P1004
   Feldman D. B., 1988, NECROPSY GUIDE RODEN
   Festing MFW, 1999, MAMM GENOME, V10, P836, DOI 10.1007/s003359901099
   Festing MFW, INBRED STRAINS MICE
   Fiette L, 2011, METHODS MOL BIOL, V691, P39, DOI 10.1007/978-1-60761-849-2_3
   Frith CH, 1998, COLOUR ATLAS NEOPLAS
   Gajewska M, MGI DIRECT DATA SUBM
   Gearhart S, 2004, COMPARATIVE MED, V54, P418
   Green EL., 1981, GENETICS PROBABILITY
   Haines DC, 2001, TOXICOL PATHOL, V29, P653, DOI 10.1080/019262301753385988
   Hawes JJ, 2007, NEUROGENETICS, V8, P121, DOI 10.1007/s10048-006-0078-5
   HAYS EF, 1992, THYMUS, V19, P219
   Jiang LI, 2001, MAMM GENOME, V12, P89, DOI 10.1007/s003350010257
   Kittel B, 2004, EXP TOXICOL PATHOL, V55, P413, DOI 10.1078/0940-2993-00349
   KODELL RL, 1995, TOXICOL PATHOL, V23, P241, DOI 10.1177/019262339502300301
   Kogan SC, 2002, BLOOD, V100, P238, DOI 10.1182/blood.V100.1.238
   Lam MYJ, 2003, APMIS, V111, P184, DOI 10.1034/j.1600-0463.2003.11101221.x
   Langlois MA, 2009, J VIROL, V83, P11550, DOI 10.1128/JVI.01430-09
   Li S, 2008, MOUSE MODELS HUMAN B
   Long G, 2004, TOXICOL PATHOL, V32, P269, DOI 10.1080/01926230490274443
   Mikaelian I., 2004, LAB MOUSE, P345
   Mohr U, 2001, INT CLASSIFICATION R, P87
   MOLONEY WC, 1960, J HISTOCHEM CYTOCHEM, V8, P200, DOI 10.1177/8.3.200
   Morahan G, 2008, MAMM GENOME, V19, P390, DOI 10.1007/s00335-008-9134-9
   Morawietz G, 2004, EXP TOXICOL PATHOL, V55, P433, DOI 10.1078/0940-2993-00350
   Morse HC, 2002, BLOOD, V100, P246, DOI 10.1182/blood.V100.1.246
   NEILSON EG, 1984, J IMMUNOL, V133, P2560
   Nicklas W, 2002, LAB ANIM-UK, V36, P20, DOI 10.1258/0023677021911740
   Nikitin AY, 2004, CANCER RES, V64, P2307, DOI 10.1158/0008-5472.CAN-03-3376
   Petkov PM, 2004, GENOMICS, V83, P902, DOI 10.1016/j.ygeno.2003.11.007
   Pettan-Brewer C, 2011, PATHOBIOL AGING AGE, V1, DOI 10.3402/pba.v1i0.7202
   Qiao G, 2010, CELL DEATH DIFFER, V17, P522, DOI 10.1038/cdd.2009.143
   Rehm S, 1996, PATHOBIOLOGY AGING M, V2, P381
   RISMA KA, 1995, P NATL ACAD SCI USA, V92, P1322, DOI 10.1073/pnas.92.5.1322
   Ruehl-Fehlert C, 2003, EXP TOXICOL PATHOL, V55, P91, DOI 10.1016/S0940-2993(04)70148-7
   Sibalic V, 1997, NEPHROL DIAL TRANSPL, V12, P1344, DOI 10.1093/ndt/12.7.1344
   Stetler-Stevenson M, 2003, BEST PRACT RES CL HA, V16, P583, DOI 10.1016/S1521-6926(03)00068-9
   Sundberg JP, 2011, PATHOBIOL AGING AGE, V1, DOI 10.3402/pba.v1i0.7179
   Threadgill DW, 2011, ILAR J, V52, P24, DOI 10.1093/ilar.52.1.24
   Threadgill DW, 1997, MAMM GENOME, V8, P390, DOI 10.1007/s003359900453
   Tillmann T, 2000, EXP TOXICOL PATHOL, V52, P221, DOI 10.1016/S0940-2993(00)80032-9
   TURUSOV V, 1994, PATHOLOGY TUMORS LAB, V2
   Vardiman JW., 2008, WHO CLASSIFICATION T
   Veit AC, 2008, VET PATHOL, V45, P654, DOI 10.1354/vp.45-5-654
   Vizor Lucie, 2009, Methods Mol Biol, V561, P285, DOI 10.1007/978-1-60327-019-9_19
   Ward JM, 2006, EXP TOXICOL PATHOL, V57, P377, DOI 10.1016/j.etp.2006.01.007
   Ward JM, 2000, PATHOLOGY OF GENETICALLY ENGINEERED MICE, P161
   Ward JM, 2001, AM J PATHOL, V158, P323, DOI 10.1016/S0002-9440(10)63972-7
   Ward M.W., 2002, J TOXICOL PATHOL, V15, P123, DOI [10.1293/tox.15.123, DOI 10.1293/TOX.15.123]
   Whary MT, 2004, COMPARATIVE MED, V54, P128
   Yang Hai-Chun, 2010, Drug Discov Today Dis Models, V7, P13, DOI 10.1016/j.ddmod.2010.08.002
   Zurcher C, 1982, MOUSE BIOMEDICAL RES, P11
NR 69
TC 24
Z9 28
U1 0
U2 4
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0300-9858
EI 1544-2217
J9 VET PATHOL
JI Vet. Pathol.
PD MAY
PY 2014
VL 51
IS 3
BP 663
EP 679
DI 10.1177/0300985813501334
PG 17
WC Pathology; Veterinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pathology; Veterinary Sciences
GA AJ5CB
UT WOS:000337697400017
PM 24019352
DA 2024-02-19
ER

PT J
AU Shin, J
   Toyoda, S
   Nishitani, S
   Onodera, T
   Fukuda, S
   Kita, S
   Fukuhara, A
   Shimomura, I
AF Shin, Jihoon
   Toyoda, Shinichiro
   Nishitani, Shigeki
   Onodera, Toshiharu
   Fukuda, Shiro
   Kita, Shunbun
   Fukuhara, Atsunori
   Shimomura, Iichiro
TI SARS-CoV-2 infection impairs the insulin/IGF signaling pathway in the
   lung, liver, adipose tissue, and pancreatic cells via IRF1
SO METABOLISM-CLINICAL AND EXPERIMENTAL
LA English
DT Article
DE SARS-CoV-2&nbsp; infection; COVID-19; Insulin; IGF signaling pathway;
   IRF1; Interferone; Cytokine; Lung; Liver; Adipose tissue; Pancreatic
   cell; Older age; Male sex; Obesity; Diabetes; Tissue damage; Multiorgan
   dysfunction; Insulin signaling; Insulin resistance; Metabolic
   abnormality; Dihydrotestosterone; Dexamethasone
ID REGULATORY FACTOR-I; METABOLIC SYNDROME; BETA-CELLS; RECEPTOR;
   EXPRESSION; RESISTANCE; KNOCKOUT; ADIPOCYTES; APOPTOSIS; COVID-19
AB Background: COVID-19 can cause multiple organ damages as well as metabolic abnormalities such as hyperglycemia, insulin resistance, and new onset of diabetes. The insulin/IGF signaling pathway plays an important role in regulating energy metabolism and cell survival, but little is known about the impact of SARS-CoV-2 infection. The aim of this work was to investigate whether SARS-CoV-2 infection impairs the insulin/IGF signaling pathway in the host cell/ tissue, and if so, the potential mechanism and association with COVID-19 pathology. Methods: To determine the impact of SARS-CoV-2 on insulin/IGF signaling pathway, we utilized transcriptome datasets of SARS-CoV-2 infected cells and tissues from public repositories for a wide range of high-throughput gene expression data: autopsy lungs from COVID-19 patients compared to the control from non-COVID-19 pa-tients; lungs from a human ACE2 transgenic mouse infected with SARS-CoV-2 compared to the control infected with mock; human pluripotent stem cell (hPSC)-derived liver organoids infected with SARS-CoV-2; adipose tissues from a mouse model of COVID-19 overexpressing human ACE2 via adeno-associated virus serotype 9 (AAV9) compared to the control GFP after SARS-CoV-2 infection; iPS-derived human pancreatic cells infected with SARS-CoV-2 compared to the mock control. Gain and loss of IRF1 function models were established in HEK293T and/or Calu3 cells to evaluate the impact on insulin signaling. To understand the mechanistic regu-lation and relevance with COVID-19 risk factors, such as older age, male sex, obesity, and diabetes, several transcriptomes of human respiratory, metabolic, and endocrine cells and tissue were analyzed. To estimate the association with COVID-19 severity, whole blood transcriptomes of critical patients with COVID-19 compared to those of hospitalized noncritical patients with COVID-19. Results: We found that SARS-CoV-2 infection impaired insulin/IGF signaling pathway genes, such as IRS, PI3K, AKT, mTOR, and MAPK, in the host lung, liver, adipose tissue, and pancreatic cells. The impairments were attributed to interferon regulatory factor 1 (IRF1), and its gene expression was highly relevant to risk factors for severe COVID-19; increased with aging in the lung, specifically in men; augmented by obese and diabetic con-ditions in liver, adipose tissue, and pancreatic islets. IRF1 activation was significantly associated with the impaired insulin signaling in human cells. IRF1 intron variant rs17622656-A, which was previously reported to be associated with COVID-19 prevalence, increased the IRF1 gene expression in human tissue and was frequently found in American and European population. Critical patients with COVID-19 exhibited higher IRF1 and lower insulin/IGF signaling pathway genes in the whole blood compared to hospitalized noncritical patients. Hormonal interventions, such as dihydrotestosterone and dexamethasone, ameliorated the pathological traits in SARS-CoV-2 infectable cells and tissues. Conclusions: The present study provides the first scientific evidence that SARS-CoV-2 infection impairs the in-sulin/IGF signaling pathway in respiratory, metabolic, and endocrine cells and tissues. This feature likely con-tributes to COVID-19 severity with cell/tissue damage and metabolic abnormalities, which may be exacerbated in older, male, obese, or diabetic patients.
C1 [Shin, Jihoon; Toyoda, Shinichiro; Nishitani, Shigeki; Onodera, Toshiharu; Fukuda, Shiro; Kita, Shunbun; Fukuhara, Atsunori; Shimomura, Iichiro] Osaka Univ, Grad Sch Med, Dept Metab Med, Suita, Osaka, Japan.
   [Shin, Jihoon] Osaka Univ, Grad Sch Med, Dept Diabet Care Med, Suita, Osaka, Japan.
   [Kita, Shunbun; Fukuhara, Atsunori] Osaka Univ, Grad Sch Med, Dept Adipose Management, Suita, Osaka, Japan.
C3 Osaka University; Osaka University; Osaka University
RP Shin, J (corresponding author), Osaka Univ, Grad Sch Med, Dept Metab Med, Suita, Osaka, Japan.
EM shinjihoon0209@endmet.med.osaka-u.ac.jp
RI Fukuhara, Atsunori/A-9601-2018
OI Fukuhara, Atsunori/0000-0002-6289-3778; Onodera,
   Toshiharu/0000-0002-4439-0077
CR Accili D, 1996, NAT GENET, V12, P106, DOI 10.1038/ng0196-106
   Accili D, 2021, NAT METAB, V3, P123, DOI 10.1038/s42255-020-00339-7
   Aly S, 2009, J CELL MOL MED, V13, P2069, DOI 10.1111/j.1582-4934.2008.00470.x
   Ayres JS, 2020, NAT METAB, V2, P572, DOI 10.1038/s42255-020-0237-2
   Babicki S, 2016, NUCLEIC ACIDS RES, V44, pW147, DOI 10.1093/nar/gkw419
   Balliu B, 2021, AM J HUM GENET, V108, P1866, DOI 10.1016/j.ajhg.2021.08.014
   Basu M, 2021, SCI ADV, V7, DOI 10.1126/sciadv.abd6991
   Ben-Sahra I, 2013, CELL DEATH DIFFER, V20, P611, DOI 10.1038/cdd.2012.157
   Boucher J, 2014, CSH PERSPECT BIOL, V6, DOI 10.1101/cshperspect.a009191
   Bruning JC, 1998, MOL CELL, V2, P559, DOI 10.1016/S1097-2765(00)80155-0
   Carapito R, 2022, SCI TRANSL MED, V14, DOI 10.1126/scitranslmed.abj7521
   CDC COVID-19 Response Team, 2020, MMWR-MORBID MORTAL W, V69, P343, DOI [10.15585/mmwr.mm6912e2, 10.15585/mmwr.mm6915e4]
   CHEATHAM B, 1995, ENDOCR REV, V16, P117, DOI 10.1210/er.16.2.117
   Chee YJ, 2020, DIABETES RES CLIN PR, V164, DOI 10.1016/j.diabres.2020.108166
   Cinislioglu AE, 2022, ANDROLOGY-US, V10, P24, DOI 10.1111/andr.13081
   Conti E, 2004, CIRCULATION, V110, P2260, DOI 10.1161/01.CIR.0000144309.87183.FB
   Desai N, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-20139-7
   Ebekozien OA, 2020, DIABETES CARE, V43, pE83, DOI 10.2337/dc20-1088
   Edgar R, 2002, NUCLEIC ACIDS RES, V30, P207, DOI 10.1093/nar/30.1.207
   Epaud R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048071
   Forero A, 2019, IMMUNITY, V51, P451, DOI 10.1016/j.immuni.2019.07.007
   Forno E, 2015, J ALLERGY CLIN IMMUN, V136, P304, DOI 10.1016/j.jaci.2015.01.010
   Friesen M, 2017, STEM CELL REP, V8, P1164, DOI 10.1016/j.stemcr.2017.03.014
   Goldman MD, 2003, DIABETES CARE, V26, P1915, DOI 10.2337/diacare.26.6.1915
   Goldman N, 2020, DIABETES RES CLIN PR, V166, DOI 10.1016/j.diabres.2020.108291
   Hollstein T, 2020, NAT METAB, V2, P1021, DOI 10.1038/s42255-020-00281-8
   Horby P, 2021, NEW ENGL J MED, V384, P693, DOI [10.1056/NEJMoa2021436, 10.1056/NEJMoa2022926]
   Joshi-Tope G, 2005, NUCLEIC ACIDS RES, V33, pD428, DOI 10.1093/nar/gki072
   KAHN CR, 1978, METABOLISM, V27, P1893
   Kanehisa M, 2000, NUCLEIC ACIDS RES, V28, P27, DOI 10.1093/nar/28.1.27
   Kano A, 1999, BIOCHEM BIOPH RES CO, V257, P672, DOI 10.1006/bbrc.1999.0276
   Kitamura T, 2003, ANNU REV PHYSIOL, V65, P313, DOI 10.1146/annurev.physiol.65.092101.142540
   Klein OL, 2010, DIABETIC MED, V27, P977, DOI 10.1111/j.1464-5491.2010.03073.x
   Kulkarni RN, 1999, CELL, V96, P329, DOI 10.1016/S0092-8674(00)80546-2
   Lee YH, 2005, DIABETOLOGIA, V48, P1776, DOI 10.1007/s00125-005-1867-3
   Li JY, 2020, DIABETES OBES METAB, V22, P1935, DOI 10.1111/dom.14057
   Li S, 2021, JCI INSIGHT, V6, DOI 10.1172/jci.insight.145027
   Lonsdale J, 2013, NAT GENET, V45, P580, DOI 10.1038/ng.2653
   Marchand L, 2020, ACTA DIABETOL, V57, P1265, DOI 10.1007/s00592-020-01570-0
   Metwally AA, 2021, DIABETES, V70, P2733, DOI 10.2337/dbi21-0029
   Mohr S, 2007, TRENDS MOL MED, V13, P422, DOI 10.1016/j.molmed.2007.08.003
   Montefusco L, 2021, NAT METAB, V3, P774, DOI 10.1038/s42255-021-00407-6
   Moore F, 2011, J BIOL CHEM, V286, P929, DOI 10.1074/jbc.M110.162131
   Müller JA, 2021, NAT METAB, V3, P149, DOI 10.1038/s42255-021-00347-1
   Munoz K, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22105244
   Nakazawa T, 2001, J AUTOIMMUN, V17, P119, DOI 10.1006/jaut.2001.0531
   Narasaraju TA, 2006, J CELL BIOCHEM, V97, P984, DOI 10.1002/jcb.20653
   Oki S, 2018, EMBO REP, V19, DOI 10.15252/embr.201846255
   Panda D, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01019
   Pavlovic D, 1999, EUR CYTOKINE NETW, V10, P403
   Peruzzi F, 1999, MOL CELL BIOL, V19, P7203, DOI 10.1128/mcb.19.10.7203
   Poma AM, 2022, J ENDOCRINOL INVEST, V45, P209, DOI 10.1007/s40618-021-01628-y
   Puelles VG, 2020, NEW ENGL J MED, V383, P590, DOI [10.1056/NEJMc2013400, 10.1056/NEJMc2011400]
   Qadir MMF, 2021, JCI INSIGHT, V6, DOI 10.1172/jci.insight.151551
   Ran FA, 2013, NAT PROTOC, V8, P2281, DOI 10.1038/nprot.2013.143
   Reiterer M, 2021, CELL METAB, V33, P2174, DOI 10.1016/j.cmet.2021.09.009
   Robinson JT, 2011, NAT BIOTECHNOL, V29, P24, DOI 10.1038/nbt.1754
   Rusmini M, 2021, FRONT MED-LAUSANNE, V8, DOI 10.3389/fmed.2021.650231
   Salciccia Stefano, 2021, Ther Adv Endocrinol Metab, V12, p20420188211010105, DOI 10.1177/20420188211010105
   Samuel RM, 2020, CELL STEM CELL, V27, P876, DOI 10.1016/j.stem.2020.11.009
   Schoggins JW, 2011, NATURE, V472, P481, DOI 10.1038/nature09907
   Sengupta A, 2018, ENDOCRINOLOGY, V159, P2917, DOI 10.1210/en.2018-00215
   Shaharuddin SH, 2021, FRONT CELL INFECT MI, V11, DOI 10.3389/fcimb.2021.678482
   Shi C, 2019, ELIFE, V8, DOI 10.7554/eLife.46413
   Shin J, 2021, DIABETES, V70, P2745, DOI 10.2337/db20-1094
   Softic S, 2016, DIABETES, V65, P2187, DOI 10.2337/db16-0213
   Song R, 2021, CELL REP, V34, DOI 10.1016/j.celrep.2021.108891
   Sparna T, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-226
   TAMEMOTO H, 1994, NATURE, V372, P182, DOI 10.1038/372182a0
   Taniguchi T, 2001, ANNU REV IMMUNOL, V19, P623, DOI 10.1146/annurev.immunol.19.1.623
   Tiengo A, 2008, DIABETES METAB, V34, P447, DOI 10.1016/j.diabet.2008.08.001
   Tsung A, 2006, AM J PHYSIOL-GASTR L, V290, pG1261, DOI 10.1152/ajpgi.00460.2005
   Vaninov Natalie, 2020, Nat Rev Immunol, V20, P277, DOI 10.1038/s41577-020-0305-6
   Vivas Y, 2011, BMC MED GENOMICS, V4, DOI 10.1186/1755-8794-4-86
   Wang TB, 2020, LANCET, V395, pE52, DOI 10.1016/S0140-6736(20)30558-4
   Wang XD, 2007, DIFFERENTIATION, V75, P219, DOI 10.1111/j.1432-0436.2006.00135.x
   Wanner N, 2022, NAT METAB, V4, P310, DOI 10.1038/s42255-022-00552-6
   Winkler ES, 2020, NAT IMMUNOL, V21, P1327, DOI 10.1038/s41590-020-0778-2
   Wu CT, 2021, CELL METAB, V33, P1565, DOI 10.1016/j.cmet.2021.05.013
   Yang LL, 2020, CELL STEM CELL, V27, P125, DOI 10.1016/j.stem.2020.06.015
   Yang SL, 2007, AM J PHYSIOL-HEART C, V293, pH142, DOI 10.1152/ajpheart.00783.2006
   Ye ZK, 2020, CAN MED ASSOC J, V192, pE756, DOI 10.1503/cmaj.200645
   Zhang DX, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15815-7
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 84
TC 22
Z9 24
U1 3
U2 7
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0026-0495
EI 1532-8600
J9 METABOLISM
JI Metab.-Clin. Exp.
PD AUG
PY 2022
VL 133
AR 155236
DI 10.1016/j.metabol.2022.155236
PG 14
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Endocrinology & Metabolism
GA 2X7DJ
UT WOS:000825359900002
PM 35688210
OA Green Published, hybrid
DA 2024-02-19
ER

PT J
AU Niiranen, K
   Keinänen, TA
   Pirinen, E
   Heikkinen, S
   Tusa, M
   Fatrai, S
   Suppola, S
   Pietilä, M
   Uimari, A
   Laakso, M
   Alhonen, L
   Jänne, J
AF Niiranen, Kirsi
   Keinanen, Tuomo A.
   Pirinen, Eija
   Heikkinen, Sami
   Tusa, Maija
   Fatrai, Szabolcs
   Suppola, Suvikki
   Pietila, Marko
   Uimari, Anne
   Laakso, Markku
   Alhonen, Leena
   Janne, Juhani
TI Mice with targeted disruption of spermidine/spermine
   N<SUP>1</SUP>-acetyltransferase gene maintain nearly normal tissue
   polyamine homeostasis but show signs of insulin resistance upon aging
SO JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
LA English
DT Article
DE polyamine; knockout; type 2 diabetes
ID SPERMINE N1-ACETYLTRANSFERASE; ORNITHINE DECARBOXYLASE;
   CARBON-TETRACHLORIDE; MELANOMA XENOGRAFTS; ANTITUMOR-ACTIVITY;
   TRANSGENIC MICE; ANALOG; OXIDASE; SENSITIVITY; CELLS
AB The N-1-acetylation of spermidine or spermine by spermidine/spermine N-1-acetyltransferase (SSAT) is the ratecontrolling enzymatic step in the polyamine catabolism. We have now generated SSAT knockout (SSAT-KO) mice, which confirmed our earlier results with SSATdeficient embryonic stem (ES) cells showing only slightly affected polyamine homeostasis, mainly manifested as an elevated molar ratio of spermidine to spen-nine in most tissues indicating the indispensability of SSAT for the spermidine backconversion. Contrary to SSAT deficient ES cells, polyamine pools in SSAT-KO mice remained almost unchanged in response to N-1,N-11-diethylnorspermine (DENSPM) treatment compared to a significant reduction of the polyamine pools in the wild-type animals and ES cells. Furthermore, SSATKO mice were more sensitive to the toxicity exerted by DENSPM in comparison with wild-type mice. The latter finding indicates that inducible SSAT plays an essential role in vivo in DENSPM treatmentevoked polyamine depletion, but a controversial role in toxicity of DENSPM. Surprisingly, liver polyamine pools were depleted similarly in wild-type and SSAT-KO mice in response to carbon tetrachloride treatment. Further characterization of SSAT knockout mice revealed insulin resistance at old age which supported the role of polyamine catabolism in glucose metabolism detected earlier with our SSAT overexpressing mice displaying enhanced basal metabolic rate, high insulin sensitivity and improved glucose tolerance. Therefore SSAT knockout mice might serve as a novel mouse model for type 2 diabetes.
C1 Univ Kuopio, AI Virtanen Inst Mol Sci, FI-70211 Kuopio, Finland.
   Univ Kuopio, Dept Med, SF-70210 Kuopio, Finland.
C3 University of Eastern Finland; University of Eastern Finland
RP Jänne, J (corresponding author), Univ Kuopio, AI Virtanen Inst Mol Sci, POB 1627, FI-70211 Kuopio, Finland.
EM Juhani.Janne@uku.fi
RI Keinänen, Tuomo/AAC-5630-2019; Heikkinen, Sami/L-1460-2013; Pirinen,
   Eija/H-9153-2015
OI Heikkinen, Sami/0000-0002-6083-2402; Keinanen,
   Tuomo/0000-0002-0659-5573; Pirinen, Eija/0000-0003-1495-3972
CR Alhonen L, 1999, MOL PHARMACOL, V55, P693
   Bellelli A, 2004, BIOCHEM BIOPH RES CO, V322, P1, DOI 10.1016/j.bbrc.2004.07.074
   Bergeron RJ, 1997, J MED CHEM, V40, P1475, DOI 10.1021/jm960849j
   Bergeron RJ, 2000, J MED CHEM, V43, P224, DOI 10.1021/jm990375z
   BERNACKI RJ, 1992, CANCER RES, V52, P2424
   Bernacki RJ, 1995, CLIN CANCER RES, V1, P847
   CASERO RA, 1993, FASEB J, V7, P653, DOI 10.1096/fasebj.7.8.8500690
   Chen C, 2004, J CELL BIOL, V167, P161, DOI 10.1083/jcb.200312166
   Chen Y, 2003, MOL PHARMACOL, V64, P1153, DOI 10.1124/mol.64.5.1153
   FogelPetrovic M, 1996, ANTICANCER RES, V16, P2517
   FogelPetrovic M, 1997, MOL PHARMACOL, V52, P69, DOI 10.1124/mol.52.1.69
   Hillary RA, 2003, BBA-PROTEINS PROTEOM, V1647, P161, DOI 10.1016/S1570-9639(03)00088-8
   HOLTTA E, 1973, BIOCHEM BIOPH RES CO, V54, P350, DOI 10.1016/0006-291X(73)90929-7
   HYVONEN T, 1992, J CHROMATOGR-BIOMED, V574, P17, DOI 10.1016/0378-4347(92)80093-6
   KANTER PM, 1994, ANTI-CANCER DRUG, V5, P448, DOI 10.1097/00001813-199408000-00010
   Laakso M, 2001, INT J CLIN PRACT, P8
   MATSUI I, 1981, J BIOL CHEM, V256, P2454
   McCloskey DE, 2000, J BIOL CHEM, V275, P28708, DOI 10.1074/jbc.M004120200
   McCloskey DE, 2003, J BIOL CHEM, V278, P13881, DOI 10.1074/jbc.M205689200
   Niiranen K, 2002, J BIOL CHEM, V277, P25323, DOI 10.1074/jbc.M203599200
   Nishimura K, 2002, GENES CELLS, V7, P41, DOI 10.1046/j.1356-9597.2001.00494.x
   Passonneau J. V., 1993, Enzymatic analysis: A practical guide
   Pendeville H, 2001, MOL CELL BIOL, V21, P6549, DOI 10.1128/MCB.21.19.6549-6558.2001
   PERSSON L, 1984, J BIOL CHEM, V259, P2364
   Pirinen E, 2002, DIABETOLOGIA, V45, pA83
   Plum L, 2005, PHYSIOLOGY, V20, P152, DOI 10.1152/physiol.00049.2004
   PORTER CW, 1985, CANCER RES, V45, P2050
   PORTER CW, 1991, CANCER RES, V51, P3715
   PORTER CW, 1993, CANCER RES, V53, P581
   REHSE K, 1990, ARCH PHARM, V323, P287, DOI 10.1002/ardp.19903230507
   Seiler N, 1996, INT J BIOCHEM CELL B, V28, P843, DOI 10.1016/1357-2725(96)00021-0
   Suppola S, 2001, BIOCHEM J, V358, P343, DOI 10.1042/0264-6021:3580343
   TABOR CW, 1976, ANNU REV BIOCHEM, V45, P285, DOI 10.1146/annurev.bi.45.070176.001441
   Vujcic S, 2003, BIOCHEM J, V370, P19, DOI 10.1042/BJ20021779
   Vujcic S, 2002, BIOCHEM J, V367, P665, DOI 10.1042/BJ20020720
   Wang YL, 2001, CANCER RES, V61, P5370
   Wang YL, 2003, BIOCHEM BIOPH RES CO, V304, P605, DOI 10.1016/S0006-291X(03)00636-3
NR 37
TC 43
Z9 50
U1 0
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
EI 1582-4934
J9 J CELL MOL MED
JI J. Cell. Mol. Med.
PD OCT-DEC
PY 2006
VL 10
IS 4
BP 933
EP 945
DI 10.2755/jcmm010.004.02
PG 13
WC Cell Biology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA 117MG
UT WOS:000242876700011
PM 17125596
OA Green Published
DA 2024-02-19
ER

PT J
AU Nakayama, M
   Ohtsuka, K
   Sato, K
   Hasegawa, K
   Yamagiwa, S
   Sakai, K
   Abo, T
AF Nakayama, M
   Ohtsuka, K
   Sato, K
   Hasegawa, K
   Yamagiwa, S
   Sakai, K
   Abo, T
TI The majority of extrathymic T cells in the liver have the phenotype of
   memory T cells
SO BIOMEDICAL RESEARCH-TOKYO
LA English
DT Article
ID INTERMEDIATE TCR CELLS; EXPRESSION; RECEPTOR; CD45; MICE; INVIVO;
   STIMULATION; LYMPHOCYTES; APPEARANCE; ACTIVATION
AB Memory T cells have been characterized by their functional and phenotypic criteria. In the case of mice, memory T cells are known to have the phenotype of CD45RB(low) CD44(+)L-selectin(-). Since extrathymic T cells also express adhesion molecules (e.g., CD44(+)L-selectin(-)) similar to memory T cells, their relationship was intensively examined in this study. Extrathymic T cells were identified as IL-2R beta(+) intermediate CD3 (or TCR) cells. Surprisingly, a subpopulation of IL-2R beta(+) intermediate CD3 cells, namely, NK1.1(+) T cells with CD4(+) phenotype, were found to be CD45RB(low) T cells. Indeed, in vivo injection of anti-IL-2R beta mAb eliminated not only intermediate CD3 cells but also a considerable proportion (up to 65%) of CD45RB(low) T cells. Even after elimination of intermediate CD3 cells and many CD45RB(low) cells, remaining T cells were able to respond to recall antigens, such as ovalbumin and allogeneic lymphocytes. In these experiments, lymphocytes were obtained from mice pretreated with either ovalbumin or allogeneic lymphocytes. Furthermore, a sorted fraction of CD45RB(low) cells from intermediate CD3 cells was not able to respond to the recall antigen, ovalbumin, whereas those from high CD3 cells were able to do so. Extrathymic T cells constitutively express IL-2R beta. Reflecting this property, many of them are primarily at sub-activated states. These results suggest that memory T cells thus far classified according to the phenotypic criteria contain extrathymic T cells. Since extrathymic T cells increase with aging, many CD45RB(low) cells in adult mice have been found to consist of not only memory T cells but also extrathymic T cells.
C1 NIIGATA UNIV,SCH MED,DEPT IMMUNOL,NIIGATA 951,JAPAN.
C3 Niigata University
RP Nakayama, M (corresponding author), NIIGATA UNIV,SCH MED,DEPT RADIOL,NIIGATA 951,JAPAN.
CR ABO T, 1991, J EXP MED, V174, P417, DOI 10.1084/jem.174.2.417
   ALDHOUS MC, 1994, J CLIN IMMUNOL, V14, P289, DOI 10.1007/BF01540982
   ARAI K, 1995, IMMUNOLOGY, V84, P64
   ARASE H, 1992, P NATL ACAD SCI USA, V89, P6506, DOI 10.1073/pnas.89.14.6506
   BELL EB, 1990, NATURE, V348, P163, DOI 10.1038/348163a0
   BEVERLEY PCL, 1990, IMMUNOL TODAY, V11, P203, DOI 10.1016/0167-5699(90)90083-L
   BIRKELAND ML, 1989, P NATL ACAD SCI USA, V86, P6734, DOI 10.1073/pnas.86.17.6734
   BRADLEY LM, 1994, J EXP MED, V180, P2401, DOI 10.1084/jem.180.6.2401
   CHARBONNEAU H, 1988, P NATL ACAD SCI USA, V85, P7182, DOI 10.1073/pnas.85.19.7182
   DOBBER R, 1994, INT IMMUNOL, V6, P1227, DOI 10.1093/intimm/6.8.1227
   ENGWERDA CR, 1994, J IMMUNOL, V152, P3740
   GAHRING LC, 1993, CELL IMMUNOL, V148, P269, DOI 10.1006/cimm.1993.1111
   GOFF LK, 1992, INT IMMUNOL, V4, P1303, DOI 10.1093/intimm/4.11.1303
   GRAY D, 1993, ANNU REV IMMUNOL, V11, P49, DOI 10.1146/annurev.immunol.11.1.49
   GRUBER MF, 1992, J IMMUNOL, V148, P1113
   IIAI T, 1992, IMMUNOLOGY, V77, P556
   JANEWAY CA, 1992, ANNU REV IMMUNOL, V10, P645, DOI 10.1146/annurev.immunol.10.1.645
   KAWACHI Y, 1994, BIOMED RES-TOKYO, V15, P325, DOI 10.2220/biomedres.15.325
   MACKAY CR, 1991, IMMUNOL TODAY, V12, P189, DOI 10.1016/0167-5699(91)90051-T
   OHTEKI T, 1992, J IMMUNOL, V149, P1562
   OHTEKI T, 1994, J EXP MED, V180, P699, DOI 10.1084/jem.180.2.699
   OHTSUKA K, 1994, CELL IMMUNOL, V153, P52, DOI 10.1006/cimm.1994.1005
   OHTSUKA K, 1995, CELL IMMUNOL, V161, P112, DOI 10.1006/cimm.1995.1015
   OHTSUKA K, 1994, MICROBIOL IMMUNOL, V38, P677, DOI 10.1111/j.1348-0421.1994.tb01840.x
   OKUMURA M, 1993, J IMMUNOL, V150, P429
   OKUYAMA R, 1992, J EXP MED, V175, P661, DOI 10.1084/jem.175.3.661
   PAGANELLI R, 1992, J CLIN IMMUNOL, V12, P84, DOI 10.1007/BF00918137
   PAGANELLI R, 1994, CELL IMMUNOL, V155, P486, DOI 10.1006/cimm.1994.1140
   PILARSKI LM, 1989, EUR J IMMUNOL, V19, P589, DOI 10.1002/eji.1830190403
   SARAWAR SR, 1993, EUR J IMMUNOL, V23, P103, DOI 10.1002/eji.1830230117
   SARAWAR SR, 1991, IMMUNOLOGY, V73, P334
   SATO K, 1994, INT HEPATOL COMMUN, V2, P398, DOI 10.1016/0928-4346(94)90040-X
   SEKI S, 1994, J IMMUNOL, V153, P637
   SPARSHOTT SM, 1994, EUR J IMMUNOL, V24, P2573, DOI 10.1002/eji.1830241102
   TAKII Y, 1994, CLIN EXP IMMUNOL, V97, P522
   THOMAS ML, 1985, CELL, V41, P83, DOI 10.1016/0092-8674(85)90063-7
   TSUCHIDA M, 1992, CELL IMMUNOL, V145, P78, DOI 10.1016/0008-8749(92)90314-F
   WANATABE H, 1992, J IMMUNOL METHODS, V146, P145
   WATANABE H, 1993, CELL IMMUNOL, V149, P331, DOI 10.1006/cimm.1993.1159
NR 39
TC 3
Z9 3
U1 0
U2 0
PU BIOMED RES FOUND
PI TOKYO
PA KANDA PO BOX 182 CHIYODAKU, TOKYO 101-91, JAPAN
SN 0388-6107
J9 BIOMED RES-TOKYO
JI Biomed. Res.
PD APR
PY 1996
VL 17
IS 2
BP 149
EP 159
DI 10.2220/biomedres.17.149
PG 11
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA UK918
UT WOS:A1996UK91800007
OA Bronze
DA 2024-02-19
ER

PT J
AU Tsutsui, H
   Maeda, T
   Min, JZ
   Inagaki, S
   Higashi, T
   Kagawa, Y
   Toyo'oka, T
AF Tsutsui, Haruhito
   Maeda, Toshio
   Min, Jun Zhe
   Inagaki, Shinsuke
   Higashi, Tatsuya
   Kagawa, Yoshiyuki
   Toyo'oka, Toshimasa
TI Biomarker discovery in biological specimens (plasma, hair, liver and
   kidney) of diabetic mice based upon metabolite profiling using
   ultra-performance liquid chromatography with electrospray ionization
   time-of-flight mass spectrometry
SO CLINICA CHIMICA ACTA
LA English
DT Article
DE Ultra-performance liquid chromatography (UPLC); Electrospray ionization
   time-of-flight mass; spectrometry (ESI-TOE-MS); Metabolite profiling;
   Diabetes mellitus; Principal component analysis (PCA); Orthogonal
   partial least-squares-discriminant; analysis (OPLS-DA); Biological
   specimens (plasma hair; liver and kidney); of diabetic mice
ID METABONOMIC ANALYSIS; RAT URINE; HYDROPHILIC INTERACTION; LIFE-STYLE;
   TOF-MS; METABOLOMICS; ZUCKER; SERUM; STRATEGY; GENDER
AB Background: The number of diabetic patients has recently been increasing worldwide. Diabetes is a multifactorial disorder based on environmental factors and genetic background. In many cases, diabetes is asymptomatic for a long period and the patient is not aware of the disease. Therefore, the potential biomarker(s), leading to the early detection and/or prevention of diabetes mellitus, are strongly required. However, the diagnosis of the prediabetic state in humans is a very difficult issue, because the lifestyle is variable its each person. Although the development of a diagnosis method in humans is the goal of our research, the extraction and structural identification of biomarker candidates in several biological specimens (i.e., plasma, hair, liver and kidney) of ddY strain mice, which undergo naturally occurring diabetes along with aging, were carried out based upon a metabolite profiling study.
   Methods: The low-molecular-mass compounds including metabolites in the biological specimens of diabetic mice (ddY-H) and normal mice (ddY-L) were globally separated by ultra-performance liquid chromatography (UPLC) using different reversed-phase columns (i.e.. T3-C18 and HS-F5) and detected by electrospray ionization time-of-flight mass spectrometry (ESI-TOF-MS). The biomarker candidates related to diabetes mellitus were extracted from a multivariate statistical analysis, such as an orthogonal partial least-squares-discriminant analysis (OPLS-DA). followed by a database search, such as ChemSpider. KEGG and HMDB.
   Results: Many metabolites and unknown compounds in each biological specimen were detected as the biomarker candidates related to diabetic mellitus. Among them, the elucidation of the chemical structures of several possible metabolites. including more than two biological specimens, was carried out along with the comparison of the tandem MS/MS analyses using authentic compounds. One metabolite was clearly identified as N-acetyl-L-leucine based upon the MS/MS spectra and the retention time on the chromatograms.
   Conclusions: N-acetyl-L-leucine is an endogenous compound included in all biological specimens (plasma, hair, liver and kidney). Therefore, this metabolite appears to be a potential biomarker candidate related to diabetes. Although the structures of other biomarker candidates have still not yet determined, the present approach based upon a metabolite profiling study using UPLC-ESI-TOF-MS could be helpful for understanding the abnormal state of various diseases. (C) 2010 Elsevier B.V. All rights reserved.
C1 [Tsutsui, Haruhito; Min, Jun Zhe; Inagaki, Shinsuke; Higashi, Tatsuya; Toyo'oka, Toshimasa] Univ Shizuoka, Grad Sch Pharmaceut Sci, Lab Analyt & Bioanalyt Chem, Suruga Ku, Shizuoka 4228526, Japan.
   [Tsutsui, Haruhito; Min, Jun Zhe; Inagaki, Shinsuke; Higashi, Tatsuya; Toyo'oka, Toshimasa] Univ Shizuoka, Global COE Program, Suruga Ku, Shizuoka 4228526, Japan.
   [Maeda, Toshio; Kagawa, Yoshiyuki] Univ Shizuoka, Grad Sch Pharmaceut Sci, Lab Clin Pharmaceut & Pharm Practice, Suruga Ku, Shizuoka 4228526, Japan.
C3 University of Shizuoka; University of Shizuoka; University of Shizuoka
RP Toyo'oka, T (corresponding author), Univ Shizuoka, Grad Sch Pharmaceut Sci, Lab Analyt & Bioanalyt Chem, Suruga Ku, 52-1 Yada, Shizuoka 4228526, Japan.
EM toyooka@u-shizuoka-ken.ac.jp
RI Kagawa, Yoshiyuki/Q-7883-2019; Inagaki, Shinsuke/L-5800-2018
OI Inagaki, Shinsuke/0000-0002-1225-6252; Higashi,
   Tatsuya/0000-0002-7890-6262
FU Ministry of Education, Culture, Sports, Science and Technology of Japan
FX This work was supported in part by the Global COE Program from the
   Ministry of Education, Culture, Sports, Science and Technology of Japan.
CR Benavente F, 2006, ELECTROPHORESIS, V27, P4570, DOI 10.1002/elps.200600055
   Bijlsma S, 2006, ANAL CHEM, V78, P567, DOI 10.1021/ac051495j
   Chen J, 2008, ANAL CHEM, V80, P1280, DOI 10.1021/ac702089h
   Coulier L, 2006, ANAL CHEM, V78, P6573, DOI 10.1021/ac0607616
   Crews B, 2009, ANAL CHEM, V81, P8538, DOI 10.1021/ac9014947
   DERTMER K, 2007, MASS SPECTROM REV, V26, P51
   Dunn WB, 2005, TRAC-TREND ANAL CHEM, V24, P285, DOI 10.1016/j.trac.2004.11.021
   Gika HG, 2008, J CHROMATOGR B, V871, P279, DOI 10.1016/j.jchromb.2008.04.020
   Gika HG, 2008, J SEP SCI, V31, P1598, DOI 10.1002/jssc.200700644
   Govorukhina NI, 2006, J CHROMATOGR A, V1120, P142, DOI 10.1016/j.chroma.2006.02.088
   Granger JH, 2007, RAPID COMMUN MASS SP, V21, P2039, DOI 10.1002/rcm.3059
   Hodson MP, 2007, ANAL BIOCHEM, V362, P182, DOI 10.1016/j.ab.2006.12.037
   Hollywood K, 2006, PROTEOMICS, V6, P4716, DOI 10.1002/pmic.200600106
   Idborg H, 2005, J CHROMATOGR B, V828, P14, DOI 10.1016/j.jchromb.2005.07.049
   Idborg H, 2005, J CHROMATOGR B, V828, P9, DOI 10.1016/j.jchromb.2005.07.031
   Idborg-Björkman H, 2003, ANAL CHEM, V75, P4784, DOI 10.1021/ac0341618
   Inagaki S, 2007, J CHROMATOGR A, V1176, P94, DOI 10.1016/j.chroma.2007.10.065
   Jordan KW, 2007, EXPERT REV PROTEOMIC, V4, P389, DOI 10.1586/14789450.4.3.389
   Kawanishi H, 2007, CLIN CHIM ACTA, V378, P122, DOI 10.1016/j.cca.2006.11.007
   Kawanishi H, 2006, J CHROMATOGR A, V1132, P148, DOI 10.1016/j.chroma.2006.07.086
   Knowler WC, 2002, NEW ENGL J MED, V346, P393, DOI 10.1056/NEJMoa012512
   Lai L, 2010, MOL BIOSYST, V6, P108, DOI 10.1039/b910482h
   Lenz EM, 2004, ANALYST, V129, P535, DOI 10.1039/b400159c
   Lenz EM, 2007, J PROTEOME RES, V6, P443, DOI 10.1021/pr0605217
   Lindon JC, 2001, PROG NUCL MAG RES SP, V39, P1, DOI 10.1016/S0079-6565(00)00036-4
   Lindon JC, 2003, TOXICOL APPL PHARM, V187, P137, DOI 10.1016/S0041-008X(02)00079-0
   Ma SG, 2006, CURR DRUG METAB, V7, P503, DOI 10.2174/138920006777697891
   Major HJ, 2006, RAPID COMMUN MASS SP, V20, P3295, DOI 10.1002/rcm.2732
   Maurer HH, 1998, J CHROMATOGR B, V713, P3, DOI 10.1016/S0378-4347(97)00514-8
   Mohamed R, 2009, ANAL CHEM, V81, P7677, DOI 10.1021/ac901087t
   Nicholson JK, 1999, XENOBIOTICA, V29, P1181, DOI 10.1080/004982599238047
   Nicholson JK, 2002, NAT REV DRUG DISCOV, V1, P153, DOI 10.1038/nrd728
   Noge I, 2010, BIOL PHARM BULL, V33, P988, DOI 10.1248/bpb.33.988
   Obeid R, 2007, CLIN CHEM, V53, P326, DOI 10.1373/clinchem.2006.076448
   Plumb R, 2003, ANALYST, V128, P819, DOI 10.1039/b304296k
   Plumb RS, 2006, RAPID COMMUN MASS SP, V20, P2800, DOI 10.1002/rcm.2655
   Plumb RS, 2005, ANALYST, V130, P844, DOI 10.1039/b501767j
   Reo NV, 2002, DRUG CHEM TOXICOL, V25, P375, DOI 10.1081/DCT-120014789
   Robertson D.G., 2005, METABONOMICS TOXICIT
   Roy SM, 2004, INT J MASS SPECTROM, V238, P163, DOI 10.1016/j.ijms.2004.03.017
   Shaw LM, 2007, NAT REV DRUG DISCOV, V6, P295, DOI 10.1038/nrd2176
   Spagou K, 2010, J SEP SCI, V33, P716, DOI 10.1002/jssc.200900803
   Teunissen CE, 2002, NEUROBIOL AGING, V23, P485, DOI 10.1016/S0197-4580(01)00328-1
   Thal LJ, 2006, ALZ DIS ASSOC DIS, V20, P6, DOI 10.1097/01.wad.0000191420.61260.a8
   Toyo'oka T, 2008, J CHROMATOGR SCI, V46, P233, DOI 10.1093/chromsci/46.3.233
   Tsutsui H, 2010, J PROTEOME RES, V9, P3912, DOI 10.1021/pr100121k
   Tuomilehto J, 2001, NEW ENGL J MED, V344, P1343, DOI 10.1056/NEJM200105033441801
   Wikoff WR, 2007, CLIN CHEM, V53, P2169, DOI 10.1373/clinchem.2007.089011
   Williams RE, 2005, J PHARMACEUT BIOMED, V38, P465, DOI 10.1016/j.jpba.2005.01.013
   Wilson ID, 2005, J CHROMATOGR B, V817, P67, DOI 10.1016/j.jchromb.2004.07.045
   Woo HM, 2009, CLIN CHIM ACTA, V400, P63, DOI 10.1016/j.cca.2008.10.014
   Yang J, 2005, J CHROMATOGR A, V1084, P214, DOI 10.1016/j.chroma.2004.10.100
   Yang J, 2004, J CHROMATOGR B, V813, P59, DOI 10.1016/j.jchromb.2004.09.032
   Yin PY, 2008, J CHROMATOGR B, V871, P322, DOI 10.1016/j.jchromb.2008.05.043
   Yoon KH, 2006, LANCET, V368, P1681, DOI 10.1016/S0140-6736(06)69703-1
   Yuan KL, 2007, J CHROMATOGR B, V850, P236, DOI 10.1016/j.jchromb.2006.11.035
   Zimmet P, 2001, NATURE, V414, P782, DOI 10.1038/414782a
NR 57
TC 44
Z9 51
U1 0
U2 53
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0009-8981
EI 1873-3492
J9 CLIN CHIM ACTA
JI Clin. Chim. Acta
PD MAY 12
PY 2011
VL 412
IS 11-12
BP 861
EP 872
DI 10.1016/j.cca.2010.12.023
PG 12
WC Medical Laboratory Technology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Medical Laboratory Technology
GA 770YU
UT WOS:000291125200011
PM 21185819
DA 2024-02-19
ER

PT J
AU Sato, K
   Fukao, K
   Seki, Y
   Akiba, Y
AF Sato, K
   Fukao, K
   Seki, Y
   Akiba, Y
TI Expression of the chicken peroxisome proliferator-activated receptor-γ
   gene is influenced by aging, nutrition, and agonist administration
SO POULTRY SCIENCE
LA English
DT Article
DE chicken; fat deposition; mRNA expression; peroxisome
   proliferator-activated receptor-gamma
ID MESSENGER-RNA EXPRESSION; PPAR-GAMMA; LIPOPROTEIN-LIPASE;
   ADIPOSE-TISSUE; DIFFERENTIAL EXPRESSION; IN-VITRO; LIGAND; ADIPOGENESIS;
   ACID; THIAZOLIDINEDIONE
AB Peroxisome proliferatior-activated receptor-gamma (PPARgamma) is a transcription factor that modulates lipid and glucose metabolism in mammals. The aim of the present study was to investigate whether chicken PPARgamma is expressed in tissues in a similar manner to mammalian PPAR and whether it is involved in the regulation of lipid metabolism, particularly in the regulation of fat accumulation in adipose tissue and ovaries. In 30-wk-old chickens, PPARgamma mRNA was detected in most tissues that were examined. Of those tissues expressing chicken PPARgamma mRNA, the lowest expression levels were found in adipose tissue, the tissue that in mammals was shown to express the highest levels of PPARgamma mRNA. Chicken PPARgamma mRNA expression in abdominal adipose tissue tended to increase with age, as shown by higher expression levels at 6 wk than at 1 and 2 wk of age. With regard to nutritional modulation, PPARgamma mRNA levels in abdominal adipose tissue were significantly higher in wbroiler chickens fed for 7 d a diet containing 8% safflower oil (18:2-rich) or linseed oil (18:3-rich) compared with chickens fed a diet containing olive oil (18:1-rich). In contrast, feeding a 3% cholesterol-supplemented diet for 7 d resulted in no changes to adipose PPARgamma mRNA expression. In broiler chickens orally administered troglitazone, a PPARgamma ligand, abdominal fat pad weight and PPARgamma and lipoprotein lipase (LPL) mRNA levels were significantly increased relative to those of control chickens. Levels of PPARgamma mRNA in liver, skeletal muscle, and ovaries were increased with the onset of egg laying, whereas in adipose tissue the level of PPARgamma mRNA was decreased. These findings suggest that PPARgamma plays an important role in the regulation of fat deposition and egg production and the characteristic pattern of PPARgamma mRNA expression may be indicative of specific differences in the lipid and glucose metabolism of chickens compared with mammals.
C1 Tohoku Univ, Grad Sch Agr Sci, Sendai, Miyagi 9818555, Japan.
C3 Tohoku University
RP Akiba, Y (corresponding author), Tohoku Univ, Grad Sch Agr Sci, Sendai, Miyagi 9818555, Japan.
EM akiba@bios.tohoku.ac.jp
RI SATO, Kan/G-1076-2013
CR Barak Y, 1999, MOL CELL, V4, P585, DOI 10.1016/S1097-2765(00)80209-9
   Braissant O, 1996, ENDOCRINOLOGY, V137, P354, DOI 10.1210/en.137.1.354
   Chambrier C, 2002, OBES RES, V10, P518, DOI 10.1038/oby.2002.70
   Clark RB, 2000, J IMMUNOL, V164, P1364, DOI 10.4049/jimmunol.164.3.1364
   Cui Y, 2002, J BIOL CHEM, V277, P17830, DOI 10.1074/jbc.M200186200
   FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0
   GRIFFIN HD, 1987, BRIT POULTRY SCI, V28, P197, DOI 10.1080/00071668708416953
   Kageyama H, 2003, BIOCHEM BIOPH RES CO, V305, P22, DOI 10.1016/S0006-291X(03)00663-6
   Keelan JA, 1999, BIOCHEM BIOPH RES CO, V262, P579, DOI 10.1006/bbrc.1999.1257
   KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0
   Kubota N, 1999, MOL CELL, V4, P597, DOI 10.1016/S1097-2765(00)80210-5
   Kubota T, 1998, CANCER RES, V58, P3344
   Lambe KG, 1996, EUR J BIOCHEM, V239, P1, DOI 10.1111/j.1432-1033.1996.0001u.x
   Law RE, 2000, CIRCULATION, V101, P1311, DOI 10.1161/01.CIR.101.11.1311
   Lefebvre AM, 1998, NAT MED, V4, P1053, DOI 10.1038/2036
   LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953
   Pighetti GM, 2001, ANTICANCER RES, V21, P825
   Rosen ED, 1999, MOL CELL, V4, P611, DOI 10.1016/S1097-2765(00)80211-7
   SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463
   Sato K, 2002, POULTRY SCI, V81, P846, DOI 10.1093/ps/81.6.846
   Sato K, 1999, POULTRY SCI, V78, P1286, DOI 10.1093/ps/78.9.1286
   Schneider WJ, 1998, BIOL CHEM, V379, P965
   Spiegelman B M, 1997, Eur J Med Res, V2, P457
   Spiegelman BM, 1996, CELL, V87, P377, DOI 10.1016/S0092-8674(00)81359-8
   Spiegelman BM, 1998, CELL, V93, P153, DOI 10.1016/S0092-8674(00)81567-6
   Sundvold H, 1997, BIOCHEM BIOPH RES CO, V239, P857, DOI 10.1006/bbrc.1997.7564
   Takada I, 2000, MOL ENDOCRINOL, V14, P733, DOI 10.1210/me.14.5.733
   TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224
   TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X
   VidalPuig A, 1996, J CLIN INVEST, V97, P2553, DOI 10.1172/JCI118703
NR 30
TC 58
Z9 68
U1 0
U2 5
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0032-5791
EI 1525-3171
J9 POULTRY SCI
JI Poult. Sci.
PD AUG
PY 2004
VL 83
IS 8
BP 1342
EP 1347
DI 10.1093/ps/83.8.1342
PG 6
WC Agriculture, Dairy & Animal Science
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Agriculture
GA 843IT
UT WOS:000223072800012
PM 15339009
OA hybrid, Green Submitted
DA 2024-02-19
ER

PT J
AU Brown, JCL
   McClelland, GB
   Faure, PA
   Klaiman, JM
   Staples, JF
AF Brown, Jason C. L.
   McClelland, Grant B.
   Faure, Paul A.
   Klaiman, Jordan M.
   Staples, James F.
TI Examining the mechanisms responsible for lower ROS release rates in
   liver mitochondria from the long-lived house sparrow (<i>Passer
   domesticus</i>) and big brown bat (<i>Eptesicus fuscus</i>) compared to
   the short-lived mouse (<i>Mus musculus</i>)
SO MECHANISMS OF AGEING AND DEVELOPMENT
LA English
DT Article
DE Aging; Longevity; Uncoupling to survive; Spare capacity; Hydrogen
   peroxide
ID FREE-RADICAL PRODUCTION; OXYGEN SPECIES PRODUCTION; ELECTRON-TRANSPORT
   CHAIN; HYDROGEN-PEROXIDE PRODUCTION; MAXIMUM LIFE-SPAN; WILD-DERIVED
   MICE; H2O2 PRODUCTION; HEART-MITOCHONDRIA; COMPLEX-I; OXIDATIVE STRESS
AB Lower ROS release rate in long-lived species is likely caused by decreased reduction of electron transport chain (ETC) complexes, but how this is achieved remains largely unknown. We compared liver mitochondrial H2O2 release rates among endotherms of comparable size and metabolic rate: house sparrow and big brown bat (both long-lived) and house mouse (short-lived). We hypothesized that low ROS release rates in long-lived species result from (i) lower mitochondrial respiration rate, (ii) increased mitochondrial proton conductance ('uncoupling to survive'), and/or (iii) increased ETC oxidative capacity ('spare oxidative capacity'). H2O2, release rate was 70% lower in bats than mice despite similar respiration rates. Consistent with 'uncoupling to survive', proton leakiness was 3-fold higher in bats at membrane potentials above 130 mV. Basal H2O2 release rate and respiration rates were 2-fold higher in sparrows than mice. Consistent with 'spare oxidative capacity', subsaturating succinate decreased H2O2 release rate in sparrows but not mice. Moreover, succinate:Cytochrome c oxidoreductase activity was 3-fold higher in sparrows, and ETC inhibitors increased ROS release rate 20-27-fold in sparrows (with glutamate or subsaturating succinate) but only 4-5-fold in mice. Taken together these data suggest that complexes I and III are less reduced under physiological conditions in sparrows. We conclude that different long-lived species may use distinct mechanisms to lower mitochondrial ROS release rate. (C) 2009 Elsevier Ireland Ltd. All rights reserved.
C1 [Brown, Jason C. L.; Klaiman, Jordan M.; Staples, James F.] Univ Western Ontario, Dept Biol, London, ON N6A 5B8, Canada.
   [McClelland, Grant B.] McMaster Univ, Dept Biol, Hamilton, ON, Canada.
   [Faure, Paul A.] McMaster Univ, Dept Psychol Neurosci & Behav, Hamilton, ON, Canada.
C3 Western University (University of Western Ontario); McMaster University;
   McMaster University
RP Brown, JCL (corresponding author), Univ Western Ontario, Dept Biol, London, ON N6A 5B8, Canada.
EM jbrow63@uwo.ca
RI McClelland, Grant B/D-1369-2012
OI McClelland, Grant B/0000-0003-1500-9983
FU Natural Sciences and Engineering Research Council of Canada
FX Financial support for this work came from the Natural Sciences and
   Engineering Research Council of Canada in the form of a Postgraduate
   Scholarship (JCLB), individual Discovery Grants (GBM, PAF, and JFS), and
   Research Tools and Infrastructure Grants (GBM and JFS). The Canada
   Foundation for Innovation and the Ontario Innovation Trust provided
   additional infrastructure support (GBM and PAF). We thank Dr.
   Christopher Guglielmo for providing us with sparrow liver and reviewing
   our manuscript. We thank Betty Zou, Edwin Price, Alexander Gerson, Marie
   Gadziola, and Daniel Re for help with acquiring and caring for animals,
   and Jacqueline Beaudry for her assistance.
CR Bains R, 2006, ACTA ANAESTH SCAND, V50, P572, DOI 10.1111/j.1399-6576.2006.00988.x
   Barja G, 1998, J BIOENERG BIOMEMBR, V30, P235, DOI 10.1023/A:1020592719405
   Barja G, 1998, ANN NY ACAD SCI, V854, P224, DOI 10.1111/j.1749-6632.1998.tb09905.x
   Barja G, 1999, J BIOENERG BIOMEMBR, V31, P347, DOI 10.1023/A:1005427919188
   BARJA G, 1994, FREE RADICAL RES, V21, P317, DOI 10.3109/10715769409056584
   Barja G, 2007, REJUV RES, V10, P215, DOI 10.1089/rej.2006.0516
   BEER JAMES R., 1956, JOUR MAMMAL, V37, P31, DOI 10.2307/1375523
   Brand MD, 2000, EXP GERONTOL, V35, P811, DOI 10.1016/S0531-5565(00)00135-2
   Brand MD, 1999, INT J OBESITY, V23, pS4, DOI 10.1038/sj.ijo.0800936
   Brookes PS, 2005, FREE RADICAL BIO MED, V38, P12, DOI 10.1016/j.freeradbiomed.2004.10.016
   Brown JCL, 2007, AM J PHYSIOL-REG I, V293, pR1833, DOI 10.1152/ajpregu.00310.2007
   Brunet-Rossinni AK, 2004, MECH AGEING DEV, V125, P11, DOI 10.1016/j.mad.2003.09.003
   Capel F, 2004, MECH AGEING DEV, V125, P367, DOI 10.1016/j.mad.2004.02.005
   Chappell MA, 1999, J EXP BIOL, V202, P2269
   Chen Q, 2003, J BIOL CHEM, V278, P36027, DOI 10.1074/jbc.M304854200
   Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687
   Fridell YWC, 2005, CELL METAB, V1, P145, DOI 10.1016/j.cmet.2005.01.005
   GRAVES JL, 1988, J INSECT PHYSIOL, V34, P1021, DOI 10.1016/0022-1910(88)90201-6
   GREEN JD, 1980, J HISTOCHEM CYTOCHEM, V28, P408, DOI 10.1177/28.5.6966645
   HAMILTON ML, 2001, PNAS, P10469
   Hanley PJ, 2002, J PHYSIOL-LONDON, V544, P687, DOI 10.1113/jphysiol.2002.025015
   HARMAN D, 1972, J AM GERIATR SOC, V20, P145, DOI 10.1111/j.1532-5415.1972.tb00787.x
   HARMAN D, 1956, J GERONTOL, V11, P298, DOI 10.1093/geronj/11.3.298
   Harper JM, 2006, J GERONTOL A-BIOL, V61, P1019, DOI 10.1093/gerona/61.10.1019
   HERREID CF, 1966, AM J PHYSIOL, V211, P1108
   Herrero A, 1998, MECH AGEING DEV, V103, P133, DOI 10.1016/S0047-6374(98)00035-9
   Herrero A, 1997, MECH AGEING DEV, V98, P95, DOI 10.1016/S0047-6374(97)00076-6
   Herrero A, 2000, J BIOENERG BIOMEMBR, V32, P609, DOI 10.1023/A:1005626712319
   JURGENS KD, 1987, COMP BIOCHEM PHYS A, V88, P361, DOI 10.1016/0300-9629(87)90498-1
   KLIMKIEWICZ MK, 1987, J FIELD ORNITHOL, V58, P318
   Konarzewski M, 1995, EVOLUTION, V49, P1239, DOI [10.2307/2410448, 10.1111/j.1558-5646.1995.tb04450.x]
   KU HH, 1993, MECH AGEING DEV, V72, P67, DOI 10.1016/0047-6374(93)90132-B
   KU HH, 1993, FREE RADICAL BIO MED, V15, P621, DOI 10.1016/0891-5849(93)90165-Q
   Kushnareva Y, 2002, BIOCHEM J, V368, P545, DOI 10.1042/BJ20021121
   Labinskyy N, 2009, AM J PHYSIOL-HEART C, V296, pH946, DOI 10.1152/ajpheart.00693.2008
   Lambert AJ, 2007, AGING CELL, V6, P607, DOI 10.1111/j.1474-9726.2007.00312.x
   Lane N, 2003, J THEOR BIOL, V225, P531, DOI 10.1016/S0022-5193(03)00304-7
   LANE N, 2005, POWER SEX SUICIDE MI, P306
   LASIEWSKI RC, 1967, CONDOR, V69, P13, DOI 10.2307/1366368
   Leary SC, 2003, AM J PHYSIOL-REG I, V285, pR817, DOI 10.1152/ajpregu.00058.2003
   Lewandowski ED, 1996, MAGN RESON MED, V35, P149, DOI 10.1002/mrm.1910350203
   Liu SS, 1997, BIOSCIENCE REP, V17, P259, DOI 10.1023/A:1027328510931
   Liu YB, 2002, J NEUROCHEM, V80, P780, DOI 10.1046/j.0022-3042.2002.00744.x
   LOPEZTORRES M, 1993, MECH AGEING DEV, V70, P177, DOI 10.1016/0047-6374(93)90047-U
   MARTIN ARTHUR W., 1955, PHYSIOL ZOOL, V28, P18
   MCCORD JM, 1969, J BIOL CHEM, V244, P6049
   Miller RA, 2002, EXP BIOL MED, V227, P500, DOI 10.1177/153537020222700715
   Miwa S, 2003, BIOCHEM SOC T, V31, P1300
   MORI A, 2006, ANN NY ACAD SCI, V854, P239
   NOHL H, 1980, EUR J BIOCHEM, V111, P203
   Pamplona R, 1999, MECH AGEING DEV, V106, P283, DOI 10.1016/S0047-6374(98)00121-3
   Pérez VI, 2009, AGING CELL, V8, P73, DOI 10.1111/j.1474-9726.2008.00449.x
   Perez-Campo R, 1998, J COMP PHYSIOL B, V168, P149, DOI 10.1007/s003600050131
   Ramsey JJ, 2005, COMP BIOCHEM PHYS B, V140, P99, DOI 10.1016/j.cbpc.2004.09.016
   REYNAFARJE B, 1985, ANAL BIOCHEM, V145, P406, DOI 10.1016/0003-2697(85)90381-1
   Rottenberg H, 2007, J EXP BIOL, V210, P2170, DOI 10.1242/jeb.004861
   Rottenberg H, 2007, EXP GERONTOL, V42, P364, DOI 10.1016/j.exger.2006.10.016
   RUCH W, 1983, J IMMUNOL METHODS, V63, P347, DOI 10.1016/S0022-1759(83)80008-8
   Sanz A, 2006, ANTIOXID REDOX SIGN, V8, P582, DOI 10.1089/ars.2006.8.582
   Servais S, 2003, FREE RADICAL BIO MED, V35, P24, DOI 10.1016/S0891-5849(03)00177-1
   Speakman Jr, 2003, ADV CELL AGING GERON, V14, P35
   Speakman JR, 2004, AGING CELL, V3, P87, DOI 10.1111/j.1474-9728.2004.00097.x
   St-Pierre J, 2002, J BIOL CHEM, V277, P44784, DOI 10.1074/jbc.M207217200
   STAHL WR, 1965, SCIENCE, V150, P1039, DOI 10.1126/science.150.3699.1039
   Starkov AA, 2003, J NEUROCHEM, V86, P1101, DOI 10.1046/j.1471-4159.2003.01908.x
   SUAREZ RK, 1988, AM J PHYSIOL, V255, pR699, DOI 10.1152/ajpregu.1988.255.5.R699
   Sutherland BA, 2004, FASEB J, V18, P258, DOI 10.1096/fj.04-2806fje
   Takaki M, 1997, JPN J PHYSIOL, V47, P87, DOI 10.2170/jjphysiol.47.87
   Trounce I A, 1996, Methods Enzymol, V264, P484, DOI 10.1016/S0076-6879(96)64044-0
   Turrens JF, 1997, BIOSCIENCE REP, V17, P3, DOI 10.1023/A:1027374931887
   Ungvari Z, 2008, FRONT BIOSCI-LANDMRK, V13, P5056, DOI 10.2741/3064
   Venditti P, 2003, MOL CELL ENDOCRINOL, V205, P185, DOI 10.1016/S0303-7207(02)00332-5
   Venditti P, 1999, ARCH BIOCHEM BIOPHYS, V372, P315, DOI 10.1006/abbi.1999.1494
   Wilkinson GS, 2002, AGING CELL, V1, P124, DOI 10.1046/j.1474-9728.2002.00020.x
   Willis CKR, 2005, CAN J ZOOL, V83, P871, DOI 10.1139/Z05-074
   Winter Y, 1998, J COMP PHYSIOL B, V168, P105, DOI 10.1007/s003600050126
   Young TA, 2002, ARCH BIOCHEM BIOPHYS, V405, P65, DOI 10.1016/S0003-9861(02)00338-7
NR 77
TC 34
Z9 40
U1 0
U2 25
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0047-6374
J9 MECH AGEING DEV
JI Mech. Ageing Dev.
PD AUG
PY 2009
VL 130
IS 8
BP 467
EP 476
DI 10.1016/j.mad.2009.05.002
PG 10
WC Cell Biology; Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Geriatrics & Gerontology
GA 487RH
UT WOS:000269292000001
PM 19464314
DA 2024-02-19
ER

PT J
AU Khatri, I
   Alexander, C
   Brandenburg, K
   Fournier, K
   Lee, L
   Mach, JP
   Rietschel, ET
   Ulmer, AJ
   Waelli, T
   Gorczynski, RM
AF Khatri, Ismat
   Alexander, C.
   Brandenburg, K.
   Fournier, K.
   Lee, L.
   Mach, J. P.
   Rietschel, E. Th.
   Ulmer, A. J.
   Waelli, Th.
   Gorczynski, R. M.
TI A role for altered TLR gene expression in association with increased
   expression of CD200R in the induction of mucosal tissue CD4<SUP>+</SUP>
   Treg in aged mice following gavage with a liver extract along with
   intramuscular monophosphoryl lipid A (MPLA) injection
SO EXPERIMENTAL GERONTOLOGY
LA English
DT Article
DE cytokine; CD4(+)CD25(+)Treg; CD4+TGF beta(+); Tr3; MPLA; CD200; CD200R;
   aging; immunoregulation; Treg; CD200R; TLR
ID REGULATORY T-CELLS; TOLL-LIKE RECEPTORS; DENDRITIC CELLS; TGF-BETA;
   MONOCLONAL-ANTIBODIES; CYTOKINE PRODUCTION; CUTTING EDGE; TOLERANCE;
   SUPPRESSION; POPULATIONS
AB Previous studies showed a fetal sheep liver extract (FSLE), in association with LPS, injected into aged (> 20 months) mice reversed the altered polarization (increased IL-4 and IL-10 with decreased IL-2 and IFN-gamma) in cytokine production seen from ConA stimulated lymphoid cells of those mice. Aged mice show a > 60% decline in numbers and suppressive function of both CD4(+)CD25(+)Foxp3(+)Treg and so-called Tr3 (CD4(+)TGF beta(+)). Their number/function is restored to levels seen in control (8-week-old) mice by FSLE. We have reported at length on the ability of a novel pair of immunoregulatory molecules, members of the TREM family, namely CD200:CD200R, to control development of dendritic cells (DCs) which themselves regulate production of Foxp3(+) Treg. The latter express a distinct subset of TLRs which control their function. We report that a feature of the altered Treg expression following combined treatment with FSLE and monophosphoryl lipid A, MPLA (a bioactive component of lipid A of LPS) is the altered gene expression both of distinct subsets of TLRs and of CD200Rs. We speculate that this may represent one of the mechanisms by which FSLE and MPLA alter immunity in aged mice. (c) 2008 Elsevier Inc. All rights reserved.
C1 [Khatri, Ismat; Lee, L.; Gorczynski, R. M.] Univ Hlth Network, Dept Surg, Toronto, ON M5G 1L7, Canada.
   [Alexander, C.; Brandenburg, K.; Rietschel, E. Th.; Ulmer, A. J.] Forschungszentrum, Borstel, Germany.
   [Alexander, C.; Brandenburg, K.; Rietschel, E. Th.; Ulmer, A. J.] Univ Freiburg, D-7800 Freiburg, Germany.
   [Waelli, Th.] Clin Prairie, Montreux, Switzerland.
   [Gorczynski, R. M.] Univ Hlth Network, Dept Immunol, Toronto, ON M5G 1L7, Canada.
C3 University of Toronto; University Health Network Toronto; University of
   Freiburg; University of Toronto; University Health Network Toronto
RP Gorczynski, RM (corresponding author), Univ Hlth Network, Dept Surg, 2-805,MaRS Tower,101 Coll St, Toronto, ON M5G 1L7, Canada.
EM reg.gorczynski@utoronto.ca
RI Gorczynski, Reginald/AAA-1435-2019
FU Clinique La Prairie Research Institute, Luxembourg, and Clarens,
   Switzerland
FX Research supported by Clinique La Prairie Research Institute,
   Luxembourg, and Clarens, Switzerland. Technicians: Nina Grohmann,
   Patricia Prilla (Borstel).
CR Aiello S, 2007, TRANSPLANTATION, V83, P474, DOI 10.1097/01.tp.0000251808.91901.c3
   Beverley PCL, 2000, VACCINE, V18, P1721, DOI 10.1016/S0264-410X(99)00514-9
   BOUDAKOV I, 2005, RECENT RES DEV IMMUN, V7, P9
   Boudakov I, 2007, TRANSPLANTATION, V84, P251, DOI 10.1097/01.tp.0000269795.04592.cc
   Caramalho I, 2003, J EXP MED, V197, P403, DOI 10.1084/jem.20021633
   Chen WJ, 2006, FRONT BIOSCI-LANDMRK, V11, P1360, DOI 10.2741/1889
   Chiu BC, 2007, MECH AGEING DEV, V128, P618, DOI 10.1016/j.mad.2007.09.002
   Cobbold SP, 2006, EUR J IMMUNOL, V36, P1360, DOI 10.1002/eji.200636171
   Colonna M, 2003, NAT REV IMMUNOL, V3, P445, DOI 10.1038/nri1106
   De la Fuente M, 2004, CELL MOL BIOL, V50, P683, DOI 10.1170/82
   Dejaco C, 2006, IMMUNOLOGY, V117, P289, DOI 10.1111/j.1365-2567.2005.02317.x
   Dejaco C, 2006, EXP GERONTOL, V41, P339, DOI 10.1016/j.exger.2006.01.008
   Encabo A, 2007, TRANSFUSION, V47, P272, DOI 10.1111/j.1537-2995.2007.01103.x
   Fallarino F, 2005, INT IMMUNOL, V17, P1429, DOI 10.1093/intimm/dxh321
   Ferguson TA, 2005, IMMUNOL RES, V32, P99, DOI 10.1385/IR:32:1-3:099
   Fulop T, 2006, MECH AGEING DEV, V127, P526, DOI 10.1016/j.mad.2006.01.025
   GORCZYNSKI R, 1993, IMMUNOL LETT, V38, P243, DOI 10.1016/0165-2478(93)90013-R
   Gorczynski RM, 2007, IMMUNOL LETT, V109, P101, DOI 10.1016/j.imlet.2007.01.009
   Gorczynski RM, 2006, IMMUNOL LETT, V105, P140, DOI 10.1016/j.imlet.2006.02.001
   Gorczynski R, 2008, J IMMUNOL, V180, P5946, DOI 10.4049/jimmunol.180.9.5946
   Gorczynski RM, 2006, J IMMUNOL, V177, P1078, DOI 10.4049/jimmunol.177.2.1078
   Gorczynski RM, 2006, TRANSPLANTATION, V81, P1027, DOI 10.1097/01.tp.0000214984.65520.50
   Gorczynski RM, 2005, IMMUNOL LETT, V100, P120, DOI 10.1016/j.imlet.2005.03.004
   Gorczynski RM, 1998, TRANSPLANTATION, V65, P1106, DOI 10.1097/00007890-199804270-00016
   Gorczynski RM, 2005, TRANSPLANTATION, V79, P488, DOI 10.1097/01.TP.0000152118.51622.F9
   Gorczynski RM, 2004, AM J REPROD IMMUNOL, V52, P147, DOI 10.1111/j.1600-0897.2004.00192.x
   Gorczynski RM, 2004, TRANSPLANTATION, V77, P1138, DOI 10.1097/01.TP.0000121773.18476.1C
   Gregg R, 2005, CLIN EXP IMMUNOL, V140, P540, DOI 10.1111/j.1365-2249.2005.02798.x
   Groux H, 2003, TRANSPLANTATION, V75, p8S, DOI 10.1097/01.TP.0000067944.90241.BD
   Hansen BS, 2006, J NEUROIMMUNOL, V172, P94, DOI 10.1016/j.jneuroim.2005.11.006
   Hussain SF, 2004, J IMMUNOTHER, V27, P339, DOI 10.1097/00002371-200409000-00002
   Ji HB, 2004, J IMMUNOL, V172, P5823, DOI 10.4049/jimmunol.172.10.5823
   Jump RL, 2002, J IMMUNOL, V168, P6113, DOI 10.4049/jimmunol.168.12.6113
   Kabelitz D, 2007, CURR OPIN IMMUNOL, V19, P39, DOI 10.1016/j.coi.2006.11.007
   Kubo T, 2004, J IMMUNOL, V173, P7249, DOI 10.4049/jimmunol.173.12.7249
   LaRosa DF, 2007, IMMUNOL LETT, V108, P183, DOI 10.1016/j.imlet.2006.12.007
   Lee L, 2006, IMMUNOL LETT, V105, P150, DOI 10.1016/j.imlet.2006.02.002
   Levings MK, 2002, INT ARCH ALLERGY IMM, V129, P263, DOI 10.1159/000067596
   Liu HY, 2006, P NATL ACAD SCI USA, V103, P7048, DOI 10.1073/pnas.0601554103
   Moseman EA, 2004, J IMMUNOL, V173, P4433, DOI 10.4049/jimmunol.173.7.4433
   Nakamura K, 2004, J IMMUNOL, V172, P834, DOI 10.4049/jimmunol.172.2.834
   Nishioka T, 2006, J IMMUNOL, V176, P6586, DOI 10.4049/jimmunol.176.11.6586
   Ostroukhova M, 2006, J CLIN INVEST, V116, P996, DOI 10.1172/JCI26490
   Ramsdell F, 2003, IMMUNITY, V19, P165, DOI 10.1016/S1074-7613(03)00207-3
   Renshaw M, 2002, J IMMUNOL, V169, P4697, DOI 10.4049/jimmunol.169.9.4697
   Sakaguchi S, 2004, ANNU REV IMMUNOL, V22, P531, DOI 10.1146/annurev.immunol.21.120601.141122
   Sharma S, 2006, J IMMUNOL, V177, P8348, DOI 10.4049/jimmunol.177.12.8348
   Shimizu J, 2003, EUR J IMMUNOL, V33, P2449, DOI 10.1002/eji.200324040
   Steinman RM, 1997, ADV EXP MED BIOL, V417, P1
   Sutmuller RPM, 2006, TRENDS IMMUNOL, V27, P387, DOI 10.1016/j.it.2006.06.005
   Sutmuller RPM, 2006, J CLIN INVEST, V116, P485, DOI 10.1172/JCI25439
   Takenaka S, 2007, J IMMUNOL, V178, P7984, DOI 10.4049/jimmunol.178.12.7984
   Tang QZ, 2004, EUR J IMMUNOL, V34, P2996, DOI 10.1002/eji.200425143
   Tsaknaridis L, 2003, J NEUROSCI RES, V74, P296, DOI 10.1002/jnr.10766
   Yagi H, 2004, INT IMMUNOL, V16, P1643, DOI 10.1093/intimm/dxh165
   Zhao L, 2007, J LEUKOCYTE BIOL, V81, P1386, DOI 10.1189/jlb.0506364
NR 56
TC 1
Z9 1
U1 0
U2 3
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0531-5565
EI 1873-6815
J9 EXP GERONTOL
JI Exp. Gerontol.
PD AUG
PY 2008
VL 43
IS 8
BP 771
EP 781
DI 10.1016/j.exger.2008.05.001
PG 11
WC Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Geriatrics & Gerontology
GA 343LQ
UT WOS:000258855700009
PM 18555631
DA 2024-02-19
ER

PT J
AU Eksakulkla, S
   Suksom, D
   Siriviriyakul, P
   Patumraj, S
AF Eksakulkla, Sukanya
   Suksom, Daroonwan
   Siriviriyakul, Prasong
   Patumraj, Suthiluk
TI Increased NO bioavailability in aging male rats by genistein and
   exercise training: using 4, 5-diaminofluorescein diacetate
SO REPRODUCTIVE BIOLOGY AND ENDOCRINOLOGY
LA English
DT Article
ID ENDOTHELIUM-DEPENDENT VASODILATION; BILATERAL OVARIECTOMIZED RATS;
   NITRIC-OXIDE; REPLACEMENT THERAPY; OXIDATIVE STRESS; SOY ISOFLAVONES;
   HUMAN FOREARM; IN-VIVO; AGE; PHYTOESTROGEN
AB Background: Several kinds of anti-oxidants have drawn a lot of intension for their benefits on vascular protection. In addition, it has been demonstrated that exercise training could improve endothelial function by up-regulating endothelial nitric oxide synthase ( eNOS) protein. Therefore, the present study aims to investigate the effects of genistein, a potent phyto-antioxidant, and exercise training on age-induced endothelial dysfunction in relation to NO bioavailability using in situ NO-sensitive fluorescent dye detection.
   Methods: Male Wistar rats (20-22-month old) were divided into four groups: aged rats treated with corn oil, (Aged+Veh, n = 5), aged rats treated with genistein (Aged+Gen, n = 5, (0.25 mg/kg BW/day, s.c.)), aged rats with and without exercise training (Aged+Ex, n = 5, swimming 40 min/day, 5 days/week for 8 weeks) (Aged+Without-Ex, n = 5). Cremaster arterioles (15-35 micrometer) were visualized by fluorescein isothiocyanate labeled dextran ( 5 microgram/ml). The vascular response to acetylcholine ( Ach; 10(-5)M, 5 ml/5 min) was accessed after 1-min norepinephrine preconstriction ( 10 micro molar). To determine NO bioavailability, the Krebs-Ringer buffer with 4, 5-diaminofluorescein-diacetate (3 micro molar DAF-2DA), and 10 micro-molar Ach saturated with 95%N-2 and 5%CO2 were used. Changes of DAF-2T-intensities along the cremaster arterioles were analyzed by the Image Pro-Plus Software (Media Cybernatics, Inc, USA). Liver malondialdehyde (MDA) level was measured by thiobarbituric acid reaction and used as an indicator for oxidative stress.
   Results: The results showed that means arterial blood pressure for both Aged+Gen and Aged+Ex groups were significantly reduced when compared to the Aged groups, Aged+Veh and Aged+Without-Ex (P < 0.05). Among the treated groups, Ach-induced vasodilatation were significantly increased (P < 0.05) and was associated with increased NO-associated fluorescent intensities (P < 0.05). On the other hand, MDA levels were significantly reduced ( P < 0.05) when Aged+Veh was compared to Aged+Without- Ex.
   Conclusion: These findings showed that genistein and exercise training could improve age-induced endothelial dysfunction and is related to the increased NO bioavailability.
C1 [Siriviriyakul, Prasong; Patumraj, Suthiluk] Chulalongkorn Univ, Dept Physiol, Fac Med, Bangkok 10330, Thailand.
   [Suksom, Daroonwan] Chulalongkorn Univ, Sch Sports Sci, Bangkok 10330, Thailand.
   [Eksakulkla, Sukanya] Chulalongkorn Univ, Grad Sch, Inter Dept Physiol, Bangkok 10330, Thailand.
C3 Chulalongkorn University; Chulalongkorn University; Chulalongkorn
   University
RP Patumraj, S (corresponding author), Chulalongkorn Univ, Dept Physiol, Fac Med, Bangkok 10330, Thailand.
EM sukunyaj21@yahoo.com; daroonwanc@hotmail.com; medspr@hotmail.com;
   suthilukp@yahoo.com
OI EKSAKULKLA, SUKANYA/0000-0003-0287-6770
FU Ratchadaphiseksomphot Fund; Faculty of Medicine; 90th Anniversary of
   Chulalongkorn University Fund; Graduate School, Chulalongkorn
   University; National Research Council of Thailand [GRB_14_50_30_12]
FX This study was supported by Ratchadaphiseksomphot Fund, Faculty of
   Medicine, the 90th Anniversary of Chulalongkorn University Fund,
   Graduate School, Chulalongkorn University, and National Research Council
   of Thailand (GRB_14_50_30_12).
CR ADLERCREUTZ H, 1993, LANCET, V342, P1209, DOI 10.1016/0140-6736(93)92188-Y
   Ahmadiasl N, 2007, J SPORT SCI MED, V6, P243
   Al-Shaer MH, 2006, INT J CARDIOL, V109, P201, DOI 10.1016/j.ijcard.2005.06.002
   Anthony MS, 1996, J NUTR, V126, P43, DOI 10.1093/jn/126.1.43
   Barnes S, 1998, P SOC EXP BIOL MED, V217, P386
   Chanawirat A, 2006, CLIN HEMORHEOL MICRO, V34, P309
   Csiszar A, 2002, CIRC RES, V90, P1159, DOI 10.1161/01.RES.0000020401.61826.EA
   DeSouza CA, 2000, CIRCULATION, V102, P1351, DOI 10.1161/01.CIR.102.12.1351
   EGASHIRA K, 1993, CIRCULATION, V88, P77, DOI 10.1161/01.CIR.88.1.77
   Gavins Felicity N. E., 2004, Journal of Pharmacological and Toxicological Methods, V49, P1, DOI 10.1016/S1056-8719(03)00057-1
   GRYGLEWSKI RJ, 1986, NATURE, V320, P454, DOI 10.1038/320454a0
   Guo XM, 2005, J BIOL CHEM, V280, P19704, DOI 10.1074/jbc.M501244200
   Hamilton CA, 2001, HYPERTENSION, V37, P529, DOI 10.1161/01.HYP.37.2.529
   Harrison DG, 1997, J CLIN INVEST, V100, P2153, DOI 10.1172/JCI119751
   Honore EK, 1997, FERTIL STERIL, V67, P148, DOI 10.1016/S0015-0282(97)81872-9
   Kashiwagi S, 2002, CIRC RES, V91, pE55, DOI 10.1161/01.RES.0000047529.26278.4D
   KEYS A, 1970, CIRCULATION, V41, pI1
   Khemapech S, 2003, CLIN HEMORHEOL MICRO, V29, P271
   Kojima H, 1998, ANAL CHEM, V70, P2446, DOI 10.1021/ac9801723
   Leosco D, 2003, AM J PHYSIOL-HEART C, V285, pH369, DOI 10.1152/ajpheart.00019.2003
   Lissin LW, 2000, J AM COLL CARDIOL, V35, P1403
   Liu DM, 2004, ENDOCRINOLOGY, V145, P5532, DOI 10.1210/en.2004-0102
   Maiorana A, 2003, SPORTS MED, V33, P1013, DOI 10.2165/00007256-200333140-00001
   Matsubara M, 2006, PHARMACOL RES, V53, P35, DOI 10.1016/j.phrs.2005.08.006
   Mitchell JH, 2001, CLIN SCI, V100, P613, DOI 10.1042/CS20000212
   Molsiri K, 2004, CLIN HEMORHEOL MICRO, V31, P59
   OGAWA T, 1992, CIRCULATION, V86, P494, DOI 10.1161/01.CIR.86.2.494
   OHKAWA H, 1979, ANAL BIOCHEM, V95, P351, DOI 10.1016/0003-2697(79)90738-3
   Roberts LJ, 2001, BIOCHEM BIOPH RES CO, V287, P254, DOI 10.1006/bbrc.2001.5583
   Si HW, 2008, J NUTR, V138, P297, DOI 10.1093/jn/138.2.297
   Sindler AL, 2009, J PHYSIOL-LONDON, V587, P3885, DOI 10.1113/jphysiol.2009.172221
   Singh N, 2002, CLIN SCI, V102, P595, DOI 10.1042/CS20010262
   Siriviriyakul P, 2006, CLIN HEMORHEOL MICRO, V34, P97
   Squadrito F, 2000, CARDIOVASC RES, V45, P454, DOI 10.1016/S0008-6363(99)00359-4
   Sridulyakul P, 2008, ASIAN BIOMED, V2, P371
   TADDEI S, 1995, CIRCULATION, V91, P1981, DOI 10.1161/01.CIR.91.7.1981
   Taddei S, 2001, HYPERTENSION, V38, P274, DOI 10.1161/01.HYP.38.2.274
   Taddei S, 2000, CIRCULATION, V101, P2896, DOI 10.1161/01.CIR.101.25.2896
   Tanabe T, 2003, ACTA PHYSIOL SCAND, V178, P3, DOI 10.1046/j.1365-201X.2003.01100.x
   Tikkanen MJ, 1998, P NATL ACAD SCI USA, V95, P3106, DOI 10.1073/pnas.95.6.3106
   van der Loo B, 2000, J EXP MED, V192, P1731, DOI 10.1084/jem.192.12.1731
   Walker HA, 2001, CIRCULATION, V103, P258, DOI 10.1161/01.CIR.103.2.258
NR 42
TC 9
Z9 9
U1 0
U2 6
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1477-7827
J9 REPROD BIOL ENDOCRIN
JI Reprod. Biol. Endocrinol.
PD SEP 7
PY 2009
VL 7
AR 93
DI 10.1186/1477-7827-7-93
PG 8
WC Endocrinology & Metabolism; Reproductive Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Endocrinology & Metabolism; Reproductive Biology
GA 498ML
UT WOS:000270144800001
PM 19735570
OA Green Published, gold
DA 2024-02-19
ER

PT J
AU VENKATRAMAN, JT
   CHANDRASEKAR, B
   KIM, JD
   FERNANDES, G
AF VENKATRAMAN, JT
   CHANDRASEKAR, B
   KIM, JD
   FERNANDES, G
TI GENOTYPE EFFECTS ON THE ANTIOXIDANT ENZYMES ACTIVITY AND MESSENGER-RNA
   EXPRESSION IN LIVER AND KIDNEY TISSUES OF AUTOIMMUNE-PRONE MRL/MPJ
   LPR/LPR MICE
SO BIOCHIMICA ET BIOPHYSICA ACTA-LIPIDS AND LIPID METABOLISM
LA English
DT Article
DE ANTIOXIDANT ENZYME; AUTOIMMUNITY; FATTY ACID COMPOSITION; GENE
   EXPRESSION; LIPID PEROXIDATION; ANTICARDIOLIPIN ANTIBODY
ID SYSTEMIC LUPUS-ERYTHEMATOSUS; SUPEROXIDE-DISMUTASE; LIPID-PEROXIDATION;
   FOOD RESTRICTION; GLUTATHIONE-PEROXIDASE; DIETARY RESTRICTION;
   NUCLEAR-ENVELOPE; FREE-RADICALS; AGING RATS; MRL MICE
AB Congeneic pairs of MRL/lpr and MRL/++(+/+) mice differ in incidence of autoantibodies, lymphoproliferative disease and survival, characteristics that are linked to immunological abnormalities. MRL/lpr mice have a significantly shorter life span compared to +/+ mice. Because a weak antioxidant defense and an increased generation of free radicals are generally implicated in the severity of many autoimmune diseases, the present study was undertaken to compare the influence of genotype on lipid composition, lipid peroxidation and expression of mRNA, and activity of antioxidant enzymes such as catalase (CAT), glutathione peroxidase (GSH-Px) and superoxide dismutase (SOD) in the livers and kidneys of these mice. The expression of SOD, GSH-Px and CAT mRNAs was significantly higher (P < 0.05) in the livers of +/+ mice, while in the kidneys only SOD expression was found significantly higher in +/+ mice when compared to MRL/lpr mice. Further, the activity of cytosolic SOD and GSH-Px was also found significantly higher (P < 0.001) in the livers of +/+ mice. Both livers and kidneys of MRL/lpr mice exhibited significantly higher levels of arachidonic acid (20:4(n-6)), significantly higher generation of thiobarbituric acid reactive substances (TBARS) and higher estimated peroxidation index than the +/+ mice. In addition, the MRL/lpr mice had higher levels of serum anti-cardiolipin antibodies. In summary, the results from the present study indicate that besides several immune-related abnormalities, the MRL/lpr mice may exhibit their inability to cope with oxidative stress due to a poor antioxidant defense system. This weak defense system is revealed by lower mRNA expression of antioxidant enzymes, weak SOD and GSH-Px enzyme activities, and an increased level of 20:4(n-6) in liver lipids, which in turn may increase generation of free radicals in the livers and kidneys, thus making the MRL/lpr mice more susceptible to autoimmune disease than the +/+ mice.
C1 UNIV TEXAS, HLTH SCI CTR, DEPT MED, SAN ANTONIO, TX 78284 USA.
   UNIV TEXAS, HLTH SCI CTR, DEPT PHYSIOL, SAN ANTONIO, TX 78284 USA.
   UNIV TEXAS, HLTH SCI CTR, DEPT MICROBIOL, SAN ANTONIO, TX 78284 USA.
C3 University of Texas System; University of Texas Health Science Center at
   San Antonio; University of Texas System; University of Texas Health
   Science Center at San Antonio; University of Texas System; University of
   Texas Health Science Center at San Antonio
FU NIA NIH HHS [R01-AG-03417, AG-10531] Funding Source: Medline
CR ALLEN RG, 1992, J NUTR, V122, P631, DOI 10.1093/jn/122.suppl_3.631
   [Anonymous], 1991, CURRENT PROTOCOLS IM
   [Anonymous], [No title captured]
   [Anonymous], 2012, FREE RADICALS BIOL
   CAMERON RG, 1986, CANCER LETT, V30, P175, DOI 10.1016/0304-3835(86)90086-8
   CAND F, 1989, FREE RADICAL BIO MED, V7, P59, DOI 10.1016/0891-5849(89)90101-9
   CHEN LC, 1993, LIPIDS, V28, P657, DOI 10.1007/BF02536062
   CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999
   COHEN PL, 1992, IMMUNOL TODAY, V13, P427, DOI 10.1016/0167-5699(92)90066-G
   DANGVU AP, 1987, J IMMUNOL, V138, P1757
   DAS UN, 1991, PROSTAG LEUKOTR ESS, V44, P201, DOI 10.1016/0952-3278(91)90018-Z
   DAVIDSON WF, 1984, J IMMUNOL, V133, P1048
   FERNANDES G, 1990, P SOC EXP BIOL MED, V193, P16, DOI 10.3181/00379727-193-42983
   FERNANDES G, 1984, P NATL ACAD SCI-BIOL, V81, P6144, DOI 10.1073/pnas.81.19.6144
   FERNANDES G, 1989, HEALTH EFFECTS OF FISH AND FISH OILS, P409
   FLOHE L, 1984, METHOD ENZYMOL, V105, P114
   FOEGH ML, 1990, JPEN-PARENTER ENTER, V14, pS218, DOI 10.1177/014860719001400512
   HAMBERG M, 1973, P NATL ACAD SCI USA, V70, P899, DOI 10.1073/pnas.70.3.899
   Harman D, 1987, MODERN BIOL THEORIES, P81
   HENDRICKS LC, 1988, FREE RADICAL BIO MED, V5, P145, DOI 10.1016/0891-5849(88)90077-9
   HUANG CJ, 1993, J NUTR, V123, P803, DOI 10.1093/jn/123.5.803
   HUGHES GRV, 1986, J RHEUMATOL, V13, P486
   KARMOCHKINE M, 1992, CLIN EXP RHEUMATOL, V10, P603
   KORC M, 1992, J CLIN INVEST, V90, P1352, DOI 10.1172/JCI116001
   KORELUK RG, 1984, J BIOL CHEM, V259, P13819
   LAGANIERE S, 1987, BIOCHEM BIOPH RES CO, V145, P1185, DOI 10.1016/0006-291X(87)91562-2
   LAGANIERE S, 1989, MECH AGEING DEV, V48, P221, DOI 10.1016/0047-6374(89)90084-5
   Lands W E, 1987, Adv Prostaglandin Thromboxane Leukot Res, V17B, P876
   LANDS WEM, 1985, RHEUMATOLOGY, P47
   LANDS WEM, 1988, LIPID PEROXIDATION B, P155
   LIEMANHURWITZ J, 1982, P NATL ACAD SCI-BIOL, V79, P2808, DOI 10.1073/pnas.79.9.2808
   LOVE PE, 1990, ANN INTERN MED, V112, P682, DOI 10.7326/0003-4819-112-9-682
   MARK DA, 1984, AM J PATHOL, V117, P110
   MCCORD JM, 1969, J BIOL CHEM, V244, P6049
   Mead JF, 1976, FREE RADICAL BIO MED, V1, P51
   MOTE PL, 1990, MECH AGEING DEV, V53, P101, DOI 10.1016/0047-6374(90)90038-H
   MULLENBACH GT, 1987, NUCLEIC ACIDS RES, V15, P13
   PENGO V, 1987, BLOOD, V70, P69
   PISETSKY DS, 1980, J EXP MED, V152, P1302, DOI 10.1084/jem.152.5.1302
   PONNAPPAN U, 1985, MOL IMMUNOL, V22, P1407, DOI 10.1016/0161-5890(85)90064-1
   RAO G, 1990, MECH AGEING DEV, V53, P49, DOI 10.1016/0047-6374(90)90033-C
   ROBINSON DR, 1986, ARTHRITIS RHEUM, V29, P539, DOI 10.1002/art.1780290412
   ROKUTAN K, 1988, INT ARCH ALLER A IMM, V87, P113, DOI 10.1159/000234660
   SEMSEI I, 1989, BIOCHEM BIOPH RES CO, V164, P620, DOI 10.1016/0006-291X(89)91505-2
   SMITH HR, 1983, ANNU REV IMMUNOL, V1, P175, DOI 10.1146/annurev.iy.01.040183.001135
   SPALLHOLZ J E, 1989, FASEB Journal, V3, pA778
   SPALLHOLZ JE, 1990, ADV EXP MED BIOL, V262, P145
   THEOFILOPOULOS AN, 1981, IMMUNOL REV, V55, P179, DOI 10.1111/j.1600-065X.1981.tb00343.x
   TIWARI RK, 1988, IMMUNOL LETT, V17, P151, DOI 10.1016/0165-2478(88)90084-3
   TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485
   VENKATRAMAN JT, 1991, LIPIDS, V26, P198, DOI 10.1007/BF02543971
   VENKATRAMAN JT, 1988, BIOCHIM BIOPHYS ACTA, V940, P33, DOI 10.1016/0005-2736(88)90005-3
   VENKATRAMAN JT, 1991, NUTRITION IMMUNOLOGY, P309
   WARSO MA, 1985, J CLIN INVEST, V75, P667, DOI 10.1172/JCI111745
   WITTING LA, 1964, J NUTR, V82, P19, DOI 10.1093/jn/82.1.19
   YU BP, 1992, MECH AGEING DEV, V65, P17, DOI 10.1016/0047-6374(92)90123-U
NR 56
TC 23
Z9 24
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0005-2760
J9 BBA-LIPID LIPID MET
JI Biochim. Biophys. Acta-Lipids Lipid Metab.
PD JUL 14
PY 1994
VL 1213
IS 2
BP 167
EP 175
DI 10.1016/0005-2760(94)90023-X
PG 9
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA NY403
UT WOS:A1994NY40300007
PM 8025127
DA 2024-02-19
ER

PT J
AU Prins, K
   Huisman, M
   McLuskey, A
   Mies, R
   Karels, B
   Delhanty, PJD
   Visser, JA
AF Prins, Karina
   Huisman, Martin
   McLuskey, Anke
   Mies, Rosinda
   Karels, Bas
   Delhanty, Patric J. D.
   Visser, Jenny A.
TI Ghrelin deficiency sex-dependently affects food intake, locomotor
   activity, and adipose and hepatic gene expression in a binge-eating
   mouse model
SO AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM
LA English
DT Article
DE binge eating; food intake; ghrelin; locomotor activity; sex differences
ID DES-ACYL GHRELIN; GLUCAGON-LIKE PEPTIDE-1; OBESE WOMEN; CIRCULATING
   GHRELIN; INSULIN SENSITIVITY; LIMITED ACCESS; MICE; BEHAVIOR; HORMONE;
   HOMEOSTASIS
AB Binge-eating disorder is the most prevalent eating disorder diagnosed, affecting three times more women than men. Ghrelin stimulates appetite and reward signaling, and loss of its receptor reduces binge-eating behavior in male mice. Here, we examined the influence of ghrelin itself on binge-eating behavior in both male and female mice. Five-wk-old wild-type (WT) and ghrelin-deficient (Ghrl(-/-)) mice were housed individually in indirect calorimetry cages for 9 wks. Binge-like eating was induced by giving mice ad libitum chow, but time-restricted access to a Western-style diet (WD; 2 h access, 3 days/wk) in the light phase (BE); control groups received ad libitum chow (CO), or ad libitum access to both diets (CW). All groups of BE mice showed binge-eating behavior, eating up to 60% of their 24-h intake during the WD access period. Subsequent dark phase chow intake was decreased in Ghrl(-/-) mice and remained decreased in Ghrl females on nonbinge days. Also, nonbinge day locomotor activity was lower in Ghrl(-/-) than in WT BE females. Upon euthanasia, Ghrl(-/-) BE mice weighed less and had a lower lean body mass percentage than WT BE mice. In BE and CW groups, ghrelin and sex altered the expression of genes involved in lipid processing, thermogenesis, and aging in white adipose tissue and livers. We conclude that, although ghrelin deficiency does not hamper the development of binge-like eating, it sex-dependently alters food intake timing, locomotor activity, and metabolism. These results add to the growing body of evidence that ghrelin signaling is sexually dimorphic.
   NEW & NOTEWORTHY Ghrelin, a peptide hormone secreted from the gut, is involved in hunger and reward signaling, which are altered in binge-eating disorder. Although sex differences have been described in both binge-eating and ghrelin signaling, this interaction has not been fully elucidated. Here, we show that ghrelin deficiency affects the behavior and metabolism of mice in a binge-like eating paradigm, and that the sex of the mice impacts the magnitude and direction of these effects.
C1 [Prins, Karina; Huisman, Martin; McLuskey, Anke; Mies, Rosinda; Karels, Bas; Delhanty, Patric J. D.; Visser, Jenny A.] Univ Med Ctr, Erasmus MC, Dept Internal Med, Rotterdam, Netherlands.
C3 Erasmus University Rotterdam; Erasmus MC
RP Visser, JA (corresponding author), Univ Med Ctr, Erasmus MC, Dept Internal Med, Rotterdam, Netherlands.
EM j.visser@erasmusmc.nl
RI Visser, Jenny A./F-8156-2011
OI Prins, Karina/0000-0002-4194-3238; Delhanty, Patric/0000-0002-0828-3143
FU departmental laboratory funds
FX This work was supported by departmental laboratory funds (to K. Prins,
   M. Huisman, A. McLuskey, R. Mies, B. Karels, P. J. D. Delhanty, and J.
   A. Visser).
CR Abizaid A, 2006, J CLIN INVEST, V116, P3229, DOI 10.1172/JCI29867
   APA. American Psychiatric Association, 2013, Diagnostic and statistical manual of mental disorders, VFifth Edition, DOI 10.1176/appi.books.9780890425596.744053
   Ayala JE, 2010, DIS MODEL MECH, V3, P525, DOI 10.1242/dmm.006239
   Babbs RK, 2011, PHYSIOL BEHAV, V103, P508, DOI 10.1016/j.physbeh.2011.03.029
   Bake T, 2017, J NEUROENDOCRINOL, V29, DOI 10.1111/jne.12463
   Bake T, 2014, APPETITE, V77, P60, DOI 10.1016/j.appet.2014.02.020
   Balodis IM, 2015, CNS SPECTRUMS, V20, P557, DOI 10.1017/S1092852915000814
   Blum ID, 2009, NEUROSCIENCE, V164, P351, DOI 10.1016/j.neuroscience.2009.08.009
   Cabral A, 2014, J NEUROENDOCRINOL, V26, P542, DOI 10.1111/jne.12168
   Clegg DJ, 2007, DIABETES, V56, P1051, DOI 10.2337/db06-0015
   Cornejo MP, 2021, FEBS J, V288, P7213, DOI 10.1111/febs.15718
   Corwin RL, 1998, PHYSIOL BEHAV, V65, P545, DOI 10.1016/S0031-9384(98)00201-7
   Czyzyk TA, 2010, OBESITY, V18, P1710, DOI 10.1038/oby.2010.46
   Delhanty PJD, 2014, FRONT HORM RES, V42, P163, DOI 10.1159/000358345
   Delhanty PJD, 2013, FASEB J, V27, P1690, DOI 10.1096/fj.12-221143
   Egecioglu E, 2010, ADDICT BIOL, V15, P304, DOI 10.1111/j.1369-1600.2010.00216.x
   Engelstoft MS, 2016, TRENDS ENDOCRIN MET, V27, P665, DOI 10.1016/j.tem.2016.07.001
   Erskine HE, 2018, CURR OPIN PSYCHIATR, V31, P462, DOI 10.1097/YCO.0000000000000449
   Farkas I, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078178
   Feillet C, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0150665
   Fernandez G, 2018, ENDOCRINOLOGY, V159, P1021, DOI 10.1210/en.2017-03101
   Frazao R, 2014, AM J PHYSIOL-ENDOC M, V306, pE606, DOI 10.1152/ajpendo.00211.2013
   Gambineri A, 2003, J ENDOCRINOL INVEST, V26, P629, DOI 10.1007/BF03347020
   Geliebter A, 2005, J NUTR, V135, P1326, DOI 10.1093/jn/135.5.1326
   Geliebter A, 2008, PHYSIOL BEHAV, V94, P696, DOI 10.1016/j.physbeh.2008.04.013
   Gray SM, 2019, J NEUROENDOCRINOL, V31, DOI 10.1111/jne.12705
   Grefhorst A, 2018, J ENDOCRINOL, V238, P91, DOI 10.1530/JOE-18-0076
   Hernandez D, 2019, OBESITY, V27, P629, DOI 10.1002/oby.22431
   Iceta S, 2019, DIABETES METAB, V45, P160, DOI 10.1016/j.diabet.2018.01.006
   Jerlhag E, 2006, ADDICT BIOL, V11, P45, DOI 10.1111/j.1369-1600.2006.00002.x
   Kaikaew K, 2019, ENDOCRINOLOGY, V160, P2367, DOI 10.1210/en.2019-00194
   Kassambara A., 2020, PIPE FRIENDLY FRAMEW, DOI DOI 10.1021/ES9003894
   Kellokoski E, 2005, J CLIN ENDOCR METAB, V90, P2954, DOI 10.1210/jc.2004-2016
   Kern A, 2015, CELL, V163, P1176, DOI 10.1016/j.cell.2015.10.062
   Kern A, 2012, NEURON, V73, P317, DOI 10.1016/j.neuron.2011.10.038
   King SJ, 2016, NEUROSCIENCE, V319, P233, DOI 10.1016/j.neuroscience.2016.01.004
   Klump KL, 2013, INT J EAT DISORDER, V46, P729, DOI 10.1002/eat.22139
   König C, 2020, FRONT NEUROSCI-SWITZ, V14, DOI 10.3389/fnins.2020.00531
   Kojima M, 1999, NATURE, V402, P656, DOI 10.1038/45230
   Lamont EW, 2014, EUR J NEUROSCI, V39, P207, DOI 10.1111/ejn.12390
   Leonie E, 2012, ENDOCRINOLOGY, V153, P2861, DOI 10.1210/en.2011-1754
   LeSauter J, 2009, P NATL ACAD SCI USA, V106, P13582, DOI 10.1073/pnas.0906426106
   Li HT, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-017-02677-9
   Lin LG, 2016, AGING-US, V8, P178, DOI 10.18632/aging.100888
   Lin LG, 2011, AGING CELL, V10, P996, DOI 10.1111/j.1474-9726.2011.00740.x
   Longo KA, 2008, REGUL PEPTIDES, V150, P55, DOI 10.1016/j.regpep.2008.03.011
   Ma XJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016391
   Manfredi L, 2021, NUTRIENTS, V13, DOI 10.3390/nu13030848
   Blanco AM, 2017, HORM BEHAV, V93, P62, DOI 10.1016/j.yhbeh.2017.05.004
   Mifune H, 2020, J ENDOCRINOL, V244, P123, DOI 10.1530/JOE-19-0213
   Monteleone P, 2005, PSYCHONEUROENDOCRINO, V30, P243, DOI 10.1016/j.psyneuen.2004.07.004
   Moran LJ, 2004, J CLIN ENDOCR METAB, V89, P3337, DOI 10.1210/jc.2003-031583
   Munsch S, 2009, PHYSIOL BEHAV, V97, P14, DOI 10.1016/j.physbeh.2009.01.015
   Novelle MG, 2019, MOL CELL ENDOCRINOL, V497, DOI 10.1016/j.mce.2019.110508
   Pagotto U, 2003, J CLIN ENDOCR METAB, V88, P4139, DOI 10.1210/jc.2003-030554
   Cornejo MP, 2019, J NEUROENDOCRINOL, V31, DOI 10.1111/jne.12785
   Paulo RC, 2008, J CLIN ENDOCR METAB, V93, P4440, DOI 10.1210/jc.2008-0783
   Perello M, 2019, J NEUROENDOCRINOL, V31, DOI 10.1111/jne.12677
   Pfluger PT, 2008, AM J PHYSIOL-GASTR L, V294, pG610, DOI 10.1152/ajpgi.00321.2007
   Reynolds TH, 2019, PHYSIOL REP, V7, DOI 10.14814/phy2.13995
   Rhea EM, 2018, MOL METAB, V18, P88, DOI 10.1016/j.molmet.2018.09.007
   Ros-Simó C, 2012, PHARMACOL BIOCHEM BE, V102, P434, DOI 10.1016/j.pbb.2012.06.001
   Santomauro DF, 2021, LANCET PSYCHIAT, V8, P320, DOI 10.1016/S2215-0366(21)00040-7
   Schipper L, 2018, OBES REV, V19, P614, DOI 10.1111/obr.12663
   Silver Z, 2021, J ENDOCRINOL, V250, P37, DOI 10.1530/JOE-20-0579
   Sinclair EB, 2017, PHYSIOL BEHAV, V176, P165, DOI 10.1016/j.physbeh.2017.03.042
   Solmi M, 2022, MOL PSYCHIATR, V27, P281, DOI 10.1038/s41380-021-01161-7
   Spierling SR, 2018, PHYSIOL BEHAV, V192, P3, DOI 10.1016/j.physbeh.2018.04.001
   Sun Y, 2006, CELL METAB, V3, P379, DOI 10.1016/j.cmet.2006.04.004
   Tschöp M, 2000, NATURE, V407, P908, DOI 10.1038/35038090
   Udo T, 2019, INT J EAT DISORDER, V52, P42, DOI 10.1002/eat.23004
   Udo T, 2018, BIOL PSYCHIAT, V84, P345, DOI 10.1016/j.biopsych.2018.03.014
   Uriarte M, 2021, MOL CELL ENDOCRINOL, V538, DOI 10.1016/j.mce.2021.111449
   Valdivia S, 2015, PSYCHONEUROENDOCRINO, V60, P206, DOI 10.1016/j.psyneuen.2015.06.018
   Van Alsten SC, 2020, EUR EAT DISORD REV, V28, P709, DOI 10.1002/erv.2767
   van den Beukel JC, 2014, FASEB J, V28, P4857, DOI 10.1096/fj.14-254839
   WEIR JBD, 1949, J PHYSIOL-LONDON, V109, P1, DOI 10.1113/jphysiol.1949.sp004363
   Westerterp KR, 2017, EUR J CLIN NUTR, V71, P340, DOI 10.1038/ejcn.2016.237
   Williams RL, 2016, APPETITE, V101, P1, DOI 10.1016/j.appet.2016.02.153
   Wortley KE, 2004, P NATL ACAD SCI USA, V101, P8227, DOI 10.1073/pnas.0402763101
   Wortley KE, 2005, J CLIN INVEST, V115, P3573, DOI 10.1172/JCI26003
   Wren AM, 2000, ENDOCRINOLOGY, V141, P4325, DOI 10.1210/en.141.11.4325
   Yamada C, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22073763
   Yamada C, 2020, BRIT J PHARMACOL, V177, P4666, DOI 10.1111/bph.15219
   Yamada C, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0140094
   Zhang WD, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-75621-5
   Zigman JM, 2005, J CLIN INVEST, V115, P3564, DOI 10.1172/JCI26002
NR 87
TC 3
Z9 3
U1 2
U2 4
PU AMER PHYSIOLOGICAL SOC
PI Rockville
PA 6120 Executive Blvd, Suite 600, Rockville, MD, UNITED STATES
SN 0193-1849
EI 1522-1555
J9 AM J PHYSIOL-ENDOC M
JI Am. J. Physiol.-Endocrinol. Metab.
PD JUN
PY 2022
VL 322
IS 6
BP E494
EP E507
DI 10.1152/ajpendo.00432.2021
PG 14
WC Endocrinology & Metabolism; Physiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Endocrinology & Metabolism; Physiology
GA 1W6AX
UT WOS:000806856000003
PM 35403437
DA 2024-02-19
ER

PT J
AU Huber, HF
   Kuo, AH
   Li, C
   Jenkins, SL
   Gerow, KG
   Clarke, GD
   Nathanielsz, PW
AF Huber, Hillary F.
   Kuo, Anderson H.
   Li, Cun
   Jenkins, Susan L.
   Gerow, Kenneth G.
   Clarke, Geoffrey D.
   Nathanielsz, Peter W.
TI Antenatal Synthetic Glucocorticoid Exposure at Human Therapeutic
   Equivalent Doses Predisposes Middle-Age Male Offspring Baboons to an
   Obese Phenotype That Emerges With Aging
SO REPRODUCTIVE SCIENCES
LA English
DT Article
DE developmental programming; skinfold; betamethasone; nonhuman primate;
   metabolic syndrome; adiposity; biomarkers
ID BODY-MASS INDEX; DISEASE RISK-FACTORS; WAIST CIRCUMFERENCE; RECEPTOR
   EXPRESSION; SKINFOLD THICKNESS; ADULT ADIPOSITY; FETAL ORIGINS; HIP
   RATIO; GROWTH; CORTICOSTEROIDS
AB Introduction: Women threatening premature delivery receive synthetic glucocorticoids (sGC) to accelerate fetal lung maturation, reducing neonatal mortality and morbidity. Few investigations have explored potential long-term offspring side effects. We previously reported increased pericardial fat and liver lipids in 10-year-old (human equivalent 40 years) male baboons exposed to 3 antenatal sGC courses. We hypothesized middle-aged sGC male offspring show obesity-related morphometric changes. Methods: Pregnant baboons received courses of 2 betamethasone injections (175 mu g center dot kg(-1)center dot d(-1) intramuscular) at 0.6, 0.64, and 0.68 gestation. At 10 to 12.5 years, we measured morphometrics and serum lipids in 5 sGC-exposed males and 10 age-matched controls. We determined whether morphometric parameters predicted amount of pericardial fat or lipids. Life-course serum lipids were measured in 25 males (7-23 years) providing normal regression formulas to compare sGC baboons' lipid biological and chronological age. Results: Birth weights were similar. When studied, sGC-exposed males showed a steeper weight increase from 8 to 12 years and had increased waist and hip circumferences, neck and triceps skinfolds, and total and low-density lipoprotein cholesterol. Triceps skinfold correlated with apical and midventricular pericardial fat thickness, hip and waist circumferences with insulin. Conclusions: Triceps skinfold and waist and hip circumferences are useful biomarkers for identifying individuals at risk for obesity and metabolic dysregulation following fetal sGC exposure. Prenatal sGC exposure predisposes male offspring to internal adiposity, greater body size, and increased serum lipids. Results provide further evidence for developmental programming by fetal sGC exposure and call attention to potential emergence of adverse life-course effects.
C1 [Huber, Hillary F.; Li, Cun; Jenkins, Susan L.; Nathanielsz, Peter W.] Univ Wyoming, Anim Sci, Laramie, WY 82071 USA.
   [Kuo, Anderson H.; Clarke, Geoffrey D.] Univ Texas Hlth Sci Ctr San Antonio, Radiol, San Antonio, TX 78229 USA.
   [Li, Cun; Clarke, Geoffrey D.; Nathanielsz, Peter W.] Southwest Natl Primate Res Ctr, San Antonio, TX USA.
   [Li, Cun; Clarke, Geoffrey D.; Nathanielsz, Peter W.] Texas Biomed Res Inst, San Antonio, TX 78245 USA.
   [Gerow, Kenneth G.] Univ Wyoming, Stat, Laramie, WY 82071 USA.
C3 University of Wyoming; University of Texas System; University of Texas
   Health Science Center at San Antonio; Texas Biomedical Research
   Institute; Texas Biomedical Research Institute; University of Wyoming
RP Nathanielsz, PW (corresponding author), Texas Biomed Res Inst, Texas Pregnancy & Life Course Hlth Res Ctr, Herff Bldg 13,POB 760549, San Antonio, TX 78245 USA.
EM peter.nathanielsz@uwyo.edu
OI Nathanielsz, Peter/0000-0001-8410-6280; Kuo,
   Anderson/0000-0002-5517-7984
FU Julio C. Palmaz Endowment for Excellence in Radiology Research; NIH
   [R24OD010916]
FX The author(s) disclosed receipt of the following financial support for
   the research, authorship, and/or publication of this article: This work
   was supported in part by the Julio C. Palmaz Endowment for Excellence in
   Radiology Research and NIH R24OD010916.
CR [Anonymous], 2016, Obstet Gynecol, V128, P940, DOI 10.1097/AOG.0000000000001706
   Antonow-Schlorke I, 2003, J PHYSIOL-LONDON, V547, P117, DOI 10.1113/jphysiol.2002.025700
   Asztalos EV, 2013, JAMA PEDIATR, V167, P1102, DOI 10.1001/jamapediatrics.2013.2764
   Audette MC, 2014, J CLIN ENDOCR METAB, V99, pE2226, DOI 10.1210/jc.2014-2157
   Berry MJ, 2013, ACTA OBSTET GYN SCAN, V92, P862, DOI 10.1111/aogs.12149
   Blanco CL, 2014, J ENDOCRINOL, V221, P253, DOI 10.1530/JOE-13-0504
   Bronikowski AM, 2002, P NATL ACAD SCI USA, V99, P9591, DOI 10.1073/pnas.142675599
   Cianfarani S, 2003, MED HYPOTHESES, V61, P401, DOI 10.1016/S0306-9877(03)00182-8
   Cleasby ME, 2003, EUR J ENDOCRINOL, V148, P129, DOI 10.1530/eje.0.1480129
   Coelho AM., 1985, Nonhuman primate models for human growth and development, P125
   Crudo A, 2013, ENDOCRINOLOGY, V154, P4170, DOI 10.1210/en.2013-1484
   Dahlgren J, 2001, AM J PHYSIOL-ENDOC M, V281, pE326, DOI 10.1152/ajpendo.2001.281.2.E326
   Dalton M, 2003, J INTERN MED, V254, P555, DOI 10.1111/j.1365-2796.2003.01229.x
   Dalziel SR, 2005, LANCET, V365, P1856, DOI 10.1016/S0140-6736(05)66617-2
   de Vries A, 2007, J CLIN INVEST, V117, P1058, DOI 10.1172/JCI30982
   Drake AJ, 2010, ENDOCRINOLOGY, V151, P1581, DOI 10.1210/en.2009-1088
   Dunn E, 2010, J PHYSIOL-LONDON, V588, P887, DOI 10.1113/jphysiol.2009.182139
   DURNIN JVG, 1967, BRIT J NUTR, V21, P681, DOI 10.1079/BJN19670070
   DURNIN JVGA, 1974, BRIT J NUTR, V32, P77, DOI 10.1079/BJN19740060
   Flegal KM, 2002, JAMA-J AM MED ASSOC, V288, P1723, DOI 10.1001/jama.288.14.1723
   Fletcher AJW, 2002, J PHYSIOL-LONDON, V545, P649, DOI 10.1113/jphysiol.2001.015693
   Freedman DS, 2005, PEDIATRICS, V115, P22, DOI 10.1542/peds.2004-0220
   Gyamfi-Bannerman C, 2016, NEW ENGL J MED, V374, P1311, DOI 10.1056/NEJMoa1516783
   Higham JP, 2008, HORM BEHAV, V53, P452, DOI 10.1016/j.yhbeh.2007.11.019
   Kapoor A, 2006, J PHYSIOL-LONDON, V572, P31, DOI 10.1113/jphysiol.2006.105254
   Koenen SV, 2002, AM J OBSTET GYNECOL, V186, P812, DOI 10.1067/mob.2002.121654
   Kuo AH, 2018, J DEV ORIG HLTH DIS, V9, P137, DOI 10.1017/S2040174417000770
   Kuo AH, 2017, INT J OBESITY, V41, P1299, DOI 10.1038/ijo.2017.82
   Kuo AH, 2017, J PHYSIOL-LONDON, V595, P4245, DOI 10.1113/JP273928
   Kuo AH, 2017, J PHYSIOL-LONDON, V595, P1093, DOI 10.1113/JP272908
   Leigh Steven R., 2009, P57, DOI 10.1007/978-0-387-75991-3_4
   Long NM, 2013, AM J OBSTET GYNECOL, V209, DOI 10.1016/j.ajog.2013.05.051
   Long NM, 2012, AM J OBSTET GYNECOL, V207, DOI 10.1016/j.ajog.2012.06.024
   Luo ZC, 2006, MED HYPOTHESES, V66, P38, DOI 10.1016/j.mehy.2005.08.020
   Luo ZC, 2010, WORLD J DIABETES, V1, P89, DOI 10.4239/wjd.v1.i3.89
   MAHANEY MC, 1993, J MED PRIMATOL, V22, P415
   MERCADO AB, 1995, J CLIN ENDOCR METAB, V80, P2014, DOI 10.1210/jc.80.7.2014
   Murphy VE, 2002, J CLIN ENDOCR METAB, V87, P1660, DOI 10.1210/jc.87.4.1660
   Nooyens ACJ, 2007, AM J CLIN NUTR, V85, P1533, DOI 10.1093/ajcn/85.6.1533
   Nyirenda MJ, 1998, J CLIN INVEST, V101, P2174, DOI 10.1172/JCI1567
   Ogden Cynthia L, 2013, NCHS Data Brief, P1
   Plavcan JM, 2001, YEARB PHYS ANTHROPOL, V44, P25, DOI 10.1002/ajpa.10011
   Roberts D, 2006, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD004454.pub2, 10.1002/14651858.CD004454.pub3]
   Rodriguez JS, 2011, AM J OBSTET GYNECOL, V204, DOI 10.1016/j.ajog.2011.01.063
   Sarría A, 2001, ACTA PAEDIATR, V90, P387, DOI 10.1080/080352501750126195
   Saydah S, 2014, OBESITY, V22, P1888, DOI 10.1002/oby.20761
   Schlabritz-Loutsevitch NE, 2009, REPROD SCI, V16, P308, DOI 10.1177/1933719108325755
   Seckl JR, 2007, PROG BRAIN RES, V167, P17, DOI 10.1016/S0079-6123(07)67002-2
   Taylor RW, 2000, AM J CLIN NUTR, V72, P490
   Thompson D, 1999, ARCH INTERN MED, V159, P2177, DOI 10.1001/archinte.159.18.2177
   Wapner RJ, 2013, SEMIN PERINATOL, V37, P410, DOI 10.1053/j.semperi.2013.06.024
   WILLIAMSON DF, 1993, ANN INTERN MED, V119, P646, DOI 10.7326/0003-4819-119-7_Part_2-199310011-00004
   Zambrano E, 2013, NUTR REV, V71, pS42, DOI 10.1111/nure.12068
NR 53
TC 8
Z9 9
U1 0
U2 3
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1933-7191
EI 1933-7205
J9 REPROD SCI
JI Reprod. Sci.
PD MAY
PY 2019
VL 26
IS 5
BP 591
EP 599
DI 10.1177/1933719118778794
PG 9
WC Obstetrics & Gynecology; Reproductive Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Obstetrics & Gynecology; Reproductive Biology
GA HZ5YB
UT WOS:000468927500003
PM 29871548
OA Green Published
DA 2024-02-19
ER

PT J
AU Tanner, EM
   Bloom, MS
   Wu, Q
   Kannan, K
   Yucel, RM
   Shrestha, S
   Fitzgerald, EF
AF Tanner, Eva M.
   Bloom, Michael S.
   Wu, Qian
   Kannan, Kurunthachalam
   Yucel, Recai M.
   Shrestha, Srishti
   Fitzgerald, Edward F.
TI Occupational exposure to perfluoroalkyl substances and serum levels of
   perfluorooctanesulfonic acid (PFOS) and perfluorooctanoic acid (PFOA) in
   an aging population from upstate New York: a retrospective cohort study
SO INTERNATIONAL ARCHIVES OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH
LA English
DT Article
DE Perfluorooctanesulfonic acid (PFOS); Perfluorooctanoic acid (PFOA);
   Exposure assessment; Biomonitoring; Occupation
ID LIVER-FUNCTION; PERFLUORINATED CHEMICALS; THYROID-FUNCTION;
   NATIONAL-HEALTH; US POPULATION; WATER; ELIMINATION; SURFACTANTS;
   BIOMARKERS; SULFONATE
AB Perfluoroalkyl substances (PFASs) are environmentally persistent amphiphilic compounds. Exposure to two PFASs, perfluorooctanesulfonic acid (PFOS) and perfluorooctanoic acid (PFOA) is linked to specific occupations and industries. This study examines the contribution of past occupational PFAS exposure to serum PFOS and PFOA levels among 154 older adults in New York State.
   Serum PFOS and PFOA levels were compared to data from the National Health and Nutrition Examination Survey (NHANES). Potential occupational exposure to any PFAS was determined from work histories, reviewed by an industrial hygienist, and assessed in relation to current serum PFOS and PFOA levels using exposure probability, duration and cumulative exposure.
   We observed 25% higher serum PFOS and 80% higher PFOA levels in study participants compared to NHANES. No participants reported PFAS chemical manufacturing work, but n = 68 reported work in occupations and industries known to use PFASs. We found that participants with high cumulative workplace exposure had 34% higher serum PFOS levels compared to participants without occupational exposure, adjusted for age, sex and income. Serum PFOS levels were 26% higher for participants with longer occupational exposure durations. The probability of occupational PFAS exposure metric was not associated with serum PFOS. Serum PFOA was not associated with any measure of occupational exposure.
   Occupational exposure may contribute to total PFOS body burden in this study population, even among workers not directly involved in manufacturing PFASs. PFAS exposure assessments should evaluate the workplace as a potential source, even when workplace exposures are assumed to be low or moderate.
C1 [Tanner, Eva M.; Bloom, Michael S.; Kannan, Kurunthachalam; Fitzgerald, Edward F.] SUNY Albany, Sch Publ Hlth, Dept Environm Hlth Sci, One Univ Pl, Rensselaer, NY 12144 USA.
   [Bloom, Michael S.; Yucel, Recai M.; Shrestha, Srishti; Fitzgerald, Edward F.] SUNY Albany, Sch Publ Hlth, Dept Epidemiol & Biostat, One Univ Pl, Rensselaer, NY 12144 USA.
   [Wu, Qian; Kannan, Kurunthachalam] New York State Dept Hlth, Wadsworth Ctr, Div Environm Hlth Sci, Albany, NY 12201 USA.
C3 State University of New York (SUNY) System; State University of New York
   (SUNY) Albany; State University of New York (SUNY) System; State
   University of New York (SUNY) Albany; Wadsworth Center; State University
   of New York (SUNY) System
RP Fitzgerald, EF (corresponding author), SUNY Albany, Sch Publ Hlth, Dept Environm Hlth Sci, One Univ Pl, Rensselaer, NY 12144 USA.; Fitzgerald, EF (corresponding author), SUNY Albany, Sch Publ Hlth, Dept Epidemiol & Biostat, One Univ Pl, Rensselaer, NY 12144 USA.
EM efitzgerald@albany.edu
RI Bloom, Michael S/A-5743-2010; Shrestha, Srishti/ABF-6248-2021
OI Kannan, Kurunthachalam/0000-0002-1926-7456; Bloom,
   Michael/0000-0002-0028-5494
FU National Institute on Aging [R15/AG0333700A1]; Agency for Toxic
   Substances and Disease Registry [H75/ATH298312]
FX This study was funded by grants from the National Institute on Aging
   (Grant #R15/AG0333700A1) and the Agency for Toxic Substances and Disease
   Registry (Grant #H75/ATH298312).
CR [Anonymous], TOX PROF PE IN PRESS
   [Anonymous], [No title captured]
   [Anonymous], NAT HLTH NUTR EX SUR
   Apel P, 2017, INT J HYG ENVIR HEAL, V220, P152, DOI 10.1016/j.ijheh.2016.09.007
   Bartell SM, 2010, ENVIRON HEALTH PERSP, V118, P222, DOI 10.1289/ehp.0901252
   Benbrahim-Tallaa L, 2014, LANCET ONCOL, V15, P924, DOI 10.1016/S1470-2045(14)70316-X
   Buck Robert C., 2011, Integrated Environmental Assessment and Management, V7, P513, DOI 10.1002/ieam.258
   Calafat AM, 2007, ENVIRON SCI TECHNOL, V41, P2237, DOI 10.1021/es062686m
   Darrow LA, 2016, ENVIRON HEALTH PERSP, V124, P1227, DOI 10.1289/ehp.1510391
   Dobraca D, 2015, J OCCUP ENVIRON MED, V57, P88, DOI 10.1097/JOM.0000000000000307
   Emmett EA, 2006, J OCCUP ENVIRON MED, V48, P759, DOI 10.1097/01.jom.0000232486.07658.74
   Fitz-Simon N, 2013, EPIDEMIOLOGY, V24, P569, DOI 10.1097/EDE.0b013e31829443ee
   Fitzgerald EF, 2008, ENVIRON HEALTH PERSP, V116, P209, DOI 10.1289/ehp.10432
   Fraser AJ, 2013, ENVIRON INT, V60, P128, DOI 10.1016/j.envint.2013.08.012
   Fromme H, 2009, INT J HYG ENVIR HEAL, V212, P239, DOI 10.1016/j.ijheh.2008.04.007
   Gallo V, 2012, ENVIRON HEALTH PERSP, V120, P655, DOI 10.1289/ehp.1104436
   Gleason JA, 2015, ENVIRON RES, V136, P8, DOI 10.1016/j.envres.2014.10.004
   Greenland S, 1999, EPIDEMIOLOGY, V10, P37, DOI 10.1097/00001648-199901000-00008
   Hölzer J, 2008, ENVIRON HEALTH PERSP, V116, P651, DOI 10.1289/ehp.11064
   Horton NJ, 2007, AM STAT, V61, P79, DOI 10.1198/000313007X172556
   Hu XC, 2016, ENV SCI TEC IN PRESS
   Kannan K, 2004, ENVIRON SCI TECHNOL, V38, P4489, DOI 10.1021/es0493446
   Kato K, 2011, ENVIRON SCI TECHNOL, V45, P8037, DOI 10.1021/es1043613
   Kissa E., 2001, FLUORINATED SURFACTA
   Lindstrom AB, 2011, ENVIRON SCI TECHNOL, V45, P8015, DOI 10.1021/es1039425
   Liu XY, 2014, CHEMOSPHERE, V98, P51, DOI 10.1016/j.chemosphere.2013.10.001
   M Company, 1999, FLUOR US DISTR REL O
   Melzer D, 2010, ENVIRON HEALTH PERSP, V118, P686, DOI 10.1289/ehp.0901584
   Minnesota Department of Health, 2012, PUBL HLTH ASS PERFL
   Olsen GW, 2007, ENVIRON HEALTH PERSP, V115, P1298, DOI 10.1289/ehp.10009
   Olsen GW, 2012, ENVIRON SCI TECHNOL, V46, P6330, DOI 10.1021/es300604p
   Olsen GW, 2003, AIHA J-J SCI OCCUP E, V64, P651, DOI 10.1080/15428110308984859
   Rotander A, 2015, ENVIRON SCI TECHNOL, V49, P2434, DOI 10.1021/es503653n
   Schisterman EF, 2006, AM J EPIDEMIOL, V163, P374, DOI 10.1093/aje/kwj039
   Scopp TS, 2003, 65 US DEP COMM US CE
   Shrestha S, 2015, ENVIRON INT, V75, P206, DOI 10.1016/j.envint.2014.11.018
   Sinclair E, 2006, ARCH ENVIRON CON TOX, V50, P398, DOI 10.1007/s00244-005-1188-z
   Tao L, 2008, ENVIRON SCI TECHNOL, V42, P3472, DOI 10.1021/es8000079
   Toms LML, 2014, ENVIRON INT, V71, P74, DOI 10.1016/j.envint.2014.05.019
   USEPA, 2016, Fed. Reg, V81
   Vestergren R, 2009, ENVIRON SCI TECHNOL, V43, P5565, DOI 10.1021/es900228k
   Wen LL, 2013, J CLIN ENDOCR METAB, V98, pE1456, DOI 10.1210/jc.2013-1282
   Wong F, 2014, ENVIRON SCI TECHNOL, V48, P8807, DOI 10.1021/es500796y
   Yamada A, 2014, SCI TOTAL ENVIRON, V491, P170, DOI 10.1016/j.scitotenv.2014.01.089
NR 44
TC 16
Z9 19
U1 7
U2 70
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0340-0131
EI 1432-1246
J9 INT ARCH OCC ENV HEA
JI Int. Arch. Occup. Environ. Health
PD FEB
PY 2018
VL 91
IS 2
BP 145
EP 154
DI 10.1007/s00420-017-1267-2
PG 10
WC Public, Environmental & Occupational Health
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Public, Environmental & Occupational Health
GA FU9VT
UT WOS:000424206000002
PM 29027000
DA 2024-02-19
ER

PT J
AU Aung, HL
   Bloch, M
   Vincent, T
   Mao, LM
   Brew, BJ
   Cysique, LA
AF Aung, Htein Linn
   Bloch, Mark
   Vincent, Trina
   Mao, Limin
   Brew, Bruce J.
   Cysique, Lucette A.
TI Low incidence of advanced neurological burden but high incidence of
   age-related conditions that are dementia risk factors in aging people
   living with HIV: a data-linkage 10-year follow-up study
SO JOURNAL OF NEUROVIROLOGY
LA English
DT Article; Early Access
DE HIV; Aging; Incidence; Comorbidities; Neurological disorders
ID INFECTED PATIENTS; NEUROCOGNITIVE IMPAIRMENT; ANTIRETROVIRAL THERAPY;
   CARDIOVASCULAR-DISEASE; MYOCARDIAL-INFARCTION; DRUG-INTERACTIONS;
   DATA-COLLECTION; OLDER; AIDS; COMORBIDITY
AB Although increasing research is focusing on age-related comorbidities (ARC) among people living with HIV (PLHIV), no studies have concomitantly assessed non-HIV age-related neurological disorders (e.g., Alzheimer's dementia). A total of 254 PLHIV and 69 HIV-negative controls completed baseline medical history and cognitive testing. ARC data were collected from medical records over the subsequent 9-10 years and included all types of strokes, all types of dementia, mild cognitive impairment, Parkinson's disease, motor neuron disease (grouped into a non-HIV age-related neurological category), cardiovascular disease, chronic kidney disease, chronic liver disease, chronic lung disease, non-AIDS cancers, osteoporosis, and diabetes. Kaplan-Meier curves assessed differences in the incident rates (per 1000 person year) of groups of ARC as defined above and combined ARC (i.e., development of any of the ARC) among younger (baseline age < 50) and older (baseline age & GE; 50) PLHIV and younger and older controls. Cox-proportional hazard models assessed the individual and interaction effects of HIV status and chronological age, in addition to a range of demographic and clinical variables including historical and baseline HIV brain involvement on the risk of developing combined ARC. Older PLHIV had a higher incidence of cardiovascular disease, osteoporosis, and combined ARC compared to other groups (p < 0.05). Incident rate of non-HIV age-related neurological disorders was 2.3 [0.93, 4.79] per 1000 person year. While this incident rate was higher in older PLHIV (5.37 [1.97, 11.92]) than older HIV-negative participants (3.58 [0.18-17.67]), this was not significant. In multivariate analyses, HIV status and chronological age, but not their interaction, and smoking were associated with higher risk of combined ARC (p < 0.05). In analyses focusing on PLHIV, older age and taking abacavir/efavirenz/atazanavir/darunavir containing antiretroviral treatments at the time of diagnosis were associated with greater ARC (p < 0.05). Non-HIV age-related neurological disorders are uncommon in older PLHIV, where the majority were < 70 years of age at the end of follow-up. However, the greater burden of ARC among older PLHIV, most of which are established dementia risk factors, warrants the establishment of commensurate prevention strategies and greater attention to neurocognitive screening.
C1 [Aung, Htein Linn; Brew, Bruce J.; Cysique, Lucette A.] St Vincents Hosp, Dept Neurol, Sydney, Australia.
   [Aung, Htein Linn; Brew, Bruce J.; Cysique, Lucette A.] St Vincents Hosp, Dept HIV Med, Sydney, Australia.
   [Aung, Htein Linn; Brew, Bruce J.; Cysique, Lucette A.] St Vincents Ctr Appl Med Res, Peter Duncan Neurosci Unit, Sydney, Australia.
   [Aung, Htein Linn; Bloch, Mark; Brew, Bruce J.] UNSW, Fac Med, Sydney, Australia.
   [Bloch, Mark; Vincent, Trina] Holdsworth House Med Practice, Sydney, Australia.
   [Mao, Limin] UNSW, Ctr Social Res Hlth, Sydney, Australia.
   [Brew, Bruce J.] Univ Notre Dame, Fac Med, Sydney, Australia.
   [Cysique, Lucette A.] Univ New South Wales, Sch Psychol, Matthews Bldg, Room 1012, 11 Bot St, Sydney, NSW 2052, Australia.
C3 NSW Health; St Vincents Hospital Sydney; NSW Health; St Vincents
   Hospital Sydney; University of New South Wales Sydney; University of New
   South Wales Sydney; The University of Notre Dame Australia; University
   of New South Wales Sydney
RP Cysique, LA (corresponding author), St Vincents Hosp, Dept Neurol, Sydney, Australia.; Cysique, LA (corresponding author), St Vincents Hosp, Dept HIV Med, Sydney, Australia.; Cysique, LA (corresponding author), St Vincents Ctr Appl Med Res, Peter Duncan Neurosci Unit, Sydney, Australia.; Cysique, LA (corresponding author), Univ New South Wales, Sch Psychol, Matthews Bldg, Room 1012, 11 Bot St, Sydney, NSW 2052, Australia.
EM lcysique@unsw.edu.au
RI Cysique, Lucette A./U-1357-2017; Mao, Limin/B-2049-2013; Brew, Bruce
   J/J-6513-2012; Aung, Htein Linn/ITU-7370-2023
OI Cysique, Lucette A./0000-0002-7711-6373; Mao, Limin/0000-0003-0995-5789;
   Aung, Htein Linn/0000-0002-8867-3220
FU CAUL; ViiV Healthcare Investigator-Sponsored Study (ISS) funding
   program; ViiV Healthcare
FX Open Access funding enabled and organized by CAUL and its Member
   Institutions. This study was partly contributed by a grant from ViiV
   Healthcare Investigator-Sponsored Study (ISS) funding program, and the
   baseline study was supported by an unrestricted study grant from ViiV
   Healthcare.
CR Aung HL, 2021, HIV MED, V22, P151, DOI 10.1111/hiv.12980
   Aung HL, 2022, AIDS, V10, P1097
   Aung HL, 2021, AIDS BEHAV, V25, P917, DOI 10.1007/s10461-020-03053-3
   Aung HL, 2019, EUR GERIATR MED, V10, P227, DOI 10.1007/s41999-019-00164-6
   Blanco JR, 2012, AIDS RES HUM RETROV, V28, P800, DOI [10.1089/aid.2011.0377, 10.1089/AID.2011.0377]
   Bloch M, 2016, CLIN INFECT DIS, V63, P687, DOI 10.1093/cid/ciw399
   Brooks JT, 2012, AM J PUBLIC HEALTH, V102, P1516, DOI 10.2105/AJPH.2012.300844
   Brown FW, 2011, J CLIN PSYCHIAT, V72, P1159, DOI 10.4088/JCP.11bk06921
   Calderón-Larrañaga A, 2019, J INTERN MED, V285, P255, DOI 10.1111/joim.12843
   Cardoso SW, 2013, BRAZ J INFECT DIS, V17, P464, DOI 10.1016/j.bjid.2012.11.007
   Carr A, 1998, AIDS, V12, pF51, DOI 10.1097/00002030-199807000-00003
   Chan Phillip, 2022, Top Antivir Med, V29, P423
   Chawla A, 2018, INFECT DIS THER, V7, P183, DOI 10.1007/s40121-018-0201-6
   Childs K, 2012, AIDS, V26, P253, DOI 10.1097/QAD.0b013e32834f324b
   Choi AI, 2011, AIDS, V25, P1289, DOI 10.1097/QAD.0b013e328347fa16
   Cohen RA, 2015, ALZHEIMERS RES THER, V7, DOI 10.1186/s13195-015-0123-4
   Cuzick J, 1999, IARC Sci Publ, P109
   Cysique LAJ, 2006, ARCH CLIN NEUROPSYCH, V21, P185, DOI 10.1016/j.acn.2005.07.011
   Cysique LA, 2019, J NEUROVIROL, V25, P710, DOI 10.1007/s13365-018-0706-5
   Cysique LA, 2010, AIDS, V24, P983, DOI 10.1097/QAD.0b013e32833336c8
   Dave JA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0144286
   Friis-Moller N, 2010, EUR J CARDIOV PREV R, V17, P491, DOI 10.1097/HJR.0b013e328336a150
   Goulet JL, 2007, CLIN INFECT DIS, V45, P1593, DOI 10.1086/523577
   Grant I, 2014, NEUROLOGY, V82, P2055, DOI 10.1212/WNL.0000000000000492
   Guaraldi G, 2017, AIDS, V31, pS129, DOI [10.1097/QAD.0000000000001478, 10.1097/qad.0000000000001478]
   Guaraldi G, 2014, AIDS REV, V16, P75
   Guaraldi G, 2011, CLIN INFECT DIS, V53, P1120, DOI 10.1093/cid/cir627
   Halloran MO, 2019, ANTIVIR THER, V24, P193, DOI 10.3851/IMP3293
   Hare DL, 2014, EUR HEART J, V35, P1365, DOI 10.1093/eurheartj/eht462
   Hasse B, 2011, CLIN INFECT DIS, V53, P1130, DOI 10.1093/cid/cir626
   Heaton RK, 2004, J INT NEUROPSYCH SOC, V10, P317, DOI 10.1017/S1355617704102130
   Hove-Skovsgaard M, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.583569
   Hughes CA, 2015, CAN MED ASSOC J, V187, P36, DOI 10.1503/cmaj.131626
   Justice Amy C, 2010, Curr HIV/AIDS Rep, V7, P69, DOI 10.1007/s11904-010-0041-9
   Kamminga J, 2017, J CLIN EXP NEUROPSYC, V39, P753, DOI 10.1080/13803395.2016.1263282
   Kong AM, 2019, AIDS PATIENT CARE ST, V33, P93, DOI 10.1089/apc.2018.0190
   Lam JO, 2021, AIDS, V35, P821, DOI 10.1097/QAD.0000000000002806
   Lang LD, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2016-011146
   Lau B, 2007, JAIDS-J ACQ IMM DEF, V44, P179, DOI 10.1097/01.qai.0000247229.68246.c5
   Li M, 2020, J AM HEART ASSOC, V9, DOI 10.1161/JAHA.120.016310
   Lloyd-Jones DM, 2004, AM J CARDIOL, V94, P20, DOI 10.1016/j.amjcard.2004.03.023
   Löppönen M, 2003, AGE AGEING, V32, P606, DOI 10.1093/ageing/afg097
   LOVIBOND PF, 1995, BEHAV RES THER, V33, P335, DOI 10.1016/0005-7967(94)00075-U
   Lundgren JD, 2008, HIV MED, V9, P72, DOI 10.1111/j.1468-1293.2007.00534.x
   Maciel RA, 2018, INT J INFECT DIS, V70, P30, DOI 10.1016/j.ijid.2018.02.009
   Marinescu CI, 2015, AIDS RES TREAT, V2015, DOI 10.1155/2015/106954
   Martinez-Sanz J, 2021, INT J ANTIMICROB AG
   Mocroft A, 2010, AIDS, V24, P1667, DOI 10.1097/QAD.0b013e328339fe53
   Montoya JL, 2018, DISSERT ABS INT B, P79
   Moore RD, 2008, CLIN INFECT DIS, V47, P1102, DOI 10.1086/592115
   Muya E, 2019, J INT ASSOC PRO AIDS, V18, DOI 10.1177/2325958219841908
   Negin Joel, 2012, AIDS, V26 Suppl 1, pS55
   Negredo E, 2017, BIOMED RES INT, V2017, DOI 10.1155/2017/5897298
   Nichols E, 2022, LANCET PUBLIC HEALTH, V7, pE105, DOI 10.1016/S2468-2667(21)00249-8
   Nightingale S, 2014, LANCET NEUROL, V13, P1139, DOI 10.1016/S1474-4422(14)70137-1
   Önen NF, 2010, HIV CLIN TRIALS, V11, P100, DOI 10.1310/hct1102-100
   Palella FJ, 2006, JAIDS-J ACQ IMM DEF, V43, P27, DOI 10.1097/01.qai.0000233310.90484.16
   Piccirillo JF, 2008, CRIT REV ONCOL HEMAT, V67, P124, DOI 10.1016/j.critrevonc.2008.01.013
   Rankgoane-Pono Goabaone, 2018, BMC Res Notes, V11, P90, DOI 10.1186/s13104-018-3144-9
   Rasmussen LD, 2015, CLIN INFECT DIS, V60, P1415, DOI 10.1093/cid/civ013
   Reisler RB, 2003, JAIDS-J ACQ IMM DEF, V34, P379, DOI 10.1097/00126334-200312010-00004
   Rourke SB, 2021, AIDS, V35, P63, DOI 10.1097/QAD.0000000000002709
   Ryom L, 2018, LANCET HIV, V5, pE291, DOI 10.1016/S2352-3018(18)30043-2
   Serrao R, 2019, INT J INFECT DIS, V79, P94, DOI 10.1016/j.ijid.2018.10.011
   Sheehan DV, 1998, J CLIN PSYCH
   Sheppard DP, 2017, J NEUROVIROL, V23, P492, DOI 10.1007/s13365-017-0523-2
   Thaler NS, 2015, NEUROPSYCHOLOGY, V29, P919, DOI 10.1037/neu0000191
   Tozzi V, 2005, AIDS RES HUM RETROV, V21, P706, DOI 10.1089/aid.2005.21.706
   Valcour V, 2011, J INT NEUROPSYCH SOC, V17, P190, DOI 10.1017/S1355617710001438
   Van Epps P, 2017, INFECT DIS CLIN N AM, V31, P791, DOI 10.1016/j.idc.2017.07.007
   Vivithanaporn P, 2010, NEUROLOGY, V75, P1150, DOI 10.1212/WNL.0b013e3181f4d5bb
   Wing EJ, 2016, INT J INFECT DIS, V53, P61, DOI 10.1016/j.ijid.2016.10.004
   Worm SW, 2010, J INFECT DIS, V201, P318, DOI 10.1086/649897
   Wright EJ, 2010, NEUROLOGY, V75, P864, DOI 10.1212/WNL.0b013e3181f11bd8
   Yang XY, 2021, AIDS, V35, pS39, DOI 10.1097/QAD.0000000000002736
NR 75
TC 0
Z9 0
U1 3
U2 5
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 1355-0284
EI 1538-2443
J9 J NEUROVIROL
JI J. Neurovirol.
PD 2023 APR
PY 2023
VL 29
IS 2
BP 141
EP 155
DI 10.1007/s13365-022-01104-0
EA DEC 2022
PG 15
WC Neurosciences; Virology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology; Virology
GA AV6L2
UT WOS:000898486100001
PM 36508059
OA Green Published, hybrid
DA 2024-02-19
ER

PT J
AU Lyssikatos, C
   Wang, ZY
   Liu, ZY
   Warden, SJ
   Bonewald, L
   Brotto, M
AF Lyssikatos, Charalampos
   Wang, Zhiying
   Liu, Ziyue
   Warden, Stuart J.
   Bonewald, Lynda
   Brotto, Marco
TI γ-Aminobutyric acids (GABA) and serum GABA/AABA (G/A) ratio as potential
   biomarkers of physical performance and aging
SO SCIENTIFIC REPORTS
LA English
DT Article
ID MUSCLE PERFORMANCE; EXERCISE; ASSOCIATION; HEALTH; SCALE; FAT
AB Declining physical performance with age and disease is an important indicator of declining health. Biomarkers that identify declining physical performance would be useful in predicting treatment outcomes and identifying potential therapeutics. gamma-aminobutyric acid (GABA), a muscle autocrine factor, is a potent inhibitor of muscle function and works as a muscle relaxant. L-alpha-aminobutyric acid (L-AABA) is a biomarker for malnutrition, liver damage, and depression. We sought to determine if GABA and L-AABA may be useful for predicting physical performance. Serum levels of GABA and L-AABA were quantified in 120 individuals divided by age, sex, and physical capacity into low, average, and high performer groups. Analyses explored correlations between serum levels and physical performance. Both GABA and the ratio of GABA/AABA (G/A), but not AABA, were highly positively associated with age (Pearson correlations r=0.35, p=0.0001 for GABA, r=0.31, p=0.0007 for G/A, n=120). GABA showed negative associations in the whole cohort with physical performance [fast gait speed, 6 min walk test (6MWT), PROMIS score, and SF36PFS raw score] and with subtotal and femoral neck bone mineral density. L-AABA was positively associated with usual gait speed, 6MWT, total SPPB score, and SF36PFS raw score in the total cohort of 120 human subjects, also with 6MWT and SF36PFS raw score in the 60 male subjects, but no associations were observed in the 60 females. As both GABA and L-AABA appear to be indicative of physical performance, but in opposite directions, we examined the G/A ratio. Unlike GABA, the G/A ratio showed a more distinct association with mobility tests such as total SPPB score, usual and fast gait speed, 6MWT, and SF36PFS raw score in the males, regardless of age and metabolic status. Serum G/A ratio could be potentially linked to physical performance in the male population. Our findings strongly suggest that GABA, L-AABA, and the G/A ratio in human serum may be useful markers for both age and physical function. These new biomarkers may significantly enhance the goal of identifying universal biomarkers to accurately predict physical performance and the beneficial effects of exercise training for older adults.
C1 [Lyssikatos, Charalampos; Liu, Ziyue; Warden, Stuart J.; Bonewald, Lynda] Indiana Univ Sch Med, Indiana Ctr Musculoskeletal Hlth, Indianapolis, IN USA.
   [Wang, Zhiying; Brotto, Marco] Univ Texas Arlington, Coll Nursing & Hlth Innovat, Bone Muscle Res Ctr, 655 W Mitchell St, Arlington, TX 76010 USA.
   [Liu, Ziyue] Indiana Univ Sch Med, Dept Biostat & Hlth Data Sci, Indianapolis, IN USA.
   [Warden, Stuart J.] Indiana Univ, Sch Hlth & Human Sci, Dept Phys Therapy, Indianapolis, IN USA.
C3 Indiana University System; Indiana University Bloomington; University of
   Texas System; University of Texas Arlington; Indiana University System;
   Indiana University Bloomington; Indiana University System; Indiana
   University-Purdue University Indianapolis
RP Brotto, M (corresponding author), Univ Texas Arlington, Coll Nursing & Hlth Innovat, Bone Muscle Res Ctr, 655 W Mitchell St, Arlington, TX 76010 USA.
EM marco.brotto@uta.edu
OI Warden, Stuart/0000-0002-6415-4936
FU National Institutes of Health [P01AG039355]; National Institute of
   Arthritis and Musculoskeletal and Skin Disease [P30AR072581]
FX This work was supported by: the National Institutes of Health [Grant
   P01AG039355 (LFB, MB)] and the National Institute of Arthritis and
   Musculoskeletal and Skin Disease (grant P30AR072581, PI Dr. Moe, Sharon
   M, SJW). We also acknowledge the Clinical Research Center (CRC) Indiana
   Center of Musculoskeletal Health (ICMH) Musculoskeletal Function,
   Imaging and Tissue Resource Core (MSK-FIT core), Indiana University
   School of Medicine, USA, and the Bone-Muscle Research Center Core
   Facility at the University of Texas at Arlington.
CR Adachi Y, 2019, GERIATR GERONTOL INT, V19, P254, DOI 10.1111/ggi.13585
   Ali S, 2014, GERONTOLOGY, V60, P294, DOI 10.1159/000356760
   ANSTEY K, 1993, PSYCHOL AGING, V8, P562, DOI 10.1037/0882-7974.8.4.562
   Awad K, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22020497
   Bohannon RW, 2010, J GERIATR PHYS THER, V33, P16, DOI 10.1097/JPT.0b013e3181d0735e
   Booth FW, 2011, J APPL PHYSIOL, V111, P1497, DOI 10.1152/japplphysiol.00420.2011
   Brigden A, 2018, HEALTH QUAL LIFE OUT, V16, DOI 10.1186/s12955-018-1028-2
   CASPERSEN CJ, 1985, PUBLIC HEALTH REP, V100, P126
   Colaianni G, 2017, ANN NY ACAD SCI, V1402, P5, DOI 10.1111/nyas.13345
   Crapo RO, 2002, AM J RESP CRIT CARE, V166, P111, DOI 10.1164/rccm.166/1/111
   Cruz-Jentoft AJ, 2019, AGE AGEING, V48, P16, DOI 10.1093/ageing/afy169
   Cuypers K, 2013, AGE, V35, P1705, DOI 10.1007/s11357-012-9471-1
   Ngo DH, 2019, MOLECULES, V24, DOI 10.3390/molecules24152678
   DAVIES CH, 1991, NATURE, V349, P609, DOI 10.1038/349609a0
   Dhakal R, 2012, BRAZ J MICROBIOL, V43, P1230, DOI 10.1590/S1517-83822012000400001
   Distefano G, 2018, CSH PERSPECT MED, V8, DOI 10.1101/cshperspect.a029785
   Effros RM, 2011, TRANSL RES, V158, P326, DOI 10.1016/j.trsl.2011.07.003
   Elosua R, 2005, J GERONTOL A-BIOL, V60, P760, DOI 10.1093/gerona/60.6.760
   Fabbri E, 2015, J AM MED DIR ASSOC, V16, P640, DOI 10.1016/j.jamda.2015.03.013
   Finsterer J, 2012, BMC MUSCULOSKEL DIS, V13, DOI 10.1186/1471-2474-13-218
   Gao F, 2013, NEUROIMAGE, V78, P75, DOI 10.1016/j.neuroimage.2013.04.012
   GURALNIK JM, 1994, J GERONTOL, V49, pM85, DOI 10.1093/geronj/49.2.M85
   Hart DA, 2023, FRONT PHYSIOL, V14, DOI 10.3389/fphys.2023.1127689
   Hewlett S, 2011, ARTHRIT CARE RES, V63, pS263, DOI 10.1002/acr.20579
   Jähn K, 2012, EUR CELLS MATER, V24, P197
   Jembrek MJ, 2015, CURR PHARM DESIGN, V21, P4943, DOI 10.2174/1381612821666150914121624
   Koch AJ, 2014, J MUSCULOSKEL NEURON, V14, P68
   Kumar S, 1997, MYCOL RES, V101, P403, DOI 10.1017/S0953756296002742
   Lee EC, 2017, J STRENGTH COND RES, V31, P2920, DOI 10.1519/JSC.0000000000002122
   Li L, 2021, PLANT SIGNAL BEHAV, V16, DOI 10.1080/15592324.2020.1862565
   Maddock RJ, 2016, J NEUROSCI, V36, P2449, DOI 10.1523/JNEUROSCI.3455-15.2016
   Manns PJ, 2003, AM J HUM BIOL, V15, P91, DOI 10.1002/ajhb.10117
   Medici V, 2010, J HEPATOL, V53, P551, DOI 10.1016/j.jhep.2010.03.029
   Mills DJ, 2021, J NUTR METAB, V2021, DOI 10.1155/2021/6655064
   Moreno Gerardo, 2014, Curr Gerontol Geriatr Res, V2014, P535071, DOI 10.1155/2014/535071
   Pasco JA, 2015, BMC MUSCULOSKEL DIS, V16, DOI 10.1186/s12891-015-0586-2
   Piasecki J, 2019, FRONT PHYSIOL, V10, DOI 10.3389/fphys.2019.01050
   Porges EC, 2017, BIOL PSYCHIAT-COGN N, V2, P38, DOI 10.1016/j.bpsc.2016.06.004
   Roberts LD, 2017, DIABETES, V66, P674, DOI 10.2337/db16-0843
   Roberts LD, 2014, CELL METAB, V19, P96, DOI 10.1016/j.cmet.2013.12.003
   Singh H, 2017, J MUSCULOSKEL NEURON, V17, P50
   Tieland M, 2018, J CACHEXIA SARCOPENI, V9, P3, DOI 10.1002/jcsm.12238
   Wang ZY, 2020, COMMUN BIOL, V3, DOI 10.1038/s42003-020-0766-y
   Warden SJ, 2022, PHYS THER, V102, DOI 10.1093/ptj/pzab299
   Warden SJ, 2019, GAIT POSTURE, V74, P83, DOI 10.1016/j.gaitpost.2019.08.020
   Wong CGT, 2003, ANN NEUROL, V54, pS3, DOI 10.1002/ana.10696
   YUDKOFF M, 1979, AM J CLIN NUTR, V32, P282, DOI 10.1093/ajcn/32.2.282
NR 47
TC 0
Z9 0
U1 0
U2 0
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD OCT 10
PY 2023
VL 13
IS 1
AR 17083
DI 10.1038/s41598-023-41628-x
PG 16
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA X5TW1
UT WOS:001099084800005
PM 37816783
OA Green Published, gold, Green Submitted
DA 2024-02-19
ER

PT J
AU Lin, J
   Chen, LZ
   Wu, DJ
   Lin, JX
   Liu, B
   Guo, CR
AF Lin, Jie
   Chen, Lizhu
   Wu, Dingjie
   Lin, Jiexiang
   Liu, Bin
   Guo, Ciren
TI Potential Diagnostic and Prognostic Values of CBX8 Expression in Liver
   Hepatocellular Carcinoma, Kidney Renal Clear Cell Carcinoma, and Ovarian
   Cancer: A Study Based on TCGA Data Mining
SO COMPUTATIONAL AND MATHEMATICAL METHODS IN MEDICINE
LA English
DT Article
ID WEB SERVER; GENE; PROLIFERATION; METASTASIS
AB Background. Chromobox protein homolog 8 (CBX8), a transcriptional repressor, participates in many biological processes in various carcinomas. Cell differentiation, aging, and cell cycle progression are examples of such processes. It is critical to investigate CBX8 expression and its relationship with clinicopathological characteristics in liver hepatocellular carcinoma (LIHC), kidney renal clear cell carcinoma (KIRC), and ovarian cancer (OV) to investigate CBX8's potential diagnostic and prognostic values. Methods. TCGA and CPTAC databases were used to compare the data between cancer and matched normal tissues on RNA and protein expression profiles and their relevant clinical information to determine the relationship between CBX8 and clinicopathological features. Kaplan-Meier analyses were used to assess CBX8 relationship's with disease-free survival (DFS), relapse-free survival (RFS), and overall survival (OS). The multivariate Cox regression analysis was used to identify independent risk factors which affect prognosis. DNA methylation and genetic changes and their impact on prognoses were evaluated by cBioPortal and MethSurv websites. Spearman's correlation was used to determine the relationship of CBX8 expression with somatic mutation. Tumor immune estimation resource (TIMER) was adopted to investigate the relationship between CBX8 and immune cell infiltration (ICI). CBX8-relevant genes and proteins are analyzed by EnhancedVolcano and STRING databases. The gene set enrichment analysis (GSEA) was performed to investigate the potential functions of CBX8. Results. CBX8 RNA and protein overexpression were confirmed in LIHC, KIRC, and OV (p < 0.05). High CBX8 was significantly related to the clinical features and poor prognoses. The CBX8 genetic alteration rate was 3%. DNA methylation was also associated with prognoses. CBX8 closely interacted with ICI, TMB, MSI, purity, and ploidy. GO analyses revealed that CBX8-associated genes were enriched in biological processes, cell cycle regulation, and molecular functions. KEGG analyses exhibited that CBX8 was gathered in signaling pathway regulation. GSEA revealed that cell cycle, DNA replication, and Wnt signaling pathways were differentially enriched in the high CBX8 expression group. Conclusions. CBX8 could be a potential diagnostic and prognostic biomarker for LIHC, KIRC, and OV cancers.
C1 [Lin, Jie; Liu, Bin; Guo, Ciren] Fujian Med Univ Canc Hosp, Fujian Canc Hosp, Dept Gynecol, Fuzhou, Fujian, Peoples R China.
   [Chen, Lizhu] Fujian Med Univ Canc Hosp, Fujian Canc Hosp, Dept Abdominal Oncol, Jinan Dist, Fuzhou, Fujian, Peoples R China.
   [Wu, Dingjie] China Med Univ, Sch Pharm, Dept Microbial & Biochem Pharm, Shenyang, Liaoning, Peoples R China.
   [Lin, Jiexiang] Fujian Med Univ, Shengli Clin Med Coll, Fuzhou, Peoples R China.
C3 China Medical University; Fujian Medical University
RP Guo, CR (corresponding author), Fujian Med Univ Canc Hosp, Fujian Canc Hosp, Dept Gynecol, Fuzhou, Fujian, Peoples R China.
EM 659695376@fjmu.edu.cn; lizhuchen2022@163.com; djw12304@163.com;
   659695376@qq.com; coco2002pipi@163.com; guozhiyin505@sina.com
OI Liu, Bin/0000-0003-0340-6084; Lin, Jiexiang/0000-0002-7212-7583; Wu,
   Dingjie/0000-0003-3614-0083; Lin, Jie/0000-0003-0338-6861
FU Fujian Provincial Health Technology Project [2021QNA043]
FX AcknowledgmentsThis work is sponsored by the Fujian Provincial Health
   Technology Project (grant number: 2021QNA043).
CR Blum A, 2018, CELL, V173, P530, DOI 10.1016/j.cell.2018.03.059
   Chalmers ZR, 2017, GENOME MED, V9, DOI 10.1186/s13073-017-0424-2
   Choi BH, 2021, CELL PROLIFERAT, V54, DOI 10.1111/cpr.13110
   Chung CY, 2016, CELL REP, V16, P472, DOI 10.1016/j.celrep.2016.06.002
   Çubuk C, 2019, NPJ SYST BIOL APPL, V5, DOI 10.1038/s41540-019-0087-2
   Ford CE, 2020, BRIT J CANCER, V123, P9, DOI 10.1038/s41416-020-0875-x
   Forner A, 2018, LANCET, V391, P1301, DOI 10.1016/S0140-6736(18)30010-2
   Jia YS, 2020, MOL THER-ONCOLYTICS, V19, P188, DOI 10.1016/j.omto.2020.09.012
   Li MJ, 2020, DNA CELL BIOL, V39, P909, DOI 10.1089/dna.2019.5170
   Li Q, 2021, J GASTROINTEST ONCOL, V12, P2310, DOI 10.21037/jgo-21-613
   Li TW, 2017, CANCER RES, V77, pE108, DOI 10.1158/0008-5472.CAN-17-0307
   Liang Y, 2021, MOL MED REP, V24, DOI 10.3892/mmr.2021.12497
   Liberzon A, 2011, BIOINFORMATICS, V27, P1739, DOI 10.1093/bioinformatics/btr260
   Liu JM, 2018, CELL PHYSIOL BIOCHEM, V48, P173, DOI 10.1159/000491716
   Morand S, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22126532
   Rhodes DR, 2007, NEOPLASIA, V9, P166, DOI 10.1593/neo.07112
   SHANG BB, 2021, PEERJ, V2315, DOI DOI 10.7717/PEERJ.12315
   Shi DJ, 2021, FRONT GENET, V12, DOI 10.3389/fgene.2021.745277
   Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI [10.3322/caac.20006, 10.3322/caac.21387, 10.3322/caac.21601, 10.3322/caac.20073, 10.3322/caac.21654, 10.3322/caac.21332, 10.3322/caac.21551, 10.3322/caac.21254]
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Sun JH, 2016, WORLD J GASTROENTERO, V22, P3547, DOI 10.3748/wjg.v22.i13.3547
   Tang B, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-018-1288-0
   Tang JJ, 2014, ONCOTARGET, V5, P10778, DOI 10.18632/oncotarget.2502
   Tang ZF, 2017, NUCLEIC ACIDS RES, V45, pW98, DOI 10.1093/nar/gkx247
   Tomczak Katarzyna, 2015, Contemp Oncol (Pozn), V19, pA68, DOI 10.5114/wo.2014.47136
   van Wijnen AJ, 2021, BONE, V143, DOI 10.1016/j.bone.2020.115659
   Vandamme J, 2011, MOL CELL PROTEOMICS, V10, DOI 10.1074/mcp.M110.002642
   Xiao LS, 2019, AGING-US, V11, P7123, DOI 10.18632/aging.102241
   Xiao WF, 2014, INT J CLIN EXP PATHO, V7, P4817
   Xu WH, 2019, AGING-US, V11, P6999, DOI 10.18632/aging.102233
   Yang SB, 2015, CELL BIOCHEM BIOPHYS, V71, P1503, DOI 10.1007/s12013-014-0373-y
   Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118
   Yuan GJ, 2017, CANCER SCI, V108, P2166, DOI 10.1111/cas.13383
   Zhang CZ, 2018, CANCER RES, V78, P51, DOI 10.1158/0008-5472.CAN-17-0700
   Zhou H, 2021, MEDICINE, V100, DOI 10.1097/MD.0000000000027056
   Zhu YY, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.700528
NR 36
TC 2
Z9 2
U1 0
U2 2
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1748-670X
EI 1748-6718
J9 COMPUT MATH METHOD M
JI Comput. Math. Method Med.
PD JUN 29
PY 2022
VL 2022
AR 1372879
DI 10.1155/2022/1372879
PG 28
WC Mathematical & Computational Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Mathematical & Computational Biology
GA 3B1JK
UT WOS:000827704400010
PM 35813444
OA gold, Green Published
DA 2024-02-19
ER

PT J
AU Vaanholt, LM
   Daan, S
   Schubert, KA
   Visser, GH
AF Vaanholt, Lobke M.
   Daan, Serge
   Schubert, Kristin A.
   Visser, G. Henk
TI Metabolism and Aging: Effects of Cold Exposure on Metabolic Rate, Body
   Composition, and Longevity in Mice
SO PHYSIOLOGICAL AND BIOCHEMICAL ZOOLOGY
LA English
DT Article
ID FREE-RADICAL PRODUCTION; BROWN ADIPOSE-TISSUE; LIFE-SPAN;
   ENERGY-METABOLISM; DIETARY RESTRICTION; OXIDATIVE STRESS; FISCHER-344
   RATS; CALORIC RESTRICTION; VOLUNTARY EXERCISE; MITOCHONDRIAL
AB The proposition that increased energy expenditure shortens life has a long history. The rate-of-living theory ( Pearl 1928) states that life span and average mass-specific metabolic rate are inversely proportional. Originally based on interspecific allometric comparisons between species of mammals, the theory was later rejected on the basis of comparisons between taxa ( e. g., birds have higher metabolic rates than mammals of the same size and yet live longer). It has rarely been experimentally tested within species. Here, we investigated the effects of increased energy expenditure, induced by cold exposure, on longevity in mice. Longevity was measured in groups of 60 male mice maintained at either 22 degrees C (WW) or 10 degrees C ( CC) throughout adult life. Forty additional mice were maintained at both of these temperatures to determine metabolic rate ( by stable isotope turnover, gas exchange, and food intake) as well as the mass of body and organs of subsets of animals at four different ages. Because energy expenditure might affect longevity by either accumulating damage or by instantaneously affecting mortality rate, we included a third group of mice exposed to 10 degrees C early in life and to 22 degrees C afterward (CW). Exposure to cold increased mean daily energy expenditure by ca. 48% (from 47.8 kJ d(-1) in WW to 70.6 kJ d(-1) in CC mice, with CW intermediate at 59.9 kJ d(-1)). However, we observed no significant differences in median life span among the groups (WW, 832 d; CC, 834 d; CW, 751 d). CC mice had reduced body mass (lifetime mean 30.7 g) compared with WW mice (33.8 g), and hence their lifetime energy potential (LEP) per gram whole-body mass had an even larger excess than per individual. Greenberg (1999) has pointed out that the size of the energetically costly organs, rather than that of the whole body, may be relevant for the rate-of-living idea. We therefore expressed LEP also in terms of energy expenditure per gram dry lean mass or per gram "metabolic" organ mass (i.e., heart, liver, kidneys, and brain). No matter how it was expressed, LEP in CC mice significantly exceeded that of WW mice. This result demonstrates that increased energy expenditure does not shorten life span and adds evidence to the intraspecific refutation of the rate-of-living theory. We suggest that increased energy expenditure has both positive and negative effects on different factors determining life span and that the relationship between energy turnover and longevity is fundamentally nonmonotonic.
C1 [Vaanholt, Lobke M.] Univ Aberdeen, Inst Biol & Environm Sci, Aberdeen AB24 2TZ, Scotland.
   [Visser, G. Henk] Univ Groningen, Ctr Isotope Res, NL-9747 AG Groningen, Netherlands.
   [Vaanholt, Lobke M.; Daan, Serge; Schubert, Kristin A.; Visser, G. Henk] Univ Groningen, Dept Behav Biol, NL-9750 AA Haren, Netherlands.
C3 University of Aberdeen; University of Groningen; University of Groningen
RP Vaanholt, LM (corresponding author), Univ Aberdeen, Inst Biol & Environm Sci, Tillydrone Ave, Aberdeen AB24 2TZ, Scotland.
EM l.vaanholt@abdn.ac.uk
OI Vaanholt, Lobke M./0000-0002-5102-7970
CR [Anonymous], EXPT ANAL DISTRIBUTI
   Argyropoulos G, 2002, J APPL PHYSIOL, V92, P2187, DOI 10.1152/japplphysiol.00994.2001
   Barja G, 1998, ANN NY ACAD SCI, V854, P224, DOI 10.1111/j.1749-6632.1998.tb09905.x
   Barja G, 2002, FREE RADICAL BIO MED, V33, P1167, DOI 10.1016/S0891-5849(02)00910-3
   BARJA G, 1994, FREE RADICAL RES, V21, P317, DOI 10.3109/10715769409056584
   BARNETT SA, 1965, BIOL REV, V40, P5, DOI 10.1111/j.1469-185X.1965.tb00794.x
   Beckman KB, 1998, PHYSIOL REV, V78, P547, DOI 10.1152/physrev.1998.78.2.547
   Brand MD, 2000, EXP GERONTOL, V35, P811, DOI 10.1016/S0531-5565(00)00135-2
   Bronikowski AM, 2006, EVOLUTION, V60, P1494, DOI 10.1554/05-590.1
   Daan S, 1996, J ANIM ECOL, V65, P539, DOI 10.2307/5734
   DAAN S, 1990, ACT 20 C INT ORN ORN, P1976
   Florez-Duquet M, 1998, AM J PHYSIOL-REG I, V274, pR196, DOI 10.1152/ajpregu.1998.274.1.R196
   FREEMAN KB, 1989, BIOCHEM CELL BIOL, V67, P147, DOI 10.1139/o89-022
   GESSAMAN JA, 1988, PHYSIOL ZOOL, V61, P507, DOI 10.1086/physzool.61.6.30156159
   Gredilla R, 2005, ENDOCRINOLOGY, V146, P3713, DOI 10.1210/en.2005-0378
   Greenberg JA, 1999, MED HYPOTHESES, V52, P15, DOI 10.1054/mehy.1997.0619
   Greenberg JA, 2000, MECH AGEING DEV, V113, P37, DOI 10.1016/S0047-6374(99)00094-9
   HARMAN D, 1956, J GERONTOL, V11, P298, DOI 10.1093/geronj/11.3.298
   Herrero A, 1999, AGING-CLIN EXP RES, V11, P294, DOI 10.1007/BF03339803
   Herrero A, 1998, MECH AGEING DEV, V103, P133, DOI 10.1016/S0047-6374(98)00035-9
   HOLLOSZY JO, 1986, J APPL PHYSIOL, V61, P1656, DOI 10.1152/jappl.1986.61.5.1656
   HOLLOSZY JO, 1987, FASEB J, V46, P1850
   Jakus PB, 2002, FEBS LETT, V519, P210, DOI 10.1016/S0014-5793(02)02707-2
   JOHNSON HD, 1963, J GERONTOL, V18, P29, DOI 10.1093/geronj/18.1.29
   KIBLER HH, 1963, J GERONTOL, V18, P235, DOI 10.1093/geronj/18.3.235
   KIBLER HH, 1961, J GERONTOL, V16, P13, DOI 10.1093/geronj/16.1.13
   LEWIS SEM, 1985, EXP GERONTOL, V20, P253, DOI 10.1016/0531-5565(85)90050-6
   Lu YP, 2006, P NATL ACAD SCI USA, V103, P16301, DOI 10.1073/pnas.0607789103
   LYMAN CP, 1981, SCIENCE, V212, P668, DOI 10.1126/science.7221552
   MASORO EJ, 1982, P NATL ACAD SCI-BIOL, V79, P4239, DOI 10.1073/pnas.79.13.4239
   MCCARTER RJ, 1992, AM J PHYSIOL, V263, pE448, DOI 10.1152/ajpendo.1992.263.3.E448
   McCay CM, 1935, J NUTR, V10, P63, DOI 10.1093/jn/10.1.63
   MIQUEL J, 1976, MECH AGEING DEV, V5, P347, DOI 10.1016/0047-6374(76)90034-8
   Navarro A, 2004, AM J PHYSIOL-REG I, V286, pR505, DOI 10.1152/ajpregu.00208.2003
   PARE WP, 1965, J GERONTOL, V20, P78, DOI 10.1093/geronj/20.1.78
   Pearl R., 1928, RATE LIVING
   Perez-Campo R, 1998, J COMP PHYSIOL B, V168, P149, DOI 10.1007/s003600050131
   Pletcher SD, 1999, J EVOLUTION BIOL, V12, P430, DOI 10.1046/j.1420-9101.1999.00058.x
   Ramsey JJ, 1996, FASEB J, V10, P4198
   Ramsey JJ, 2000, FREE RADICAL BIO MED, V29, P946, DOI 10.1016/S0891-5849(00)00417-2
   RAO G, 1990, J NUTR, V120, P602, DOI 10.1093/jn/120.6.602
   ROMIJN C, 1961, 2ND P S EN MET WAG, P49
   Rubner M., 1908, PROBLEM LEBENSDAUER
   SACHER GA, 1977, HDB BIOL AGING, P582
   Speakman J.R., 1997, Doubly Labelled Water: Theory and Practice, V1st
   Speakman JR, 2005, AGING CELL, V4, P167, DOI 10.1111/j.1474-9726.2005.00162.x
   Speakman JR, 2005, J EXP BIOL, V208, P1717, DOI 10.1242/jeb.01556
   Speakman JR, 2004, AGING CELL, V3, P87, DOI 10.1111/j.1474-9728.2004.00097.x
   Speakman JR, 2003, AGING CELL, V2, P265, DOI 10.1046/j.1474-9728.2003.00061.x
   Speakman JR, 2002, J NUTR, V132, p1583S, DOI 10.1093/jn/132.6.1583S
   Vaanholt LM, 2007, J COMP PHYSIOL B, V177, P109, DOI 10.1007/s00360-006-0113-8
   Van Voorhies WA, 1999, P NATL ACAD SCI USA, V96, P11399, DOI 10.1073/pnas.96.20.11399
   Visser GH, 1999, PHYSIOL BIOCHEM ZOOL, V72, P740, DOI 10.1086/316713
   WOLF TJ, 1989, J ANIM ECOL, V58, P943, DOI 10.2307/5134
   Yamashita H, 1999, FEBS LETT, V458, P157, DOI 10.1016/S0014-5793(99)01143-6
NR 55
TC 32
Z9 39
U1 0
U2 38
PU UNIV CHICAGO PRESS
PI CHICAGO
PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA
SN 1522-2152
J9 PHYSIOL BIOCHEM ZOOL
JI Physiol. Biochem. Zool.
PD JUL-AUG
PY 2009
VL 82
IS 4
BP 314
EP 324
DI 10.1086/589727
PG 11
WC Physiology; Zoology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Physiology; Zoology
GA 450AM
UT WOS:000266373400002
PM 19115965
OA Green Published
DA 2024-02-19
ER

PT J
AU Inal, ME
   Akgün, A
   Kahraman, A
AF Inal, ME
   Akgün, A
   Kahraman, A
TI Radioprotective effects of exogenous glutathione against whole-body
   γ-ray irradiation:: Age- and gender-related changes in malondialdehyde
   levels, superoxide dismutase and catalase activities in rat liver
SO METHODS AND FINDINGS IN EXPERIMENTAL AND CLINICAL PHARMACOLOGY
LA English
DT Article
DE aging; catalase; malondialdehyde; gamma-ray radiation; gender;
   superoxide
ID ANTIOXIDANT; RADIATION; ENZYMES; SYSTEMS; SEX
AB Age- and gender-related changes in malondialdehyde (MDA) levels, superoxide dismutase (SOD) and catalase (CAT) activities in rat livers exposed to different doses a whole-body gamma-ray radiation were determined. In addition, the effects of exogenous glutathione (GSH) against radiation injury in rat livers were investigated. We found that MDA levels have an age-associated increment and an increasing radiation dose-related elevation, although they decrease slighty in the 4 Gy group. The MDA levels in old rats were lower in males than in females, while those of young rats did not change. There were no observed age-related changes in SOD activities, although male rats had higher SOD activity than females. Female rats had the highest CAT activities in the 4 Gy group, while male rats had the highest CAT activities in the 6 G, group. CAT activities in the 8 Qv group were lower than those of the 2 Gy group for each gender and age. While MDA levels were decreased and CAT activities increased by GSH, SOD activities remained unchanged. The results indicate that gamma-ray radiation affects gender- and age-dependent MDA levels, SOD laid CAT-activities. Administration of GSH appears to be a useful approach to reduce radiation injury by reducing MDA levels and increasing CAT activities. (C) 2002 Prous Science All rights reserved.
C1 Afyon Kocatepe Univ, Sch Med, Dept Biochem, TR-03200 Afyon, Turkey.
   Osmangazi Univ, Sch Med, Dept Biochem, Eskisehir, Turkey.
C3 Afyon Kocatepe University; Eskisehir Osmangazi University
RP Kahraman, A (corresponding author), Afyon Kocatepe Univ, Sch Med, Dept Biochem, TR-03200 Afyon, Turkey.
RI Kahraman, Ahmet/JDD-5660-2023
OI Kahraman, Ahmet/0000-0003-3310-3252
CR BEUTLER E, 1973, RED CELL METABOLISM, P76
   BUMP EA, 1990, PHARMACOL THERAPEUT, V47, P117, DOI 10.1016/0163-7258(90)90048-7
   CARRILLO MC, 1992, MECH AGEING DEV, V65, P187, DOI 10.1016/0047-6374(92)90035-C
   FROOQUI MYH, 1987, COMP BIOCH PHYSL, V88, P177
   HARMAN D, 1981, P NATL ACAD SCI-BIOL, V78, P7124, DOI 10.1073/pnas.78.11.7124
   Kojima S, 1997, BIOL PHARM BULL, V20, P601
   Lenton KJ, 1999, MECH AGEING DEV, V107, P15, DOI 10.1016/S0047-6374(98)00128-6
   LIO J, 1993, MECH AGEING DEV, V71, P23
   Okhawa H, 1979, ANAL BIOCHEM, V95, P351
   PELTOLA V, 1993, J ANDROL, V14, P267
   RAO G, 1990, MECH AGEING DEV, V53, P49, DOI 10.1016/0047-6374(90)90033-C
   RIKANS LE, 1991, BIOCHIM BIOPHYS ACTA, V1074, P195, DOI 10.1016/0304-4165(91)90061-K
   Sanz N, 1997, J HEPATOL, V27, P525, DOI 10.1016/S0168-8278(97)80358-3
   Sanz N, 1996, BBA-MOL BASIS DIS, V1315, P123, DOI 10.1016/0925-4439(95)00113-1
   STOHS SJ, 1984, AGE, V7, P3, DOI 10.1007/BF02431888
   WINTERBOURN CC, 1975, J LAB CLIN MED, V85, P337
NR 16
TC 27
Z9 29
U1 0
U2 5
PU PROUS SCIENCE, SA
PI BARCELONA
PA PO BOX 540, PROVENZA 388, 08025 BARCELONA, SPAIN
SN 0379-0355
J9 METHOD FIND EXP CLIN
JI Methods Find. Exp. Clin. Pharmacol.
PD MAY
PY 2002
VL 24
IS 4
BP 209
EP 212
AR UNSP 0379-0355/2002
DI 10.1358/mf.2002.24.4.678452
PG 4
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 561YD
UT WOS:000176169900004
PM 12092007
DA 2024-02-19
ER

PT J
AU Nasta, P
   Maida, I
   Cattelan, AM
   Pontali, E
   Angeli, E
   Giralda, M
   Verucchi, G
   Caputo, A
   Iannacone, C
   Puoti, M
   Carosi, G
AF Nasta, Paola
   Maida, Ivana
   Cattelan, Anna Maria
   Pontali, Emanuele
   Angeli, Elena
   Giralda, Mariarosaria
   Verucchi, Gabriella
   Caputo, Antonietta
   Iannacone, Claudio
   Puoti, Massimo
   Carosi, Giampiero
TI Effect of Aging, Glucose Level, and HIV Viral Load on Response to
   Treatment with Pegylated Interferon Plus Ribavirin in HIV/HCV
   Co-Infected Women
SO JOURNAL OF WOMENS HEALTH
LA English
DT Article
ID CHRONIC HEPATITIS-C; LIVER FIBROSIS; INSULIN-RESISTANCE;
   VIRUS-INFECTION; HEPATOCELLULAR-CARCINOMA; NATURAL-HISTORY; MENOPAUSE;
   PROGRESSION; ESTROGEN; HCV
AB Background: This was a post-hoc analysis of the Optimized Pegylated interferons Efficacy and anti-Retroviral Approach (OPERA) study, originally designed to document routine clinical and treatment data in HIV/HCV coinfected patients treated with pegylated interferon/ribavirin (PEG-IFN/RBV). The aim of this study was to define the impact of several variables, such as age, glucose metabolism, and HIV viral load, on PEG-IFN/RBV treatment outcomes, in HIV/HCV coinfected women.
   Methods: Female subjects from the OPERA database were retrospectively evaluated and factors associated with sustained virological response (SVR) were assessed and compared to the male population by logistic regression analysis. At baseline, clinical and demographic data were collected. Patients were then administered with PEG-IFN/RBV therapy for 48 weeks. After a 24-week follow-up period, SVR was evaluated.
   Results: A total of 1523 patients were enrolled in 98 centers across Italy, 1284 of whom were IFN therapy naive and were included in the post-hoc analysis. In the female group, factors associated with SVR were the presence of HCV genotype 2,3 (adjusted odds ratio [AOR]=6.87, p<0.0001), age <= 45 years (AOR=2.61, p=0.014), >= 80% exposure to PEG-IFN (AOR=3.85, p=0.019) and RBV (AOR=3.94, p=0.015) therapy. Also, increased glucose plasma level negatively correlated with SVR (AOR=0.98, p=0.066). In the male population, undetectable HIV-RNA (AOR=1.47, p=0.033) but not glucose level (AOR=1.0, p=0.95) predicted SVR.
   Conclusions: Findings from the present study demonstrate that several factors may be predictive of SVR when pegylated interferon plus ribavirin is used (i.e., age, gender, HIV viral load and HCV genotype) that need to be carefully considered prior to therapeutic intervention, since they may hinder successful therapy. Use of PEG-IFN/RBV with novel direct antiviral agents will likely be still maintained until less expensive and effective interferon-free strategies become available.
C1 [Nasta, Paola; Giralda, Mariarosaria; Carosi, Giampiero] Univ Brescia, Univ Div Infect & Trop Dis, I-25123 Brescia, Italy.
   [Nasta, Paola; Giralda, Mariarosaria; Carosi, Giampiero] Spedali Civili Gen Hosp, I-25123 Brescia, Italy.
   [Maida, Ivana] Univ Sassari, Div Infect Dis, Dept Clin Expt & Oncol Med, I-07100 Sassari, Italy.
   [Cattelan, Anna Maria] Santa Maria Della Misericordia Hosp, Dept Infect Dis, Rovigo, Italy.
   [Pontali, Emanuele] Galliera Hosp, Dept Infect Dis, Genoa, Italy.
   [Angeli, Elena] L Sacco Hosp Vialba, Dept Infect Dis 2, Milan, Italy.
   [Verucchi, Gabriella] Univ Hosp Policlin S Orsola Malpighi, Operat Unit Infect Dis, Bologna, Italy.
   [Caputo, Antonietta] Roche SpA, Monza, Italy.
   [Iannacone, Claudio] SPARC Consulting, Milan, Italy.
   [Puoti, Massimo] Osped Niguarda Ca Granda, Dept Infect Dis, Milan, Italy.
C3 University of Brescia; Hospital Spedali Civili Brescia; University of
   Sassari; Hospital Santa Maria della Misericordia; University of Genoa;
   Ente Ospedaliero Ospedali Galliera; University of Milan; Luigi Sacco
   Hospital; IRCCS Azienda Ospedaliero-Universitaria di Bologna; Roche
   Holding; IRCCS Ca Granda Ospedale Maggiore Policlinico; Ospedale
   Niguarda Ca' Granda
RP Nasta, P (corresponding author), Univ Brescia, Univ Div Infect & Trop Dis, Ple Spedali Civili 1, I-25123 Brescia, Italy.
EM paola.nasta@tin.it
RI Puoti, Massimo/AAA-6580-2020; CATTELAN, ANNA MARIA/AAL-3654-2020
OI CATTELAN, ANNA MARIA/0000-0003-2869-2945; Puoti,
   Massimo/0000-0003-3278-7138; Pontali, Emanuele/0000-0002-1085-0442;
   MAIDA, Ivana/0000-0003-4895-7576
FU Roche; Roche S.p.A. [ML21545]
FX The authors would like to thank Selene Mogavero, PhD and Colin G. Egan,
   PhD (Primula Multimedia S.r.L., Pisa, Italy) for writing support. This
   assistance was sponsored by Roche. This study was funded by Roche S.p.A.
   (ML21545).
CR Boonyanurak P, 2012, MENOPAUSE, V19, P820, DOI 10.1097/gme.0b013e31824cfc0f
   Carosi G, 2014, ANTIVIR THER, V19, P735, DOI 10.3851/IMP2757
   Chen JY, 2014, NAT REV GASTRO HEPAT, V11, DOI 10.1038/nrgastro.2014.17
   Codes L, 2007, GUT, V56, P390, DOI 10.1136/gut.2006.101931
   del Campo JA, 2013, ALIMENT PHARM THER, V37, P74, DOI 10.1111/apt.12113
   Di Martino V, 2004, HEPATOLOGY, V40, P1426, DOI 10.1002/hep.20463
   Evans JL, 2013, DIABETES, V62, P346, DOI 10.2337/db12-1239
   Global Health Observatory (GHO), 2012, PREV HIV AD AG 15 49
   Goss AM, 2012, METABOLISM, V61, P1817, DOI 10.1016/j.metabol.2012.05.016
   Itagaki T, 2005, GUT, V54, P1782, DOI 10.1136/gut.2005.053278
   Kalra S, 2013, CURR DIABETES REP, V13, P419, DOI 10.1007/s11892-013-0369-9
   Khattab MA, 2012, ANN HEPATOL, V11, P487, DOI 10.1016/S1665-2681(19)31462-0
   Kojic EM, 2007, J WOMENS HEALTH, V16, P1402, DOI 10.1089/jwh.2007.0345
   Lo Re V, 2014, ANN INTERN MED, V160, P369, DOI 10.7326/M13-1829
   Nasta Paola, 2011, Acta Biomed, V82, P115
   Pfeilschifter J, 2002, ENDOCR REV, V23, P90, DOI 10.1210/er.23.1.90
   Poynard T, 1997, LANCET, V349, P825, DOI 10.1016/S0140-6736(96)07642-8
   Rockstroh JK, 2005, J INFECT DIS, V192, P992, DOI 10.1086/432762
   Sadashiv, 2012, WOMENS HEALTH, V8, P521, DOI [10.2217/whe.12.46, 10.2217/WHE.12.46]
   Shimizu I, 2007, WORLD J GASTROENTERO, V13, P4295, DOI 10.3748/wjg.v13.i32.4295
   Shimizu M, 2013, SEMIN IMMUNOPATHOL, V35, P191, DOI 10.1007/s00281-012-0336-6
   Soriano V, 2008, J INFECT DIS, V198, P1337, DOI 10.1086/592171
   Tossing G, 2005, EUR J MED RES, V10, P43
   Tuomikoski P, 2012, MENOPAUSE, V19, P1116, DOI 10.1097/gme.0b013e3182503d5d
   van der Helm J, 2013, GASTROENTEROLOGY, V144, P751, DOI 10.1053/j.gastro.2012.12.026
   Villa E, 2011, GASTROENTEROLOGY, V140, P818, DOI 10.1053/j.gastro.2010.12.027
   Wright M, 2003, GUT, V52, P574, DOI 10.1136/gut.52.4.574
   Xu JW, 2002, WORLD J GASTROENTERO, V8, P883, DOI 10.3748/wjg.v8.i5.883
NR 28
TC 0
Z9 1
U1 0
U2 1
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1540-9996
EI 1931-843X
J9 J WOMENS HEALTH
JI J. Womens Health
PD FEB 1
PY 2015
VL 24
IS 2
BP 159
EP 164
DI 10.1089/jwh.2014.4796
PG 6
WC Public, Environmental & Occupational Health; Medicine, General &
   Internal; Obstetrics & Gynecology; Women's Studies
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Public, Environmental & Occupational Health; General & Internal
   Medicine; Obstetrics & Gynecology; Women's Studies
GA CB0NI
UT WOS:000349322700010
PM 25682817
DA 2024-02-19
ER

PT J
AU Bagheri, R
   Shakibaee, A
   Camera, DM
   Sobhani, V
   Ghobadi, H
   Nazar, E
   Fakhari, H
   Dutheil, F
AF Bagheri, Reza
   Shakibaee, Abolfazl
   Camera, Donny M.
   Sobhani, Vahid
   Ghobadi, Hamid
   Nazar, Eisa
   Fakhari, Hadi
   Dutheil, Fred
TI Effects of 8 weeks of resistance training in combination with a high
   protein diet on body composition, muscular performance, and markers of
   liver and kidney function in untrained older ex-military men
SO FRONTIERS IN NUTRITION
LA English
DT Article
DE resistance exercise; skeletal muscle adaptation; nutrition; aging;
   protein
ID SKELETAL-MUSCLE HYPERTROPHY; BONE HEALTH; EXERCISE; ADULTS;
   SUPPLEMENTATION; STRENGTH; RECOMMENDATIONS; METAANALYSIS; ALLOWANCE;
   POWER
AB BackgroundThe effects of a high protein diet in combination with chronic resistance training (RT) on skeletal muscle adaptation responses in untrained older ex-military men is unknown. Therefore, we compared the effects of 8 weeks of RT in combination with either a high (1.6 g/kg/d) or low protein diet (0.8 g/kg/d) on body composition [skeletal muscle mass (SMM) and body fat percentage (BFP)], muscular strength, power, and endurance (upper and lower body), markers of liver [alanine transaminase (ALT), aspartate aminotransferase (AST), and gamma-glutamyl transferase (GGT)] and kidney (creatinine and urea) function, and lipid profile low-density lipoprotein (LDL), high-density lipoprotein (HDL), and cholesterol levels in a cohort of healthy, untrained older ex-military males. MethodsForty healthy untrained older ex-military males (age: 61 & PLUSMN; 2 yr, body mass index: 23.2 & PLUSMN; 1.3 kg.m(-2)) performed 8 weeks (three sessions & BULL;w(-1)) of RT with either 1.6 g/kg/d (RHP; n = 20) or 0.8 g/kg/d of protein (RLP; n = 20). Body composition (assessed by Inbody 720), muscular strength (1-RM for chest and leg press), power (Wingate test), endurance (75% 1-RM for chest and leg press), and markers of liver and kidney function (biochemical kits) were assessed pre and post-intervention. ResultsSMM and muscular strength (upper and lower body) increased post-intervention in both groups and were significantly greater in RHP compared to RLP, while muscular power increased to the same extent in both groups (p < 0.05) with no between-group differences (p > 0.05). In contrast, there were no post-intervention changes in muscular endurance, HDL, and BFP remained in either group (p > 0.05). ALT and creatinine significantly increased in RHP compared to RLP while GGT, AST, and urea only increased in the RLP group (p < 0.05). LDL and cholesterol significantly decreased in both groups (p < 0.05). ConclusionA daily intake of 1.6 g/kg/d protein was superior to 0.8 g/kg/d (current recommended daily intake) for promoting greater improvements in SMM and muscle strength and thus may be a more suitable level of intake for promoting such adaptive responses. Notwithstanding observed between-group differences in ALT and creatinine and the fact that levels remained within normal ranges, it is feasible to conclude that this daily protein intake is efficacious and well tolerated by healthy, untrained older ex-military males.
C1 [Bagheri, Reza; Shakibaee, Abolfazl; Sobhani, Vahid] Baqiyatallah Univ Med Sci, Lifestyle Inst, Exercise Physiol Res Ctr, Tehran, Iran.
   [Camera, Donny M.] Swinburne Univ, Dept Hlth & Biostat, Melbourne, Vic, Australia.
   [Ghobadi, Hamid] Ferdowsi Univ Mashhad, Dept Exercise Physiol, Mashhad, Iran.
   [Nazar, Eisa] Mazandaran Univ Med Sci, Addict Inst, Psychiat & Behav Sci Res Ctr, Sari, Iran.
   [Fakhari, Hadi] Univ Isfahan, Dept Exercise Physiol, Esfahan, Iran.
   [Dutheil, Fred] Univ Clermont Auvergne, Univ Hosp Clermont Ferrand, CHU Clermont Ferrand,CNRS,LaPSCo,, Physiol & Psychosocial Stres,Prevent & Occupation, Clermont Ferrand, France.
C3 Baqiyatallah University of Medical Sciences (BMSU); Swinburne University
   of Technology; Ferdowsi University Mashhad; Mazandaran University
   Medical Sciences; University of Isfahan; CHU Clermont Ferrand; Centre
   National de la Recherche Scientifique (CNRS); Universite Clermont
   Auvergne (UCA)
RP Shakibaee, A (corresponding author), Baqiyatallah Univ Med Sci, Lifestyle Inst, Exercise Physiol Res Ctr, Tehran, Iran.
EM shakibaeeabolfazl2@gmail.com
RI Nazar, Eisa/JKH-7112-2023
OI Nazar, Eisa/0000-0002-2860-6034
CR Bagheri R, 2022, SPORTS MED, V52, P2713, DOI 10.1007/s40279-022-01707-x
   Bagheri R, 2022, BRIT J NUTR, V127, P1334, DOI 10.1017/S0007114521002166
   Bagheri R, 2020, EXP GERONTOL, V133, DOI 10.1016/j.exger.2020.110869
   Bagheri R, 2019, EUR J APPL PHYSIOL, V119, P1921, DOI 10.1007/s00421-019-04180-z
   Barclay RD, 2019, FRONT NUTR, V6, DOI 10.3389/fnut.2019.00146
   Bauer J, 2013, J AM MED DIR ASSOC, V14, P542, DOI 10.1016/j.jamda.2013.05.021
   Biolo G, 1997, AM J PHYSIOL-ENDOC M, V273, pE122, DOI 10.1152/ajpendo.1997.273.1.E122
   BRENNER BM, 1982, NEW ENGL J MED, V307, P652, DOI 10.1056/NEJM198209093071104
   Cadore EL, 2010, INT J SPORTS MED, V31, P689, DOI 10.1055/s-0030-1261895
   Cardon-Thomas DK, 2017, NUTRIENTS, V9, DOI 10.3390/nu9030184
   Cermak NM, 2012, AM J CLIN NUTR, V96, P1454, DOI 10.3945/ajcn.112.037556
   Chapman S, 2020, NUTRIENTS, V12, DOI 10.3390/nu12072125
   Church DD, 2016, J APPL PHYSIOL, V121, P123, DOI 10.1152/japplphysiol.00233.2016
   Churchward-Venne TA, 2015, J AM MED DIR ASSOC, V16, P400, DOI 10.1016/j.jamda.2015.01.071
   Cirillo M, 2015, NEPHROL DIAL TRANSPL, V30, P1156, DOI 10.1093/ndt/gfv026
   Colantonio Emilson, 2003, Rev Bras Med Esporte, V9, P141, DOI 10.1590/S1517-86922003000300003
   Cruz-Jentoft AJ, 2019, AGE AGEING, V48, P16, DOI 10.1093/ageing/afy169
   Cunha PM, 2020, J STRENGTH COND RES, V34, P1008, DOI 10.1519/JSC.0000000000002847
   Deutz NEP, 2014, CLIN NUTR, V33, P929, DOI 10.1016/j.clnu.2014.04.007
   Devries MC, 2018, J NUTR, V148, P1760, DOI 10.1093/jn/nxy197
   Fouque D, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001892.pub3
   Goodpaster BH, 2006, J GERONTOL A-BIOL, V61, P1059, DOI 10.1093/gerona/61.10.1059
   Gowda Shivaraj, 2009, Pan Afr Med J, V3, P17
   Hamilton D.L., 2013, Cell. Mol. Exerc. Physiol, V2, pe4, DOI DOI 10.7457/CMEP.V2I1.E4
   Hazell T, 2007, J AGING PHYS ACTIV, V15, P349, DOI 10.1123/japa.15.3.349
   Holwerda AM, 2018, J NUTR, V148, P1723, DOI 10.1093/jn/nxy169
   Hosten AO, 1990, BUN and creatinine. Clinical methods: the history, physical, and laboratory examinations
   Hou L, 2019, J NUTR HEALTH AGING, V23, P451, DOI 10.1007/s12603-019-1181-2
   Huschtscha Z, 2021, FRONT NUTR, V8, DOI 10.3389/fnut.2021.644865
   JACKSON AS, 1988, J APPL PHYSIOL, V64, P529, DOI 10.1152/jappl.1988.64.2.529
   Kalantar-Zadeh K, 2020, NEPHROL DIAL TRANSPL, V35, P1, DOI 10.1093/ndt/gfz216
   Kim H, 2016, GERIATR GERONTOL INT, V16, P110, DOI 10.1111/ggi.12723
   Kirk B, 2019, FRONT PHYSIOL, V10, DOI 10.3389/fphys.2019.00445
   Ko GJ, 2020, J AM SOC NEPHROL, V31, P1667, DOI 10.1681/ASN.2020010028
   Ling CHY, 2011, CLIN NUTR, V30, P610, DOI 10.1016/j.clnu.2011.04.001
   Maltais ML, 2016, J STRENGTH COND RES, V30, P1680, DOI 10.1519/JSC.0000000000001255
   Marcell TJ, 2014, J STRENGTH COND RES, V28, P504, DOI 10.1519/JSC.0b013e3182a952cc
   McGrath R, 2020, J AGING HEALTH, V32, P1075, DOI 10.1177/0898264319881864
   McLean RR, 2016, J GERONTOL A-BIOL, V71, P356, DOI 10.1093/gerona/glv184
   Mertz KH, 2021, AM J CLIN NUTR, V113, P790, DOI 10.1093/ajcn/nqaa372
   Morton RW, 2018, BRIT J SPORT MED, V52, P376, DOI 10.1136/bjsports-2017-097608
   Murach KA, 2016, SPORTS MED, V46, P1029, DOI 10.1007/s40279-016-0496-y
   Nicoll D., 1997, BASIC PRINCIPLES DIA, V36th, P1
   Otsuka R, 2020, PUBLIC HEALTH NUTR, V23, P1090, DOI 10.1017/S1368980019002921
   Paddon-Jones D, 2009, CURR OPIN CLIN NUTR, V12, P86, DOI 10.1097/MCO.0b013e32831cef8b
   Perez-Schindler J, 2015, EUR J SPORT SCI, V15, P41, DOI 10.1080/17461391.2014.950345
   Phillips SM, 1997, AM J PHYSIOL-ENDOC M, V273, pE99, DOI 10.1152/ajpendo.1997.273.1.E99
   Phillips SM, 2011, J SPORT SCI, V29, pS29, DOI 10.1080/02640414.2011.619204
   Ratner B., 2009, J TARGET MEAS ANAL M, V17, P139, DOI [10.1057/jt.2009.5, DOI 10.1057/JT.2009.5]
   Rodrigues F, 2022, INT J ENV RES PUB HE, V19, DOI 10.3390/ijerph19020874
   Schoenfeld BJ, 2020, J STRENGTH COND RES, V34, P678, DOI 10.1519/JSC.0000000000002708
   Schwingshackl L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097656
   Shafiee G, 2017, J DIABETES METAB DIS, V16, DOI 10.1186/s40200-017-0302-x
   Shahbaz H., 2019, Creatinine clearance
   Shamim B, 2018, SPORTS MED, V48, P2869, DOI 10.1007/s40279-018-0999-9
   Shams-White MM, 2017, AM J CLIN NUTR, V105, P1528, DOI 10.3945/ajcn.116.145110
   Steib S, 2010, MED SCI SPORT EXER, V42, P902, DOI 10.1249/MSS.0b013e3181c34465
   Straight CR, 2016, SPORTS MED, V46, P353, DOI 10.1007/s40279-015-0418-4
   Talar K, 2021, J CLIN MED, V10, DOI 10.3390/jcm10081630
   Traylor DA, 2018, ADV NUTR, V9, P171, DOI 10.1093/advances/nmy003
   Van Elswyk ME, 2018, ADV NUTR, V9, P404, DOI 10.1093/advances/nmy026
   Verdijk LB, 2009, AM J CLIN NUTR, V89, P608, DOI 10.3945/ajcn.2008.26626
   Wallace TC, 2017, J AM COLL NUTR, V36, P481, DOI 10.1080/07315724.2017.1322924
   Wilborn CD, 2013, J SPORT SCI MED, V12, P74
   Wolfe RR, 2017, ADV NUTR, V8, P266, DOI 10.3945/an.116.013821
   Zdzieblik D, 2015, BRIT J NUTR, V114, P1237, DOI 10.1017/S0007114515002810
   Zempo H, 2017, J PHYS FITNESS SPORT, V6, P25, DOI [10.7600/jpfsm.6.25, DOI 10.7600/JPFSM.6.25]
NR 68
TC 0
Z9 0
U1 1
U2 2
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2296-861X
J9 FRONT NUTR
JI Front. Nutr.
PD JUN 29
PY 2023
VL 10
AR 1205310
DI 10.3389/fnut.2023.1205310
PG 14
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Nutrition & Dietetics
GA L6MK7
UT WOS:001024382200001
PM 37457969
OA Green Published, gold
DA 2024-02-19
ER

PT J
AU Muche, A
   Bigl, M
   Arendt, T
   Schliebs, R
AF Muche, Abebe
   Bigl, Marina
   Arendt, Thomas
   Schliebs, Reinhard
TI Expression of vascular endothelial growth factor (VEGF) mRNA, VEGF
   receptor 2 (Flk-1) mRNA, and of VEGF co-receptor neuropilin (Nrp)-1 mRNA
   in brain tissue of aging Tg2576 mice by in situ hybridization
SO INTERNATIONAL JOURNAL OF DEVELOPMENTAL NEUROSCIENCE
LA English
DT Article
DE Beta amyloid plaques; VEGF mRNA; Flk-1 mRNA; Nrp-1 mRNA; Transgenic
   mouse brain
ID AMYLOID PRECURSOR PROTEIN; FOCAL CEREBRAL-ISCHEMIA; ANGIOGENIC FACTORS
   VEGF; ALZHEIMERS-DISEASE; MOUSE MODEL; GENE-EXPRESSION; UP-REGULATION;
   BETA; HIPPOCAMPUS; CELLS
AB Vascular endothelial growth factor (VEGF) has been characterized as a heparin binding angiogenic growth factor displaying high specificity for endothelial cells. It is profoundly accumulated and co-localized with amyloid beta (A beta) plaques in the brain of Alzheimer's disease patients. In order to examine the effect of AS plaques on the expression level of VEGF mRNA and its receptors, brain tissue of both transgenic Tg2576 and wild type mice at ages ranging from 13 to 22 months was subjected to in situ hybridization followed by densitometric assessment using computer-assisted image analysis. Strong expression of VEGF mRNA, fetal liver kinase (Flk)-1 mRNA, and neuropilin (Nrp)-1 mRNA in the piriform, entorhinal, somatosensory, frontal cortex and hippocampal formation of both transgenic and non-transgenic mice brain was detected. Developmentally, only expression of VEGF mRNA was increased with age in the entorhinal, and somatosensory cortex of wild type mice. In 20-month-old transgenic Tg2576 mice, upregulation of VEGF mRNA, Flk-1 mRNA, and Nrp-1 mRNA transcripts was observed in the entorhinal cortex compared to age-matched wild type mice. Our data suggest up-regulation of VEGF mRNA, Flk-1 mRNA and Nrp-1 mRNA, at least in the entorhinal cortex at ages when AS deposition in Tg2576 is typically increasing. (C) 2015 Elsevier Ltd. All rights reserved.
C1 [Muche, Abebe] Univ Gondar, Coll Med & Hlth Sci, Dept Human Anat, Gondar, Ethiopia.
   [Muche, Abebe; Arendt, Thomas; Schliebs, Reinhard] Univ Leipzig, Fac Med, Paul Flechsig Inst Brain Res, D-04109 Leipzig, Germany.
   [Bigl, Marina] Univ Leipzig, Inst Biochem, D-04109 Leipzig, Germany.
C3 University of Gondar; Leipzig University; Leipzig University
RP Muche, A (corresponding author), Univ Gondar, Coll Med & Hlth Sci, Dept Human Anat, POB 196, Gondar, Ethiopia.
EM abemuche@yahoo.com
RI Arendt, Thomas/C-8747-2012
OI Arendt, Thomas/0000-0003-4553-1625
FU Ministry of Research and Education of the State Saxonia; Medical Faculty
   of the University of Leipzig; Alzheimer Forschungsinitiative (AFI);
   Deutscher Akademischer Austauschdienst (DAAD)
FX The expert technical assistance of Mrs. Renate Jendrek is gratefully
   acknowledged. The authors like to express their gratitude to Dr. Karen
   Hsiao Ashe, Department of Neurology, University of Minnesota, USA, for
   kindly providing three Tg2576 founder mice. The study was supported by
   grants of the Ministry of Research and Education of the State Saxonia,
   the Medical Faculty of the University of Leipzig, and the Alzheimer
   Forschungsinitiative (AFI). A.M. acknowledges the receipt of a
   scholarship by the Deutscher Akademischer Austauschdienst (DAAD).
CR Apelt J, 2004, INT J DEV NEUROSCI, V22, P475, DOI 10.1016/j.ijdevneu.2004.07.006
   Bao XJ, 2011, EUR J NEUROSCI, V34, P87, DOI 10.1111/j.1460-9568.2011.07733.x
   Bates DO, 2002, VASC PHARMACOL, V39, P225, DOI 10.1016/S1537-1891(03)00011-9
   Berchtold NC, 2008, P NATL ACAD SCI USA, V105, P15605, DOI 10.1073/pnas.0806883105
   Bürger S, 2010, INT J DEV NEUROSCI, V28, P597, DOI 10.1016/j.ijdevneu.2010.07.231
   Bürger S, 2009, INT J DEV NEUROSCI, V27, P517, DOI 10.1016/j.ijdevneu.2009.06.011
   Buga AM, 2008, J CELL MOL MED, V12, P2731, DOI 10.1111/j.1582-4934.2008.00252.x
   Buga AM, 2014, FRONT AGING NEUROSCI, V6, DOI 10.3389/fnagi.2014.00044
   Cao YH, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.259re1
   Chapuis J, 2006, NEUROBIOL AGING, V27, P1212, DOI 10.1016/j.neurobiolaging.2005.07.013
   Chiarini A, 2010, J ALZHEIMERS DIS, V21, P915, DOI 10.3233/JAD-2010-100471
   Choi JS, 2010, J COMP NEUROL, V518, P1064, DOI 10.1002/cne.22263
   Corsi MM, 2011, BIOGERONTOLOGY, V12, P451, DOI 10.1007/s10522-011-9335-6
   Darrington E, 2012, ASIAN J ANDROL, V14, P745, DOI 10.1038/aja.2011.197
   DELATORRE JC, 1993, NEUROL RES, V15, P146
   Desai BS, 2009, J NEURAL TRANSM, V116, P587, DOI 10.1007/s00702-009-0226-9
   FERRARA N, 1992, ENDOCR REV, V13, P18, DOI 10.1210/er.13.1.18
   Gage FH, 1998, J NEUROBIOL, V36, P249, DOI 10.1002/(SICI)1097-4695(199808)36:2<249::AID-NEU11>3.0.CO;2-9
   Ge SJ, 2005, J NEUROSCI RES, V79, P421, DOI 10.1002/jnr.20313
   HARDY JA, 1992, SCIENCE, V256, P184, DOI 10.1126/science.1566067
   Hou ST, 2008, BIOCHEM BIOPH RES CO, V367, P109, DOI 10.1016/j.bbrc.2007.12.103
   Hou Y, 2011, J CHEM NEUROANAT, V42, P56, DOI 10.1016/j.jchemneu.2011.06.001
   Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99
   Huang L, 2013, NEUROSCI LETT, V550, P60, DOI 10.1016/j.neulet.2013.06.031
   Iida K, 2002, LIFE SCI, V71, P1607, DOI 10.1016/S0024-3205(02)01842-8
   Isingrini E, 2009, CURR OPIN INVEST DR, V10, P46
   Jain RK, 2003, NAT MED, V9, P685, DOI 10.1038/nm0603-685
   Kara F, 2012, NEUROIMAGE, V60, P958, DOI 10.1016/j.neuroimage.2011.12.055
   Khaibullina AA, 2004, DEV BRAIN RES, V148, P59, DOI 10.1016/j.devbrainres.2003.09.022
   Koch S, 2011, BIOCHEM J, V437, P169, DOI 10.1042/BJ20110301
   Koike MA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042665
   Kouznetsova E, 2006, INT J DEV NEUROSCI, V24, P187, DOI 10.1016/j.ijdevneu.2005.11.011
   Kuznetsova E, 2013, CURR PHARM DESIGN, V19, P6749
   Lagercrantz J, 1998, BBA-GENE STRUCT EXPR, V1398, P157, DOI 10.1016/S0167-4781(98)00040-2
   Li YN, 2014, J NEUROCHEM, V129, P120, DOI 10.1111/jnc.12611
   Liu H, 2012, NEUROBIOL AGING, V33, DOI 10.1016/j.neurobiolaging.2011.05.027
   Mateo I, 2007, ACTA NEUROL SCAND, V116, P56, DOI 10.1111/j.1600-0404.2006.00775.x
   MITO T, 1991, PEDIATR NEUROL, V7, P18, DOI 10.1016/0887-8994(91)90100-Y
   Muche A., 2013, NUTR NEUROSCI
   Murugesan N, 2012, NEUROBIOL AGING, V33, DOI 10.1016/j.neurobiolaging.2011.09.022
   Narasimhan P, 2009, STROKE, V40, P1467, DOI 10.1161/STROKEAHA.108.534644
   Nicolakakis N, 2011, J CEREBR BLOOD F MET, V31, P1354, DOI 10.1038/jcbfm.2011.43
   Nitzan A, 2006, GLIA, V54, P545, DOI 10.1002/glia.20398
   Paris D, 2005, MOL BRAIN RES, V136, P212, DOI 10.1016/j.molbrainres.2005.02.011
   Paris D, 2004, NEUROSCI LETT, V366, P80, DOI 10.1016/j.neulet.2004.05.017
   Paris Daniel, 2004, Angiogenesis, V7, P75, DOI 10.1023/B:AGEN.0000037335.17717.bf
   Pitzer MR, 2003, EXP NEUROL, V182, P435, DOI 10.1016/S0014-4886(03)00100-6
   Rosenstein JM, 2003, J NEUROSCI, V23, P11036
   Rosenstein JM, 2004, EXP NEUROL, V187, P246, DOI 10.1016/j.expneurol.2004.01.022
   Roskoski R, 2008, BIOCHEM BIOPH RES CO, V375, P287, DOI 10.1016/j.bbrc.2008.07.121
   Schliebs R., 2013, HDB NEUROINFORMATICS, P889
   Schliebs R, 2011, BEHAV BRAIN RES, V221, P555, DOI 10.1016/j.bbr.2010.11.058
   Shin YJ, 2008, ACTA NEUROPATHOL, V116, P517, DOI 10.1007/s00401-008-0423-x
   Sköld MK, 2005, J NEUROTRAUM, V22, P353, DOI 10.1089/neu.2005.22.353
   Smith CP, 2007, EXP EYE RES, V85, P817, DOI 10.1016/j.exer.2007.08.017
   Tang HD, 2013, NEUROBIOL AGING, V34, P1412, DOI 10.1016/j.neurobiolaging.2012.10.029
   Tarkowski E, 2002, NEUROBIOL AGING, V23, P237, DOI 10.1016/S0197-4580(01)00285-8
   Wang WY, 2005, NEUROSCIENCE, V134, P1167, DOI 10.1016/j.neuroscience.2005.04.064
   Whitehead SN, 2010, BRAIN RES, V1344, P209, DOI 10.1016/j.brainres.2010.05.036
   Ye YL, 2012, BIOL PHARM BULL, V35, P355, DOI 10.1248/bpb.35.355
   Zhang ZG, 2001, J CEREBR BLOOD F MET, V21, P541, DOI 10.1097/00004647-200105000-00008
NR 61
TC 11
Z9 12
U1 0
U2 14
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0736-5748
EI 1873-474X
J9 INT J DEV NEUROSCI
JI Int. J. Dev. Neurosci.
PD JUN
PY 2015
VL 43
BP 25
EP 34
DI 10.1016/j.ijdevneu.2015.03.003
PG 10
WC Developmental Biology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Developmental Biology; Neurosciences & Neurology
GA CK4KP
UT WOS:000356193000004
PM 25797338
DA 2024-02-19
ER

PT J
AU COHN, SM
   ROTH, KA
   BIRKENMEIER, EH
   GORDON, JI
AF COHN, SM
   ROTH, KA
   BIRKENMEIER, EH
   GORDON, JI
TI TEMPORAL AND SPATIAL PATTERNS OF TRANSGENE EXPRESSION IN AGING ADULT
   MICE PROVIDE INSIGHTS ABOUT THE ORIGINS, ORGANIZATION, AND
   DIFFERENTIATION OF THE INTESTINAL EPITHELIUM
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE COLON; STEM CELLS; PROGENITOR CELLS; TRANSGENIC MICE; PATTERN FORMATION
ID MUTATION
AB We have used liver fatty acid-binding protein/human growth hormone (L-FABP/hGH) fusion genes to explore the temporal and spatial differentiation of intestinal epithelial cells in 1- to 12-month-old transgenic mice.  The intact, endogenous L-FABP gene (Fabpl) was not expressed in the colon at any time.  Young adult transgenic mice containing nucleotides -596 to +21 of the rat L-FABP gene linked to the hGH gene (minus its 5' nontranscribed domain) demonstrated inappropriate expression of hGH in enterocytes and many enteroendocrine cells of most proximal and mid-colonic crypts (glands).  Rare patches of hGH-negative crypts were present.  With increasing age, a wave of "extinction" of L-FABP(-596 to +21)/hGH expression occurred, first in the distal colon and then in successively more proximal regions, leaving by 10 months of age only rare hGH-positive multicrypt patches.  At no time during this progressive silencing of transgene expression were crypts observed that contained a mixture of hGH-positive and -negative cells at a particular cell stratum.  Young (5-7 weeks) mice containing a L-FABP(-4000 to +21)/hGH transgene also demonstrated inappropriate expression of the transgene in most proximal colonic crypts.  However, the additional 3.3 kilobases of upstream sequence resulted in much more rapid extinction of reporter expression, leaving by 5 months of age only scattered single crypts with detectable levels of hGH.  This age-related extinction of L-FABP/hGH expression did not involve enterocytes and enteroendocrine cells in the (proximal) small intestine.  These results indicate that cis-acting elements outside of nucleotides -4000 to +21 are necessary to fully modulate suppression of colonic L-FABP expression.  They also define fundamental changes in colonic epithelial cell populations during adult life.  Our data suggest that (i) a single stem cell gives rise to all cells that populate a given colonic crypt, (ii) stem cells represented in several adjacent crypts may be derived from a common progenitor, and (iii) such a progenitor cell may repopulate colonic crypts with stem cells during adult life.  Since each colonic crypt contains the amplified descendants of its stem cell, transgenes may be powerful tools for characterizing the spatial and biological features of gut stem cells and their progenitors during life.
C1 JACKSON LAB,BAR HARBOR,ME 04609.
   WASHINGTON UNIV,SCH MED,DEPT PATHOL,ST LOUIS,MO 63110.
   WASHINGTON UNIV,SCH MED,DEPT BIOCHEM & MOLEC BIOPHYS,ST LOUIS,MO 63110.
C3 Jackson Laboratory; Washington University (WUSTL); Washington University
   (WUSTL)
RP COHN, SM (corresponding author), WASHINGTON UNIV,SCH MED,DEPT MED,ST LOUIS,MO 63110, USA.
OI Roth, Kevin/0000-0002-0643-995X
FU NIDDK NIH HHS [DK30292, DK37690] Funding Source: Medline
CR GORDON JI, 1989, J CELL BIOL, V108, P1187, DOI 10.1083/jcb.108.4.1187
   GRIFFITHS DFR, 1988, NATURE, V333, P461, DOI 10.1038/333461a0
   PONDER BAJ, 1985, NATURE, V313, P689, DOI 10.1038/313689a0
   PONDER BAJ, 1985, J EMBRYOL EXP MORPH, V87, P229
   ROTH KA, 1990, P NATL ACAD SCI USA, V87, P6408, DOI 10.1073/pnas.87.16.6408
   ROTH KA, 1990, J CELL BIOL, V110, P1791, DOI 10.1083/jcb.110.5.1791
   ROTH KA, 1991, IN PRESS J BIOL CHEM
   SCHMIDT GH, 1990, MUTAT RES, V228, P149, DOI 10.1016/0027-5107(90)90071-B
   SCHMIDT GH, 1988, DEVELOPMENT, V103, P785
   SCHMIDT GH, 1985, CELL, V40, P425, DOI 10.1016/0092-8674(85)90156-4
   SCHMIDT GH, 1986, J EMBRYOL EXP MORPH, V91, P197
   SWEETSER DA, 1988, GENE DEV, V2, P1318, DOI 10.1101/gad.2.10.1318
   WINTON DJ, 1990, P ROY SOC B-BIOL SCI, V241, P13, DOI 10.1098/rspb.1990.0059
   WINTON DJ, 1989, MUTAGENESIS, V4, P404, DOI 10.1093/mutage/4.5.404
   WINTON DJ, 1988, NATURE, V333, P463, DOI 10.1038/333463a0
NR 15
TC 52
Z9 52
U1 0
U2 1
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD FEB
PY 1991
VL 88
IS 3
BP 1034
EP 1038
DI 10.1073/pnas.88.3.1034
PG 5
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA EW400
UT WOS:A1991EW40000073
PM 1992454
OA Green Published
DA 2024-02-19
ER

EF